PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33930347-0	2021	Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis.	Berberine	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	84-89
6768879-0	1980	Inhibition of human pregnancy plasma diamine oxidase with alkaloids of Argemone mexicana--berberine and sanguinarine.	Berberine	90-99	amine oxidase copper containing 1	Homo sapiens	37-52
33887260-6	2021	BBR treatment induced DNA replication defects and cell cycle arrest, resulting in apoptosis or cell senescence, depending on p53 status, in BCa cells.	Berberine	0-3	tumor protein p53	Homo sapiens	125-128
33930347-0	2021	Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis.	Berberine	0-9	CD47 molecule	Homo sapiens	90-94
33930347-3	2021	Here, we validated berberine, a natural compound, as a suppressor of CD47 and revealed the involved mechanism and biological function in DLBCL.	Berberine	19-28	CD47 molecule	Homo sapiens	69-73
33930347-4	2021	Berberine downregulated the expression of CD47 in DLBCL at the transcriptional level by suppressing c-myc expression.	Berberine	0-9	CD47 molecule	Homo sapiens	42-46
33930347-4	2021	Berberine downregulated the expression of CD47 in DLBCL at the transcriptional level by suppressing c-myc expression.	Berberine	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	100-105
33930347-5	2021	Berberine-induced CD47 inhibition enhanced the phagocytosis of macrophages, thereby eliminating DLBCL cells in vitro and in vivo.	Berberine	0-9	CD47 molecule	Homo sapiens	18-22
33930347-6	2021	Interestingly, berberine enhanced the efficiency of anti-CD47 antibody and rituximab-mediated phagocytosis.	Berberine	15-24	CD47 molecule	Homo sapiens	57-61
33930347-8	2021	Our results highlighted for the first time that berberine could restore macrophage function in the tumor microenvironment, enhance rituximab-mediated phagocytosis and promote anti-CD47 antibody function via suppressing CD47 expression, which revealed a new anti-tumor mechanism of berberine and provided novel insights into the rituximab-based immunochemotherapy and CD47-targeted immunotherapy in DLBCL.	Berberine	48-57	CD47 molecule	Homo sapiens	180-184
33930347-8	2021	Our results highlighted for the first time that berberine could restore macrophage function in the tumor microenvironment, enhance rituximab-mediated phagocytosis and promote anti-CD47 antibody function via suppressing CD47 expression, which revealed a new anti-tumor mechanism of berberine and provided novel insights into the rituximab-based immunochemotherapy and CD47-targeted immunotherapy in DLBCL.	Berberine	48-57	CD47 molecule	Homo sapiens	219-223
33930347-8	2021	Our results highlighted for the first time that berberine could restore macrophage function in the tumor microenvironment, enhance rituximab-mediated phagocytosis and promote anti-CD47 antibody function via suppressing CD47 expression, which revealed a new anti-tumor mechanism of berberine and provided novel insights into the rituximab-based immunochemotherapy and CD47-targeted immunotherapy in DLBCL.	Berberine	48-57	CD47 molecule	Homo sapiens	219-223
34050236-6	2021	Berberine also significantly inhibited the phosphorylation of p38 MAPK, ERK1/2, IkB-alpha, and STAT3 in poly I:C-induced RAW 264.7 cells.	Berberine	0-9	mitogen-activated protein kinase 14	Mus musculus	62-70
33846796-0	2021	Berberine inhibits the proliferation, invasion and migration of endometrial stromal cells by downregulating miR-429.	Berberine	0-9	microRNA 429	Homo sapiens	108-115
33846796-11	2021	The results revealed that treatment with 80 microM BBR significantly inhibited cell proliferation and colony formation, and inhibited the expression of Ki-67 and PCNA proteins in HESCs.	Berberine	51-54	proliferating cell nuclear antigen	Homo sapiens	162-166
33846796-12	2021	BBR inhibited cell invasion and migration, as well as the expression of MMP2, MMP4 and MMP9.	Berberine	0-3	matrix metallopeptidase 2	Homo sapiens	72-76
33846796-12	2021	BBR inhibited cell invasion and migration, as well as the expression of MMP2, MMP4 and MMP9.	Berberine	0-3	interleukin enhancer binding factor 3	Homo sapiens	78-82
33846796-12	2021	BBR inhibited cell invasion and migration, as well as the expression of MMP2, MMP4 and MMP9.	Berberine	0-3	matrix metallopeptidase 9	Homo sapiens	87-91
33846796-13	2021	In this process, it was found that the expression of miR-429 decreased following treatment of the cells with BBR, whereas the inhibitory effects of BBR on cell proliferation, invasion and migration were suppressed following the overexpression of miR-429.	Berberine	109-112	microRNA 429	Homo sapiens	53-60
33846796-13	2021	In this process, it was found that the expression of miR-429 decreased following treatment of the cells with BBR, whereas the inhibitory effects of BBR on cell proliferation, invasion and migration were suppressed following the overexpression of miR-429.	Berberine	148-151	microRNA 429	Homo sapiens	246-253
33846796-14	2021	Overall, the findings of the present study indicated that BBR inhibited the proliferation, invasion and migration of HESCs by downregulating the expression of miR-429.	Berberine	58-61	microRNA 429	Homo sapiens	159-166
34050236-6	2021	Berberine also significantly inhibited the phosphorylation of p38 MAPK, ERK1/2, IkB-alpha, and STAT3 in poly I:C-induced RAW 264.7 cells.	Berberine	0-9	mitogen-activated protein kinase 3	Mus musculus	72-78
34050236-6	2021	Berberine also significantly inhibited the phosphorylation of p38 MAPK, ERK1/2, IkB-alpha, and STAT3 in poly I:C-induced RAW 264.7 cells.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	80-89
34050236-6	2021	Berberine also significantly inhibited the phosphorylation of p38 MAPK, ERK1/2, IkB-alpha, and STAT3 in poly I:C-induced RAW 264.7 cells.	Berberine	0-9	signal transducer and activator of transcription 3	Mus musculus	95-100
34050236-7	2021	Additionally, berberine significantly decreased the mRNA expressions of Chop (GADD153), Stat1, Stat3, and Fas in poly I:C-induced RAW 264.7 cells.	Berberine	14-23	DNA-damage inducible transcript 3	Mus musculus	72-76
34050236-7	2021	Additionally, berberine significantly decreased the mRNA expressions of Chop (GADD153), Stat1, Stat3, and Fas in poly I:C-induced RAW 264.7 cells.	Berberine	14-23	DNA-damage inducible transcript 3	Mus musculus	78-85
34050236-7	2021	Additionally, berberine significantly decreased the mRNA expressions of Chop (GADD153), Stat1, Stat3, and Fas in poly I:C-induced RAW 264.7 cells.	Berberine	14-23	signal transducer and activator of transcription 1	Mus musculus	88-93
34050236-7	2021	Additionally, berberine significantly decreased the mRNA expressions of Chop (GADD153), Stat1, Stat3, and Fas in poly I:C-induced RAW 264.7 cells.	Berberine	14-23	signal transducer and activator of transcription 3	Mus musculus	95-100
34050236-8	2021	Taken together, berberine has anti-inflammatory properties related to its inhibition of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 in dsRNA-induced macrophages via the endoplasmic reticulum stress-related calcium-CHOP/STAT pathway.	Berberine	16-25	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	103-109
34050236-8	2021	Taken together, berberine has anti-inflammatory properties related to its inhibition of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 in dsRNA-induced macrophages via the endoplasmic reticulum stress-related calcium-CHOP/STAT pathway.	Berberine	16-25	leukemia inhibitory factor	Mus musculus	111-114
34050236-8	2021	Taken together, berberine has anti-inflammatory properties related to its inhibition of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 in dsRNA-induced macrophages via the endoplasmic reticulum stress-related calcium-CHOP/STAT pathway.	Berberine	16-25	chemokine (C-X-C motif) ligand 5	Mus musculus	116-119
34050236-8	2021	Taken together, berberine has anti-inflammatory properties related to its inhibition of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 in dsRNA-induced macrophages via the endoplasmic reticulum stress-related calcium-CHOP/STAT pathway.	Berberine	16-25	chemokine (C-C motif) ligand 5	Mus musculus	121-127
34050236-8	2021	Taken together, berberine has anti-inflammatory properties related to its inhibition of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 in dsRNA-induced macrophages via the endoplasmic reticulum stress-related calcium-CHOP/STAT pathway.	Berberine	16-25	chemokine (C-X-C motif) ligand 2	Mus musculus	133-138
34050236-8	2021	Taken together, berberine has anti-inflammatory properties related to its inhibition of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 in dsRNA-induced macrophages via the endoplasmic reticulum stress-related calcium-CHOP/STAT pathway.	Berberine	16-25	DNA-damage inducible transcript 3	Mus musculus	221-225
34052738-0	2021	Structure-activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents.	Berberine	61-70	proprotein convertase subtilisin/kexin type 9	Homo sapiens	86-91
34050236-0	2021	Berberine modulates hyper-inflammation in mouse macrophages stimulated with polyinosinic-polycytidylic acid via calcium-CHOP/STAT pathway.	Berberine	0-9	DNA-damage inducible transcript 3	Mus musculus	120-124
34050236-5	2021	Berberine significantly inhibited the production of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 as well as calcium release in poly I:C-induced RAW 264.7 cells at concentrations of up to 50 muM.	Berberine	0-9	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	67-73
34050236-5	2021	Berberine significantly inhibited the production of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 as well as calcium release in poly I:C-induced RAW 264.7 cells at concentrations of up to 50 muM.	Berberine	0-9	leukemia inhibitory factor	Mus musculus	75-78
34050236-5	2021	Berberine significantly inhibited the production of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 as well as calcium release in poly I:C-induced RAW 264.7 cells at concentrations of up to 50 muM.	Berberine	0-9	chemokine (C-X-C motif) ligand 5	Mus musculus	80-83
34050236-5	2021	Berberine significantly inhibited the production of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 as well as calcium release in poly I:C-induced RAW 264.7 cells at concentrations of up to 50 muM.	Berberine	0-9	chemokine (C-C motif) ligand 5	Mus musculus	85-91
34050236-5	2021	Berberine significantly inhibited the production of NO, PGE2, Fas, GM-CSF, LIF, LIX, RANTES, and MIP-2 as well as calcium release in poly I:C-induced RAW 264.7 cells at concentrations of up to 50 muM.	Berberine	0-9	chemokine (C-X-C motif) ligand 2	Mus musculus	97-102
34048925-5	2021	This review summarizes bitter chemosensation in the intestines for GLP-1 secretion and metabolic regulation based on recent advances in biological research of bitter taste receptors and preclinical and clinical investigation of bitter medicinal plants, including bitter melon, hops strobile, and berberine-containing herbs (e.g. coptis rhizome and barberry root).	Berberine	296-305	glucagon	Homo sapiens	67-72
34052738-2	2021	Forty berberine (BBR) derivatives were synthesized and evaluated for their activities on down-regulating the transcription of PCSK9 in HepG2 cells, taking BBR as the lead.	Berberine	6-15	proprotein convertase subtilisin/kexin type 9	Homo sapiens	126-131
34052738-2	2021	Forty berberine (BBR) derivatives were synthesized and evaluated for their activities on down-regulating the transcription of PCSK9 in HepG2 cells, taking BBR as the lead.	Berberine	17-20	proprotein convertase subtilisin/kexin type 9	Homo sapiens	126-131
33751936-0	2021	Berberine-photodynamic induced apoptosis by activating endoplasmic reticulum stress-autophagy pathway involving CHOP in human malignant melanoma cells.	Berberine	0-9	DNA damage inducible transcript 3	Homo sapiens	112-116
33983710-7	2021	Our results revealed that berberine treatment may inhibit PERK/eIF2alpha signaling-mediated BACE1 translation, thus reducing Abeta production and resultant neuronal apoptosis.	Berberine	26-35	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	58-62
33983710-7	2021	Our results revealed that berberine treatment may inhibit PERK/eIF2alpha signaling-mediated BACE1 translation, thus reducing Abeta production and resultant neuronal apoptosis.	Berberine	26-35	eukaryotic translation initiation factor 2A	Mus musculus	63-72
33983710-7	2021	Our results revealed that berberine treatment may inhibit PERK/eIF2alpha signaling-mediated BACE1 translation, thus reducing Abeta production and resultant neuronal apoptosis.	Berberine	26-35	beta-site APP cleaving enzyme 1	Mus musculus	92-97
33984720-0	2021	Berberine attenuates the inflammatory response by activating the Keap1/Nrf2 signaling pathway in bovine endometrial epithelial cells.	Berberine	0-9	kelch like ECH associated protein 1	Bos taurus	65-70
33984720-0	2021	Berberine attenuates the inflammatory response by activating the Keap1/Nrf2 signaling pathway in bovine endometrial epithelial cells.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Bos taurus	71-75
33984720-3	2021	Berberine treatment significantly reduced the LPS-induced expression levels of CRP, IL-1beta, IL-6, and TNF-alpha in bEECs.	Berberine	0-9	C-reactive protein	Bos taurus	79-82
33984720-3	2021	Berberine treatment significantly reduced the LPS-induced expression levels of CRP, IL-1beta, IL-6, and TNF-alpha in bEECs.	Berberine	0-9	interleukin 1 alpha	Bos taurus	84-92
33984720-3	2021	Berberine treatment significantly reduced the LPS-induced expression levels of CRP, IL-1beta, IL-6, and TNF-alpha in bEECs.	Berberine	0-9	interferon beta-2	Bos taurus	94-98
33984720-3	2021	Berberine treatment significantly reduced the LPS-induced expression levels of CRP, IL-1beta, IL-6, and TNF-alpha in bEECs.	Berberine	0-9	tumor necrosis factor	Bos taurus	104-113
33984720-4	2021	The Nrf2 signaling pathway in these cells was also activated by berberine.	Berberine	64-73	NFE2 like bZIP transcription factor 2	Bos taurus	4-8
33984720-7	2021	However, an inhibitor of Nrf2 only partially inhibited the anti-inflammatory effects of berberine on the LPS-induced inflammatory response in bEECs.	Berberine	88-97	NFE2 like bZIP transcription factor 2	Bos taurus	25-29
33984720-8	2021	In conclusion, our findings suggest that berberine exerts anti-inflammatory effects partially by activating the Keap1/Nrf2 signaling pathway.	Berberine	41-50	kelch like ECH associated protein 1	Bos taurus	112-117
33984720-8	2021	In conclusion, our findings suggest that berberine exerts anti-inflammatory effects partially by activating the Keap1/Nrf2 signaling pathway.	Berberine	41-50	NFE2 like bZIP transcription factor 2	Bos taurus	118-122
33544461-4	2021	The present study was to explore whether KLF4 determined the cardioprotective benefits of berberine in dietary-induced obese mice.	Berberine	90-99	Kruppel-like factor 4 (gut)	Mus musculus	41-45
34025574-14	2021	Treatment with berberine was associated with reductions in food intake, FBG level, insulin resistance, and plasma LPS level, as well as increases in fasting plasma GLP-2 level and glutamine-induced intestinal GLP-2 secretion.	Berberine	15-24	mast cell protease 10	Rattus norvegicus	164-169
34025574-14	2021	Treatment with berberine was associated with reductions in food intake, FBG level, insulin resistance, and plasma LPS level, as well as increases in fasting plasma GLP-2 level and glutamine-induced intestinal GLP-2 secretion.	Berberine	15-24	mast cell protease 10	Rattus norvegicus	209-214
34025574-15	2021	Berberine could increase the goblet cell number and villi length, and also reverse the suppressed expressions of mucin, occludin, ZO-1 and the upregulated expressions of TLR-4, NF-kappaB and TNF-alpha induced in IGT rats (P<0.05).	Berberine	0-9	solute carrier family 13 member 2	Rattus norvegicus	113-118
34025574-15	2021	Berberine could increase the goblet cell number and villi length, and also reverse the suppressed expressions of mucin, occludin, ZO-1 and the upregulated expressions of TLR-4, NF-kappaB and TNF-alpha induced in IGT rats (P<0.05).	Berberine	0-9	occludin	Rattus norvegicus	120-128
34025574-15	2021	Berberine could increase the goblet cell number and villi length, and also reverse the suppressed expressions of mucin, occludin, ZO-1 and the upregulated expressions of TLR-4, NF-kappaB and TNF-alpha induced in IGT rats (P<0.05).	Berberine	0-9	tight junction protein 1	Rattus norvegicus	130-134
34025574-15	2021	Berberine could increase the goblet cell number and villi length, and also reverse the suppressed expressions of mucin, occludin, ZO-1 and the upregulated expressions of TLR-4, NF-kappaB and TNF-alpha induced in IGT rats (P<0.05).	Berberine	0-9	toll-like receptor 4	Rattus norvegicus	170-175
34025574-15	2021	Berberine could increase the goblet cell number and villi length, and also reverse the suppressed expressions of mucin, occludin, ZO-1 and the upregulated expressions of TLR-4, NF-kappaB and TNF-alpha induced in IGT rats (P<0.05).	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	191-200
34025574-17	2021	Conclusion: Berberine may slow the progression of prediabetes to T2DM in ZDF rats by improving GLP-2 secretion, intestinal permeability, and the structure of the gut microbiota.	Berberine	12-21	mast cell protease 10	Rattus norvegicus	95-100
33957209-10	2021	The identified BP-target-pathway network revealed the underlying mechanisms of BBR antidiabetic activity were mediated by core targets such as RXRA, KCNQ1, and NR3C1.	Berberine	79-82	retinoid X receptor alpha	Mus musculus	143-147
33957209-10	2021	The identified BP-target-pathway network revealed the underlying mechanisms of BBR antidiabetic activity were mediated by core targets such as RXRA, KCNQ1, and NR3C1.	Berberine	79-82	potassium voltage-gated channel, subfamily Q, member 1	Mus musculus	149-154
33957209-10	2021	The identified BP-target-pathway network revealed the underlying mechanisms of BBR antidiabetic activity were mediated by core targets such as RXRA, KCNQ1, and NR3C1.	Berberine	79-82	nuclear receptor subfamily 3, group C, member 1	Mus musculus	160-165
33957209-12	2021	Moreover, BBR treatment promoted RXRA expression, whereas it reduced KCNQ1 and NR3C1 expression in the liver.	Berberine	10-13	retinoid X receptor alpha	Mus musculus	33-37
33957209-12	2021	Moreover, BBR treatment promoted RXRA expression, whereas it reduced KCNQ1 and NR3C1 expression in the liver.	Berberine	10-13	nuclear receptor subfamily 3, group C, member 1	Mus musculus	79-84
32770172-11	2021	Furthermore, we demonstrated that the inhibitory effect of BBR on intralipid-induced IR was mainly mediated by skeletal muscle, but not by intestine, liver, or microvasculature; BBR administration suppressed intralipid-induced upregulation of CypD expression in skeletal muscle.	Berberine	178-181	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	243-247
32770172-12	2021	These results suggest that BBR alleviates intralipid-induced IR, which is related to the inhibition of CypD protein expression in skeletal muscle.	Berberine	27-30	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	103-107
33524788-0	2021	Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways.	Berberine	3-12	AKT serine/threonine kinase 1	Rattus norvegicus	112-115
33524788-0	2021	Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways.	Berberine	3-12	NFE2 like bZIP transcription factor 2	Rattus norvegicus	120-124
33325633-0	2021	Dual down-regulation of EGFR and ErbB2 by berberine contributes to suppression of migration and invasion of human ovarian cancer cells.	Berberine	42-51	epidermal growth factor receptor	Homo sapiens	24-28
33325633-0	2021	Dual down-regulation of EGFR and ErbB2 by berberine contributes to suppression of migration and invasion of human ovarian cancer cells.	Berberine	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-38
33325633-2	2021	The purpose of this study was to examine the anticancer effects and molecular mechanisms of berberine on human ovarian cancer cells with different levels of EGFR and/or ErbB2.	Berberine	92-101	epidermal growth factor receptor	Homo sapiens	157-161
33325633-2	2021	The purpose of this study was to examine the anticancer effects and molecular mechanisms of berberine on human ovarian cancer cells with different levels of EGFR and/or ErbB2.	Berberine	92-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-174
33325633-4	2021	Berberine depleted both EGFR and ErbB2 in ovarian cancer cells.	Berberine	0-9	epidermal growth factor receptor	Homo sapiens	24-28
33325633-4	2021	Berberine depleted both EGFR and ErbB2 in ovarian cancer cells.	Berberine	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-38
33325633-5	2021	Furthermore, berberine suppressed the activation of the EGFR and ErbB2 downstream targets cyclin D1, MMPs, and VEGF by down-regulating the EGFR-ErbB2/PI3K/Akt signaling pathway.	Berberine	13-22	epidermal growth factor receptor	Homo sapiens	56-60
33325633-5	2021	Furthermore, berberine suppressed the activation of the EGFR and ErbB2 downstream targets cyclin D1, MMPs, and VEGF by down-regulating the EGFR-ErbB2/PI3K/Akt signaling pathway.	Berberine	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-70
33325633-5	2021	Furthermore, berberine suppressed the activation of the EGFR and ErbB2 downstream targets cyclin D1, MMPs, and VEGF by down-regulating the EGFR-ErbB2/PI3K/Akt signaling pathway.	Berberine	13-22	cyclin D1	Homo sapiens	90-99
33325633-5	2021	Furthermore, berberine suppressed the activation of the EGFR and ErbB2 downstream targets cyclin D1, MMPs, and VEGF by down-regulating the EGFR-ErbB2/PI3K/Akt signaling pathway.	Berberine	13-22	vascular endothelial growth factor A	Homo sapiens	111-115
33325633-5	2021	Furthermore, berberine suppressed the activation of the EGFR and ErbB2 downstream targets cyclin D1, MMPs, and VEGF by down-regulating the EGFR-ErbB2/PI3K/Akt signaling pathway.	Berberine	13-22	epidermal growth factor receptor	Homo sapiens	139-143
33325633-5	2021	Furthermore, berberine suppressed the activation of the EGFR and ErbB2 downstream targets cyclin D1, MMPs, and VEGF by down-regulating the EGFR-ErbB2/PI3K/Akt signaling pathway.	Berberine	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-149
33325633-5	2021	Furthermore, berberine suppressed the activation of the EGFR and ErbB2 downstream targets cyclin D1, MMPs, and VEGF by down-regulating the EGFR-ErbB2/PI3K/Akt signaling pathway.	Berberine	13-22	AKT serine/threonine kinase 1	Homo sapiens	155-158
33325633-6	2021	The berberine-mediated inhibition of MMP-2 and MMP-9 activity could be rescued by co-treatment with EGF.	Berberine	4-13	matrix metallopeptidase 2	Homo sapiens	37-42
33325633-6	2021	The berberine-mediated inhibition of MMP-2 and MMP-9 activity could be rescued by co-treatment with EGF.	Berberine	4-13	matrix metallopeptidase 9	Homo sapiens	47-52
33325633-7	2021	Finally, we demonstrated that berberine induced ErbB2 depletion through ubiquitin-mediated proteasome degradation.	Berberine	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-53
33325633-8	2021	In conclusion, the suppressive effects of berberine on the ovarian cancer cells that differ in the expression of EGFR and ErbB2 may be mediated by the dual depletion of EGFR and/or ErbB2.	Berberine	42-51	epidermal growth factor receptor	Homo sapiens	113-117
33325633-8	2021	In conclusion, the suppressive effects of berberine on the ovarian cancer cells that differ in the expression of EGFR and ErbB2 may be mediated by the dual depletion of EGFR and/or ErbB2.	Berberine	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-127
33325633-8	2021	In conclusion, the suppressive effects of berberine on the ovarian cancer cells that differ in the expression of EGFR and ErbB2 may be mediated by the dual depletion of EGFR and/or ErbB2.	Berberine	42-51	epidermal growth factor receptor	Homo sapiens	169-173
33325633-8	2021	In conclusion, the suppressive effects of berberine on the ovarian cancer cells that differ in the expression of EGFR and ErbB2 may be mediated by the dual depletion of EGFR and/or ErbB2.	Berberine	42-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	181-186
33749495-8	2021	Long-chain omega-3 fatty acids, the soy isoflavone genistein, the AMPK activator berberine, glucosamine, and ketone bodies can down-regulate NF-kappaB activation.	Berberine	81-90	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	66-70
33749495-8	2021	Long-chain omega-3 fatty acids, the soy isoflavone genistein, the AMPK activator berberine, glucosamine, and ketone bodies can down-regulate NF-kappaB activation.	Berberine	81-90	nuclear factor kappa B subunit 1	Homo sapiens	141-150
33709493-0	2021	Protective effects of berberine in a rat model of polycystic ovary syndrome mediated via the PI3K/AKT pathway.	Berberine	22-31	AKT serine/threonine kinase 1	Rattus norvegicus	98-101
33709493-2	2021	In the present study, we aimed to elucidate the effect of berberine (Ber) on a rat model of PCOS mediated via the PI3K/AKT signaling pathway.	Berberine	58-67	AKT serine/threonine kinase 1	Rattus norvegicus	119-122
33709493-2	2021	In the present study, we aimed to elucidate the effect of berberine (Ber) on a rat model of PCOS mediated via the PI3K/AKT signaling pathway.	Berberine	69-72	AKT serine/threonine kinase 1	Rattus norvegicus	119-122
33716044-14	2021	In conclusion, berberine-PDT could be used as a chemo-sensitizer by promoting cell death through activation of a ROS/p38/caspase cascade.	Berberine	15-24	mitogen-activated protein kinase 14	Homo sapiens	117-120
33930193-9	2021	Also, reduced prolactin level and acetylcholinesterase, angiotensin-1 converting enzyme, adenosine deaminase and arginase activities were observed in berberine treated diabetic rat with ED.	Berberine	150-159	prolactin	Rattus norvegicus	14-23
33995012-0	2021	Berberine Attenuates Cerebral Ischemia-Reperfusion Injury Induced Neuronal Apoptosis by Down-Regulating the CNPY2 Signaling Pathway.	Berberine	0-9	canopy FGF signaling regulator 2	Rattus norvegicus	108-113
33995012-6	2021	In the ischemic penumbra, the expression levels of CNPY2-regulated endoplasmic reticulum stress-induced apoptosis proteins (CNPY2, glucose-regulated protein 78 (GRP78), double-stranded RNA-activated protein kinase-like ER kinase (PERK), C/EBP homologous protein (CHOP), and Caspase-3) were significantly increased, but these levels were decreased after BBR treatment (p < 0.05).	Berberine	353-356	canopy FGF signaling regulator 2	Rattus norvegicus	51-56
33995012-9	2021	These results confirm that berberine may inhibit CIRI-induced neuronal apoptosis by downregulating the CNPY2 signaling pathway, thereby exerting a neuroprotective effect.	Berberine	27-36	canopy FGF signaling regulator 2	Rattus norvegicus	103-108
34033838-4	2021	In order to gain insights into how these alkaloids could inhibit AChE, berberine, palmatine, and cyclanoline were selected to investigate in terms of binding orientation and their key interactions with AChE using molecular docking and molecular dynamics simulations and quantum chemical calculations.	Berberine	71-80	acetylcholinesterase (Cartwright blood group)	Homo sapiens	65-69
34033838-4	2021	In order to gain insights into how these alkaloids could inhibit AChE, berberine, palmatine, and cyclanoline were selected to investigate in terms of binding orientation and their key interactions with AChE using molecular docking and molecular dynamics simulations and quantum chemical calculations.	Berberine	71-80	acetylcholinesterase (Cartwright blood group)	Homo sapiens	202-206
33981233-13	2021	Conclusion: Berberine can improve obesity and hyperlipidemia by reducing TG, TC, and LDL and increasing HDL; reduce insulin resistance to improve type II diabetes; and prevent diabetic encephalopathy.	Berberine	12-21	insulin	Homo sapiens	116-123
33885638-0	2021	A fluorescent aptasensor based on berberine for ultrasensitive detection of bisphenol A in tap water.	Berberine	34-43	nuclear RNA export factor 1	Homo sapiens	91-94
33880775-5	2021	In the rats" plasma, berberine had good linearity in the range of 0.5-100 ng mL-1 with the lower limit of quantitation of 0.5 ng mL-1 , and the accuracy, intra-day and inter-day precision were less than 12.33%.	Berberine	21-30	L1 cell adhesion molecule	Mus musculus	77-81
33880775-5	2021	In the rats" plasma, berberine had good linearity in the range of 0.5-100 ng mL-1 with the lower limit of quantitation of 0.5 ng mL-1 , and the accuracy, intra-day and inter-day precision were less than 12.33%.	Berberine	21-30	L1 cell adhesion molecule	Mus musculus	129-133
33959010-0	2021	Berberine Regulated miR150-5p to Inhibit P2X7 Receptor, EMMPRIN and MMP-9 Expression in oxLDL Induced Macrophages.	Berberine	0-9	purinergic receptor P2X 7	Homo sapiens	41-54
33959010-0	2021	Berberine Regulated miR150-5p to Inhibit P2X7 Receptor, EMMPRIN and MMP-9 Expression in oxLDL Induced Macrophages.	Berberine	0-9	basigin (Ok blood group)	Homo sapiens	56-63
33959010-0	2021	Berberine Regulated miR150-5p to Inhibit P2X7 Receptor, EMMPRIN and MMP-9 Expression in oxLDL Induced Macrophages.	Berberine	0-9	matrix metallopeptidase 9	Homo sapiens	68-73
33959010-2	2021	Our previous report showed that berberine regulates the expression of both EMMPRIN and MMP-9.	Berberine	32-41	basigin (Ok blood group)	Homo sapiens	75-82
33959010-2	2021	Our previous report showed that berberine regulates the expression of both EMMPRIN and MMP-9.	Berberine	32-41	matrix metallopeptidase 9	Homo sapiens	87-92
33959010-10	2021	Accordingly, exposure to berberine markedly upregulated miR150-5p, decreased P2X7R expression and downregulated MMP-9 and EMMPRIN levels in oxLDL-induced macrophages, resulting in AMPK-alpha/MAPK (JNK, p38, and ERK) inactivation.	Berberine	25-34	purinergic receptor P2X 7	Homo sapiens	77-82
33959010-10	2021	Accordingly, exposure to berberine markedly upregulated miR150-5p, decreased P2X7R expression and downregulated MMP-9 and EMMPRIN levels in oxLDL-induced macrophages, resulting in AMPK-alpha/MAPK (JNK, p38, and ERK) inactivation.	Berberine	25-34	matrix metallopeptidase 9	Homo sapiens	112-117
33959010-10	2021	Accordingly, exposure to berberine markedly upregulated miR150-5p, decreased P2X7R expression and downregulated MMP-9 and EMMPRIN levels in oxLDL-induced macrophages, resulting in AMPK-alpha/MAPK (JNK, p38, and ERK) inactivation.	Berberine	25-34	basigin (Ok blood group)	Homo sapiens	122-129
33959010-10	2021	Accordingly, exposure to berberine markedly upregulated miR150-5p, decreased P2X7R expression and downregulated MMP-9 and EMMPRIN levels in oxLDL-induced macrophages, resulting in AMPK-alpha/MAPK (JNK, p38, and ERK) inactivation.	Berberine	25-34	mitogen-activated protein kinase 8	Homo sapiens	197-200
33959010-10	2021	Accordingly, exposure to berberine markedly upregulated miR150-5p, decreased P2X7R expression and downregulated MMP-9 and EMMPRIN levels in oxLDL-induced macrophages, resulting in AMPK-alpha/MAPK (JNK, p38, and ERK) inactivation.	Berberine	25-34	mitogen-activated protein kinase 14	Homo sapiens	202-205
33959010-10	2021	Accordingly, exposure to berberine markedly upregulated miR150-5p, decreased P2X7R expression and downregulated MMP-9 and EMMPRIN levels in oxLDL-induced macrophages, resulting in AMPK-alpha/MAPK (JNK, p38, and ERK) inactivation.	Berberine	25-34	mitogen-activated protein kinase 1	Homo sapiens	211-214
33959010-11	2021	Overall, these results indicate that berberine increased miR150-5p level, subsequently inhibits P2X7R-mediated EMMPRIN and MMP-9 expression by suppressing AMPK-alpha and MAPK signaling in oxLDL-induced macrophages.	Berberine	37-46	purinergic receptor P2X 7	Homo sapiens	96-101
33959010-11	2021	Overall, these results indicate that berberine increased miR150-5p level, subsequently inhibits P2X7R-mediated EMMPRIN and MMP-9 expression by suppressing AMPK-alpha and MAPK signaling in oxLDL-induced macrophages.	Berberine	37-46	basigin (Ok blood group)	Homo sapiens	111-118
33959010-11	2021	Overall, these results indicate that berberine increased miR150-5p level, subsequently inhibits P2X7R-mediated EMMPRIN and MMP-9 expression by suppressing AMPK-alpha and MAPK signaling in oxLDL-induced macrophages.	Berberine	37-46	matrix metallopeptidase 9	Homo sapiens	123-128
33959013-3	2021	A new oxidation-responsive nano prodrug was constructed from a phenylboronic esters-modified carboxylmethyl chitosan (OC-B) conjugated with berberine (BBR) that degrades selectively in response to ROS.	Berberine	140-149	bone gamma-carboxyglutamate protein 2	Mus musculus	118-122
33959013-3	2021	A new oxidation-responsive nano prodrug was constructed from a phenylboronic esters-modified carboxylmethyl chitosan (OC-B) conjugated with berberine (BBR) that degrades selectively in response to ROS.	Berberine	151-154	bone gamma-carboxyglutamate protein 2	Mus musculus	118-122
33959013-5	2021	OC-B-BBR micelles could effectively encapsulate the anti-inflammatory drug berberine and exhibit ideal H2O2-triggered release behavior as confirmed by in vitro drug loading and release studies.	Berberine	75-84	bone gamma-carboxyglutamate protein 2	Mus musculus	0-4
33544461-6	2021	In dietary-induced obese mouse model, administration of berberine obviously increased cardiac level of KLF4, which closely correlated with improvement of cardiac functional parameters.	Berberine	56-65	Kruppel-like factor 4 (gut)	Mus musculus	103-107
33544461-7	2021	Co-treatment of lentivirus encoding Klf4 siRNA abolished cardioprotective benefits of berberine, including induction of cardiac hypertrophy, fibrosis, functional disorders, inflammatory response and oxidative stress.	Berberine	86-95	Kruppel-like factor 4 (gut)	Mus musculus	36-40
33544461-8	2021	Mechanistically, we found berberine improved cardiac mitochondrial biogenesis and activities, whereas silencing Klf4 decreased berberine-upregulated mitochondrial quality, ATP production and oxygen consumption.	Berberine	127-136	Kruppel-like factor 4 (gut)	Mus musculus	112-116
33544461-9	2021	Our present study demonstrated that berberine protected against dietary-induced cardiac structural disorders and mitochondrial dysfunction dependent on cardiac KLF4 signaling.	Berberine	36-45	Kruppel-like factor 4 (gut)	Mus musculus	160-164
33863898-3	2021	Here, we show that BBR attenuated TMA/TMAO production in the C57BL/6J and ApoE KO mice fed with choline-supplemented chow diet, and mitigated atherosclerotic lesion areas in ApoE KO mice.	Berberine	19-22	apolipoprotein E	Mus musculus	74-78
33863898-3	2021	Here, we show that BBR attenuated TMA/TMAO production in the C57BL/6J and ApoE KO mice fed with choline-supplemented chow diet, and mitigated atherosclerotic lesion areas in ApoE KO mice.	Berberine	19-22	apolipoprotein E	Mus musculus	174-178
33994854-6	2021	BBR ameliorated mitochondrial swelling, facilitated mitochondrial fusion, and reduced mtDNA and citrate synthase activity.	Berberine	0-3	citrate synthase	Mus musculus	96-112
33856290-5	2021	The binding constant values are 9.0 x 105 mol-1 dm3 and 5.7 x 104 mol-1 dm3 for the formation of host: guest complexes of the beta-CD derivative with ethidium bromide and berberine respectively.	Berberine	171-180	ACD shelterin complex subunit and telomerase recruitment factor	Bos taurus	126-133
33856290-6	2021	The proximity of the protons of ethidium bromide and berberine protons with those of the internal cavity of beta-CD in the anthraquinonesulfonyl-beta-CD conjugate is confirmed by two-dimensional rotating-frame Overhauser effect spectroscopy.	Berberine	53-62	ACD shelterin complex subunit and telomerase recruitment factor	Bos taurus	108-115
33924725-0	2021	The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice.	Berberine	19-28	microRNA 122	Mus musculus	158-165
33924725-0	2021	The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice.	Berberine	19-28	microRNA 34a	Mus musculus	170-177
33856290-6	2021	The proximity of the protons of ethidium bromide and berberine protons with those of the internal cavity of beta-CD in the anthraquinonesulfonyl-beta-CD conjugate is confirmed by two-dimensional rotating-frame Overhauser effect spectroscopy.	Berberine	53-62	ACD shelterin complex subunit and telomerase recruitment factor	Bos taurus	145-152
33749932-7	2021	An orally available immunotherapeutic-berberine nanomedicine, named NIT-X, has been developed by our group and has shown significantly increased oral bioavailability of berberine, increased IFN-gamma production by CD8+ T cells, and inhibition of mast cell histamine release in vivo, suggesting a protective immune response.	Berberine	38-47	interferon gamma	Homo sapiens	190-199
33829324-8	2021	Moreover, role of cAMP/PKA/CREB signaling pathway in berberine affecting bone marrow mesenchymal stem cells (BMSCs) differentiation was clarified by enzyme-linked immunosorbent assay and western blot analysis.	Berberine	53-62	cAMP responsive element binding protein 1	Mus musculus	27-31
33829324-11	2021	Furthermore, berberine promotes osteogenic and inhibits adipogenic differentiation of BMSCs via cAMP/PKA/CREB signaling.	Berberine	13-22	cAMP responsive element binding protein 1	Mus musculus	105-109
33749932-7	2021	An orally available immunotherapeutic-berberine nanomedicine, named NIT-X, has been developed by our group and has shown significantly increased oral bioavailability of berberine, increased IFN-gamma production by CD8+ T cells, and inhibition of mast cell histamine release in vivo, suggesting a protective immune response.	Berberine	38-47	CD8a molecule	Homo sapiens	214-217
33174291-0	2021	Apoptotic effect of berberine via Bcl-2, ROR1, and mir-21 in patients with B-chronic lymphocytic leukemia.	Berberine	20-29	BCL2 apoptosis regulator	Homo sapiens	34-39
33849702-0	2021	Berberine prevents diabetic retinopathy through inhibiting HIF-1alpha /VEGF/ NF-kappa B pathway in db/db mice.	Berberine	0-9	hypoxia inducible factor 1, alpha subunit	Mus musculus	59-69
33174291-0	2021	Apoptotic effect of berberine via Bcl-2, ROR1, and mir-21 in patients with B-chronic lymphocytic leukemia.	Berberine	20-29	receptor tyrosine kinase like orphan receptor 1	Homo sapiens	41-45
33849702-0	2021	Berberine prevents diabetic retinopathy through inhibiting HIF-1alpha /VEGF/ NF-kappa B pathway in db/db mice.	Berberine	0-9	vascular endothelial growth factor A	Mus musculus	71-75
33174291-0	2021	Apoptotic effect of berberine via Bcl-2, ROR1, and mir-21 in patients with B-chronic lymphocytic leukemia.	Berberine	20-29	microRNA 21	Homo sapiens	51-57
33849702-0	2021	Berberine prevents diabetic retinopathy through inhibiting HIF-1alpha /VEGF/ NF-kappa B pathway in db/db mice.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	77-87
33174291-9	2021	Examination of treated cells demonstrated that berberine decreased Bcl-2 and ROR1 levels.	Berberine	47-56	BCL2 apoptosis regulator	Homo sapiens	67-72
33174291-9	2021	Examination of treated cells demonstrated that berberine decreased Bcl-2 and ROR1 levels.	Berberine	47-56	receptor tyrosine kinase like orphan receptor 1	Homo sapiens	77-81
33849702-3	2021	Moreover, berberine could protect the retinal morphology against the hyperglycemic insults and decrease glycogen accumulation, the contents of TNF-alpha and IL-1beta in the retinas, as demonstrated by HE staining, PAS staining and ELISA kits, respectively.	Berberine	10-19	tumor necrosis factor	Mus musculus	143-152
33849702-3	2021	Moreover, berberine could protect the retinal morphology against the hyperglycemic insults and decrease glycogen accumulation, the contents of TNF-alpha and IL-1beta in the retinas, as demonstrated by HE staining, PAS staining and ELISA kits, respectively.	Berberine	10-19	interleukin 1 alpha	Mus musculus	157-165
33849702-5	2021	Berberine prevent DR development through modulating the glucolipid metabolism and inhibiting the HIF-1alpha /VEGF/NF-kappa B pathway, suggesting that berberine maybe a potential agent for the treatment of DR.	Berberine	0-9	hypoxia inducible factor 1, alpha subunit	Mus musculus	97-107
33849702-5	2021	Berberine prevent DR development through modulating the glucolipid metabolism and inhibiting the HIF-1alpha /VEGF/NF-kappa B pathway, suggesting that berberine maybe a potential agent for the treatment of DR.	Berberine	0-9	vascular endothelial growth factor A	Mus musculus	109-113
33849702-5	2021	Berberine prevent DR development through modulating the glucolipid metabolism and inhibiting the HIF-1alpha /VEGF/NF-kappa B pathway, suggesting that berberine maybe a potential agent for the treatment of DR.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	114-124
33849702-5	2021	Berberine prevent DR development through modulating the glucolipid metabolism and inhibiting the HIF-1alpha /VEGF/NF-kappa B pathway, suggesting that berberine maybe a potential agent for the treatment of DR.	Berberine	150-159	hypoxia inducible factor 1, alpha subunit	Mus musculus	97-107
33174291-10	2021	Although western blot results did not show any change in Bax as a pro-apoptotic protein, an increased Bax/Bcl-2 ratio indicated that mitochondrial pathway is involved in berberine-induced apoptosis of CLL cells.	Berberine	170-179	BCL2 associated X, apoptosis regulator	Homo sapiens	102-105
33849702-5	2021	Berberine prevent DR development through modulating the glucolipid metabolism and inhibiting the HIF-1alpha /VEGF/NF-kappa B pathway, suggesting that berberine maybe a potential agent for the treatment of DR.	Berberine	150-159	vascular endothelial growth factor A	Mus musculus	109-113
33849702-5	2021	Berberine prevent DR development through modulating the glucolipid metabolism and inhibiting the HIF-1alpha /VEGF/NF-kappa B pathway, suggesting that berberine maybe a potential agent for the treatment of DR.	Berberine	150-159	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	114-124
33174291-10	2021	Although western blot results did not show any change in Bax as a pro-apoptotic protein, an increased Bax/Bcl-2 ratio indicated that mitochondrial pathway is involved in berberine-induced apoptosis of CLL cells.	Berberine	170-179	BCL2 apoptosis regulator	Homo sapiens	106-111
33174291-11	2021	Interestingly, berberine could reduce the expression of miR-21 in comparison to the untreated group.	Berberine	15-24	microRNA 21	Homo sapiens	56-62
33174291-12	2021	Our findings describe some of the molecular mechanisms of berberine by decreasing Bcl-2, ROR1, and mir-21 which may be considered as a novel apoptosis inducer in CLL cells.	Berberine	58-67	BCL2 apoptosis regulator	Homo sapiens	82-87
33174291-12	2021	Our findings describe some of the molecular mechanisms of berberine by decreasing Bcl-2, ROR1, and mir-21 which may be considered as a novel apoptosis inducer in CLL cells.	Berberine	58-67	receptor tyrosine kinase like orphan receptor 1	Homo sapiens	89-93
33174291-12	2021	Our findings describe some of the molecular mechanisms of berberine by decreasing Bcl-2, ROR1, and mir-21 which may be considered as a novel apoptosis inducer in CLL cells.	Berberine	58-67	microRNA 21	Homo sapiens	99-105
33682914-9	2022	Meanwhile, berberine reversed elevated expression of cytokines interleukin-1beta and TNF-alpha in the serum and downregulated nuclear factor kappaB expression.	Berberine	11-20	interleukin 1 beta	Rattus norvegicus	63-80
33982476-6	2021	A total of 14 kinds of traditional Chinese medicine and natural medicine extracts including white peony root, and 21 kinds of natural monomer compounds, including berberine, play an anti-MTX-induced hepatotoxic effect by resisting oxidative stress, inhibiting inflammation and regulating signal pathways.	Berberine	163-172	metaxin 1	Homo sapiens	187-190
33301912-11	2021	Both CCF and berberine suppressed the cellular calcium influx and ROCK-1 expression upon ACh stimulation, demonstrating that berberine was one of the active compounds that contributed to CCF-improved micturition symptoms and function.	Berberine	13-22	Rho-associated coiled-coil containing protein kinase 1	Rattus norvegicus	66-72
33301912-11	2021	Both CCF and berberine suppressed the cellular calcium influx and ROCK-1 expression upon ACh stimulation, demonstrating that berberine was one of the active compounds that contributed to CCF-improved micturition symptoms and function.	Berberine	125-134	Rho-associated coiled-coil containing protein kinase 1	Rattus norvegicus	66-72
33301912-12	2021	CONCLUSIONS: Taken together, our findings give evidence that CCF and its active compound berberine inhibited BPH and bladder dysfunction via Ca2+ and ROCK signaling, supporting their clinical use for BPH and BPH-related LUTS treatment.	Berberine	89-98	Rho-associated coiled-coil containing protein kinase 1	Rattus norvegicus	150-154
33740285-12	2021	Furthermore, berberine decreased GSK3beta Y216 expressions, inhibited the production of oligomer Abeta42 and extended neuronal axon.	Berberine	13-22	glycogen synthase kinase 3 alpha	Homo sapiens	33-41
33740285-13	2021	The monomeric berberine treatment improves IR that may be involved in glucose effective application, rectifying the related proteins of the aberrant insulin pathway.	Berberine	14-23	insulin	Homo sapiens	149-156
33482182-0	2021	Berberine inhibits chemotherapy-exacerbated ovarian cancer stem cell-like characteristics and metastasis through GLI1.	Berberine	0-9	GLI family zinc finger 1	Homo sapiens	113-117
33482182-4	2021	Berberine could not only down-regulate CSC-like characteristics but also reverse EMT and migration through inhibiting chemotherapy-activated GLI1/BMI1 signaling pathway.	Berberine	0-9	GLI family zinc finger 1	Homo sapiens	141-145
33482182-4	2021	Berberine could not only down-regulate CSC-like characteristics but also reverse EMT and migration through inhibiting chemotherapy-activated GLI1/BMI1 signaling pathway.	Berberine	0-9	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	146-150
33682914-9	2022	Meanwhile, berberine reversed elevated expression of cytokines interleukin-1beta and TNF-alpha in the serum and downregulated nuclear factor kappaB expression.	Berberine	11-20	tumor necrosis factor	Rattus norvegicus	85-94
33746756-17	2021	SLC6A4 and MAOA in tryptophan metabolism were modulated by berberine, baicalein, tetrahydroberberine, candicine and may be the main antidepressant targets for HLJDD.	Berberine	59-68	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	0-6
33746756-17	2021	SLC6A4 and MAOA in tryptophan metabolism were modulated by berberine, baicalein, tetrahydroberberine, candicine and may be the main antidepressant targets for HLJDD.	Berberine	59-68	monoamine oxidase A	Mus musculus	11-15
33643762-5	2021	Furthermore, the bioactive compounds such as cordifolioside, berberine, and magnoflorine were appraised as human immunomodulatory and potent inhibitor against Main Protease (Mpro) of SARS-CoV-2 through multiple docking strategies.	Berberine	61-70	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	174-178
33376148-0	2021	The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal FXR Signaling Pathway and Inhibition of Hepatic Gluconeogenesis.	Berberine	27-36	nuclear receptor subfamily 1, group H, member 4	Mus musculus	88-91
33539814-0	2021	Berberine induces anti-atopic dermatitis effects through the downregulation of cutaneous EIF3F and MALT1 in NC/Nga mice with atopy-like dermatitis.	Berberine	0-9	eukaryotic translation initiation factor 3, subunit F	Mus musculus	89-94
33539814-0	2021	Berberine induces anti-atopic dermatitis effects through the downregulation of cutaneous EIF3F and MALT1 in NC/Nga mice with atopy-like dermatitis.	Berberine	0-9	MALT1 paracaspase	Mus musculus	99-104
33539814-0	2021	Berberine induces anti-atopic dermatitis effects through the downregulation of cutaneous EIF3F and MALT1 in NC/Nga mice with atopy-like dermatitis.	Berberine	0-9	reticulon 4	Mus musculus	111-114
33539814-5	2021	In dermatitis mice, intermittent oral administrations of berberine 3 times a week for 12 days inhibited skin symptom, itching, cutaneous infiltration of eosinophils and mast cells, and the expression of cutaneous eotaxin, macrophage migration inhibitory factor (MIF) and IL-4.	Berberine	57-66	chemokine (C-C motif) ligand 11	Mus musculus	213-220
33539814-5	2021	In dermatitis mice, intermittent oral administrations of berberine 3 times a week for 12 days inhibited skin symptom, itching, cutaneous infiltration of eosinophils and mast cells, and the expression of cutaneous eotaxin, macrophage migration inhibitory factor (MIF) and IL-4.	Berberine	57-66	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	222-260
33539814-5	2021	In dermatitis mice, intermittent oral administrations of berberine 3 times a week for 12 days inhibited skin symptom, itching, cutaneous infiltration of eosinophils and mast cells, and the expression of cutaneous eotaxin, macrophage migration inhibitory factor (MIF) and IL-4.	Berberine	57-66	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	262-265
33539814-5	2021	In dermatitis mice, intermittent oral administrations of berberine 3 times a week for 12 days inhibited skin symptom, itching, cutaneous infiltration of eosinophils and mast cells, and the expression of cutaneous eotaxin, macrophage migration inhibitory factor (MIF) and IL-4.	Berberine	57-66	interleukin 4	Mus musculus	271-275
33539814-6	2021	Berberine also attenuated IL-4/MIF-induced eotaxin in fibroblasts and allergen-induced MIF and IL-4 in mast cells.	Berberine	0-9	interleukin 4	Mus musculus	26-30
33539814-6	2021	Berberine also attenuated IL-4/MIF-induced eotaxin in fibroblasts and allergen-induced MIF and IL-4 in mast cells.	Berberine	0-9	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	31-34
33539814-6	2021	Berberine also attenuated IL-4/MIF-induced eotaxin in fibroblasts and allergen-induced MIF and IL-4 in mast cells.	Berberine	0-9	chemokine (C-C motif) ligand 11	Mus musculus	43-50
33539814-6	2021	Berberine also attenuated IL-4/MIF-induced eotaxin in fibroblasts and allergen-induced MIF and IL-4 in mast cells.	Berberine	0-9	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	87-90
33539814-6	2021	Berberine also attenuated IL-4/MIF-induced eotaxin in fibroblasts and allergen-induced MIF and IL-4 in mast cells.	Berberine	0-9	interleukin 4	Mus musculus	95-99
33539814-7	2021	In mast cells, the GeneChip  microarray showed that antigen increased the expression of EIF3F and MALT1, inhibited by berberine.	Berberine	118-127	eukaryotic translation initiation factor 3, subunit F	Mus musculus	88-93
33539814-7	2021	In mast cells, the GeneChip  microarray showed that antigen increased the expression of EIF3F and MALT1, inhibited by berberine.	Berberine	118-127	MALT1 paracaspase	Mus musculus	98-103
33539814-9	2021	These results suggest that berberine improves AD-like symptoms through the inhibition of the eotaxin and pro-inflammatory cytokine expression and the related inflammatory cell recruitment.	Berberine	27-36	chemokine (C-C motif) ligand 11	Mus musculus	93-100
33539814-10	2021	It is also suggested that the downregulation of EIF3F and MALT1 by berberine is involved in suppressing the cytokine expression.	Berberine	67-76	eukaryotic translation initiation factor 3, subunit F	Mus musculus	48-53
33539814-10	2021	It is also suggested that the downregulation of EIF3F and MALT1 by berberine is involved in suppressing the cytokine expression.	Berberine	67-76	MALT1 paracaspase	Mus musculus	58-63
33376148-1	2021	Our previous study suggests that berberine (BBR) lowers lipid by modulating bile acids and activating intestinal farnesoid X receptor (FXR).	Berberine	33-42	nuclear receptor subfamily 1, group H, member 4	Mus musculus	135-138
33376148-1	2021	Our previous study suggests that berberine (BBR) lowers lipid by modulating bile acids and activating intestinal farnesoid X receptor (FXR).	Berberine	44-47	nuclear receptor subfamily 1, group H, member 4	Mus musculus	135-138
33376148-11	2021	Significance Statement This investigation revealed BBR and its metabolite, BRB, significantly lowered blood glucose, mainly through activating intestinal FXR signaling pathway directly by themselves or indirectly by modulating the composition of systemic bile acids, thus inhibited the expression of gluconeogenic genes in the liver, finally reduced hepatic gluconeogenesis and lowered blood glucose.	Berberine	51-54	nuclear receptor subfamily 1, group H, member 4	Mus musculus	154-157
33673431-3	2021	Several berberine-benzothiazole derivatives (BBDs), such as BBD1, BBD3, BBD4, BBD5, BBD7, and BBD11, demonstrated interesting anti-influenza virus activity on influenza A viruses (A/PR/8/34, A/Vic/3/75) and influenza B viral (B/Lee/40, and B/Maryland/1/59) strain, respectively.	Berberine	8-17	b/maryland/1/59	None	240-255
33673431-0	2021	Molecular Docking Studies and Biological Evaluation of Berberine-Benzothiazole Derivatives as an Anti-Influenza Agent via Blocking of Neuraminidase.	Berberine	55-64	neuraminidase 1	Homo sapiens	134-147
33716449-12	2021	RESULTS: Compared with the Mo group, the Me and Be groups displayed significant differences in FBG (P < 0.01) and GLP-1 (P < 0.05).	Berberine	48-50	glucagon	Rattus norvegicus	114-119
33732240-7	2021	Most importantly, berberine treatment protected myocardial cells by decreasing CD4+ and CD8+ T cell infiltration and by inhibiting T cell function in allografts.	Berberine	18-27	CD4 antigen	Mus musculus	79-82
33680978-5	2020	The mechanism underlying the role of berberine in lipid-lowering and insulin resistance is incompletely understood, but one of the possible mechanisms is related to its effect on the gastrointestinal microbiota.	Berberine	37-46	insulin	Homo sapiens	69-76
33340526-0	2021	Berberine regulates macrophage polarization through IL-4-STAT6 signaling pathway in Helicobacter pylori-induced chronic atrophic gastritis.	Berberine	0-9	interleukin 4	Homo sapiens	52-56
33621262-7	2021	RESULTS: Ang II resulted in a significant increase in the blood pressure of mice, which was suppressed by berberine.	Berberine	106-115	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	9-15
33621262-9	2021	Microarray data revealed that 578 lncRNAs and 554 mRNAs were up-regulated, while 320 lncRNAs and 377 mRNAs were down-regulated in the aortae by Ang II; both were reversed by berberine treatment.	Berberine	174-183	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	144-150
33594316-8	2021	BBR also markedly suppressed H/R-triggered excessive mitochondrial ROS generation and inhibited Smad4 expression.	Berberine	0-3	SMAD family member 4	Homo sapiens	96-101
33594316-9	2021	Overexpressing Smad4 in BBR-treated H/R-exposed cardiomyocytes reversed the effect of BBR treatment on apoptosis.	Berberine	24-27	SMAD family member 4	Homo sapiens	15-20
33594316-9	2021	Overexpressing Smad4 in BBR-treated H/R-exposed cardiomyocytes reversed the effect of BBR treatment on apoptosis.	Berberine	86-89	SMAD family member 4	Homo sapiens	15-20
33594316-10	2021	Therefore, BBR protects H/R-treated cardiomyocytes from apoptosis by inhibiting the TGF-beta/Smad4 signaling pathway.	Berberine	11-14	transforming growth factor alpha	Homo sapiens	84-92
33594316-10	2021	Therefore, BBR protects H/R-treated cardiomyocytes from apoptosis by inhibiting the TGF-beta/Smad4 signaling pathway.	Berberine	11-14	SMAD family member 4	Homo sapiens	93-98
33491733-0	2021	Berberine accelerated wound healing by restoring TrxR1/JNK in diabetes.	Berberine	0-9	thioredoxin reductase 1	Homo sapiens	49-54
33491733-0	2021	Berberine accelerated wound healing by restoring TrxR1/JNK in diabetes.	Berberine	0-9	mitogen-activated protein kinase 8	Homo sapiens	55-58
33491733-3	2021	In this study, the effect of berberine (BBR) on diabetic wounds was investigated by utilizing streptozotocin (STZ)-induced diabetic rats and a high glucose-induced cell model, and the mechanism of BBR on TrxR1 was elucidated.	Berberine	29-38	thioredoxin reductase 1	Homo sapiens	204-209
33491733-3	2021	In this study, the effect of berberine (BBR) on diabetic wounds was investigated by utilizing streptozotocin (STZ)-induced diabetic rats and a high glucose-induced cell model, and the mechanism of BBR on TrxR1 was elucidated.	Berberine	197-200	thioredoxin reductase 1	Homo sapiens	204-209
33491733-7	2021	Moreover, in diabetic wounds induced by a combination of STZ injection and high fat diet, BBR significantly increased wound closure rate and TrxR1 expression, and this was reversed by TrxR1 inhibitor.	Berberine	90-93	thioredoxin reductase 1	Homo sapiens	141-146
33491733-7	2021	Moreover, in diabetic wounds induced by a combination of STZ injection and high fat diet, BBR significantly increased wound closure rate and TrxR1 expression, and this was reversed by TrxR1 inhibitor.	Berberine	90-93	thioredoxin reductase 1	Homo sapiens	184-189
33491733-8	2021	These data indicated that topical BBR treatment accelerated diabetic wound healing by activating TrxR1.	Berberine	34-37	thioredoxin reductase 1	Homo sapiens	97-102
33654403-0	2021	Berberine Suppresses Mice Depression Behaviors and Promotes Hippocampal Neurons Growth Through Regulating the miR-34b-5p/miR-470-5p/BDNF Axis.	Berberine	0-9	microRNA 470	Mus musculus	121-128
33654403-0	2021	Berberine Suppresses Mice Depression Behaviors and Promotes Hippocampal Neurons Growth Through Regulating the miR-34b-5p/miR-470-5p/BDNF Axis.	Berberine	0-9	brain derived neurotrophic factor	Mus musculus	132-136
33654403-10	2021	Results: Our data indicated that Berberine could inhibit CUMS mice depression behaviors and enhance hippocampal neurons growth by targeting miR-34b-5p and miR-470-5p.	Berberine	33-42	microRNA 470	Mus musculus	155-162
33654403-13	2021	Furthermore, Berberine could promote BDNF expression to regulate CUMS mice depression behaviors and hippocampal neurons growth.	Berberine	13-22	brain derived neurotrophic factor	Mus musculus	37-41
33654403-14	2021	Conclusion: Berberine might inhibit the progression of depression disorder by regulating the miR-34b-5p/miR-470-5p/BDNF axis.	Berberine	12-21	microRNA 470	Mus musculus	104-111
33654403-14	2021	Conclusion: Berberine might inhibit the progression of depression disorder by regulating the miR-34b-5p/miR-470-5p/BDNF axis.	Berberine	12-21	brain derived neurotrophic factor	Mus musculus	115-119
33376517-11	2021	This prophylactic effect of berberine was associated with reduced phosphorylation of p65 and with decreased levels of pro-inflammatory cytokines IL-6 and TNF-alpha.	Berberine	28-37	tumor necrosis factor	Rattus norvegicus	154-163
33376517-11	2021	This prophylactic effect of berberine was associated with reduced phosphorylation of p65 and with decreased levels of pro-inflammatory cytokines IL-6 and TNF-alpha.	Berberine	28-37	synaptotagmin 1	Rattus norvegicus	85-88
33376517-11	2021	This prophylactic effect of berberine was associated with reduced phosphorylation of p65 and with decreased levels of pro-inflammatory cytokines IL-6 and TNF-alpha.	Berberine	28-37	interleukin 6	Rattus norvegicus	145-149
32000592-2	2021	This study was aimed at developing a method for the preparation of Berberine nanoparticles (Nano-Ber) in order to improve its aqueous-phase solubility and its complex formation with human serum albumin (HSA) and holo-transferrin (HTF) from the viewpoint of interaction behavior.	Berberine	67-76	transferrin	Homo sapiens	217-228
33454441-8	2021	In addition, molecular docking revealed that both berberine and quercetin could bond with NOS2 and PPARalpha, respectively.	Berberine	50-59	nitric oxide synthase 2	Homo sapiens	90-94
33454441-8	2021	In addition, molecular docking revealed that both berberine and quercetin could bond with NOS2 and PPARalpha, respectively.	Berberine	50-59	peroxisome proliferator activated receptor alpha	Homo sapiens	99-108
33340526-0	2021	Berberine regulates macrophage polarization through IL-4-STAT6 signaling pathway in Helicobacter pylori-induced chronic atrophic gastritis.	Berberine	0-9	signal transducer and activator of transcription 6	Homo sapiens	57-62
33340526-11	2021	The mRNA expression of M1-polarized Mphis, including TNF-alpha, NOS2, CCR7, and IRF-8, were suppressed by BBR administration and the mRNA expression of M2-polarized Mphis, including IL-4, STAT6, IL-10 and Chil3, were increased by BBR intervention.	Berberine	106-109	tumor necrosis factor	Homo sapiens	53-62
33340526-11	2021	The mRNA expression of M1-polarized Mphis, including TNF-alpha, NOS2, CCR7, and IRF-8, were suppressed by BBR administration and the mRNA expression of M2-polarized Mphis, including IL-4, STAT6, IL-10 and Chil3, were increased by BBR intervention.	Berberine	106-109	nitric oxide synthase 2	Homo sapiens	64-68
33340526-11	2021	The mRNA expression of M1-polarized Mphis, including TNF-alpha, NOS2, CCR7, and IRF-8, were suppressed by BBR administration and the mRNA expression of M2-polarized Mphis, including IL-4, STAT6, IL-10 and Chil3, were increased by BBR intervention.	Berberine	106-109	C-C motif chemokine receptor 7	Homo sapiens	70-74
33340526-11	2021	The mRNA expression of M1-polarized Mphis, including TNF-alpha, NOS2, CCR7, and IRF-8, were suppressed by BBR administration and the mRNA expression of M2-polarized Mphis, including IL-4, STAT6, IL-10 and Chil3, were increased by BBR intervention.	Berberine	106-109	interferon regulatory factor 8	Homo sapiens	80-85
33340526-15	2021	BBR activates IL-4-STAT6 signaling pathway, which is crucial exceedingly in M2 Mphis activation and anti-inflammatory response.	Berberine	0-3	interleukin 4	Homo sapiens	14-18
33340526-15	2021	BBR activates IL-4-STAT6 signaling pathway, which is crucial exceedingly in M2 Mphis activation and anti-inflammatory response.	Berberine	0-3	signal transducer and activator of transcription 6	Homo sapiens	19-24
32524150-0	2021	Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio.	Berberine	0-9	retinoic acid receptor responder 2	Rattus norvegicus	65-73
32524150-0	2021	Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio.	Berberine	0-9	chemerin chemokine-like receptor 1	Rattus norvegicus	74-80
32524150-9	2021	Moreover, the protein and mRNA expression of chemerin, CMKLR1 and CCR2 in the liver were obviously reduced by BBR treatment.	Berberine	110-113	retinoic acid receptor responder 2	Rattus norvegicus	45-53
32524150-9	2021	Moreover, the protein and mRNA expression of chemerin, CMKLR1 and CCR2 in the liver were obviously reduced by BBR treatment.	Berberine	110-113	chemerin chemokine-like receptor 1	Rattus norvegicus	55-61
32524150-9	2021	Moreover, the protein and mRNA expression of chemerin, CMKLR1 and CCR2 in the liver were obviously reduced by BBR treatment.	Berberine	110-113	C-C motif chemokine receptor 2	Rattus norvegicus	66-70
32524150-11	2021	Berberine can ameliorate non-alcoholic steatohepatitis, and its mechanism may be related to restoring the Treg/Th17 ratio, regulating the chemerin/CMKLR1 signalling pathway to reduce liver inflammation and reducing lipid deposition.	Berberine	0-9	retinoic acid receptor responder 2	Rattus norvegicus	138-146
32524150-11	2021	Berberine can ameliorate non-alcoholic steatohepatitis, and its mechanism may be related to restoring the Treg/Th17 ratio, regulating the chemerin/CMKLR1 signalling pathway to reduce liver inflammation and reducing lipid deposition.	Berberine	0-9	chemerin chemokine-like receptor 1	Rattus norvegicus	147-153
33285228-0	2021	Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites.	Berberine	0-9	aryl hydrocarbon receptor	Rattus norvegicus	41-44
33285228-6	2021	At last, our in vitro mechanism exploration was implemented with a Caco-2 cell monolayer model, which verified that the modulation of the dysregulated gut microbiota to change microbial metabolites coordinated the improvement effect of BBR on gut barrier disruption in the colitis, and we also confirmed that the activation of AhR induced by microbial metabolites is indispensable to the improvement of gut barrier disruption by BBR.	Berberine	236-239	aryl hydrocarbon receptor	Homo sapiens	327-330
33285228-7	2021	Collectively, BBR has the capacity to treat DSS-induced colitis in rats through the regulation of gut microbiota associated tryptophan metabolite to activate AhR, which can greatly improve the disrupted gut barrier function.	Berberine	14-17	aryl hydrocarbon receptor	Rattus norvegicus	158-161
33544523-5	2021	However, berberine (IC50=0.17 mg/mL) had slight higher AChE inhibitory effect than piperine and neostigmine (p<0.05).	Berberine	9-18	acetylcholinesterase (Cartwright blood group)	Homo sapiens	55-59
33544523-6	2021	Also, berberine had the highest BChE inhibitory effect (IC50=0.16 mg/mL) while piperine exhibited the highest MAO inhibitory effect (IC50=0.21 mg/mL).	Berberine	6-15	butyrylcholinesterase	Homo sapiens	32-36
33544523-9	2021	The modulatory and antioxidant berberine and piperine properties on these enzymes (AChE, BChE and MAO) could be possible underlying mechanisms in employing these compounds as a complementary therapy in neurodegenerative diseases (NDDs) management.	Berberine	31-40	acetylcholinesterase (Cartwright blood group)	Homo sapiens	83-87
33544523-9	2021	The modulatory and antioxidant berberine and piperine properties on these enzymes (AChE, BChE and MAO) could be possible underlying mechanisms in employing these compounds as a complementary therapy in neurodegenerative diseases (NDDs) management.	Berberine	31-40	butyrylcholinesterase	Homo sapiens	89-93
33584302-0	2020	Berberine Protects Against NLRP3 Inflammasome via Ameliorating Autophagic Impairment in MPTP-Induced Parkinson"s Disease Model.	Berberine	0-9	NLR family, pyrin domain containing 3	Mus musculus	27-32
33584302-3	2020	However, the effect of Berberine on NLRP3 inflammasome in PD and its potential mechanisms remain unclear.	Berberine	23-32	NLR family, pyrin domain containing 3	Mus musculus	36-41
33584302-7	2020	In our in vivo studies, compared to MPTP group, mice in MPTP + BBR group showed significant amelioration of behavioral disorders, mitigation of neurotoxicity and NLRP3-associated neuroinflammation, enhancement of the autophagic process in substantia nigra (SN).	Berberine	63-66	NLR family, pyrin domain containing 3	Mus musculus	162-167
33442785-4	2021	Herein, co-encapsulated pegylated liposomal formulation of mitoxantrone (MIT) and berberine (BER) at an optimal ratio has been developed (MBL) with high encapsulation efficiency (EE) and drug loading in order to achieve the purpose of ratiometric loading and delivery.	Berberine	82-91	mannose-binding lectin (protein C) 2	Mus musculus	138-141
33442785-4	2021	Herein, co-encapsulated pegylated liposomal formulation of mitoxantrone (MIT) and berberine (BER) at an optimal ratio has been developed (MBL) with high encapsulation efficiency (EE) and drug loading in order to achieve the purpose of ratiometric loading and delivery.	Berberine	93-96	mannose-binding lectin (protein C) 2	Mus musculus	138-141
33450878-6	2021	Further analyses exhibited that berberine treatment caused G0/G1 phase arrest at 48 h due to high cyclin D1 (CCND1) and low cyclin-dependent kinase 4 (CDK4) protein and mRNA levels, simultaneous downregulation of human telomerase reverse transcriptase (TERT) mRNA and human telomerase RNA component (TERC) levels, as well as a decrease in the TERT protein level and telomerase activity.	Berberine	32-41	cyclin D1	Homo sapiens	98-107
33450878-6	2021	Further analyses exhibited that berberine treatment caused G0/G1 phase arrest at 48 h due to high cyclin D1 (CCND1) and low cyclin-dependent kinase 4 (CDK4) protein and mRNA levels, simultaneous downregulation of human telomerase reverse transcriptase (TERT) mRNA and human telomerase RNA component (TERC) levels, as well as a decrease in the TERT protein level and telomerase activity.	Berberine	32-41	cyclin D1	Homo sapiens	109-114
33450878-6	2021	Further analyses exhibited that berberine treatment caused G0/G1 phase arrest at 48 h due to high cyclin D1 (CCND1) and low cyclin-dependent kinase 4 (CDK4) protein and mRNA levels, simultaneous downregulation of human telomerase reverse transcriptase (TERT) mRNA and human telomerase RNA component (TERC) levels, as well as a decrease in the TERT protein level and telomerase activity.	Berberine	32-41	cyclin dependent kinase 4	Homo sapiens	124-149
33450878-6	2021	Further analyses exhibited that berberine treatment caused G0/G1 phase arrest at 48 h due to high cyclin D1 (CCND1) and low cyclin-dependent kinase 4 (CDK4) protein and mRNA levels, simultaneous downregulation of human telomerase reverse transcriptase (TERT) mRNA and human telomerase RNA component (TERC) levels, as well as a decrease in the TERT protein level and telomerase activity.	Berberine	32-41	cyclin dependent kinase 4	Homo sapiens	151-155
33450878-6	2021	Further analyses exhibited that berberine treatment caused G0/G1 phase arrest at 48 h due to high cyclin D1 (CCND1) and low cyclin-dependent kinase 4 (CDK4) protein and mRNA levels, simultaneous downregulation of human telomerase reverse transcriptase (TERT) mRNA and human telomerase RNA component (TERC) levels, as well as a decrease in the TERT protein level and telomerase activity.	Berberine	32-41	telomerase reverse transcriptase	Homo sapiens	219-251
33450878-6	2021	Further analyses exhibited that berberine treatment caused G0/G1 phase arrest at 48 h due to high cyclin D1 (CCND1) and low cyclin-dependent kinase 4 (CDK4) protein and mRNA levels, simultaneous downregulation of human telomerase reverse transcriptase (TERT) mRNA and human telomerase RNA component (TERC) levels, as well as a decrease in the TERT protein level and telomerase activity.	Berberine	32-41	telomerase reverse transcriptase	Homo sapiens	253-257
33450878-6	2021	Further analyses exhibited that berberine treatment caused G0/G1 phase arrest at 48 h due to high cyclin D1 (CCND1) and low cyclin-dependent kinase 4 (CDK4) protein and mRNA levels, simultaneous downregulation of human telomerase reverse transcriptase (TERT) mRNA and human telomerase RNA component (TERC) levels, as well as a decrease in the TERT protein level and telomerase activity.	Berberine	32-41	telomerase RNA component	Homo sapiens	300-304
33450878-6	2021	Further analyses exhibited that berberine treatment caused G0/G1 phase arrest at 48 h due to high cyclin D1 (CCND1) and low cyclin-dependent kinase 4 (CDK4) protein and mRNA levels, simultaneous downregulation of human telomerase reverse transcriptase (TERT) mRNA and human telomerase RNA component (TERC) levels, as well as a decrease in the TERT protein level and telomerase activity.	Berberine	32-41	telomerase reverse transcriptase	Homo sapiens	343-347
33307514-6	2021	Concomitant with enlarged colonic patches, the cultured colon of infected mice treated with berberine secreted significantly higher levels of interleukin-1beta (IL-1beta), IL-6, TNF-alpha, and CCL-2, while NLRP3 inhibitor MMC950 or knockout of NLRP3 gene abrogated berberine-induced hypertrophy of colonic patches, suggesting the involvement of the NLRP3 signaling pathway in this process.	Berberine	92-101	interleukin 1 beta	Mus musculus	142-159
33348308-3	2021	Berberine, extracted from Chinese medicine, can identify bitter taste receptor on intestinal Tuft cells and activate IL-25-ILC2-IL-13 immune pathway to impair damaged intestinal tract by promoting differentiation of intestinal stem cells, which might be a potential approach for the treatment of UC.	Berberine	0-9	interleukin 25	Homo sapiens	117-122
33348308-3	2021	Berberine, extracted from Chinese medicine, can identify bitter taste receptor on intestinal Tuft cells and activate IL-25-ILC2-IL-13 immune pathway to impair damaged intestinal tract by promoting differentiation of intestinal stem cells, which might be a potential approach for the treatment of UC.	Berberine	0-9	interleukin 13	Homo sapiens	128-133
33407557-2	2021	Berberine (BBR) has many pharmacological properties and is used as an insulin sensitizer.	Berberine	0-9	insulin	Homo sapiens	70-77
33407557-2	2021	Berberine (BBR) has many pharmacological properties and is used as an insulin sensitizer.	Berberine	11-14	insulin	Homo sapiens	70-77
33407557-10	2021	RESULTS: BBR reduced the levels of insulin resistance and testosterone in PCOS rats.	Berberine	9-12	insulin	Homo sapiens	35-42
33407557-13	2021	CONCLUSIONS: BBR may relieve PCOS pathology and IR values by inhibiting cell apoptosis and by regulating the expression levels of TLR4, LYN, PI3K, Akt, NF-kB, TNF-alpha, IL-1, IL-6, and caspase-3.	Berberine	13-16	toll-like receptor 4	Rattus norvegicus	130-134
33407557-13	2021	CONCLUSIONS: BBR may relieve PCOS pathology and IR values by inhibiting cell apoptosis and by regulating the expression levels of TLR4, LYN, PI3K, Akt, NF-kB, TNF-alpha, IL-1, IL-6, and caspase-3.	Berberine	13-16	LYN proto-oncogene, Src family tyrosine kinase	Rattus norvegicus	136-139
33407557-13	2021	CONCLUSIONS: BBR may relieve PCOS pathology and IR values by inhibiting cell apoptosis and by regulating the expression levels of TLR4, LYN, PI3K, Akt, NF-kB, TNF-alpha, IL-1, IL-6, and caspase-3.	Berberine	13-16	AKT serine/threonine kinase 1	Rattus norvegicus	147-150
33407557-13	2021	CONCLUSIONS: BBR may relieve PCOS pathology and IR values by inhibiting cell apoptosis and by regulating the expression levels of TLR4, LYN, PI3K, Akt, NF-kB, TNF-alpha, IL-1, IL-6, and caspase-3.	Berberine	13-16	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	152-157
33407557-13	2021	CONCLUSIONS: BBR may relieve PCOS pathology and IR values by inhibiting cell apoptosis and by regulating the expression levels of TLR4, LYN, PI3K, Akt, NF-kB, TNF-alpha, IL-1, IL-6, and caspase-3.	Berberine	13-16	tumor necrosis factor	Rattus norvegicus	159-168
33407557-13	2021	CONCLUSIONS: BBR may relieve PCOS pathology and IR values by inhibiting cell apoptosis and by regulating the expression levels of TLR4, LYN, PI3K, Akt, NF-kB, TNF-alpha, IL-1, IL-6, and caspase-3.	Berberine	13-16	interleukin 6	Rattus norvegicus	176-180
33407557-13	2021	CONCLUSIONS: BBR may relieve PCOS pathology and IR values by inhibiting cell apoptosis and by regulating the expression levels of TLR4, LYN, PI3K, Akt, NF-kB, TNF-alpha, IL-1, IL-6, and caspase-3.	Berberine	13-16	caspase 3	Rattus norvegicus	186-195
33506010-10	2021	Moreover, the TNF-alpha decreased significantly accompanied by the increase of berberine, chlorogenic acid, jatrorrhizine, palmatine, evodin, and evodiamine in serum (negative correlation, p < 0.05).	Berberine	79-88	tumor necrosis factor	Rattus norvegicus	14-23
33407764-0	2021	Berberine inhibited metastasis through miR-145/MMP16 axis in vitro.	Berberine	0-9	microRNA 145	Homo sapiens	39-46
33407764-0	2021	Berberine inhibited metastasis through miR-145/MMP16 axis in vitro.	Berberine	0-9	matrix metallopeptidase 16	Homo sapiens	47-52
33407764-10	2021	The results demonstrated berberine inhibited proliferation, migration and invasion, promoted miR-145 expression, and decreased MMP16 expression in SKOV3 and 3AO cells.	Berberine	25-34	microRNA 145	Homo sapiens	93-100
33407764-10	2021	The results demonstrated berberine inhibited proliferation, migration and invasion, promoted miR-145 expression, and decreased MMP16 expression in SKOV3 and 3AO cells.	Berberine	25-34	matrix metallopeptidase 16	Homo sapiens	127-132
33407764-12	2021	Moreover, downregulation of MMP16 contributed to the inhibition of proliferation, migration and invasion by berberine.	Berberine	108-117	matrix metallopeptidase 16	Homo sapiens	28-33
33407764-13	2021	Together, our results revealed that berberine inhibited proliferation, migration and invasion through miR-145/MMP16 in SKOV3 and 3AO cells, highlighting the potentiality of berberine to be used as a therapeutic agent for ovarian cancer.	Berberine	36-45	microRNA 145	Homo sapiens	102-109
33407764-13	2021	Together, our results revealed that berberine inhibited proliferation, migration and invasion through miR-145/MMP16 in SKOV3 and 3AO cells, highlighting the potentiality of berberine to be used as a therapeutic agent for ovarian cancer.	Berberine	36-45	matrix metallopeptidase 16	Homo sapiens	110-115
33407764-13	2021	Together, our results revealed that berberine inhibited proliferation, migration and invasion through miR-145/MMP16 in SKOV3 and 3AO cells, highlighting the potentiality of berberine to be used as a therapeutic agent for ovarian cancer.	Berberine	173-182	microRNA 145	Homo sapiens	102-109
33407764-13	2021	Together, our results revealed that berberine inhibited proliferation, migration and invasion through miR-145/MMP16 in SKOV3 and 3AO cells, highlighting the potentiality of berberine to be used as a therapeutic agent for ovarian cancer.	Berberine	173-182	matrix metallopeptidase 16	Homo sapiens	110-115
32895042-9	2021	Berberine markedly downregulated the expression of both TNF-alpha and IL1beta and inhibits TNF-alpha and IL-1beta secretion from LPS-stimulated PBMCs.	Berberine	0-9	tumor necrosis factor	Homo sapiens	56-65
32895042-9	2021	Berberine markedly downregulated the expression of both TNF-alpha and IL1beta and inhibits TNF-alpha and IL-1beta secretion from LPS-stimulated PBMCs.	Berberine	0-9	interleukin 1 alpha	Homo sapiens	70-77
32895042-9	2021	Berberine markedly downregulated the expression of both TNF-alpha and IL1beta and inhibits TNF-alpha and IL-1beta secretion from LPS-stimulated PBMCs.	Berberine	0-9	tumor necrosis factor	Homo sapiens	91-100
32895042-9	2021	Berberine markedly downregulated the expression of both TNF-alpha and IL1beta and inhibits TNF-alpha and IL-1beta secretion from LPS-stimulated PBMCs.	Berberine	0-9	interleukin 1 alpha	Homo sapiens	105-113
32895042-10	2021	DISCUSSION: This study provided molecular basis for anti-inflammatory effect of berberine on human mononuclear cells through the suppression of TNF-a and IL-1secretion.	Berberine	80-89	tumor necrosis factor	Homo sapiens	144-149
32895042-10	2021	DISCUSSION: This study provided molecular basis for anti-inflammatory effect of berberine on human mononuclear cells through the suppression of TNF-a and IL-1secretion.	Berberine	80-89	interleukin 1 alpha	Homo sapiens	154-158
32895042-12	2021	We observed that berberine at high concentration exhibited anti-inflammatory effect in PBMCs of both healthy and patient groups by suppression of TNF-a and IL-1cytokines at both mRNA and protein levels.	Berberine	17-26	tumor necrosis factor	Homo sapiens	146-151
32988344-0	2021	Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate-Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/Protein Kinase B (PI3K/AKT) Signaling Pathways.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	52-100
32988344-0	2021	Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate-Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/Protein Kinase B (PI3K/AKT) Signaling Pathways.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	102-106
32988344-0	2021	Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate-Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/Protein Kinase B (PI3K/AKT) Signaling Pathways.	Berberine	0-9	protein tyrosine kinase 2 beta	Homo sapiens	146-162
32988344-0	2021	Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate-Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/Protein Kinase B (PI3K/AKT) Signaling Pathways.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	169-172
32988344-6	2021	Most of these mechanisms converge on regulation of the balance of AMPK and PI3K/AKT signaling by berberine.	Berberine	97-106	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	66-70
32988344-6	2021	Most of these mechanisms converge on regulation of the balance of AMPK and PI3K/AKT signaling by berberine.	Berberine	97-106	AKT serine/threonine kinase 1	Homo sapiens	80-83
32988344-7	2021	CONCLUSION: This evidence supports the possibility that berberine is a promising anti-cancer natural product, with pharmaceutical potential in inhibiting cancer growth, metastasis and angiogenesis via multiple pathways, particularly by regulating the balance of AMPK and PI3K/AKT signaling.	Berberine	56-65	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	262-266
32988344-7	2021	CONCLUSION: This evidence supports the possibility that berberine is a promising anti-cancer natural product, with pharmaceutical potential in inhibiting cancer growth, metastasis and angiogenesis via multiple pathways, particularly by regulating the balance of AMPK and PI3K/AKT signaling.	Berberine	56-65	AKT serine/threonine kinase 1	Homo sapiens	276-279
33459225-8	2021	Regarding terpenoids and alkaloids, nimbin, withaferin A, andrographolide, zingiberene and, berberine, piperine and thebaine, respectively, showed binding affinity with molecular ACE-2 target in silico.	Berberine	92-101	angiotensin converting enzyme 2	Homo sapiens	179-184
33307514-6	2021	Concomitant with enlarged colonic patches, the cultured colon of infected mice treated with berberine secreted significantly higher levels of interleukin-1beta (IL-1beta), IL-6, TNF-alpha, and CCL-2, while NLRP3 inhibitor MMC950 or knockout of NLRP3 gene abrogated berberine-induced hypertrophy of colonic patches, suggesting the involvement of the NLRP3 signaling pathway in this process.	Berberine	92-101	interleukin 1 alpha	Mus musculus	161-169
33307514-6	2021	Concomitant with enlarged colonic patches, the cultured colon of infected mice treated with berberine secreted significantly higher levels of interleukin-1beta (IL-1beta), IL-6, TNF-alpha, and CCL-2, while NLRP3 inhibitor MMC950 or knockout of NLRP3 gene abrogated berberine-induced hypertrophy of colonic patches, suggesting the involvement of the NLRP3 signaling pathway in this process.	Berberine	92-101	interleukin 6	Mus musculus	172-176
33307514-6	2021	Concomitant with enlarged colonic patches, the cultured colon of infected mice treated with berberine secreted significantly higher levels of interleukin-1beta (IL-1beta), IL-6, TNF-alpha, and CCL-2, while NLRP3 inhibitor MMC950 or knockout of NLRP3 gene abrogated berberine-induced hypertrophy of colonic patches, suggesting the involvement of the NLRP3 signaling pathway in this process.	Berberine	92-101	tumor necrosis factor	Mus musculus	178-187
33307514-6	2021	Concomitant with enlarged colonic patches, the cultured colon of infected mice treated with berberine secreted significantly higher levels of interleukin-1beta (IL-1beta), IL-6, TNF-alpha, and CCL-2, while NLRP3 inhibitor MMC950 or knockout of NLRP3 gene abrogated berberine-induced hypertrophy of colonic patches, suggesting the involvement of the NLRP3 signaling pathway in this process.	Berberine	92-101	chemokine (C-C motif) ligand 2	Mus musculus	193-198
33307514-6	2021	Concomitant with enlarged colonic patches, the cultured colon of infected mice treated with berberine secreted significantly higher levels of interleukin-1beta (IL-1beta), IL-6, TNF-alpha, and CCL-2, while NLRP3 inhibitor MMC950 or knockout of NLRP3 gene abrogated berberine-induced hypertrophy of colonic patches, suggesting the involvement of the NLRP3 signaling pathway in this process.	Berberine	92-101	NLR family, pyrin domain containing 3	Mus musculus	206-211
33307514-6	2021	Concomitant with enlarged colonic patches, the cultured colon of infected mice treated with berberine secreted significantly higher levels of interleukin-1beta (IL-1beta), IL-6, TNF-alpha, and CCL-2, while NLRP3 inhibitor MMC950 or knockout of NLRP3 gene abrogated berberine-induced hypertrophy of colonic patches, suggesting the involvement of the NLRP3 signaling pathway in this process.	Berberine	92-101	NLR family, pyrin domain containing 3	Mus musculus	244-249
33307514-6	2021	Concomitant with enlarged colonic patches, the cultured colon of infected mice treated with berberine secreted significantly higher levels of interleukin-1beta (IL-1beta), IL-6, TNF-alpha, and CCL-2, while NLRP3 inhibitor MMC950 or knockout of NLRP3 gene abrogated berberine-induced hypertrophy of colonic patches, suggesting the involvement of the NLRP3 signaling pathway in this process.	Berberine	92-101	NLR family, pyrin domain containing 3	Mus musculus	244-249
33361598-0	2021	Ameliorating Ribosylation-Induced Amyloid-beta Pathology by Berberine via Inhibiting mTOR/p70S6K Signaling.	Berberine	60-69	mechanistic target of rapamycin kinase	Mus musculus	85-89
33361598-0	2021	Ameliorating Ribosylation-Induced Amyloid-beta Pathology by Berberine via Inhibiting mTOR/p70S6K Signaling.	Berberine	60-69	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	90-96
33361598-1	2021	BACKGROUND: Berberine (BBR) plays a neuroprotective role in the pathogenesis of Alzheimer"s disease (AD), inhibiting amyloid-beta (Abeta) production and promoting Abeta clearance.	Berberine	12-21	amyloid beta (A4) precursor protein	Mus musculus	131-136
33361598-1	2021	BACKGROUND: Berberine (BBR) plays a neuroprotective role in the pathogenesis of Alzheimer"s disease (AD), inhibiting amyloid-beta (Abeta) production and promoting Abeta clearance.	Berberine	12-21	amyloid beta (A4) precursor protein	Mus musculus	163-168
33361598-1	2021	BACKGROUND: Berberine (BBR) plays a neuroprotective role in the pathogenesis of Alzheimer"s disease (AD), inhibiting amyloid-beta (Abeta) production and promoting Abeta clearance.	Berberine	23-26	amyloid beta (A4) precursor protein	Mus musculus	131-136
33361598-1	2021	BACKGROUND: Berberine (BBR) plays a neuroprotective role in the pathogenesis of Alzheimer"s disease (AD), inhibiting amyloid-beta (Abeta) production and promoting Abeta clearance.	Berberine	23-26	amyloid beta (A4) precursor protein	Mus musculus	163-168
33361598-4	2021	This work focused on whether BBR regulates the production and clearance of ribosylation-induced Abeta pathology via inhibiting mTOR signaling.	Berberine	29-32	amyloid beta (A4) precursor protein	Mus musculus	96-101
33361598-4	2021	This work focused on whether BBR regulates the production and clearance of ribosylation-induced Abeta pathology via inhibiting mTOR signaling.	Berberine	29-32	mechanistic target of rapamycin kinase	Mus musculus	127-131
33361598-5	2021	OBJECTIVE: To explore whether BBR ameliorates ribosylation-induced Abeta pathology in APP/PS1 mice.	Berberine	30-33	amyloid beta (A4) precursor protein	Mus musculus	67-72
33361598-5	2021	OBJECTIVE: To explore whether BBR ameliorates ribosylation-induced Abeta pathology in APP/PS1 mice.	Berberine	30-33	presenilin 1	Mus musculus	90-93
33361598-11	2021	BBR reduces the activity of BACE1 and gamma-secretase induced by D-ribose, and enhances Abeta-degrading enzymes and Neprilysin, and inhibits the expression of Abeta in APP/PS1 mice.	Berberine	0-3	beta-site APP cleaving enzyme 1	Mus musculus	28-33
33361598-11	2021	BBR reduces the activity of BACE1 and gamma-secretase induced by D-ribose, and enhances Abeta-degrading enzymes and Neprilysin, and inhibits the expression of Abeta in APP/PS1 mice.	Berberine	0-3	amyloid beta (A4) precursor protein	Mus musculus	88-93
33361598-11	2021	BBR reduces the activity of BACE1 and gamma-secretase induced by D-ribose, and enhances Abeta-degrading enzymes and Neprilysin, and inhibits the expression of Abeta in APP/PS1 mice.	Berberine	0-3	membrane metallo endopeptidase	Mus musculus	116-126
33361598-11	2021	BBR reduces the activity of BACE1 and gamma-secretase induced by D-ribose, and enhances Abeta-degrading enzymes and Neprilysin, and inhibits the expression of Abeta in APP/PS1 mice.	Berberine	0-3	amyloid beta (A4) precursor protein	Mus musculus	159-164
33361598-11	2021	BBR reduces the activity of BACE1 and gamma-secretase induced by D-ribose, and enhances Abeta-degrading enzymes and Neprilysin, and inhibits the expression of Abeta in APP/PS1 mice.	Berberine	0-3	presenilin 1	Mus musculus	172-175
33361598-12	2021	CONCLUSION: BBR ameliorates ribosylation-induced Abeta pathology via inhibiting mTOR/p70S6K signaling and improves spatial learning and memory of the APP/PS1 mice.	Berberine	12-15	amyloid beta (A4) precursor protein	Mus musculus	49-54
33361598-12	2021	CONCLUSION: BBR ameliorates ribosylation-induced Abeta pathology via inhibiting mTOR/p70S6K signaling and improves spatial learning and memory of the APP/PS1 mice.	Berberine	12-15	mechanistic target of rapamycin kinase	Mus musculus	80-84
33361598-12	2021	CONCLUSION: BBR ameliorates ribosylation-induced Abeta pathology via inhibiting mTOR/p70S6K signaling and improves spatial learning and memory of the APP/PS1 mice.	Berberine	12-15	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	85-91
33361598-12	2021	CONCLUSION: BBR ameliorates ribosylation-induced Abeta pathology via inhibiting mTOR/p70S6K signaling and improves spatial learning and memory of the APP/PS1 mice.	Berberine	12-15	presenilin 1	Mus musculus	154-157
33391417-0	2021	Berberine inhibits the Warburg effect through TET3/miR-145/HK2 pathways in ovarian cancer cells.	Berberine	0-9	tet methylcytosine dioxygenase 3	Homo sapiens	46-50
33391417-0	2021	Berberine inhibits the Warburg effect through TET3/miR-145/HK2 pathways in ovarian cancer cells.	Berberine	0-9	microRNA 145	Homo sapiens	51-58
33391417-0	2021	Berberine inhibits the Warburg effect through TET3/miR-145/HK2 pathways in ovarian cancer cells.	Berberine	0-9	hexokinase 2	Homo sapiens	59-62
33391417-3	2021	Methods: Treatment by berberine in SKOV3 and 3AO cells or inhibited by miR-145 inhibitor transfection in berberine-treated cells to examine the changes in HK2 expression, glucose consumption and lactate production.	Berberine	105-114	microRNA 145	Homo sapiens	71-78
33391417-7	2021	Results: We found berberine inhibited the Warburg effect by up-regulating miR-145, miR-145 targeted HK2 directly.	Berberine	18-27	microRNA 145	Homo sapiens	74-81
33391417-7	2021	Results: We found berberine inhibited the Warburg effect by up-regulating miR-145, miR-145 targeted HK2 directly.	Berberine	18-27	microRNA 145	Homo sapiens	83-90
33391417-7	2021	Results: We found berberine inhibited the Warburg effect by up-regulating miR-145, miR-145 targeted HK2 directly.	Berberine	18-27	hexokinase 2	Homo sapiens	100-103
33391417-8	2021	Berberine increased the expression of miR-145 by promoting the expression of TET3 and reducing the methylation level of the promoter region of miR-145 precursor gene.	Berberine	0-9	microRNA 145	Homo sapiens	38-45
33391417-8	2021	Berberine increased the expression of miR-145 by promoting the expression of TET3 and reducing the methylation level of the promoter region of miR-145 precursor gene.	Berberine	0-9	tet methylcytosine dioxygenase 3	Homo sapiens	77-81
33391417-8	2021	Berberine increased the expression of miR-145 by promoting the expression of TET3 and reducing the methylation level of the promoter region of miR-145 precursor gene.	Berberine	0-9	microRNA 145	Homo sapiens	143-150
33391417-10	2021	Conclusions: Our results revealed berberine increased the TET3-mediated demethylation and promoted the suppression of miR-145 on HK2 to antagonize the Warburg effect of ovarian cancer cells.	Berberine	34-43	tet methylcytosine dioxygenase 3	Homo sapiens	58-62
33391417-10	2021	Conclusions: Our results revealed berberine increased the TET3-mediated demethylation and promoted the suppression of miR-145 on HK2 to antagonize the Warburg effect of ovarian cancer cells.	Berberine	34-43	microRNA 145	Homo sapiens	118-125
33391417-10	2021	Conclusions: Our results revealed berberine increased the TET3-mediated demethylation and promoted the suppression of miR-145 on HK2 to antagonize the Warburg effect of ovarian cancer cells.	Berberine	34-43	hexokinase 2	Homo sapiens	129-132
33130557-0	2021	Berberine represses beta-catenin translation involving 4E-BPs in hepatocellular carcinoma cells.	Berberine	0-9	catenin beta 1	Homo sapiens	20-32
33130557-3	2021	While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner.	Berberine	119-128	catenin beta 1	Homo sapiens	53-65
33130557-3	2021	While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner.	Berberine	119-128	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	158-186
33130557-3	2021	While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner.	Berberine	119-128	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	188-192
33130557-3	2021	While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner.	Berberine	119-128	catenin beta 1	Homo sapiens	206-218
33130557-3	2021	While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner.	Berberine	130-133	catenin beta 1	Homo sapiens	53-65
33130557-3	2021	While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner.	Berberine	130-133	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	158-186
33130557-3	2021	While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner.	Berberine	130-133	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	188-192
33130557-3	2021	While studying pharmaceutical agents that can target beta-catenin in cancer cells, we observed that the plant compound berberine (BBR), a potent activator of AMP-activated protein kinase (AMPK), can reduce beta-catenin expression and downstream signaling in HCC cells in a dose dependent manner.	Berberine	130-133	catenin beta 1	Homo sapiens	206-218
33130557-4	2021	More in depth analyses to understand the mechanism revealed that BBR-induced reduction of beta-catenin occurs independently of AMPK activation, and does-not involve transcriptional or post-translational mechanisms.	Berberine	65-68	catenin beta 1	Homo sapiens	90-102
33130557-4	2021	More in depth analyses to understand the mechanism revealed that BBR-induced reduction of beta-catenin occurs independently of AMPK activation, and does-not involve transcriptional or post-translational mechanisms.	Berberine	65-68	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	127-131
33130557-5	2021	Pretreatment with protein synthesis inhibitor Cycloheximide antagonized BBR-induced beta-catenin reduction, suggesting that BBR affects beta-catenin translation.	Berberine	72-75	catenin beta 1	Homo sapiens	84-96
33130557-5	2021	Pretreatment with protein synthesis inhibitor Cycloheximide antagonized BBR-induced beta-catenin reduction, suggesting that BBR affects beta-catenin translation.	Berberine	72-75	catenin beta 1	Homo sapiens	136-148
33130557-5	2021	Pretreatment with protein synthesis inhibitor Cycloheximide antagonized BBR-induced beta-catenin reduction, suggesting that BBR affects beta-catenin translation.	Berberine	124-127	catenin beta 1	Homo sapiens	84-96
33130557-5	2021	Pretreatment with protein synthesis inhibitor Cycloheximide antagonized BBR-induced beta-catenin reduction, suggesting that BBR affects beta-catenin translation.	Berberine	124-127	catenin beta 1	Homo sapiens	136-148
33130557-6	2021	BBR treatment also antagonized mTOR activity, and was associated with increased recruitment of eIF4E-binding protein 1 (4E-BP1) in the translational complex, as revealed by m7-cap-binding assays, suggesting inhibition of cap-dependent translation.	Berberine	0-3	mechanistic target of rapamycin kinase	Homo sapiens	31-35
33130557-6	2021	BBR treatment also antagonized mTOR activity, and was associated with increased recruitment of eIF4E-binding protein 1 (4E-BP1) in the translational complex, as revealed by m7-cap-binding assays, suggesting inhibition of cap-dependent translation.	Berberine	0-3	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	95-118
33130557-6	2021	BBR treatment also antagonized mTOR activity, and was associated with increased recruitment of eIF4E-binding protein 1 (4E-BP1) in the translational complex, as revealed by m7-cap-binding assays, suggesting inhibition of cap-dependent translation.	Berberine	0-3	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	120-126
33130557-7	2021	Interestingly, knocking down 4E-BP1 and -2 significantly attenuated BBR-induced reduction of beta-catenin levels and expression of its downstream target genes.	Berberine	68-71	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	29-42
33130557-7	2021	Interestingly, knocking down 4E-BP1 and -2 significantly attenuated BBR-induced reduction of beta-catenin levels and expression of its downstream target genes.	Berberine	68-71	catenin beta 1	Homo sapiens	93-105
32688361-0	2021	Berberine Promotes the Proliferation and Osteogenic Differentiation of Alveolar Osteoblasts through Regulating the Expression of miR-214.	Berberine	0-9	microRNA 214	Homo sapiens	129-136
32688361-9	2021	Different concentrations of BBR significantly promoted the proliferation of HAOBs and increased the expression levels of ALP, osteocalcin (OCN), collagen type I alpha 1 (COL1A1), runt related transcription factor 2 (RUNX2), and osterix (OSX).	Berberine	28-31	alkaline phosphatase, placental	Homo sapiens	121-124
32688361-9	2021	Different concentrations of BBR significantly promoted the proliferation of HAOBs and increased the expression levels of ALP, osteocalcin (OCN), collagen type I alpha 1 (COL1A1), runt related transcription factor 2 (RUNX2), and osterix (OSX).	Berberine	28-31	bone gamma-carboxyglutamate protein	Homo sapiens	126-137
32688361-9	2021	Different concentrations of BBR significantly promoted the proliferation of HAOBs and increased the expression levels of ALP, osteocalcin (OCN), collagen type I alpha 1 (COL1A1), runt related transcription factor 2 (RUNX2), and osterix (OSX).	Berberine	28-31	bone gamma-carboxyglutamate protein	Homo sapiens	139-142
32688361-9	2021	Different concentrations of BBR significantly promoted the proliferation of HAOBs and increased the expression levels of ALP, osteocalcin (OCN), collagen type I alpha 1 (COL1A1), runt related transcription factor 2 (RUNX2), and osterix (OSX).	Berberine	28-31	collagen type I alpha 1 chain	Homo sapiens	145-168
32688361-9	2021	Different concentrations of BBR significantly promoted the proliferation of HAOBs and increased the expression levels of ALP, osteocalcin (OCN), collagen type I alpha 1 (COL1A1), runt related transcription factor 2 (RUNX2), and osterix (OSX).	Berberine	28-31	collagen type I alpha 1 chain	Homo sapiens	170-176
32688361-9	2021	Different concentrations of BBR significantly promoted the proliferation of HAOBs and increased the expression levels of ALP, osteocalcin (OCN), collagen type I alpha 1 (COL1A1), runt related transcription factor 2 (RUNX2), and osterix (OSX).	Berberine	28-31	RUNX family transcription factor 2	Homo sapiens	179-214
32688361-9	2021	Different concentrations of BBR significantly promoted the proliferation of HAOBs and increased the expression levels of ALP, osteocalcin (OCN), collagen type I alpha 1 (COL1A1), runt related transcription factor 2 (RUNX2), and osterix (OSX).	Berberine	28-31	RUNX family transcription factor 2	Homo sapiens	216-221
32688361-9	2021	Different concentrations of BBR significantly promoted the proliferation of HAOBs and increased the expression levels of ALP, osteocalcin (OCN), collagen type I alpha 1 (COL1A1), runt related transcription factor 2 (RUNX2), and osterix (OSX).	Berberine	28-31	Sp7 transcription factor	Homo sapiens	228-235
32688361-9	2021	Different concentrations of BBR significantly promoted the proliferation of HAOBs and increased the expression levels of ALP, osteocalcin (OCN), collagen type I alpha 1 (COL1A1), runt related transcription factor 2 (RUNX2), and osterix (OSX).	Berberine	28-31	Sp7 transcription factor	Homo sapiens	237-240
32688361-10	2021	Moreover, the expression of miR-214 was reduced as BBR concentrations increased, and the increase of miR-214 reversed the BBR-induced proliferation and osteogenic differentiation of HAOBs.	Berberine	51-54	microRNA 214	Homo sapiens	28-35
32688361-10	2021	Moreover, the expression of miR-214 was reduced as BBR concentrations increased, and the increase of miR-214 reversed the BBR-induced proliferation and osteogenic differentiation of HAOBs.	Berberine	122-125	microRNA 214	Homo sapiens	101-108
33645072-19	2021	The results of molecular docking showed that limonin, palmatine and berberine could bind to CASP3 and MMP9 by hydrogen bond.	Berberine	68-77	caspase 3	Mus musculus	92-97
33645072-19	2021	The results of molecular docking showed that limonin, palmatine and berberine could bind to CASP3 and MMP9 by hydrogen bond.	Berberine	68-77	matrix metallopeptidase 9	Mus musculus	102-106
33645072-21	2021	The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1beta, IL-6 and TNF-alpha in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated.	Berberine	167-176	interleukin 1 alpha	Mus musculus	98-106
33645072-21	2021	The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1beta, IL-6 and TNF-alpha in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated.	Berberine	167-176	interleukin 6	Mus musculus	108-112
33645072-21	2021	The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1beta, IL-6 and TNF-alpha in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated.	Berberine	167-176	tumor necrosis factor	Mus musculus	117-126
33645072-21	2021	The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1beta, IL-6 and TNF-alpha in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated.	Berberine	167-176	interleukin 17A	Mus musculus	188-193
33645072-21	2021	The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1beta, IL-6 and TNF-alpha in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated.	Berberine	167-176	tumor necrosis factor	Mus musculus	117-120
33645072-21	2021	The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1beta, IL-6 and TNF-alpha in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated.	Berberine	167-176	caspase 3	Mus musculus	236-241
33645072-21	2021	The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1beta, IL-6 and TNF-alpha in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated.	Berberine	167-176	matrix metallopeptidase 9	Mus musculus	246-250
33426081-6	2020	Results: The active components of ZR-CR-shogaol, daucosterol, ginkgetin, berberine, quercetin, chlorogenic acid, and vanillic acid-exhibited antitumor activities via the MAPK, PI3K-AKT, TNF, FOXO, HIF-1, and VEGF signaling pathways.	Berberine	73-82	AKT serine/threonine kinase 1	Homo sapiens	181-184
33426081-6	2020	Results: The active components of ZR-CR-shogaol, daucosterol, ginkgetin, berberine, quercetin, chlorogenic acid, and vanillic acid-exhibited antitumor activities via the MAPK, PI3K-AKT, TNF, FOXO, HIF-1, and VEGF signaling pathways.	Berberine	73-82	tumor necrosis factor	Homo sapiens	186-189
33426081-6	2020	Results: The active components of ZR-CR-shogaol, daucosterol, ginkgetin, berberine, quercetin, chlorogenic acid, and vanillic acid-exhibited antitumor activities via the MAPK, PI3K-AKT, TNF, FOXO, HIF-1, and VEGF signaling pathways.	Berberine	73-82	hypoxia inducible factor 1 subunit alpha	Homo sapiens	197-202
33426081-6	2020	Results: The active components of ZR-CR-shogaol, daucosterol, ginkgetin, berberine, quercetin, chlorogenic acid, and vanillic acid-exhibited antitumor activities via the MAPK, PI3K-AKT, TNF, FOXO, HIF-1, and VEGF signaling pathways.	Berberine	73-82	vascular endothelial growth factor A	Homo sapiens	208-212
33426081-7	2020	Molecular docking and SPR analyses suggested direct binding of berberine with AKT1 and TP53; quercetin with EGFR and VEGF165; and ginkgetin, isoginkgetin, and daucosterol with VEGF165 with weak affinities.	Berberine	63-72	AKT serine/threonine kinase 1	Homo sapiens	78-82
33426081-7	2020	Molecular docking and SPR analyses suggested direct binding of berberine with AKT1 and TP53; quercetin with EGFR and VEGF165; and ginkgetin, isoginkgetin, and daucosterol with VEGF165 with weak affinities.	Berberine	63-72	tumor protein p53	Homo sapiens	87-91
33292691-3	2020	There are many Nrf2-interacting nutrients (berberine, curcumin, epigallocatechin gallate, genistein, quercetin, resveratrol, sulforaphane) that all act similarly to reduce insulin resistance, endothelial damage, lung injury and cytokine storm.	Berberine	43-52	NFE2 like bZIP transcription factor 2	Homo sapiens	15-19
33354502-0	2020	Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5.	Berberine	0-9	CD274 antigen	Mus musculus	33-38
33354502-0	2020	Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5.	Berberine	0-9	COP9 signalosome subunit 5	Mus musculus	133-137
33354502-3	2020	Here we identified berberine (BBR), a proven anti-inflammation drug, as a negative regulator of PD-L1 from a set of traditional Chinese medicine (TCM) chemical monomers.	Berberine	19-28	CD274 molecule	Sus scrofa	96-101
33354502-4	2020	BBR enhanced the sensitivity of tumour cells to co-cultured T-cells by decreasing the level of PD-L1 in cancer cells.	Berberine	0-3	CD274 molecule	Sus scrofa	95-100
33440945-0	2021	Berberine Directly Targets the NEK7 Protein to Block the NEK7-NLRP3 Interaction and Exert Anti-inflammatory Activity.	Berberine	0-9	NIMA related kinase 7	Homo sapiens	31-35
33440945-0	2021	Berberine Directly Targets the NEK7 Protein to Block the NEK7-NLRP3 Interaction and Exert Anti-inflammatory Activity.	Berberine	0-9	NIMA related kinase 7	Homo sapiens	57-61
33440945-0	2021	Berberine Directly Targets the NEK7 Protein to Block the NEK7-NLRP3 Interaction and Exert Anti-inflammatory Activity.	Berberine	0-9	NLR family pyrin domain containing 3	Homo sapiens	62-67
33440945-4	2021	Moreover, BBR displays in vivo anti-inflammatory efficacy in a NEK7-dependent manner.	Berberine	10-13	NIMA related kinase 7	Homo sapiens	63-67
33390968-0	2020	Adipose Tissue SIRT1 Regulates Insulin Sensitizing and Anti-Inflammatory Effects of Berberine.	Berberine	84-93	sirtuin 1	Mus musculus	15-20
33390968-1	2020	Berberine (BBR), which is an active component of Coptis chinensis Franch, has been reported to improve glucose metabolism and insulin resistance in animal and human studies, predominantly via activation of the 5"-adenosine monophosphate kinase (AMPK) pathway and suppression of the inflammation response.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	210-243
33390968-1	2020	Berberine (BBR), which is an active component of Coptis chinensis Franch, has been reported to improve glucose metabolism and insulin resistance in animal and human studies, predominantly via activation of the 5"-adenosine monophosphate kinase (AMPK) pathway and suppression of the inflammation response.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	245-249
33390968-1	2020	Berberine (BBR), which is an active component of Coptis chinensis Franch, has been reported to improve glucose metabolism and insulin resistance in animal and human studies, predominantly via activation of the 5"-adenosine monophosphate kinase (AMPK) pathway and suppression of the inflammation response.	Berberine	11-14	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	210-243
33390968-1	2020	Berberine (BBR), which is an active component of Coptis chinensis Franch, has been reported to improve glucose metabolism and insulin resistance in animal and human studies, predominantly via activation of the 5"-adenosine monophosphate kinase (AMPK) pathway and suppression of the inflammation response.	Berberine	11-14	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	245-249
33390968-3	2020	In this present study, we found that BBR upregulated SIRT1 expression in 3T3L-1 adipocytes and adipose tissue.	Berberine	37-40	sirtuin 1	Homo sapiens	53-58
33390968-4	2020	Inhibition of SIRT1 blunted the BBR-induced increase in glucose consumption and uptake in adipocytes.	Berberine	32-35	sirtuin 1	Homo sapiens	14-19
33390968-5	2020	The BBR-induced activation of the AMPK pathway and AKT phosphorylation in adipocytes and adipose tissue were also attenuated by inhibition or knockout of Sirt1.	Berberine	4-7	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	34-38
33390968-5	2020	The BBR-induced activation of the AMPK pathway and AKT phosphorylation in adipocytes and adipose tissue were also attenuated by inhibition or knockout of Sirt1.	Berberine	4-7	thymoma viral proto-oncogene 1	Mus musculus	51-54
33390968-5	2020	The BBR-induced activation of the AMPK pathway and AKT phosphorylation in adipocytes and adipose tissue were also attenuated by inhibition or knockout of Sirt1.	Berberine	4-7	sirtuin 1	Homo sapiens	154-159
33390968-6	2020	The BBR-induced improvement of systemic insulin sensitivity was impaired by Sirt1 knockout in HFD-induced obese mice.	Berberine	4-7	sirtuin 1	Mus musculus	76-81
33390968-8	2020	The BBR-induced decrease in PGC-1alpha acetylation was reversed by inhibition or knockout of Sirt1 in adipocytes and adipose tissue.	Berberine	4-7	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	28-38
33390968-8	2020	The BBR-induced decrease in PGC-1alpha acetylation was reversed by inhibition or knockout of Sirt1 in adipocytes and adipose tissue.	Berberine	4-7	sirtuin 1	Mus musculus	93-98
33390968-9	2020	Together, these results indicate that adipose tissue SIRT1 is a key regulator of the insulin sensitizing and anti-inflammatory effects of BBR, which contributes to the improvement of metabolic dysregulation.	Berberine	138-141	sirtuin 1	Mus musculus	53-58
33415147-6	2020	In the second experiment, we set out to validate the effect of BBR on central neuropeptide Y (NPY) stimulated rats.	Berberine	63-66	neuropeptide Y	Rattus norvegicus	78-92
33415147-6	2020	In the second experiment, we set out to validate the effect of BBR on central neuropeptide Y (NPY) stimulated rats.	Berberine	63-66	neuropeptide Y	Rattus norvegicus	94-97
33415147-10	2020	In the first experiment, treatment with BBR in the HF diet mice reduced food intake, body weight, fat contents, serum leptin, and glucose level.	Berberine	40-43	leptin	Mus musculus	118-124
33415147-12	2020	Also, the serum glucose level in the NPY+BBR (100 nM) group was significantly lower than that in the NPY (100 nM) group.	Berberine	41-44	neuropeptide Y	Mus musculus	37-40
33298057-0	2020	Berberine reduces temozolomide resistance by inducing autophagy via the ERK1/2 signaling pathway in glioblastoma.	Berberine	0-9	mitogen-activated protein kinase 3	Mus musculus	72-78
33298057-5	2020	RESULTS: Through these experiments, our findings indicated that berberine enhanced autophagy and apoptosis in TMZ-resistant cells upon TMZ treatment in a manner that was linked with ERK1/2 signaling.	Berberine	64-73	mitogen-activated protein kinase 3	Mus musculus	182-188
33298057-6	2020	Similarly, when used in vivo, berberine increased GBM sensitivity to TMZ through ERK1/2 signaling pathways.	Berberine	30-39	mitogen-activated protein kinase 3	Mus musculus	81-87
33298057-7	2020	CONCLUSIONS: These findings demonstrate that berberine is an effective method of increasing the sensitization of GBM cells to TMZ treatment in a manner that is dependent upon the ERK1/2-mediated induction of autophagy, thus making berberine a potentially viable therapeutic agent for GBM treatment.	Berberine	45-54	mitogen-activated protein kinase 3	Mus musculus	179-185
33298057-7	2020	CONCLUSIONS: These findings demonstrate that berberine is an effective method of increasing the sensitization of GBM cells to TMZ treatment in a manner that is dependent upon the ERK1/2-mediated induction of autophagy, thus making berberine a potentially viable therapeutic agent for GBM treatment.	Berberine	231-240	mitogen-activated protein kinase 3	Mus musculus	179-185
33362566-0	2020	Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	98-101
33362566-0	2020	Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	102-106
33362566-7	2020	Furthermore, berberine treatment concentration-dependently down-regulated the multidrug resistance-associated protein 1 and multi-drug resistance-1 protein levels in the BGC-823/DDP and SGC7901/DDP cells.	Berberine	13-22	ATP binding cassette subfamily C member 1	Homo sapiens	78-119
33362566-7	2020	Furthermore, berberine treatment concentration-dependently down-regulated the multidrug resistance-associated protein 1 and multi-drug resistance-1 protein levels in the BGC-823/DDP and SGC7901/DDP cells.	Berberine	13-22	ATP binding cassette subfamily B member 1	Homo sapiens	124-147
33362566-10	2020	Mechanistically, berberine significantly suppressed the PI3K/AKT/mTOR in the BGC-823/DDP and SGC-7901/DDP cells treated with DDP.	Berberine	17-26	AKT serine/threonine kinase 1	Homo sapiens	61-64
33362566-10	2020	Mechanistically, berberine significantly suppressed the PI3K/AKT/mTOR in the BGC-823/DDP and SGC-7901/DDP cells treated with DDP.	Berberine	17-26	mechanistic target of rapamycin kinase	Homo sapiens	65-69
33362566-12	2020	Further mechanistic findings suggested that berberine-mediated DDP-sensitivity may be associated with reduced expression of drug transporters (multi-drug resistance-1 and multidrug resistance-associated protein 1), enhanced apoptosis and repressed PI3K/AKT/mTOR signaling.	Berberine	44-53	ATP binding cassette subfamily C member 1	Homo sapiens	124-212
33362566-12	2020	Further mechanistic findings suggested that berberine-mediated DDP-sensitivity may be associated with reduced expression of drug transporters (multi-drug resistance-1 and multidrug resistance-associated protein 1), enhanced apoptosis and repressed PI3K/AKT/mTOR signaling.	Berberine	44-53	AKT serine/threonine kinase 1	Homo sapiens	253-256
33362566-12	2020	Further mechanistic findings suggested that berberine-mediated DDP-sensitivity may be associated with reduced expression of drug transporters (multi-drug resistance-1 and multidrug resistance-associated protein 1), enhanced apoptosis and repressed PI3K/AKT/mTOR signaling.	Berberine	44-53	mechanistic target of rapamycin kinase	Homo sapiens	257-261
32815562-9	2020	Berberine-mediated radiosensitization was associated with elevated levels of LC3II and p62 suggesting blocked autophagy that was followed by mitotic catastrophe and senescence.	Berberine	0-9	nucleoporin 62	Homo sapiens	87-90
33010366-9	2020	The checkerboard assay showed that 32 mug mL-1 berberine and 64 mug mL-1 thymol was a synergistic combination, concentrations below their cytotoxicity limits for many cells.	Berberine	47-56	L1 cell adhesion molecule	Mus musculus	42-46
32393087-0	2020	Berberine attenuates fructose-induced insulin resistance by stimulating the hepatic LKB1/AMPK/PGC1alpha pathway in mice.	Berberine	0-9	serine/threonine kinase 11	Mus musculus	84-88
32393087-0	2020	Berberine attenuates fructose-induced insulin resistance by stimulating the hepatic LKB1/AMPK/PGC1alpha pathway in mice.	Berberine	0-9	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	94-103
32393087-6	2020	The hepatic AMP and ATP contents were detected using high performance liquid chromatography (HPLC) analysis, and the protein expression was examined by immunoblotting.Results: Berberine significantly reversed the insulin resistance induced by fructose, including lowering fasting insulin levels (from 113.9 to 67.4) and area under the curve (AUC) during OGTT (from 1310 to 1073), decreasing serum leptin (from 0.28 to 0.13) and increasing serum adiponectin levels (from 1.50 to 2.80).	Berberine	176-185	leptin	Mus musculus	397-403
32393087-6	2020	The hepatic AMP and ATP contents were detected using high performance liquid chromatography (HPLC) analysis, and the protein expression was examined by immunoblotting.Results: Berberine significantly reversed the insulin resistance induced by fructose, including lowering fasting insulin levels (from 113.9 to 67.4) and area under the curve (AUC) during OGTT (from 1310 to 1073), decreasing serum leptin (from 0.28 to 0.13) and increasing serum adiponectin levels (from 1.50 to 2.80).	Berberine	176-185	adiponectin, C1Q and collagen domain containing	Mus musculus	445-456
32393087-7	2020	Moreover, berberine enhanced the phosphorylation levels of protein kinase B (PKB/AKT; 2.27-fold) and glycogen synthase kinase-3beta (GSK3beta; 2.56-fold), and increased hepatic glycogen content (from 0.19 to 1.65).	Berberine	10-19	thymoma viral proto-oncogene 1	Mus musculus	77-80
32393087-7	2020	Moreover, berberine enhanced the phosphorylation levels of protein kinase B (PKB/AKT; 2.27-fold) and glycogen synthase kinase-3beta (GSK3beta; 2.56-fold), and increased hepatic glycogen content (from 0.19 to 1.65).	Berberine	10-19	thymoma viral proto-oncogene 1	Mus musculus	81-84
32393087-7	2020	Moreover, berberine enhanced the phosphorylation levels of protein kinase B (PKB/AKT; 2.27-fold) and glycogen synthase kinase-3beta (GSK3beta; 2.56-fold), and increased hepatic glycogen content (from 0.19 to 1.65).	Berberine	10-19	glycogen synthase kinase 3 beta	Mus musculus	101-131
32393087-7	2020	Moreover, berberine enhanced the phosphorylation levels of protein kinase B (PKB/AKT; 2.27-fold) and glycogen synthase kinase-3beta (GSK3beta; 2.56-fold), and increased hepatic glycogen content (from 0.19 to 1.65).	Berberine	10-19	glycogen synthase kinase 3 alpha	Mus musculus	133-141
33011398-8	2020	Treatment with berberine associated with photodynamic therapy promoted an increase in the production of reactive species of oxygen (ROS) and caspase-3 activity, indicating a preferential cell death mechanism by caspase-dependent apoptosis.	Berberine	15-24	caspase 3	Homo sapiens	141-150
33626003-0	2020	Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-kappaB pathway.	Berberine	0-9	toll-like receptor 4	Rattus norvegicus	93-97
33626003-0	2020	Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-kappaB pathway.	Berberine	0-9	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	98-103
33626003-10	2020	RESULTS: BBR could significantly alleviate the liver tissue steatosis and inflammatory cell infiltration; reduce the NAFLD activity scores and serum levels of ALT, AST, TC, and LDL-C; decrease the levels of TNF-alpha, IL-6, and IL-1beta, and reduce the expression of TLR4, MyD88, and NF-kappaB in the liver tissues.	Berberine	9-12	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	164-167
33626003-10	2020	RESULTS: BBR could significantly alleviate the liver tissue steatosis and inflammatory cell infiltration; reduce the NAFLD activity scores and serum levels of ALT, AST, TC, and LDL-C; decrease the levels of TNF-alpha, IL-6, and IL-1beta, and reduce the expression of TLR4, MyD88, and NF-kappaB in the liver tissues.	Berberine	9-12	tumor necrosis factor	Rattus norvegicus	207-216
33626003-10	2020	RESULTS: BBR could significantly alleviate the liver tissue steatosis and inflammatory cell infiltration; reduce the NAFLD activity scores and serum levels of ALT, AST, TC, and LDL-C; decrease the levels of TNF-alpha, IL-6, and IL-1beta, and reduce the expression of TLR4, MyD88, and NF-kappaB in the liver tissues.	Berberine	9-12	interleukin 6	Rattus norvegicus	218-222
33626003-10	2020	RESULTS: BBR could significantly alleviate the liver tissue steatosis and inflammatory cell infiltration; reduce the NAFLD activity scores and serum levels of ALT, AST, TC, and LDL-C; decrease the levels of TNF-alpha, IL-6, and IL-1beta, and reduce the expression of TLR4, MyD88, and NF-kappaB in the liver tissues.	Berberine	9-12	interleukin 1 alpha	Rattus norvegicus	228-236
33626003-10	2020	RESULTS: BBR could significantly alleviate the liver tissue steatosis and inflammatory cell infiltration; reduce the NAFLD activity scores and serum levels of ALT, AST, TC, and LDL-C; decrease the levels of TNF-alpha, IL-6, and IL-1beta, and reduce the expression of TLR4, MyD88, and NF-kappaB in the liver tissues.	Berberine	9-12	toll-like receptor 4	Rattus norvegicus	267-271
33626003-10	2020	RESULTS: BBR could significantly alleviate the liver tissue steatosis and inflammatory cell infiltration; reduce the NAFLD activity scores and serum levels of ALT, AST, TC, and LDL-C; decrease the levels of TNF-alpha, IL-6, and IL-1beta, and reduce the expression of TLR4, MyD88, and NF-kappaB in the liver tissues.	Berberine	9-12	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	273-278
33626003-12	2020	CONCLUSION: BBR alleviated the progress of NAFLD and liver damage, which might contribute to inhibit the nuclear translocation of NF-kappaB via the TLR4/MyD88/NF-kappaB pathway.	Berberine	12-15	toll-like receptor 4	Rattus norvegicus	148-152
33626003-12	2020	CONCLUSION: BBR alleviated the progress of NAFLD and liver damage, which might contribute to inhibit the nuclear translocation of NF-kappaB via the TLR4/MyD88/NF-kappaB pathway.	Berberine	12-15	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	153-158
33496116-9	2020	The results of molecular docking showed that baicalein,berberine,licochalcone A and 6-gingerol had a high affinity with SRC,STAT3,TNF and IL6.	Berberine	55-64	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	120-123
33496116-9	2020	The results of molecular docking showed that baicalein,berberine,licochalcone A and 6-gingerol had a high affinity with SRC,STAT3,TNF and IL6.	Berberine	55-64	signal transducer and activator of transcription 3	Homo sapiens	124-129
33496116-9	2020	The results of molecular docking showed that baicalein,berberine,licochalcone A and 6-gingerol had a high affinity with SRC,STAT3,TNF and IL6.	Berberine	55-64	tumor necrosis factor	Homo sapiens	130-133
33496116-9	2020	The results of molecular docking showed that baicalein,berberine,licochalcone A and 6-gingerol had a high affinity with SRC,STAT3,TNF and IL6.	Berberine	55-64	interleukin 6	Homo sapiens	138-141
33312221-0	2020	Berberine Inhibits the Expression of SCT through miR-214-3p Stimulation in Breast Cancer Cells.	Berberine	0-9	secretin	Homo sapiens	37-40
33312221-5	2020	Both BBR and miR-214-3p mimic reduced the cell viability, repressed migration and invasion capacities, increased rates of total apoptotic cells and ratio of Bax/Bcl-2, and increased the percentage of G2/M cells of MCF-7 and MDA-MB-231 cells by colony formation and CKK8 assay, scratch wound healing and gelatin-based 3D conformation assay, transwell invasion assay, and cell cycle analysis, respectively.	Berberine	5-8	BCL2 associated X, apoptosis regulator	Homo sapiens	157-160
33312221-5	2020	Both BBR and miR-214-3p mimic reduced the cell viability, repressed migration and invasion capacities, increased rates of total apoptotic cells and ratio of Bax/Bcl-2, and increased the percentage of G2/M cells of MCF-7 and MDA-MB-231 cells by colony formation and CKK8 assay, scratch wound healing and gelatin-based 3D conformation assay, transwell invasion assay, and cell cycle analysis, respectively.	Berberine	5-8	BCL2 apoptosis regulator	Homo sapiens	161-166
33312221-10	2020	In conclusion, BBR suppressed MCF-7 and MDA-MB-231 breast cancer cells by upregulating miR-214-3p and increasing its inhibition to SCT.	Berberine	15-18	secretin	Homo sapiens	131-134
33262612-0	2020	Berberine Inhibits Cell Proliferation by Interfering with Wild-Type and Mutant P53 in Human Glioma Cells.	Berberine	0-9	tumor protein p53	Homo sapiens	79-82
33262612-12	2020	Results: Berberine promoted the phosphorylation of wtp53, increased the expression of p21 protein, reduced cyclin D1 content, and caused G1 phase arrest in U87 cells.	Berberine	9-18	cyclin D1	Mus musculus	107-116
33262612-13	2020	Berberine also reduced mutp53 content and caused G2 phase arrest in U251 cells with a concurrent decrease in p21, cyclin D1, and cyclin B1 content.	Berberine	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	109-112
33262612-13	2020	Berberine also reduced mutp53 content and caused G2 phase arrest in U251 cells with a concurrent decrease in p21, cyclin D1, and cyclin B1 content.	Berberine	0-9	cyclin D1	Homo sapiens	114-123
33262612-13	2020	Berberine also reduced mutp53 content and caused G2 phase arrest in U251 cells with a concurrent decrease in p21, cyclin D1, and cyclin B1 content.	Berberine	0-9	cyclin B1	Homo sapiens	129-138
33262612-19	2020	This indicates that berberine could be used as a potential drug to treat wild-type and mutant p53 glioma.	Berberine	20-29	transformation related protein 53, pseudogene	Mus musculus	94-97
33262628-0	2020	Berberine Down-Regulated Myostatin Expression and Facilitated Metabolism via Smad Pathway in Insulin Resistant Mice.	Berberine	0-9	myostatin	Mus musculus	25-34
33262628-12	2020	RT-PCR and Western blotting analysis showed that, after being fed with HFD the expression of Mstn mRNA and Mstn were significantly increased, and decreased after being treated with BBR.	Berberine	181-184	myostatin	Mus musculus	93-97
33262628-12	2020	RT-PCR and Western blotting analysis showed that, after being fed with HFD the expression of Mstn mRNA and Mstn were significantly increased, and decreased after being treated with BBR.	Berberine	181-184	myostatin	Mus musculus	107-111
33262628-13	2020	Western blotting analysis also showed that, compared with the NCD group, the expressions of Smad2, Smad3, and Smad4 were all increased in the HFD group, but after being treated with BBR, the expressions of Smad3 and Smad4 were decreased.	Berberine	182-185	SMAD family member 2	Mus musculus	92-97
33262628-13	2020	Western blotting analysis also showed that, compared with the NCD group, the expressions of Smad2, Smad3, and Smad4 were all increased in the HFD group, but after being treated with BBR, the expressions of Smad3 and Smad4 were decreased.	Berberine	182-185	SMAD family member 3	Mus musculus	99-104
33262628-13	2020	Western blotting analysis also showed that, compared with the NCD group, the expressions of Smad2, Smad3, and Smad4 were all increased in the HFD group, but after being treated with BBR, the expressions of Smad3 and Smad4 were decreased.	Berberine	182-185	SMAD family member 4	Mus musculus	110-115
33262628-13	2020	Western blotting analysis also showed that, compared with the NCD group, the expressions of Smad2, Smad3, and Smad4 were all increased in the HFD group, but after being treated with BBR, the expressions of Smad3 and Smad4 were decreased.	Berberine	182-185	SMAD family member 3	Mus musculus	206-211
33262628-13	2020	Western blotting analysis also showed that, compared with the NCD group, the expressions of Smad2, Smad3, and Smad4 were all increased in the HFD group, but after being treated with BBR, the expressions of Smad3 and Smad4 were decreased.	Berberine	182-185	SMAD family member 4	Mus musculus	216-221
32738596-0	2020	Anti-arthritis effect of berberine associated with regulating energy metabolism of macrophages through AMPK/ HIF-1alpha pathway.	Berberine	25-34	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	103-107
32682817-0	2020	Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway.	Berberine	0-9	SIK family kinase 3	Homo sapiens	102-106
32682817-0	2020	Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	115-119
32682817-0	2020	Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	124-127
32682817-5	2020	Furthermore, our findings showed that Emodin (EMO) combined with Berberine (BBR) significantly inhibited SIK3 activity, leading to reduced cell growth, increased cell cycle arrest and apoptosis in breast cancer cells, but not in non-malignant breast epithelial cell line.	Berberine	65-74	SIK family kinase 3	Homo sapiens	105-109
32682817-5	2020	Furthermore, our findings showed that Emodin (EMO) combined with Berberine (BBR) significantly inhibited SIK3 activity, leading to reduced cell growth, increased cell cycle arrest and apoptosis in breast cancer cells, but not in non-malignant breast epithelial cell line.	Berberine	76-79	SIK family kinase 3	Homo sapiens	105-109
32682817-6	2020	Mechanistic studies further reveal that EMO and BBR in combined treatment inhibited SIK3-potentiated mTOR-mediated aerobic glycolysis and cell growth in breast cancer cells.	Berberine	48-51	SIK family kinase 3	Homo sapiens	84-88
32682817-6	2020	Mechanistic studies further reveal that EMO and BBR in combined treatment inhibited SIK3-potentiated mTOR-mediated aerobic glycolysis and cell growth in breast cancer cells.	Berberine	48-51	mechanistic target of rapamycin kinase	Homo sapiens	101-105
32682817-9	2020	Collectively, our findings reveal that combination of EMO and BBR attenuates SIK3-driven tumor growth in breast cancer, and thus, EMO and BBR might be a novel SIK3 inhibitor explored into the prevention of breast cancer.	Berberine	62-65	SIK family kinase 3	Homo sapiens	77-81
32682817-9	2020	Collectively, our findings reveal that combination of EMO and BBR attenuates SIK3-driven tumor growth in breast cancer, and thus, EMO and BBR might be a novel SIK3 inhibitor explored into the prevention of breast cancer.	Berberine	138-141	SIK family kinase 3	Homo sapiens	77-81
32682817-9	2020	Collectively, our findings reveal that combination of EMO and BBR attenuates SIK3-driven tumor growth in breast cancer, and thus, EMO and BBR might be a novel SIK3 inhibitor explored into the prevention of breast cancer.	Berberine	138-141	SIK family kinase 3	Homo sapiens	159-163
33074411-5	2020	Also, berberine significantly reduced the expression of matrix metalloproteinase (MMP)-2, suggesting its inhibitory action on the matrix metalloproteinases that are required for cancer cell invasion.	Berberine	6-15	matrix metallopeptidase 2	Homo sapiens	56-88
33719277-10	2020	Conclusion: Berberine may reduce oxidative stress, inhibit inflammation, enhance immune function, and reduce cerebral ischemia/reperfusion injury in rats, which may be related to the inhibition of NF-kappaB-NLRP3 signaling.	Berberine	12-21	NLR family, pyrin domain containing 3	Rattus norvegicus	207-212
33092516-6	2021	In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4alpha (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes.	Berberine	9-18	sterol regulatory element binding transcription factor 1	Homo sapiens	35-41
33092516-6	2021	In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4alpha (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes.	Berberine	9-18	MLX interacting protein like	Homo sapiens	46-52
32800336-0	2020	Regulation of MFN2 by berberine alleviates obesity exacerbated colitis.	Berberine	22-31	mitofusin 2	Homo sapiens	14-18
32800336-6	2020	In vitro, we stimulated Caco-2 cells with palmitic acid (PA) to replicate the lipotoxicity damage in the intestine, and the results presented that intervention therapy of berberine effectively enhanced the MFN2 expression, inhibited the mRNA levels of inflammatory factors, and reversed the PA induced protein level changes of AMPK and BIP/Grp78.	Berberine	171-180	mitofusin 2	Homo sapiens	206-210
32800336-6	2020	In vitro, we stimulated Caco-2 cells with palmitic acid (PA) to replicate the lipotoxicity damage in the intestine, and the results presented that intervention therapy of berberine effectively enhanced the MFN2 expression, inhibited the mRNA levels of inflammatory factors, and reversed the PA induced protein level changes of AMPK and BIP/Grp78.	Berberine	171-180	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	327-331
32800336-6	2020	In vitro, we stimulated Caco-2 cells with palmitic acid (PA) to replicate the lipotoxicity damage in the intestine, and the results presented that intervention therapy of berberine effectively enhanced the MFN2 expression, inhibited the mRNA levels of inflammatory factors, and reversed the PA induced protein level changes of AMPK and BIP/Grp78.	Berberine	171-180	heat shock protein family A (Hsp70) member 5	Homo sapiens	336-339
32800336-6	2020	In vitro, we stimulated Caco-2 cells with palmitic acid (PA) to replicate the lipotoxicity damage in the intestine, and the results presented that intervention therapy of berberine effectively enhanced the MFN2 expression, inhibited the mRNA levels of inflammatory factors, and reversed the PA induced protein level changes of AMPK and BIP/Grp78.	Berberine	171-180	heat shock protein family A (Hsp70) member 5	Homo sapiens	340-345
32800336-7	2020	In general, we proposed that berberine could regulate MFN2 to alleviate obesity exacerbated colitis.	Berberine	29-38	mitofusin 2	Homo sapiens	54-58
32795536-0	2020	Berberine inhibits proliferation and apoptosis of vascular smooth muscle cells induced by mechanical stretch via the PDI/ERS and MAPK pathways.	Berberine	0-9	prolyl 4-hydroxylase, beta polypeptide	Mus musculus	117-120
32795536-8	2020	KEY FINDINGS: Our results showed that berberine inhibits the PDI-endoplasmic reticulum stress system, thereby attenuating the simultaneous increase of VSMC proliferation and apoptosis in response to mechanical stretch.	Berberine	38-47	prolyl 4-hydroxylase, beta polypeptide	Mus musculus	61-64
32795536-11	2020	Moreover, caspase-3 and caspase-12 were downregulated by berberine.	Berberine	57-66	caspase 3	Mus musculus	10-19
32795536-11	2020	Moreover, caspase-3 and caspase-12 were downregulated by berberine.	Berberine	57-66	caspase 12	Mus musculus	24-34
33060638-7	2020	These alterations are associated with increased levels of vascular endothelial growth factor aa (vegfaa) mRNA, suggesting an important role for Vegfaa as mediator of berberine-induced cardiovascular defects.	Berberine	166-175	vascular endothelial growth factor Aa	Danio rerio	58-95
33060638-7	2020	These alterations are associated with increased levels of vascular endothelial growth factor aa (vegfaa) mRNA, suggesting an important role for Vegfaa as mediator of berberine-induced cardiovascular defects.	Berberine	166-175	vascular endothelial growth factor Aa	Danio rerio	97-103
33060638-7	2020	These alterations are associated with increased levels of vascular endothelial growth factor aa (vegfaa) mRNA, suggesting an important role for Vegfaa as mediator of berberine-induced cardiovascular defects.	Berberine	166-175	vascular endothelial growth factor Aa	Danio rerio	144-150
33254441-0	2020	Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice.	Berberine	0-9	G protein-coupled bile acid receptor 1	Mus musculus	75-79
33254441-0	2020	Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice.	Berberine	0-9	euchromatic histone methyltransferase 1	Mus musculus	80-83
33658925-0	2020	Berberine Suppresses Colonic Inflammation in Dextran Sulfate Sodium-Induced Murine Colitis Through Inhibition of Cytosolic Phospholipase A2 Activity.	Berberine	0-9	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	113-139
33658925-7	2020	We then demonstrated berberine inhibits the phosphorylation of cytosolic phospholipase A2a (PLA2G4A) in the colon tissue of experimental colitis mice and inflamed macrophage RAW 264.7 cells.	Berberine	21-30	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	92-99
33658925-8	2020	Subsequently, we revealed berberine suppressed the expression of pro-inflammatory factors including TNF-alpha and IL-6 through regulating PLA2G4A dysfunction in macrophage RAW 264.7 cells.	Berberine	26-35	tumor necrosis factor	Mus musculus	100-109
33658925-8	2020	Subsequently, we revealed berberine suppressed the expression of pro-inflammatory factors including TNF-alpha and IL-6 through regulating PLA2G4A dysfunction in macrophage RAW 264.7 cells.	Berberine	26-35	interleukin 6	Mus musculus	114-118
33658925-8	2020	Subsequently, we revealed berberine suppressed the expression of pro-inflammatory factors including TNF-alpha and IL-6 through regulating PLA2G4A dysfunction in macrophage RAW 264.7 cells.	Berberine	26-35	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	138-145
33658925-9	2020	Mechanistically, we found that berberine directly binds to PLA2G4A and inhibits MAPK/JNK signaling pathway to inhibit PLA2G4A activity in inflammatory status.	Berberine	31-40	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	59-66
33658925-9	2020	Mechanistically, we found that berberine directly binds to PLA2G4A and inhibits MAPK/JNK signaling pathway to inhibit PLA2G4A activity in inflammatory status.	Berberine	31-40	mitogen-activated protein kinase 8	Mus musculus	85-88
33658925-9	2020	Mechanistically, we found that berberine directly binds to PLA2G4A and inhibits MAPK/JNK signaling pathway to inhibit PLA2G4A activity in inflammatory status.	Berberine	31-40	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	118-125
33658925-10	2020	Therefore, we concluded that berberine inhibits colonic PLA2G4A activity to ameliorate colonic inflammation in experimental colitic mice, suggesting modulation of the PC metabolism via PLA2G4A might be beneficial for establishing new therapies strategy for UC.	Berberine	29-38	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	56-63
33658925-10	2020	Therefore, we concluded that berberine inhibits colonic PLA2G4A activity to ameliorate colonic inflammation in experimental colitic mice, suggesting modulation of the PC metabolism via PLA2G4A might be beneficial for establishing new therapies strategy for UC.	Berberine	29-38	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	185-192
32961234-0	2020	Berberine reduces gut-vascular barrier permeability via modulation of ApoM/S1P pathway in a model of polymicrobial sepsis.	Berberine	0-9	apolipoprotein M	Rattus norvegicus	70-74
32961234-2	2020	The goal of this study was to evaluate if berberine might improve hepatic apolipoprotein M (ApoM) generation and raise plasma ApoM level to protect the compromised GVB.	Berberine	42-51	apolipoprotein M	Rattus norvegicus	74-90
32961234-2	2020	The goal of this study was to evaluate if berberine might improve hepatic apolipoprotein M (ApoM) generation and raise plasma ApoM level to protect the compromised GVB.	Berberine	42-51	apolipoprotein M	Rattus norvegicus	92-96
32961234-2	2020	The goal of this study was to evaluate if berberine might improve hepatic apolipoprotein M (ApoM) generation and raise plasma ApoM level to protect the compromised GVB.	Berberine	42-51	apolipoprotein M	Rattus norvegicus	126-130
32961234-12	2020	Berberine in a dose-dependent manner raised hepatic ApoM mRNA and plasma ApoM level, but decreased septic hyperglycemia, insulin resistance and plasma TNF-alpha and IL-1beta levels.	Berberine	0-9	apolipoprotein M	Rattus norvegicus	52-56
32961234-12	2020	Berberine in a dose-dependent manner raised hepatic ApoM mRNA and plasma ApoM level, but decreased septic hyperglycemia, insulin resistance and plasma TNF-alpha and IL-1beta levels.	Berberine	0-9	apolipoprotein M	Rattus norvegicus	73-77
32961234-12	2020	Berberine in a dose-dependent manner raised hepatic ApoM mRNA and plasma ApoM level, but decreased septic hyperglycemia, insulin resistance and plasma TNF-alpha and IL-1beta levels.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	151-160
32961234-12	2020	Berberine in a dose-dependent manner raised hepatic ApoM mRNA and plasma ApoM level, but decreased septic hyperglycemia, insulin resistance and plasma TNF-alpha and IL-1beta levels.	Berberine	0-9	interleukin 1 alpha	Rattus norvegicus	165-173
32961234-13	2020	Berberine reduced sepsis-induced PEPCK and TLR4 mRNA overexpression in the liver.	Berberine	0-9	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	33-38
32961234-13	2020	Berberine reduced sepsis-induced PEPCK and TLR4 mRNA overexpression in the liver.	Berberine	0-9	toll-like receptor 4	Rattus norvegicus	43-47
32961234-14	2020	SIGNIFICANCE: This study demonstrated berberine inhibited TLR4-mediated hyperglycemia, insulin resistance and proinflammatory molecule production, thereby increasing ApoM gene expression and plasma ApoM.	Berberine	38-47	toll-like receptor 4	Rattus norvegicus	58-62
32961234-14	2020	SIGNIFICANCE: This study demonstrated berberine inhibited TLR4-mediated hyperglycemia, insulin resistance and proinflammatory molecule production, thereby increasing ApoM gene expression and plasma ApoM.	Berberine	38-47	apolipoprotein M	Rattus norvegicus	166-170
32961234-14	2020	SIGNIFICANCE: This study demonstrated berberine inhibited TLR4-mediated hyperglycemia, insulin resistance and proinflammatory molecule production, thereby increasing ApoM gene expression and plasma ApoM.	Berberine	38-47	apolipoprotein M	Rattus norvegicus	198-202
32961234-15	2020	Berberine protected the damaged GVB via modulation of ApoM/S1P pathway.	Berberine	0-9	apolipoprotein M	Rattus norvegicus	54-58
32969153-5	2020	The present review aimed to clarify determinant cellular and molecular targets of berberine in RA and found that berberine through modulating several signalling pathways involved in the joint inflammation, including PI3K/Akt, Wnt1/beta-catenin, AMPK/lipogenesis and LPA/LPA1 /ERK/p38 MAPK can inhibit inflammatory proliferation of FLS cells, suppress DC activation and modulate Th17/Treg balance and thus prevent cartilage and bone destruction.	Berberine	113-122	AKT serine/threonine kinase 1	Homo sapiens	221-224
32969153-5	2020	The present review aimed to clarify determinant cellular and molecular targets of berberine in RA and found that berberine through modulating several signalling pathways involved in the joint inflammation, including PI3K/Akt, Wnt1/beta-catenin, AMPK/lipogenesis and LPA/LPA1 /ERK/p38 MAPK can inhibit inflammatory proliferation of FLS cells, suppress DC activation and modulate Th17/Treg balance and thus prevent cartilage and bone destruction.	Berberine	113-122	Wnt family member 1	Homo sapiens	226-230
32969153-5	2020	The present review aimed to clarify determinant cellular and molecular targets of berberine in RA and found that berberine through modulating several signalling pathways involved in the joint inflammation, including PI3K/Akt, Wnt1/beta-catenin, AMPK/lipogenesis and LPA/LPA1 /ERK/p38 MAPK can inhibit inflammatory proliferation of FLS cells, suppress DC activation and modulate Th17/Treg balance and thus prevent cartilage and bone destruction.	Berberine	113-122	catenin beta 1	Homo sapiens	231-243
32969153-5	2020	The present review aimed to clarify determinant cellular and molecular targets of berberine in RA and found that berberine through modulating several signalling pathways involved in the joint inflammation, including PI3K/Akt, Wnt1/beta-catenin, AMPK/lipogenesis and LPA/LPA1 /ERK/p38 MAPK can inhibit inflammatory proliferation of FLS cells, suppress DC activation and modulate Th17/Treg balance and thus prevent cartilage and bone destruction.	Berberine	113-122	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	245-249
32969153-5	2020	The present review aimed to clarify determinant cellular and molecular targets of berberine in RA and found that berberine through modulating several signalling pathways involved in the joint inflammation, including PI3K/Akt, Wnt1/beta-catenin, AMPK/lipogenesis and LPA/LPA1 /ERK/p38 MAPK can inhibit inflammatory proliferation of FLS cells, suppress DC activation and modulate Th17/Treg balance and thus prevent cartilage and bone destruction.	Berberine	113-122	lysophosphatidic acid receptor 1	Homo sapiens	270-274
32969153-5	2020	The present review aimed to clarify determinant cellular and molecular targets of berberine in RA and found that berberine through modulating several signalling pathways involved in the joint inflammation, including PI3K/Akt, Wnt1/beta-catenin, AMPK/lipogenesis and LPA/LPA1 /ERK/p38 MAPK can inhibit inflammatory proliferation of FLS cells, suppress DC activation and modulate Th17/Treg balance and thus prevent cartilage and bone destruction.	Berberine	113-122	mitogen-activated protein kinase 1	Homo sapiens	276-279
32926933-0	2020	Berberine inhibits proliferation and induces G0/G1 phase arrest in colorectal cancer cells by downregulating IGF2BP3.	Berberine	0-9	insulin like growth factor 2 mRNA binding protein 3	Homo sapiens	109-116
32926933-6	2020	KEY FINDINGS: Our results showed that BBR inhibits proliferation and induces G0/G1 phase arrest in CRC cells by downregulating IGF2BP3.	Berberine	38-41	insulin like growth factor 2 mRNA binding protein 3	Homo sapiens	127-134
32779043-0	2020	Berberine attenuates Abeta-induced neuronal damage through regulating miR-188/NOS1 in Alzheimer"s disease.	Berberine	0-9	amyloid beta (A4) precursor protein	Mus musculus	21-26
32779043-0	2020	Berberine attenuates Abeta-induced neuronal damage through regulating miR-188/NOS1 in Alzheimer"s disease.	Berberine	0-9	microRNA 188	Mus musculus	70-77
32779043-0	2020	Berberine attenuates Abeta-induced neuronal damage through regulating miR-188/NOS1 in Alzheimer"s disease.	Berberine	0-9	nitric oxide synthase 1, neuronal	Mus musculus	78-82
32779043-6	2020	Ber treatment or miR-188 overexpression expedited proliferation and inhibited caspase-3 activity and apoptotic rate in amyloid-beta (Abeta)-treated BV2 and N2a cells.	Berberine	0-3	caspase 3	Mus musculus	78-87
32779043-6	2020	Ber treatment or miR-188 overexpression expedited proliferation and inhibited caspase-3 activity and apoptotic rate in amyloid-beta (Abeta)-treated BV2 and N2a cells.	Berberine	0-3	amyloid beta (A4) precursor protein	Mus musculus	133-138
33045871-0	2021	Berberine modulates Keratin 17 to inhibit cervical cancer cell viability and metastasis.	Berberine	0-9	keratin 17	Homo sapiens	20-30
33045871-9	2021	BBR promoted cell apoptosis by increasing Bax and C caspase-3 expressions and decreasing Bcl-2 expression.	Berberine	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	42-45
33045871-9	2021	BBR promoted cell apoptosis by increasing Bax and C caspase-3 expressions and decreasing Bcl-2 expression.	Berberine	0-3	caspase 3	Homo sapiens	52-61
33045871-9	2021	BBR promoted cell apoptosis by increasing Bax and C caspase-3 expressions and decreasing Bcl-2 expression.	Berberine	0-3	BCL2 apoptosis regulator	Homo sapiens	89-94
33045871-10	2021	Besides, BBR inhibited EMT in cells by decreasing the expressions of MMP-9, N-cadherin and Vimentin and increasing E-cadherin expression.	Berberine	9-12	matrix metallopeptidase 9	Homo sapiens	69-74
33045871-10	2021	Besides, BBR inhibited EMT in cells by decreasing the expressions of MMP-9, N-cadherin and Vimentin and increasing E-cadherin expression.	Berberine	9-12	cadherin 2	Homo sapiens	76-86
33045871-10	2021	Besides, BBR inhibited EMT in cells by decreasing the expressions of MMP-9, N-cadherin and Vimentin and increasing E-cadherin expression.	Berberine	9-12	vimentin	Homo sapiens	91-99
33045871-10	2021	Besides, BBR inhibited EMT in cells by decreasing the expressions of MMP-9, N-cadherin and Vimentin and increasing E-cadherin expression.	Berberine	9-12	cadherin 1	Homo sapiens	115-125
33045871-14	2021	CONCLUSION: BBR inhibited cervical cancer cell viability, metastasis and EMT but promoted cell apoptosis via suppressing KRT 17 expression.	Berberine	12-15	keratin 17	Homo sapiens	121-127
33163337-5	2020	During the last decade, several products, including naturally occurring dietary agents as well as a wide variety of products from plant sources, including curcumin, quercetin, berberin, and ginsenosides, have been identified as potent modulators of the Wnt/beta-catenin signaling and have gained interest as promising candidates for the development of chemopreventive or therapeutic drugs for cancer.	Berberine	176-184	catenin beta 1	Homo sapiens	257-269
32770668-0	2020	Berberine enhances L1 expression and axonal remyelination in rats after brachial plexus root avulsion.	Berberine	0-9	L1 cell adhesion molecule	Rattus norvegicus	19-21
32770668-4	2020	Herein, we investigated whether berberine (BBR) can affect the expression of L1 and enhance the axonal remyelination in rats following BPRA.	Berberine	32-41	L1 cell adhesion molecule	Rattus norvegicus	77-79
32770668-4	2020	Herein, we investigated whether berberine (BBR) can affect the expression of L1 and enhance the axonal remyelination in rats following BPRA.	Berberine	43-46	L1 cell adhesion molecule	Rattus norvegicus	77-79
32770668-7	2020	RESULTS: We observed that, BBR treatment ameliorated the abnormal musculocutaneous nerve fibers morphology, up-regulated the L1 expression, increased the myelination-related genes, decreased the differentiated-associated genes, and up-regulated the phosphorylation of ERK.	Berberine	27-30	L1 cell adhesion molecule	Rattus norvegicus	125-127
32770668-7	2020	RESULTS: We observed that, BBR treatment ameliorated the abnormal musculocutaneous nerve fibers morphology, up-regulated the L1 expression, increased the myelination-related genes, decreased the differentiated-associated genes, and up-regulated the phosphorylation of ERK.	Berberine	27-30	Eph receptor B1	Rattus norvegicus	268-271
32688201-0	2020	Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.	Berberine	19-28	butyrylcholinesterase	Homo sapiens	55-69
32688201-0	2020	Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.	Berberine	19-28	prolyl endopeptidase	Homo sapiens	74-95
32738596-0	2020	Anti-arthritis effect of berberine associated with regulating energy metabolism of macrophages through AMPK/ HIF-1alpha pathway.	Berberine	25-34	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	109-119
32738596-5	2020	Meanwhile, we found BBR up-regulated the expression of AMP-activated protein kinase phosphorylation (p-AMPK) and down-regulated the expression of Hypoxia inducible factor 1alpha (HIF-1alpha) in synovial macrophages of AA rats.	Berberine	20-23	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	103-107
32738596-5	2020	Meanwhile, we found BBR up-regulated the expression of AMP-activated protein kinase phosphorylation (p-AMPK) and down-regulated the expression of Hypoxia inducible factor 1alpha (HIF-1alpha) in synovial macrophages of AA rats.	Berberine	20-23	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	146-177
32738596-5	2020	Meanwhile, we found BBR up-regulated the expression of AMP-activated protein kinase phosphorylation (p-AMPK) and down-regulated the expression of Hypoxia inducible factor 1alpha (HIF-1alpha) in synovial macrophages of AA rats.	Berberine	20-23	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	179-189
32738596-6	2020	In vitro, using LPS-stimulated peritoneal macrophages from normal rats, we also verified that pretreatment with BBR promoted transition from M1 to M2 by up-regulating the expression of p-AMPK and suppressing the expression of HIF-1alpha.	Berberine	112-115	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	187-191
32738596-6	2020	In vitro, using LPS-stimulated peritoneal macrophages from normal rats, we also verified that pretreatment with BBR promoted transition from M1 to M2 by up-regulating the expression of p-AMPK and suppressing the expression of HIF-1alpha.	Berberine	112-115	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	226-236
33061833-6	2020	Notable downregulation of mRNA expression of p38 MAPK and increased protein expression of TGF-beta were achieved by BER treatment.	Berberine	116-119	transforming growth factor alpha	Rattus norvegicus	90-98
32524872-9	2020	Pre-treatment with berberine reduced the expression of inflammatory factors and was positively correlated with its concentration, and dose dependently inhibited the expression of IkappaBalpha, p-IkappaBalpha, p-p65, p-p38 and JNK.	Berberine	19-28	NFKB inhibitor alpha	Sus scrofa	179-191
32524872-9	2020	Pre-treatment with berberine reduced the expression of inflammatory factors and was positively correlated with its concentration, and dose dependently inhibited the expression of IkappaBalpha, p-IkappaBalpha, p-p65, p-p38 and JNK.	Berberine	19-28	NFKB inhibitor alpha	Sus scrofa	195-207
32524872-9	2020	Pre-treatment with berberine reduced the expression of inflammatory factors and was positively correlated with its concentration, and dose dependently inhibited the expression of IkappaBalpha, p-IkappaBalpha, p-p65, p-p38 and JNK.	Berberine	19-28	mitogen-activated protein kinase 8	Sus scrofa	226-229
32998385-0	2020	The First Berberine-Based Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), an Important DNA Repair Enzyme.	Berberine	10-19	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	40-71
32998385-0	2020	The First Berberine-Based Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), an Important DNA Repair Enzyme.	Berberine	10-19	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	73-77
32998385-1	2020	A series of berberine and tetrahydroberberine sulfonate derivatives were prepared and tested against the tyrosyl-DNA phosphodiesterase 1 (Tdp1) DNA-repair enzyme.	Berberine	12-21	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	105-136
32998385-1	2020	A series of berberine and tetrahydroberberine sulfonate derivatives were prepared and tested against the tyrosyl-DNA phosphodiesterase 1 (Tdp1) DNA-repair enzyme.	Berberine	12-21	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	138-142
32998385-1	2020	A series of berberine and tetrahydroberberine sulfonate derivatives were prepared and tested against the tyrosyl-DNA phosphodiesterase 1 (Tdp1) DNA-repair enzyme.	Berberine	12-21	DNA ligase 4	Homo sapiens	144-161
32998385-2	2020	The berberine derivatives inhibit the Tdp1 enzyme in the low micromolar range; this is the first reported berberine based Tdp1 inhibitor.	Berberine	4-13	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	38-42
32998385-2	2020	The berberine derivatives inhibit the Tdp1 enzyme in the low micromolar range; this is the first reported berberine based Tdp1 inhibitor.	Berberine	4-13	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	122-126
32998385-2	2020	The berberine derivatives inhibit the Tdp1 enzyme in the low micromolar range; this is the first reported berberine based Tdp1 inhibitor.	Berberine	106-115	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	38-42
32998385-2	2020	The berberine derivatives inhibit the Tdp1 enzyme in the low micromolar range; this is the first reported berberine based Tdp1 inhibitor.	Berberine	106-115	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	122-126
33101051-0	2020	Berberine Promotes Cardiac Function by Upregulating PINK1/Parkin-Mediated Mitophagy in Heart Failure.	Berberine	0-9	PTEN induced kinase 1	Homo sapiens	52-57
33101051-7	2020	Furthermore, mitophagy regulators PINK1 and mito-Parkin were downregulated in TAC-induced HF, while berberine upregulated PINK1/Parkin-mediated mitophagy.	Berberine	100-109	PTEN induced kinase 1	Homo sapiens	122-127
33101051-8	2020	Notably, knockdown of PINK1 by small interfering RNA significantly suppressed Parkin-mediated mitochondrial ubiquitination and nullified the beneficial actions on HF exerted by berberine.	Berberine	177-186	PTEN induced kinase 1	Homo sapiens	22-27
32987920-0	2020	Quasi-Irreversible Inhibition of CYP2D6 by Berberine.	Berberine	43-52	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	33-39
32987920-1	2020	In our previous study, Hwang-Ryun-Hae-Dok-Tang, which contains berberine (BBR) as a main active ingredient, inhibited cytochrome P450 (CYP) 2D6 in a quasi-irreversible manner.	Berberine	63-72	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	118-143
32987920-1	2020	In our previous study, Hwang-Ryun-Hae-Dok-Tang, which contains berberine (BBR) as a main active ingredient, inhibited cytochrome P450 (CYP) 2D6 in a quasi-irreversible manner.	Berberine	74-77	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	118-143
32987920-2	2020	However, no information is available on the detailed mechanism of BBR-induced CYP2D6 inhibition.	Berberine	66-69	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
32987920-3	2020	Thus, the present study aimed to characterize the inhibition mode and kinetics of BBR and its analogues against CYP2D6 using pooled human liver microsomes (HLM).	Berberine	82-85	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	112-118
32987920-7	2020	Notably, TFD, but not DMB, exhibited metabolism-dependent CYP2D6 inhibition as in the case of BBR, which suggests that methylenedioxybenzene moiety of BBR may play a critical role in the quasi-irreversible inhibition.	Berberine	151-154	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	58-64
32987920-8	2020	Moreover, the metabolic clearance of nebivolol (beta-blocker; CYP2D6 substrate) was reduced in the presence of BBR.	Berberine	111-114	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	62-68
32958873-0	2021	Berberine inhibits colorectal tumor growth by suppressing SHH secretion.	Berberine	0-9	sonic hedgehog signaling molecule	Homo sapiens	58-61
32972060-13	2020	Conclusions: Berberine can improve myocardial injury and cardiac function in sepsis rats, the mechanism is considered to be related to that it can inhibit the activation of TLR4/NF-kappaB signaling pathway induced by LPS and further reducing the production of TNF-alpha and IL-1beta.	Berberine	13-22	toll-like receptor 4	Rattus norvegicus	173-177
32972060-13	2020	Conclusions: Berberine can improve myocardial injury and cardiac function in sepsis rats, the mechanism is considered to be related to that it can inhibit the activation of TLR4/NF-kappaB signaling pathway induced by LPS and further reducing the production of TNF-alpha and IL-1beta.	Berberine	13-22	tumor necrosis factor	Rattus norvegicus	260-269
32972060-13	2020	Conclusions: Berberine can improve myocardial injury and cardiac function in sepsis rats, the mechanism is considered to be related to that it can inhibit the activation of TLR4/NF-kappaB signaling pathway induced by LPS and further reducing the production of TNF-alpha and IL-1beta.	Berberine	13-22	interleukin 1 alpha	Rattus norvegicus	274-282
32957491-0	2020	Enhanced Intestinal Absorption and Pharmacokinetic Modulation of Berberine and Its Metabolites through the Inhibition of P-Glycoprotein and Intestinal Metabolism in Rats Using a Berberine Mixed Micelle Formulation.	Berberine	65-74	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	121-135
32957491-0	2020	Enhanced Intestinal Absorption and Pharmacokinetic Modulation of Berberine and Its Metabolites through the Inhibition of P-Glycoprotein and Intestinal Metabolism in Rats Using a Berberine Mixed Micelle Formulation.	Berberine	178-187	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	121-135
32957491-1	2020	We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats.	Berberine	22-31	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	146-160
32957491-1	2020	We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats.	Berberine	22-31	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	162-166
32957491-1	2020	We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats.	Berberine	110-119	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	146-160
32957491-1	2020	We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats.	Berberine	110-119	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	162-166
32957491-1	2020	We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats.	Berberine	110-119	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	146-160
32957491-1	2020	We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats.	Berberine	110-119	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	162-166
32957491-4	2020	This berberine mixed micelle formulation had a mean size of 12 nm and increased the cellular accumulation of digoxin via P-gp inhibition.	Berberine	5-14	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	121-125
32957491-7	2020	The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation.	Berberine	23-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	234-238
32957491-7	2020	The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation.	Berberine	84-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	234-238
32957491-7	2020	The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation.	Berberine	84-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	234-238
32957491-7	2020	The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation.	Berberine	84-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	234-238
32957491-7	2020	The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation.	Berberine	84-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	234-238
32957491-7	2020	The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation.	Berberine	84-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	234-238
32957491-7	2020	The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation.	Berberine	84-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	234-238
32957491-8	2020	In conclusion, we successfully prepared berberine mixed micelle formulation using P85 and tween 80 that has inhibitory potential for P-gp and CYPs (CYP2C19, 2D6, and 3A4) and increased the berberine plasma exposure.	Berberine	40-49	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	133-137
32702446-10	2020	It was also revealed that, through activating AMPK, berberine inhibited ACC activity then suppressed intracellular fatty acid synthesis, finally decreased the biogenesis of extracellular vesicles.	Berberine	52-61	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	46-50
32721432-0	2020	Berberine attenuates severity of chronic pancreatitis and fibrosis via AMPK-mediated inhibition of TGF-beta1/Smad signaling and M2 polarization.	Berberine	0-9	transforming growth factor, beta 1	Mus musculus	99-108
32721432-5	2020	BR treatment also prevented cerulein-induced pancreatic stellate cells (PSCs) activation and extracellular matrix (ECM) deposition via downregulation of alpha-SMA, collagen1a, collagen3a and fibronectin expression.	Berberine	0-2	actin alpha 2, smooth muscle, aorta	Mus musculus	153-162
32721432-5	2020	BR treatment also prevented cerulein-induced pancreatic stellate cells (PSCs) activation and extracellular matrix (ECM) deposition via downregulation of alpha-SMA, collagen1a, collagen3a and fibronectin expression.	Berberine	0-2	fibronectin 1	Mus musculus	191-202
32721432-7	2020	Further, administration of BR also inhibited TGF-beta/Smad signaling and macrophages polarization in cerulein-induced CP in-vivo models and TGF-beta1 stimulated RAW 264.7 macrophages in-vitro.	Berberine	27-29	transforming growth factor alpha	Mus musculus	45-53
32721432-8	2020	Together, our results strongly suggest that BR treatment protected against cerulein-induced CP and associated fibrosis progression by inhibiting TGF-beta1/Smad signaling and M2 macrophages polarization in an AMPK dependent manner.	Berberine	44-46	transforming growth factor, beta 1	Mus musculus	145-154
32888284-0	2021	Macrovascular Protecting Effects of Berberine through Anti-inflammation and Intervention of BKCa in Type 2 Diabetes Mellitus Rats.	Berberine	36-45	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	92-96
32888284-8	2021	Berberine significantly inhibited the C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) production, and increased the adiponectin level compared with the model group.	Berberine	0-9	C-reactive protein	Rattus norvegicus	38-56
32888284-8	2021	Berberine significantly inhibited the C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) production, and increased the adiponectin level compared with the model group.	Berberine	0-9	C-reactive protein	Rattus norvegicus	58-61
32888284-8	2021	Berberine significantly inhibited the C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) production, and increased the adiponectin level compared with the model group.	Berberine	0-9	interleukin 6	Rattus norvegicus	64-77
32888284-8	2021	Berberine significantly inhibited the C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) production, and increased the adiponectin level compared with the model group.	Berberine	0-9	interleukin 6	Rattus norvegicus	79-83
32888284-8	2021	Berberine significantly inhibited the C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) production, and increased the adiponectin level compared with the model group.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	90-117
32888284-8	2021	Berberine significantly inhibited the C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) production, and increased the adiponectin level compared with the model group.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	119-128
32888284-8	2021	Berberine significantly inhibited the C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) production, and increased the adiponectin level compared with the model group.	Berberine	0-9	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	160-171
32888284-9	2021	Compared with the model group, berberine inhibited the proliferation and migration of VSMCs in vitro, and reduced tumor growth factor-beta1 (TGF-beta1), IL-6, and TNF-alpha levels.	Berberine	31-40	transforming growth factor, beta 1	Rattus norvegicus	141-150
32888284-9	2021	Compared with the model group, berberine inhibited the proliferation and migration of VSMCs in vitro, and reduced tumor growth factor-beta1 (TGF-beta1), IL-6, and TNF-alpha levels.	Berberine	31-40	interleukin 6	Rattus norvegicus	153-157
32888284-9	2021	Compared with the model group, berberine inhibited the proliferation and migration of VSMCs in vitro, and reduced tumor growth factor-beta1 (TGF-beta1), IL-6, and TNF-alpha levels.	Berberine	31-40	tumor necrosis factor	Rattus norvegicus	163-172
32888284-12	2021	CONCLUSIONS: Protective effects of berberine against macrovascular complications induced by diabetes mellitus may be attributed to inhibiting the inflammation and intervening the calcium-activated potassium (BKCa).	Berberine	35-44	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	208-212
32964031-2	2020	We set out to investigate the impact of high-intensity interval training (HIIT) and berberine supplementation on the gene expression of angiogenesis-related factors and caspase-3 protein in rats suffering from myocardial ischemic-reperfusion injury.	Berberine	84-93	caspase 3	Rattus norvegicus	169-178
33088695-0	2020	Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe (-/-) mice.	Berberine	62-71	apolipoprotein E	Mus musculus	75-79
33088695-3	2020	The aim of this study was to develop an effective BBR-entrapped nano-system for treating AS in high-fat diet (HFD)-fed Apoe (-/-) mice, and also explore the possible underlying mechanisms involved.	Berberine	50-53	apolipoprotein E	Mus musculus	119-123
32650294-0	2020	Berberine ameliorates obesity-induced chronic inflammation through suppression of ER stress and promotion of macrophage M2 polarization at least partly via downregulating lncRNA Gomafu.	Berberine	0-9	myocardial infarction associated transcript (non-protein coding)	Mus musculus	178-184
32650294-9	2020	Overexpression of lncRNA Gomafu partially blocked the protective effects of berberine in free fatty acids-treated adipocytes by increasing endoplasmic reticulum stress.	Berberine	76-85	myocardial infarction associated transcript (non-protein coding)	Mus musculus	25-31
32650294-10	2020	Moreover, Gomafu overexpression partly reversed berberine-induced enhancement of M2 polarization in macrophages.	Berberine	48-57	myocardial infarction associated transcript (non-protein coding)	Mus musculus	10-16
32650294-11	2020	Finally, Gomafu overexpression induced ER stress and inflammation in mice, which were improved by berberine administration.	Berberine	98-107	myocardial infarction associated transcript (non-protein coding)	Mus musculus	9-15
31721320-10	2020	The isozymes CYP3A and CYP2D were found to be involved in the metabolism of berberine.	Berberine	76-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-18
31721320-10	2020	The isozymes CYP3A and CYP2D were found to be involved in the metabolism of berberine.	Berberine	76-85	cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene)	Homo sapiens	23-28
32908938-0	2020	Berberine Improves Inflammatory Responses of Diabetes Mellitus in Zucker Diabetic Fatty Rats and Insulin-Resistant HepG2 Cells through the PPM1B Pathway.	Berberine	0-9	protein phosphatase, Mg2+/Mn2+ dependent 1B	Homo sapiens	139-144
32908938-10	2020	The administration of BBR drastically decreased the body weight, urine volume, blood glucose, blood urea nitrogen (BUN), CHOL, hepatic index levels, and pathologic changes and improved ALB levels in ZDF rats with PPM1B upregulation.	Berberine	22-25	albumin	Rattus norvegicus	185-188
32908938-10	2020	The administration of BBR drastically decreased the body weight, urine volume, blood glucose, blood urea nitrogen (BUN), CHOL, hepatic index levels, and pathologic changes and improved ALB levels in ZDF rats with PPM1B upregulation.	Berberine	22-25	protein phosphatase, Mg2+/Mn2+ dependent, 1B	Rattus norvegicus	213-218
32785222-14	2020	Berberine can improve the sensitivity of insulin by regulating the signal pathway of insulin receptor substrate-1 (IRS-1) and mammalian target of rapamycin (mTOR) in PCOS patients and achieve a therapeutic effect of treating PCOS.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	157-161
32748032-1	2020	Possible role of P-glycoprotein in the neuroprotective mechanism of berberine in intracerebroventricular streptozotocin-induced cognitive dysfunction.	Berberine	68-77	ATP binding cassette subfamily B member 1	Homo sapiens	17-31
32958873-4	2021	In this study we investigated whether BBR inhibited the growth of colon cancer through suppressing the paracrine sonic hedgehog (SHH) signaling in vitro and in vivo.	Berberine	38-41	sonic hedgehog signaling molecule	Homo sapiens	113-127
32958873-4	2021	In this study we investigated whether BBR inhibited the growth of colon cancer through suppressing the paracrine sonic hedgehog (SHH) signaling in vitro and in vivo.	Berberine	38-41	sonic hedgehog signaling molecule	Homo sapiens	129-132
32958873-5	2021	We showed that BBR (1-10 muM) dose-dependently inhibited the secretion and expression of SHH protein in HT-29 and SW480 cells.	Berberine	15-18	sonic hedgehog signaling molecule	Homo sapiens	89-92
32958873-6	2021	BBR did not influence the transcription of SHH, but promoted the degradation of SHH mRNA, thus decreased the SHH mRNA expression in the colorectal cancer cells.	Berberine	0-3	sonic hedgehog signaling molecule	Homo sapiens	80-83
32958873-6	2021	BBR did not influence the transcription of SHH, but promoted the degradation of SHH mRNA, thus decreased the SHH mRNA expression in the colorectal cancer cells.	Berberine	0-3	sonic hedgehog signaling molecule	Homo sapiens	80-83
32958873-10	2021	In conclusion, BBR promotes the degradation of SHH mRNA in colorectal cancer cells, interrupting the paracrine Hedgehog signaling pathway activity thus suppresses the colorectal cancer growth.	Berberine	15-18	sonic hedgehog signaling molecule	Homo sapiens	47-50
32454290-0	2020	Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	130-134
32454290-0	2020	Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways.	Berberine	0-9	ribosomal protein S6 kinase B1	Homo sapiens	135-141
32454290-0	2020	Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	146-149
32454290-5	2020	Treatment with berberine triggered cell autophagy, as demonstrated by the punctuate distribution of monodansylcadaverine staining and GFP-LC3, as well as the LC3-II, Beclin-1 and p-ULK1 promotion, and p62 degradation.	Berberine	15-24	beclin 1	Homo sapiens	166-174
32454290-5	2020	Treatment with berberine triggered cell autophagy, as demonstrated by the punctuate distribution of monodansylcadaverine staining and GFP-LC3, as well as the LC3-II, Beclin-1 and p-ULK1 promotion, and p62 degradation.	Berberine	15-24	unc-51 like autophagy activating kinase 1	Homo sapiens	181-185
32454290-5	2020	Treatment with berberine triggered cell autophagy, as demonstrated by the punctuate distribution of monodansylcadaverine staining and GFP-LC3, as well as the LC3-II, Beclin-1 and p-ULK1 promotion, and p62 degradation.	Berberine	15-24	nucleoporin 62	Homo sapiens	201-204
32454290-6	2020	Inhibition of autophagy by 3-MA, CQ, Baf-A1 and BECN1 siRNA obviously increased cell viability of berberine-exposed gastric cancer cells, which confirmed the anti-cancer role of autophagy induced by berberine.	Berberine	98-107	beclin 1	Homo sapiens	48-53
32454290-6	2020	Inhibition of autophagy by 3-MA, CQ, Baf-A1 and BECN1 siRNA obviously increased cell viability of berberine-exposed gastric cancer cells, which confirmed the anti-cancer role of autophagy induced by berberine.	Berberine	199-208	beclin 1	Homo sapiens	48-53
32454290-7	2020	Mechanistic studies showed that berberine inhibited mTOR, Akt and MAPK (ERK, JNK and p38) pathways thereby inducing autophagy.	Berberine	32-41	mechanistic target of rapamycin kinase	Homo sapiens	52-56
32454290-7	2020	Mechanistic studies showed that berberine inhibited mTOR, Akt and MAPK (ERK, JNK and p38) pathways thereby inducing autophagy.	Berberine	32-41	AKT serine/threonine kinase 1	Homo sapiens	58-61
32454290-7	2020	Mechanistic studies showed that berberine inhibited mTOR, Akt and MAPK (ERK, JNK and p38) pathways thereby inducing autophagy.	Berberine	32-41	mitogen-activated protein kinase 1	Homo sapiens	72-75
32454290-7	2020	Mechanistic studies showed that berberine inhibited mTOR, Akt and MAPK (ERK, JNK and p38) pathways thereby inducing autophagy.	Berberine	32-41	mitogen-activated protein kinase 8	Homo sapiens	77-80
32454290-7	2020	Mechanistic studies showed that berberine inhibited mTOR, Akt and MAPK (ERK, JNK and p38) pathways thereby inducing autophagy.	Berberine	32-41	mitogen-activated protein kinase 14	Homo sapiens	85-88
32454290-10	2020	Furthermore, inhibition of autophagy reversed berberine down-regulated mTOR, Akt and MAPK.	Berberine	46-55	mechanistic target of rapamycin kinase	Homo sapiens	71-75
32454290-10	2020	Furthermore, inhibition of autophagy reversed berberine down-regulated mTOR, Akt and MAPK.	Berberine	46-55	AKT serine/threonine kinase 1	Homo sapiens	77-80
32454290-11	2020	In xenografts, the berberine induced autophagy leads to suppression of tumor proliferation with no side-effect, and western blotting displayed an apparent attenuation of p-mTOR, p-p70S6K, p-Akt, p-ERK, p-JNK and p-p38 in tumors from berberine treated mice.	Berberine	19-28	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	180-186
32454290-11	2020	In xenografts, the berberine induced autophagy leads to suppression of tumor proliferation with no side-effect, and western blotting displayed an apparent attenuation of p-mTOR, p-p70S6K, p-Akt, p-ERK, p-JNK and p-p38 in tumors from berberine treated mice.	Berberine	19-28	thymoma viral proto-oncogene 1	Mus musculus	190-193
32454290-11	2020	In xenografts, the berberine induced autophagy leads to suppression of tumor proliferation with no side-effect, and western blotting displayed an apparent attenuation of p-mTOR, p-p70S6K, p-Akt, p-ERK, p-JNK and p-p38 in tumors from berberine treated mice.	Berberine	19-28	mitogen-activated protein kinase 1	Mus musculus	197-200
32454290-11	2020	In xenografts, the berberine induced autophagy leads to suppression of tumor proliferation with no side-effect, and western blotting displayed an apparent attenuation of p-mTOR, p-p70S6K, p-Akt, p-ERK, p-JNK and p-p38 in tumors from berberine treated mice.	Berberine	19-28	mitogen-activated protein kinase 8	Mus musculus	204-207
32454290-11	2020	In xenografts, the berberine induced autophagy leads to suppression of tumor proliferation with no side-effect, and western blotting displayed an apparent attenuation of p-mTOR, p-p70S6K, p-Akt, p-ERK, p-JNK and p-p38 in tumors from berberine treated mice.	Berberine	19-28	mitogen-activated protein kinase 14	Mus musculus	214-217
32454290-12	2020	Briefly, these results indicated that berberine repressed human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt, and provided a molecular basis for the treatment of gastric cancer.	Berberine	38-47	mechanistic target of rapamycin kinase	Homo sapiens	168-172
32454290-12	2020	Briefly, these results indicated that berberine repressed human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt, and provided a molecular basis for the treatment of gastric cancer.	Berberine	38-47	ribosomal protein S6 kinase B1	Homo sapiens	173-179
32454290-12	2020	Briefly, these results indicated that berberine repressed human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt, and provided a molecular basis for the treatment of gastric cancer.	Berberine	38-47	AKT serine/threonine kinase 1	Homo sapiens	184-187
31734944-0	2020	Berberine protects against diabetic kidney disease via promoting PGC-1alpha-regulated mitochondrial energy homeostasis.	Berberine	0-9	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	65-75
31734944-9	2020	The protective mechanism of BBR might involve the activation of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) signaling pathway, thereby promoting mitochondrial energy homeostasis and fatty acid oxidation in podocytes.	Berberine	28-31	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	64-131
31734944-9	2020	The protective mechanism of BBR might involve the activation of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) signaling pathway, thereby promoting mitochondrial energy homeostasis and fatty acid oxidation in podocytes.	Berberine	28-31	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	133-143
31734944-11	2020	Restoration of PGC-1alpha activity and the energy homeostasis by BBR might be a potential therapeutic strategy against DKD.	Berberine	65-68	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	15-25
32915362-11	2020	The increase in berberine concentration led to an increase in miRNA-582-5p and miRNA-188-5p expression and a decrease in the expression of mRNA for the corresponding target genes encoding CDK1, CDK2, and cyclins D1 and A.	Berberine	16-25	cyclin dependent kinase 1	Homo sapiens	188-192
32915362-11	2020	The increase in berberine concentration led to an increase in miRNA-582-5p and miRNA-188-5p expression and a decrease in the expression of mRNA for the corresponding target genes encoding CDK1, CDK2, and cyclins D1 and A.	Berberine	16-25	cyclin dependent kinase 2	Homo sapiens	194-198
32915362-11	2020	The increase in berberine concentration led to an increase in miRNA-582-5p and miRNA-188-5p expression and a decrease in the expression of mRNA for the corresponding target genes encoding CDK1, CDK2, and cyclins D1 and A.	Berberine	16-25	cyclin D1	Homo sapiens	204-220
32394178-0	2020	Berberine Attenuates Cardiac Hypertrophy Through Inhibition of mTOR Signaling Pathway.	Berberine	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	63-67
32394178-9	2020	Western blot showed that mammalian target of rapamycin (mTOR) signaling-related protein expressions, including phospho-mTOR, phospho-4EBP1, and phospho-p70 S6K (Thr389), but not phospho-p70 S6K (Ser371), were significantly increased in the TAC group, which were inhibited by berberine treatment.	Berberine	275-284	mechanistic target of rapamycin kinase	Homo sapiens	25-54
32394178-9	2020	Western blot showed that mammalian target of rapamycin (mTOR) signaling-related protein expressions, including phospho-mTOR, phospho-4EBP1, and phospho-p70 S6K (Thr389), but not phospho-p70 S6K (Ser371), were significantly increased in the TAC group, which were inhibited by berberine treatment.	Berberine	275-284	mechanistic target of rapamycin kinase	Homo sapiens	56-60
32394178-11	2020	Berberine of 10 muM, but not 1 muM, significantly ameliorated NE-induced hypertrophy and inhibited protein expressions of mTOR signaling pathway similar to those in the rat model.	Berberine	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	122-126
32098768-0	2020	Discovery of berberine that targetedly induce autophagic degradation of both BCR-ABL and BCR-ABL T315I through recruiting LRSAM1 for overcoming imatinib-resistance.	Berberine	13-22	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	77-84
32098768-0	2020	Discovery of berberine that targetedly induce autophagic degradation of both BCR-ABL and BCR-ABL T315I through recruiting LRSAM1 for overcoming imatinib-resistance.	Berberine	13-22	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	89-96
32098768-0	2020	Discovery of berberine that targetedly induce autophagic degradation of both BCR-ABL and BCR-ABL T315I through recruiting LRSAM1 for overcoming imatinib-resistance.	Berberine	13-22	leucine rich repeat and sterile alpha motif containing 1	Homo sapiens	122-128
32098768-4	2020	Berberine (BBR) is a potent BCR-ABL inhibitor for imatinib-sensitive and -resistant CML.	Berberine	0-9	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	28-35
32098768-4	2020	Berberine (BBR) is a potent BCR-ABL inhibitor for imatinib-sensitive and -resistant CML.	Berberine	11-14	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	28-35
32690176-2	2020	This systematic review and meta-analysis were done based upon randomized controlled trials (RCTs) to analyze the effects of berberine on anthropometric parameters, CRP and liver enzymes.	Berberine	124-133	C-reactive protein	Homo sapiens	164-167
32690176-9	2020	CONCLUSION: This meta-analysis found a significant reduction of body weight, BMI, WC and CRP levels associated with berberine intake which may have played an indirect role in improved clinical symptoms in diseases with metabolic disorders.	Berberine	116-125	C-reactive protein	Homo sapiens	89-92
32790968-11	2020	Berberine activated IL6/STAT3 signaling in in vitro culture of G-MSDCs-like population, while inhibition of STAT3 activity attenuated the activation of this population by berberine.	Berberine	0-9	interleukin 6	Mus musculus	20-23
32790968-11	2020	Berberine activated IL6/STAT3 signaling in in vitro culture of G-MSDCs-like population, while inhibition of STAT3 activity attenuated the activation of this population by berberine.	Berberine	0-9	signal transducer and activator of transcription 3	Mus musculus	24-29
32790968-11	2020	Berberine activated IL6/STAT3 signaling in in vitro culture of G-MSDCs-like population, while inhibition of STAT3 activity attenuated the activation of this population by berberine.	Berberine	171-180	signal transducer and activator of transcription 3	Mus musculus	108-113
32412317-0	2020	Effect of Low Dose of Berberine on the Radioresistance of Cervical Cancer Cells via a PI3K/HIF-1 Pathway under Nutrient Deprived Conditions.	Berberine	22-31	hypoxia inducible factor 1 subunit alpha	Homo sapiens	91-96
32412317-4	2020	And berberine can regulate HIF-1.	Berberine	4-13	hypoxia inducible factor 1 subunit alpha	Homo sapiens	27-32
32412317-9	2020	Protein-protein interaction (PPI) network analyses of DEGs related to HIF-1alpha were conducted by using the STRING database and Cytoscape software.Results: Berberine dramatically damaged HeLa cells under hypoxic and low glucose conditions compared with the normoxic and high glucose conditions.	Berberine	157-166	hypoxia inducible factor 1 subunit alpha	Homo sapiens	70-80
32412317-11	2020	Low doses of berberine might decrease the level of phospho-PI3K and HIF-1alpha under the nutrient deprived conditions.	Berberine	13-22	hypoxia inducible factor 1 subunit alpha	Homo sapiens	68-78
32412317-12	2020	Moreover, we found that most of the differentially expressed genes which were related to CDKN1B were the downstream molecules regulated by HIF-1alpha.Conclusion: The results indicated that berberine could dramatically overcome the low glucose and hypoxia induced radioresistance.	Berberine	189-198	cyclin dependent kinase inhibitor 1B	Homo sapiens	89-95
32412317-12	2020	Moreover, we found that most of the differentially expressed genes which were related to CDKN1B were the downstream molecules regulated by HIF-1alpha.Conclusion: The results indicated that berberine could dramatically overcome the low glucose and hypoxia induced radioresistance.	Berberine	189-198	hypoxia inducible factor 1 subunit alpha	Homo sapiens	139-149
32412317-13	2020	And the regulation berberine on nutrition deficient conditions might involve in PI3K/HIF-1 pathway.	Berberine	19-28	hypoxia inducible factor 1 subunit alpha	Homo sapiens	85-90
32944532-0	2020	Berberine alleviates cisplatin-induced acute kidney injury by regulating mitophagy via PINK 1/Parkin pathway.	Berberine	0-9	PTEN induced putative kinase 1	Mus musculus	87-93
32944532-11	2020	PAS staining and immunohistochemistry showed that BBR ameliorated cisplatin-induced nephrotoxicity and reduced cisplatin-induced increase in protein expression levels of KIM-1.	Berberine	50-53	hepatitis A virus cellular receptor 1	Mus musculus	170-175
32944532-12	2020	Compared to cisplatin-treated mice, the mice treated with BBR showed increased LC3 II/LC3 I, PINK 1, and Parkin, and decreased p62 protein expression.	Berberine	58-61	PTEN induced putative kinase 1	Mus musculus	93-99
32944532-12	2020	Compared to cisplatin-treated mice, the mice treated with BBR showed increased LC3 II/LC3 I, PINK 1, and Parkin, and decreased p62 protein expression.	Berberine	58-61	nucleoporin 62	Mus musculus	127-130
32792855-0	2020	Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance via reduction in association of the Glucocorticoid Receptor with phosphatidylinositol-3-kinase.	Berberine	20-29	nuclear receptor subfamily 3, group C, member 1	Mus musculus	51-74
32792855-0	2020	Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance via reduction in association of the Glucocorticoid Receptor with phosphatidylinositol-3-kinase.	Berberine	20-29	nuclear receptor subfamily 3, group C, member 1	Mus musculus	139-162
30902523-7	2020	These beneficial properties of berberine are mediated in part through its ability to target multiple signaling pathways, including PKA, p38 MAPK, Wnt/beta-catenin, AMPK, RANK/RANKL/OPG, PI3K/Akt, NFAT, NF-kappaB, Hedgehog, and oxidative stress signaling.	Berberine	31-40	catenin beta 1	Homo sapiens	150-162
32785222-0	2020	The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome.	Berberine	45-54	insulin	Homo sapiens	62-69
32785222-1	2020	OBJECTIVE: To study the role of selected serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome (PCOS).	Berberine	74-83	insulin	Homo sapiens	91-98
32785222-7	2020	Fluorescence microscope and flow cytometry were used to detect the glucose uptake capacity of ovarian granulosa cells in PCOS patients under the action of insulin after berberine.	Berberine	169-178	insulin	Homo sapiens	155-162
32785222-11	2020	Berberine significantly reduced the expression level of mTOR mRNA (P = 0.001), and increased the expression level of IRS-1 mRNA (P = 0.009) in the PCOS granule cells.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	56-60
32785222-11	2020	Berberine significantly reduced the expression level of mTOR mRNA (P = 0.001), and increased the expression level of IRS-1 mRNA (P = 0.009) in the PCOS granule cells.	Berberine	0-9	insulin receptor substrate 1	Homo sapiens	117-122
32785222-14	2020	Berberine can improve the sensitivity of insulin by regulating the signal pathway of insulin receptor substrate-1 (IRS-1) and mammalian target of rapamycin (mTOR) in PCOS patients and achieve a therapeutic effect of treating PCOS.	Berberine	0-9	insulin	Homo sapiens	41-48
32785222-14	2020	Berberine can improve the sensitivity of insulin by regulating the signal pathway of insulin receptor substrate-1 (IRS-1) and mammalian target of rapamycin (mTOR) in PCOS patients and achieve a therapeutic effect of treating PCOS.	Berberine	0-9	insulin receptor substrate 1	Homo sapiens	85-113
32785222-14	2020	Berberine can improve the sensitivity of insulin by regulating the signal pathway of insulin receptor substrate-1 (IRS-1) and mammalian target of rapamycin (mTOR) in PCOS patients and achieve a therapeutic effect of treating PCOS.	Berberine	0-9	insulin receptor substrate 1	Homo sapiens	115-120
32785222-14	2020	Berberine can improve the sensitivity of insulin by regulating the signal pathway of insulin receptor substrate-1 (IRS-1) and mammalian target of rapamycin (mTOR) in PCOS patients and achieve a therapeutic effect of treating PCOS.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	126-155
30902523-7	2020	These beneficial properties of berberine are mediated in part through its ability to target multiple signaling pathways, including PKA, p38 MAPK, Wnt/beta-catenin, AMPK, RANK/RANKL/OPG, PI3K/Akt, NFAT, NF-kappaB, Hedgehog, and oxidative stress signaling.	Berberine	31-40	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	164-168
30902523-7	2020	These beneficial properties of berberine are mediated in part through its ability to target multiple signaling pathways, including PKA, p38 MAPK, Wnt/beta-catenin, AMPK, RANK/RANKL/OPG, PI3K/Akt, NFAT, NF-kappaB, Hedgehog, and oxidative stress signaling.	Berberine	31-40	TNF superfamily member 11	Homo sapiens	175-180
30902523-7	2020	These beneficial properties of berberine are mediated in part through its ability to target multiple signaling pathways, including PKA, p38 MAPK, Wnt/beta-catenin, AMPK, RANK/RANKL/OPG, PI3K/Akt, NFAT, NF-kappaB, Hedgehog, and oxidative stress signaling.	Berberine	31-40	basic transcription factor 3 pseudogene 11	Homo sapiens	181-184
30902523-7	2020	These beneficial properties of berberine are mediated in part through its ability to target multiple signaling pathways, including PKA, p38 MAPK, Wnt/beta-catenin, AMPK, RANK/RANKL/OPG, PI3K/Akt, NFAT, NF-kappaB, Hedgehog, and oxidative stress signaling.	Berberine	31-40	AKT serine/threonine kinase 1	Homo sapiens	191-194
30902523-7	2020	These beneficial properties of berberine are mediated in part through its ability to target multiple signaling pathways, including PKA, p38 MAPK, Wnt/beta-catenin, AMPK, RANK/RANKL/OPG, PI3K/Akt, NFAT, NF-kappaB, Hedgehog, and oxidative stress signaling.	Berberine	31-40	nuclear factor kappa B subunit 1	Homo sapiens	202-211
32475643-4	2020	Berberine increased the level of p53 protein and of its target p21 both time- and dose-dependently in MCF7 cells.	Berberine	0-9	tumor protein p53	Homo sapiens	33-36
32679729-3	2020	Pharmacological reagents, including statins, metformin, berberine, polyphenol, and resveratrol, all of which are widely used therapeutics for cardiovascular disorders, appear to deliver their protective/therapeutic effects partially via AMPK signaling modulation.	Berberine	56-65	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	237-241
32475643-4	2020	Berberine increased the level of p53 protein and of its target p21 both time- and dose-dependently in MCF7 cells.	Berberine	0-9	H3 histone pseudogene 16	Homo sapiens	63-66
32475643-7	2020	Therefore, we evaluated the possibility of berberine-induced nucleolar stress and observed the disappearance of ribosomal protein (RP)L5 from the nucleolus and accumulation of p53 protein in the nucleus after treatment with 10 or 100 muM berberine in MCF7 cells.	Berberine	238-247	ribosomal protein L5	Homo sapiens	112-136
32475643-7	2020	Therefore, we evaluated the possibility of berberine-induced nucleolar stress and observed the disappearance of ribosomal protein (RP)L5 from the nucleolus and accumulation of p53 protein in the nucleus after treatment with 10 or 100 muM berberine in MCF7 cells.	Berberine	238-247	tumor protein p53	Homo sapiens	176-179
32475643-9	2020	Moreover, downregulation of RPL5 inhibited berberine-driven induction of p53 and p21 and cell death in MCF7 cells.	Berberine	43-52	ribosomal protein L5	Homo sapiens	28-32
32475643-9	2020	Moreover, downregulation of RPL5 inhibited berberine-driven induction of p53 and p21 and cell death in MCF7 cells.	Berberine	43-52	tumor protein p53	Homo sapiens	73-76
32475643-9	2020	Moreover, downregulation of RPL5 inhibited berberine-driven induction of p53 and p21 and cell death in MCF7 cells.	Berberine	43-52	H3 histone pseudogene 16	Homo sapiens	81-84
32475643-11	2020	These results indicated that cell growth inhibition and cell death induced by higher doses (>10 muM) of berberine in MCF7 cells were due to the upregulation of p53 under the nucleolar stress response caused by a significant accumulation of berberine in the nucleoli.	Berberine	104-113	tumor protein p53	Homo sapiens	160-163
32475643-11	2020	These results indicated that cell growth inhibition and cell death induced by higher doses (>10 muM) of berberine in MCF7 cells were due to the upregulation of p53 under the nucleolar stress response caused by a significant accumulation of berberine in the nucleoli.	Berberine	240-249	tumor protein p53	Homo sapiens	160-163
32660149-0	2020	Glutamic-Pyruvic Transaminase 1 Facilitates Alternative Fuels for Hepatocellular Carcinoma Growth-A Small Molecule Inhibitor, Berberine.	Berberine	126-135	glutamic--pyruvic transaminase	Homo sapiens	0-31
32754040-0	2020	Berberine Ameliorates Subarachnoid Hemorrhage Injury via Induction of Sirtuin 1 and Inhibiting HMGB1/Nf-kappaB Pathway.	Berberine	0-9	sirtuin 1	Homo sapiens	70-79
32754040-0	2020	Berberine Ameliorates Subarachnoid Hemorrhage Injury via Induction of Sirtuin 1 and Inhibiting HMGB1/Nf-kappaB Pathway.	Berberine	0-9	high mobility group box 1	Homo sapiens	95-100
32754040-0	2020	Berberine Ameliorates Subarachnoid Hemorrhage Injury via Induction of Sirtuin 1 and Inhibiting HMGB1/Nf-kappaB Pathway.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	101-110
32754040-6	2020	Moreover, berberine significantly inhibited high mobile group box 1 (HMGB1)/nuclear factor-kappaB (Nf-kappaB)-dependent pathway and enhanced sirtuin 1 (SIRT1) expression after SAH.	Berberine	10-19	high mobility group box 1	Homo sapiens	44-67
32754040-6	2020	Moreover, berberine significantly inhibited high mobile group box 1 (HMGB1)/nuclear factor-kappaB (Nf-kappaB)-dependent pathway and enhanced sirtuin 1 (SIRT1) expression after SAH.	Berberine	10-19	high mobility group box 1	Homo sapiens	69-74
32754040-6	2020	Moreover, berberine significantly inhibited high mobile group box 1 (HMGB1)/nuclear factor-kappaB (Nf-kappaB)-dependent pathway and enhanced sirtuin 1 (SIRT1) expression after SAH.	Berberine	10-19	nuclear factor kappa B subunit 1	Homo sapiens	99-108
32754040-6	2020	Moreover, berberine significantly inhibited high mobile group box 1 (HMGB1)/nuclear factor-kappaB (Nf-kappaB)-dependent pathway and enhanced sirtuin 1 (SIRT1) expression after SAH.	Berberine	10-19	sirtuin 1	Homo sapiens	141-150
32754040-6	2020	Moreover, berberine significantly inhibited high mobile group box 1 (HMGB1)/nuclear factor-kappaB (Nf-kappaB)-dependent pathway and enhanced sirtuin 1 (SIRT1) expression after SAH.	Berberine	10-19	sirtuin 1	Homo sapiens	152-157
32754040-7	2020	Treatment with ex527, a selective SIRT1 inhibitor, reversed berberine-induced SIRT1 activation and inhibitory effects on HMGB1/Nf-kappaB activation.	Berberine	60-69	sirtuin 1	Homo sapiens	34-39
32754040-7	2020	Treatment with ex527, a selective SIRT1 inhibitor, reversed berberine-induced SIRT1 activation and inhibitory effects on HMGB1/Nf-kappaB activation.	Berberine	60-69	sirtuin 1	Homo sapiens	78-83
32754040-9	2020	Taken together, these findings suggest that berberine provides beneficial effects against SAH-triggered cerebral inflammation by inhibiting HMGB1/Nf-kappaB pathway, which may be modulated by SIRT1 activation.	Berberine	44-53	high mobility group box 1	Homo sapiens	140-145
32754040-9	2020	Taken together, these findings suggest that berberine provides beneficial effects against SAH-triggered cerebral inflammation by inhibiting HMGB1/Nf-kappaB pathway, which may be modulated by SIRT1 activation.	Berberine	44-53	nuclear factor kappa B subunit 1	Homo sapiens	146-155
32754040-9	2020	Taken together, these findings suggest that berberine provides beneficial effects against SAH-triggered cerebral inflammation by inhibiting HMGB1/Nf-kappaB pathway, which may be modulated by SIRT1 activation.	Berberine	44-53	sirtuin 1	Homo sapiens	191-196
32660149-7	2020	Combining molecular docking and metabolomics analyses, our study further identified a naturally occurring alkaloid, berberine (BBR), as the GPT1 inhibitor in HCC.	Berberine	116-125	glutamic--pyruvic transaminase	Homo sapiens	140-144
32660149-7	2020	Combining molecular docking and metabolomics analyses, our study further identified a naturally occurring alkaloid, berberine (BBR), as the GPT1 inhibitor in HCC.	Berberine	127-130	glutamic--pyruvic transaminase	Homo sapiens	140-144
32353823-6	2020	Other mechanism ascribed to Berberine are related to its inhibition of hepatic gluconeogenesis through the Phospheoenolpyruvate carboxykinase (PEPCK), Glucose-6-phosphate (G6Pase) and AMP-activated protein kinase (AMPK).	Berberine	28-37	phosphoenolpyruvate carboxykinase 2, mitochondrial	Homo sapiens	107-141
32623439-11	2020	The key roles of Erbb4, Erbb2, Ar, and Grin2a in berberine treatment were identified.	Berberine	49-58	erb-b2 receptor tyrosine kinase 4	Rattus norvegicus	17-22
32623439-11	2020	The key roles of Erbb4, Erbb2, Ar, and Grin2a in berberine treatment were identified.	Berberine	49-58	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	24-29
32623439-11	2020	The key roles of Erbb4, Erbb2, Ar, and Grin2a in berberine treatment were identified.	Berberine	49-58	glutamate ionotropic receptor NMDA type subunit 2A	Rattus norvegicus	39-45
32353823-6	2020	Other mechanism ascribed to Berberine are related to its inhibition of hepatic gluconeogenesis through the Phospheoenolpyruvate carboxykinase (PEPCK), Glucose-6-phosphate (G6Pase) and AMP-activated protein kinase (AMPK).	Berberine	28-37	phosphoenolpyruvate carboxykinase 2, mitochondrial	Homo sapiens	143-148
32353823-6	2020	Other mechanism ascribed to Berberine are related to its inhibition of hepatic gluconeogenesis through the Phospheoenolpyruvate carboxykinase (PEPCK), Glucose-6-phosphate (G6Pase) and AMP-activated protein kinase (AMPK).	Berberine	28-37	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	172-178
32353823-6	2020	Other mechanism ascribed to Berberine are related to its inhibition of hepatic gluconeogenesis through the Phospheoenolpyruvate carboxykinase (PEPCK), Glucose-6-phosphate (G6Pase) and AMP-activated protein kinase (AMPK).	Berberine	28-37	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	184-212
32353823-6	2020	Other mechanism ascribed to Berberine are related to its inhibition of hepatic gluconeogenesis through the Phospheoenolpyruvate carboxykinase (PEPCK), Glucose-6-phosphate (G6Pase) and AMP-activated protein kinase (AMPK).	Berberine	28-37	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	214-218
32555173-10	2020	BBR induced the expression of beta-catenin and enhanced beta-catenin entering into the nucleus, to up-regulate more runt-related nuclear factor 2 downstream.	Berberine	0-3	catenin beta 1	Rattus norvegicus	30-42
32080865-0	2020	Combination of metformin and berberine represses the apoptosis of sebocytes in high-fat diet-induced diabetic hamsters and an insulin-treated human cell line.	Berberine	29-38	insulin	Homo sapiens	126-133
32080865-8	2020	Sebocytes isolated from high-fat diet-induced diabetic hamsters and insulin-treated human sebocytes displayed elevated cell death rates, which were attenuated by berberine and metformin treatments.	Berberine	162-171	insulin	Homo sapiens	68-75
32080865-9	2020	Further studies showed that the effects of metformin and berberine on cellular apoptosis were mediated via the Bik pathway.	Berberine	57-66	BCL2 interacting killer	Homo sapiens	111-114
32080865-10	2020	Thus, berberine may effectively decrease circulating glucose levels, ameliorate insulin resistance, reduce body weight, and attenuate sebocyte apoptosis in diabetic hamsters, potentially decreasing vulnerability to the cardiovascular complications of diabetes.	Berberine	6-15	insulin	Homo sapiens	80-87
31598896-0	2020	Berberine Promotes Osteogenic Differentiation of Human Dental Pulp Stem Cells Through Activating EGFR-MAPK-Runx2 Pathways.	Berberine	0-9	epidermal growth factor receptor	Homo sapiens	97-101
31598896-0	2020	Berberine Promotes Osteogenic Differentiation of Human Dental Pulp Stem Cells Through Activating EGFR-MAPK-Runx2 Pathways.	Berberine	0-9	RUNX family transcription factor 2	Homo sapiens	107-112
31598896-7	2020	BBR (1 muM and 5 muM) was pre-added to into medium, and then cell proliferation, spheroid formation and osteogenic differentiation capacities of DPSCs were analyzed, as well as the underlying molecules modulation mechanism.	Berberine	0-3	latexin	Homo sapiens	7-10
31598896-7	2020	BBR (1 muM and 5 muM) was pre-added to into medium, and then cell proliferation, spheroid formation and osteogenic differentiation capacities of DPSCs were analyzed, as well as the underlying molecules modulation mechanism.	Berberine	0-3	latexin	Homo sapiens	17-20
31598896-9	2020	BBR enhanced the cell proliferation of hDPSCs in a dose-dependent pattern, and promoted dexamethasone-induced osteogenic differentiation via enhancing Runx2 transcription factor activity followed by upregulating osteogenesis markers expression, whereas the adipogenic differentiation of hDPSCs was suppressed dramatically by BBR.	Berberine	0-3	RUNX family transcription factor 2	Homo sapiens	151-156
31598896-10	2020	The EGFR and MAPK pathways were activated by BBR, and inhibitors for these pathways significantly suppressed the osteogenic differentiation promotion of BBR.	Berberine	45-48	epidermal growth factor receptor	Homo sapiens	4-8
31598896-10	2020	The EGFR and MAPK pathways were activated by BBR, and inhibitors for these pathways significantly suppressed the osteogenic differentiation promotion of BBR.	Berberine	153-156	epidermal growth factor receptor	Homo sapiens	4-8
31598896-11	2020	These results have revealed a novel mechanism that berberine might promote hDPSCs osteogenic differentiation through activating EGFR-MAPK-Runx2 signaling pathways.	Berberine	51-60	epidermal growth factor receptor	Homo sapiens	128-132
31598896-11	2020	These results have revealed a novel mechanism that berberine might promote hDPSCs osteogenic differentiation through activating EGFR-MAPK-Runx2 signaling pathways.	Berberine	51-60	RUNX family transcription factor 2	Homo sapiens	138-143
32598269-1	2021	BACKGROUND: Berberine (BBR), an isoquinoline alkaloid, acts as a multipotent active pharmaceutical ingredient to counteract several types of dementia based on its numerous pharmacological actions including antioxidant, antiinflammatory, cholesterol-lowering effect, and inhibition of Abeta production and AChE.	Berberine	12-21	amyloid beta precursor protein	Rattus norvegicus	284-289
32598269-1	2021	BACKGROUND: Berberine (BBR), an isoquinoline alkaloid, acts as a multipotent active pharmaceutical ingredient to counteract several types of dementia based on its numerous pharmacological actions including antioxidant, antiinflammatory, cholesterol-lowering effect, and inhibition of Abeta production and AChE.	Berberine	12-21	acetylcholinesterase	Rattus norvegicus	305-309
32598269-1	2021	BACKGROUND: Berberine (BBR), an isoquinoline alkaloid, acts as a multipotent active pharmaceutical ingredient to counteract several types of dementia based on its numerous pharmacological actions including antioxidant, antiinflammatory, cholesterol-lowering effect, and inhibition of Abeta production and AChE.	Berberine	23-26	amyloid beta precursor protein	Rattus norvegicus	284-289
32598269-1	2021	BACKGROUND: Berberine (BBR), an isoquinoline alkaloid, acts as a multipotent active pharmaceutical ingredient to counteract several types of dementia based on its numerous pharmacological actions including antioxidant, antiinflammatory, cholesterol-lowering effect, and inhibition of Abeta production and AChE.	Berberine	23-26	acetylcholinesterase	Rattus norvegicus	305-309
32606611-7	2020	In addition, the AS + DH + BBR + 3-MA group exhibited a significantly enlarged plaque, substantial foam cell and macrophage infiltration, increased levels of IL-1beta and TNF-alpha, and decreased LC3-II and P62 (P < 0.01) expression when compared to the AS + DH + BBR group.	Berberine	27-30	interleukin 1 alpha	Rattus norvegicus	158-166
32606611-7	2020	In addition, the AS + DH + BBR + 3-MA group exhibited a significantly enlarged plaque, substantial foam cell and macrophage infiltration, increased levels of IL-1beta and TNF-alpha, and decreased LC3-II and P62 (P < 0.01) expression when compared to the AS + DH + BBR group.	Berberine	27-30	tumor necrosis factor	Rattus norvegicus	171-180
32606611-7	2020	In addition, the AS + DH + BBR + 3-MA group exhibited a significantly enlarged plaque, substantial foam cell and macrophage infiltration, increased levels of IL-1beta and TNF-alpha, and decreased LC3-II and P62 (P < 0.01) expression when compared to the AS + DH + BBR group.	Berberine	27-30	annexin A3	Rattus norvegicus	196-199
32606611-7	2020	In addition, the AS + DH + BBR + 3-MA group exhibited a significantly enlarged plaque, substantial foam cell and macrophage infiltration, increased levels of IL-1beta and TNF-alpha, and decreased LC3-II and P62 (P < 0.01) expression when compared to the AS + DH + BBR group.	Berberine	27-30	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	207-210
32272506-0	2020	Berberine suppresses influenza virus-triggered NLRP3 inflammasome activation in macrophages by inducing mitophagy and decreasing mitochondrial ROS.	Berberine	0-9	NLR family pyrin domain containing 3	Homo sapiens	47-52
32272506-4	2020	This study focuses on the reactive oxygen species-Nod-like receptor protein 3 (ROS-NLRP3) pathway to investigate whether BBR inhibits NLRP3 inflammasome activation by inducing mitophagy.	Berberine	121-124	NLR family pyrin domain containing 3	Homo sapiens	83-88
32272506-4	2020	This study focuses on the reactive oxygen species-Nod-like receptor protein 3 (ROS-NLRP3) pathway to investigate whether BBR inhibits NLRP3 inflammasome activation by inducing mitophagy.	Berberine	121-124	NLR family pyrin domain containing 3	Homo sapiens	134-139
32272506-7	2020	BBR treatment induced regular mitophagy, as evident from the increase in microtubule-associated protein 1 light chain 3 II, decrease in p62, colocalization of LC3 and mitochondria, and formation of autophagosomes.	Berberine	0-3	nucleoporin 62	Homo sapiens	136-139
32272506-7	2020	BBR treatment induced regular mitophagy, as evident from the increase in microtubule-associated protein 1 light chain 3 II, decrease in p62, colocalization of LC3 and mitochondria, and formation of autophagosomes.	Berberine	0-3	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	159-162
32272506-8	2020	However, 3-methyladenine, an autophagy inhibitor, reversed the inhibitory effects of BBR on mitochondrial damage and NLRP3 inflammasome activation in influenza virus-infected macrophages, indicating the involvement of mitophagy in mediating the inhibitory effects of BBR on NLRP3 inflammasome activation.	Berberine	85-88	NLR family pyrin domain containing 3	Homo sapiens	274-279
32272506-9	2020	Furthermore, the knockdown of Bcl-2/adenovirus E18-19-kDa interacting protein 3 (BNIP3) expression attenuated the effects of BBR on mitophagy induction to some extent, suggesting that the BBR-induced mitophagy may be, at least in part, mediated in a BNIP3-dependent manner.	Berberine	125-128	BCL2 apoptosis regulator	Homo sapiens	30-79
32272506-9	2020	Furthermore, the knockdown of Bcl-2/adenovirus E18-19-kDa interacting protein 3 (BNIP3) expression attenuated the effects of BBR on mitophagy induction to some extent, suggesting that the BBR-induced mitophagy may be, at least in part, mediated in a BNIP3-dependent manner.	Berberine	188-191	BCL2 apoptosis regulator	Homo sapiens	30-79
32272506-11	2020	Taken together, these findings suggest that restricting NLRP3 inflammasome activation by decreasing ROS generation through mitophagy induction may be crucial for the BBR-mediated alleviation of influenza virus-induced inflammatory lesions.	Berberine	166-169	NLR family pyrin domain containing 3	Homo sapiens	56-61
32251633-0	2020	Berberine attenuates Abeta42-induced neuronal damage through regulating circHDAC9/miR-142-5p axis in human neuronal cells.	Berberine	0-9	histone deacetylase 9	Homo sapiens	72-81
32251633-3	2020	In the current work, we aimed to investigate whether circRNA histone deacetylase 9 (circHDAC9) was involved in the regulation of berberine in AD.	Berberine	129-138	histone deacetylase 9	Homo sapiens	84-93
32251633-12	2020	Moreover, berberine resulted in increased circHDAC9 expression and decreased miR-142-5p level in Abeta42-treated HN cells.	Berberine	10-19	histone deacetylase 9	Homo sapiens	42-51
32251633-13	2020	Berberine alleviated Abeta42-induced neuronal damage in HN cells by up-regulating circHDAC9.	Berberine	0-9	histone deacetylase 9	Homo sapiens	82-91
32251633-16	2020	CONCLUSION: Our current study suggested that berberine protected HN cell from Abeta42-induced neuronal damage at least partly through regulating the circHDAC9/miR-142-5p axis, highlighting novel evidence for the neuroprotective effect of berberine in AD.	Berberine	45-54	histone deacetylase 9	Homo sapiens	149-158
32905254-10	2020	Moreover, pretreatment of oocytes with Ac-DEVD-cho, a caspase-3-specific inhibitor, effectively blocked berberine-induced negative impacts on oocyte maturation, fertilization and subsequent development.	Berberine	104-113	caspase 3	Mus musculus	54-63
32905254-11	2020	Collectively, these findings establish the dose-dependent beneficial versus deleterious effects of berberine and suggest that the mechanism underlying the deleterious effects of berberine involves a caspase-3-dependent apoptotic process acting downstream of an increase in intracellular ROS levels.	Berberine	178-187	caspase 3	Mus musculus	199-208
32440681-5	2020	However, MECR protein was decreased in the liver of DIO mice, and the reduction was blocked by treatment of the DIO mice with berberine (BBR).	Berberine	126-135	mitochondrial trans-2-enoyl-CoA reductase	Mus musculus	9-13
32440681-5	2020	However, MECR protein was decreased in the liver of DIO mice, and the reduction was blocked by treatment of the DIO mice with berberine (BBR).	Berberine	137-140	mitochondrial trans-2-enoyl-CoA reductase	Mus musculus	9-13
32555173-10	2020	BBR induced the expression of beta-catenin and enhanced beta-catenin entering into the nucleus, to up-regulate more runt-related nuclear factor 2 downstream.	Berberine	0-3	catenin beta 1	Rattus norvegicus	56-68
32560082-6	2020	The administration of berberine resulted in an increased soluble protein level, decreased activity of AR, and lowered AOPP and AGEs levels.	Berberine	22-31	aldo-keto reductase family 1 member B1	Rattus norvegicus	102-104
32581538-8	2020	Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-kappaB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.	Berberine	23-26	myeloperoxidase	Mus musculus	111-114
32606611-6	2020	After four weeks of BBR intervention, the plaque area in the AS + DH + BBR group was reduced with decreased foam cells and macrophage infiltration, and decreased levels of TNF-alpha and IL-1beta, whereas LC3-II protein expression was increased and P62 protein expression was decreased in the AS + DH + BBR group when compared to AS + DH group.	Berberine	20-23	tumor necrosis factor	Rattus norvegicus	172-181
32606611-6	2020	After four weeks of BBR intervention, the plaque area in the AS + DH + BBR group was reduced with decreased foam cells and macrophage infiltration, and decreased levels of TNF-alpha and IL-1beta, whereas LC3-II protein expression was increased and P62 protein expression was decreased in the AS + DH + BBR group when compared to AS + DH group.	Berberine	20-23	interleukin 1 alpha	Rattus norvegicus	186-194
32606611-6	2020	After four weeks of BBR intervention, the plaque area in the AS + DH + BBR group was reduced with decreased foam cells and macrophage infiltration, and decreased levels of TNF-alpha and IL-1beta, whereas LC3-II protein expression was increased and P62 protein expression was decreased in the AS + DH + BBR group when compared to AS + DH group.	Berberine	20-23	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	248-251
30168114-13	2020	Moreover, berberine administration reversed the mRNA and protein expression of TRPV1 in dorsal root ganglion neurons after peripheral nerve injury.	Berberine	10-19	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	79-84
30168114-15	2020	The amelioration of neuropathic pain by berberine may be associated with the down-regulation of TRPV1 in DRG of neuropathic pain rats.	Berberine	40-49	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	96-101
32681256-0	2020	Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway.	Berberine	0-9	serine/threonine kinase 11	Rattus norvegicus	119-123
32681256-0	2020	Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	124-128
32681256-0	2020	Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway.	Berberine	0-9	CREB regulated transcription coactivator 2	Rattus norvegicus	129-134
32681256-12	2020	In addition, we found that berberine significantly increased the expression of p-AMPK and LKB1, while decreasing the p-TORC2 levels in skeletal muscles and adipose tissues.	Berberine	27-36	serine/threonine kinase 11	Rattus norvegicus	90-94
32681256-12	2020	In addition, we found that berberine significantly increased the expression of p-AMPK and LKB1, while decreasing the p-TORC2 levels in skeletal muscles and adipose tissues.	Berberine	27-36	CREB regulated transcription coactivator 2	Rattus norvegicus	119-124
32681256-13	2020	Moreover, the expression of PEPCK and G6Pase was significantly down-regulated after the treatment with berberine compared to the model group.	Berberine	103-112	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	28-33
32681256-13	2020	Moreover, the expression of PEPCK and G6Pase was significantly down-regulated after the treatment with berberine compared to the model group.	Berberine	103-112	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	38-44
32681256-14	2020	It was suggested that the mechanism by which berberine inhibited peripheral tissue gluconeogenesis may be attributed to the activation of the LKB1-AMPK-TORC2 signaling pathway.	Berberine	45-54	serine/threonine kinase 11	Rattus norvegicus	142-146
32681256-14	2020	It was suggested that the mechanism by which berberine inhibited peripheral tissue gluconeogenesis may be attributed to the activation of the LKB1-AMPK-TORC2 signaling pathway.	Berberine	45-54	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	147-151
32681256-14	2020	It was suggested that the mechanism by which berberine inhibited peripheral tissue gluconeogenesis may be attributed to the activation of the LKB1-AMPK-TORC2 signaling pathway.	Berberine	45-54	CREB regulated transcription coactivator 2	Rattus norvegicus	152-157
31909440-7	2020	Zebrafish larvae pretreated with BBR and its derivatives showed recovery on c-fos expression and neuronal discharges during seizures.	Berberine	33-36	v-fos FBJ murine osteosarcoma viral oncogene homolog Ab	Danio rerio	76-81
31909440-14	2020	Zebrafish larvae pretreated with BBR and its derivatives showed recovery on c-fos expression and neuronal discharges during seizures.	Berberine	33-36	v-fos FBJ murine osteosarcoma viral oncogene homolog Ab	Danio rerio	76-81
32108297-0	2020	The Secretion from Bone Marrow Mesenchymal Stem Cells Pretreated with Berberine Rescues Neurons with Oxidative Damage Through Activation of the Keap1-Nrf2-HO-1 Signaling Pathway.	Berberine	70-79	kelch like ECH associated protein 1	Homo sapiens	144-149
32108297-0	2020	The Secretion from Bone Marrow Mesenchymal Stem Cells Pretreated with Berberine Rescues Neurons with Oxidative Damage Through Activation of the Keap1-Nrf2-HO-1 Signaling Pathway.	Berberine	70-79	NFE2 like bZIP transcription factor 2	Homo sapiens	150-154
32108297-0	2020	The Secretion from Bone Marrow Mesenchymal Stem Cells Pretreated with Berberine Rescues Neurons with Oxidative Damage Through Activation of the Keap1-Nrf2-HO-1 Signaling Pathway.	Berberine	70-79	heme oxygenase 1	Homo sapiens	155-159
32108297-2	2020	Berberine (BBR) can improve antioxidative capacity and inhibit Abeta protein aggregation and tau protein hyperphosphorylation in AD, and stem cell therapy is also increasingly recognized as a therapy for AD.	Berberine	0-9	microtubule associated protein tau	Homo sapiens	93-96
32108297-2	2020	Berberine (BBR) can improve antioxidative capacity and inhibit Abeta protein aggregation and tau protein hyperphosphorylation in AD, and stem cell therapy is also increasingly recognized as a therapy for AD.	Berberine	11-14	microtubule associated protein tau	Homo sapiens	93-96
32656311-10	2020	Our study exhibited that curcumin, nimbin, withaferin A, piperine, mangiferin, thebaine, berberine, and andrographolide have significant binding affinity towards spike glycoprotein of SARS-CoV-2 and ACE2 receptor and may be useful as a therapeutic and/or prophylactic agent for restricting viral attachment to the host cells.	Berberine	89-98	angiotensin converting enzyme 2	Homo sapiens	199-203
32566106-6	2020	Here, we demonstrated that berberine reduced serum lipid levels, antagonized hepatic lipid accumulation, improved intima-media thickening, and alleviated atherosclerotic lesions in ApoE-/- mice fed a western-type diet for 12 weeks.	Berberine	27-36	apolipoprotein E	Mus musculus	181-185
32566106-7	2020	Meanwhile, berberine reduced aortic reactive oxygen species (ROS) generation and reduced the serum levels of malondialdehyde (MDA), oxidized low-density lipoprotein (ox-LDL), and interleukin-6 (IL-6).	Berberine	11-20	interleukin 6	Mus musculus	179-192
32566106-7	2020	Meanwhile, berberine reduced aortic reactive oxygen species (ROS) generation and reduced the serum levels of malondialdehyde (MDA), oxidized low-density lipoprotein (ox-LDL), and interleukin-6 (IL-6).	Berberine	11-20	interleukin 6	Mus musculus	194-198
32566106-9	2020	Furthermore, 4,956 proteins were identified by proteomic analysis, and 199 differentially expressed proteins regulated by berberine were found to be involved in many biological pathways, such as mitochondrial dysfunction, fatty acid beta-oxidation I, and FXR/RXR activation.	Berberine	122-131	nuclear receptor subfamily 1, group H, member 4	Mus musculus	255-258
32270794-4	2020	A berberine/hydroxylpropyl-beta-cyclodextrin (HP-beta-CD) inclusion complex was first prepared to improve the solubility of berberine and loaded into a thermoresponsive hydrogel system of poloxamers.	Berberine	2-11	ACD, shelterin complex subunit and telomerase recruitment factor	Rattus norvegicus	49-56
32270794-4	2020	A berberine/hydroxylpropyl-beta-cyclodextrin (HP-beta-CD) inclusion complex was first prepared to improve the solubility of berberine and loaded into a thermoresponsive hydrogel system of poloxamers.	Berberine	124-133	ACD, shelterin complex subunit and telomerase recruitment factor	Rattus norvegicus	49-56
32429849-0	2020	Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway.	Berberine	30-39	angiopoietin-like 2	Rattus norvegicus	85-92
32429849-3	2020	Our study investigated the possible molecular mechanisms of berberine (BBR) in the treatment of the liver inflammatory response in the livers of rats with high-fat diet-induced NAFLD via the Angptl2 pathway.	Berberine	60-69	angiopoietin-like 2	Rattus norvegicus	191-198
32429849-3	2020	Our study investigated the possible molecular mechanisms of berberine (BBR) in the treatment of the liver inflammatory response in the livers of rats with high-fat diet-induced NAFLD via the Angptl2 pathway.	Berberine	71-74	angiopoietin-like 2	Rattus norvegicus	191-198
32429849-6	2020	Nevertheless, following treatment with BBR, liver tissue pathology, biochemical data, and Angptl2 pathway-related genes expression were significantly ameliorated.	Berberine	39-42	angiopoietin-like 2	Rattus norvegicus	90-97
32391701-0	2020	Structure-Activity Relationship Study Enables the Discovery of a Novel Berberine Analogue as RXRalpha Activator to Inhibit Colon Cancer.	Berberine	71-80	retinoid X receptor alpha	Mus musculus	93-101
32391701-1	2020	We reported recently that berberine, a traditional oriental medicine to treat gastroenteritis, binds and activates Retinoid X receptor alpha (RXRalpha) to suppress the growth of colon cancer cells.	Berberine	26-35	retinoid X receptor alpha	Mus musculus	115-140
32391701-1	2020	We reported recently that berberine, a traditional oriental medicine to treat gastroenteritis, binds and activates Retinoid X receptor alpha (RXRalpha) to suppress the growth of colon cancer cells.	Berberine	26-35	retinoid X receptor alpha	Mus musculus	142-150
32391701-2	2020	Here, we extended our studies based on the binding mode of berberine with RXRalpha by design, synthesis and biological evaluation of a focused library of 15 novel berberine analogues.	Berberine	59-68	retinoid X receptor alpha	Mus musculus	74-82
32391701-2	2020	Here, we extended our studies based on the binding mode of berberine with RXRalpha by design, synthesis and biological evaluation of a focused library of 15 novel berberine analogues.	Berberine	163-172	retinoid X receptor alpha	Mus musculus	74-82
32391701-7	2020	Together, our study describes an approach for the rational design of berberine-derived RXRalpha activators as novel effective antineoplastic agents for colon cancer.	Berberine	69-78	retinoid X receptor alpha	Mus musculus	87-95
32606742-0	2020	Berberine Inhibits the Apoptosis-Induced Metastasis by Suppressing the iPLA2/LOX-5/LTB4 Pathway in Hepatocellular Carcinoma.	Berberine	0-9	phospholipase A2 group VI	Homo sapiens	71-76
32606742-0	2020	Berberine Inhibits the Apoptosis-Induced Metastasis by Suppressing the iPLA2/LOX-5/LTB4 Pathway in Hepatocellular Carcinoma.	Berberine	0-9	arachidonate 5-lipoxygenase	Homo sapiens	77-82
32606742-9	2020	Berberine can reverse the adhesion and migration of HepG2 cells by inhibiting the expression of LOX-5 and reducing the LTB4 production in the tumor microenvironment.	Berberine	0-9	arachidonate 5-lipoxygenase	Homo sapiens	96-101
32624703-0	2020	Berberine Inhibits Pro-inflammatory Cytokine-induced IL-6 and CCL11 Production via Modulation of STAT6 Pathway in Human Bronchial Epithelial Cells.	Berberine	0-9	interleukin 6	Homo sapiens	53-57
32624703-0	2020	Berberine Inhibits Pro-inflammatory Cytokine-induced IL-6 and CCL11 Production via Modulation of STAT6 Pathway in Human Bronchial Epithelial Cells.	Berberine	0-9	C-C motif chemokine ligand 11	Homo sapiens	62-67
32624703-0	2020	Berberine Inhibits Pro-inflammatory Cytokine-induced IL-6 and CCL11 Production via Modulation of STAT6 Pathway in Human Bronchial Epithelial Cells.	Berberine	0-9	signal transducer and activator of transcription 6	Homo sapiens	97-102
32624703-10	2020	Berberine significantly inhibited the secretion of IL-6 and CCL11 from pro-inflammatory cytokine-activated BEAS-2B cells.	Berberine	0-9	interleukin 6	Homo sapiens	51-55
32624703-10	2020	Berberine significantly inhibited the secretion of IL-6 and CCL11 from pro-inflammatory cytokine-activated BEAS-2B cells.	Berberine	0-9	C-C motif chemokine ligand 11	Homo sapiens	60-65
32624703-12	2020	Significant reduction of nuclear STAT6 protein expression in activated BEAS-2B cells with berberine treatment was observed.	Berberine	90-99	signal transducer and activator of transcription 6	Homo sapiens	33-38
32624703-13	2020	Current study reveals that berberine has inhibitory effect in pro-inflammatory cytokine-activated BEAS-2B cells through reducing IL-6 and CCL11 production, which is possibly modulated by suppressing STAT6 signaling pathway.	Berberine	27-36	interleukin 6	Homo sapiens	129-133
32624703-13	2020	Current study reveals that berberine has inhibitory effect in pro-inflammatory cytokine-activated BEAS-2B cells through reducing IL-6 and CCL11 production, which is possibly modulated by suppressing STAT6 signaling pathway.	Berberine	27-36	C-C motif chemokine ligand 11	Homo sapiens	138-143
32624703-13	2020	Current study reveals that berberine has inhibitory effect in pro-inflammatory cytokine-activated BEAS-2B cells through reducing IL-6 and CCL11 production, which is possibly modulated by suppressing STAT6 signaling pathway.	Berberine	27-36	signal transducer and activator of transcription 6	Homo sapiens	199-204
32581538-8	2020	Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-kappaB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.	Berberine	23-26	interleukin 1 alpha	Mus musculus	232-240
32581538-8	2020	Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-kappaB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.	Berberine	23-26	interleukin 6	Mus musculus	242-246
32581538-8	2020	Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-kappaB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.	Berberine	23-26	matrix metallopeptidase 9	Mus musculus	248-253
32581538-8	2020	Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-kappaB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.	Berberine	23-26	chemokine (C-X3-C motif) receptor 1	Mus musculus	255-261
32581538-8	2020	Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-kappaB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.	Berberine	23-26	cytochrome c oxidase II, mitochondrial	Mus musculus	263-268
32581538-8	2020	Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-kappaB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.	Berberine	23-26	telomerase reverse transcriptase	Mus musculus	270-274
32581538-8	2020	Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-kappaB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.	Berberine	23-26	tight junction protein 1	Mus musculus	332-336
31949294-3	2020	Among these compounds, B10 showed 3.6-fold higher intracellular concentration than BBR, as well as 60-fold increased anti-proliferation activity against human lung cancer A549 cells compared with BBR.	Berberine	83-86	ectonucleotide pyrophosphatase/phosphodiesterase 3	Homo sapiens	23-26
31949294-3	2020	Among these compounds, B10 showed 3.6-fold higher intracellular concentration than BBR, as well as 60-fold increased anti-proliferation activity against human lung cancer A549 cells compared with BBR.	Berberine	196-199	ectonucleotide pyrophosphatase/phosphodiesterase 3	Homo sapiens	23-26
32581538-8	2020	Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-kappaB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.	Berberine	23-26	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-156
32109457-7	2020	We found that the combination of berberine and evodiamine showed synergistic anticancer activity in P-glycoprotein (P-gp)-positive colorectal cancer cells through attenuating the overexpression of P-gp mRNA independent of cell cycle arrest and cell apoptosis.	Berberine	33-42	ATP binding cassette subfamily B member 1	Homo sapiens	100-114
32109457-7	2020	We found that the combination of berberine and evodiamine showed synergistic anticancer activity in P-glycoprotein (P-gp)-positive colorectal cancer cells through attenuating the overexpression of P-gp mRNA independent of cell cycle arrest and cell apoptosis.	Berberine	33-42	ATP binding cassette subfamily B member 1	Homo sapiens	116-120
32109457-7	2020	We found that the combination of berberine and evodiamine showed synergistic anticancer activity in P-glycoprotein (P-gp)-positive colorectal cancer cells through attenuating the overexpression of P-gp mRNA independent of cell cycle arrest and cell apoptosis.	Berberine	33-42	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
32109457-9	2020	Furthermore, berberine attenuated evodiamine-induced cardiotoxicity by regulating extrinsic apoptosis via nuclear factor erythroid-2-related factor 2 (Nrf2)-dependent and reactive oxygen species-independent pathways.	Berberine	13-22	NFE2 like bZIP transcription factor 2	Homo sapiens	106-149
32109457-9	2020	Furthermore, berberine attenuated evodiamine-induced cardiotoxicity by regulating extrinsic apoptosis via nuclear factor erythroid-2-related factor 2 (Nrf2)-dependent and reactive oxygen species-independent pathways.	Berberine	13-22	NFE2 like bZIP transcription factor 2	Homo sapiens	151-155
32494123-0	2020	Berberine Induces Autophagic Cell Death in Acute Lymphoblastic Leukemia by Inactivating AKT/mTORC1 Signaling.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	88-91
32494123-0	2020	Berberine Induces Autophagic Cell Death in Acute Lymphoblastic Leukemia by Inactivating AKT/mTORC1 Signaling.	Berberine	0-9	CREB regulated transcription coactivator 1	Mus musculus	92-98
32494123-9	2020	Mechanistic studies exhibit that berberine induces autophagic death in ALL cells by inactivating AKT/mTORC1 signaling.	Berberine	33-42	thymoma viral proto-oncogene 1	Mus musculus	97-100
32494123-9	2020	Mechanistic studies exhibit that berberine induces autophagic death in ALL cells by inactivating AKT/mTORC1 signaling.	Berberine	33-42	CREB regulated transcription coactivator 1	Mus musculus	101-107
32494123-10	2020	Chemically targeting AKT/mTORC1 signaling controls berberine-induced cell autophagy in vitro, and blockade of autophagic process blunts berberine-alleviated pathological condition in vivo.	Berberine	51-60	thymoma viral proto-oncogene 1	Mus musculus	21-24
32494123-10	2020	Chemically targeting AKT/mTORC1 signaling controls berberine-induced cell autophagy in vitro, and blockade of autophagic process blunts berberine-alleviated pathological condition in vivo.	Berberine	51-60	CREB regulated transcription coactivator 1	Mus musculus	25-31
32494123-11	2020	Discussion: In conclusion, our study reveals that berberine could induce ALL cell autophagic death by inactivating AKT/mTORC1 signaling that could be used to develop small molecule drug for ALL treatment.	Berberine	50-59	thymoma viral proto-oncogene 1	Mus musculus	115-118
32494123-11	2020	Discussion: In conclusion, our study reveals that berberine could induce ALL cell autophagic death by inactivating AKT/mTORC1 signaling that could be used to develop small molecule drug for ALL treatment.	Berberine	50-59	CREB regulated transcription coactivator 1	Mus musculus	119-125
32457629-0	2020	Berberine Improves Glucose and Lipid Metabolism in HepG2 Cells Through AMPKalpha1 Activation.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	71-81
32182342-5	2020	Subsequent in vitro study in FSHD patient myoblasts indicated that berberine treatment reduced DUX4 expression and also expression of genes normally switched on by DUX4.	Berberine	67-76	FSHMD1A	Homo sapiens	29-33
32182342-5	2020	Subsequent in vitro study in FSHD patient myoblasts indicated that berberine treatment reduced DUX4 expression and also expression of genes normally switched on by DUX4.	Berberine	67-76	double homeobox 4	Homo sapiens	95-99
32182342-5	2020	Subsequent in vitro study in FSHD patient myoblasts indicated that berberine treatment reduced DUX4 expression and also expression of genes normally switched on by DUX4.	Berberine	67-76	double homeobox 4	Homo sapiens	164-168
32182342-6	2020	Further investigation in a mouse model overexpressing exogenous DUX4 confirmed the therapeutic effects of berberine in downregulating DUX4 protein expression, inhibiting muscle fibrosis, and consequently rescuing muscle function.	Berberine	106-115	double homeobox	Mus musculus	64-68
32182342-6	2020	Further investigation in a mouse model overexpressing exogenous DUX4 confirmed the therapeutic effects of berberine in downregulating DUX4 protein expression, inhibiting muscle fibrosis, and consequently rescuing muscle function.	Berberine	106-115	double homeobox	Mus musculus	134-138
32528829-0	2020	Berberine prevents primary peritoneal adhesion and adhesion reformation by directly inhibiting TIMP-1.	Berberine	0-9	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	95-101
32012485-0	2020	Protective effect of Berberine on reproductive function and spermatogenesis in diabetic rats via inhibition of ROS/JAK2/NFkappaB pathway.	Berberine	21-30	Janus kinase 2	Rattus norvegicus	115-119
32012485-4	2020	Additionally, to investigate the protective effect of monomeric Berberine (BB), that inhibits ROS/JAK2/NFkappaB pathway, in the pathogenesis of DM-induced infertility.	Berberine	64-73	Janus kinase 2	Rattus norvegicus	98-102
32012485-4	2020	Additionally, to investigate the protective effect of monomeric Berberine (BB), that inhibits ROS/JAK2/NFkappaB pathway, in the pathogenesis of DM-induced infertility.	Berberine	75-77	Janus kinase 2	Rattus norvegicus	98-102
32012485-15	2020	However, BB could attenuate the ROS production and abrogate activation of JAK2/NFkappaB pathway, thus inhibiting the apoptosis in the testicular cells of DM rats.	Berberine	9-11	Janus kinase 2	Rattus norvegicus	74-78
32012485-17	2020	BB can play a protective role in preserving the reproductive function and spermatogenesis in DM by inhibiting ROS/JAK2/NFkappaB pathway.	Berberine	0-2	Janus kinase 2	Rattus norvegicus	114-118
30145915-0	2020	Berberine ameliorates renal injury in a rat model of D-galactose-induced aging through a PTEN/Akt-dependent mechanism.	Berberine	0-9	phosphatase and tensin homolog	Rattus norvegicus	89-93
30145915-0	2020	Berberine ameliorates renal injury in a rat model of D-galactose-induced aging through a PTEN/Akt-dependent mechanism.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	94-97
30145915-1	2020	This study aimed to investigate the protective effects of berberine (BBR) against D-galactose (D-gal)-induced renal aging in rats, pointing to its ability to modulate phosphatase and tensin homolog deleted on chromosome ten (PTEN)/Akt signalling, and to attenuate oxidative stress, inflammation and apoptosis.	Berberine	58-67	phosphatase and tensin homolog	Rattus norvegicus	225-229
30145915-1	2020	This study aimed to investigate the protective effects of berberine (BBR) against D-galactose (D-gal)-induced renal aging in rats, pointing to its ability to modulate phosphatase and tensin homolog deleted on chromosome ten (PTEN)/Akt signalling, and to attenuate oxidative stress, inflammation and apoptosis.	Berberine	58-67	AKT serine/threonine kinase 1	Rattus norvegicus	231-234
32528829-8	2020	Berberine promoted the activation of MMP-3 and MMP-8 by directly blocking TIMP-1 activation core, which was reversed by TIMP-1 overexpression in fibroblasts.	Berberine	0-9	matrix metallopeptidase 3	Rattus norvegicus	37-42
32528829-8	2020	Berberine promoted the activation of MMP-3 and MMP-8 by directly blocking TIMP-1 activation core, which was reversed by TIMP-1 overexpression in fibroblasts.	Berberine	0-9	matrix metallopeptidase 8	Rattus norvegicus	47-52
32528829-8	2020	Berberine promoted the activation of MMP-3 and MMP-8 by directly blocking TIMP-1 activation core, which was reversed by TIMP-1 overexpression in fibroblasts.	Berberine	0-9	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	74-80
32528829-8	2020	Berberine promoted the activation of MMP-3 and MMP-8 by directly blocking TIMP-1 activation core, which was reversed by TIMP-1 overexpression in fibroblasts.	Berberine	0-9	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	120-126
32147507-0	2020	Berberine alleviates pulmonary hypertension through Trx1 and beta-catenin signaling pathways in pulmonary artery smooth muscle cells.	Berberine	0-9	thioredoxin	Homo sapiens	52-56
31828466-8	2020	Moreover, BBR significantly suppressed cytochrome c expression, upregulated the ratio of Bcl-2/Bax, and ameliorated mitochondrial dysfunction by optimizing mitochondria membrane potential (DeltaPsim) status and ATP production.	Berberine	10-13	BCL2, apoptosis regulator	Rattus norvegicus	89-94
31828466-8	2020	Moreover, BBR significantly suppressed cytochrome c expression, upregulated the ratio of Bcl-2/Bax, and ameliorated mitochondrial dysfunction by optimizing mitochondria membrane potential (DeltaPsim) status and ATP production.	Berberine	10-13	BCL2 associated X, apoptosis regulator	Rattus norvegicus	95-98
31828466-9	2020	In addition, BBR reduced the expression of autophagy-specific marker LC3, SQTM1/p62, and maintained lysosome normal function which involved the restoration of upstream signaling pathway AKT and mTOR phosphorylation level.	Berberine	13-16	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	80-83
31828466-9	2020	In addition, BBR reduced the expression of autophagy-specific marker LC3, SQTM1/p62, and maintained lysosome normal function which involved the restoration of upstream signaling pathway AKT and mTOR phosphorylation level.	Berberine	13-16	AKT serine/threonine kinase 1	Rattus norvegicus	186-189
31828466-9	2020	In addition, BBR reduced the expression of autophagy-specific marker LC3, SQTM1/p62, and maintained lysosome normal function which involved the restoration of upstream signaling pathway AKT and mTOR phosphorylation level.	Berberine	13-16	mechanistic target of rapamycin kinase	Rattus norvegicus	194-198
31828466-10	2020	Collectively, these findings suggested that BBR protects PC-12 cells from oxidative injury through inhibiting ROS level, mitochondria dysfunction, and mitophagy via PI3K/AKT/mTOR signaling pathways, which suggest a potential therapeutic strategy for oxidative stress and neurotoxic damages.	Berberine	44-47	AKT serine/threonine kinase 1	Rattus norvegicus	170-173
31828466-10	2020	Collectively, these findings suggested that BBR protects PC-12 cells from oxidative injury through inhibiting ROS level, mitochondria dysfunction, and mitophagy via PI3K/AKT/mTOR signaling pathways, which suggest a potential therapeutic strategy for oxidative stress and neurotoxic damages.	Berberine	44-47	mechanistic target of rapamycin kinase	Rattus norvegicus	174-178
32147507-0	2020	Berberine alleviates pulmonary hypertension through Trx1 and beta-catenin signaling pathways in pulmonary artery smooth muscle cells.	Berberine	0-9	catenin beta 1	Rattus norvegicus	61-73
32147507-7	2020	Furthermore, berberine had an antiproliferative effect on hypoxia-induced HPASMC proliferation in a manner likely mediated by inhibiting Trx1 and its target gene beta-catenin expression.	Berberine	13-22	thioredoxin	Homo sapiens	137-141
32147507-7	2020	Furthermore, berberine had an antiproliferative effect on hypoxia-induced HPASMC proliferation in a manner likely mediated by inhibiting Trx1 and its target gene beta-catenin expression.	Berberine	13-22	catenin beta 1	Rattus norvegicus	162-174
31833107-5	2020	Glucose metabolism, the balance of alpha- and beta-cells, and mucin-2 expression were ameliorated by combined treatment of BBR and Sta, with stronger effects than upon treatment with BBR alone.	Berberine	123-126	mucin 2	Mus musculus	62-69
31642068-7	2020	Moreover, the expression level of YAP1 suppressed by TNF-alpha was reversed by berberine in concentration-dependent manner.	Berberine	79-88	yes-associated protein 1	Mus musculus	34-38
31642068-7	2020	Moreover, the expression level of YAP1 suppressed by TNF-alpha was reversed by berberine in concentration-dependent manner.	Berberine	79-88	tumor necrosis factor	Mus musculus	53-62
32248643-0	2020	Novel regulation of miR-34a-5p and HOTAIR by the combination of berberine and gefitinib  leading to inhibition of EMT in human lung cancer.	Berberine	64-73	HOX transcript antisense RNA	Homo sapiens	35-41
32248643-12	2020	Collectively, this is the first report demonstrating reciprocal interaction of miR-34a-5p- and HOTAIR-mediated regulation of snail resulting in inhibition of EMT process by the combination of berberine and gefitinib suggesting that regulation of miR-34a-5p- and HOTAIR-mediated inhibition of EMT may provide novel treatment paradigms for lung cancer.	Berberine	192-201	HOX transcript antisense RNA	Homo sapiens	95-101
32248643-12	2020	Collectively, this is the first report demonstrating reciprocal interaction of miR-34a-5p- and HOTAIR-mediated regulation of snail resulting in inhibition of EMT process by the combination of berberine and gefitinib suggesting that regulation of miR-34a-5p- and HOTAIR-mediated inhibition of EMT may provide novel treatment paradigms for lung cancer.	Berberine	192-201	snail family transcriptional repressor 1	Homo sapiens	125-130
32248643-12	2020	Collectively, this is the first report demonstrating reciprocal interaction of miR-34a-5p- and HOTAIR-mediated regulation of snail resulting in inhibition of EMT process by the combination of berberine and gefitinib suggesting that regulation of miR-34a-5p- and HOTAIR-mediated inhibition of EMT may provide novel treatment paradigms for lung cancer.	Berberine	192-201	HOX transcript antisense RNA	Homo sapiens	262-268
32001311-3	2020	At a cellular level, the inhibitory effect of BBR on mitochondrial enzymes is probably responsible for many of its biological activities, including the activation of low-density lipoprotein receptor (LDLR), AMP-activated protein kinase (AMPK) and insulin receptor (InsR); these biological activities contribute to ameliorate peripheral blood metabolic profiles, e.g. by reducing plasma lipids and glucose levels, thus improving signs and symptoms of metabolic disorders.	Berberine	46-49	low density lipoprotein receptor	Homo sapiens	166-198
32001311-3	2020	At a cellular level, the inhibitory effect of BBR on mitochondrial enzymes is probably responsible for many of its biological activities, including the activation of low-density lipoprotein receptor (LDLR), AMP-activated protein kinase (AMPK) and insulin receptor (InsR); these biological activities contribute to ameliorate peripheral blood metabolic profiles, e.g. by reducing plasma lipids and glucose levels, thus improving signs and symptoms of metabolic disorders.	Berberine	46-49	low density lipoprotein receptor	Homo sapiens	200-204
32001311-3	2020	At a cellular level, the inhibitory effect of BBR on mitochondrial enzymes is probably responsible for many of its biological activities, including the activation of low-density lipoprotein receptor (LDLR), AMP-activated protein kinase (AMPK) and insulin receptor (InsR); these biological activities contribute to ameliorate peripheral blood metabolic profiles, e.g. by reducing plasma lipids and glucose levels, thus improving signs and symptoms of metabolic disorders.	Berberine	46-49	insulin receptor	Homo sapiens	247-263
32001311-3	2020	At a cellular level, the inhibitory effect of BBR on mitochondrial enzymes is probably responsible for many of its biological activities, including the activation of low-density lipoprotein receptor (LDLR), AMP-activated protein kinase (AMPK) and insulin receptor (InsR); these biological activities contribute to ameliorate peripheral blood metabolic profiles, e.g. by reducing plasma lipids and glucose levels, thus improving signs and symptoms of metabolic disorders.	Berberine	46-49	insulin receptor	Homo sapiens	265-269
32357187-9	2020	PA/LPS-mediated activation of ERK1/2 was inhibited by BBR in a dose-dependent manner.	Berberine	54-57	mitogen-activated protein kinase 3	Mus musculus	30-36
32357187-10	2020	In summary, BBR inhibits PA/LPS-induced inflammatory responses through modulating ER stress-mediated ERK1/2 activation in macrophages and hepatocytes.	Berberine	12-15	mitogen-activated protein kinase 3	Mus musculus	101-107
32057894-0	2020	Berberine-mediated up-regulation of surfactant protein D facilitates cartilage repair by modulating immune responses via the inhibition of TLR4/NF-kB signaling.	Berberine	0-9	surfactant protein D	Homo sapiens	36-56
32057894-0	2020	Berberine-mediated up-regulation of surfactant protein D facilitates cartilage repair by modulating immune responses via the inhibition of TLR4/NF-kB signaling.	Berberine	0-9	toll like receptor 4	Homo sapiens	139-143
32057894-5	2020	We found that BBR up-regulated the expression of surfactant protein D (SP-D) in OA cartilage, a key regulator of inflammation and innate immunity both in the airways and extrapulmonary tissues, including joint cartilage.	Berberine	14-17	surfactant protein D	Homo sapiens	49-69
32057894-5	2020	We found that BBR up-regulated the expression of surfactant protein D (SP-D) in OA cartilage, a key regulator of inflammation and innate immunity both in the airways and extrapulmonary tissues, including joint cartilage.	Berberine	14-17	surfactant protein D	Homo sapiens	71-75
32057894-9	2020	In addition, animals co-treated with BBR + recombinant human SP-D (rhSP-D) exhibited significantly lower histological scores than those treated with BBR alone.	Berberine	37-40	surfactant protein D	Homo sapiens	61-65
32057894-9	2020	In addition, animals co-treated with BBR + recombinant human SP-D (rhSP-D) exhibited significantly lower histological scores than those treated with BBR alone.	Berberine	149-152	surfactant protein D	Homo sapiens	61-65
32057894-10	2020	BBR treatment led to significantly reduced immune cell infiltration mediated through TLR4, F4/80, CD68 and CD34, whilst SP-D silencing reversed this improvement.	Berberine	0-3	toll like receptor 4	Homo sapiens	85-89
32057894-10	2020	BBR treatment led to significantly reduced immune cell infiltration mediated through TLR4, F4/80, CD68 and CD34, whilst SP-D silencing reversed this improvement.	Berberine	0-3	CD68 molecule	Homo sapiens	98-102
32057894-10	2020	BBR treatment led to significantly reduced immune cell infiltration mediated through TLR4, F4/80, CD68 and CD34, whilst SP-D silencing reversed this improvement.	Berberine	0-3	CD34 molecule	Homo sapiens	107-111
32057894-12	2020	We further explored how BBR influences SP-D and other OA-associated genes in vitro.	Berberine	24-27	surfactant protein D	Homo sapiens	39-43
32057894-17	2020	These findings suggest that BBR achieves this function through releasing SP-D from MD2/SP-D complexes and through the inhibition of TLR4/NF-kappaB signaling.	Berberine	28-31	surfactant protein D	Homo sapiens	73-77
32057894-17	2020	These findings suggest that BBR achieves this function through releasing SP-D from MD2/SP-D complexes and through the inhibition of TLR4/NF-kappaB signaling.	Berberine	28-31	lymphocyte antigen 96	Homo sapiens	83-86
32057894-17	2020	These findings suggest that BBR achieves this function through releasing SP-D from MD2/SP-D complexes and through the inhibition of TLR4/NF-kappaB signaling.	Berberine	28-31	surfactant protein D	Homo sapiens	87-91
32057894-17	2020	These findings suggest that BBR achieves this function through releasing SP-D from MD2/SP-D complexes and through the inhibition of TLR4/NF-kappaB signaling.	Berberine	28-31	toll like receptor 4	Homo sapiens	132-136
31833107-5	2020	Glucose metabolism, the balance of alpha- and beta-cells, and mucin-2 expression were ameliorated by combined treatment of BBR and Sta, with stronger effects than upon treatment with BBR alone.	Berberine	183-186	mucin 2	Mus musculus	62-69
32483416-10	2020	Furthermore, we found that anastrozole, berberine, and pranoprofen could promote Dicer expression and protect cells from hydrogen peroxide-induced DNA damage, thereby reducing cytosolic DNA and partially repressing interleukin-6 expression upon hydrogen peroxide treatment.	Berberine	40-49	interleukin 6	Mus musculus	215-228
32411101-5	2020	Under the sub-MIC doses of BER, cell membrane permeability gradually increased in a dose-dependent manner, and 1 x MIC led to 43.8% higher K+ leakage and fourfold higher ALP secretion.	Berberine	27-30	alkaline phosphatase, placental	Homo sapiens	170-173
32382284-10	2020	Moreover, GRP78 and caspase-3 expression levels were significantly decreased in the medium- and high-dose BBR groups, caspase-12 expression was significantly decreased in the high-dose BBR group, and the GRP78 mRNA expression level was significantly decreased in the high-dose BBR group.	Berberine	106-109	heat shock protein 5	Mus musculus	10-15
32332711-0	2020	Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis.	Berberine	60-69	oncostatin M	Homo sapiens	16-28
32332711-7	2020	In accordance with infiltrations of antigen-presenting cells (APCs), innate lymphoid cells (ILCs), and activated NK cells in colonic lamina propria, increased expression of OSM and OSMR were observed in the inflamed tissue of chronic UC, which were decreased following berberine treatment.	Berberine	269-278	oncostatin M receptor	Homo sapiens	181-185
32332711-8	2020	Moreover, berberine inhibited the overactivation of human intestinal stromal cells through OSM-mediated JAK-STAT pathway, which was obviously blocked upon siRNA targeting OSMR.	Berberine	10-19	oncostatin M receptor	Homo sapiens	171-175
32332711-9	2020	The research provided an infusive mechanism of berberine and illustrated that OSM and OSMR intervention might function as the potential target in chronic UC.	Berberine	47-56	oncostatin M receptor	Homo sapiens	86-90
32382284-10	2020	Moreover, GRP78 and caspase-3 expression levels were significantly decreased in the medium- and high-dose BBR groups, caspase-12 expression was significantly decreased in the high-dose BBR group, and the GRP78 mRNA expression level was significantly decreased in the high-dose BBR group.	Berberine	106-109	caspase 3	Mus musculus	20-29
32382284-10	2020	Moreover, GRP78 and caspase-3 expression levels were significantly decreased in the medium- and high-dose BBR groups, caspase-12 expression was significantly decreased in the high-dose BBR group, and the GRP78 mRNA expression level was significantly decreased in the high-dose BBR group.	Berberine	106-109	heat shock protein 5	Mus musculus	204-209
32382284-10	2020	Moreover, GRP78 and caspase-3 expression levels were significantly decreased in the medium- and high-dose BBR groups, caspase-12 expression was significantly decreased in the high-dose BBR group, and the GRP78 mRNA expression level was significantly decreased in the high-dose BBR group.	Berberine	185-188	caspase 12	Mus musculus	118-128
32382284-10	2020	Moreover, GRP78 and caspase-3 expression levels were significantly decreased in the medium- and high-dose BBR groups, caspase-12 expression was significantly decreased in the high-dose BBR group, and the GRP78 mRNA expression level was significantly decreased in the high-dose BBR group.	Berberine	185-188	caspase 12	Mus musculus	118-128
32390837-8	2020	Intriguingly, the berberine treatment with or without extinction training altered expression of plasticity-related proteins such as brain-derived neurotrophic factor (BDNF), AMPA receptors (GluA1 and GluA2) in the nucleus accumbens (NAc).	Berberine	18-27	brain-derived neurotrophic factor	Rattus norvegicus	132-165
32390837-8	2020	Intriguingly, the berberine treatment with or without extinction training altered expression of plasticity-related proteins such as brain-derived neurotrophic factor (BDNF), AMPA receptors (GluA1 and GluA2) in the nucleus accumbens (NAc).	Berberine	18-27	brain-derived neurotrophic factor	Rattus norvegicus	167-171
32390837-8	2020	Intriguingly, the berberine treatment with or without extinction training altered expression of plasticity-related proteins such as brain-derived neurotrophic factor (BDNF), AMPA receptors (GluA1 and GluA2) in the nucleus accumbens (NAc).	Berberine	18-27	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	190-195
32390837-8	2020	Intriguingly, the berberine treatment with or without extinction training altered expression of plasticity-related proteins such as brain-derived neurotrophic factor (BDNF), AMPA receptors (GluA1 and GluA2) in the nucleus accumbens (NAc).	Berberine	18-27	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	200-205
32001218-3	2020	Berberine has multiple effects on all types of diabetic complications as an activator of AMPK.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	89-93
32403887-12	2020	Berberine intervention had significantly reduced endotoxin (0.213 +- 0.025) and TNF-alpha level (0.93 +- 0.07) (P < 0.05).	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	80-89
32403887-13	2020	The expression level of occludin protein was significantly lower in the intestinal mucosa of model group than that of control group (0.166 +- 0.014), and berberine had promoted the expression of occludin protein in intestinal mucosa (0.055 +- 0.009), but the difference was not statistically significant (P > 0.05).	Berberine	154-163	occludin	Rattus norvegicus	195-203
32081663-2	2020	Berberine, which is a modulator of TRPV1, has proven antiobesity and antidiabetic potentials.	Berberine	0-9	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	35-40
32081663-3	2020	The present study was aimed to investigate the protective effects of berberine in olanzapine-induced alterations in hypothalamic appetite control, inflammation and metabolic aberrations in mice targeting TRPV1 channels.	Berberine	69-78	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	204-209
32081663-11	2020	Berberine treatment reduced serum ghrelin and leptin levels as well decrease in hypothalamic mRNA expression of orexigenic neuropeptides, inflammatory markers and ghrelin receptor in olanzapine-treated mice.	Berberine	0-9	ghrelin	Mus musculus	34-41
32081663-11	2020	Berberine treatment reduced serum ghrelin and leptin levels as well decrease in hypothalamic mRNA expression of orexigenic neuropeptides, inflammatory markers and ghrelin receptor in olanzapine-treated mice.	Berberine	0-9	leptin	Mus musculus	46-52
32081663-11	2020	Berberine treatment reduced serum ghrelin and leptin levels as well decrease in hypothalamic mRNA expression of orexigenic neuropeptides, inflammatory markers and ghrelin receptor in olanzapine-treated mice.	Berberine	0-9	growth hormone secretagogue receptor	Mus musculus	163-179
32081663-12	2020	Olanzapine treatment increased expression of TRPV1/TRPV3 in the hypothalamus which was significantly decreased by berberine treatment.	Berberine	114-123	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	45-50
32081663-12	2020	Olanzapine treatment increased expression of TRPV1/TRPV3 in the hypothalamus which was significantly decreased by berberine treatment.	Berberine	114-123	transient receptor potential cation channel, subfamily V, member 3	Mus musculus	51-56
32081663-13	2020	Our results suggest that berberine, by TRPV1/TRPV3 modulation, attenuated the olanzapine-induced metabolic alterations in mice.	Berberine	25-34	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	39-44
32081663-13	2020	Our results suggest that berberine, by TRPV1/TRPV3 modulation, attenuated the olanzapine-induced metabolic alterations in mice.	Berberine	25-34	transient receptor potential cation channel, subfamily V, member 3	Mus musculus	45-50
32327976-0	2020	Berberine Ameliorates Prenatal Dihydrotestosterone Exposure-Induced Autism-Like Behavior by Suppression of Androgen Receptor.	Berberine	0-9	androgen receptor	Homo sapiens	107-124
32328135-6	2020	Berberine induced the accumulation of fatty acid of MGC803 and suppressed the protein expression of FABPs and PPARalpha.	Berberine	0-9	peroxisome proliferator activated receptor alpha	Homo sapiens	110-119
32328135-9	2020	Berberine significantly elevated the fatty acid content and inhibited the expression of FABPs and PPARalpha in the MGC803 xenograft models.	Berberine	0-9	peroxisome proliferator activated receptor alpha	Homo sapiens	98-107
32410828-10	2020	Numerous drugs were found exerting their anti-tumor function through Id1-related signaling pathways, such as fucoidan, berberine, tetramethylpyrazine, crizotinib, cannabidiol and vinblastine.	Berberine	119-128	inhibitor of DNA binding 1, HLH protein	Homo sapiens	69-72
31874145-0	2020	Berberine suppresses colon cancer cell proliferation by inhibiting the SCAP/SREBP-1 signaling pathway-mediated lipogenesis.	Berberine	0-9	SREBF chaperone	Homo sapiens	71-75
31874145-0	2020	Berberine suppresses colon cancer cell proliferation by inhibiting the SCAP/SREBP-1 signaling pathway-mediated lipogenesis.	Berberine	0-9	sterol regulatory element binding transcription factor 1	Homo sapiens	76-83
31874145-5	2020	Moreover, the expressions of key lipogenic enzymes were down-regulated by berberine and led to the suppressed lipid synthesis, which was linked to cell proliferation via Wnt/beta-catenin pathway.	Berberine	74-83	catenin beta 1	Homo sapiens	174-186
31874145-6	2020	Importantly, berberine inhibited sterol regulatory element-binding protein-1 (SREBP-1) activation and SREBP cleavage-activating protein (SCAP) expression, resulting in the downregulation of these lipogenic enzymes.	Berberine	13-22	sterol regulatory element binding transcription factor 1	Homo sapiens	33-76
31874145-6	2020	Importantly, berberine inhibited sterol regulatory element-binding protein-1 (SREBP-1) activation and SREBP cleavage-activating protein (SCAP) expression, resulting in the downregulation of these lipogenic enzymes.	Berberine	13-22	sterol regulatory element binding transcription factor 1	Homo sapiens	78-85
31874145-6	2020	Importantly, berberine inhibited sterol regulatory element-binding protein-1 (SREBP-1) activation and SREBP cleavage-activating protein (SCAP) expression, resulting in the downregulation of these lipogenic enzymes.	Berberine	13-22	SREBF chaperone	Homo sapiens	102-135
31874145-6	2020	Importantly, berberine inhibited sterol regulatory element-binding protein-1 (SREBP-1) activation and SREBP cleavage-activating protein (SCAP) expression, resulting in the downregulation of these lipogenic enzymes.	Berberine	13-22	SREBF chaperone	Homo sapiens	137-141
31874145-7	2020	Knockdown of SCAP by shRNA could abolish the effect of berberine on SREBP-1 activation.	Berberine	55-64	SREBF chaperone	Homo sapiens	13-17
31874145-7	2020	Knockdown of SCAP by shRNA could abolish the effect of berberine on SREBP-1 activation.	Berberine	55-64	sterol regulatory element binding transcription factor 1	Homo sapiens	68-75
31874145-8	2020	Besides the inhibitory effects in vitro, berberine suppressed the growth and lipogenesis of colon cancer xenograft in a SCAP-dependent manner as well.	Berberine	41-50	SREBF chaperone	Homo sapiens	120-124
31874145-9	2020	Together, our results suggest that berberine may serve as a candidate against tumor growth of colon cancer partially through targeting SCAP/SREBP-1 pathway driving lipogenesis.	Berberine	35-44	SREBF chaperone	Homo sapiens	135-139
31874145-9	2020	Together, our results suggest that berberine may serve as a candidate against tumor growth of colon cancer partially through targeting SCAP/SREBP-1 pathway driving lipogenesis.	Berberine	35-44	sterol regulatory element binding transcription factor 1	Homo sapiens	140-147
31958765-7	2020	Meanwhile, BBR treatment significantly increased the expression of Occludin in ileum and decreased the d-lactate content in serum.	Berberine	11-14	occludin	Rattus norvegicus	67-75
31958765-8	2020	Moreover, the expression of IL-1beta, IL-6 and TNF-alpha in ileum were suppressed by BBR treatment.	Berberine	85-88	interleukin 1 alpha	Rattus norvegicus	28-36
31958765-8	2020	Moreover, the expression of IL-1beta, IL-6 and TNF-alpha in ileum were suppressed by BBR treatment.	Berberine	85-88	interleukin 6	Rattus norvegicus	38-42
31958765-8	2020	Moreover, the expression of IL-1beta, IL-6 and TNF-alpha in ileum were suppressed by BBR treatment.	Berberine	85-88	tumor necrosis factor	Rattus norvegicus	47-56
32068029-0	2020	Berberine encapsulated PEG-coated liposomes attenuate Wnt1/beta-catenin signaling in rheumatoid arthritis via miR-23a activation.	Berberine	0-9	Wnt family member 1	Rattus norvegicus	54-58
32068029-0	2020	Berberine encapsulated PEG-coated liposomes attenuate Wnt1/beta-catenin signaling in rheumatoid arthritis via miR-23a activation.	Berberine	0-9	catenin beta 1	Rattus norvegicus	59-71
32068029-0	2020	Berberine encapsulated PEG-coated liposomes attenuate Wnt1/beta-catenin signaling in rheumatoid arthritis via miR-23a activation.	Berberine	0-9	microRNA 23a	Rattus norvegicus	110-117
32068029-9	2020	Overall, our findings endorsed that miR-23a possesses a multifaceted therapeutic efficiency like berberine in RA pathogenesis and can be considered as a potential candidate for therapeutic targeting of Wnt1/beta-catenin signaling in RA disease condition.	Berberine	97-106	microRNA 23a	Rattus norvegicus	36-43
31520444-10	2020	Berberine can protect the intestinal mucosa of NSAID users and the mechanism is associated with the reparation of the ENS via up-regulating the expression of PGP9.5, GFAP and GDNF.	Berberine	0-9	ubiquitin C-terminal hydrolase L1	Rattus norvegicus	158-164
31520444-10	2020	Berberine can protect the intestinal mucosa of NSAID users and the mechanism is associated with the reparation of the ENS via up-regulating the expression of PGP9.5, GFAP and GDNF.	Berberine	0-9	glial fibrillary acidic protein	Rattus norvegicus	166-170
31520444-10	2020	Berberine can protect the intestinal mucosa of NSAID users and the mechanism is associated with the reparation of the ENS via up-regulating the expression of PGP9.5, GFAP and GDNF.	Berberine	0-9	glial cell derived neurotrophic factor	Rattus norvegicus	175-179
32292349-0	2020	Berberine Promotes OATP1B1 Expression and Rosuvastatin Uptake by Inducing Nuclear Translocation of FXR and LXRalpha.	Berberine	0-9	solute carrier organic anion transporter family member 1B1	Homo sapiens	19-26
32327976-5	2020	Our findings showed that DHT treatment suppresses the expression of estrogen receptor beta (ERbeta) and superoxide dismutase 2 (SOD2) through AR-mediated hypermethylation on the ERbeta promoter, and BBR treatment suppresses AR expression through hypermethylation on the AR promoter.	Berberine	199-202	estrogen receptor 1	Homo sapiens	92-98
32327976-5	2020	Our findings showed that DHT treatment suppresses the expression of estrogen receptor beta (ERbeta) and superoxide dismutase 2 (SOD2) through AR-mediated hypermethylation on the ERbeta promoter, and BBR treatment suppresses AR expression through hypermethylation on the AR promoter.	Berberine	199-202	superoxide dismutase 2	Homo sapiens	128-132
32327976-5	2020	Our findings showed that DHT treatment suppresses the expression of estrogen receptor beta (ERbeta) and superoxide dismutase 2 (SOD2) through AR-mediated hypermethylation on the ERbeta promoter, and BBR treatment suppresses AR expression through hypermethylation on the AR promoter.	Berberine	199-202	androgen receptor	Homo sapiens	224-226
32327976-5	2020	Our findings showed that DHT treatment suppresses the expression of estrogen receptor beta (ERbeta) and superoxide dismutase 2 (SOD2) through AR-mediated hypermethylation on the ERbeta promoter, and BBR treatment suppresses AR expression through hypermethylation on the AR promoter.	Berberine	199-202	androgen receptor	Homo sapiens	224-226
32327976-8	2020	In conclusion, DHT suppresses ERbeta expression through the AR signaling pathway by hypermethylation on the ERbeta promoter, and BBR restores this effect through AR suppression.	Berberine	129-132	androgen receptor	Homo sapiens	162-164
32327976-10	2020	We conclude that BBR ameliorates prenatal DHT exposure-induced ALB through AR suppression, this study may help elucidate the potential mechanism and identify a potential treatment through using BBR for PCOS-mediated ASD.	Berberine	17-20	androgen receptor	Homo sapiens	75-77
32044663-16	2020	CONCLUSIONS: BBR inhibited IRBP induced EAU, which was associated with a significant change in the spleen transcriptome and intestinal microbial composition.	Berberine	13-16	retinol binding protein 3, interstitial	Mus musculus	27-31
32050154-9	2020	The results showed that BBR reduced GVHD-induced weight loss and GVHD index scores, attenuated liver and intestinal injury, and inhibited ALT and AST activities, inflammation, oxidative stress and NF-kappaB activation in liver and intestine.	Berberine	24-27	glutamic pyruvic transaminase, soluble	Mus musculus	138-141
32050154-9	2020	The results showed that BBR reduced GVHD-induced weight loss and GVHD index scores, attenuated liver and intestinal injury, and inhibited ALT and AST activities, inflammation, oxidative stress and NF-kappaB activation in liver and intestine.	Berberine	24-27	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	146-149
32050154-9	2020	The results showed that BBR reduced GVHD-induced weight loss and GVHD index scores, attenuated liver and intestinal injury, and inhibited ALT and AST activities, inflammation, oxidative stress and NF-kappaB activation in liver and intestine.	Berberine	24-27	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	197-206
31898085-0	2020	The Combined Therapy of Berberine Treatment with lncRNA BACE1-AS Depletion Attenuates Abeta25-35 Induced Neuronal Injury Through Regulating the Expression of miR-132-3p in Neuronal Cells.	Berberine	24-33	beta-secretase 1	Homo sapiens	56-61
31898085-0	2020	The Combined Therapy of Berberine Treatment with lncRNA BACE1-AS Depletion Attenuates Abeta25-35 Induced Neuronal Injury Through Regulating the Expression of miR-132-3p in Neuronal Cells.	Berberine	24-33	microRNA 1323	Homo sapiens	158-167
31898085-12	2020	The enrichment of BACE1-AS was positively regulated by Abeta25-35 and was inversely modulated by Ber in neuronal cells.	Berberine	97-100	BACE1 antisense RNA	Homo sapiens	18-26
31898085-17	2020	Ber up-regulated the level of miR-132-3p via BACE1-AS in SK-N-SH and HPN neuronal cells.	Berberine	0-3	microRNA 1323	Homo sapiens	30-40
31898085-17	2020	Ber up-regulated the level of miR-132-3p via BACE1-AS in SK-N-SH and HPN neuronal cells.	Berberine	0-3	BACE1 antisense RNA	Homo sapiens	45-53
31898085-18	2020	in conclucsion, Ber protected neuronal cells against Abeta25-35 at least partly through BACE1-AS/miR-132-3p axis.	Berberine	16-19	BACE1 antisense RNA	Homo sapiens	88-96
31898085-18	2020	in conclucsion, Ber protected neuronal cells against Abeta25-35 at least partly through BACE1-AS/miR-132-3p axis.	Berberine	16-19	microRNA 1323	Homo sapiens	97-107
31898085-19	2020	The combined therapy of Ber treatment with BACE1-AS depletion might provide new insight into AD treatment.	Berberine	24-27	beta-secretase 1	Homo sapiens	43-48
32070767-7	2020	BBR protected HCAECs from injury by inhibiting expression of THBD, vWF and EDN1.	Berberine	0-3	thrombomodulin	Homo sapiens	61-65
32070767-7	2020	BBR protected HCAECs from injury by inhibiting expression of THBD, vWF and EDN1.	Berberine	0-3	von Willebrand factor	Homo sapiens	67-70
32070767-7	2020	BBR protected HCAECs from injury by inhibiting expression of THBD, vWF and EDN1.	Berberine	0-3	endothelin 1	Homo sapiens	75-79
32292349-0	2020	Berberine Promotes OATP1B1 Expression and Rosuvastatin Uptake by Inducing Nuclear Translocation of FXR and LXRalpha.	Berberine	0-9	nuclear receptor subfamily 1 group H member 4	Homo sapiens	99-102
32292349-0	2020	Berberine Promotes OATP1B1 Expression and Rosuvastatin Uptake by Inducing Nuclear Translocation of FXR and LXRalpha.	Berberine	0-9	nuclear receptor subfamily 1 group H member 3	Homo sapiens	107-115
32292349-5	2020	The aim of this study was to investigate the effects of berberine on the expression of OATP1B1 in HepG2 and explore the underlying mechanism.	Berberine	56-65	solute carrier organic anion transporter family member 1B1	Homo sapiens	87-94
32292349-6	2020	In HepG2 cells, 10-50 muM berberine significantly increased the uptake of rosuvastatin by inducing the expression of OATP1B1 mRNA and protein.	Berberine	26-35	solute carrier organic anion transporter family member 1B1	Homo sapiens	117-124
32292349-7	2020	Dual-Luciferase reporter assay showed that luciferase activity of hFXR and hLXRalpha activated OATP1B1 promoter was increased by 2.5-50 muM berberine in a concentration-dependent manner, with half-maximal effective concentration (EC50) of 12.19 +- 0.86 and 32.15 +- 2.32 muM, respectively.	Berberine	140-149	nuclear receptor subfamily 1 group H member 3	Homo sapiens	75-84
32292349-7	2020	Dual-Luciferase reporter assay showed that luciferase activity of hFXR and hLXRalpha activated OATP1B1 promoter was increased by 2.5-50 muM berberine in a concentration-dependent manner, with half-maximal effective concentration (EC50) of 12.19 +- 0.86 and 32.15 +- 2.32 muM, respectively.	Berberine	140-149	solute carrier organic anion transporter family member 1B1	Homo sapiens	95-102
32292349-8	2020	In addition, after silencing FXR or LXRalpha by small interfering RNA (siRNA), berberine-induced OATP1B1 expression was significantly attenuated.	Berberine	79-88	nuclear receptor subfamily 1 group H member 4	Homo sapiens	29-32
32292349-8	2020	In addition, after silencing FXR or LXRalpha by small interfering RNA (siRNA), berberine-induced OATP1B1 expression was significantly attenuated.	Berberine	79-88	nuclear receptor subfamily 1 group H member 3	Homo sapiens	36-44
32292345-0	2020	Berberine Protects Against Simulated Ischemia/Reperfusion Injury-Induced H9C2 Cardiomyocytes Apoptosis In Vitro and Myocardial Ischemia/Reperfusion-Induced Apoptosis In Vivo by Regulating the Mitophagy-Mediated HIF-1alpha/BNIP3 Pathway.	Berberine	0-9	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	211-221
32292345-0	2020	Berberine Protects Against Simulated Ischemia/Reperfusion Injury-Induced H9C2 Cardiomyocytes Apoptosis In Vitro and Myocardial Ischemia/Reperfusion-Induced Apoptosis In Vivo by Regulating the Mitophagy-Mediated HIF-1alpha/BNIP3 Pathway.	Berberine	0-9	BCL2 interacting protein 3	Rattus norvegicus	222-227
32292345-5	2020	In addition, upon BNIP3 knockdown, the regulatory effects of BBR on the above indicators were weakened both in H9C2 cells and in vivo.	Berberine	61-64	BCL2 interacting protein 3	Rattus norvegicus	18-23
32292349-8	2020	In addition, after silencing FXR or LXRalpha by small interfering RNA (siRNA), berberine-induced OATP1B1 expression was significantly attenuated.	Berberine	79-88	solute carrier organic anion transporter family member 1B1	Homo sapiens	97-104
32292349-9	2020	Western blot analysis of FXR and LXRalpha protein levels in the cytoplasm and nucleus of HepG2 cells after treatment with berberine showed that berberine induced nuclear translocation and activation of FXR and LXRalpha.	Berberine	122-131	nuclear receptor subfamily 1 group H member 4	Homo sapiens	25-28
32292349-9	2020	Western blot analysis of FXR and LXRalpha protein levels in the cytoplasm and nucleus of HepG2 cells after treatment with berberine showed that berberine induced nuclear translocation and activation of FXR and LXRalpha.	Berberine	122-131	nuclear receptor subfamily 1 group H member 3	Homo sapiens	33-41
32292349-9	2020	Western blot analysis of FXR and LXRalpha protein levels in the cytoplasm and nucleus of HepG2 cells after treatment with berberine showed that berberine induced nuclear translocation and activation of FXR and LXRalpha.	Berberine	122-131	nuclear receptor subfamily 1 group H member 4	Homo sapiens	202-205
32292349-9	2020	Western blot analysis of FXR and LXRalpha protein levels in the cytoplasm and nucleus of HepG2 cells after treatment with berberine showed that berberine induced nuclear translocation and activation of FXR and LXRalpha.	Berberine	144-153	nuclear receptor subfamily 1 group H member 4	Homo sapiens	25-28
32292345-7	2020	BBR protects against myocardial I/R injury by inducing cardiomyocytes proliferation, inhibiting cardiomyocytes apoptosis, and inducing the mitophagy-mediated HIF-1alpha/BNIP3 pathway.	Berberine	0-3	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	158-168
32292349-9	2020	Western blot analysis of FXR and LXRalpha protein levels in the cytoplasm and nucleus of HepG2 cells after treatment with berberine showed that berberine induced nuclear translocation and activation of FXR and LXRalpha.	Berberine	144-153	nuclear receptor subfamily 1 group H member 3	Homo sapiens	33-41
32292345-7	2020	BBR protects against myocardial I/R injury by inducing cardiomyocytes proliferation, inhibiting cardiomyocytes apoptosis, and inducing the mitophagy-mediated HIF-1alpha/BNIP3 pathway.	Berberine	0-3	BCL2 interacting protein 3	Rattus norvegicus	169-174
32292349-9	2020	Western blot analysis of FXR and LXRalpha protein levels in the cytoplasm and nucleus of HepG2 cells after treatment with berberine showed that berberine induced nuclear translocation and activation of FXR and LXRalpha.	Berberine	144-153	nuclear receptor subfamily 1 group H member 4	Homo sapiens	202-205
32292349-9	2020	Western blot analysis of FXR and LXRalpha protein levels in the cytoplasm and nucleus of HepG2 cells after treatment with berberine showed that berberine induced nuclear translocation and activation of FXR and LXRalpha.	Berberine	144-153	nuclear receptor subfamily 1 group H member 3	Homo sapiens	210-218
32292349-10	2020	In conclusion, berberine-induced nuclear translocation of FXR and LXRalpha could activate OATP1B1 promoter, resulting in enhanced expression of OATP1B1 and increased uptake of rosuvastatin.	Berberine	15-24	nuclear receptor subfamily 1 group H member 4	Homo sapiens	58-61
32213189-0	2020	Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1.	Berberine	18-27	ubiquitin-like, containing PHD and RING finger domains, 1	Mus musculus	96-101
32213189-7	2020	BBR treatment induced UHRF1 degradation via the ubiquitin-dependent proteasome system and reactivated p16INK4A and p73 in MM cells.	Berberine	0-3	ubiquitin-like, containing PHD and RING finger domains, 1	Mus musculus	22-27
32213189-7	2020	BBR treatment induced UHRF1 degradation via the ubiquitin-dependent proteasome system and reactivated p16INK4A and p73 in MM cells.	Berberine	0-3	cyclin dependent kinase inhibitor 2A	Mus musculus	102-110
32213189-7	2020	BBR treatment induced UHRF1 degradation via the ubiquitin-dependent proteasome system and reactivated p16INK4A and p73 in MM cells.	Berberine	0-3	transformation related protein 73	Mus musculus	115-118
32213189-8	2020	Overexpression of UHRF1 promoted the MM cell proliferation and rendered MM cells more resistant to BBR, while silencing of UHRF1 with siRNA attenuated BBR-induced cytotoxicity.	Berberine	99-102	ubiquitin-like, containing PHD and RING finger domains, 1	Mus musculus	18-23
32245183-0	2020	Berberine Hampers Influenza A Replication through Inhibition of MAPK/ERK Pathway.	Berberine	0-9	mapk	None	64-68
32245183-0	2020	Berberine Hampers Influenza A Replication through Inhibition of MAPK/ERK Pathway.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	69-72
32245062-3	2020	The cellular targets that account to the anticancer effect of berberine are incredibly large and range from kinases (protein kinase B (Akt), mitogen activated protein kinases (MAPKs), cell cycle checkpoint kinases, etc.)	Berberine	62-71	AKT serine/threonine kinase 1	Homo sapiens	135-138
32256641-16	2020	KEGG pathway analysis found that the pathways directly associated with berberine against atherosclerosis were cell cycle, ubiquitin mediated proteolysis, MAPK signaling pathway, and PI3K-Akt signaling pathway.	Berberine	71-80	AKT serine/threonine kinase 1	Homo sapiens	187-190
32258115-6	2020	Furthermore, our results demonstrated that berberine inhibited the increased phosphorylation of c-Jun and c-Fos in these scratched cancer cells.	Berberine	43-52	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	96-101
32258115-6	2020	Furthermore, our results demonstrated that berberine inhibited the increased phosphorylation of c-Jun and c-Fos in these scratched cancer cells.	Berberine	43-52	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	106-111
32258115-7	2020	With the cotreatment with LPS, which could boost the expression of cytokines in these cancer cells, berberine significantly reduced the increased expression of TNF-alpha and IL-6.	Berberine	100-109	tumor necrosis factor	Homo sapiens	160-169
32258115-7	2020	With the cotreatment with LPS, which could boost the expression of cytokines in these cancer cells, berberine significantly reduced the increased expression of TNF-alpha and IL-6.	Berberine	100-109	interleukin 6	Homo sapiens	174-178
32258115-8	2020	Meanwhile, we found that berberine inhibited the activation of NF-kappaB by preventing the degradation of IkappaBalpha.	Berberine	25-34	nuclear factor kappa B subunit 1	Homo sapiens	63-72
32258115-8	2020	Meanwhile, we found that berberine inhibited the activation of NF-kappaB by preventing the degradation of IkappaBalpha.	Berberine	25-34	NFKB inhibitor alpha	Homo sapiens	106-118
32231564-6	2020	Decreased pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and increased anti-inflammatory IL-10 and adiponectin levels were observed in the high-dose BBR group, but no decrease in IL-6 or increase in IL-10 was evident using the low-dose of BBR.	Berberine	187-190	interleukin 10	Mus musculus	237-242
32184626-0	2020	Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer.	Berberine	0-9	phosphatase and tensin homolog	Homo sapiens	78-82
32184626-0	2020	Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	83-86
32184626-0	2020	Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	87-91
32184626-8	2020	Mechanistically, we found that BBR inhibited autophagy by modulating the PTEN/Akt/mTOR signaling pathway.	Berberine	31-34	phosphatase and tensin homolog	Homo sapiens	73-77
32184626-8	2020	Mechanistically, we found that BBR inhibited autophagy by modulating the PTEN/Akt/mTOR signaling pathway.	Berberine	31-34	AKT serine/threonine kinase 1	Homo sapiens	78-81
32184626-8	2020	Mechanistically, we found that BBR inhibited autophagy by modulating the PTEN/Akt/mTOR signaling pathway.	Berberine	31-34	mechanistic target of rapamycin kinase	Homo sapiens	82-86
32194416-0	2020	Berberine Inhibits Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome Activation and Pyroptosis in Nonalcoholic Steatohepatitis via the ROS/TXNIP Axis.	Berberine	0-9	thioredoxin interacting protein	Mus musculus	153-158
32194416-4	2020	In the current study, we found that BBR significantly decreased lipid accumulation, ameliorated reactive oxygen species (ROS) and lipid peroxides, Tumor necrosis factor alpha (TNF-alpha) expression, and phosphorylation of Nuclear factor kappa B (NF-kappaB) p65 both in vivo and in vitro.	Berberine	36-39	tumor necrosis factor	Mus musculus	147-174
32194416-4	2020	In the current study, we found that BBR significantly decreased lipid accumulation, ameliorated reactive oxygen species (ROS) and lipid peroxides, Tumor necrosis factor alpha (TNF-alpha) expression, and phosphorylation of Nuclear factor kappa B (NF-kappaB) p65 both in vivo and in vitro.	Berberine	36-39	tumor necrosis factor	Mus musculus	176-185
32194416-4	2020	In the current study, we found that BBR significantly decreased lipid accumulation, ameliorated reactive oxygen species (ROS) and lipid peroxides, Tumor necrosis factor alpha (TNF-alpha) expression, and phosphorylation of Nuclear factor kappa B (NF-kappaB) p65 both in vivo and in vitro.	Berberine	36-39	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	222-244
32194416-4	2020	In the current study, we found that BBR significantly decreased lipid accumulation, ameliorated reactive oxygen species (ROS) and lipid peroxides, Tumor necrosis factor alpha (TNF-alpha) expression, and phosphorylation of Nuclear factor kappa B (NF-kappaB) p65 both in vivo and in vitro.	Berberine	36-39	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	246-255
32194416-4	2020	In the current study, we found that BBR significantly decreased lipid accumulation, ameliorated reactive oxygen species (ROS) and lipid peroxides, Tumor necrosis factor alpha (TNF-alpha) expression, and phosphorylation of Nuclear factor kappa B (NF-kappaB) p65 both in vivo and in vitro.	Berberine	36-39	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	257-260
31874443-10	2020	Additionally, three target genes of anti-cancer drugs were differentially expressed in 786-O cells, being that Vascular Endothelial Growth Factor-D (FIGF) and Human Telomerase Reverse Transcriptase (TERT) gene presented low expression and Polo Like Kinase 3 (PLK3) presented overexpression after treatment with berberine associated with PDT.	Berberine	311-320	vascular endothelial growth factor D	Homo sapiens	111-147
31874443-10	2020	Additionally, three target genes of anti-cancer drugs were differentially expressed in 786-O cells, being that Vascular Endothelial Growth Factor-D (FIGF) and Human Telomerase Reverse Transcriptase (TERT) gene presented low expression and Polo Like Kinase 3 (PLK3) presented overexpression after treatment with berberine associated with PDT.	Berberine	311-320	telomerase reverse transcriptase	Homo sapiens	165-197
31874443-10	2020	Additionally, three target genes of anti-cancer drugs were differentially expressed in 786-O cells, being that Vascular Endothelial Growth Factor-D (FIGF) and Human Telomerase Reverse Transcriptase (TERT) gene presented low expression and Polo Like Kinase 3 (PLK3) presented overexpression after treatment with berberine associated with PDT.	Berberine	311-320	telomerase reverse transcriptase	Homo sapiens	199-203
31874443-10	2020	Additionally, three target genes of anti-cancer drugs were differentially expressed in 786-O cells, being that Vascular Endothelial Growth Factor-D (FIGF) and Human Telomerase Reverse Transcriptase (TERT) gene presented low expression and Polo Like Kinase 3 (PLK3) presented overexpression after treatment with berberine associated with PDT.	Berberine	311-320	polo like kinase 3	Homo sapiens	239-257
31761520-0	2020	Preparation of novel berberine nano-colloids for improving wound healing of diabetic rats by acting Sirt1/NF-kappaB pathway.	Berberine	21-30	sirtuin 1	Rattus norvegicus	100-105
32292349-10	2020	In conclusion, berberine-induced nuclear translocation of FXR and LXRalpha could activate OATP1B1 promoter, resulting in enhanced expression of OATP1B1 and increased uptake of rosuvastatin.	Berberine	15-24	nuclear receptor subfamily 1 group H member 3	Homo sapiens	66-74
32292349-10	2020	In conclusion, berberine-induced nuclear translocation of FXR and LXRalpha could activate OATP1B1 promoter, resulting in enhanced expression of OATP1B1 and increased uptake of rosuvastatin.	Berberine	15-24	solute carrier organic anion transporter family member 1B1	Homo sapiens	90-97
32292349-10	2020	In conclusion, berberine-induced nuclear translocation of FXR and LXRalpha could activate OATP1B1 promoter, resulting in enhanced expression of OATP1B1 and increased uptake of rosuvastatin.	Berberine	15-24	solute carrier organic anion transporter family member 1B1	Homo sapiens	144-151
31336024-0	2020	Berberine ameliorates renal impairment and inhibits podocyte dysfunction by targeting the phosphatidylinositol 3-kinase-protein kinase B pathway in diabetic rats.	Berberine	0-9	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	Rattus norvegicus	90-119
32231564-0	2020	Effect of Berberine on Atherosclerosis and Gut Microbiota Modulation and Their Correlation in High-Fat Diet-Fed ApoE-/- Mice.	Berberine	10-19	apolipoprotein E	Mus musculus	112-116
32231564-6	2020	Decreased pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and increased anti-inflammatory IL-10 and adiponectin levels were observed in the high-dose BBR group, but no decrease in IL-6 or increase in IL-10 was evident using the low-dose of BBR.	Berberine	187-190	interleukin 6	Mus musculus	90-94
32231564-6	2020	Decreased pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and increased anti-inflammatory IL-10 and adiponectin levels were observed in the high-dose BBR group, but no decrease in IL-6 or increase in IL-10 was evident using the low-dose of BBR.	Berberine	187-190	interleukin 10	Mus musculus	127-132
32231564-6	2020	Decreased pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and increased anti-inflammatory IL-10 and adiponectin levels were observed in the high-dose BBR group, but no decrease in IL-6 or increase in IL-10 was evident using the low-dose of BBR.	Berberine	187-190	adiponectin, C1Q and collagen domain containing	Mus musculus	137-148
32231564-6	2020	Decreased pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and increased anti-inflammatory IL-10 and adiponectin levels were observed in the high-dose BBR group, but no decrease in IL-6 or increase in IL-10 was evident using the low-dose of BBR.	Berberine	187-190	interleukin 6	Mus musculus	217-221
31336024-9	2020	RESULTS: Berberine reduces the increased levels of biochemical indicators, and significantly improves the abnormal expression of PI3K, Akt and phosphorylated Akt in a rat kidney model.	Berberine	9-18	AKT serine/threonine kinase 1	Rattus norvegicus	135-138
31336024-9	2020	RESULTS: Berberine reduces the increased levels of biochemical indicators, and significantly improves the abnormal expression of PI3K, Akt and phosphorylated Akt in a rat kidney model.	Berberine	9-18	AKT serine/threonine kinase 1	Rattus norvegicus	158-161
31336024-10	2020	In vitro, a costimulating factor could obviously reduce the podocyte adhesion activity, including decreased expression of nephrin, podocin and adhesion molecule alpha3beta1 levels, to induce podocyte dysfunction, and the trends were markedly reversed by berberine and LY294002 therapy.	Berberine	254-263	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	122-129
31336024-11	2020	Furthermore, reduction of PI3K and phosphorylated Akt levels were observed in the berberine (30 and 60 mumol/L) and LY294002 (40 mumol/L) treatment group, but the Akt protein expression showed little change.	Berberine	82-91	AKT serine/threonine kinase 1	Rattus norvegicus	50-53
31336024-12	2020	CONCLUSIONS: Berberine could be a promising antidiabetic nephropathy drug through ameliorating renal impairment and inhibiting podocyte dysfunction in diabetic rats, and the underlying molecular mechanisms might be involved in the regulation of the PI3K-Akt signaling pathway.	Berberine	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	254-257
31812013-4	2020	Nutraceuticals like berberine, curcumin and polydatin have been found effective in modulating PCSK9 expression by lowering LDL levels.	Berberine	20-29	proprotein convertase subtilisin/kexin type 9	Homo sapiens	94-99
32005442-13	2020	The results demonstrate that berberine exerts beneficial effects directly in the brain: enhancing cholinergic neurotransmission, improving cerebral blood flow, protecting neurons from inflammation, limiting hyperphosphorylation of tau and facilitating beta-amyloid peptide clearance.	Berberine	29-38	amyloid beta precursor protein	Homo sapiens	252-272
31894475-8	2020	It was speculated that baicalin and berberine produced vasorelaxant effects by activating the NO/cGMP pathway and that the BKCa channel and the DAG/PKC/CPI-17 pathway were also involved.	Berberine	36-45	protein phosphatase 1, regulatory (inhibitor) subunit 14A	Rattus norvegicus	152-158
32062612-0	2020	Berberine promotes XIAP-mediated cells apoptosis by upregulation of miR-24-3p in acute lymphoblastic leukemia.	Berberine	0-9	X-linked inhibitor of apoptosis	Homo sapiens	19-23
32072839-0	2020	Berberine alleviates monosodium glutamate induced postnatal metabolic disorders associated vascular endothelial dysfunction in newborn rats: possible role of matrix metalloproteinase-1.	Berberine	0-9	matrix metallopeptidase 1	Rattus norvegicus	158-184
31926252-0	2020	Berberine mitigates high glucose-induced podocyte apoptosis by modulating autophagy via the mTOR/P70S6K/4EBP1 pathway.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	92-96
31926252-7	2020	KEY FINDINGS: In this study, we found significantly reduced LC3II/LC3I and increased p62 in podocytes stimulated with HG for 24 h, and the level of autophagy reached a minimum at 24 h. Berberine restored podocyte viability and significantly attenuated HG-mediated inhibition of autophagy, as evidenced by the increased expression of LC3II/LC3I, the number of autophagosomes and the inhibition of p62.	Berberine	185-194	nucleoporin 62	Homo sapiens	85-88
31926252-7	2020	KEY FINDINGS: In this study, we found significantly reduced LC3II/LC3I and increased p62 in podocytes stimulated with HG for 24 h, and the level of autophagy reached a minimum at 24 h. Berberine restored podocyte viability and significantly attenuated HG-mediated inhibition of autophagy, as evidenced by the increased expression of LC3II/LC3I, the number of autophagosomes and the inhibition of p62.	Berberine	185-194	nucleoporin 62	Homo sapiens	396-399
31926252-9	2020	Notably, silencing mTOR with siRNA augmented the inhibition of P70S6k and 4EBP1 phosphorylation, which was similar to the effect of berberine.	Berberine	132-141	mechanistic target of rapamycin kinase	Homo sapiens	19-23
31926252-10	2020	SIGNIFICANCE: Berberine activates podocyte autophagy by inhibiting the mTOR/P70S6K/4EBP1 signaling pathway, thereby alleviating podocyte apoptosis.	Berberine	14-23	mechanistic target of rapamycin kinase	Homo sapiens	71-75
32075082-4	2020	We investigated five individually tested alkaloids (coptisine, berberine, chelidonine, chelerythrine, and sanguinarine) as well as C. majus root extract for their effect on the secretion of IL-1beta, IL-8, and TNF-alpha in human polymorphonuclear leukocytes (neutrophils).	Berberine	63-72	interleukin 1 alpha	Homo sapiens	190-198
32075082-5	2020	Berberine, chelidonine, and chelerythrine significantly decreased the secretion of TNF-alpha in a concentration-dependent manner.	Berberine	0-9	tumor necrosis factor	Homo sapiens	83-92
32062612-2	2020	BBR can induce apoptosis of acute lymphoblastic leukemia (ALL) cells through the MDM2/p53 pathway.	Berberine	0-3	MDM2 proto-oncogene	Homo sapiens	81-85
32062612-2	2020	BBR can induce apoptosis of acute lymphoblastic leukemia (ALL) cells through the MDM2/p53 pathway.	Berberine	0-3	tumor protein p53	Homo sapiens	86-89
32062612-4	2020	RESULTS: We found that BBR reduced ALL cell viability and induced apoptosis in p53-null EU-4 and p53-mutant EU-6 cells by downregulating X-linked inhibitor of apoptosis protein (XIAP), which is increased in ALL tissues and cells.	Berberine	23-26	tumor protein p53	Homo sapiens	79-82
32062612-4	2020	RESULTS: We found that BBR reduced ALL cell viability and induced apoptosis in p53-null EU-4 and p53-mutant EU-6 cells by downregulating X-linked inhibitor of apoptosis protein (XIAP), which is increased in ALL tissues and cells.	Berberine	23-26	tumor protein p53	Homo sapiens	97-100
32062612-4	2020	RESULTS: We found that BBR reduced ALL cell viability and induced apoptosis in p53-null EU-4 and p53-mutant EU-6 cells by downregulating X-linked inhibitor of apoptosis protein (XIAP), which is increased in ALL tissues and cells.	Berberine	23-26	X-linked inhibitor of apoptosis	Homo sapiens	137-176
32062612-4	2020	RESULTS: We found that BBR reduced ALL cell viability and induced apoptosis in p53-null EU-4 and p53-mutant EU-6 cells by downregulating X-linked inhibitor of apoptosis protein (XIAP), which is increased in ALL tissues and cells.	Berberine	23-26	X-linked inhibitor of apoptosis	Homo sapiens	178-182
32062612-5	2020	BBR-induced cell apoptosis was attenuated by inhibition of XIAP that was controlled by PIM-2.	Berberine	0-3	X-linked inhibitor of apoptosis	Homo sapiens	59-63
32062612-5	2020	BBR-induced cell apoptosis was attenuated by inhibition of XIAP that was controlled by PIM-2.	Berberine	0-3	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	87-92
32062612-8	2020	Blockade of PIM-2 or miR-24-3p reversed BBR-induced cell apoptosis.	Berberine	40-43	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	12-17
32062612-10	2020	CONCLUSIONS: miR-24-3p/PIM-2/XIAP signaling contributes to BBR-mediated leukemia mitigation in p53-defect ALL, which should be further developed as a treatment strategy in ALL patients with p53 deficiency.	Berberine	59-62	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	23-28
32062612-10	2020	CONCLUSIONS: miR-24-3p/PIM-2/XIAP signaling contributes to BBR-mediated leukemia mitigation in p53-defect ALL, which should be further developed as a treatment strategy in ALL patients with p53 deficiency.	Berberine	59-62	X-linked inhibitor of apoptosis	Homo sapiens	29-33
32062612-10	2020	CONCLUSIONS: miR-24-3p/PIM-2/XIAP signaling contributes to BBR-mediated leukemia mitigation in p53-defect ALL, which should be further developed as a treatment strategy in ALL patients with p53 deficiency.	Berberine	59-62	tumor protein p53	Homo sapiens	95-98
32062612-10	2020	CONCLUSIONS: miR-24-3p/PIM-2/XIAP signaling contributes to BBR-mediated leukemia mitigation in p53-defect ALL, which should be further developed as a treatment strategy in ALL patients with p53 deficiency.	Berberine	59-62	tumor protein p53	Homo sapiens	190-193
31743135-0	2020	Berberine inhibits proliferation and migration of colorectal cancer cells by downregulation of GRP78.	Berberine	0-9	heat shock protein family A (Hsp70) member 5	Homo sapiens	95-100
31837588-0	2020	Berberine reduces inflammation of human dental pulp fibroblast via miR-21/KBTBD7 axis.	Berberine	0-9	microRNA 21	Homo sapiens	67-73
31743135-8	2020	BBR inhibited the expression of GRP78 and its localization on the cell surface.	Berberine	0-3	heat shock protein family A (Hsp70) member 5	Homo sapiens	32-37
31743135-9	2020	Moreover, BBR inhibited the expression of Bax, Bcl-2, c-Myc, and Vimentin and up-regulated the cytokeratin expression in SW480 cells.	Berberine	10-13	BCL2 associated X, apoptosis regulator	Homo sapiens	42-45
31837588-0	2020	Berberine reduces inflammation of human dental pulp fibroblast via miR-21/KBTBD7 axis.	Berberine	0-9	kelch repeat and BTB domain containing 7	Homo sapiens	74-80
31743135-9	2020	Moreover, BBR inhibited the expression of Bax, Bcl-2, c-Myc, and Vimentin and up-regulated the cytokeratin expression in SW480 cells.	Berberine	10-13	BCL2 apoptosis regulator	Homo sapiens	47-52
31837588-11	2020	BBR (25 uM) treatment in LPS-HDPF could ameliorate cell inflammatory response, presented by reduced expressions of IL-1beta, IL-6 and TNF-alpha, as well as enhanced cell proliferation and miR-21 expression.	Berberine	0-3	interleukin 1 alpha	Homo sapiens	115-123
31837588-11	2020	BBR (25 uM) treatment in LPS-HDPF could ameliorate cell inflammatory response, presented by reduced expressions of IL-1beta, IL-6 and TNF-alpha, as well as enhanced cell proliferation and miR-21 expression.	Berberine	0-3	interleukin 6	Homo sapiens	125-129
31743135-9	2020	Moreover, BBR inhibited the expression of Bax, Bcl-2, c-Myc, and Vimentin and up-regulated the cytokeratin expression in SW480 cells.	Berberine	10-13	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	54-59
31837588-11	2020	BBR (25 uM) treatment in LPS-HDPF could ameliorate cell inflammatory response, presented by reduced expressions of IL-1beta, IL-6 and TNF-alpha, as well as enhanced cell proliferation and miR-21 expression.	Berberine	0-3	tumor necrosis factor	Homo sapiens	134-143
31743135-9	2020	Moreover, BBR inhibited the expression of Bax, Bcl-2, c-Myc, and Vimentin and up-regulated the cytokeratin expression in SW480 cells.	Berberine	10-13	vimentin	Homo sapiens	65-73
31837588-11	2020	BBR (25 uM) treatment in LPS-HDPF could ameliorate cell inflammatory response, presented by reduced expressions of IL-1beta, IL-6 and TNF-alpha, as well as enhanced cell proliferation and miR-21 expression.	Berberine	0-3	microRNA 21	Homo sapiens	188-194
31743135-11	2020	Our findings demonstrated that BBR inhibited the proliferation and migration and induced the apoptosis of SW480 cells by downregulating the expression of GRP78, and targeting GRP78 might be a potential way to develop the effective anticancer therapy.	Berberine	31-34	heat shock protein family A (Hsp70) member 5	Homo sapiens	154-159
31743135-11	2020	Our findings demonstrated that BBR inhibited the proliferation and migration and induced the apoptosis of SW480 cells by downregulating the expression of GRP78, and targeting GRP78 might be a potential way to develop the effective anticancer therapy.	Berberine	31-34	heat shock protein family A (Hsp70) member 5	Homo sapiens	175-180
31866303-3	2020	Berberine activity toward Rev-erbalpha was determined by luciferase reporter, Gal4-cotransfection assay and target gene expression analyses.	Berberine	0-9	nuclear receptor subfamily 1, group D, member 1	Mus musculus	26-38
31399854-11	2020	In addition, BBR induced apoptosis in EMT-like HCoEpiC cells in a concentration-dependent manner with upregulation of Bax and downregulation of Bcl-2.	Berberine	13-16	BCL2 associated X, apoptosis regulator	Homo sapiens	118-121
31399854-11	2020	In addition, BBR induced apoptosis in EMT-like HCoEpiC cells in a concentration-dependent manner with upregulation of Bax and downregulation of Bcl-2.	Berberine	13-16	BCL2 apoptosis regulator	Homo sapiens	144-149
31399854-14	2020	In conclusion, berberine inhibits EMT and promotes apoptosis in TAF-induced colonic epithelial cells through mediation of the Smad-dependent and SMAD-independent TGF-beta signalling pathways.	Berberine	15-24	TATA-box binding protein associated factor 8	Homo sapiens	64-67
31968208-5	2020	In this review, we have attempted to discuss the reported anti-inflammatory properties of berberine that function through several pathways such as, the NF-kappaB, ERK1/2 and p38 MAPK pathways which affect several pro-inflammatory cytokines in the pathophysiological processes involved in chronic respiratory diseases.	Berberine	90-99	mitogen-activated protein kinase 3	Homo sapiens	163-169
31881227-0	2020	MDM2 inhibition-mediated autophagy contributes to the pro-apoptotic effect of berberine in p53-null leukemic cells.	Berberine	78-87	transformed mouse 3T3 cell double minute 2	Mus musculus	0-4
31881227-0	2020	MDM2 inhibition-mediated autophagy contributes to the pro-apoptotic effect of berberine in p53-null leukemic cells.	Berberine	78-87	transformation related protein 53, pseudogene	Mus musculus	91-94
31881227-9	2020	KEY FINDINGS: BBR induced autophagy in p53-null leukemic cells, which was inhibited by autophagy inhibitors 3-methyladenine.	Berberine	14-17	transformation related protein 53, pseudogene	Mus musculus	39-42
31881227-12	2020	Forced overexpression of MDM2 reversed the effect of BBR on autophagy and apoptosis.	Berberine	53-56	transformed mouse 3T3 cell double minute 2	Mus musculus	25-29
31778716-0	2020	Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways.	Berberine	0-9	solute carrier family 2 member 4	Rattus norvegicus	67-72
31778716-0	2020	Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	102-105
31778716-6	2020	Berberine treatment was able to help restore HOMA-IR and ISI values to normal levels while simultaneously bolstering the expression of GLUT4.	Berberine	0-9	solute carrier family 2 member 4	Rattus norvegicus	135-140
31778716-8	2020	We further found that 400 mg/kg berberine treatment was associated with activation of PI3K/AKT signaling and suppression of the MAPK pathway.	Berberine	32-41	AKT serine/threonine kinase 1	Rattus norvegicus	91-94
31866303-3	2020	Berberine activity toward Rev-erbalpha was determined by luciferase reporter, Gal4-cotransfection assay and target gene expression analyses.	Berberine	0-9	lectin, galactose binding, soluble 4	Mus musculus	78-82
31866303-6	2020	Berberine significantly inhibited Bmal1 (-2000/+100 bp)- and Nlrp3 (-1310/+100 bp)-Luc reporter activities, and dose-dependently decreased cellular expressions of both Bmal1 and Nlrp3.	Berberine	0-9	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	34-39
31866303-6	2020	Berberine significantly inhibited Bmal1 (-2000/+100 bp)- and Nlrp3 (-1310/+100 bp)-Luc reporter activities, and dose-dependently decreased cellular expressions of both Bmal1 and Nlrp3.	Berberine	0-9	NLR family, pyrin domain containing 3	Mus musculus	61-66
31866303-6	2020	Berberine significantly inhibited Bmal1 (-2000/+100 bp)- and Nlrp3 (-1310/+100 bp)-Luc reporter activities, and dose-dependently decreased cellular expressions of both Bmal1 and Nlrp3.	Berberine	0-9	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	168-173
31866303-6	2020	Berberine significantly inhibited Bmal1 (-2000/+100 bp)- and Nlrp3 (-1310/+100 bp)-Luc reporter activities, and dose-dependently decreased cellular expressions of both Bmal1 and Nlrp3.	Berberine	0-9	NLR family, pyrin domain containing 3	Mus musculus	178-183
31866303-8	2020	These data indicated berberine as a Rev-erbalpha agonist.	Berberine	21-30	nuclear receptor subfamily 1, group D, member 1	Mus musculus	36-48
31866303-10	2020	However, the anti-inflammatory effects of berberine were lost in BMDMs derived from Rev-erbalpha-deficient mice.	Berberine	42-51	nuclear receptor subfamily 1, group D, member 1	Mus musculus	84-96
31866303-15	2020	In conclusion, circadian pharmacological effects of berberine on chronic colitis were mainly contributed by diurnal rhythms of both disease severity and Rev-erbalpha (as a drug target).	Berberine	52-61	nuclear receptor subfamily 1, group D, member 1	Mus musculus	153-165
31746359-11	2020	In addition, BBR inhibited translocation of nuclear factor (NF)-kappaB p65 from the cytosol to the nucleus, and degradation of inhibitory kappa-Balpha in LPS-exposed mIMCD-3 cells.	Berberine	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	44-70
31778716-9	2020	In conclusion, berberine has the potential to reduce PCOS pathology and IR values in a rat model system through a mechanism linked to GLUT4 upregulation via PI3K/AKT activation and MAPK pathway suppression.	Berberine	15-24	solute carrier family 2 member 4	Rattus norvegicus	134-139
31778716-9	2020	In conclusion, berberine has the potential to reduce PCOS pathology and IR values in a rat model system through a mechanism linked to GLUT4 upregulation via PI3K/AKT activation and MAPK pathway suppression.	Berberine	15-24	AKT serine/threonine kinase 1	Rattus norvegicus	162-165
31986125-5	2020	RPPA analysis demonstrated expression of tumor promoting proteins in cells that lacked WT-TP53; and this feature could be reversed significantly when the cells were transfected with vector encoding WT-TP53 or treated with berberine or a modified berberine (BBR).	Berberine	222-231	tumor protein p53	Homo sapiens	90-94
31986125-5	2020	RPPA analysis demonstrated expression of tumor promoting proteins in cells that lacked WT-TP53; and this feature could be reversed significantly when the cells were transfected with vector encoding WT-TP53 or treated with berberine or a modified berberine (BBR).	Berberine	222-231	tumor protein p53	Homo sapiens	201-205
31986125-5	2020	RPPA analysis demonstrated expression of tumor promoting proteins in cells that lacked WT-TP53; and this feature could be reversed significantly when the cells were transfected with vector encoding WT-TP53 or treated with berberine or a modified berberine (BBR).	Berberine	246-255	tumor protein p53	Homo sapiens	201-205
31812467-1	2020	Novel berberine derivatives with disubstituents on positions C9 and C13 were synthesized and evaluated for antiproliferative activities against human prostate cancer cell lines (PC3 and DU145), breast cancer cell line (MDA-MB-231) and human colon cancer cell lines (HT29 and HCT116).	Berberine	6-15	homeobox C13	Homo sapiens	68-71
31688419-0	2020	Berberine alleviates rotenone-induced cytotoxicity by antioxidation and activation of PI3K/Akt signaling pathway in SH-SY5Y cells.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	91-94
31688419-5	2020	Further studies demonstrated that berberine suppressed the production of intracellular reactive oxygen species, restored the mitochondrial transmembrane potential, increased Bcl-2/Bax ratio, and decreased caspase-3 activation that induced by rotenone.	Berberine	34-43	BCL2 apoptosis regulator	Homo sapiens	174-179
31688419-5	2020	Further studies demonstrated that berberine suppressed the production of intracellular reactive oxygen species, restored the mitochondrial transmembrane potential, increased Bcl-2/Bax ratio, and decreased caspase-3 activation that induced by rotenone.	Berberine	34-43	BCL2 associated X, apoptosis regulator	Homo sapiens	180-183
31688419-5	2020	Further studies demonstrated that berberine suppressed the production of intracellular reactive oxygen species, restored the mitochondrial transmembrane potential, increased Bcl-2/Bax ratio, and decreased caspase-3 activation that induced by rotenone.	Berberine	34-43	caspase 3	Homo sapiens	205-214
31688419-6	2020	Furthermore, berberine also restored the phosphorylation of Akt, which was downregulated by rotenone in SH-SY5Y cells.	Berberine	13-22	AKT serine/threonine kinase 1	Homo sapiens	60-63
31688419-7	2020	These results suggest that berberine protects rotenone-treated SH-SY5Y cells by antioxidation and activation of PI3K/Akt signaling pathway.	Berberine	27-36	AKT serine/threonine kinase 1	Homo sapiens	117-120
31976031-0	2020	Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice.	Berberine	0-9	glucagon	Mus musculus	61-69
31431734-0	2020	The lncRNA Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation.	Berberine	56-65	metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA)	Mus musculus	11-17
31431734-0	2020	The lncRNA Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation.	Berberine	56-65	high mobility group box 1	Mus musculus	89-94
31431734-0	2020	The lncRNA Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation.	Berberine	56-65	microRNA 181c	Mus musculus	107-115
31431734-2	2020	Our previous study shows that berberine (BBR) hampers the nuclear-to-cytosolic translocation of high-mobility group box 1 (HMGB1) in the process of poststroke inflammation.	Berberine	30-39	high mobility group box 1	Mus musculus	96-121
31431734-2	2020	Our previous study shows that berberine (BBR) hampers the nuclear-to-cytosolic translocation of high-mobility group box 1 (HMGB1) in the process of poststroke inflammation.	Berberine	30-39	high mobility group box 1	Mus musculus	123-128
31431734-2	2020	Our previous study shows that berberine (BBR) hampers the nuclear-to-cytosolic translocation of high-mobility group box 1 (HMGB1) in the process of poststroke inflammation.	Berberine	41-44	high mobility group box 1	Mus musculus	96-121
31431734-2	2020	Our previous study shows that berberine (BBR) hampers the nuclear-to-cytosolic translocation of high-mobility group box 1 (HMGB1) in the process of poststroke inflammation.	Berberine	41-44	high mobility group box 1	Mus musculus	123-128
31431734-11	2020	Taken together, our results demonstrate for the first time that Malat1/miR-181c-5p/HMGB1 axis may be a key pathway of BBR-induced antiinflammation effects in stroke, and they may provide a novel avenue for targeted therapy.	Berberine	118-121	metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA)	Mus musculus	64-70
31431734-11	2020	Taken together, our results demonstrate for the first time that Malat1/miR-181c-5p/HMGB1 axis may be a key pathway of BBR-induced antiinflammation effects in stroke, and they may provide a novel avenue for targeted therapy.	Berberine	118-121	microRNA 181c	Mus musculus	71-79
31431734-11	2020	Taken together, our results demonstrate for the first time that Malat1/miR-181c-5p/HMGB1 axis may be a key pathway of BBR-induced antiinflammation effects in stroke, and they may provide a novel avenue for targeted therapy.	Berberine	118-121	high mobility group box 1	Mus musculus	83-88
31773901-0	2020	Berberine ameliorates cellular senescence and extends the lifespan of mice via regulating p16 and cyclin protein expression.	Berberine	0-9	cyclin dependent kinase inhibitor 2A	Mus musculus	90-93
31773901-0	2020	Berberine ameliorates cellular senescence and extends the lifespan of mice via regulating p16 and cyclin protein expression.	Berberine	0-9	proliferating cell nuclear antigen	Mus musculus	98-104
32060683-3	2020	Berberine is shown to be effective against insulin resistance and obesity, particularly against visceral adipose tissue (VAT).	Berberine	0-9	insulin	Homo sapiens	43-50
32060683-8	2020	Two authors find out that berberine induced a redistribution of adipose tissue, reducing VAT in the absence of weight loss and improved insulin sensitivity, quite like metformin.	Berberine	26-35	insulin	Homo sapiens	136-143
32060683-10	2020	Moreover, three authors demonstrated that berberine improved insulin resistance in theca cells with an improvement of the ovulation rate per cycle, so berberine is also effective on fertility and live birth rates.	Berberine	42-51	insulin	Homo sapiens	61-68
31706105-3	2020	This study unveiled a new mechanism by which berberine promotes ovarian cell glucose uptake, and demonstrated that SIRT3 ubiquitination is involved in the insulin sensitizing effect of berberine.	Berberine	185-194	sirtuin 3	Homo sapiens	115-120
31706105-6	2020	RESULTS: Berberine administration led to mitochondrial depolarization and AMP accumulation by promoting SIRT3 ubiquitination.	Berberine	9-18	sirtuin 3	Homo sapiens	104-109
31706105-10	2020	Berberine caused significant SIRT3 ubiquitination and degradation by activating the AMPK pathway and increasing intracellular ROS levels.	Berberine	0-9	sirtuin 3	Homo sapiens	29-34
31706105-11	2020	Interestingly, berberine induced ubiquitination paralleled the increased FOXO3a phosphorylation and FOXO3a/Parkin pathway activation.	Berberine	15-24	forkhead box O3	Homo sapiens	73-79
31706105-11	2020	Interestingly, berberine induced ubiquitination paralleled the increased FOXO3a phosphorylation and FOXO3a/Parkin pathway activation.	Berberine	15-24	forkhead box O3	Homo sapiens	100-106
31706105-12	2020	CONCLUSIONS: Berberine promotes glucose uptake and inhibits mitochondrial function by promoting SIRT3 ubiquitination, and is likely to regulate autophagy related function in ovarian cells by activating the AMPK pathway.	Berberine	13-22	sirtuin 3	Homo sapiens	96-101
32586251-0	2020	Hepatoprotective Role of Berberine on Doxorubicin Induced Hepatotoxici-ty - Involvement of Cyp.	Berberine	25-34	peptidylprolyl isomerase G	Homo sapiens	91-94
32586251-5	2020	OBJECTIVE: The study aims to evaluate the reversal potentials of berberine on Doxorubicin induced cyp conversion.	Berberine	65-74	peptidylprolyl isomerase G	Homo sapiens	98-101
32445451-2	2020	Here we summarized the energy sensor adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK) and its agonist berberine can combat the common underlying pathological events of neurodegeneration including oxidative stress, neuroinflammation, mitochondrial disorder, glutamate excitotoxicity, apoptosis, autophagy disorder and neurovascular units disruption.	Berberine	118-127	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	96-100
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	63-67
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	mechanistic target of rapamycin kinase	Homo sapiens	103-132
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	mechanistic target of rapamycin kinase	Homo sapiens	134-138
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	sirtuin 1	Homo sapiens	141-149
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	sirtuin 1	Homo sapiens	151-156
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	NFE2 like bZIP transcription factor 2	Homo sapiens	160-203
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	NFE2 like bZIP transcription factor 2	Homo sapiens	205-209
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	protein tyrosine kinase 2 beta	Homo sapiens	275-291
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	AKT serine/threonine kinase 1	Homo sapiens	298-301
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	mitogen-activated protein kinase 14	Homo sapiens	351-387
32445451-3	2020	The above actions of berberine may mainly depend on activating AMPK and its downstream targets such as mammalian target of rapamycin (mTOR), sirtuin1 (SIRT1) , nuclear factor erythroid-2 related factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase / protein kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+ ), and p38 mitogen-activated protein kinase (p38 MAPK).	Berberine	21-30	mitogen-activated protein kinase 14	Homo sapiens	389-397
31863867-0	2020	Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-kappaB pathway.	Berberine	3-12	toll-like receptor 4	Mus musculus	179-183
31863867-0	2020	Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-kappaB pathway.	Berberine	3-12	myeloid differentiation primary response gene 88	Mus musculus	184-189
31863867-0	2020	Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-kappaB pathway.	Berberine	3-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	190-199
32077836-13	2020	CONCLUSION: Ber attenuated renal injury by activating Nrf2/HO-1 and inhibiting JNK/p38MAPKs/PARP/Beclin-1 expression which prevented oxidative stress, inflammation, apoptosis and autophagy in renal tissue.	Berberine	12-15	NFE2 like bZIP transcription factor 2	Rattus norvegicus	54-58
32077836-13	2020	CONCLUSION: Ber attenuated renal injury by activating Nrf2/HO-1 and inhibiting JNK/p38MAPKs/PARP/Beclin-1 expression which prevented oxidative stress, inflammation, apoptosis and autophagy in renal tissue.	Berberine	12-15	heme oxygenase 1	Rattus norvegicus	59-63
32077836-13	2020	CONCLUSION: Ber attenuated renal injury by activating Nrf2/HO-1 and inhibiting JNK/p38MAPKs/PARP/Beclin-1 expression which prevented oxidative stress, inflammation, apoptosis and autophagy in renal tissue.	Berberine	12-15	mitogen-activated protein kinase 8	Rattus norvegicus	79-82
32077836-13	2020	CONCLUSION: Ber attenuated renal injury by activating Nrf2/HO-1 and inhibiting JNK/p38MAPKs/PARP/Beclin-1 expression which prevented oxidative stress, inflammation, apoptosis and autophagy in renal tissue.	Berberine	12-15	beclin 1	Rattus norvegicus	97-105
32277648-0	2020	Berberine inhibits human gastric cancer cell growth via deactivation of p38/JNK pathway, induction of mitochondrial-mediated apoptosis, caspase activation and NF-kappaB inhibition.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	72-75
32277648-0	2020	Berberine inhibits human gastric cancer cell growth via deactivation of p38/JNK pathway, induction of mitochondrial-mediated apoptosis, caspase activation and NF-kappaB inhibition.	Berberine	0-9	mitogen-activated protein kinase 8	Homo sapiens	76-79
32277648-12	2020	Berberine also suppressed the migration and invasion of the gastric cancer cells via blocking of the JNK/p38 signalling pathway.	Berberine	0-9	mitogen-activated protein kinase 8	Homo sapiens	101-104
32277648-12	2020	Berberine also suppressed the migration and invasion of the gastric cancer cells via blocking of the JNK/p38 signalling pathway.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	105-108
32474504-0	2020	Berberine enhances the radiosensitivity of osteosarcoma by targeting Rad51 and epithelial-mesenchymal transition.	Berberine	0-9	RAD51 recombinase	Homo sapiens	69-74
32474504-2	2020	The aim of the present study was to investigate the radiosensitization effects of berberine on osteosarcoma cells and the role of Rad51 in radiosensitivity by berberine.	Berberine	159-168	RAD51 recombinase	Homo sapiens	130-135
32474504-10	2020	The mRNA and protein expressions of Rad51 were significantly decreased by berberine in MG-63 cells.	Berberine	74-83	RAD51 recombinase	Homo sapiens	36-41
32474504-12	2020	Berberine inhibited their invasive capability as well as increased E-cadherin and decreased vimentin protein levels; this indicated that berberine suppressed the EMT process in MG-63 cells exposed to gamma-rays irradiation.	Berberine	137-146	cadherin 1	Homo sapiens	67-77
32474504-12	2020	Berberine inhibited their invasive capability as well as increased E-cadherin and decreased vimentin protein levels; this indicated that berberine suppressed the EMT process in MG-63 cells exposed to gamma-rays irradiation.	Berberine	137-146	vimentin	Homo sapiens	92-100
32474504-14	2020	Rad51 is a potential target of berberine in the radiosensitization of osteosarcoma.	Berberine	31-40	RAD51 recombinase	Homo sapiens	0-5
31746359-11	2020	In addition, BBR inhibited translocation of nuclear factor (NF)-kappaB p65 from the cytosol to the nucleus, and degradation of inhibitory kappa-Balpha in LPS-exposed mIMCD-3 cells.	Berberine	13-16	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	71-74
31671426-11	2020	Further investigation indicated that berberine enhances the heterodimerization of PPARalpha and RXRalpha, which together bind to the CYP2J2 promoter to induce the expression of CYP2J2 in U251 cells.	Berberine	37-46	retinoid X receptor alpha	Homo sapiens	96-104
31671426-0	2020	Berberine Induces CYP2J2 Expression in Human U251 Glioma Cells via Regulation of Peroxisome Proliferator-Activated Receptor Alpha.	Berberine	0-9	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	18-24
31671426-11	2020	Further investigation indicated that berberine enhances the heterodimerization of PPARalpha and RXRalpha, which together bind to the CYP2J2 promoter to induce the expression of CYP2J2 in U251 cells.	Berberine	37-46	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	133-139
31671426-0	2020	Berberine Induces CYP2J2 Expression in Human U251 Glioma Cells via Regulation of Peroxisome Proliferator-Activated Receptor Alpha.	Berberine	0-9	peroxisome proliferator activated receptor alpha	Homo sapiens	81-129
31671426-2	2020	OBJECTIVES: Using U251 cells in vitro, we investigated whether berberine exerts its neuroprotective effect via regulation of CYP2J2.	Berberine	63-72	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	125-131
31671426-11	2020	Further investigation indicated that berberine enhances the heterodimerization of PPARalpha and RXRalpha, which together bind to the CYP2J2 promoter to induce the expression of CYP2J2 in U251 cells.	Berberine	37-46	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	177-183
31671426-9	2020	At these concentrations, berberine increased the CYP2J2 mRNA levels by 1.31-fold (p &lt; 0.05), 1.48-fold (p &lt; 0.01), and 1.88-fold (p &lt; 0.01), respectively, and increased the PPARalpha mRNA levels 1.17-fold (p &lt; 0.05), 1.29-fold (p &lt; 0.05), and 1.53-fold (p &lt; 0.01), respectively, compared with the respective control groups.	Berberine	25-34	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	49-55
31671426-12	2020	CONCLUSION: Upon exposure of U251 cells to berberine, CYP2J2 expression is induced as a result of PPARalpha stimulation, resulting in a neuroprotective effect.	Berberine	43-52	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	54-60
31671426-9	2020	At these concentrations, berberine increased the CYP2J2 mRNA levels by 1.31-fold (p &lt; 0.05), 1.48-fold (p &lt; 0.01), and 1.88-fold (p &lt; 0.01), respectively, and increased the PPARalpha mRNA levels 1.17-fold (p &lt; 0.05), 1.29-fold (p &lt; 0.05), and 1.53-fold (p &lt; 0.01), respectively, compared with the respective control groups.	Berberine	25-34	peroxisome proliferator activated receptor alpha	Homo sapiens	182-191
31671426-10	2020	In addition, the CYP2J2 and PPARalpha protein level was also significantly upregulated in U251 cells by berberine (concentrations in 1, 3, and 10 mumol/L) in a dose-dependent manner, compared with the respective control groups.	Berberine	104-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	17-23
31671426-10	2020	In addition, the CYP2J2 and PPARalpha protein level was also significantly upregulated in U251 cells by berberine (concentrations in 1, 3, and 10 mumol/L) in a dose-dependent manner, compared with the respective control groups.	Berberine	104-113	peroxisome proliferator activated receptor alpha	Homo sapiens	28-37
31671426-11	2020	Further investigation indicated that berberine enhances the heterodimerization of PPARalpha and RXRalpha, which together bind to the CYP2J2 promoter to induce the expression of CYP2J2 in U251 cells.	Berberine	37-46	peroxisome proliferator activated receptor alpha	Homo sapiens	82-91
31671426-12	2020	CONCLUSION: Upon exposure of U251 cells to berberine, CYP2J2 expression is induced as a result of PPARalpha stimulation, resulting in a neuroprotective effect.	Berberine	43-52	peroxisome proliferator activated receptor alpha	Homo sapiens	98-107
32789786-7	2020	As the second achievement of this review, among the signaling pathways through which berberine regulates intracellular processes, AMP-activated protein kinase (AMPK) has a central and critical role, showing that enhancing activity of AMPK pathway can be considered as a promising therapeutic approach for atherosclerosis treatment.	Berberine	85-94	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	130-158
32789786-7	2020	As the second achievement of this review, among the signaling pathways through which berberine regulates intracellular processes, AMP-activated protein kinase (AMPK) has a central and critical role, showing that enhancing activity of AMPK pathway can be considered as a promising therapeutic approach for atherosclerosis treatment.	Berberine	85-94	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	160-164
32789786-5	2020	In the present literature review, we put together this studies and provide integrated evidence that exhibits berberine has the potential atheroprotective effect through reducing increased levels of plasma cholesterol, particularly low-density lipoprotein (LDL) cholesterol (LDL-C) via LDL receptor (LDLR)-dependent and LDL receptor-independent mechanisms, inhibiting migration and inflammatory activity of macrophages, improving the functionality of endothelial cells via anti-oxidant activities, and suppressing proliferation of vascular smooth muscle cells.	Berberine	109-118	low density lipoprotein receptor	Homo sapiens	285-297
32789786-5	2020	In the present literature review, we put together this studies and provide integrated evidence that exhibits berberine has the potential atheroprotective effect through reducing increased levels of plasma cholesterol, particularly low-density lipoprotein (LDL) cholesterol (LDL-C) via LDL receptor (LDLR)-dependent and LDL receptor-independent mechanisms, inhibiting migration and inflammatory activity of macrophages, improving the functionality of endothelial cells via anti-oxidant activities, and suppressing proliferation of vascular smooth muscle cells.	Berberine	109-118	low density lipoprotein receptor	Homo sapiens	299-303
32789786-7	2020	As the second achievement of this review, among the signaling pathways through which berberine regulates intracellular processes, AMP-activated protein kinase (AMPK) has a central and critical role, showing that enhancing activity of AMPK pathway can be considered as a promising therapeutic approach for atherosclerosis treatment.	Berberine	85-94	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	234-238
32789786-5	2020	In the present literature review, we put together this studies and provide integrated evidence that exhibits berberine has the potential atheroprotective effect through reducing increased levels of plasma cholesterol, particularly low-density lipoprotein (LDL) cholesterol (LDL-C) via LDL receptor (LDLR)-dependent and LDL receptor-independent mechanisms, inhibiting migration and inflammatory activity of macrophages, improving the functionality of endothelial cells via anti-oxidant activities, and suppressing proliferation of vascular smooth muscle cells.	Berberine	109-118	low density lipoprotein receptor	Homo sapiens	319-331
31920677-0	2019	Combined Use of Astragalus Polysaccharide and Berberine Attenuates Insulin Resistance in IR-HepG2 Cells via Regulation of the Gluconeogenesis Signaling Pathway.	Berberine	46-55	insulin	Homo sapiens	67-74
32021249-9	2019	Berberine suppressed the glutamine uptake by inhibiting SLC1A5.	Berberine	0-9	solute carrier family 1 member 5	Homo sapiens	56-62
32021249-10	2019	The upregulation of SLC1A5 led to an increased glutamine uptake and improved tolerance to berberine.	Berberine	90-99	solute carrier family 1 member 5	Homo sapiens	20-26
32021249-11	2019	Berberine suppresses SLC1A5 expression by inhibiting c-Myc.	Berberine	0-9	solute carrier family 1 member 5	Homo sapiens	21-27
32021249-11	2019	Berberine suppresses SLC1A5 expression by inhibiting c-Myc.	Berberine	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	53-58
32021249-12	2019	Furthermore, berberine suppresses the growth of tumor xenografts, and the expression of SLC1A5 and c-Myc in vivo.	Berberine	13-22	solute carrier family 1 member 5	Homo sapiens	88-94
32021249-12	2019	Furthermore, berberine suppresses the growth of tumor xenografts, and the expression of SLC1A5 and c-Myc in vivo.	Berberine	13-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	99-104
32021249-14	2019	Conclusion: Berberine can suppress the proliferation of liver cancer cells by reducing SLC1A5 expression.	Berberine	12-21	solute carrier family 1 member 5	Homo sapiens	87-93
31888678-4	2019	The quantitative proteomics conjugated gene ontology analysis revealed the inhibitory effect of CORT on the expression of mitochondrial oxidative phosphorylation-related proteins, which can be antagonized by berberine (BBR) treatment.	Berberine	208-217	cortistatin	Mus musculus	96-100
31888678-4	2019	The quantitative proteomics conjugated gene ontology analysis revealed the inhibitory effect of CORT on the expression of mitochondrial oxidative phosphorylation-related proteins, which can be antagonized by berberine (BBR) treatment.	Berberine	219-222	cortistatin	Mus musculus	96-100
31920677-9	2019	The expression of p-FoxO1Ser256 and PEPCK protein was increased, and the expression of GLUT2 protein was decreased significantly in the IR-HepG2 cell model, and both of these effects could be reversed by AP-BBR intervention.	Berberine	207-210	phosphoenolpyruvate carboxykinase 2, mitochondrial	Homo sapiens	36-41
31920677-9	2019	The expression of p-FoxO1Ser256 and PEPCK protein was increased, and the expression of GLUT2 protein was decreased significantly in the IR-HepG2 cell model, and both of these effects could be reversed by AP-BBR intervention.	Berberine	207-210	solute carrier family 2 member 2	Homo sapiens	87-92
31841506-0	2019	Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively than did individual treatments.	Berberine	25-34	AKT serine/threonine kinase 1	Homo sapiens	110-113
31841506-0	2019	Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively than did individual treatments.	Berberine	25-34	mechanistic target of rapamycin kinase	Homo sapiens	114-118
31847089-1	2019	Alkaloids having acetylcholinesterase (AChE) inhibitory activity are commonly found in traditional Chinese medicine (TCM); for example, berberine from Coptis chinensis, galantamine from Lycoris radiata, and huperzine A from Huperzia serrata.	Berberine	136-145	acetylcholinesterase (Cartwright blood group)	Homo sapiens	17-37
31847089-1	2019	Alkaloids having acetylcholinesterase (AChE) inhibitory activity are commonly found in traditional Chinese medicine (TCM); for example, berberine from Coptis chinensis, galantamine from Lycoris radiata, and huperzine A from Huperzia serrata.	Berberine	136-145	acetylcholinesterase (Cartwright blood group)	Homo sapiens	39-43
31847089-3	2019	Fangchinoline from STR and coptisine and/or berberine from CR and/or PCC are active alkaloids in inhibiting AChE.	Berberine	44-53	acetylcholinesterase (Cartwright blood group)	Homo sapiens	108-112
31895879-0	2020	Berberine Attenuates Cholesterol Accumulation in Macrophage Foam Cells by Suppressing AP-1 Activity and Activation of the Nrf2/HO-1 Pathway.	Berberine	0-9	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-90
31847089-8	2019	It was found that fangchinoline showed AChE inhibitory potency; furthermore, fangchinoline-coptisine/berberine pairs (at ratios of 1:5, 1:2, 1:1, and 2:1) synergistically inhibited AChE; the combination index (CI) at different ratios was less than one when Fa = 0.5, suggesting synergistic inhibition of AChE.	Berberine	101-110	acetylcholinesterase (Cartwright blood group)	Homo sapiens	181-185
31847089-8	2019	It was found that fangchinoline showed AChE inhibitory potency; furthermore, fangchinoline-coptisine/berberine pairs (at ratios of 1:5, 1:2, 1:1, and 2:1) synergistically inhibited AChE; the combination index (CI) at different ratios was less than one when Fa = 0.5, suggesting synergistic inhibition of AChE.	Berberine	101-110	acetylcholinesterase (Cartwright blood group)	Homo sapiens	181-185
31563690-12	2019	Our findings revealed the pivotal role of BER in overcoming chemotherapy-exacerbated HCC repopulation through Caspase-3-iPLA2-COX-2 pathway, thereby providing a promising and stable nanocarrier integrating DOX and BER for effective HCC chemotherapy without repopulation.	Berberine	42-45	caspase 3	Mus musculus	110-119
31885776-0	2019	Berberine Ameliorates Doxorubicin-Induced Cardiotoxicity via a SIRT1/p66Shc-Mediated Pathway.	Berberine	0-9	sirtuin 1	Rattus norvegicus	63-68
31885776-0	2019	Berberine Ameliorates Doxorubicin-Induced Cardiotoxicity via a SIRT1/p66Shc-Mediated Pathway.	Berberine	0-9	SHC adaptor protein 1	Rattus norvegicus	69-75
31824172-5	2019	Results: In vitro the IC50 values (~15-40 muM) of 13-Cys-BBR against the proliferation of eight cancer cell lines were significantly lower than those of BBR (~25-140 muM); the content of ROS formed inside HCT-8 cells treated by 13-Cys-BBR was ~3.44-folds higher than that inside HCT-8 cells treated by BBR; the expression of XIAP in HCT-8 cells treated by 13-Cys-BBR was ~1.21-folds lower than that in HCT-8 cells treated by BBR; the tumor weight of S180 mice orally treated by 2 mumol/kg/day of 13-Cys-BBR (~1.5 g) was significantly lower than that of S180 mice orally treated by 2 mumol/kg/day of BBR (~2.5 g); and the active pocket of XIAP was more suitable for 13-Cys-BBR than for BBR.	Berberine	57-60	X-linked inhibitor of apoptosis	Homo sapiens	325-329
31824172-5	2019	Results: In vitro the IC50 values (~15-40 muM) of 13-Cys-BBR against the proliferation of eight cancer cell lines were significantly lower than those of BBR (~25-140 muM); the content of ROS formed inside HCT-8 cells treated by 13-Cys-BBR was ~3.44-folds higher than that inside HCT-8 cells treated by BBR; the expression of XIAP in HCT-8 cells treated by 13-Cys-BBR was ~1.21-folds lower than that in HCT-8 cells treated by BBR; the tumor weight of S180 mice orally treated by 2 mumol/kg/day of 13-Cys-BBR (~1.5 g) was significantly lower than that of S180 mice orally treated by 2 mumol/kg/day of BBR (~2.5 g); and the active pocket of XIAP was more suitable for 13-Cys-BBR than for BBR.	Berberine	57-60	X-linked inhibitor of apoptosis	Mus musculus	638-642
31270434-0	2019	Podoplanin mediates the renoprotective effect of berberine on diabetic kidney disease in mice.	Berberine	49-58	podoplanin	Mus musculus	0-10
31270434-7	2019	Administration of berberine (100, 200 mg/kg every day, ig, for 8 weeks) significantly improved hyperglycemia and the renal function of STZ-induced diabetic mice and restored the expression level of podoplanin in renal glomerulus.	Berberine	18-27	podoplanin	Mus musculus	198-208
31270434-8	2019	In high glucose-cultured MPC5 cells, treatment with berberine (30-120 muM) dose-dependently decreased the apoptosis rate, increased the expression of podoplanin, and inhibited the activation of NF-kappaB signaling pathway.	Berberine	52-61	podoplanin	Mus musculus	150-160
31270434-9	2019	When podoplanin expression was silenced with shRNA, berberine treatment still inhibited the NF-kappaB signaling pathway, but its antiapoptotic effect on podocytes almost disappeared.	Berberine	52-61	podoplanin	Mus musculus	5-15
31270434-10	2019	Our results suggest that berberine inhibits the activation of NF-kappaB signaling pathway, thus increasing the podoplanin expression to exert renoprotective effects.	Berberine	25-34	podoplanin	Mus musculus	111-121
31563690-12	2019	Our findings revealed the pivotal role of BER in overcoming chemotherapy-exacerbated HCC repopulation through Caspase-3-iPLA2-COX-2 pathway, thereby providing a promising and stable nanocarrier integrating DOX and BER for effective HCC chemotherapy without repopulation.	Berberine	42-45	phospholipase A2, group VI	Mus musculus	120-125
31563690-12	2019	Our findings revealed the pivotal role of BER in overcoming chemotherapy-exacerbated HCC repopulation through Caspase-3-iPLA2-COX-2 pathway, thereby providing a promising and stable nanocarrier integrating DOX and BER for effective HCC chemotherapy without repopulation.	Berberine	42-45	cytochrome c oxidase II, mitochondrial	Mus musculus	126-131
31563690-14	2019	We then developed a promising strategy that simultaneously inhibits HCC and its recurrence with an HCC-targeted co-delivery nanocarrier HA-MSN@DB and revealed that such an inhibition was related with the suppression of Caspase-3-iPLA2-COX-2 pathway by berberine.	Berberine	252-261	caspase 3	Mus musculus	219-228
31563690-14	2019	We then developed a promising strategy that simultaneously inhibits HCC and its recurrence with an HCC-targeted co-delivery nanocarrier HA-MSN@DB and revealed that such an inhibition was related with the suppression of Caspase-3-iPLA2-COX-2 pathway by berberine.	Berberine	252-261	phospholipase A2, group VI	Mus musculus	229-234
31563690-14	2019	We then developed a promising strategy that simultaneously inhibits HCC and its recurrence with an HCC-targeted co-delivery nanocarrier HA-MSN@DB and revealed that such an inhibition was related with the suppression of Caspase-3-iPLA2-COX-2 pathway by berberine.	Berberine	252-261	cytochrome c oxidase II, mitochondrial	Mus musculus	235-240
31557705-9	2019	The most active extracts from Z. schreberi and Z. monophylum showed the highest presence of berberine and chelerythrine, previously reported as cholinesterase inhibitors.	Berberine	92-101	butyrylcholinesterase	Homo sapiens	144-158
31612504-0	2019	Myocardial hypertrophy is improved with berberine treatment via long non-coding RNA MIAT-mediated autophagy.	Berberine	40-49	myocardial infarction associated transcript	Rattus norvegicus	84-88
31612504-7	2019	CAA upregulated beta myosin heavy chain and atrial natriuretic peptide expressions in heart tissues, which was attenuated by BBR.	Berberine	125-128	myosin heavy chain 7	Rattus norvegicus	16-39
31612504-8	2019	BBR suppressed myocardial infarction associated transcript (MIAT) expression in rats with CAA.	Berberine	0-3	myocardial infarction associated transcript	Rattus norvegicus	60-64
31612504-11	2019	In vitro studies showed that BBR ameliorated angiotensin II-induced MH and attenuated Ang II-induced MIAT expression in H9C2 cells.	Berberine	29-32	angiotensinogen	Rattus norvegicus	45-59
31612504-11	2019	In vitro studies showed that BBR ameliorated angiotensin II-induced MH and attenuated Ang II-induced MIAT expression in H9C2 cells.	Berberine	29-32	angiogenin	Rattus norvegicus	86-89
31612504-11	2019	In vitro studies showed that BBR ameliorated angiotensin II-induced MH and attenuated Ang II-induced MIAT expression in H9C2 cells.	Berberine	29-32	myocardial infarction associated transcript	Rattus norvegicus	101-105
31612504-12	2019	Expressions of phosphorylated mTOR, phosphorylated AMPK and LC3 were upregulated in H9C2 cells after Ang II stimulation, and the effects were abolished by BBR.	Berberine	155-158	mechanistic target of rapamycin kinase	Rattus norvegicus	30-34
31612504-12	2019	Expressions of phosphorylated mTOR, phosphorylated AMPK and LC3 were upregulated in H9C2 cells after Ang II stimulation, and the effects were abolished by BBR.	Berberine	155-158	angiogenin	Rattus norvegicus	101-104
31612504-13	2019	CONCLUSIONS: BBR exerted beneficial effects on MH induced by CCA, and the mechanisms were associated with decreased MIAT expression and enhanced autophagy.	Berberine	13-16	myocardial infarction associated transcript	Rattus norvegicus	116-120
31779025-11	2019	When the concentration was higher than 10 muM, the suppressive effects of berberine on viability and MTDH reached significant level.	Berberine	74-83	latexin	Homo sapiens	42-45
31779025-11	2019	When the concentration was higher than 10 muM, the suppressive effects of berberine on viability and MTDH reached significant level.	Berberine	74-83	metadherin	Homo sapiens	101-105
31779025-0	2019	Berberine Inhibits Proliferative Ability of Breast Cancer Cells by Reducing Metadherin.	Berberine	0-9	metadherin	Homo sapiens	76-86
31779025-6	2019	The cell viability and MTDH mRNA level were detected under the si-MTDH vector and different concentrations of berberine.	Berberine	110-119	metadherin	Homo sapiens	23-27
31779025-12	2019	As MTDH expression increased, the enhanced apoptosis rates of breast cancer cells by berberine were remarkably inhibited.	Berberine	85-94	metadherin	Homo sapiens	3-7
31779025-7	2019	The MTDH-expression vector was transfected into MCF-7 and MDA-MB-231 cells, and the changes of cell viability and apoptosis were determined after berberine (50 muM) treatment.	Berberine	146-155	metadherin	Homo sapiens	4-8
31779025-14	2019	The anti-cancer ability of berberine in breast cancer may be partially dependent on the regulation of MTDH.	Berberine	27-36	metadherin	Homo sapiens	102-106
31519237-0	2019	Ratiometric fluorescence strategy for p53 gene assay by using nitrogen doped graphene quantum dots and berberine as fluorescence reporters.	Berberine	103-112	tumor protein p53	Homo sapiens	38-41
31519237-4	2019	P1 DNA can be hydrolyzed by Exonuclease I (Exo I) when target p53 gene was absent, resulting in the release of berberine and the decrease of fluorescence intensity at 537 nm.	Berberine	111-120	tumor protein p53	Homo sapiens	62-65
31744490-10	2019	The binding of TLR4 to MyD88 was tested by CoIP, and the affinity of BBR for TLR4 was assessed by molecular docking.	Berberine	69-72	toll-like receptor 4	Mus musculus	77-81
31744490-14	2019	Molecular docking suggested that BBR might interact with TLR4.	Berberine	33-36	toll-like receptor 4	Mus musculus	57-61
31744490-0	2019	Inhibitory effects of berberine on proinflammatory M1 macrophage polarization through interfering with the interaction between TLR4 and MyD88.	Berberine	22-31	toll-like receptor 4	Mus musculus	127-131
31744490-16	2019	BBR might interact with TLR4 and disturb TLR4/MyD88/NFkappaB signalling pathway, and it might be the mechanism by which BBR attenuated inflammation in the early phase.	Berberine	0-3	toll-like receptor 4	Mus musculus	24-28
31744490-0	2019	Inhibitory effects of berberine on proinflammatory M1 macrophage polarization through interfering with the interaction between TLR4 and MyD88.	Berberine	22-31	myeloid differentiation primary response gene 88	Mus musculus	136-141
31744490-16	2019	BBR might interact with TLR4 and disturb TLR4/MyD88/NFkappaB signalling pathway, and it might be the mechanism by which BBR attenuated inflammation in the early phase.	Berberine	0-3	toll-like receptor 4	Mus musculus	41-45
31744490-16	2019	BBR might interact with TLR4 and disturb TLR4/MyD88/NFkappaB signalling pathway, and it might be the mechanism by which BBR attenuated inflammation in the early phase.	Berberine	0-3	myeloid differentiation primary response gene 88	Mus musculus	46-51
31744490-16	2019	BBR might interact with TLR4 and disturb TLR4/MyD88/NFkappaB signalling pathway, and it might be the mechanism by which BBR attenuated inflammation in the early phase.	Berberine	0-3	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	52-60
31744490-16	2019	BBR might interact with TLR4 and disturb TLR4/MyD88/NFkappaB signalling pathway, and it might be the mechanism by which BBR attenuated inflammation in the early phase.	Berberine	120-123	toll-like receptor 4	Mus musculus	24-28
31744490-16	2019	BBR might interact with TLR4 and disturb TLR4/MyD88/NFkappaB signalling pathway, and it might be the mechanism by which BBR attenuated inflammation in the early phase.	Berberine	120-123	toll-like receptor 4	Mus musculus	41-45
31744490-16	2019	BBR might interact with TLR4 and disturb TLR4/MyD88/NFkappaB signalling pathway, and it might be the mechanism by which BBR attenuated inflammation in the early phase.	Berberine	120-123	myeloid differentiation primary response gene 88	Mus musculus	46-51
31744490-16	2019	BBR might interact with TLR4 and disturb TLR4/MyD88/NFkappaB signalling pathway, and it might be the mechanism by which BBR attenuated inflammation in the early phase.	Berberine	120-123	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	52-60
31717305-9	2019	The activation of caspase 3/7 and accumulation in the sub-G1 phase of CCRF-CEM cells treated with C60-Ber nanocomplexes evidenced apoptosis induction.	Berberine	102-105	caspase 3	Homo sapiens	18-27
31781264-0	2019	Berberine Modulates LPA Function to Inhibit the Proliferation and Inflammation of FLS-RA via p38/ERK MAPK Pathway Mediated by LPA1.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	93-96
31781264-0	2019	Berberine Modulates LPA Function to Inhibit the Proliferation and Inflammation of FLS-RA via p38/ERK MAPK Pathway Mediated by LPA1.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	97-100
31781264-0	2019	Berberine Modulates LPA Function to Inhibit the Proliferation and Inflammation of FLS-RA via p38/ERK MAPK Pathway Mediated by LPA1.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	101-105
31781264-0	2019	Berberine Modulates LPA Function to Inhibit the Proliferation and Inflammation of FLS-RA via p38/ERK MAPK Pathway Mediated by LPA1.	Berberine	0-9	lysophosphatidic acid receptor 1	Homo sapiens	126-130
31781264-7	2019	Berberine remarkably inhibited the proliferation and the excessive production of IL-6 and TNF-alpha in FLS-RA, whereas suppressing the expression of K-ras, c-Raf, and p-38/ERK-phosphorylation.	Berberine	0-9	interleukin 6	Homo sapiens	81-85
31781264-7	2019	Berberine remarkably inhibited the proliferation and the excessive production of IL-6 and TNF-alpha in FLS-RA, whereas suppressing the expression of K-ras, c-Raf, and p-38/ERK-phosphorylation.	Berberine	0-9	tumor necrosis factor	Homo sapiens	90-99
31781264-7	2019	Berberine remarkably inhibited the proliferation and the excessive production of IL-6 and TNF-alpha in FLS-RA, whereas suppressing the expression of K-ras, c-Raf, and p-38/ERK-phosphorylation.	Berberine	0-9	KRAS proto-oncogene, GTPase	Homo sapiens	149-154
31781264-7	2019	Berberine remarkably inhibited the proliferation and the excessive production of IL-6 and TNF-alpha in FLS-RA, whereas suppressing the expression of K-ras, c-Raf, and p-38/ERK-phosphorylation.	Berberine	0-9	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	156-161
31781264-7	2019	Berberine remarkably inhibited the proliferation and the excessive production of IL-6 and TNF-alpha in FLS-RA, whereas suppressing the expression of K-ras, c-Raf, and p-38/ERK-phosphorylation.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	167-171
31781264-7	2019	Berberine remarkably inhibited the proliferation and the excessive production of IL-6 and TNF-alpha in FLS-RA, whereas suppressing the expression of K-ras, c-Raf, and p-38/ERK-phosphorylation.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	172-175
31781264-8	2019	In addition, berberine inhibited the LPA-induced p-38/ERK-phosphorylation through binding to LPA1.	Berberine	13-22	mitogen-activated protein kinase 14	Homo sapiens	49-53
31781264-8	2019	In addition, berberine inhibited the LPA-induced p-38/ERK-phosphorylation through binding to LPA1.	Berberine	13-22	mitogen-activated protein kinase 1	Homo sapiens	54-57
31781264-8	2019	In addition, berberine inhibited the LPA-induced p-38/ERK-phosphorylation through binding to LPA1.	Berberine	13-22	lysophosphatidic acid receptor 1	Homo sapiens	93-97
31781264-10	2019	Berberine potentially modulates LPA function to suppress the proliferation and inflammation of FLS-RA through blocking the p38/ERK MAPK pathway mediated by LPA1.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	123-126
31781264-10	2019	Berberine potentially modulates LPA function to suppress the proliferation and inflammation of FLS-RA through blocking the p38/ERK MAPK pathway mediated by LPA1.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	127-130
31781264-10	2019	Berberine potentially modulates LPA function to suppress the proliferation and inflammation of FLS-RA through blocking the p38/ERK MAPK pathway mediated by LPA1.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	131-135
31781264-10	2019	Berberine potentially modulates LPA function to suppress the proliferation and inflammation of FLS-RA through blocking the p38/ERK MAPK pathway mediated by LPA1.	Berberine	0-9	lysophosphatidic acid receptor 1	Homo sapiens	156-160
26142340-0	2019	Berberine Induces Cell Apoptosis through Cytochrome C/Apoptotic Protease-Activating Factor 1/Caspase-3 and Apoptosis Inducing Factor Pathway in Mouse Insulinoma Cells.	Berberine	0-9	caspase 3	Mus musculus	93-102
26142340-0	2019	Berberine Induces Cell Apoptosis through Cytochrome C/Apoptotic Protease-Activating Factor 1/Caspase-3 and Apoptosis Inducing Factor Pathway in Mouse Insulinoma Cells.	Berberine	0-9	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	107-132
26142340-8	2019	Berberine treatment dramatically elevated the expression ratio of Bax to Bcl-2.	Berberine	0-9	BCL2-associated X protein	Mus musculus	66-69
26142340-8	2019	Berberine treatment dramatically elevated the expression ratio of Bax to Bcl-2.	Berberine	0-9	B cell leukemia/lymphoma 2	Mus musculus	73-78
26142340-12	2019	CONCLUSION: High concentration (5 and 10 mumol/L) of berberine could induce the apoptosis of MIN6 cells through cytochrome C/Apaf-1/caspase-3 and apoptosis inducing factor (AIF) pathway.	Berberine	53-62	apoptotic peptidase activating factor 1	Mus musculus	125-131
26142340-12	2019	CONCLUSION: High concentration (5 and 10 mumol/L) of berberine could induce the apoptosis of MIN6 cells through cytochrome C/Apaf-1/caspase-3 and apoptosis inducing factor (AIF) pathway.	Berberine	53-62	caspase 3	Mus musculus	132-141
26142340-12	2019	CONCLUSION: High concentration (5 and 10 mumol/L) of berberine could induce the apoptosis of MIN6 cells through cytochrome C/Apaf-1/caspase-3 and apoptosis inducing factor (AIF) pathway.	Berberine	53-62	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	146-171
26142340-12	2019	CONCLUSION: High concentration (5 and 10 mumol/L) of berberine could induce the apoptosis of MIN6 cells through cytochrome C/Apaf-1/caspase-3 and apoptosis inducing factor (AIF) pathway.	Berberine	53-62	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	173-176
31795609-9	2019	Berberine also increased cell proliferation and short-term memory, as well as decreasing the expression of GFAP, Iba1, Bax, and cytochrome c and increasing Bcl-2 expression.	Berberine	0-9	glial fibrillary acidic protein	Rattus norvegicus	107-111
31795609-9	2019	Berberine also increased cell proliferation and short-term memory, as well as decreasing the expression of GFAP, Iba1, Bax, and cytochrome c and increasing Bcl-2 expression.	Berberine	0-9	allograft inflammatory factor 1	Rattus norvegicus	113-117
31795609-9	2019	Berberine also increased cell proliferation and short-term memory, as well as decreasing the expression of GFAP, Iba1, Bax, and cytochrome c and increasing Bcl-2 expression.	Berberine	0-9	BCL2 associated X, apoptosis regulator	Rattus norvegicus	119-122
31795609-9	2019	Berberine also increased cell proliferation and short-term memory, as well as decreasing the expression of GFAP, Iba1, Bax, and cytochrome c and increasing Bcl-2 expression.	Berberine	0-9	BCL2, apoptosis regulator	Rattus norvegicus	156-161
31306972-8	2019	NF-kappaB p65, MLCK and TRAF6 levels were increased in A20 IEC-KO berberine mice as compared to WT berberine mice (P all&lt;0.05).	Berberine	66-75	TNF receptor-associated factor 6	Mus musculus	24-29
31564534-0	2019	Role of JAK2 in the Pathogenesis of Diabetic Erectile Dysfunction and an Intervention With Berberine.	Berberine	91-100	Janus kinase 2	Rattus norvegicus	8-12
31564534-13	2019	In vivo experiments also confirmed that the erectile function of the DMED+BB group was improved, accompanied by decreased phosphorylated JAK2/JAK2 and decreased oxidative stress.	Berberine	74-76	Janus kinase 2	Rattus norvegicus	137-141
31564534-13	2019	In vivo experiments also confirmed that the erectile function of the DMED+BB group was improved, accompanied by decreased phosphorylated JAK2/JAK2 and decreased oxidative stress.	Berberine	74-76	Janus kinase 2	Rattus norvegicus	142-146
31691998-10	2019	Knockdown of Ampka1 markedly reversed the inhibitory effect of berberine on lipid accumulation and mRNA expression of the above genes except Cebpb in porcine adipocytes.	Berberine	63-72	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	13-19
31691998-12	2019	These results suggest that berberine inhibits adipogenesis in porcine adipocytes via AMPK-dependent and -independent multiple mechanisms, which would provide an important idea for the reduction of porcine body fat, as well as the prevention and treatment of human obesity.	Berberine	27-36	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	85-89
31545468-3	2019	Through systematic pharmacological analysis, it was found that BBR serves a significant role in inhibiting HCC by affecting multiple pathways, especially the PI3K/AKT signaling pathway.	Berberine	63-66	AKT serine/threonine kinase 1	Homo sapiens	163-166
31545468-4	2019	Furthermore, the docking approach indicated that the binding of BBR to AKT could lead to the suppression of AKT activity.	Berberine	64-67	AKT serine/threonine kinase 1	Homo sapiens	71-74
31545468-4	2019	Furthermore, the docking approach indicated that the binding of BBR to AKT could lead to the suppression of AKT activity.	Berberine	64-67	AKT serine/threonine kinase 1	Homo sapiens	108-111
31545468-5	2019	The present study examined the inhibitory effect of BBR on the PI3K/AKT pathway in HCC and identified that BBR downregulated the expressions of phosphorylated AKT and PI3K in MHCC97-H and HepG2 cells, inhibiting their growth, cell migration and invasion in a dose-dependent manner.	Berberine	107-110	AKT serine/threonine kinase 1	Homo sapiens	68-71
31545468-5	2019	The present study examined the inhibitory effect of BBR on the PI3K/AKT pathway in HCC and identified that BBR downregulated the expressions of phosphorylated AKT and PI3K in MHCC97-H and HepG2 cells, inhibiting their growth, cell migration and invasion in a dose-dependent manner.	Berberine	107-110	AKT serine/threonine kinase 1	Homo sapiens	159-162
31545468-6	2019	In addition, inhibition of the AKT pathway by BBR also contributed to cell apoptosis in MHCC97-H and HepG2 cells.	Berberine	46-49	AKT serine/threonine kinase 1	Homo sapiens	31-34
31545468-7	2019	Taken together, the results of the present study suggested that BBR may be a promising antitumor drug for HCC that acts by inhibiting the PI3K/AKT pathway.	Berberine	64-67	AKT serine/threonine kinase 1	Homo sapiens	143-146
31666640-0	2019	Berberine decreases plasma triglyceride levels and upregulates hepatic TRIB1 in LDLR wild type mice and in LDLR deficient mice.	Berberine	0-9	tribbles pseudokinase 1	Mus musculus	71-76
31666640-0	2019	Berberine decreases plasma triglyceride levels and upregulates hepatic TRIB1 in LDLR wild type mice and in LDLR deficient mice.	Berberine	0-9	low density lipoprotein receptor	Mus musculus	80-84
31666640-0	2019	Berberine decreases plasma triglyceride levels and upregulates hepatic TRIB1 in LDLR wild type mice and in LDLR deficient mice.	Berberine	0-9	low density lipoprotein receptor	Mus musculus	107-111
31666640-3	2019	Berberine (BBR) is a natural lipid lowering drug that reduces plasma LDL-cholesterol (LDL-C), total cholesterol (TC) and TG in hyperlipidemic patients and in mice by mechanisms involving upregulation of hepatic LDL receptor (LDLR).	Berberine	0-9	low density lipoprotein receptor	Mus musculus	211-223
31666640-3	2019	Berberine (BBR) is a natural lipid lowering drug that reduces plasma LDL-cholesterol (LDL-C), total cholesterol (TC) and TG in hyperlipidemic patients and in mice by mechanisms involving upregulation of hepatic LDL receptor (LDLR).	Berberine	0-9	low density lipoprotein receptor	Mus musculus	225-229
31666640-3	2019	Berberine (BBR) is a natural lipid lowering drug that reduces plasma LDL-cholesterol (LDL-C), total cholesterol (TC) and TG in hyperlipidemic patients and in mice by mechanisms involving upregulation of hepatic LDL receptor (LDLR).	Berberine	11-14	low density lipoprotein receptor	Mus musculus	211-223
31666640-3	2019	Berberine (BBR) is a natural lipid lowering drug that reduces plasma LDL-cholesterol (LDL-C), total cholesterol (TC) and TG in hyperlipidemic patients and in mice by mechanisms involving upregulation of hepatic LDL receptor (LDLR).	Berberine	11-14	low density lipoprotein receptor	Mus musculus	225-229
31666640-4	2019	Here, we demonstrated that BBR treatment reduced plasma LDL-C, TC and TG in LDLR wildtype (WT) mice fed a high fat and high cholesterol diet and it only lowered TG in LDLR WT mice fed a normal chow diet.	Berberine	27-30	low density lipoprotein receptor	Mus musculus	76-80
31666640-4	2019	Here, we demonstrated that BBR treatment reduced plasma LDL-C, TC and TG in LDLR wildtype (WT) mice fed a high fat and high cholesterol diet and it only lowered TG in LDLR WT mice fed a normal chow diet.	Berberine	27-30	low density lipoprotein receptor	Mus musculus	167-171
31666640-5	2019	In hypercholesterolemic LDLR deficient mice (Ldlr-/-), BBR treatment reduced plasma TG levels by 51% compared to the vehicle control without affecting plasma cholesterol levels.	Berberine	55-58	low density lipoprotein receptor	Mus musculus	45-49
31615408-11	2019	Moreover, BBR administration reduced macrophage infiltration into the myocardium of ISO-treated rats and inhibited transforming growth factor (TGF)-beta1/smads signaling pathways in comparison to that seen in the ISO group.	Berberine	10-13	transforming growth factor, beta 1	Rattus norvegicus	115-153
31615408-12	2019	Besides, in vitro study showed that BBR-pretreatment reduced ISO-induced TGF-beta1 mRNA expression in macrophages and ISO stimulation of macrophages significantly increased the expression of fibrotic markers in fibroblasts, but BBR-pretreatment blocked this increase.	Berberine	36-39	transforming growth factor, beta 1	Rattus norvegicus	73-82
31607744-0	2019	Berberine (BBR) Attenuated Palmitic Acid (PA)-Induced Lipotoxicity in Human HK-2 Cells by Promoting Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha).	Berberine	0-9	peroxisome proliferator activated receptor alpha	Homo sapiens	100-148
31607744-0	2019	Berberine (BBR) Attenuated Palmitic Acid (PA)-Induced Lipotoxicity in Human HK-2 Cells by Promoting Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha).	Berberine	0-9	peroxisome proliferator activated receptor alpha	Homo sapiens	150-160
31607744-0	2019	Berberine (BBR) Attenuated Palmitic Acid (PA)-Induced Lipotoxicity in Human HK-2 Cells by Promoting Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha).	Berberine	11-14	peroxisome proliferator activated receptor alpha	Homo sapiens	100-148
31607744-0	2019	Berberine (BBR) Attenuated Palmitic Acid (PA)-Induced Lipotoxicity in Human HK-2 Cells by Promoting Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha).	Berberine	11-14	peroxisome proliferator activated receptor alpha	Homo sapiens	150-160
31607744-2	2019	Evidence suggests that BBR ameliorates palmitate-induced lipid deposition and apoptosis in renal tubular epithelial cells (TECs), which tracks in tandem with the enhancement of peroxisome proliferator-activated receptor alpha (PPAR-alpha).	Berberine	23-26	peroxisome proliferator activated receptor alpha	Homo sapiens	177-225
31306972-0	2019	Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice.	Berberine	0-9	tumor necrosis factor, alpha-induced protein 3	Mus musculus	73-76
31306972-1	2019	To investigate effects of berberine exerts on A20 expression and regulation of intestinal epithelial tight junctions via the TNF-alpha-NF-kappaB-MLCK pathway in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).	Berberine	26-35	tumor necrosis factor, alpha-induced protein 3	Mus musculus	46-49
31306972-1	2019	To investigate effects of berberine exerts on A20 expression and regulation of intestinal epithelial tight junctions via the TNF-alpha-NF-kappaB-MLCK pathway in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).	Berberine	26-35	tumor necrosis factor	Mus musculus	125-134
31306972-1	2019	To investigate effects of berberine exerts on A20 expression and regulation of intestinal epithelial tight junctions via the TNF-alpha-NF-kappaB-MLCK pathway in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).	Berberine	26-35	myosin light chain kinase 3	Mus musculus	145-149
31306972-6	2019	WT berberine mice exhibited greater expression of A20 compared with MC mice(P &lt; 0.01).	Berberine	3-12	tumor necrosis factor, alpha-induced protein 3	Mus musculus	50-53
31471002-0	2019	Corrigendum to "Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice" [Biomed.	Berberine	16-25	tumor necrosis factor, alpha-induced protein 3	Mus musculus	89-92
31552528-11	2019	The addition of 200 muM VO(acac)2 significantly induced ROS generation in HUVECs, while 0.01 or 0.1 muM BBR reversed the change of ROS.	Berberine	104-107	latexin	Homo sapiens	20-23
31552528-11	2019	The addition of 200 muM VO(acac)2 significantly induced ROS generation in HUVECs, while 0.01 or 0.1 muM BBR reversed the change of ROS.	Berberine	104-107	latexin	Homo sapiens	100-103
31612392-0	2019	Berberine Attenuates Cigarette Smoke Extract-induced Airway Inflammation in Mice: Involvement of TGF-beta1/Smads Signaling Pathway.	Berberine	0-9	transforming growth factor, beta 1	Mus musculus	97-106
30868509-10	2019	CS nano-encapsulation and surface modification of BBR-NPs altered the neuroprotective and hepatoprotective effects of BBR depending on the physicochemical and/or biological effects of BBR, CS, coating materials, and NP-related features.	Berberine	50-53	citrate synthase	Rattus norvegicus	189-191
30868509-10	2019	CS nano-encapsulation and surface modification of BBR-NPs altered the neuroprotective and hepatoprotective effects of BBR depending on the physicochemical and/or biological effects of BBR, CS, coating materials, and NP-related features.	Berberine	118-121	citrate synthase	Rattus norvegicus	0-2
30868509-10	2019	CS nano-encapsulation and surface modification of BBR-NPs altered the neuroprotective and hepatoprotective effects of BBR depending on the physicochemical and/or biological effects of BBR, CS, coating materials, and NP-related features.	Berberine	118-121	citrate synthase	Rattus norvegicus	189-191
30868509-10	2019	CS nano-encapsulation and surface modification of BBR-NPs altered the neuroprotective and hepatoprotective effects of BBR depending on the physicochemical and/or biological effects of BBR, CS, coating materials, and NP-related features.	Berberine	118-121	citrate synthase	Rattus norvegicus	0-2
30868509-10	2019	CS nano-encapsulation and surface modification of BBR-NPs altered the neuroprotective and hepatoprotective effects of BBR depending on the physicochemical and/or biological effects of BBR, CS, coating materials, and NP-related features.	Berberine	118-121	citrate synthase	Rattus norvegicus	189-191
31338966-0	2019	Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs.	Berberine	0-9	X-ray repair cross complementing 1	Homo sapiens	21-26
31485658-6	2019	Furthermore, berberine inhibited miR-212-induced ESCC cell migration, unlike the PI3K inhibitor LY294002, rapamycin (mTOR inhibitor), 5-(Tetradecyloxy)-2-furoic acid (TOFA; an acetyl-CoA carboxylase 1 inhibitor), metformin and propranolol.	Berberine	13-22	microRNA 212	Homo sapiens	33-40
31485658-8	2019	Berberine may be a potential therapeutic agent against metastasis in patients with ESCC, who express high levels of miR-212.	Berberine	0-9	microRNA 212	Homo sapiens	116-123
31527742-0	2019	Berberine inhibits adipocyte differentiation, proliferation and adiposity through down-regulating galectin-3.	Berberine	0-9	lectin, galactose binding, soluble 3	Mus musculus	98-108
31527742-1	2019	This study is designed to investigate the effects of berberine (BBR) on galectin-3 (Gal-3) and the relationships to its suppressive activities on adipocyte differentiation, proliferation and adiposity.	Berberine	53-62	lectin, galactose binding, soluble 3	Mus musculus	72-82
31527742-1	2019	This study is designed to investigate the effects of berberine (BBR) on galectin-3 (Gal-3) and the relationships to its suppressive activities on adipocyte differentiation, proliferation and adiposity.	Berberine	53-62	lectin, galactose binding, soluble 3	Mus musculus	84-89
31351968-13	2019	Berberine treatment induced TJ protein (claudin-1 and occludin) and raised TEER in LPS-treated Caco-2 cells.	Berberine	0-9	claudin 1	Homo sapiens	40-49
31351968-13	2019	Berberine treatment induced TJ protein (claudin-1 and occludin) and raised TEER in LPS-treated Caco-2 cells.	Berberine	0-9	occludin	Homo sapiens	54-62
31351968-14	2019	These effects of berberine in vitro were partially inhibited by ZIP14 siRNA.	Berberine	17-26	solute carrier family 39 member 14	Homo sapiens	64-69
31351968-15	2019	SIGNIFICANCE: The present study reveals that berberine induces ZIP14 expression and affects zinc re- distribution to protect intestinal barrier in sepsis, which is partially linked with the activation of IGF-I signaling.	Berberine	45-54	solute carrier family 39 member 14	Homo sapiens	63-68
31351968-15	2019	SIGNIFICANCE: The present study reveals that berberine induces ZIP14 expression and affects zinc re- distribution to protect intestinal barrier in sepsis, which is partially linked with the activation of IGF-I signaling.	Berberine	45-54	insulin like growth factor 1	Homo sapiens	204-209
31895879-0	2020	Berberine Attenuates Cholesterol Accumulation in Macrophage Foam Cells by Suppressing AP-1 Activity and Activation of the Nrf2/HO-1 Pathway.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	122-126
31895879-0	2020	Berberine Attenuates Cholesterol Accumulation in Macrophage Foam Cells by Suppressing AP-1 Activity and Activation of the Nrf2/HO-1 Pathway.	Berberine	0-9	heme oxygenase 1	Homo sapiens	127-131
31895879-6	2020	Here, we demonstrated that berberine could inhibit atherosclerosis in apolipoprotein E-deficient mice and induce cholesterol reduction as well as decrease the content of macrophages.	Berberine	27-36	apolipoprotein E	Mus musculus	70-86
31895879-8	2020	Mechanisms study showed that berberine can suppress scavenger receptor expression via inhibiting the activity of AP-1 and upregulate ATP-binding cassette transporter via activating Nrf2/HO-1 signaling in human macrophage.	Berberine	29-38	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	113-117
31895879-8	2020	Mechanisms study showed that berberine can suppress scavenger receptor expression via inhibiting the activity of AP-1 and upregulate ATP-binding cassette transporter via activating Nrf2/HO-1 signaling in human macrophage.	Berberine	29-38	ATP binding cassette subfamily A member 4	Homo sapiens	133-165
31895879-8	2020	Mechanisms study showed that berberine can suppress scavenger receptor expression via inhibiting the activity of AP-1 and upregulate ATP-binding cassette transporter via activating Nrf2/HO-1 signaling in human macrophage.	Berberine	29-38	NFE2 like bZIP transcription factor 2	Homo sapiens	181-185
31895879-8	2020	Mechanisms study showed that berberine can suppress scavenger receptor expression via inhibiting the activity of AP-1 and upregulate ATP-binding cassette transporter via activating Nrf2/HO-1 signaling in human macrophage.	Berberine	29-38	heme oxygenase 1	Homo sapiens	186-190
31564534-17	2019	CONCLUSIONS: JAK2 can induce DMED by enhancing oxidative stress and BB can play a role in treating DMED by inhibiting JAK2 and reducing oxidative stress.	Berberine	68-70	Janus kinase 2	Rattus norvegicus	118-122
31564534-20	2019	Role of JAK2 in the Pathogenesis of Diabetic Erectile Dysfunction and an Intervention With Berberine.	Berberine	91-100	Janus kinase 2	Rattus norvegicus	8-12
31652442-0	2019	Berberine improves insulin resistance in adipocyte models by regulating the methylation of hypoxia-inducible factor-3alpha.	Berberine	0-9	insulin	Homo sapiens	19-26
31652442-0	2019	Berberine improves insulin resistance in adipocyte models by regulating the methylation of hypoxia-inducible factor-3alpha.	Berberine	0-9	hypoxia inducible factor 3 subunit alpha	Homo sapiens	91-122
31652442-6	2019	Transfection of HIF3A siRNA further confirmed the role of HIF3A in the BBR-induced improving effects.	Berberine	71-74	hypoxia inducible factor 3 subunit alpha	Homo sapiens	16-21
31652442-6	2019	Transfection of HIF3A siRNA further confirmed the role of HIF3A in the BBR-induced improving effects.	Berberine	71-74	hypoxia inducible factor 3 subunit alpha	Homo sapiens	58-63
31652442-8	2019	BBR treatment noticeably increased the glucose usage rates, adiponectin secretion and cell differentiation of IR 3T3-L1 adipocytes.	Berberine	0-3	adiponectin, C1Q and collagen domain containing	Homo sapiens	60-71
31652442-10	2019	Furthermore, HIF3A silencing not only reversed the effects of BBR on improving insulin sensibility, but also partially abolished the expression alterations of insulin-related genes in IR adipocytes induced by BBR treatment.	Berberine	62-65	hypoxia inducible factor 3 subunit alpha	Homo sapiens	13-18
31652442-10	2019	Furthermore, HIF3A silencing not only reversed the effects of BBR on improving insulin sensibility, but also partially abolished the expression alterations of insulin-related genes in IR adipocytes induced by BBR treatment.	Berberine	62-65	insulin	Homo sapiens	79-86
31652442-10	2019	Furthermore, HIF3A silencing not only reversed the effects of BBR on improving insulin sensibility, but also partially abolished the expression alterations of insulin-related genes in IR adipocytes induced by BBR treatment.	Berberine	209-212	hypoxia inducible factor 3 subunit alpha	Homo sapiens	13-18
31652442-10	2019	Furthermore, HIF3A silencing not only reversed the effects of BBR on improving insulin sensibility, but also partially abolished the expression alterations of insulin-related genes in IR adipocytes induced by BBR treatment.	Berberine	209-212	insulin	Homo sapiens	159-166
31652442-11	2019	Our results suggest that BBR improves insulin sensibility in IR adipocyte models, and the improving effects of BBR are possibly realized through the inhibition of HIF3A methylation.	Berberine	25-28	insulin	Homo sapiens	38-45
31652442-11	2019	Our results suggest that BBR improves insulin sensibility in IR adipocyte models, and the improving effects of BBR are possibly realized through the inhibition of HIF3A methylation.	Berberine	111-114	hypoxia inducible factor 3 subunit alpha	Homo sapiens	163-168
31607744-2	2019	Evidence suggests that BBR ameliorates palmitate-induced lipid deposition and apoptosis in renal tubular epithelial cells (TECs), which tracks in tandem with the enhancement of peroxisome proliferator-activated receptor alpha (PPAR-alpha).	Berberine	23-26	peroxisome proliferator activated receptor alpha	Homo sapiens	227-237
31607744-10	2019	However, the protective effect of BBR in PA-induced lipotoxicity in HK-2 cells was significantly ameliorated by PPAR-alpha inhibitor.	Berberine	34-37	peroxisome proliferator activated receptor alpha	Homo sapiens	112-122
31607744-11	2019	CONCLUSIONS BBR attenuated PA-induced lipotoxicity via the PPAR-alpha pathway.	Berberine	12-15	peroxisome proliferator activated receptor alpha	Homo sapiens	59-69
31552528-8	2019	The results showed that the viability of HUVECs was decreased by treatment with vanadium compounds 50-400 muM in a concentration-dependent manner, while 0.01-1 muM BBR effectively protected HUVECs from the inhibitory effects of vanadium compounds on cell viability.	Berberine	164-167	latexin	Homo sapiens	160-163
31519292-0	2019	Effect of Berberine on C-reactive protein: A systematic review and meta-analysis of randomized controlled trials.	Berberine	10-19	C-reactive protein	Homo sapiens	23-41
32184858-8	2019	The lowest dose of the combination [Metformin (0.25 mM) and berberine (5 muM)] also synergistically reduced the expression of the FAS and SREBP-1c genes in HepG2 cells treated with high glucose.	Berberine	60-69	sterol regulatory element binding transcription factor 1	Homo sapiens	138-146
31432116-0	2019	Berberine ameliorates CCl4-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways.	Berberine	0-9	C-C motif chemokine ligand 4	Rattus norvegicus	22-26
31432116-0	2019	Berberine ameliorates CCl4-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	82-86
31432116-0	2019	Berberine ameliorates CCl4-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways.	Berberine	0-9	Kelch-like ECH-associated protein 1	Rattus norvegicus	87-92
31432116-0	2019	Berberine ameliorates CCl4-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways.	Berberine	0-9	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	101-104
31432116-11	2019	In conclusion, BBR exerts a protective action against CCl4-induced acute liver injury in rats via effectively regulating the expression of Nrf2-Keap1-antioxidant responsive element-related genes and proteins, and inhibiting p53 pathway-mediated hepatocyte apoptosis.	Berberine	15-18	C-C motif chemokine ligand 4	Rattus norvegicus	54-58
31432116-11	2019	In conclusion, BBR exerts a protective action against CCl4-induced acute liver injury in rats via effectively regulating the expression of Nrf2-Keap1-antioxidant responsive element-related genes and proteins, and inhibiting p53 pathway-mediated hepatocyte apoptosis.	Berberine	15-18	NFE2 like bZIP transcription factor 2	Rattus norvegicus	139-143
31432116-11	2019	In conclusion, BBR exerts a protective action against CCl4-induced acute liver injury in rats via effectively regulating the expression of Nrf2-Keap1-antioxidant responsive element-related genes and proteins, and inhibiting p53 pathway-mediated hepatocyte apoptosis.	Berberine	15-18	Kelch-like ECH-associated protein 1	Rattus norvegicus	144-149
31432116-11	2019	In conclusion, BBR exerts a protective action against CCl4-induced acute liver injury in rats via effectively regulating the expression of Nrf2-Keap1-antioxidant responsive element-related genes and proteins, and inhibiting p53 pathway-mediated hepatocyte apoptosis.	Berberine	15-18	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	224-227
31643170-2	2019	In a study in the mouse model of L-arginine-induced acute pancreatitis, we showed that BRB administered by the intravenous route at 0.1 and 0.5 mg / kg body weight significantly reduces the level of myeloperoxidase activity (an indicator of inflammation) in the pancreas and lungs.	Berberine	87-90	myeloperoxidase	Mus musculus	199-214
31029761-8	2019	Inhibitory activities of demethyleneberberine, palmatine, berberine and timosaponin A-I were confirmed by an enzyme assay of COX-2, which validated the reliability of our approach.	Berberine	36-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	125-130
31306972-8	2019	NF-kappaB p65, MLCK and TRAF6 levels were increased in A20 IEC-KO berberine mice as compared to WT berberine mice (P all&lt;0.05).	Berberine	66-75	tumor necrosis factor, alpha-induced protein 3	Mus musculus	55-58
31306972-9	2019	Intestinal epithelial levels of occludin, claudin-1, ZO-1 and F-actin increased in all berberine mice (P all&lt;0.01-0.05), while occludin, claudin-1, and ZO-1 levels were lower in A20 IEC-KO berberine mice(P &lt; 0.05).	Berberine	87-96	occludin	Mus musculus	32-40
31306972-10	2019	Berberine downregulates abnormal activation of the TNF-alpha-NF-kappaB-MLCK pathway by upregulating expression of A20 in a mouse model of IBS-D, thereby protecting intestinal epithelial tight junctions and repairing the damage IBS-D causes to the intestinal epithelial barrier.	Berberine	0-9	tumor necrosis factor	Mus musculus	51-60
31306972-10	2019	Berberine downregulates abnormal activation of the TNF-alpha-NF-kappaB-MLCK pathway by upregulating expression of A20 in a mouse model of IBS-D, thereby protecting intestinal epithelial tight junctions and repairing the damage IBS-D causes to the intestinal epithelial barrier.	Berberine	0-9	myosin light chain kinase 3	Mus musculus	71-75
31306972-10	2019	Berberine downregulates abnormal activation of the TNF-alpha-NF-kappaB-MLCK pathway by upregulating expression of A20 in a mouse model of IBS-D, thereby protecting intestinal epithelial tight junctions and repairing the damage IBS-D causes to the intestinal epithelial barrier.	Berberine	0-9	tumor necrosis factor, alpha-induced protein 3	Mus musculus	114-117
31564939-8	2019	BBR decreased levels of hypothalamic Orexin-A, the OX2R receptor, the corticotropin-releasing hormone, the pituitary and the plasma adrenocorticotropic hormone, as well as serum and urine corticosterone.	Berberine	0-3	hypocretin neuropeptide precursor	Rattus norvegicus	37-45
31351968-0	2019	Berberine induces ZIP14 expression and modulates zinc redistribution to protect intestinal mucosal barrier during polymicrobial sepsis.	Berberine	0-9	solute carrier family 39 member 14	Homo sapiens	18-23
31351968-1	2019	AIMS: The present study investigated if berberine might induce Zrt-Irt-like protein 14 (ZIP14) and affect zinc redistribution to protect intestinal barrier in sepsis.	Berberine	40-49	solute carrier family 39 member 14	Homo sapiens	63-86
31351968-1	2019	AIMS: The present study investigated if berberine might induce Zrt-Irt-like protein 14 (ZIP14) and affect zinc redistribution to protect intestinal barrier in sepsis.	Berberine	40-49	solute carrier family 39 member 14	Homo sapiens	88-93
31351968-8	2019	KEY FINDINGS: Berberine and zinc gluconate pretreatment to CLP rats improved survival rate, reduced plasma endotoxin level, alleviated hypozincemia, increased zinc accumulation and ZIP14 mRNA expression in the intestinal mucosa.	Berberine	14-23	solute carrier family 39 member 14	Homo sapiens	181-186
31351968-12	2019	Berberine and IGF-I treatment increased ZIP14 protein expression and promoted zinc transfer into Caco-2 cells exposed to zinc gluconate plus LPS.	Berberine	0-9	solute carrier family 39 member 14	Homo sapiens	40-45
31551713-12	2019	Besides, berberine increased C17.2 cell viability via up-regulating Extracellular-signal-Related Kinase (ERK) and phosphor-Extracellular-signal-Related Kinase (pERK) expression.	Berberine	9-18	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	114-158
31551713-12	2019	Besides, berberine increased C17.2 cell viability via up-regulating Extracellular-signal-Related Kinase (ERK) and phosphor-Extracellular-signal-Related Kinase (pERK) expression.	Berberine	9-18	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	160-164
31551713-13	2019	Then, berberine promoted C17.2 cell to differentiate into neurons and the differentiation mechanism involved the activation of WNT/beta-catenin pathway as well as the upregulation of expression levels of pro-neural factors Achaete-Scute Complex-Like 1 (ASCL1), Neurogenin 1 (NeuroG1), Neuronal Differentiation 2 (NeuroD2) and Doublecortin (DCX).	Berberine	6-15	catenin (cadherin associated protein), beta 1	Mus musculus	131-143
31551713-13	2019	Then, berberine promoted C17.2 cell to differentiate into neurons and the differentiation mechanism involved the activation of WNT/beta-catenin pathway as well as the upregulation of expression levels of pro-neural factors Achaete-Scute Complex-Like 1 (ASCL1), Neurogenin 1 (NeuroG1), Neuronal Differentiation 2 (NeuroD2) and Doublecortin (DCX).	Berberine	6-15	achaete-scute family bHLH transcription factor 1	Mus musculus	223-251
31551713-13	2019	Then, berberine promoted C17.2 cell to differentiate into neurons and the differentiation mechanism involved the activation of WNT/beta-catenin pathway as well as the upregulation of expression levels of pro-neural factors Achaete-Scute Complex-Like 1 (ASCL1), Neurogenin 1 (NeuroG1), Neuronal Differentiation 2 (NeuroD2) and Doublecortin (DCX).	Berberine	6-15	achaete-scute family bHLH transcription factor 1	Mus musculus	253-258
31551713-13	2019	Then, berberine promoted C17.2 cell to differentiate into neurons and the differentiation mechanism involved the activation of WNT/beta-catenin pathway as well as the upregulation of expression levels of pro-neural factors Achaete-Scute Complex-Like 1 (ASCL1), Neurogenin 1 (NeuroG1), Neuronal Differentiation 2 (NeuroD2) and Doublecortin (DCX).	Berberine	6-15	neurogenin 1	Mus musculus	261-273
31551713-13	2019	Then, berberine promoted C17.2 cell to differentiate into neurons and the differentiation mechanism involved the activation of WNT/beta-catenin pathway as well as the upregulation of expression levels of pro-neural factors Achaete-Scute Complex-Like 1 (ASCL1), Neurogenin 1 (NeuroG1), Neuronal Differentiation 2 (NeuroD2) and Doublecortin (DCX).	Berberine	6-15	neurogenin 1	Mus musculus	275-282
31551713-13	2019	Then, berberine promoted C17.2 cell to differentiate into neurons and the differentiation mechanism involved the activation of WNT/beta-catenin pathway as well as the upregulation of expression levels of pro-neural factors Achaete-Scute Complex-Like 1 (ASCL1), Neurogenin 1 (NeuroG1), Neuronal Differentiation 2 (NeuroD2) and Doublecortin (DCX).	Berberine	6-15	neurogenic differentiation 2	Mus musculus	285-311
31551713-13	2019	Then, berberine promoted C17.2 cell to differentiate into neurons and the differentiation mechanism involved the activation of WNT/beta-catenin pathway as well as the upregulation of expression levels of pro-neural factors Achaete-Scute Complex-Like 1 (ASCL1), Neurogenin 1 (NeuroG1), Neuronal Differentiation 2 (NeuroD2) and Doublecortin (DCX).	Berberine	6-15	neurogenic differentiation 2	Mus musculus	313-320
31551713-13	2019	Then, berberine promoted C17.2 cell to differentiate into neurons and the differentiation mechanism involved the activation of WNT/beta-catenin pathway as well as the upregulation of expression levels of pro-neural factors Achaete-Scute Complex-Like 1 (ASCL1), Neurogenin 1 (NeuroG1), Neuronal Differentiation 2 (NeuroD2) and Doublecortin (DCX).	Berberine	6-15	doublecortin	Mus musculus	340-343
31564939-8	2019	BBR decreased levels of hypothalamic Orexin-A, the OX2R receptor, the corticotropin-releasing hormone, the pituitary and the plasma adrenocorticotropic hormone, as well as serum and urine corticosterone.	Berberine	0-3	corticotropin releasing hormone	Rattus norvegicus	70-101
31264347-8	2019	Dietary berberine significantly mitigated the LPS-induced decreases in the mRNA expression of nuclear factor-kappa B (NF-kappaB), TNF-alpha, IL-1beta, inducible nitrite synthase and cyclooxygenase-2 (p &lt; 0.05) in the liver.	Berberine	8-17	nuclear factor kappa B subunit 1	Homo sapiens	94-116
31264347-8	2019	Dietary berberine significantly mitigated the LPS-induced decreases in the mRNA expression of nuclear factor-kappa B (NF-kappaB), TNF-alpha, IL-1beta, inducible nitrite synthase and cyclooxygenase-2 (p &lt; 0.05) in the liver.	Berberine	8-17	nuclear factor kappa B subunit 1	Homo sapiens	118-127
31264347-8	2019	Dietary berberine significantly mitigated the LPS-induced decreases in the mRNA expression of nuclear factor-kappa B (NF-kappaB), TNF-alpha, IL-1beta, inducible nitrite synthase and cyclooxygenase-2 (p &lt; 0.05) in the liver.	Berberine	8-17	tumor necrosis factor	Homo sapiens	130-139
31264347-8	2019	Dietary berberine significantly mitigated the LPS-induced decreases in the mRNA expression of nuclear factor-kappa B (NF-kappaB), TNF-alpha, IL-1beta, inducible nitrite synthase and cyclooxygenase-2 (p &lt; 0.05) in the liver.	Berberine	8-17	interleukin 1 beta	Homo sapiens	141-149
31264347-8	2019	Dietary berberine significantly mitigated the LPS-induced decreases in the mRNA expression of nuclear factor-kappa B (NF-kappaB), TNF-alpha, IL-1beta, inducible nitrite synthase and cyclooxygenase-2 (p &lt; 0.05) in the liver.	Berberine	8-17	prostaglandin-endoperoxide synthase 2	Homo sapiens	182-198
31264347-9	2019	In conclusion, berberine supplementation has a positive effect on LPS challenge, which may be related to the increase in antioxidant enzyme activity and inhibition of both NF-kappaB signalling and the expression of inflammatory mediators.	Berberine	15-24	nuclear factor kappa B subunit 1	Homo sapiens	172-181
31226399-0	2019	Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.	Berberine	0-9	sterol regulatory element binding transcription factor 1	Mus musculus	69-82
31226399-4	2019	Therefore, we hypothesized that SCD1 mediated the beneficial effect of BBR on NAFLD.	Berberine	71-74	stearoyl-Coenzyme A desaturase 1	Mus musculus	32-36
31226399-14	2019	Mechanistically, BBR promoted the phosphorylation of AMP-activated protein kinase (AMPK) and sterol regulatory element-binding protein-1c (SREBP-1c) in HepG2 cells and the liver of HFD-fed mice.	Berberine	17-20	sterol regulatory element binding transcription factor 1	Homo sapiens	93-137
31226399-14	2019	Mechanistically, BBR promoted the phosphorylation of AMP-activated protein kinase (AMPK) and sterol regulatory element-binding protein-1c (SREBP-1c) in HepG2 cells and the liver of HFD-fed mice.	Berberine	17-20	sterol regulatory element binding transcription factor 1	Homo sapiens	139-147
31318159-2	2019	In this study, we test whether berberine has a positive effect on the activity of PKC in quinolinic acid (QA)-induced neuronal cell death.	Berberine	31-40	protein kinase C, gamma	Rattus norvegicus	82-85
31261037-0	2019	Berberine coated mannosylated liposomes curtail RANKL stimulated osteoclastogenesis through the modulation of GSK3beta pathway via upregulating miR-23a.	Berberine	0-9	TNF superfamily member 11	Homo sapiens	48-53
31261037-0	2019	Berberine coated mannosylated liposomes curtail RANKL stimulated osteoclastogenesis through the modulation of GSK3beta pathway via upregulating miR-23a.	Berberine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	110-118
31261037-0	2019	Berberine coated mannosylated liposomes curtail RANKL stimulated osteoclastogenesis through the modulation of GSK3beta pathway via upregulating miR-23a.	Berberine	0-9	microRNA 23a	Homo sapiens	144-151
31261037-3	2019	Accordingly, the present study was designed to examine the therapeutic effect of berberine coated mannosylated liposomes (ML-BBR) on RANKL (100 ng/ml) stimulated bone marrow-derived monocytes/macrophages (BMMs) via altering miR-23a expression.	Berberine	81-90	TNF superfamily member 11	Homo sapiens	133-138
31332900-2	2019	In this study berberine (BBR) effects on arsenic-induced sirtuin 3 (Sirt3) modifications in isolated mitochondria from rat pancreas were evaluated and compared with metformin (MET).	Berberine	14-23	sirtuin 3	Rattus norvegicus	68-73
31332900-2	2019	In this study berberine (BBR) effects on arsenic-induced sirtuin 3 (Sirt3) modifications in isolated mitochondria from rat pancreas were evaluated and compared with metformin (MET).	Berberine	25-28	sirtuin 3	Rattus norvegicus	68-73
31332900-6	2019	Metformin compared with BBR exhibited a less significant effect on ROS levels and since its direct antioxidant property is minor, depressed the ROS level mainly through the Sirt3 modification.	Berberine	24-27	sirtuin 3	Rattus norvegicus	173-178
31318159-6	2019	We used in vivo infusion of Go6983, a PKC inhibitor to disturb PKC activity in mice brain, and found that the effect of berberine to reverse motor and cognitive deficits was significantly reduced.	Berberine	120-129	protein kinase C, gamma	Rattus norvegicus	38-41
31318159-6	2019	We used in vivo infusion of Go6983, a PKC inhibitor to disturb PKC activity in mice brain, and found that the effect of berberine to reverse motor and cognitive deficits was significantly reduced.	Berberine	120-129	protein kinase C, gamma	Rattus norvegicus	63-66
31318159-7	2019	Moreover, inhibition of PKC also blocked the anti-excitotoxicity effect of berberine, which is induced by glutamate in PC12 cells and BV2 cells, as well as anti-neuroinflammatory effect in LPS-stimulated BV2 cells.	Berberine	75-84	protein kinase C, gamma	Rattus norvegicus	24-27
31318159-8	2019	Above all, berberine showed neuroprotective effect against QA-induced acute neurotoxicity by activating PKC and its downstream molecules.	Berberine	11-20	protein kinase C, gamma	Rattus norvegicus	104-107
31417110-0	2019	Berberine improved experimental chronic colitis by regulating interferon-gamma- and IL-17A-producing lamina propria CD4+ T cells through AMPK activation.	Berberine	0-9	interferon gamma	Mus musculus	62-78
31417110-0	2019	Berberine improved experimental chronic colitis by regulating interferon-gamma- and IL-17A-producing lamina propria CD4+ T cells through AMPK activation.	Berberine	0-9	interleukin 17A	Mus musculus	84-90
31564939-9	2019	At the same time, BBR increased mRNA and protein expressions of GLUT4 in skeletal muscles of model rats as well.	Berberine	18-21	solute carrier family 2 member 4	Rattus norvegicus	64-69
31564939-10	2019	Conclusion: Those results suggested that BBR can exert inhibition on the HPA-axis and increased skeletal muscle expression of GLUT4 proteins, which may be one of the important mechanisms in BBR to improve IR and regulating glucose and lipid metabolism in T2DM rats.	Berberine	41-44	solute carrier family 2 member 4	Rattus norvegicus	126-131
31564939-10	2019	Conclusion: Those results suggested that BBR can exert inhibition on the HPA-axis and increased skeletal muscle expression of GLUT4 proteins, which may be one of the important mechanisms in BBR to improve IR and regulating glucose and lipid metabolism in T2DM rats.	Berberine	190-193	solute carrier family 2 member 4	Rattus norvegicus	126-131
31413530-10	2019	Oral administration of BBR inhibited the NF-kappaB signal transduction pathway, reduced the expression of pro-inflammatory cytokines [interleukin (IL)-1beta, IL-6, interferon-gamma, and tumor necrosis factor-alpha], promoted the expression of anti-inflammatory cytokines (IL-10 and transforming growth factor-beta), and improved the terminal ileum tissue inflammation.	Berberine	23-26	interleukin 1 alpha	Rattus norvegicus	134-156
31413530-10	2019	Oral administration of BBR inhibited the NF-kappaB signal transduction pathway, reduced the expression of pro-inflammatory cytokines [interleukin (IL)-1beta, IL-6, interferon-gamma, and tumor necrosis factor-alpha], promoted the expression of anti-inflammatory cytokines (IL-10 and transforming growth factor-beta), and improved the terminal ileum tissue inflammation.	Berberine	23-26	interleukin 6	Rattus norvegicus	158-162
31413530-10	2019	Oral administration of BBR inhibited the NF-kappaB signal transduction pathway, reduced the expression of pro-inflammatory cytokines [interleukin (IL)-1beta, IL-6, interferon-gamma, and tumor necrosis factor-alpha], promoted the expression of anti-inflammatory cytokines (IL-10 and transforming growth factor-beta), and improved the terminal ileum tissue inflammation.	Berberine	23-26	interferon gamma	Rattus norvegicus	164-180
31413530-10	2019	Oral administration of BBR inhibited the NF-kappaB signal transduction pathway, reduced the expression of pro-inflammatory cytokines [interleukin (IL)-1beta, IL-6, interferon-gamma, and tumor necrosis factor-alpha], promoted the expression of anti-inflammatory cytokines (IL-10 and transforming growth factor-beta), and improved the terminal ileum tissue inflammation.	Berberine	23-26	tumor necrosis factor	Rattus norvegicus	186-213
31413530-10	2019	Oral administration of BBR inhibited the NF-kappaB signal transduction pathway, reduced the expression of pro-inflammatory cytokines [interleukin (IL)-1beta, IL-6, interferon-gamma, and tumor necrosis factor-alpha], promoted the expression of anti-inflammatory cytokines (IL-10 and transforming growth factor-beta), and improved the terminal ileum tissue inflammation.	Berberine	23-26	interleukin 10	Rattus norvegicus	272-277
31413530-11	2019	BBR inhibited the expression of BDNF, TrkB, and C-kit in IBS rats, leading to the reduction of intestinal motility and visceral hypersensitivity.	Berberine	0-3	brain-derived neurotrophic factor	Rattus norvegicus	32-36
31413530-11	2019	BBR inhibited the expression of BDNF, TrkB, and C-kit in IBS rats, leading to the reduction of intestinal motility and visceral hypersensitivity.	Berberine	0-3	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	38-42
31413530-14	2019	BBR reduces the expression of BDNF, its receptor TrkB, and C-kit.	Berberine	0-3	brain-derived neurotrophic factor	Rattus norvegicus	30-34
31413530-14	2019	BBR reduces the expression of BDNF, its receptor TrkB, and C-kit.	Berberine	0-3	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	49-53
31152700-0	2019	Berberine inhibits low shear stress-induced glycocalyx degradation via modulating AMPK and p47phox/Hyal2 signal pathway.	Berberine	0-9	neutrophil cytosolic factor 1	Homo sapiens	91-98
31152700-0	2019	Berberine inhibits low shear stress-induced glycocalyx degradation via modulating AMPK and p47phox/Hyal2 signal pathway.	Berberine	0-9	hyaluronidase 2	Homo sapiens	99-104
31152700-7	2019	Further, berberine, by increasing AMPK phosphorylation, decreased the dissociation of p47phox/Hyal2, and subsequently inhibited Hyal2 activation and p47phox phosphorylation, leading to the metabolic maintaining of hyaluronic acid.	Berberine	9-18	neutrophil cytosolic factor 1	Homo sapiens	86-93
31152700-7	2019	Further, berberine, by increasing AMPK phosphorylation, decreased the dissociation of p47phox/Hyal2, and subsequently inhibited Hyal2 activation and p47phox phosphorylation, leading to the metabolic maintaining of hyaluronic acid.	Berberine	9-18	hyaluronidase 2	Homo sapiens	94-99
31152700-7	2019	Further, berberine, by increasing AMPK phosphorylation, decreased the dissociation of p47phox/Hyal2, and subsequently inhibited Hyal2 activation and p47phox phosphorylation, leading to the metabolic maintaining of hyaluronic acid.	Berberine	9-18	hyaluronidase 2	Homo sapiens	128-133
31152700-7	2019	Further, berberine, by increasing AMPK phosphorylation, decreased the dissociation of p47phox/Hyal2, and subsequently inhibited Hyal2 activation and p47phox phosphorylation, leading to the metabolic maintaining of hyaluronic acid.	Berberine	9-18	neutrophil cytosolic factor 1	Homo sapiens	149-156
31152700-9	2019	On the other hand, berberine also increased the expression of hyaluronic acid synthase 2 (HAS2) by regulating AMPKalpha/p47phox signaling pathway.	Berberine	19-28	hyaluronan synthase 2	Homo sapiens	62-88
31152700-9	2019	On the other hand, berberine also increased the expression of hyaluronic acid synthase 2 (HAS2) by regulating AMPKalpha/p47phox signaling pathway.	Berberine	19-28	hyaluronan synthase 2	Homo sapiens	90-94
31152700-9	2019	On the other hand, berberine also increased the expression of hyaluronic acid synthase 2 (HAS2) by regulating AMPKalpha/p47phox signaling pathway.	Berberine	19-28	pleckstrin	Homo sapiens	120-123
31152700-10	2019	Taken together, berberine treatment can attenuate low shear stress-induced hyaluronic acid degradation via increasing phosphorylation of AMPKa, and then not only downregulates p47phox and Hyal2 activity but also upregulates the expression of HAS2.	Berberine	16-25	neutrophil cytosolic factor 1	Homo sapiens	176-183
31152700-10	2019	Taken together, berberine treatment can attenuate low shear stress-induced hyaluronic acid degradation via increasing phosphorylation of AMPKa, and then not only downregulates p47phox and Hyal2 activity but also upregulates the expression of HAS2.	Berberine	16-25	hyaluronidase 2	Homo sapiens	188-193
31152700-10	2019	Taken together, berberine treatment can attenuate low shear stress-induced hyaluronic acid degradation via increasing phosphorylation of AMPKa, and then not only downregulates p47phox and Hyal2 activity but also upregulates the expression of HAS2.	Berberine	16-25	hyaluronan synthase 2	Homo sapiens	242-246
31111379-0	2019	Berberine mitigates IL-21/IL-21R mediated autophagic influx in fibroblast-like synoviocytes and regulates Th17/Treg imbalance in rheumatoid arthritis.	Berberine	0-9	interleukin 21	Homo sapiens	20-25
31111379-0	2019	Berberine mitigates IL-21/IL-21R mediated autophagic influx in fibroblast-like synoviocytes and regulates Th17/Treg imbalance in rheumatoid arthritis.	Berberine	0-9	interleukin 21 receptor	Homo sapiens	26-32
31111379-1	2019	In our previous study, we explored the therapeutic effect of berberine (BBR) against IL-21/IL-21R mediated inflammatory proliferation of adjuvant-induced arthritic fibroblast-like synoviocytes (AA-FLS) through the PI3K/Akt pathway.	Berberine	61-70	interleukin 21	Homo sapiens	85-90
31111379-1	2019	In our previous study, we explored the therapeutic effect of berberine (BBR) against IL-21/IL-21R mediated inflammatory proliferation of adjuvant-induced arthritic fibroblast-like synoviocytes (AA-FLS) through the PI3K/Akt pathway.	Berberine	61-70	interleukin 21 receptor	Homo sapiens	91-97
31111379-1	2019	In our previous study, we explored the therapeutic effect of berberine (BBR) against IL-21/IL-21R mediated inflammatory proliferation of adjuvant-induced arthritic fibroblast-like synoviocytes (AA-FLS) through the PI3K/Akt pathway.	Berberine	61-70	AKT serine/threonine kinase 1	Homo sapiens	219-222
31111379-1	2019	In our previous study, we explored the therapeutic effect of berberine (BBR) against IL-21/IL-21R mediated inflammatory proliferation of adjuvant-induced arthritic fibroblast-like synoviocytes (AA-FLS) through the PI3K/Akt pathway.	Berberine	72-75	interleukin 21	Homo sapiens	85-90
31111379-1	2019	In our previous study, we explored the therapeutic effect of berberine (BBR) against IL-21/IL-21R mediated inflammatory proliferation of adjuvant-induced arthritic fibroblast-like synoviocytes (AA-FLS) through the PI3K/Akt pathway.	Berberine	72-75	interleukin 21 receptor	Homo sapiens	91-97
31111379-1	2019	In our previous study, we explored the therapeutic effect of berberine (BBR) against IL-21/IL-21R mediated inflammatory proliferation of adjuvant-induced arthritic fibroblast-like synoviocytes (AA-FLS) through the PI3K/Akt pathway.	Berberine	72-75	AKT serine/threonine kinase 1	Homo sapiens	219-222
31111379-2	2019	The current study was designed to explore the therapeutic potential of BBR (15-45 microM) against IL-21/IL-21R mediated autophagy in AA-FLS mediated through PI3K/Akt signaling and Th17/Treg imbalance.	Berberine	71-74	interleukin 21	Homo sapiens	98-103
31111379-2	2019	The current study was designed to explore the therapeutic potential of BBR (15-45 microM) against IL-21/IL-21R mediated autophagy in AA-FLS mediated through PI3K/Akt signaling and Th17/Treg imbalance.	Berberine	71-74	interleukin 21 receptor	Homo sapiens	104-110
31111379-2	2019	The current study was designed to explore the therapeutic potential of BBR (15-45 microM) against IL-21/IL-21R mediated autophagy in AA-FLS mediated through PI3K/Akt signaling and Th17/Treg imbalance.	Berberine	71-74	AKT serine/threonine kinase 1	Homo sapiens	162-165
31032997-0	2019	Berberine inhibits the interleukin-1 beta-induced inflammatory response via MAPK downregulation in rat articular chondrocytes.	Berberine	0-9	interleukin 1 beta	Rattus norvegicus	23-41
30916407-11	2019	Natural products like berberine, quercetin, resveratrol, and so forth have shown significant potential in regulating and activating the AMPK pathway which can lead to manage diabetes mellitus and its complications.	Berberine	22-31	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	136-140
30786011-11	2019	Moreover, peroxisome proliferator-activated receptor gamma expression was significantly decreased in the hypoxia group, and this decrease was reversed by BBR treatment.	Berberine	154-157	peroxisome proliferator activated receptor gamma	Mus musculus	10-58
31318159-5	2019	QA inhibited the phosphorylation of PKC and its downstream molecules, GSK-3beta, ERK and CREB, enhanced the glutamate level and release of neuroinflammatory cytokines; these effects were attenuated by berberine.	Berberine	201-210	protein kinase C, gamma	Rattus norvegicus	36-39
30786011-12	2019	Our study demonstrated that the protective effect of BBR against hypoxia-induced PAH in a mouse model may be achieved through altered BMPR-II and TGF-beta signaling.	Berberine	53-56	bone morphogenetic protein receptor, type II (serine/threonine kinase)	Mus musculus	134-141
30911957-0	2019	Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt.	Berberine	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	58-61
31603884-8	2019	Berberine reduced blood urea, serum creatinine, malondialdehyde, neutrophil gelatinase associated lipocalin, kidney injury molecules-1 and Interleukin-18 significantly compared to diclofenac-induced acute kidney injury (p&lt;0.01 each).	Berberine	0-9	lipocalin 2	Rattus norvegicus	65-107
31603884-8	2019	Berberine reduced blood urea, serum creatinine, malondialdehyde, neutrophil gelatinase associated lipocalin, kidney injury molecules-1 and Interleukin-18 significantly compared to diclofenac-induced acute kidney injury (p&lt;0.01 each).	Berberine	0-9	interleukin 18	Rattus norvegicus	139-153
31603884-9	2019	Berberine improved anti-oxidant capacity through significant elevation of superoxide dismutase and glutathione reductase sera levels (p&lt;0.01 each).	Berberine	0-9	glutathione-disulfide reductase	Rattus norvegicus	99-120
31464934-0	2019	Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review.	Berberine	23-32	insulin	Homo sapiens	74-81
30911957-3	2019	Herein, we studied the key regulatory mechanisms involved in berberine-mediated up-regulation of p21/cip1 and p27/kip1.	Berberine	61-70	cyclin dependent kinase inhibitor 1A	Homo sapiens	97-100
30911957-3	2019	Herein, we studied the key regulatory mechanisms involved in berberine-mediated up-regulation of p21/cip1 and p27/kip1.	Berberine	61-70	cyclin dependent kinase inhibitor 1A	Homo sapiens	101-105
30911957-0	2019	Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt.	Berberine	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	62-66
30911957-3	2019	Herein, we studied the key regulatory mechanisms involved in berberine-mediated up-regulation of p21/cip1 and p27/kip1.	Berberine	61-70	dynactin subunit 6	Homo sapiens	110-113
30911957-3	2019	Herein, we studied the key regulatory mechanisms involved in berberine-mediated up-regulation of p21/cip1 and p27/kip1.	Berberine	61-70	cyclin dependent kinase inhibitor 1B	Homo sapiens	114-118
30911957-5	2019	Cells were arrested in G1 phase by berberine which was accompanied with up-regulation of mRNA and protein level of both p21/cip1 and p27/kip1.	Berberine	35-44	cyclin dependent kinase inhibitor 1A	Homo sapiens	120-123
30911957-5	2019	Cells were arrested in G1 phase by berberine which was accompanied with up-regulation of mRNA and protein level of both p21/cip1 and p27/kip1.	Berberine	35-44	cyclin dependent kinase inhibitor 1A	Homo sapiens	124-128
30911957-5	2019	Cells were arrested in G1 phase by berberine which was accompanied with up-regulation of mRNA and protein level of both p21/cip1 and p27/kip1.	Berberine	35-44	dynactin subunit 6	Homo sapiens	133-136
30911957-5	2019	Cells were arrested in G1 phase by berberine which was accompanied with up-regulation of mRNA and protein level of both p21/cip1 and p27/kip1.	Berberine	35-44	cyclin dependent kinase inhibitor 1B	Homo sapiens	137-141
30911957-6	2019	Berberine decreased the expression of protein levels of cyclin D1, cyclin E, CDK2, CDK4, and CDK6 to cause G1 phase arrest.	Berberine	0-9	cyclin D1	Homo sapiens	56-65
30911957-6	2019	Berberine decreased the expression of protein levels of cyclin D1, cyclin E, CDK2, CDK4, and CDK6 to cause G1 phase arrest.	Berberine	0-9	cyclin dependent kinase 2	Homo sapiens	77-81
30911957-6	2019	Berberine decreased the expression of protein levels of cyclin D1, cyclin E, CDK2, CDK4, and CDK6 to cause G1 phase arrest.	Berberine	0-9	cyclin dependent kinase 4	Homo sapiens	83-87
30911957-6	2019	Berberine decreased the expression of protein levels of cyclin D1, cyclin E, CDK2, CDK4, and CDK6 to cause G1 phase arrest.	Berberine	0-9	cyclin dependent kinase 6	Homo sapiens	93-97
30911957-7	2019	Berberine caused nuclear localization of p21/cip1 in both the cell lines.	Berberine	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	41-44
30911957-7	2019	Berberine caused nuclear localization of p21/cip1 in both the cell lines.	Berberine	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	45-49
30911957-9	2019	Inhibition of Akt was associated with berberine-mediated up-regulation of p21/cip1 and also led to a decrease in cell viability accompanied with significant G1 phase cell cycle arrest.	Berberine	38-47	AKT serine/threonine kinase 1	Homo sapiens	14-17
30911957-9	2019	Inhibition of Akt was associated with berberine-mediated up-regulation of p21/cip1 and also led to a decrease in cell viability accompanied with significant G1 phase cell cycle arrest.	Berberine	38-47	cyclin dependent kinase inhibitor 1A	Homo sapiens	74-77
30911957-9	2019	Inhibition of Akt was associated with berberine-mediated up-regulation of p21/cip1 and also led to a decrease in cell viability accompanied with significant G1 phase cell cycle arrest.	Berberine	38-47	cyclin dependent kinase inhibitor 1A	Homo sapiens	78-82
30911957-10	2019	Our study revealed that berberine not only up-regulates mRNA and protein levels of p21/cip1 and p27/kip1 but also increases their nuclear localization and post-translational protein stability.	Berberine	24-33	cyclin dependent kinase inhibitor 1A	Homo sapiens	83-86
30911957-10	2019	Our study revealed that berberine not only up-regulates mRNA and protein levels of p21/cip1 and p27/kip1 but also increases their nuclear localization and post-translational protein stability.	Berberine	24-33	cyclin dependent kinase inhibitor 1A	Homo sapiens	87-91
30911957-10	2019	Our study revealed that berberine not only up-regulates mRNA and protein levels of p21/cip1 and p27/kip1 but also increases their nuclear localization and post-translational protein stability.	Berberine	24-33	dynactin subunit 6	Homo sapiens	96-99
30911957-10	2019	Our study revealed that berberine not only up-regulates mRNA and protein levels of p21/cip1 and p27/kip1 but also increases their nuclear localization and post-translational protein stability.	Berberine	24-33	cyclin dependent kinase inhibitor 1B	Homo sapiens	100-104
30911957-11	2019	Further, Akt inhibition was found to mediate berberine-mediated up-regulation of p21/cip1 but not the p27/kip1.	Berberine	45-54	AKT serine/threonine kinase 1	Homo sapiens	9-12
30911957-11	2019	Further, Akt inhibition was found to mediate berberine-mediated up-regulation of p21/cip1 but not the p27/kip1.	Berberine	45-54	cyclin dependent kinase inhibitor 1A	Homo sapiens	81-84
30911957-11	2019	Further, Akt inhibition was found to mediate berberine-mediated up-regulation of p21/cip1 but not the p27/kip1.	Berberine	45-54	cyclin dependent kinase inhibitor 1A	Homo sapiens	85-89
31173223-0	2019	Long non-coding RNA CASC2 enhances berberine-induced cytotoxicity in colorectal cancer cells by silencing BCL2.	Berberine	35-44	cancer susceptibility 2	Homo sapiens	20-25
31173223-0	2019	Long non-coding RNA CASC2 enhances berberine-induced cytotoxicity in colorectal cancer cells by silencing BCL2.	Berberine	35-44	BCL2 apoptosis regulator	Homo sapiens	106-110
31173223-6	2019	In addition, RNA immunoprecipitation, chromatin immunoprecipitation and western blot analysis were used to identify the functional regulation of CASC2/EZH2/BCL2 axis in berberine-induced CRC cell apoptosis.	Berberine	169-178	cancer susceptibility 2	Homo sapiens	145-150
31173223-6	2019	In addition, RNA immunoprecipitation, chromatin immunoprecipitation and western blot analysis were used to identify the functional regulation of CASC2/EZH2/BCL2 axis in berberine-induced CRC cell apoptosis.	Berberine	169-178	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	151-155
31173223-6	2019	In addition, RNA immunoprecipitation, chromatin immunoprecipitation and western blot analysis were used to identify the functional regulation of CASC2/EZH2/BCL2 axis in berberine-induced CRC cell apoptosis.	Berberine	169-178	BCL2 apoptosis regulator	Homo sapiens	156-160
31173223-7	2019	The data revealed that lncRNA CASC2 was upregulated by berberine treatment.	Berberine	55-64	cancer susceptibility 2	Homo sapiens	30-35
31173223-8	2019	Gain- or loss-of-function assays suggested that lncRNA CASC2 was required for the berberine-induced inhibition of cell viability and activation of cell apoptosis.	Berberine	82-91	cancer susceptibility 2	Homo sapiens	55-60
31173223-9	2019	Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity.	Berberine	98-107	BCL2 apoptosis regulator	Homo sapiens	48-52
31173223-9	2019	Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity.	Berberine	98-107	cancer susceptibility 2	Homo sapiens	108-113
31173223-9	2019	Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity.	Berberine	98-107	BCL2 apoptosis regulator	Homo sapiens	128-132
31173223-9	2019	Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity.	Berberine	98-107	cancer susceptibility 2	Homo sapiens	156-161
31173223-9	2019	Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity.	Berberine	146-155	BCL2 apoptosis regulator	Homo sapiens	48-52
31173223-9	2019	Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity.	Berberine	146-155	cancer susceptibility 2	Homo sapiens	108-113
31173223-9	2019	Subsequently, the downstream antiapoptotic gene BCL2 was identified as a functional target of the berberine/CASC2 mechanism, as BCL2 reversed the berberine/CASC2-induced cell cytotoxicity.	Berberine	146-155	BCL2 apoptosis regulator	Homo sapiens	128-132
31173223-11	2019	In summary, berberine may be a novel therapeutic agent for CRC and lncRNA CASC2 may serve as an important therapeutic target to improve the anticancer effect of berberine.	Berberine	161-170	cancer susceptibility 2	Homo sapiens	74-79
30911957-0	2019	Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	113-116
30911957-2	2019	Berberine showed cytotoxicity to breast cancer cells, with an increase in the levels of p21/cip1 and p27/kip1, cyclin-dependent kinase inhibitors (CDKI), but mechanisms involved in up-regulating these molecules are largely unknown.	Berberine	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	88-91
30911957-2	2019	Berberine showed cytotoxicity to breast cancer cells, with an increase in the levels of p21/cip1 and p27/kip1, cyclin-dependent kinase inhibitors (CDKI), but mechanisms involved in up-regulating these molecules are largely unknown.	Berberine	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	92-96
30911957-2	2019	Berberine showed cytotoxicity to breast cancer cells, with an increase in the levels of p21/cip1 and p27/kip1, cyclin-dependent kinase inhibitors (CDKI), but mechanisms involved in up-regulating these molecules are largely unknown.	Berberine	0-9	dynactin subunit 6	Homo sapiens	101-104
30911957-2	2019	Berberine showed cytotoxicity to breast cancer cells, with an increase in the levels of p21/cip1 and p27/kip1, cyclin-dependent kinase inhibitors (CDKI), but mechanisms involved in up-regulating these molecules are largely unknown.	Berberine	0-9	cyclin dependent kinase inhibitor 1B	Homo sapiens	105-109
31360147-0	2019	Ameliorative Effect of Berberine on Neonatally Induced Type 2 Diabetic Neuropathy via Modulation of BDNF, IGF-1, PPAR-gamma, and AMPK Expressions.	Berberine	23-32	brain-derived neurotrophic factor	Rattus norvegicus	100-104
31701723-9	2019	Compared with VCI group, the escape latency in berberine-treated groups was shortened significantly (P<0.01, P<0.05) and the times of passing through the platform were increased remarkably (P<0.01, P<0.05), the levels of SOD, GSH and 5-HT were increased significantly (P<0.01), while the contents of TNF-alpha, IL-1beta and MAO were decreased remarkably (P<0.01).	Berberine	47-56	tumor necrosis factor	Rattus norvegicus	300-309
31701723-9	2019	Compared with VCI group, the escape latency in berberine-treated groups was shortened significantly (P<0.01, P<0.05) and the times of passing through the platform were increased remarkably (P<0.01, P<0.05), the levels of SOD, GSH and 5-HT were increased significantly (P<0.01), while the contents of TNF-alpha, IL-1beta and MAO were decreased remarkably (P<0.01).	Berberine	47-56	interleukin 1 alpha	Rattus norvegicus	311-319
31701723-9	2019	Compared with VCI group, the escape latency in berberine-treated groups was shortened significantly (P<0.01, P<0.05) and the times of passing through the platform were increased remarkably (P<0.01, P<0.05), the levels of SOD, GSH and 5-HT were increased significantly (P<0.01), while the contents of TNF-alpha, IL-1beta and MAO were decreased remarkably (P<0.01).	Berberine	47-56	monoamine oxidase A	Rattus norvegicus	324-327
31360147-0	2019	Ameliorative Effect of Berberine on Neonatally Induced Type 2 Diabetic Neuropathy via Modulation of BDNF, IGF-1, PPAR-gamma, and AMPK Expressions.	Berberine	23-32	insulin-like growth factor 1	Rattus norvegicus	106-111
31360147-0	2019	Ameliorative Effect of Berberine on Neonatally Induced Type 2 Diabetic Neuropathy via Modulation of BDNF, IGF-1, PPAR-gamma, and AMPK Expressions.	Berberine	23-32	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	113-123
31360147-0	2019	Ameliorative Effect of Berberine on Neonatally Induced Type 2 Diabetic Neuropathy via Modulation of BDNF, IGF-1, PPAR-gamma, and AMPK Expressions.	Berberine	23-32	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	129-133
31360147-10	2019	Streptozotocin-induced downregulated mRNA expressions of brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF-1), and peroxisome proliferator-activated receptors-gamma (PPAR-gamma) in sciatic nerve were significantly upregulated (P &lt; .05) by berberine.	Berberine	266-275	brain-derived neurotrophic factor	Rattus norvegicus	57-90
31360147-10	2019	Streptozotocin-induced downregulated mRNA expressions of brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF-1), and peroxisome proliferator-activated receptors-gamma (PPAR-gamma) in sciatic nerve were significantly upregulated (P &lt; .05) by berberine.	Berberine	266-275	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	190-200
31360147-11	2019	Western blot analysis revealed that STZ-induced alterations in adenosine monophosphate protein kinase (AMPK; Thr-172) and protein phosphatase 2C-alpha protein expressions in dorsal root ganglia were inhibited by berberine.	Berberine	212-221	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	103-107
31360147-13	2019	In conclusion, berberine exerts its neuroprotective effect against n-STZ-induced diabetic peripheral neuropathy via modulation of pro-inflammatory cytokines (TNF alpha, IL-1beta, and IL-6), oxido-nitrosative stress, BDNF, IGF-1, PPAR-gamma, and AMPK expression to ameliorate impaired allodynia, hyperalgesia, and nerve conduction velocity during T2DM.	Berberine	15-24	tumor necrosis factor	Rattus norvegicus	158-167
31360147-13	2019	In conclusion, berberine exerts its neuroprotective effect against n-STZ-induced diabetic peripheral neuropathy via modulation of pro-inflammatory cytokines (TNF alpha, IL-1beta, and IL-6), oxido-nitrosative stress, BDNF, IGF-1, PPAR-gamma, and AMPK expression to ameliorate impaired allodynia, hyperalgesia, and nerve conduction velocity during T2DM.	Berberine	15-24	interleukin 1 beta	Rattus norvegicus	169-177
31360147-13	2019	In conclusion, berberine exerts its neuroprotective effect against n-STZ-induced diabetic peripheral neuropathy via modulation of pro-inflammatory cytokines (TNF alpha, IL-1beta, and IL-6), oxido-nitrosative stress, BDNF, IGF-1, PPAR-gamma, and AMPK expression to ameliorate impaired allodynia, hyperalgesia, and nerve conduction velocity during T2DM.	Berberine	15-24	interleukin 6	Rattus norvegicus	183-187
31360147-13	2019	In conclusion, berberine exerts its neuroprotective effect against n-STZ-induced diabetic peripheral neuropathy via modulation of pro-inflammatory cytokines (TNF alpha, IL-1beta, and IL-6), oxido-nitrosative stress, BDNF, IGF-1, PPAR-gamma, and AMPK expression to ameliorate impaired allodynia, hyperalgesia, and nerve conduction velocity during T2DM.	Berberine	15-24	brain-derived neurotrophic factor	Rattus norvegicus	216-220
31360147-13	2019	In conclusion, berberine exerts its neuroprotective effect against n-STZ-induced diabetic peripheral neuropathy via modulation of pro-inflammatory cytokines (TNF alpha, IL-1beta, and IL-6), oxido-nitrosative stress, BDNF, IGF-1, PPAR-gamma, and AMPK expression to ameliorate impaired allodynia, hyperalgesia, and nerve conduction velocity during T2DM.	Berberine	15-24	insulin-like growth factor 1	Rattus norvegicus	222-227
31360147-13	2019	In conclusion, berberine exerts its neuroprotective effect against n-STZ-induced diabetic peripheral neuropathy via modulation of pro-inflammatory cytokines (TNF alpha, IL-1beta, and IL-6), oxido-nitrosative stress, BDNF, IGF-1, PPAR-gamma, and AMPK expression to ameliorate impaired allodynia, hyperalgesia, and nerve conduction velocity during T2DM.	Berberine	15-24	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	229-239
31360147-13	2019	In conclusion, berberine exerts its neuroprotective effect against n-STZ-induced diabetic peripheral neuropathy via modulation of pro-inflammatory cytokines (TNF alpha, IL-1beta, and IL-6), oxido-nitrosative stress, BDNF, IGF-1, PPAR-gamma, and AMPK expression to ameliorate impaired allodynia, hyperalgesia, and nerve conduction velocity during T2DM.	Berberine	15-24	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	245-249
31337982-0	2019	Amorphous solid dispersion of Berberine mitigates apoptosis via iPLA2beta/Cardiolipin/Opa1 pathway in db/db mice and in Palmitate-treated MIN6 beta-cells.	Berberine	30-39	phospholipase A2, group VI	Mus musculus	64-73
31354497-0	2019	Berberine Protects Mice Against Dextran Sulfate Sodium-Induced Colitis by Activating mTORC1 Pathway.	Berberine	0-9	CREB regulated transcription coactivator 1	Mus musculus	85-91
31354497-8	2019	As a result, the relative expression levels of downstream effector genes of mTORC were further determined, and data obtained showed that berberine could significantly increase the relative expression levels of S6K1 and 4EBP1.	Berberine	137-146	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	210-224
31354497-10	2019	Together, these results suggest that berberine exhibits significant protective effects against DSS colitis by activating the mTORC1 pathway to increase the proportion of Treg cells.	Berberine	37-46	CREB regulated transcription coactivator 1	Mus musculus	125-131
31099559-2	2019	Aiming to find a novel PDE4 inhibitor acting as an effective, safe, and convenient therapeutic agent, we constructed a library consisting of berberine analogues, and compound 2 with a tetrahydroisoquinoline scaffold was identified as a novel and potent hit.	Berberine	141-150	phosphodiesterase 4A	Homo sapiens	23-27
31522439-9	2019	Proposed mechanisms for the relaxant effect of berberine are histamine (H1) receptor blockade, inhibition of cyclooxygenase pathways and/or nitric oxide formation.	Berberine	47-56	histamine receptor H 1	Rattus norvegicus	61-84
30796904-0	2019	Berberine attenuates arthritis in adjuvant-induced arthritic rats associated with regulating polarization of macrophages through AMPK/NF-kB pathway.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	129-133
30796904-0	2019	Berberine attenuates arthritis in adjuvant-induced arthritic rats associated with regulating polarization of macrophages through AMPK/NF-kB pathway.	Berberine	0-9	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	134-139
31337982-0	2019	Amorphous solid dispersion of Berberine mitigates apoptosis via iPLA2beta/Cardiolipin/Opa1 pathway in db/db mice and in Palmitate-treated MIN6 beta-cells.	Berberine	30-39	OPA1, mitochondrial dynamin like GTPase	Mus musculus	86-90
31337982-6	2019	iPLA2beta overexpression and silencing technology were used to examine how the iPLA2beta/CL/Opa1 interaction may play an important role in BBR treatment.	Berberine	139-142	phospholipase A2, group VI	Mus musculus	79-88
31337982-6	2019	iPLA2beta overexpression and silencing technology were used to examine how the iPLA2beta/CL/Opa1 interaction may play an important role in BBR treatment.	Berberine	139-142	OPA1, mitochondrial dynamin like GTPase	Mus musculus	92-96
31337982-11	2019	In addition, iPLA2beta silencing could simultaneously partly abolish the anti-apoptotic effect of BBR and decrease CL/Opa1 signaling in MIN6 cells.	Berberine	98-101	phospholipase A2, group VI	Mus musculus	13-22
30848932-0	2019	Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.	Berberine	0-9	sirtuin 3	Mus musculus	95-100
30991048-0	2019	Berberine stimulates fibroblast growth factor 21 by modulating the molecular clock component brain and muscle Arnt-like 1 in brown adipose tissue.	Berberine	0-9	fibroblast growth factor 21	Homo sapiens	21-48
30991048-0	2019	Berberine stimulates fibroblast growth factor 21 by modulating the molecular clock component brain and muscle Arnt-like 1 in brown adipose tissue.	Berberine	0-9	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	93-121
30991048-3	2019	In the present study, we demonstrated that berberine, a naturally occurring compound, stimulated FGF21 expression in brown adipose tissue (BAT).	Berberine	43-52	fibroblast growth factor 21	Homo sapiens	97-102
30991048-4	2019	Furthermore, the up-regulated expression of FGF21 in brown adipocytes in response to berberine was due, at least in part, to the activation of the AMP-activated protein kinase pathway.	Berberine	85-94	fibroblast growth factor 21	Homo sapiens	44-49
30991048-5	2019	We also found that berberine reversed high-fat diet-induced obesity concomitant with its regulation of the expression of Fgf21 and the core clock component brain and muscle Arnt-like 1 (Bmal1) in BAT.	Berberine	19-28	fibroblast growth factor 21	Homo sapiens	121-126
30991048-5	2019	We also found that berberine reversed high-fat diet-induced obesity concomitant with its regulation of the expression of Fgf21 and the core clock component brain and muscle Arnt-like 1 (Bmal1) in BAT.	Berberine	19-28	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	156-184
30991048-5	2019	We also found that berberine reversed high-fat diet-induced obesity concomitant with its regulation of the expression of Fgf21 and the core clock component brain and muscle Arnt-like 1 (Bmal1) in BAT.	Berberine	19-28	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	186-191
30991048-6	2019	Berberine significantly up-regulated the gene expression and production of FGF21 in a dose-dependent manner in C3H10T1/2 brown adipocytes.	Berberine	0-9	fibroblast growth factor 21	Homo sapiens	75-80
30991048-7	2019	Furthermore, the knockdown of Bmal1 prevented the up-regulated expression of FGF21 in response to berberine in C3H10T1/2 brown adipocytes, suggesting that Bmal1 links the regulatory mechanisms of FGF21 in response to berberine.	Berberine	98-107	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	30-35
30991048-7	2019	Furthermore, the knockdown of Bmal1 prevented the up-regulated expression of FGF21 in response to berberine in C3H10T1/2 brown adipocytes, suggesting that Bmal1 links the regulatory mechanisms of FGF21 in response to berberine.	Berberine	98-107	fibroblast growth factor 21	Homo sapiens	77-82
30991048-7	2019	Furthermore, the knockdown of Bmal1 prevented the up-regulated expression of FGF21 in response to berberine in C3H10T1/2 brown adipocytes, suggesting that Bmal1 links the regulatory mechanisms of FGF21 in response to berberine.	Berberine	98-107	fibroblast growth factor 21	Homo sapiens	196-201
30991048-7	2019	Furthermore, the knockdown of Bmal1 prevented the up-regulated expression of FGF21 in response to berberine in C3H10T1/2 brown adipocytes, suggesting that Bmal1 links the regulatory mechanisms of FGF21 in response to berberine.	Berberine	217-226	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	30-35
30991048-7	2019	Furthermore, the knockdown of Bmal1 prevented the up-regulated expression of FGF21 in response to berberine in C3H10T1/2 brown adipocytes, suggesting that Bmal1 links the regulatory mechanisms of FGF21 in response to berberine.	Berberine	217-226	fibroblast growth factor 21	Homo sapiens	77-82
30991048-7	2019	Furthermore, the knockdown of Bmal1 prevented the up-regulated expression of FGF21 in response to berberine in C3H10T1/2 brown adipocytes, suggesting that Bmal1 links the regulatory mechanisms of FGF21 in response to berberine.	Berberine	217-226	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	155-160
30991048-7	2019	Furthermore, the knockdown of Bmal1 prevented the up-regulated expression of FGF21 in response to berberine in C3H10T1/2 brown adipocytes, suggesting that Bmal1 links the regulatory mechanisms of FGF21 in response to berberine.	Berberine	217-226	fibroblast growth factor 21	Homo sapiens	196-201
30991048-8	2019	The present results suggest that berberine stimulates the expression of FGF21 by modulating molecular clock Bmal1 in BAT, which may, in turn, attenuate diet-induced obesity.	Berberine	33-42	fibroblast growth factor 21	Homo sapiens	72-77
30991048-8	2019	The present results suggest that berberine stimulates the expression of FGF21 by modulating molecular clock Bmal1 in BAT, which may, in turn, attenuate diet-induced obesity.	Berberine	33-42	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	108-113
31298400-3	2019	This study aimed to investigate the effect of Berberine and Hesperidin on inflammatory cytokine secretion, proliferation, differentiation, and collagen synthesis of cardiac fibroblasts stimulated by the transforming growth factor-beta1 (TGF-beta1), and the potential of these drugs to regulate the Notch1 signaling pathway.	Berberine	46-55	transforming growth factor beta 1	Homo sapiens	203-235
31298400-3	2019	This study aimed to investigate the effect of Berberine and Hesperidin on inflammatory cytokine secretion, proliferation, differentiation, and collagen synthesis of cardiac fibroblasts stimulated by the transforming growth factor-beta1 (TGF-beta1), and the potential of these drugs to regulate the Notch1 signaling pathway.	Berberine	46-55	transforming growth factor beta 1	Homo sapiens	237-246
31298400-5	2019	In the Berberine (TGF+B) group cells were given TGF-beta1, along with 1.25/2.5/5/10 mg/L Berberine, while the Hesperidin (TGF+H) group was treated with TGF-beta1 and 12.5/25/50/100 micrommol/L Hesperidin.	Berberine	7-16	transforming growth factor beta 1	Homo sapiens	18-23
31298400-7	2019	The role of the Notch1 signaling pathway in the protective effects of Berberine and Hesperidin was analyzed by using gamma-secretase inhibitor (DAPT) to block the Notch1 pathway.	Berberine	70-79	notch receptor 1	Homo sapiens	16-22
31298400-8	2019	RESULTS: 5/10 mg/L Berberine intervention could noticeably decrease both TGF-beta1 and IL-1beta levels, 25/50/100 micromol/L Hesperidin could reduce IL-1beta secretion from TGF-beta1 stimulated cardiac fibroblasts.	Berberine	19-28	transforming growth factor, beta 1	Rattus norvegicus	73-82
31298400-8	2019	RESULTS: 5/10 mg/L Berberine intervention could noticeably decrease both TGF-beta1 and IL-1beta levels, 25/50/100 micromol/L Hesperidin could reduce IL-1beta secretion from TGF-beta1 stimulated cardiac fibroblasts.	Berberine	19-28	interleukin 1 alpha	Homo sapiens	87-95
31136975-0	2019	Berberine enhances the radiosensitivity of hepatoma cells by Nrf2 pathway.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	61-65
31059099-0	2019	Berberine improves advanced glycation end products-induced osteogenic differentiation responses in human periodontal ligament stem cells through the canonical Wnt/beta-catenin pathway.	Berberine	0-9	catenin beta 1	Homo sapiens	163-175
30861392-0	2019	Berberine suppresses mast cell-mediated allergic responses via regulating FceRI-mediated and MAPK signaling.	Berberine	0-9	membrane spanning 4-domains A2	Rattus norvegicus	74-79
30861392-2	2019	In this study, the results of the in vitro model of immunoglobulin (Ig) E-mediated mast cell degranulation showed that berberine significantly inhibited the release of beta-hexosaminidase (beta-HEX), histamine, IL-4 and TNF-alpha in rat basophilic leukemia cells (RBL-2H3 cells).	Berberine	119-128	O-GlcNAcase	Rattus norvegicus	168-187
30861392-2	2019	In this study, the results of the in vitro model of immunoglobulin (Ig) E-mediated mast cell degranulation showed that berberine significantly inhibited the release of beta-hexosaminidase (beta-HEX), histamine, IL-4 and TNF-alpha in rat basophilic leukemia cells (RBL-2H3 cells).	Berberine	119-128	O-GlcNAcase	Rattus norvegicus	189-197
30861392-2	2019	In this study, the results of the in vitro model of immunoglobulin (Ig) E-mediated mast cell degranulation showed that berberine significantly inhibited the release of beta-hexosaminidase (beta-HEX), histamine, IL-4 and TNF-alpha in rat basophilic leukemia cells (RBL-2H3 cells).	Berberine	119-128	interleukin 4	Rattus norvegicus	211-215
30861392-2	2019	In this study, the results of the in vitro model of immunoglobulin (Ig) E-mediated mast cell degranulation showed that berberine significantly inhibited the release of beta-hexosaminidase (beta-HEX), histamine, IL-4 and TNF-alpha in rat basophilic leukemia cells (RBL-2H3 cells).	Berberine	119-128	tumor necrosis factor	Rattus norvegicus	220-229
30861392-4	2019	Pretreatment with berberine also suppressed the phosphorylation of antigen-induced Lyn, Syk, and Gab2, thus suppressing the downstream MAPK pathways.	Berberine	18-27	LYN proto-oncogene, Src family tyrosine kinase	Rattus norvegicus	83-86
30861392-4	2019	Pretreatment with berberine also suppressed the phosphorylation of antigen-induced Lyn, Syk, and Gab2, thus suppressing the downstream MAPK pathways.	Berberine	18-27	spleen associated tyrosine kinase	Rattus norvegicus	88-91
30861392-4	2019	Pretreatment with berberine also suppressed the phosphorylation of antigen-induced Lyn, Syk, and Gab2, thus suppressing the downstream MAPK pathways.	Berberine	18-27	GRB2-associated binding protein 2	Rattus norvegicus	97-101
31142783-0	2019	Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice.	Berberine	0-9	glucokinase	Mus musculus	56-67
31186788-0	2019	hERG1 is involved in the pathophysiological process and inhibited by berberine in SKOV3 cells.	Berberine	69-78	potassium voltage-gated channel subfamily H member 2	Homo sapiens	0-5
31186788-11	2019	In addition, berberine (BBR) may be used as a potential drug in the treatment of ovarian cancer, possibly due to its inhibitory effects on the hERG1 channels.	Berberine	13-22	potassium voltage-gated channel subfamily H member 2	Homo sapiens	143-148
31186788-11	2019	In addition, berberine (BBR) may be used as a potential drug in the treatment of ovarian cancer, possibly due to its inhibitory effects on the hERG1 channels.	Berberine	24-27	potassium voltage-gated channel subfamily H member 2	Homo sapiens	143-148
31186788-12	2019	In conclusion, the present study demonstrated that hERG1 may be a potential therapeutic target in the treatment of ovarian cancer and provided novel insights into the mechanism underlying the antitumor effects of BBR in ovarian cancer.	Berberine	213-216	potassium voltage-gated channel subfamily H member 2	Homo sapiens	51-56
31142783-1	2019	Berberine (BBR) is a widely used anti-diabetic agent, and liver glucokinase (GK) has been reported to be involved.	Berberine	0-9	glucokinase	Mus musculus	77-79
31142783-1	2019	Berberine (BBR) is a widely used anti-diabetic agent, and liver glucokinase (GK) has been reported to be involved.	Berberine	11-14	glucokinase	Mus musculus	64-75
31142783-3	2019	Here, we found that BBR upregulated GK immunofluorescence expression in AML12 cells cultured in high glucose and increased glycogen content simultaneously.	Berberine	20-23	glucokinase	Mus musculus	36-38
31142783-6	2019	G-6-P is solely catalyzed by GK, and GK activity and expression showed a positive correlation with liver BBR levels.	Berberine	105-108	glucokinase	Mus musculus	37-39
31142783-9	2019	In conclusion, our study suggests the dissociation of GK from GKRP as the potential mechanism for liver GK increase upon BBR treatment, which contributes to the anti-diabetic effect of BBR.	Berberine	121-124	glucokinase	Mus musculus	54-56
31142783-9	2019	In conclusion, our study suggests the dissociation of GK from GKRP as the potential mechanism for liver GK increase upon BBR treatment, which contributes to the anti-diabetic effect of BBR.	Berberine	121-124	glucokinase regulatory protein	Mus musculus	62-66
31142783-9	2019	In conclusion, our study suggests the dissociation of GK from GKRP as the potential mechanism for liver GK increase upon BBR treatment, which contributes to the anti-diabetic effect of BBR.	Berberine	121-124	glucokinase	Mus musculus	62-64
31142783-9	2019	In conclusion, our study suggests the dissociation of GK from GKRP as the potential mechanism for liver GK increase upon BBR treatment, which contributes to the anti-diabetic effect of BBR.	Berberine	185-188	glucokinase	Mus musculus	54-56
31142783-9	2019	In conclusion, our study suggests the dissociation of GK from GKRP as the potential mechanism for liver GK increase upon BBR treatment, which contributes to the anti-diabetic effect of BBR.	Berberine	185-188	glucokinase regulatory protein	Mus musculus	62-66
31142783-9	2019	In conclusion, our study suggests the dissociation of GK from GKRP as the potential mechanism for liver GK increase upon BBR treatment, which contributes to the anti-diabetic effect of BBR.	Berberine	185-188	glucokinase	Mus musculus	62-64
31122236-10	2019	Our analysis revealed that in multiple memory defects animal models, berberine showed significant memory-improving activities with multiple mechanisms, such as anti-inflammation, anti-oxidative stress, cholinesterase (ChE) inhibition and anti-amyloid effects.	Berberine	69-78	butyrylcholinesterase	Homo sapiens	202-216
31122236-10	2019	Our analysis revealed that in multiple memory defects animal models, berberine showed significant memory-improving activities with multiple mechanisms, such as anti-inflammation, anti-oxidative stress, cholinesterase (ChE) inhibition and anti-amyloid effects.	Berberine	69-78	butyrylcholinesterase	Homo sapiens	218-221
31217846-6	2019	Berberine significantly reduced the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glucose (GLU), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol (TC).	Berberine	0-9	glutamic pyruvic transaminase, soluble	Mus musculus	46-70
31118464-13	2019	Interestingly, the reduction of PCSK9 can be blocked by the treatment of berberine, a natural cholesterol-lowering compound which functions as a HNF-1alpha antagonist.	Berberine	73-82	proprotein convertase subtilisin/kexin type 9	Homo sapiens	32-37
31118464-13	2019	Interestingly, the reduction of PCSK9 can be blocked by the treatment of berberine, a natural cholesterol-lowering compound which functions as a HNF-1alpha antagonist.	Berberine	73-82	HNF1 homeobox A	Homo sapiens	145-155
31217846-9	2019	Moreover, our results showed that berberine suppressed phosphorylation of p38MAPK and ERK as well as COX2 expression significantly.	Berberine	34-43	mitogen-activated protein kinase 14	Mus musculus	74-81
31217846-6	2019	Berberine significantly reduced the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glucose (GLU), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol (TC).	Berberine	0-9	glutamic pyruvic transaminase, soluble	Mus musculus	72-75
31217846-9	2019	Moreover, our results showed that berberine suppressed phosphorylation of p38MAPK and ERK as well as COX2 expression significantly.	Berberine	34-43	mitogen-activated protein kinase 1	Mus musculus	86-89
31217846-6	2019	Berberine significantly reduced the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glucose (GLU), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol (TC).	Berberine	0-9	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	78-104
31217846-9	2019	Moreover, our results showed that berberine suppressed phosphorylation of p38MAPK and ERK as well as COX2 expression significantly.	Berberine	34-43	cytochrome c oxidase II, mitochondrial	Mus musculus	101-105
31217846-6	2019	Berberine significantly reduced the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glucose (GLU), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol (TC).	Berberine	0-9	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	106-109
31217846-10	2019	This suggested berberine achieved its biological functions mainly by regulating inflammation and angiogenesis genes involving p38MAPK/ERK-COX2 pathways.	Berberine	15-24	mitogen-activated protein kinase 14	Mus musculus	126-133
31217846-10	2019	This suggested berberine achieved its biological functions mainly by regulating inflammation and angiogenesis genes involving p38MAPK/ERK-COX2 pathways.	Berberine	15-24	mitogen-activated protein kinase 1	Mus musculus	134-137
30867696-0	2019	Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	101-105
31217846-10	2019	This suggested berberine achieved its biological functions mainly by regulating inflammation and angiogenesis genes involving p38MAPK/ERK-COX2 pathways.	Berberine	15-24	cytochrome c oxidase II, mitochondrial	Mus musculus	138-142
30536411-1	2019	OBJECTIVES: The role of nuclear factor-2 erythroid related factor-2 (Nrf2) activator, berberine (BBR), has been established in rat model of streptozotocin induced diabetic neuropathy.	Berberine	86-95	NFE2 like bZIP transcription factor 2	Rattus norvegicus	69-73
30536411-1	2019	OBJECTIVES: The role of nuclear factor-2 erythroid related factor-2 (Nrf2) activator, berberine (BBR), has been established in rat model of streptozotocin induced diabetic neuropathy.	Berberine	97-100	NFE2 like bZIP transcription factor 2	Rattus norvegicus	69-73
30944202-10	2019	More importantly, MMP not only significantly enhanced berberine uptake driven by cell membrane potential (P&lt;0.01) but also inhibited p-glycoprotein (P-gp)-mediated berberine efflux (P&lt;0.01).	Berberine	167-176	ATP binding cassette subfamily B member 1	Homo sapiens	136-150
30944202-10	2019	More importantly, MMP not only significantly enhanced berberine uptake driven by cell membrane potential (P&lt;0.01) but also inhibited p-glycoprotein (P-gp)-mediated berberine efflux (P&lt;0.01).	Berberine	167-176	ATP binding cassette subfamily B member 1	Homo sapiens	152-156
31013627-0	2019	Inhibitory Effect of Berberine on Broiler P-glycoprotein Expression and Function: In Situ and In Vitro Studies.	Berberine	21-30	phosphoglycolate phosphatase	Gallus gallus	42-56
31013627-2	2019	Berberine inhibits P-gp and thereby increases the bioavailability of the P-gp substrate digoxin in rodents.	Berberine	0-9	phosphoglycolate phosphatase	Gallus gallus	19-23
31013627-2	2019	Berberine inhibits P-gp and thereby increases the bioavailability of the P-gp substrate digoxin in rodents.	Berberine	0-9	phosphoglycolate phosphatase	Gallus gallus	73-77
31013627-4	2019	Here, we studied the role of berberine in modulating broilers P-gp expression and function through both in situ and in vitro models.	Berberine	29-38	phosphoglycolate phosphatase	Gallus gallus	62-66
31013627-5	2019	In addition, molecular docking was applied to analyze the interactions of berberine with P-gp as well as with chicken xenobiotic receptor (CXR).	Berberine	74-83	phosphoglycolate phosphatase	Gallus gallus	89-93
31013627-6	2019	The results showed that the mRNA expression levels of chicken P-gp and CXR decreased in the ileum following exposure to berberine.	Berberine	120-129	phosphoglycolate phosphatase	Gallus gallus	62-66
31013627-6	2019	The results showed that the mRNA expression levels of chicken P-gp and CXR decreased in the ileum following exposure to berberine.	Berberine	120-129	nuclear receptor subfamily 1 group I member 3	Gallus gallus	71-74
31013627-8	2019	Efflux ratios of P-gp substrates (tilmicosin, ciprofloxacin, clindamycin, ampicillin, and enrofloxacin) decreased and the apparent permeability coefficients increased after co-incubation with berberine in MDCK-chAbcb1 cell models.	Berberine	192-201	phosphoglycolate phosphatase	Gallus gallus	17-21
31013627-9	2019	Bidirectional assay results showed that berberine could be transported by chicken P-gp with a transport ratio of 4.20, and this was attenuated by verapamil (an inhibitor of P-gp), which resulted in a ratio of 1.13.	Berberine	40-49	phosphoglycolate phosphatase	Gallus gallus	82-86
31013627-9	2019	Bidirectional assay results showed that berberine could be transported by chicken P-gp with a transport ratio of 4.20, and this was attenuated by verapamil (an inhibitor of P-gp), which resulted in a ratio of 1.13.	Berberine	40-49	phosphoglycolate phosphatase	Gallus gallus	173-177
31013627-10	2019	Molecular docking revealed that berberine could form favorable interactions with the binding pockets of both CXR and P-gp, with docking scores of -7.8 and -9.5 kcal/mol, respectively.	Berberine	32-41	nuclear receptor subfamily 1 group I member 3	Gallus gallus	109-112
31013627-10	2019	Molecular docking revealed that berberine could form favorable interactions with the binding pockets of both CXR and P-gp, with docking scores of -7.8 and -9.5 kcal/mol, respectively.	Berberine	32-41	phosphoglycolate phosphatase	Gallus gallus	117-121
31013627-11	2019	These results indicate that berberine is a substrate of chicken P-gp and down-regulates P-gp expression in chicken tissues, thereby increasing the absorption of P-gp substrates.	Berberine	28-37	phosphoglycolate phosphatase	Gallus gallus	64-68
31013627-11	2019	These results indicate that berberine is a substrate of chicken P-gp and down-regulates P-gp expression in chicken tissues, thereby increasing the absorption of P-gp substrates.	Berberine	28-37	phosphoglycolate phosphatase	Gallus gallus	88-92
31013627-11	2019	These results indicate that berberine is a substrate of chicken P-gp and down-regulates P-gp expression in chicken tissues, thereby increasing the absorption of P-gp substrates.	Berberine	28-37	phosphoglycolate phosphatase	Gallus gallus	88-92
31013627-12	2019	Our findings suggest that berberine increases the bioavailability of other drugs and that drug-drug interactions should be considered when it is co-administered with other P-gp substrates with narrow therapeutic windows.	Berberine	26-35	phosphoglycolate phosphatase	Gallus gallus	172-176
30969881-0	2019	Berberine Accelerates Odontoblast Differentiation by Wnt/beta-Catenin Activation.	Berberine	0-9	catenin beta 1	Homo sapiens	57-69
30969881-8	2019	In addition, while treated with berberine, beta-catenin translocated to the nucleus evaluated by western blot and immunofluorescent staining.	Berberine	32-41	catenin beta 1	Homo sapiens	43-55
30969881-9	2019	Our results revealed that berberine functions as a promoter of odontoblast differentiation by promoting Wnt/beta-catenin pathway, suggesting that it may be useful in guiding therapeutic strategies for the treatment of dental caries.	Berberine	26-35	catenin beta 1	Homo sapiens	108-120
30936971-10	2019	The combined application of berberine in patients with metabolic syndrome can effectively regulate blood glucose and blood lipid of patients, alleviate insulin resistance and reduce the level of inflammatory response in the body.	Berberine	28-37	insulin	Homo sapiens	152-159
30816449-0	2019	Berberine prevents human nucleus pulposus cells from IL-1beta-induced extracellular matrix degradation and apoptosis by inhibiting the NF-kappaB pathway.	Berberine	0-9	interleukin 1 beta	Homo sapiens	53-61
30661612-0	2019	Phenanthroline-linked berberine dimer and fluorophore-tagged DNA conjugate for the selective detection of microRNA-185: Experimental and molecular docking studies.	Berberine	22-31	microRNA 185	Homo sapiens	106-118
30894513-0	2019	Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes.	Berberine	0-9	cell division cycle 6	Homo sapiens	24-28
30894513-0	2019	Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes.	Berberine	0-9	signal transducer and activator of transcription 3	Homo sapiens	74-79
30894513-7	2019	We also revealed that berberine (BBR) could inhibit CDK4/6-RB-CDC6 signaling in keratinocytes, leading to reduced proliferation of keratinocytes.	Berberine	22-31	cell division cycle 6	Homo sapiens	62-66
30894513-7	2019	We also revealed that berberine (BBR) could inhibit CDK4/6-RB-CDC6 signaling in keratinocytes, leading to reduced proliferation of keratinocytes.	Berberine	33-36	cell division cycle 6	Homo sapiens	62-66
31298400-9	2019	Both Berberine and Hesperidin decreased the expression of alpha-SMA and cell viability in a concentration-dependent manner; however, the apoptosis of cardiac fibroblasts was not influenced.	Berberine	5-14	actin alpha 1, skeletal muscle	Homo sapiens	58-67
31298400-10	2019	10 mg/L Berberine or at least 50 micromol/L Hesperidin could noticeably decrease MMP-1 expression, and at least 5 mg/L Berberine or 100 micromol/L Hesperidin could markedly reduce MMP-9 expression.	Berberine	8-17	matrix metallopeptidase 1	Homo sapiens	81-86
31298400-10	2019	10 mg/L Berberine or at least 50 micromol/L Hesperidin could noticeably decrease MMP-1 expression, and at least 5 mg/L Berberine or 100 micromol/L Hesperidin could markedly reduce MMP-9 expression.	Berberine	8-17	matrix metallopeptidase 9	Homo sapiens	180-185
31298400-10	2019	10 mg/L Berberine or at least 50 micromol/L Hesperidin could noticeably decrease MMP-1 expression, and at least 5 mg/L Berberine or 100 micromol/L Hesperidin could markedly reduce MMP-9 expression.	Berberine	119-128	matrix metallopeptidase 9	Homo sapiens	180-185
31298400-11	2019	Using DAPT to block Notch1 signaling could reverse the protective effects of Berberine and Hesperidin.	Berberine	77-86	notch receptor 1	Homo sapiens	20-26
31298400-12	2019	CONCLUSIONS: Berberine and Hesperidin can reduce the secretion of inflammatory cytokines, differentiation, and proliferation, and increase the collagen synthesis of cardiac fibroblasts stimulated by TGF-beta1 via the Notch1 signaling pathway.	Berberine	13-22	transforming growth factor, beta 1	Rattus norvegicus	199-208
31298400-12	2019	CONCLUSIONS: Berberine and Hesperidin can reduce the secretion of inflammatory cytokines, differentiation, and proliferation, and increase the collagen synthesis of cardiac fibroblasts stimulated by TGF-beta1 via the Notch1 signaling pathway.	Berberine	13-22	notch receptor 1	Homo sapiens	217-223
31139563-0	2019	Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1beta and IL-18 Release.	Berberine	21-30	caspase 1	Homo sapiens	62-71
31139563-0	2019	Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1beta and IL-18 Release.	Berberine	21-30	interleukin 1 beta	Homo sapiens	81-89
31139563-0	2019	Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1beta and IL-18 Release.	Berberine	21-30	interleukin 18	Homo sapiens	94-99
31139563-6	2019	In this study, we demonstrate that berberine significantly inhibits inflammatory cytokine Caspase-1 activation via ERK1/2 signaling and subsequent production of IL-1beta and IL-18 by glioma cells.	Berberine	35-44	caspase 1	Homo sapiens	90-99
31139563-6	2019	In this study, we demonstrate that berberine significantly inhibits inflammatory cytokine Caspase-1 activation via ERK1/2 signaling and subsequent production of IL-1beta and IL-18 by glioma cells.	Berberine	35-44	mitogen-activated protein kinase 3	Homo sapiens	115-121
31139563-6	2019	In this study, we demonstrate that berberine significantly inhibits inflammatory cytokine Caspase-1 activation via ERK1/2 signaling and subsequent production of IL-1beta and IL-18 by glioma cells.	Berberine	35-44	interleukin 1 beta	Homo sapiens	161-169
31139563-6	2019	In this study, we demonstrate that berberine significantly inhibits inflammatory cytokine Caspase-1 activation via ERK1/2 signaling and subsequent production of IL-1beta and IL-18 by glioma cells.	Berberine	35-44	interleukin 18	Homo sapiens	174-179
30771347-7	2019	Further comparisons and bioinformatics analysis demonstrated that among the identified DEPs, 26, including Hist2h2be, Tubb3, and five immunoglobulins, were oppositely regulated by DSS and DSS plus berberine treatments.	Berberine	197-206	H2B clustered histone 21	Mus musculus	107-116
30771347-7	2019	Further comparisons and bioinformatics analysis demonstrated that among the identified DEPs, 26, including Hist2h2be, Tubb3, and five immunoglobulins, were oppositely regulated by DSS and DSS plus berberine treatments.	Berberine	197-206	tubulin, beta 3 class III	Mus musculus	118-123
31052469-5	2019	Improved antitumor activity of novel berberine derivatives was revealed by MTT assay, by flow cytometry and by detection of apoptotic DNA fragmentation and caspase-3 activation, respectively.	Berberine	37-46	caspase 3	Homo sapiens	156-165
31142385-0	2019	Berberine inhibits lipopolysaccharide-induced expression of inflammatory cytokines by suppressing TLR4-mediated NF-kB and MAPK signaling pathways in rumen epithelial cells of Holstein calves.	Berberine	0-9	toll like receptor 4	Bos taurus	98-102
31142385-9	2019	In conclusion, the protective effects of BBR on LPS-induced inflammatory responses in REC may be due to its ability to suppress the TLR4-mediated NF-kappaB and MAPK signaling pathways.	Berberine	41-44	toll like receptor 4	Bos taurus	132-136
31040878-0	2019	Erratum: Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients.	Berberine	49-58	insulin	Homo sapiens	27-34
30987854-0	2019	Berberine protects immortalized line of human melanocytes from H2O2-induced oxidative stress via activation of Nrf2 and Mitf signaling pathway.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	111-115
30987854-0	2019	Berberine protects immortalized line of human melanocytes from H2O2-induced oxidative stress via activation of Nrf2 and Mitf signaling pathway.	Berberine	0-9	melanocyte inducing transcription factor	Homo sapiens	120-124
30987854-4	2019	OBJECTIVE: In the present study, we investigated the potential protective effect of BBR against oxidative stress on an immortalized normal human melanocyte cell line PIG1.	Berberine	84-87	nuclear FMR1 interacting protein 2	Homo sapiens	166-170
30832407-7	2019	In further investigations of the mechanisms involved, resveratrol, catechin, and berberine increased SIRT1 enzyme activity and p-AMPKalphaThr172 protein, which are involved in mitochondrial biogenesis.	Berberine	81-90	sirtuin 1	Homo sapiens	101-106
30136405-8	2019	RESULTS: DPP-4 inhibitors (40 nmol/L linagliptin, 30 mumol/L berberine) offer protection from hypoxia/high glucose induced impairments in the proliferation and migration of rBMVECs.	Berberine	61-70	dipeptidylpeptidase 4	Rattus norvegicus	9-14
30867696-15	2019	In conclusion, BBR may alleviate hepatic oxidative stress in rats with NAFLD, which may be partly attributed to the activation of the Nrf2/ARE signalling pathway.	Berberine	15-18	NFE2 like bZIP transcription factor 2	Rattus norvegicus	134-138
31037132-0	2019	Berberine Protects Glomerular Podocytes via Inhibiting Drp1-Mediated Mitochondrial Fission and Dysfunction.	Berberine	0-9	dynamin 1-like	Mus musculus	55-59
30868489-0	2019	Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.	Berberine	0-9	sirtuin 3	Rattus norvegicus	104-109
30553371-5	2019	Berberine, an anti-apoptotic and anti-arthritis naturally occurring compound, was encapsulated within the CHC/LMW HA gels.	Berberine	0-9	clathrin heavy chain	Homo sapiens	106-116
30899370-0	2019	Protective effect of berberine on high glucose and hypoxia-induced apoptosis via the modulation of HIF-1alpha in renal tubular epithelial cells.	Berberine	21-30	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	99-109
30899370-9	2019	The present study thereby provided evidence that BBR protected renal tubular epithelial cells from hypoxia/HG-induced apoptosis through activation of HIF-1alpha in the PI3K/Akt signal pathway and suggested that BBR could be a potential drug in DKD.	Berberine	49-52	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	150-160
30899370-9	2019	The present study thereby provided evidence that BBR protected renal tubular epithelial cells from hypoxia/HG-induced apoptosis through activation of HIF-1alpha in the PI3K/Akt signal pathway and suggested that BBR could be a potential drug in DKD.	Berberine	49-52	AKT serine/threonine kinase 1	Rattus norvegicus	173-176
30868489-0	2019	Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	110-114
30868489-1	2019	This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD).	Berberine	42-51	sirtuin 3	Rattus norvegicus	105-114
30868489-1	2019	This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD).	Berberine	42-51	sirtuin 3	Rattus norvegicus	116-121
30868489-1	2019	This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD).	Berberine	42-51	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	182-186
30868489-1	2019	This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD).	Berberine	53-56	sirtuin 3	Rattus norvegicus	105-114
30868489-1	2019	This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD).	Berberine	53-56	sirtuin 3	Rattus norvegicus	116-121
30868489-1	2019	This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD).	Berberine	53-56	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	182-186
30868489-10	2019	In conclusion, our data suggest that the mechanism by which BBR ameliorates HFD-induced hepatic steatosis may be related to the activation of the SIRT3/AMPK/ACC pathway in the liver.	Berberine	60-63	sirtuin 3	Rattus norvegicus	146-151
30868489-10	2019	In conclusion, our data suggest that the mechanism by which BBR ameliorates HFD-induced hepatic steatosis may be related to the activation of the SIRT3/AMPK/ACC pathway in the liver.	Berberine	60-63	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	152-156
30343043-0	2019	Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.	Berberine	21-30	epidermal growth factor receptor	Homo sapiens	39-43
30456649-7	2019	Furthermore, berberine lowered hippocampal activity of acetylcholinesterase (AChE), malondialdehyde (MDA), protein carbonyl, activity of caspase 3, and DNA fragmentation and improved antioxidant capacity through enhancing glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase, and glutathione (GSH).	Berberine	13-22	acetylcholinesterase	Rattus norvegicus	55-75
30456649-7	2019	Furthermore, berberine lowered hippocampal activity of acetylcholinesterase (AChE), malondialdehyde (MDA), protein carbonyl, activity of caspase 3, and DNA fragmentation and improved antioxidant capacity through enhancing glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase, and glutathione (GSH).	Berberine	13-22	acetylcholinesterase	Rattus norvegicus	77-81
30456649-7	2019	Furthermore, berberine lowered hippocampal activity of acetylcholinesterase (AChE), malondialdehyde (MDA), protein carbonyl, activity of caspase 3, and DNA fragmentation and improved antioxidant capacity through enhancing glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase, and glutathione (GSH).	Berberine	13-22	caspase 3	Rattus norvegicus	137-146
30456649-7	2019	Furthermore, berberine lowered hippocampal activity of acetylcholinesterase (AChE), malondialdehyde (MDA), protein carbonyl, activity of caspase 3, and DNA fragmentation and improved antioxidant capacity through enhancing glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase, and glutathione (GSH).	Berberine	13-22	catalase	Rattus norvegicus	280-288
30456649-8	2019	Besides, berberine attenuated inflammation-related indices, as was evident by lower levels of nuclear factor-kappa B (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), and interleukin 6 (IL-6).	Berberine	9-18	toll-like receptor 4	Rattus norvegicus	130-150
30456649-8	2019	Besides, berberine attenuated inflammation-related indices, as was evident by lower levels of nuclear factor-kappa B (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), and interleukin 6 (IL-6).	Berberine	9-18	toll-like receptor 4	Rattus norvegicus	152-156
30456649-8	2019	Besides, berberine attenuated inflammation-related indices, as was evident by lower levels of nuclear factor-kappa B (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), and interleukin 6 (IL-6).	Berberine	9-18	tumor necrosis factor	Rattus norvegicus	159-186
30456649-8	2019	Besides, berberine attenuated inflammation-related indices, as was evident by lower levels of nuclear factor-kappa B (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), and interleukin 6 (IL-6).	Berberine	9-18	tumor necrosis factor	Rattus norvegicus	188-196
30456649-8	2019	Besides, berberine attenuated inflammation-related indices, as was evident by lower levels of nuclear factor-kappa B (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), and interleukin 6 (IL-6).	Berberine	9-18	interleukin 6	Rattus norvegicus	203-216
30456649-8	2019	Besides, berberine attenuated inflammation-related indices, as was evident by lower levels of nuclear factor-kappa B (NF-kappaB), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNFalpha), and interleukin 6 (IL-6).	Berberine	9-18	interleukin 6	Rattus norvegicus	218-222
30456649-9	2019	Berberine also appropriately restored hippocampal 3-nitrotyrosine (3-NT), cyclooxygenase 2 (Cox 2), glial fibrillary acidic protein (GFAP), sirtuin 1, and mitogen-activated protein kinase (p38 MAPK) with no significant alteration of brain-derived neurotrophic factor (BDNF).	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	74-90
30456649-9	2019	Berberine also appropriately restored hippocampal 3-nitrotyrosine (3-NT), cyclooxygenase 2 (Cox 2), glial fibrillary acidic protein (GFAP), sirtuin 1, and mitogen-activated protein kinase (p38 MAPK) with no significant alteration of brain-derived neurotrophic factor (BDNF).	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	92-97
30456649-9	2019	Berberine also appropriately restored hippocampal 3-nitrotyrosine (3-NT), cyclooxygenase 2 (Cox 2), glial fibrillary acidic protein (GFAP), sirtuin 1, and mitogen-activated protein kinase (p38 MAPK) with no significant alteration of brain-derived neurotrophic factor (BDNF).	Berberine	0-9	glial fibrillary acidic protein	Rattus norvegicus	100-131
30456649-9	2019	Berberine also appropriately restored hippocampal 3-nitrotyrosine (3-NT), cyclooxygenase 2 (Cox 2), glial fibrillary acidic protein (GFAP), sirtuin 1, and mitogen-activated protein kinase (p38 MAPK) with no significant alteration of brain-derived neurotrophic factor (BDNF).	Berberine	0-9	glial fibrillary acidic protein	Rattus norvegicus	133-137
30456649-9	2019	Berberine also appropriately restored hippocampal 3-nitrotyrosine (3-NT), cyclooxygenase 2 (Cox 2), glial fibrillary acidic protein (GFAP), sirtuin 1, and mitogen-activated protein kinase (p38 MAPK) with no significant alteration of brain-derived neurotrophic factor (BDNF).	Berberine	0-9	sirtuin 1	Rattus norvegicus	140-149
30456649-9	2019	Berberine also appropriately restored hippocampal 3-nitrotyrosine (3-NT), cyclooxygenase 2 (Cox 2), glial fibrillary acidic protein (GFAP), sirtuin 1, and mitogen-activated protein kinase (p38 MAPK) with no significant alteration of brain-derived neurotrophic factor (BDNF).	Berberine	0-9	brain-derived neurotrophic factor	Rattus norvegicus	233-266
30456649-9	2019	Berberine also appropriately restored hippocampal 3-nitrotyrosine (3-NT), cyclooxygenase 2 (Cox 2), glial fibrillary acidic protein (GFAP), sirtuin 1, and mitogen-activated protein kinase (p38 MAPK) with no significant alteration of brain-derived neurotrophic factor (BDNF).	Berberine	0-9	brain-derived neurotrophic factor	Rattus norvegicus	268-272
30456649-10	2019	In summary, berberine could partially ameliorate LPS-induced cognitive deficits via partial suppression of apoptotic cascade, neuroinflammation, oxido-nitrosative stress, AChE, MAPK, and restoration of sirtuin 1.	Berberine	12-21	acetylcholinesterase	Rattus norvegicus	171-175
30456649-10	2019	In summary, berberine could partially ameliorate LPS-induced cognitive deficits via partial suppression of apoptotic cascade, neuroinflammation, oxido-nitrosative stress, AChE, MAPK, and restoration of sirtuin 1.	Berberine	12-21	sirtuin 1	Rattus norvegicus	202-211
30343043-9	2019	The activity of EGFR, AKT, P38, and ERK1/2 were affected by berberine; however, berberine dramatically reduced EGFR and AKT phosphorylation.	Berberine	80-89	epidermal growth factor receptor	Homo sapiens	16-20
30343043-9	2019	The activity of EGFR, AKT, P38, and ERK1/2 were affected by berberine; however, berberine dramatically reduced EGFR and AKT phosphorylation.	Berberine	80-89	epidermal growth factor receptor	Homo sapiens	111-115
30343043-9	2019	The activity of EGFR, AKT, P38, and ERK1/2 were affected by berberine; however, berberine dramatically reduced EGFR and AKT phosphorylation.	Berberine	80-89	AKT serine/threonine kinase 1	Homo sapiens	120-123
30343043-10	2019	CONCLUSION: By way of its multikinase inhibitory effects, berberine might be a useful replacement for lapatinib, an EGFR inhibitor which can cause acquired drug resistance in patients.	Berberine	58-67	epidermal growth factor receptor	Homo sapiens	116-120
30402951-0	2019	Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-kappaB and AMPK signaling pathways.	Berberine	0-9	galectin 3	Homo sapiens	102-112
30402951-14	2019	In conclusion, BBR alleviates ox-LDL-induced macrophage activation by downregulating galectin-3 via the NF-kappaB and AMPK signaling pathways.	Berberine	15-18	galectin 3	Homo sapiens	85-95
30385301-8	2019	Protective effect of metformin and berberine against these toxic insults were found to be associated with the mitochondrial SirT3 pathway.	Berberine	35-44	sirtuin 3	Rattus norvegicus	124-129
30691220-4	2019	This study aimed to validate the DPP-4 inhibitory activity of clerodane diterpene 16-hydroxycleroda-3,13-dien-15,16-olide (HCD) from Polyalthia longifolia, rutin, quercetin, and berberine, previously selected through molecular docking.	Berberine	178-187	dipeptidyl peptidase 4	Homo sapiens	33-38
30343043-0	2019	Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.	Berberine	21-30	mitogen-activated protein kinase 3	Homo sapiens	45-51
30343043-0	2019	Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.	Berberine	21-30	mitogen-activated protein kinase 1	Homo sapiens	53-56
30343043-0	2019	Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.	Berberine	21-30	AKT serine/threonine kinase 1	Homo sapiens	61-64
30343043-5	2019	The effects of berberine and lapatinib on MAPK and PI3K pathways in MDA-MB231 and MCF-7 cells were evaluated using immunoflorescence assays, and the amounts of phosphorylated kinases were compared to total kinases after treating with different concentrations of berberine.	Berberine	15-24	mitogen-activated protein kinase 3	Homo sapiens	42-46
30343043-6	2019	RESULTS: Simulations showed berberine accurately interacted with EGFR, AKT, P38, and ERK1/2 active sites in silico (scores = -7.57 to -7.92 Kcal/mol) and decreased the levels of active forms of corresponding enzymes in both cell lines; however, berberine binding to p38 showed less stability.	Berberine	28-37	epidermal growth factor receptor	Homo sapiens	65-69
30343043-6	2019	RESULTS: Simulations showed berberine accurately interacted with EGFR, AKT, P38, and ERK1/2 active sites in silico (scores = -7.57 to -7.92 Kcal/mol) and decreased the levels of active forms of corresponding enzymes in both cell lines; however, berberine binding to p38 showed less stability.	Berberine	28-37	AKT serine/threonine kinase 1	Homo sapiens	71-74
30343043-6	2019	RESULTS: Simulations showed berberine accurately interacted with EGFR, AKT, P38, and ERK1/2 active sites in silico (scores = -7.57 to -7.92 Kcal/mol) and decreased the levels of active forms of corresponding enzymes in both cell lines; however, berberine binding to p38 showed less stability.	Berberine	28-37	mitogen-activated protein kinase 1	Homo sapiens	76-79
30343043-6	2019	RESULTS: Simulations showed berberine accurately interacted with EGFR, AKT, P38, and ERK1/2 active sites in silico (scores = -7.57 to -7.92 Kcal/mol) and decreased the levels of active forms of corresponding enzymes in both cell lines; however, berberine binding to p38 showed less stability.	Berberine	28-37	mitogen-activated protein kinase 3	Homo sapiens	85-91
30343043-6	2019	RESULTS: Simulations showed berberine accurately interacted with EGFR, AKT, P38, and ERK1/2 active sites in silico (scores = -7.57 to -7.92 Kcal/mol) and decreased the levels of active forms of corresponding enzymes in both cell lines; however, berberine binding to p38 showed less stability.	Berberine	28-37	mitogen-activated protein kinase 1	Homo sapiens	266-269
30343043-6	2019	RESULTS: Simulations showed berberine accurately interacted with EGFR, AKT, P38, and ERK1/2 active sites in silico (scores = -7.57 to -7.92 Kcal/mol) and decreased the levels of active forms of corresponding enzymes in both cell lines; however, berberine binding to p38 showed less stability.	Berberine	245-254	mitogen-activated protein kinase 3	Homo sapiens	85-91
30343043-9	2019	The activity of EGFR, AKT, P38, and ERK1/2 were affected by berberine; however, berberine dramatically reduced EGFR and AKT phosphorylation.	Berberine	60-69	epidermal growth factor receptor	Homo sapiens	16-20
30343043-9	2019	The activity of EGFR, AKT, P38, and ERK1/2 were affected by berberine; however, berberine dramatically reduced EGFR and AKT phosphorylation.	Berberine	60-69	AKT serine/threonine kinase 1	Homo sapiens	22-25
30343043-9	2019	The activity of EGFR, AKT, P38, and ERK1/2 were affected by berberine; however, berberine dramatically reduced EGFR and AKT phosphorylation.	Berberine	60-69	mitogen-activated protein kinase 1	Homo sapiens	27-30
30343043-9	2019	The activity of EGFR, AKT, P38, and ERK1/2 were affected by berberine; however, berberine dramatically reduced EGFR and AKT phosphorylation.	Berberine	60-69	mitogen-activated protein kinase 3	Homo sapiens	36-42
30428337-7	2019	Metformin (&gt;=1 or &gt;=0.3 mM) decreased berberine transport in MDCK-rOCT1, MDCK-rOCT2, and MDCK-rMATE1 cells.	Berberine	44-53	solute carrier family 22 member 1	Rattus norvegicus	72-77
30428337-7	2019	Metformin (&gt;=1 or &gt;=0.3 mM) decreased berberine transport in MDCK-rOCT1, MDCK-rOCT2, and MDCK-rMATE1 cells.	Berberine	44-53	solute carrier family 22 member 2	Rattus norvegicus	84-89
30428337-9	2019	These results suggest that the combination of metformin and berberine induced a pharmacokinetic interaction by cooperatively inhibiting OCT and MATE1-mediated transport.	Berberine	60-69	solute carrier family 47 member 1	Rattus norvegicus	144-149
30606998-2	2019	This study aimed to investigate the effects of berberine, a benzylisoquinoline alkaloid used in traditional Chinese medicine, on energy expenditure, expression of the UCP1 gene, the cell stress protein inositol-requiring enzyme 1alpha (IRE1alpha), apoptosis genes, and macrophage phenotype (M1 and M2) in white and brown adipose tissue in an obese mouse model fed a high-fat diet.	Berberine	47-56	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	167-171
30606998-9	2019	RESULTS Berberine treatment in mice fed a high-fat diet increased energy metabolism, glucose tolerance, and expression of UCP1, and reduced expression of pro-inflammatory cytokines, macrophage recruitment, and resulted in M2 macrophage polarization in white adipose tissue.	Berberine	8-17	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	122-126
30442987-0	2019	Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacity.	Berberine	24-33	phosphoglycolate phosphatase	Mus musculus	86-100
30827151-0	2019	Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.	Berberine	0-9	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	21-26
30827151-0	2019	Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.	Berberine	0-9	FBJ osteosarcoma oncogene	Mus musculus	76-81
30827151-0	2019	Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.	Berberine	0-9	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	86-92
30422704-8	2019	Furthermore, the Western blotting results implied that BBR could promote the BCAA catabolism in the liver and epididymal white adipose tissues of HFD-fed mice by activation of the multienzyme branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), whereas by inhibition of the phosphorylation state of BCKDHA (E1alpha subunit) and branched-chain alpha-ketoacid dehydrogenase kinase (BCKDK).	Berberine	55-58	AT rich interactive domain 4B (RBP1-like)	Mus musculus	77-81
30422704-8	2019	Furthermore, the Western blotting results implied that BBR could promote the BCAA catabolism in the liver and epididymal white adipose tissues of HFD-fed mice by activation of the multienzyme branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), whereas by inhibition of the phosphorylation state of BCKDHA (E1alpha subunit) and branched-chain alpha-ketoacid dehydrogenase kinase (BCKDK).	Berberine	55-58	branched chain ketoacid dehydrogenase E1, alpha polypeptide	Mus musculus	307-313
30422704-8	2019	Furthermore, the Western blotting results implied that BBR could promote the BCAA catabolism in the liver and epididymal white adipose tissues of HFD-fed mice by activation of the multienzyme branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), whereas by inhibition of the phosphorylation state of BCKDHA (E1alpha subunit) and branched-chain alpha-ketoacid dehydrogenase kinase (BCKDK).	Berberine	55-58	branched chain ketoacid dehydrogenase kinase	Mus musculus	336-386
30422704-8	2019	Furthermore, the Western blotting results implied that BBR could promote the BCAA catabolism in the liver and epididymal white adipose tissues of HFD-fed mice by activation of the multienzyme branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), whereas by inhibition of the phosphorylation state of BCKDHA (E1alpha subunit) and branched-chain alpha-ketoacid dehydrogenase kinase (BCKDK).	Berberine	55-58	branched chain ketoacid dehydrogenase kinase	Mus musculus	388-393
30451117-7	2019	Our results also showed that both berberine and cinnamic acid-induced apoptosis by increasing the Bax/Bcl-2 ratio (74.1 and 45.1, respectively) and caspase-3 expression (14.3- and 11.6-fold increase, respectively).	Berberine	34-43	BCL2-associated X protein	Mus musculus	98-101
30451117-7	2019	Our results also showed that both berberine and cinnamic acid-induced apoptosis by increasing the Bax/Bcl-2 ratio (74.1 and 45.1, respectively) and caspase-3 expression (14.3- and 11.6-fold increase, respectively).	Berberine	34-43	B cell leukemia/lymphoma 2	Mus musculus	102-107
30451117-7	2019	Our results also showed that both berberine and cinnamic acid-induced apoptosis by increasing the Bax/Bcl-2 ratio (74.1 and 45.1, respectively) and caspase-3 expression (14.3- and 11.6-fold increase, respectively).	Berberine	34-43	caspase 3	Mus musculus	148-157
30526471-0	2019	Berberine Effects on NFkappaB, HIF1A and NFE2L2/AP-1 Pathways in HeLa Cells.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	21-29
30526471-0	2019	Berberine Effects on NFkappaB, HIF1A and NFE2L2/AP-1 Pathways in HeLa Cells.	Berberine	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	31-36
30526471-0	2019	Berberine Effects on NFkappaB, HIF1A and NFE2L2/AP-1 Pathways in HeLa Cells.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	41-47
30526471-0	2019	Berberine Effects on NFkappaB, HIF1A and NFE2L2/AP-1 Pathways in HeLa Cells.	Berberine	0-9	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	48-52
30526471-4	2019	RESULTS: Berberine effects appeared to be highly dose-dependent, with the lower concentration being capable of suppressing the NFkappaB functioning and the higher concentration causing severe signaling side-effects seen in the HIF1A pathway and the NFE2L2 sub-pathways, and especially and more importantly in the AP-1 sub-pathway.	Berberine	9-18	nuclear factor kappa B subunit 1	Homo sapiens	127-135
30526471-4	2019	RESULTS: Berberine effects appeared to be highly dose-dependent, with the lower concentration being capable of suppressing the NFkappaB functioning and the higher concentration causing severe signaling side-effects seen in the HIF1A pathway and the NFE2L2 sub-pathways, and especially and more importantly in the AP-1 sub-pathway.	Berberine	9-18	hypoxia inducible factor 1 subunit alpha	Homo sapiens	227-232
30526471-4	2019	RESULTS: Berberine effects appeared to be highly dose-dependent, with the lower concentration being capable of suppressing the NFkappaB functioning and the higher concentration causing severe signaling side-effects seen in the HIF1A pathway and the NFE2L2 sub-pathways, and especially and more importantly in the AP-1 sub-pathway.	Berberine	9-18	NFE2 like bZIP transcription factor 2	Homo sapiens	249-255
30526471-4	2019	RESULTS: Berberine effects appeared to be highly dose-dependent, with the lower concentration being capable of suppressing the NFkappaB functioning and the higher concentration causing severe signaling side-effects seen in the HIF1A pathway and the NFE2L2 sub-pathways, and especially and more importantly in the AP-1 sub-pathway.	Berberine	9-18	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	313-317
30526471-5	2019	CONCLUSION: The results of the study suggest that berberine has clinically valuable anti-NFkappaB effects however jeopardized by its side effects on the HIF1A and especially NFE2L2/AP-1 pathways, its therapeutic window phenomenon and its cancer type-specificity.	Berberine	50-59	nuclear factor kappa B subunit 1	Homo sapiens	89-97
30526471-5	2019	CONCLUSION: The results of the study suggest that berberine has clinically valuable anti-NFkappaB effects however jeopardized by its side effects on the HIF1A and especially NFE2L2/AP-1 pathways, its therapeutic window phenomenon and its cancer type-specificity.	Berberine	50-59	hypoxia inducible factor 1 subunit alpha	Homo sapiens	153-158
30526471-5	2019	CONCLUSION: The results of the study suggest that berberine has clinically valuable anti-NFkappaB effects however jeopardized by its side effects on the HIF1A and especially NFE2L2/AP-1 pathways, its therapeutic window phenomenon and its cancer type-specificity.	Berberine	50-59	NFE2 like bZIP transcription factor 2	Homo sapiens	174-180
30526471-5	2019	CONCLUSION: The results of the study suggest that berberine has clinically valuable anti-NFkappaB effects however jeopardized by its side effects on the HIF1A and especially NFE2L2/AP-1 pathways, its therapeutic window phenomenon and its cancer type-specificity.	Berberine	50-59	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	181-185
30396091-0	2019	The impact of Keap1/Nrf2, P38MAPK/NF-kappaB and Bax/Bcl2/caspase-3 signaling pathways in the protective effects of berberine against methotrexate-induced nephrotoxicity.	Berberine	115-124	kelch like ECH associated protein 1	Homo sapiens	14-19
30396091-0	2019	The impact of Keap1/Nrf2, P38MAPK/NF-kappaB and Bax/Bcl2/caspase-3 signaling pathways in the protective effects of berberine against methotrexate-induced nephrotoxicity.	Berberine	115-124	NFE2 like bZIP transcription factor 2	Homo sapiens	20-24
30396091-0	2019	The impact of Keap1/Nrf2, P38MAPK/NF-kappaB and Bax/Bcl2/caspase-3 signaling pathways in the protective effects of berberine against methotrexate-induced nephrotoxicity.	Berberine	115-124	nuclear factor kappa B subunit 1	Homo sapiens	34-43
30396091-0	2019	The impact of Keap1/Nrf2, P38MAPK/NF-kappaB and Bax/Bcl2/caspase-3 signaling pathways in the protective effects of berberine against methotrexate-induced nephrotoxicity.	Berberine	115-124	BCL2 associated X, apoptosis regulator	Homo sapiens	48-51
30396091-0	2019	The impact of Keap1/Nrf2, P38MAPK/NF-kappaB and Bax/Bcl2/caspase-3 signaling pathways in the protective effects of berberine against methotrexate-induced nephrotoxicity.	Berberine	115-124	BCL2 apoptosis regulator	Homo sapiens	52-56
30396091-0	2019	The impact of Keap1/Nrf2, P38MAPK/NF-kappaB and Bax/Bcl2/caspase-3 signaling pathways in the protective effects of berberine against methotrexate-induced nephrotoxicity.	Berberine	115-124	caspase 3	Homo sapiens	57-66
30472896-0	2019	Berberine suppresses the ectopic expression of miR-133a in endothelial cells to improve vascular dementia in diabetic rats.	Berberine	0-9	microRNA 133a-1	Rattus norvegicus	47-55
30472896-5	2019	The learning and memory were evaluated by step-down, step-through, and morris water maze (MWM) tests.Results: In streptozotocin-injected rats, hyperglycemia dramatically induced miR-133a ectopic expressions in vascular endothelium, reduced GTPCH1 gene expressions and BH4 levels, which were reversed by berberine administration (1.0 g/kg/day, 8 weeks).	Berberine	303-312	microRNA 133a-1	Rattus norvegicus	178-186
30472896-7	2019	Ex vivo studies indicated that miR-133a agomirs abolished these beneficial effects of berberine on acetylcholine-induced vasorelaxation, while supplement of L-sepiapterin prevented endothelial dysfunction in middle cerebral artery isolated from rats.	Berberine	86-95	microRNA 133a-1	Rattus norvegicus	31-39
30472896-10	2019	Finally, berberine reduced miR-133a expression, and increased both BH4 levels and NO production in cultured endothelial cells treated with high glucose.Conclusion: Berberine improves vascular dementia in diabetes, which is possibly related to the suppression of miR-133a ectopic expression in endothelial cells.	Berberine	9-18	microRNA 133a-1	Rattus norvegicus	27-35
30472896-10	2019	Finally, berberine reduced miR-133a expression, and increased both BH4 levels and NO production in cultured endothelial cells treated with high glucose.Conclusion: Berberine improves vascular dementia in diabetes, which is possibly related to the suppression of miR-133a ectopic expression in endothelial cells.	Berberine	9-18	microRNA 133a-1	Rattus norvegicus	262-270
30472896-10	2019	Finally, berberine reduced miR-133a expression, and increased both BH4 levels and NO production in cultured endothelial cells treated with high glucose.Conclusion: Berberine improves vascular dementia in diabetes, which is possibly related to the suppression of miR-133a ectopic expression in endothelial cells.	Berberine	164-173	microRNA 133a-1	Rattus norvegicus	262-270
29714135-6	2019	RESULTS: In-vitro and in-vivo evidence supports the effect of berberine, trigonelline, piperine, oxymatrine, vindoneline, evodiamine and neferine on insulin-signaling and related cascades in beta-cells, myocytes, adipocytes, hepatocytes and other cells.	Berberine	62-71	insulin	Homo sapiens	149-156
30873920-0	2019	Berberine Alleviates Amyloid-beta Pathogenesis Via Activating LKB1/AMPK Signaling in the Brain of APP/PS1 Transgenic Mice.	Berberine	0-9	serine/threonine kinase 11	Mus musculus	62-66
30873920-0	2019	Berberine Alleviates Amyloid-beta Pathogenesis Via Activating LKB1/AMPK Signaling in the Brain of APP/PS1 Transgenic Mice.	Berberine	0-9	presenilin 1	Mus musculus	102-105
30873920-3	2019	The aim of the present study was to explore whether berberine (BBR) activates LKB1/AMPK signaling and ameliorates Abeta pathology.	Berberine	52-61	serine/threonine kinase 11	Mus musculus	78-82
30873920-3	2019	The aim of the present study was to explore whether berberine (BBR) activates LKB1/AMPK signaling and ameliorates Abeta pathology.	Berberine	52-61	amyloid beta (A4) precursor protein	Mus musculus	114-119
30873920-3	2019	The aim of the present study was to explore whether berberine (BBR) activates LKB1/AMPK signaling and ameliorates Abeta pathology.	Berberine	63-66	serine/threonine kinase 11	Mus musculus	78-82
30873920-3	2019	The aim of the present study was to explore whether berberine (BBR) activates LKB1/AMPK signaling and ameliorates Abeta pathology.	Berberine	63-66	amyloid beta (A4) precursor protein	Mus musculus	114-119
30873920-7	2019	RESULTS: BBR inhibited Abeta expression in the brain of APP/PS1 mice.	Berberine	9-12	amyloid beta (A4) precursor protein	Mus musculus	23-28
30873920-7	2019	RESULTS: BBR inhibited Abeta expression in the brain of APP/PS1 mice.	Berberine	9-12	presenilin 1	Mus musculus	60-63
30873920-8	2019	There was a strong up-regulation of both p-LKB1 (Ser334 and Thr189) and p-AMPK (AMPKalpha and AMPKbeta1) in the brains of APP/PS1 transgenic mice after BBR-treatment (P<0.01).	Berberine	152-155	serine/threonine kinase 11	Mus musculus	43-47
30873920-8	2019	There was a strong up-regulation of both p-LKB1 (Ser334 and Thr189) and p-AMPK (AMPKalpha and AMPKbeta1) in the brains of APP/PS1 transgenic mice after BBR-treatment (P<0.01).	Berberine	152-155	presenilin 1	Mus musculus	126-129
30873920-10	2019	CONCLUSION: BBR alleviates Abeta pathogenesis and rescues synapse damage via activating LKB1/AMPK signaling in the brain of APP/PS1 transgenic mice.	Berberine	12-15	amyloid beta (A4) precursor protein	Mus musculus	27-32
30873920-10	2019	CONCLUSION: BBR alleviates Abeta pathogenesis and rescues synapse damage via activating LKB1/AMPK signaling in the brain of APP/PS1 transgenic mice.	Berberine	12-15	serine/threonine kinase 11	Mus musculus	88-92
30873920-10	2019	CONCLUSION: BBR alleviates Abeta pathogenesis and rescues synapse damage via activating LKB1/AMPK signaling in the brain of APP/PS1 transgenic mice.	Berberine	12-15	presenilin 1	Mus musculus	128-131
30651787-0	2019	Berberine protects myocardial cells against anoxia-reoxygenation injury via p38 MAPK-mediated NF-kappaB signaling pathways.	Berberine	0-9	mitogen-activated protein kinase 14	Mus musculus	76-79
30651787-5	2019	The results revealed that berberine treatment downregulated the serum expression of inflammatory factors, including interleukin (IL)-6, tumor necrosis factor-alpha, IL-10 and IL-17A in mice with anoxia-reoxygenation injury.	Berberine	26-35	interleukin 10	Mus musculus	165-170
30651787-5	2019	The results revealed that berberine treatment downregulated the serum expression of inflammatory factors, including interleukin (IL)-6, tumor necrosis factor-alpha, IL-10 and IL-17A in mice with anoxia-reoxygenation injury.	Berberine	26-35	interleukin 17A	Mus musculus	175-181
30651787-9	2019	The expression of p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-kappaB expression was downregulated in myocardial cells from in mice with anoxia-reoxygenation injury following berberine treatment compared with untreated mice.	Berberine	198-207	mitogen-activated protein kinase 14	Mus musculus	18-21
30651787-9	2019	The expression of p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-kappaB expression was downregulated in myocardial cells from in mice with anoxia-reoxygenation injury following berberine treatment compared with untreated mice.	Berberine	198-207	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	66-92
30651787-10	2019	However, p38 MAPK overexpression ameliorated the berberine-induced decrease in NF-kappaB activity and expression, as well as the berberine-induced inhibition of myocardial apoptosis in myocardial cells isolated from experimental mice.	Berberine	49-58	mitogen-activated protein kinase 14	Mus musculus	9-17
30651787-11	2019	In conclusion, the results of the present study indicate that berberine is able to decrease the expression of inflammatory cytokines expression and inhibit myocardial cell apoptosis via downregulating the p38 MAPK-mediated NF-kappaB signaling pathway.	Berberine	62-71	mitogen-activated protein kinase 14	Mus musculus	205-208
30391673-0	2019	Berberine mitigates high glucose-potentiated platelet aggregation and apoptosis by modulating aldose reductase and NADPH oxidase activity.	Berberine	0-9	aldo-keto reductase family 1 member B	Homo sapiens	94-110
30391673-7	2019	Berberine was found to inhibit platelet aggregation, superoxide production via modulating AR, NOX, and glutathione reductase activities in high glucose (HG) treated platelets.	Berberine	0-9	aldo-keto reductase family 1 member B	Homo sapiens	90-92
30391673-7	2019	Berberine was found to inhibit platelet aggregation, superoxide production via modulating AR, NOX, and glutathione reductase activities in high glucose (HG) treated platelets.	Berberine	0-9	glutathione-disulfide reductase	Homo sapiens	103-124
30391673-9	2019	In addition, berberine inhibited p38-p53 mediated BAX activation, mitochondrial dysfunction and platelet apoptosis induced by HG.	Berberine	13-22	mitogen-activated protein kinase 14	Homo sapiens	33-36
30391673-9	2019	In addition, berberine inhibited p38-p53 mediated BAX activation, mitochondrial dysfunction and platelet apoptosis induced by HG.	Berberine	13-22	tumor protein p53	Homo sapiens	37-40
30391673-9	2019	In addition, berberine inhibited p38-p53 mediated BAX activation, mitochondrial dysfunction and platelet apoptosis induced by HG.	Berberine	13-22	BCL2 associated X, apoptosis regulator	Homo sapiens	50-53
30391673-10	2019	The platelet protective effect of berberine by inhibiting AR and NOX in high glucose-treated platelets suggest that berberine could be developed as a potential therapeutic molecule in the treating pathologies associated with DM.	Berberine	34-43	aldo-keto reductase family 1 member B	Homo sapiens	58-60
30391673-10	2019	The platelet protective effect of berberine by inhibiting AR and NOX in high glucose-treated platelets suggest that berberine could be developed as a potential therapeutic molecule in the treating pathologies associated with DM.	Berberine	116-125	aldo-keto reductase family 1 member B	Homo sapiens	58-60
30445310-0	2019	Berberine suppresses IL-33-induced inflammatory responses in mast cells by inactivating NF-kappaB and p38 signaling.	Berberine	0-9	interleukin 33	Rattus norvegicus	21-26
30445310-0	2019	Berberine suppresses IL-33-induced inflammatory responses in mast cells by inactivating NF-kappaB and p38 signaling.	Berberine	0-9	mitogen activated protein kinase 14	Rattus norvegicus	102-105
30502647-0	2019	Inhibitory effect of berberine on interleukin-2 secretion from PHA-treated lymphocytic Jurkat cells.	Berberine	21-30	interleukin 2	Homo sapiens	34-47
30502647-3	2019	In addition, berberine has been reported to exert anti-inflammatory effect both in vivo and in vitro, where mitogen-activated protein kinase (MAPK) and cyclooxygenase-2 (COX-2) expressions are critically implicated.	Berberine	13-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	152-168
30502647-3	2019	In addition, berberine has been reported to exert anti-inflammatory effect both in vivo and in vitro, where mitogen-activated protein kinase (MAPK) and cyclooxygenase-2 (COX-2) expressions are critically implicated.	Berberine	13-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	170-175
30502647-4	2019	We herein tested the hypothesis that berberine exerts an anti-inflammatory effect through MAPK and COX-2 signaling pathway in T-cell acute lymphoblastic leukemia (T-ALL).	Berberine	37-46	prostaglandin-endoperoxide synthase 2	Homo sapiens	99-104
30502647-6	2019	PHA-stimulated reactions were steeply suppressed by berberine, such as IL-2 mRNA expression and protein secretion.	Berberine	52-61	interleukin 2	Homo sapiens	71-75
30502647-8	2019	In addition, the possible molecular mechanism of anti-inflammation effect of berberine could be the inhibition of PHA-evoked phosphorylation of p38, since c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinase (ERK) expressions did not alter.	Berberine	77-86	mitogen-activated protein kinase 1	Homo sapiens	144-147
30502647-8	2019	In addition, the possible molecular mechanism of anti-inflammation effect of berberine could be the inhibition of PHA-evoked phosphorylation of p38, since c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinase (ERK) expressions did not alter.	Berberine	77-86	mitogen-activated protein kinase 8	Homo sapiens	155-179
30502647-8	2019	In addition, the possible molecular mechanism of anti-inflammation effect of berberine could be the inhibition of PHA-evoked phosphorylation of p38, since c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinase (ERK) expressions did not alter.	Berberine	77-86	mitogen-activated protein kinase 8	Homo sapiens	181-184
30502647-8	2019	In addition, the possible molecular mechanism of anti-inflammation effect of berberine could be the inhibition of PHA-evoked phosphorylation of p38, since c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinase (ERK) expressions did not alter.	Berberine	77-86	mitogen-activated protein kinase 1	Homo sapiens	190-227
30502647-8	2019	In addition, the possible molecular mechanism of anti-inflammation effect of berberine could be the inhibition of PHA-evoked phosphorylation of p38, since c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinase (ERK) expressions did not alter.	Berberine	77-86	mitogen-activated protein kinase 1	Homo sapiens	229-232
30502647-9	2019	Consistent with above results, berberine inhibition on PHA-induced IL-2 secretion could be reversed by treatment of SB203580, a specific inhibitor of p38-MAPK.	Berberine	31-40	interleukin 2	Homo sapiens	67-71
30502647-9	2019	Consistent with above results, berberine inhibition on PHA-induced IL-2 secretion could be reversed by treatment of SB203580, a specific inhibitor of p38-MAPK.	Berberine	31-40	mitogen-activated protein kinase 1	Homo sapiens	150-153
30502647-10	2019	Interestingly, upregulation of PHA-induced COX-2 expression was also observed following berberine treatment of Jurkat cells.	Berberine	88-97	prostaglandin-endoperoxide synthase 2	Homo sapiens	43-48
30502647-12	2019	In conclusion, our study demonstrated that the anti-inflammatory effect of berberine largely potentially results from its ability to attenuate p38 MAPK expression, and does not exclude a positive action of berberine on cell cycle arrest.	Berberine	75-84	mitogen-activated protein kinase 1	Homo sapiens	143-146
31337260-7	2019	Berberine inhibited the expression of pro-inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), and interleukin-1beta (IL-1beta), along with inflammatory proteins including iNOS and COX-2.	Berberine	0-9	tumor necrosis factor	Mus musculus	75-108
30681073-0	2019	Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis.	Berberine	0-9	heterogeneous nuclear ribonucleoprotein D	Homo sapiens	164-168
30681073-0	2019	Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis.	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	170-191
30681073-0	2019	Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis.	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	193-198
30681073-3	2019	Therefore, the present study investigated the involvement and regulatory function of lncRNA cancer susceptibility candidate 2 (CASC2) during the treatment of human colorectal cancer using berberine.	Berberine	188-197	cancer susceptibility 2	Homo sapiens	127-132
30681073-9	2019	LncRNA CASC2 was upregulated in cells treated with berberine, and knockdown of lncRNA CASC2 reversed the berberine-induced apoptosis.	Berberine	51-60	cancer susceptibility 2	Homo sapiens	7-12
30681073-9	2019	LncRNA CASC2 was upregulated in cells treated with berberine, and knockdown of lncRNA CASC2 reversed the berberine-induced apoptosis.	Berberine	105-114	cancer susceptibility 2	Homo sapiens	7-12
30681073-9	2019	LncRNA CASC2 was upregulated in cells treated with berberine, and knockdown of lncRNA CASC2 reversed the berberine-induced apoptosis.	Berberine	105-114	cancer susceptibility 2	Homo sapiens	86-91
30681073-10	2019	In addition, anti-apoptotic gene Bcl-2 was suppressed by berberine treatment and lncRNA CASC2, inducing the pro-apoptotic effects.	Berberine	57-66	BCL2 apoptosis regulator	Homo sapiens	33-38
30681073-12	2019	CONCLUSIONS Our study reveals that lncRNA CASC2 mediates the berberine-induced pro-apoptotic effect via inhibition of Bcl-2 expression at the post-transcriptional level.	Berberine	61-70	cancer susceptibility 2	Homo sapiens	42-47
30681073-12	2019	CONCLUSIONS Our study reveals that lncRNA CASC2 mediates the berberine-induced pro-apoptotic effect via inhibition of Bcl-2 expression at the post-transcriptional level.	Berberine	61-70	BCL2 apoptosis regulator	Homo sapiens	118-123
30346043-0	2019	Berberine ameliorates lipopolysaccharide-induced acute lung injury via the PERK-mediated Nrf2/HO-1 signaling axis.	Berberine	0-9	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	75-79
30346043-0	2019	Berberine ameliorates lipopolysaccharide-induced acute lung injury via the PERK-mediated Nrf2/HO-1 signaling axis.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	89-93
30346043-0	2019	Berberine ameliorates lipopolysaccharide-induced acute lung injury via the PERK-mediated Nrf2/HO-1 signaling axis.	Berberine	0-9	heme oxygenase 1	Homo sapiens	94-98
30346043-6	2019	Berberine promoted Nrf2 nuclear translocation and phosphorylation in vitro.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	19-23
30346043-9	2019	Berberine also significantly reduced histopathological inflammatory changes via inhibition of ER stress and activation of Nrf2 signaling.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	122-126
30346043-10	2019	Thapsigargin-induced ER stress and small interference RNA (siRNA)-mediated Nrf2 inhibition abrogated the protective effects of berberine in vitro, whereas siRNA-mediated suppression of ER stress and sulforaphane-induced Nrf2 activation further improved those effects.	Berberine	127-136	NFE2 like bZIP transcription factor 2	Homo sapiens	75-79
30346043-12	2019	Therefore, berberine inhibits LPS-induced ALI through the PERK-mediated Nrf2/HO-1 signaling axis.	Berberine	11-20	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	58-62
30346043-12	2019	Therefore, berberine inhibits LPS-induced ALI through the PERK-mediated Nrf2/HO-1 signaling axis.	Berberine	11-20	NFE2 like bZIP transcription factor 2	Homo sapiens	72-76
30346043-12	2019	Therefore, berberine inhibits LPS-induced ALI through the PERK-mediated Nrf2/HO-1 signaling axis.	Berberine	11-20	heme oxygenase 1	Homo sapiens	77-81
30809499-9	2018	Superoxide dismutase levels, reduced glutathione levels, and bcl-2 gene expression were significantly higher in the BBR group than in the PTZ group.	Berberine	116-119	BCL2, apoptosis regulator	Rattus norvegicus	61-66
30693045-0	2018	Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients.	Berberine	40-49	insulin	Homo sapiens	18-25
30693045-3	2018	The present study was conducted to determine the effects of berberine (BBR) therapy on serum MGO and insulin resistance in newly diagnosed type 2 diabetic patients.	Berberine	60-69	insulin	Homo sapiens	101-108
30693045-3	2018	The present study was conducted to determine the effects of berberine (BBR) therapy on serum MGO and insulin resistance in newly diagnosed type 2 diabetic patients.	Berberine	71-74	insulin	Homo sapiens	101-108
30541217-0	2018	[Effects of berberine on the serum cystatin C levels and urine albumin/creatine ratio in patients with type 2 diabetes mellitus].	Berberine	12-21	cystatin C	Homo sapiens	35-45
30622603-0	2018	The Role of Berberine in the Prevention of HIF-1alpha Activation to Alleviate Adipose Tissue Fibrosis in High-Fat-Diet-Induced Obese Mice.	Berberine	12-21	hypoxia inducible factor 1, alpha subunit	Mus musculus	43-53
30372821-0	2018	Berberine attenuates apoptosis in rat retinal Muller cells stimulated with high glucose via enhancing autophagy and the AMPK/mTOR signaling.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	120-124
30372821-0	2018	Berberine attenuates apoptosis in rat retinal Muller cells stimulated with high glucose via enhancing autophagy and the AMPK/mTOR signaling.	Berberine	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	125-129
30341486-0	2018	Berberine-Promoted CXCR4 Expression Accelerates Endothelial Repair Capacity of Early Endothelial Progenitor Cells in Persons with Prehypertension.	Berberine	0-9	C-X-C motif chemokine receptor 4	Homo sapiens	19-24
30341486-1	2018	OBJECTIVE: To evaluate whether the berberine treatment can improve endothelial repair capacity of early endothelial progenitor cells (EPCs) from prehypertensive subjects through increasing CXC chemokine receptor 4 (CXCR4) signaling.	Berberine	35-44	C-X-C motif chemokine receptor 4	Homo sapiens	189-213
30341486-1	2018	OBJECTIVE: To evaluate whether the berberine treatment can improve endothelial repair capacity of early endothelial progenitor cells (EPCs) from prehypertensive subjects through increasing CXC chemokine receptor 4 (CXCR4) signaling.	Berberine	35-44	C-X-C motif chemokine receptor 4	Homo sapiens	215-220
30341486-8	2018	Berberine promoted CXCR4/JAK-2 signaling expression of in vitro EPCs (P&lt;0.01).	Berberine	0-9	C-X-C motif chemokine receptor 4	Homo sapiens	19-24
30341486-8	2018	Berberine promoted CXCR4/JAK-2 signaling expression of in vitro EPCs (P&lt;0.01).	Berberine	0-9	Janus kinase 2	Homo sapiens	25-30
30341486-11	2018	CONCLUSION: Berberinemodified EPCs via up-regulation of CXCR4 signaling contributes to enhanced endothelial repair capacity in prehypertension, indicating that berberine may be used as a novel potential primary prevention means against prehypertension-related atherosclerotic cardiovascular disease.	Berberine	160-169	C-X-C motif chemokine receptor 4	Homo sapiens	56-61
30681073-0	2019	Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis.	Berberine	0-9	cancer susceptibility 2	Homo sapiens	136-141
30199654-9	2019	In parallel, IL-17A-related immune responses were attenuated in berberine-treated OVX-periodontitis rats with a lower serum level of proinflammatory cytokines and reduced IL-17A+ cells in alveolar bone as compared with vehicle-treated OVX-periodontitis rats.	Berberine	64-73	interleukin 17A	Rattus norvegicus	13-19
30199654-9	2019	In parallel, IL-17A-related immune responses were attenuated in berberine-treated OVX-periodontitis rats with a lower serum level of proinflammatory cytokines and reduced IL-17A+ cells in alveolar bone as compared with vehicle-treated OVX-periodontitis rats.	Berberine	64-73	interleukin 17A	Rattus norvegicus	171-177
30599901-0	2019	Chronic infusion of berberine into the hypothalamic paraventricular nucleus attenuates hypertension and sympathoexcitation via the ROS/Erk1/2/iNOS pathway.	Berberine	20-29	mitogen activated protein kinase 3	Rattus norvegicus	135-141
30599901-0	2019	Chronic infusion of berberine into the hypothalamic paraventricular nucleus attenuates hypertension and sympathoexcitation via the ROS/Erk1/2/iNOS pathway.	Berberine	20-29	nitric oxide synthase 2	Rattus norvegicus	142-146
30558158-7	2018	In the in vitro experiments, OPCs significantly inhibited the efflux and increased the uptake of the P-glycoprotein (P-gp) substrate rhodamine-123 (R123) and BB in Caco-2 intestinal cells.	Berberine	158-160	ATP binding cassette subfamily B member 1	Homo sapiens	117-121
30563192-2	2018	In our previous study, we found that such compounds upregulate expression of sirtuin 1-a key molecule in caloric restriction, it is, therefore, of great interest to examine the lipid-lowering activity of berberine in combination with a sirtuin 1 activator resveratrol.	Berberine	204-213	sirtuin 1	Homo sapiens	77-86
30563192-7	2018	In addition, the combination of berberine with resveratrol significantly increases the low-density-lipoprotein receptor expression in HepG2 cells to a level about one-fold higher in comparison to individual compound.	Berberine	32-41	low density lipoprotein receptor	Homo sapiens	87-119
30563192-8	2018	These results implied that the enhanced effect of the combination of berberine with resveratrol on lipid-lowering may be associated with upregulation of low-density-lipoprotein receptor, and could be an effective therapy for hyperlipidemia in some obese-associated disease, such as type II diabetes and metabolic syndrome.	Berberine	69-78	low density lipoprotein receptor	Homo sapiens	153-185
30117113-3	2018	Here we show a new mechanism by which berberine antagonizes glucagon signaling and find that SIRT3 is involved in the hypoglycemic effect of berberine.	Berberine	141-150	sirtuin 3	Homo sapiens	93-98
30117113-4	2018	METHODS: Gene knockout and overexpression were used to assess the inhibitory effect of berberine on SIRT3.	Berberine	87-96	sirtuin 3	Homo sapiens	100-105
30117113-6	2018	RESULTS: We found that berberine led to mitochondrial dysfunction and AMP accumulation by inhibiting deacetylase SIRT3.	Berberine	23-32	sirtuin 3	Homo sapiens	113-118
30117113-10	2018	Berberine caused significant PEPCK1 ubiquitination and degradation by antagonizing glucagon and was accompanied by high levels of PEPCK1 acetylation.	Berberine	0-9	phosphoenolpyruvate carboxykinase 1	Homo sapiens	29-35
30117113-10	2018	Berberine caused significant PEPCK1 ubiquitination and degradation by antagonizing glucagon and was accompanied by high levels of PEPCK1 acetylation.	Berberine	0-9	phosphoenolpyruvate carboxykinase 1	Homo sapiens	130-136
30117113-13	2018	CONCLUSIONS: Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting SIRT3, and regulating mitochondria-related pathways may provide a novel approach to the development of antidiabetic drugs.	Berberine	13-22	sirtuin 3	Homo sapiens	90-95
31337260-7	2019	Berberine inhibited the expression of pro-inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), and interleukin-1beta (IL-1beta), along with inflammatory proteins including iNOS and COX-2.	Berberine	0-9	interleukin 6	Mus musculus	110-123
31337260-7	2019	Berberine inhibited the expression of pro-inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), and interleukin-1beta (IL-1beta), along with inflammatory proteins including iNOS and COX-2.	Berberine	0-9	interleukin 6	Mus musculus	125-129
31337260-7	2019	Berberine inhibited the expression of pro-inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), and interleukin-1beta (IL-1beta), along with inflammatory proteins including iNOS and COX-2.	Berberine	0-9	interleukin 1 beta	Mus musculus	136-153
31337260-7	2019	Berberine inhibited the expression of pro-inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), and interleukin-1beta (IL-1beta), along with inflammatory proteins including iNOS and COX-2.	Berberine	0-9	interleukin 1 beta	Mus musculus	155-163
31337260-7	2019	Berberine inhibited the expression of pro-inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), and interleukin-1beta (IL-1beta), along with inflammatory proteins including iNOS and COX-2.	Berberine	0-9	nitric oxide synthase 2, inducible	Mus musculus	209-213
31337260-7	2019	Berberine inhibited the expression of pro-inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), and interleukin-1beta (IL-1beta), along with inflammatory proteins including iNOS and COX-2.	Berberine	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	218-223
30542485-7	2018	TLR4, NF-kappaB, iNOS, TNF-alpha, IL-6 and IL-10 expression was decreased following berberine intervention.	Berberine	84-93	toll-like receptor 4	Rattus norvegicus	0-4
30268048-3	2018	Herein, to find a more effective agent, several berberine analogues (A1-A13) were isolated and synthesized, and the triglyceride-lowering effects and potential mechanisms were investigated in HepG2 cells.	Berberine	48-57	immunoglobulin kappa variable 2D-18 (pseudogene)	Homo sapiens	72-75
30268048-4	2018	Among these berberine analogues, 9-O-benzoyl-substituted berberine (A13) showed strong affinity to AMPK and significantly up-regulated the levels of phospho-Thr172 AMPK alpha subunit.	Berberine	12-21	immunoglobulin kappa variable 2D-18 (pseudogene)	Homo sapiens	68-71
30542485-7	2018	TLR4, NF-kappaB, iNOS, TNF-alpha, IL-6 and IL-10 expression was decreased following berberine intervention.	Berberine	84-93	tumor necrosis factor	Rattus norvegicus	23-32
30542485-7	2018	TLR4, NF-kappaB, iNOS, TNF-alpha, IL-6 and IL-10 expression was decreased following berberine intervention.	Berberine	84-93	interleukin 6	Rattus norvegicus	34-38
30542485-7	2018	TLR4, NF-kappaB, iNOS, TNF-alpha, IL-6 and IL-10 expression was decreased following berberine intervention.	Berberine	84-93	nitric oxide synthase 2	Rattus norvegicus	17-21
30542485-7	2018	TLR4, NF-kappaB, iNOS, TNF-alpha, IL-6 and IL-10 expression was decreased following berberine intervention.	Berberine	84-93	interleukin 10	Rattus norvegicus	43-48
30542485-8	2018	Furthermore, the expression of mucin-2 (MUC2) and RNA polymerase sigma factor SigA (SIgA) were decreased in the NEC model group and increased following berberine intervention, when compared with the untreated group.	Berberine	152-161	mucin 2, oligomeric mucus/gel-forming	Rattus norvegicus	31-38
30129983-5	2018	Preincubation at high glucose concentration followed by moderate-glucose incubation activated the AMPK pathway, but the activation was abolished with berberine or metformin treatment.	Berberine	150-159	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	98-102
30542485-8	2018	Furthermore, the expression of mucin-2 (MUC2) and RNA polymerase sigma factor SigA (SIgA) were decreased in the NEC model group and increased following berberine intervention, when compared with the untreated group.	Berberine	152-161	mucin 2, oligomeric mucus/gel-forming	Rattus norvegicus	40-44
30129983-6	2018	In contrast, alteration from normal glucose to moderate glucose concentration in the medium suppressed AMPK activity, which was activated by berberine or metformin.	Berberine	141-150	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	103-107
30129983-8	2018	In conclusion, AMPK activated by glucose reduction is inhibited by berberine or metformin.	Berberine	67-76	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	15-19
30129983-10	2018	The potent glucose-lowering effects with minimal hypoglycemia of berberine and metformin may be partially due to their bidirectional regulation of the AMPK signaling pathway.	Berberine	65-74	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	151-155
30272344-0	2018	Berberine promotes nerve regeneration through IGFR-mediated JNK-AKT signal pathway.	Berberine	0-9	insulin like growth factor 1 receptor	Homo sapiens	46-50
30272344-0	2018	Berberine promotes nerve regeneration through IGFR-mediated JNK-AKT signal pathway.	Berberine	0-9	mitogen-activated protein kinase 8	Homo sapiens	60-63
30272344-0	2018	Berberine promotes nerve regeneration through IGFR-mediated JNK-AKT signal pathway.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	64-67
30272344-5	2018	Berberine treatment inhibited apoptosis of hippocampal pyramidal neurons and increased apoptosis regulator Bcl-2 and Bcl-w expression.	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	107-112
30272344-5	2018	Berberine treatment inhibited apoptosis of hippocampal pyramidal neurons and increased apoptosis regulator Bcl-2 and Bcl-w expression.	Berberine	0-9	BCL2 like 2	Homo sapiens	117-122
30272344-6	2018	Neuroinflammation of tumor necrosis factor alpha, interleukin (IL)1beta, IL6 levels and autophagy-related proteins microtubule-associated proteins 1A/1B light chain 3B, autophagy related 16 like 1 and autophagy related 7 were downregulated by berberine treatment in hippocampal pyramidal neurons.	Berberine	243-252	microtubule associated protein 1 light chain 3 beta	Homo sapiens	115-167
30272344-7	2018	Notably, study has found that berberine increased insulin-like growth factor receptor (IGFR) and decreased c-Jun N-terminal kinase (JNK) and protein kinase B (AKT) expression in hippocampal pyramidal neurons.	Berberine	30-39	insulin like growth factor 1 receptor	Homo sapiens	50-85
30272344-7	2018	Notably, study has found that berberine increased insulin-like growth factor receptor (IGFR) and decreased c-Jun N-terminal kinase (JNK) and protein kinase B (AKT) expression in hippocampal pyramidal neurons.	Berberine	30-39	insulin like growth factor 1 receptor	Homo sapiens	87-91
30272344-7	2018	Notably, study has found that berberine increased insulin-like growth factor receptor (IGFR) and decreased c-Jun N-terminal kinase (JNK) and protein kinase B (AKT) expression in hippocampal pyramidal neurons.	Berberine	30-39	mitogen-activated protein kinase 8	Homo sapiens	107-136
30272344-7	2018	Notably, study has found that berberine increased insulin-like growth factor receptor (IGFR) and decreased c-Jun N-terminal kinase (JNK) and protein kinase B (AKT) expression in hippocampal pyramidal neurons.	Berberine	30-39	AKT serine/threonine kinase 1	Homo sapiens	159-162
30272344-8	2018	IGFR antagonist abolished berberine-increased growth of hippocampal pyramidal neurons.	Berberine	26-35	insulin like growth factor 1 receptor	Homo sapiens	0-4
30272344-9	2018	In conclusion, these results indicate that berberine can promote nerve regeneration through IGFR-mediated JNK-AKT signal pathway.	Berberine	43-52	insulin like growth factor 1 receptor	Homo sapiens	92-96
30272344-9	2018	In conclusion, these results indicate that berberine can promote nerve regeneration through IGFR-mediated JNK-AKT signal pathway.	Berberine	43-52	mitogen-activated protein kinase 8	Homo sapiens	106-109
30272344-9	2018	In conclusion, these results indicate that berberine can promote nerve regeneration through IGFR-mediated JNK-AKT signal pathway.	Berberine	43-52	AKT serine/threonine kinase 1	Homo sapiens	110-113
30306659-5	2018	Berberine suppressed the viral infection-induced up-regulation of TLR7 signaling pathway, such as TLR7, MyD88, and NF-kappaB (p65), at both the mRNA and protein levels.	Berberine	0-9	toll-like receptor 7	Mus musculus	66-70
30078229-0	2018	Berberine attenuates pulmonary arterial hypertension via protein phosphatase 2A signaling pathway both in vivo and in vitro.	Berberine	0-9	protein phosphatase 2 phosphatase activator	Homo sapiens	65-79
30272347-3	2018	Our results showed that berberine inhibited the proliferation of NCI-H2452 cells in a dose- and time-dependent manner and could induce apoptosis, possibly through a caspase-9-dependent intrinsic mitochondrial pathway.	Berberine	24-33	caspase 9	Homo sapiens	165-174
30272347-4	2018	In addition, autophagy was induced by berberine, which was characterized by the accumulation of LC3-II and decreased p62 expression.	Berberine	38-47	nucleoporin 62	Homo sapiens	117-120
30306659-5	2018	Berberine suppressed the viral infection-induced up-regulation of TLR7 signaling pathway, such as TLR7, MyD88, and NF-kappaB (p65), at both the mRNA and protein levels.	Berberine	0-9	toll-like receptor 7	Mus musculus	98-102
30306659-5	2018	Berberine suppressed the viral infection-induced up-regulation of TLR7 signaling pathway, such as TLR7, MyD88, and NF-kappaB (p65), at both the mRNA and protein levels.	Berberine	0-9	myeloid differentiation primary response gene 88	Mus musculus	104-109
30306659-5	2018	Berberine suppressed the viral infection-induced up-regulation of TLR7 signaling pathway, such as TLR7, MyD88, and NF-kappaB (p65), at both the mRNA and protein levels.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	115-124
30306659-5	2018	Berberine suppressed the viral infection-induced up-regulation of TLR7 signaling pathway, such as TLR7, MyD88, and NF-kappaB (p65), at both the mRNA and protein levels.	Berberine	0-9	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	126-129
30306659-6	2018	Furthermore, berberine significantly inhibited the viral infection-induced increase in Th1/Th2 and Th17/Treg ratios as well as the production of inflammatory cytokines.	Berberine	13-22	negative elongation factor complex member C/D, Th1l	Mus musculus	87-90
30306659-6	2018	Furthermore, berberine significantly inhibited the viral infection-induced increase in Th1/Th2 and Th17/Treg ratios as well as the production of inflammatory cytokines.	Berberine	13-22	heart and neural crest derivatives expressed 2	Mus musculus	91-94
30534049-0	2018	Syntaxin 1B Mediates Berberine"s Roles in Epilepsy-Like Behavior in a Pentylenetetrazole-Induced Seizure Zebrafish Model.	Berberine	21-30	syntaxin 1B	Danio rerio	0-11
31070539-0	2018	Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway.	Berberine	0-9	kinase insert domain receptor	Homo sapiens	76-82
31070539-0	2018	Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	83-86
31070539-8	2018	Berberine significantly decreased haemoglobin content (28.81 +- 3.64 mug/mg vs. 40.84 +- 5.15 mug/mg in vehicle group, p   0.001) and CD31 mRNA expression in tumour tissue.	Berberine	0-9	platelet and endothelial cell adhesion molecule 1	Homo sapiens	134-138
31070539-10	2018	Berberine inhibited (p   0.001) the phosphorylation of VEGFR2 and ERK.	Berberine	0-9	kinase insert domain receptor	Homo sapiens	55-61
31070539-10	2018	Berberine inhibited (p   0.001) the phosphorylation of VEGFR2 and ERK.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	66-69
31070539-11	2018	DISCUSSION AND CONCLUSIONS: Berberine inhibited angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway.	Berberine	28-37	kinase insert domain receptor	Homo sapiens	105-111
31070539-11	2018	DISCUSSION AND CONCLUSIONS: Berberine inhibited angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway.	Berberine	28-37	mitogen-activated protein kinase 1	Homo sapiens	112-115
30305576-0	2018	Increased Bioavailable Berberine Protects Against Myocardial Ischemia Reperfusion Injury Through Attenuation of NFkappaB and JNK Signaling Pathways.	Berberine	23-32	mitogen-activated protein kinase 8	Rattus norvegicus	125-128
30534049-9	2018	In addition, we found that berberine (BBR) reduced larvae hyperexcitatory locomotion and abnormal movement trajectory in a concentration-dependent manner, slowed down excessive photosensitive seizure-like swimming, and assisted in the recovery of the expression levels of STX1B.	Berberine	27-36	syntaxin 1B	Danio rerio	272-277
30534049-11	2018	These findings further demonstrate that STX1B protein levels are negatively correlated with a seizure and can decrease the sensitivity of the photosensitive response in a PTZ-induced seizure zebrafish larvae; furthermore, STX1B may partially mediate the anticonvulsant effect of BBR.	Berberine	279-282	syntaxin 1B	Danio rerio	40-45
30534049-11	2018	These findings further demonstrate that STX1B protein levels are negatively correlated with a seizure and can decrease the sensitivity of the photosensitive response in a PTZ-induced seizure zebrafish larvae; furthermore, STX1B may partially mediate the anticonvulsant effect of BBR.	Berberine	279-282	syntaxin 1B	Danio rerio	222-227
30466991-0	2018	Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells.	Berberine	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	25-29
30240693-0	2018	Berberine modulates ASK1 signaling mediated through TLR4/TRAF2 via upregulation of miR-23a.	Berberine	0-9	mitogen-activated protein kinase kinase kinase 5	Mus musculus	20-24
30240693-0	2018	Berberine modulates ASK1 signaling mediated through TLR4/TRAF2 via upregulation of miR-23a.	Berberine	0-9	toll-like receptor 4	Mus musculus	52-56
30240693-0	2018	Berberine modulates ASK1 signaling mediated through TLR4/TRAF2 via upregulation of miR-23a.	Berberine	0-9	TNF receptor-associated factor 2	Mus musculus	57-62
30466991-0	2018	Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells.	Berberine	0-9	epidermal growth factor receptor	Homo sapiens	67-71
30466991-0	2018	Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells.	Berberine	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	72-75
30466991-0	2018	Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	76-79
30466991-2	2018	PURPOSE: Here, we investigated the regulatory mechanism of IL-8 expression as well as the pharmacological effect of berberine (BBR) on IL-8 expression in triple-negative breast cancer (TNBC) cells.	Berberine	116-125	C-X-C motif chemokine ligand 8	Homo sapiens	135-139
30466991-2	2018	PURPOSE: Here, we investigated the regulatory mechanism of IL-8 expression as well as the pharmacological effect of berberine (BBR) on IL-8 expression in triple-negative breast cancer (TNBC) cells.	Berberine	127-130	C-X-C motif chemokine ligand 8	Homo sapiens	135-139
30538756-0	2018	The Effect of Berberine on Polycystic Ovary Syndrome Patients with Insulin Resistance (PCOS-IR): A Meta-Analysis and Systematic Review.	Berberine	14-23	insulin	Homo sapiens	67-74
30538756-1	2018	Purpose: To evaluate the effect of berberine (BBR) on polycystic ovary syndrome (PCOS) patients with insulin resistance (IR).	Berberine	35-44	insulin	Homo sapiens	101-108
30538756-1	2018	Purpose: To evaluate the effect of berberine (BBR) on polycystic ovary syndrome (PCOS) patients with insulin resistance (IR).	Berberine	46-49	insulin	Homo sapiens	101-108
30266998-0	2018	Berberine attenuates ischemia-reperfusion injury through inhibiting HMGB1 release and NF-kappaB nuclear translocation.	Berberine	0-9	high mobility group box 1	Mus musculus	68-73
30266998-0	2018	Berberine attenuates ischemia-reperfusion injury through inhibiting HMGB1 release and NF-kappaB nuclear translocation.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	86-95
30266998-10	2018	Furthermore, pretreatment with berberine dose-dependently suppressed the nuclear-to cytosolic translocation of high-mobility group box1 (HMGB1) protein, the cytosolic-to nuclear translocation of nuclear factor kappa B (NF-kappaB) and decreased the expression of TLR4 in ischemic cortical tissue.	Berberine	31-40	high mobility group box 1	Mus musculus	111-135
30266998-10	2018	Furthermore, pretreatment with berberine dose-dependently suppressed the nuclear-to cytosolic translocation of high-mobility group box1 (HMGB1) protein, the cytosolic-to nuclear translocation of nuclear factor kappa B (NF-kappaB) and decreased the expression of TLR4 in ischemic cortical tissue.	Berberine	31-40	high mobility group box 1	Mus musculus	137-142
30266998-10	2018	Furthermore, pretreatment with berberine dose-dependently suppressed the nuclear-to cytosolic translocation of high-mobility group box1 (HMGB1) protein, the cytosolic-to nuclear translocation of nuclear factor kappa B (NF-kappaB) and decreased the expression of TLR4 in ischemic cortical tissue.	Berberine	31-40	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	195-217
30266998-10	2018	Furthermore, pretreatment with berberine dose-dependently suppressed the nuclear-to cytosolic translocation of high-mobility group box1 (HMGB1) protein, the cytosolic-to nuclear translocation of nuclear factor kappa B (NF-kappaB) and decreased the expression of TLR4 in ischemic cortical tissue.	Berberine	31-40	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	219-228
30266998-10	2018	Furthermore, pretreatment with berberine dose-dependently suppressed the nuclear-to cytosolic translocation of high-mobility group box1 (HMGB1) protein, the cytosolic-to nuclear translocation of nuclear factor kappa B (NF-kappaB) and decreased the expression of TLR4 in ischemic cortical tissue.	Berberine	31-40	toll-like receptor 4	Mus musculus	262-266
30266998-11	2018	Moreover, co-administration of glycyrrhizin and berberine exerted more potent suppression on the HMGB1/TLR4/NF-kappaB pathway than berberine or glycyrrhizin administered alone.	Berberine	48-57	high mobility group box 1	Mus musculus	97-102
30266998-11	2018	Moreover, co-administration of glycyrrhizin and berberine exerted more potent suppression on the HMGB1/TLR4/NF-kappaB pathway than berberine or glycyrrhizin administered alone.	Berberine	48-57	toll-like receptor 4	Mus musculus	103-107
30266998-11	2018	Moreover, co-administration of glycyrrhizin and berberine exerted more potent suppression on the HMGB1/TLR4/NF-kappaB pathway than berberine or glycyrrhizin administered alone.	Berberine	48-57	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	108-117
30266998-12	2018	These results demonstrate that berberine protects the brain from ischemia-reperfusion injury and the mechanism may rely on its anti-inflammatory effects mediated by suppressing the activation of HMGB1/TLR4/NF-kappaB signaling.	Berberine	31-40	high mobility group box 1	Mus musculus	195-200
30266998-12	2018	These results demonstrate that berberine protects the brain from ischemia-reperfusion injury and the mechanism may rely on its anti-inflammatory effects mediated by suppressing the activation of HMGB1/TLR4/NF-kappaB signaling.	Berberine	31-40	toll-like receptor 4	Mus musculus	201-205
30266998-12	2018	These results demonstrate that berberine protects the brain from ischemia-reperfusion injury and the mechanism may rely on its anti-inflammatory effects mediated by suppressing the activation of HMGB1/TLR4/NF-kappaB signaling.	Berberine	31-40	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	206-215
30257361-10	2018	Western blot showed that berberine inhibited the expressions of ODC, C-MYC and HIF-1alpha, but up-regulated those of OAZ1 and SSAT.	Berberine	25-34	ornithine decarboxylase, structural 1	Mus musculus	64-67
30257361-10	2018	Western blot showed that berberine inhibited the expressions of ODC, C-MYC and HIF-1alpha, but up-regulated those of OAZ1 and SSAT.	Berberine	25-34	hypoxia inducible factor 1, alpha subunit	Mus musculus	79-89
30257361-10	2018	Western blot showed that berberine inhibited the expressions of ODC, C-MYC and HIF-1alpha, but up-regulated those of OAZ1 and SSAT.	Berberine	25-34	ornithine decarboxylase antizyme 1	Mus musculus	117-121
30257361-10	2018	Western blot showed that berberine inhibited the expressions of ODC, C-MYC and HIF-1alpha, but up-regulated those of OAZ1 and SSAT.	Berberine	25-34	spermidine/spermine N1-acetyl transferase 1	Mus musculus	126-130
30257374-0	2018	Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice.	Berberine	0-9	apolipoprotein E	Mus musculus	75-79
30266118-1	2018	OBJECTIVE: To investigate the effect of berberine on angiogenesis and signal transduction pathway of hypoxia-inducible growth factor-1&amp;alpha; (HIF-1&amp;alpha;) / vascular endothelial growth factor (VEGF) in rats with cerebral ischemia-reperfusion injury.	Berberine	40-49	vascular endothelial growth factor A	Rattus norvegicus	167-201
30240693-0	2018	Berberine modulates ASK1 signaling mediated through TLR4/TRAF2 via upregulation of miR-23a.	Berberine	0-9	microRNA 23a	Mus musculus	83-90
30240693-1	2018	The current study was designed to explore the underlying therapeutic effect of berberine (BBR), an alkaloid compound against LPS (1 mug/ml)/TNFalpha (10 ng/ml) mediated apoptosis signal-regulating kinase 1 (ASK1) signaling in RAW 264.7 macrophages and adjuvant-induced arthritic synovial macrophages (AA-SM) with relation to miR-23a levels.	Berberine	79-88	tumor necrosis factor	Mus musculus	140-148
30240693-1	2018	The current study was designed to explore the underlying therapeutic effect of berberine (BBR), an alkaloid compound against LPS (1 mug/ml)/TNFalpha (10 ng/ml) mediated apoptosis signal-regulating kinase 1 (ASK1) signaling in RAW 264.7 macrophages and adjuvant-induced arthritic synovial macrophages (AA-SM) with relation to miR-23a levels.	Berberine	79-88	mitogen-activated protein kinase kinase kinase 5	Mus musculus	169-205
30240693-1	2018	The current study was designed to explore the underlying therapeutic effect of berberine (BBR), an alkaloid compound against LPS (1 mug/ml)/TNFalpha (10 ng/ml) mediated apoptosis signal-regulating kinase 1 (ASK1) signaling in RAW 264.7 macrophages and adjuvant-induced arthritic synovial macrophages (AA-SM) with relation to miR-23a levels.	Berberine	79-88	mitogen-activated protein kinase kinase kinase 5	Mus musculus	207-211
30240693-1	2018	The current study was designed to explore the underlying therapeutic effect of berberine (BBR), an alkaloid compound against LPS (1 mug/ml)/TNFalpha (10 ng/ml) mediated apoptosis signal-regulating kinase 1 (ASK1) signaling in RAW 264.7 macrophages and adjuvant-induced arthritic synovial macrophages (AA-SM) with relation to miR-23a levels.	Berberine	79-88	microRNA 23a	Mus musculus	325-332
30240693-1	2018	The current study was designed to explore the underlying therapeutic effect of berberine (BBR), an alkaloid compound against LPS (1 mug/ml)/TNFalpha (10 ng/ml) mediated apoptosis signal-regulating kinase 1 (ASK1) signaling in RAW 264.7 macrophages and adjuvant-induced arthritic synovial macrophages (AA-SM) with relation to miR-23a levels.	Berberine	90-93	tumor necrosis factor	Mus musculus	140-148
30240693-1	2018	The current study was designed to explore the underlying therapeutic effect of berberine (BBR), an alkaloid compound against LPS (1 mug/ml)/TNFalpha (10 ng/ml) mediated apoptosis signal-regulating kinase 1 (ASK1) signaling in RAW 264.7 macrophages and adjuvant-induced arthritic synovial macrophages (AA-SM) with relation to miR-23a levels.	Berberine	90-93	mitogen-activated protein kinase kinase kinase 5	Mus musculus	169-205
30240693-1	2018	The current study was designed to explore the underlying therapeutic effect of berberine (BBR), an alkaloid compound against LPS (1 mug/ml)/TNFalpha (10 ng/ml) mediated apoptosis signal-regulating kinase 1 (ASK1) signaling in RAW 264.7 macrophages and adjuvant-induced arthritic synovial macrophages (AA-SM) with relation to miR-23a levels.	Berberine	90-93	mitogen-activated protein kinase kinase kinase 5	Mus musculus	207-211
30240693-1	2018	The current study was designed to explore the underlying therapeutic effect of berberine (BBR), an alkaloid compound against LPS (1 mug/ml)/TNFalpha (10 ng/ml) mediated apoptosis signal-regulating kinase 1 (ASK1) signaling in RAW 264.7 macrophages and adjuvant-induced arthritic synovial macrophages (AA-SM) with relation to miR-23a levels.	Berberine	90-93	microRNA 23a	Mus musculus	325-332
30335889-1	2018	Berberine (BBR), the major isoquinoline alkaloid in Chinese herb Rhizoma coptidis, has significant lipid-lowering effect by upregulating hepatic low-density lipoprotein receptor (LDLR) expression.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	145-177
30335889-1	2018	Berberine (BBR), the major isoquinoline alkaloid in Chinese herb Rhizoma coptidis, has significant lipid-lowering effect by upregulating hepatic low-density lipoprotein receptor (LDLR) expression.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	179-183
30335889-1	2018	Berberine (BBR), the major isoquinoline alkaloid in Chinese herb Rhizoma coptidis, has significant lipid-lowering effect by upregulating hepatic low-density lipoprotein receptor (LDLR) expression.	Berberine	11-14	low density lipoprotein receptor	Homo sapiens	145-177
30335889-1	2018	Berberine (BBR), the major isoquinoline alkaloid in Chinese herb Rhizoma coptidis, has significant lipid-lowering effect by upregulating hepatic low-density lipoprotein receptor (LDLR) expression.	Berberine	11-14	low density lipoprotein receptor	Homo sapiens	179-183
30344490-6	2018	Results: Compounds with potential to promote anti-CCL17 production in HaCaT were identified (e.g., berberine, pyrogallol and catechin dimers) as a result of the developed model and their potential to act as anti-inflammatory agents were also supported by relevant literature.	Berberine	99-108	C-C motif chemokine ligand 17	Homo sapiens	50-55
29957017-7	2018	In contrast, berberine treatment significantly inhibited IGF-1R expression and exerted an antifibrotic effect in high glucose-cultured cardiac fibroblasts, as manifested by decreased MMP-2/MMP-9, alpha-SMA, and collagen type I expression, whereas IGF-1R siRNA plus berberine treatment did not further enhance this antifibrotic effect compared with berberine treatment alone.	Berberine	13-22	insulin-like growth factor 1 receptor	Rattus norvegicus	57-63
29957017-7	2018	In contrast, berberine treatment significantly inhibited IGF-1R expression and exerted an antifibrotic effect in high glucose-cultured cardiac fibroblasts, as manifested by decreased MMP-2/MMP-9, alpha-SMA, and collagen type I expression, whereas IGF-1R siRNA plus berberine treatment did not further enhance this antifibrotic effect compared with berberine treatment alone.	Berberine	13-22	matrix metallopeptidase 2	Rattus norvegicus	183-188
29957017-7	2018	In contrast, berberine treatment significantly inhibited IGF-1R expression and exerted an antifibrotic effect in high glucose-cultured cardiac fibroblasts, as manifested by decreased MMP-2/MMP-9, alpha-SMA, and collagen type I expression, whereas IGF-1R siRNA plus berberine treatment did not further enhance this antifibrotic effect compared with berberine treatment alone.	Berberine	13-22	matrix metallopeptidase 9	Rattus norvegicus	189-194
29957017-7	2018	In contrast, berberine treatment significantly inhibited IGF-1R expression and exerted an antifibrotic effect in high glucose-cultured cardiac fibroblasts, as manifested by decreased MMP-2/MMP-9, alpha-SMA, and collagen type I expression, whereas IGF-1R siRNA plus berberine treatment did not further enhance this antifibrotic effect compared with berberine treatment alone.	Berberine	13-22	actin gamma 2, smooth muscle	Rattus norvegicus	196-205
29957017-7	2018	In contrast, berberine treatment significantly inhibited IGF-1R expression and exerted an antifibrotic effect in high glucose-cultured cardiac fibroblasts, as manifested by decreased MMP-2/MMP-9, alpha-SMA, and collagen type I expression, whereas IGF-1R siRNA plus berberine treatment did not further enhance this antifibrotic effect compared with berberine treatment alone.	Berberine	13-22	insulin-like growth factor 1 receptor	Rattus norvegicus	247-253
29957017-8	2018	Taken together, long-term berberine treatment ameliorates cardiac fibrosis and dysfunction by downregulating IGF-1R expression in cardiac fibroblasts and subsequently reducing MMP-2/MMP-9, alpha-SMA, and collagen type I expression in diabetic hearts.	Berberine	26-35	insulin-like growth factor 1 receptor	Rattus norvegicus	109-115
29957017-8	2018	Taken together, long-term berberine treatment ameliorates cardiac fibrosis and dysfunction by downregulating IGF-1R expression in cardiac fibroblasts and subsequently reducing MMP-2/MMP-9, alpha-SMA, and collagen type I expression in diabetic hearts.	Berberine	26-35	matrix metallopeptidase 2	Rattus norvegicus	176-181
29957017-8	2018	Taken together, long-term berberine treatment ameliorates cardiac fibrosis and dysfunction by downregulating IGF-1R expression in cardiac fibroblasts and subsequently reducing MMP-2/MMP-9, alpha-SMA, and collagen type I expression in diabetic hearts.	Berberine	26-35	matrix metallopeptidase 9	Rattus norvegicus	182-187
29957017-8	2018	Taken together, long-term berberine treatment ameliorates cardiac fibrosis and dysfunction by downregulating IGF-1R expression in cardiac fibroblasts and subsequently reducing MMP-2/MMP-9, alpha-SMA, and collagen type I expression in diabetic hearts.	Berberine	26-35	actin gamma 2, smooth muscle	Rattus norvegicus	189-198
30322611-1	2018	A series of berberine derivatives were synthesized by introducing substituted benzyl groups at C-9.	Berberine	12-21	complement C9	Homo sapiens	95-98
30117113-0	2018	Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3.	Berberine	0-9	sirtuin 3	Homo sapiens	89-94
30117113-2	2018	Although the mechanism of action of berberine involves the improvement of insulin sensitivity, its hypoglycemic mechanism remains elusive.	Berberine	36-45	insulin	Homo sapiens	74-81
30221732-8	2018	These results demonstrated that metformin and BBR could improve NAFLD, which may be via the activation of AMPK signaling, and the high expression of CCL19 in NAFLD was significantly reduced by metformin and BBR.	Berberine	207-210	C-C motif chemokine ligand 19	Homo sapiens	149-154
30405404-0	2018	Berberine Attenuated Proliferation, Invasion and Migration by Targeting the AMPK/HNF4alpha/WNT5A Pathway in Gastric Carcinoma.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	76-80
30405404-0	2018	Berberine Attenuated Proliferation, Invasion and Migration by Targeting the AMPK/HNF4alpha/WNT5A Pathway in Gastric Carcinoma.	Berberine	0-9	hepatocyte nuclear factor 4 alpha	Homo sapiens	81-90
30405404-0	2018	Berberine Attenuated Proliferation, Invasion and Migration by Targeting the AMPK/HNF4alpha/WNT5A Pathway in Gastric Carcinoma.	Berberine	0-9	Wnt family member 5A	Homo sapiens	91-96
30405404-3	2018	Berberine, a natural isoquinoline alkaloid, could modulate lipid metabolism and glucose homeostasis by regulating the expression of HNF4alpha in many metabolic diseases.	Berberine	0-9	hepatocyte nuclear factor 4 alpha	Homo sapiens	132-141
30405404-4	2018	Here, we investigated the effect of Berberine on GC and its possible molecular mechanism through targeting HNF4alpha.	Berberine	36-45	hepatocyte nuclear factor 4 alpha	Homo sapiens	107-116
30405404-16	2018	Berberine also downregulated WNT5A and cytoplasmic beta-catenin, the same as LV-HNF4alpha-RNAi and BI6015 in GC cells.	Berberine	0-9	wingless-type MMTV integration site family, member 5A	Mus musculus	29-34
30405404-16	2018	Berberine also downregulated WNT5A and cytoplasmic beta-catenin, the same as LV-HNF4alpha-RNAi and BI6015 in GC cells.	Berberine	0-9	catenin (cadherin associated protein), beta 1	Mus musculus	51-63
30405404-21	2018	HNF4alpha antagonists, such as BBR, could be a promising anti-gastric cancer treatment supplement.	Berberine	31-34	hepatocyte nuclear factor 4 alpha	Homo sapiens	0-9
30304866-9	2018	The complex paradigm will be discussed within the context of if/how dietary components, nutrients including fatty acids and non-nutrient food components, such as resveratrol, berberine, curcumin and the flavonoid genistein, modulate AMPK dependent processes relating to inflammation and metabolism.	Berberine	175-184	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	233-237
29957017-0	2018	Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats.	Berberine	33-42	insulin-like growth factor 1 receptor	Rattus norvegicus	73-87
29957017-0	2018	Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats.	Berberine	33-42	matrix metallopeptidase 2	Rattus norvegicus	98-103
29957017-0	2018	Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats.	Berberine	33-42	matrix metallopeptidase 9	Rattus norvegicus	104-109
30119256-6	2018	Combined treatment of Berberine and theophylline reduced extracellular level of HMGB1 and down regulated HMGB1 and MMP-9 mRNA expression.	Berberine	22-31	high mobility group box 1	Homo sapiens	80-85
30119256-6	2018	Combined treatment of Berberine and theophylline reduced extracellular level of HMGB1 and down regulated HMGB1 and MMP-9 mRNA expression.	Berberine	22-31	high mobility group box 1	Homo sapiens	105-110
30119256-6	2018	Combined treatment of Berberine and theophylline reduced extracellular level of HMGB1 and down regulated HMGB1 and MMP-9 mRNA expression.	Berberine	22-31	matrix metallopeptidase 9	Homo sapiens	115-120
30138605-14	2018	The relative phosphorylation of Akt was determined in hepatic homogenates that was increased with TAA injection and decreased by BBR treatment.	Berberine	129-132	AKT serine/threonine kinase 1	Rattus norvegicus	32-35
30266118-11	2018	After 7 days of administration, neurological score of berberine group was lower than that of model group (p &lt;0.001), MVD, HIF-1&amp;alpha; mRNA and VEGF mRNA expression.	Berberine	54-63	vascular endothelial growth factor A	Rattus norvegicus	151-155
30266118-12	2018	HIF-1&amp;alpha; and VEGF protein expression levels were lower in model group than berberine group (all p &lt;0.001).	Berberine	83-92	vascular endothelial growth factor A	Rattus norvegicus	21-25
30021340-11	2018	At the same time, berberine increased the activation of p-AMPK and inhibited the activation of p-mTOR induced by NaH2PO4.	Berberine	18-27	mechanistic target of rapamycin kinase	Homo sapiens	97-101
28852897-1	2018	PURPOSE: In this study, we elucidated the effects of berberine, a major alkaloid component contained in medicinal herbs, such as Phellodendri Cortex and Coptidis Rhizoma, on expression of monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8) in a human retinal pigment epithelial cell line (ARPE-19) caused by lipopolysaccharide (LPS) stimulation.	Berberine	53-62	C-C motif chemokine ligand 2	Homo sapiens	188-218
28852897-1	2018	PURPOSE: In this study, we elucidated the effects of berberine, a major alkaloid component contained in medicinal herbs, such as Phellodendri Cortex and Coptidis Rhizoma, on expression of monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8) in a human retinal pigment epithelial cell line (ARPE-19) caused by lipopolysaccharide (LPS) stimulation.	Berberine	53-62	C-C motif chemokine ligand 2	Homo sapiens	220-225
28852897-1	2018	PURPOSE: In this study, we elucidated the effects of berberine, a major alkaloid component contained in medicinal herbs, such as Phellodendri Cortex and Coptidis Rhizoma, on expression of monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8) in a human retinal pigment epithelial cell line (ARPE-19) caused by lipopolysaccharide (LPS) stimulation.	Berberine	53-62	C-X-C motif chemokine ligand 8	Homo sapiens	231-244
28852897-1	2018	PURPOSE: In this study, we elucidated the effects of berberine, a major alkaloid component contained in medicinal herbs, such as Phellodendri Cortex and Coptidis Rhizoma, on expression of monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8) in a human retinal pigment epithelial cell line (ARPE-19) caused by lipopolysaccharide (LPS) stimulation.	Berberine	53-62	C-X-C motif chemokine ligand 8	Homo sapiens	246-250
28852897-1	2018	PURPOSE: In this study, we elucidated the effects of berberine, a major alkaloid component contained in medicinal herbs, such as Phellodendri Cortex and Coptidis Rhizoma, on expression of monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8) in a human retinal pigment epithelial cell line (ARPE-19) caused by lipopolysaccharide (LPS) stimulation.	Berberine	53-62	toll-like receptor 4	Mus musculus	340-343
28852897-6	2018	RESULTS: After stimulation with LPS, MCP-1 and IL-8 mRNA in ARPE-19 cells reached maximum levels at 3 h, and MCP-1 and IL-8 protein in the culture media reached maximum levels at 24 h. Berberine dose-dependently inhibited MCP-1 and IL-8 mRNA expression of the cells and protein levels in the media stimulated with LPS.	Berberine	185-194	toll-like receptor 4	Mus musculus	32-35
28852897-6	2018	RESULTS: After stimulation with LPS, MCP-1 and IL-8 mRNA in ARPE-19 cells reached maximum levels at 3 h, and MCP-1 and IL-8 protein in the culture media reached maximum levels at 24 h. Berberine dose-dependently inhibited MCP-1 and IL-8 mRNA expression of the cells and protein levels in the media stimulated with LPS.	Berberine	185-194	chemokine (C-C motif) ligand 2	Mus musculus	37-42
28852897-6	2018	RESULTS: After stimulation with LPS, MCP-1 and IL-8 mRNA in ARPE-19 cells reached maximum levels at 3 h, and MCP-1 and IL-8 protein in the culture media reached maximum levels at 24 h. Berberine dose-dependently inhibited MCP-1 and IL-8 mRNA expression of the cells and protein levels in the media stimulated with LPS.	Berberine	185-194	toll-like receptor 4	Mus musculus	314-317
28852897-7	2018	CONCLUSIONS: These findings indicate that berberine inhibited the expression of MCP-1 and IL-8 induced by LPS.	Berberine	42-51	C-C motif chemokine ligand 2	Homo sapiens	80-85
28852897-7	2018	CONCLUSIONS: These findings indicate that berberine inhibited the expression of MCP-1 and IL-8 induced by LPS.	Berberine	42-51	C-X-C motif chemokine ligand 8	Homo sapiens	90-94
28852897-7	2018	CONCLUSIONS: These findings indicate that berberine inhibited the expression of MCP-1 and IL-8 induced by LPS.	Berberine	42-51	toll-like receptor 4	Mus musculus	106-109
29363059-2	2018	GLP-1 release is stimulated when berberine interacts with a novel G protein family (TAS2Rs) in enteroendocrine cells.	Berberine	33-42	glucagon	Mus musculus	0-5
29363059-5	2018	STC-1 cells showed berberine-up-regulated preproglucagon (GLP-1 precursor) mRNA and GLP-1 secretion.	Berberine	19-28	glucagon	Mus musculus	58-63
29363059-5	2018	STC-1 cells showed berberine-up-regulated preproglucagon (GLP-1 precursor) mRNA and GLP-1 secretion.	Berberine	19-28	glucagon	Mus musculus	84-89
29363059-7	2018	Berberine-mediated GLP-1 secretion was attenuated in response to small interfering RNA silencing of TAS2R38.	Berberine	0-9	glucagon	Mus musculus	19-24
29363059-9	2018	We further utilized inhibitors of PLC and TRPM5, which are known to participate in taste signal transduction, to investigate the underlying pathways mediated in berberine-induced GLP-1 secretion.	Berberine	161-170	glucagon	Mus musculus	179-184
29363059-10	2018	Berberine-induced GLP-1 release from enteroendocrine cells is modulated in a PLC-dependent manner through a process involving the activation of bitter taste receptors.	Berberine	0-9	glucagon	Mus musculus	18-23
29363059-11	2018	Together, our data demonstrated a berberine-mediated GLP-1 secretion pathway in mouse enteroendocrine cells that could be of therapeutic relevance to hyperglycemia and the role of bitter taste receptors in the function of the small intestine.	Berberine	34-43	glucagon	Mus musculus	53-58
30250193-0	2018	Restoration of GLP-1 secretion by Berberine is associated with protection of colon enterocytes from mitochondrial overheating in diet-induced obese mice.	Berberine	34-43	glucagon	Mus musculus	15-20
30086269-0	2018	The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins.	Berberine	102-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-72
30086269-7	2018	Based on these findings, berberine in combination with statins has a greater inhibitory effect on CYP3A4 activity and CYP3A4 protein and mRNA expression than berberine alone.	Berberine	25-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
30086269-7	2018	Based on these findings, berberine in combination with statins has a greater inhibitory effect on CYP3A4 activity and CYP3A4 protein and mRNA expression than berberine alone.	Berberine	25-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
30086269-10	2018	These results indicate that berberine in combination with statins can increase cardiotoxicity by inhibiting CYP3A4 and hERG channel.	Berberine	28-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
30021340-12	2018	in vivo, berberine significantly reduced the levels of CRP, TNF-alpha and IL-6 in the patients" plasma.	Berberine	9-18	C-reactive protein	Homo sapiens	55-58
30021340-12	2018	in vivo, berberine significantly reduced the levels of CRP, TNF-alpha and IL-6 in the patients" plasma.	Berberine	9-18	tumor necrosis factor	Homo sapiens	60-69
30021340-12	2018	in vivo, berberine significantly reduced the levels of CRP, TNF-alpha and IL-6 in the patients" plasma.	Berberine	9-18	interleukin 6	Homo sapiens	74-78
30021340-13	2018	CONCLUSION: It was concluded that berberine therapy reduced myocardial injury partly by reducing myocardial autophagy and apoptosis through the AMPK/mTOR pathway.	Berberine	34-43	mechanistic target of rapamycin kinase	Homo sapiens	149-153
29365334-0	2018	Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway.	Berberine	0-9	toll-like receptor 4	Rattus norvegicus	74-78
30186432-0	2018	Therapeutic effect of berberine on renal ischemia-reperfusion injury in rats and its effect on Bax and Bcl-2.	Berberine	22-31	BCL2 associated X, apoptosis regulator	Rattus norvegicus	95-98
30186432-0	2018	Therapeutic effect of berberine on renal ischemia-reperfusion injury in rats and its effect on Bax and Bcl-2.	Berberine	22-31	BCL2, apoptosis regulator	Rattus norvegicus	103-108
30186432-1	2018	This study aimed to investigate the therapeutic effect of berberine on renal ischemia-reperfusion injury in rats and its effect on Bax and Bcl-2.	Berberine	58-67	BCL2 associated X, apoptosis regulator	Rattus norvegicus	131-134
30186432-1	2018	This study aimed to investigate the therapeutic effect of berberine on renal ischemia-reperfusion injury in rats and its effect on Bax and Bcl-2.	Berberine	58-67	BCL2, apoptosis regulator	Rattus norvegicus	139-144
30186432-13	2018	In conclusion, berberine can effectively improve renal function in rats with renal ischemia-reperfusion injury by inhibiting Bax expression and promoting Bcl-2 expression.	Berberine	15-24	BCL2 associated X, apoptosis regulator	Rattus norvegicus	125-128
30186432-13	2018	In conclusion, berberine can effectively improve renal function in rats with renal ischemia-reperfusion injury by inhibiting Bax expression and promoting Bcl-2 expression.	Berberine	15-24	BCL2, apoptosis regulator	Rattus norvegicus	154-159
30186485-12	2018	In conclusion, Berberine can inhibit the myocardium cell apoptosis of heart failure after myocardial infarction, and its mechanism may be realized by affecting the ERS in myocardial tissue of heart failure after myocardial infarction and CHOP and caspase-12 apoptotic signaling pathway, upregulating Bcl-2/Bax expression and downregulating caspase-3 expression, thus inhibiting the cardiac remodeling and protecting the cardiac function.	Berberine	15-24	DNA-damage inducible transcript 3	Rattus norvegicus	238-242
30186485-12	2018	In conclusion, Berberine can inhibit the myocardium cell apoptosis of heart failure after myocardial infarction, and its mechanism may be realized by affecting the ERS in myocardial tissue of heart failure after myocardial infarction and CHOP and caspase-12 apoptotic signaling pathway, upregulating Bcl-2/Bax expression and downregulating caspase-3 expression, thus inhibiting the cardiac remodeling and protecting the cardiac function.	Berberine	15-24	caspase 12	Rattus norvegicus	247-257
30186485-12	2018	In conclusion, Berberine can inhibit the myocardium cell apoptosis of heart failure after myocardial infarction, and its mechanism may be realized by affecting the ERS in myocardial tissue of heart failure after myocardial infarction and CHOP and caspase-12 apoptotic signaling pathway, upregulating Bcl-2/Bax expression and downregulating caspase-3 expression, thus inhibiting the cardiac remodeling and protecting the cardiac function.	Berberine	15-24	BCL2, apoptosis regulator	Rattus norvegicus	300-305
30186485-12	2018	In conclusion, Berberine can inhibit the myocardium cell apoptosis of heart failure after myocardial infarction, and its mechanism may be realized by affecting the ERS in myocardial tissue of heart failure after myocardial infarction and CHOP and caspase-12 apoptotic signaling pathway, upregulating Bcl-2/Bax expression and downregulating caspase-3 expression, thus inhibiting the cardiac remodeling and protecting the cardiac function.	Berberine	15-24	BCL2 associated X, apoptosis regulator	Rattus norvegicus	306-309
30186485-12	2018	In conclusion, Berberine can inhibit the myocardium cell apoptosis of heart failure after myocardial infarction, and its mechanism may be realized by affecting the ERS in myocardial tissue of heart failure after myocardial infarction and CHOP and caspase-12 apoptotic signaling pathway, upregulating Bcl-2/Bax expression and downregulating caspase-3 expression, thus inhibiting the cardiac remodeling and protecting the cardiac function.	Berberine	15-24	caspase 3	Rattus norvegicus	340-349
30027364-10	2018	Treatment with berberine significantly reduced cortical lesion volume, neuronal loss, COX-2, iNOS and 8-OHdG expression in both the cortical lesion border zone (LBZ) and ipsilateral hippocampal CA1 region (CA1), compared to TBI-saline.	Berberine	15-24	prostaglandin-endoperoxide synthase 2	Mus musculus	86-91
30027364-10	2018	Treatment with berberine significantly reduced cortical lesion volume, neuronal loss, COX-2, iNOS and 8-OHdG expression in both the cortical lesion border zone (LBZ) and ipsilateral hippocampal CA1 region (CA1), compared to TBI-saline.	Berberine	15-24	nitric oxide synthase 2, inducible	Mus musculus	93-97
30027364-10	2018	Treatment with berberine significantly reduced cortical lesion volume, neuronal loss, COX-2, iNOS and 8-OHdG expression in both the cortical lesion border zone (LBZ) and ipsilateral hippocampal CA1 region (CA1), compared to TBI-saline.	Berberine	15-24	carbonic anhydrase 1	Mus musculus	194-197
30027364-10	2018	Treatment with berberine significantly reduced cortical lesion volume, neuronal loss, COX-2, iNOS and 8-OHdG expression in both the cortical lesion border zone (LBZ) and ipsilateral hippocampal CA1 region (CA1), compared to TBI-saline.	Berberine	15-24	carbonic anhydrase 1	Mus musculus	206-209
30027364-11	2018	Berberine treatment also significantly decreased Iba1- and GFAP-positive cell number in both the cortical LBZ and ipsilateral CA1, relative to saline controls.	Berberine	0-9	allograft inflammatory factor 1	Mus musculus	49-53
30027364-11	2018	Berberine treatment also significantly decreased Iba1- and GFAP-positive cell number in both the cortical LBZ and ipsilateral CA1, relative to saline controls.	Berberine	0-9	carbonic anhydrase 1	Mus musculus	126-129
30104528-0	2018	Berberine Inhibits Human Melanoma A375.S2 Cell Migration and Invasion via Affecting the FAK, uPA, and NF-kappaB Signaling Pathways and Inhibits PLX4032 Resistant A375.S2 Cell Migration In Vitro.	Berberine	0-9	protein tyrosine kinase 2	Homo sapiens	88-91
29365334-7	2018	Berberine reversed these effects and inhibited LPS-induced TLR4/TNF-alpha activation, resulting in increased insulin receptor and insulin receptor substrate-1 expression in the liver.	Berberine	0-9	toll-like receptor 4	Rattus norvegicus	59-63
29365334-7	2018	Berberine reversed these effects and inhibited LPS-induced TLR4/TNF-alpha activation, resulting in increased insulin receptor and insulin receptor substrate-1 expression in the liver.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	64-73
29365334-8	2018	These findings suggested that berberine may reduce insulin resistance, at least in part by modulating the gut microbiota along with inhibiting LPS/TLR4/TNF-alpha signaling in the liver.	Berberine	30-39	toll-like receptor 4	Rattus norvegicus	147-151
29365334-8	2018	These findings suggested that berberine may reduce insulin resistance, at least in part by modulating the gut microbiota along with inhibiting LPS/TLR4/TNF-alpha signaling in the liver.	Berberine	30-39	tumor necrosis factor	Rattus norvegicus	152-161
30104528-0	2018	Berberine Inhibits Human Melanoma A375.S2 Cell Migration and Invasion via Affecting the FAK, uPA, and NF-kappaB Signaling Pathways and Inhibits PLX4032 Resistant A375.S2 Cell Migration In Vitro.	Berberine	0-9	proline rich acidic protein 1	Homo sapiens	93-96
30104528-5	2018	The gelatin zymography assay showed that berberine slightly inhibited MMP-9 activity in A375.S2 cells.	Berberine	41-50	matrix metallopeptidase 9	Homo sapiens	70-75
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	matrix metallopeptidase 1	Homo sapiens	83-88
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	matrix metallopeptidase 13	Homo sapiens	90-96
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	cadherin 1	Homo sapiens	98-108
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	cadherin 2	Homo sapiens	110-120
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	ras homolog family member A	Homo sapiens	122-126
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	128-133
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	SOS Ras/Rac guanine nucleotide exchange factor 1	Homo sapiens	135-140
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	growth factor receptor bound protein 2	Homo sapiens	142-146
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	mitogen-activated protein kinase 3	Homo sapiens	155-161
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	protein tyrosine kinase 2	Homo sapiens	174-177
30104528-6	2018	Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells.	Berberine	45-54	proline rich acidic protein 1	Homo sapiens	201-204
30068904-0	2018	Berberine ameliorates blockade of autophagic flux in the liver by regulating cholesterol metabolism and inhibiting COX2-prostaglandin synthesis.	Berberine	0-9	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	115-119
29980405-7	2018	Furthermore, the sensitivity to certain inhibitors which target: PI3K/mTORC1, PDK1, SRC, GSK-3, and biochemical processes such as proteasomal degradation and the nutraceutical berberine as increased upon introduction of WT-TP53.	Berberine	176-185	CREB regulated transcription coactivator 1	Mus musculus	70-76
29980405-7	2018	Furthermore, the sensitivity to certain inhibitors which target: PI3K/mTORC1, PDK1, SRC, GSK-3, and biochemical processes such as proteasomal degradation and the nutraceutical berberine as increased upon introduction of WT-TP53.	Berberine	176-185	tumor protein p53	Homo sapiens	223-227
30061203-8	2018	Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders.	Berberine	0-9	insulin	Homo sapiens	155-162
29732634-4	2018	Well-known pathways such as Pl3K/Akt/Bcl-2 pathway, Nrf2/HO-1 pathway, and MAPK signaling pathway help berberine to protect neurons through antiapoptotic, antioxidative, and anti-inflammatory activities.	Berberine	103-112	AKT serine/threonine kinase 1	Homo sapiens	33-36
30093307-0	2018	Berberine Reduces Pyruvate-driven Hepatic Glucose Production by Limiting Mitochondrial Import of Pyruvate through Mitochondrial Pyruvate Carrier 1.	Berberine	0-9	mitochondrial pyruvate carrier 1	Homo sapiens	114-146
30093307-3	2018	This study aims to investigate whether berberine could reduce excessive hepatic glucose production (HGP) by limiting mitochondrial import of pyruvate through MPC1.	Berberine	39-48	mitochondrial pyruvate carrier 1	Homo sapiens	158-162
30093307-9	2018	Berberine preserved the acetylation of MPC1 by suppression of SIRT3 induction and impaired MPC1 protein stabilization via protein degradation, resultantly limiting mitochondrial pyruvate supply for gluconeogenesis.	Berberine	0-9	mitochondrial pyruvate carrier 1	Homo sapiens	39-43
30093307-9	2018	Berberine preserved the acetylation of MPC1 by suppression of SIRT3 induction and impaired MPC1 protein stabilization via protein degradation, resultantly limiting mitochondrial pyruvate supply for gluconeogenesis.	Berberine	0-9	sirtuin 3	Homo sapiens	62-67
30093307-9	2018	Berberine preserved the acetylation of MPC1 by suppression of SIRT3 induction and impaired MPC1 protein stabilization via protein degradation, resultantly limiting mitochondrial pyruvate supply for gluconeogenesis.	Berberine	0-9	mitochondrial pyruvate carrier 1	Homo sapiens	91-95
30093307-10	2018	INTERPRETATION: Berberine reduced acetyl CoA contents by limiting fatty acid oxidation and increased MPC1 degradation via preserving acetylation, thereby restraining HGP by blocking mitochondrial import of pyruvate.	Berberine	16-25	mitochondrial pyruvate carrier 1	Homo sapiens	101-105
29508174-9	2018	Consistently, STAT3 inhibitor and berberine (a CXCL12 antagonist) also reduced CXCL12 treatment-induced apoptosis.	Berberine	34-43	C-X-C motif chemokine ligand 12	Homo sapiens	47-53
29508174-9	2018	Consistently, STAT3 inhibitor and berberine (a CXCL12 antagonist) also reduced CXCL12 treatment-induced apoptosis.	Berberine	34-43	C-X-C motif chemokine ligand 12	Homo sapiens	79-85
29645002-6	2018	Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) and long-chain fatty acid-CoA ligase 1 (ACSL1), two proteins involved in fatty acid metabolism, were expressed differently in the berberine8998 group than in the untreated group and the berberine treatment group.	Berberine	220-229	acyl-CoA oxidase 1	Rattus norvegicus	44-81
29645002-6	2018	Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) and long-chain fatty acid-CoA ligase 1 (ACSL1), two proteins involved in fatty acid metabolism, were expressed differently in the berberine8998 group than in the untreated group and the berberine treatment group.	Berberine	220-229	acyl-CoA oxidase 1	Rattus norvegicus	83-88
29645002-6	2018	Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) and long-chain fatty acid-CoA ligase 1 (ACSL1), two proteins involved in fatty acid metabolism, were expressed differently in the berberine8998 group than in the untreated group and the berberine treatment group.	Berberine	220-229	acyl-CoA synthetase long-chain family member 1	Rattus norvegicus	94-128
29645002-6	2018	Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) and long-chain fatty acid-CoA ligase 1 (ACSL1), two proteins involved in fatty acid metabolism, were expressed differently in the berberine8998 group than in the untreated group and the berberine treatment group.	Berberine	220-229	acyl-CoA synthetase long-chain family member 1	Rattus norvegicus	130-135
28679068-2	2018	In present study, berberine hydrochloride (BER) triggered proliferative inhibition and G2/M arrest in AGS cells, down-regulated protein expression of cyclin B1, Bcl-2, up-regulated expression of p21, p53 and cleaved caspase 3, but showed no effect on protein expression of CHOP, Bip, and caspase 4.	Berberine	43-46	cyclin B1	Homo sapiens	150-159
28679068-2	2018	In present study, berberine hydrochloride (BER) triggered proliferative inhibition and G2/M arrest in AGS cells, down-regulated protein expression of cyclin B1, Bcl-2, up-regulated expression of p21, p53 and cleaved caspase 3, but showed no effect on protein expression of CHOP, Bip, and caspase 4.	Berberine	43-46	BCL2 apoptosis regulator	Homo sapiens	161-166
28679068-2	2018	In present study, berberine hydrochloride (BER) triggered proliferative inhibition and G2/M arrest in AGS cells, down-regulated protein expression of cyclin B1, Bcl-2, up-regulated expression of p21, p53 and cleaved caspase 3, but showed no effect on protein expression of CHOP, Bip, and caspase 4.	Berberine	43-46	H3 histone pseudogene 16	Homo sapiens	195-198
28679068-2	2018	In present study, berberine hydrochloride (BER) triggered proliferative inhibition and G2/M arrest in AGS cells, down-regulated protein expression of cyclin B1, Bcl-2, up-regulated expression of p21, p53 and cleaved caspase 3, but showed no effect on protein expression of CHOP, Bip, and caspase 4.	Berberine	43-46	tumor protein p53	Homo sapiens	200-203
28679068-2	2018	In present study, berberine hydrochloride (BER) triggered proliferative inhibition and G2/M arrest in AGS cells, down-regulated protein expression of cyclin B1, Bcl-2, up-regulated expression of p21, p53 and cleaved caspase 3, but showed no effect on protein expression of CHOP, Bip, and caspase 4.	Berberine	43-46	caspase 3	Homo sapiens	216-225
28679068-2	2018	In present study, berberine hydrochloride (BER) triggered proliferative inhibition and G2/M arrest in AGS cells, down-regulated protein expression of cyclin B1, Bcl-2, up-regulated expression of p21, p53 and cleaved caspase 3, but showed no effect on protein expression of CHOP, Bip, and caspase 4.	Berberine	43-46	DNA damage inducible transcript 3	Homo sapiens	273-277
28679068-2	2018	In present study, berberine hydrochloride (BER) triggered proliferative inhibition and G2/M arrest in AGS cells, down-regulated protein expression of cyclin B1, Bcl-2, up-regulated expression of p21, p53 and cleaved caspase 3, but showed no effect on protein expression of CHOP, Bip, and caspase 4.	Berberine	43-46	growth differentiation factor 10	Homo sapiens	279-282
28679068-2	2018	In present study, berberine hydrochloride (BER) triggered proliferative inhibition and G2/M arrest in AGS cells, down-regulated protein expression of cyclin B1, Bcl-2, up-regulated expression of p21, p53 and cleaved caspase 3, but showed no effect on protein expression of CHOP, Bip, and caspase 4.	Berberine	43-46	caspase 4	Homo sapiens	288-297
29732634-4	2018	Well-known pathways such as Pl3K/Akt/Bcl-2 pathway, Nrf2/HO-1 pathway, and MAPK signaling pathway help berberine to protect neurons through antiapoptotic, antioxidative, and anti-inflammatory activities.	Berberine	103-112	BCL2 apoptosis regulator	Homo sapiens	37-42
29732634-4	2018	Well-known pathways such as Pl3K/Akt/Bcl-2 pathway, Nrf2/HO-1 pathway, and MAPK signaling pathway help berberine to protect neurons through antiapoptotic, antioxidative, and anti-inflammatory activities.	Berberine	103-112	NFE2 like bZIP transcription factor 2	Homo sapiens	52-56
29732634-4	2018	Well-known pathways such as Pl3K/Akt/Bcl-2 pathway, Nrf2/HO-1 pathway, and MAPK signaling pathway help berberine to protect neurons through antiapoptotic, antioxidative, and anti-inflammatory activities.	Berberine	103-112	heme oxygenase 1	Homo sapiens	57-61
29604589-0	2018	Oncosis-like cell death is induced by berberine through ERK1/2-mediated impairment of mitochondrial aerobic respiration in gliomas.	Berberine	38-47	mitogen-activated protein kinase 3	Homo sapiens	56-62
29891588-0	2018	Berberine Upregulates P-Glycoprotein in Human Caco-2 Cells and in an Experimental Model of Colitis in the Rat via Activation of Nrf2-Dependent Mechanisms.	Berberine	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	22-36
29891588-0	2018	Berberine Upregulates P-Glycoprotein in Human Caco-2 Cells and in an Experimental Model of Colitis in the Rat via Activation of Nrf2-Dependent Mechanisms.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	128-132
29891588-3	2018	In this study, we used a dextran sulfate sodium (DSS)-induced colitis rat model to evaluate the effect of berberine on P-gp and explore its mechanism of action.	Berberine	106-115	phosphoglycolate phosphatase	Rattus norvegicus	119-123
29891588-4	2018	Berberine treatment improved DSS-induced colitis symptoms, attenuated inflammatory markers (myeloperoxidase, tumor necrosis factor-alpha, and interleukin-1beta and -6), and enhanced P-gp expression in a dose-dependent manner.	Berberine	0-9	myeloperoxidase	Homo sapiens	92-107
29891588-4	2018	Berberine treatment improved DSS-induced colitis symptoms, attenuated inflammatory markers (myeloperoxidase, tumor necrosis factor-alpha, and interleukin-1beta and -6), and enhanced P-gp expression in a dose-dependent manner.	Berberine	0-9	tumor necrosis factor	Homo sapiens	109-136
29891588-4	2018	Berberine treatment improved DSS-induced colitis symptoms, attenuated inflammatory markers (myeloperoxidase, tumor necrosis factor-alpha, and interleukin-1beta and -6), and enhanced P-gp expression in a dose-dependent manner.	Berberine	0-9	interleukin 1 beta	Homo sapiens	142-166
29891588-4	2018	Berberine treatment improved DSS-induced colitis symptoms, attenuated inflammatory markers (myeloperoxidase, tumor necrosis factor-alpha, and interleukin-1beta and -6), and enhanced P-gp expression in a dose-dependent manner.	Berberine	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	182-186
29891588-5	2018	Although colonic expression of the P-gp-related nuclear receptor pregnane X receptor and transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) were downregulated in the colitis model, gene and protein expression analysis revealed that berberine treatment reversed only the downregulation of Nrf2.	Berberine	253-262	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
29891588-5	2018	Although colonic expression of the P-gp-related nuclear receptor pregnane X receptor and transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) were downregulated in the colitis model, gene and protein expression analysis revealed that berberine treatment reversed only the downregulation of Nrf2.	Berberine	253-262	NFE2 like bZIP transcription factor 2	Homo sapiens	110-153
29891588-5	2018	Although colonic expression of the P-gp-related nuclear receptor pregnane X receptor and transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) were downregulated in the colitis model, gene and protein expression analysis revealed that berberine treatment reversed only the downregulation of Nrf2.	Berberine	253-262	NFE2 like bZIP transcription factor 2	Homo sapiens	155-159
29891588-5	2018	Although colonic expression of the P-gp-related nuclear receptor pregnane X receptor and transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) were downregulated in the colitis model, gene and protein expression analysis revealed that berberine treatment reversed only the downregulation of Nrf2.	Berberine	253-262	NFE2 like bZIP transcription factor 2	Homo sapiens	309-313
29891588-6	2018	In vitro studies using Caco-2 cells showed that the multidrug resistance 1 (MDR1) gene and P-gp protein were upregulated by berberine in a dose- and time-dependent manner.	Berberine	124-133	ATP binding cassette subfamily B member 1	Homo sapiens	52-74
29891588-6	2018	In vitro studies using Caco-2 cells showed that the multidrug resistance 1 (MDR1) gene and P-gp protein were upregulated by berberine in a dose- and time-dependent manner.	Berberine	124-133	ATP binding cassette subfamily B member 1	Homo sapiens	76-80
29891588-6	2018	In vitro studies using Caco-2 cells showed that the multidrug resistance 1 (MDR1) gene and P-gp protein were upregulated by berberine in a dose- and time-dependent manner.	Berberine	124-133	ATP binding cassette subfamily B member 1	Homo sapiens	91-95
29891588-7	2018	Significant upregulation of the MDR1 gene by berberine was abrogated by Nrf2 silencing, indicating that the Nrf2-mediated pathway was responsible for this activation.	Berberine	45-54	ATP binding cassette subfamily B member 1	Homo sapiens	32-36
29891588-7	2018	Significant upregulation of the MDR1 gene by berberine was abrogated by Nrf2 silencing, indicating that the Nrf2-mediated pathway was responsible for this activation.	Berberine	45-54	NFE2 like bZIP transcription factor 2	Homo sapiens	72-76
29891588-7	2018	Significant upregulation of the MDR1 gene by berberine was abrogated by Nrf2 silencing, indicating that the Nrf2-mediated pathway was responsible for this activation.	Berberine	45-54	NFE2 like bZIP transcription factor 2	Homo sapiens	108-112
29891588-8	2018	Luciferase assays showed a dose-dependent increase in Nrf2 reporter gene activity after berberine treatment in Caco-2 cells, with a significant 2-fold elevation at 2.5 muM berberine, suggesting that berberine is a strong Nrf2 activator.	Berberine	88-97	NFE2 like bZIP transcription factor 2	Homo sapiens	54-58
29891588-8	2018	Luciferase assays showed a dose-dependent increase in Nrf2 reporter gene activity after berberine treatment in Caco-2 cells, with a significant 2-fold elevation at 2.5 muM berberine, suggesting that berberine is a strong Nrf2 activator.	Berberine	88-97	NFE2 like bZIP transcription factor 2	Homo sapiens	221-225
29891588-8	2018	Luciferase assays showed a dose-dependent increase in Nrf2 reporter gene activity after berberine treatment in Caco-2 cells, with a significant 2-fold elevation at 2.5 muM berberine, suggesting that berberine is a strong Nrf2 activator.	Berberine	172-181	NFE2 like bZIP transcription factor 2	Homo sapiens	54-58
29891588-8	2018	Luciferase assays showed a dose-dependent increase in Nrf2 reporter gene activity after berberine treatment in Caco-2 cells, with a significant 2-fold elevation at 2.5 muM berberine, suggesting that berberine is a strong Nrf2 activator.	Berberine	172-181	NFE2 like bZIP transcription factor 2	Homo sapiens	221-225
29891588-8	2018	Luciferase assays showed a dose-dependent increase in Nrf2 reporter gene activity after berberine treatment in Caco-2 cells, with a significant 2-fold elevation at 2.5 muM berberine, suggesting that berberine is a strong Nrf2 activator.	Berberine	172-181	NFE2 like bZIP transcription factor 2	Homo sapiens	54-58
29891588-8	2018	Luciferase assays showed a dose-dependent increase in Nrf2 reporter gene activity after berberine treatment in Caco-2 cells, with a significant 2-fold elevation at 2.5 muM berberine, suggesting that berberine is a strong Nrf2 activator.	Berberine	172-181	NFE2 like bZIP transcription factor 2	Homo sapiens	221-225
29891588-9	2018	These results indicate the possible involvement of Nrf2-mediated upregulation of P-gp in the therapeutic effect of berberine on colitis and highlight the potential of P-gp and/or Nrf2 as new therapeutic targets for IBD.	Berberine	115-124	NFE2 like bZIP transcription factor 2	Homo sapiens	51-55
29891588-9	2018	These results indicate the possible involvement of Nrf2-mediated upregulation of P-gp in the therapeutic effect of berberine on colitis and highlight the potential of P-gp and/or Nrf2 as new therapeutic targets for IBD.	Berberine	115-124	ATP binding cassette subfamily B member 1	Homo sapiens	81-85
30087941-0	2018	Drug-Carrying Capacity and Anticancer Effect of the Folic Acid- and Berberine-Loaded Silver Nanomaterial To Regulate the AKT-ERK Pathway in Breast Cancer.	Berberine	68-77	AKT serine/threonine kinase 1	Homo sapiens	121-124
30087941-0	2018	Drug-Carrying Capacity and Anticancer Effect of the Folic Acid- and Berberine-Loaded Silver Nanomaterial To Regulate the AKT-ERK Pathway in Breast Cancer.	Berberine	68-77	mitogen-activated protein kinase 1	Homo sapiens	125-128
30087614-8	2018	Further study indicated that berberine acted as a high-affinity BACE1 inhibitor and prevented Abeta1-42 aggregation to delay the pathological process of Alzheimer"s disease.	Berberine	29-38	beta-secretase 1	Homo sapiens	64-69
30061836-0	2018	Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	89-126
29679725-14	2018	CONCLUSIONS: The enhanced articular distribution of berberine in SMW was attributed to the lower-guiding effect of ABR, which could evidently increase the plasma concentration of berberine, improve the supply of blood of inflamed joint, reduce the distribution of berberine in heart and lung and significantly inhibit the MDR1 mRNA and P-gp expression of synovial tissues of knee joints in AGA rats.	Berberine	52-61	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	322-326
29679725-14	2018	CONCLUSIONS: The enhanced articular distribution of berberine in SMW was attributed to the lower-guiding effect of ABR, which could evidently increase the plasma concentration of berberine, improve the supply of blood of inflamed joint, reduce the distribution of berberine in heart and lung and significantly inhibit the MDR1 mRNA and P-gp expression of synovial tissues of knee joints in AGA rats.	Berberine	52-61	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	336-340
30006630-5	2018	Berberine also affects cell cycle progression, senescence, caspase-3 activity, autophagy and migration in a cell-specific manner.	Berberine	0-9	caspase 3	Homo sapiens	59-68
30006630-6	2018	In particular, in HDF it induces cell cycle arrest in G2 and senescence, but not autophagy; in the U343 cells, berberine leads to cell cycle arrest in G2 and induces both senescence and autophagy; in MIA PaCa-2 cells, the alkaloid induces arrest in G1, senescence, autophagy, it increases caspase-3 activity and impairs migration/invasion.	Berberine	111-120	caspase 3	Homo sapiens	289-298
30006630-7	2018	As demonstrated by decreased citrate synthase activity, the three cell lines show mitochondrial dysfunction following berberine exposure.	Berberine	118-127	citrate synthase	Homo sapiens	29-45
29790698-0	2018	Inhibition of migration and invasion by berberine via inactivation of PI3K/Akt and p38 in human retinoblastoma cell line.	Berberine	40-49	AKT serine/threonine kinase 1	Homo sapiens	75-78
29790698-0	2018	Inhibition of migration and invasion by berberine via inactivation of PI3K/Akt and p38 in human retinoblastoma cell line.	Berberine	40-49	mitogen-activated protein kinase 14	Homo sapiens	83-86
29790698-0	2018	Inhibition of migration and invasion by berberine via inactivation of PI3K/Akt and p38 in human retinoblastoma cell line.	Berberine	40-49	RB transcriptional corepressor 1	Homo sapiens	96-110
29790698-2	2018	OBJECTIVES: This study was aimed to investigate the effect of berberine on cell migration and invasion in human retinoblastoma (Rb) cells.	Berberine	62-71	RB transcriptional corepressor 1	Homo sapiens	112-126
29790698-11	2018	Berberine remarkably down-regulated expression of E-cadherin and up-regulated expression of vimentin and alpha-SMA compared to the control (p &lt; 0.01 or p &lt; 0.001).	Berberine	0-9	cadherin 1	Homo sapiens	50-60
29790698-11	2018	Berberine remarkably down-regulated expression of E-cadherin and up-regulated expression of vimentin and alpha-SMA compared to the control (p &lt; 0.01 or p &lt; 0.001).	Berberine	0-9	vimentin	Homo sapiens	92-100
29790698-12	2018	Furthermore, the phosphorylation levels of Akt and p38 were both down-regulated by berberine in comparison to the control.	Berberine	83-92	AKT serine/threonine kinase 1	Homo sapiens	43-46
29790698-12	2018	Furthermore, the phosphorylation levels of Akt and p38 were both down-regulated by berberine in comparison to the control.	Berberine	83-92	mitogen-activated protein kinase 14	Homo sapiens	51-54
29790698-14	2018	CONCLUSIONS: Berberine suppressed cell migration and invasion via inactivation of PI3K/Akt and p38.	Berberine	13-22	AKT serine/threonine kinase 1	Homo sapiens	87-90
29790698-14	2018	CONCLUSIONS: Berberine suppressed cell migration and invasion via inactivation of PI3K/Akt and p38.	Berberine	13-22	mitogen-activated protein kinase 14	Homo sapiens	95-98
29345340-0	2018	Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor.	Berberine	0-9	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	162-186
29988733-5	2018	Results: The results indicated that BS20 could significantly enhance the intracellular uptake of BBR in MDCK-MDR1 cells via a short-term and reversible modulation on the Pgp function, accompanied by a marked increase in Pgp mRNA expression but without significant influence on the Pgp protein expression.	Berberine	97-100	ATP binding cassette subfamily B member 1	Canis lupus familiaris	109-113
29988733-5	2018	Results: The results indicated that BS20 could significantly enhance the intracellular uptake of BBR in MDCK-MDR1 cells via a short-term and reversible modulation on the Pgp function, accompanied by a marked increase in Pgp mRNA expression but without significant influence on the Pgp protein expression.	Berberine	97-100	PGP	Canis lupus familiaris	170-173
29988733-5	2018	Results: The results indicated that BS20 could significantly enhance the intracellular uptake of BBR in MDCK-MDR1 cells via a short-term and reversible modulation on the Pgp function, accompanied by a marked increase in Pgp mRNA expression but without significant influence on the Pgp protein expression.	Berberine	97-100	PGP	Canis lupus familiaris	220-223
29988733-5	2018	Results: The results indicated that BS20 could significantly enhance the intracellular uptake of BBR in MDCK-MDR1 cells via a short-term and reversible modulation on the Pgp function, accompanied by a marked increase in Pgp mRNA expression but without significant influence on the Pgp protein expression.	Berberine	97-100	PGP	Canis lupus familiaris	220-223
29882814-0	2018	Berberine Protects against NEFA-Induced Impairment of Mitochondrial Respiratory Chain Function and Insulin Signaling in Bovine Hepatocytes.	Berberine	0-9	insulin	Bos taurus	99-106
29882814-2	2018	Berberine (BBR) has been reported to improve insulin sensitivity in mice with hepatic steatosis.	Berberine	0-9	insulin	Bos taurus	45-52
29882814-2	2018	Berberine (BBR) has been reported to improve insulin sensitivity in mice with hepatic steatosis.	Berberine	11-14	insulin	Bos taurus	45-52
29747507-6	2018	However, the expression, maturation, as well as the specific DNA binding capacity of their coordinate transcription factor, sterol response element binding protein 2 (SREBP2), was not affected by Rhizoma Coptidis extract (RCE) or its typical active alkaloid berberine.	Berberine	258-267	sterol regulatory element binding transcription factor 2	Homo sapiens	167-173
29604589-4	2018	We also found that berberine induced autophagy as a protective effect and decreased the oxygen consumption rate (OCR), which could inhibit mitochondrial aerobic respiration by repressing phosphorylated extracellular regulated protein kinases (p-ERK1/2).	Berberine	19-28	mitogen-activated protein kinase 3	Homo sapiens	245-251
29604589-5	2018	Furthermore, the down-regulation of mitochondrial p-ERK1/2 by berberine inhibited aerobic respiration and led to glycolysis, an inefficient energy production pathway.	Berberine	62-71	mitogen-activated protein kinase 3	Homo sapiens	52-58
29604589-6	2018	In addition, berberine reduced tumor growth and inhibited Ki-67 and p-ERK1/2 expression in vivo.	Berberine	13-22	mitogen-activated protein kinase 3	Homo sapiens	70-76
29604589-7	2018	The results demonstrate that berberine, which represses aerobic oxidation in mitochondria and decreases their energy production efficiency, decreases metabolic activity by reducing ERK1/2 activity.	Berberine	29-38	mitogen-activated protein kinase 3	Homo sapiens	181-187
29549724-1	2018	The current study investigated the therapeutic effect of berberine (BBR), an alkaloid derivative against IL-21/IL-21R mediated phosphotidyl inositol 3 kinase/protein kinase B (PI3K/Akt) signaling in adjuvant induced arthritic fibroblast-like synoviocytes (AA-FLS) isolated from rats and IL-21 mediated osteoclastogenesis in bone-marrow derived monocytes (BMMs).	Berberine	57-66	AKT serine/threonine kinase 1	Rattus norvegicus	181-184
29549724-1	2018	The current study investigated the therapeutic effect of berberine (BBR), an alkaloid derivative against IL-21/IL-21R mediated phosphotidyl inositol 3 kinase/protein kinase B (PI3K/Akt) signaling in adjuvant induced arthritic fibroblast-like synoviocytes (AA-FLS) isolated from rats and IL-21 mediated osteoclastogenesis in bone-marrow derived monocytes (BMMs).	Berberine	57-66	interleukin 21	Rattus norvegicus	111-116
29549724-1	2018	The current study investigated the therapeutic effect of berberine (BBR), an alkaloid derivative against IL-21/IL-21R mediated phosphotidyl inositol 3 kinase/protein kinase B (PI3K/Akt) signaling in adjuvant induced arthritic fibroblast-like synoviocytes (AA-FLS) isolated from rats and IL-21 mediated osteoclastogenesis in bone-marrow derived monocytes (BMMs).	Berberine	68-71	interleukin 21	Rattus norvegicus	105-110
29549724-1	2018	The current study investigated the therapeutic effect of berberine (BBR), an alkaloid derivative against IL-21/IL-21R mediated phosphotidyl inositol 3 kinase/protein kinase B (PI3K/Akt) signaling in adjuvant induced arthritic fibroblast-like synoviocytes (AA-FLS) isolated from rats and IL-21 mediated osteoclastogenesis in bone-marrow derived monocytes (BMMs).	Berberine	68-71	interleukin 21 receptor	Rattus norvegicus	111-117
29549724-1	2018	The current study investigated the therapeutic effect of berberine (BBR), an alkaloid derivative against IL-21/IL-21R mediated phosphotidyl inositol 3 kinase/protein kinase B (PI3K/Akt) signaling in adjuvant induced arthritic fibroblast-like synoviocytes (AA-FLS) isolated from rats and IL-21 mediated osteoclastogenesis in bone-marrow derived monocytes (BMMs).	Berberine	68-71	AKT serine/threonine kinase 1	Rattus norvegicus	181-184
29549724-1	2018	The current study investigated the therapeutic effect of berberine (BBR), an alkaloid derivative against IL-21/IL-21R mediated phosphotidyl inositol 3 kinase/protein kinase B (PI3K/Akt) signaling in adjuvant induced arthritic fibroblast-like synoviocytes (AA-FLS) isolated from rats and IL-21 mediated osteoclastogenesis in bone-marrow derived monocytes (BMMs).	Berberine	68-71	interleukin 21	Rattus norvegicus	111-116
29687521-1	2018	BACKGROUND: Berberine downregulated miR-19a/92a cluster expression in multiple myeloma (MM) cells.	Berberine	12-21	microRNA 19a	Homo sapiens	36-43
29687521-7	2018	RESULTS: Berberine inhibited the cell viability of MM cells and downregulated the expression of miR-19a/92a.	Berberine	9-18	microRNA 19a	Homo sapiens	96-103
29680964-0	2018	Berberine protects renal tubular cells against hypoxia/reoxygenation injury via the Sirt1/p53 pathway.	Berberine	0-9	sirtuin 1	Rattus norvegicus	84-89
29680964-0	2018	Berberine protects renal tubular cells against hypoxia/reoxygenation injury via the Sirt1/p53 pathway.	Berberine	0-9	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	90-93
29680964-2	2018	In the present study, we examined the role of silent information regulator 1 (Sirt1)/p53 in the protective effect of BBR on hypoxia/reoxygenation (H/R)-mediated mitochondrial dysfunction in rat renal tubular epithelial cells (NRK-52E cells).	Berberine	117-120	sirtuin 1	Rattus norvegicus	78-83
29680964-2	2018	In the present study, we examined the role of silent information regulator 1 (Sirt1)/p53 in the protective effect of BBR on hypoxia/reoxygenation (H/R)-mediated mitochondrial dysfunction in rat renal tubular epithelial cells (NRK-52E cells).	Berberine	117-120	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	85-88
29680964-10	2018	Furthermore, both nuclear translocation of p53 and its acetylation were inhibited in NRK-52E cells pretreated with BBR.	Berberine	115-118	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	43-46
29680964-11	2018	However, the knockdown of Sirt1 counteracted the renoprotection of BBR.	Berberine	67-70	sirtuin 1	Rattus norvegicus	26-31
28782427-0	2018	Berberine Improves Diabetic Encephalopathy Through the SIRT1/ER Stress Pathway in db/db Mice.	Berberine	0-9	sirtuin 1	Mus musculus	55-60
29549724-0	2018	Berberine inhibits IL-21/IL-21R mediated inflammatory proliferation of fibroblast-like synoviocytes through the attenuation of PI3K/Akt signaling pathway and ameliorates IL-21 mediated osteoclastogenesis.	Berberine	0-9	interleukin 21	Rattus norvegicus	19-24
29549724-0	2018	Berberine inhibits IL-21/IL-21R mediated inflammatory proliferation of fibroblast-like synoviocytes through the attenuation of PI3K/Akt signaling pathway and ameliorates IL-21 mediated osteoclastogenesis.	Berberine	0-9	interleukin 21 receptor	Rattus norvegicus	25-31
29549724-0	2018	Berberine inhibits IL-21/IL-21R mediated inflammatory proliferation of fibroblast-like synoviocytes through the attenuation of PI3K/Akt signaling pathway and ameliorates IL-21 mediated osteoclastogenesis.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	132-135
29549724-0	2018	Berberine inhibits IL-21/IL-21R mediated inflammatory proliferation of fibroblast-like synoviocytes through the attenuation of PI3K/Akt signaling pathway and ameliorates IL-21 mediated osteoclastogenesis.	Berberine	0-9	interleukin 21	Rattus norvegicus	25-30
29549724-1	2018	The current study investigated the therapeutic effect of berberine (BBR), an alkaloid derivative against IL-21/IL-21R mediated phosphotidyl inositol 3 kinase/protein kinase B (PI3K/Akt) signaling in adjuvant induced arthritic fibroblast-like synoviocytes (AA-FLS) isolated from rats and IL-21 mediated osteoclastogenesis in bone-marrow derived monocytes (BMMs).	Berberine	57-66	interleukin 21	Rattus norvegicus	105-110
29549724-1	2018	The current study investigated the therapeutic effect of berberine (BBR), an alkaloid derivative against IL-21/IL-21R mediated phosphotidyl inositol 3 kinase/protein kinase B (PI3K/Akt) signaling in adjuvant induced arthritic fibroblast-like synoviocytes (AA-FLS) isolated from rats and IL-21 mediated osteoclastogenesis in bone-marrow derived monocytes (BMMs).	Berberine	57-66	interleukin 21 receptor	Rattus norvegicus	111-117
29565467-0	2018	Berberine decelerates glucose metabolism via suppression of mTOR-dependent HIF-1alpha protein synthesis in colon cancer cells.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	60-64
29565467-0	2018	Berberine decelerates glucose metabolism via suppression of mTOR-dependent HIF-1alpha protein synthesis in colon cancer cells.	Berberine	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	75-85
29565467-4	2018	In the present study, we revealed that berberine, which suppressed the growth of colon cancer cell lines HCT116 and KM12C, greatly inhibited the glucose uptake and the transcription of glucose metabolic genes, GLUT1, LDHA and HK2 in these two cell lines as assessed by RT-qPCR.	Berberine	39-48	solute carrier family 2 member 1	Homo sapiens	210-215
29565467-4	2018	In the present study, we revealed that berberine, which suppressed the growth of colon cancer cell lines HCT116 and KM12C, greatly inhibited the glucose uptake and the transcription of glucose metabolic genes, GLUT1, LDHA and HK2 in these two cell lines as assessed by RT-qPCR.	Berberine	39-48	lactate dehydrogenase A	Homo sapiens	217-221
29565467-4	2018	In the present study, we revealed that berberine, which suppressed the growth of colon cancer cell lines HCT116 and KM12C, greatly inhibited the glucose uptake and the transcription of glucose metabolic genes, GLUT1, LDHA and HK2 in these two cell lines as assessed by RT-qPCR.	Berberine	39-48	hexokinase 2	Homo sapiens	226-229
29565467-7	2018	In addition, mTOR signaling previously reported to regulate HIF-1alpha protein synthesis was further found to be suppressed by berberine.	Berberine	127-136	mechanistic target of rapamycin kinase	Homo sapiens	13-17
29565467-7	2018	In addition, mTOR signaling previously reported to regulate HIF-1alpha protein synthesis was further found to be suppressed by berberine.	Berberine	127-136	hypoxia inducible factor 1 subunit alpha	Homo sapiens	60-70
29565467-8	2018	Taken together, our results indicated that berberine inhibits overactive glucose metabolism of colon cancer cells via suppressing mTOR-depended HIF-1alpha protein synthesis, which provided not only a novel mechanism involved in berberine"s tumor-specific toxicity but also a theoretical basis for the development of berberine for colon cancer treatment.	Berberine	43-52	mechanistic target of rapamycin kinase	Homo sapiens	130-134
29565467-8	2018	Taken together, our results indicated that berberine inhibits overactive glucose metabolism of colon cancer cells via suppressing mTOR-depended HIF-1alpha protein synthesis, which provided not only a novel mechanism involved in berberine"s tumor-specific toxicity but also a theoretical basis for the development of berberine for colon cancer treatment.	Berberine	43-52	hypoxia inducible factor 1 subunit alpha	Homo sapiens	144-154
29565467-8	2018	Taken together, our results indicated that berberine inhibits overactive glucose metabolism of colon cancer cells via suppressing mTOR-depended HIF-1alpha protein synthesis, which provided not only a novel mechanism involved in berberine"s tumor-specific toxicity but also a theoretical basis for the development of berberine for colon cancer treatment.	Berberine	228-237	mechanistic target of rapamycin kinase	Homo sapiens	130-134
29565467-8	2018	Taken together, our results indicated that berberine inhibits overactive glucose metabolism of colon cancer cells via suppressing mTOR-depended HIF-1alpha protein synthesis, which provided not only a novel mechanism involved in berberine"s tumor-specific toxicity but also a theoretical basis for the development of berberine for colon cancer treatment.	Berberine	228-237	mechanistic target of rapamycin kinase	Homo sapiens	130-134
29899701-0	2018	Berberine Attenuates Macrophages Infiltration in Intracranial Aneurysms Potentially Through FAK/Grp78/UPR Axis.	Berberine	0-9	protein tyrosine kinase 2	Rattus norvegicus	92-95
29899701-0	2018	Berberine Attenuates Macrophages Infiltration in Intracranial Aneurysms Potentially Through FAK/Grp78/UPR Axis.	Berberine	0-9	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	96-101
29873328-0	2018	Correction: Berberine-targeted miR-21 chemosensitizes oral carcinomas stem cells.	Berberine	12-21	microRNA 21	Homo sapiens	31-37
29626488-0	2018	Berberine induced modulation of PHLPP2-Akt-MST1 kinase signaling is coupled with mitochondrial impairment and hepatoma cell death.	Berberine	0-9	PH domain and leucine rich repeat protein phosphatase 2	Homo sapiens	32-38
29626488-0	2018	Berberine induced modulation of PHLPP2-Akt-MST1 kinase signaling is coupled with mitochondrial impairment and hepatoma cell death.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	39-42
29626488-0	2018	Berberine induced modulation of PHLPP2-Akt-MST1 kinase signaling is coupled with mitochondrial impairment and hepatoma cell death.	Berberine	0-9	macrophage stimulating 1	Homo sapiens	43-47
29626488-4	2018	Present study decoded the crucial role of PHLPP2 in inducing apoptosis by its interaction with the newly found binding partner Mammalian sterile 20-like kinase 1 (Mst1) in berberine (BBR)-treated human hepatoma cells.	Berberine	172-181	PH domain and leucine rich repeat protein phosphatase 2	Homo sapiens	42-48
29626488-4	2018	Present study decoded the crucial role of PHLPP2 in inducing apoptosis by its interaction with the newly found binding partner Mammalian sterile 20-like kinase 1 (Mst1) in berberine (BBR)-treated human hepatoma cells.	Berberine	172-181	macrophage stimulating 1	Homo sapiens	163-167
29626488-4	2018	Present study decoded the crucial role of PHLPP2 in inducing apoptosis by its interaction with the newly found binding partner Mammalian sterile 20-like kinase 1 (Mst1) in berberine (BBR)-treated human hepatoma cells.	Berberine	183-186	PH domain and leucine rich repeat protein phosphatase 2	Homo sapiens	42-48
29626488-4	2018	Present study decoded the crucial role of PHLPP2 in inducing apoptosis by its interaction with the newly found binding partner Mammalian sterile 20-like kinase 1 (Mst1) in berberine (BBR)-treated human hepatoma cells.	Berberine	183-186	macrophage stimulating 1	Homo sapiens	163-167
29626488-6	2018	The results showed enhanced expression of PHLPP2 at transcriptional (2.13 fold, P &lt; 0.01) and translational level (4 fold, P &lt; 0.001), but not of PHLPP1, in berberine-treated HepG2 cells.	Berberine	163-172	PH domain and leucine rich repeat protein phosphatase 2	Homo sapiens	42-48
29626488-10	2018	Further, PHLPP2/Mst1 knock-down efficiently curtailed anti-proliferative effect of berberine by restoring the basal level of downstream anti-apoptotic proteins.	Berberine	83-92	PH domain and leucine rich repeat protein phosphatase 2	Homo sapiens	9-15
29626488-10	2018	Further, PHLPP2/Mst1 knock-down efficiently curtailed anti-proliferative effect of berberine by restoring the basal level of downstream anti-apoptotic proteins.	Berberine	83-92	macrophage stimulating 1	Homo sapiens	16-20
29626488-12	2018	Thus, our findings suggest that PHLPP2, Akt and Mst1 constitute an autoinhibitory triangle which may be partly responsible for antiproliferative effect of berberine.	Berberine	155-164	PH domain and leucine rich repeat protein phosphatase 2	Homo sapiens	32-38
29626488-12	2018	Thus, our findings suggest that PHLPP2, Akt and Mst1 constitute an autoinhibitory triangle which may be partly responsible for antiproliferative effect of berberine.	Berberine	155-164	AKT serine/threonine kinase 1	Homo sapiens	40-43
29626488-12	2018	Thus, our findings suggest that PHLPP2, Akt and Mst1 constitute an autoinhibitory triangle which may be partly responsible for antiproliferative effect of berberine.	Berberine	155-164	macrophage stimulating 1	Homo sapiens	48-52
29758057-9	2018	The induction of glycolytic metabolism in C2C12 cells with high glucose concentration or treatment with berberine caused a significant increase in the ANKK1 mRNA.	Berberine	104-113	ankyrin repeat and kinase domain containing 1	Mus musculus	151-156
29525677-2	2018	Several studies have suggested that dietary antioxidants (such as polyphenols and berberine) may counteract oxidative stress through the involvement of the Sirtuin 1/Adenosine Monophosphate-Activated Protein Kinase (SIRT1/AMPK) pathway.	Berberine	82-91	sirtuin 1	Homo sapiens	156-214
29525677-2	2018	Several studies have suggested that dietary antioxidants (such as polyphenols and berberine) may counteract oxidative stress through the involvement of the Sirtuin 1/Adenosine Monophosphate-Activated Protein Kinase (SIRT1/AMPK) pathway.	Berberine	82-91	sirtuin 1	Homo sapiens	216-221
29525677-2	2018	Several studies have suggested that dietary antioxidants (such as polyphenols and berberine) may counteract oxidative stress through the involvement of the Sirtuin 1/Adenosine Monophosphate-Activated Protein Kinase (SIRT1/AMPK) pathway.	Berberine	82-91	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	222-226
29512719-0	2018	Neuroprotective effect of berberine agonist against impairment of learning and memory skills in severe traumatic brain injury via Sirt1/p38 MAPK expression.	Berberine	26-35	mitogen-activated protein kinase 14	Mus musculus	136-139
29512719-3	2018	The protective effect of berberine agonist significantly recovered learning and memory skills, attenuated brain edema and inhibited matrix metalloproteinase-3 and -9 protein expression in mice with severe TBI.	Berberine	25-34	matrix metallopeptidase 3	Mus musculus	132-165
29512719-5	2018	Berberine agonist promoted choline acetyltransferase activity and inhibited the activity of acetylcholinesterase.	Berberine	0-9	choline acetyltransferase	Mus musculus	27-52
29512719-5	2018	Berberine agonist promoted choline acetyltransferase activity and inhibited the activity of acetylcholinesterase.	Berberine	0-9	acetylcholinesterase	Mus musculus	92-112
29724298-2	2018	In the present study, we examined the inhibitory effect of berberine on alpha-melanocyte-stimulating hormone (alpha-MSH)-induced melanogenesis in B16F1 melanoma cells.	Berberine	59-68	pro-opiomelanocortin-alpha	Mus musculus	72-108
29724298-2	2018	In the present study, we examined the inhibitory effect of berberine on alpha-melanocyte-stimulating hormone (alpha-MSH)-induced melanogenesis in B16F1 melanoma cells.	Berberine	59-68	pro-opiomelanocortin-alpha	Mus musculus	110-119
29724298-3	2018	The results showed that berberine decreased the expression of tyrosinase and microphthalmia-associated transcription factor (MITF) in a dose-dependent manner.	Berberine	24-33	tyrosinase	Mus musculus	62-72
29724298-3	2018	The results showed that berberine decreased the expression of tyrosinase and microphthalmia-associated transcription factor (MITF) in a dose-dependent manner.	Berberine	24-33	melanogenesis associated transcription factor	Mus musculus	77-123
29724298-3	2018	The results showed that berberine decreased the expression of tyrosinase and microphthalmia-associated transcription factor (MITF) in a dose-dependent manner.	Berberine	24-33	melanogenesis associated transcription factor	Mus musculus	125-129
29467344-9	2018	In addition, berberine attenuated glucose-stimulated expression of fatty acid synthase.	Berberine	13-22	fatty acid synthase	Rattus norvegicus	67-86
28782427-9	2018	Taken together, the present results suggest that the SIRT1/ER stress pathway might be a crucial mechanism in the neuroprotective effect of BBR against DE.	Berberine	139-142	sirtuin 1	Mus musculus	53-58
29477657-0	2018	Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway.	Berberine	0-9	microRNA 373	Homo sapiens	18-25
29477657-0	2018	Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	95-98
29477657-7	2018	Global miRNA expression levels were measured in berberine-treated MIHA cells by quantitative reverse transcription PCR miRNA panel, and the potential berberine regulated miRNAs were then validated in MIHA and HepG2 cells.	Berberine	48-57	X-linked inhibitor of apoptosis	Homo sapiens	66-70
29477657-8	2018	MicroRNA-373 (MiR-373) was consistently upregulated in both cell lines upon berberine treatments.	Berberine	76-85	microRNA 373	Homo sapiens	0-12
29477657-8	2018	MicroRNA-373 (MiR-373) was consistently upregulated in both cell lines upon berberine treatments.	Berberine	76-85	microRNA 373	Homo sapiens	14-21
29477657-9	2018	Gene expression microarray showed that berberine upregulated Early Growth Response 1 (EGR1) level which functioned to transactivate miR-373 expression.	Berberine	39-48	early growth response 1	Homo sapiens	61-84
29477657-9	2018	Gene expression microarray showed that berberine upregulated Early Growth Response 1 (EGR1) level which functioned to transactivate miR-373 expression.	Berberine	39-48	early growth response 1	Homo sapiens	86-90
29477657-9	2018	Gene expression microarray showed that berberine upregulated Early Growth Response 1 (EGR1) level which functioned to transactivate miR-373 expression.	Berberine	39-48	microRNA 373	Homo sapiens	132-139
29690724-15	2018	Conclusion: Berberine can reverse chronic inflammatory pain induced by CFA and alleviated the comorbid depression.	Berberine	12-21	tubulin cofactor A	Mus musculus	71-74
29505790-0	2018	Berberine alleviates hepatic lipid accumulation by increasing ABCA1 through the protein kinase C delta pathway.	Berberine	0-9	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	62-67
29505790-4	2018	Here, we examined the effect of berberine (BBR) on ABCA1 in QSG-7701 hepatocytes and in mice.	Berberine	32-41	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	51-56
29615720-0	2018	Involvement of AMP-activated protein kinase and Death Receptor 5 in TRAIL-Berberine-induced apoptosis of cancer cells.	Berberine	74-83	TNF receptor superfamily member 10b	Homo sapiens	48-64
29615720-0	2018	Involvement of AMP-activated protein kinase and Death Receptor 5 in TRAIL-Berberine-induced apoptosis of cancer cells.	Berberine	74-83	TNF superfamily member 10	Homo sapiens	68-73
29615720-7	2018	These showed induction of several genes including TNFRSF10B (expresses DR5) and Harakiri following BBR treatment, which were further validated by qPCR analysis.	Berberine	99-102	TNF receptor superfamily member 10b	Homo sapiens	50-59
29615720-7	2018	These showed induction of several genes including TNFRSF10B (expresses DR5) and Harakiri following BBR treatment, which were further validated by qPCR analysis.	Berberine	99-102	TNF receptor superfamily member 10b	Homo sapiens	71-74
29545879-13	2018	Western blot analysis indicated that the expression of the anti-apoptotic genes c-Myc and p53 were upregulated by berberine, whereas caspase-3 and -9 levels were downregulated in epithelial cells following treatment with berberine.	Berberine	114-123	transformation related protein 53, pseudogene	Mus musculus	90-93
29545879-13	2018	Western blot analysis indicated that the expression of the anti-apoptotic genes c-Myc and p53 were upregulated by berberine, whereas caspase-3 and -9 levels were downregulated in epithelial cells following treatment with berberine.	Berberine	221-230	caspase 3	Mus musculus	133-149
29545879-14	2018	In addition, the expression and phosphorylation levels of PI3K and AKT were downregulated in epithelial cells following treatment with berberine.	Berberine	135-144	thymoma viral proto-oncogene 1	Mus musculus	67-70
29545879-16	2018	Treatment with berberine markedly increased epidermal growth factor (EGF) and Bcl-2 expression levels, the activity of epithelial cells and decreased the infarction area of the small intestine.	Berberine	15-24	B cell leukemia/lymphoma 2	Mus musculus	78-83
29545879-18	2018	Therefore, the results of the present study demonstrate that berberine inhibits inflammation and apoptosis via the PI3K/AKT signaling pathway and may therefore attenuate the progression of NEC.	Berberine	61-70	thymoma viral proto-oncogene 1	Mus musculus	120-123
29482156-0	2018	Berberine inhibits macrophage M1 polarization via AKT1/SOCS1/NF-kappaB signaling pathway to protect against DSS-induced colitis.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	50-54
29482156-0	2018	Berberine inhibits macrophage M1 polarization via AKT1/SOCS1/NF-kappaB signaling pathway to protect against DSS-induced colitis.	Berberine	0-9	suppressor of cytokine signaling 1	Mus musculus	55-60
29482156-0	2018	Berberine inhibits macrophage M1 polarization via AKT1/SOCS1/NF-kappaB signaling pathway to protect against DSS-induced colitis.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	61-70
29482156-8	2018	Further investigation showed that berberine promoted AKT1 expression in mRNA and protein level.	Berberine	34-43	thymoma viral proto-oncogene 1	Mus musculus	53-57
29482156-9	2018	Silence of AKT1 abolished the inhibitory effect of berberine on macrophages M1 polarization.	Berberine	51-60	thymoma viral proto-oncogene 1	Mus musculus	11-15
29482156-10	2018	The berberine-induced AKT1 expression promoted suppressers of cytokine signaling (SOCS1) activation, which inhibited nuclear factor-kappa B (NF-kappaB) phosphorylation.	Berberine	4-13	thymoma viral proto-oncogene 1	Mus musculus	22-26
29482156-10	2018	The berberine-induced AKT1 expression promoted suppressers of cytokine signaling (SOCS1) activation, which inhibited nuclear factor-kappa B (NF-kappaB) phosphorylation.	Berberine	4-13	suppressor of cytokine signaling 1	Mus musculus	82-87
29482156-10	2018	The berberine-induced AKT1 expression promoted suppressers of cytokine signaling (SOCS1) activation, which inhibited nuclear factor-kappa B (NF-kappaB) phosphorylation.	Berberine	4-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	117-139
29482156-10	2018	The berberine-induced AKT1 expression promoted suppressers of cytokine signaling (SOCS1) activation, which inhibited nuclear factor-kappa B (NF-kappaB) phosphorylation.	Berberine	4-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	141-150
29482156-11	2018	In addition, we also found that berberine activated AKT1/SOCS1 signaling pathway but inhibited p65 phosphorylation in macrophages in vivo.	Berberine	32-41	thymoma viral proto-oncogene 1	Mus musculus	52-56
29482156-11	2018	In addition, we also found that berberine activated AKT1/SOCS1 signaling pathway but inhibited p65 phosphorylation in macrophages in vivo.	Berberine	32-41	suppressor of cytokine signaling 1	Mus musculus	57-62
29482156-11	2018	In addition, we also found that berberine activated AKT1/SOCS1 signaling pathway but inhibited p65 phosphorylation in macrophages in vivo.	Berberine	32-41	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	95-98
29482156-12	2018	Therefore, we concluded that berberine played a regulatory role in macrophages M1 polarization in DSS-induced colitis via AKT1/SOCS1/NF-kappaB signaling pathway.	Berberine	29-38	thymoma viral proto-oncogene 1	Mus musculus	122-126
29482156-12	2018	Therefore, we concluded that berberine played a regulatory role in macrophages M1 polarization in DSS-induced colitis via AKT1/SOCS1/NF-kappaB signaling pathway.	Berberine	29-38	suppressor of cytokine signaling 1	Mus musculus	127-132
29482156-12	2018	Therefore, we concluded that berberine played a regulatory role in macrophages M1 polarization in DSS-induced colitis via AKT1/SOCS1/NF-kappaB signaling pathway.	Berberine	29-38	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	133-142
29393413-0	2018	Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction.	Berberine	23-32	nicotinamide phosphoribosyltransferase	Mus musculus	71-79
29393413-0	2018	Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction.	Berberine	23-32	nicotinamide phosphoribosyltransferase	Mus musculus	107-115
29393413-5	2018	The effect of BBR on attenuating visfatin-induced endothelial dysfunction was also evaluated in cultured human umbilical vein endothelial cells (HUVECs).	Berberine	14-17	nicotinamide phosphoribosyltransferase	Homo sapiens	33-41
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	nicotinamide phosphoribosyltransferase	Mus musculus	102-110
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	interleukin 6	Mus musculus	119-132
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	interleukin 6	Mus musculus	134-138
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	tumor necrosis factor	Mus musculus	144-171
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	tumor necrosis factor	Mus musculus	173-182
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	nicotinamide phosphoribosyltransferase	Mus musculus	211-219
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	mitogen-activated protein kinase 14	Mus musculus	223-226
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	mitogen-activated protein kinase 8	Mus musculus	236-261
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	mitogen-activated protein kinase 8	Mus musculus	263-266
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	nicotinamide phosphoribosyltransferase	Mus musculus	211-219
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	apolipoprotein E	Mus musculus	349-353
29393413-7	2018	In addition, in vitro experiments indicated that visfatin (100 microg/l) significantly increased apoptosis, the contents of IL-6 and TNF-alpha, the protein levels of p-p38 MAPK, p-JNK and Bax in HUVECs, which were reversed by BBR administration (50 micromol/l).	Berberine	226-229	nicotinamide phosphoribosyltransferase	Mus musculus	49-57
29703381-7	2018	Cell study indicated that CR decoction, berberine, coptisine, palmatine all activated the efflux transport of P-gp.	Berberine	40-49	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	110-114
29537893-4	2018	Now we take further our research by evaluating the effect of berberine, quercetin, tyrosol, and ferulic acid on the mTOR/S6K1/4E-BP1 signaling, along with the existence of any synergistic effect between the following associations: berberine + tyrosol, tyrosol + ferulic acid, ferulic acid + quercetin.	Berberine	61-70	mechanistic target of rapamycin kinase	Homo sapiens	116-120
29724298-4	2018	In order to observe the potential target for the inhibitory effect of berberine, we examined the effect of berberine on TRP-1 and TRP-2.	Berberine	107-116	tyrosinase-related protein 1	Mus musculus	120-125
29724298-5	2018	The results showed that berberine led to a reduction of TRP-1, while the change of TRP-2 was inconspicuous.	Berberine	24-33	tyrosinase-related protein 1	Mus musculus	56-61
29724298-7	2018	Overall, the results suggested that berberine inhibits tyrosinase activity and melanin synthesis by attenuating the expression of tyrosinase and MITF.	Berberine	36-45	tyrosinase	Mus musculus	55-65
29724298-7	2018	Overall, the results suggested that berberine inhibits tyrosinase activity and melanin synthesis by attenuating the expression of tyrosinase and MITF.	Berberine	36-45	tyrosinase	Mus musculus	130-140
29724298-7	2018	Overall, the results suggested that berberine inhibits tyrosinase activity and melanin synthesis by attenuating the expression of tyrosinase and MITF.	Berberine	36-45	melanogenesis associated transcription factor	Mus musculus	145-149
29278748-0	2018	Protective effect of berberine against cardiac ischemia/reperfusion injury by inhibiting apoptosis through the activation of Smad7.	Berberine	21-30	SMAD family member 7	Rattus norvegicus	125-130
29278748-9	2018	The knockdown of Smad7 confirmed our conclusion about the key role of Smad7 in the function of BBR administration.	Berberine	95-98	SMAD family member 7	Rattus norvegicus	17-22
29278748-9	2018	The knockdown of Smad7 confirmed our conclusion about the key role of Smad7 in the function of BBR administration.	Berberine	95-98	SMAD family member 7	Rattus norvegicus	70-75
29604956-0	2018	Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-kappaB pathway.	Berberine	0-9	toll-like receptor 4	Rattus norvegicus	57-61
29564000-0	2018	Berberine regulates the microRNA-21-ITGBeta4-PDCD4 axis and inhibits colon cancer viability.	Berberine	0-9	programmed cell death 4	Homo sapiens	45-50
29564000-3	2018	The present study aimed to investigate whether berberine inhibited the viability of colon cancer and whether it regulated the three-gene network microRNA (miR)-21-integrin beta4 (ITGbeta4)-programmed cell death 4 (PDCD4).	Berberine	47-56	microRNA 21	Homo sapiens	145-162
29564000-3	2018	The present study aimed to investigate whether berberine inhibited the viability of colon cancer and whether it regulated the three-gene network microRNA (miR)-21-integrin beta4 (ITGbeta4)-programmed cell death 4 (PDCD4).	Berberine	47-56	integrin subunit beta 4	Homo sapiens	163-177
29564000-3	2018	The present study aimed to investigate whether berberine inhibited the viability of colon cancer and whether it regulated the three-gene network microRNA (miR)-21-integrin beta4 (ITGbeta4)-programmed cell death 4 (PDCD4).	Berberine	47-56	programmed cell death 4	Homo sapiens	214-219
29564000-4	2018	It was demonstrated that berberine treatment suppressed colon cancer cell viability, and induced apoptosis and activated caspase-3 activity in the human colon carcinoma HCT116 cell line.	Berberine	25-34	caspase 3	Homo sapiens	121-130
29564000-5	2018	Berberine inhibited miR-21 expression and promoted ITGbeta4 and PDCD4 protein expression in the HCT116 cell line.	Berberine	0-9	microRNA 21	Homo sapiens	20-26
29564000-5	2018	Berberine inhibited miR-21 expression and promoted ITGbeta4 and PDCD4 protein expression in the HCT116 cell line.	Berberine	0-9	programmed cell death 4	Homo sapiens	64-69
29564000-6	2018	Overexpression of miR-21 reduced the anti-cancer effects of berberine on cell viability, apoptosis rate and caspase-3 activity of the HCT116 cell line.	Berberine	60-69	microRNA 21	Homo sapiens	18-24
29564000-6	2018	Overexpression of miR-21 reduced the anti-cancer effects of berberine on cell viability, apoptosis rate and caspase-3 activity of the HCT116 cell line.	Berberine	60-69	caspase 3	Homo sapiens	108-117
29564000-8	2018	In conclusion, miR-21, ITGbeta4 and PDCD4 are involved in the anti-cancer effects of berberine on cell viability and apoptosis in the HCT116 cell line.	Berberine	85-94	microRNA 21	Homo sapiens	15-21
29564000-8	2018	In conclusion, miR-21, ITGbeta4 and PDCD4 are involved in the anti-cancer effects of berberine on cell viability and apoptosis in the HCT116 cell line.	Berberine	85-94	programmed cell death 4	Homo sapiens	36-41
29604956-14	2018	Furthermore, blockade of TLR4/NF-kappaB pathway by resatorvid (TAK-242) or pyrrolidine dithiocarbamate aggravated the inhibitory effect of BBR on HG-induced inflammatory response and apoptosis in podocytes.	Berberine	139-142	toll-like receptor 4	Rattus norvegicus	25-29
29604956-15	2018	CONCLUSIONS: Berberine ameliorated DN through relieving STZ-induced renal injury, inflammatory response, and podocyte HG-induced apoptosis via inactivating TLR4/NF-kappaB pathway.	Berberine	13-22	toll-like receptor 4	Rattus norvegicus	156-160
29408570-0	2018	Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-gamma and subsequent expression of HGF in colons.	Berberine	20-29	peroxisome proliferator activated receptor gamma	Mus musculus	119-129
29273519-0	2018	Adenosine monophosphate-activated protein kinase modulation by berberine attenuates mitochondrial deficits and redox imbalance in experimental diabetic neuropathy.	Berberine	63-72	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	0-48
29273519-3	2018	The present study is aimed at evaluating the pharmacological efficacy of berberine (BRB), a natural AMPK activator against experimental diabetic neuropathy (DN) phenotype developed in STZ (55 mg/kg, i.p.)	Berberine	73-82	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	100-104
29273519-6	2018	BRB (50 &amp; 100 mg/kg, po) administration to diabetic rats for 2-weeks rescued mitochondrial functional deficits and autophagy impairment by increasing the p-AMPK expression.	Berberine	0-3	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	160-164
29408570-0	2018	Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-gamma and subsequent expression of HGF in colons.	Berberine	20-29	hepatocyte growth factor	Mus musculus	159-162
29408570-5	2018	Moreover, berberine promoted both mRNA and protein levels of HGF and PTEN in colons, but only their protein levels in lungs of PF mice.	Berberine	10-19	hepatocyte growth factor	Mus musculus	61-64
29408570-5	2018	Moreover, berberine promoted both mRNA and protein levels of HGF and PTEN in colons, but only their protein levels in lungs of PF mice.	Berberine	10-19	phosphatase and tensin homolog	Mus musculus	69-73
29408570-7	2018	In vitro, berberine preferentially induced expression of HGF in fibroblast cells than epithelial, preadipocyte and endothelial cells.	Berberine	10-19	hepatocyte growth factor	Mus musculus	57-60
29408570-8	2018	Similarly, rosiglitazone and 15dPGJ2 also enhanced expression of HGF in fibroblasts cells, and GW9662 and siPPAR-gamma diminished induction of berberine on HGF expression.	Berberine	143-152	hepatocyte growth factor	Mus musculus	156-159
29408570-9	2018	Berberine could enter into the cytoplasm, activate PPAR-gamma directly and synergistically with 15dPGJ2, as shown by an up-regulation of CD36 and aP2 mRNA expression, nuclear translocation and DNA-binding activity of PPAR-gamma both in vitro and in vivo.	Berberine	0-9	peroxisome proliferator activated receptor gamma	Mus musculus	51-61
29408570-9	2018	Berberine could enter into the cytoplasm, activate PPAR-gamma directly and synergistically with 15dPGJ2, as shown by an up-regulation of CD36 and aP2 mRNA expression, nuclear translocation and DNA-binding activity of PPAR-gamma both in vitro and in vivo.	Berberine	0-9	peroxisome proliferator activated receptor gamma	Mus musculus	217-227
29408570-11	2018	In conclusion, oral administration of berberine displays anti-PF action probably in a colon-dependent manner, and mechanisms involve activation of PPAR-gamma and resultant promotion of HGF expression in colonic fibroblasts.	Berberine	38-47	peroxisome proliferator activated receptor gamma	Mus musculus	147-157
29408570-11	2018	In conclusion, oral administration of berberine displays anti-PF action probably in a colon-dependent manner, and mechanisms involve activation of PPAR-gamma and resultant promotion of HGF expression in colonic fibroblasts.	Berberine	38-47	hepatocyte growth factor	Mus musculus	185-188
29353208-9	2018	Lower expression of SREBP-1c, pERK, TNF-alpha, and pJNK were also observed in berberine + curcumin group.	Berberine	78-87	sterol regulatory element binding transcription factor 1	Rattus norvegicus	20-28
29353208-9	2018	Lower expression of SREBP-1c, pERK, TNF-alpha, and pJNK were also observed in berberine + curcumin group.	Berberine	78-87	tumor necrosis factor	Rattus norvegicus	36-45
29628980-0	2018	Berberine Suppresses Fibronectin Expression through Inhibition of c-Jun Phosphorylation in Breast Cancer Cells.	Berberine	0-9	fibronectin 1	Homo sapiens	21-32
29282578-0	2018	MicroRNA-21-Mediated Inhibition of Mast Cell Degranulation Involved in the Protective Effect of Berberine on 2,4-Dinitrofluorobenzene-Induced Allergic Contact Dermatitis in Rats via p38 Pathway.	Berberine	96-105	microRNA 21	Rattus norvegicus	0-11
29282578-0	2018	MicroRNA-21-Mediated Inhibition of Mast Cell Degranulation Involved in the Protective Effect of Berberine on 2,4-Dinitrofluorobenzene-Induced Allergic Contact Dermatitis in Rats via p38 Pathway.	Berberine	96-105	mitogen activated protein kinase 14	Rattus norvegicus	182-185
29282578-8	2018	Berberine treatment inhibited miR-21 expression, suppressed beta-hexosaminidase and histamine release, and prevented p38 phosphorylation (all P &lt; 0.05), which was abrogated by pretreatment with miR-21 overexpression.	Berberine	0-9	microRNA 21	Rattus norvegicus	30-36
29628980-10	2018	Interestingly, FN expression in TNBC cells was dose-dependently decreased by BBR treatment.	Berberine	77-80	fibronectin 1	Homo sapiens	15-17
29260413-0	2018	Berberine protects HK-2 cells from hypoxia/reoxygenation induced apoptosis via inhibiting SPHK1 expression.	Berberine	0-9	sphingosine kinase 1	Homo sapiens	90-95
29260413-5	2018	Here, we found increased SPHK1 levels in H/R injured HK-2 cells, which could be significantly down regulated after berberine treatment.	Berberine	115-124	sphingosine kinase 1	Homo sapiens	25-30
29260413-7	2018	So, in our present study, we planned to investigate whether SPHK1 participated in the anti-apoptosis process of berberine in H/R injured HK-2 cells.	Berberine	112-121	sphingosine kinase 1	Homo sapiens	60-65
29260413-8	2018	Our study confirmed the protective effect of berberine against H/R-induced apoptosis in HK-2 cells through promoting cells viability, inhibiting cells apoptosis, and down-regulating p-P38, caspase-3, caspase-9 as well as SPHK1, while up regulating the ratio of Bcl-2/Bax.	Berberine	45-54	mitogen-activated protein kinase 14	Homo sapiens	184-187
29260413-8	2018	Our study confirmed the protective effect of berberine against H/R-induced apoptosis in HK-2 cells through promoting cells viability, inhibiting cells apoptosis, and down-regulating p-P38, caspase-3, caspase-9 as well as SPHK1, while up regulating the ratio of Bcl-2/Bax.	Berberine	45-54	caspase 3	Homo sapiens	189-198
29260413-8	2018	Our study confirmed the protective effect of berberine against H/R-induced apoptosis in HK-2 cells through promoting cells viability, inhibiting cells apoptosis, and down-regulating p-P38, caspase-3, caspase-9 as well as SPHK1, while up regulating the ratio of Bcl-2/Bax.	Berberine	45-54	caspase 9	Homo sapiens	200-209
29260413-8	2018	Our study confirmed the protective effect of berberine against H/R-induced apoptosis in HK-2 cells through promoting cells viability, inhibiting cells apoptosis, and down-regulating p-P38, caspase-3, caspase-9 as well as SPHK1, while up regulating the ratio of Bcl-2/Bax.	Berberine	45-54	sphingosine kinase 1	Homo sapiens	221-226
29260413-8	2018	Our study confirmed the protective effect of berberine against H/R-induced apoptosis in HK-2 cells through promoting cells viability, inhibiting cells apoptosis, and down-regulating p-P38, caspase-3, caspase-9 as well as SPHK1, while up regulating the ratio of Bcl-2/Bax.	Berberine	45-54	BCL2 apoptosis regulator	Homo sapiens	261-266
29260413-8	2018	Our study confirmed the protective effect of berberine against H/R-induced apoptosis in HK-2 cells through promoting cells viability, inhibiting cells apoptosis, and down-regulating p-P38, caspase-3, caspase-9 as well as SPHK1, while up regulating the ratio of Bcl-2/Bax.	Berberine	45-54	BCL2 associated X, apoptosis regulator	Homo sapiens	267-270
29260413-9	2018	However, SPHK1 overexpression in HK-2 cells induced severe apoptosis, which can be significantly ameliorated with additional berberine treatment.	Berberine	125-134	sphingosine kinase 1	Homo sapiens	9-14
29260413-10	2018	We concluded that berberine could remarkably prevent H/R-induced apoptosis in HK-2 cells through down-regulating SPHK1 expression levels, and the mechanisms included the suppression of p38 MAPK activation and mitochondrial stress pathways.	Berberine	18-27	sphingosine kinase 1	Homo sapiens	113-118
29260413-10	2018	We concluded that berberine could remarkably prevent H/R-induced apoptosis in HK-2 cells through down-regulating SPHK1 expression levels, and the mechanisms included the suppression of p38 MAPK activation and mitochondrial stress pathways.	Berberine	18-27	mitogen-activated protein kinase 14	Homo sapiens	185-188
29357017-0	2018	Berberine Ameliorates MCAO Induced Cerebral Ischemia/Reperfusion Injury via Activation of the BDNF-TrkB-PI3K/Akt Signaling Pathway.	Berberine	0-9	brain-derived neurotrophic factor	Rattus norvegicus	94-98
29357017-0	2018	Berberine Ameliorates MCAO Induced Cerebral Ischemia/Reperfusion Injury via Activation of the BDNF-TrkB-PI3K/Akt Signaling Pathway.	Berberine	0-9	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	99-103
29357017-10	2018	Berberine also increased the expression of BDNF, TrkB, and p-Akt, which were reduced after MCAO.	Berberine	0-9	brain-derived neurotrophic factor	Rattus norvegicus	43-47
29357017-10	2018	Berberine also increased the expression of BDNF, TrkB, and p-Akt, which were reduced after MCAO.	Berberine	0-9	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	49-53
29357017-12	2018	However, treatment with LY294002 (PI3K inhibitor) reversed the BBR-induced increases in BDNF and p-Akt proteins and decreased cleaved caspase-3 protein expression in focal cerebral ischemic rats.	Berberine	63-66	brain-derived neurotrophic factor	Rattus norvegicus	88-92
29357017-13	2018	In summary, our results demonstrated that BBR could exert neuroprotective effects through reduction of striatum apoptosis via the BDNF-TrkB-PI3K/Akt signaling pathway.	Berberine	42-45	brain-derived neurotrophic factor	Rattus norvegicus	130-134
29357017-13	2018	In summary, our results demonstrated that BBR could exert neuroprotective effects through reduction of striatum apoptosis via the BDNF-TrkB-PI3K/Akt signaling pathway.	Berberine	42-45	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	135-139
29441600-0	2018	Berberine inhibits experimental varicocele-induced cell cycle arrest via regulating cyclin D1, cdk4 and p21 proteins expression in rat testicles.	Berberine	0-9	cyclin D1	Rattus norvegicus	84-93
29441600-0	2018	Berberine inhibits experimental varicocele-induced cell cycle arrest via regulating cyclin D1, cdk4 and p21 proteins expression in rat testicles.	Berberine	0-9	cyclin-dependent kinase 4	Rattus norvegicus	95-99
29441600-0	2018	Berberine inhibits experimental varicocele-induced cell cycle arrest via regulating cyclin D1, cdk4 and p21 proteins expression in rat testicles.	Berberine	0-9	KRAS proto-oncogene, GTPase	Rattus norvegicus	104-107
29434321-0	2018	The promotion function of Berberine for osteogenic differentiation of human periodontal ligament stem cells via ERK-FOS pathway mediated by EGFR.	Berberine	26-35	mitogen-activated protein kinase 1	Homo sapiens	112-115
29434321-0	2018	The promotion function of Berberine for osteogenic differentiation of human periodontal ligament stem cells via ERK-FOS pathway mediated by EGFR.	Berberine	26-35	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	116-119
29434321-0	2018	The promotion function of Berberine for osteogenic differentiation of human periodontal ligament stem cells via ERK-FOS pathway mediated by EGFR.	Berberine	26-35	epidermal growth factor receptor	Homo sapiens	140-144
29618945-5	2018	We herein describe in vitro and in vivo effects of fifteen Nrf2-interacting natural compounds (tocotrienols, curcumin, epigallocatechin gallate, quercetin, genistein, resveratrol, silybin, phenethyl isothiocyanate, sulforaphane, triptolide, allicin, berberine, piperlongumine, fisetin, and phloretin) on cellular senescence and discuss their use in adjuvant cancer therapy.	Berberine	250-259	NFE2 like bZIP transcription factor 2	Homo sapiens	59-63
29403554-10	2018	Mechanism analysis demonstrated that berberine inhibited apoptotic protease-activating factor 1, caspase-3 and caspase-9 expression in myocardial cells.	Berberine	37-46	caspase 3	Mus musculus	97-106
29403554-10	2018	Mechanism analysis demonstrated that berberine inhibited apoptotic protease-activating factor 1, caspase-3 and caspase-9 expression in myocardial cells.	Berberine	37-46	caspase 9	Mus musculus	111-120
29403554-13	2018	In conclusion, the results of the present study indicate that berberine inhibits inflammatory responses through the NF-kappaB signaling pathway and suppresses the apoptosis of myocardial cells via the PI3K/AKT signaling pathway in a mouse model of ischemia-reperfusion injury.	Berberine	62-71	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-125
29403554-13	2018	In conclusion, the results of the present study indicate that berberine inhibits inflammatory responses through the NF-kappaB signaling pathway and suppresses the apoptosis of myocardial cells via the PI3K/AKT signaling pathway in a mouse model of ischemia-reperfusion injury.	Berberine	62-71	thymoma viral proto-oncogene 1	Mus musculus	206-209
29282578-8	2018	Berberine treatment inhibited miR-21 expression, suppressed beta-hexosaminidase and histamine release, and prevented p38 phosphorylation (all P &lt; 0.05), which was abrogated by pretreatment with miR-21 overexpression.	Berberine	0-9	O-GlcNAcase	Rattus norvegicus	60-79
29282578-8	2018	Berberine treatment inhibited miR-21 expression, suppressed beta-hexosaminidase and histamine release, and prevented p38 phosphorylation (all P &lt; 0.05), which was abrogated by pretreatment with miR-21 overexpression.	Berberine	0-9	mitogen activated protein kinase 14	Rattus norvegicus	117-120
29282578-8	2018	Berberine treatment inhibited miR-21 expression, suppressed beta-hexosaminidase and histamine release, and prevented p38 phosphorylation (all P &lt; 0.05), which was abrogated by pretreatment with miR-21 overexpression.	Berberine	0-9	microRNA 21	Rattus norvegicus	197-203
29282578-9	2018	These findings indicate that miR-21-mediated inhibition of MC degranulation is involved in the anti-ACD effect of berberine via inhibiting p38 pathway, which provide a new insight into the immunopharmacological role of berberine and suggest its potential application for the treatment of allergic inflammation, such as ACD.	Berberine	114-123	microRNA 21	Rattus norvegicus	29-35
29282578-9	2018	These findings indicate that miR-21-mediated inhibition of MC degranulation is involved in the anti-ACD effect of berberine via inhibiting p38 pathway, which provide a new insight into the immunopharmacological role of berberine and suggest its potential application for the treatment of allergic inflammation, such as ACD.	Berberine	114-123	mitogen activated protein kinase 14	Rattus norvegicus	139-142
29282578-9	2018	These findings indicate that miR-21-mediated inhibition of MC degranulation is involved in the anti-ACD effect of berberine via inhibiting p38 pathway, which provide a new insight into the immunopharmacological role of berberine and suggest its potential application for the treatment of allergic inflammation, such as ACD.	Berberine	219-228	microRNA 21	Rattus norvegicus	29-35
29282578-9	2018	These findings indicate that miR-21-mediated inhibition of MC degranulation is involved in the anti-ACD effect of berberine via inhibiting p38 pathway, which provide a new insight into the immunopharmacological role of berberine and suggest its potential application for the treatment of allergic inflammation, such as ACD.	Berberine	219-228	mitogen activated protein kinase 14	Rattus norvegicus	139-142
28298174-0	2018	The involvement of multidrug and toxin extrusion protein 1 in the distribution and excretion of berberine.	Berberine	96-105	solute carrier family 47 member 1	Homo sapiens	19-58
28298174-7	2018	In primary rat hepatocytes, pH-dependent uptake and efflux studies suggested that the transport of BBR was driven by the exchange of H+ and involved Mate1.	Berberine	99-102	solute carrier family 47 member 1	Rattus norvegicus	149-154
28665143-5	2018	Berberine (BBR), an effective suppressor of SREBP1 and lipogenesis regulated through reactive oxygen species (ROS)/AMPK pathway, selectively inhibited the growth of G-R NSCLC cells and RASFs but not that of normal cells.	Berberine	0-9	sterol regulatory element binding transcription factor 1	Homo sapiens	44-50
28665143-5	2018	Berberine (BBR), an effective suppressor of SREBP1 and lipogenesis regulated through reactive oxygen species (ROS)/AMPK pathway, selectively inhibited the growth of G-R NSCLC cells and RASFs but not that of normal cells.	Berberine	11-14	sterol regulatory element binding transcription factor 1	Homo sapiens	44-50
29207123-0	2018	NACHT, LRR and PYD domains-containing protein 3 inflammasome is activated and inhibited by berberine via toll-like receptor 4/myeloid differentiation primary response gene 88/nuclear factor-kappaB pathway, in phorbol 12-myristate 13-acetate-induced macrophages.	Berberine	91-100	NLR family pyrin domain containing 3	Homo sapiens	0-47
29207123-0	2018	NACHT, LRR and PYD domains-containing protein 3 inflammasome is activated and inhibited by berberine via toll-like receptor 4/myeloid differentiation primary response gene 88/nuclear factor-kappaB pathway, in phorbol 12-myristate 13-acetate-induced macrophages.	Berberine	91-100	toll like receptor 4	Homo sapiens	105-125
29294034-7	2018	However, after berberine treatment, periodontal bone regeneration in the PCSK9 knockout group was significantly lower than that in wild-type.	Berberine	15-24	proprotein convertase subtilisin/kexin type 9	Homo sapiens	73-78
29360760-0	2018	Regulation of Akt/FoxO3a/Skp2 Axis Is Critically Involved in Berberine-Induced Cell Cycle Arrest in Hepatocellular Carcinoma Cells.	Berberine	61-70	AKT serine/threonine kinase 1	Homo sapiens	14-17
29360760-0	2018	Regulation of Akt/FoxO3a/Skp2 Axis Is Critically Involved in Berberine-Induced Cell Cycle Arrest in Hepatocellular Carcinoma Cells.	Berberine	61-70	forkhead box O3	Homo sapiens	18-24
29360760-0	2018	Regulation of Akt/FoxO3a/Skp2 Axis Is Critically Involved in Berberine-Induced Cell Cycle Arrest in Hepatocellular Carcinoma Cells.	Berberine	61-70	S-phase kinase associated protein 2	Homo sapiens	25-29
29360760-4	2018	In our present study, G0/G1 phase cell cycle arrest was observed in berberine-treated Huh-7 and HepG2 cells.	Berberine	68-77	MIR7-3 host gene	Homo sapiens	86-91
29360760-7	2018	In conclusion, BBR promotes the expression of CDKIs p21Cip1 and p27Kip1 via regulating the Akt/FoxO3a/Skp2 axis and further induces HCC G0/G1 phase cell cycle arrest.	Berberine	15-18	cyclin dependent kinase inhibitor 1A	Homo sapiens	52-59
29360760-7	2018	In conclusion, BBR promotes the expression of CDKIs p21Cip1 and p27Kip1 via regulating the Akt/FoxO3a/Skp2 axis and further induces HCC G0/G1 phase cell cycle arrest.	Berberine	15-18	cyclin dependent kinase inhibitor 1B	Homo sapiens	64-71
29360760-7	2018	In conclusion, BBR promotes the expression of CDKIs p21Cip1 and p27Kip1 via regulating the Akt/FoxO3a/Skp2 axis and further induces HCC G0/G1 phase cell cycle arrest.	Berberine	15-18	AKT serine/threonine kinase 1	Homo sapiens	91-94
29360760-7	2018	In conclusion, BBR promotes the expression of CDKIs p21Cip1 and p27Kip1 via regulating the Akt/FoxO3a/Skp2 axis and further induces HCC G0/G1 phase cell cycle arrest.	Berberine	15-18	forkhead box O3	Homo sapiens	95-101
29360760-7	2018	In conclusion, BBR promotes the expression of CDKIs p21Cip1 and p27Kip1 via regulating the Akt/FoxO3a/Skp2 axis and further induces HCC G0/G1 phase cell cycle arrest.	Berberine	15-18	S-phase kinase associated protein 2	Homo sapiens	102-106
29628980-0	2018	Berberine Suppresses Fibronectin Expression through Inhibition of c-Jun Phosphorylation in Breast Cancer Cells.	Berberine	0-9	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	66-71
29628980-2	2018	In this study, we investigated the pharmacological mechanism of berberine (BBR) with respect to FN expression in triple-negative breast cancer (TNBC) cells.	Berberine	64-73	fibronectin 1	Homo sapiens	96-98
29628980-2	2018	In this study, we investigated the pharmacological mechanism of berberine (BBR) with respect to FN expression in triple-negative breast cancer (TNBC) cells.	Berberine	75-78	fibronectin 1	Homo sapiens	96-98
29805448-7	2018	In addition, several concentrations of berberine, when combined with the NO donor used at IC30, induced a synergistic cytotoxic activity at concentrations ranging from 8.40 muM to 33.60 muM, as revealed by the combination index values, using the Chou-Talalay method.	Berberine	39-48	latexin	Homo sapiens	173-176
29805448-7	2018	In addition, several concentrations of berberine, when combined with the NO donor used at IC30, induced a synergistic cytotoxic activity at concentrations ranging from 8.40 muM to 33.60 muM, as revealed by the combination index values, using the Chou-Talalay method.	Berberine	39-48	latexin	Homo sapiens	186-189
29247651-0	2018	Berberine-induced activation of AMPK increases hepatic FGF21 expression via NUR77.	Berberine	0-9	fibroblast growth factor 21	Mus musculus	55-60
29247651-0	2018	Berberine-induced activation of AMPK increases hepatic FGF21 expression via NUR77.	Berberine	0-9	nuclear receptor subfamily 4, group A, member 1	Mus musculus	76-81
29247651-4	2018	Here we investigated the effect of berberine on FGF21 expression in primary mouse hepatocytes.	Berberine	35-44	fibroblast growth factor 21	Mus musculus	48-53
29247651-5	2018	As expected, berberine induced hepatic FGF21 expression in a dose-dependent and time-dependent manner, along with the increased expression of NUR77, a proved transcription factor of FGF21.	Berberine	13-22	fibroblast growth factor 21	Mus musculus	39-44
29247651-5	2018	As expected, berberine induced hepatic FGF21 expression in a dose-dependent and time-dependent manner, along with the increased expression of NUR77, a proved transcription factor of FGF21.	Berberine	13-22	nuclear receptor subfamily 4, group A, member 1	Mus musculus	142-147
29247651-5	2018	As expected, berberine induced hepatic FGF21 expression in a dose-dependent and time-dependent manner, along with the increased expression of NUR77, a proved transcription factor of FGF21.	Berberine	13-22	fibroblast growth factor 21	Mus musculus	182-187
29247651-8	2018	The inhibition of AMPK by compound C abolished berberine-stimulated FGF21 and NUR77 expressions.	Berberine	47-56	fibroblast growth factor 21	Mus musculus	68-73
29247651-8	2018	The inhibition of AMPK by compound C abolished berberine-stimulated FGF21 and NUR77 expressions.	Berberine	47-56	nuclear receptor subfamily 4, group A, member 1	Mus musculus	78-83
29247651-9	2018	These results suggest that berberine-induced activation of AMPK may contribute to hepatic FGF21 expression via NUR77.	Berberine	27-36	fibroblast growth factor 21	Mus musculus	90-95
29247651-9	2018	These results suggest that berberine-induced activation of AMPK may contribute to hepatic FGF21 expression via NUR77.	Berberine	27-36	nuclear receptor subfamily 4, group A, member 1	Mus musculus	111-116
29305670-6	2018	RESULTS: Berberine-loaded chylomicrons showed spherical vesicles of size (175.6 nm), PDI (0.229), zeta potential (-16 .6 mV) and entrapment efficiency (95.5%).	Berberine	9-18	peptidyl arginine deiminase 1	Homo sapiens	85-88
29202334-0	2018	Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe-/- mice.	Berberine	0-9	apolipoprotein E	Mus musculus	107-111
29962406-4	2018	In contrast, less than 50 microg/mL berberine inhibited the vascular endothelial growth factor (VEGF) expression to some extent after a 24-h incubation, suggesting that berberine suppressed angiogenic action under the condition of little cytotoxicity.	Berberine	36-45	vascular endothelial growth factor A	Mus musculus	60-94
29962406-4	2018	In contrast, less than 50 microg/mL berberine inhibited the vascular endothelial growth factor (VEGF) expression to some extent after a 24-h incubation, suggesting that berberine suppressed angiogenic action under the condition of little cytotoxicity.	Berberine	36-45	vascular endothelial growth factor A	Mus musculus	96-100
29962406-4	2018	In contrast, less than 50 microg/mL berberine inhibited the vascular endothelial growth factor (VEGF) expression to some extent after a 24-h incubation, suggesting that berberine suppressed angiogenic action under the condition of little cytotoxicity.	Berberine	169-178	vascular endothelial growth factor A	Mus musculus	60-94
29962406-4	2018	In contrast, less than 50 microg/mL berberine inhibited the vascular endothelial growth factor (VEGF) expression to some extent after a 24-h incubation, suggesting that berberine suppressed angiogenic action under the condition of little cytotoxicity.	Berberine	169-178	vascular endothelial growth factor A	Mus musculus	96-100
29065218-0	2018	Renal vectorial transport of berberine mediated by organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins 1 (MATE1) in rats.	Berberine	29-38	solute carrier family 22 member 2	Rattus norvegicus	51-79
29065218-0	2018	Renal vectorial transport of berberine mediated by organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins 1 (MATE1) in rats.	Berberine	29-38	solute carrier family 22 member 2	Rattus norvegicus	81-85
29065218-0	2018	Renal vectorial transport of berberine mediated by organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins 1 (MATE1) in rats.	Berberine	29-38	solute carrier family 47 member 1	Rattus norvegicus	133-138
29065218-4	2018	In Madin-Darby canine kidney (MDCK) cells stably expressing rat OCT2 (MDCK-rOCT2) and kidney slices, saturable and non-saturable uptake of berberine was observed, and corticosterone could inhibit the uptake of berberine, with IC50 values of 0.1 mum and 147.9 mum, respectively.	Berberine	139-148	solute carrier family 22 member 2	Rattus norvegicus	64-68
29065218-4	2018	In Madin-Darby canine kidney (MDCK) cells stably expressing rat OCT2 (MDCK-rOCT2) and kidney slices, saturable and non-saturable uptake of berberine was observed, and corticosterone could inhibit the uptake of berberine, with IC50 values of 0.1 mum and 147.9 mum, respectively.	Berberine	210-219	solute carrier family 22 member 2	Rattus norvegicus	64-68
29065218-5	2018	In double-transfected cells, the cellular accumulation of berberine into MDCK-rOCT2 and MDCK-rOCT2-rMATE1 (MDCK cells stably expressing rOCT2 and rMATE1) cells was significantly higher than the uptake into MDCK cells.	Berberine	58-67	solute carrier family 22 member 2	Rattus norvegicus	78-83
29065218-5	2018	In double-transfected cells, the cellular accumulation of berberine into MDCK-rOCT2 and MDCK-rOCT2-rMATE1 (MDCK cells stably expressing rOCT2 and rMATE1) cells was significantly higher than the uptake into MDCK cells.	Berberine	58-67	solute carrier family 47 member 1	Rattus norvegicus	146-152
29065218-6	2018	Meanwhile, berberine transcellular transport was considerably higher in double-transfected MDCK-rOCT2-rMATE1 cells than in MDCK and MDCK-rOCT2 cells.	Berberine	11-20	solute carrier family 22 member 2	Rattus norvegicus	96-101
29065218-6	2018	Meanwhile, berberine transcellular transport was considerably higher in double-transfected MDCK-rOCT2-rMATE1 cells than in MDCK and MDCK-rOCT2 cells.	Berberine	11-20	solute carrier family 47 member 1	Rattus norvegicus	102-108
29065218-6	2018	Meanwhile, berberine transcellular transport was considerably higher in double-transfected MDCK-rOCT2-rMATE1 cells than in MDCK and MDCK-rOCT2 cells.	Berberine	11-20	solute carrier family 22 member 2	Rattus norvegicus	137-142
29065218-7	2018	Corticosterone for MDCK-rMATE1 and MDCK-MDR1 and pyrimethamine for MDCK-rMATE1 at high concentrations could inhibit the efflux of berberine.	Berberine	130-139	ATP binding cassette subfamily B member 1	Canis lupus familiaris	35-44
29065218-7	2018	Corticosterone for MDCK-rMATE1 and MDCK-MDR1 and pyrimethamine for MDCK-rMATE1 at high concentrations could inhibit the efflux of berberine.	Berberine	130-139	solute carrier family 47 member 1	Rattus norvegicus	72-78
29065218-11	2018	Thus, berberine is not only a substrate of OCT2 and P-glycoprotein, but is also a substrate of MATE1.	Berberine	6-15	solute carrier family 22 member 2	Canis lupus familiaris	43-47
29065218-11	2018	Thus, berberine is not only a substrate of OCT2 and P-glycoprotein, but is also a substrate of MATE1.	Berberine	6-15	solute carrier family 47 member 1	Rattus norvegicus	95-100
29065218-12	2018	Both OCT2 and MATE1 mediate the renal vectorial transport of berberine.	Berberine	61-70	solute carrier family 22 member 2	Canis lupus familiaris	5-9
29065218-12	2018	Both OCT2 and MATE1 mediate the renal vectorial transport of berberine.	Berberine	61-70	solute carrier family 47 member 1	Rattus norvegicus	14-19
29065221-0	2018	Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21.	Berberine	0-9	fibroblast growth factor 21	Mus musculus	105-132
29065221-4	2018	EXPERIMENTAL APPROACH: Liver-specific SIRT1 knockout mice and their wild-type littermates were fed a high-fat, high-sucrose (HFHS) diet and treated with berberine by i.p.	Berberine	153-162	sirtuin 1	Mus musculus	38-43
29065221-7	2018	KEY RESULTS: Berberine attenuated hepatic steatosis and controlled energy balance in mice by inducing autophagy and FGF21.	Berberine	13-22	fibroblast growth factor 21	Mus musculus	116-121
29065221-8	2018	These beneficial effects of berberine on autophagy and hepatic steatosis were abolished by a deficiency of the nutrient sensor SIRT1 in the liver of HFHS diet-fed obese mice and in mouse primary hepatocytes.	Berberine	28-37	sirtuin 1	Mus musculus	127-132
29065221-9	2018	SIRT1 is essential for berberine to potentiate autophagy and inhibit lipid storage in mouse livers in response to fasting.	Berberine	23-32	sirtuin 1	Mus musculus	0-5
29065221-10	2018	Mechanistically, the berberine stimulates SIRT1 deacetylation activity and induces autophagy in an autophagy protein 5-dependent manner.	Berberine	21-30	sirtuin 1	Mus musculus	42-47
29065221-11	2018	Moreover, the administration of berberine was shown to promote hepatic gene expression and circulating levels of FGF21 and ketone bodies in mice in a SIRT1-dependent manner.	Berberine	32-41	fibroblast growth factor 21	Mus musculus	113-118
29065221-11	2018	Moreover, the administration of berberine was shown to promote hepatic gene expression and circulating levels of FGF21 and ketone bodies in mice in a SIRT1-dependent manner.	Berberine	32-41	sirtuin 1	Mus musculus	150-155
29065221-12	2018	CONCLUSIONS AND IMPLICATIONS: Berberine acts in the liver to regulate lipid utilization and maintain whole-body energy metabolism by mediating autophagy and FGF21 activation.	Berberine	30-39	fibroblast growth factor 21	Mus musculus	157-162
29422010-0	2018	Berberine Encapsulated PLGA-PEG Nanoparticles Modulate PCSK-9 in HepG2 Cells.	Berberine	0-9	proprotein convertase subtilisin/kexin type 9	Homo sapiens	55-61
29422010-7	2018	RESULTS: The PCSK-9 mRNA and protein expression shows a relationship to the release of Berberine from the encapsulating PLGA-PEG-PLGA polymer in a time dependent manner.	Berberine	87-96	proprotein convertase subtilisin/kexin type 9	Homo sapiens	13-19
29422010-8	2018	CONCLUSION: PCSK-9 modulation by oral administration of Berberine using nanotechnology approach can improve its pharmacokinetic profile.	Berberine	56-65	proprotein convertase subtilisin/kexin type 9	Homo sapiens	12-18
30205381-0	2018	Berberine Exerts a Protective Effect on Gut-Vascular Barrier via the Modulation of the Wnt/Beta-Catenin Signaling Pathway During Sepsis.	Berberine	0-9	Wnt family member 2	Rattus norvegicus	87-90
30205381-0	2018	Berberine Exerts a Protective Effect on Gut-Vascular Barrier via the Modulation of the Wnt/Beta-Catenin Signaling Pathway During Sepsis.	Berberine	0-9	catenin beta 1	Rattus norvegicus	91-103
30205381-10	2018	CONCLUSION: Berberine exerted a protective effect on GVB function in sepsis, which was strictly related to the modulation of the Wnt/beta-catenin signaling pathway.	Berberine	12-21	Wnt family member 2	Rattus norvegicus	129-132
30205381-10	2018	CONCLUSION: Berberine exerted a protective effect on GVB function in sepsis, which was strictly related to the modulation of the Wnt/beta-catenin signaling pathway.	Berberine	12-21	catenin beta 1	Rattus norvegicus	133-145
29414799-0	2018	Berberine Suppresses Cell Motility Through Downregulation of TGF-beta1 in Triple Negative Breast Cancer Cells.	Berberine	0-9	transforming growth factor beta 1	Homo sapiens	61-70
29414799-2	2018	Here, we demonstrated the inhibitory effect of berberine (BBR) on tumor growth and metastasis of triple negative breast cancer (TNBC) cells via suppression of TGF-beta1 expression.	Berberine	47-56	transforming growth factor beta 1	Homo sapiens	159-168
29133053-0	2018	Synthesis and biological evaluation of new berberine derivatives as cancer immunotherapy agents through targeting IDO1.	Berberine	43-52	indoleamine 2,3-dioxygenase 1	Homo sapiens	114-118
29207123-6	2018	Furthermore, berberine also suppressed the toll-like receptor 4 (TLR4)/myeloid differentiation primary response gene 88 (Myd88)/nuclear factor (NF)-kappaB signaling pathway which was activated during the conversion of THP-1 cells to macrophages by PMA.	Berberine	13-22	toll like receptor 4	Homo sapiens	43-63
29207123-6	2018	Furthermore, berberine also suppressed the toll-like receptor 4 (TLR4)/myeloid differentiation primary response gene 88 (Myd88)/nuclear factor (NF)-kappaB signaling pathway which was activated during the conversion of THP-1 cells to macrophages by PMA.	Berberine	13-22	toll like receptor 4	Homo sapiens	65-69
29207123-6	2018	Furthermore, berberine also suppressed the toll-like receptor 4 (TLR4)/myeloid differentiation primary response gene 88 (Myd88)/nuclear factor (NF)-kappaB signaling pathway which was activated during the conversion of THP-1 cells to macrophages by PMA.	Berberine	13-22	MYD88 innate immune signal transduction adaptor	Homo sapiens	121-126
29207123-7	2018	In conclusion, berberine reduced NLRP3 inflammasone expression by suppressing the activation of the TLR4/Myd88/NF-kappaB signaling pathway in PMA-induced macrophages.	Berberine	15-24	NLR family pyrin domain containing 3	Homo sapiens	33-38
29207123-7	2018	In conclusion, berberine reduced NLRP3 inflammasone expression by suppressing the activation of the TLR4/Myd88/NF-kappaB signaling pathway in PMA-induced macrophages.	Berberine	15-24	toll like receptor 4	Homo sapiens	100-104
29207123-7	2018	In conclusion, berberine reduced NLRP3 inflammasone expression by suppressing the activation of the TLR4/Myd88/NF-kappaB signaling pathway in PMA-induced macrophages.	Berberine	15-24	MYD88 innate immune signal transduction adaptor	Homo sapiens	105-110
29207123-7	2018	In conclusion, berberine reduced NLRP3 inflammasone expression by suppressing the activation of the TLR4/Myd88/NF-kappaB signaling pathway in PMA-induced macrophages.	Berberine	15-24	nuclear factor kappa B subunit 1	Homo sapiens	111-120
29962345-0	2018	Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting beta/gamma-Secretases Activity and Enhancing alpha-Secretases.	Berberine	0-9	presenilin 1	Mus musculus	64-67
29962345-4	2018	The aim of our work was to investigate whether the neuroprotective effects of BBR on AD is related to inhibiting Abeta pathology.	Berberine	78-81	amyloid beta (A4) precursor protein	Mus musculus	113-118
29962345-9	2018	BACE1 and sAPP -beta levels in the BBR-treated groups were significantly reduced in the hippocampus of AD mice.	Berberine	35-38	beta-site APP cleaving enzyme 1	Mus musculus	0-5
29962345-10	2018	BBR markedly decreased the expression of PS1, Aph-1alpha and Pen-2, but had no effect on NCT.	Berberine	0-3	presenilin 1	Mus musculus	41-44
29962345-10	2018	BBR markedly decreased the expression of PS1, Aph-1alpha and Pen-2, but had no effect on NCT.	Berberine	0-3	aph1 homolog A, gamma secretase subunit	Mus musculus	46-56
29962345-10	2018	BBR markedly decreased the expression of PS1, Aph-1alpha and Pen-2, but had no effect on NCT.	Berberine	0-3	presenilin enhancer gamma secretase subunit	Mus musculus	61-66
29962345-11	2018	The levels of sAPPalpha, ADAM10 and ADAM17 in the hippocampus of BBR-treated mice significantly increased, compared with the control ones (P<0.05).	Berberine	65-68	a disintegrin and metallopeptidase domain 10	Mus musculus	25-31
29962345-11	2018	The levels of sAPPalpha, ADAM10 and ADAM17 in the hippocampus of BBR-treated mice significantly increased, compared with the control ones (P<0.05).	Berberine	65-68	a disintegrin and metallopeptidase domain 17	Mus musculus	36-42
29399112-5	2018	Notably, berberine significantly suppressed the levels of tumor necrosis factor, interleukin-1beta and monocyte chemoattractant protein-1, as well as reduced the protein expression levels of nuclear factor-kappaB, Bcl-2-associated X protein and cytochrome c in DAI rats.	Berberine	9-18	interleukin 1 beta	Rattus norvegicus	81-98
29399112-5	2018	Notably, berberine significantly suppressed the levels of tumor necrosis factor, interleukin-1beta and monocyte chemoattractant protein-1, as well as reduced the protein expression levels of nuclear factor-kappaB, Bcl-2-associated X protein and cytochrome c in DAI rats.	Berberine	9-18	C-C motif chemokine ligand 2	Rattus norvegicus	103-137
29399112-5	2018	Notably, berberine significantly suppressed the levels of tumor necrosis factor, interleukin-1beta and monocyte chemoattractant protein-1, as well as reduced the protein expression levels of nuclear factor-kappaB, Bcl-2-associated X protein and cytochrome c in DAI rats.	Berberine	9-18	BCL2, apoptosis regulator	Rattus norvegicus	214-219
29154866-6	2018	Inhibition of IGF-I/IGFBP-3 signaling by AG1024 or siRNAs reduced berberine-induced occludin and claudin-1 production.	Berberine	66-75	insulin-like growth factor 1	Rattus norvegicus	14-19
29154866-0	2018	Activation of IGF-1/IGFBP-3 signaling by berberine improves intestinal mucosal barrier of rats with acute endotoxemia.	Berberine	41-50	insulin-like growth factor 1	Rattus norvegicus	14-19
29154866-0	2018	Activation of IGF-1/IGFBP-3 signaling by berberine improves intestinal mucosal barrier of rats with acute endotoxemia.	Berberine	41-50	insulin-like growth factor binding protein 3	Rattus norvegicus	20-27
29154866-3	2018	In this model of acute endotoxemia, the regulatory effect of berberine on IGF-I/IGFBP-3 and TJP expression in ileal mucosa was evaluated.	Berberine	61-70	insulin-like growth factor 1	Rattus norvegicus	74-79
29154866-3	2018	In this model of acute endotoxemia, the regulatory effect of berberine on IGF-I/IGFBP-3 and TJP expression in ileal mucosa was evaluated.	Berberine	61-70	insulin-like growth factor binding protein 3	Rattus norvegicus	80-87
29154866-5	2018	LPS injection inhibited occludin and claudin-1 protein generation, and this inhibitory effect of LPS was abolished by berberine.	Berberine	118-127	occludin	Rattus norvegicus	24-32
29115406-0	2018	Berberine prevents the apoptosis of mouse podocytes induced by TRAF5 overexpression by suppressing NF-kappaB activation.	Berberine	0-9	TNF receptor-associated factor 5	Mus musculus	63-68
30175975-0	2018	Berberine Alleviates Tau Hyperphosphorylation and Axonopathy-Associated with Diabetic Encephalopathy via Restoring PI3K/Akt/GSK3beta Pathway.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	120-123
30175975-0	2018	Berberine Alleviates Tau Hyperphosphorylation and Axonopathy-Associated with Diabetic Encephalopathy via Restoring PI3K/Akt/GSK3beta Pathway.	Berberine	0-9	glycogen synthase kinase 3 beta	Rattus norvegicus	124-132
30175975-10	2018	Berberine significantly attenuated memory impairment, axonopathy, and tau hyperphosphorylation, and also restored PI3K/Akt/GSK3beta signaling pathway in T2D rats.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	119-122
30175975-10	2018	Berberine significantly attenuated memory impairment, axonopathy, and tau hyperphosphorylation, and also restored PI3K/Akt/GSK3beta signaling pathway in T2D rats.	Berberine	0-9	glycogen synthase kinase 3 beta	Rattus norvegicus	123-131
30175975-11	2018	In vitro, berberine induced an increase in the phosphorylation of PI3K/Akt as well as GSK3beta in high glucose-treated primary neurons.	Berberine	10-19	AKT serine/threonine kinase 1	Rattus norvegicus	71-74
30175975-11	2018	In vitro, berberine induced an increase in the phosphorylation of PI3K/Akt as well as GSK3beta in high glucose-treated primary neurons.	Berberine	10-19	glycogen synthase kinase 3 beta	Rattus norvegicus	86-94
30175975-12	2018	Furthermore, berberine-induced PI3K/Akt activation also resulted in the dephosphorylation of tau protein, which could improve axonal transport impairment in high glucose-treated primary neurons.	Berberine	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	36-39
30175975-13	2018	Pretreated neurons with LY294002, an inhibitor of PI3K, partially blocked berberine-inhibited tau phosphorylation and berberine-activated PI3K/Akt signaling pathway.	Berberine	74-83	AKT serine/threonine kinase 1	Rattus norvegicus	143-146
30175975-13	2018	Pretreated neurons with LY294002, an inhibitor of PI3K, partially blocked berberine-inhibited tau phosphorylation and berberine-activated PI3K/Akt signaling pathway.	Berberine	118-127	AKT serine/threonine kinase 1	Rattus norvegicus	143-146
30175975-14	2018	CONCLUSIONS: Berberine exerts the protective effect against cognitive deficits by improving tau hyperphosphorylation and the axonal damage through restoring PI3K/Akt/GSK3beta signaling pathway.	Berberine	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	162-165
30175975-14	2018	CONCLUSIONS: Berberine exerts the protective effect against cognitive deficits by improving tau hyperphosphorylation and the axonal damage through restoring PI3K/Akt/GSK3beta signaling pathway.	Berberine	13-22	glycogen synthase kinase 3 beta	Rattus norvegicus	166-174
28495517-1	2018	SCOPE: Existing research indicates that anti-inflammatory and antioxidant properties of berberine play major roles in coping with oxidative stress in neurodegenerative diseases, but it is not known if this isoquinoline alkaloid affects inflammatory cytokines such as interleukin 10 in focal cerebral ischemia.	Berberine	88-97	interleukin 10	Rattus norvegicus	267-281
29491275-4	2018	Osthole, gramine, and hordenine were identified as both mouse and human beta2-AR agonists, whereas berberine was identified as a mouse beta2-AR agonist only.	Berberine	99-108	adrenergic receptor, beta 2	Mus musculus	135-143
29451201-5	2018	Finally, we will illustrate some of the promising results obtained using berberine, a plant extract with potent inhibitory activity on DPP-IV.	Berberine	73-82	dipeptidyl peptidase 4	Homo sapiens	135-141
29283990-7	2017	RESULTS Serum ALT and AST levels were significantly reduced by berberine (100 and 200 mg/kg/day) in mice with Con A-induced hepatitis.	Berberine	63-72	glutamic pyruvic transaminase, soluble	Mus musculus	14-17
29283990-7	2017	RESULTS Serum ALT and AST levels were significantly reduced by berberine (100 and 200 mg/kg/day) in mice with Con A-induced hepatitis.	Berberine	63-72	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	22-25
29283990-9	2017	Serum levels of tumor necrosis factor (TNF)-alpha, interferon (IF)-gamma, interleukin (IL)-2, and IL-1beta were reduced by berberine pre-treatment; levels of serum IL-10, an anti-inflammatory cytokine, was elevated.	Berberine	123-132	tumor necrosis factor	Mus musculus	16-49
29283990-9	2017	Serum levels of tumor necrosis factor (TNF)-alpha, interferon (IF)-gamma, interleukin (IL)-2, and IL-1beta were reduced by berberine pre-treatment; levels of serum IL-10, an anti-inflammatory cytokine, was elevated.	Berberine	123-132	interleukin 1 beta	Mus musculus	98-106
29283990-9	2017	Serum levels of tumor necrosis factor (TNF)-alpha, interferon (IF)-gamma, interleukin (IL)-2, and IL-1beta were reduced by berberine pre-treatment; levels of serum IL-10, an anti-inflammatory cytokine, was elevated.	Berberine	123-132	interleukin 10	Mus musculus	164-169
28846104-0	2017	Berberine binds RXRalpha to suppress beta-catenin signaling in colon cancer cells.	Berberine	0-9	retinoid X receptor alpha	Homo sapiens	16-24
28846104-0	2017	Berberine binds RXRalpha to suppress beta-catenin signaling in colon cancer cells.	Berberine	0-9	catenin beta 1	Homo sapiens	37-49
28846104-4	2017	Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXRalpha), where berberine concomitantly binding to and synergistically activating RXRalpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXRalpha.	Berberine	31-40	catenin beta 1	Homo sapiens	50-62
29115406-8	2018	The NF-kappaB inhibitor, caffeic acid phenethyl ester (CAPE), mimicked the protective effects of BBR, as evidenced by the increased expression of nephrin and podocin, and the decreased the expression of caspase-3 and the ratio of Bax/Bcl-2.	Berberine	97-100	nephrosis 1, nephrin	Mus musculus	146-153
29115406-8	2018	The NF-kappaB inhibitor, caffeic acid phenethyl ester (CAPE), mimicked the protective effects of BBR, as evidenced by the increased expression of nephrin and podocin, and the decreased the expression of caspase-3 and the ratio of Bax/Bcl-2.	Berberine	97-100	nephrosis 2, podocin	Mus musculus	158-165
29115406-8	2018	The NF-kappaB inhibitor, caffeic acid phenethyl ester (CAPE), mimicked the protective effects of BBR, as evidenced by the increased expression of nephrin and podocin, and the decreased the expression of caspase-3 and the ratio of Bax/Bcl-2.	Berberine	97-100	caspase 3	Mus musculus	203-212
29115406-8	2018	The NF-kappaB inhibitor, caffeic acid phenethyl ester (CAPE), mimicked the protective effects of BBR, as evidenced by the increased expression of nephrin and podocin, and the decreased the expression of caspase-3 and the ratio of Bax/Bcl-2.	Berberine	97-100	BCL2-associated X protein	Mus musculus	230-233
29115406-8	2018	The NF-kappaB inhibitor, caffeic acid phenethyl ester (CAPE), mimicked the protective effects of BBR, as evidenced by the increased expression of nephrin and podocin, and the decreased the expression of caspase-3 and the ratio of Bax/Bcl-2.	Berberine	97-100	B cell leukemia/lymphoma 2	Mus musculus	234-239
28840963-0	2018	The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1.	Berberine	34-43	DNA methyltransferase 1	Homo sapiens	75-80
28840963-0	2018	The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1.	Berberine	34-43	3-phosphoinositide dependent protein kinase 1	Homo sapiens	126-131
28840963-2	2018	We have showed that BBR inhibited growth of non-small cell lung cancer (NSCLC) cells through mitogen-activated protein kinase (MAPK)-mediated increase in forkhead box O3a (FOXO3a).	Berberine	20-23	forkhead box O3	Homo sapiens	154-170
28840963-2	2018	We have showed that BBR inhibited growth of non-small cell lung cancer (NSCLC) cells through mitogen-activated protein kinase (MAPK)-mediated increase in forkhead box O3a (FOXO3a).	Berberine	20-23	forkhead box O3	Homo sapiens	172-178
28840963-5	2018	Mechanistically, we observed that BBR reduced 3-phosphoinositide-dependent protein kinase-1 (PDPK1) and transcription factor SP1 protein expressions.	Berberine	34-37	3-phosphoinositide dependent protein kinase 1	Homo sapiens	46-91
28840963-5	2018	Mechanistically, we observed that BBR reduced 3-phosphoinositide-dependent protein kinase-1 (PDPK1) and transcription factor SP1 protein expressions.	Berberine	34-37	3-phosphoinositide dependent protein kinase 1	Homo sapiens	93-98
28840963-8	2018	Intriguingly, overexpressed PDPK1 antagonized BBR-inhibited SP1 and DNMT1 expressions.	Berberine	46-49	3-phosphoinositide dependent protein kinase 1	Homo sapiens	28-33
28840963-8	2018	Intriguingly, overexpressed PDPK1 antagonized BBR-inhibited SP1 and DNMT1 expressions.	Berberine	46-49	DNA methyltransferase 1	Homo sapiens	68-73
29806860-0	2018	Berberine Improves Cognitive Deficiency and Muscular Dysfunction via Activation of the AMPK/SIRT1/PGC-1a Pathway in Skeletal Muscle from Naturally Aging Rats.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	87-91
29806860-0	2018	Berberine Improves Cognitive Deficiency and Muscular Dysfunction via Activation of the AMPK/SIRT1/PGC-1a Pathway in Skeletal Muscle from Naturally Aging Rats.	Berberine	0-9	sirtuin 1	Rattus norvegicus	92-97
29806860-0	2018	Berberine Improves Cognitive Deficiency and Muscular Dysfunction via Activation of the AMPK/SIRT1/PGC-1a Pathway in Skeletal Muscle from Naturally Aging Rats.	Berberine	0-9	PPARG coactivator 1 alpha	Rattus norvegicus	98-104
29806860-14	2018	Berberine increased the protein expression of p-AMPK, SIRT1 and PGC-1alpha and increased the production of ATP in the skeletal muscle of aging rats (p&lt;0.01).	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	48-52
29806860-14	2018	Berberine increased the protein expression of p-AMPK, SIRT1 and PGC-1alpha and increased the production of ATP in the skeletal muscle of aging rats (p&lt;0.01).	Berberine	0-9	sirtuin 1	Rattus norvegicus	54-59
29806860-14	2018	Berberine increased the protein expression of p-AMPK, SIRT1 and PGC-1alpha and increased the production of ATP in the skeletal muscle of aging rats (p&lt;0.01).	Berberine	0-9	PPARG coactivator 1 alpha	Rattus norvegicus	64-74
29806860-15	2018	CONCLUSIONS: Berberine markedly ameliorates aging-related reductions in cognitive ability and muscular function, and the activation of the AMPK/SIRT1/PGC-1alpha pathway in skeletal muscle may be the underlying protective mechanism of berberine on muscular function.	Berberine	234-243	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	139-143
29806860-15	2018	CONCLUSIONS: Berberine markedly ameliorates aging-related reductions in cognitive ability and muscular function, and the activation of the AMPK/SIRT1/PGC-1alpha pathway in skeletal muscle may be the underlying protective mechanism of berberine on muscular function.	Berberine	234-243	sirtuin 1	Rattus norvegicus	144-149
29806860-15	2018	CONCLUSIONS: Berberine markedly ameliorates aging-related reductions in cognitive ability and muscular function, and the activation of the AMPK/SIRT1/PGC-1alpha pathway in skeletal muscle may be the underlying protective mechanism of berberine on muscular function.	Berberine	234-243	PPARG coactivator 1 alpha	Rattus norvegicus	150-160
29154866-6	2018	Inhibition of IGF-I/IGFBP-3 signaling by AG1024 or siRNAs reduced berberine-induced occludin and claudin-1 production.	Berberine	66-75	insulin-like growth factor binding protein 3	Rattus norvegicus	20-27
29154866-6	2018	Inhibition of IGF-I/IGFBP-3 signaling by AG1024 or siRNAs reduced berberine-induced occludin and claudin-1 production.	Berberine	66-75	occludin	Rattus norvegicus	84-92
29154866-6	2018	Inhibition of IGF-I/IGFBP-3 signaling by AG1024 or siRNAs reduced berberine-induced occludin and claudin-1 production.	Berberine	66-75	claudin 1	Rattus norvegicus	97-106
29154866-7	2018	Additionally, GW9662 was found to repress berberine-induced IGF-I/IGFBP-3 expression, indicating of a cross-link between PPARgamma and IGF-I/IGFBP-3 axis.	Berberine	42-51	insulin-like growth factor 1	Rattus norvegicus	60-65
29154866-7	2018	Additionally, GW9662 was found to repress berberine-induced IGF-I/IGFBP-3 expression, indicating of a cross-link between PPARgamma and IGF-I/IGFBP-3 axis.	Berberine	42-51	insulin-like growth factor binding protein 3	Rattus norvegicus	66-73
29154866-7	2018	Additionally, GW9662 was found to repress berberine-induced IGF-I/IGFBP-3 expression, indicating of a cross-link between PPARgamma and IGF-I/IGFBP-3 axis.	Berberine	42-51	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	121-130
29154866-7	2018	Additionally, GW9662 was found to repress berberine-induced IGF-I/IGFBP-3 expression, indicating of a cross-link between PPARgamma and IGF-I/IGFBP-3 axis.	Berberine	42-51	insulin-like growth factor 1	Rattus norvegicus	135-140
29154866-7	2018	Additionally, GW9662 was found to repress berberine-induced IGF-I/IGFBP-3 expression, indicating of a cross-link between PPARgamma and IGF-I/IGFBP-3 axis.	Berberine	42-51	insulin-like growth factor binding protein 3	Rattus norvegicus	141-148
29170048-6	2018	Docking results showed that berberine inhibited AChE, COX-2 and TACE.	Berberine	28-37	acetylcholinesterase	Rattus norvegicus	48-52
29170048-6	2018	Docking results showed that berberine inhibited AChE, COX-2 and TACE.	Berberine	28-37	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	54-59
29170048-6	2018	Docking results showed that berberine inhibited AChE, COX-2 and TACE.	Berberine	28-37	ADAM metallopeptidase domain 17	Rattus norvegicus	64-68
29170048-7	2018	Matching with in silico study, berberine downregulated the AChE expression and inhibited its activity in the brain tissues.	Berberine	31-40	acetylcholinesterase	Rattus norvegicus	59-63
29285168-0	2017	Berberine inhibits the LPS-induced proliferation and inflammatory response of stromal cells of adenomyosis tissues mediated by the LPS/TLR4 signaling pathway.	Berberine	0-9	toll like receptor 4	Homo sapiens	135-139
29228954-11	2017	In addition, immunohistochemical analysis revealed that BB + EV treatment down-regulated the expressions of intestinal NPC1L1 and ACAT2, and ApoB48 in HFD induced rats.	Berberine	56-58	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	119-125
29228954-11	2017	In addition, immunohistochemical analysis revealed that BB + EV treatment down-regulated the expressions of intestinal NPC1L1 and ACAT2, and ApoB48 in HFD induced rats.	Berberine	56-58	acetyl-CoA acetyltransferase 2	Rattus norvegicus	130-135
29228954-11	2017	In addition, immunohistochemical analysis revealed that BB + EV treatment down-regulated the expressions of intestinal NPC1L1 and ACAT2, and ApoB48 in HFD induced rats.	Berberine	56-58	apolipoprotein B	Rattus norvegicus	141-147
28847510-8	2017	Our studies provide novel insight into potential approaches to treatment of FOP, since several AMPK activators (e.g. metformin, berberine, and aspirin) are already in clinical use for the treatment of diabetes and metabolic syndromes.	Berberine	128-137	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	95-99
28990249-0	2017	Berberine inhibits the chemotherapy-induced repopulation by suppressing the arachidonic acid metabolic pathway and phosphorylation of FAK in ovarian cancer.	Berberine	0-9	protein tyrosine kinase 2	Homo sapiens	134-137
28990249-8	2017	Berberine can block the caspase 3-iPLA2 -AA-COX-2-PGE2 pathway by inhibiting the expression of iPLA2 and COX-2.	Berberine	0-9	caspase 3	Homo sapiens	24-33
28990249-8	2017	Berberine can block the caspase 3-iPLA2 -AA-COX-2-PGE2 pathway by inhibiting the expression of iPLA2 and COX-2.	Berberine	0-9	phospholipase A2 group VI	Homo sapiens	34-39
28990249-8	2017	Berberine can block the caspase 3-iPLA2 -AA-COX-2-PGE2 pathway by inhibiting the expression of iPLA2 and COX-2.	Berberine	0-9	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	44-49
28990249-8	2017	Berberine can block the caspase 3-iPLA2 -AA-COX-2-PGE2 pathway by inhibiting the expression of iPLA2 and COX-2.	Berberine	0-9	phospholipase A2 group VI	Homo sapiens	95-100
28990249-8	2017	Berberine can block the caspase 3-iPLA2 -AA-COX-2-PGE2 pathway by inhibiting the expression of iPLA2 and COX-2.	Berberine	0-9	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	105-110
28990249-9	2017	Berberine can also reverse the increased phosphorylation of FAK caused by abnormal PGE2 level and thus reverse the repopulation of ovarian cancer cells after VP16 treatment.	Berberine	0-9	protein tyrosine kinase 2	Homo sapiens	60-63
28990249-9	2017	Berberine can also reverse the increased phosphorylation of FAK caused by abnormal PGE2 level and thus reverse the repopulation of ovarian cancer cells after VP16 treatment.	Berberine	0-9	host cell factor C1	Homo sapiens	158-162
28990249-10	2017	CONCLUSIONS: Our observation suggested that Berberine could inhibit the chemotherapy-induced repopulation of ovarian cancer cells by suppressing the AA pathway and phosphorylation of FAK.	Berberine	44-53	protein tyrosine kinase 2	Homo sapiens	183-186
29171745-1	2017	We have been following up on concerns of overlapping text and duplicate Western blots within the following PLOS ONE article:[1] Berberine Improves Kidney Function in Diabetic Mice via AMPK Activationhttps://doi.org/10.1371/journal.pone.0113398Received: June 9, 2014; Accepted: October 23, 2014; Published: November 19, 2014It was initially brought to our attention that there is duplication of Western blot images between the PLOS ONE article and the following published papers:[2] Brain Injury (Received 28 Oct 2013, Accepted 4 Jan 2015, Published online 20 Mar 2015) doi: 10.3109/02699052.2015.1004746: Figure 6b GAPDH is similar to Figure 2A AMPK in [1] [3] Exp Mol Pathol (Received 24 Feb 2014, Accepted 10 Sep 2014, Available online 16 Sep 2014) doi:10.1016/j.yexmp.2014.09.006: Figure 5B GAPDH is similar to Figure 2A AMPK in [1]; Figure 5C Occludin is similar to Figure 2A LKB1 in [1] [4] Korean J Physiol Pharmacol, (Received 7 Nov 2013, Accepted 3 Jan 2016) doi: 10.4196/kjpp.2016.20.4.325 RETRACTED: Figure 6B GAPDH is similar to Figure 2A AMPK [1] Please note that the KJPP paper has been retracted as a result of the content duplication issues.During the course of our follow up, we have discovered additional instances of possible duplication as follows: [5] Gastroenterology and Hepatology (Accepted 6 Aug 2014, Accepted ms online 28 Aug 2014, Published 23 Feb 2015) doi:10.1111/jgh.12723: Figure 1d AMPK is similar to Figure 2A AMPK in [1], Figure 3a iNOS is similar to Figure 2A LKB1 in [1] [6] Acta Pharmacologica Sinica (Received 4 Mar 2014, Accepted 28 July 2014, Published 17 Nov 2014) doi: 10.1038/aps.2014.88: Figure 1 A and B bar charts are similar to Figure 1 A and B bar charts in [1], Figure 1E AMPK is similar to Figure 2A AMPK in [1], Figure 1E p-AMPK is similar to Figure 2A P-AMPK in [1], Figure 1E bar chart is similar to the Figure 2A bar chart in [1] [7] Asian Pac J Cancer Prev (Published Jan 2014) doi: 10.7314/APJCP.2014.15.2.677: Figure 3A GAPDH is similar to Figure 2A AMPK in [1] and p27 kip1 is similar to Figure 2A P-AMPK in [1] [8] Clinical and Experimental Hypertension (Received 15 Sep 2015, Accepted 24 Nov 2015, Published 5 May 2016) doi: 10.3109/10641963.2015.1131288: Figure 2A LKB1 and P-AMPK are similar to Figure 2A LKB1 and P-AMPK in [1], Figure 2B P-AMPK and AMPK are similar to Figure 2B P-AMPK and AMPK in [1], Figure 2A and B bar charts appear similar in both articles.	Berberine	128-137	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	615-620
28436095-0	2017	Berberine Alleviates Oxidative Stress in Islets of Diabetic Mice by Inhibiting miR-106b Expression and Up-Regulating SIRT1.	Berberine	0-9	microRNA 106b	Mus musculus	79-87
28436095-0	2017	Berberine Alleviates Oxidative Stress in Islets of Diabetic Mice by Inhibiting miR-106b Expression and Up-Regulating SIRT1.	Berberine	0-9	sirtuin 1	Mus musculus	117-122
28436095-13	2017	In addition, miR-106b over-expression could reverse the protection of berberine in NIT-1 cells against from oxidative stress induced by high glucose.	Berberine	70-79	microRNA 106b	Mus musculus	13-21
28436095-14	2017	Berberine could attenuate oxidative stress of diabetic mice at least partly through miR-106b/SIRT1 pathway and affecting the function of islets, which might be beneficial in reducing the cardiovascular risk factors in diabetes.	Berberine	0-9	microRNA 106b	Mus musculus	84-92
28436095-14	2017	Berberine could attenuate oxidative stress of diabetic mice at least partly through miR-106b/SIRT1 pathway and affecting the function of islets, which might be beneficial in reducing the cardiovascular risk factors in diabetes.	Berberine	0-9	sirtuin 1	Mus musculus	93-98
27927051-0	2017	Effect of berberine on PPARalpha-NO signalling pathway in vascular smooth muscle cell proliferation induced by angiotensin IV.	Berberine	10-19	peroxisome proliferator activated receptor alpha	Homo sapiens	23-32
27927051-4	2017	OBJECTIVE: To evaluate the effect of berberine and its possible influence on PPARalpha-NO pathway in angiotensin IV-stimulated VSMCs.	Berberine	37-46	peroxisome proliferator activated receptor alpha	Homo sapiens	77-86
27927051-11	2017	DISCUSSION AND CONCLUSION: The results support the therapeutic effects of berberine on angiotensin IV-induced proliferation in cultured VSMCs at least partially through targeting the PPARalpha-NO signalling pathway.	Berberine	74-83	peroxisome proliferator activated receptor alpha	Homo sapiens	183-192
29132092-0	2017	Berberine attenuates cognitive impairment and ameliorates tau hyperphosphorylation by limiting the self-perpetuating pathogenic cycle between NF-kappaB signaling, oxidative stress and neuroinflammation.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	142-151
29132092-8	2017	BBR decreased the hyperphosphorylated tau protein in the hippocampus of APP/PS1 mice.	Berberine	0-3	presenilin 1	Mus musculus	76-79
29132092-9	2017	BBR lowered the activity of NF-kappaB signaling in the hippocampus of AD mice.	Berberine	0-3	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	28-37
29132092-11	2017	CONCLUSION: BBR attenuated cognitive deficits and limited hyperphosphorylation of tau via inhibiting the activation of NF-kappaB signaling pathway, and by retarding oxidative stress and neuro-inflammation.	Berberine	12-15	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	119-128
29171745-1	2017	We have been following up on concerns of overlapping text and duplicate Western blots within the following PLOS ONE article:[1] Berberine Improves Kidney Function in Diabetic Mice via AMPK Activationhttps://doi.org/10.1371/journal.pone.0113398Received: June 9, 2014; Accepted: October 23, 2014; Published: November 19, 2014It was initially brought to our attention that there is duplication of Western blot images between the PLOS ONE article and the following published papers:[2] Brain Injury (Received 28 Oct 2013, Accepted 4 Jan 2015, Published online 20 Mar 2015) doi: 10.3109/02699052.2015.1004746: Figure 6b GAPDH is similar to Figure 2A AMPK in [1] [3] Exp Mol Pathol (Received 24 Feb 2014, Accepted 10 Sep 2014, Available online 16 Sep 2014) doi:10.1016/j.yexmp.2014.09.006: Figure 5B GAPDH is similar to Figure 2A AMPK in [1]; Figure 5C Occludin is similar to Figure 2A LKB1 in [1] [4] Korean J Physiol Pharmacol, (Received 7 Nov 2013, Accepted 3 Jan 2016) doi: 10.4196/kjpp.2016.20.4.325 RETRACTED: Figure 6B GAPDH is similar to Figure 2A AMPK [1] Please note that the KJPP paper has been retracted as a result of the content duplication issues.During the course of our follow up, we have discovered additional instances of possible duplication as follows: [5] Gastroenterology and Hepatology (Accepted 6 Aug 2014, Accepted ms online 28 Aug 2014, Published 23 Feb 2015) doi:10.1111/jgh.12723: Figure 1d AMPK is similar to Figure 2A AMPK in [1], Figure 3a iNOS is similar to Figure 2A LKB1 in [1] [6] Acta Pharmacologica Sinica (Received 4 Mar 2014, Accepted 28 July 2014, Published 17 Nov 2014) doi: 10.1038/aps.2014.88: Figure 1 A and B bar charts are similar to Figure 1 A and B bar charts in [1], Figure 1E AMPK is similar to Figure 2A AMPK in [1], Figure 1E p-AMPK is similar to Figure 2A P-AMPK in [1], Figure 1E bar chart is similar to the Figure 2A bar chart in [1] [7] Asian Pac J Cancer Prev (Published Jan 2014) doi: 10.7314/APJCP.2014.15.2.677: Figure 3A GAPDH is similar to Figure 2A AMPK in [1] and p27 kip1 is similar to Figure 2A P-AMPK in [1] [8] Clinical and Experimental Hypertension (Received 15 Sep 2015, Accepted 24 Nov 2015, Published 5 May 2016) doi: 10.3109/10641963.2015.1131288: Figure 2A LKB1 and P-AMPK are similar to Figure 2A LKB1 and P-AMPK in [1], Figure 2B P-AMPK and AMPK are similar to Figure 2B P-AMPK and AMPK in [1], Figure 2A and B bar charts appear similar in both articles.	Berberine	128-137	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	794-799
29171745-1	2017	We have been following up on concerns of overlapping text and duplicate Western blots within the following PLOS ONE article:[1] Berberine Improves Kidney Function in Diabetic Mice via AMPK Activationhttps://doi.org/10.1371/journal.pone.0113398Received: June 9, 2014; Accepted: October 23, 2014; Published: November 19, 2014It was initially brought to our attention that there is duplication of Western blot images between the PLOS ONE article and the following published papers:[2] Brain Injury (Received 28 Oct 2013, Accepted 4 Jan 2015, Published online 20 Mar 2015) doi: 10.3109/02699052.2015.1004746: Figure 6b GAPDH is similar to Figure 2A AMPK in [1] [3] Exp Mol Pathol (Received 24 Feb 2014, Accepted 10 Sep 2014, Available online 16 Sep 2014) doi:10.1016/j.yexmp.2014.09.006: Figure 5B GAPDH is similar to Figure 2A AMPK in [1]; Figure 5C Occludin is similar to Figure 2A LKB1 in [1] [4] Korean J Physiol Pharmacol, (Received 7 Nov 2013, Accepted 3 Jan 2016) doi: 10.4196/kjpp.2016.20.4.325 RETRACTED: Figure 6B GAPDH is similar to Figure 2A AMPK [1] Please note that the KJPP paper has been retracted as a result of the content duplication issues.During the course of our follow up, we have discovered additional instances of possible duplication as follows: [5] Gastroenterology and Hepatology (Accepted 6 Aug 2014, Accepted ms online 28 Aug 2014, Published 23 Feb 2015) doi:10.1111/jgh.12723: Figure 1d AMPK is similar to Figure 2A AMPK in [1], Figure 3a iNOS is similar to Figure 2A LKB1 in [1] [6] Acta Pharmacologica Sinica (Received 4 Mar 2014, Accepted 28 July 2014, Published 17 Nov 2014) doi: 10.1038/aps.2014.88: Figure 1 A and B bar charts are similar to Figure 1 A and B bar charts in [1], Figure 1E AMPK is similar to Figure 2A AMPK in [1], Figure 1E p-AMPK is similar to Figure 2A P-AMPK in [1], Figure 1E bar chart is similar to the Figure 2A bar chart in [1] [7] Asian Pac J Cancer Prev (Published Jan 2014) doi: 10.7314/APJCP.2014.15.2.677: Figure 3A GAPDH is similar to Figure 2A AMPK in [1] and p27 kip1 is similar to Figure 2A P-AMPK in [1] [8] Clinical and Experimental Hypertension (Received 15 Sep 2015, Accepted 24 Nov 2015, Published 5 May 2016) doi: 10.3109/10641963.2015.1131288: Figure 2A LKB1 and P-AMPK are similar to Figure 2A LKB1 and P-AMPK in [1], Figure 2B P-AMPK and AMPK are similar to Figure 2B P-AMPK and AMPK in [1], Figure 2A and B bar charts appear similar in both articles.	Berberine	128-137	serine/threonine kinase 11	Mus musculus	880-884
29171745-1	2017	We have been following up on concerns of overlapping text and duplicate Western blots within the following PLOS ONE article:[1] Berberine Improves Kidney Function in Diabetic Mice via AMPK Activationhttps://doi.org/10.1371/journal.pone.0113398Received: June 9, 2014; Accepted: October 23, 2014; Published: November 19, 2014It was initially brought to our attention that there is duplication of Western blot images between the PLOS ONE article and the following published papers:[2] Brain Injury (Received 28 Oct 2013, Accepted 4 Jan 2015, Published online 20 Mar 2015) doi: 10.3109/02699052.2015.1004746: Figure 6b GAPDH is similar to Figure 2A AMPK in [1] [3] Exp Mol Pathol (Received 24 Feb 2014, Accepted 10 Sep 2014, Available online 16 Sep 2014) doi:10.1016/j.yexmp.2014.09.006: Figure 5B GAPDH is similar to Figure 2A AMPK in [1]; Figure 5C Occludin is similar to Figure 2A LKB1 in [1] [4] Korean J Physiol Pharmacol, (Received 7 Nov 2013, Accepted 3 Jan 2016) doi: 10.4196/kjpp.2016.20.4.325 RETRACTED: Figure 6B GAPDH is similar to Figure 2A AMPK [1] Please note that the KJPP paper has been retracted as a result of the content duplication issues.During the course of our follow up, we have discovered additional instances of possible duplication as follows: [5] Gastroenterology and Hepatology (Accepted 6 Aug 2014, Accepted ms online 28 Aug 2014, Published 23 Feb 2015) doi:10.1111/jgh.12723: Figure 1d AMPK is similar to Figure 2A AMPK in [1], Figure 3a iNOS is similar to Figure 2A LKB1 in [1] [6] Acta Pharmacologica Sinica (Received 4 Mar 2014, Accepted 28 July 2014, Published 17 Nov 2014) doi: 10.1038/aps.2014.88: Figure 1 A and B bar charts are similar to Figure 1 A and B bar charts in [1], Figure 1E AMPK is similar to Figure 2A AMPK in [1], Figure 1E p-AMPK is similar to Figure 2A P-AMPK in [1], Figure 1E bar chart is similar to the Figure 2A bar chart in [1] [7] Asian Pac J Cancer Prev (Published Jan 2014) doi: 10.7314/APJCP.2014.15.2.677: Figure 3A GAPDH is similar to Figure 2A AMPK in [1] and p27 kip1 is similar to Figure 2A P-AMPK in [1] [8] Clinical and Experimental Hypertension (Received 15 Sep 2015, Accepted 24 Nov 2015, Published 5 May 2016) doi: 10.3109/10641963.2015.1131288: Figure 2A LKB1 and P-AMPK are similar to Figure 2A LKB1 and P-AMPK in [1], Figure 2B P-AMPK and AMPK are similar to Figure 2B P-AMPK and AMPK in [1], Figure 2A and B bar charts appear similar in both articles.	Berberine	128-137	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	794-799
29171745-1	2017	We have been following up on concerns of overlapping text and duplicate Western blots within the following PLOS ONE article:[1] Berberine Improves Kidney Function in Diabetic Mice via AMPK Activationhttps://doi.org/10.1371/journal.pone.0113398Received: June 9, 2014; Accepted: October 23, 2014; Published: November 19, 2014It was initially brought to our attention that there is duplication of Western blot images between the PLOS ONE article and the following published papers:[2] Brain Injury (Received 28 Oct 2013, Accepted 4 Jan 2015, Published online 20 Mar 2015) doi: 10.3109/02699052.2015.1004746: Figure 6b GAPDH is similar to Figure 2A AMPK in [1] [3] Exp Mol Pathol (Received 24 Feb 2014, Accepted 10 Sep 2014, Available online 16 Sep 2014) doi:10.1016/j.yexmp.2014.09.006: Figure 5B GAPDH is similar to Figure 2A AMPK in [1]; Figure 5C Occludin is similar to Figure 2A LKB1 in [1] [4] Korean J Physiol Pharmacol, (Received 7 Nov 2013, Accepted 3 Jan 2016) doi: 10.4196/kjpp.2016.20.4.325 RETRACTED: Figure 6B GAPDH is similar to Figure 2A AMPK [1] Please note that the KJPP paper has been retracted as a result of the content duplication issues.During the course of our follow up, we have discovered additional instances of possible duplication as follows: [5] Gastroenterology and Hepatology (Accepted 6 Aug 2014, Accepted ms online 28 Aug 2014, Published 23 Feb 2015) doi:10.1111/jgh.12723: Figure 1d AMPK is similar to Figure 2A AMPK in [1], Figure 3a iNOS is similar to Figure 2A LKB1 in [1] [6] Acta Pharmacologica Sinica (Received 4 Mar 2014, Accepted 28 July 2014, Published 17 Nov 2014) doi: 10.1038/aps.2014.88: Figure 1 A and B bar charts are similar to Figure 1 A and B bar charts in [1], Figure 1E AMPK is similar to Figure 2A AMPK in [1], Figure 1E p-AMPK is similar to Figure 2A P-AMPK in [1], Figure 1E bar chart is similar to the Figure 2A bar chart in [1] [7] Asian Pac J Cancer Prev (Published Jan 2014) doi: 10.7314/APJCP.2014.15.2.677: Figure 3A GAPDH is similar to Figure 2A AMPK in [1] and p27 kip1 is similar to Figure 2A P-AMPK in [1] [8] Clinical and Experimental Hypertension (Received 15 Sep 2015, Accepted 24 Nov 2015, Published 5 May 2016) doi: 10.3109/10641963.2015.1131288: Figure 2A LKB1 and P-AMPK are similar to Figure 2A LKB1 and P-AMPK in [1], Figure 2B P-AMPK and AMPK are similar to Figure 2B P-AMPK and AMPK in [1], Figure 2A and B bar charts appear similar in both articles.	Berberine	128-137	serine/threonine kinase 11	Mus musculus	1495-1499
29171745-1	2017	We have been following up on concerns of overlapping text and duplicate Western blots within the following PLOS ONE article:[1] Berberine Improves Kidney Function in Diabetic Mice via AMPK Activationhttps://doi.org/10.1371/journal.pone.0113398Received: June 9, 2014; Accepted: October 23, 2014; Published: November 19, 2014It was initially brought to our attention that there is duplication of Western blot images between the PLOS ONE article and the following published papers:[2] Brain Injury (Received 28 Oct 2013, Accepted 4 Jan 2015, Published online 20 Mar 2015) doi: 10.3109/02699052.2015.1004746: Figure 6b GAPDH is similar to Figure 2A AMPK in [1] [3] Exp Mol Pathol (Received 24 Feb 2014, Accepted 10 Sep 2014, Available online 16 Sep 2014) doi:10.1016/j.yexmp.2014.09.006: Figure 5B GAPDH is similar to Figure 2A AMPK in [1]; Figure 5C Occludin is similar to Figure 2A LKB1 in [1] [4] Korean J Physiol Pharmacol, (Received 7 Nov 2013, Accepted 3 Jan 2016) doi: 10.4196/kjpp.2016.20.4.325 RETRACTED: Figure 6B GAPDH is similar to Figure 2A AMPK [1] Please note that the KJPP paper has been retracted as a result of the content duplication issues.During the course of our follow up, we have discovered additional instances of possible duplication as follows: [5] Gastroenterology and Hepatology (Accepted 6 Aug 2014, Accepted ms online 28 Aug 2014, Published 23 Feb 2015) doi:10.1111/jgh.12723: Figure 1d AMPK is similar to Figure 2A AMPK in [1], Figure 3a iNOS is similar to Figure 2A LKB1 in [1] [6] Acta Pharmacologica Sinica (Received 4 Mar 2014, Accepted 28 July 2014, Published 17 Nov 2014) doi: 10.1038/aps.2014.88: Figure 1 A and B bar charts are similar to Figure 1 A and B bar charts in [1], Figure 1E AMPK is similar to Figure 2A AMPK in [1], Figure 1E p-AMPK is similar to Figure 2A P-AMPK in [1], Figure 1E bar chart is similar to the Figure 2A bar chart in [1] [7] Asian Pac J Cancer Prev (Published Jan 2014) doi: 10.7314/APJCP.2014.15.2.677: Figure 3A GAPDH is similar to Figure 2A AMPK in [1] and p27 kip1 is similar to Figure 2A P-AMPK in [1] [8] Clinical and Experimental Hypertension (Received 15 Sep 2015, Accepted 24 Nov 2015, Published 5 May 2016) doi: 10.3109/10641963.2015.1131288: Figure 2A LKB1 and P-AMPK are similar to Figure 2A LKB1 and P-AMPK in [1], Figure 2B P-AMPK and AMPK are similar to Figure 2B P-AMPK and AMPK in [1], Figure 2A and B bar charts appear similar in both articles.	Berberine	128-137	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	794-799
29171745-1	2017	We have been following up on concerns of overlapping text and duplicate Western blots within the following PLOS ONE article:[1] Berberine Improves Kidney Function in Diabetic Mice via AMPK Activationhttps://doi.org/10.1371/journal.pone.0113398Received: June 9, 2014; Accepted: October 23, 2014; Published: November 19, 2014It was initially brought to our attention that there is duplication of Western blot images between the PLOS ONE article and the following published papers:[2] Brain Injury (Received 28 Oct 2013, Accepted 4 Jan 2015, Published online 20 Mar 2015) doi: 10.3109/02699052.2015.1004746: Figure 6b GAPDH is similar to Figure 2A AMPK in [1] [3] Exp Mol Pathol (Received 24 Feb 2014, Accepted 10 Sep 2014, Available online 16 Sep 2014) doi:10.1016/j.yexmp.2014.09.006: Figure 5B GAPDH is similar to Figure 2A AMPK in [1]; Figure 5C Occludin is similar to Figure 2A LKB1 in [1] [4] Korean J Physiol Pharmacol, (Received 7 Nov 2013, Accepted 3 Jan 2016) doi: 10.4196/kjpp.2016.20.4.325 RETRACTED: Figure 6B GAPDH is similar to Figure 2A AMPK [1] Please note that the KJPP paper has been retracted as a result of the content duplication issues.During the course of our follow up, we have discovered additional instances of possible duplication as follows: [5] Gastroenterology and Hepatology (Accepted 6 Aug 2014, Accepted ms online 28 Aug 2014, Published 23 Feb 2015) doi:10.1111/jgh.12723: Figure 1d AMPK is similar to Figure 2A AMPK in [1], Figure 3a iNOS is similar to Figure 2A LKB1 in [1] [6] Acta Pharmacologica Sinica (Received 4 Mar 2014, Accepted 28 July 2014, Published 17 Nov 2014) doi: 10.1038/aps.2014.88: Figure 1 A and B bar charts are similar to Figure 1 A and B bar charts in [1], Figure 1E AMPK is similar to Figure 2A AMPK in [1], Figure 1E p-AMPK is similar to Figure 2A P-AMPK in [1], Figure 1E bar chart is similar to the Figure 2A bar chart in [1] [7] Asian Pac J Cancer Prev (Published Jan 2014) doi: 10.7314/APJCP.2014.15.2.677: Figure 3A GAPDH is similar to Figure 2A AMPK in [1] and p27 kip1 is similar to Figure 2A P-AMPK in [1] [8] Clinical and Experimental Hypertension (Received 15 Sep 2015, Accepted 24 Nov 2015, Published 5 May 2016) doi: 10.3109/10641963.2015.1131288: Figure 2A LKB1 and P-AMPK are similar to Figure 2A LKB1 and P-AMPK in [1], Figure 2B P-AMPK and AMPK are similar to Figure 2B P-AMPK and AMPK in [1], Figure 2A and B bar charts appear similar in both articles.	Berberine	128-137	cyclin-dependent kinase inhibitor 1B	Mus musculus	2023-2031
29171745-1	2017	We have been following up on concerns of overlapping text and duplicate Western blots within the following PLOS ONE article:[1] Berberine Improves Kidney Function in Diabetic Mice via AMPK Activationhttps://doi.org/10.1371/journal.pone.0113398Received: June 9, 2014; Accepted: October 23, 2014; Published: November 19, 2014It was initially brought to our attention that there is duplication of Western blot images between the PLOS ONE article and the following published papers:[2] Brain Injury (Received 28 Oct 2013, Accepted 4 Jan 2015, Published online 20 Mar 2015) doi: 10.3109/02699052.2015.1004746: Figure 6b GAPDH is similar to Figure 2A AMPK in [1] [3] Exp Mol Pathol (Received 24 Feb 2014, Accepted 10 Sep 2014, Available online 16 Sep 2014) doi:10.1016/j.yexmp.2014.09.006: Figure 5B GAPDH is similar to Figure 2A AMPK in [1]; Figure 5C Occludin is similar to Figure 2A LKB1 in [1] [4] Korean J Physiol Pharmacol, (Received 7 Nov 2013, Accepted 3 Jan 2016) doi: 10.4196/kjpp.2016.20.4.325 RETRACTED: Figure 6B GAPDH is similar to Figure 2A AMPK [1] Please note that the KJPP paper has been retracted as a result of the content duplication issues.During the course of our follow up, we have discovered additional instances of possible duplication as follows: [5] Gastroenterology and Hepatology (Accepted 6 Aug 2014, Accepted ms online 28 Aug 2014, Published 23 Feb 2015) doi:10.1111/jgh.12723: Figure 1d AMPK is similar to Figure 2A AMPK in [1], Figure 3a iNOS is similar to Figure 2A LKB1 in [1] [6] Acta Pharmacologica Sinica (Received 4 Mar 2014, Accepted 28 July 2014, Published 17 Nov 2014) doi: 10.1038/aps.2014.88: Figure 1 A and B bar charts are similar to Figure 1 A and B bar charts in [1], Figure 1E AMPK is similar to Figure 2A AMPK in [1], Figure 1E p-AMPK is similar to Figure 2A P-AMPK in [1], Figure 1E bar chart is similar to the Figure 2A bar chart in [1] [7] Asian Pac J Cancer Prev (Published Jan 2014) doi: 10.7314/APJCP.2014.15.2.677: Figure 3A GAPDH is similar to Figure 2A AMPK in [1] and p27 kip1 is similar to Figure 2A P-AMPK in [1] [8] Clinical and Experimental Hypertension (Received 15 Sep 2015, Accepted 24 Nov 2015, Published 5 May 2016) doi: 10.3109/10641963.2015.1131288: Figure 2A LKB1 and P-AMPK are similar to Figure 2A LKB1 and P-AMPK in [1], Figure 2B P-AMPK and AMPK are similar to Figure 2B P-AMPK and AMPK in [1], Figure 2A and B bar charts appear similar in both articles.	Berberine	128-137	serine/threonine kinase 11	Mus musculus	1495-1499
29171745-1	2017	We have been following up on concerns of overlapping text and duplicate Western blots within the following PLOS ONE article:[1] Berberine Improves Kidney Function in Diabetic Mice via AMPK Activationhttps://doi.org/10.1371/journal.pone.0113398Received: June 9, 2014; Accepted: October 23, 2014; Published: November 19, 2014It was initially brought to our attention that there is duplication of Western blot images between the PLOS ONE article and the following published papers:[2] Brain Injury (Received 28 Oct 2013, Accepted 4 Jan 2015, Published online 20 Mar 2015) doi: 10.3109/02699052.2015.1004746: Figure 6b GAPDH is similar to Figure 2A AMPK in [1] [3] Exp Mol Pathol (Received 24 Feb 2014, Accepted 10 Sep 2014, Available online 16 Sep 2014) doi:10.1016/j.yexmp.2014.09.006: Figure 5B GAPDH is similar to Figure 2A AMPK in [1]; Figure 5C Occludin is similar to Figure 2A LKB1 in [1] [4] Korean J Physiol Pharmacol, (Received 7 Nov 2013, Accepted 3 Jan 2016) doi: 10.4196/kjpp.2016.20.4.325 RETRACTED: Figure 6B GAPDH is similar to Figure 2A AMPK [1] Please note that the KJPP paper has been retracted as a result of the content duplication issues.During the course of our follow up, we have discovered additional instances of possible duplication as follows: [5] Gastroenterology and Hepatology (Accepted 6 Aug 2014, Accepted ms online 28 Aug 2014, Published 23 Feb 2015) doi:10.1111/jgh.12723: Figure 1d AMPK is similar to Figure 2A AMPK in [1], Figure 3a iNOS is similar to Figure 2A LKB1 in [1] [6] Acta Pharmacologica Sinica (Received 4 Mar 2014, Accepted 28 July 2014, Published 17 Nov 2014) doi: 10.1038/aps.2014.88: Figure 1 A and B bar charts are similar to Figure 1 A and B bar charts in [1], Figure 1E AMPK is similar to Figure 2A AMPK in [1], Figure 1E p-AMPK is similar to Figure 2A P-AMPK in [1], Figure 1E bar chart is similar to the Figure 2A bar chart in [1] [7] Asian Pac J Cancer Prev (Published Jan 2014) doi: 10.7314/APJCP.2014.15.2.677: Figure 3A GAPDH is similar to Figure 2A AMPK in [1] and p27 kip1 is similar to Figure 2A P-AMPK in [1] [8] Clinical and Experimental Hypertension (Received 15 Sep 2015, Accepted 24 Nov 2015, Published 5 May 2016) doi: 10.3109/10641963.2015.1131288: Figure 2A LKB1 and P-AMPK are similar to Figure 2A LKB1 and P-AMPK in [1], Figure 2B P-AMPK and AMPK are similar to Figure 2B P-AMPK and AMPK in [1], Figure 2A and B bar charts appear similar in both articles.	Berberine	128-137	serine/threonine kinase 11	Mus musculus	1495-1499
29055350-0	2017	Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway.	Berberine	0-9	TNF receptor superfamily member 11B	Rattus norvegicus	135-150
29055350-0	2017	Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway.	Berberine	0-9	TNF superfamily member 11	Rattus norvegicus	157-162
29055350-0	2017	Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway.	Berberine	0-9	TNF receptor superfamily member 11B	Rattus norvegicus	163-166
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	0-9	glutathione peroxidase 1	Rattus norvegicus	78-84
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	0-9	TNF receptor superfamily member 11B	Rattus norvegicus	90-93
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	0-9	bone gamma-carboxyglutamate protein	Rattus norvegicus	128-139
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	0-9	TNF superfamily member 11	Rattus norvegicus	154-159
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	40-49	glutathione peroxidase 1	Rattus norvegicus	78-84
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	40-49	TNF receptor superfamily member 11B	Rattus norvegicus	90-93
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	40-49	bone gamma-carboxyglutamate protein	Rattus norvegicus	128-139
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	40-49	TNF superfamily member 11	Rattus norvegicus	154-159
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	170-179	glutathione peroxidase 1	Rattus norvegicus	78-84
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	170-179	bone gamma-carboxyglutamate protein	Rattus norvegicus	128-139
29055350-11	2017	Berberine, especially the high doses of berberine, effectively increased SOD, GSH Px, and OPG levels as well as decreased serum osteocalcin, ALP, MDA and RANKL levels in berberine-treated osteoporosis groups (all p &lt; 0.05).	Berberine	170-179	TNF superfamily member 11	Rattus norvegicus	154-159
28969581-0	2017	Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs.	Berberine	23-32	smoothened, frizzled class receptor	Homo sapiens	68-78
28969581-4	2017	OBJECTIVE: The current study aimed to model and verify the anti-Smo activity of berberine and its derivatives using a novel automated script.	Berberine	80-89	smoothened, frizzled class receptor	Homo sapiens	64-67
28969581-6	2017	RESULTS: Berberine was found to interact with Lys395 of Smo receptor via hydrogen bonding and cation-pi interactions.	Berberine	9-18	smoothened, frizzled class receptor	Homo sapiens	56-59
28969581-7	2017	In addition, pi-pi interactions between berberine aromatic rings and two aromatic residues in the Smo transmembrane domain, Tyr394 and Phe484, were noted.	Berberine	40-49	smoothened, frizzled class receptor	Homo sapiens	98-101
28969581-9	2017	The mRNA level of Gli1 was studied as the outcome of Hh signalling pathway to show the effect of berberine on hedgehog signalling.	Berberine	97-106	GLI family zinc finger 1	Homo sapiens	18-22
28969581-10	2017	CONCLUSION: This study predicted the role of berberine as an inhibitor of Smo receptor, suggesting its effectiveness in hedgehog signalling during cancer treatment.	Berberine	45-54	smoothened, frizzled class receptor	Homo sapiens	74-77
28893642-0	2017	Enzyme-inducing effects of berberine on cytochrome P450 1A2 in vitro and in vivo.	Berberine	27-36	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	40-59
28893642-2	2017	Here we provide evidence that the effects of berberine on cytochrome P450 (CYP) 1A2 in vitro and in vivo.	Berberine	45-54	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	58-83
29263046-0	2017	Berberine Attenuates NLRP3 Inflammasome Activation in Macrophages to Reduce the Secretion of Interleukin-1beta.	Berberine	0-9	NLR family pyrin domain containing 3	Homo sapiens	21-26
29263046-0	2017	Berberine Attenuates NLRP3 Inflammasome Activation in Macrophages to Reduce the Secretion of Interleukin-1beta.	Berberine	0-9	interleukin 1 beta	Homo sapiens	93-110
29263046-4	2017	Human peripheral blood mononuclear cells were then pretreated with different concentrations of berberine after treatment with NLRP3 activator ATP.	Berberine	95-104	NLR family pyrin domain containing 3	Homo sapiens	126-131
29263046-7	2017	RESULTS: In this study we observed that berberine suppressed IL-1beta secretion that was induced by the activation of the NLRP3 inflammasome in macrophages.	Berberine	40-49	interleukin 1 beta	Homo sapiens	61-69
29263046-7	2017	RESULTS: In this study we observed that berberine suppressed IL-1beta secretion that was induced by the activation of the NLRP3 inflammasome in macrophages.	Berberine	40-49	NLR family pyrin domain containing 3	Homo sapiens	122-127
29263046-8	2017	In addition, we demonstrated that berberine may possibly reduce reactive oxygen species (ROS)-dependent NLRP3 inflammasome activation.	Berberine	34-43	NLR family pyrin domain containing 3	Homo sapiens	104-109
29263046-9	2017	Moreover, Berberine inhibited the expression of pro-IL-1beta through inhibition of the nuclear factor kappab (NF-kappaB) pathway, which prevented the priming IL-1beta secretion.	Berberine	10-19	interleukin 1 beta	Homo sapiens	48-60
29263046-9	2017	Moreover, Berberine inhibited the expression of pro-IL-1beta through inhibition of the nuclear factor kappab (NF-kappaB) pathway, which prevented the priming IL-1beta secretion.	Berberine	10-19	interleukin 1 beta	Homo sapiens	52-60
29263046-10	2017	CONCLUSION: Our results suggest that berberine alleviates NLRP3 inflammation activation by reducing IL-1beta secretion from macrophages, which could be an important therapeutic target in atherosclerosis.	Berberine	37-46	NLR family pyrin domain containing 3	Homo sapiens	58-63
29263046-10	2017	CONCLUSION: Our results suggest that berberine alleviates NLRP3 inflammation activation by reducing IL-1beta secretion from macrophages, which could be an important therapeutic target in atherosclerosis.	Berberine	37-46	interleukin 1 beta	Homo sapiens	100-108
28836036-0	2017	Modulation of adenylate cyclase signaling in association with MKK3/6 stabilization under combination of SAC and berberine to reduce HepG2 cell survivability.	Berberine	112-121	mitogen-activated protein kinase kinase 3	Homo sapiens	62-66
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	Berberine	92-101	latexin	Homo sapiens	106-109
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	Berberine	92-101	cyclin dependent kinase 4	Homo sapiens	325-328
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	Berberine	92-101	H3 histone pseudogene 16	Homo sapiens	340-343
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	Berberine	92-101	dynactin subunit 6	Homo sapiens	348-351
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	Berberine	92-101	cyclin D1	Homo sapiens	440-449
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	Berberine	92-101	cyclin dependent kinase 4	Homo sapiens	461-465
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	Berberine	92-101	cyclin dependent kinase 6	Homo sapiens	471-475
28759012-0	2017	Berberine inhibits colitis-associated tumorigenesis via suppressing inflammatory responses and the consequent EGFR signaling-involved tumor cell growth.	Berberine	0-9	epidermal growth factor receptor	Mus musculus	110-114
28846104-4	2017	Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXRalpha), where berberine concomitantly binding to and synergistically activating RXRalpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXRalpha.	Berberine	31-40	retinoid X receptor alpha	Homo sapiens	178-203
28846104-4	2017	Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXRalpha), where berberine concomitantly binding to and synergistically activating RXRalpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXRalpha.	Berberine	31-40	retinoid X receptor alpha	Homo sapiens	205-213
28846104-4	2017	Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXRalpha), where berberine concomitantly binding to and synergistically activating RXRalpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXRalpha.	Berberine	31-40	retinoid X receptor alpha	Homo sapiens	288-296
28846104-4	2017	Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXRalpha), where berberine concomitantly binding to and synergistically activating RXRalpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXRalpha.	Berberine	31-40	retinoid X receptor alpha	Homo sapiens	288-296
28846104-4	2017	Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXRalpha), where berberine concomitantly binding to and synergistically activating RXRalpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXRalpha.	Berberine	222-231	catenin beta 1	Homo sapiens	50-62
28846104-4	2017	Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXRalpha), where berberine concomitantly binding to and synergistically activating RXRalpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXRalpha.	Berberine	222-231	retinoid X receptor alpha	Homo sapiens	178-203
28846104-4	2017	Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXRalpha), where berberine concomitantly binding to and synergistically activating RXRalpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXRalpha.	Berberine	222-231	retinoid X receptor alpha	Homo sapiens	205-213
28846104-5	2017	Berberine binding promotes RXRalpha interaction with nuclear beta-catenin, leading to c-Cbl mediated degradation of beta-catenin, and consequently inhibits the proliferation of colon cancer cells.	Berberine	0-9	retinoid X receptor alpha	Homo sapiens	27-35
28846104-5	2017	Berberine binding promotes RXRalpha interaction with nuclear beta-catenin, leading to c-Cbl mediated degradation of beta-catenin, and consequently inhibits the proliferation of colon cancer cells.	Berberine	0-9	catenin beta 1	Homo sapiens	61-73
28846104-5	2017	Berberine binding promotes RXRalpha interaction with nuclear beta-catenin, leading to c-Cbl mediated degradation of beta-catenin, and consequently inhibits the proliferation of colon cancer cells.	Berberine	0-9	Cbl proto-oncogene	Homo sapiens	86-91
28846104-5	2017	Berberine binding promotes RXRalpha interaction with nuclear beta-catenin, leading to c-Cbl mediated degradation of beta-catenin, and consequently inhibits the proliferation of colon cancer cells.	Berberine	0-9	catenin beta 1	Homo sapiens	116-128
28846104-6	2017	Furthermore, berberine suppresses the growth of human colon carcinoma xenograft in nude mice in an RXRalpha-dependent manner.	Berberine	13-22	retinoid X receptor alpha	Mus musculus	99-107
28846104-7	2017	Together, our study not only identifies RXRalpha as a direct protein target for berberine but also dissects their binding mode and validates that berberine indeed suppresses beta-catenin signaling and cell growth in colon cancer via binding RXRalpha, which provide new strategies for the design of new RXRalpha-based antitumor agents and drug combinations.	Berberine	80-89	retinoid X receptor alpha	Homo sapiens	40-48
28846104-7	2017	Together, our study not only identifies RXRalpha as a direct protein target for berberine but also dissects their binding mode and validates that berberine indeed suppresses beta-catenin signaling and cell growth in colon cancer via binding RXRalpha, which provide new strategies for the design of new RXRalpha-based antitumor agents and drug combinations.	Berberine	146-155	retinoid X receptor alpha	Homo sapiens	40-48
28846104-7	2017	Together, our study not only identifies RXRalpha as a direct protein target for berberine but also dissects their binding mode and validates that berberine indeed suppresses beta-catenin signaling and cell growth in colon cancer via binding RXRalpha, which provide new strategies for the design of new RXRalpha-based antitumor agents and drug combinations.	Berberine	146-155	catenin beta 1	Homo sapiens	174-186
28846104-7	2017	Together, our study not only identifies RXRalpha as a direct protein target for berberine but also dissects their binding mode and validates that berberine indeed suppresses beta-catenin signaling and cell growth in colon cancer via binding RXRalpha, which provide new strategies for the design of new RXRalpha-based antitumor agents and drug combinations.	Berberine	146-155	retinoid X receptor alpha	Homo sapiens	241-249
28846104-7	2017	Together, our study not only identifies RXRalpha as a direct protein target for berberine but also dissects their binding mode and validates that berberine indeed suppresses beta-catenin signaling and cell growth in colon cancer via binding RXRalpha, which provide new strategies for the design of new RXRalpha-based antitumor agents and drug combinations.	Berberine	146-155	retinoid X receptor alpha	Homo sapiens	241-249
28760703-4	2017	Our hypothesis is that pharmacological modulation by berberine (BER) pre-conditioning of Sirt3 protein levels decreases DOX-induced cardiotoxicity.	Berberine	53-62	sirtuin 3	Homo sapiens	89-94
28826092-0	2017	Berberine activates caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo.	Berberine	0-9	caspase 9	Homo sapiens	20-29
28826092-0	2017	Berberine activates caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo.	Berberine	0-9	cytochrome c, somatic	Homo sapiens	30-42
28931215-5	2017	We found that berberine inhibited the proliferation of C643, OCUT1 and TPC1 thyroid carcinoma cells in a dose- and time-dependent manner (p&lt;0.01, compared with the control), while normal human thyroid cells showed less sensitivity to the cytotoxicity of berberine.	Berberine	14-23	two pore segment channel 1	Homo sapiens	71-75
28931215-8	2017	Additionally, berberine caused markedly decreased p-AKT1 expression and disturbances in classic ERK MAPK as well as P38 and JNK MAPK pathways in diverse thyroid carcinoma cells.	Berberine	14-23	AKT serine/threonine kinase 1	Homo sapiens	52-56
28931215-8	2017	Additionally, berberine caused markedly decreased p-AKT1 expression and disturbances in classic ERK MAPK as well as P38 and JNK MAPK pathways in diverse thyroid carcinoma cells.	Berberine	14-23	mitogen-activated protein kinase 14	Homo sapiens	116-119
28931215-8	2017	Additionally, berberine caused markedly decreased p-AKT1 expression and disturbances in classic ERK MAPK as well as P38 and JNK MAPK pathways in diverse thyroid carcinoma cells.	Berberine	14-23	mitogen-activated protein kinase 8	Homo sapiens	124-127
29075339-0	2017	Berberine ameliorates non-alcoholic steatohepatitis in ApoE-/- mice.	Berberine	0-9	apolipoprotein E	Mus musculus	55-59
29075339-7	2017	BBR supplementation significantly lowered serum alanine aminotransferase and aspartate aminotransferase levels in mice with HFHC diet-induced NASH, and significantly downregulated hepatic expression and activity of NE, whereas alpha1-antitrypsin (alpha1-AT) expression was significantly recovered by BBR (all P&lt;0.05 vs. the HFHC group).	Berberine	0-3	elastase, neutrophil expressed	Mus musculus	215-217
29075339-8	2017	Furthermore, treatment with BBR induced a significant reduction in the expression of key genes, including phospoinositide 3-kinase, nuclear factor-kappaB and interleukin-8, in the C-X-C chemokine receptor type 4 (CXCR4) signaling pathway (all P&lt;0.05 vs. the HFHC group).	Berberine	28-31	chemokine (C-X-C motif) ligand 15	Mus musculus	158-171
29075339-8	2017	Furthermore, treatment with BBR induced a significant reduction in the expression of key genes, including phospoinositide 3-kinase, nuclear factor-kappaB and interleukin-8, in the C-X-C chemokine receptor type 4 (CXCR4) signaling pathway (all P&lt;0.05 vs. the HFHC group).	Berberine	28-31	chemokine (C-X-C motif) receptor 4	Mus musculus	180-211
29075339-8	2017	Furthermore, treatment with BBR induced a significant reduction in the expression of key genes, including phospoinositide 3-kinase, nuclear factor-kappaB and interleukin-8, in the C-X-C chemokine receptor type 4 (CXCR4) signaling pathway (all P&lt;0.05 vs. the HFHC group).	Berberine	28-31	chemokine (C-X-C motif) receptor 4	Mus musculus	213-218
29075339-10	2017	Restoration of the balance of NE and alpha1-AT levels, which in turn facilitate the inhibition of the CXCR4 signaling pathways, may be involved in the hepatoprotective effect of BBR.	Berberine	178-181	chemokine (C-X-C motif) receptor 4	Mus musculus	102-107
28888780-0	2017	Berberine suppresses LPS-induced inflammation through modulating Sirt1/NF-kappaB signaling pathway in RAW264.7 cells.	Berberine	0-9	sirtuin 1	Mus musculus	65-70
28888780-0	2017	Berberine suppresses LPS-induced inflammation through modulating Sirt1/NF-kappaB signaling pathway in RAW264.7 cells.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	71-80
28888780-4	2017	Thus, we speculate that Sirt1 might mediate the inhibitory effect of BBR on inflammation.	Berberine	69-72	sirtuin 1	Mus musculus	24-29
28888780-7	2017	Consistently, the inhibitory effects of BBR on proinflammatory cytokines expression was largely abrogated by Sirt1 inhibition either by EX527, a Sirt1 inhibitor or Sirt1 siRNA.	Berberine	40-43	sirtuin 1	Mus musculus	109-114
28888780-7	2017	Consistently, the inhibitory effects of BBR on proinflammatory cytokines expression was largely abrogated by Sirt1 inhibition either by EX527, a Sirt1 inhibitor or Sirt1 siRNA.	Berberine	40-43	sirtuin 1	Mus musculus	145-150
28888780-7	2017	Consistently, the inhibitory effects of BBR on proinflammatory cytokines expression was largely abrogated by Sirt1 inhibition either by EX527, a Sirt1 inhibitor or Sirt1 siRNA.	Berberine	40-43	sirtuin 1	Mus musculus	145-150
28888780-8	2017	Further mechanistic studies revealed that BBR-induced inhibition of NF-kappaB is Sirt1-dependent, as either pharmacologically or genetically inactivating Sirt1 enhanced the IkappaBetaalpha degradation, IKK phosphorylation, NF-kappaB p65 acetylation and DNA-binding activity.	Berberine	42-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	68-77
28888780-8	2017	Further mechanistic studies revealed that BBR-induced inhibition of NF-kappaB is Sirt1-dependent, as either pharmacologically or genetically inactivating Sirt1 enhanced the IkappaBetaalpha degradation, IKK phosphorylation, NF-kappaB p65 acetylation and DNA-binding activity.	Berberine	42-45	sirtuin 1	Mus musculus	81-86
28888780-8	2017	Further mechanistic studies revealed that BBR-induced inhibition of NF-kappaB is Sirt1-dependent, as either pharmacologically or genetically inactivating Sirt1 enhanced the IkappaBetaalpha degradation, IKK phosphorylation, NF-kappaB p65 acetylation and DNA-binding activity.	Berberine	42-45	sirtuin 1	Mus musculus	154-159
28888780-8	2017	Further mechanistic studies revealed that BBR-induced inhibition of NF-kappaB is Sirt1-dependent, as either pharmacologically or genetically inactivating Sirt1 enhanced the IkappaBetaalpha degradation, IKK phosphorylation, NF-kappaB p65 acetylation and DNA-binding activity.	Berberine	42-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	223-232
28888780-8	2017	Further mechanistic studies revealed that BBR-induced inhibition of NF-kappaB is Sirt1-dependent, as either pharmacologically or genetically inactivating Sirt1 enhanced the IkappaBetaalpha degradation, IKK phosphorylation, NF-kappaB p65 acetylation and DNA-binding activity.	Berberine	42-45	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	233-236
28942573-11	2017	BBR treatment resulted in a decrease in membrane-associated PKCdelta and attenuated the palmitate-mediated increase in PKCdelta membrane-association.	Berberine	0-3	protein kinase C, delta	Rattus norvegicus	60-68
28942573-11	2017	BBR treatment resulted in a decrease in membrane-associated PKCdelta and attenuated the palmitate-mediated increase in PKCdelta membrane-association.	Berberine	0-3	protein kinase C, delta	Rattus norvegicus	119-127
28759012-2	2017	However, whether the anti-inflammatory effect of berberine contributes to its anti-tumor effect on colitis-associated colorectal cancer (CACRC) remains unknown.	Berberine	49-58	cation channel, sperm associated 3	Mus musculus	99-135
28759012-2	2017	However, whether the anti-inflammatory effect of berberine contributes to its anti-tumor effect on colitis-associated colorectal cancer (CACRC) remains unknown.	Berberine	49-58	cation channel, sperm associated 3	Mus musculus	137-142
28759012-4	2017	A mechanistic study identified that these inhibitory effects of berberine occurred through blocking interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) expression in colonic macrophages.	Berberine	64-73	interleukin 6	Mus musculus	100-113
28759012-4	2017	A mechanistic study identified that these inhibitory effects of berberine occurred through blocking interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) expression in colonic macrophages.	Berberine	64-73	interleukin 6	Mus musculus	115-119
28759012-4	2017	A mechanistic study identified that these inhibitory effects of berberine occurred through blocking interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) expression in colonic macrophages.	Berberine	64-73	tumor necrosis factor	Mus musculus	125-152
28759012-4	2017	A mechanistic study identified that these inhibitory effects of berberine occurred through blocking interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) expression in colonic macrophages.	Berberine	64-73	tumor necrosis factor	Mus musculus	154-163
28759012-6	2017	EGFR-ERK signaling act downstream of berberine/pro-inflammatory cytokines axis to regulate CACRC cell proliferation.	Berberine	37-46	epidermal growth factor receptor	Mus musculus	0-4
28759012-6	2017	EGFR-ERK signaling act downstream of berberine/pro-inflammatory cytokines axis to regulate CACRC cell proliferation.	Berberine	37-46	mitogen-activated protein kinase 1	Mus musculus	5-8
28759012-6	2017	EGFR-ERK signaling act downstream of berberine/pro-inflammatory cytokines axis to regulate CACRC cell proliferation.	Berberine	37-46	cation channel, sperm associated 3	Mus musculus	91-96
28759012-7	2017	Furthermore, in vivo administration of IL-6 to DSS-treated ApcMin/+ mice effectively weakened the inhibitory effects of berberine on tumorigenesis and EGFR-ERK signaling in colon tissues.	Berberine	120-129	interleukin 6	Mus musculus	39-43
28981112-0	2017	Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition.	Berberine	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	142-146
28981112-8	2017	In addition, the level of RAD51 and the capacity of HRR were also reduced by berberine.	Berberine	77-86	RAD51 recombinase	Homo sapiens	26-31
28981112-9	2017	Correspondingly, PARP became hyperactivated in response to berberine treatment.	Berberine	59-68	poly(ADP-ribose) polymerase 1	Homo sapiens	17-21
28981112-11	2017	Together, the results indicate that by inducing oxidative DNA damage and downregulating HRR in cancer cells berberine is able to further sensitize cancer cells to PARP inhibition.	Berberine	108-117	poly(ADP-ribose) polymerase 1	Homo sapiens	163-167
29079630-0	2017	ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis.	Berberine	42-51	mitogen-activated protein kinase 1	Homo sapiens	0-3
29079630-0	2017	ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis.	Berberine	42-51	mechanistic target of rapamycin kinase	Homo sapiens	14-18
29143794-0	2017	Berberine Activates Aryl Hydrocarbon Receptor but Suppresses CYP1A1 Induction through miR-21-3p Stimulation in MCF-7 Breast Cancer Cells.	Berberine	0-9	aryl hydrocarbon receptor	Homo sapiens	20-45
29143794-0	2017	Berberine Activates Aryl Hydrocarbon Receptor but Suppresses CYP1A1 Induction through miR-21-3p Stimulation in MCF-7 Breast Cancer Cells.	Berberine	0-9	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	61-67
29143794-0	2017	Berberine Activates Aryl Hydrocarbon Receptor but Suppresses CYP1A1 Induction through miR-21-3p Stimulation in MCF-7 Breast Cancer Cells.	Berberine	0-9	microRNA 181a-1	Homo sapiens	86-94
29143794-4	2017	The 24-h exposure to 10 muM berberine did not change CYP1A1 mRNA stability, protein level and function.	Berberine	28-37	latexin	Homo sapiens	24-27
29143794-5	2017	Berberine significantly increased micro RNA (miR)-21-3p by 36% and the transfection of an inhibitor of miR-21-3p restored the induction of CYP1A1 protein with a 50% increase.	Berberine	0-9	microRNA 21	Homo sapiens	34-52
29143794-6	2017	These findings demonstrate that the ring opening of the methylenedioxyl moiety in berberine decreased AhR activation in MCF-7 cells.	Berberine	82-91	aryl hydrocarbon receptor	Homo sapiens	102-105
29143794-7	2017	While CYP1A1 mRNA was elevated, berberine-induced miR-21-3p suppressed the increase of functional CYP1A1 protein expression.	Berberine	32-41	microRNA 181a-1	Homo sapiens	50-59
29143794-7	2017	While CYP1A1 mRNA was elevated, berberine-induced miR-21-3p suppressed the increase of functional CYP1A1 protein expression.	Berberine	32-41	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	98-104
29118901-9	2017	Taken together, our data suggested that BBR inhibited ox-LDL-induced HUVECs proliferation by decreasing the expression of PCNA, NF-kB and LOX-1 and suppressing the activation of PI3K/Akt, ERK1/2 and p38MAPK pathways, indicating a latent candidate for anti-atherosclerosis clinically.	Berberine	40-43	proliferating cell nuclear antigen	Homo sapiens	122-126
29118901-9	2017	Taken together, our data suggested that BBR inhibited ox-LDL-induced HUVECs proliferation by decreasing the expression of PCNA, NF-kB and LOX-1 and suppressing the activation of PI3K/Akt, ERK1/2 and p38MAPK pathways, indicating a latent candidate for anti-atherosclerosis clinically.	Berberine	40-43	oxidized low density lipoprotein receptor 1	Homo sapiens	138-143
29118901-9	2017	Taken together, our data suggested that BBR inhibited ox-LDL-induced HUVECs proliferation by decreasing the expression of PCNA, NF-kB and LOX-1 and suppressing the activation of PI3K/Akt, ERK1/2 and p38MAPK pathways, indicating a latent candidate for anti-atherosclerosis clinically.	Berberine	40-43	AKT serine/threonine kinase 1	Homo sapiens	183-186
29118901-9	2017	Taken together, our data suggested that BBR inhibited ox-LDL-induced HUVECs proliferation by decreasing the expression of PCNA, NF-kB and LOX-1 and suppressing the activation of PI3K/Akt, ERK1/2 and p38MAPK pathways, indicating a latent candidate for anti-atherosclerosis clinically.	Berberine	40-43	mitogen-activated protein kinase 3	Homo sapiens	188-194
28763751-10	2017	Histological and immunohistochemical examination showed improved histological structure and decreased expression of Bax in liver of MTX-induced rats treated with BBR.	Berberine	162-165	BCL2 associated X, apoptosis regulator	Rattus norvegicus	116-119
28759012-8	2017	Altogether, the results of our studies have revealed that berberine inhibits the development of CACRC by interfering with inflammatory response-driven EGFR signaling in tumor cell growth.	Berberine	58-67	cation channel, sperm associated 3	Mus musculus	96-101
28759012-8	2017	Altogether, the results of our studies have revealed that berberine inhibits the development of CACRC by interfering with inflammatory response-driven EGFR signaling in tumor cell growth.	Berberine	58-67	epidermal growth factor receptor	Mus musculus	151-155
28759012-9	2017	The findings of this study support the possibility that berberine and other anti-inflammatory drugs may be beneficial in the treatment of CACRC.	Berberine	56-65	cation channel, sperm associated 3	Mus musculus	138-143
28810524-13	2017	Whereas, berberine treatment alone and in combination with pioglitazone remarkably ameliorates the abnormal urinary calcium, mRNA expression of AMPK, bone turnover markers, femur epiphysis micro-architecture, histology and also increases BMD in diabetic rats.	Berberine	9-18	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	144-148
28783583-4	2017	On the other hand, berberine and naringenin supplementation to diabetic animals improved brain IRS 1 levels and restored GLUT 1 and GLUT 3 expression without significant effect on PI3K and Akt 1 activation and GLUT 4 levels.	Berberine	19-28	insulin receptor substrate 1	Rattus norvegicus	95-100
28783583-4	2017	On the other hand, berberine and naringenin supplementation to diabetic animals improved brain IRS 1 levels and restored GLUT 1 and GLUT 3 expression without significant effect on PI3K and Akt 1 activation and GLUT 4 levels.	Berberine	19-28	solute carrier family 2 member 1	Rattus norvegicus	121-127
28783583-4	2017	On the other hand, berberine and naringenin supplementation to diabetic animals improved brain IRS 1 levels and restored GLUT 1 and GLUT 3 expression without significant effect on PI3K and Akt 1 activation and GLUT 4 levels.	Berberine	19-28	solute carrier family 2 member 3	Rattus norvegicus	132-138
28810524-14	2017	In conclusion, berberine shows protective effect against pioglitazone-induced bone loss in diabetic rats possibly through AMPK activation pathway.	Berberine	15-24	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	122-126
28822725-4	2017	Berberine, which is the main active component of the traditional medicinal herb Coptidis rhizoma, has a positive effect on reducing Abeta levels.	Berberine	0-9	amyloid beta (A4) precursor protein	Mus musculus	132-137
28515053-8	2017	Furthermore, berberine markedly increased the function and expression of BKCa beta1-subunit in cerebral vascular smooth muscle cells (VSMCs) isolated from diabetic rats or when exposed to hyperglycemia condition.	Berberine	13-22	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	73-77
28515053-9	2017	The present study provided initial evidences that berberine reduced blood pressure and improved vasodilation in diabetic rats by activation of BKCa channel in VSMCs, which suggested that berberine might provide a combinational therapy for controlling hyperglycemia and blood pressure in diabetes.	Berberine	50-59	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	143-147
28515053-9	2017	The present study provided initial evidences that berberine reduced blood pressure and improved vasodilation in diabetic rats by activation of BKCa channel in VSMCs, which suggested that berberine might provide a combinational therapy for controlling hyperglycemia and blood pressure in diabetes.	Berberine	187-196	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	143-147
28515053-10	2017	Furthermore, our work indicated that activation of BKCa channel might be the underlying mechanism responsible for the vascular protection of berberine in diabetes.	Berberine	141-150	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	51-55
28822725-7	2017	The results indicate that berberine reduces Abeta generation and decreases the expression of beta-site APP cleaving enzyme-1 (BACE1) via activating AMPK in N2a mouse neuroblastoma cells stably expressing human Swedish mutant APP695 (N2a/APP695sw), N2a cells, and primary cultured cortical neurons.	Berberine	26-35	amyloid beta (A4) precursor protein	Mus musculus	44-49
28822725-7	2017	The results indicate that berberine reduces Abeta generation and decreases the expression of beta-site APP cleaving enzyme-1 (BACE1) via activating AMPK in N2a mouse neuroblastoma cells stably expressing human Swedish mutant APP695 (N2a/APP695sw), N2a cells, and primary cultured cortical neurons.	Berberine	26-35	beta-site APP cleaving enzyme 1	Mus musculus	93-124
28822725-7	2017	The results indicate that berberine reduces Abeta generation and decreases the expression of beta-site APP cleaving enzyme-1 (BACE1) via activating AMPK in N2a mouse neuroblastoma cells stably expressing human Swedish mutant APP695 (N2a/APP695sw), N2a cells, and primary cultured cortical neurons.	Berberine	26-35	beta-site APP cleaving enzyme 1	Mus musculus	126-131
28822725-8	2017	Therefore, berberine reduced the accumulation of Abeta, which likely contributes to its memory enhancing effect in patients with AD.	Berberine	11-20	amyloid beta (A4) precursor protein	Mus musculus	49-54
28842306-7	2017	In addition, chronic berberine treatment inhibited nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling pathway as the phosphorylated proteins of NF-kappaB, IkappaB kinase (IKK)alpha and IKKbeta in the hippocampus were suppressed after berberine administration.	Berberine	21-30	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	115-124
29228691-9	2017	In addition, berberine upregulated CNPase positive oligodendrocyte expressing ATG5, promoted neuronal survival and reduced the cleaved caspase-3 expression after SCI.	Berberine	13-22	2',3'-cyclic nucleotide 3' phosphodiesterase	Rattus norvegicus	35-41
29228691-9	2017	In addition, berberine upregulated CNPase positive oligodendrocyte expressing ATG5, promoted neuronal survival and reduced the cleaved caspase-3 expression after SCI.	Berberine	13-22	autophagy related 5	Rattus norvegicus	78-82
28900305-9	2017	The activation and nuclear distribution of Nrf2 was decreased in the hepatocytes of rats that received BBR treatment, while on a HFD.	Berberine	103-106	NFE2 like bZIP transcription factor 2	Rattus norvegicus	43-47
29113353-0	2017	Berberine-targeted miR-21 chemosensitizes oral carcinomas stem cells.	Berberine	0-9	microRNA 21a	Mus musculus	19-25
29113353-4	2017	Our results demonstrated that berberine dose dependently downregulated the oncogenicity in vitro, including ALDH1 activity, self-renewal property, and colony formation and invasion abilities as well as potentiated chemosensitivity of OSCC-CSCs.	Berberine	30-39	aldehyde dehydrogenase family 1, subfamily A1	Mus musculus	108-113
29113353-6	2017	We showed that the expression of miR-21 was suppressed following administration of berberine in OSCC-CSCs.	Berberine	83-92	microRNA 21a	Mus musculus	33-39
28619831-9	2017	Among 17 interfering substances, only berberine at high concentrations inhibited fecal detection of methylated SDC2SDC2 was overexpressed in colorectal cancer tissues compared with normal epithelia.Conclusions: Fecal methylated SDC2 is a valuable biomarker for the noninvasive detection of colorectal neoplasms.Impact: Stool DNA test of methylated SDC2 would serve as an alternative method for screening colorectal neoplasms.	Berberine	38-47	syndecan 2	Homo sapiens	111-115
28619831-9	2017	Among 17 interfering substances, only berberine at high concentrations inhibited fecal detection of methylated SDC2SDC2 was overexpressed in colorectal cancer tissues compared with normal epithelia.Conclusions: Fecal methylated SDC2 is a valuable biomarker for the noninvasive detection of colorectal neoplasms.Impact: Stool DNA test of methylated SDC2 would serve as an alternative method for screening colorectal neoplasms.	Berberine	38-47	syndecan 2	Homo sapiens	115-119
28668383-10	2017	Furthermore, it"s found that expression of cytochrome C, as well as the restoration of Bcl-2/Bax and Bcl-xl/Bax ratio in the presence of Berberine, led to a decline in the apoptotic rate.	Berberine	137-146	B cell leukemia/lymphoma 2	Mus musculus	87-92
28668383-10	2017	Furthermore, it"s found that expression of cytochrome C, as well as the restoration of Bcl-2/Bax and Bcl-xl/Bax ratio in the presence of Berberine, led to a decline in the apoptotic rate.	Berberine	137-146	BCL2-associated X protein	Mus musculus	93-96
28668383-10	2017	Furthermore, it"s found that expression of cytochrome C, as well as the restoration of Bcl-2/Bax and Bcl-xl/Bax ratio in the presence of Berberine, led to a decline in the apoptotic rate.	Berberine	137-146	BCL2-like 1	Mus musculus	101-107
28668383-10	2017	Furthermore, it"s found that expression of cytochrome C, as well as the restoration of Bcl-2/Bax and Bcl-xl/Bax ratio in the presence of Berberine, led to a decline in the apoptotic rate.	Berberine	137-146	BCL2-associated X protein	Mus musculus	108-111
29100319-4	2017	Together, berberine and cinnamaldehyde reduced mouse susceptibility to urethane-induced lung carcinogenesis, and reversed the urethane-induced AMPK, mTOR, AQP-1, and NF-kappaB expression patterns.	Berberine	10-19	mechanistic target of rapamycin kinase	Mus musculus	149-153
29100319-4	2017	Together, berberine and cinnamaldehyde reduced mouse susceptibility to urethane-induced lung carcinogenesis, and reversed the urethane-induced AMPK, mTOR, AQP-1, and NF-kappaB expression patterns.	Berberine	10-19	aquaporin 1	Mus musculus	155-160
29100319-4	2017	Together, berberine and cinnamaldehyde reduced mouse susceptibility to urethane-induced lung carcinogenesis, and reversed the urethane-induced AMPK, mTOR, AQP-1, and NF-kappaB expression patterns.	Berberine	10-19	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	166-175
29100319-5	2017	In vitro, berberine and cinnamaldehyde together induced A549 cell apoptosis, prevented cell proliferation, autophagy, and wound healing, upregulated AMPK, and downregulated AQP-1.	Berberine	10-19	aquaporin 1	Mus musculus	173-178
29100319-8	2017	These results suggest the combination of berberine and cinnamaldehyde limited both primary and adaptive nutrient acquisition by lung tumors via AMPK-reduced AQP-1 expression, which ultimately starved the tumor cells.	Berberine	41-50	aquaporin 1	Mus musculus	157-162
28763751-0	2017	Berberine ameliorates methotrexate-induced liver injury by activating Nrf2/HO-1 pathway and PPARgamma, and suppressing oxidative stress and apoptosis in rats.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	70-74
28763751-0	2017	Berberine ameliorates methotrexate-induced liver injury by activating Nrf2/HO-1 pathway and PPARgamma, and suppressing oxidative stress and apoptosis in rats.	Berberine	0-9	heme oxygenase 1	Rattus norvegicus	75-79
28763751-0	2017	Berberine ameliorates methotrexate-induced liver injury by activating Nrf2/HO-1 pathway and PPARgamma, and suppressing oxidative stress and apoptosis in rats.	Berberine	0-9	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	92-101
28614117-8	2017	In addition to drugs such as metformin and 5-aminoimidazole-4-carboxamide ribonucleotide that are classically used as AMPK activators, recent studies have identified the therapeutic potential of other compounds that function at least partly as AMPK activators, such as salicylates, statins, berberine, and resveratrol, in preventing the progression of CKD.	Berberine	291-300	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	244-248
28636167-0	2017	Berberine ameliorates collagen-induced arthritis in rats by suppressing Th17 cell responses via inducing cortistatin in the gut.	Berberine	0-9	cortistatin	Rattus norvegicus	105-116
28636167-7	2017	Further studies revealed that oral berberine selectively elevated the levels of cortistatin, of five gut-derived neuropeptides tested, in the intestines and sera of arthrititic rats.	Berberine	35-44	cortistatin	Rattus norvegicus	80-91
28636167-8	2017	Antagonists of ghrelin/growth hormone secretagogue receptor 1 (a subtype of cortistatin receptor) almost completely abolished the ameliorative effect of berberine on arthritis and Th17 cell responses in rats.	Berberine	153-162	cortistatin	Rattus norvegicus	76-87
28636167-9	2017	In vitro, berberine showed a moderate ability to promote the expression of cortistatin in nerve cells, which was strengthened when the nerve cells were cocultured with enteroendocrine cells to induce an autocrine/paracrine environment.	Berberine	10-19	cortistatin	Rattus norvegicus	75-86
28636167-10	2017	In summary, oral berberine exerted anti-arthritic effect through inhibiting the Th17 cell response, which was closely associated with the induction of cortistatin generation from gut through augmenting autocrine/paracrine action between enteric nerve cells and endocrine cells.	Berberine	17-26	cortistatin	Rattus norvegicus	151-162
28703366-0	2017	Synergistic Effect of TPD7 and Berberine against Leukemia Jurkat Cell Growth through Regulating Ephrin-B2 Signaling.	Berberine	31-40	ephrin B2	Homo sapiens	96-105
28703366-1	2017	TPD7, a novel biphenyl urea taspine derivative, and berberine have presented inhibition on VEGFR2 that can be regulated by ephrin-B2 reverse signaling through interactions with the PDZ domain.	Berberine	52-61	kinase insert domain receptor	Homo sapiens	91-97
28703366-1	2017	TPD7, a novel biphenyl urea taspine derivative, and berberine have presented inhibition on VEGFR2 that can be regulated by ephrin-B2 reverse signaling through interactions with the PDZ domain.	Berberine	52-61	ephrin B2	Homo sapiens	123-132
28784988-6	2017	Further characterization of several other berberine-utilizing bacteria and the genes encoding key demethylenation enzymes revealed that these enzymes are tetrahydrofolate dependent and similar to demethylation enzymes such as GcvT.	Berberine	42-51	aminomethyltransferase	Homo sapiens	226-230
28579298-3	2017	This review will focus on the effects of curcumin (CUR), berberine (BBR) and resveratrol (RES), on the PI3K/PTEN/Akt/mTORC1/GSK-3 pathway, with a special focus on GSK-3.	Berberine	57-66	CREB regulated transcription coactivator 1	Mus musculus	117-123
28579298-3	2017	This review will focus on the effects of curcumin (CUR), berberine (BBR) and resveratrol (RES), on the PI3K/PTEN/Akt/mTORC1/GSK-3 pathway, with a special focus on GSK-3.	Berberine	68-71	CREB regulated transcription coactivator 1	Mus musculus	117-123
28693796-8	2017	The role of miR regulation in the putative anti-diabetic effects of BBR is discussed, as well.	Berberine	68-71	membrane associated ring-CH-type finger 8	Homo sapiens	12-15
29067464-10	2017	The protein and mRNA expression levels of TGF-beta, vimentin and alpha-SMA were significantly increased in DN rats compared with the control group; however, this increase was reduced following treatment with BBR.	Berberine	208-211	transforming growth factor, beta 1	Rattus norvegicus	42-50
29067464-10	2017	The protein and mRNA expression levels of TGF-beta, vimentin and alpha-SMA were significantly increased in DN rats compared with the control group; however, this increase was reduced following treatment with BBR.	Berberine	208-211	vimentin	Rattus norvegicus	52-60
29067464-10	2017	The protein and mRNA expression levels of TGF-beta, vimentin and alpha-SMA were significantly increased in DN rats compared with the control group; however, this increase was reduced following treatment with BBR.	Berberine	208-211	actin gamma 2, smooth muscle	Rattus norvegicus	65-74
28627660-4	2017	However, berberine significantly reduced hypoxia-induced autophagy in H9c2 myocytes, as demonstrated by the ratio of microtubule-associated proteins 1A/1B light chain 3 I/II and the expression levels of B-cell lymphoma 2 (Bcl-2)/adenovirus E1B 19 kDa protein-interacting protein 3, and promoted cell viability.	Berberine	9-18	BCL2, apoptosis regulator	Rattus norvegicus	203-220
28627660-4	2017	However, berberine significantly reduced hypoxia-induced autophagy in H9c2 myocytes, as demonstrated by the ratio of microtubule-associated proteins 1A/1B light chain 3 I/II and the expression levels of B-cell lymphoma 2 (Bcl-2)/adenovirus E1B 19 kDa protein-interacting protein 3, and promoted cell viability.	Berberine	9-18	BCL2, apoptosis regulator	Rattus norvegicus	222-227
28749438-0	2017	Synthesis and Identification of Novel Berberine Derivatives as Potent Inhibitors against TNF-alpha-Induced NF-kappaB Activation.	Berberine	38-47	tumor necrosis factor	Homo sapiens	89-98
28749438-1	2017	Twenty-three new berberine (BBR) analogues defined on substituents of ring D were synthesized and evaluated for their activity for suppression of tumor necrosis factor (TNF)-alpha-induced nuclear factor (NF)-kappaB activation.	Berberine	17-26	tumor necrosis factor	Homo sapiens	146-179
28749438-1	2017	Twenty-three new berberine (BBR) analogues defined on substituents of ring D were synthesized and evaluated for their activity for suppression of tumor necrosis factor (TNF)-alpha-induced nuclear factor (NF)-kappaB activation.	Berberine	28-31	tumor necrosis factor	Homo sapiens	146-179
28842306-7	2017	In addition, chronic berberine treatment inhibited nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling pathway as the phosphorylated proteins of NF-kappaB, IkappaB kinase (IKK)alpha and IKKbeta in the hippocampus were suppressed after berberine administration.	Berberine	21-30	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	178-187
28842306-7	2017	In addition, chronic berberine treatment inhibited nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling pathway as the phosphorylated proteins of NF-kappaB, IkappaB kinase (IKK)alpha and IKKbeta in the hippocampus were suppressed after berberine administration.	Berberine	21-30	conserved helix-loop-helix ubiquitous kinase	Mus musculus	189-214
28842306-7	2017	In addition, chronic berberine treatment inhibited nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling pathway as the phosphorylated proteins of NF-kappaB, IkappaB kinase (IKK)alpha and IKKbeta in the hippocampus were suppressed after berberine administration.	Berberine	21-30	inhibitor of kappaB kinase beta	Mus musculus	219-226
28842306-7	2017	In addition, chronic berberine treatment inhibited nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling pathway as the phosphorylated proteins of NF-kappaB, IkappaB kinase (IKK)alpha and IKKbeta in the hippocampus were suppressed after berberine administration.	Berberine	268-277	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	115-124
28842306-8	2017	Furthermore, inducible nitric oxide synthase (iNOS), one downstream target of NF-kappaB signaling pathway was also inhibited by berberine.	Berberine	128-137	nitric oxide synthase 2, inducible	Mus musculus	13-44
28842306-8	2017	Furthermore, inducible nitric oxide synthase (iNOS), one downstream target of NF-kappaB signaling pathway was also inhibited by berberine.	Berberine	128-137	nitric oxide synthase 2, inducible	Mus musculus	46-50
28842306-8	2017	Furthermore, inducible nitric oxide synthase (iNOS), one downstream target of NF-kappaB signaling pathway was also inhibited by berberine.	Berberine	128-137	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	78-87
28686226-5	2017	Both in vitro and in vivo, lipid-lowering alkaloid berberine (BBR) exhibited an anti-lymphoma activity through inhibiting MYC-driven downstream PCYT1A expression and inducing mitophagy-dependent necroptosis.	Berberine	51-60	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	122-125
28686226-5	2017	Both in vitro and in vivo, lipid-lowering alkaloid berberine (BBR) exhibited an anti-lymphoma activity through inhibiting MYC-driven downstream PCYT1A expression and inducing mitophagy-dependent necroptosis.	Berberine	51-60	phosphate cytidylyltransferase 1A, choline	Homo sapiens	144-150
28686226-5	2017	Both in vitro and in vivo, lipid-lowering alkaloid berberine (BBR) exhibited an anti-lymphoma activity through inhibiting MYC-driven downstream PCYT1A expression and inducing mitophagy-dependent necroptosis.	Berberine	62-65	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	122-125
28686226-5	2017	Both in vitro and in vivo, lipid-lowering alkaloid berberine (BBR) exhibited an anti-lymphoma activity through inhibiting MYC-driven downstream PCYT1A expression and inducing mitophagy-dependent necroptosis.	Berberine	62-65	phosphate cytidylyltransferase 1A, choline	Homo sapiens	144-150
28870132-4	2017	In comparison, the berberine-induced phototoxicity to the A549 cells was mediated by reactive oxygen species generation, mitochondrial membrane permeabilisation and caspase-9/caspase-3 activation.	Berberine	19-28	caspase 9	Homo sapiens	165-174
28870132-4	2017	In comparison, the berberine-induced phototoxicity to the A549 cells was mediated by reactive oxygen species generation, mitochondrial membrane permeabilisation and caspase-9/caspase-3 activation.	Berberine	19-28	caspase 3	Homo sapiens	175-184
28839371-12	2017	CONCLUSION: The present work gives a deep insight into the molecular mechanism for the treatment of diarrhea with berberine, i.e., berberine could suppress the contractility of smooth muscle through binding to MLCK and depressing the catalysis activity of MLCK.	Berberine	114-123	myosin light chain kinase	Homo sapiens	256-260
28556490-3	2017	Various conditions such as the amount of aptamer-functionalized Fe3 O4 magnetic nanoparticles, extraction time, temperature, pH value, Mg2+ concentration, elution time and solvent were optimized for the solid-phase extraction of berberine.	Berberine	229-238	mucin 7, secreted	Homo sapiens	135-138
28839371-0	2017	Berberine Depresses Contraction of Smooth Muscle via Inhibiting Myosin Light-chain Kinase.	Berberine	0-9	myosin heavy chain 14	Homo sapiens	64-70
28839371-12	2017	CONCLUSION: The present work gives a deep insight into the molecular mechanism for the treatment of diarrhea with berberine, i.e., berberine could suppress the contractility of smooth muscle through binding to MLCK and depressing the catalysis activity of MLCK.	Berberine	131-140	myosin light chain kinase	Homo sapiens	210-214
28839371-2	2017	Smooth muscle myosin light-chain kinase (MLCK) plays a crucial role in the smooth muscle relaxation-contraction events, and it is well known that berberine can effectively depress the contraction of smooth muscle.	Berberine	146-155	myosin light chain kinase	Homo sapiens	0-39
28839371-2	2017	Smooth muscle myosin light-chain kinase (MLCK) plays a crucial role in the smooth muscle relaxation-contraction events, and it is well known that berberine can effectively depress the contraction of smooth muscle.	Berberine	146-155	myosin light chain kinase	Homo sapiens	41-45
28839371-12	2017	CONCLUSION: The present work gives a deep insight into the molecular mechanism for the treatment of diarrhea with berberine, i.e., berberine could suppress the contractility of smooth muscle through binding to MLCK and depressing the catalysis activity of MLCK.	Berberine	131-140	myosin light chain kinase	Homo sapiens	256-260
28839371-3	2017	Hence, whether berberine could inhibit MLCK and then depress the smooth muscle contractility might be researched.	Berberine	15-24	myosin light chain kinase	Homo sapiens	39-43
28839371-13	2017	SUMMARY: Berberine significantly reduced the amplitude of contraction in isolated duodenum and gastric strips in ratsBerberine inhibited the phosphorylated extents of MLC20 and Mg2+-ATPase activity of phosphorylated myosin induced by MLCKBerberine binds to the ATP binding site of MLCK by hydrophobic effect and hydrogen bondingBerberine may modulate contraction of smooth muscle by inhibiting MLCK.	Berberine	9-18	myosin light chain 12B	Homo sapiens	167-172
28839371-4	2017	OBJECTIVE: The purpose of this study is to investigate the effects of berberine on MLCK.	Berberine	70-79	myosin light chain kinase	Homo sapiens	83-87
28839371-7	2017	The effects of berberine on MLCK were measured in the presence of Ca2+-calmodulin, using the activities of 20 kDa myosin light chain (MLC20) phosphorylation, and myosin Mg2+-ATPase induced by MLCK.	Berberine	15-24	myosin light chain kinase	Homo sapiens	28-32
28839371-7	2017	The effects of berberine on MLCK were measured in the presence of Ca2+-calmodulin, using the activities of 20 kDa myosin light chain (MLC20) phosphorylation, and myosin Mg2+-ATPase induced by MLCK.	Berberine	15-24	calmodulin 1	Homo sapiens	71-81
28839371-13	2017	SUMMARY: Berberine significantly reduced the amplitude of contraction in isolated duodenum and gastric strips in ratsBerberine inhibited the phosphorylated extents of MLC20 and Mg2+-ATPase activity of phosphorylated myosin induced by MLCKBerberine binds to the ATP binding site of MLCK by hydrophobic effect and hydrogen bondingBerberine may modulate contraction of smooth muscle by inhibiting MLCK.	Berberine	9-18	myosin heavy chain 14	Homo sapiens	216-222
28839371-7	2017	The effects of berberine on MLCK were measured in the presence of Ca2+-calmodulin, using the activities of 20 kDa myosin light chain (MLC20) phosphorylation, and myosin Mg2+-ATPase induced by MLCK.	Berberine	15-24	myosin light chain 9	Homo sapiens	107-132
28839371-13	2017	SUMMARY: Berberine significantly reduced the amplitude of contraction in isolated duodenum and gastric strips in ratsBerberine inhibited the phosphorylated extents of MLC20 and Mg2+-ATPase activity of phosphorylated myosin induced by MLCKBerberine binds to the ATP binding site of MLCK by hydrophobic effect and hydrogen bondingBerberine may modulate contraction of smooth muscle by inhibiting MLCK.	Berberine	9-18	myosin light chain kinase	Homo sapiens	234-238
28839371-9	2017	RESULTS: The phosphorylation of myosin and the Mg2+-ATPase activity is reduced in the presence of berberine.	Berberine	98-107	myosin heavy chain 14	Homo sapiens	32-38
28839371-13	2017	SUMMARY: Berberine significantly reduced the amplitude of contraction in isolated duodenum and gastric strips in ratsBerberine inhibited the phosphorylated extents of MLC20 and Mg2+-ATPase activity of phosphorylated myosin induced by MLCKBerberine binds to the ATP binding site of MLCK by hydrophobic effect and hydrogen bondingBerberine may modulate contraction of smooth muscle by inhibiting MLCK.	Berberine	9-18	myosin light chain kinase	Homo sapiens	281-285
28839371-11	2017	Berberine could bind to the ATP binding site of MLCK through hydrophobic effect and hydrogen bonding according to the docking study.	Berberine	0-9	myosin light chain kinase	Homo sapiens	48-52
28839371-12	2017	CONCLUSION: The present work gives a deep insight into the molecular mechanism for the treatment of diarrhea with berberine, i.e., berberine could suppress the contractility of smooth muscle through binding to MLCK and depressing the catalysis activity of MLCK.	Berberine	114-123	myosin light chain kinase	Homo sapiens	210-214
27799459-0	2017	Berberine Inhibits Uterine Leiomyoma Cell Proliferation via Downregulation of Cyclooxygenase 2 and Pituitary Tumor-Transforming Gene 1.	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	78-134
28775788-0	2017	Berberine Enhances Chemosensitivity and Induces Apoptosis Through Dose-orchestrated AMPK Signaling in Breast Cancer.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	84-88
28775788-4	2017	Berberine, known as AMPK activator, has shown multiple activities including antitumor effect.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	20-24
28775788-5	2017	In this study, we investigate the chemosensitive effect of different dosages berberine on drug-resistant human breast cancer MCF-7/MDR cell in vitro and in vivo, and the mechanisms underlying AMPK activation on Doxorubicin (DOX) chemosensitivity.	Berberine	77-86	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	192-196
28775788-6	2017	Our results showed that berberine could overcome DOX resistance in dose-orchestrated manner: On one hand, low-dose berberine can enhance DOX sensitivity in drug-resistance breast cancer cells through AMPK-HIF-1alpha-P-gp pathway.	Berberine	24-33	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	200-204
28775788-6	2017	Our results showed that berberine could overcome DOX resistance in dose-orchestrated manner: On one hand, low-dose berberine can enhance DOX sensitivity in drug-resistance breast cancer cells through AMPK-HIF-1alpha-P-gp pathway.	Berberine	24-33	hypoxia inducible factor 1 subunit alpha	Homo sapiens	205-215
28775788-6	2017	Our results showed that berberine could overcome DOX resistance in dose-orchestrated manner: On one hand, low-dose berberine can enhance DOX sensitivity in drug-resistance breast cancer cells through AMPK-HIF-1alpha-P-gp pathway.	Berberine	115-124	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	200-204
28775788-6	2017	Our results showed that berberine could overcome DOX resistance in dose-orchestrated manner: On one hand, low-dose berberine can enhance DOX sensitivity in drug-resistance breast cancer cells through AMPK-HIF-1alpha-P-gp pathway.	Berberine	115-124	hypoxia inducible factor 1 subunit alpha	Homo sapiens	205-215
28775788-7	2017	On the other hand, high-dose berberine alone directly induces apoptosis through the AMPK-p53 pathway with the independence of HIF-1alpha expression.	Berberine	29-38	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	84-88
28775788-7	2017	On the other hand, high-dose berberine alone directly induces apoptosis through the AMPK-p53 pathway with the independence of HIF-1alpha expression.	Berberine	29-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	126-136
28775788-8	2017	Taken together, our findings demonstrate that berberine sensitizes drug-resistant breast cancer to DOX chemotherapy and directly induces apoptosis through the dose-orchestrated AMPK signaling pathway in vitro and in vivo.	Berberine	46-55	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	177-181
28587416-8	2017	Berberine also significantly inhibited the expression of interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha mRNA and phosphorylation of signal transducer and activator of transcription 3.	Berberine	0-9	interleukin 1 beta	Mus musculus	57-79
28587416-8	2017	Berberine also significantly inhibited the expression of interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha mRNA and phosphorylation of signal transducer and activator of transcription 3.	Berberine	0-9	interleukin 6	Mus musculus	81-117
28587416-8	2017	Berberine also significantly inhibited the expression of interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha mRNA and phosphorylation of signal transducer and activator of transcription 3.	Berberine	0-9	signal transducer and activator of transcription 3	Mus musculus	146-196
28587416-9	2017	Furthermore, berberine reduced the levels of myeloperoxidase and increased the levels of superoxide dismutase and catalase in colon and serum samples relative to the control group.	Berberine	13-22	myeloperoxidase	Mus musculus	45-60
28587416-9	2017	Furthermore, berberine reduced the levels of myeloperoxidase and increased the levels of superoxide dismutase and catalase in colon and serum samples relative to the control group.	Berberine	13-22	catalase	Mus musculus	114-122
28656004-0	2017	Berberine Reverses Hypoxia-induced Chemoresistance in Breast Cancer through the Inhibition of AMPK- HIF-1alpha.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	94-98
28656004-0	2017	Berberine Reverses Hypoxia-induced Chemoresistance in Breast Cancer through the Inhibition of AMPK- HIF-1alpha.	Berberine	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	100-110
28656004-8	2017	The intriguing fact was that the protein expressions of AMPK and HIF-1alpha were down-regulated by berberine, either low dose or high dose.	Berberine	99-108	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	56-60
28656004-8	2017	The intriguing fact was that the protein expressions of AMPK and HIF-1alpha were down-regulated by berberine, either low dose or high dose.	Berberine	99-108	hypoxia inducible factor 1 subunit alpha	Homo sapiens	65-75
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	85-94	hypoxia inducible factor 1 subunit alpha	Homo sapiens	22-32
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	85-94	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	96-100
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	85-94	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	85-94	phosphoglycolate phosphatase	Homo sapiens	112-116
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	85-94	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	209-213
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	85-94	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	85-94	tumor protein p53	Homo sapiens	248-251
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	192-201	hypoxia inducible factor 1 subunit alpha	Homo sapiens	22-32
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	192-201	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	96-100
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	192-201	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	192-201	phosphoglycolate phosphatase	Homo sapiens	112-116
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	192-201	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	192-201	hypoxia inducible factor 1 subunit alpha	Homo sapiens	22-32
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	192-201	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	96-100
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	192-201	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	192-201	phosphoglycolate phosphatase	Homo sapiens	112-116
28656004-9	2017	But the downstream of HIF-1alpha occurred the bifurcation dependent on the dosage of berberine: AMPK-HIF-1alpha-P-gp inactivation played a crucial role on the DOX chemosensitivity of low-dose berberine, while AMPK-HIF-1alpha downregulaton inducing p53 activation led to apoptosis in high-dose berberine.	Berberine	192-201	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
28487951-0	2017	Berberine activates AMPK to suppress proteolytic processing, nuclear translocation and target DNA binding of SREBP-1c in 3T3-L1 adipocytes.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	20-24
28487951-0	2017	Berberine activates AMPK to suppress proteolytic processing, nuclear translocation and target DNA binding of SREBP-1c in 3T3-L1 adipocytes.	Berberine	0-9	sterol regulatory element binding transcription factor 1	Homo sapiens	109-117
28487951-2	2017	In the present study, the fat-reducing mechanisms of berberine (BBR), a natural isoquinoline, was investigated by examining the AMPK-mediated modulation of SREBP-1c in 3T3-L1 adipocytes.	Berberine	53-62	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	128-132
28487951-2	2017	In the present study, the fat-reducing mechanisms of berberine (BBR), a natural isoquinoline, was investigated by examining the AMPK-mediated modulation of SREBP-1c in 3T3-L1 adipocytes.	Berberine	53-62	sterol regulatory element binding transcription factor 1	Homo sapiens	156-164
28487951-2	2017	In the present study, the fat-reducing mechanisms of berberine (BBR), a natural isoquinoline, was investigated by examining the AMPK-mediated modulation of SREBP-1c in 3T3-L1 adipocytes.	Berberine	64-67	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	128-132
28487951-2	2017	In the present study, the fat-reducing mechanisms of berberine (BBR), a natural isoquinoline, was investigated by examining the AMPK-mediated modulation of SREBP-1c in 3T3-L1 adipocytes.	Berberine	64-67	sterol regulatory element binding transcription factor 1	Homo sapiens	156-164
28487951-5	2017	Transfection with AMPKalpha1 siRNA, and not control siRNA, inhibited BBR-induced phosphorylation of the 125-kDa SREBP-1c, which confirmed that AMPK was responsible for phosphorylating SREBP-1c.	Berberine	69-72	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	18-28
28487951-5	2017	Transfection with AMPKalpha1 siRNA, and not control siRNA, inhibited BBR-induced phosphorylation of the 125-kDa SREBP-1c, which confirmed that AMPK was responsible for phosphorylating SREBP-1c.	Berberine	69-72	sterol regulatory element binding transcription factor 1	Homo sapiens	112-120
28487951-5	2017	Transfection with AMPKalpha1 siRNA, and not control siRNA, inhibited BBR-induced phosphorylation of the 125-kDa SREBP-1c, which confirmed that AMPK was responsible for phosphorylating SREBP-1c.	Berberine	69-72	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	18-22
28487951-5	2017	Transfection with AMPKalpha1 siRNA, and not control siRNA, inhibited BBR-induced phosphorylation of the 125-kDa SREBP-1c, which confirmed that AMPK was responsible for phosphorylating SREBP-1c.	Berberine	69-72	sterol regulatory element binding transcription factor 1	Homo sapiens	184-192
28487951-7	2017	In addition, BBR-induced suppression of lipogenic gene expression and intracellular fat accumulation were rescued by AMPKalpha1 siRNA transfection.	Berberine	13-16	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	117-127
28487951-8	2017	In conclusion, the results of the present study demonstrate that BBR activates AMPK to induce phosphorylation of SREBP-1c, thereby suppressing proteolytic processing, nuclear translocation and target DNA binding of SREBP-1c, which leads to a reduction in lipogenic gene expression and intracellular fat accumulation.	Berberine	65-68	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	79-83
28487951-8	2017	In conclusion, the results of the present study demonstrate that BBR activates AMPK to induce phosphorylation of SREBP-1c, thereby suppressing proteolytic processing, nuclear translocation and target DNA binding of SREBP-1c, which leads to a reduction in lipogenic gene expression and intracellular fat accumulation.	Berberine	65-68	sterol regulatory element binding transcription factor 1	Homo sapiens	113-121
28487951-8	2017	In conclusion, the results of the present study demonstrate that BBR activates AMPK to induce phosphorylation of SREBP-1c, thereby suppressing proteolytic processing, nuclear translocation and target DNA binding of SREBP-1c, which leads to a reduction in lipogenic gene expression and intracellular fat accumulation.	Berberine	65-68	sterol regulatory element binding transcription factor 1	Homo sapiens	215-223
30108832-2	2017	The screen resulted in the identification of the natural product alkaloids, berberine and palmatine as well as alpha-tocopheryl succinate (alpha-TOS) as potential inhibitors of PTP1B.	Berberine	76-85	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	177-182
28587416-7	2017	In addition, berberine significantly inhibited the increase of fluorescein isothiocyanate-dextran in serum and the decrease of zonula occluden-1 (also known as tight junction protein-1), occludin and epithelial cadherin expression in colonic tissue, relative to a DSS-treated control group.	Berberine	13-22	tight junction protein 1	Mus musculus	160-184
28587416-7	2017	In addition, berberine significantly inhibited the increase of fluorescein isothiocyanate-dextran in serum and the decrease of zonula occluden-1 (also known as tight junction protein-1), occludin and epithelial cadherin expression in colonic tissue, relative to a DSS-treated control group.	Berberine	13-22	occludin	Mus musculus	187-195
28587416-7	2017	In addition, berberine significantly inhibited the increase of fluorescein isothiocyanate-dextran in serum and the decrease of zonula occluden-1 (also known as tight junction protein-1), occludin and epithelial cadherin expression in colonic tissue, relative to a DSS-treated control group.	Berberine	13-22	cadherin 1	Mus musculus	200-219
28238768-6	2017	Natural products such as resveratrol, berberine, and curcumin that are present in our diet, can trigger autophagy via canonical (Beclin-1-dependent) and non-canonical (Beclin-1-independent) pathways.	Berberine	38-47	beclin 1	Homo sapiens	129-137
28238768-6	2017	Natural products such as resveratrol, berberine, and curcumin that are present in our diet, can trigger autophagy via canonical (Beclin-1-dependent) and non-canonical (Beclin-1-independent) pathways.	Berberine	38-47	beclin 1	Homo sapiens	168-176
28656088-2	2017	Berberine (BBR) is an isoquinoline alkaloid, which has been known as an aryl hydrocarbon receptor (AhR) ligand.	Berberine	0-9	aryl hydrocarbon receptor	Homo sapiens	72-97
28656088-2	2017	Berberine (BBR) is an isoquinoline alkaloid, which has been known as an aryl hydrocarbon receptor (AhR) ligand.	Berberine	0-9	aryl hydrocarbon receptor	Homo sapiens	99-102
28656088-2	2017	Berberine (BBR) is an isoquinoline alkaloid, which has been known as an aryl hydrocarbon receptor (AhR) ligand.	Berberine	11-14	aryl hydrocarbon receptor	Homo sapiens	72-97
28656088-2	2017	Berberine (BBR) is an isoquinoline alkaloid, which has been known as an aryl hydrocarbon receptor (AhR) ligand.	Berberine	11-14	aryl hydrocarbon receptor	Homo sapiens	99-102
28656094-7	2017	Moreover, berberine showed anti-apoptotic effects by reducing the glutamate-evoked caspase-3 and bax/bcl-2 overexpression.	Berberine	10-19	BCL2 associated X, apoptosis regulator	Rattus norvegicus	97-100
28656094-7	2017	Moreover, berberine showed anti-apoptotic effects by reducing the glutamate-evoked caspase-3 and bax/bcl-2 overexpression.	Berberine	10-19	BCL2, apoptosis regulator	Rattus norvegicus	101-106
28447763-6	2017	In addition, berberine was reported to restore aberrant levels of gut hormones in the portal plasma, such as glucagon-like peptide-1 and -2, peptide YY, glucose-dependent insulinotropic polypeptide and pancreatic polypeptide.	Berberine	13-22	peptide YY	Rattus norvegicus	141-151
28447763-6	2017	In addition, berberine was reported to restore aberrant levels of gut hormones in the portal plasma, such as glucagon-like peptide-1 and -2, peptide YY, glucose-dependent insulinotropic polypeptide and pancreatic polypeptide.	Berberine	13-22	gastric inhibitory polypeptide	Rattus norvegicus	153-197
28447763-6	2017	In addition, berberine was reported to restore aberrant levels of gut hormones in the portal plasma, such as glucagon-like peptide-1 and -2, peptide YY, glucose-dependent insulinotropic polypeptide and pancreatic polypeptide.	Berberine	13-22	pancreatic polypeptide	Rattus norvegicus	202-224
28511903-5	2017	The aim of this study was to investigate the effect of BBR on oxLDL- and TNFalpha-induced endothelial dysfunction in human umbilical vein endothelial cells (HUVECs) and to compare it with that of lovastatin (LOVA).	Berberine	55-58	tumor necrosis factor	Homo sapiens	73-81
28511903-10	2017	BBR but not LOVA treatment abolished the TNFalpha-induced cytotoxicity and restored the activation of Akt signaling.	Berberine	0-3	tumor necrosis factor	Homo sapiens	41-49
28822177-0	2017	[Berberine regulates type 2 diabetes mellitus related with insulin resistance].	Berberine	1-10	insulin	Homo sapiens	59-66
28822177-3	2017	Berberine, a traditional Chinese herb extract, has been shown to be safe and effective in lowering blood sugar, alleviating insulin resistance and moderating type 2 diabetes mellitus and its complications.	Berberine	0-9	insulin	Homo sapiens	124-131
28465511-5	2017	In the forced swimming test, berberine decreased the immobility time in a dose-dependent manner, reversing the depressive-like effect observed in ovariectomized mice, and this effect was blocked by the 5-HT2 antagonist ketanserin.	Berberine	29-38	hypothermia due to alcohol sensitivity 2	Mus musculus	204-207
28465511-6	2017	In addition, western blotting indicated that BDNF and peEF2 in the hippocampus, but not pCREB/CREB in the frontal cortex, were affected by berberine treatment.	Berberine	139-148	brain derived neurotrophic factor	Mus musculus	45-49
28465511-7	2017	Furthermore, immunohistochemistry demonstrated that the reduction in c-Fos induced by ovariectomy were greater after berberine treatment.	Berberine	117-126	FBJ osteosarcoma oncogene	Mus musculus	69-74
28465511-8	2017	Ketanserin also antagonized the effect of berberine on the c-Fos expression.	Berberine	42-51	FBJ osteosarcoma oncogene	Mus musculus	59-64
28465511-9	2017	Our findings suggest that berberine exerts antidepressant-like effects in ovariectomized mice, and 5-HT2 receptor activation may be partially related to the antidepressant-like effects of the berberine by BDNF-CREB and eEF2 pathways.	Berberine	192-201	hypothermia due to alcohol sensitivity 2	Mus musculus	101-104
28465511-9	2017	Our findings suggest that berberine exerts antidepressant-like effects in ovariectomized mice, and 5-HT2 receptor activation may be partially related to the antidepressant-like effects of the berberine by BDNF-CREB and eEF2 pathways.	Berberine	192-201	brain derived neurotrophic factor	Mus musculus	205-209
28465511-9	2017	Our findings suggest that berberine exerts antidepressant-like effects in ovariectomized mice, and 5-HT2 receptor activation may be partially related to the antidepressant-like effects of the berberine by BDNF-CREB and eEF2 pathways.	Berberine	192-201	cAMP responsive element binding protein 1	Mus musculus	210-214
28465511-9	2017	Our findings suggest that berberine exerts antidepressant-like effects in ovariectomized mice, and 5-HT2 receptor activation may be partially related to the antidepressant-like effects of the berberine by BDNF-CREB and eEF2 pathways.	Berberine	192-201	eukaryotic translation elongation factor 2	Mus musculus	219-223
28282788-0	2017	Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement.	Berberine	0-9	NLR family, pyrin domain containing 3	Mus musculus	37-42
28282788-0	2017	Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement.	Berberine	131-140	NLR family, pyrin domain containing 3	Mus musculus	37-42
28282788-3	2017	In the present study, we showed that berberine (BBR) significantly suppressed saturated fatty acid palmitate (PA)-induced NLRP3 inflammasome activation and interleukin-1beta (IL-1beta) release in macrophages, which was one of the most important mediators in the insulin sensitivity of adipose tissue.	Berberine	37-46	NLR family, pyrin domain containing 3	Mus musculus	122-127
28282788-3	2017	In the present study, we showed that berberine (BBR) significantly suppressed saturated fatty acid palmitate (PA)-induced NLRP3 inflammasome activation and interleukin-1beta (IL-1beta) release in macrophages, which was one of the most important mediators in the insulin sensitivity of adipose tissue.	Berberine	37-46	interleukin 1 beta	Mus musculus	156-173
28282788-3	2017	In the present study, we showed that berberine (BBR) significantly suppressed saturated fatty acid palmitate (PA)-induced NLRP3 inflammasome activation and interleukin-1beta (IL-1beta) release in macrophages, which was one of the most important mediators in the insulin sensitivity of adipose tissue.	Berberine	37-46	interleukin 1 beta	Mus musculus	175-183
28282788-3	2017	In the present study, we showed that berberine (BBR) significantly suppressed saturated fatty acid palmitate (PA)-induced NLRP3 inflammasome activation and interleukin-1beta (IL-1beta) release in macrophages, which was one of the most important mediators in the insulin sensitivity of adipose tissue.	Berberine	48-51	NLR family, pyrin domain containing 3	Mus musculus	122-127
28282788-3	2017	In the present study, we showed that berberine (BBR) significantly suppressed saturated fatty acid palmitate (PA)-induced NLRP3 inflammasome activation and interleukin-1beta (IL-1beta) release in macrophages, which was one of the most important mediators in the insulin sensitivity of adipose tissue.	Berberine	48-51	interleukin 1 beta	Mus musculus	156-173
28282788-3	2017	In the present study, we showed that berberine (BBR) significantly suppressed saturated fatty acid palmitate (PA)-induced NLRP3 inflammasome activation and interleukin-1beta (IL-1beta) release in macrophages, which was one of the most important mediators in the insulin sensitivity of adipose tissue.	Berberine	48-51	interleukin 1 beta	Mus musculus	175-183
28282791-8	2017	Meanwhile, berberine significantly decreased the levels of IL-6 and IL-17, and increased the levels of IL-10 and TGF-beta.	Berberine	11-20	interleukin 6	Rattus norvegicus	59-63
28282791-8	2017	Meanwhile, berberine significantly decreased the levels of IL-6 and IL-17, and increased the levels of IL-10 and TGF-beta.	Berberine	11-20	interleukin 17A	Rattus norvegicus	68-73
28282791-8	2017	Meanwhile, berberine significantly decreased the levels of IL-6 and IL-17, and increased the levels of IL-10 and TGF-beta.	Berberine	11-20	interleukin 10	Rattus norvegicus	103-108
28282791-8	2017	Meanwhile, berberine significantly decreased the levels of IL-6 and IL-17, and increased the levels of IL-10 and TGF-beta.	Berberine	11-20	transforming growth factor, beta 1	Rattus norvegicus	113-121
28223223-0	2017	Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of beta-amyloid in APP/tau/PS1 mouse model of Alzheimer"s disease.	Berberine	0-9	presenilin 1	Mus musculus	127-130
28223223-1	2017	This study investigates the neuroprotective properties of berberine (a natural isoquinoline alkaloid isolated from the Rhizoma coptidis) and finds that berberine could promote beta-amyloid (Abeta) clearance and inhibit Abeta production in the triple-transgenic mouse model of Alzheimer"s disease (3xTg-AD).	Berberine	152-161	amyloid beta (A4) precursor protein	Mus musculus	190-195
28223223-1	2017	This study investigates the neuroprotective properties of berberine (a natural isoquinoline alkaloid isolated from the Rhizoma coptidis) and finds that berberine could promote beta-amyloid (Abeta) clearance and inhibit Abeta production in the triple-transgenic mouse model of Alzheimer"s disease (3xTg-AD).	Berberine	152-161	amyloid beta (A4) precursor protein	Mus musculus	219-224
28223223-4	2017	The result showed that berberine significantly improved 3xTg-AD mice"s spatial learning capacity and memory retention, promoted autophagy activity identified by the enhancement of brain LC3-II, beclin-1, hVps34, and Cathepsin-D levels as well as the reduction of brain P62 and Bcl-2 levels in AD mice, facilitated reduction of Abeta and APP levels, reduced Abeta plaque deposition in the hippocampus of AD mice, and inhibited b-site APP cleavage enzyme 1 (BACE1) expression.	Berberine	23-32	beclin 1, autophagy related	Mus musculus	194-202
28223223-4	2017	The result showed that berberine significantly improved 3xTg-AD mice"s spatial learning capacity and memory retention, promoted autophagy activity identified by the enhancement of brain LC3-II, beclin-1, hVps34, and Cathepsin-D levels as well as the reduction of brain P62 and Bcl-2 levels in AD mice, facilitated reduction of Abeta and APP levels, reduced Abeta plaque deposition in the hippocampus of AD mice, and inhibited b-site APP cleavage enzyme 1 (BACE1) expression.	Berberine	23-32	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	204-210
28223223-4	2017	The result showed that berberine significantly improved 3xTg-AD mice"s spatial learning capacity and memory retention, promoted autophagy activity identified by the enhancement of brain LC3-II, beclin-1, hVps34, and Cathepsin-D levels as well as the reduction of brain P62 and Bcl-2 levels in AD mice, facilitated reduction of Abeta and APP levels, reduced Abeta plaque deposition in the hippocampus of AD mice, and inhibited b-site APP cleavage enzyme 1 (BACE1) expression.	Berberine	23-32	cathepsin D	Mus musculus	216-227
28223223-4	2017	The result showed that berberine significantly improved 3xTg-AD mice"s spatial learning capacity and memory retention, promoted autophagy activity identified by the enhancement of brain LC3-II, beclin-1, hVps34, and Cathepsin-D levels as well as the reduction of brain P62 and Bcl-2 levels in AD mice, facilitated reduction of Abeta and APP levels, reduced Abeta plaque deposition in the hippocampus of AD mice, and inhibited b-site APP cleavage enzyme 1 (BACE1) expression.	Berberine	23-32	B cell leukemia/lymphoma 2	Mus musculus	277-282
28223223-4	2017	The result showed that berberine significantly improved 3xTg-AD mice"s spatial learning capacity and memory retention, promoted autophagy activity identified by the enhancement of brain LC3-II, beclin-1, hVps34, and Cathepsin-D levels as well as the reduction of brain P62 and Bcl-2 levels in AD mice, facilitated reduction of Abeta and APP levels, reduced Abeta plaque deposition in the hippocampus of AD mice, and inhibited b-site APP cleavage enzyme 1 (BACE1) expression.	Berberine	23-32	amyloid beta (A4) precursor protein	Mus musculus	327-332
28223223-4	2017	The result showed that berberine significantly improved 3xTg-AD mice"s spatial learning capacity and memory retention, promoted autophagy activity identified by the enhancement of brain LC3-II, beclin-1, hVps34, and Cathepsin-D levels as well as the reduction of brain P62 and Bcl-2 levels in AD mice, facilitated reduction of Abeta and APP levels, reduced Abeta plaque deposition in the hippocampus of AD mice, and inhibited b-site APP cleavage enzyme 1 (BACE1) expression.	Berberine	23-32	amyloid beta (A4) precursor protein	Mus musculus	357-362
28223223-4	2017	The result showed that berberine significantly improved 3xTg-AD mice"s spatial learning capacity and memory retention, promoted autophagy activity identified by the enhancement of brain LC3-II, beclin-1, hVps34, and Cathepsin-D levels as well as the reduction of brain P62 and Bcl-2 levels in AD mice, facilitated reduction of Abeta and APP levels, reduced Abeta plaque deposition in the hippocampus of AD mice, and inhibited b-site APP cleavage enzyme 1 (BACE1) expression.	Berberine	23-32	beta-site APP cleaving enzyme 1	Mus musculus	426-454
28223223-4	2017	The result showed that berberine significantly improved 3xTg-AD mice"s spatial learning capacity and memory retention, promoted autophagy activity identified by the enhancement of brain LC3-II, beclin-1, hVps34, and Cathepsin-D levels as well as the reduction of brain P62 and Bcl-2 levels in AD mice, facilitated reduction of Abeta and APP levels, reduced Abeta plaque deposition in the hippocampus of AD mice, and inhibited b-site APP cleavage enzyme 1 (BACE1) expression.	Berberine	23-32	beta-site APP cleaving enzyme 1	Mus musculus	456-461
28447763-6	2017	In addition, berberine was reported to restore aberrant levels of gut hormones in the portal plasma, such as glucagon-like peptide-1 and -2, peptide YY, glucose-dependent insulinotropic polypeptide and pancreatic polypeptide.	Berberine	13-22	glucagon	Rattus norvegicus	109-139
29926645-7	2017	The Traditional Chinese Medicine berberine decrease the levels of MDA, DGAT, HMG-CoA and increase the activities of HTGL, CYP7A, SOD and GSH-Px in liver tissue.	Berberine	33-42	diacylglycerol O-acyltransferase 1	Rattus norvegicus	71-75
29926645-7	2017	The Traditional Chinese Medicine berberine decrease the levels of MDA, DGAT, HMG-CoA and increase the activities of HTGL, CYP7A, SOD and GSH-Px in liver tissue.	Berberine	33-42	glutathione peroxidase 1	Rattus norvegicus	137-143
28465635-10	2017	In KYSE-70 cells treated with 50 mumol/L berberine for 48 h, the number of cells in G2/M phase (25.94% +- 5.01%) was significantly higher than that in the control group (9.77% +- 1.28%, P &lt; 0.01), and berberine treatment resulted in p21 up-regulation in KYSE-70 cells.	Berberine	41-50	H3 histone pseudogene 16	Homo sapiens	236-239
30108832-5	2017	Using NMR spectroscopy, self-association via stacking interactions was detected for berberine in aqueous media, which may also contribute to the non-specific inhibition of PTP1B.	Berberine	84-93	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	172-177
28685558-1	2017	Berberine, a quaternary isoquinoline alkaloid present in Berberis aristata, is well known in terms of cholesterol-lowering, hypoglycemic, and insulin sensitizing effects.	Berberine	0-9	insulin	Homo sapiens	142-149
28483181-0	2017	Decreased Levels of Spleen Tissue CD4+CD25+Foxp3+ Regulatory T Lymphocytes in Mice Exposed to Berberine.	Berberine	94-103	CD4 antigen	Mus musculus	34-37
28483181-0	2017	Decreased Levels of Spleen Tissue CD4+CD25+Foxp3+ Regulatory T Lymphocytes in Mice Exposed to Berberine.	Berberine	94-103	forkhead box P3	Mus musculus	43-48
28483181-1	2017	The effects of isoquinoline alkaloid berberine (BER) on spleen tissue CD4+CD25+Foxp3+ regulatory T (Treg) cells were evaluated in BALB/c mice.	Berberine	48-51	CD4 antigen	Mus musculus	70-73
28483181-1	2017	The effects of isoquinoline alkaloid berberine (BER) on spleen tissue CD4+CD25+Foxp3+ regulatory T (Treg) cells were evaluated in BALB/c mice.	Berberine	48-51	forkhead box P3	Mus musculus	79-84
28483181-4	2017	The results showed that a high dose of BER (10 mg/kg) could decrease both the absolute and relative percentages of spleen Treg cells as well as decrease the production of IL-10 by splenocytes in the treated mice (p&lt;0.05).	Berberine	39-42	interleukin 10	Mus musculus	171-176
27652986-11	2017	Berberine, salicylates, and resveratrol are newer promising agents in the management of diabetes, having well-documented evidence of AMPK stimulation medicated glycemic efficacy.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	133-137
28411686-0	2017	Mechanism underlying berberine"s effects on HSP70/TNFalpha under heat stress: Correlation with the TATA boxes.	Berberine	21-30	heat shock protein family A (Hsp70) member 4	Homo sapiens	44-49
28350122-3	2017	This study aimed to investigate the effect of berberine on the proliferation, cell cycle regulation, apoptosis, radioresistance of NPC cells and whether specificity protein 1 (Sp1) is a functional target of berberine.	Berberine	207-216	Sp1 transcription factor	Homo sapiens	153-174
28350122-9	2017	Berberine inhibited transforming growth factor-beta (TGF-beta)-induced tumor invasion and suppressed epithelial-to-mesenchymal transition (EMT) process, as evidenced by increased E-cadherin and decreased vimentin proteins.	Berberine	0-9	transforming growth factor beta 1	Homo sapiens	53-61
28350122-9	2017	Berberine inhibited transforming growth factor-beta (TGF-beta)-induced tumor invasion and suppressed epithelial-to-mesenchymal transition (EMT) process, as evidenced by increased E-cadherin and decreased vimentin proteins.	Berberine	0-9	cadherin 1	Homo sapiens	179-189
28350122-9	2017	Berberine inhibited transforming growth factor-beta (TGF-beta)-induced tumor invasion and suppressed epithelial-to-mesenchymal transition (EMT) process, as evidenced by increased E-cadherin and decreased vimentin proteins.	Berberine	0-9	vimentin	Homo sapiens	204-212
28350122-10	2017	Sp1 may be required for the TGF-beta1-induced invasion and EMT by berberine.	Berberine	66-75	transforming growth factor beta 1	Homo sapiens	28-37
28408805-0	2017	Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice.	Berberine	10-19	snail family zinc finger 1	Mus musculus	105-110
28157699-0	2017	Berberine-induced autophagic cell death by elevating GRP78 levels in cancer cells.	Berberine	0-9	heat shock protein family A (Hsp70) member 5	Homo sapiens	53-58
28157699-3	2017	However, the related mechanisms between berberine-induced cancer cell autophagy and GRP78 remain to be elucidated.	Berberine	40-49	heat shock protein family A (Hsp70) member 5	Homo sapiens	84-89
28157699-4	2017	Here, we report that berberine can induce autophagic cancer cell death by elevating levels of GRP78.	Berberine	21-30	heat shock protein family A (Hsp70) member 5	Homo sapiens	94-99
28157699-5	2017	These results further demonstrated that berberine enhanced GRP78 by suppression of ubiquitination / proteasomal degradation of GRP78 and activation of ATF6.	Berberine	40-49	heat shock protein family A (Hsp70) member 5	Homo sapiens	59-64
28157699-5	2017	These results further demonstrated that berberine enhanced GRP78 by suppression of ubiquitination / proteasomal degradation of GRP78 and activation of ATF6.	Berberine	40-49	heat shock protein family A (Hsp70) member 5	Homo sapiens	127-132
28157699-5	2017	These results further demonstrated that berberine enhanced GRP78 by suppression of ubiquitination / proteasomal degradation of GRP78 and activation of ATF6.	Berberine	40-49	activating transcription factor 6	Homo sapiens	151-155
28157699-6	2017	Moreover, fluorescence spectrum assay revealed that berberine could bind to GRP78 and form complexes.	Berberine	52-61	heat shock protein family A (Hsp70) member 5	Homo sapiens	76-81
28157699-7	2017	Finally, co-IP analysis showed that the ability of GRP78 to bind to VPS34 was increased with berberine treatment.	Berberine	93-102	heat shock protein family A (Hsp70) member 5	Homo sapiens	51-56
28157699-7	2017	Finally, co-IP analysis showed that the ability of GRP78 to bind to VPS34 was increased with berberine treatment.	Berberine	93-102	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	68-73
28157699-8	2017	Taken together, our results suggest that berberine induces autophagic cancer cell death via enhancing GRP78 levels and the ability of GRP78 to bind to VPS34.	Berberine	41-50	heat shock protein family A (Hsp70) member 5	Homo sapiens	102-107
28157699-8	2017	Taken together, our results suggest that berberine induces autophagic cancer cell death via enhancing GRP78 levels and the ability of GRP78 to bind to VPS34.	Berberine	41-50	heat shock protein family A (Hsp70) member 5	Homo sapiens	134-139
28157699-8	2017	Taken together, our results suggest that berberine induces autophagic cancer cell death via enhancing GRP78 levels and the ability of GRP78 to bind to VPS34.	Berberine	41-50	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	151-156
28154180-5	2017	However, berberine effects on Ntcp/NTCP expression are unknown, prompting use to investigate this possible connection.	Berberine	9-18	solute carrier family 10 member 1	Homo sapiens	30-34
28154180-6	2017	Our results showed that berberine dose-dependently increased Ntcp expression in male mouse liver and decreased taurocholic acid levels in serum but increased them in the liver.	Berberine	24-33	solute carrier family 10 (sodium/bile acid cotransporter family), member 1	Mus musculus	61-65
28154180-7	2017	In mouse and human hepatoma cells, berberine induced Ntcp/NTCP mRNA and protein expression and increased cellular uptake of [3H] taurocholate.	Berberine	35-44	solute carrier family 10 member 1	Homo sapiens	53-57
28154180-7	2017	In mouse and human hepatoma cells, berberine induced Ntcp/NTCP mRNA and protein expression and increased cellular uptake of [3H] taurocholate.	Berberine	35-44	solute carrier family 10 member 1	Homo sapiens	58-62
28154180-8	2017	Mechanistically, berberine decreased nuclear protein levels of phospho-JAK2 and phospho-STAT5, thus disrupting the JAK2-STAT5 signaling.	Berberine	17-26	Janus kinase 2	Homo sapiens	71-75
28154180-8	2017	Mechanistically, berberine decreased nuclear protein levels of phospho-JAK2 and phospho-STAT5, thus disrupting the JAK2-STAT5 signaling.	Berberine	17-26	signal transducer and activator of transcription 5A	Homo sapiens	88-93
28154180-8	2017	Mechanistically, berberine decreased nuclear protein levels of phospho-JAK2 and phospho-STAT5, thus disrupting the JAK2-STAT5 signaling.	Berberine	17-26	Janus kinase 2	Homo sapiens	115-119
28154180-8	2017	Mechanistically, berberine decreased nuclear protein levels of phospho-JAK2 and phospho-STAT5, thus disrupting the JAK2-STAT5 signaling.	Berberine	17-26	signal transducer and activator of transcription 5A	Homo sapiens	120-125
28154180-9	2017	Moreover, berberine stimulated luciferase reporter expression from the mouse Ntcp promoter when one putative STAT5 response element (RE) (-1137 bp) was deleted and from the human NTCP promoter when three putative STAT5REs (-2898, -2164, and -691 bp) were deleted.	Berberine	10-19	solute carrier family 10 (sodium/bile acid cotransporter family), member 1	Mus musculus	77-81
28154180-9	2017	Moreover, berberine stimulated luciferase reporter expression from the mouse Ntcp promoter when one putative STAT5 response element (RE) (-1137 bp) was deleted and from the human NTCP promoter when three putative STAT5REs (-2898, -2164, and -691 bp) were deleted.	Berberine	10-19	signal transducer and activator of transcription 5A	Mus musculus	109-114
28154180-9	2017	Moreover, berberine stimulated luciferase reporter expression from the mouse Ntcp promoter when one putative STAT5 response element (RE) (-1137 bp) was deleted and from the human NTCP promoter when three putative STAT5REs (-2898, -2164, and -691 bp) were deleted.	Berberine	10-19	solute carrier family 10 member 1	Homo sapiens	179-183
28154180-9	2017	Moreover, berberine stimulated luciferase reporter expression from the mouse Ntcp promoter when one putative STAT5 response element (RE) (-1137 bp) was deleted and from the human NTCP promoter when three putative STAT5REs (-2898, -2164, and -691 bp) were deleted.	Berberine	10-19	signal transducer and activator of transcription 5A	Homo sapiens	213-218
28154180-10	2017	Chromatin immunoprecipitation demonstrated that berberine decreased binding of phospho-STAT5 protein to the-2164 and -691 bp STAT5REs in the human NTCP promoter.	Berberine	48-57	signal transducer and activator of transcription 5A	Homo sapiens	87-92
28154180-10	2017	Chromatin immunoprecipitation demonstrated that berberine decreased binding of phospho-STAT5 protein to the-2164 and -691 bp STAT5REs in the human NTCP promoter.	Berberine	48-57	signal transducer and activator of transcription 5A	Homo sapiens	125-130
28154180-10	2017	Chromatin immunoprecipitation demonstrated that berberine decreased binding of phospho-STAT5 protein to the-2164 and -691 bp STAT5REs in the human NTCP promoter.	Berberine	48-57	solute carrier family 10 member 1	Homo sapiens	147-151
28154180-11	2017	In summary, berberine-disrupted STAT5 signaling promoted mouse and human Ntcp/NTCP expression, resulting in enhanced bile acid uptake.	Berberine	12-21	signal transducer and activator of transcription 5A	Mus musculus	32-37
28154180-11	2017	In summary, berberine-disrupted STAT5 signaling promoted mouse and human Ntcp/NTCP expression, resulting in enhanced bile acid uptake.	Berberine	12-21	solute carrier family 10 member 1	Homo sapiens	73-77
28154180-11	2017	In summary, berberine-disrupted STAT5 signaling promoted mouse and human Ntcp/NTCP expression, resulting in enhanced bile acid uptake.	Berberine	12-21	solute carrier family 10 member 1	Homo sapiens	78-82
28088519-7	2017	Experimental studies indicated that berberine inhibited 5-LOX (100 muM) and PGE2 (50 muM) production by 72.2 and 72.0% and ferulic acid by 74.3 and 54.4% respectively.	Berberine	36-45	latexin	Homo sapiens	67-70
28088519-7	2017	Experimental studies indicated that berberine inhibited 5-LOX (100 muM) and PGE2 (50 muM) production by 72.2 and 72.0% and ferulic acid by 74.3 and 54.4% respectively.	Berberine	36-45	latexin	Homo sapiens	85-88
28276481-0	2017	Identification of berberine as a direct thrombin inhibitor from traditional Chinese medicine through structural, functional and binding studies.	Berberine	18-27	coagulation factor II, thrombin	Homo sapiens	40-48
28276481-4	2017	Berberine (BBR) was first confirmed as a thrombin inhibitor using an enzymatic assay.	Berberine	0-9	coagulation factor II, thrombin	Homo sapiens	41-49
28276481-4	2017	Berberine (BBR) was first confirmed as a thrombin inhibitor using an enzymatic assay.	Berberine	11-14	coagulation factor II, thrombin	Homo sapiens	41-49
28087385-0	2017	Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy.	Berberine	0-9	MOK protein kinase	Rattus norvegicus	63-67
28087385-1	2017	In this study, we explored the effect of berberine treatment on the AGEs-RAGE pathway in a rat model of diabetic nephropathy, and we investigated the mechanism by which key factors caused kidney injury and the effects of berberine.	Berberine	41-50	MOK protein kinase	Rattus norvegicus	73-77
28087385-3	2017	Western blotting and immunohistochemistry revealed significant increases in the levels of AGEs, RAGE, P-PKC-beta and TGF-beta1 in injured kidneys, and these levels were markedly decreased by treatment with berberine.	Berberine	206-215	MOK protein kinase	Rattus norvegicus	96-100
28087385-3	2017	Western blotting and immunohistochemistry revealed significant increases in the levels of AGEs, RAGE, P-PKC-beta and TGF-beta1 in injured kidneys, and these levels were markedly decreased by treatment with berberine.	Berberine	206-215	transforming growth factor, beta 1	Rattus norvegicus	117-126
28087385-5	2017	Cells treated with berberine showed reduced levels of AGEs, accompanied by decreased RAGE, p-PKC and TGF-beta1 levels soon afterwards.	Berberine	19-28	MOK protein kinase	Rattus norvegicus	85-89
28087385-5	2017	Cells treated with berberine showed reduced levels of AGEs, accompanied by decreased RAGE, p-PKC and TGF-beta1 levels soon afterwards.	Berberine	19-28	transforming growth factor, beta 1	Rattus norvegicus	101-110
28087385-6	2017	Berberine exhibited renoprotective effects in diabetic nephropathy rats, and the molecular mechanism was associated with changes in the levels and regulation of the AGEs-RAGE-PKC-beta-TGF-beta1 signaling pathway.	Berberine	0-9	MOK protein kinase	Rattus norvegicus	170-174
28087385-6	2017	Berberine exhibited renoprotective effects in diabetic nephropathy rats, and the molecular mechanism was associated with changes in the levels and regulation of the AGEs-RAGE-PKC-beta-TGF-beta1 signaling pathway.	Berberine	0-9	transforming growth factor, beta 1	Rattus norvegicus	184-193
28068647-0	2017	Berberine, an isoquinoline alkaloid suppresses TXNIP mediated NLRP3 inflammasome activation in MSU crystal stimulated RAW 264.7 macrophages through the upregulation of Nrf2 transcription factor and alleviates MSU crystal induced inflammation in rats.	Berberine	0-9	thioredoxin interacting protein	Rattus norvegicus	47-52
28068647-0	2017	Berberine, an isoquinoline alkaloid suppresses TXNIP mediated NLRP3 inflammasome activation in MSU crystal stimulated RAW 264.7 macrophages through the upregulation of Nrf2 transcription factor and alleviates MSU crystal induced inflammation in rats.	Berberine	0-9	NLR family, pyrin domain containing 3	Rattus norvegicus	62-67
28068647-0	2017	Berberine, an isoquinoline alkaloid suppresses TXNIP mediated NLRP3 inflammasome activation in MSU crystal stimulated RAW 264.7 macrophages through the upregulation of Nrf2 transcription factor and alleviates MSU crystal induced inflammation in rats.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	168-172
28068647-2	2017	Our results indicate that berberine (25, 50 and 75muM) suppressed the levels of pro-inflammatory cytokines (interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha)) and intracellular reactive oxygen species in MSU crystal stimulated RAW 264.7 macrophages.	Berberine	26-35	interleukin 1 beta	Rattus norvegicus	108-125
28068647-2	2017	Our results indicate that berberine (25, 50 and 75muM) suppressed the levels of pro-inflammatory cytokines (interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha)) and intracellular reactive oxygen species in MSU crystal stimulated RAW 264.7 macrophages.	Berberine	26-35	interleukin 1 beta	Rattus norvegicus	127-135
28068647-2	2017	Our results indicate that berberine (25, 50 and 75muM) suppressed the levels of pro-inflammatory cytokines (interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha)) and intracellular reactive oxygen species in MSU crystal stimulated RAW 264.7 macrophages.	Berberine	26-35	tumor necrosis factor	Rattus norvegicus	141-168
28068647-2	2017	Our results indicate that berberine (25, 50 and 75muM) suppressed the levels of pro-inflammatory cytokines (interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha)) and intracellular reactive oxygen species in MSU crystal stimulated RAW 264.7 macrophages.	Berberine	26-35	tumor necrosis factor	Rattus norvegicus	170-178
28259949-11	2017	Berberine also suppressed the activity of signal transducer and activator of transcription 3 which is a new therapeutic target in a series of malignancies, including NPC.	Berberine	0-9	signal transducer and activator of transcription 3	Homo sapiens	42-92
28259949-12	2017	Viral titer experiments demonstrated that berberine decreased the production of virions in HONE1 and HK1-EBV cells.	Berberine	42-51	hexokinase 1	Homo sapiens	101-104
27835779-0	2017	Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	127-130
27835779-0	2017	Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways.	Berberine	0-9	BCL2 apoptosis regulator a	Danio rerio	131-136
27835779-0	2017	Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways.	Berberine	0-9	nfe2 like bZIP transcription factor 2a	Danio rerio	141-145
27835779-0	2017	Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways.	Berberine	0-9	heme oxygenase 1	Rattus norvegicus	146-150
28068647-4	2017	Subsequently, western blot analysis revealed that berberine decreased the protein expression of IL-1beta and caspase 1 and increased Nrf2 expression in RAW 264.7 macrophages.	Berberine	50-59	interleukin 1 beta	Rattus norvegicus	96-104
28068647-4	2017	Subsequently, western blot analysis revealed that berberine decreased the protein expression of IL-1beta and caspase 1 and increased Nrf2 expression in RAW 264.7 macrophages.	Berberine	50-59	caspase 1	Rattus norvegicus	109-118
28068647-4	2017	Subsequently, western blot analysis revealed that berberine decreased the protein expression of IL-1beta and caspase 1 and increased Nrf2 expression in RAW 264.7 macrophages.	Berberine	50-59	NFE2 like bZIP transcription factor 2	Rattus norvegicus	133-137
28068647-5	2017	Immunofluorescence analysis also explored increased expression of Nrf2 in MSU crystal stimulated RAW 264.7 macrophages by berberine treatment.	Berberine	122-131	NFE2 like bZIP transcription factor 2	Rattus norvegicus	66-70
28068647-6	2017	In addition, the paw edema, pain score, pro-inflammatory cytokines (IL-1beta and TNFalpha) and articular elastase activity were found significantly reduced in berberine (50mg/kgb wt) administered MSU crystal-induced rats.	Berberine	159-168	interleukin 1 beta	Rattus norvegicus	68-76
28068647-6	2017	In addition, the paw edema, pain score, pro-inflammatory cytokines (IL-1beta and TNFalpha) and articular elastase activity were found significantly reduced in berberine (50mg/kgb wt) administered MSU crystal-induced rats.	Berberine	159-168	tumor necrosis factor	Rattus norvegicus	81-89
28068647-7	2017	Conclusively, our current findings suggest that berberine may represent as a potential candidate for the treatment of gouty arthritis by suppressing inflammatory mediators and activating Nrf2 anti-oxidant pathway.	Berberine	48-57	NFE2 like bZIP transcription factor 2	Rattus norvegicus	187-191
28411686-0	2017	Mechanism underlying berberine"s effects on HSP70/TNFalpha under heat stress: Correlation with the TATA boxes.	Berberine	21-30	tumor necrosis factor	Homo sapiens	50-58
28098901-0	2017	Effect of evodiamine and berberine on the interaction between DNMTs and target microRNAs during malignant transformation of the colon by TGF-beta1.	Berberine	25-34	transforming growth factor, beta 1	Rattus norvegicus	137-146
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	Berberine	21-30	DNA methyltransferase 1	Rattus norvegicus	94-99
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	Berberine	21-30	DNA methyltransferase 3 alpha	Rattus norvegicus	101-107
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	Berberine	21-30	DNA methyltransferase 3 beta	Rattus norvegicus	109-115
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	Berberine	21-30	microRNA 152	Rattus norvegicus	120-127
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	Berberine	21-30	microRNA 429	Rattus norvegicus	129-136
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	Berberine	21-30	microRNA 29a	Rattus norvegicus	138-145
28065862-8	2017	In vitro, free berberine significantly inhibited IL-6 secretion (IC50=10.4muM), whereas encapsulated berberine did not as it was not released from the formulation in the time frame of the in vitro study.	Berberine	15-24	interleukin 6	Mus musculus	49-53
28190470-0	2017	Berberine inhibits the proliferation and migration of breast cancer ZR-75-30 cells by targeting Ephrin-B2.	Berberine	0-9	ephrin B2	Homo sapiens	96-105
28190470-2	2017	However, no study has shown that berberine could target ephrin-B2, which plays a critical role in cell proliferation and migration.	Berberine	33-42	ephrin B2	Homo sapiens	56-65
28190470-3	2017	PURPOSE: The aim of this study is to investigate the effect of berberine on cancer cell growth and migration, through the regulation of ephrin-B2 and downstream signaling molecules.	Berberine	63-72	ephrin B2	Homo sapiens	136-145
28190470-7	2017	RESULTS: Berberine was isolated from C. chinensis extracts and showed activity on the HEK293/ephrin-B2 cell membrane chromatography column.	Berberine	9-18	ephrin B2	Homo sapiens	93-102
28190470-8	2017	Berberine showed a greater inhibitory effect in high-expressing ephrin-B2 cells (HEK293/ephrin-B2 cells) than in normal HEK293 cells, and decreased the expression of ephrin-B2 and its PDZ binding proteins, which indicates that ephrin-B2 is a target of berberine.	Berberine	0-9	ephrin B2	Homo sapiens	64-73
28190470-8	2017	Berberine showed a greater inhibitory effect in high-expressing ephrin-B2 cells (HEK293/ephrin-B2 cells) than in normal HEK293 cells, and decreased the expression of ephrin-B2 and its PDZ binding proteins, which indicates that ephrin-B2 is a target of berberine.	Berberine	0-9	ephrin B2	Homo sapiens	88-97
28190470-8	2017	Berberine showed a greater inhibitory effect in high-expressing ephrin-B2 cells (HEK293/ephrin-B2 cells) than in normal HEK293 cells, and decreased the expression of ephrin-B2 and its PDZ binding proteins, which indicates that ephrin-B2 is a target of berberine.	Berberine	0-9	ephrin B2	Homo sapiens	88-97
28190470-8	2017	Berberine showed a greater inhibitory effect in high-expressing ephrin-B2 cells (HEK293/ephrin-B2 cells) than in normal HEK293 cells, and decreased the expression of ephrin-B2 and its PDZ binding proteins, which indicates that ephrin-B2 is a target of berberine.	Berberine	0-9	ephrin B2	Homo sapiens	88-97
28190470-9	2017	Furthermore, berberine downregulates the phosphorylation of VEGFR2 and downstream signaling members (AKT and Erk1/2), which in turn downregulates the expression of MMP2 and MMP9.	Berberine	13-22	kinase insert domain receptor	Homo sapiens	60-66
28190470-9	2017	Furthermore, berberine downregulates the phosphorylation of VEGFR2 and downstream signaling members (AKT and Erk1/2), which in turn downregulates the expression of MMP2 and MMP9.	Berberine	13-22	mitogen-activated protein kinase 3	Homo sapiens	109-115
28190470-9	2017	Furthermore, berberine downregulates the phosphorylation of VEGFR2 and downstream signaling members (AKT and Erk1/2), which in turn downregulates the expression of MMP2 and MMP9.	Berberine	13-22	matrix metallopeptidase 2	Homo sapiens	164-168
28190470-9	2017	Furthermore, berberine downregulates the phosphorylation of VEGFR2 and downstream signaling members (AKT and Erk1/2), which in turn downregulates the expression of MMP2 and MMP9.	Berberine	13-22	matrix metallopeptidase 9	Homo sapiens	173-177
28190470-11	2017	Overall, our studies demonstrate that berberine inhibits cell growth and migration by targeting ephrin-B2.	Berberine	38-47	ephrin B2	Homo sapiens	96-105
27796611-0	2017	Synergy of 2-deoxy-D-glucose combined with berberine in inducing the lysosome/autophagy and transglutaminase activation-facilitated apoptosis.	Berberine	43-52	transglutaminase 1	Homo sapiens	92-108
28077277-0	2017	Berberine protects against ischemia/reperfusion injury after orthotopic liver transplantation via activating Sirt1/FoxO3alpha induced autophagy.	Berberine	0-9	sirtuin 1	Rattus norvegicus	109-114
28077277-0	2017	Berberine protects against ischemia/reperfusion injury after orthotopic liver transplantation via activating Sirt1/FoxO3alpha induced autophagy.	Berberine	0-9	forkhead box O3	Rattus norvegicus	115-125
28077277-11	2017	The deacetylation of FoxO3alpha by Sirt1 was enhanced in the nuclear of liver after pretreated with BBR.	Berberine	100-103	forkhead box O3	Rattus norvegicus	21-31
28077277-11	2017	The deacetylation of FoxO3alpha by Sirt1 was enhanced in the nuclear of liver after pretreated with BBR.	Berberine	100-103	sirtuin 1	Rattus norvegicus	35-40
27832398-0	2017	Berberine Attenuates Inflammation Associated with Delayed-Type Hypersensitivity via Suppressing Th1 Response and Inhibiting Apoptosis.	Berberine	0-9	negative elongation factor complex member C/D, Th1l	Mus musculus	96-99
27832398-6	2017	Concanavalin A stimulation assay and MTT assay also indicated inhibiting effect of berberine treatment on IFN-gamma production and decreased cytotoxicity in lymphocytes proliferation, respectively.	Berberine	83-92	interferon gamma	Mus musculus	106-115
27832398-2	2017	The aim of this study was to determine the role of berberine on ovalbumin (OVA)-induced delayed-type hypersensitivity (DTH) and its potential mechanisms.	Berberine	51-60	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	64-73
27832398-7	2017	Additionally, berberine obviously decreased the cell apoptosis and enzymatic activity of caspase-3, which was further confirmed by the facts that berberine clearly lowered Bax/Bcl-2 ratio and expression of cleaved caspase-3 protein.	Berberine	14-23	caspase 3	Mus musculus	89-98
27832398-7	2017	Additionally, berberine obviously decreased the cell apoptosis and enzymatic activity of caspase-3, which was further confirmed by the facts that berberine clearly lowered Bax/Bcl-2 ratio and expression of cleaved caspase-3 protein.	Berberine	14-23	BCL2-associated X protein	Mus musculus	172-175
27832398-4	2017	In homogenized footpad tissue, the production of Th1-mediated cytokines including IFN-gamma, TNF-alpha, and IL-2 were suppressed following the administration of berberine.	Berberine	161-170	negative elongation factor complex member C/D, Th1l	Mus musculus	49-52
27832398-7	2017	Additionally, berberine obviously decreased the cell apoptosis and enzymatic activity of caspase-3, which was further confirmed by the facts that berberine clearly lowered Bax/Bcl-2 ratio and expression of cleaved caspase-3 protein.	Berberine	14-23	B cell leukemia/lymphoma 2	Mus musculus	176-181
27832398-4	2017	In homogenized footpad tissue, the production of Th1-mediated cytokines including IFN-gamma, TNF-alpha, and IL-2 were suppressed following the administration of berberine.	Berberine	161-170	interferon gamma	Mus musculus	82-91
27832398-7	2017	Additionally, berberine obviously decreased the cell apoptosis and enzymatic activity of caspase-3, which was further confirmed by the facts that berberine clearly lowered Bax/Bcl-2 ratio and expression of cleaved caspase-3 protein.	Berberine	14-23	caspase 3	Mus musculus	214-223
27832398-7	2017	Additionally, berberine obviously decreased the cell apoptosis and enzymatic activity of caspase-3, which was further confirmed by the facts that berberine clearly lowered Bax/Bcl-2 ratio and expression of cleaved caspase-3 protein.	Berberine	146-155	caspase 3	Mus musculus	89-98
27832398-4	2017	In homogenized footpad tissue, the production of Th1-mediated cytokines including IFN-gamma, TNF-alpha, and IL-2 were suppressed following the administration of berberine.	Berberine	161-170	tumor necrosis factor	Mus musculus	93-102
27832398-7	2017	Additionally, berberine obviously decreased the cell apoptosis and enzymatic activity of caspase-3, which was further confirmed by the facts that berberine clearly lowered Bax/Bcl-2 ratio and expression of cleaved caspase-3 protein.	Berberine	146-155	BCL2-associated X protein	Mus musculus	172-175
27832398-4	2017	In homogenized footpad tissue, the production of Th1-mediated cytokines including IFN-gamma, TNF-alpha, and IL-2 were suppressed following the administration of berberine.	Berberine	161-170	interleukin 2	Mus musculus	108-112
27832398-7	2017	Additionally, berberine obviously decreased the cell apoptosis and enzymatic activity of caspase-3, which was further confirmed by the facts that berberine clearly lowered Bax/Bcl-2 ratio and expression of cleaved caspase-3 protein.	Berberine	146-155	B cell leukemia/lymphoma 2	Mus musculus	176-181
27832398-7	2017	Additionally, berberine obviously decreased the cell apoptosis and enzymatic activity of caspase-3, which was further confirmed by the facts that berberine clearly lowered Bax/Bcl-2 ratio and expression of cleaved caspase-3 protein.	Berberine	146-155	caspase 3	Mus musculus	214-223
27832398-5	2017	Detailed studies revealed that berberine prevented differentiation into Th1 cells in the OVA-primed lymphocytes, resulting from suppressing the expression of T-bet and secretion of IFN-gamma but not IL-4.	Berberine	31-40	negative elongation factor complex member C/D, Th1l	Mus musculus	72-75
27832398-8	2017	On correlation analysis, the percentage of apoptotic cells showed a significant positive relationship with IFN-gamma/IL-4 ratio of supernatant from footpad tissue in berberine-treated DTH mice.	Berberine	166-175	interferon gamma	Mus musculus	107-116
27832398-8	2017	On correlation analysis, the percentage of apoptotic cells showed a significant positive relationship with IFN-gamma/IL-4 ratio of supernatant from footpad tissue in berberine-treated DTH mice.	Berberine	166-175	interleukin 4	Mus musculus	117-121
27832398-5	2017	Detailed studies revealed that berberine prevented differentiation into Th1 cells in the OVA-primed lymphocytes, resulting from suppressing the expression of T-bet and secretion of IFN-gamma but not IL-4.	Berberine	31-40	T-box 21	Mus musculus	158-163
27832398-9	2017	These results demonstrated that berberine attenuated Th1-mediated inflammation in OVA-induced DTH by curbing Th1 response and inhibiting cell apoptosis, suggesting a therapeutic potential for berberine for the treatment of type IV hypersensitivity.	Berberine	32-41	negative elongation factor complex member C/D, Th1l	Mus musculus	53-56
27832398-9	2017	These results demonstrated that berberine attenuated Th1-mediated inflammation in OVA-induced DTH by curbing Th1 response and inhibiting cell apoptosis, suggesting a therapeutic potential for berberine for the treatment of type IV hypersensitivity.	Berberine	32-41	negative elongation factor complex member C/D, Th1l	Mus musculus	109-112
27832398-9	2017	These results demonstrated that berberine attenuated Th1-mediated inflammation in OVA-induced DTH by curbing Th1 response and inhibiting cell apoptosis, suggesting a therapeutic potential for berberine for the treatment of type IV hypersensitivity.	Berberine	192-201	negative elongation factor complex member C/D, Th1l	Mus musculus	53-56
27832398-5	2017	Detailed studies revealed that berberine prevented differentiation into Th1 cells in the OVA-primed lymphocytes, resulting from suppressing the expression of T-bet and secretion of IFN-gamma but not IL-4.	Berberine	31-40	interferon gamma	Mus musculus	181-190
27932556-0	2017	Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.	Berberine	20-29	nuclear receptor subfamily 1, group H, member 4	Mus musculus	127-130
27932556-1	2017	Previous studies suggest that the lipid-lowering effect of berberine (BBR) involves actions on the low-density lipoprotein receptor and the AMP-activated protein kinase signaling pathways.	Berberine	59-68	low density lipoprotein receptor	Mus musculus	99-131
27932556-1	2017	Previous studies suggest that the lipid-lowering effect of berberine (BBR) involves actions on the low-density lipoprotein receptor and the AMP-activated protein kinase signaling pathways.	Berberine	70-73	low density lipoprotein receptor	Mus musculus	99-131
28000894-0	2017	Berberine affects osteosarcoma via downregulating the caspase-1/IL-1beta signaling axis.	Berberine	0-9	caspase 1	Homo sapiens	54-63
28000894-0	2017	Berberine affects osteosarcoma via downregulating the caspase-1/IL-1beta signaling axis.	Berberine	0-9	interleukin 1 beta	Homo sapiens	64-72
28000894-8	2017	Furthermore, administration of berberine is capable of reducing the expression of caspase-1 and IL-1beta in osteosarcoma cells and inhibiting the growth of tumor cells.	Berberine	31-40	caspase 1	Homo sapiens	82-91
28000894-8	2017	Furthermore, administration of berberine is capable of reducing the expression of caspase-1 and IL-1beta in osteosarcoma cells and inhibiting the growth of tumor cells.	Berberine	31-40	interleukin 1 beta	Homo sapiens	96-104
28000894-9	2017	Based on the above, for the first time, we propose the hyposis that berberine could gengerate an anti-osteosarcoma property through downregulating caspase-1/IL-1beta inflammatory signaling axis.	Berberine	68-77	caspase 1	Homo sapiens	147-156
28063518-7	2017	Finally, the individual administration of berberine, quercetin, ferulic acid, and tyrosol resulted in a statistically significant increase in AMPK activation and mTOR inhibition, whereas their associated administration did not reveal a synergistic effect.	Berberine	42-51	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	142-146
28000894-9	2017	Based on the above, for the first time, we propose the hyposis that berberine could gengerate an anti-osteosarcoma property through downregulating caspase-1/IL-1beta inflammatory signaling axis.	Berberine	68-77	interleukin 1 beta	Homo sapiens	157-165
28063518-7	2017	Finally, the individual administration of berberine, quercetin, ferulic acid, and tyrosol resulted in a statistically significant increase in AMPK activation and mTOR inhibition, whereas their associated administration did not reveal a synergistic effect.	Berberine	42-51	mechanistic target of rapamycin kinase	Homo sapiens	162-166
27565766-3	2017	The interaction mechanism between the G-quadruplex of KRAS promoter and three isoquinoline alkaloids (jatrorrhizine, berberine and sanguinarine) has been investigated by UV-visible, fluorescence and circular dichroism spectroscopic methods.	Berberine	117-126	KRAS proto-oncogene, GTPase	Homo sapiens	54-58
28277195-0	2017	Induction of Apoptosis by Berberine in Hepatocellular Carcinoma HepG2 Cells via Downregulation of NF-kappaB.	Berberine	26-35	nuclear factor kappa B subunit 1	Homo sapiens	98-107
28277195-4	2017	In the present study, we found that berberine sensitized HepG cells to NF-kappaB-mediated apoptosis.	Berberine	36-45	nuclear factor kappa B subunit 1	Homo sapiens	71-80
28277195-6	2017	Both qRT-PCR and immunofluorescence staining revealed that berberine reduced the NF-kappaB p65 levels in HepG2 cells.	Berberine	59-68	nuclear factor kappa B subunit 1	Homo sapiens	81-90
28277195-6	2017	Both qRT-PCR and immunofluorescence staining revealed that berberine reduced the NF-kappaB p65 levels in HepG2 cells.	Berberine	59-68	RELA proto-oncogene, NF-kB subunit	Homo sapiens	91-94
28277195-7	2017	Moreover, p65 overexpression rescued berberine-induced cell proliferation and prevented HepG2 cells from undergoing apoptosis.	Berberine	37-46	RELA proto-oncogene, NF-kB subunit	Homo sapiens	10-13
28277195-8	2017	These results suggest that berberine inhibits the growth of HepG2 cells by promoting apoptosis through the NF-kappaB p65 pathway.	Berberine	27-36	nuclear factor kappa B subunit 1	Homo sapiens	107-116
28277195-8	2017	These results suggest that berberine inhibits the growth of HepG2 cells by promoting apoptosis through the NF-kappaB p65 pathway.	Berberine	27-36	RELA proto-oncogene, NF-kB subunit	Homo sapiens	117-120
27462872-5	2017	Furthermore, both berberine and nandinine inhibited serine phosphorylation of insulin receptor substrate-1 induced by IkappaB kinase beta and increased tyrosine phosphorylation of insulin receptor substrate-1 to activate the PI3K/Akt pathway, which finally led to insulin-mediated glucose uptake.	Berberine	18-27	insulin receptor substrate 1	Mus musculus	78-106
27462872-5	2017	Furthermore, both berberine and nandinine inhibited serine phosphorylation of insulin receptor substrate-1 induced by IkappaB kinase beta and increased tyrosine phosphorylation of insulin receptor substrate-1 to activate the PI3K/Akt pathway, which finally led to insulin-mediated glucose uptake.	Berberine	18-27	insulin receptor substrate 1	Mus musculus	180-208
27462872-5	2017	Furthermore, both berberine and nandinine inhibited serine phosphorylation of insulin receptor substrate-1 induced by IkappaB kinase beta and increased tyrosine phosphorylation of insulin receptor substrate-1 to activate the PI3K/Akt pathway, which finally led to insulin-mediated glucose uptake.	Berberine	18-27	thymoma viral proto-oncogene 1	Mus musculus	230-233
28102849-3	2017	In the present study, berberine-mediated sonodynamic therapy (BBR-SDT) was used to induce autophagy and cholesterol efflux in THP-1 macrophages and derived foam cells.	Berberine	22-31	GLI family zinc finger 2	Homo sapiens	126-131
27565766-4	2017	The results showed that the three alkaloids can form complexes with G-quadruplex KRAS promoter with the molecular ratio of 1:1, and the binding constants were (0.90+-0.16)x106Lmol-1, (0.93+-0.21)x106Lmol-1 and (1.16+-0.45)x106Lmol-1 for jatrorrhizine, berberine and sanguinarine.	Berberine	252-261	KRAS proto-oncogene, GTPase	Homo sapiens	81-85
27887947-0	2017	Berberine enhances the AMPK activation and autophagy and mitigates high glucose-induced apoptosis of mouse podocytes.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	23-27
27887947-4	2017	The results indicated that berberine significantly mitigated high glucose-decreased cell viability, and nephrin and podocin expression as well as apoptosis in mouse podocytes.	Berberine	27-36	nephrosis 1, nephrin	Mus musculus	104-111
27887947-4	2017	The results indicated that berberine significantly mitigated high glucose-decreased cell viability, and nephrin and podocin expression as well as apoptosis in mouse podocytes.	Berberine	27-36	nephrosis 2, podocin	Mus musculus	116-123
27887947-5	2017	Berberine significantly increased the AMPK activation and mitigated high glucose and/or the AMPK inhibitor, compound C-mediated mTOR activation and apoptosis in podocytes.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	38-42
27887947-5	2017	Berberine significantly increased the AMPK activation and mitigated high glucose and/or the AMPK inhibitor, compound C-mediated mTOR activation and apoptosis in podocytes.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	92-96
27887947-5	2017	Berberine significantly increased the AMPK activation and mitigated high glucose and/or the AMPK inhibitor, compound C-mediated mTOR activation and apoptosis in podocytes.	Berberine	0-9	mechanistic target of rapamycin kinase	Mus musculus	128-132
27887947-6	2017	Berberine significantly enhanced the AMPK activation and protected from high glucose-induced apoptosis in the AMPK-silencing podocytes.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	37-41
27887947-6	2017	Berberine significantly enhanced the AMPK activation and protected from high glucose-induced apoptosis in the AMPK-silencing podocytes.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	110-114
27887947-7	2017	Furthermore, berberine significantly increased the high glucose-elevated Unc-51-like autophagy-activating kinase 1 (ULK1) S317/S555 phosphorylation, Beclin-1 expression, the ratios of LC3II to LC3I expression and the numbers of autophagosomes, but reduced ULK1 S757 phosphorylation in podocytes.	Berberine	13-22	unc-51 like kinase 1	Mus musculus	73-114
27887947-7	2017	Furthermore, berberine significantly increased the high glucose-elevated Unc-51-like autophagy-activating kinase 1 (ULK1) S317/S555 phosphorylation, Beclin-1 expression, the ratios of LC3II to LC3I expression and the numbers of autophagosomes, but reduced ULK1 S757 phosphorylation in podocytes.	Berberine	13-22	unc-51 like kinase 1	Mus musculus	116-120
27887947-7	2017	Furthermore, berberine significantly increased the high glucose-elevated Unc-51-like autophagy-activating kinase 1 (ULK1) S317/S555 phosphorylation, Beclin-1 expression, the ratios of LC3II to LC3I expression and the numbers of autophagosomes, but reduced ULK1 S757 phosphorylation in podocytes.	Berberine	13-22	beclin 1, autophagy related	Mus musculus	149-157
27887947-7	2017	Furthermore, berberine significantly increased the high glucose-elevated Unc-51-like autophagy-activating kinase 1 (ULK1) S317/S555 phosphorylation, Beclin-1 expression, the ratios of LC3II to LC3I expression and the numbers of autophagosomes, but reduced ULK1 S757 phosphorylation in podocytes.	Berberine	13-22	unc-51 like kinase 1	Mus musculus	256-260
27887947-10	2017	Collectively, berberine enhanced autophagy and protected from high glucose-induced injury in podocytes by promoting the AMPK activation.	Berberine	14-23	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	120-124
29025293-0	2017	Berberine Induces Apoptotic Cell Death via Activation of Caspase-3 and -8 in HL-60 Human Leukemia Cells: Nuclear Localization and Structure-Activity Relationships.	Berberine	0-9	caspase 3	Homo sapiens	57-73
27980220-4	2017	Our results showed that berberine significantly increased ATP-induced inflammasome activation as reflected by enhanced pyroptosis as well as increased release of caspase-1p10 and mature interleukin-1beta (IL-1beta) in macrophages.	Berberine	24-33	interleukin 1 beta	Mus musculus	186-203
27980220-4	2017	Our results showed that berberine significantly increased ATP-induced inflammasome activation as reflected by enhanced pyroptosis as well as increased release of caspase-1p10 and mature interleukin-1beta (IL-1beta) in macrophages.	Berberine	24-33	interleukin 1 beta	Mus musculus	205-213
27980220-6	2017	In line with increased IL-1beta release, the ability of macrophages to kill engulfed bacteria was also intensified by berberine.	Berberine	118-127	interleukin 1 beta	Mus musculus	23-31
27980220-8	2017	Moreover, berberine administration significantly improved survival of bacterial infected mice, concomitant with increased IL-1beta levels and elevated neutrophil recruitment in the peritoneal cavity.	Berberine	10-19	interleukin 1 beta	Mus musculus	122-130
29121795-0	2017	Berberine Ameliorates Diabetic Neuropathy: TRPV1 Modulation by PKC Pathway.	Berberine	0-9	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	43-48
29121795-5	2017	It was found that the administration of berberine (20, 60 mg/kg; 30, 90 mg/kg) suppressed the expression of PKCepsilon and TRPV1 which could be activated by hyperglycemia-induced inflammatory reaction.	Berberine	40-49	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	123-128
29121795-8	2017	Consequently, we supposed that berberine exerts its therapeutic effects in part by suppressing the inflammatory process and blocking the PKC pathway to inhibit TRPV1 activation, which damages neurons and causes diabetic pain.	Berberine	31-40	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	160-165
27889102-10	2017	Using berberine or retinoic acid (which can regulate the activities of Hnf4a and Foxd3, respectively), we demonstrated suppression of C2H9orf152 by the chemicals in chicken primary hepatocytes.	Berberine	6-15	hepatocyte nuclear factor 4 alpha	Gallus gallus	71-76
28566619-0	2017	Berberine Induces Cell Cycle Arrest in Cholangiocarcinoma Cell Lines via Inhibition of NF-kappaB and STAT3 Pathways.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	87-96
28566619-0	2017	Berberine Induces Cell Cycle Arrest in Cholangiocarcinoma Cell Lines via Inhibition of NF-kappaB and STAT3 Pathways.	Berberine	0-9	signal transducer and activator of transcription 3	Homo sapiens	101-106
28566619-7	2017	The inhibition was largely attributed to cell cycle arrest at the G1 phase through the reduction of cyclin D1, and cyclin E. Moreover, berberine could reduce the expression and activation of signal transducers and activator of transcription 3 (STAT3) and probably nuclear factor-kappaB (NF-kappaB) via suppression of extracellular signal-regulated kinase (ERK) 1/2 action.	Berberine	135-144	cyclin D1	Homo sapiens	100-109
28566619-7	2017	The inhibition was largely attributed to cell cycle arrest at the G1 phase through the reduction of cyclin D1, and cyclin E. Moreover, berberine could reduce the expression and activation of signal transducers and activator of transcription 3 (STAT3) and probably nuclear factor-kappaB (NF-kappaB) via suppression of extracellular signal-regulated kinase (ERK) 1/2 action.	Berberine	135-144	signal transducer and activator of transcription 3	Homo sapiens	191-242
28566619-7	2017	The inhibition was largely attributed to cell cycle arrest at the G1 phase through the reduction of cyclin D1, and cyclin E. Moreover, berberine could reduce the expression and activation of signal transducers and activator of transcription 3 (STAT3) and probably nuclear factor-kappaB (NF-kappaB) via suppression of extracellular signal-regulated kinase (ERK) 1/2 action.	Berberine	135-144	signal transducer and activator of transcription 3	Homo sapiens	244-249
28566619-7	2017	The inhibition was largely attributed to cell cycle arrest at the G1 phase through the reduction of cyclin D1, and cyclin E. Moreover, berberine could reduce the expression and activation of signal transducers and activator of transcription 3 (STAT3) and probably nuclear factor-kappaB (NF-kappaB) via suppression of extracellular signal-regulated kinase (ERK) 1/2 action.	Berberine	135-144	nuclear factor kappa B subunit 1	Homo sapiens	264-285
28566619-7	2017	The inhibition was largely attributed to cell cycle arrest at the G1 phase through the reduction of cyclin D1, and cyclin E. Moreover, berberine could reduce the expression and activation of signal transducers and activator of transcription 3 (STAT3) and probably nuclear factor-kappaB (NF-kappaB) via suppression of extracellular signal-regulated kinase (ERK) 1/2 action.	Berberine	135-144	nuclear factor kappa B subunit 1	Homo sapiens	287-296
28566619-7	2017	The inhibition was largely attributed to cell cycle arrest at the G1 phase through the reduction of cyclin D1, and cyclin E. Moreover, berberine could reduce the expression and activation of signal transducers and activator of transcription 3 (STAT3) and probably nuclear factor-kappaB (NF-kappaB) via suppression of extracellular signal-regulated kinase (ERK) 1/2 action.	Berberine	135-144	mitogen-activated protein kinase 3	Homo sapiens	317-364
27889102-10	2017	Using berberine or retinoic acid (which can regulate the activities of Hnf4a and Foxd3, respectively), we demonstrated suppression of C2H9orf152 by the chemicals in chicken primary hepatocytes.	Berberine	6-15	forkhead box D3	Gallus gallus	81-86
27889102-10	2017	Using berberine or retinoic acid (which can regulate the activities of Hnf4a and Foxd3, respectively), we demonstrated suppression of C2H9orf152 by the chemicals in chicken primary hepatocytes.	Berberine	6-15	chromosome 2 open reading frame, human C9orf152	Gallus gallus	134-144
27922688-12	2017	Furthermore, the expression of p-STAT3 was significantly decreased in the presence of BBR in healthy controls.	Berberine	86-89	signal transducer and activator of transcription 3	Homo sapiens	33-38
28751929-0	2017	The Preconditioning of Berberine Suppresses Hydrogen Peroxide-Induced Premature Senescence via Regulation of Sirtuin 1.	Berberine	23-32	sirtuin 1	Homo sapiens	109-118
28751929-6	2017	H2O2-induced activation of checkpoint kinase 2 (Chk2) was significantly attenuated after the preconditioning of BBR.	Berberine	112-115	checkpoint kinase 2	Homo sapiens	27-46
28751929-6	2017	H2O2-induced activation of checkpoint kinase 2 (Chk2) was significantly attenuated after the preconditioning of BBR.	Berberine	112-115	checkpoint kinase 2	Homo sapiens	48-52
26871196-8	2017	Berberine also prevented the elevated levels of enzymes (alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase) and the decrease in body weight and albumin.	Berberine	0-9	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	83-109
29163755-6	2017	Moreover, drugs (fenofibrate and sitagliptin) and several vegetable compounds (extracts from Brassicaceae, berberine, curcumin, and capsaicin) are able to induce UCP2 expression level and to exert beneficial effects on the occurrence of vascular damage.	Berberine	107-116	uncoupling protein 2	Homo sapiens	162-166
27702567-8	2016	KEY FINDINGS: Berberine significantly decreased F4/80+/CD11c+/CD206- cells in the stromal vascular fraction from adipose tissue and improved glucose tolerance in obsess mice.	Berberine	14-23	adhesion G protein-coupled receptor E1	Mus musculus	48-54
27705930-6	2016	Administration of berberine inhibited the viability, migration and invasion capacity of HepG2 cells through the induction of pyroptosis both in vitro and in vivo, which was attenuated by caspase-1 inhibitor Ac-YVAD-CMK.	Berberine	18-27	caspase 1	Homo sapiens	187-196
27705930-6	2016	Administration of berberine inhibited the viability, migration and invasion capacity of HepG2 cells through the induction of pyroptosis both in vitro and in vivo, which was attenuated by caspase-1 inhibitor Ac-YVAD-CMK.	Berberine	18-27	C-X-C motif chemokine ligand 9	Homo sapiens	215-218
27938388-0	2016	Berberine increases adipose triglyceride lipase in 3T3-L1 adipocytes through the AMPK pathway.	Berberine	0-9	patatin-like phospholipase domain containing 2	Mus musculus	20-47
27938388-9	2016	Compound C, an inhibitor of AMP-activated protein kinase (AMPK), was used to explore the possible pathway that involved in the effect of BBR on ATGL.	Berberine	137-140	patatin-like phospholipase domain containing 2	Mus musculus	144-148
27938388-12	2016	The effect of BBR on ATGL expression could be abolished by Compound C which suggested that AMPK pathway was involved in the effects of BBR on p-HSL and ATGL.	Berberine	14-17	patatin-like phospholipase domain containing 2	Mus musculus	21-25
27938388-12	2016	The effect of BBR on ATGL expression could be abolished by Compound C which suggested that AMPK pathway was involved in the effects of BBR on p-HSL and ATGL.	Berberine	14-17	lipase, hormone sensitive	Mus musculus	144-147
27938388-12	2016	The effect of BBR on ATGL expression could be abolished by Compound C which suggested that AMPK pathway was involved in the effects of BBR on p-HSL and ATGL.	Berberine	14-17	patatin-like phospholipase domain containing 2	Mus musculus	152-156
27938388-12	2016	The effect of BBR on ATGL expression could be abolished by Compound C which suggested that AMPK pathway was involved in the effects of BBR on p-HSL and ATGL.	Berberine	135-138	patatin-like phospholipase domain containing 2	Mus musculus	21-25
27938388-12	2016	The effect of BBR on ATGL expression could be abolished by Compound C which suggested that AMPK pathway was involved in the effects of BBR on p-HSL and ATGL.	Berberine	135-138	lipase, hormone sensitive	Mus musculus	144-147
27938388-12	2016	The effect of BBR on ATGL expression could be abolished by Compound C which suggested that AMPK pathway was involved in the effects of BBR on p-HSL and ATGL.	Berberine	135-138	patatin-like phospholipase domain containing 2	Mus musculus	152-156
27876206-6	2016	Treatment with galangin and berberine alone caused the decreased expressions of Wnt3a and beta-catenin.	Berberine	28-37	Wnt family member 3A	Homo sapiens	80-85
27876206-6	2016	Treatment with galangin and berberine alone caused the decreased expressions of Wnt3a and beta-catenin.	Berberine	28-37	catenin beta 1	Homo sapiens	90-102
27876206-7	2016	Interestingly, combination of galangin with berberine could further suppress Wnt3a and beta-catenin expression and induce apoptosis in cancer cells.	Berberine	44-53	Wnt family member 3A	Homo sapiens	77-82
27876206-7	2016	Interestingly, combination of galangin with berberine could further suppress Wnt3a and beta-catenin expression and induce apoptosis in cancer cells.	Berberine	44-53	catenin beta 1	Homo sapiens	87-99
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	tumor necrosis factor	Mus musculus	60-69
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	interleukin 6	Mus musculus	71-75
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	mast cell protease 1	Mus musculus	80-85
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	tumor necrosis factor	Mus musculus	109-118
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	interleukin 6	Mus musculus	120-124
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	mast cell protease 1	Mus musculus	129-134
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	mitogen-activated protein kinase 8	Mus musculus	173-176
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	inhibitor of kappaB kinase beta	Mus musculus	181-188
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	211-220
27702567-8	2016	KEY FINDINGS: Berberine significantly decreased F4/80+/CD11c+/CD206- cells in the stromal vascular fraction from adipose tissue and improved glucose tolerance in obsess mice.	Berberine	14-23	integrin subunit alpha X	Homo sapiens	55-60
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	221-224
27702567-10	2016	The phosphorylation of IRS-1 (Ser307) was inhibited by berberine in adipose tissue and cultured adipocytes.	Berberine	55-64	insulin receptor substrate 1	Mus musculus	23-28
27896586-0	2016	Effect of berberine on the ratio of high-molecular weight adiponectin to total adiponectin and adiponectin receptors expressions in high-fat diet fed rats.	Berberine	10-19	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	58-69
27702567-11	2016	The phosphorylation of AKT (Ser473) was increased in berberine-treated adipose tissue.	Berberine	53-62	thymoma viral proto-oncogene 1	Mus musculus	23-26
27702567-13	2016	Berberine partly restored the impaired glucose consumption and the activation of IRS-1 (Ser307) in adipocytes induced by the activation of macrophages.	Berberine	0-9	insulin receptor substrate 1	Mus musculus	81-86
27896586-0	2016	Effect of berberine on the ratio of high-molecular weight adiponectin to total adiponectin and adiponectin receptors expressions in high-fat diet fed rats.	Berberine	10-19	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	79-90
27896586-0	2016	Effect of berberine on the ratio of high-molecular weight adiponectin to total adiponectin and adiponectin receptors expressions in high-fat diet fed rats.	Berberine	10-19	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	79-90
27896586-18	2016	CONCLUSION: Berberine may improve insulin resistance by increasing the expression of adiponectin receptors and the ratio of HMW to total adiponectin.	Berberine	12-21	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	85-96
27896586-18	2016	CONCLUSION: Berberine may improve insulin resistance by increasing the expression of adiponectin receptors and the ratio of HMW to total adiponectin.	Berberine	12-21	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	137-148
27904693-0	2016	Berberine upregulates miR-22-3p to suppress hepatocellular carcinoma cell proliferation by targeting Sp1.	Berberine	0-9	microRNA 223	Homo sapiens	22-31
27904693-2	2016	In this study, berberine treatment upregulated miR-22-3p expression in HepG2 cells.	Berberine	15-24	microRNA 223	Homo sapiens	47-56
27904693-5	2016	Berberine also downregulated the expression of SP1, CCND1, and BCL2, determined with western blotting.	Berberine	0-9	cyclin D1	Homo sapiens	52-57
27904693-5	2016	Berberine also downregulated the expression of SP1, CCND1, and BCL2, determined with western blotting.	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	63-67
27904693-8	2016	Therefore, we conclude that berberine treatment suppresses cancer cell growth by regulating miR-22-3p and SP1 and its downstream targets, CCND1 and BCL2, in HCC.	Berberine	28-37	microRNA 223	Homo sapiens	92-101
27904693-8	2016	Therefore, we conclude that berberine treatment suppresses cancer cell growth by regulating miR-22-3p and SP1 and its downstream targets, CCND1 and BCL2, in HCC.	Berberine	28-37	cyclin D1	Homo sapiens	138-143
27904693-8	2016	Therefore, we conclude that berberine treatment suppresses cancer cell growth by regulating miR-22-3p and SP1 and its downstream targets, CCND1 and BCL2, in HCC.	Berberine	28-37	BCL2 apoptosis regulator	Homo sapiens	148-152
27738318-0	2016	Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer.	Berberine	0-9	epidermal growth factor receptor	Homo sapiens	19-23
27854312-0	2016	Berberine Suppresses Cyclin D1 Expression through Proteasomal Degradation in Human Hepatoma Cells.	Berberine	0-9	cyclin D1	Homo sapiens	21-30
27854312-1	2016	The aim of this study is to explore the underlying mechanism on berberine-induced Cyclin D1 degradation in human hepatic carcinoma.	Berberine	64-73	cyclin D1	Homo sapiens	82-91
27738318-0	2016	Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer.	Berberine	0-9	epidermal growth factor receptor	Homo sapiens	72-76
27738318-3	2016	Studies have demonstrated that berberine can suppress the activation of EGFR in tumors.	Berberine	31-40	epidermal growth factor receptor	Homo sapiens	72-76
27738318-4	2016	In this study, we evaluated whether berberine could enhance the effects of EGFR-TKIs in GC cell lines and xenograft models.	Berberine	36-45	epidermal growth factor receptor	Homo sapiens	75-79
27738318-8	2016	The expressions of Bcl-xL and Cyclind1 proteins were decreased, whereas the levels of cleavage of poly-ADP ribose polymerase (PARP) were considerably increased in the cell lines in response to berberine treatment.	Berberine	193-202	BCL2 like 1	Homo sapiens	19-25
27738318-8	2016	The expressions of Bcl-xL and Cyclind1 proteins were decreased, whereas the levels of cleavage of poly-ADP ribose polymerase (PARP) were considerably increased in the cell lines in response to berberine treatment.	Berberine	193-202	cyclin D1	Homo sapiens	30-38
27738318-8	2016	The expressions of Bcl-xL and Cyclind1 proteins were decreased, whereas the levels of cleavage of poly-ADP ribose polymerase (PARP) were considerably increased in the cell lines in response to berberine treatment.	Berberine	193-202	poly(ADP-ribose) polymerase 1	Homo sapiens	98-124
27846294-13	2016	There was a tendency for berberine to reduce AST, ALT, BUN except increase CREA levels.	Berberine	25-34	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	45-48
27738318-8	2016	The expressions of Bcl-xL and Cyclind1 proteins were decreased, whereas the levels of cleavage of poly-ADP ribose polymerase (PARP) were considerably increased in the cell lines in response to berberine treatment.	Berberine	193-202	poly(ADP-ribose) polymerase 1	Homo sapiens	126-130
27738318-10	2016	Berberine may be a competent therapeutic agent in GC where it can enhance the effects of EGFR inhibitors.	Berberine	0-9	epidermal growth factor receptor	Homo sapiens	89-93
27181586-0	2016	Berberine activates peroxisome proliferator-activated receptor gamma to increase atherosclerotic plaque stability in Apoe-/- mice with hyperhomocysteinemia.	Berberine	0-9	apolipoprotein E	Mus musculus	117-121
27995884-12	2016	(3) Berberine in combination with bortezomib significantly upregulated expressions of caspase-3, -8 and -9, which were statistically significant (P&lt;0.05).	Berberine	4-13	caspase 3	Homo sapiens	86-106
27995884-13	2016	(4)Berberine in combination with bortezomib significantly upregulated expressions of TRADD (0.91+-0.01, 0.70+-0.01) and FADD (0.98+-0.01, 0.98+-0.01) compared with control group (both P&lt;0.05).	Berberine	3-12	TNFRSF1A associated via death domain	Homo sapiens	85-90
27995884-13	2016	(4)Berberine in combination with bortezomib significantly upregulated expressions of TRADD (0.91+-0.01, 0.70+-0.01) and FADD (0.98+-0.01, 0.98+-0.01) compared with control group (both P&lt;0.05).	Berberine	3-12	Fas associated via death domain	Homo sapiens	120-124
27995884-14	2016	Conclusion: Berberine in combination with bortezomib had synergistic effects on proliferation inhibition and apoptosis, which were mediated by up-regulated levels of TRADD and FADD.	Berberine	12-21	TNFRSF1A associated via death domain	Homo sapiens	166-171
27995884-14	2016	Conclusion: Berberine in combination with bortezomib had synergistic effects on proliferation inhibition and apoptosis, which were mediated by up-regulated levels of TRADD and FADD.	Berberine	12-21	Fas associated via death domain	Homo sapiens	176-180
27854312-2	2016	We observed that berberine could suppress both in vitro and in vivo expression of Cyclin D1 in hepatoma cells.	Berberine	17-26	cyclin D1	Homo sapiens	82-91
27854312-3	2016	Berberine exhibits dose- and time-dependent inhibition on Cyclin D1 expression in human hepatoma cell HepG2.	Berberine	0-9	cyclin D1	Homo sapiens	58-67
27854312-4	2016	Berberine increases the phosphorylation of Cyclin D1 at Thr286 site and potentiates Cyclin D1 nuclear export to cytoplasm for proteasomal degradation.	Berberine	0-9	cyclin D1	Homo sapiens	43-52
27854312-4	2016	Berberine increases the phosphorylation of Cyclin D1 at Thr286 site and potentiates Cyclin D1 nuclear export to cytoplasm for proteasomal degradation.	Berberine	0-9	cyclin D1	Homo sapiens	84-93
27854312-5	2016	In addition, berberine recruits the Skp, Cullin, F-box containing complex-beta-Transducin Repeat Containing Protein (SCFbeta-TrCP) complex to facilitate Cyclin D1 ubiquitin-proteasome dependent proteolysis.	Berberine	13-22	CDK2 associated cullin domain 1	Homo sapiens	41-47
27854312-5	2016	In addition, berberine recruits the Skp, Cullin, F-box containing complex-beta-Transducin Repeat Containing Protein (SCFbeta-TrCP) complex to facilitate Cyclin D1 ubiquitin-proteasome dependent proteolysis.	Berberine	13-22	cyclin D1	Homo sapiens	153-162
27854312-6	2016	Knockdown of beta-TrCP blocks Cyclin D1 turnover induced by berberine; blocking the protein degradation induced by berberine in HepG2 cells increases tumor cell resistance to berberine.	Berberine	60-69	beta-transducin repeat containing E3 ubiquitin protein ligase	Homo sapiens	13-22
27854312-6	2016	Knockdown of beta-TrCP blocks Cyclin D1 turnover induced by berberine; blocking the protein degradation induced by berberine in HepG2 cells increases tumor cell resistance to berberine.	Berberine	60-69	cyclin D1	Homo sapiens	30-39
27506986-5	2016	Berberine treatment resulted in significant decreases in the serum D-lactate level, intestinal permeability, intestinal myeloperoxidase activity, and intestinal mucosal and submucosal edema and inflammation, and the Chiu"s scores assessed for intestinal mucosal injury.	Berberine	0-9	myeloperoxidase	Rattus norvegicus	120-135
27843297-0	2016	Erratum: Mechanism and pharmacological rescue of berberine-induced hERG channel deficiency [Corrigendum].	Berberine	49-58	ETS transcription factor ERG	Homo sapiens	67-71
27181586-6	2016	RESULTS: Homocysteine thiolactone (50 mg/kg/day, 8 weeks) reduced the atherosclerotic plaque stability in the carotid artery of Apoe-/- mice, which was reversed by BBR administration (1.0 g/kg/day).	Berberine	164-167	apolipoprotein E	Mus musculus	128-132
27181586-11	2016	CONCLUSIONS: Berberine increases atherosclerotic plaque stability in hyperhomocysteinemia mice, which is related to the activation of peroxisome proliferator-activated receptor-gamma and subsequent suppression of oxidative stress in endothelial cells.	Berberine	13-22	peroxisome proliferator activated receptor gamma	Mus musculus	134-182
27769241-0	2016	Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS.	Berberine	22-31	TAR DNA binding protein	Homo sapiens	35-41
27658958-0	2016	ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis.	Berberine	42-51	mitogen-activated protein kinase 1	Mus musculus	0-3
27658958-0	2016	ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis.	Berberine	42-51	mechanistic target of rapamycin kinase	Mus musculus	14-18
28929697-12	2016	This study showed that berberine in addition to the general therapy can significantly lower the levels of serum MIF and IL-6, reduce the degree of carotid atherosclerosis to some extent and improve neurological impairment and the prognosis of patients with AIS.	Berberine	23-32	macrophage migration inhibitory factor	Homo sapiens	112-115
28929697-12	2016	This study showed that berberine in addition to the general therapy can significantly lower the levels of serum MIF and IL-6, reduce the degree of carotid atherosclerosis to some extent and improve neurological impairment and the prognosis of patients with AIS.	Berberine	23-32	interleukin 6	Homo sapiens	120-124
27769241-7	2016	RESULTS: Here we studied the molecular mechanism of berberine in cell culture model with TDP-43 proteinopathies, and found that berberine is able to reverse the processing of insoluble TDP-43 aggregates formation through deregulation of mTOR/p70S6K signal and activation of autophagic degradation pathway.	Berberine	52-61	TAR DNA binding protein	Homo sapiens	89-95
27769241-7	2016	RESULTS: Here we studied the molecular mechanism of berberine in cell culture model with TDP-43 proteinopathies, and found that berberine is able to reverse the processing of insoluble TDP-43 aggregates formation through deregulation of mTOR/p70S6K signal and activation of autophagic degradation pathway.	Berberine	128-137	TAR DNA binding protein	Homo sapiens	89-95
27769241-7	2016	RESULTS: Here we studied the molecular mechanism of berberine in cell culture model with TDP-43 proteinopathies, and found that berberine is able to reverse the processing of insoluble TDP-43 aggregates formation through deregulation of mTOR/p70S6K signal and activation of autophagic degradation pathway.	Berberine	128-137	ribosomal protein S6 kinase B1	Homo sapiens	242-248
27769284-0	2016	The effect of berberine on insulin resistance in women with polycystic ovary syndrome: detailed statistical analysis plan (SAP) for a multicenter randomized controlled trial.	Berberine	14-23	insulin	Homo sapiens	27-34
27769241-8	2016	And inhibition of autophagy by specific autophagosome inhibitor, 3-MA, reverses the effect of berberine on reducing the accumulation of insoluble TDP-43 and aggregates formation.	Berberine	94-103	TAR DNA binding protein	Homo sapiens	146-152
27769241-9	2016	These results gave us the notion that inhibition of autophagy by 3-MA reverses the effect of berberine on TDP-43 pathogenesis, and activation of mTOR-regulated autophagy plays an important role in berberine-mediated therapeutic effect on TDP-43 proteinopathies.	Berberine	93-102	TAR DNA binding protein	Homo sapiens	106-112
27769241-10	2016	CONCLUSION: We supported an important notion that the traditional herb berberine is a potential alternative therapy for TDP-43-related neuropathology.	Berberine	71-80	TAR DNA binding protein	Homo sapiens	120-126
27769241-11	2016	Here we demonstrated that berberine is able to reverse the processing of insoluble TDP-43 aggregates formation through deregulation of mTOR/p70S6K signal and activation of autophagic degradation pathway.	Berberine	26-35	TAR DNA binding protein	Homo sapiens	83-89
27769241-11	2016	Here we demonstrated that berberine is able to reverse the processing of insoluble TDP-43 aggregates formation through deregulation of mTOR/p70S6K signal and activation of autophagic degradation pathway.	Berberine	26-35	ribosomal protein S6 kinase B1	Homo sapiens	140-146
27769241-12	2016	mTOR-autophagy signals plays an important role in berberine-mediated autophagic clearance of TDP-43 aggregates.	Berberine	50-59	TAR DNA binding protein	Homo sapiens	93-99
27445236-0	2016	Berberine promotes proliferation of sodium nitroprusside-stimulated rat chondrocytes and osteoarthritic rat cartilage via Wnt/beta-catenin pathway.	Berberine	0-9	catenin beta 1	Rattus norvegicus	126-138
27754444-6	2016	Additionally, reduction of proprotein convertase subtilisin/kexin 9 (PCSK9) expression and DNA methylation are also involved in pharmacological mechanisms of berberine in the treatment of NAFLD.	Berberine	158-167	proprotein convertase subtilisin/kexin type 9	Homo sapiens	27-67
27754444-6	2016	Additionally, reduction of proprotein convertase subtilisin/kexin 9 (PCSK9) expression and DNA methylation are also involved in pharmacological mechanisms of berberine in the treatment of NAFLD.	Berberine	158-167	proprotein convertase subtilisin/kexin type 9	Homo sapiens	69-74
27557493-0	2016	Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	66-70
27557493-0	2016	Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway.	Berberine	0-9	unc-51 like autophagy activating kinase 1	Homo sapiens	71-75
27695006-1	2016	Conformational change in helix 12 can alter ligand-induced PPARgamma activity; based on this reason, isoquinolinoquinazolinones, structural homologs of berberine, were designed and synthesized as PPARgamma antagonists.	Berberine	152-161	peroxisome proliferator activated receptor gamma	Homo sapiens	59-68
27639645-0	2016	Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARalpha/RARbeta in melanoma cells.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	93-96
27639645-0	2016	Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARalpha/RARbeta in melanoma cells.	Berberine	0-9	retinoic acid receptor, alpha	Mus musculus	101-109
27639645-0	2016	Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARalpha/RARbeta in melanoma cells.	Berberine	0-9	retinoic acid receptor, beta	Mus musculus	110-117
27639645-4	2016	We found that berberine also downregulation the expression level of p-PI3K, p-AKT and retinoic acid receptor alpha (RARalpha) and upregulation the expression level of retinoic acid receptor beta and gamma (RARbeta and RARgamma).	Berberine	14-23	thymoma viral proto-oncogene 1	Mus musculus	78-81
27639645-4	2016	We found that berberine also downregulation the expression level of p-PI3K, p-AKT and retinoic acid receptor alpha (RARalpha) and upregulation the expression level of retinoic acid receptor beta and gamma (RARbeta and RARgamma).	Berberine	14-23	retinoic acid receptor, alpha	Mus musculus	86-114
27639645-4	2016	We found that berberine also downregulation the expression level of p-PI3K, p-AKT and retinoic acid receptor alpha (RARalpha) and upregulation the expression level of retinoic acid receptor beta and gamma (RARbeta and RARgamma).	Berberine	14-23	retinoic acid receptor, alpha	Mus musculus	116-124
27639645-4	2016	We found that berberine also downregulation the expression level of p-PI3K, p-AKT and retinoic acid receptor alpha (RARalpha) and upregulation the expression level of retinoic acid receptor beta and gamma (RARbeta and RARgamma).	Berberine	14-23	retinoic acid receptor, beta	Mus musculus	167-194
27639645-4	2016	We found that berberine also downregulation the expression level of p-PI3K, p-AKT and retinoic acid receptor alpha (RARalpha) and upregulation the expression level of retinoic acid receptor beta and gamma (RARbeta and RARgamma).	Berberine	14-23	retinoic acid receptor, beta	Mus musculus	206-213
27639645-4	2016	We found that berberine also downregulation the expression level of p-PI3K, p-AKT and retinoic acid receptor alpha (RARalpha) and upregulation the expression level of retinoic acid receptor beta and gamma (RARbeta and RARgamma).	Berberine	14-23	retinoic acid receptor, gamma	Mus musculus	218-226
27639645-7	2016	In conclusion, Our study reveal that berberine can reverse the epithelial to mesenchymal transition of mouse melanoma B16 cells and may be a useful adjuvant therapeutic agent in the treatment of melanoma through the PI3K/Akt pathway and inactivation PI3K/AKT could regulate RARalpha/RARbeta expression.	Berberine	37-46	thymoma viral proto-oncogene 1	Mus musculus	221-224
27639645-7	2016	In conclusion, Our study reveal that berberine can reverse the epithelial to mesenchymal transition of mouse melanoma B16 cells and may be a useful adjuvant therapeutic agent in the treatment of melanoma through the PI3K/Akt pathway and inactivation PI3K/AKT could regulate RARalpha/RARbeta expression.	Berberine	37-46	thymoma viral proto-oncogene 1	Mus musculus	255-258
27639645-7	2016	In conclusion, Our study reveal that berberine can reverse the epithelial to mesenchymal transition of mouse melanoma B16 cells and may be a useful adjuvant therapeutic agent in the treatment of melanoma through the PI3K/Akt pathway and inactivation PI3K/AKT could regulate RARalpha/RARbeta expression.	Berberine	37-46	retinoic acid receptor, alpha	Mus musculus	274-282
27639645-7	2016	In conclusion, Our study reveal that berberine can reverse the epithelial to mesenchymal transition of mouse melanoma B16 cells and may be a useful adjuvant therapeutic agent in the treatment of melanoma through the PI3K/Akt pathway and inactivation PI3K/AKT could regulate RARalpha/RARbeta expression.	Berberine	37-46	retinoic acid receptor, beta	Mus musculus	283-290
27695006-1	2016	Conformational change in helix 12 can alter ligand-induced PPARgamma activity; based on this reason, isoquinolinoquinazolinones, structural homologs of berberine, were designed and synthesized as PPARgamma antagonists.	Berberine	152-161	peroxisome proliferator activated receptor gamma	Homo sapiens	196-205
27439970-0	2016	NLRP3 inflammasome as a target of berberine in experimental murine liver injury: interference with P2X7 signalling.	Berberine	34-43	NLR family, pyrin domain containing 3	Mus musculus	0-5
27439970-0	2016	NLRP3 inflammasome as a target of berberine in experimental murine liver injury: interference with P2X7 signalling.	Berberine	34-43	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	99-103
26531813-0	2016	Renoprotective effects of berberine and its potential effect on the expression of beta-arrestins and intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in streptozocin-diabetic nephropathy rats.	Berberine	26-35	vascular cell adhesion molecule 1	Rattus norvegicus	139-172
27667461-7	2016	Conclusion Berberine improves cardiac fibrosis in diabetic rats through down-regulating the expressions of TGF-beta1 and CTGF and reducing the synthesis and deposition of Col1 and Col3.	Berberine	11-20	transforming growth factor, beta 1	Rattus norvegicus	107-116
27667461-7	2016	Conclusion Berberine improves cardiac fibrosis in diabetic rats through down-regulating the expressions of TGF-beta1 and CTGF and reducing the synthesis and deposition of Col1 and Col3.	Berberine	11-20	cellular communication network factor 2	Rattus norvegicus	121-125
27416292-0	2016	Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS.	Berberine	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
27416292-9	2016	However, berberine can upset the ROS balance by downregulating c-Myc to reverse the lapatinib resistance.	Berberine	9-18	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	63-68
27142767-0	2016	Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203.	Berberine	0-9	microRNA 203a	Homo sapiens	91-98
27376853-11	2016	Notably, berberine treatment rescued surgery-induced cognitive impairment and inhibited the release of IBA1, IL-1beta, and IL-6 in the hippocampus.	Berberine	9-18	induction of brown adipocytes 1	Mus musculus	103-107
27376853-11	2016	Notably, berberine treatment rescued surgery-induced cognitive impairment and inhibited the release of IBA1, IL-1beta, and IL-6 in the hippocampus.	Berberine	9-18	interleukin 1 beta	Mus musculus	109-117
27376853-11	2016	Notably, berberine treatment rescued surgery-induced cognitive impairment and inhibited the release of IBA1, IL-1beta, and IL-6 in the hippocampus.	Berberine	9-18	interleukin 6	Mus musculus	123-127
27376853-12	2016	In line with the in vivo study, berberine treatment suppressed LPS-stimulated production of TNF-alpha and IL-1beta in BV2 cells.	Berberine	32-41	tumor necrosis factor	Mus musculus	92-101
27376853-12	2016	In line with the in vivo study, berberine treatment suppressed LPS-stimulated production of TNF-alpha and IL-1beta in BV2 cells.	Berberine	32-41	interleukin 1 beta	Mus musculus	106-114
26846272-14	2016	In addition, BBR may mediate this cardioprotective effect through AMPK activation, AKT phosphorylation, and GSK3beta inhibition in the nonischemic areas of the diabetic heart.	Berberine	13-16	AKT serine/threonine kinase 1	Rattus norvegicus	83-86
26846272-14	2016	In addition, BBR may mediate this cardioprotective effect through AMPK activation, AKT phosphorylation, and GSK3beta inhibition in the nonischemic areas of the diabetic heart.	Berberine	13-16	glycogen synthase kinase 3 beta	Rattus norvegicus	108-116
26531813-2	2016	The aim of the present study was to explore the effects of berberine on the expression of beta-arrestins, intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in DN rat kidneys and investigate the underlying molecular mechanisms.	Berberine	59-68	intercellular adhesion molecule 1	Rattus norvegicus	106-144
26531813-2	2016	The aim of the present study was to explore the effects of berberine on the expression of beta-arrestins, intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in DN rat kidneys and investigate the underlying molecular mechanisms.	Berberine	59-68	intercellular adhesion molecule 1	Rattus norvegicus	146-152
26531813-2	2016	The aim of the present study was to explore the effects of berberine on the expression of beta-arrestins, intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in DN rat kidneys and investigate the underlying molecular mechanisms.	Berberine	59-68	vascular cell adhesion molecule 1	Rattus norvegicus	158-191
26531813-2	2016	The aim of the present study was to explore the effects of berberine on the expression of beta-arrestins, intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in DN rat kidneys and investigate the underlying molecular mechanisms.	Berberine	59-68	vascular cell adhesion molecule 1	Rattus norvegicus	193-199
26531813-8	2016	Western blot analysis revealed significant increases in ICAM-1 and VCAM-1 levels in the kidneys of DN rats, which were reversed by treatment with 100 and 200 mg/kg berberine.	Berberine	164-173	intercellular adhesion molecule 1	Rattus norvegicus	56-62
26531813-8	2016	Western blot analysis revealed significant increases in ICAM-1 and VCAM-1 levels in the kidneys of DN rats, which were reversed by treatment with 100 and 200 mg/kg berberine.	Berberine	164-173	vascular cell adhesion molecule 1	Rattus norvegicus	67-73
26531813-9	2016	In addition, berberine treatment (50, 100, 200 mg/kg) increased diabetic-induced decreases in beta-arrestin 1 and beta-arrestin 2.	Berberine	13-22	arrestin, beta 1	Rattus norvegicus	94-109
26531813-9	2016	In addition, berberine treatment (50, 100, 200 mg/kg) increased diabetic-induced decreases in beta-arrestin 1 and beta-arrestin 2.	Berberine	13-22	arrestin, beta 2, pseudogene	Rattus norvegicus	114-129
27292312-3	2016	In this study, we explored the role of TGR5 in the BBR-induced downregulation of sphingosine 1-phosphate receptor 2 (S1P2)/mitogen-activated protein kinase (MAPK)-mediated fibrosis in glomerular mesangial cells (GMCs).	Berberine	51-54	sphingosine-1-phosphate receptor 2	Homo sapiens	117-121
27292312-0	2016	Berberine attenuates high glucose-induced fibrosis by activating the G protein-coupled bile acid receptor TGR5 and repressing the S1P2/MAPK signaling pathway in glomerular mesangial cells.	Berberine	0-9	G protein-coupled bile acid receptor 1	Homo sapiens	106-110
27529235-6	2016	We found that BBR treatment attenuated renal fibrosis by activating the nuclear factor-erythroid 2-related factor 2 (Nrf2) signaling pathway in the diabetic kidneys.	Berberine	14-17	nuclear factor, erythroid derived 2, like 2	Mus musculus	72-115
27292312-0	2016	Berberine attenuates high glucose-induced fibrosis by activating the G protein-coupled bile acid receptor TGR5 and repressing the S1P2/MAPK signaling pathway in glomerular mesangial cells.	Berberine	0-9	sphingosine-1-phosphate receptor 2	Homo sapiens	130-134
27292312-3	2016	In this study, we explored the role of TGR5 in the BBR-induced downregulation of sphingosine 1-phosphate receptor 2 (S1P2)/mitogen-activated protein kinase (MAPK)-mediated fibrosis in glomerular mesangial cells (GMCs).	Berberine	51-54	G protein-coupled bile acid receptor 1	Homo sapiens	39-43
27292312-3	2016	In this study, we explored the role of TGR5 in the BBR-induced downregulation of sphingosine 1-phosphate receptor 2 (S1P2)/mitogen-activated protein kinase (MAPK)-mediated fibrosis in glomerular mesangial cells (GMCs).	Berberine	51-54	sphingosine-1-phosphate receptor 2	Homo sapiens	81-115
27529235-6	2016	We found that BBR treatment attenuated renal fibrosis by activating the nuclear factor-erythroid 2-related factor 2 (Nrf2) signaling pathway in the diabetic kidneys.	Berberine	14-17	nuclear factor, erythroid derived 2, like 2	Mus musculus	117-121
27529235-7	2016	Further revealed that BBR abrogated HG-induced EMT and oxidative stress in relation not only with the activation of Nrf2 and two Nrf2-targeted antioxidative genes (NQO-1 and HO-1), but also with the suppressing the activation of TGF-beta/Smad signaling pathway.	Berberine	22-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	116-120
27529235-7	2016	Further revealed that BBR abrogated HG-induced EMT and oxidative stress in relation not only with the activation of Nrf2 and two Nrf2-targeted antioxidative genes (NQO-1 and HO-1), but also with the suppressing the activation of TGF-beta/Smad signaling pathway.	Berberine	22-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	129-133
27529235-7	2016	Further revealed that BBR abrogated HG-induced EMT and oxidative stress in relation not only with the activation of Nrf2 and two Nrf2-targeted antioxidative genes (NQO-1 and HO-1), but also with the suppressing the activation of TGF-beta/Smad signaling pathway.	Berberine	22-25	NAD(P)H dehydrogenase, quinone 1	Mus musculus	164-169
27529235-7	2016	Further revealed that BBR abrogated HG-induced EMT and oxidative stress in relation not only with the activation of Nrf2 and two Nrf2-targeted antioxidative genes (NQO-1 and HO-1), but also with the suppressing the activation of TGF-beta/Smad signaling pathway.	Berberine	22-25	heme oxygenase 1	Mus musculus	174-178
27462166-0	2016	Effect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer.	Berberine	25-34	microRNA 429	Homo sapiens	38-45
27098986-0	2016	Renoprotective effect of berberine via regulating the PGE2 -EP1-Galphaq-Ca(2+) signalling pathway in glomerular mesangial cells of diabetic rats.	Berberine	25-34	prostaglandin E receptor 1	Rattus norvegicus	60-63
27098986-0	2016	Renoprotective effect of berberine via regulating the PGE2 -EP1-Galphaq-Ca(2+) signalling pathway in glomerular mesangial cells of diabetic rats.	Berberine	25-34	G protein subunit alpha q	Rattus norvegicus	64-71
27098986-12	2016	Berberine decreased the abnormal concentration of Ca(2+) , the increased levels of PGE2 , the high expression of EP1 and Galphaq and suppressed the proliferation of mesangial cells.	Berberine	0-9	prostaglandin E receptor 1	Rattus norvegicus	113-116
27098986-12	2016	Berberine decreased the abnormal concentration of Ca(2+) , the increased levels of PGE2 , the high expression of EP1 and Galphaq and suppressed the proliferation of mesangial cells.	Berberine	0-9	G protein subunit alpha q	Rattus norvegicus	121-128
27098986-14	2016	The observed renoprotective effects of berberine via regulating the PGE2 -EP1-Galphaq-Ca(2+) signalling pathway indicating that berberine could be a promising anti-DN medicine in the future.	Berberine	39-48	prostaglandin E receptor 1	Rattus norvegicus	74-77
27098986-14	2016	The observed renoprotective effects of berberine via regulating the PGE2 -EP1-Galphaq-Ca(2+) signalling pathway indicating that berberine could be a promising anti-DN medicine in the future.	Berberine	39-48	G protein subunit alpha q	Rattus norvegicus	78-85
27098986-14	2016	The observed renoprotective effects of berberine via regulating the PGE2 -EP1-Galphaq-Ca(2+) signalling pathway indicating that berberine could be a promising anti-DN medicine in the future.	Berberine	128-137	prostaglandin E receptor 1	Rattus norvegicus	74-77
27098986-14	2016	The observed renoprotective effects of berberine via regulating the PGE2 -EP1-Galphaq-Ca(2+) signalling pathway indicating that berberine could be a promising anti-DN medicine in the future.	Berberine	128-137	G protein subunit alpha q	Rattus norvegicus	78-85
26634613-8	2016	Additionally, uptake of berberine, glycyrrhizic acid were clearly inhibited by the inhibitors of P-glycoprotein and MRP2, indicating that P-gp and MRP2 may be involved in the transport of berberine and glycyrrhizic acid, respectively.	Berberine	24-33	ATP binding cassette subfamily C member 2	Canis lupus familiaris	116-120
26634613-8	2016	Additionally, uptake of berberine, glycyrrhizic acid were clearly inhibited by the inhibitors of P-glycoprotein and MRP2, indicating that P-gp and MRP2 may be involved in the transport of berberine and glycyrrhizic acid, respectively.	Berberine	24-33	PGP	Canis lupus familiaris	138-142
26634613-8	2016	Additionally, uptake of berberine, glycyrrhizic acid were clearly inhibited by the inhibitors of P-glycoprotein and MRP2, indicating that P-gp and MRP2 may be involved in the transport of berberine and glycyrrhizic acid, respectively.	Berberine	24-33	ATP binding cassette subfamily C member 2	Canis lupus familiaris	147-151
26634613-8	2016	Additionally, uptake of berberine, glycyrrhizic acid were clearly inhibited by the inhibitors of P-glycoprotein and MRP2, indicating that P-gp and MRP2 may be involved in the transport of berberine and glycyrrhizic acid, respectively.	Berberine	188-197	ATP binding cassette subfamily C member 2	Canis lupus familiaris	116-120
26634613-8	2016	Additionally, uptake of berberine, glycyrrhizic acid were clearly inhibited by the inhibitors of P-glycoprotein and MRP2, indicating that P-gp and MRP2 may be involved in the transport of berberine and glycyrrhizic acid, respectively.	Berberine	188-197	PGP	Canis lupus familiaris	138-142
26634613-8	2016	Additionally, uptake of berberine, glycyrrhizic acid were clearly inhibited by the inhibitors of P-glycoprotein and MRP2, indicating that P-gp and MRP2 may be involved in the transport of berberine and glycyrrhizic acid, respectively.	Berberine	188-197	ATP binding cassette subfamily C member 2	Canis lupus familiaris	147-151
27322681-0	2016	Tumor suppressor berberine binds VASP to inhibit cell migration in basal-like breast cancer.	Berberine	17-26	vasodilator stimulated phosphoprotein	Homo sapiens	33-37
27322681-4	2016	Here we investigated whether the anti-tumorigenic effects of berberine are mediated by binding VASP in basal-like breast cancer.	Berberine	61-70	vasodilator stimulated phosphoprotein	Homo sapiens	95-99
27322681-6	2016	We also show that berberine binds to VASP, inducing changes in its secondary structure and inhibits actin polymerization.	Berberine	18-27	vasodilator stimulated phosphoprotein	Homo sapiens	37-41
26969793-13	2016	Notably, berberine treatment pronouncedly reduced DSS-upregulated Th17-related cytokine (IL-17 and ROR-gammat) mRNAs in the colon.	Berberine	9-18	interleukin 17A	Mus musculus	66-94
26969793-14	2016	Furthermore, the mRNA expression of IL-6 and IL-23, and the phosphorylation of STAT3 in colon tissues from DSS-treated mice were pronouncedly inhibited by berberine.	Berberine	155-164	interleukin 6	Mus musculus	36-40
26969793-14	2016	Furthermore, the mRNA expression of IL-6 and IL-23, and the phosphorylation of STAT3 in colon tissues from DSS-treated mice were pronouncedly inhibited by berberine.	Berberine	155-164	interleukin 23, alpha subunit p19	Mus musculus	45-50
26969793-14	2016	Furthermore, the mRNA expression of IL-6 and IL-23, and the phosphorylation of STAT3 in colon tissues from DSS-treated mice were pronouncedly inhibited by berberine.	Berberine	155-164	signal transducer and activator of transcription 3	Mus musculus	79-84
26969793-15	2016	Moreover, the up-regulation of IL-17 secretion from CD4(+) cells of spleens and MLNs caused by DSS were significantly reversed by berberine treatment.	Berberine	130-139	interleukin 17A	Mus musculus	31-36
27462166-4	2016	An in vitro culture of colorectal tissue was established to analyze the effect of berberine (BER) and evodiamine (EVO) on the level of miR-429.	Berberine	82-91	microRNA 429	Homo sapiens	135-142
27462166-4	2016	An in vitro culture of colorectal tissue was established to analyze the effect of berberine (BER) and evodiamine (EVO) on the level of miR-429.	Berberine	93-96	microRNA 429	Homo sapiens	135-142
27189969-0	2016	Berberine Decreased Inducible Nitric Oxide Synthase mRNA Stability through Negative Regulation of Human Antigen R in Lipopolysaccharide-Induced Macrophages.	Berberine	0-9	nitric oxide synthase 2, inducible	Mus musculus	20-51
26698234-2	2016	Herein, we investigated whether berberine delayed the progression of castrate-resistant prostate cancer by reducing androgen synthesis through the inhibition of Aldo-keto reductase family 1 member C3.	Berberine	32-41	aldo-keto reductase family 1 member C3	Homo sapiens	161-199
26698234-5	2016	Computer analysis with AutoDock Tools explored the molecular interaction of berberine with Aldo-keto reductase family 1 member C3.	Berberine	76-85	aldo-keto reductase family 1 member C3	Homo sapiens	91-129
26698234-7	2016	Berberine inhibited Aldo-keto reductase family 1 member C3 enzyme activity, rather than influenced mRNA and protein expressions.	Berberine	0-9	aldo-keto reductase family 1 member C3	Homo sapiens	20-58
26698234-8	2016	Molecular docking study demonstrated that berberine could enter the active center of Aldo-keto reductase family 1 member C3 and form p-p interaction with the amino-acid residue Phe306 and Phe311.	Berberine	42-51	aldo-keto reductase family 1 member C3	Homo sapiens	85-123
26698234-9	2016	In conclusion, the structural interaction of berberine with Aldo-keto reductase family 1 member C3 is attributed to the suppression of Aldo-keto reductase family 1 member C3 enzyme activity and the inhibition of 22Rv1 prostate cancer cell growth by decreasing the intracellular androgen synthesis.	Berberine	45-54	aldo-keto reductase family 1 member C3	Homo sapiens	60-98
26698234-9	2016	In conclusion, the structural interaction of berberine with Aldo-keto reductase family 1 member C3 is attributed to the suppression of Aldo-keto reductase family 1 member C3 enzyme activity and the inhibition of 22Rv1 prostate cancer cell growth by decreasing the intracellular androgen synthesis.	Berberine	45-54	aldo-keto reductase family 1 member C3	Homo sapiens	135-173
26698234-10	2016	Our result provides the experimental basis for the design, research, and development of AKR1C3 inhibitors using berberine as the lead compound.	Berberine	112-121	aldo-keto reductase family 1 member C3	Homo sapiens	88-94
25491540-0	2016	Effects of berberine and cinnamic acid on palmitic acid-induced intracellular triglyceride accumulation in NIT-1 pancreatic beta cells.	Berberine	11-20	nitrilase 1	Mus musculus	107-112
27189969-6	2016	Pretreatment with berberine reduced LPS-induced iNOS protein expression and the cytoplasmic translocation of HuR in liver tissues and increased the survival rate of mice with LPS-induced endotoxemia.	Berberine	18-27	ELAV (embryonic lethal, abnormal vision)-like 1 (Hu antigen R)	Mus musculus	109-112
27189969-7	2016	These results show that the suppression of iNOS protein expression by berberine under LPS-induced inflammatory conditions is associated with a reduction in iNOS mRNA stability resulting from inhibition of the cytoplasmic translocation of HuR.	Berberine	70-79	nitric oxide synthase 2, inducible	Mus musculus	43-47
27189969-7	2016	These results show that the suppression of iNOS protein expression by berberine under LPS-induced inflammatory conditions is associated with a reduction in iNOS mRNA stability resulting from inhibition of the cytoplasmic translocation of HuR.	Berberine	70-79	nitric oxide synthase 2, inducible	Mus musculus	156-160
27189969-7	2016	These results show that the suppression of iNOS protein expression by berberine under LPS-induced inflammatory conditions is associated with a reduction in iNOS mRNA stability resulting from inhibition of the cytoplasmic translocation of HuR.	Berberine	70-79	ELAV (embryonic lethal, abnormal vision)-like 1 (Hu antigen R)	Mus musculus	238-241
27189969-3	2016	In both macrophage cell types, berberine inhibited the LPS-induced nitric oxide (NO) production and inducible NO synthase (iNOS) protein expression, but it had no effect on iNOS mRNA transcription.	Berberine	31-40	nitric oxide synthase 2, inducible	Mus musculus	100-121
27189969-3	2016	In both macrophage cell types, berberine inhibited the LPS-induced nitric oxide (NO) production and inducible NO synthase (iNOS) protein expression, but it had no effect on iNOS mRNA transcription.	Berberine	31-40	nitric oxide synthase 2, inducible	Mus musculus	123-127
27189969-4	2016	Suppression of LPS-induced iNOS protein expression by berberine occurred via a human antigen R (HuR)-mediated reduction of iNOS mRNA stability.	Berberine	54-63	nitric oxide synthase 2, inducible	Mus musculus	27-31
27189969-4	2016	Suppression of LPS-induced iNOS protein expression by berberine occurred via a human antigen R (HuR)-mediated reduction of iNOS mRNA stability.	Berberine	54-63	ELAV (embryonic lethal, abnormal vision)-like 1 (Hu antigen R)	Mus musculus	96-99
27189969-4	2016	Suppression of LPS-induced iNOS protein expression by berberine occurred via a human antigen R (HuR)-mediated reduction of iNOS mRNA stability.	Berberine	54-63	nitric oxide synthase 2, inducible	Mus musculus	123-127
27189969-5	2016	Molecular data revealed that the suppression on the LPS-induced HuR binding to iNOS mRNA by berberine was accompanied by a reduction in nucleocytoplasmic HuR shuttling.	Berberine	92-101	ELAV (embryonic lethal, abnormal vision)-like 1 (Hu antigen R)	Mus musculus	64-67
27189969-5	2016	Molecular data revealed that the suppression on the LPS-induced HuR binding to iNOS mRNA by berberine was accompanied by a reduction in nucleocytoplasmic HuR shuttling.	Berberine	92-101	nitric oxide synthase 2, inducible	Mus musculus	79-83
27189969-5	2016	Molecular data revealed that the suppression on the LPS-induced HuR binding to iNOS mRNA by berberine was accompanied by a reduction in nucleocytoplasmic HuR shuttling.	Berberine	92-101	ELAV (embryonic lethal, abnormal vision)-like 1 (Hu antigen R)	Mus musculus	154-157
27189969-6	2016	Pretreatment with berberine reduced LPS-induced iNOS protein expression and the cytoplasmic translocation of HuR in liver tissues and increased the survival rate of mice with LPS-induced endotoxemia.	Berberine	18-27	nitric oxide synthase 2, inducible	Mus musculus	48-52
27045865-14	2016	CONCLUSIONS: Berberine, baicalin and geniposide could neutralize LPS by binding with lipid A and then reduce the release of IL-6 and TNF-alpha induced by LPS.	Berberine	13-22	interferon regulatory factor 6	Homo sapiens	65-68
27177238-0	2016	Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis.	Berberine	0-9	caspase 3	Homo sapiens	113-122
27177238-7	2016	After treatment of BBR and cisplatin, the cellular pro-apoptotic capase-3 and cleaved capspase-3 and caspase-9 were upregulated and the anti-apoptotic Bcl-2 was downregulated.	Berberine	19-22	caspase 9	Homo sapiens	101-110
27177238-7	2016	After treatment of BBR and cisplatin, the cellular pro-apoptotic capase-3 and cleaved capspase-3 and caspase-9 were upregulated and the anti-apoptotic Bcl-2 was downregulated.	Berberine	19-22	BCL2 apoptosis regulator	Homo sapiens	151-156
30204365-0	2016	[Study of Berberine on Attenuating PM2.5-Induced Vascular Endothelial Cells Injury by ERK1/2 Signal Pathway].	Berberine	10-19	mitogen-activated protein kinase 3	Homo sapiens	86-92
27382358-0	2016	Activating transcription factor-3 induction is involved in the anti-inflammatory action of berberine in RAW264.7 murine macrophages.	Berberine	91-100	activating transcription factor 3	Mus musculus	0-33
27382358-2	2016	Based on previous reports that activating transcription factor-3 (ATF-3) acts as a negative regulator of LPS signaling, the authors investigated the possible involvement of ATF-3 in the anti-inflammatory effects of berberine.	Berberine	215-224	activating transcription factor 3	Mus musculus	173-178
27382358-3	2016	It was found berberine concentration-dependently induced the expressions of ATF-3 at the mRNA and protein levels and concomitantly suppressed the LPS-induced productions of proinflammatory cytokines (TNF-alpha, IL-6, and IL-1beta).	Berberine	13-22	activating transcription factor 3	Mus musculus	76-81
27382358-3	2016	It was found berberine concentration-dependently induced the expressions of ATF-3 at the mRNA and protein levels and concomitantly suppressed the LPS-induced productions of proinflammatory cytokines (TNF-alpha, IL-6, and IL-1beta).	Berberine	13-22	tumor necrosis factor	Mus musculus	200-209
27382358-3	2016	It was found berberine concentration-dependently induced the expressions of ATF-3 at the mRNA and protein levels and concomitantly suppressed the LPS-induced productions of proinflammatory cytokines (TNF-alpha, IL-6, and IL-1beta).	Berberine	13-22	interleukin 6	Mus musculus	211-215
27382358-3	2016	It was found berberine concentration-dependently induced the expressions of ATF-3 at the mRNA and protein levels and concomitantly suppressed the LPS-induced productions of proinflammatory cytokines (TNF-alpha, IL-6, and IL-1beta).	Berberine	13-22	interleukin 1 beta	Mus musculus	221-229
27382358-4	2016	In addition, ATF-3 knockdown abolished the inhibitory effects of berberine on LPS-induced proinflammatory cytokine production, and prevented the berberine-induced suppression of MAPK phosphorylation, but had little effect on AMPK phosphorylation.	Berberine	65-74	activating transcription factor 3	Mus musculus	13-18
27382358-4	2016	In addition, ATF-3 knockdown abolished the inhibitory effects of berberine on LPS-induced proinflammatory cytokine production, and prevented the berberine-induced suppression of MAPK phosphorylation, but had little effect on AMPK phosphorylation.	Berberine	145-154	activating transcription factor 3	Mus musculus	13-18
27382358-5	2016	On the other hand, the effects of berberine, that is, ATF-3 induction, proinflammatory cytokine inhibition, and MAPK inactivation, were prevented by AMPK knockdown, suggesting ATF-3 induction occurs downstream of AMPK activation.	Berberine	34-43	activating transcription factor 3	Mus musculus	54-59
27382358-5	2016	On the other hand, the effects of berberine, that is, ATF-3 induction, proinflammatory cytokine inhibition, and MAPK inactivation, were prevented by AMPK knockdown, suggesting ATF-3 induction occurs downstream of AMPK activation.	Berberine	34-43	activating transcription factor 3	Mus musculus	176-181
27382358-6	2016	The in vivo administration of berberine to mice with LPS-induced endotoxemia increased ATF-3 expression and AMPK phosphorylation in spleen and lung tissues, and concomitantly reduced the plasma and tissue levels of proinflammatory cytokines.	Berberine	30-39	activating transcription factor 3	Mus musculus	87-92
27382358-7	2016	These results suggest berberine has an anti-inflammatory effect on macrophages and that this effect is attributable, at least in part, to pathways involving AMPK activation and ATF-3 induction.	Berberine	22-31	activating transcription factor 3	Mus musculus	177-182
27045865-14	2016	CONCLUSIONS: Berberine, baicalin and geniposide could neutralize LPS by binding with lipid A and then reduce the release of IL-6 and TNF-alpha induced by LPS.	Berberine	13-22	interleukin 6	Homo sapiens	124-128
27045865-14	2016	CONCLUSIONS: Berberine, baicalin and geniposide could neutralize LPS by binding with lipid A and then reduce the release of IL-6 and TNF-alpha induced by LPS.	Berberine	13-22	tumor necrosis factor	Homo sapiens	133-142
27045865-14	2016	CONCLUSIONS: Berberine, baicalin and geniposide could neutralize LPS by binding with lipid A and then reduce the release of IL-6 and TNF-alpha induced by LPS.	Berberine	13-22	interferon regulatory factor 6	Homo sapiens	154-157
27045865-15	2016	Furthermore, berberine, baicalin and geniposide exhibited protective activities on varying organs compared to the animal model established by the LPS-induced.	Berberine	13-22	interferon regulatory factor 6	Homo sapiens	146-149
27082997-0	2016	Berberine in combination with yohimbine attenuates sepsis-induced neutrophil tissue infiltration and multiorgan dysfunction partly via IL-10-mediated inhibition of CCR2 expression in neutrophils.	Berberine	0-9	interleukin 10	Mus musculus	135-140
27235712-8	2016	RESULTS: We demonstrate berberine induces neuronal differentiation accompanying increased neuronal differentiation markers like MAP2, beta-III tubulin and NCAM; generated neurons were viable.	Berberine	24-33	microtubule-associated protein 2	Mus musculus	128-132
27235712-8	2016	RESULTS: We demonstrate berberine induces neuronal differentiation accompanying increased neuronal differentiation markers like MAP2, beta-III tubulin and NCAM; generated neurons were viable.	Berberine	24-33	tubulin, beta 3 class III	Mus musculus	134-150
27235712-8	2016	RESULTS: We demonstrate berberine induces neuronal differentiation accompanying increased neuronal differentiation markers like MAP2, beta-III tubulin and NCAM; generated neurons were viable.	Berberine	24-33	neural cell adhesion molecule 1	Mus musculus	155-159
27235712-9	2016	Berberine attenuated cancer stemness markers CD133, beta-catenin, n-myc, sox2, notch2 and nestin.	Berberine	0-9	prominin 1	Mus musculus	45-50
27235712-9	2016	Berberine attenuated cancer stemness markers CD133, beta-catenin, n-myc, sox2, notch2 and nestin.	Berberine	0-9	catenin (cadherin associated protein), beta 1	Mus musculus	52-64
27235712-9	2016	Berberine attenuated cancer stemness markers CD133, beta-catenin, n-myc, sox2, notch2 and nestin.	Berberine	0-9	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	66-71
27235712-9	2016	Berberine attenuated cancer stemness markers CD133, beta-catenin, n-myc, sox2, notch2 and nestin.	Berberine	0-9	SRY (sex determining region Y)-box 2	Mus musculus	73-77
27235712-9	2016	Berberine attenuated cancer stemness markers CD133, beta-catenin, n-myc, sox2, notch2 and nestin.	Berberine	0-9	notch 2	Mus musculus	79-85
27235712-10	2016	Berberine potentiated G0/G1 cell cycle arrest by inhibiting proliferation, cyclin dependent kinases and cyclins resulting in apoptosis through increased bax/bcl-2 ratio.	Berberine	0-9	BCL2-associated X protein	Mus musculus	153-156
27235712-10	2016	Berberine potentiated G0/G1 cell cycle arrest by inhibiting proliferation, cyclin dependent kinases and cyclins resulting in apoptosis through increased bax/bcl-2 ratio.	Berberine	0-9	B cell leukemia/lymphoma 2	Mus musculus	157-162
27235712-14	2016	Molecular insights revealed that berberine regulates EMT via downregulation of PI3/Akt and Ras-Raf-ERK signalling and subsequent upregulation of p38-MAPK.	Berberine	33-42	IL2 inducible T cell kinase	Mus musculus	53-56
27235712-14	2016	Molecular insights revealed that berberine regulates EMT via downregulation of PI3/Akt and Ras-Raf-ERK signalling and subsequent upregulation of p38-MAPK.	Berberine	33-42	serine (or cysteine) peptidase inhibitor, clade A, member 1C	Mus musculus	79-82
27235712-14	2016	Molecular insights revealed that berberine regulates EMT via downregulation of PI3/Akt and Ras-Raf-ERK signalling and subsequent upregulation of p38-MAPK.	Berberine	33-42	thymoma viral proto-oncogene 1	Mus musculus	83-86
27235712-14	2016	Molecular insights revealed that berberine regulates EMT via downregulation of PI3/Akt and Ras-Raf-ERK signalling and subsequent upregulation of p38-MAPK.	Berberine	33-42	mitogen-activated protein kinase 14	Mus musculus	145-148
27235712-15	2016	TGF-beta secretion from N2a cells was potentiated by high glucose and negatively regulated by berberine through modulation of TGF-beta receptors II and III.	Berberine	94-103	transforming growth factor, beta receptor II	Mus musculus	126-155
27235712-16	2016	Berberine reverted mesenchymal markers, vimentin and fibronectin, with restoration of epithelial marker E-cadherin, highlighting the role of berberine in reversal of EMT.	Berberine	0-9	vimentin	Mus musculus	40-48
27235712-16	2016	Berberine reverted mesenchymal markers, vimentin and fibronectin, with restoration of epithelial marker E-cadherin, highlighting the role of berberine in reversal of EMT.	Berberine	0-9	fibronectin 1	Mus musculus	53-64
27235712-16	2016	Berberine reverted mesenchymal markers, vimentin and fibronectin, with restoration of epithelial marker E-cadherin, highlighting the role of berberine in reversal of EMT.	Berberine	0-9	IL2 inducible T cell kinase	Mus musculus	166-169
27235712-17	2016	CONCLUSION: Collectively, the study demonstrates prospective use of berberine against neuroblastoma as elucidated through inhibition of fundamental characteristics of cancer stem cells: tumorigenicity and failure to differentiation and instigates reversal in the EMT.	Berberine	68-77	IL2 inducible T cell kinase	Mus musculus	263-266
26979714-0	2016	Berberine activates Nrf2 nuclear translocation and inhibits apoptosis induced by high glucose in renal tubular epithelial cells through a phosphatidylinositol 3-kinase/Akt-dependent mechanism.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	20-24
26979714-0	2016	Berberine activates Nrf2 nuclear translocation and inhibits apoptosis induced by high glucose in renal tubular epithelial cells through a phosphatidylinositol 3-kinase/Akt-dependent mechanism.	Berberine	0-9	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	138-167
26979714-0	2016	Berberine activates Nrf2 nuclear translocation and inhibits apoptosis induced by high glucose in renal tubular epithelial cells through a phosphatidylinositol 3-kinase/Akt-dependent mechanism.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	168-171
26979714-7	2016	BBR-induced anti-apoptotic function was demonstrated by decreasing apoptotic proteins (cytochrome c, Bax, caspase3 and caspase9).	Berberine	0-3	BCL2 associated X, apoptosis regulator	Rattus norvegicus	101-104
26979714-7	2016	BBR-induced anti-apoptotic function was demonstrated by decreasing apoptotic proteins (cytochrome c, Bax, caspase3 and caspase9).	Berberine	0-3	caspase 3	Rattus norvegicus	106-114
27311637-0	2016	Antiproliferation of berberine is mediated by epigenetic modification of constitutive androstane receptor (CAR) metabolic pathway in hepatoma cells.	Berberine	21-30	nuclear receptor subfamily 1 group I member 3	Homo sapiens	73-105
27311637-0	2016	Antiproliferation of berberine is mediated by epigenetic modification of constitutive androstane receptor (CAR) metabolic pathway in hepatoma cells.	Berberine	21-30	nuclear receptor subfamily 1 group I member 3	Homo sapiens	107-110
27311637-4	2016	Berberine induces more apoptosis, cell cycle arrest, but less ROS production in CAR overexpressed mCAR-HepG2 cells.	Berberine	0-9	nuclear receptor subfamily 1 group I member 3	Homo sapiens	80-83
27311637-4	2016	Berberine induces more apoptosis, cell cycle arrest, but less ROS production in CAR overexpressed mCAR-HepG2 cells.	Berberine	0-9	coxsackie virus and adenovirus receptor	Mus musculus	98-102
27311637-5	2016	Moreover, berberine inhibits expressions of CAR and its target genes CYP2B6 and CYP3A4.	Berberine	10-19	nuclear receptor subfamily 1 group I member 3	Homo sapiens	44-47
27311637-5	2016	Moreover, berberine inhibits expressions of CAR and its target genes CYP2B6 and CYP3A4.	Berberine	10-19	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	69-75
27311637-5	2016	Moreover, berberine inhibits expressions of CAR and its target genes CYP2B6 and CYP3A4.	Berberine	10-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
27311637-6	2016	Furthermore, berberine enhances DNA methylation level in whole genome but reduces that in promoter regions CpG sites of CYP2B6 and CYP3A4 genes under the presence of CAR condition.	Berberine	13-22	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	120-126
27311637-6	2016	Furthermore, berberine enhances DNA methylation level in whole genome but reduces that in promoter regions CpG sites of CYP2B6 and CYP3A4 genes under the presence of CAR condition.	Berberine	13-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-137
27311637-6	2016	Furthermore, berberine enhances DNA methylation level in whole genome but reduces that in promoter regions CpG sites of CYP2B6 and CYP3A4 genes under the presence of CAR condition.	Berberine	13-22	nuclear receptor subfamily 1 group I member 3	Homo sapiens	166-169
27311637-7	2016	These results indicated that the antiproliferation of berberine might be mediated by the unique epigenetic modifying mechanism of CAR metabolic pathway, suggesting that berberine is a promising candidate in anticancer adjuvant chemotherapy, due to its distinct pharmacological properties in clinic.	Berberine	54-63	nuclear receptor subfamily 1 group I member 3	Homo sapiens	130-133
27311637-7	2016	These results indicated that the antiproliferation of berberine might be mediated by the unique epigenetic modifying mechanism of CAR metabolic pathway, suggesting that berberine is a promising candidate in anticancer adjuvant chemotherapy, due to its distinct pharmacological properties in clinic.	Berberine	169-178	nuclear receptor subfamily 1 group I member 3	Homo sapiens	130-133
27235712-4	2016	STUDY DESIGN: Potential of berberine was investigated for (i) neuronal differentiation and cancer stemness inhibition, (ii) underlying molecular mechanisms regulating cancer-stemness and (iii) EMT reversal.	Berberine	27-36	IL2 inducible T cell kinase	Mus musculus	193-196
26979714-7	2016	BBR-induced anti-apoptotic function was demonstrated by decreasing apoptotic proteins (cytochrome c, Bax, caspase3 and caspase9).	Berberine	0-3	caspase 9	Rattus norvegicus	119-127
27100490-0	2016	Berberine is a potent agonist of peroxisome proliferator activated receptor alpha.	Berberine	0-9	peroxisome proliferator activated receptor alpha	Rattus norvegicus	33-81
27100490-2	2016	Here, we determine whether berberine is an agonist of peroxisome proliferator-activated receptor alpha (PPARalpha), with a lipid-lowering effect.	Berberine	27-36	peroxisome proliferator activated receptor alpha	Rattus norvegicus	54-102
27100490-2	2016	Here, we determine whether berberine is an agonist of peroxisome proliferator-activated receptor alpha (PPARalpha), with a lipid-lowering effect.	Berberine	27-36	peroxisome proliferator activated receptor alpha	Rattus norvegicus	104-113
27100490-3	2016	The cell-based reporter gene analysis showed that berberine selectively activates PPARalpha (EC50 =0.58 mM, Emax =102.4).	Berberine	50-59	peroxisome proliferator activated receptor alpha	Rattus norvegicus	82-91
27100490-4	2016	The radioligand binding assay shows that berberine binds directly to the ligand-binding domain of PPARalpha (Ki=0.73 mM) with similar affinity to fenofibrate.	Berberine	41-50	peroxisome proliferator activated receptor alpha	Rattus norvegicus	98-107
27100490-5	2016	The mRNA and protein levels of CPT-Ialpha gene from HepG2 cells and hyperlipidemic rat liver are remarkably up-regulated by berberine, and this effect can be blocked by MK886, a non-competitive antagonist of PPARalpha.	Berberine	124-133	peroxisome proliferator activated receptor alpha	Rattus norvegicus	208-217
27100490-7	2016	These findings provide the first evidence that berberine is a potent agonist of PPARalpha and seems to be superior to fenofibrate for treating hyperlipidemia.	Berberine	47-56	peroxisome proliferator activated receptor alpha	Rattus norvegicus	80-89
27082997-0	2016	Berberine in combination with yohimbine attenuates sepsis-induced neutrophil tissue infiltration and multiorgan dysfunction partly via IL-10-mediated inhibition of CCR2 expression in neutrophils.	Berberine	0-9	chemokine (C-C motif) receptor 2	Mus musculus	164-168
28901090-2	2016	This experiment was mainly to study the effect of berberine on mRNA expression levels of PPARgamma and adipocytokines in insulin resistant adipocytes, and investigate the molecular mechanism of berberine in enhancing insulin sensitization and application advantages of droplet digital PCR (ddPCR).	Berberine	194-203	insulin	Homo sapiens	217-224
28901090-0	2016	[Effects of berberine on mRNA expression levels of PPARgamma and adipocytokines in insulin-resistant adipocytes].	Berberine	12-21	peroxisome proliferator activated receptor gamma	Homo sapiens	51-60
27367504-9	2016	CONCLUSIONS: Berberine inhibits modified LDL-induced Muller cell injury by activating the AMPK pathway, and merits further study as an agent for preventing and/or treating DR.	Berberine	13-22	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	90-94
27148818-0	2016	Berberine inhibits inflammatory mediators and attenuates acute pancreatitis through deactivation of JNK signaling pathways.	Berberine	0-9	mitogen-activated protein kinase 8	Mus musculus	100-103
29879347-8	2016	Dopamine, glutamine, piperine, berberine, nuciferine, lisinopril and fosinopril could inhibit ergothioneine or mildronate uptake by MDCK- hOCTN1/2.	Berberine	31-40	solute carrier family 22 member 4	Homo sapiens	138-146
28901090-0	2016	[Effects of berberine on mRNA expression levels of PPARgamma and adipocytokines in insulin-resistant adipocytes].	Berberine	12-21	insulin	Homo sapiens	83-90
28901090-4	2016	ddPCR and quantitative Real-time PCR (qPCR) were used to compare the effect of different doses of berberine (10, 20, 50, 100 mumol L-1) on mRNA expression levels of PPARgamma, adiponectin, resistin and leptin in IR 3T3-L1adipocytes.	Berberine	98-107	peroxisome proliferator activated receptor gamma	Homo sapiens	165-174
28901090-2	2016	This experiment was mainly to study the effect of berberine on mRNA expression levels of PPARgamma and adipocytokines in insulin resistant adipocytes, and investigate the molecular mechanism of berberine in enhancing insulin sensitization and application advantages of droplet digital PCR (ddPCR).	Berberine	50-59	peroxisome proliferator activated receptor gamma	Homo sapiens	89-98
28901090-2	2016	This experiment was mainly to study the effect of berberine on mRNA expression levels of PPARgamma and adipocytokines in insulin resistant adipocytes, and investigate the molecular mechanism of berberine in enhancing insulin sensitization and application advantages of droplet digital PCR (ddPCR).	Berberine	50-59	insulin	Homo sapiens	121-128
28901090-4	2016	ddPCR and quantitative Real-time PCR (qPCR) were used to compare the effect of different doses of berberine (10, 20, 50, 100 mumol L-1) on mRNA expression levels of PPARgamma, adiponectin, resistin and leptin in IR 3T3-L1adipocytes.	Berberine	98-107	adiponectin, C1Q and collagen domain containing	Homo sapiens	176-187
28901090-10	2016	In conclusion, berberine enhanced insulin sensitization effect not by up-regulating adiponect in expression of transcriptional level in PPARgamma-dependent manner, but may by the elevated multimerization of adiponectin in the posttranslational regulation level.	Berberine	15-24	insulin	Homo sapiens	34-41
28901090-10	2016	In conclusion, berberine enhanced insulin sensitization effect not by up-regulating adiponect in expression of transcriptional level in PPARgamma-dependent manner, but may by the elevated multimerization of adiponectin in the posttranslational regulation level.	Berberine	15-24	peroxisome proliferator activated receptor gamma	Homo sapiens	136-145
28901090-10	2016	In conclusion, berberine enhanced insulin sensitization effect not by up-regulating adiponect in expression of transcriptional level in PPARgamma-dependent manner, but may by the elevated multimerization of adiponectin in the posttranslational regulation level.	Berberine	15-24	adiponectin, C1Q and collagen domain containing	Homo sapiens	207-218
27036040-8	2016	In Sawano cells and normal HEEs, a decrease of LSR induced by leptin and an increase of LSR induced by adiponectin and the drugs for type 2 diabetes metformin and berberine were observed via distinct signaling pathways including JAK2/STAT.	Berberine	163-172	lipolysis stimulated lipoprotein receptor	Homo sapiens	88-91
28087908-0	2016	[Berberine regulates glycemia via local inhibition of intestinal dipeptidyl peptidase-IV].	Berberine	1-10	dipeptidylpeptidase 4	Rattus norvegicus	65-88
28087908-8	2016	Compared with control group, serum levels of GLP-1 and insulin were increased in high-and moderate-dose berberine groups, while 2h-PPG was decreased (all P&lt;0.05); GLP-1 levels in the intestinal samples were increased, while DPP-IV levels were decreased in all berberine groups (all P&lt;0.05).	Berberine	104-113	glucagon	Rattus norvegicus	45-50
28087908-8	2016	Compared with control group, serum levels of GLP-1 and insulin were increased in high-and moderate-dose berberine groups, while 2h-PPG was decreased (all P&lt;0.05); GLP-1 levels in the intestinal samples were increased, while DPP-IV levels were decreased in all berberine groups (all P&lt;0.05).	Berberine	104-113	glucagon	Rattus norvegicus	166-171
28087908-9	2016	Conclusions: Short-term berberine administration can decrease 2h-PPG level in streptozotocin-induced diabetic rat model through local inhibition of intestinal DPP-IV.	Berberine	24-33	dipeptidylpeptidase 4	Rattus norvegicus	159-165
27036040-8	2016	In Sawano cells and normal HEEs, a decrease of LSR induced by leptin and an increase of LSR induced by adiponectin and the drugs for type 2 diabetes metformin and berberine were observed via distinct signaling pathways including JAK2/STAT.	Berberine	163-172	adiponectin, C1Q and collagen domain containing	Homo sapiens	103-114
27036040-8	2016	In Sawano cells and normal HEEs, a decrease of LSR induced by leptin and an increase of LSR induced by adiponectin and the drugs for type 2 diabetes metformin and berberine were observed via distinct signaling pathways including JAK2/STAT.	Berberine	163-172	Janus kinase 2	Homo sapiens	229-233
27036040-9	2016	In Sawano cells, metformin and berberine prevented cell migration and invasion induced by downregulation of LSR by the siRNA and leptin treatment.	Berberine	31-40	lipolysis stimulated lipoprotein receptor	Homo sapiens	108-111
27035325-8	2016	By performing hepcidin promoter-luciferase assay, RT-qPCR and animal experiments, we demonstrated that icariin and berberine were potent stimulators of hepcidin transcription.	Berberine	115-124	hepcidin antimicrobial peptide	Mus musculus	14-22
26914282-0	2016	Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signalling in diabetic rats.	Berberine	0-9	insulin receptor	Rattus norvegicus	79-95
26914282-3	2016	Here, we investigated the mechanism by which berberine improves vascular insulin sensitivity in diabetic rats.	Berberine	45-54	insulin	Homo sapiens	73-80
26914282-8	2016	KEY RESULTS: Berberine treatment for 4 weeks significantly restored the impaired ACh- and insulin-induced vasodilatation of mesenteric arteries from diabetic rats.	Berberine	13-22	insulin	Homo sapiens	90-97
26914282-9	2016	In isolated mesenteric artery rings, berberine (2.5-10 mumol L(-1)) elicited dose-dependent vasodilatation and significantly enhanced insulin-induced vasodilatation.	Berberine	37-46	insulin	Homo sapiens	134-141
26914282-10	2016	Mechanistically, berberine up-regulated phosphorylation of the insulin receptor and its downstream signalling molecules AMPK, Akt and eNOS, and increased cell viability and autophagy in cultured endothelial cells.	Berberine	17-26	insulin receptor	Rattus norvegicus	63-79
26914282-10	2016	Mechanistically, berberine up-regulated phosphorylation of the insulin receptor and its downstream signalling molecules AMPK, Akt and eNOS, and increased cell viability and autophagy in cultured endothelial cells.	Berberine	17-26	AKT serine/threonine kinase 1	Rattus norvegicus	126-129
26914282-11	2016	Moreover, down-regulating insulin receptors with specific siRNA significantly attenuated berberine-induced phosphorylation of AMPK.	Berberine	89-98	insulin	Homo sapiens	26-33
26914282-12	2016	CONCLUSIONS AND IMPLICATIONS: Berberine improves diabetic vascular insulin sensitivity and mesenteric vasodilatation by up-regulating insulin receptor-mediated signalling in diabetic rats.	Berberine	30-39	insulin receptor	Rattus norvegicus	134-150
26648584-0	2016	Molecular Modeling on Berberine Derivatives toward BuChE: An Integrated Study with Quantitative Structure-Activity Relationships Models, Molecular Docking, and Molecular Dynamics Simulations.	Berberine	22-31	butyrylcholinesterase	Homo sapiens	51-56
26648584-1	2016	A dataset of 67 berberine derivatives for the inhibition of butyrylcholinesterase (BuChE) was studied based on the combination of quantitative structure-activity relationships models, molecular docking, and molecular dynamics methods.	Berberine	16-25	butyrylcholinesterase	Homo sapiens	60-81
26648584-1	2016	A dataset of 67 berberine derivatives for the inhibition of butyrylcholinesterase (BuChE) was studied based on the combination of quantitative structure-activity relationships models, molecular docking, and molecular dynamics methods.	Berberine	16-25	butyrylcholinesterase	Homo sapiens	83-88
26648584-2	2016	First, a series of berberine derivatives were reported, and their inhibitory activities toward butyrylcholinesterase (BuChE) were evaluated.	Berberine	19-28	butyrylcholinesterase	Homo sapiens	95-116
26648584-2	2016	First, a series of berberine derivatives were reported, and their inhibitory activities toward butyrylcholinesterase (BuChE) were evaluated.	Berberine	19-28	butyrylcholinesterase	Homo sapiens	118-123
26648584-5	2016	In addition, the molecular docking and molecular dynamics simulation were performed to better elucidate the inhibitory mechanism of three typical berberine derivatives (berberine, C2, and C55) toward BuChE.	Berberine	146-155	butyrylcholinesterase	Homo sapiens	200-205
26648584-5	2016	In addition, the molecular docking and molecular dynamics simulation were performed to better elucidate the inhibitory mechanism of three typical berberine derivatives (berberine, C2, and C55) toward BuChE.	Berberine	169-178	butyrylcholinesterase	Homo sapiens	200-205
26648584-8	2016	In conclusion, the results of this study provide useful clues for new drug design and discovery of BuChE inhibitors from berberine derivatives.	Berberine	121-130	butyrylcholinesterase	Homo sapiens	99-104
27398330-0	2016	Berberine Induced Apoptosis of Human Osteosarcoma Cells by Inhibiting Phosphoinositide 3 Kinase/Protein Kinase B (PI3K/Akt) Signal Pathway Activation.	Berberine	0-9	protein tyrosine kinase 2 beta	Homo sapiens	96-112
27398330-0	2016	Berberine Induced Apoptosis of Human Osteosarcoma Cells by Inhibiting Phosphoinositide 3 Kinase/Protein Kinase B (PI3K/Akt) Signal Pathway Activation.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	119-122
27398330-7	2016	Mechanistically, berberine inhibits PI3K/AKT activation that, in turn, results in up-regulating the expression of Bax, and PARP and down-regulating the expression of Bcl-2 and caspase3.	Berberine	17-26	AKT serine/threonine kinase 1	Homo sapiens	41-44
27398330-7	2016	Mechanistically, berberine inhibits PI3K/AKT activation that, in turn, results in up-regulating the expression of Bax, and PARP and down-regulating the expression of Bcl-2 and caspase3.	Berberine	17-26	BCL2 associated X, apoptosis regulator	Homo sapiens	114-117
27398330-7	2016	Mechanistically, berberine inhibits PI3K/AKT activation that, in turn, results in up-regulating the expression of Bax, and PARP and down-regulating the expression of Bcl-2 and caspase3.	Berberine	17-26	collagen type XI alpha 2 chain	Homo sapiens	123-127
27035325-8	2016	By performing hepcidin promoter-luciferase assay, RT-qPCR and animal experiments, we demonstrated that icariin and berberine were potent stimulators of hepcidin transcription.	Berberine	115-124	hepcidin antimicrobial peptide	Mus musculus	152-160
27398330-7	2016	Mechanistically, berberine inhibits PI3K/AKT activation that, in turn, results in up-regulating the expression of Bax, and PARP and down-regulating the expression of Bcl-2 and caspase3.	Berberine	17-26	BCL2 apoptosis regulator	Homo sapiens	166-171
27398330-7	2016	Mechanistically, berberine inhibits PI3K/AKT activation that, in turn, results in up-regulating the expression of Bax, and PARP and down-regulating the expression of Bcl-2 and caspase3.	Berberine	17-26	caspase 3	Homo sapiens	176-184
27035325-9	2016	Mechanistic experiments indicated that icariin and berberine increased hepcidin expression by activating the signal transducer and activator of transcription 3 (Stat3) and Smad1/5/8 signaling pathways.	Berberine	51-60	hepcidin antimicrobial peptide	Mus musculus	71-79
27398330-8	2016	In all, berberine can suppress the proliferation and induce the apoptosis of U2OS cell through inhibiting the PI3K/Akt signaling pathway activation.	Berberine	8-17	AKT serine/threonine kinase 1	Homo sapiens	115-118
27398330-9	2016	CONCLUSION: Berberine can suppress the proliferation and induce the apoptosis of U2OS cell through inhibiting the PI3K/Akt signaling pathway activation.	Berberine	12-21	AKT serine/threonine kinase 1	Homo sapiens	119-122
27035325-9	2016	Mechanistic experiments indicated that icariin and berberine increased hepcidin expression by activating the signal transducer and activator of transcription 3 (Stat3) and Smad1/5/8 signaling pathways.	Berberine	51-60	signal transducer and activator of transcription 3	Mus musculus	109-159
27035325-9	2016	Mechanistic experiments indicated that icariin and berberine increased hepcidin expression by activating the signal transducer and activator of transcription 3 (Stat3) and Smad1/5/8 signaling pathways.	Berberine	51-60	signal transducer and activator of transcription 3	Mus musculus	161-166
27035325-9	2016	Mechanistic experiments indicated that icariin and berberine increased hepcidin expression by activating the signal transducer and activator of transcription 3 (Stat3) and Smad1/5/8 signaling pathways.	Berberine	51-60	SMAD family member 1	Mus musculus	172-179
27035325-13	2016	Although berberine exhibited a robust capacity to promote hepcidin expression in vitro, it failed to alter hepcidin expression in mice.	Berberine	9-18	hepcidin antimicrobial peptide	Mus musculus	58-66
27104513-8	2016	Gallic acid and chlorogenic acid could suppress the release of pro-inflammatory cytokine IL-6 and chemokine CCL7 and CXCL8, respectively, in IL-31- and IL-33-treated eosinophils-dermal fibroblasts co-culture; while berberine could suppress the release of IL-6, CXCL8, CCL2 and CCL7 in the eosinophil culture and eosinophils-dermal fibroblasts co-culture (all p &lt; 0.05).	Berberine	215-224	interleukin 31	Homo sapiens	141-157
25649126-11	2016	Although 3,4-dihydroxybenzaldehyde, baicalin and ginsenoside Rb1 as HST components increased S100A8/S100A9 expression, oleanolic acid and berberine decreased their expression.	Berberine	138-147	RB transcriptional corepressor 1	Homo sapiens	61-64
25649126-11	2016	Although 3,4-dihydroxybenzaldehyde, baicalin and ginsenoside Rb1 as HST components increased S100A8/S100A9 expression, oleanolic acid and berberine decreased their expression.	Berberine	138-147	S100 calcium binding protein A9	Homo sapiens	100-106
26936230-0	2016	Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity.	Berberine	0-9	WD and tetratricopeptide repeats 1	Mus musculus	65-72
27044832-10	2016	Our current study demonstrated that berberine could ameliorate EAM and the underling mechanisms may be due to the fact that berberine differentially modulates the activities of p-STAT1, p-STAT3 and p-STAT4 to suppress Th17 and Th1 cell differentiation.	Berberine	36-45	signal transducer and activator of transcription 1	Rattus norvegicus	179-184
27044832-10	2016	Our current study demonstrated that berberine could ameliorate EAM and the underling mechanisms may be due to the fact that berberine differentially modulates the activities of p-STAT1, p-STAT3 and p-STAT4 to suppress Th17 and Th1 cell differentiation.	Berberine	36-45	signal transducer and activator of transcription 3	Rattus norvegicus	188-193
27044832-10	2016	Our current study demonstrated that berberine could ameliorate EAM and the underling mechanisms may be due to the fact that berberine differentially modulates the activities of p-STAT1, p-STAT3 and p-STAT4 to suppress Th17 and Th1 cell differentiation.	Berberine	36-45	signal transducer and activator of transcription 4	Rattus norvegicus	200-205
27044832-10	2016	Our current study demonstrated that berberine could ameliorate EAM and the underling mechanisms may be due to the fact that berberine differentially modulates the activities of p-STAT1, p-STAT3 and p-STAT4 to suppress Th17 and Th1 cell differentiation.	Berberine	124-133	signal transducer and activator of transcription 1	Rattus norvegicus	179-184
27044832-10	2016	Our current study demonstrated that berberine could ameliorate EAM and the underling mechanisms may be due to the fact that berberine differentially modulates the activities of p-STAT1, p-STAT3 and p-STAT4 to suppress Th17 and Th1 cell differentiation.	Berberine	124-133	signal transducer and activator of transcription 3	Rattus norvegicus	188-193
27044832-10	2016	Our current study demonstrated that berberine could ameliorate EAM and the underling mechanisms may be due to the fact that berberine differentially modulates the activities of p-STAT1, p-STAT3 and p-STAT4 to suppress Th17 and Th1 cell differentiation.	Berberine	124-133	signal transducer and activator of transcription 4	Rattus norvegicus	200-205
26475979-10	2016	Consistent with OCT results, the mRNA levels of Rho in the NSR, and Rpe65 and Mct3 in the RPE, were significantly higher in mice treated with BBR.	Berberine	142-145	retinal pigment epithelium 65	Mus musculus	68-73
26475979-10	2016	Consistent with OCT results, the mRNA levels of Rho in the NSR, and Rpe65 and Mct3 in the RPE, were significantly higher in mice treated with BBR.	Berberine	142-145	solute carrier family 16 (monocarboxylic acid transporters), member 3	Mus musculus	78-82
27015087-0	2016	Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine.	Berberine	133-142	low density lipoprotein receptor	Homo sapiens	20-24
27015087-0	2016	Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine.	Berberine	133-142	proprotein convertase subtilisin/kexin type 9	Homo sapiens	29-34
27092498-0	2016	Up-Regulation of PAI-1 and Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine.	Berberine	163-172	serpin family E member 1	Homo sapiens	17-22
27092498-0	2016	Up-Regulation of PAI-1 and Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine.	Berberine	163-172	plasminogen activator, urokinase	Homo sapiens	46-49
27092498-5	2016	This was accompanied by a dose-dependent down-regulation of expression of Cyclooxygenase-2 (COX-2), nuclear factor kappa B (NF-kappaB), urokinase-type plasminogen activator (uPA) and matrix metalloproteinase (MMP)-9 in berberine-treated HCC cells.	Berberine	219-228	prostaglandin-endoperoxide synthase 2	Homo sapiens	74-90
27092498-6	2016	Furthermore, berberine inactivated p38 and Erk1/2 signaling pathway in HCC cells.	Berberine	13-22	mitogen-activated protein kinase 1	Homo sapiens	35-38
27092498-6	2016	Furthermore, berberine inactivated p38 and Erk1/2 signaling pathway in HCC cells.	Berberine	13-22	mitogen-activated protein kinase 3	Homo sapiens	43-49
27092498-8	2016	Blockade of uPA receptor-associated pathways leads to reduced invasiveness and motility of berberine-treated HCC cells.	Berberine	91-100	plasminogen activator, urokinase	Homo sapiens	12-15
27092498-9	2016	In conclusion, our findings identified for the first time that inactivation of uPA receptor by up-regulation of PAI-1 and down-regulation of uPA is involved in the inhibitory effect of berberine on HCC cell invasion and migration.	Berberine	185-194	plasminogen activator, urokinase	Homo sapiens	79-82
27092498-9	2016	In conclusion, our findings identified for the first time that inactivation of uPA receptor by up-regulation of PAI-1 and down-regulation of uPA is involved in the inhibitory effect of berberine on HCC cell invasion and migration.	Berberine	185-194	serpin family E member 1	Homo sapiens	112-117
27092498-9	2016	In conclusion, our findings identified for the first time that inactivation of uPA receptor by up-regulation of PAI-1 and down-regulation of uPA is involved in the inhibitory effect of berberine on HCC cell invasion and migration.	Berberine	185-194	plasminogen activator, urokinase	Homo sapiens	141-144
27011261-0	2016	Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4alpha miR122 Pathway.	Berberine	0-9	hepatocyte nuclear factor 4 alpha	Homo sapiens	184-194
27011261-0	2016	Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4alpha miR122 Pathway.	Berberine	0-9	microRNA 122	Homo sapiens	195-201
27011261-7	2016	Expression of HNF-4alpha in HepG2 cells increased expression of gluconeogenic and lipid metabolism enzymes and BBR treatment or knock down of miR122 attenuated the effect of HNF-4alpha expression.	Berberine	111-114	hepatocyte nuclear factor 4 alpha	Homo sapiens	14-24
26849937-9	2016	Berberine decreased the mRNA expression of neuritin, p38, and JNK and the protein expression of neuritin, p-p38, and p-JNK.	Berberine	0-9	neuritin 1	Rattus norvegicus	43-51
26849937-9	2016	Berberine decreased the mRNA expression of neuritin, p38, and JNK and the protein expression of neuritin, p-p38, and p-JNK.	Berberine	0-9	mitogen activated protein kinase 14	Rattus norvegicus	53-56
26849937-9	2016	Berberine decreased the mRNA expression of neuritin, p38, and JNK and the protein expression of neuritin, p-p38, and p-JNK.	Berberine	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	62-65
26849937-9	2016	Berberine decreased the mRNA expression of neuritin, p38, and JNK and the protein expression of neuritin, p-p38, and p-JNK.	Berberine	0-9	neuritin 1	Rattus norvegicus	96-104
26849937-9	2016	Berberine decreased the mRNA expression of neuritin, p38, and JNK and the protein expression of neuritin, p-p38, and p-JNK.	Berberine	0-9	mitogen activated protein kinase 14	Rattus norvegicus	108-111
26849937-9	2016	Berberine decreased the mRNA expression of neuritin, p38, and JNK and the protein expression of neuritin, p-p38, and p-JNK.	Berberine	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	119-122
26849937-11	2016	These findings suggest that berberine has a beneficial effect against diabetic neuropathy by improving micropathology and increasing neuritin expression via the mitogen-activated protein kinase signaling pathway.	Berberine	28-37	neuritin 1	Rattus norvegicus	133-141
26936230-4	2016	In C57BL/6J mice fed a high-fat diet (HFD), treatment with BBR decreased inflammation in both the liver and adipose tissue as indicated by reduction of the phosphorylation state of JNK1 and the mRNA levels of proinflammatory cytokines.	Berberine	59-62	WD and tetratricopeptide repeats 1	Mus musculus	108-115
26936230-4	2016	In C57BL/6J mice fed a high-fat diet (HFD), treatment with BBR decreased inflammation in both the liver and adipose tissue as indicated by reduction of the phosphorylation state of JNK1 and the mRNA levels of proinflammatory cytokines.	Berberine	59-62	mitogen-activated protein kinase 8	Mus musculus	181-185
26936230-5	2016	BBR treatment also decreased hepatic steatosis, as well as the expression of acetyl-CoA carboxylase and fatty acid synthase.	Berberine	0-3	fatty acid synthase	Mus musculus	104-123
26806299-0	2016	Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress.	Berberine	0-9	Janus kinase 2	Rattus norvegicus	77-81
26848864-6	2016	Cell cycle analysis further revealed that down-regulation of HNF4alpha and Exo70 was essential to berberine-stimulated G2/M cell cycle arrest in hepatoma cells.	Berberine	98-107	hepatocyte nuclear factor 4 alpha	Homo sapiens	61-70
26806299-0	2016	Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress.	Berberine	0-9	signal transducer and activator of transcription 3	Rattus norvegicus	82-87
26806299-10	2016	Furthermore, pretreatment with BBR suppressed MI/R-induced ER stress, evidenced by down-regulating the phosphorylation levels of myocardial PERK and eIF2alpha and the expression of ATF4 and CHOP in heart tissues.	Berberine	31-34	eukaryotic translation initiation factor 2A	Rattus norvegicus	149-158
26806299-10	2016	Furthermore, pretreatment with BBR suppressed MI/R-induced ER stress, evidenced by down-regulating the phosphorylation levels of myocardial PERK and eIF2alpha and the expression of ATF4 and CHOP in heart tissues.	Berberine	31-34	activating transcription factor 4	Rattus norvegicus	181-185
26806299-10	2016	Furthermore, pretreatment with BBR suppressed MI/R-induced ER stress, evidenced by down-regulating the phosphorylation levels of myocardial PERK and eIF2alpha and the expression of ATF4 and CHOP in heart tissues.	Berberine	31-34	DNA-damage inducible transcript 3	Rattus norvegicus	190-194
26806299-11	2016	Pretreatment with BBR also activated the JAK2/STAT3 signaling pathway in heart tissues, and co-treatment with AG490, a specific JAK2/STAT3 inhibitor, blocked not only the protective effects of BBR, but also the inhibition of BBR on MI/R-induced ER stress.	Berberine	18-21	Janus kinase 2	Rattus norvegicus	41-45
26806299-11	2016	Pretreatment with BBR also activated the JAK2/STAT3 signaling pathway in heart tissues, and co-treatment with AG490, a specific JAK2/STAT3 inhibitor, blocked not only the protective effects of BBR, but also the inhibition of BBR on MI/R-induced ER stress.	Berberine	18-21	signal transducer and activator of transcription 3	Rattus norvegicus	46-51
26806299-11	2016	Pretreatment with BBR also activated the JAK2/STAT3 signaling pathway in heart tissues, and co-treatment with AG490, a specific JAK2/STAT3 inhibitor, blocked not only the protective effects of BBR, but also the inhibition of BBR on MI/R-induced ER stress.	Berberine	18-21	Janus kinase 2	Rattus norvegicus	128-132
26806299-11	2016	Pretreatment with BBR also activated the JAK2/STAT3 signaling pathway in heart tissues, and co-treatment with AG490, a specific JAK2/STAT3 inhibitor, blocked not only the protective effects of BBR, but also the inhibition of BBR on MI/R-induced ER stress.	Berberine	18-21	signal transducer and activator of transcription 3	Rattus norvegicus	133-138
26806299-12	2016	In H9C2 cells, treatment with BBR (50 mumol/L) markedly reduced SIR-induced cell apoptosis, oxidative stress and ER stress, which were abolished by transfection with JAK2 siRNA.	Berberine	30-33	Janus kinase 2	Rattus norvegicus	166-170
26806299-13	2016	CONCLUSION: BBR ameliorates MI/R injury in rats by activating the AK2/STAT3 signaling pathway and attenuating ER stress-induced apoptosis.	Berberine	12-15	adenylate kinase 2	Rattus norvegicus	66-69
26806299-13	2016	CONCLUSION: BBR ameliorates MI/R injury in rats by activating the AK2/STAT3 signaling pathway and attenuating ER stress-induced apoptosis.	Berberine	12-15	signal transducer and activator of transcription 3	Rattus norvegicus	70-75
26998023-0	2016	Berberine attenuates myocardial ischemia reperfusion injury by suppressing the activation of PI3K/AKT signaling.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	98-101
28875685-8	2016	Network pharmacology analysis using ingenuity pathway analysis (IPA) software revealed that TCM-derived drugs interacting with AMPK target proteins included berberine, emodin, curcumin, resveratrol, alcohol, cordyceps, arctiin, suggesting in a certain extent the feasibility of "medicine -food homology" drugs to extend the lifespan through the AMPK pathway.	Berberine	157-166	AMP-activated protein kinase alpha subunit	Drosophila melanogaster	127-131
26848864-6	2016	Cell cycle analysis further revealed that down-regulation of HNF4alpha and Exo70 was essential to berberine-stimulated G2/M cell cycle arrest in hepatoma cells.	Berberine	98-107	exocyst complex component 7	Homo sapiens	75-80
26773864-0	2016	Berberine up-regulates the BDNF expression in hippocampus and attenuates corticosterone-induced depressive-like behavior in mice.	Berberine	0-9	brain derived neurotrophic factor	Mus musculus	27-31
26773864-6	2016	Our findings confirmed the antidepressant-like effect of berberine and suggested its mechanisms might be partially mediated by up-regulation of BDNF in hippocampus.	Berberine	57-66	brain derived neurotrophic factor	Mus musculus	144-148
26672764-5	2016	Further mechanism study showed that melatonin promoted the cleavage of caspse-9 and PARP, enhanced the inhibition of Bcl2, and triggered the releasing of cytochrome C (Cyto C), thereby increasing the berberine-induced apoptosis.	Berberine	200-209	cytochrome c, somatic	Homo sapiens	154-166
26838742-0	2016	Berberine relieves insulin resistance via the cholinergic anti-inflammatory pathway in HepG2 cells.	Berberine	0-9	insulin	Homo sapiens	19-26
26838742-6	2016	However, the treatment with BBR enhanced the glucose uptake, increased the expression of alpha7nAChR protein and inhibited AChE activity.	Berberine	28-31	acetylcholinesterase (Cartwright blood group)	Homo sapiens	123-127
26672764-0	2016	Melatonin inhibits AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.	Berberine	139-148	transcription factor AP-2 beta	Homo sapiens	19-27
26672764-5	2016	Further mechanism study showed that melatonin promoted the cleavage of caspse-9 and PARP, enhanced the inhibition of Bcl2, and triggered the releasing of cytochrome C (Cyto C), thereby increasing the berberine-induced apoptosis.	Berberine	200-209	cytochrome c, somatic	Homo sapiens	168-174
26672764-0	2016	Melatonin inhibits AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.	Berberine	139-148	telomerase reverse transcriptase	Homo sapiens	28-33
26672764-6	2016	Melatonin also enhanced the berberine-mediated inhibition of telomerase reverses transcriptase (hTERT) by down-regulating the expression of AP-2beta and its binding on hTERT promoter.	Berberine	28-37	telomerase reverse transcriptase	Homo sapiens	96-101
26672764-0	2016	Melatonin inhibits AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.	Berberine	139-148	nuclear factor kappa B subunit 1	Homo sapiens	35-44
26672764-0	2016	Melatonin inhibits AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.	Berberine	139-148	prostaglandin-endoperoxide synthase 2	Homo sapiens	45-50
26672764-6	2016	Melatonin also enhanced the berberine-mediated inhibition of telomerase reverses transcriptase (hTERT) by down-regulating the expression of AP-2beta and its binding on hTERT promoter.	Berberine	28-37	transcription factor AP-2 beta	Homo sapiens	140-148
26672764-0	2016	Melatonin inhibits AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.	Berberine	139-148	AKT serine/threonine kinase 1	Homo sapiens	55-58
26672764-0	2016	Melatonin inhibits AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.	Berberine	139-148	mitogen-activated protein kinase 1	Homo sapiens	59-62
26672764-6	2016	Melatonin also enhanced the berberine-mediated inhibition of telomerase reverses transcriptase (hTERT) by down-regulating the expression of AP-2beta and its binding on hTERT promoter.	Berberine	28-37	telomerase reverse transcriptase	Homo sapiens	168-173
26672764-0	2016	Melatonin inhibits AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.	Berberine	139-148	cytochrome c, somatic	Homo sapiens	85-91
26672764-7	2016	Moreover, melatonin enhanced the berberine-mediated inhibition of cyclooxygenase 2 (COX-2) by inhibiting the nuclear translocation of NF-kappaB and its binding on COX-2 promoter.	Berberine	33-42	prostaglandin-endoperoxide synthase 2	Homo sapiens	66-82
26672764-7	2016	Moreover, melatonin enhanced the berberine-mediated inhibition of cyclooxygenase 2 (COX-2) by inhibiting the nuclear translocation of NF-kappaB and its binding on COX-2 promoter.	Berberine	33-42	prostaglandin-endoperoxide synthase 2	Homo sapiens	84-89
26672764-7	2016	Moreover, melatonin enhanced the berberine-mediated inhibition of cyclooxygenase 2 (COX-2) by inhibiting the nuclear translocation of NF-kappaB and its binding on COX-2 promoter.	Berberine	33-42	nuclear factor kappa B subunit 1	Homo sapiens	134-143
26672764-7	2016	Moreover, melatonin enhanced the berberine-mediated inhibition of cyclooxygenase 2 (COX-2) by inhibiting the nuclear translocation of NF-kappaB and its binding on COX-2 promoter.	Berberine	33-42	prostaglandin-endoperoxide synthase 2	Homo sapiens	163-168
26672764-8	2016	Melatonin also increased the berberine-mediated inhibition of the phosphorylated Akt and ERK.	Berberine	29-38	AKT serine/threonine kinase 1	Homo sapiens	81-84
26672764-8	2016	Melatonin also increased the berberine-mediated inhibition of the phosphorylated Akt and ERK.	Berberine	29-38	mitogen-activated protein kinase 1	Homo sapiens	89-92
26672764-9	2016	Collectively, our results demonstrated that melatonin enhanced the antitumor activity of berberine by activating caspase/Cyto C and inhibiting AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK signaling pathways.	Berberine	89-98	cytochrome c, somatic	Homo sapiens	121-127
26672764-9	2016	Collectively, our results demonstrated that melatonin enhanced the antitumor activity of berberine by activating caspase/Cyto C and inhibiting AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK signaling pathways.	Berberine	89-98	transcription factor AP-2 beta	Homo sapiens	143-151
26672764-9	2016	Collectively, our results demonstrated that melatonin enhanced the antitumor activity of berberine by activating caspase/Cyto C and inhibiting AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK signaling pathways.	Berberine	89-98	telomerase reverse transcriptase	Homo sapiens	152-157
26672764-9	2016	Collectively, our results demonstrated that melatonin enhanced the antitumor activity of berberine by activating caspase/Cyto C and inhibiting AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK signaling pathways.	Berberine	89-98	nuclear factor kappa B subunit 1	Homo sapiens	159-168
26672764-9	2016	Collectively, our results demonstrated that melatonin enhanced the antitumor activity of berberine by activating caspase/Cyto C and inhibiting AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK signaling pathways.	Berberine	89-98	prostaglandin-endoperoxide synthase 2	Homo sapiens	169-174
26672764-9	2016	Collectively, our results demonstrated that melatonin enhanced the antitumor activity of berberine by activating caspase/Cyto C and inhibiting AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK signaling pathways.	Berberine	89-98	AKT serine/threonine kinase 1	Homo sapiens	179-182
26672764-9	2016	Collectively, our results demonstrated that melatonin enhanced the antitumor activity of berberine by activating caspase/Cyto C and inhibiting AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK signaling pathways.	Berberine	89-98	mitogen-activated protein kinase 1	Homo sapiens	183-186
27689075-11	2016	Meanwhile, there was significant reduction in the expressions of NLRP3 and IL-1beta mRNA in groups 6.25 muM berberine and 25 muM berberine when compared with model group (P &lt; 0.05).	Berberine	108-117	NLR family pyrin domain containing 3	Homo sapiens	65-70
26712469-0	2016	Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine-treated HepG2 cells.	Berberine	138-147	forkhead box O1	Homo sapiens	26-31
26712469-0	2016	Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine-treated HepG2 cells.	Berberine	138-147	tumor protein p53	Homo sapiens	39-42
26712469-2	2016	The current study aimed to decode the impact of acetylation/deacetylation of non-histone targets i.e. FoxO1/3a and p53 of sirtuins (NAD(+) dependent enzymes with lysine deacetylase activity) in berberine treated human hepatoma cells.	Berberine	194-203	forkhead box O1	Homo sapiens	102-107
26712469-2	2016	The current study aimed to decode the impact of acetylation/deacetylation of non-histone targets i.e. FoxO1/3a and p53 of sirtuins (NAD(+) dependent enzymes with lysine deacetylase activity) in berberine treated human hepatoma cells.	Berberine	194-203	tumor protein p53	Homo sapiens	115-118
26712469-4	2016	Combination of nicotinamide (sirtuin inhibitor) with berberine potentiated sirtuins inhibition and increased the expression of FoxO1/3a and phosphorylation of p53 tumor suppressor protein.	Berberine	53-62	forkhead box O1	Homo sapiens	127-132
26712469-4	2016	Combination of nicotinamide (sirtuin inhibitor) with berberine potentiated sirtuins inhibition and increased the expression of FoxO1/3a and phosphorylation of p53 tumor suppressor protein.	Berberine	53-62	tumor protein p53	Homo sapiens	159-162
26478571-0	2016	Berberine promotes bone marrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt/beta-catenin signaling pathway.	Berberine	0-9	catenin beta 1	Homo sapiens	107-119
26478571-10	2016	After treated with 10muM BBR for 7 days, beta-catenin, OPN and OCN expression were significantly induced, which could be effectively suppressed by the addition of DKK-1 or beta-catenin siRNA beta-catenin.	Berberine	25-28	catenin beta 1	Homo sapiens	41-53
26478571-10	2016	After treated with 10muM BBR for 7 days, beta-catenin, OPN and OCN expression were significantly induced, which could be effectively suppressed by the addition of DKK-1 or beta-catenin siRNA beta-catenin.	Berberine	25-28	secreted phosphoprotein 1	Homo sapiens	55-58
26478571-10	2016	After treated with 10muM BBR for 7 days, beta-catenin, OPN and OCN expression were significantly induced, which could be effectively suppressed by the addition of DKK-1 or beta-catenin siRNA beta-catenin.	Berberine	25-28	bone gamma-carboxyglutamate protein	Homo sapiens	63-66
26478571-10	2016	After treated with 10muM BBR for 7 days, beta-catenin, OPN and OCN expression were significantly induced, which could be effectively suppressed by the addition of DKK-1 or beta-catenin siRNA beta-catenin.	Berberine	25-28	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	163-168
26478571-10	2016	After treated with 10muM BBR for 7 days, beta-catenin, OPN and OCN expression were significantly induced, which could be effectively suppressed by the addition of DKK-1 or beta-catenin siRNA beta-catenin.	Berberine	25-28	catenin beta 1	Homo sapiens	172-184
26478571-10	2016	After treated with 10muM BBR for 7 days, beta-catenin, OPN and OCN expression were significantly induced, which could be effectively suppressed by the addition of DKK-1 or beta-catenin siRNA beta-catenin.	Berberine	25-28	catenin beta 1	Homo sapiens	172-184
26478571-12	2016	These findings suggest that BBR can stimulate osteogenic differentiation of MSCs not only by enhancing Runx2 expression but also by activating canonical Wnt/beta-catenin signaling pathway, and canonical Wnt/beta-catenin signaling pathway is in part responsible for BBR-induced osteogenic differentiation of MSCs in vitro.	Berberine	28-31	RUNX family transcription factor 2	Homo sapiens	103-108
26478571-12	2016	These findings suggest that BBR can stimulate osteogenic differentiation of MSCs not only by enhancing Runx2 expression but also by activating canonical Wnt/beta-catenin signaling pathway, and canonical Wnt/beta-catenin signaling pathway is in part responsible for BBR-induced osteogenic differentiation of MSCs in vitro.	Berberine	28-31	catenin beta 1	Homo sapiens	157-169
26478571-12	2016	These findings suggest that BBR can stimulate osteogenic differentiation of MSCs not only by enhancing Runx2 expression but also by activating canonical Wnt/beta-catenin signaling pathway, and canonical Wnt/beta-catenin signaling pathway is in part responsible for BBR-induced osteogenic differentiation of MSCs in vitro.	Berberine	28-31	catenin beta 1	Homo sapiens	207-219
27430910-1	2016	Berberine exerts neuroprotective and modulates hypoxia inducible factor-1-alpha (HIF-1[Formula: see text].	Berberine	0-9	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	47-79
26712469-5	2016	As sirtuins deacetylate non-histone targets including FoxO1/3a and p53, berberine increased the acetylation load of FoxO1/3a and p53 proteins.	Berberine	72-81	forkhead box O1	Homo sapiens	54-59
26712469-5	2016	As sirtuins deacetylate non-histone targets including FoxO1/3a and p53, berberine increased the acetylation load of FoxO1/3a and p53 proteins.	Berberine	72-81	tumor protein p53	Homo sapiens	67-70
26712469-5	2016	As sirtuins deacetylate non-histone targets including FoxO1/3a and p53, berberine increased the acetylation load of FoxO1/3a and p53 proteins.	Berberine	72-81	forkhead box O1	Homo sapiens	116-121
26712469-5	2016	As sirtuins deacetylate non-histone targets including FoxO1/3a and p53, berberine increased the acetylation load of FoxO1/3a and p53 proteins.	Berberine	72-81	tumor protein p53	Homo sapiens	129-132
26712469-11	2016	Thus, our findings suggest that berberine mediated sirtuins inhibition resulting into FoxO1/3a and p53 acetylation followed by BH3-only protein Bim/PUMA activation may in part be responsible for mitochondria-mediated apoptosis.	Berberine	32-41	forkhead box O1	Homo sapiens	86-91
26712469-11	2016	Thus, our findings suggest that berberine mediated sirtuins inhibition resulting into FoxO1/3a and p53 acetylation followed by BH3-only protein Bim/PUMA activation may in part be responsible for mitochondria-mediated apoptosis.	Berberine	32-41	tumor protein p53	Homo sapiens	99-102
27689075-11	2016	Meanwhile, there was significant reduction in the expressions of NLRP3 and IL-1beta mRNA in groups 6.25 muM berberine and 25 muM berberine when compared with model group (P &lt; 0.05).	Berberine	108-117	interleukin 1 beta	Homo sapiens	75-83
27689075-11	2016	Meanwhile, there was significant reduction in the expressions of NLRP3 and IL-1beta mRNA in groups 6.25 muM berberine and 25 muM berberine when compared with model group (P &lt; 0.05).	Berberine	108-117	latexin	Homo sapiens	104-107
27689075-11	2016	Meanwhile, there was significant reduction in the expressions of NLRP3 and IL-1beta mRNA in groups 6.25 muM berberine and 25 muM berberine when compared with model group (P &lt; 0.05).	Berberine	129-138	NLR family pyrin domain containing 3	Homo sapiens	65-70
27689075-11	2016	Meanwhile, there was significant reduction in the expressions of NLRP3 and IL-1beta mRNA in groups 6.25 muM berberine and 25 muM berberine when compared with model group (P &lt; 0.05).	Berberine	129-138	interleukin 1 beta	Homo sapiens	75-83
27689075-11	2016	Meanwhile, there was significant reduction in the expressions of NLRP3 and IL-1beta mRNA in groups 6.25 muM berberine and 25 muM berberine when compared with model group (P &lt; 0.05).	Berberine	129-138	latexin	Homo sapiens	125-128
27689075-13	2016	Therefore, berberine alleviates monosodium urate crystals-induced inflammation by downregulating NLRP3 and IL-1beta expressions.	Berberine	11-20	NLR family pyrin domain containing 3	Homo sapiens	97-102
27689075-13	2016	Therefore, berberine alleviates monosodium urate crystals-induced inflammation by downregulating NLRP3 and IL-1beta expressions.	Berberine	11-20	interleukin 1 beta	Homo sapiens	107-115
27689075-14	2016	The regulatory effects of berberine may be related to the inactivation of NLRP3 inflammasome.	Berberine	26-35	NLR family pyrin domain containing 3	Homo sapiens	74-79
27642351-0	2016	In Vivo Interrelationship between Insulin Resistance and Interferon Gamma Production: Protective and Therapeutic Effect of Berberine.	Berberine	123-132	interferon gamma	Rattus norvegicus	57-73
27446224-8	2016	The subgroup analyses on TG, AST, and FBG indicated that treatment combined with berberine decreased TG level in NAFLD patients significantly.	Berberine	81-90	solute carrier family 17 member 5	Homo sapiens	29-32
27446224-10	2016	We also conducted a descriptive analysis on insulin resistance and radiography results that berberine can improve NAFLD patients" insulin resistance and fatty liver.	Berberine	92-101	insulin	Homo sapiens	44-51
27446224-10	2016	We also conducted a descriptive analysis on insulin resistance and radiography results that berberine can improve NAFLD patients" insulin resistance and fatty liver.	Berberine	92-101	insulin	Homo sapiens	130-137
27446224-12	2016	According to analysis result, berberine has positive efficacy on blood lipids, blood glucose, liver function, insulin resistance, and fatty liver condition of NAFLD patients.	Berberine	30-39	insulin	Homo sapiens	110-117
27239214-9	2016	High doses of BBR induced apoptosis of activated HSC, which was mediated by loss of mitochondrial membrane potential and Bcl-2/Bax imbalance.	Berberine	14-17	BCL2, apoptosis regulator	Rattus norvegicus	121-126
27239214-9	2016	High doses of BBR induced apoptosis of activated HSC, which was mediated by loss of mitochondrial membrane potential and Bcl-2/Bax imbalance.	Berberine	14-17	BCL2 associated X, apoptosis regulator	Rattus norvegicus	127-130
27239214-10	2016	Low doses of BBR suppressed activation of HSC as evidenced by the inhibition of alpha-smooth muscle actin (alpha-SMA) expression and cell motility.	Berberine	13-16	actin gamma 2, smooth muscle	Rattus norvegicus	80-105
27239214-10	2016	Low doses of BBR suppressed activation of HSC as evidenced by the inhibition of alpha-smooth muscle actin (alpha-SMA) expression and cell motility.	Berberine	13-16	actin gamma 2, smooth muscle	Rattus norvegicus	107-116
27642351-10	2016	Treatment and protection with berberine 50 mg/kg/day for 2 weeks were found to be effective against the features of insulin resistance syndrome, improved levels of insulin resistance parameters, lipid profile, antioxidant enzymes, proinflammatory cytokines, and IFN-gamma.	Berberine	30-39	interferon gamma	Rattus norvegicus	262-271
26788242-0	2016	Berberine Attenuates Myocardial Ischemia/Reperfusion Injury by Reducing Oxidative Stress and Inflammation Response: Role of Silent Information Regulator 1.	Berberine	0-9	sirtuin 1	Rattus norvegicus	124-154
26889237-0	2016	Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-gamma and insulin receptor in a rat model of nonalcoholic fatty liver disease.	Berberine	51-60	insulin receptor	Rattus norvegicus	124-140
26889237-6	2016	In conclusion, a combination of puerarin, baicalin and berberine induced favorable effects on NAFLD by upregulating hepatic PPAR-gamma and IR expression levels, and different proportions of monomer compositions exerted variable positive effects on various stages of NAFLD.	Berberine	55-64	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	124-134
26889237-6	2016	In conclusion, a combination of puerarin, baicalin and berberine induced favorable effects on NAFLD by upregulating hepatic PPAR-gamma and IR expression levels, and different proportions of monomer compositions exerted variable positive effects on various stages of NAFLD.	Berberine	55-64	insulin receptor	Rattus norvegicus	139-141
27478481-0	2016	Berberine Protects Human Umbilical Vein Endothelial Cells against LPS-Induced Apoptosis by Blocking JNK-Mediated Signaling.	Berberine	0-9	mitogen-activated protein kinase 8	Homo sapiens	100-103
27478481-7	2016	The results demonstrated that berberine pretreatment protected HUVECs from LPS-induced apoptosis, attenuated LPS-induced injury, inhibited LPS-induced JNK phosphorylation, increased MCL-1 expression and SOD activity, and decreased proinflammatory cytokine production.	Berberine	30-39	mitogen-activated protein kinase 8	Homo sapiens	151-154
27478481-7	2016	The results demonstrated that berberine pretreatment protected HUVECs from LPS-induced apoptosis, attenuated LPS-induced injury, inhibited LPS-induced JNK phosphorylation, increased MCL-1 expression and SOD activity, and decreased proinflammatory cytokine production.	Berberine	30-39	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	182-187
27478481-8	2016	The effects of berberine on LPS-treated HUVECs were prevented by SP600125, a JNK-specific inhibitor.	Berberine	15-24	mitogen-activated protein kinase 8	Homo sapiens	77-80
27493671-0	2016	Berberine Inhibits Intestinal Polyps Growth in Apc (min/+) Mice via Regulation of Macrophage Polarization.	Berberine	0-9	APC, WNT signaling pathway regulator	Mus musculus	47-50
27493671-2	2016	The aim of this study was to investigate the hypothesis that berberine suppresses tumorigenesis in the familial adenomatous polyposis (FAP) by regulating the macrophage polarization in Apc (min/+) mouse model.	Berberine	61-70	APC, WNT signaling pathway regulator	Mus musculus	185-188
27493671-3	2016	Berberine was given to Apc (min/+) mice for 12 weeks.	Berberine	0-9	APC, WNT signaling pathway regulator	Mus musculus	23-26
27493671-6	2016	A significant decrease in protein levels of F4/80, mannose receptor (MR), and COX-2 in stroma of intestinal polyps and an increase in the level of iNOS were observed after berberine treatment.	Berberine	172-181	adhesion G protein-coupled receptor E1	Mus musculus	44-67
27493671-6	2016	A significant decrease in protein levels of F4/80, mannose receptor (MR), and COX-2 in stroma of intestinal polyps and an increase in the level of iNOS were observed after berberine treatment.	Berberine	172-181	cytochrome c oxidase II, mitochondrial	Mus musculus	78-83
27493671-6	2016	A significant decrease in protein levels of F4/80, mannose receptor (MR), and COX-2 in stroma of intestinal polyps and an increase in the level of iNOS were observed after berberine treatment.	Berberine	172-181	nitric oxide synthase 2, inducible	Mus musculus	147-151
27493671-7	2016	The mRNA level of MR and Arg-1 in berberine group was significantly lower than those in IL-10 or IL-4 group, while no significant difference in mRNA levels of iNOS and CXCL10 was observed.	Berberine	34-43	arginase, liver	Mus musculus	25-30
26788242-5	2016	BBR conferred cardioprotective effects by improving postischemic cardiac function, decreasing infarct size, reducing apoptotic index, diminishing serum creatine kinase and lactate dehydrogenase levels, upregulating SIRT1, Bcl-2 expressions, and downregulating Bax and caspase-3 expressions.	Berberine	0-3	sirtuin 1	Rattus norvegicus	215-220
26788242-5	2016	BBR conferred cardioprotective effects by improving postischemic cardiac function, decreasing infarct size, reducing apoptotic index, diminishing serum creatine kinase and lactate dehydrogenase levels, upregulating SIRT1, Bcl-2 expressions, and downregulating Bax and caspase-3 expressions.	Berberine	0-3	BCL2, apoptosis regulator	Rattus norvegicus	222-227
26788242-5	2016	BBR conferred cardioprotective effects by improving postischemic cardiac function, decreasing infarct size, reducing apoptotic index, diminishing serum creatine kinase and lactate dehydrogenase levels, upregulating SIRT1, Bcl-2 expressions, and downregulating Bax and caspase-3 expressions.	Berberine	0-3	BCL2 associated X, apoptosis regulator	Rattus norvegicus	260-263
26788242-5	2016	BBR conferred cardioprotective effects by improving postischemic cardiac function, decreasing infarct size, reducing apoptotic index, diminishing serum creatine kinase and lactate dehydrogenase levels, upregulating SIRT1, Bcl-2 expressions, and downregulating Bax and caspase-3 expressions.	Berberine	0-3	caspase 3	Rattus norvegicus	268-277
26700862-7	2015	In physiological conditions the effects of berberine were mediated by mu- (MOR) and delta- (DOR) opioid receptors; hypermotility, excessive secretion and nociception were reversed by berberine through MOR and DOR-dependent action.	Berberine	43-52	opioid receptor, mu 1	Mus musculus	70-113
26446867-0	2016	Possible role of P-glycoprotein in the neuroprotective mechanism of berberine in intracerebroventricular streptozotocin-induced cognitive dysfunction.	Berberine	68-77	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	17-31
26446867-2	2016	However, the neurological mechanism of berberine remains untapped in the light of its P-glycoprotein (P-gp)-mediated gut efflux properties responsible for reduced bioavailability.	Berberine	39-48	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	86-100
26446867-2	2016	However, the neurological mechanism of berberine remains untapped in the light of its P-glycoprotein (P-gp)-mediated gut efflux properties responsible for reduced bioavailability.	Berberine	39-48	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	102-106
26446867-10	2016	CONCLUSION: The augmentative outcome of verapamil on the neuroprotective effect of berberine can be speculated due to the inhibition of P-gp efflux mechanism and the prevention of calcium homeostasis alteration.	Berberine	83-92	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	136-140
28861978-6	2016	According to the in vitro mice study, berberine, coptisine, jatrorrhizine and palmatine significantly inhibited mice liver microsome UGTs activity, and the six alkaloids all significantly activated UGT1A1.	Berberine	38-47	UDP glucuronosyltransferase 1 family, polypeptide A1	Mus musculus	198-204
26700862-7	2015	In physiological conditions the effects of berberine were mediated by mu- (MOR) and delta- (DOR) opioid receptors; hypermotility, excessive secretion and nociception were reversed by berberine through MOR and DOR-dependent action.	Berberine	43-52	opioid receptor, mu 1	Mus musculus	75-78
26700862-7	2015	In physiological conditions the effects of berberine were mediated by mu- (MOR) and delta- (DOR) opioid receptors; hypermotility, excessive secretion and nociception were reversed by berberine through MOR and DOR-dependent action.	Berberine	43-52	opioid receptor, delta 1	Mus musculus	92-95
26700862-8	2015	We also found that berberine increased the expression of MOR and DOR in the mouse bowel and rat fetal cortical neurons.	Berberine	19-28	opioid receptor, mu 1	Mus musculus	57-60
26700862-8	2015	We also found that berberine increased the expression of MOR and DOR in the mouse bowel and rat fetal cortical neurons.	Berberine	19-28	opioid receptor, delta 1	Mus musculus	65-68
26645811-8	2015	Sex hormone binding globulin, insulin resistance, total cholesterol, total triglyceride and low-density lipoprotein cholesterol decreased after berberine treatment in the normal weight group only.	Berberine	144-153	sex hormone binding globulin	Homo sapiens	0-28
26522928-5	2015	In addition, berberine treatment of diabetic animals increased cardiac 5"-adenosine monophosphate-activated protein kinase (AMPK) and protein kinase B (AKT) activation and reduced glycogen synthase kinase 3 beta (GSK3beta) activation compared to control.	Berberine	13-22	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	124-128
26522928-5	2015	In addition, berberine treatment of diabetic animals increased cardiac 5"-adenosine monophosphate-activated protein kinase (AMPK) and protein kinase B (AKT) activation and reduced glycogen synthase kinase 3 beta (GSK3beta) activation compared to control.	Berberine	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	152-155
26522928-5	2015	In addition, berberine treatment of diabetic animals increased cardiac 5"-adenosine monophosphate-activated protein kinase (AMPK) and protein kinase B (AKT) activation and reduced glycogen synthase kinase 3 beta (GSK3beta) activation compared to control.	Berberine	13-22	glycogen synthase kinase 3 beta	Rattus norvegicus	180-211
26522928-5	2015	In addition, berberine treatment of diabetic animals increased cardiac 5"-adenosine monophosphate-activated protein kinase (AMPK) and protein kinase B (AKT) activation and reduced glycogen synthase kinase 3 beta (GSK3beta) activation compared to control.	Berberine	13-22	glycogen synthase kinase 3 beta	Rattus norvegicus	213-221
26522928-7	2015	Berberine treatment of palmitate-incubated H9c2 cells reduced hypertrophy, increased alpha-MHC expression and decreased beta-MHC expression.	Berberine	0-9	myosin heavy chain 7	Rattus norvegicus	120-128
26522928-8	2015	In addition, berberine treatment of palmitate-incubated H9c2 cells increased AMPK and AKT activation and reduced GSK3beta activation.	Berberine	13-22	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	77-81
26522928-8	2015	In addition, berberine treatment of palmitate-incubated H9c2 cells increased AMPK and AKT activation and reduced GSK3beta activation.	Berberine	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	86-89
26522928-8	2015	In addition, berberine treatment of palmitate-incubated H9c2 cells increased AMPK and AKT activation and reduced GSK3beta activation.	Berberine	13-22	glycogen synthase kinase 3 beta	Rattus norvegicus	113-121
26522928-9	2015	The presence of the AMPK inhibitor Compound C attenuated the effects of berberine.	Berberine	72-81	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	20-24
26645811-8	2015	Sex hormone binding globulin, insulin resistance, total cholesterol, total triglyceride and low-density lipoprotein cholesterol decreased after berberine treatment in the normal weight group only.	Berberine	144-153	insulin	Homo sapiens	30-37
26645811-10	2015	Berberine can also decrease sex hormone binding globulin, insulin resistance, total cholesterol, triglycerides and low-density lipoprotein cholesterol in normal weight polycystic ovary syndrome women.	Berberine	0-9	sex hormone binding globulin	Homo sapiens	28-56
26645811-10	2015	Berberine can also decrease sex hormone binding globulin, insulin resistance, total cholesterol, triglycerides and low-density lipoprotein cholesterol in normal weight polycystic ovary syndrome women.	Berberine	0-9	insulin	Homo sapiens	58-65
26483344-6	2015	Pharmacological upregulation of Fbxo32 by Berberine ameliorated hypertrophic remodeling and improved cardiac performance in cardiac-deficient Pak1 mice under pressure overload.	Berberine	42-51	F-box protein 32	Mus musculus	32-38
26642326-9	2015	Moreover, the addition of berberine to 5-ASA more significantly inhibited lymphocyte TNF-alpha secretion of DSS mice than 5-ASA alone.	Berberine	26-35	tumor necrosis factor	Mus musculus	85-94
26483344-6	2015	Pharmacological upregulation of Fbxo32 by Berberine ameliorated hypertrophic remodeling and improved cardiac performance in cardiac-deficient Pak1 mice under pressure overload.	Berberine	42-51	p21 (RAC1) activated kinase 1	Mus musculus	142-146
26503508-7	2015	The pan-caspase inhibitor Z-VAD-fmk suppressed the activation of caspase-3 and prevented cytotoxicity in FaDu cells treated with berberine.	Berberine	129-138	caspase 3	Homo sapiens	65-74
26503508-8	2015	Interestingly, berberine suppressed cell migration through downregulation of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2, and MMP-9.	Berberine	15-24	vascular endothelial growth factor A	Homo sapiens	77-111
26503508-4	2015	Berberine also induced the upregulation of apoptotic ligands, such as FasL and TNF-related apoptosis-inducing ligand, and triggered the activation of caspase-8, -7 and -3, and poly(ADP ribose) polymerase, characteristic of death receptor-dependent extrinsic apoptosis.	Berberine	0-9	Fas ligand	Homo sapiens	70-74
26503508-8	2015	Interestingly, berberine suppressed cell migration through downregulation of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2, and MMP-9.	Berberine	15-24	vascular endothelial growth factor A	Homo sapiens	113-117
26503508-4	2015	Berberine also induced the upregulation of apoptotic ligands, such as FasL and TNF-related apoptosis-inducing ligand, and triggered the activation of caspase-8, -7 and -3, and poly(ADP ribose) polymerase, characteristic of death receptor-dependent extrinsic apoptosis.	Berberine	0-9	caspase 8	Homo sapiens	150-170
26503508-5	2015	Moreover, berberine activated the mitochondria-dependent apoptotic signaling pathway by upregulating pro-apoptotic factors, such as Bax, Bad, Apaf-1, and the active form of caspase-9, and downregulating anti-apoptotic factors, such as Bcl-2 and Bcl-xL.	Berberine	10-19	BCL2 associated X, apoptosis regulator	Homo sapiens	132-135
26503508-8	2015	Interestingly, berberine suppressed cell migration through downregulation of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2, and MMP-9.	Berberine	15-24	matrix metallopeptidase 2	Homo sapiens	120-152
26503508-8	2015	Interestingly, berberine suppressed cell migration through downregulation of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2, and MMP-9.	Berberine	15-24	matrix metallopeptidase 9	Homo sapiens	158-163
26503508-5	2015	Moreover, berberine activated the mitochondria-dependent apoptotic signaling pathway by upregulating pro-apoptotic factors, such as Bax, Bad, Apaf-1, and the active form of caspase-9, and downregulating anti-apoptotic factors, such as Bcl-2 and Bcl-xL.	Berberine	10-19	apoptotic peptidase activating factor 1	Homo sapiens	142-148
26503508-5	2015	Moreover, berberine activated the mitochondria-dependent apoptotic signaling pathway by upregulating pro-apoptotic factors, such as Bax, Bad, Apaf-1, and the active form of caspase-9, and downregulating anti-apoptotic factors, such as Bcl-2 and Bcl-xL.	Berberine	10-19	caspase 9	Homo sapiens	173-182
26503508-9	2015	Moreover, the phosphorylation of extracellular signal-regulated kinase (ERK1/2) and p38, components of the mitogen-activated protein kinase pathway that are associated with the expression of MMP and VEGF, was suppressed in FaDu cells treated with berberine for 24 h. Therefore, these data suggested that berberine exerted anticancer effects in FaDu cells through induction of apoptosis and suppression of migration.	Berberine	247-256	mitogen-activated protein kinase 3	Homo sapiens	72-78
26503508-5	2015	Moreover, berberine activated the mitochondria-dependent apoptotic signaling pathway by upregulating pro-apoptotic factors, such as Bax, Bad, Apaf-1, and the active form of caspase-9, and downregulating anti-apoptotic factors, such as Bcl-2 and Bcl-xL.	Berberine	10-19	BCL2 apoptosis regulator	Homo sapiens	235-240
26503508-9	2015	Moreover, the phosphorylation of extracellular signal-regulated kinase (ERK1/2) and p38, components of the mitogen-activated protein kinase pathway that are associated with the expression of MMP and VEGF, was suppressed in FaDu cells treated with berberine for 24 h. Therefore, these data suggested that berberine exerted anticancer effects in FaDu cells through induction of apoptosis and suppression of migration.	Berberine	247-256	mitogen-activated protein kinase 1	Homo sapiens	84-87
26503508-5	2015	Moreover, berberine activated the mitochondria-dependent apoptotic signaling pathway by upregulating pro-apoptotic factors, such as Bax, Bad, Apaf-1, and the active form of caspase-9, and downregulating anti-apoptotic factors, such as Bcl-2 and Bcl-xL.	Berberine	10-19	BCL2 like 1	Homo sapiens	245-251
26503508-9	2015	Moreover, the phosphorylation of extracellular signal-regulated kinase (ERK1/2) and p38, components of the mitogen-activated protein kinase pathway that are associated with the expression of MMP and VEGF, was suppressed in FaDu cells treated with berberine for 24 h. Therefore, these data suggested that berberine exerted anticancer effects in FaDu cells through induction of apoptosis and suppression of migration.	Berberine	304-313	mitogen-activated protein kinase 3	Homo sapiens	72-78
26503508-6	2015	In addition, berberine increased the expression of the tumor suppressor p53 in FaDu cells.	Berberine	13-22	tumor protein p53	Homo sapiens	72-75
26503508-9	2015	Moreover, the phosphorylation of extracellular signal-regulated kinase (ERK1/2) and p38, components of the mitogen-activated protein kinase pathway that are associated with the expression of MMP and VEGF, was suppressed in FaDu cells treated with berberine for 24 h. Therefore, these data suggested that berberine exerted anticancer effects in FaDu cells through induction of apoptosis and suppression of migration.	Berberine	304-313	mitogen-activated protein kinase 1	Homo sapiens	84-87
26867315-0	2015	[Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance].	Berberine	11-20	toll-like receptor 4	Rattus norvegicus	51-55
27141680-7	2015	Berberine, coptisine and palmatine had up-regulation effects on respiratory burst activity of mouse peritoneal macrophages stimulated by PMA and regulatory activity on the mRNA expression of PKC, p40phox or p47phox, whereas the epiberberine had no significant influence on respiratory burst.	Berberine	0-9	neutrophil cytosolic factor 4	Mus musculus	196-203
27141680-7	2015	Berberine, coptisine and palmatine had up-regulation effects on respiratory burst activity of mouse peritoneal macrophages stimulated by PMA and regulatory activity on the mRNA expression of PKC, p40phox or p47phox, whereas the epiberberine had no significant influence on respiratory burst.	Berberine	0-9	neutrophil cytosolic factor 1	Mus musculus	207-214
26344001-0	2015	Berberine attenuates CCN2-induced IL-1beta expression and prevents cartilage degradation in a rat model of osteoarthritis.	Berberine	0-9	interleukin 1 beta	Rattus norvegicus	34-42
26344001-5	2015	This IL-1beta expression in OASFs is attenuated by N-acetylcysteine (NAC), inhibitors of ASK1, p38, or JNK, or treatment with berberine.	Berberine	126-135	interleukin 1 beta	Rattus norvegicus	5-13
26823767-0	2015	Protective effects of berberine on high fat-induced kidney damage by increasing serum adiponectin and promoting insulin sensitivity.	Berberine	22-31	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	86-97
26177349-0	2015	Berberine via suppression of transient receptor potential vanilloid 4 channel improves vascular stiffness in mice.	Berberine	0-9	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	29-69
26177349-5	2015	Overexpression of transient receptor potential vanilloid 4 (TRPV4) channel by genetic approaches abolished the berberine-induced reduction in intracellular Ca(2+) concentration in VSMCs and attenuated berberine-elicited vessel dilation in mice aortas.	Berberine	111-120	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	18-58
26177349-5	2015	Overexpression of transient receptor potential vanilloid 4 (TRPV4) channel by genetic approaches abolished the berberine-induced reduction in intracellular Ca(2+) concentration in VSMCs and attenuated berberine-elicited vessel dilation in mice aortas.	Berberine	111-120	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	60-65
26177349-5	2015	Overexpression of transient receptor potential vanilloid 4 (TRPV4) channel by genetic approaches abolished the berberine-induced reduction in intracellular Ca(2+) concentration in VSMCs and attenuated berberine-elicited vessel dilation in mice aortas.	Berberine	201-210	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	18-58
26177349-5	2015	Overexpression of transient receptor potential vanilloid 4 (TRPV4) channel by genetic approaches abolished the berberine-induced reduction in intracellular Ca(2+) concentration in VSMCs and attenuated berberine-elicited vessel dilation in mice aortas.	Berberine	201-210	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	60-65
26177349-6	2015	In deoxycorticosterone acetate (DOCA)-induced hypertensive model, treatment of mice with berberine or RN-1734, a pharmacological inhibitor of TRPV4, significantly decreased systemic blood pressure (BP) in control mice or mice infected with an adenovirus vector.	Berberine	89-98	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	142-147
26177349-7	2015	However, berberine-induced effects of lowering BP were reversed by overexpressing TRPV4 in mice by infecting with adenovirus.	Berberine	9-18	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	82-87
26177349-8	2015	Furthermore, long-term administration of berberine decreased mean BP and pulse BP, increased artery response to vasodilator and reduced vascular collagen content in aged mice deficient in apolipoprotein E (Apoe-KO), but not in Apoe-KO old mice with lentivirus-mediated overexpression of TRPV4 channel.	Berberine	41-50	apolipoprotein E	Mus musculus	188-204
26177349-8	2015	Furthermore, long-term administration of berberine decreased mean BP and pulse BP, increased artery response to vasodilator and reduced vascular collagen content in aged mice deficient in apolipoprotein E (Apoe-KO), but not in Apoe-KO old mice with lentivirus-mediated overexpression of TRPV4 channel.	Berberine	41-50	apolipoprotein E	Mus musculus	206-210
26177349-8	2015	Furthermore, long-term administration of berberine decreased mean BP and pulse BP, increased artery response to vasodilator and reduced vascular collagen content in aged mice deficient in apolipoprotein E (Apoe-KO), but not in Apoe-KO old mice with lentivirus-mediated overexpression of TRPV4 channel.	Berberine	41-50	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	287-292
26177349-9	2015	In conclusion, berberine induces direct vasorelaxation to lower BP and reduces vascular stiffness in aged mice through suppression of TRPV4.	Berberine	15-24	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	134-139
26867315-14	2015	Berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF- kappaB inflammation signaling pathway and improve insulin resistance of skeletal muscle in obese rats.	Berberine	0-9	toll-like receptor 4	Rattus norvegicus	72-76
26867315-14	2015	Berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF- kappaB inflammation signaling pathway and improve insulin resistance of skeletal muscle in obese rats.	Berberine	0-9	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	77-84
26867315-15	2015	CONCLUSION: Our study revealed that berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF-kappaB inflammation signaling pathway in skeletal muscle and berberine can improve insulin resistance of skeletal muscle through inhibiting the active of the TLR4/IKKbeta/NF-kappaB signaling pathway.	Berberine	36-45	toll-like receptor 4	Rattus norvegicus	108-112
26867315-15	2015	CONCLUSION: Our study revealed that berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF-kappaB inflammation signaling pathway in skeletal muscle and berberine can improve insulin resistance of skeletal muscle through inhibiting the active of the TLR4/IKKbeta/NF-kappaB signaling pathway.	Berberine	36-45	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	113-120
26867315-15	2015	CONCLUSION: Our study revealed that berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF-kappaB inflammation signaling pathway in skeletal muscle and berberine can improve insulin resistance of skeletal muscle through inhibiting the active of the TLR4/IKKbeta/NF-kappaB signaling pathway.	Berberine	36-45	toll-like receptor 4	Rattus norvegicus	282-286
26867315-15	2015	CONCLUSION: Our study revealed that berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF-kappaB inflammation signaling pathway in skeletal muscle and berberine can improve insulin resistance of skeletal muscle through inhibiting the active of the TLR4/IKKbeta/NF-kappaB signaling pathway.	Berberine	36-45	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	287-294
26867315-15	2015	CONCLUSION: Our study revealed that berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF-kappaB inflammation signaling pathway in skeletal muscle and berberine can improve insulin resistance of skeletal muscle through inhibiting the active of the TLR4/IKKbeta/NF-kappaB signaling pathway.	Berberine	185-194	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	113-120
26867315-15	2015	CONCLUSION: Our study revealed that berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF-kappaB inflammation signaling pathway in skeletal muscle and berberine can improve insulin resistance of skeletal muscle through inhibiting the active of the TLR4/IKKbeta/NF-kappaB signaling pathway.	Berberine	185-194	toll-like receptor 4	Rattus norvegicus	282-286
26867315-15	2015	CONCLUSION: Our study revealed that berberine could reduce the level of ET of obese rats, down-regulate the TLR4/IKKbeta/NF-kappaB inflammation signaling pathway in skeletal muscle and berberine can improve insulin resistance of skeletal muscle through inhibiting the active of the TLR4/IKKbeta/NF-kappaB signaling pathway.	Berberine	185-194	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	287-294
26192633-0	2015	Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats.	Berberine	26-35	matrix metallopeptidase 2	Rattus norvegicus	62-66
26543354-0	2015	Mechanism and pharmacological rescue of berberine-induced hERG channel deficiency.	Berberine	40-49	ETS transcription factor ERG	Homo sapiens	58-62
26543354-10	2015	Considering both our previous and present work, we propose that BBR reduces hERG membrane stability with multiple mechanisms.	Berberine	64-67	ETS transcription factor ERG	Homo sapiens	76-80
26192633-2	2015	Hence, we aimed to explore the renoprotective mechanism of berberine on the accumulation of extracellular matrix, alterations of its major components and corresponding changes in the regulatory system, including the matrix metalloproteinases/tissue inhibitor of matrix metalloproteinases (MMPs/TIMPs) system, in diabetic nephropathy rats.	Berberine	59-68	matrix metallopeptidase 2	Rattus norvegicus	289-293
26192633-9	2015	Berberine (100 and 200 mg/kg) could significantly improve the abnormal changes in the MMPs/TIMPs system.	Berberine	0-9	matrix metallopeptidase 2	Rattus norvegicus	86-90
26192633-10	2015	Meanwhile, reductions in the transforming growth factor-beta1, fibronectin and type IV collagen expression levels were observed in the berberine treatment groups.	Berberine	135-144	transforming growth factor, beta 1	Rattus norvegicus	29-61
26192633-10	2015	Meanwhile, reductions in the transforming growth factor-beta1, fibronectin and type IV collagen expression levels were observed in the berberine treatment groups.	Berberine	135-144	fibronectin 1	Rattus norvegicus	63-74
26192633-11	2015	Therefore, the renoprotective effects of berberine on diabetic nephropathy might be associated with changes in the extracellular matrix through the regulation of the MMPs/TIMPs system in the rat kidney.	Berberine	41-50	matrix metallopeptidase 2	Rattus norvegicus	166-170
24838344-4	2015	Berberine also decreased AOM/DSS induced Ki-67 and COX-2 expression.	Berberine	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	51-56
25716428-7	2015	Compared with normal group, T1/2 and AUC(0-t) of berberine in the model group were significantly increased, respectively (573.21 +- 127.53 vs 948.22 +- 388.57 min; 8,657.19 +- 1,562.54 vs 11,415.12 +- 1,670.72 min.ng/ml).	Berberine	49-58	brachyury 2	Rattus norvegicus	28-40
25716428-11	2015	Especially, improved exposure to berberine in rat plasma in CVH-IBS model rats was attributed to increased the expression of MLCK.	Berberine	33-42	myosin light chain kinase	Rattus norvegicus	125-129
26168818-0	2015	Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma.	Berberine	43-52	erb-b2 receptor tyrosine kinase 2	Mus musculus	112-116
26168818-0	2015	Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma.	Berberine	43-52	erb-b2 receptor tyrosine kinase 2	Mus musculus	117-120
26722438-0	2015	Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	109-113
26722438-0	2015	Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway.	Berberine	0-9	ribosomal protein S6 kinase B1	Homo sapiens	114-120
26722438-4	2015	And then we detected the role of AMPK/mTOR signaling pathway in berberine treatment of cardiac fibroblasts.	Berberine	64-73	mechanistic target of rapamycin kinase	Homo sapiens	38-42
26722438-8	2015	And the protein secretion of TGFbeta1 was inhibited; however, the protein secretion of IL-10 was increased in cardiac fibroblasts with berberine treatment.	Berberine	135-144	interleukin 10	Homo sapiens	87-92
26722438-9	2015	Mechanistically, the phosphorylation level of AMPK was increased; and the phosphorylation levels of mTOR and p70S6K were decreased in berberine treatment group.	Berberine	134-143	mechanistic target of rapamycin kinase	Homo sapiens	100-104
26722438-9	2015	Mechanistically, the phosphorylation level of AMPK was increased; and the phosphorylation levels of mTOR and p70S6K were decreased in berberine treatment group.	Berberine	134-143	ribosomal protein S6 kinase B1	Homo sapiens	109-115
26722438-10	2015	CONCLUSION: These results illustrated that the protective effects of berberine on cellular behaviors of cardiac fibroblasts were at least in part due to activate AMPK signaling pathway and downregulate mTOR/p70S6K signaling pathway.	Berberine	69-78	mechanistic target of rapamycin kinase	Homo sapiens	202-206
26722438-10	2015	CONCLUSION: These results illustrated that the protective effects of berberine on cellular behaviors of cardiac fibroblasts were at least in part due to activate AMPK signaling pathway and downregulate mTOR/p70S6K signaling pathway.	Berberine	69-78	ribosomal protein S6 kinase B1	Homo sapiens	207-213
24838344-7	2015	Furthermore, 4E-binding protein-1 and p70 ribosomal S6 kinases, downstream targets of mTOR, were down regulated by berberine treatment.	Berberine	115-124	E74 like ETS transcription factor 1	Mus musculus	38-41
24838344-7	2015	Furthermore, 4E-binding protein-1 and p70 ribosomal S6 kinases, downstream targets of mTOR, were down regulated by berberine treatment.	Berberine	115-124	mechanistic target of rapamycin kinase	Mus musculus	86-90
24838344-9	2015	Berberine inhibited Nuclear Factor kappa-B (NF-kappaB) activity, reduced the expression of cyclin D1 and survivin, induced phosphorylation of p53 and increased caspase-3 cleavage in vitro.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	20-42
24838344-9	2015	Berberine inhibited Nuclear Factor kappa-B (NF-kappaB) activity, reduced the expression of cyclin D1 and survivin, induced phosphorylation of p53 and increased caspase-3 cleavage in vitro.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	44-53
26166377-0	2015	Berberine inhibits tumor necrosis factor-alpha-induced expression of inflammatory molecules and activation of nuclear factor-kappaB via the activation of AMPK in vascular endothelial cells.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	154-158
24838344-9	2015	Berberine inhibited Nuclear Factor kappa-B (NF-kappaB) activity, reduced the expression of cyclin D1 and survivin, induced phosphorylation of p53 and increased caspase-3 cleavage in vitro.	Berberine	0-9	cyclin D1	Mus musculus	91-100
26166377-4	2015	The effect of berberine on tumor necrosis factor (TNF)-alpha-induced inflammatory molecule expression was examined in cultured human aortic endothelial cells (HAECs).	Berberine	14-23	tumor necrosis factor	Homo sapiens	27-60
24838344-9	2015	Berberine inhibited Nuclear Factor kappa-B (NF-kappaB) activity, reduced the expression of cyclin D1 and survivin, induced phosphorylation of p53 and increased caspase-3 cleavage in vitro.	Berberine	0-9	baculoviral IAP repeat-containing 5	Mus musculus	105-113
26166377-8	2015	The results of the present study demonstrated that berberine significantly inhibited the TNF-alpha-induced expression of ICAM-1 and MCP-1, as well as the activation of NF-kappaB in the HAECs.	Berberine	51-60	tumor necrosis factor	Homo sapiens	89-98
26166377-8	2015	The results of the present study demonstrated that berberine significantly inhibited the TNF-alpha-induced expression of ICAM-1 and MCP-1, as well as the activation of NF-kappaB in the HAECs.	Berberine	51-60	intercellular adhesion molecule 1	Homo sapiens	121-127
26166377-8	2015	The results of the present study demonstrated that berberine significantly inhibited the TNF-alpha-induced expression of ICAM-1 and MCP-1, as well as the activation of NF-kappaB in the HAECs.	Berberine	51-60	C-C motif chemokine ligand 2	Homo sapiens	132-137
26166377-10	2015	In conclusion, the results of the present study indicated that berberine inhibits the TNF-alpha-induced expression of ICAM-1 and MCP-1, and the activation of NF-kappaB in HAECs in vitro, possibly through the AMPK-dependent pathway.	Berberine	63-72	tumor necrosis factor	Homo sapiens	86-95
26166377-10	2015	In conclusion, the results of the present study indicated that berberine inhibits the TNF-alpha-induced expression of ICAM-1 and MCP-1, and the activation of NF-kappaB in HAECs in vitro, possibly through the AMPK-dependent pathway.	Berberine	63-72	intercellular adhesion molecule 1	Homo sapiens	118-124
26224047-0	2015	Berberine ameliorates TNBS induced colitis by inhibiting inflammatory responses and Th1/Th17 differentiation.	Berberine	0-9	negative elongation factor complex member C/D, Th1l	Mus musculus	84-87
24838344-9	2015	Berberine inhibited Nuclear Factor kappa-B (NF-kappaB) activity, reduced the expression of cyclin D1 and survivin, induced phosphorylation of p53 and increased caspase-3 cleavage in vitro.	Berberine	0-9	transformation related protein 53, pseudogene	Mus musculus	142-145
26166377-10	2015	In conclusion, the results of the present study indicated that berberine inhibits the TNF-alpha-induced expression of ICAM-1 and MCP-1, and the activation of NF-kappaB in HAECs in vitro, possibly through the AMPK-dependent pathway.	Berberine	63-72	C-C motif chemokine ligand 2	Homo sapiens	129-134
26166377-10	2015	In conclusion, the results of the present study indicated that berberine inhibits the TNF-alpha-induced expression of ICAM-1 and MCP-1, and the activation of NF-kappaB in HAECs in vitro, possibly through the AMPK-dependent pathway.	Berberine	63-72	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	208-212
24838344-9	2015	Berberine inhibited Nuclear Factor kappa-B (NF-kappaB) activity, reduced the expression of cyclin D1 and survivin, induced phosphorylation of p53 and increased caspase-3 cleavage in vitro.	Berberine	0-9	caspase 3	Mus musculus	160-169
24838344-10	2015	Berberine inhibition of mTOR activity and p53 phosphorylation was found to be AMPK dependent, while inhibition NF-kappaB was AMPK independent.	Berberine	0-9	mechanistic target of rapamycin kinase	Mus musculus	24-28
24838344-11	2015	In vivo, berberine also activated AMPK, inhibited mTOR and p65 phosphorylation and activated caspase-3 cleavage.	Berberine	9-18	mechanistic target of rapamycin kinase	Mus musculus	50-54
24838344-11	2015	In vivo, berberine also activated AMPK, inhibited mTOR and p65 phosphorylation and activated caspase-3 cleavage.	Berberine	9-18	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	59-62
24838344-11	2015	In vivo, berberine also activated AMPK, inhibited mTOR and p65 phosphorylation and activated caspase-3 cleavage.	Berberine	9-18	caspase 3	Mus musculus	93-102
24838344-12	2015	Our data suggests that berberine suppresses colon epithelial proliferation and tumorigenesis via AMPK dependent inhibition of mTOR activity and AMPK independent inhibition of NF-kappaB.	Berberine	23-32	mechanistic target of rapamycin kinase	Mus musculus	126-130
24838344-12	2015	Our data suggests that berberine suppresses colon epithelial proliferation and tumorigenesis via AMPK dependent inhibition of mTOR activity and AMPK independent inhibition of NF-kappaB.	Berberine	23-32	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	175-184
26206195-2	2015	This study was designed to ascertain whether berberine-induced secretion of GLP-1 was related with activation of bitter taste receptors expressed in gastrointestinal tract.	Berberine	45-54	glucagon like peptide 1 receptor	Homo sapiens	76-81
26421434-6	2015	Our results demonstrated that berberine at low dose range (1.25 ~ 5 muM) promoted cell proliferation to 112% ~170% of the untreated control in various cancer cells, while berberine at high dose rage (10 ~ 80 muM) inhibited cell proliferation.	Berberine	30-39	latexin	Homo sapiens	68-71
26421434-8	2015	The hormetic effect and thereby the attenuated anticancer activity of chemotherapeutic drugs by berberine may attributable to the activated protective stress response in cancer cells triggered by berberine, as evidenced by up-regulated MAPK/ERK1/2 and PI3K/AKT signaling pathways.	Berberine	96-105	mitogen-activated protein kinase 3	Homo sapiens	236-240
26421434-8	2015	The hormetic effect and thereby the attenuated anticancer activity of chemotherapeutic drugs by berberine may attributable to the activated protective stress response in cancer cells triggered by berberine, as evidenced by up-regulated MAPK/ERK1/2 and PI3K/AKT signaling pathways.	Berberine	96-105	mitogen-activated protein kinase 3	Homo sapiens	241-247
26421434-8	2015	The hormetic effect and thereby the attenuated anticancer activity of chemotherapeutic drugs by berberine may attributable to the activated protective stress response in cancer cells triggered by berberine, as evidenced by up-regulated MAPK/ERK1/2 and PI3K/AKT signaling pathways.	Berberine	196-205	mitogen-activated protein kinase 3	Homo sapiens	236-240
26206195-0	2015	Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways.	Berberine	0-9	glucagon like peptide 1 receptor	Homo sapiens	18-23
26206195-1	2015	Our previous studies revealed that berberine-mediated GLP-1 secretion was a possible mechanism for berberine exerting good effects on hyperglycemia.	Berberine	35-44	glucagon like peptide 1 receptor	Homo sapiens	54-59
26206195-1	2015	Our previous studies revealed that berberine-mediated GLP-1 secretion was a possible mechanism for berberine exerting good effects on hyperglycemia.	Berberine	99-108	glucagon like peptide 1 receptor	Homo sapiens	54-59
26206195-4	2015	GLP-1 secretion induced by berberine from NCI-H716 cells was inhibited by incubation with anti-TAS2R38 antibody.	Berberine	27-36	glucagon like peptide 1 receptor	Homo sapiens	0-5
26206195-4	2015	GLP-1 secretion induced by berberine from NCI-H716 cells was inhibited by incubation with anti-TAS2R38 antibody.	Berberine	27-36	taste 2 receptor member 38	Homo sapiens	95-102
26206195-5	2015	We further performed gene silencing using siRNA to knockdown TAS2R38 from NCI-H716 cells, which showed that siRNA knockdown of the TAS2R38 reduced berberine-mediated GLP-1 secretion.	Berberine	147-156	taste 2 receptor member 38	Homo sapiens	61-68
26206195-5	2015	We further performed gene silencing using siRNA to knockdown TAS2R38 from NCI-H716 cells, which showed that siRNA knockdown of the TAS2R38 reduced berberine-mediated GLP-1 secretion.	Berberine	147-156	taste 2 receptor member 38	Homo sapiens	131-138
26206195-5	2015	We further performed gene silencing using siRNA to knockdown TAS2R38 from NCI-H716 cells, which showed that siRNA knockdown of the TAS2R38 reduced berberine-mediated GLP-1 secretion.	Berberine	147-156	glucagon like peptide 1 receptor	Homo sapiens	166-171
26206195-6	2015	We adopted inhibitors of PLC and TRPM5 known to be involved in bitter taste transduction to investigate the underlying pathways mediated in berberine-induced GLP-1 secretion.	Berberine	140-149	glucagon like peptide 1 receptor	Homo sapiens	158-163
26206195-7	2015	It was found that PLC inhibitor U73122 inhibited berberine-induced GLP-1 release in NCI-H716 cells, while TRPM5 blocker quinine failed to attenuate berberine-induced secretion of GLP-1.	Berberine	49-58	heparan sulfate proteoglycan 2	Homo sapiens	18-21
26206195-7	2015	It was found that PLC inhibitor U73122 inhibited berberine-induced GLP-1 release in NCI-H716 cells, while TRPM5 blocker quinine failed to attenuate berberine-induced secretion of GLP-1.	Berberine	49-58	glucagon like peptide 1 receptor	Homo sapiens	67-72
26206195-8	2015	The present results demonstrated that berberine stimulated GLP-1 secretion via activation of gut-expressed bitter taste receptors in a PLC-dependent manner.	Berberine	38-47	glucagon like peptide 1 receptor	Homo sapiens	59-64
26206195-8	2015	The present results demonstrated that berberine stimulated GLP-1 secretion via activation of gut-expressed bitter taste receptors in a PLC-dependent manner.	Berberine	38-47	heparan sulfate proteoglycan 2	Homo sapiens	135-138
26594754-3	2015	Berberine added to the cultured medium could significantly down-regulate transcription factors, including CCAAT/enhancer binding protein beta, CCAAT/enhancer binding protein a, and peroxisome pro liferator-activated receptor y, and suppress peroxisome proliferator-activated receptor target genes, such as adipocyte fatty acid binding protein and fatty acid synthase, and inhibit 3T3-Ll fibroblast differentiation to adipocytes.	Berberine	0-9	CCAAT/enhancer binding protein beta	Rattus norvegicus	106-141
25877860-3	2015	We earlier reported berberine"s amelioration against TGF-beta1-mediated pro-fibrotic effects in bleomycin-induced pulmonary fibrosis.	Berberine	20-29	transforming growth factor, beta 1	Rattus norvegicus	53-62
25877860-4	2015	The present study aimed to determine the regulatory role of berberine on abrogated Smad 2/3 and FAK-dependent PI3K/Akt-mTOR signaling cascades in bleomycin-induced pulmonary fibrosis.	Berberine	60-69	SMAD family member 2	Rattus norvegicus	83-91
25877860-4	2015	The present study aimed to determine the regulatory role of berberine on abrogated Smad 2/3 and FAK-dependent PI3K/Akt-mTOR signaling cascades in bleomycin-induced pulmonary fibrosis.	Berberine	60-69	protein tyrosine kinase 2	Rattus norvegicus	96-99
25877860-4	2015	The present study aimed to determine the regulatory role of berberine on abrogated Smad 2/3 and FAK-dependent PI3K/Akt-mTOR signaling cascades in bleomycin-induced pulmonary fibrosis.	Berberine	60-69	AKT serine/threonine kinase 1	Rattus norvegicus	115-118
25877860-4	2015	The present study aimed to determine the regulatory role of berberine on abrogated Smad 2/3 and FAK-dependent PI3K/Akt-mTOR signaling cascades in bleomycin-induced pulmonary fibrosis.	Berberine	60-69	mechanistic target of rapamycin kinase	Rattus norvegicus	119-123
25877860-6	2015	Berberine mitigated the elevated expression of fibrotic markers, alpha-smooth muscle actin (alpha-SMA), fibronectin, collagens I and III and reversed bleomycin-induced ultrastructural alterations in the lungs.	Berberine	0-9	actin gamma 2, smooth muscle	Rattus norvegicus	65-90
26400287-3	2015	Berberine was reported to inhibit the proliferation of A431 cells in a dose- and time-dependent manner and was observed to induce a series of biochemical events, including the loss of mitochondrial membrane potential, release of cytochrome-c to cytosol, induction of proteins of the Bcl-2 family and caspases, and the cleavage of poly(ADP)-ribose polymerase.	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	283-288
26400287-7	2015	The level of expression of Ezrin in the transfected A431 cells was observed to decrease with berberine treatment, which suggested that berberine might inhibit the invasion of A431 cells through Ezrin.	Berberine	93-102	ezrin	Homo sapiens	27-32
26400287-7	2015	The level of expression of Ezrin in the transfected A431 cells was observed to decrease with berberine treatment, which suggested that berberine might inhibit the invasion of A431 cells through Ezrin.	Berberine	135-144	ezrin	Homo sapiens	27-32
26400287-7	2015	The level of expression of Ezrin in the transfected A431 cells was observed to decrease with berberine treatment, which suggested that berberine might inhibit the invasion of A431 cells through Ezrin.	Berberine	135-144	ezrin	Homo sapiens	194-199
26004523-7	2015	The beneficial effect of berberine is associated with inhibiting the cellular autophagy level, due to decreasing the expression level of autophagy-related proteins such as SIRT1, BNIP3, and Beclin-1.	Berberine	25-34	sirtuin 1	Mus musculus	172-177
26004523-7	2015	The beneficial effect of berberine is associated with inhibiting the cellular autophagy level, due to decreasing the expression level of autophagy-related proteins such as SIRT1, BNIP3, and Beclin-1.	Berberine	25-34	BCL2/adenovirus E1B interacting protein 3	Mus musculus	179-184
26004523-7	2015	The beneficial effect of berberine is associated with inhibiting the cellular autophagy level, due to decreasing the expression level of autophagy-related proteins such as SIRT1, BNIP3, and Beclin-1.	Berberine	25-34	beclin 1, autophagy related	Mus musculus	190-198
26004523-8	2015	Furthermore, both the level of p-AMPK and p-mTORC2 (Ser2481) in H9c2 myocytes exposed to H/R were decreased by berberine.	Berberine	111-120	CREB regulated transcription coactivator 2	Mus musculus	44-50
26184498-0	2015	Berberine prevents nitric oxide-induced rat chondrocyte apoptosis and cartilage degeneration in a rat osteoarthritis model via AMPK and p38 MAPK signaling.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	127-131
26184498-0	2015	Berberine prevents nitric oxide-induced rat chondrocyte apoptosis and cartilage degeneration in a rat osteoarthritis model via AMPK and p38 MAPK signaling.	Berberine	0-9	mitogen activated protein kinase 14	Rattus norvegicus	136-139
25877860-6	2015	Berberine mitigated the elevated expression of fibrotic markers, alpha-smooth muscle actin (alpha-SMA), fibronectin, collagens I and III and reversed bleomycin-induced ultrastructural alterations in the lungs.	Berberine	0-9	actin gamma 2, smooth muscle	Rattus norvegicus	92-101
25877860-6	2015	Berberine mitigated the elevated expression of fibrotic markers, alpha-smooth muscle actin (alpha-SMA), fibronectin, collagens I and III and reversed bleomycin-induced ultrastructural alterations in the lungs.	Berberine	0-9	fibronectin 1	Rattus norvegicus	104-115
25877860-7	2015	Berberine inhibited the bleomycin-induced raise in p-Smad 2/3 and enhanced Smad 7 expression.	Berberine	0-9	SMAD family member 2	Rattus norvegicus	53-61
25877860-7	2015	Berberine inhibited the bleomycin-induced raise in p-Smad 2/3 and enhanced Smad 7 expression.	Berberine	0-9	SMAD family member 7	Rattus norvegicus	75-81
25877860-8	2015	Berberine blocked the activation of FAK and PI3K/Akt against bleomycin-induced dysregulation, with subsequent raise in PTEN expression.	Berberine	0-9	protein tyrosine kinase 2	Rattus norvegicus	36-39
25877860-8	2015	Berberine blocked the activation of FAK and PI3K/Akt against bleomycin-induced dysregulation, with subsequent raise in PTEN expression.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	49-52
25877860-8	2015	Berberine blocked the activation of FAK and PI3K/Akt against bleomycin-induced dysregulation, with subsequent raise in PTEN expression.	Berberine	0-9	phosphatase and tensin homolog	Rattus norvegicus	119-123
25877860-9	2015	In addition, by inhibiting p-mTOR, berberine stimulated autophagy as evidenced by increase in Beclin-1, LC3-II levels with enhanced autophagosome formation.	Berberine	35-44	mechanistic target of rapamycin kinase	Rattus norvegicus	29-33
25877860-9	2015	In addition, by inhibiting p-mTOR, berberine stimulated autophagy as evidenced by increase in Beclin-1, LC3-II levels with enhanced autophagosome formation.	Berberine	35-44	beclin 1	Rattus norvegicus	94-102
25877860-10	2015	Cumulatively, through targeted inhibition of dysregulated Smad and FAK-dependent PI3K/Akt-mTOR signaling axis, berberine attenuated the fibrotic insults of bleomycin.	Berberine	111-120	protein tyrosine kinase 2	Rattus norvegicus	67-70
25877860-10	2015	Cumulatively, through targeted inhibition of dysregulated Smad and FAK-dependent PI3K/Akt-mTOR signaling axis, berberine attenuated the fibrotic insults of bleomycin.	Berberine	111-120	AKT serine/threonine kinase 1	Rattus norvegicus	86-89
25877860-10	2015	Cumulatively, through targeted inhibition of dysregulated Smad and FAK-dependent PI3K/Akt-mTOR signaling axis, berberine attenuated the fibrotic insults of bleomycin.	Berberine	111-120	mechanistic target of rapamycin kinase	Rattus norvegicus	90-94
25877860-11	2015	KEY MESSAGE: Berberine inhibits Smad 2/3 activation and enhances Smad 7 in bleomycin-induced rat lungs.	Berberine	13-22	SMAD family member 2	Rattus norvegicus	32-40
25877860-11	2015	KEY MESSAGE: Berberine inhibits Smad 2/3 activation and enhances Smad 7 in bleomycin-induced rat lungs.	Berberine	13-22	SMAD family member 7	Rattus norvegicus	65-71
25877860-12	2015	Bleomycin-induced activation of FAK is inhibited by berberine.	Berberine	52-61	protein tyrosine kinase 2	Rattus norvegicus	32-35
25877860-13	2015	Berberine inhibits bleomycin-induced activation of PI3K/Akt cascade.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	56-59
25877860-14	2015	Berberine inhibits mTOR activation to enhance autophagy and suppresses fibrotic markers.	Berberine	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	19-23
26594754-3	2015	Berberine added to the cultured medium could significantly down-regulate transcription factors, including CCAAT/enhancer binding protein beta, CCAAT/enhancer binding protein a, and peroxisome pro liferator-activated receptor y, and suppress peroxisome proliferator-activated receptor target genes, such as adipocyte fatty acid binding protein and fatty acid synthase, and inhibit 3T3-Ll fibroblast differentiation to adipocytes.	Berberine	0-9	fatty acid synthase	Rattus norvegicus	347-366
25976224-9	2015	(2) The combination of Berberine with Azithromycin reduced hERG currents, producing an inhibitive effect stronger than use of a single drug alone, due to the high binding affinity for the onset of inactivation.	Berberine	23-32	ETS transcription factor ERG	Homo sapiens	59-63
26622773-0	2015	Inhibition of p38 mitogen-activated protein kinase potentiates the apoptotic effect of berberine/tumor necrosis factor-related apoptosis-inducing ligand combination therapy.	Berberine	87-96	mitogen-activated protein kinase 14	Homo sapiens	14-17
26622773-1	2015	It was previously reported that berberine (BBR) and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) exhibited a synergistic apoptotic effect on triple negative breast cancer (TNBC) cells.	Berberine	32-41	TNF superfamily member 10	Homo sapiens	115-120
25976224-10	2015	(3) When cells were perfused concomitantly with Berberine and Clarithromycin, they showed a stronger inhibitive effect on hERG currents by decreasing the time constant for the onset of inactivation.	Berberine	48-57	ETS transcription factor ERG	Homo sapiens	122-126
25976224-11	2015	(4) The combined administration of Berberine with Clarithromycin had a powerful inhibitive effect on CYP3A activities than use of a single drug alone.	Berberine	35-44	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-106
26305257-3	2015	Our previous studies and those of others on Chinese medicinal herbs and miRNAs in various cancer models have provided a possibility of new cancer therapies, for example, up-regulating the expression of miR-23a may activate the positive regulatory network of p53 and miR-23a involved in the mechanism underlying the anti-tumor effect of berberine in hepatocellular carcinoma (HCC).	Berberine	336-345	microRNA 23a	Homo sapiens	202-209
26159088-3	2015	Berberine, an isoquinoline alkaloid is reported to exhibit antioxidant effect and cholinesterase (ChE) inhibitor activity.	Berberine	0-9	butyrylcholinesterase	Rattus norvegicus	82-96
26159088-3	2015	Berberine, an isoquinoline alkaloid is reported to exhibit antioxidant effect and cholinesterase (ChE) inhibitor activity.	Berberine	0-9	butyrylcholinesterase	Rattus norvegicus	98-101
26159088-8	2015	In contrast, chronic treatment with berberine (25-100mg/kg, p.o., once a day for 45days) improved cognitive performance, and lowered oxidative stress and ChE activity in ethanol treated rats.	Berberine	36-45	butyrylcholinesterase	Rattus norvegicus	154-157
26159088-9	2015	In another set of experiments, berberine (100mg/kg) treatment during training trials also improved learning and memory, and lowered oxidative stress and ChE activity.	Berberine	31-40	butyrylcholinesterase	Rattus norvegicus	153-156
26159088-11	2015	In conclusion, the present study demonstrates that treatment with berberine prevents the changes in oxidative stress and ChE activity, and consequently memory impairment in ethanol treated rats.	Berberine	66-75	butyrylcholinesterase	Rattus norvegicus	121-124
26307103-0	2015	Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.	Berberine	96-105	ret proto-oncogene	Homo sapiens	24-27
26307103-3	2015	In this study we have demonstrated a therapeutic strategy for MTC by suppressing the transcription of RET proto-oncogene though the stabilization of G-quadruplex structure formed on the promoter region of this gene using a natural product berberine.	Berberine	239-248	ret proto-oncogene	Homo sapiens	102-105
26307103-4	2015	METHODS: Medullary thyroid carcinoma (MTC) TT cell line has been used to evaluate the effects of berberine on RET expression and its downstream signaling pathways.	Berberine	97-106	ret proto-oncogene	Homo sapiens	110-113
26307103-5	2015	The specificity of berberine was demonstrated by using the papillary thyroid carcinoma TPC1 cell line, which lacks the G-quadruplex forming sequence on the RET promoter region due to chromosomal rearrangement.	Berberine	19-28	two pore segment channel 1	Homo sapiens	87-91
26307103-5	2015	The specificity of berberine was demonstrated by using the papillary thyroid carcinoma TPC1 cell line, which lacks the G-quadruplex forming sequence on the RET promoter region due to chromosomal rearrangement.	Berberine	19-28	ret proto-oncogene	Homo sapiens	156-159
26307103-6	2015	RESULTS: Berberine suppressed the RET expression by more than 90 % in MTC TT cells at a concentration of 2.5 mug/ml with minimal effect on the TPC1 cells.	Berberine	9-18	ret proto-oncogene	Homo sapiens	34-37
26307103-8	2015	The down-regulation of RET with berberine further inhibited the cell proliferation through cell cycle arrest and activation of apoptosis in TT cells, which was confirmed by a 2-fold increase in the caspase-3 activity and the down-regulation of cell-cycle regulatory proteins.	Berberine	32-41	ret proto-oncogene	Homo sapiens	23-26
26307103-8	2015	The down-regulation of RET with berberine further inhibited the cell proliferation through cell cycle arrest and activation of apoptosis in TT cells, which was confirmed by a 2-fold increase in the caspase-3 activity and the down-regulation of cell-cycle regulatory proteins.	Berberine	32-41	caspase 3	Homo sapiens	198-207
26307103-9	2015	CONCLUSION: Our data strongly suggest that the G-quadruplex forming region and the stabilization of this structure play a critical role in mediating the repressive effect of berberine on RET transcription.	Berberine	174-183	ret proto-oncogene	Homo sapiens	187-190
26310319-2	2015	Mechanistic studies have shown that BBR activates the extracellular-signal regulated kinase pathway by stabilizing low-density-lipoprotein receptor mRNA.	Berberine	36-39	low density lipoprotein receptor	Homo sapiens	115-147
26305257-3	2015	Our previous studies and those of others on Chinese medicinal herbs and miRNAs in various cancer models have provided a possibility of new cancer therapies, for example, up-regulating the expression of miR-23a may activate the positive regulatory network of p53 and miR-23a involved in the mechanism underlying the anti-tumor effect of berberine in hepatocellular carcinoma (HCC).	Berberine	336-345	tumor protein p53	Homo sapiens	258-261
26305257-3	2015	Our previous studies and those of others on Chinese medicinal herbs and miRNAs in various cancer models have provided a possibility of new cancer therapies, for example, up-regulating the expression of miR-23a may activate the positive regulatory network of p53 and miR-23a involved in the mechanism underlying the anti-tumor effect of berberine in hepatocellular carcinoma (HCC).	Berberine	336-345	microRNA 23a	Homo sapiens	266-273
26677714-8	2015	Its major effective component berberine could inhibit each CYP450 isoform at high concentrations (except for CYP1A2, CYP3A1/2).	Berberine	30-39	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	117-123
26302344-8	2015	The gap junction function between the cells was enhanced through increased Cx43 protein expression and localization of Cx43 on the membrane after berberine treatment.	Berberine	146-155	gap junction protein alpha 1	Homo sapiens	75-79
26302344-8	2015	The gap junction function between the cells was enhanced through increased Cx43 protein expression and localization of Cx43 on the membrane after berberine treatment.	Berberine	146-155	gap junction protein alpha 1	Homo sapiens	119-123
26225560-5	2015	We found that BBR can reduce the accumulation of mutant huntingtin in cultured cells.	Berberine	14-17	huntingtin	Mus musculus	56-66
26550442-10	2015	Our results suggested that berberine decreased myocardial infarction area, and decreased serum levels of CK-MB, LDH and cTnI.	Berberine	27-36	troponin I3, cardiac type	Rattus norvegicus	120-124
26550442-12	2015	Berberine up-regulates the expression of Bcl-2 and mitochondrial cytochrome c and down-regulates the expression of Bax and cytosolic cytochrome c. In conclusion, berberine protects the heart from ischemia/reperfusion injury via attenuating mitochondrial dysfunction and myocardial apoptosis.	Berberine	0-9	BCL2, apoptosis regulator	Rattus norvegicus	41-46
26550442-12	2015	Berberine up-regulates the expression of Bcl-2 and mitochondrial cytochrome c and down-regulates the expression of Bax and cytosolic cytochrome c. In conclusion, berberine protects the heart from ischemia/reperfusion injury via attenuating mitochondrial dysfunction and myocardial apoptosis.	Berberine	0-9	BCL2 associated X, apoptosis regulator	Rattus norvegicus	115-118
26550442-12	2015	Berberine up-regulates the expression of Bcl-2 and mitochondrial cytochrome c and down-regulates the expression of Bax and cytosolic cytochrome c. In conclusion, berberine protects the heart from ischemia/reperfusion injury via attenuating mitochondrial dysfunction and myocardial apoptosis.	Berberine	162-171	BCL2, apoptosis regulator	Rattus norvegicus	41-46
26550442-12	2015	Berberine up-regulates the expression of Bcl-2 and mitochondrial cytochrome c and down-regulates the expression of Bax and cytosolic cytochrome c. In conclusion, berberine protects the heart from ischemia/reperfusion injury via attenuating mitochondrial dysfunction and myocardial apoptosis.	Berberine	162-171	BCL2 associated X, apoptosis regulator	Rattus norvegicus	115-118
25600690-8	2015	Berberine also caused decrease in TNF-alpha level and caspase-3 activity which was higher with HgCl2.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	34-43
25600690-8	2015	Berberine also caused decrease in TNF-alpha level and caspase-3 activity which was higher with HgCl2.	Berberine	0-9	caspase 3	Rattus norvegicus	54-63
25600690-9	2015	Furthermore, treatment with BN inhibited apoptosis, as indicated by the reduction of Bax/Bcl-2 ratio in brain tissue.	Berberine	28-30	BCL2 associated X, apoptosis regulator	Rattus norvegicus	85-88
25600690-9	2015	Furthermore, treatment with BN inhibited apoptosis, as indicated by the reduction of Bax/Bcl-2 ratio in brain tissue.	Berberine	28-30	BCL2, apoptosis regulator	Rattus norvegicus	89-94
26302344-4	2015	METHODS: The total Cx43 protein amount, localization of Cx43 on cell membrane, and gap junction function were observed after the A549 cells were treated with berberine.	Berberine	158-167	gap junction protein alpha 1	Homo sapiens	19-23
26226164-0	2015	Protection of Gastrointestinal Mucosa from Acute Heavy Alcohol Consumption: The Effect of Berberine and Its Correlation with TLR2, 4/IL1beta-TNFalpha Signaling.	Berberine	90-99	toll like receptor 2	Homo sapiens	125-132
26226164-0	2015	Protection of Gastrointestinal Mucosa from Acute Heavy Alcohol Consumption: The Effect of Berberine and Its Correlation with TLR2, 4/IL1beta-TNFalpha Signaling.	Berberine	90-99	tumor necrosis factor	Homo sapiens	141-149
26226164-4	2015	Oral administration of BBR was able to significantly reduce this alcohol-induced damage, inhibit increases of alcohol-induced TNFalpha and IL-1beta expression in gastrointestinal mucosa as well as their upstream signals TLR2 and TLR4, and regulate cytokines that modulate tight junctions.	Berberine	23-26	tumor necrosis factor	Homo sapiens	126-134
26226164-4	2015	Oral administration of BBR was able to significantly reduce this alcohol-induced damage, inhibit increases of alcohol-induced TNFalpha and IL-1beta expression in gastrointestinal mucosa as well as their upstream signals TLR2 and TLR4, and regulate cytokines that modulate tight junctions.	Berberine	23-26	interleukin 1 beta	Homo sapiens	139-147
26226164-4	2015	Oral administration of BBR was able to significantly reduce this alcohol-induced damage, inhibit increases of alcohol-induced TNFalpha and IL-1beta expression in gastrointestinal mucosa as well as their upstream signals TLR2 and TLR4, and regulate cytokines that modulate tight junctions.	Berberine	23-26	toll like receptor 2	Homo sapiens	220-224
26226164-4	2015	Oral administration of BBR was able to significantly reduce this alcohol-induced damage, inhibit increases of alcohol-induced TNFalpha and IL-1beta expression in gastrointestinal mucosa as well as their upstream signals TLR2 and TLR4, and regulate cytokines that modulate tight junctions.	Berberine	23-26	toll like receptor 4	Homo sapiens	229-233
26167077-0	2015	Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.	Berberine	0-9	serine/threonine kinase 11	Rattus norvegicus	51-55
26167077-0	2015	Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	56-60
26167077-0	2015	Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.	Berberine	0-9	CREB regulated transcription coactivator 2	Rattus norvegicus	61-66
26167077-12	2015	Berberine upregulated protein expression of liver kinase (LK)B1, AMP-activated protein kinase (AMPK) and phosphorylated AMPK (p-AMPK).	Berberine	0-9	serine/threonine kinase 11	Rattus norvegicus	44-63
26167077-12	2015	Berberine upregulated protein expression of liver kinase (LK)B1, AMP-activated protein kinase (AMPK) and phosphorylated AMPK (p-AMPK).	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	65-93
26167077-12	2015	Berberine upregulated protein expression of liver kinase (LK)B1, AMP-activated protein kinase (AMPK) and phosphorylated AMPK (p-AMPK).	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	95-99
25861937-0	2015	The therapeutic potential of berberine against the altered intrinsic properties of the CA1 neurons induced by Abeta neurotoxicity.	Berberine	29-38	carbonic anhydrase 1	Rattus norvegicus	87-90
26167077-12	2015	Berberine upregulated protein expression of liver kinase (LK)B1, AMP-activated protein kinase (AMPK) and phosphorylated AMPK (p-AMPK).	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	120-124
25861937-4	2015	The present study aimed to investigate the effects of berberine (BER) on the Abeta-induced impairments in learning and memory.	Berberine	54-63	amyloid beta precursor protein	Rattus norvegicus	77-82
25861937-4	2015	The present study aimed to investigate the effects of berberine (BER) on the Abeta-induced impairments in learning and memory.	Berberine	65-68	amyloid beta precursor protein	Rattus norvegicus	77-82
26167077-12	2015	Berberine upregulated protein expression of liver kinase (LK)B1, AMP-activated protein kinase (AMPK) and phosphorylated AMPK (p-AMPK).	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	120-124
26167077-13	2015	The level of phophorylated TORC2 (p-TORC2) protein in the cytoplasm was higher in the berberine group than in the model group, and no significant difference in total TORC2 protein level was observed.	Berberine	86-95	CREB regulated transcription coactivator 2	Rattus norvegicus	27-32
26167077-13	2015	The level of phophorylated TORC2 (p-TORC2) protein in the cytoplasm was higher in the berberine group than in the model group, and no significant difference in total TORC2 protein level was observed.	Berberine	86-95	CREB regulated transcription coactivator 2	Rattus norvegicus	36-41
26167077-13	2015	The level of phophorylated TORC2 (p-TORC2) protein in the cytoplasm was higher in the berberine group than in the model group, and no significant difference in total TORC2 protein level was observed.	Berberine	86-95	CREB regulated transcription coactivator 2	Rattus norvegicus	36-41
26167077-14	2015	Immunohistochemical staining revealed that more TORC2 was localized in the cytoplasm of the berberine group than in the model group.	Berberine	92-101	CREB regulated transcription coactivator 2	Rattus norvegicus	48-53
26167077-15	2015	Moreover, berberine treatment downregulated protein expression of the key gluconeogenic enzymes (phosphoenolpyruvate carboxykinase and glucose-6-phosphatase) in the liver tissues.	Berberine	10-19	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	135-156
26167077-16	2015	CONCLUSION: Our findings revealed that berberine inhibited hepatic gluconeogenesis via the regulation of the LKB1-AMPK-TORC2 signaling pathway.	Berberine	39-48	serine/threonine kinase 11	Rattus norvegicus	109-113
26167077-16	2015	CONCLUSION: Our findings revealed that berberine inhibited hepatic gluconeogenesis via the regulation of the LKB1-AMPK-TORC2 signaling pathway.	Berberine	39-48	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	114-118
26167077-16	2015	CONCLUSION: Our findings revealed that berberine inhibited hepatic gluconeogenesis via the regulation of the LKB1-AMPK-TORC2 signaling pathway.	Berberine	39-48	CREB regulated transcription coactivator 2	Rattus norvegicus	119-124
26154585-6	2015	Analyzed alpha-glucosidase activity reveals natural compound inhibitors (below 0.5 mM) are Curcumin, Actinodaphnine, 16-H, Quercetin, Berberine, and Catechin when compared to the commercial drug Acarbose (3 mM).	Berberine	134-143	sucrase-isomaltase	Homo sapiens	9-26
25640685-9	2015	Tetrahydropalmatine and Ber demonstrated both reversible and irreversible inhibition of CYP2D6 and CYP3A4.	Berberine	24-27	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	88-94
25796198-5	2015	In addition to Src induction, berberine also inhibited LPS-mediated Src activation in Src overexpressing macrophages and S-nitroso-N-acetylpenicillamine (a nitric oxide donor) could partly restore it.	Berberine	30-39	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	68-71
25796198-5	2015	In addition to Src induction, berberine also inhibited LPS-mediated Src activation in Src overexpressing macrophages and S-nitroso-N-acetylpenicillamine (a nitric oxide donor) could partly restore it.	Berberine	30-39	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	68-71
25796198-6	2015	Moreover, berberine suppressed Src activity in fibronectin-stimulated macrophages and in v-Src transformed cells.	Berberine	10-19	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	31-34
25796198-6	2015	Moreover, berberine suppressed Src activity in fibronectin-stimulated macrophages and in v-Src transformed cells.	Berberine	10-19	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	91-94
25796198-7	2015	These results implied that by effectively reducing Src expression and activity, berberine inhibited TLR-mediated cell motility in macrophages.	Berberine	80-89	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-54
25889370-0	2015	Berberine regulates neurite outgrowth through AMPK-dependent pathways by lowering energy status.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	46-50
25889370-1	2015	As a widely used anti-bacterial agent and a metabolic inhibitor as well as AMP-activated protein kinase (AMPK) activator, berberine (BBR) has been shown to cross the blood-brain barrier.	Berberine	122-131	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	75-103
25889370-1	2015	As a widely used anti-bacterial agent and a metabolic inhibitor as well as AMP-activated protein kinase (AMPK) activator, berberine (BBR) has been shown to cross the blood-brain barrier.	Berberine	122-131	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	105-109
25889370-1	2015	As a widely used anti-bacterial agent and a metabolic inhibitor as well as AMP-activated protein kinase (AMPK) activator, berberine (BBR) has been shown to cross the blood-brain barrier.	Berberine	133-136	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	75-103
25953522-0	2015	The Effect of Oxidation on Berberine-Mediated CYP1 Inhibition: Oxidation Behavior and Metabolite-Mediated Inhibition.	Berberine	27-36	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	46-50
25953522-2	2015	Berberine causes potent CYP1B1 inhibition, whereas CYP1A2 shows resistance to the inhibition.	Berberine	0-9	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	24-30
25953522-3	2015	To reveal the influence of oxidative metabolism on CYP1 inhibition by berberine, berberine oxidation and the metabolite-mediated inhibition were determined.	Berberine	70-79	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	51-55
25953522-4	2015	After NADPH-fortified preincubation of berberine with P450, the inhibition of CYP1A1 and CYP1B1 variants (CYP1B1.1, CYP1B1.3, and CYP1B1.4) by berberine was not enhanced, and CYP1A2 remained resistant.	Berberine	39-48	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	89-95
25953522-4	2015	After NADPH-fortified preincubation of berberine with P450, the inhibition of CYP1A1 and CYP1B1 variants (CYP1B1.1, CYP1B1.3, and CYP1B1.4) by berberine was not enhanced, and CYP1A2 remained resistant.	Berberine	143-152	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	89-95
25953522-6	2015	CYP1A1-catalyzed berberine oxidation had the highest maximal velocity (V max) and exhibited positive cooperativity, suggesting the assistance of substrate binding when the first substrate was present.	Berberine	17-26	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	0-6
25953522-8	2015	CYP1B1-catalyzed berberine oxidation had low K m values, but it had V max values less than 8% of those of CYP1A1.	Berberine	17-26	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	0-6
25953522-8	2015	CYP1B1-catalyzed berberine oxidation had low K m values, but it had V max values less than 8% of those of CYP1A1.	Berberine	17-26	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	106-112
25953522-9	2015	The dissociation constants generated from the binding spectrum and fluorescence quenching suggested that the low K m values of CYP1B1-catalyzed oxidation might include more than the rate constants describing berberine binding.	Berberine	208-217	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	127-133
25953522-10	2015	The natural protoberberine/berberine fmetabolites with methylenedioxy ring-opening (palmatine, jatrorrhizine, and demethyleneberberine) and the demethylation (thalifendine and berberrubine) caused weak CYP1 inhibition.	Berberine	17-26	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	202-206
25953522-12	2015	Metabolites of berberine caused a relatively weak inhibition of CYP1.	Berberine	15-24	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	64-68
25796198-0	2015	Berberine reduces Toll-like receptor-mediated macrophage migration by suppression of Src enhancement.	Berberine	0-9	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	85-88
25796198-3	2015	The simultaneous suppression of lipopolysaccharide (LPS)-mediated upregulation of inducible nitric oxide synthase, cyclooxygenase 2, and cell mobility in berberine-treated macrophages suggested Src might be a target of berberine.	Berberine	154-163	prostaglandin-endoperoxide synthase 2	Homo sapiens	115-131
25796198-3	2015	The simultaneous suppression of lipopolysaccharide (LPS)-mediated upregulation of inducible nitric oxide synthase, cyclooxygenase 2, and cell mobility in berberine-treated macrophages suggested Src might be a target of berberine.	Berberine	154-163	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	194-197
25796198-4	2015	Indeed, th reduced migration, greatly suppressed Src induction in both protein and RNA transcript by berberine were observed in macrophages exposed to LPS, peptidoglycan, polyinosinic-polycytidylic acid, and CpG-oligodeoxynucleotides.	Berberine	101-110	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	49-52
26309516-9	2015	In summary, berberine inhibits cigarette smoke exposure-induced airway inflammation and mucus hypersecretion in mice, which may partly act through inhibition of ERK and P38.	Berberine	12-21	mitogen-activated protein kinase 1	Mus musculus	161-164
26309516-9	2015	In summary, berberine inhibits cigarette smoke exposure-induced airway inflammation and mucus hypersecretion in mice, which may partly act through inhibition of ERK and P38.	Berberine	12-21	mitogen-activated protein kinase 14	Mus musculus	169-172
25889370-1	2015	As a widely used anti-bacterial agent and a metabolic inhibitor as well as AMP-activated protein kinase (AMPK) activator, berberine (BBR) has been shown to cross the blood-brain barrier.	Berberine	133-136	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	105-109
26042820-8	2015	Berberine also significantly increased miRNA-21 and Bcl-2 transcription levels and significantly decreased caspase-3 and PTEN transcription levels.	Berberine	0-9	B cell leukemia/lymphoma 2	Mus musculus	52-57
26042820-8	2015	Berberine also significantly increased miRNA-21 and Bcl-2 transcription levels and significantly decreased caspase-3 and PTEN transcription levels.	Berberine	0-9	caspase 3	Mus musculus	107-116
26042820-8	2015	Berberine also significantly increased miRNA-21 and Bcl-2 transcription levels and significantly decreased caspase-3 and PTEN transcription levels.	Berberine	0-9	phosphatase and tensin homolog	Mus musculus	121-125
26042820-10	2015	Additionally, berberine treatment significantly increased the Bcl-2 protein level and significantly decreased the caspase-3 and PTEN protein levels in blastocysts, but there were no significant differences observed in the levels of these proteins in 2- and 4-cell embryos.	Berberine	14-23	B cell leukemia/lymphoma 2	Mus musculus	62-67
26042820-10	2015	Additionally, berberine treatment significantly increased the Bcl-2 protein level and significantly decreased the caspase-3 and PTEN protein levels in blastocysts, but there were no significant differences observed in the levels of these proteins in 2- and 4-cell embryos.	Berberine	14-23	caspase 3	Mus musculus	114-123
26042820-10	2015	Additionally, berberine treatment significantly increased the Bcl-2 protein level and significantly decreased the caspase-3 and PTEN protein levels in blastocysts, but there were no significant differences observed in the levels of these proteins in 2- and 4-cell embryos.	Berberine	14-23	phosphatase and tensin homolog	Mus musculus	128-132
26042820-12	2015	Berberine elevates miRNA-21 expression, decreases PTEN and caspase-3 levels, increases Bcl-2 levels, and exerts anti-apoptotic and pro-growth effects.	Berberine	0-9	phosphatase and tensin homolog	Mus musculus	50-54
26042820-12	2015	Berberine elevates miRNA-21 expression, decreases PTEN and caspase-3 levels, increases Bcl-2 levels, and exerts anti-apoptotic and pro-growth effects.	Berberine	0-9	caspase 3	Mus musculus	59-68
26042820-12	2015	Berberine elevates miRNA-21 expression, decreases PTEN and caspase-3 levels, increases Bcl-2 levels, and exerts anti-apoptotic and pro-growth effects.	Berberine	0-9	B cell leukemia/lymphoma 2	Mus musculus	87-92
25824534-0	2015	Protective effect of berberine against myocardial ischemia reperfusion injury: role of Notch1/Hes1-PTEN/Akt signaling.	Berberine	21-30	hes family bHLH transcription factor 1	Rattus norvegicus	94-98
25824534-0	2015	Protective effect of berberine against myocardial ischemia reperfusion injury: role of Notch1/Hes1-PTEN/Akt signaling.	Berberine	21-30	AKT serine/threonine kinase 1	Rattus norvegicus	104-107
25824534-3	2015	We hypothesize that BBR may protect against MI/RI by modulating Notch1/Hes1-Phosphatase and tensin homolog deleted on chromosome ten (PTEN)/Akt signaling.	Berberine	20-23	notch receptor 1	Rattus norvegicus	64-70
25824534-3	2015	We hypothesize that BBR may protect against MI/RI by modulating Notch1/Hes1-Phosphatase and tensin homolog deleted on chromosome ten (PTEN)/Akt signaling.	Berberine	20-23	hes family bHLH transcription factor 1	Rattus norvegicus	71-75
25824534-3	2015	We hypothesize that BBR may protect against MI/RI by modulating Notch1/Hes1-Phosphatase and tensin homolog deleted on chromosome ten (PTEN)/Akt signaling.	Berberine	20-23	phosphatase and tensin homolog	Rattus norvegicus	134-138
25824534-3	2015	We hypothesize that BBR may protect against MI/RI by modulating Notch1/Hes1-Phosphatase and tensin homolog deleted on chromosome ten (PTEN)/Akt signaling.	Berberine	20-23	AKT serine/threonine kinase 1	Rattus norvegicus	140-143
25824534-9	2015	In summary, our results demonstrate that BBR treatment attenuates MI/RI by modulating Notch1/Hes1-PTEN/Akt signaling.	Berberine	41-44	notch receptor 1	Rattus norvegicus	86-92
25824534-9	2015	In summary, our results demonstrate that BBR treatment attenuates MI/RI by modulating Notch1/Hes1-PTEN/Akt signaling.	Berberine	41-44	hes family bHLH transcription factor 1	Rattus norvegicus	93-97
25824534-9	2015	In summary, our results demonstrate that BBR treatment attenuates MI/RI by modulating Notch1/Hes1-PTEN/Akt signaling.	Berberine	41-44	phosphatase and tensin homolog	Rattus norvegicus	98-102
25824534-9	2015	In summary, our results demonstrate that BBR treatment attenuates MI/RI by modulating Notch1/Hes1-PTEN/Akt signaling.	Berberine	41-44	AKT serine/threonine kinase 1	Rattus norvegicus	103-106
25640685-1	2015	The three purified herbal compounds tetrahydropalmatine (Tet), neferine and berberine (Ber) were explored in vitro for basic inhibition mechanisms towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	76-85	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	173-179
25640685-1	2015	The three purified herbal compounds tetrahydropalmatine (Tet), neferine and berberine (Ber) were explored in vitro for basic inhibition mechanisms towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	76-85	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	181-187
25640685-1	2015	The three purified herbal compounds tetrahydropalmatine (Tet), neferine and berberine (Ber) were explored in vitro for basic inhibition mechanisms towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	76-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	192-198
25640685-1	2015	The three purified herbal compounds tetrahydropalmatine (Tet), neferine and berberine (Ber) were explored in vitro for basic inhibition mechanisms towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	87-90	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	173-179
25640685-1	2015	The three purified herbal compounds tetrahydropalmatine (Tet), neferine and berberine (Ber) were explored in vitro for basic inhibition mechanisms towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	87-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	181-187
25640685-9	2015	Tetrahydropalmatine and Ber demonstrated both reversible and irreversible inhibition of CYP2D6 and CYP3A4.	Berberine	24-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
26221297-0	2015	Berberine reverses abnormal expression of L-type pyruvate kinase by DNA demethylation and histone acetylation in the livers of the non-alcoholic fatty disease rat.	Berberine	0-9	pyruvate kinase L/R	Rattus norvegicus	42-64
26221297-9	2015	Notably, BBR treatment can restore the expression of L-PK by the demethylation of L-PK promoter and the increase in acetylation levels of histone H3 and H4 around L-PK, which indicated that BBR may be a potential drug for epigenetic-included diseases.	Berberine	9-12	pyruvate kinase L/R	Rattus norvegicus	53-57
26221297-9	2015	Notably, BBR treatment can restore the expression of L-PK by the demethylation of L-PK promoter and the increase in acetylation levels of histone H3 and H4 around L-PK, which indicated that BBR may be a potential drug for epigenetic-included diseases.	Berberine	9-12	pyruvate kinase L/R	Rattus norvegicus	82-86
26221297-9	2015	Notably, BBR treatment can restore the expression of L-PK by the demethylation of L-PK promoter and the increase in acetylation levels of histone H3 and H4 around L-PK, which indicated that BBR may be a potential drug for epigenetic-included diseases.	Berberine	9-12	pyruvate kinase L/R	Rattus norvegicus	82-86
26463023-0	2015	[Effect and mechanism of EGFR expression in macrophages on the anti-cancer effect of berberine on colorectal cancer].	Berberine	85-94	epidermal growth factor receptor	Mus musculus	25-29
25572870-4	2015	PC3 human and RM-1 mouse prostate cancer cells were treated with increasing concentrations of berberine, followed by analysis of the cell viability with an MTT assay.	Berberine	94-103	proprotein convertase subtilisin/kexin type 1	Homo sapiens	0-3
25572870-5	2015	The results demonstrated that berberine markedly inhibited the proliferation of PC3 and RM-1 cells, and that the inhibitory effects to PC3 and RM-1 were enhanced in a concentration- and time-dependent manner.	Berberine	30-39	proprotein convertase subtilisin/kexin type 1	Mus musculus	80-83
25572870-5	2015	The results demonstrated that berberine markedly inhibited the proliferation of PC3 and RM-1 cells, and that the inhibitory effects to PC3 and RM-1 were enhanced in a concentration- and time-dependent manner.	Berberine	30-39	proprotein convertase subtilisin/kexin type 1	Mus musculus	135-138
25572870-6	2015	Flow cytometry was used to analyze the cell cycle of PC3 human prostate cancer cells, and the results demonstrated that G0/G1 phase arrest was induced following treatment with 10 microM berberine (P&lt;0.05).	Berberine	186-195	proprotein convertase subtilisin/kexin type 1	Homo sapiens	53-56
25572870-7	2015	However, with an increased concentration of berberine (50 microM) the survival rate of PC3 cells at the G2/M phase was significantly increased compared with the cells treated with 10 microM berberine, which suggests that different cell cycle signaling pathways were activated when PC3 cells were treated with low and high concentrations of berberine.	Berberine	44-53	proprotein convertase subtilisin/kexin type 1	Mus musculus	87-90
25572870-7	2015	However, with an increased concentration of berberine (50 microM) the survival rate of PC3 cells at the G2/M phase was significantly increased compared with the cells treated with 10 microM berberine, which suggests that different cell cycle signaling pathways were activated when PC3 cells were treated with low and high concentrations of berberine.	Berberine	44-53	proprotein convertase subtilisin/kexin type 1	Mus musculus	281-284
25713177-3	2015	Whereas the biosyntheses of nicotine and terpenoid indole alkaloid in Nicotiana plants and Catharanthus roseus are directly or indirectly regulated by Arabidopsis thaliana MYC2 homologs, a non-MYC2-type bHLH transcription factor, CjbHLH1, comprehensively regulates berberine biosynthesis in Coptis japonica.	Berberine	265-274	Basic helix-loop-helix (bHLH) DNA-binding family protein	Arabidopsis thaliana	172-176
26463023-1	2015	OBJECTIVE: To investigate the effect and explore its possible mechanisms of epidermal growth factor receptor(EGFR) expression in macrophages on the anti-cancer effect of berberine (BER) on the growth of colorectal cancer.	Berberine	170-179	epidermal growth factor receptor	Mus musculus	76-108
26463023-1	2015	OBJECTIVE: To investigate the effect and explore its possible mechanisms of epidermal growth factor receptor(EGFR) expression in macrophages on the anti-cancer effect of berberine (BER) on the growth of colorectal cancer.	Berberine	170-179	epidermal growth factor receptor	Mus musculus	109-113
26463023-1	2015	OBJECTIVE: To investigate the effect and explore its possible mechanisms of epidermal growth factor receptor(EGFR) expression in macrophages on the anti-cancer effect of berberine (BER) on the growth of colorectal cancer.	Berberine	181-184	epidermal growth factor receptor	Mus musculus	76-108
25928058-0	2015	Berberine Suppresses Adipocyte Differentiation via Decreasing CREB Transcriptional Activity.	Berberine	0-9	cAMP responsive element binding protein 1	Homo sapiens	62-66
26463023-1	2015	OBJECTIVE: To investigate the effect and explore its possible mechanisms of epidermal growth factor receptor(EGFR) expression in macrophages on the anti-cancer effect of berberine (BER) on the growth of colorectal cancer.	Berberine	181-184	epidermal growth factor receptor	Mus musculus	109-113
25928058-4	2015	In the present study, we found that berberine significantly suppressed the expressions of CCAAT/enhancer-binding protein (C/EBP)alpha, peroxisome proliferators-activated receptor gamma2 (PPARgamma2), and other adipogenic genes in the process of adipogenesis.	Berberine	36-45	CCAAT enhancer binding protein alpha	Homo sapiens	122-133
25623616-9	2015	Compared to conventional in vitro BDI methodologies of assessment, the introduction of human plasma into the in vitro study model changed the observed inhibitory effect of silybin A, silybin B and hydrastine and berberine on CYP2C9 and CYP3A4/5, respectively, results which more closely mirrored those generated in clinical study.	Berberine	212-221	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	225-231
25928058-5	2015	Berberine decreased cAMP-response element-binding protein (CREB) phosphorylation and C/EBPbeta expression at the early stage of 3T3-L1 preadipocyte differentiation.	Berberine	0-9	cAMP responsive element binding protein 1	Homo sapiens	20-57
25928058-5	2015	Berberine decreased cAMP-response element-binding protein (CREB) phosphorylation and C/EBPbeta expression at the early stage of 3T3-L1 preadipocyte differentiation.	Berberine	0-9	cAMP responsive element binding protein 1	Homo sapiens	59-63
25928058-5	2015	Berberine decreased cAMP-response element-binding protein (CREB) phosphorylation and C/EBPbeta expression at the early stage of 3T3-L1 preadipocyte differentiation.	Berberine	0-9	CCAAT enhancer binding protein beta	Homo sapiens	85-94
25928058-6	2015	In addition, CREB phosphorylation and C/EBPbeta expression induced by 3-isobutyl-1-methylxanthine (IBMX) and forskolin were also attenuated by berberine.	Berberine	143-152	cAMP responsive element binding protein 1	Homo sapiens	13-17
25928058-6	2015	In addition, CREB phosphorylation and C/EBPbeta expression induced by 3-isobutyl-1-methylxanthine (IBMX) and forskolin were also attenuated by berberine.	Berberine	143-152	CCAAT enhancer binding protein beta	Homo sapiens	38-47
25928058-8	2015	The binding of phosphorylated CREB to the promoter of C/EBPbeta was abrogated by berberine after the induction of preadipocyte differentiation.	Berberine	81-90	cAMP responsive element binding protein 1	Homo sapiens	30-34
25928058-8	2015	The binding of phosphorylated CREB to the promoter of C/EBPbeta was abrogated by berberine after the induction of preadipocyte differentiation.	Berberine	81-90	CCAAT enhancer binding protein beta	Homo sapiens	54-63
25928058-9	2015	These results suggest that berberine blocks adipogenesis mainly via suppressing CREB activity, which leads to a decrease in C/EBPbeta-triggered transcriptional cascades.	Berberine	27-36	cAMP responsive element binding protein 1	Homo sapiens	80-84
25928058-9	2015	These results suggest that berberine blocks adipogenesis mainly via suppressing CREB activity, which leads to a decrease in C/EBPbeta-triggered transcriptional cascades.	Berberine	27-36	CCAAT enhancer binding protein beta	Homo sapiens	124-133
25700642-11	2015	The major components in HLJDD, geniposide, berberine and baicalin, additively act on eEF2, and contributed to the responsible activity.	Berberine	43-52	eukaryotic translation elongation factor 2	Homo sapiens	85-89
25686503-8	2015	Furthermore, AMPK inhibitor compound C or dominant negative AMPK adenovirus inhibited the effects of berberine on above-mentioned marker proteins and EDCs.	Berberine	101-110	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	13-17
25716948-0	2015	Berberine regulates melanin synthesis by activating PI3K/AKT, ERK and GSK3beta in B16F10 melanoma cells.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	57-60
25716948-0	2015	Berberine regulates melanin synthesis by activating PI3K/AKT, ERK and GSK3beta in B16F10 melanoma cells.	Berberine	0-9	mitogen-activated protein kinase 1	Mus musculus	62-65
25716948-0	2015	Berberine regulates melanin synthesis by activating PI3K/AKT, ERK and GSK3beta in B16F10 melanoma cells.	Berberine	0-9	glycogen synthase kinase 3 beta	Mus musculus	70-78
25716948-3	2015	In the present study, we examined the mechanism underlying the inhibitory effect of berberine on alpha-melanocyte-stimulating hormone (alpha-MSH)-stimulated B16F10 melanoma cells.	Berberine	84-93	pro-opiomelanocortin-alpha	Mus musculus	97-133
25716948-3	2015	In the present study, we examined the mechanism underlying the inhibitory effect of berberine on alpha-melanocyte-stimulating hormone (alpha-MSH)-stimulated B16F10 melanoma cells.	Berberine	84-93	pro-opiomelanocortin-alpha	Mus musculus	135-144
25716948-4	2015	The results showed that berberine attenuated alpha-MSH induction of the microphthalmia-associated transcription factor (MITF) and tyrosinase in a dose-dependent manner.	Berberine	24-33	pro-opiomelanocortin-alpha	Mus musculus	45-54
25716948-4	2015	The results showed that berberine attenuated alpha-MSH induction of the microphthalmia-associated transcription factor (MITF) and tyrosinase in a dose-dependent manner.	Berberine	24-33	melanogenesis associated transcription factor	Mus musculus	72-118
25716948-4	2015	The results showed that berberine attenuated alpha-MSH induction of the microphthalmia-associated transcription factor (MITF) and tyrosinase in a dose-dependent manner.	Berberine	24-33	melanogenesis associated transcription factor	Mus musculus	120-124
25716948-4	2015	The results showed that berberine attenuated alpha-MSH induction of the microphthalmia-associated transcription factor (MITF) and tyrosinase in a dose-dependent manner.	Berberine	24-33	tyrosinase	Mus musculus	130-140
25716948-5	2015	To elucidate the mechanism underlying the inhibitory effect of berberine, we examined the effect of alpha-MSH-stimulated phosphorylation of PI3K/AKT, ERK, and GSK3beta.	Berberine	63-72	pro-opiomelanocortin-alpha	Mus musculus	100-109
25716948-6	2015	The results showed that treatment with berberine resulted in a reduction in the phosphorylation of PI3K/AKT, ERK, and GSK3beta.	Berberine	39-48	thymoma viral proto-oncogene 1	Mus musculus	104-107
25716948-6	2015	The results showed that treatment with berberine resulted in a reduction in the phosphorylation of PI3K/AKT, ERK, and GSK3beta.	Berberine	39-48	mitogen-activated protein kinase 1	Mus musculus	109-112
25716948-6	2015	The results showed that treatment with berberine resulted in a reduction in the phosphorylation of PI3K/AKT, ERK, and GSK3beta.	Berberine	39-48	glycogen synthase kinase 3 beta	Mus musculus	118-126
25716948-7	2015	Taken together, the results suggested that berberine inhibits melanin synthesis and tyrosinase activity by downregulating the expression of MITF and tyrosinase.	Berberine	43-52	tyrosinase	Mus musculus	84-94
25716948-7	2015	Taken together, the results suggested that berberine inhibits melanin synthesis and tyrosinase activity by downregulating the expression of MITF and tyrosinase.	Berberine	43-52	melanogenesis associated transcription factor	Mus musculus	140-144
25716948-7	2015	Taken together, the results suggested that berberine inhibits melanin synthesis and tyrosinase activity by downregulating the expression of MITF and tyrosinase.	Berberine	43-52	tyrosinase	Mus musculus	149-159
25634589-0	2015	Berberine induces FasL-related apoptosis through p38 activation in KB human oral cancer cells.	Berberine	0-9	Fas ligand	Homo sapiens	18-22
25634589-0	2015	Berberine induces FasL-related apoptosis through p38 activation in KB human oral cancer cells.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	49-52
25634589-6	2015	Berberine was also found to upregulate significantly the expression of the death receptor ligand, FasL.	Berberine	0-9	Fas ligand	Homo sapiens	98-102
25634589-8	2015	Furthermore, pro-apoptotic factors such as Bax, Bad and Apaf-1 were also significantly upregulated by berberine.	Berberine	102-111	BCL2 associated X, apoptosis regulator	Homo sapiens	43-46
25634589-8	2015	Furthermore, pro-apoptotic factors such as Bax, Bad and Apaf-1 were also significantly upregulated by berberine.	Berberine	102-111	apoptotic peptidase activating factor 1	Homo sapiens	56-62
25634589-12	2015	In addition, berberine-induced upregulation of FasL was shown to be mediated by the p38 MAPK signaling pathway.	Berberine	13-22	Fas ligand	Homo sapiens	47-51
25634589-12	2015	In addition, berberine-induced upregulation of FasL was shown to be mediated by the p38 MAPK signaling pathway.	Berberine	13-22	mitogen-activated protein kinase 14	Homo sapiens	84-87
25634589-13	2015	We also found that berberine-induced migration suppression was mediated by downregulation of MMP-2 and MMP-9 through phosphorylation of p38 MAPK.	Berberine	19-28	matrix metallopeptidase 2	Homo sapiens	93-98
25634589-13	2015	We also found that berberine-induced migration suppression was mediated by downregulation of MMP-2 and MMP-9 through phosphorylation of p38 MAPK.	Berberine	19-28	matrix metallopeptidase 9	Homo sapiens	103-108
25634589-13	2015	We also found that berberine-induced migration suppression was mediated by downregulation of MMP-2 and MMP-9 through phosphorylation of p38 MAPK.	Berberine	19-28	mitogen-activated protein kinase 14	Homo sapiens	136-139
25686503-8	2015	Furthermore, AMPK inhibitor compound C or dominant negative AMPK adenovirus inhibited the effects of berberine on above-mentioned marker proteins and EDCs.	Berberine	101-110	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	60-64
25686503-10	2015	Taken together, the present results suggest that berberine reduces EDCs likely through activating AMPK, thus inhibiting ER stress and subsequently scavenging ROS leading to COX-2 down-regulation in SHR carotid arteries.	Berberine	49-58	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	98-102
25686503-10	2015	Taken together, the present results suggest that berberine reduces EDCs likely through activating AMPK, thus inhibiting ER stress and subsequently scavenging ROS leading to COX-2 down-regulation in SHR carotid arteries.	Berberine	49-58	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	173-178
25769560-3	2015	In the present study, we examined the role of phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) and mammalian target of rapamycin (mTOR) in the protective effect of BBR on hepatic I/R-mediated apoptosis in rats.	Berberine	173-176	protein tyrosine kinase 2 beta	Homo sapiens	76-92
25884210-10	2015	In addition, berberine increased the ratio of p-AMPK/AMPK and decreased the ratio of p-mTOR/mTOR.	Berberine	13-22	mechanistic target of rapamycin kinase	Mus musculus	92-96
25884210-12	2015	CONCLUSION: Berberine treatment inhibits inflammation in J774A.1 cells by inducing autophagy, which is mediated through activation of the AMPK/mTOR signaling pathway.	Berberine	12-21	mechanistic target of rapamycin kinase	Mus musculus	143-147
25496992-0	2015	Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma.	Berberine	0-9	inhibitor of DNA binding 1, HLH protein	Mus musculus	21-25
25496992-7	2015	Consistent with previous reports in other cancer, berberine"s anti-tumor activity was accompanied by suppression of cellular proliferation, invasiveness and HIF-1alpha/VEGF signaling.	Berberine	50-59	hypoxia inducible factor 1, alpha subunit	Mus musculus	157-167
25496992-7	2015	Consistent with previous reports in other cancer, berberine"s anti-tumor activity was accompanied by suppression of cellular proliferation, invasiveness and HIF-1alpha/VEGF signaling.	Berberine	50-59	vascular endothelial growth factor A	Mus musculus	168-172
25496992-8	2015	Strikingly, further mechanistic investigation revealed that berberine exerted profound inhibitory effect on the expression of Id-1, which is a key regulator for HCC development and metastasis.	Berberine	60-69	inhibitor of DNA binding 1, HLH protein	Mus musculus	126-130
25496992-9	2015	Berberine could suppress the transcription level of Id-1 through inhibiting its promotor activity.	Berberine	0-9	inhibitor of DNA binding 1, HLH protein	Mus musculus	52-56
25496992-10	2015	Specific downregulation of Id-1 by knocking down its RNA transcripts in HCC cells inhibited cellular growth, invasion and VEGF secretion, demonstrating the functional relevance of Id-1 downregulation induced by berberine.	Berberine	211-220	inhibitor of DNA binding 1, HLH protein	Mus musculus	27-31
25496992-10	2015	Specific downregulation of Id-1 by knocking down its RNA transcripts in HCC cells inhibited cellular growth, invasion and VEGF secretion, demonstrating the functional relevance of Id-1 downregulation induced by berberine.	Berberine	211-220	vascular endothelial growth factor A	Mus musculus	122-126
25496992-10	2015	Specific downregulation of Id-1 by knocking down its RNA transcripts in HCC cells inhibited cellular growth, invasion and VEGF secretion, demonstrating the functional relevance of Id-1 downregulation induced by berberine.	Berberine	211-220	inhibitor of DNA binding 1, HLH protein	Mus musculus	180-184
25496992-11	2015	Lastly, berberine"s anti-proliferative and anti-invasive activities could be partially rescued by Id-1 overexpression in HCC models, revealing a novel anti-cancer/anti-invasive mechanism of berberine via Id-1 suppression.	Berberine	8-17	inhibitor of DNA binding 1, HLH protein	Mus musculus	98-102
25496992-11	2015	Lastly, berberine"s anti-proliferative and anti-invasive activities could be partially rescued by Id-1 overexpression in HCC models, revealing a novel anti-cancer/anti-invasive mechanism of berberine via Id-1 suppression.	Berberine	8-17	inhibitor of DNA binding 1, HLH protein	Mus musculus	204-208
25496992-11	2015	Lastly, berberine"s anti-proliferative and anti-invasive activities could be partially rescued by Id-1 overexpression in HCC models, revealing a novel anti-cancer/anti-invasive mechanism of berberine via Id-1 suppression.	Berberine	190-199	inhibitor of DNA binding 1, HLH protein	Mus musculus	98-102
25496992-11	2015	Lastly, berberine"s anti-proliferative and anti-invasive activities could be partially rescued by Id-1 overexpression in HCC models, revealing a novel anti-cancer/anti-invasive mechanism of berberine via Id-1 suppression.	Berberine	190-199	inhibitor of DNA binding 1, HLH protein	Mus musculus	204-208
25394789-0	2015	Berberine targets epidermal growth factor receptor signaling to suppress prostate cancer proliferation in vitro.	Berberine	0-9	epidermal growth factor receptor	Homo sapiens	18-50
25394789-6	2015	Western blot analysis demonstrated that berberine inhibited the expression of prostate-specific antigen and the activation of epidermal growth factor receptor (EGFR), and it attenuated EGFR activation following EGF treatment in vitro.	Berberine	40-49	kallikrein related peptidase 3	Homo sapiens	78-103
25394789-6	2015	Western blot analysis demonstrated that berberine inhibited the expression of prostate-specific antigen and the activation of epidermal growth factor receptor (EGFR), and it attenuated EGFR activation following EGF treatment in vitro.	Berberine	40-49	epidermal growth factor receptor	Homo sapiens	126-158
25394789-6	2015	Western blot analysis demonstrated that berberine inhibited the expression of prostate-specific antigen and the activation of epidermal growth factor receptor (EGFR), and it attenuated EGFR activation following EGF treatment in vitro.	Berberine	40-49	epidermal growth factor receptor	Homo sapiens	160-164
25394789-7	2015	In conclusion, the results indicate that berberine inhibits the proliferation of prostate cancer cells through apoptosis and/or cell cycle arrest by inactivation of the EGFR signaling pathway.	Berberine	41-50	epidermal growth factor receptor	Homo sapiens	169-173
25884210-0	2015	Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway.	Berberine	0-9	mechanistic target of rapamycin kinase	Mus musculus	96-100
25884210-8	2015	RESULTS: Berberine dose- and time-dependently reduced ox-LDL-induced inflammation and increased the ratio of LC3II/LC3I, and SQSTM1/p62 in J774A.1 cells.	Berberine	9-18	sequestosome 1	Mus musculus	125-131
25884210-8	2015	RESULTS: Berberine dose- and time-dependently reduced ox-LDL-induced inflammation and increased the ratio of LC3II/LC3I, and SQSTM1/p62 in J774A.1 cells.	Berberine	9-18	sequestosome 1	Mus musculus	132-135
25884210-10	2015	In addition, berberine increased the ratio of p-AMPK/AMPK and decreased the ratio of p-mTOR/mTOR.	Berberine	13-22	mechanistic target of rapamycin kinase	Mus musculus	87-91
25769560-3	2015	In the present study, we examined the role of phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) and mammalian target of rapamycin (mTOR) in the protective effect of BBR on hepatic I/R-mediated apoptosis in rats.	Berberine	173-176	mechanistic target of rapamycin kinase	Homo sapiens	108-137
25769560-3	2015	In the present study, we examined the role of phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) and mammalian target of rapamycin (mTOR) in the protective effect of BBR on hepatic I/R-mediated apoptosis in rats.	Berberine	173-176	mechanistic target of rapamycin kinase	Homo sapiens	139-143
25769560-12	2015	CONCLUSION: Our study reveals that BBR preconditioning protects against hepatic I/R partly by reducing apoptosis, which is possibly involved with the modulation of the PI3K/Akt/mTOR signaling pathway.	Berberine	35-38	AKT serine/threonine kinase 1	Rattus norvegicus	173-176
25951637-14	2015	Compared with the model group, the expression of LXRalpha and FAS at mRNA and protein levels was obviously down-regulated in the berberine group (P &lt; 0.01).	Berberine	129-138	nuclear receptor subfamily 1, group H, member 3	Rattus norvegicus	49-57
25769560-12	2015	CONCLUSION: Our study reveals that BBR preconditioning protects against hepatic I/R partly by reducing apoptosis, which is possibly involved with the modulation of the PI3K/Akt/mTOR signaling pathway.	Berberine	35-38	mechanistic target of rapamycin kinase	Rattus norvegicus	177-181
25540198-1	2015	Our previous in vitro studies have identified hepatocyte nuclear factor 1alpha (HNF1alpha) as an obligated trans-activator for PCSK9 gene expression and demonstrated its functional involvement in the suppression of PCSK9 expression by berberine (BBR), a natural cholesterol-lowering compound.	Berberine	246-249	proprotein convertase subtilisin/kexin type 9	Homo sapiens	215-220
25498346-9	2015	In the treatment of type 2 diabetes mellitus, we found that berberine with lifestyle intervention tended to lower the level of FPG, PPG and HbA1c than lifestyle intervention alone or placebo; the same as berberine combined with oral hypoglycaemics to the same hypoglycaemics; but there was no statistical significance between berberine and oral hypoglycaemics.	Berberine	60-69	serglycin	Homo sapiens	132-135
25540198-0	2015	Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1alpha protein expression through the ubiquitin-proteasome degradation pathway.	Berberine	37-46	proprotein convertase subtilisin/kexin type 9	Homo sapiens	14-19
25540198-8	2015	Moreover, HNF1alpha protein displayed a multiubiquitination ladder pattern in cells treated with BBR or overexpressing ubiquitin.	Berberine	97-100	HNF1 homeobox A	Homo sapiens	10-19
25540198-0	2015	Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1alpha protein expression through the ubiquitin-proteasome degradation pathway.	Berberine	37-46	HNF1 homeobox A	Homo sapiens	83-92
25540198-1	2015	Our previous in vitro studies have identified hepatocyte nuclear factor 1alpha (HNF1alpha) as an obligated trans-activator for PCSK9 gene expression and demonstrated its functional involvement in the suppression of PCSK9 expression by berberine (BBR), a natural cholesterol-lowering compound.	Berberine	235-244	HNF1 homeobox A	Homo sapiens	46-89
24893659-0	2015	Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia.	Berberine	82-91	proprotein convertase subtilisin/kexin type 9	Rattus norvegicus	14-59
25540198-1	2015	Our previous in vitro studies have identified hepatocyte nuclear factor 1alpha (HNF1alpha) as an obligated trans-activator for PCSK9 gene expression and demonstrated its functional involvement in the suppression of PCSK9 expression by berberine (BBR), a natural cholesterol-lowering compound.	Berberine	235-244	proprotein convertase subtilisin/kexin type 9	Homo sapiens	215-220
25517919-10	2015	Upon treatment of PANC-1 and MIA-PaCa2 with berberine at a half-maximal inhibitory concentration (IC50), apoptosis was induced by a mechanism that involved the production of reactive oxygen species (ROS) rather than caspase 3/7 activation.	Berberine	44-53	caspase 3	Homo sapiens	216-225
24893659-10	2015	However, the addition of berberine or Hdber reversed the blood lipid profile changes (P&lt;0.05 or P&lt;0.01), decreased the expression levels of PCSK-9 proteins (P&lt;0.01), and increased the expression levels of LDL-R proteins in the hyperlipidemic rats (P&lt;0.01).	Berberine	25-34	proprotein convertase subtilisin/kexin type 9	Rattus norvegicus	146-152
24893659-10	2015	However, the addition of berberine or Hdber reversed the blood lipid profile changes (P&lt;0.05 or P&lt;0.01), decreased the expression levels of PCSK-9 proteins (P&lt;0.01), and increased the expression levels of LDL-R proteins in the hyperlipidemic rats (P&lt;0.01).	Berberine	25-34	low density lipoprotein receptor	Rattus norvegicus	214-219
25504754-0	2015	Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway.	Berberine	0-9	epidermal growth factor receptor	Homo sapiens	79-83
25209439-9	2015	Treatment of ROR2-expressing breast cancer cells with the novel berberine derivative, NAX53, significantly inhibited cell proliferation and migration.	Berberine	64-73	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	13-17
25504754-5	2015	In glioblastoma cells treated with berberine, the level of epidermal growth factor receptor (EGFR) was greatly reduced.	Berberine	35-44	epidermal growth factor receptor	Homo sapiens	59-91
25504754-0	2015	Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway.	Berberine	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
25504754-5	2015	In glioblastoma cells treated with berberine, the level of epidermal growth factor receptor (EGFR) was greatly reduced.	Berberine	35-44	epidermal growth factor receptor	Homo sapiens	93-97
25504754-9	2015	Berberine also potently inhibited the growth of tumor xenografts, which was accompanied by downregulation of EGFR and induction of senescence.	Berberine	0-9	epidermal growth factor receptor	Homo sapiens	109-113
25352028-6	2015	In both MCF-7 and MDA-MB-231 cells, berberine increased the production of reactive oxygen species (ROS), which activated the pro-apoptotic JNK signaling.	Berberine	36-45	mitogen-activated protein kinase 8	Homo sapiens	139-142
25504754-11	2015	Because EGFR is commonly upregulated in glioblastoma, the demonstration of effective inhibition of EGFR by berberine points to the possibility of using berberine in the treatment of patients with glioblastoma.	Berberine	107-116	epidermal growth factor receptor	Homo sapiens	99-103
25504754-11	2015	Because EGFR is commonly upregulated in glioblastoma, the demonstration of effective inhibition of EGFR by berberine points to the possibility of using berberine in the treatment of patients with glioblastoma.	Berberine	152-161	epidermal growth factor receptor	Homo sapiens	99-103
25048007-0	2015	Berberine protects homocysteic acid-induced HT-22 cell death: involvement of Akt pathway.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	77-80
26225680-6	2015	Berberine derivatives, B2 and B4, showed approximately the same level of CAT expression and significant up-regulation of SOD expression in a dose-dependent manner compared to berberine treatment for 7-day exposure using reverse transcription- polymerase chain reaction (RT-PCR) assays.	Berberine	0-9	immunoglobulin kappa variable 5-2	Homo sapiens	23-32
26503561-0	2015	Berberine Increases Doxorubicin Sensitivity by Suppressing STAT3 in Lung Cancer.	Berberine	0-9	signal transducer and activator of transcription 3	Homo sapiens	59-64
25544381-11	2015	In addition, Berberine was found to restore the demethylation status of the hMLH1 promoter and up-regulate the mRNA expression of hMLH1.	Berberine	13-22	mutL homolog 1	Homo sapiens	76-81
25544381-11	2015	In addition, Berberine was found to restore the demethylation status of the hMLH1 promoter and up-regulate the mRNA expression of hMLH1.	Berberine	13-22	mutL homolog 1	Homo sapiens	130-135
25145883-10	2015	Neither CYP1A2 nor CYP3A4 was markedly inhibited by berberine, palmatine, and geniposide-major components in HR-and CYP2D6 was inhibited by berberine (IC50, 13.8 mug/ml) in a metabolism-dependent manner.	Berberine	140-149	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	116-122
25359200-4	2015	To investigate whether this inhibitory effect of berberine on OCT1 and OCT2 could change the pharmacokinetics of metformin in vivo, we measured the effect of berberine co-administration on the pharmacokinetics of metformin at a single intravenous dose of 2 mg/kg metformin and 10 mg/kg berberine.	Berberine	49-58	solute carrier family 22 member 1	Homo sapiens	62-66
25359200-4	2015	To investigate whether this inhibitory effect of berberine on OCT1 and OCT2 could change the pharmacokinetics of metformin in vivo, we measured the effect of berberine co-administration on the pharmacokinetics of metformin at a single intravenous dose of 2 mg/kg metformin and 10 mg/kg berberine.	Berberine	49-58	solute carrier family 22 member 2	Homo sapiens	71-75
25359200-5	2015	In HEK293 cells, berberine inhibited OCT1- and OCT2-mediated metformin uptake in a concentration dependent manner and IC50 values for OCT1 and OCT2 were 7.28 and 11.3 muM, respectively.	Berberine	17-26	solute carrier family 22 member 1	Homo sapiens	37-41
25359200-5	2015	In HEK293 cells, berberine inhibited OCT1- and OCT2-mediated metformin uptake in a concentration dependent manner and IC50 values for OCT1 and OCT2 were 7.28 and 11.3 muM, respectively.	Berberine	17-26	solute carrier family 22 member 2	Homo sapiens	47-51
25359200-5	2015	In HEK293 cells, berberine inhibited OCT1- and OCT2-mediated metformin uptake in a concentration dependent manner and IC50 values for OCT1 and OCT2 were 7.28 and 11.3 muM, respectively.	Berberine	17-26	solute carrier family 22 member 1	Homo sapiens	134-138
25359200-5	2015	In HEK293 cells, berberine inhibited OCT1- and OCT2-mediated metformin uptake in a concentration dependent manner and IC50 values for OCT1 and OCT2 were 7.28 and 11.3 muM, respectively.	Berberine	17-26	solute carrier family 22 member 2	Homo sapiens	143-147
25359200-5	2015	In HEK293 cells, berberine inhibited OCT1- and OCT2-mediated metformin uptake in a concentration dependent manner and IC50 values for OCT1 and OCT2 were 7.28 and 11.3 muM, respectively.	Berberine	17-26	latexin	Homo sapiens	167-170
25359200-6	2015	Co-administration of berberine increased the initial plasma concentration and AUC of metformin and decreased systemic clearance and volume of distribution of metformin in rats, suggesting that berberine inhibited disposition of metformin, which is governed by OCT1 and OCT2.	Berberine	21-30	solute carrier family 22 member 1	Rattus norvegicus	260-264
25359200-6	2015	Co-administration of berberine increased the initial plasma concentration and AUC of metformin and decreased systemic clearance and volume of distribution of metformin in rats, suggesting that berberine inhibited disposition of metformin, which is governed by OCT1 and OCT2.	Berberine	21-30	POU class 2 homeobox 2	Rattus norvegicus	269-273
25359200-6	2015	Co-administration of berberine increased the initial plasma concentration and AUC of metformin and decreased systemic clearance and volume of distribution of metformin in rats, suggesting that berberine inhibited disposition of metformin, which is governed by OCT1 and OCT2.	Berberine	193-202	solute carrier family 22 member 1	Rattus norvegicus	260-264
25359200-6	2015	Co-administration of berberine increased the initial plasma concentration and AUC of metformin and decreased systemic clearance and volume of distribution of metformin in rats, suggesting that berberine inhibited disposition of metformin, which is governed by OCT1 and OCT2.	Berberine	193-202	POU class 2 homeobox 2	Rattus norvegicus	269-273
25359200-7	2015	Berberine inhibited the transport activity of OCT1 and OCT2 and showed significant potential drug-drug interactions with metformin in in vivo rats.	Berberine	0-9	solute carrier family 22 member 1	Rattus norvegicus	46-50
25359200-7	2015	Berberine inhibited the transport activity of OCT1 and OCT2 and showed significant potential drug-drug interactions with metformin in in vivo rats.	Berberine	0-9	POU class 2 homeobox 2	Rattus norvegicus	55-59
26225680-6	2015	Berberine derivatives, B2 and B4, showed approximately the same level of CAT expression and significant up-regulation of SOD expression in a dose-dependent manner compared to berberine treatment for 7-day exposure using reverse transcription- polymerase chain reaction (RT-PCR) assays.	Berberine	175-184	immunoglobulin kappa variable 5-2	Homo sapiens	23-32
26087719-0	2015	Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway.	Berberine	0-9	microRNA 9-3	Homo sapiens	69-75
26027825-10	2015	In conclusion, our data show that berberine improves vascular inflammation and remodeling in the MS condition, and this is correlated with the ability of berberine to inhibit p38 MAPK activation, ATF-2 phosphorylation, and MMP-2 expression.	Berberine	154-163	activating transcription factor 2	Rattus norvegicus	196-201
26027825-10	2015	In conclusion, our data show that berberine improves vascular inflammation and remodeling in the MS condition, and this is correlated with the ability of berberine to inhibit p38 MAPK activation, ATF-2 phosphorylation, and MMP-2 expression.	Berberine	154-163	matrix metallopeptidase 2	Rattus norvegicus	223-228
25341882-8	2015	The results revealed that berberine decreased the serum D-lactate level, intestinal FD4 clearance, and myeloperoxidase activity.	Berberine	26-35	myeloperoxidase	Rattus norvegicus	103-118
26027825-10	2015	In conclusion, our data show that berberine improves vascular inflammation and remodeling in the MS condition, and this is correlated with the ability of berberine to inhibit p38 MAPK activation, ATF-2 phosphorylation, and MMP-2 expression.	Berberine	154-163	mitogen activated protein kinase 14	Rattus norvegicus	175-178
25705654-8	2015	Berberine treatment increased expression of skeletal muscle glucose transporter 4 mRNA and significantly decreased liver low density lipoprotein receptor mRNA expression.	Berberine	0-9	low density lipoprotein receptor	Mus musculus	121-153
26087719-0	2015	Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway.	Berberine	0-9	phosphatase and tensin homolog	Homo sapiens	76-80
26087719-0	2015	Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	81-84
26087719-9	2015	Furthermore, our study found berberine could inhibit miR-93 expression and function in ovarian cancer, as shown by an increase of its target PTEN, an important tumor suppressor in ovarian cancer.	Berberine	29-38	microRNA 9-3	Homo sapiens	53-59
26087719-9	2015	Furthermore, our study found berberine could inhibit miR-93 expression and function in ovarian cancer, as shown by an increase of its target PTEN, an important tumor suppressor in ovarian cancer.	Berberine	29-38	phosphatase and tensin homolog	Homo sapiens	141-145
26087719-12	2015	CONCLUSION: The results suggested that berberine modulated the sensitivity of cisplatin through miR-93/PTEN/AKT signaling pathway in the ovarian cancer cells.	Berberine	39-48	microRNA 9-3	Homo sapiens	96-102
26087719-12	2015	CONCLUSION: The results suggested that berberine modulated the sensitivity of cisplatin through miR-93/PTEN/AKT signaling pathway in the ovarian cancer cells.	Berberine	39-48	phosphatase and tensin homolog	Homo sapiens	103-107
26087719-12	2015	CONCLUSION: The results suggested that berberine modulated the sensitivity of cisplatin through miR-93/PTEN/AKT signaling pathway in the ovarian cancer cells.	Berberine	39-48	AKT serine/threonine kinase 1	Homo sapiens	108-111
25867076-9	2015	Furthermore, berberine could inhibit the activities of RAS and pre-inflammatory cytokines IL-6, IL-17 and IL-23, which are involved in the pathophysiology of hypertension.	Berberine	13-22	interleukin 6	Rattus norvegicus	90-94
25660286-7	2015	Several compounds, such as berberine, berberrubine and epiberberine, dose-dependently inhibited PGE2 production in human KB cells, and the effects were similar in the presence or absence of TPA.	Berberine	27-36	plasminogen activator, tissue type	Homo sapiens	190-193
25867076-9	2015	Furthermore, berberine could inhibit the activities of RAS and pre-inflammatory cytokines IL-6, IL-17 and IL-23, which are involved in the pathophysiology of hypertension.	Berberine	13-22	interleukin 17A	Rattus norvegicus	96-101
26351511-0	2015	Berberine Regulated Lipid Metabolism in the Presence of C75, Compound C, and TOFA in Breast Cancer Cell Line MCF-7.	Berberine	0-9	BTG anti-proliferation factor 3	Homo sapiens	77-81
26351511-3	2015	In the presence of some energy-related inhibitors, including C75, compound C, and TOFA, the discrete roles of berberine in lipid metabolism and mitochondrial function were elucidated.	Berberine	110-119	BTG anti-proliferation factor 3	Homo sapiens	82-86
26351511-4	2015	An altered lipid metabolism induced by berberine was observed under the inhibition of FASN, AMPK, and ACC in breast cancer cell MCF-7.	Berberine	39-48	fatty acid synthase	Homo sapiens	86-90
26783411-6	2015	The ALP and BGP levels decreased in diabetic rats but were successfully corrected by insulin and berberine combined treatment.	Berberine	97-106	bone gamma-carboxyglutamate protein	Rattus norvegicus	12-15
26351511-4	2015	An altered lipid metabolism induced by berberine was observed under the inhibition of FASN, AMPK, and ACC in breast cancer cell MCF-7.	Berberine	39-48	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	92-96
26351511-5	2015	And the reversion of berberine-induced lipid suppression indicated that ACC inhibition might be involved in that process instead of FASN inhibition.	Berberine	21-30	fatty acid synthase	Homo sapiens	132-136
26351511-6	2015	A robust apoptosis induced by berberine even under the inhibition of AMPK and lipid synthesis was also indicated.	Berberine	30-39	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	69-73
26068524-5	2015	Our studies indicated that berberine uptake was significantly suppressed by rifampicin, cyclosporine A and glycyrrhizic acid, which act as specific inhibitors of different Oatp isoforms (Oatp1a1, Oatp1a4 and Oatp1b2) in rat hepatocytes.	Berberine	27-36	solute carrier organic anion transporter family member 1A2	Homo sapiens	172-176
25481375-4	2015	Our data show that hydroalcoholic extracts of greater celandine and its alkaloids, especially berberine, chelidonine and sanguinarine have a significant hERG potassium channel blocking effect.	Berberine	94-103	ETS transcription factor ERG	Homo sapiens	153-157
25422142-4	2015	In fact, AMPK is a target of some pharmacological agents implemented in the treatment of diabetes (metformin and thiazolidinediones) as well as other naturally derived products, such as berberine, which is used in traditional medicine.	Berberine	186-195	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	9-13
25837881-0	2015	Akt signaling is associated with the berberine-induced apoptosis of human gastric cancer cells.	Berberine	37-46	AKT serine/threonine kinase 1	Homo sapiens	0-3
25837881-2	2015	Here, we found that berberine-induced cell apoptosis in human gastric cancer cells with the increase of the expression level of cleaved poly ADP-ribose polymerase and caspase-3, and the impairment of mitochondrial membrane potential (Deltapsim) in berberine-treated gastric cancer cells.	Berberine	20-29	poly(ADP-ribose) polymerase 1	Homo sapiens	136-162
25837881-2	2015	Here, we found that berberine-induced cell apoptosis in human gastric cancer cells with the increase of the expression level of cleaved poly ADP-ribose polymerase and caspase-3, and the impairment of mitochondrial membrane potential (Deltapsim) in berberine-treated gastric cancer cells.	Berberine	20-29	caspase 3	Homo sapiens	167-176
25837881-3	2015	In our further studies, the results demonstrated that Akt-related mitochondrial pathway may partly involve in the berberine-induced apoptosis in human gastric cancer cells.	Berberine	114-123	AKT serine/threonine kinase 1	Homo sapiens	54-57
25837881-4	2015	Moreover, berberine inhibited the Akt/mTOR/p70S6/S6 pathway in berberine-treated BGC-823 cells.	Berberine	10-19	AKT serine/threonine kinase 1	Homo sapiens	34-37
25837881-4	2015	Moreover, berberine inhibited the Akt/mTOR/p70S6/S6 pathway in berberine-treated BGC-823 cells.	Berberine	10-19	mechanistic target of rapamycin kinase	Homo sapiens	38-42
25837881-4	2015	Moreover, berberine inhibited the Akt/mTOR/p70S6/S6 pathway in berberine-treated BGC-823 cells.	Berberine	63-72	AKT serine/threonine kinase 1	Homo sapiens	34-37
25837881-4	2015	Moreover, berberine inhibited the Akt/mTOR/p70S6/S6 pathway in berberine-treated BGC-823 cells.	Berberine	63-72	mechanistic target of rapamycin kinase	Homo sapiens	38-42
25837881-5	2015	Meanwhile, berberine significantly inhibited the activation of Akt and suppressed tumor growth in xenograft nude mice injected with human gastric cancer cells.	Berberine	11-20	thymoma viral proto-oncogene 1	Mus musculus	63-66
25837881-6	2015	Thus, our findings reveal that the underlying mechanism that Akt signaling may contribute to berberine-induced cell apoptosis in gastric cancer cells and might represent an important molecular basis for berberine to act as an anticancer agent.	Berberine	93-102	AKT serine/threonine kinase 1	Homo sapiens	61-64
25837881-6	2015	Thus, our findings reveal that the underlying mechanism that Akt signaling may contribute to berberine-induced cell apoptosis in gastric cancer cells and might represent an important molecular basis for berberine to act as an anticancer agent.	Berberine	203-212	AKT serine/threonine kinase 1	Homo sapiens	61-64
25785174-5	2015	Among these compounds, berberine, an isoquinoline alkaloid derived from plants of the generis Berberis, has been recognized as being capable of decreasing oxidative stress, LDL, triglycerides, and insulin resistance and of improving the mood.	Berberine	23-32	insulin	Homo sapiens	197-204
25970816-9	2015	Berberine reduced the activity of myocardial enzymes, including aspartate aminotransferase (AST), creatine kinase (CK), CK isoenzyme (CK-MB) and lactate dehydrogenase (LDH).	Berberine	0-9	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	64-90
25970816-9	2015	Berberine reduced the activity of myocardial enzymes, including aspartate aminotransferase (AST), creatine kinase (CK), CK isoenzyme (CK-MB) and lactate dehydrogenase (LDH).	Berberine	0-9	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	92-95
25605990-5	2015	Results showed that the tumor necrosis factor-alpha (TNF-alpha ) and interleukin-6 (IL-6) level were significantly lower in berberine-treated rats compared to the control animals.	Berberine	124-133	tumor necrosis factor	Rattus norvegicus	24-51
25605990-5	2015	Results showed that the tumor necrosis factor-alpha (TNF-alpha ) and interleukin-6 (IL-6) level were significantly lower in berberine-treated rats compared to the control animals.	Berberine	124-133	tumor necrosis factor	Rattus norvegicus	53-62
25605990-5	2015	Results showed that the tumor necrosis factor-alpha (TNF-alpha ) and interleukin-6 (IL-6) level were significantly lower in berberine-treated rats compared to the control animals.	Berberine	124-133	interleukin 6	Rattus norvegicus	69-82
25605990-5	2015	Results showed that the tumor necrosis factor-alpha (TNF-alpha ) and interleukin-6 (IL-6) level were significantly lower in berberine-treated rats compared to the control animals.	Berberine	124-133	interleukin 6	Rattus norvegicus	84-88
25605990-7	2015	The mRNA expression of TLR 2, TLR 4, and TLR 9 were significantly affected by berberine treatment.	Berberine	78-87	toll-like receptor 2	Rattus norvegicus	23-28
25605990-7	2015	The mRNA expression of TLR 2, TLR 4, and TLR 9 were significantly affected by berberine treatment.	Berberine	78-87	toll-like receptor 4	Rattus norvegicus	30-35
25605990-7	2015	The mRNA expression of TLR 2, TLR 4, and TLR 9 were significantly affected by berberine treatment.	Berberine	78-87	toll-like receptor 9	Rattus norvegicus	41-46
26492225-5	2015	Curcumin, berberine, and quercetin effectively downregulated pSTAT3 levels, survivin expression, and gastric cancer cells viability in a dose-dependent manner (with corresponding IC50 values of 40.3muM, 29.2muM and 37.5muM, respectively).	Berberine	10-19	latexin	Homo sapiens	198-201
26492225-7	2015	5-FU in combination with berberine or curcumin showed a synergistic inhibition of survivin and STAT3 level resulting in enhanced cell death in gastric cancer cells.	Berberine	25-34	signal transducer and activator of transcription 3	Homo sapiens	95-100
26068524-7	2015	The uptake of berberine could be increased in human HEK293-OATP1B3 but not in OATP1B1-transfected HEK 293 cells.	Berberine	14-23	solute carrier organic anion transporter family member 1B3	Homo sapiens	59-66
25224725-9	2014	The cardioprotective action of berberine was associated with increased LC-3B II and Beclin-1 expressions.	Berberine	31-40	beclin 1	Rattus norvegicus	84-92
25546475-11	2014	In mixed glial cultures, berberine reduced TLR4/MyD88/NF-kappaB signaling.	Berberine	25-34	toll-like receptor 4	Mus musculus	43-47
25546475-11	2014	In mixed glial cultures, berberine reduced TLR4/MyD88/NF-kappaB signaling.	Berberine	25-34	myeloid differentiation primary response gene 88	Mus musculus	48-53
25546475-11	2014	In mixed glial cultures, berberine reduced TLR4/MyD88/NF-kappaB signaling.	Berberine	25-34	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	54-63
25547724-7	2014	Among them, a berberine derivative, already known to remarkably inhibit telomerase activity, was related to a better theoretical affinity versus c-myc.	Berberine	14-23	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	145-150
25493642-0	2014	Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells.	Berberine	60-69	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	15-19
25493642-4	2014	Mechanistic studies revealed that berberine decreased mitochondrial membrane potential and intracellular ATP levels and induced potent AMPK activation, as shown by phosphorylation of AMPK alpha subunit at Thr-172 and acetyl-CoA carboxylase (ACC) at Ser79.	Berberine	34-43	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	135-139
25493642-4	2014	Mechanistic studies revealed that berberine decreased mitochondrial membrane potential and intracellular ATP levels and induced potent AMPK activation, as shown by phosphorylation of AMPK alpha subunit at Thr-172 and acetyl-CoA carboxylase (ACC) at Ser79.	Berberine	34-43	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	183-187
25493642-5	2014	Furthermore, berberine dose-dependently inhibited mTORC1 (phosphorylation of S6K at Thr389 and S6 at Ser240/244) and ERK activation in PDAC cells stimulated by insulin and neurotensin or fetal bovine serum.	Berberine	13-22	CREB regulated transcription coactivator 1	Mus musculus	50-56
25493642-5	2014	Furthermore, berberine dose-dependently inhibited mTORC1 (phosphorylation of S6K at Thr389 and S6 at Ser240/244) and ERK activation in PDAC cells stimulated by insulin and neurotensin or fetal bovine serum.	Berberine	13-22	mitogen-activated protein kinase 1	Homo sapiens	117-120
25493642-6	2014	Knockdown of alpha1 and alpha2 catalytic subunit expression of AMPK reversed the inhibitory effect produced by treatment with low concentrations of berberine on mTORC1, ERK and DNA synthesis in PDAC cells.	Berberine	148-157	adrenoceptor alpha 1D	Homo sapiens	13-30
25493642-6	2014	Knockdown of alpha1 and alpha2 catalytic subunit expression of AMPK reversed the inhibitory effect produced by treatment with low concentrations of berberine on mTORC1, ERK and DNA synthesis in PDAC cells.	Berberine	148-157	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	63-67
25493642-6	2014	Knockdown of alpha1 and alpha2 catalytic subunit expression of AMPK reversed the inhibitory effect produced by treatment with low concentrations of berberine on mTORC1, ERK and DNA synthesis in PDAC cells.	Berberine	148-157	CREB regulated transcription coactivator 1	Mus musculus	161-167
25493642-6	2014	Knockdown of alpha1 and alpha2 catalytic subunit expression of AMPK reversed the inhibitory effect produced by treatment with low concentrations of berberine on mTORC1, ERK and DNA synthesis in PDAC cells.	Berberine	148-157	mitogen-activated protein kinase 1	Homo sapiens	169-172
25493642-7	2014	However, at higher concentrations, berberine inhibited mitogenic signaling (mTORC1 and ERK) and DNA synthesis through an AMPK-independent mechanism.	Berberine	35-44	CREB regulated transcription coactivator 1	Mus musculus	76-82
25493642-7	2014	However, at higher concentrations, berberine inhibited mitogenic signaling (mTORC1 and ERK) and DNA synthesis through an AMPK-independent mechanism.	Berberine	35-44	mitogen-activated protein kinase 1	Homo sapiens	87-90
25493642-7	2014	However, at higher concentrations, berberine inhibited mitogenic signaling (mTORC1 and ERK) and DNA synthesis through an AMPK-independent mechanism.	Berberine	35-44	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	121-125
25493642-9	2014	We propose that berberine and metformin inhibit mitogenic signaling in PDAC cells through dose-dependent AMPK-dependent and independent pathways.	Berberine	16-25	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	105-109
25448308-5	2014	Analytical data on interactions of berberine with pBR322 through fourier transform infrared (FTIR) and gel migration assay strengthen berberine s biologically significant DNA binding abilities.	Berberine	35-44	translocator protein	Homo sapiens	50-53
25448308-5	2014	Analytical data on interactions of berberine with pBR322 through fourier transform infrared (FTIR) and gel migration assay strengthen berberine s biologically significant DNA binding abilities.	Berberine	134-143	translocator protein	Homo sapiens	50-53
25224725-10	2014	Furthermore, cardioprotection with berberine was potentially related to p38 MAPK inhibition and phospho-Akt activation.	Berberine	35-44	mitogen activated protein kinase 14	Rattus norvegicus	72-75
25310356-4	2014	Recent research has demonstrated that berberine has anticancer activity against various types of cancer, mediated through the suppression of mammalian target of rapamycin (mTOR).	Berberine	38-47	mechanistic target of rapamycin kinase	Homo sapiens	141-170
25455889-7	2014	Either the total cytochrome P450 2E1 or the mitochondria-located cytochrome P450 2E1, which is implicated in ethanol-mediated oxidative stress, was suppressed by berberine.	Berberine	162-171	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	17-36
25455889-7	2014	Either the total cytochrome P450 2E1 or the mitochondria-located cytochrome P450 2E1, which is implicated in ethanol-mediated oxidative stress, was suppressed by berberine.	Berberine	162-171	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	65-84
25455889-8	2014	On the other hand, berberine significantly blunted the lipid accumulation in liver due to chronic alcohol consumption, at least partially, through restoring peroxisome proliferator-activated receptor alpha/peroxisome proliferator-activated receptor-gamma Co-activator-1alpha and hepatocyte nuclear factor 4alpha/microsomal triglyceride transfer protein pathways.	Berberine	19-28	hepatocyte nuclear factor 4 alpha	Homo sapiens	279-311
25217495-4	2014	In this study, we provided molecular evidence that is associated with the antimetastatic effect of berberine by showing a nearly complete inhibition on invasion (P &lt; 0.001) of highly metastatic SiHa cells via reduced transcriptional activities of matrix metalloproteinase-2 and urokinase-type plasminogen activator.	Berberine	99-108	matrix metallopeptidase 2	Homo sapiens	250-276
25217495-5	2014	Berberine reversed transforming growth factor-beta1-induced EMT and caused upregulation of epithelial markers such as E-cadherin and inhibited mesenchymal markers such as N-cadherin and snail-1.	Berberine	0-9	cadherin 1	Homo sapiens	118-128
25217495-5	2014	Berberine reversed transforming growth factor-beta1-induced EMT and caused upregulation of epithelial markers such as E-cadherin and inhibited mesenchymal markers such as N-cadherin and snail-1.	Berberine	0-9	cadherin 2	Homo sapiens	171-181
25217495-5	2014	Berberine reversed transforming growth factor-beta1-induced EMT and caused upregulation of epithelial markers such as E-cadherin and inhibited mesenchymal markers such as N-cadherin and snail-1.	Berberine	0-9	snail family transcriptional repressor 1	Homo sapiens	186-193
25310356-4	2014	Recent research has demonstrated that berberine has anticancer activity against various types of cancer, mediated through the suppression of mammalian target of rapamycin (mTOR).	Berberine	38-47	mechanistic target of rapamycin kinase	Homo sapiens	172-176
25310356-7	2014	Moreover, the cells treated with the combination of the two agents exhibited significantly decreased protein levels of phosphorylated (p)-p70S6 kinase 1 (Thr389), the downstream effector of mTOR, compared with the cells treated with rapamycin or berberine alone.	Berberine	246-255	mechanistic target of rapamycin kinase	Homo sapiens	190-194
25310356-8	2014	Furthermore, overexpression of cluster of differentiation (CD) 147, a transmembrance glycoprotein associated with the anticancer effects of berberine, was found to upregulate p-mTOR expression and inhibit cell death in SMMC7721 cells co-treated with rapamycin and berberine.	Berberine	140-149	mechanistic target of rapamycin kinase	Homo sapiens	177-181
24849498-0	2014	The renoprotective effects of berberine via the EP4-Galphas-cAMP signaling pathway in different stages of diabetes in rats.	Berberine	30-39	prostaglandin E receptor 4	Rattus norvegicus	48-51
25310356-8	2014	Furthermore, overexpression of cluster of differentiation (CD) 147, a transmembrance glycoprotein associated with the anticancer effects of berberine, was found to upregulate p-mTOR expression and inhibit cell death in SMMC7721 cells co-treated with rapamycin and berberine.	Berberine	264-273	mechanistic target of rapamycin kinase	Homo sapiens	177-181
25310356-9	2014	In conclusion, the findings of the present study suggest that the combined use of rapamycin and berberine may improve HCC therapy through synergistically inhibiting the mTOR signaling pathway, which is at least in part, mediated through CD147.	Berberine	96-105	mechanistic target of rapamycin kinase	Homo sapiens	169-173
25310356-9	2014	In conclusion, the findings of the present study suggest that the combined use of rapamycin and berberine may improve HCC therapy through synergistically inhibiting the mTOR signaling pathway, which is at least in part, mediated through CD147.	Berberine	96-105	basigin (Ok blood group)	Homo sapiens	237-242
25128467-0	2014	FoxO proteins" nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.	Berberine	122-131	BCL2 like 11	Homo sapiens	54-57
25409232-0	2014	Berberine improves kidney function in diabetic mice via AMPK activation.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	56-60
25409232-5	2014	Here, we reported that activation of AMP-activated protein kinase (AMPK) is required for BBR-induced improvement of kidney function in vivo.	Berberine	89-92	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	67-71
25257463-0	2014	Berberine protects endothelial progenitor cell from damage of TNF-alpha via the PI3K/AKT/eNOS signaling pathway.	Berberine	0-9	tumor necrosis factor	Homo sapiens	62-71
25257463-0	2014	Berberine protects endothelial progenitor cell from damage of TNF-alpha via the PI3K/AKT/eNOS signaling pathway.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	85-88
25257463-0	2014	Berberine protects endothelial progenitor cell from damage of TNF-alpha via the PI3K/AKT/eNOS signaling pathway.	Berberine	0-9	nitric oxide synthase 3	Homo sapiens	89-93
25257463-3	2014	The aim of this study was to investigate whether berberine (BBR) can protect EPCs from the inhibition caused by TNF-alpha via the PI3K (Phosphatidyl Inositol 3-kinase) /AKT (Serine/threonine protein kinase B) /eNOS (endothelial Nitric Oxide synthase) signaling pathway.	Berberine	49-58	tumor necrosis factor	Homo sapiens	112-121
25257463-3	2014	The aim of this study was to investigate whether berberine (BBR) can protect EPCs from the inhibition caused by TNF-alpha via the PI3K (Phosphatidyl Inositol 3-kinase) /AKT (Serine/threonine protein kinase B) /eNOS (endothelial Nitric Oxide synthase) signaling pathway.	Berberine	49-58	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	136-166
25257463-3	2014	The aim of this study was to investigate whether berberine (BBR) can protect EPCs from the inhibition caused by TNF-alpha via the PI3K (Phosphatidyl Inositol 3-kinase) /AKT (Serine/threonine protein kinase B) /eNOS (endothelial Nitric Oxide synthase) signaling pathway.	Berberine	49-58	AKT serine/threonine kinase 1	Homo sapiens	169-172
25257463-3	2014	The aim of this study was to investigate whether berberine (BBR) can protect EPCs from the inhibition caused by TNF-alpha via the PI3K (Phosphatidyl Inositol 3-kinase) /AKT (Serine/threonine protein kinase B) /eNOS (endothelial Nitric Oxide synthase) signaling pathway.	Berberine	49-58	nitric oxide synthase 3	Homo sapiens	210-214
25257463-3	2014	The aim of this study was to investigate whether berberine (BBR) can protect EPCs from the inhibition caused by TNF-alpha via the PI3K (Phosphatidyl Inositol 3-kinase) /AKT (Serine/threonine protein kinase B) /eNOS (endothelial Nitric Oxide synthase) signaling pathway.	Berberine	49-58	nitric oxide synthase 3	Homo sapiens	216-249
25257463-3	2014	The aim of this study was to investigate whether berberine (BBR) can protect EPCs from the inhibition caused by TNF-alpha via the PI3K (Phosphatidyl Inositol 3-kinase) /AKT (Serine/threonine protein kinase B) /eNOS (endothelial Nitric Oxide synthase) signaling pathway.	Berberine	60-63	tumor necrosis factor	Homo sapiens	112-121
25257463-3	2014	The aim of this study was to investigate whether berberine (BBR) can protect EPCs from the inhibition caused by TNF-alpha via the PI3K (Phosphatidyl Inositol 3-kinase) /AKT (Serine/threonine protein kinase B) /eNOS (endothelial Nitric Oxide synthase) signaling pathway.	Berberine	60-63	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	136-166
25257463-3	2014	The aim of this study was to investigate whether berberine (BBR) can protect EPCs from the inhibition caused by TNF-alpha via the PI3K (Phosphatidyl Inositol 3-kinase) /AKT (Serine/threonine protein kinase B) /eNOS (endothelial Nitric Oxide synthase) signaling pathway.	Berberine	60-63	AKT serine/threonine kinase 1	Homo sapiens	169-172
25257463-3	2014	The aim of this study was to investigate whether berberine (BBR) can protect EPCs from the inhibition caused by TNF-alpha via the PI3K (Phosphatidyl Inositol 3-kinase) /AKT (Serine/threonine protein kinase B) /eNOS (endothelial Nitric Oxide synthase) signaling pathway.	Berberine	60-63	nitric oxide synthase 3	Homo sapiens	210-214
25257463-3	2014	The aim of this study was to investigate whether berberine (BBR) can protect EPCs from the inhibition caused by TNF-alpha via the PI3K (Phosphatidyl Inositol 3-kinase) /AKT (Serine/threonine protein kinase B) /eNOS (endothelial Nitric Oxide synthase) signaling pathway.	Berberine	60-63	nitric oxide synthase 3	Homo sapiens	216-249
25257463-10	2014	BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME).	Berberine	0-3	AKT serine/threonine kinase 1	Homo sapiens	35-38
25257463-10	2014	BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME).	Berberine	0-3	nitric oxide synthase 3	Homo sapiens	39-43
25257463-10	2014	BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME).	Berberine	0-3	AKT serine/threonine kinase 1	Homo sapiens	82-85
25257463-10	2014	BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME).	Berberine	0-3	nitric oxide synthase 3	Homo sapiens	87-91
25257463-10	2014	BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME).	Berberine	0-3	nitric oxide synthase 3	Homo sapiens	87-91
25257463-10	2014	BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME).	Berberine	0-3	nitric oxide synthase 3	Homo sapiens	87-91
25425200-0	2014	Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE(-/-) mice.	Berberine	0-9	apolipoprotein E	Mus musculus	78-82
25155085-15	2014	Phosphorylated IkappaBalpha level was significantly suppressed and mRNA expressions of T-box transcription factor TBX21 and signal transducer and activator of transcription-3 were significantly increased by berberine.	Berberine	207-216	NFKB inhibitor alpha	Homo sapiens	15-27
25155085-15	2014	Phosphorylated IkappaBalpha level was significantly suppressed and mRNA expressions of T-box transcription factor TBX21 and signal transducer and activator of transcription-3 were significantly increased by berberine.	Berberine	207-216	T-box transcription factor 21	Homo sapiens	114-119
25155085-15	2014	Phosphorylated IkappaBalpha level was significantly suppressed and mRNA expressions of T-box transcription factor TBX21 and signal transducer and activator of transcription-3 were significantly increased by berberine.	Berberine	207-216	signal transducer and activator of transcription 3	Homo sapiens	124-174
25155085-17	2014	The mechanism by which berberine modulates epsilon-germline transcript expression might be through regulating the phosphorylated IkappaBalpha level and the expressions of signal transducer and activator of transcription-3 and T-box transcription factor TBX21.	Berberine	23-32	NFKB inhibitor alpha	Homo sapiens	129-141
25155085-17	2014	The mechanism by which berberine modulates epsilon-germline transcript expression might be through regulating the phosphorylated IkappaBalpha level and the expressions of signal transducer and activator of transcription-3 and T-box transcription factor TBX21.	Berberine	23-32	signal transducer and activator of transcription 3	Homo sapiens	171-221
25155085-17	2014	The mechanism by which berberine modulates epsilon-germline transcript expression might be through regulating the phosphorylated IkappaBalpha level and the expressions of signal transducer and activator of transcription-3 and T-box transcription factor TBX21.	Berberine	23-32	T-box transcription factor 21	Homo sapiens	253-258
25128467-4	2014	We observed that berberine significantly upregulated the mRNA expression of both FoxO1 and FoxO3a.	Berberine	17-26	forkhead box O1	Homo sapiens	81-86
25128467-4	2014	We observed that berberine significantly upregulated the mRNA expression of both FoxO1 and FoxO3a.	Berberine	17-26	forkhead box O3	Homo sapiens	91-97
25128467-5	2014	Their phosphorylation-mediated cytoplasmic sequestration followed by degradation was prevented by berberine-induced downmodulation of the PI3K/Akt/mTOR pathway which promoted FoxO nuclear retention.	Berberine	98-107	AKT serine/threonine kinase 1	Homo sapiens	143-146
25128467-5	2014	Their phosphorylation-mediated cytoplasmic sequestration followed by degradation was prevented by berberine-induced downmodulation of the PI3K/Akt/mTOR pathway which promoted FoxO nuclear retention.	Berberine	98-107	mechanistic target of rapamycin kinase	Homo sapiens	147-151
25128467-9	2014	The pivotal role of Bim in berberine-mediated cytotoxicity was further corroborated by knockdown experiments where Bim-silencing partially restored HepG2 cell viability during berberine exposure.	Berberine	27-36	BCL2 like 11	Homo sapiens	20-23
25128467-9	2014	The pivotal role of Bim in berberine-mediated cytotoxicity was further corroborated by knockdown experiments where Bim-silencing partially restored HepG2 cell viability during berberine exposure.	Berberine	27-36	BCL2 like 11	Homo sapiens	115-118
25128467-9	2014	The pivotal role of Bim in berberine-mediated cytotoxicity was further corroborated by knockdown experiments where Bim-silencing partially restored HepG2 cell viability during berberine exposure.	Berberine	176-185	BCL2 like 11	Homo sapiens	115-118
25128467-11	2014	Thus, our findings suggest that the antiproliferative effect of berberine may in part be due to mitochondria-mediated apoptosis with Bim acting as a pivotal downstream factor of FoxO-induced transcriptional activation.	Berberine	64-73	BCL2 like 11	Homo sapiens	133-136
25126729-0	2014	Berberine attenuates autophagy in adipocytes by targeting BECN1.	Berberine	0-9	beclin 1, autophagy related	Mus musculus	58-63
24973693-5	2014	Some signaling pathways affected by berberine, including the MAP (mitogen-activated protein) kinase and Wnt/beta-catenin pathways, are critical for reducing cellular migration and sensitivity to various growth factors.	Berberine	36-45	catenin beta 1	Homo sapiens	108-120
25126729-5	2014	We also show that berberine, a natural plant alkaloid, inhibits basal autophagy in adipocytes and adipose tissue of mice fed a high-fat diet via downregulation of BECN1 expression.	Berberine	18-27	beclin 1, autophagy related	Mus musculus	163-168
25126729-6	2014	We further demonstrate that berberine has a pronounced effect on the stability of Becn 1 mRNA through the Mir30 family.	Berberine	28-37	beclin 1, autophagy related	Mus musculus	82-88
25069720-0	2014	The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1.	Berberine	32-41	sirtuin 1	Homo sapiens	106-115
24803296-5	2014	The expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-17 and vascular endothelial growth factor (VEGF) were obviously reduced in the sera of berberine-treated rats (all P&lt;0.05).	Berberine	180-189	tumor necrosis factor	Rattus norvegicus	25-58
24803296-5	2014	The expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-17 and vascular endothelial growth factor (VEGF) were obviously reduced in the sera of berberine-treated rats (all P&lt;0.05).	Berberine	180-189	interleukin 1 beta	Rattus norvegicus	60-82
24803296-5	2014	The expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-17 and vascular endothelial growth factor (VEGF) were obviously reduced in the sera of berberine-treated rats (all P&lt;0.05).	Berberine	180-189	interleukin 6	Rattus norvegicus	84-88
24803296-5	2014	The expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-17 and vascular endothelial growth factor (VEGF) were obviously reduced in the sera of berberine-treated rats (all P&lt;0.05).	Berberine	180-189	interleukin 17A	Rattus norvegicus	90-95
24803296-5	2014	The expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-17 and vascular endothelial growth factor (VEGF) were obviously reduced in the sera of berberine-treated rats (all P&lt;0.05).	Berberine	180-189	vascular endothelial growth factor A	Rattus norvegicus	100-134
24803296-5	2014	The expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-17 and vascular endothelial growth factor (VEGF) were obviously reduced in the sera of berberine-treated rats (all P&lt;0.05).	Berberine	180-189	vascular endothelial growth factor A	Rattus norvegicus	136-140
24803296-6	2014	Moreover, berberine showed marked inhibition of the expression of VEGF and CD34 (all P&lt;0.05).	Berberine	10-19	vascular endothelial growth factor A	Rattus norvegicus	66-70
24803296-6	2014	Moreover, berberine showed marked inhibition of the expression of VEGF and CD34 (all P&lt;0.05).	Berberine	10-19	CD34 molecule	Rattus norvegicus	75-79
24803296-7	2014	Interestingly, berberine significantly suppresses p-ERK, p-p38 and p-JNK activation (all P&lt;0.05), which may partially explain the anti-RA activity of berberine.	Berberine	15-24	Eph receptor B1	Rattus norvegicus	52-55
24803296-7	2014	Interestingly, berberine significantly suppresses p-ERK, p-p38 and p-JNK activation (all P&lt;0.05), which may partially explain the anti-RA activity of berberine.	Berberine	153-162	Eph receptor B1	Rattus norvegicus	52-55
25069720-4	2014	THP-1-derived macrophages were pre-treated with BBR (5, 10 and 20 mg/l) for 2 h prior to the addition of oxidized low density lipoprotein (ox-LDL; 50 mg/l).	Berberine	48-51	GLI family zinc finger 2	Homo sapiens	0-5
25069720-11	2014	Pre-treatment of the cells with SIRT1-siRNA or compound C attenuated the anti-atherosclerotic effects of BBR.	Berberine	105-108	sirtuin 1	Homo sapiens	32-37
25222223-7	2014	Moreover, HG impaired the function of HIF-1 inhibitors [HIF-1 small interfering RNA (siRNA) and berberine] to affect the VEGF transcription level in tumor cells.	Berberine	96-105	hypoxia inducible factor 1 subunit alpha	Homo sapiens	38-43
25227736-9	2014	In addition, the combination of BBR and SAHA, a pan-HDAC inhibitor, synergistically inhibited cell proliferation and induced cell cycle arrest.	Berberine	32-35	histone deacetylase 9	Homo sapiens	52-56
25222223-7	2014	Moreover, HG impaired the function of HIF-1 inhibitors [HIF-1 small interfering RNA (siRNA) and berberine] to affect the VEGF transcription level in tumor cells.	Berberine	96-105	vascular endothelial growth factor A	Mus musculus	121-125
24942805-0	2014	Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma.	Berberine	0-9	tumor protein p53	Homo sapiens	35-38
24942805-5	2014	The role of miR-23a in mediating suppression of HCC by berberine was determined both in vitro and in vivo.	Berberine	55-64	microRNA 23a	Homo sapiens	12-19
24942805-0	2014	Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma.	Berberine	0-9	microRNA 23a	Homo sapiens	96-103
24942805-6	2014	RESULTS: miR-23a was up-regulated upon berberine treatment in human HCC cells, and berberine could increase the expression of primary precursor, precursor and mature forms of miR-23a.	Berberine	39-48	microRNA 23a	Homo sapiens	9-16
24942805-1	2014	AIM OF THE STUDY: To investigate the involvement of p53 in the regulatory network of microRNA-23a (miR-23a) in berberine-treated hepatocellular carcinoma (HCC) cells.	Berberine	111-120	tumor protein p53	Homo sapiens	52-55
24942805-6	2014	RESULTS: miR-23a was up-regulated upon berberine treatment in human HCC cells, and berberine could increase the expression of primary precursor, precursor and mature forms of miR-23a.	Berberine	83-92	microRNA 23a	Homo sapiens	175-182
24942805-7	2014	The up-regulation of miR-23a by berberine is p53-dependent.	Berberine	32-41	microRNA 23a	Homo sapiens	21-28
24942805-1	2014	AIM OF THE STUDY: To investigate the involvement of p53 in the regulatory network of microRNA-23a (miR-23a) in berberine-treated hepatocellular carcinoma (HCC) cells.	Berberine	111-120	microRNA 23a	Homo sapiens	85-97
24942805-7	2014	The up-regulation of miR-23a by berberine is p53-dependent.	Berberine	32-41	tumor protein p53	Homo sapiens	45-48
24942805-1	2014	AIM OF THE STUDY: To investigate the involvement of p53 in the regulatory network of microRNA-23a (miR-23a) in berberine-treated hepatocellular carcinoma (HCC) cells.	Berberine	111-120	microRNA 23a	Homo sapiens	99-106
24942805-8	2014	Inhibition of p53 expression and activity could block the up-regulation of miR-23a induced by berberine.	Berberine	94-103	tumor protein p53	Homo sapiens	14-17
24942805-2	2014	METHODS: The biogenesis of miR-23a upon berberine treatment was monitored by detecting the transcript expression of primary precursor, precursor and mature forms of miR-23a.	Berberine	40-49	microRNA 23a	Homo sapiens	27-34
24942805-8	2014	Inhibition of p53 expression and activity could block the up-regulation of miR-23a induced by berberine.	Berberine	94-103	microRNA 23a	Homo sapiens	75-82
24942805-9	2014	Furthermore, berberine-induced miR-23a expression may mediate the transcription activation of p53-related tumor suppressive genes p21 and GADD45alpha.	Berberine	13-22	microRNA 23a	Homo sapiens	31-38
24942805-2	2014	METHODS: The biogenesis of miR-23a upon berberine treatment was monitored by detecting the transcript expression of primary precursor, precursor and mature forms of miR-23a.	Berberine	40-49	microRNA 23a	Homo sapiens	165-172
24942805-9	2014	Furthermore, berberine-induced miR-23a expression may mediate the transcription activation of p53-related tumor suppressive genes p21 and GADD45alpha.	Berberine	13-22	tumor protein p53	Homo sapiens	94-97
25279238-0	2014	Inhibitory Effects of Isoquinoline Alkaloid Berberine on Ischemia-Induced Apoptosis via Activation of Phosphoinositide 3-Kinase/Protein Kinase B Signaling Pathway.	Berberine	44-53	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	102-127
24942805-9	2014	Furthermore, berberine-induced miR-23a expression may mediate the transcription activation of p53-related tumor suppressive genes p21 and GADD45alpha.	Berberine	13-22	H3 histone pseudogene 16	Homo sapiens	130-133
24942805-9	2014	Furthermore, berberine-induced miR-23a expression may mediate the transcription activation of p53-related tumor suppressive genes p21 and GADD45alpha.	Berberine	13-22	growth arrest and DNA damage inducible alpha	Homo sapiens	138-149
24942805-11	2014	Target prediction and experimental validation demonstrate that berberine-induced miR-23a may target to Nek6 to suppress its expression.	Berberine	63-72	microRNA 23a	Homo sapiens	81-88
24942805-11	2014	Target prediction and experimental validation demonstrate that berberine-induced miR-23a may target to Nek6 to suppress its expression.	Berberine	63-72	NIMA related kinase 6	Homo sapiens	103-107
24942805-12	2014	Berberine-induced G2/M cell cycle arrest in HCC was attenuated when miR-23a was inhibited.	Berberine	0-9	microRNA 23a	Homo sapiens	68-75
24942805-13	2014	Berberine-induced cell death and in vivo tumor growth inhibition are attenuated upon inhibition of miR-23a.	Berberine	0-9	microRNA 23a	Homo sapiens	99-106
24942805-14	2014	CONCLUSION: Our study reveals that miR-23a may be involved in regulating the anti-HCC effect of berberine by mediating the regulation of p53.	Berberine	96-105	microRNA 23a	Homo sapiens	35-42
24942805-14	2014	CONCLUSION: Our study reveals that miR-23a may be involved in regulating the anti-HCC effect of berberine by mediating the regulation of p53.	Berberine	96-105	tumor protein p53	Homo sapiens	137-140
24501112-11	2014	Wogonin, baicalin, and berberine inhibited expression of COX-2 mRNA without affecting PGE2 metabolic activity.	Berberine	23-32	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	57-62
25279238-9	2014	Furthermore, berberine enhanced phospho-PI3K and phospho-Akt expression in the hippocampus of ischemic gerbils.	Berberine	13-22	AKT serine/threonine kinase 1	Homo sapiens	57-60
25279238-10	2014	CONCLUSIONS: Berberine exerted a neuroprotective effect against ischemic insult by inhibiting neuronal apoptosis via activation of the PI3K/Akt signaling pathway.	Berberine	13-22	AKT serine/threonine kinase 1	Homo sapiens	140-143
25317299-10	2014	Berberine at 2 muM produced peak of protection, and increased cell viability to 83%, 77%, and 79% during 30, 60, 240 min ischemic experiments, respectively (P &lt; 0.001).	Berberine	0-9	latexin	Homo sapiens	15-18
24867960-6	2014	The proteasomal turnover of the AR is abetted by diets with a high ratio of long-chain omega-3 to omega-6 fatty acids, which are beneficial in prostate cancer xenograft models; berberine and sulforaphane, by inhibiting AR"s interaction with its chaperone Hsp90, likewise promote AR proteasomal degradation and retard growth of human prostate cancer in nude mice.	Berberine	177-186	androgen receptor	Homo sapiens	32-34
25017321-0	2014	Berberine attenuates spontaneous action potentials in sinoatrial node cells and the currents of human HCN4 channels expressed in Xenopus laevis oocytes.	Berberine	0-9	hyperpolarization activated cyclic nucleotide gated potassium channel 4	Homo sapiens	102-106
24894821-7	2014	After berberine and gemcitabine treatment of PANC-1, of the four stem cell-associated genes (SOX2, POU5F1, NANOG, and NOTCH1), all but NOTCH1 were down-regulated.	Berberine	6-15	SRY-box transcription factor 2	Homo sapiens	93-97
24894821-7	2014	After berberine and gemcitabine treatment of PANC-1, of the four stem cell-associated genes (SOX2, POU5F1, NANOG, and NOTCH1), all but NOTCH1 were down-regulated.	Berberine	6-15	POU class 5 homeobox 1	Homo sapiens	99-105
24894821-7	2014	After berberine and gemcitabine treatment of PANC-1, of the four stem cell-associated genes (SOX2, POU5F1, NANOG, and NOTCH1), all but NOTCH1 were down-regulated.	Berberine	6-15	Nanog homeobox	Homo sapiens	107-112
24894821-7	2014	After berberine and gemcitabine treatment of PANC-1, of the four stem cell-associated genes (SOX2, POU5F1, NANOG, and NOTCH1), all but NOTCH1 were down-regulated.	Berberine	6-15	notch receptor 1	Homo sapiens	118-124
24894821-7	2014	After berberine and gemcitabine treatment of PANC-1, of the four stem cell-associated genes (SOX2, POU5F1, NANOG, and NOTCH1), all but NOTCH1 were down-regulated.	Berberine	6-15	notch receptor 1	Homo sapiens	135-141
25017321-1	2014	The present study investigated the electropharmacological effects of a traditional Chinese herbal drug, berberine, on the spontaneous activity of sinoatrial nodes (SANs) of the rabbit heart and on human hyperpolarization-activated cyclic nucleotide-gated 4 (hHCN4) channels, which are heterologously expressed in xenopus oocytes, and which contribute to pacemaker currents (Ifs).	Berberine	104-113	hyperpolarization activated cyclic nucleotide gated potassium channel 4	Homo sapiens	258-263
25017321-4	2014	In addition, berberine suppressed the hHCN4 channel currents in a concentration- (1-300 microM) and use-dependent manner, and simultaneously decreased the activation and deactivation kinetics of the hHCN4 channels.	Berberine	13-22	hyperpolarization activated cyclic nucleotide gated potassium channel 4	Homo sapiens	38-43
25017321-4	2014	In addition, berberine suppressed the hHCN4 channel currents in a concentration- (1-300 microM) and use-dependent manner, and simultaneously decreased the activation and deactivation kinetics of the hHCN4 channels.	Berberine	13-22	hyperpolarization activated cyclic nucleotide gated potassium channel 4	Homo sapiens	199-204
24946211-0	2014	Mitochondrial protein cyclophilin-D-mediated programmed necrosis attributes to berberine-induced cytotoxicity in cultured prostate cancer cells.	Berberine	79-88	peptidylprolyl isomerase F	Homo sapiens	22-35
25072399-2	2014	Activation of AMP-activated protein kinase (AMPK) pathway has been proposed as mechanism for berberine"s action.	Berberine	93-102	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	14-42
25072399-2	2014	Activation of AMP-activated protein kinase (AMPK) pathway has been proposed as mechanism for berberine"s action.	Berberine	93-102	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	44-48
25072399-3	2014	This study aimed to examine whether AMPK activation was necessary for berberine"s glucose-lowering effect.	Berberine	70-79	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	36-40
25072399-5	2014	AMPK and acetyl coenzyme A synthetase (ACC) phosphorylation were stimulated by 20 micromol/L berberine.	Berberine	93-102	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	0-4
25072399-6	2014	Nevertheless, berberine was still effective on stimulating glucose utilization and lactate production, when the AMPK activation was blocked by (1) inhibition of AMPK activity by Compound C, (2) suppression of AMPKalpha expression by siRNA, and (3) blockade of AMPK pathway by adenoviruses containing dominant-negative forms of AMPKalpha1/alpha2.	Berberine	14-23	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	112-116
25072399-6	2014	Nevertheless, berberine was still effective on stimulating glucose utilization and lactate production, when the AMPK activation was blocked by (1) inhibition of AMPK activity by Compound C, (2) suppression of AMPKalpha expression by siRNA, and (3) blockade of AMPK pathway by adenoviruses containing dominant-negative forms of AMPKalpha1/alpha2.	Berberine	14-23	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	161-165
25072399-6	2014	Nevertheless, berberine was still effective on stimulating glucose utilization and lactate production, when the AMPK activation was blocked by (1) inhibition of AMPK activity by Compound C, (2) suppression of AMPKalpha expression by siRNA, and (3) blockade of AMPK pathway by adenoviruses containing dominant-negative forms of AMPKalpha1/alpha2.	Berberine	14-23	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	161-165
25072399-6	2014	Nevertheless, berberine was still effective on stimulating glucose utilization and lactate production, when the AMPK activation was blocked by (1) inhibition of AMPK activity by Compound C, (2) suppression of AMPKalpha expression by siRNA, and (3) blockade of AMPK pathway by adenoviruses containing dominant-negative forms of AMPKalpha1/alpha2.	Berberine	14-23	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	327-337
24754438-10	2014	Berberine treatment significantly ameliorated UUO-induced inflammation, and decreased TGF-beta1, pSmad3 and alpha-SMA expression of UUO kidneys.	Berberine	0-9	transforming growth factor, beta 1	Rattus norvegicus	86-95
24754438-10	2014	Berberine treatment significantly ameliorated UUO-induced inflammation, and decreased TGF-beta1, pSmad3 and alpha-SMA expression of UUO kidneys.	Berberine	0-9	actin gamma 2, smooth muscle	Rattus norvegicus	108-117
24754438-12	2014	CONCLUSION: Berberine treatment ameliorates RIF in a UUO rat model by inhibition of oxidative stress, inflammatory responses, and TGF-beta1/pSmad3 signalling.	Berberine	12-21	transforming growth factor, beta 1	Rattus norvegicus	130-139
24946211-9	2014	The anti-oxidant N-acetylcysteine (NAC), the P53 inhibitor pifithrin-alpha (PFTalpha) as well as P53 siRNA knockdown suppressed berberine-induced P53 mitochondrial translocation and Cyp-D association, thus inhibiting mitochondrial membrane potential (MMP) decrease and prostate cancer cell necrosis.	Berberine	128-137	tumor protein p53	Homo sapiens	45-48
24946211-9	2014	The anti-oxidant N-acetylcysteine (NAC), the P53 inhibitor pifithrin-alpha (PFTalpha) as well as P53 siRNA knockdown suppressed berberine-induced P53 mitochondrial translocation and Cyp-D association, thus inhibiting mitochondrial membrane potential (MMP) decrease and prostate cancer cell necrosis.	Berberine	128-137	tumor protein p53	Homo sapiens	97-100
24946211-9	2014	The anti-oxidant N-acetylcysteine (NAC), the P53 inhibitor pifithrin-alpha (PFTalpha) as well as P53 siRNA knockdown suppressed berberine-induced P53 mitochondrial translocation and Cyp-D association, thus inhibiting mitochondrial membrane potential (MMP) decrease and prostate cancer cell necrosis.	Berberine	128-137	tumor protein p53	Homo sapiens	97-100
24946211-6	2014	We demonstrated that mitochondrial protein cyclophilin-D (Cyp-D) is required for berberine-induced programmed necrosis.	Berberine	81-90	peptidylprolyl isomerase F	Homo sapiens	43-56
24946211-9	2014	The anti-oxidant N-acetylcysteine (NAC), the P53 inhibitor pifithrin-alpha (PFTalpha) as well as P53 siRNA knockdown suppressed berberine-induced P53 mitochondrial translocation and Cyp-D association, thus inhibiting mitochondrial membrane potential (MMP) decrease and prostate cancer cell necrosis.	Berberine	128-137	peptidylprolyl isomerase F	Homo sapiens	182-187
24946211-6	2014	We demonstrated that mitochondrial protein cyclophilin-D (Cyp-D) is required for berberine-induced programmed necrosis.	Berberine	81-90	peptidylprolyl isomerase F	Homo sapiens	58-63
24946211-7	2014	Inhibition of Cyp-D by its inhibitors cyclosporin A (CSA) or sanglifehrin A (SFA), and by Cyp-D shRNA depletion alleviated berberine-induced prostate cancer cell necrosis (but not apoptosis).	Berberine	123-132	peptidylprolyl isomerase F	Homo sapiens	14-19
24946211-7	2014	Inhibition of Cyp-D by its inhibitors cyclosporin A (CSA) or sanglifehrin A (SFA), and by Cyp-D shRNA depletion alleviated berberine-induced prostate cancer cell necrosis (but not apoptosis).	Berberine	123-132	peptidylprolyl isomerase F	Homo sapiens	90-95
24946211-8	2014	Our data found that in prostate cancer cells, berberine induced reactive oxygen species (ROS) production, which dictated P53 translocation to mitochondria, where it physically interacted with Cyp-D to open mitochondrial permeability transition pore (mPTP).	Berberine	46-55	tumor protein p53	Homo sapiens	121-124
24946211-8	2014	Our data found that in prostate cancer cells, berberine induced reactive oxygen species (ROS) production, which dictated P53 translocation to mitochondria, where it physically interacted with Cyp-D to open mitochondrial permeability transition pore (mPTP).	Berberine	46-55	peptidylprolyl isomerase F	Homo sapiens	192-197
24588674-0	2014	Uncoupling protein-2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS-1E cells and in diabetic mouse islets.	Berberine	55-64	uncoupling protein 2	Rattus norvegicus	0-20
24588674-15	2014	UCP2 is an important signalling molecule in mediating anti-diabetic effects of berberine.	Berberine	79-88	uncoupling protein 2	Rattus norvegicus	0-4
24286329-0	2014	Berberine suppresses in vitro migration of human aortic smooth muscle cells through the inhibitions of MMP-2/9, u-PA, AP-1, and NF-kappaB.	Berberine	0-9	matrix metallopeptidase 2	Homo sapiens	103-110
24588674-2	2014	The current study investigated the effects of berberine, an alkaloid found in many medicinal plants, on oxidative stress and insulin secretion through restoration of UCP2 expression in high glucose (HG)-treated INS-1E cells and rat islets or in db/db mouse islets.	Berberine	46-55	uncoupling protein 2	Rattus norvegicus	166-170
24286329-0	2014	Berberine suppresses in vitro migration of human aortic smooth muscle cells through the inhibitions of MMP-2/9, u-PA, AP-1, and NF-kappaB.	Berberine	0-9	plasminogen activator, urokinase	Homo sapiens	112-116
24286329-0	2014	Berberine suppresses in vitro migration of human aortic smooth muscle cells through the inhibitions of MMP-2/9, u-PA, AP-1, and NF-kappaB.	Berberine	0-9	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	118-122
24588674-10	2014	The AMPK inhibitor compound C, the UCP2 inhibitor genipin and adenovirus ucp2 shRNA inhibited these protective effects of berberine.	Berberine	122-131	uncoupling protein 2	Rattus norvegicus	35-39
24286329-0	2014	Berberine suppresses in vitro migration of human aortic smooth muscle cells through the inhibitions of MMP-2/9, u-PA, AP-1, and NF-kappaB.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	128-137
24588674-10	2014	The AMPK inhibitor compound C, the UCP2 inhibitor genipin and adenovirus ucp2 shRNA inhibited these protective effects of berberine.	Berberine	122-131	uncoupling protein 2	Rattus norvegicus	73-77
24286329-6	2014	Real-time PCR and Western blotting analyses showed that levels of matrix metalloproteinase (MMP)-2, MMP-9, and urokinase-type plasminogen activator (u-PA) were reduced by berberine at both the mRNA and protein levels.	Berberine	171-180	matrix metallopeptidase 2	Homo sapiens	66-98
24588674-11	2014	Furthermore, compound C normalized berberine-stimulated UCP2 expression but genipin did not affect AMPK phosphorylation.	Berberine	35-44	uncoupling protein 2	Rattus norvegicus	56-60
24286329-6	2014	Real-time PCR and Western blotting analyses showed that levels of matrix metalloproteinase (MMP)-2, MMP-9, and urokinase-type plasminogen activator (u-PA) were reduced by berberine at both the mRNA and protein levels.	Berberine	171-180	matrix metallopeptidase 9	Homo sapiens	100-105
24286329-6	2014	Real-time PCR and Western blotting analyses showed that levels of matrix metalloproteinase (MMP)-2, MMP-9, and urokinase-type plasminogen activator (u-PA) were reduced by berberine at both the mRNA and protein levels.	Berberine	171-180	plasminogen activator, urokinase	Homo sapiens	111-147
24588674-14	2014	CONCLUSIONS AND IMPLICATIONS: Berberine inhibited oxidative stress and restored insulin secretion in HG-treated INS-IE cells and diabetic mouse islets by activating AMPK and UCP2.	Berberine	30-39	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	174-178
24286329-6	2014	Real-time PCR and Western blotting analyses showed that levels of matrix metalloproteinase (MMP)-2, MMP-9, and urokinase-type plasminogen activator (u-PA) were reduced by berberine at both the mRNA and protein levels.	Berberine	171-180	plasminogen activator, urokinase	Homo sapiens	149-153
24751971-9	2014	BN also inhibited the apoptotic effect of HgCl2 by increasing the expression of Bcl-2 protein in liver and kidney.	Berberine	0-2	BCL2, apoptosis regulator	Rattus norvegicus	80-85
24286329-8	2014	These results suggest that berberine effectively inhibited HASMC migration, possibly by down-regulating MMP-2, MMP-9, and u-PA; and interrupting AP-1 and NF-kappaB mediated signaling pathways.	Berberine	27-36	matrix metallopeptidase 2	Homo sapiens	104-109
24286329-8	2014	These results suggest that berberine effectively inhibited HASMC migration, possibly by down-regulating MMP-2, MMP-9, and u-PA; and interrupting AP-1 and NF-kappaB mediated signaling pathways.	Berberine	27-36	matrix metallopeptidase 9	Homo sapiens	111-116
24286329-8	2014	These results suggest that berberine effectively inhibited HASMC migration, possibly by down-regulating MMP-2, MMP-9, and u-PA; and interrupting AP-1 and NF-kappaB mediated signaling pathways.	Berberine	27-36	plasminogen activator, urokinase	Homo sapiens	122-126
24286329-8	2014	These results suggest that berberine effectively inhibited HASMC migration, possibly by down-regulating MMP-2, MMP-9, and u-PA; and interrupting AP-1 and NF-kappaB mediated signaling pathways.	Berberine	27-36	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	145-149
24286329-8	2014	These results suggest that berberine effectively inhibited HASMC migration, possibly by down-regulating MMP-2, MMP-9, and u-PA; and interrupting AP-1 and NF-kappaB mediated signaling pathways.	Berberine	27-36	nuclear factor kappa B subunit 1	Homo sapiens	154-163
24984966-9	2014	As an example, the inclusion of berberine, a natural alkaloid with reported anti-aging properties and a long history of use in traditional Chinese medicine, is shown to markedly attenuate the Mxt-induced SI and phosphorylation of rpS6.	Berberine	32-41	ribosomal protein S6	Homo sapiens	230-234
24793543-0	2014	Synergistic inhibition on acetylcholinesterase by the combination of berberine and palmatine originally isolated from Chinese medicinal herbs.	Berberine	69-78	acetylcholinesterase (Cartwright blood group)	Homo sapiens	26-46
24756769-0	2014	Berberine combined with atorvastatin downregulates LOX-1 expression through the ET-1 receptor in monocyte/macrophages.	Berberine	0-9	oxidized low density lipoprotein receptor 1	Rattus norvegicus	51-56
24756769-0	2014	Berberine combined with atorvastatin downregulates LOX-1 expression through the ET-1 receptor in monocyte/macrophages.	Berberine	0-9	endothelin 1	Rattus norvegicus	80-84
24756769-4	2014	In the present study, we aimed to investigate the effect of berberine combined with atorvastatin on LOX-1 and explore the underlying molecular mechanism involved.	Berberine	60-69	oxidized low density lipoprotein receptor 1	Rattus norvegicus	100-105
24756769-5	2014	Expression of LOX-1 in monocyte-derived macrophages (MDMs) exposed to berberine (0, 0.1, 1, 10 and 100 nM) and atorvastatin (100 nM) were analyzed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot analysis.	Berberine	70-79	oxidized low density lipoprotein receptor 1	Rattus norvegicus	14-19
24756769-7	2014	Additionally, knockdown of the endothelin-1 (ET-1) receptor significantly blocked the inhibitory effect of berberine on LOX-1 expression.	Berberine	107-116	endothelin 1	Rattus norvegicus	31-43
24756769-7	2014	Additionally, knockdown of the endothelin-1 (ET-1) receptor significantly blocked the inhibitory effect of berberine on LOX-1 expression.	Berberine	107-116	endothelin 1	Rattus norvegicus	45-49
24756769-7	2014	Additionally, knockdown of the endothelin-1 (ET-1) receptor significantly blocked the inhibitory effect of berberine on LOX-1 expression.	Berberine	107-116	oxidized low density lipoprotein receptor 1	Rattus norvegicus	120-125
24756769-10	2014	Furthermore, plasma ET-1 levels and LOX-1 expression were decreased by berberine combined with atorvastatin treatment, and the inhibitory effect on LOX-1 was impeded by an ET-1 receptor antagonist.	Berberine	71-80	endothelin 1	Rattus norvegicus	20-24
24756769-10	2014	Furthermore, plasma ET-1 levels and LOX-1 expression were decreased by berberine combined with atorvastatin treatment, and the inhibitory effect on LOX-1 was impeded by an ET-1 receptor antagonist.	Berberine	71-80	oxidized low density lipoprotein receptor 1	Rattus norvegicus	36-41
24756769-10	2014	Furthermore, plasma ET-1 levels and LOX-1 expression were decreased by berberine combined with atorvastatin treatment, and the inhibitory effect on LOX-1 was impeded by an ET-1 receptor antagonist.	Berberine	71-80	oxidized low density lipoprotein receptor 1	Rattus norvegicus	148-153
24756769-10	2014	Furthermore, plasma ET-1 levels and LOX-1 expression were decreased by berberine combined with atorvastatin treatment, and the inhibitory effect on LOX-1 was impeded by an ET-1 receptor antagonist.	Berberine	71-80	endothelin 1	Rattus norvegicus	172-176
24756769-11	2014	The results demonstrated that berberine combined with atorvastatin downregulates LOX-1 expression through ET-1 receptors in monocyte/macrophages in vitro and in vivo.	Berberine	30-39	oxidized low density lipoprotein receptor 1	Rattus norvegicus	81-86
24756769-11	2014	The results demonstrated that berberine combined with atorvastatin downregulates LOX-1 expression through ET-1 receptors in monocyte/macrophages in vitro and in vivo.	Berberine	30-39	endothelin 1	Rattus norvegicus	106-110
24744190-3	2014	The hepatoprotective effect of berberine was evaluated by assaying liver function markers, the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha), antioxidant defense system and gene expressions of both TNF-alpha and cyclooxygenase 2 (COX-2).	Berberine	31-40	tumor necrosis factor	Rattus norvegicus	121-148
24744190-3	2014	The hepatoprotective effect of berberine was evaluated by assaying liver function markers, the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha), antioxidant defense system and gene expressions of both TNF-alpha and cyclooxygenase 2 (COX-2).	Berberine	31-40	tumor necrosis factor	Rattus norvegicus	150-159
24744190-3	2014	The hepatoprotective effect of berberine was evaluated by assaying liver function markers, the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha), antioxidant defense system and gene expressions of both TNF-alpha and cyclooxygenase 2 (COX-2).	Berberine	31-40	tumor necrosis factor	Rattus norvegicus	218-227
24744190-3	2014	The hepatoprotective effect of berberine was evaluated by assaying liver function markers, the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha), antioxidant defense system and gene expressions of both TNF-alpha and cyclooxygenase 2 (COX-2).	Berberine	31-40	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	232-248
24744190-3	2014	The hepatoprotective effect of berberine was evaluated by assaying liver function markers, the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha), antioxidant defense system and gene expressions of both TNF-alpha and cyclooxygenase 2 (COX-2).	Berberine	31-40	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	250-255
24793543-5	2014	Our results showed that the combination of berberine and palmatine inhibited acetylcholinesterase in a mixed competitive pattern.	Berberine	43-52	acetylcholinesterase (Cartwright blood group)	Homo sapiens	77-97
24793543-6	2014	By the median-effect principle, the calculated combination index of the combination was less than 1, suggesting that berberine and plamatine inhibited acetylcholinesterase synergistically.	Berberine	117-126	acetylcholinesterase (Cartwright blood group)	Homo sapiens	151-171
24676878-7	2014	Results showed significant lower expression of IL-1beta, IL-6, TGF-beta, TNF-alpha, and ICAM-1, in berberine groups compared with the operation group.	Berberine	99-108	interleukin 1 beta	Rattus norvegicus	47-55
24991192-4	2014	Inhibition of AMPK by RNA interference (RNAi) or by its inhibitor compound C suppressed berberine-induced caspase-3 cleavage, apoptosis and autophagy in HepG2 cells, while AICAR, the AMPK activator, possessed strong cytotoxic effects.	Berberine	88-97	caspase 3	Homo sapiens	106-115
24991192-5	2014	In HepG2 cells, mammalian target of rapamycin complex 1 (mTORC1) activation was important for cell survival, and berberine inhibited mTORC1 via AMPK activation.	Berberine	113-122	CREB regulated transcription coactivator 1	Mus musculus	133-139
24664781-0	2014	Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K-Akt signaling in diabetic rats.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	83-87
24664781-0	2014	Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K-Akt signaling in diabetic rats.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	97-100
24664781-12	2014	Our findings demonstrate that BBR exerts anti-apoptotic effect and improves cardiac functional recovery following myocardial I/R via activating AMPK and PI3K-Akt-eNOS signaling in diabetic rats.	Berberine	30-33	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	144-148
24664781-12	2014	Our findings demonstrate that BBR exerts anti-apoptotic effect and improves cardiac functional recovery following myocardial I/R via activating AMPK and PI3K-Akt-eNOS signaling in diabetic rats.	Berberine	30-33	AKT serine/threonine kinase 1	Rattus norvegicus	158-161
24912407-0	2014	Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine.	Berberine	0-9	glucagon	Rattus norvegicus	56-61
24912407-8	2014	Plasma postprandial glucagon-like peptide-1 (GLP-1) levels were increased in the berberine-treated groups.	Berberine	81-90	glucagon	Rattus norvegicus	45-50
24676878-7	2014	Results showed significant lower expression of IL-1beta, IL-6, TGF-beta, TNF-alpha, and ICAM-1, in berberine groups compared with the operation group.	Berberine	99-108	interleukin 6	Rattus norvegicus	57-61
24676878-7	2014	Results showed significant lower expression of IL-1beta, IL-6, TGF-beta, TNF-alpha, and ICAM-1, in berberine groups compared with the operation group.	Berberine	99-108	tumor necrosis factor	Rattus norvegicus	73-82
24676878-7	2014	Results showed significant lower expression of IL-1beta, IL-6, TGF-beta, TNF-alpha, and ICAM-1, in berberine groups compared with the operation group.	Berberine	99-108	intercellular adhesion molecule 1	Rattus norvegicus	88-94
24676878-8	2014	Activities of phosphorylated JNK and phosphorylated NF-kappaB were inhibited in the berberine groups compared with the surgery group.	Berberine	84-93	mitogen-activated protein kinase 8	Rattus norvegicus	29-32
24886405-7	2014	RESULTS: Berberine increased radiosensitivity of prostate cancer cells and xenografts in a dose dependent manner, and this was correlated with the inhibition of HIF-1alpha and VEGF expression.	Berberine	9-18	hypoxia inducible factor 1 subunit alpha	Homo sapiens	161-171
24905527-0	2014	Berberine inhibits LPS-induced TF procoagulant activity and expression through NF-kappaB/p65, Akt and MAPK pathway in THP-1 cells.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	79-88
24905527-0	2014	Berberine inhibits LPS-induced TF procoagulant activity and expression through NF-kappaB/p65, Akt and MAPK pathway in THP-1 cells.	Berberine	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	89-92
24905527-0	2014	Berberine inhibits LPS-induced TF procoagulant activity and expression through NF-kappaB/p65, Akt and MAPK pathway in THP-1 cells.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	94-97
24905527-3	2014	RESULTS: Our results showed that berberine could inhibit LPS-induced TF activity and expression, and down-regulate NF-kappaB, Akt and MAPK/JNK/p38/ERK pathways.	Berberine	33-42	nuclear factor kappa B subunit 1	Homo sapiens	115-124
24905527-3	2014	RESULTS: Our results showed that berberine could inhibit LPS-induced TF activity and expression, and down-regulate NF-kappaB, Akt and MAPK/JNK/p38/ERK pathways.	Berberine	33-42	AKT serine/threonine kinase 1	Homo sapiens	126-129
24905527-3	2014	RESULTS: Our results showed that berberine could inhibit LPS-induced TF activity and expression, and down-regulate NF-kappaB, Akt and MAPK/JNK/p38/ERK pathways.	Berberine	33-42	mitogen-activated protein kinase 14	Homo sapiens	143-146
24905527-3	2014	RESULTS: Our results showed that berberine could inhibit LPS-induced TF activity and expression, and down-regulate NF-kappaB, Akt and MAPK/JNK/p38/ERK pathways.	Berberine	33-42	mitogen-activated protein kinase 1	Homo sapiens	147-150
24886405-7	2014	RESULTS: Berberine increased radiosensitivity of prostate cancer cells and xenografts in a dose dependent manner, and this was correlated with the inhibition of HIF-1alpha and VEGF expression.	Berberine	9-18	vascular endothelial growth factor A	Homo sapiens	176-180
24886405-8	2014	CONCLUSIONS: Berberine may inhibit the expression of HIF-1alpha and VEGF and thus confer radiosensitivity on prostatic cancer cells.	Berberine	13-22	hypoxia inducible factor 1 subunit alpha	Homo sapiens	53-63
24886405-8	2014	CONCLUSIONS: Berberine may inhibit the expression of HIF-1alpha and VEGF and thus confer radiosensitivity on prostatic cancer cells.	Berberine	13-22	vascular endothelial growth factor A	Homo sapiens	68-72
24843889-0	2014	Berberine induces apoptosis in human multiple myeloma cell line U266 through hypomethylation of p53 promoter.	Berberine	0-9	tumor protein p53	Homo sapiens	96-99
24530556-5	2014	Results showed that the Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) level in were significantly lower in berberine treated rats compared to the control animals.	Berberine	126-135	tumor necrosis factor	Rattus norvegicus	24-51
24530556-5	2014	Results showed that the Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) level in were significantly lower in berberine treated rats compared to the control animals.	Berberine	126-135	tumor necrosis factor	Rattus norvegicus	53-62
24530556-5	2014	Results showed that the Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) level in were significantly lower in berberine treated rats compared to the control animals.	Berberine	126-135	interleukin 6	Rattus norvegicus	68-81
24530556-5	2014	Results showed that the Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) level in were significantly lower in berberine treated rats compared to the control animals.	Berberine	126-135	interleukin 6	Rattus norvegicus	83-87
24843889-6	2014	By using epigenetic chromatin modification enzymes PCR Array, gene expression microarray, RT-PCR and Bisulphite sequencing, the results show that berberine can repress the expression of DNMT1 and DNMT3B, which triggers hypomethylation of TP53 by changing the DNA methylation level and the alteration of p53 dependent signal pathway in human multiple melanoma cell U266.	Berberine	146-155	DNA methyltransferase 1	Homo sapiens	186-191
24843889-6	2014	By using epigenetic chromatin modification enzymes PCR Array, gene expression microarray, RT-PCR and Bisulphite sequencing, the results show that berberine can repress the expression of DNMT1 and DNMT3B, which triggers hypomethylation of TP53 by changing the DNA methylation level and the alteration of p53 dependent signal pathway in human multiple melanoma cell U266.	Berberine	146-155	DNA methyltransferase 3 beta	Homo sapiens	196-202
24843889-6	2014	By using epigenetic chromatin modification enzymes PCR Array, gene expression microarray, RT-PCR and Bisulphite sequencing, the results show that berberine can repress the expression of DNMT1 and DNMT3B, which triggers hypomethylation of TP53 by changing the DNA methylation level and the alteration of p53 dependent signal pathway in human multiple melanoma cell U266.	Berberine	146-155	tumor protein p53	Homo sapiens	238-242
24843889-6	2014	By using epigenetic chromatin modification enzymes PCR Array, gene expression microarray, RT-PCR and Bisulphite sequencing, the results show that berberine can repress the expression of DNMT1 and DNMT3B, which triggers hypomethylation of TP53 by changing the DNA methylation level and the alteration of p53 dependent signal pathway in human multiple melanoma cell U266.	Berberine	146-155	tumor protein p53	Homo sapiens	303-306
25185305-8	2014	The pharmacological results and metabolomic data revealed that berberine can strengthen the sensitivity of insulin and rectify the dyslipidemia of overweight PCOS patients.	Berberine	63-72	insulin	Homo sapiens	107-114
24626784-4	2014	The mRNA expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and transferrin receptor (TFRC) significantly increased during the course of 3T3-L1 adipocyte differentiation, which was decreased by berberine, an inhibitor of adipogenesis.	Berberine	213-222	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	30-70
24626784-4	2014	The mRNA expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and transferrin receptor (TFRC) significantly increased during the course of 3T3-L1 adipocyte differentiation, which was decreased by berberine, an inhibitor of adipogenesis.	Berberine	213-222	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	72-77
24626784-4	2014	The mRNA expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and transferrin receptor (TFRC) significantly increased during the course of 3T3-L1 adipocyte differentiation, which was decreased by berberine, an inhibitor of adipogenesis.	Berberine	213-222	transferrin receptor	Homo sapiens	83-103
24626784-4	2014	The mRNA expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and transferrin receptor (TFRC) significantly increased during the course of 3T3-L1 adipocyte differentiation, which was decreased by berberine, an inhibitor of adipogenesis.	Berberine	213-222	transferrin receptor	Homo sapiens	105-109
24626784-8	2014	In addition, western blot analysis revealed that the increased protein expression of GAPDH was markedly inhibited by berberine during adipocyte differentiation.	Berberine	117-126	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	85-90
24713870-8	2014	Berberine also partially reversed the phosphorylation of the catalytic subunit of PP-2A at Tyrosine 307, a crucial site negatively regulating the activity of PP-2A, and reduced the levels of malondialdehyde and the activity of superoxide dismutase, markers of oxidative stress, induced by CA.	Berberine	0-9	protein phosphatase 2, regulatory subunit A, alpha	Mus musculus	82-87
24755036-0	2014	Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats.	Berberine	44-53	proprotein convertase subtilisin/kexin type 9	Rattus norvegicus	21-26
24755036-0	2014	Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats.	Berberine	44-53	sterol regulatory element binding transcription factor 2	Rattus norvegicus	62-69
24508518-7	2014	Moreover, berberine significantly inhibited the upstream signaling of autophagy, such as the mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK1/2), and p38 mitogen-activated protein kinase (MAPK) phosphorylation.	Berberine	10-19	mechanistic target of rapamycin kinase	Homo sapiens	93-122
24508518-7	2014	Moreover, berberine significantly inhibited the upstream signaling of autophagy, such as the mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK1/2), and p38 mitogen-activated protein kinase (MAPK) phosphorylation.	Berberine	10-19	mechanistic target of rapamycin kinase	Homo sapiens	124-128
24508518-7	2014	Moreover, berberine significantly inhibited the upstream signaling of autophagy, such as the mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK1/2), and p38 mitogen-activated protein kinase (MAPK) phosphorylation.	Berberine	10-19	mitogen-activated protein kinase 3	Homo sapiens	170-176
24766860-0	2014	p38alpha MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine.	Berberine	162-171	mitogen-activated protein kinase 14	Homo sapiens	0-8
24766860-0	2014	p38alpha MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine.	Berberine	162-171	forkhead box O3	Homo sapiens	52-58
24766860-0	2014	p38alpha MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine.	Berberine	162-171	tumor protein p53	Homo sapiens	63-66
24766860-9	2014	Interestingly, inhibition of p53 using one specific inhibitor (Pifithrin-alpha) and silencing of p53 using siRNAs overcome the inhibitory effect of BBR on cell growth.	Berberine	148-151	tumor protein p53	Homo sapiens	97-100
24766860-11	2014	Furthermore, BBR induces the protein expression of cell cycle inhibitor p21 (CIP1/WAF1), which was not observed in cells silencing of p53 or FOXO3alpha gene.	Berberine	13-16	cyclin dependent kinase inhibitor 1A	Homo sapiens	72-75
24766860-11	2014	Furthermore, BBR induces the protein expression of cell cycle inhibitor p21 (CIP1/WAF1), which was not observed in cells silencing of p53 or FOXO3alpha gene.	Berberine	13-16	cyclin dependent kinase inhibitor 1A	Homo sapiens	77-81
24766860-11	2014	Furthermore, BBR induces the protein expression of cell cycle inhibitor p21 (CIP1/WAF1), which was not observed in cells silencing of p53 or FOXO3alpha gene.	Berberine	13-16	cyclin dependent kinase inhibitor 1A	Homo sapiens	82-86
24508518-7	2014	Moreover, berberine significantly inhibited the upstream signaling of autophagy, such as the mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK1/2), and p38 mitogen-activated protein kinase (MAPK) phosphorylation.	Berberine	10-19	mitogen-activated protein kinase 14	Homo sapiens	183-219
24508518-7	2014	Moreover, berberine significantly inhibited the upstream signaling of autophagy, such as the mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK1/2), and p38 mitogen-activated protein kinase (MAPK) phosphorylation.	Berberine	10-19	mitogen-activated protein kinase 3	Homo sapiens	221-225
24508518-8	2014	We conclude that berberine could attenuate left ventricular remodeling and cardiomyocyte apoptosis through an autophagy-dependent mechanism in a rat model of cardiac hypertrophy, which is, at least in part, associated with enhanced autophagy through inhibition of mTOR, p38 and ERK1/2 MAPK signaling pathways.	Berberine	17-26	mechanistic target of rapamycin kinase	Rattus norvegicus	264-268
24713870-8	2014	Berberine also partially reversed the phosphorylation of the catalytic subunit of PP-2A at Tyrosine 307, a crucial site negatively regulating the activity of PP-2A, and reduced the levels of malondialdehyde and the activity of superoxide dismutase, markers of oxidative stress, induced by CA.	Berberine	0-9	protein phosphatase 2, regulatory subunit A, alpha	Mus musculus	158-163
24508518-8	2014	We conclude that berberine could attenuate left ventricular remodeling and cardiomyocyte apoptosis through an autophagy-dependent mechanism in a rat model of cardiac hypertrophy, which is, at least in part, associated with enhanced autophagy through inhibition of mTOR, p38 and ERK1/2 MAPK signaling pathways.	Berberine	17-26	mitogen activated protein kinase 14	Rattus norvegicus	270-273
24713870-9	2014	The present work for the first time demonstrates that Berberine may play a role in protecting against CA-induced axonal transport impairment by modulating the activity of PP-2A and oxidative stress.	Berberine	54-63	protein phosphatase 2, regulatory subunit A, alpha	Mus musculus	171-176
24508518-8	2014	We conclude that berberine could attenuate left ventricular remodeling and cardiomyocyte apoptosis through an autophagy-dependent mechanism in a rat model of cardiac hypertrophy, which is, at least in part, associated with enhanced autophagy through inhibition of mTOR, p38 and ERK1/2 MAPK signaling pathways.	Berberine	17-26	mitogen activated protein kinase 3	Rattus norvegicus	278-284
24508518-8	2014	We conclude that berberine could attenuate left ventricular remodeling and cardiomyocyte apoptosis through an autophagy-dependent mechanism in a rat model of cardiac hypertrophy, which is, at least in part, associated with enhanced autophagy through inhibition of mTOR, p38 and ERK1/2 MAPK signaling pathways.	Berberine	17-26	mitogen-activated protein kinase 3	Homo sapiens	285-289
24248330-3	2014	Several drugs and nutraceuticals which slightly and safely impede the efficiency of mitochondrial ATP generation-most notably metformin and berberine-can be employed as clinical AMPK activators and, hence, may have potential as calorie restriction mimetics for extending healthspan.	Berberine	140-149	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	178-182
24560603-8	2014	Western blot analysis showed that proteins Akt, GSK3beta, ERK and JNK appear to play a role in berberine-mediated neuroprotection.	Berberine	95-104	AKT serine/threonine kinase 1	Rattus norvegicus	43-46
24560603-8	2014	Western blot analysis showed that proteins Akt, GSK3beta, ERK and JNK appear to play a role in berberine-mediated neuroprotection.	Berberine	95-104	glycogen synthase kinase 3 beta	Rattus norvegicus	48-56
24560603-8	2014	Western blot analysis showed that proteins Akt, GSK3beta, ERK and JNK appear to play a role in berberine-mediated neuroprotection.	Berberine	95-104	Eph receptor B1	Rattus norvegicus	58-61
24560603-8	2014	Western blot analysis showed that proteins Akt, GSK3beta, ERK and JNK appear to play a role in berberine-mediated neuroprotection.	Berberine	95-104	mitogen-activated protein kinase 8	Rattus norvegicus	66-69
24560603-10	2014	These findings suggest that berberine-mediated neuroprotection after ischemia involves Akt/GSK3beta/ERK 1/2 survival/apoptotic signaling pathway as well as JNK and caspase-3 activity inhibition.	Berberine	28-37	AKT serine/threonine kinase 1	Rattus norvegicus	87-90
24560603-10	2014	These findings suggest that berberine-mediated neuroprotection after ischemia involves Akt/GSK3beta/ERK 1/2 survival/apoptotic signaling pathway as well as JNK and caspase-3 activity inhibition.	Berberine	28-37	glycogen synthase kinase 3 beta	Rattus norvegicus	91-99
24560603-10	2014	These findings suggest that berberine-mediated neuroprotection after ischemia involves Akt/GSK3beta/ERK 1/2 survival/apoptotic signaling pathway as well as JNK and caspase-3 activity inhibition.	Berberine	28-37	mitogen activated protein kinase 3	Rattus norvegicus	100-107
24560603-10	2014	These findings suggest that berberine-mediated neuroprotection after ischemia involves Akt/GSK3beta/ERK 1/2 survival/apoptotic signaling pathway as well as JNK and caspase-3 activity inhibition.	Berberine	28-37	mitogen-activated protein kinase 8	Rattus norvegicus	156-159
24560603-10	2014	These findings suggest that berberine-mediated neuroprotection after ischemia involves Akt/GSK3beta/ERK 1/2 survival/apoptotic signaling pathway as well as JNK and caspase-3 activity inhibition.	Berberine	28-37	caspase 3	Rattus norvegicus	164-173
24176840-4	2014	Berberine showed stronger inhibitory effect on ERK1/2 phosphorylation as compared to Akt phosphorylation, whereas the combination of the drugs showed greater inhibitory effect on Akt phosphorylation.	Berberine	0-9	mitogen-activated protein kinase 3	Mus musculus	47-53
24113841-11	2014	In conclusion, the present study demonstrated that the treatment with berberine resulted in an obvious reduction of oxidative stress and GFAP-immunoreactive astrocytes in the hippocampus of STZ-induced diabetic rats.	Berberine	70-79	glial fibrillary acidic protein	Rattus norvegicus	137-141
24671102-2	2014	Recently, we found that berberine, a major alkaloid compound in HLJDT, reduced amyloid-beta (Abeta) accumulation in an Alzheimer"s disease (AD) mouse model.	Berberine	24-33	amyloid beta (A4) precursor protein	Mus musculus	93-98
24671102-4	2014	Here we show that treatment with HLJDT-M and its components RC, CP, and the main compound berberine on N2a mouse neuroblastoma cells stably expressing human APP with the Swedish mutation (N2a-SwedAPP) significantly decreased the levels of full-length APP, phosphorylated APP at threonine 668, C-terminal fragments of APP, soluble APP (sAPP)-alpha and sAPPbeta-Swedish and reduced the generation of Abeta peptide in the cell lysates of N2a-SwedAPP.	Berberine	90-99	amyloid beta precursor protein	Homo sapiens	330-346
24671102-4	2014	Here we show that treatment with HLJDT-M and its components RC, CP, and the main compound berberine on N2a mouse neuroblastoma cells stably expressing human APP with the Swedish mutation (N2a-SwedAPP) significantly decreased the levels of full-length APP, phosphorylated APP at threonine 668, C-terminal fragments of APP, soluble APP (sAPP)-alpha and sAPPbeta-Swedish and reduced the generation of Abeta peptide in the cell lysates of N2a-SwedAPP.	Berberine	90-99	amyloid beta precursor protein	Homo sapiens	398-403
24508662-0	2014	Berberine attenuates high glucose-induced proliferation and extracellular matrix accumulation in mesangial cells: involvement of suppression of cell cycle progression and NF-kappaB/AP-1 pathways.	Berberine	0-9	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	181-185
24508662-1	2014	Berberine has been shown to have renoprotective effects on diabetes through attenuating TGF-beta1 and fibronectin (FN) expression.	Berberine	0-9	transforming growth factor beta 1	Homo sapiens	88-97
24508662-1	2014	Berberine has been shown to have renoprotective effects on diabetes through attenuating TGF-beta1 and fibronectin (FN) expression.	Berberine	0-9	fibronectin 1	Homo sapiens	102-113
24508662-1	2014	Berberine has been shown to have renoprotective effects on diabetes through attenuating TGF-beta1 and fibronectin (FN) expression.	Berberine	0-9	fibronectin 1	Homo sapiens	115-117
24508662-2	2014	However, how berberine regulates TGF-beta1 and FN is not fully clear.	Berberine	13-22	transforming growth factor beta 1	Homo sapiens	33-42
24508662-2	2014	However, how berberine regulates TGF-beta1 and FN is not fully clear.	Berberine	13-22	fibronectin 1	Homo sapiens	47-49
24508662-3	2014	Here we investigated whether berberine inhibited TGF-beta1 and FN expression in high glucose-cultured mesangial cells.	Berberine	29-38	transforming growth factor beta 1	Homo sapiens	49-58
24508662-3	2014	Here we investigated whether berberine inhibited TGF-beta1 and FN expression in high glucose-cultured mesangial cells.	Berberine	29-38	fibronectin 1	Homo sapiens	63-65
24508662-5	2014	In addition, berberine reversed high glucose-induced down-regulation of cyclin-dependent kinase inhibitor p21(Waf1)/(Cip1) and p27(Kip1).	Berberine	13-22	cyclin dependent kinase inhibitor 1A	Homo sapiens	106-115
24508662-5	2014	In addition, berberine reversed high glucose-induced down-regulation of cyclin-dependent kinase inhibitor p21(Waf1)/(Cip1) and p27(Kip1).	Berberine	13-22	cyclin dependent kinase inhibitor 1A	Homo sapiens	117-121
24508662-5	2014	In addition, berberine reversed high glucose-induced down-regulation of cyclin-dependent kinase inhibitor p21(Waf1)/(Cip1) and p27(Kip1).	Berberine	13-22	interferon alpha inducible protein 27	Homo sapiens	127-130
24508662-5	2014	In addition, berberine reversed high glucose-induced down-regulation of cyclin-dependent kinase inhibitor p21(Waf1)/(Cip1) and p27(Kip1).	Berberine	13-22	cyclin dependent kinase inhibitor 1B	Homo sapiens	131-135
24508662-6	2014	Berberine inhibited p65 translocation to the nucleus and c-jun phosphorylation induced by high glucose.	Berberine	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	20-23
24508662-6	2014	Berberine inhibited p65 translocation to the nucleus and c-jun phosphorylation induced by high glucose.	Berberine	0-9	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	57-62
24508662-7	2014	Furthermore, berberine attenuated high glucose-induced expression of TGF-beta1 and FN.	Berberine	13-22	transforming growth factor beta 1	Homo sapiens	69-78
24508662-7	2014	Furthermore, berberine attenuated high glucose-induced expression of TGF-beta1 and FN.	Berberine	13-22	fibronectin 1	Homo sapiens	83-85
24508662-8	2014	Using a luciferase reporter assay, we found that high glucose-induced transcription activity of NF-kappaB and AP-1 was blocked by berberine.	Berberine	130-139	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	110-114
24508662-11	2014	In addition, berberine suppressed high glucose-induced TGF-beta1 and FN expression by blocking NF-kappaB/AP-1 pathways.	Berberine	13-22	transforming growth factor beta 1	Homo sapiens	55-64
24508662-11	2014	In addition, berberine suppressed high glucose-induced TGF-beta1 and FN expression by blocking NF-kappaB/AP-1 pathways.	Berberine	13-22	fibronectin 1	Homo sapiens	69-71
24508662-11	2014	In addition, berberine suppressed high glucose-induced TGF-beta1 and FN expression by blocking NF-kappaB/AP-1 pathways.	Berberine	13-22	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	105-109
24603897-0	2014	Inhibition of retinoblastoma mRNA degradation through Poly (A) involved in the neuroprotective effect of berberine against cerebral ischemia.	Berberine	105-114	RB transcriptional corepressor 1	Homo sapiens	14-28
24603897-3	2014	According to the in vitro neurons with oxygen-glucose deprivation and in vivo ICR mice with cerebral ischemia/reperfusion, it was found that berberine could protect the mRNA of retinoblastoma (Rb) from degradation through its function on the poly(A) tail.	Berberine	141-150	RB transcriptional corepressor 1	Homo sapiens	177-191
24603897-5	2014	The poly(A) tail of RB1 mRNA, as a newly identified target of berberine, could help people focus on the interaction between berberine and mRNA to further understand the biological activities and functions of berberine.	Berberine	62-71	RB transcriptional corepressor 1	Homo sapiens	20-23
24603897-5	2014	The poly(A) tail of RB1 mRNA, as a newly identified target of berberine, could help people focus on the interaction between berberine and mRNA to further understand the biological activities and functions of berberine.	Berberine	124-133	RB transcriptional corepressor 1	Homo sapiens	20-23
24603897-5	2014	The poly(A) tail of RB1 mRNA, as a newly identified target of berberine, could help people focus on the interaction between berberine and mRNA to further understand the biological activities and functions of berberine.	Berberine	124-133	RB transcriptional corepressor 1	Homo sapiens	20-23
24246570-0	2014	Inhibition of organic cation transporter 2 and 3 may be involved in the mechanism of the antidepressant-like action of berberine.	Berberine	119-128	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	14-48
24246570-4	2014	In consideration of the relation between OCT2/3 and antidepressant action, and the characteristic of berberine as an organic cation, we investigated the potential involvement of OCT2 and OCT3 in the antidepressant-like action of berberine in the present study.	Berberine	229-238	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	178-182
24246570-4	2014	In consideration of the relation between OCT2/3 and antidepressant action, and the characteristic of berberine as an organic cation, we investigated the potential involvement of OCT2 and OCT3 in the antidepressant-like action of berberine in the present study.	Berberine	229-238	solute carrier family 22 (organic cation transporter), member 3	Mus musculus	187-191
24246570-6	2014	The inhibitory study in transfected MDCK cells displayed that berberine is a potent inhibitor of human OCT2 and OCT3, and its IC50 values for inhibition of transporter-mediated 5-HT/NE uptake are between 0.1 and 1muM.	Berberine	62-71	solute carrier family 22 member 2	Homo sapiens	103-107
24246570-6	2014	The inhibitory study in transfected MDCK cells displayed that berberine is a potent inhibitor of human OCT2 and OCT3, and its IC50 values for inhibition of transporter-mediated 5-HT/NE uptake are between 0.1 and 1muM.	Berberine	62-71	solute carrier family 22 member 3	Homo sapiens	112-116
24246570-7	2014	In addition, berberine was identified as a substrate of hOCT2 and hOCT3.	Berberine	13-22	POU class 2 homeobox 2	Homo sapiens	56-61
24246570-7	2014	In addition, berberine was identified as a substrate of hOCT2 and hOCT3.	Berberine	13-22	solute carrier family 22 member 3	Homo sapiens	66-71
24246570-8	2014	In conclusion, berberine is a substrate and an inhibitor of hOCT2 and hOCT3, and its inhibition on OCT2- and OCT3-mediated 5-HT and NE uptake may contribute to the enhanced monoamine neurotransmission in mouse brain.	Berberine	15-24	POU class 2 homeobox 2	Homo sapiens	60-65
24246570-8	2014	In conclusion, berberine is a substrate and an inhibitor of hOCT2 and hOCT3, and its inhibition on OCT2- and OCT3-mediated 5-HT and NE uptake may contribute to the enhanced monoamine neurotransmission in mouse brain.	Berberine	15-24	solute carrier family 22 member 3	Homo sapiens	70-75
24246570-8	2014	In conclusion, berberine is a substrate and an inhibitor of hOCT2 and hOCT3, and its inhibition on OCT2- and OCT3-mediated 5-HT and NE uptake may contribute to the enhanced monoamine neurotransmission in mouse brain.	Berberine	15-24	solute carrier family 22 (organic cation transporter), member 2	Mus musculus	61-65
24246570-8	2014	In conclusion, berberine is a substrate and an inhibitor of hOCT2 and hOCT3, and its inhibition on OCT2- and OCT3-mediated 5-HT and NE uptake may contribute to the enhanced monoamine neurotransmission in mouse brain.	Berberine	15-24	solute carrier family 22 (organic cation transporter), member 3	Mus musculus	71-75
25039167-4	2014	The mechanisms of berberine in diabetes include: improving the function of beta-cell; prompting insulin secretion and islets regeneration, lowing lipid level, regulating glucose and lipid metabolic by influence transcriptional factors expression such as PPARgamma, C/EBPalpha, SREBP-1c, LXR, having the activities of anti-oxidation and inhibiting reductase to repress oxidative stress state and regulate metabolic signal pathway.	Berberine	18-27	peroxisome proliferator activated receptor gamma	Homo sapiens	254-263
25039167-4	2014	The mechanisms of berberine in diabetes include: improving the function of beta-cell; prompting insulin secretion and islets regeneration, lowing lipid level, regulating glucose and lipid metabolic by influence transcriptional factors expression such as PPARgamma, C/EBPalpha, SREBP-1c, LXR, having the activities of anti-oxidation and inhibiting reductase to repress oxidative stress state and regulate metabolic signal pathway.	Berberine	18-27	CCAAT enhancer binding protein alpha	Homo sapiens	265-275
25039167-4	2014	The mechanisms of berberine in diabetes include: improving the function of beta-cell; prompting insulin secretion and islets regeneration, lowing lipid level, regulating glucose and lipid metabolic by influence transcriptional factors expression such as PPARgamma, C/EBPalpha, SREBP-1c, LXR, having the activities of anti-oxidation and inhibiting reductase to repress oxidative stress state and regulate metabolic signal pathway.	Berberine	18-27	sterol regulatory element binding transcription factor 1	Homo sapiens	277-285
25039167-5	2014	Although numbers of data supported that berberine could improving insulin resistance by clinical trials and animal studies, the large scale, multicenter clinical trials are needed to evaluate the effects of berberine for diabetes and its complications in the time of evidence-based medicine.	Berberine	40-49	insulin	Homo sapiens	66-73
24412384-2	2014	MAIN METHODS: CCl4-induced chronic liver fibrosis model in mice was established and activated rat hepatic stellate cell was treated with BBR.	Berberine	137-140	chemokine (C-C motif) ligand 4	Mus musculus	14-18
24412384-4	2014	KEY FINDINGS: Our results showed that BBR ameliorated the liver fibrosis in mice with CCl4-induced liver injury and inhibited the proliferation of hepatic stellate cell in dose- and time-dependent manner.	Berberine	38-41	chemokine (C-C motif) ligand 4	Mus musculus	86-90
24412384-8	2014	The expression of smooth muscle actin (alpha-SMA), the marker of activated hepatic stellate cell, was also reduced by BBR treatment.	Berberine	118-121	actin alpha 2, smooth muscle, aorta	Mus musculus	39-48
24602493-0	2014	Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor.	Berberine	8-17	toll-like receptor 4	Mus musculus	81-85
24602493-8	2014	The studies of molecular mechanism demonstrated that Berberine was able to bind to the TLR4/MD-2 receptor, and presented higher affinity in comparison with LPS.	Berberine	53-62	toll-like receptor 4	Mus musculus	87-91
24602493-9	2014	Furthermore, berberine could significantly suppressed the increasing expression of NF-kappaB, IL-6, TNFalpha, and IFNbeta in the RAW264.7 challenged with LPS.	Berberine	13-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	83-92
24602493-9	2014	Furthermore, berberine could significantly suppressed the increasing expression of NF-kappaB, IL-6, TNFalpha, and IFNbeta in the RAW264.7 challenged with LPS.	Berberine	13-22	interleukin 6	Mus musculus	94-98
24602493-9	2014	Furthermore, berberine could significantly suppressed the increasing expression of NF-kappaB, IL-6, TNFalpha, and IFNbeta in the RAW264.7 challenged with LPS.	Berberine	13-22	tumor necrosis factor	Mus musculus	100-108
24602493-10	2014	CONCLUSION: Berberine can act as a LPS antagonist and block the LPS/TLR4 signaling from the sourse, resulting in the anti-bacterial action.	Berberine	12-21	toll-like receptor 4	Mus musculus	68-72
24236461-4	2014	Among different phyto-constituents, alkaloids that contain isoquinoline/bis(isoquinoline)and related ring structures (such as berberine, palmatine, coptisine, and jateorrhizine) have shown very potent aldose reductase inhibitory activity.	Berberine	126-135	aldo-keto reductase family 1 member B	Homo sapiens	201-217
24325635-0	2014	Berberine radiosensitizes human nasopharyngeal carcinoma by suppressing hypoxia-inducible factor-1alpha expression.	Berberine	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	72-103
24325635-1	2014	CONCLUSION: Berberine confers radiosensitivity on nasopharyngeal carcinoma (NPC) and this is associated with the down-regulation of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression.	Berberine	12-21	hypoxia inducible factor 1 subunit alpha	Homo sapiens	132-163
24325635-1	2014	CONCLUSION: Berberine confers radiosensitivity on nasopharyngeal carcinoma (NPC) and this is associated with the down-regulation of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression.	Berberine	12-21	hypoxia inducible factor 1 subunit alpha	Homo sapiens	165-175
24325635-1	2014	CONCLUSION: Berberine confers radiosensitivity on nasopharyngeal carcinoma (NPC) and this is associated with the down-regulation of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression.	Berberine	12-21	vascular endothelial growth factor A	Homo sapiens	181-215
24325635-1	2014	CONCLUSION: Berberine confers radiosensitivity on nasopharyngeal carcinoma (NPC) and this is associated with the down-regulation of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) expression.	Berberine	12-21	vascular endothelial growth factor A	Homo sapiens	217-221
24325635-10	2014	RESULTS: Berberine efficiently radiosensitized NPC cells and xenografts in mice, and inhibited hypoxia/radiation-induced up-regulation of HIF-1alpha and VEGF expression.	Berberine	9-18	hypoxia inducible factor 1, alpha subunit	Mus musculus	138-148
24325635-10	2014	RESULTS: Berberine efficiently radiosensitized NPC cells and xenografts in mice, and inhibited hypoxia/radiation-induced up-regulation of HIF-1alpha and VEGF expression.	Berberine	9-18	vascular endothelial growth factor A	Mus musculus	153-157
23875776-0	2014	The crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice.	Berberine	101-110	nuclear factor, erythroid derived 2, like 2	Mus musculus	22-26
24286347-0	2014	Berberine ameliorates cartilage degeneration in interleukin-1beta-stimulated rat chondrocytes and in a rat model of osteoarthritis via Akt signalling.	Berberine	0-9	interleukin 1 beta	Rattus norvegicus	48-65
23875776-3	2014	In the present study, we investigated the relationship between AMPK and Nrf2 signal pathways in lipopolysaccharide (LPS)-triggered inflammatory system, in which berberine (BBR), a known AMPK activator, was used for inflammation suppression.	Berberine	161-170	nuclear factor, erythroid derived 2, like 2	Mus musculus	72-76
23875776-3	2014	In the present study, we investigated the relationship between AMPK and Nrf2 signal pathways in lipopolysaccharide (LPS)-triggered inflammatory system, in which berberine (BBR), a known AMPK activator, was used for inflammation suppression.	Berberine	172-175	nuclear factor, erythroid derived 2, like 2	Mus musculus	72-76
23875776-5	2014	Importantly, we found BBR-induced activation of Nrf2 is AMPK-dependent, as either pharmacologically or genetically inactivating AMPK blocked the activation of Nrf2.	Berberine	22-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	48-52
23875776-5	2014	Importantly, we found BBR-induced activation of Nrf2 is AMPK-dependent, as either pharmacologically or genetically inactivating AMPK blocked the activation of Nrf2.	Berberine	22-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	159-163
24286347-0	2014	Berberine ameliorates cartilage degeneration in interleukin-1beta-stimulated rat chondrocytes and in a rat model of osteoarthritis via Akt signalling.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	135-138
24286347-4	2014	Here, we assessed the effects of berberine on cartilage degeneration in interleukin-1beta (IL-1beta)-stimulated rat chondrocytes and in a rat model of OA.	Berberine	33-42	interleukin 1 beta	Rattus norvegicus	72-89
24286347-5	2014	The results of an MTT assay and western blotting analysis showed that berberine attenuated the inhibitory effect of IL-1beta on the cell viability and proliferating cell nuclear antigen expression in rat chondrocytes.	Berberine	70-79	interleukin 1 beta	Rattus norvegicus	116-124
24286347-6	2014	Furthermore, berberine activated Akt, which triggered p70S6K/S6 pathway and up-regulated the levels of aggrecan and Col II expression in IL-1beta-stimulated rat chondrocytes.	Berberine	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	33-36
24286347-6	2014	Furthermore, berberine activated Akt, which triggered p70S6K/S6 pathway and up-regulated the levels of aggrecan and Col II expression in IL-1beta-stimulated rat chondrocytes.	Berberine	13-22	ribosomal protein S6 kinase B1	Rattus norvegicus	54-60
24286347-6	2014	Furthermore, berberine activated Akt, which triggered p70S6K/S6 pathway and up-regulated the levels of aggrecan and Col II expression in IL-1beta-stimulated rat chondrocytes.	Berberine	13-22	interleukin 1 beta	Rattus norvegicus	137-145
24286347-7	2014	In addition, berberine increased the level of proteoglycans in cartilage matrix and the thickness of articular cartilage, with the elevated levels of Col II, p-Akt and p-S6 expression in a rat OA model, as demonstrated by histopathological and immunohistochemistry techniques.	Berberine	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	160-163
24286347-8	2014	The data thus strongly suggest that berberine may ameliorate cartilage degeneration from OA by promoting cell survival and matrix production of chondrocytes, which was partly attributed to the activation of Akt in IL-1beta-stimulated articular chondrocytes and in a rat OA model.	Berberine	36-45	AKT serine/threonine kinase 1	Rattus norvegicus	207-210
24286347-8	2014	The data thus strongly suggest that berberine may ameliorate cartilage degeneration from OA by promoting cell survival and matrix production of chondrocytes, which was partly attributed to the activation of Akt in IL-1beta-stimulated articular chondrocytes and in a rat OA model.	Berberine	36-45	interleukin 1 beta	Rattus norvegicus	214-222
24342459-5	2014	We also found that berberine rescued D-galactose-induced memory impairment and additionally rescued the mRNA and protein levels of Arc/Arg3.1, an important immediate early gene that is crucial for maintaining normal synaptic plasticity.	Berberine	19-28	activity regulated cytoskeleton associated protein	Homo sapiens	131-141
24456611-8	2014	Berberine inhibited invasion and migration of A549 cells, increased expression of the epithelial phenotype marker E-cadherin, repressed the expression of the mesenchymal phenotype marker Vimentin, as well as decreased the level of epithelial-to-mesenchymal -inducing transcription factors Snail1 and Slug during the initiation of TGF-beta1-induced epithelial-to-mesenchymal.	Berberine	0-9	cadherin 1	Homo sapiens	114-124
24456611-2	2014	Since epithelial-to-mesenchymal transition is a cellular process associated with cancer invasion and metastasis, we attempted to investigate the potential use of berberine as an inhibitor of TGF-beta1-induced epithelial-to-mesenchymal in A549 cells.	Berberine	162-171	transforming growth factor beta 1	Homo sapiens	191-200
24456611-8	2014	Berberine inhibited invasion and migration of A549 cells, increased expression of the epithelial phenotype marker E-cadherin, repressed the expression of the mesenchymal phenotype marker Vimentin, as well as decreased the level of epithelial-to-mesenchymal -inducing transcription factors Snail1 and Slug during the initiation of TGF-beta1-induced epithelial-to-mesenchymal.	Berberine	0-9	vimentin	Homo sapiens	187-195
24456611-8	2014	Berberine inhibited invasion and migration of A549 cells, increased expression of the epithelial phenotype marker E-cadherin, repressed the expression of the mesenchymal phenotype marker Vimentin, as well as decreased the level of epithelial-to-mesenchymal -inducing transcription factors Snail1 and Slug during the initiation of TGF-beta1-induced epithelial-to-mesenchymal.	Berberine	0-9	snail family transcriptional repressor 1	Homo sapiens	289-295
24456611-8	2014	Berberine inhibited invasion and migration of A549 cells, increased expression of the epithelial phenotype marker E-cadherin, repressed the expression of the mesenchymal phenotype marker Vimentin, as well as decreased the level of epithelial-to-mesenchymal -inducing transcription factors Snail1 and Slug during the initiation of TGF-beta1-induced epithelial-to-mesenchymal.	Berberine	0-9	snail family transcriptional repressor 2	Homo sapiens	300-304
24456611-8	2014	Berberine inhibited invasion and migration of A549 cells, increased expression of the epithelial phenotype marker E-cadherin, repressed the expression of the mesenchymal phenotype marker Vimentin, as well as decreased the level of epithelial-to-mesenchymal -inducing transcription factors Snail1 and Slug during the initiation of TGF-beta1-induced epithelial-to-mesenchymal.	Berberine	0-9	transforming growth factor beta 1	Homo sapiens	330-339
24456611-10	2014	CONCLUSIONS: Our findings provided new evidence that berberine is an effective inhibitor of the metastatic potential of A549 cells through suppression of TGF-beta1-induced epithelial-to-mesenchymal.	Berberine	53-62	transforming growth factor beta 1	Homo sapiens	154-163
24158514-1	2014	OBJECTIVE: Previous studies showed that low-density lipoprotein receptor (LDLR) mRNA 3" untranslated region (UTR) contains regulatory elements responsible for rapid mRNA turnover in hepatic cells and mediates the mRNA stabilization induced by berberine (BBR).	Berberine	243-252	low density lipoprotein receptor	Mus musculus	40-72
24158514-1	2014	OBJECTIVE: Previous studies showed that low-density lipoprotein receptor (LDLR) mRNA 3" untranslated region (UTR) contains regulatory elements responsible for rapid mRNA turnover in hepatic cells and mediates the mRNA stabilization induced by berberine (BBR).	Berberine	243-252	low density lipoprotein receptor	Mus musculus	74-78
24158514-1	2014	OBJECTIVE: Previous studies showed that low-density lipoprotein receptor (LDLR) mRNA 3" untranslated region (UTR) contains regulatory elements responsible for rapid mRNA turnover in hepatic cells and mediates the mRNA stabilization induced by berberine (BBR).	Berberine	254-257	low density lipoprotein receptor	Mus musculus	40-72
24158514-1	2014	OBJECTIVE: Previous studies showed that low-density lipoprotein receptor (LDLR) mRNA 3" untranslated region (UTR) contains regulatory elements responsible for rapid mRNA turnover in hepatic cells and mediates the mRNA stabilization induced by berberine (BBR).	Berberine	254-257	low density lipoprotein receptor	Mus musculus	74-78
25131260-10	2014	Berberine and hesperidin, which are found in large quantities in HMC05, also induced NQO-1 gene expression.	Berberine	0-9	NAD(P)H quinone dehydrogenase 1	Homo sapiens	85-90
24528081-0	2014	Preferential induction of CYP1A1 over CYP1B1 in human breast cancer MCF-7 cells after exposure to berberine.	Berberine	98-107	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	26-32
24528081-0	2014	Preferential induction of CYP1A1 over CYP1B1 in human breast cancer MCF-7 cells after exposure to berberine.	Berberine	98-107	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	38-44
24528081-5	2014	In the present study, we investigated the effects of the berberine on the expression profile of the estrogen metabolizing enzymes CYP1A1 and CYP1B1 in breast cancer MCF-7 cells.	Berberine	57-66	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	130-136
24528081-5	2014	In the present study, we investigated the effects of the berberine on the expression profile of the estrogen metabolizing enzymes CYP1A1 and CYP1B1 in breast cancer MCF-7 cells.	Berberine	57-66	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	141-147
24528081-6	2014	Berberine treatment produced significant induction of both forms at the level of mRNA expression, but with increased doses produced 16~ to 52~fold greater inductions of CYP1A1 mRNA over CYP1B1 mRNA.	Berberine	0-9	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	169-175
24528081-6	2014	Berberine treatment produced significant induction of both forms at the level of mRNA expression, but with increased doses produced 16~ to 52~fold greater inductions of CYP1A1 mRNA over CYP1B1 mRNA.	Berberine	0-9	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	186-192
24528081-7	2014	Furthermore, berberine dramatically increased CYP1A1 protein levels but did not influence CYP1B1 protein levels in MCF-7 cells.	Berberine	13-22	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	46-52
24528081-8	2014	In conclusion, we present the first report to show that berberine may provide protection against breast cancer by altering the ratio of CYP1A1/CYP1B1, could redirect E2 metabolism in a more protective pathway in the breast cancer MCF-7 cells.	Berberine	56-65	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	136-142
24528081-8	2014	In conclusion, we present the first report to show that berberine may provide protection against breast cancer by altering the ratio of CYP1A1/CYP1B1, could redirect E2 metabolism in a more protective pathway in the breast cancer MCF-7 cells.	Berberine	56-65	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	143-149
25196457-0	2014	Berberine up-regulates hepatic low-density lipoprotein receptor through Ras-independent but AMP-activated protein kinase-dependent Raf-1 activation.	Berberine	0-9	low density lipoprotein receptor	Rattus norvegicus	31-63
25196457-0	2014	Berberine up-regulates hepatic low-density lipoprotein receptor through Ras-independent but AMP-activated protein kinase-dependent Raf-1 activation.	Berberine	0-9	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	131-136
25196457-1	2014	Our previous studies showed that berberine (BBR) increases liver low-density lipoprotein (LDL) receptor expression in an extracellular signal-regulated kinase (ERK)-dependent manner.	Berberine	33-42	low density lipoprotein receptor	Rattus norvegicus	65-103
25470292-8	2014	We also showed that CD147 increased the viability of A375 cells exposed to berberine-induced mitochondrial damage, and protected them from apoptosis through a mitochondrial-dependent pathway.	Berberine	75-84	basigin (Ok blood group)	Homo sapiens	20-25
25196457-1	2014	Our previous studies showed that berberine (BBR) increases liver low-density lipoprotein (LDL) receptor expression in an extracellular signal-regulated kinase (ERK)-dependent manner.	Berberine	33-42	Eph receptor B1	Rattus norvegicus	121-158
25196457-1	2014	Our previous studies showed that berberine (BBR) increases liver low-density lipoprotein (LDL) receptor expression in an extracellular signal-regulated kinase (ERK)-dependent manner.	Berberine	33-42	Eph receptor B1	Rattus norvegicus	160-163
25196457-1	2014	Our previous studies showed that berberine (BBR) increases liver low-density lipoprotein (LDL) receptor expression in an extracellular signal-regulated kinase (ERK)-dependent manner.	Berberine	44-47	low density lipoprotein receptor	Rattus norvegicus	65-103
25196457-1	2014	Our previous studies showed that berberine (BBR) increases liver low-density lipoprotein (LDL) receptor expression in an extracellular signal-regulated kinase (ERK)-dependent manner.	Berberine	44-47	Eph receptor B1	Rattus norvegicus	121-158
25196457-1	2014	Our previous studies showed that berberine (BBR) increases liver low-density lipoprotein (LDL) receptor expression in an extracellular signal-regulated kinase (ERK)-dependent manner.	Berberine	44-47	Eph receptor B1	Rattus norvegicus	160-163
25171176-0	2014	Berberine induces hERG channel deficiency through trafficking inhibition.	Berberine	0-9	ETS transcription factor ERG	Homo sapiens	18-22
25171176-3	2014	Berberine (BBR) was previously found to acutely inhibit hERG currents and prolong action potential duration.	Berberine	0-9	ETS transcription factor ERG	Homo sapiens	56-60
25171176-3	2014	Berberine (BBR) was previously found to acutely inhibit hERG currents and prolong action potential duration.	Berberine	11-14	ETS transcription factor ERG	Homo sapiens	56-60
24376206-3	2014	Compound 7 d (N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-2-(2-fluorophenyl)acetamide) significantly decreased the MIC80 values of fluconazole from 128.0 mug mL-1 to 0.5 mug mL-1 against fluconazole-resistant C. albicans and exhibited much lower levels of cytotoxicity than berberine toward human umbilical vein endothelial cells.	Berberine	268-277	2'-5' oligoadenylate synthetase 1B	Mus musculus	152-163
24376206-3	2014	Compound 7 d (N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-2-(2-fluorophenyl)acetamide) significantly decreased the MIC80 values of fluconazole from 128.0 mug mL-1 to 0.5 mug mL-1 against fluconazole-resistant C. albicans and exhibited much lower levels of cytotoxicity than berberine toward human umbilical vein endothelial cells.	Berberine	268-277	2'-5' oligoadenylate synthetase 1B	Mus musculus	152-156
25052035-3	2014	In this study, we report that knockdown of nhr-8, a gene involved in the xenobiotic response, increased the worm"s sensitivity to the lipid-reducing effects of some isoquinoline alkaloids, especially berberine.	Berberine	200-209	Nuclear hormone receptor family member nhr-8	Caenorhabditis elegans	43-48
25477998-0	2014	Protective Effects of Berberine on Isoproterenol-Induced Acute Myocardial Ischemia in Rats through Regulating HMGB1-TLR4 Axis.	Berberine	22-31	high mobility group box 1	Rattus norvegicus	110-115
25276218-4	2014	Among AC-mix ingredients, AA, CC, and their main constituents mangiferin and berberine potently inhibited the expression of proinflammatory cytokines TNF-alpha and IL-1beta, as well as the activation of NF-kappaB in LPS-stimulated peritoneal macrophages.	Berberine	77-86	tumor necrosis factor	Mus musculus	150-159
25276218-4	2014	Among AC-mix ingredients, AA, CC, and their main constituents mangiferin and berberine potently inhibited the expression of proinflammatory cytokines TNF-alpha and IL-1beta, as well as the activation of NF-kappaB in LPS-stimulated peritoneal macrophages.	Berberine	77-86	interleukin 1 beta	Mus musculus	164-172
25276218-5	2014	AA and mangiferin potently inhibited IRAK phosphorylation, but CC and berberine potently inhibited the binding of LPS to TLR4 on macrophages, as well as the phosphorylation of IRAK1.	Berberine	70-79	toll-like receptor 4	Mus musculus	121-125
25477998-0	2014	Protective Effects of Berberine on Isoproterenol-Induced Acute Myocardial Ischemia in Rats through Regulating HMGB1-TLR4 Axis.	Berberine	22-31	toll-like receptor 4	Rattus norvegicus	116-120
25276218-5	2014	AA and mangiferin potently inhibited IRAK phosphorylation, but CC and berberine potently inhibited the binding of LPS to TLR4 on macrophages, as well as the phosphorylation of IRAK1.	Berberine	70-79	interleukin-1 receptor-associated kinase 1	Mus musculus	176-181
25477998-8	2014	Berberine decreased the ST elevation induced by acute myocardial ischemia, and decreased serum levels of CK-MB, LDH, TNF-alpha, and IL-6.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	117-126
25477998-8	2014	Berberine decreased the ST elevation induced by acute myocardial ischemia, and decreased serum levels of CK-MB, LDH, TNF-alpha, and IL-6.	Berberine	0-9	interleukin 6	Rattus norvegicus	132-136
25477998-10	2014	Berberine can regulate HMGB1-TLR4 axis to protect myocardial ischemia.	Berberine	0-9	high mobility group box 1	Rattus norvegicus	23-28
25477998-10	2014	Berberine can regulate HMGB1-TLR4 axis to protect myocardial ischemia.	Berberine	0-9	toll-like receptor 4	Rattus norvegicus	29-33
24321576-0	2014	Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	35-67
24321576-5	2014	Here, RT-PCR, Western blotting and Oil Red O staining were used to investigate the effects of four BBR metabolites on LDLR expression and lipid accumulation in human hepatoma Hep G2 cells.	Berberine	99-102	low density lipoprotein receptor	Homo sapiens	118-122
24321576-7	2014	Four metabolites of BBR, jatrorrhizine, columbamine, berberrubine and demethyleneberberine, were found to be able to up-regulate LDLR mRNA and protein expression.	Berberine	20-23	low density lipoprotein receptor	Homo sapiens	129-133
23604974-6	2014	Cell cycle analysis of 40 muM berberine-treated LoVo cells by flow cytometry showed accumulation of cells in the G2/M phase.	Berberine	30-39	latexin	Homo sapiens	26-29
24317011-3	2014	The hepatic HMG-CoA reductase activity was significantly lower in the PME and berberine groups than in the glycyrrhizin group (P &lt; 0.05), while the hepatic ACAT activity was significantly decreased by all treatments with respect to the high cholesterol fed group (P &lt; 0.05).	Berberine	78-87	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	12-29
24317011-4	2014	The overall potential of the antioxidant system was significantly enhanced by the PME, berberine and glycyrrhizin supplements as the plasma and hepatic TBARS levels were lowered while the hepatic superoxide dismutase activity and glutathione levels, HMG-CoA reductase, LDL receptor, PPAR, SREBP-2 and CYP7A1 mRNA expressions were increased by the treatments of PME and berberine in comparison with the high cholesterol fed hamsters (P &lt; 0.05).	Berberine	87-96	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	250-267
24317011-4	2014	The overall potential of the antioxidant system was significantly enhanced by the PME, berberine and glycyrrhizin supplements as the plasma and hepatic TBARS levels were lowered while the hepatic superoxide dismutase activity and glutathione levels, HMG-CoA reductase, LDL receptor, PPAR, SREBP-2 and CYP7A1 mRNA expressions were increased by the treatments of PME and berberine in comparison with the high cholesterol fed hamsters (P &lt; 0.05).	Berberine	87-96	low density lipoprotein receptor	Homo sapiens	269-281
24317011-4	2014	The overall potential of the antioxidant system was significantly enhanced by the PME, berberine and glycyrrhizin supplements as the plasma and hepatic TBARS levels were lowered while the hepatic superoxide dismutase activity and glutathione levels, HMG-CoA reductase, LDL receptor, PPAR, SREBP-2 and CYP7A1 mRNA expressions were increased by the treatments of PME and berberine in comparison with the high cholesterol fed hamsters (P &lt; 0.05).	Berberine	87-96	peroxisome proliferator activated receptor alpha	Homo sapiens	283-287
24317011-4	2014	The overall potential of the antioxidant system was significantly enhanced by the PME, berberine and glycyrrhizin supplements as the plasma and hepatic TBARS levels were lowered while the hepatic superoxide dismutase activity and glutathione levels, HMG-CoA reductase, LDL receptor, PPAR, SREBP-2 and CYP7A1 mRNA expressions were increased by the treatments of PME and berberine in comparison with the high cholesterol fed hamsters (P &lt; 0.05).	Berberine	87-96	sterol regulatory element binding transcription factor 2	Homo sapiens	289-296
24317011-4	2014	The overall potential of the antioxidant system was significantly enhanced by the PME, berberine and glycyrrhizin supplements as the plasma and hepatic TBARS levels were lowered while the hepatic superoxide dismutase activity and glutathione levels, HMG-CoA reductase, LDL receptor, PPAR, SREBP-2 and CYP7A1 mRNA expressions were increased by the treatments of PME and berberine in comparison with the high cholesterol fed hamsters (P &lt; 0.05).	Berberine	87-96	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	301-307
25393968-4	2014	The results show that berberine is able to arrest cell cycle and activate apoptotic pathway as shown in both cell lines by deoxyribonucleic acid fragmentation, caspase-3 cleavage, p53 and p27 protein overexpression.	Berberine	22-31	caspase 3	Homo sapiens	160-169
25393968-4	2014	The results show that berberine is able to arrest cell cycle and activate apoptotic pathway as shown in both cell lines by deoxyribonucleic acid fragmentation, caspase-3 cleavage, p53 and p27 protein overexpression.	Berberine	22-31	tumor protein p53	Homo sapiens	180-183
25393968-4	2014	The results show that berberine is able to arrest cell cycle and activate apoptotic pathway as shown in both cell lines by deoxyribonucleic acid fragmentation, caspase-3 cleavage, p53 and p27 protein overexpression.	Berberine	22-31	interferon alpha inducible protein 27	Homo sapiens	188-191
23604974-7	2014	The inhibition of LoVo cell growth by berberine was associated with the suppression of cyclin B1, cdc2, and cdc25c proteins.	Berberine	38-47	cyclin B1	Homo sapiens	87-96
23604974-7	2014	The inhibition of LoVo cell growth by berberine was associated with the suppression of cyclin B1, cdc2, and cdc25c proteins.	Berberine	38-47	cyclin dependent kinase 1	Homo sapiens	98-102
23604974-7	2014	The inhibition of LoVo cell growth by berberine was associated with the suppression of cyclin B1, cdc2, and cdc25c proteins.	Berberine	38-47	cell division cycle 25C	Homo sapiens	108-114
24380387-0	2013	Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts.	Berberine	0-9	signal transducer and activator of transcription 3	Homo sapiens	95-100
24173769-5	2014	Berberine suppressed CPT-11-induced NF-kappaB activation in a dose-dependent manner and enhanced chemosensitivity to CPT-11 by downregulating NF-kappaB activation of antiapoptotic genes, c-IAP1, c-IAP2, survivin and Bcl-xL.	Berberine	0-9	baculoviral IAP repeat containing 2	Homo sapiens	187-193
24173769-5	2014	Berberine suppressed CPT-11-induced NF-kappaB activation in a dose-dependent manner and enhanced chemosensitivity to CPT-11 by downregulating NF-kappaB activation of antiapoptotic genes, c-IAP1, c-IAP2, survivin and Bcl-xL.	Berberine	0-9	baculoviral IAP repeat containing 3	Homo sapiens	195-201
24173769-5	2014	Berberine suppressed CPT-11-induced NF-kappaB activation in a dose-dependent manner and enhanced chemosensitivity to CPT-11 by downregulating NF-kappaB activation of antiapoptotic genes, c-IAP1, c-IAP2, survivin and Bcl-xL.	Berberine	0-9	BCL2 like 1	Homo sapiens	216-222
26168133-0	2014	Induction of G2/M Arrest by Berberine via Activation of PI3K/Akt and p38 in Human Chondrosarcoma Cell Line.	Berberine	28-37	AKT serine/threonine kinase 1	Homo sapiens	61-64
26168133-0	2014	Induction of G2/M Arrest by Berberine via Activation of PI3K/Akt and p38 in Human Chondrosarcoma Cell Line.	Berberine	28-37	mitogen-activated protein kinase 14	Homo sapiens	69-72
26168133-7	2014	Berberine induced cell cycle arrest at the G2/M phase by upregulation of p53 and p21 expression and suppressed cyclin B1, cyclin-dependent kinase 1 (cdc2), cdc25c, and phosphorylated retinoblastoma tumor-suppressor protein (pRb) expression.	Berberine	0-9	tumor protein p53	Homo sapiens	73-76
26168133-7	2014	Berberine induced cell cycle arrest at the G2/M phase by upregulation of p53 and p21 expression and suppressed cyclin B1, cyclin-dependent kinase 1 (cdc2), cdc25c, and phosphorylated retinoblastoma tumor-suppressor protein (pRb) expression.	Berberine	0-9	H3 histone pseudogene 16	Homo sapiens	81-84
26168133-7	2014	Berberine induced cell cycle arrest at the G2/M phase by upregulation of p53 and p21 expression and suppressed cyclin B1, cyclin-dependent kinase 1 (cdc2), cdc25c, and phosphorylated retinoblastoma tumor-suppressor protein (pRb) expression.	Berberine	0-9	cyclin B1	Homo sapiens	111-120
26168133-7	2014	Berberine induced cell cycle arrest at the G2/M phase by upregulation of p53 and p21 expression and suppressed cyclin B1, cyclin-dependent kinase 1 (cdc2), cdc25c, and phosphorylated retinoblastoma tumor-suppressor protein (pRb) expression.	Berberine	0-9	cyclin dependent kinase 1	Homo sapiens	122-147
26168133-7	2014	Berberine induced cell cycle arrest at the G2/M phase by upregulation of p53 and p21 expression and suppressed cyclin B1, cyclin-dependent kinase 1 (cdc2), cdc25c, and phosphorylated retinoblastoma tumor-suppressor protein (pRb) expression.	Berberine	0-9	cyclin dependent kinase 1	Homo sapiens	149-153
26168133-7	2014	Berberine induced cell cycle arrest at the G2/M phase by upregulation of p53 and p21 expression and suppressed cyclin B1, cyclin-dependent kinase 1 (cdc2), cdc25c, and phosphorylated retinoblastoma tumor-suppressor protein (pRb) expression.	Berberine	0-9	cell division cycle 25C	Homo sapiens	156-162
26168133-7	2014	Berberine induced cell cycle arrest at the G2/M phase by upregulation of p53 and p21 expression and suppressed cyclin B1, cyclin-dependent kinase 1 (cdc2), cdc25c, and phosphorylated retinoblastoma tumor-suppressor protein (pRb) expression.	Berberine	0-9	RB transcriptional corepressor 1	Homo sapiens	224-227
26168133-8	2014	In addition, berberine stimulated phosphorylation of protein kinase B (Akt) and p38 kinase.	Berberine	13-22	AKT serine/threonine kinase 1	Homo sapiens	71-74
26168133-8	2014	In addition, berberine stimulated phosphorylation of protein kinase B (Akt) and p38 kinase.	Berberine	13-22	mitogen-activated protein kinase 14	Homo sapiens	80-83
26168133-9	2014	Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt with LY294002 (LY) and p38 kinase with SB203580 (SB), respectively, decreased berberine-induced p53 and p21 expression and restored cell proliferation and expression of cyclin B1, cdc2, cdc25c, and pRb cell cycle progression proteins.	Berberine	133-142	AKT serine/threonine kinase 1	Homo sapiens	51-54
26168133-9	2014	Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt with LY294002 (LY) and p38 kinase with SB203580 (SB), respectively, decreased berberine-induced p53 and p21 expression and restored cell proliferation and expression of cyclin B1, cdc2, cdc25c, and pRb cell cycle progression proteins.	Berberine	133-142	mitogen-activated protein kinase 14	Homo sapiens	78-81
26168133-9	2014	Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt with LY294002 (LY) and p38 kinase with SB203580 (SB), respectively, decreased berberine-induced p53 and p21 expression and restored cell proliferation and expression of cyclin B1, cdc2, cdc25c, and pRb cell cycle progression proteins.	Berberine	133-142	tumor protein p53	Homo sapiens	151-154
26168133-9	2014	Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt with LY294002 (LY) and p38 kinase with SB203580 (SB), respectively, decreased berberine-induced p53 and p21 expression and restored cell proliferation and expression of cyclin B1, cdc2, cdc25c, and pRb cell cycle progression proteins.	Berberine	133-142	H3 histone pseudogene 16	Homo sapiens	159-162
26168133-9	2014	Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt with LY294002 (LY) and p38 kinase with SB203580 (SB), respectively, decreased berberine-induced p53 and p21 expression and restored cell proliferation and expression of cyclin B1, cdc2, cdc25c, and pRb cell cycle progression proteins.	Berberine	133-142	cyclin B1	Homo sapiens	224-233
26168133-9	2014	Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt with LY294002 (LY) and p38 kinase with SB203580 (SB), respectively, decreased berberine-induced p53 and p21 expression and restored cell proliferation and expression of cyclin B1, cdc2, cdc25c, and pRb cell cycle progression proteins.	Berberine	133-142	cyclin dependent kinase 1	Homo sapiens	235-239
26168133-9	2014	Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt with LY294002 (LY) and p38 kinase with SB203580 (SB), respectively, decreased berberine-induced p53 and p21 expression and restored cell proliferation and expression of cyclin B1, cdc2, cdc25c, and pRb cell cycle progression proteins.	Berberine	133-142	cell division cycle 25C	Homo sapiens	241-247
26168133-9	2014	Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt with LY294002 (LY) and p38 kinase with SB203580 (SB), respectively, decreased berberine-induced p53 and p21 expression and restored cell proliferation and expression of cyclin B1, cdc2, cdc25c, and pRb cell cycle progression proteins.	Berberine	133-142	RB transcriptional corepressor 1	Homo sapiens	253-256
26168133-10	2014	These results suggest that berberine-induced inhibition of cell proliferation by cell cycle arrest at the G2/M phases was regulated through PI3K/Akt and p38 kinase pathways in HTB-94 chondrosarcoma cells.	Berberine	27-36	AKT serine/threonine kinase 1	Homo sapiens	145-148
26168133-10	2014	These results suggest that berberine-induced inhibition of cell proliferation by cell cycle arrest at the G2/M phases was regulated through PI3K/Akt and p38 kinase pathways in HTB-94 chondrosarcoma cells.	Berberine	27-36	mitogen-activated protein kinase 14	Homo sapiens	153-156
24380387-4	2013	The anti-inflammatory property of berberine, involving inhibition of Signal Transducer and Activator of Transcription 3 (STAT3) activation, has also been documented.	Berberine	34-43	signal transducer and activator of transcription 3	Homo sapiens	69-119
24380387-4	2013	The anti-inflammatory property of berberine, involving inhibition of Signal Transducer and Activator of Transcription 3 (STAT3) activation, has also been documented.	Berberine	34-43	signal transducer and activator of transcription 3	Homo sapiens	121-126
24380387-8	2013	In vitro, berberine inhibited both constitutive and IL-6-induced STAT3 activation in NPC cells.	Berberine	10-19	interleukin 6	Homo sapiens	52-56
24380387-8	2013	In vitro, berberine inhibited both constitutive and IL-6-induced STAT3 activation in NPC cells.	Berberine	10-19	signal transducer and activator of transcription 3	Homo sapiens	65-70
24380387-9	2013	Inhibition of STAT3 activation by berberine induced growth inhibition and apoptotic response in NPC cells.	Berberine	34-43	signal transducer and activator of transcription 3	Homo sapiens	14-19
24380387-11	2013	Furthermore, STAT3 activation by conditioned medium of tumor-associated fibroblasts could be blocked by berberine or antibodies against IL-6 and IL-6R.	Berberine	104-113	signal transducer and activator of transcription 3	Homo sapiens	13-18
24380387-12	2013	CONCLUSIONS: Our observation that berberine effectively inhibited activation of STAT3 induced by tumor-associated fibroblasts suggests a role of berberine in modulating the effects of tumor stroma on the growth of NPC cells.	Berberine	34-43	signal transducer and activator of transcription 3	Homo sapiens	80-85
24380387-12	2013	CONCLUSIONS: Our observation that berberine effectively inhibited activation of STAT3 induced by tumor-associated fibroblasts suggests a role of berberine in modulating the effects of tumor stroma on the growth of NPC cells.	Berberine	145-154	signal transducer and activator of transcription 3	Homo sapiens	80-85
24380387-13	2013	The effective inhibition of STAT3 activation in NPC cells by berberine supports its potential use in the treatment of NPC.	Berberine	61-70	signal transducer and activator of transcription 3	Homo sapiens	28-33
24279644-12	2013	Furthermore, berberine decreased the activation levels of Wnt and EGFR signaling pathways, and down-regulated COX-2 expression in intestinal tumor cells and prostaglandin E2 production in the small intestine.	Berberine	13-22	epidermal growth factor receptor	Mus musculus	66-70
23896433-0	2013	Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting the activation of RhoA/ROCK signaling.	Berberine	0-9	fibronectin 1	Rattus norvegicus	75-86
23896433-0	2013	Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting the activation of RhoA/ROCK signaling.	Berberine	0-9	ras homolog family member A	Rattus norvegicus	119-123
23896433-6	2013	Results showed that BBR effectively inhibited RhoA/ROCK signaling activation in diabetic rat kidneys and high glucose-induced glomerular mesangial cells (GMCs) and simultaneously down-regulated NF-kappaB activity, which was accompanied by reduced intercellular adhesionmolecule-1, transforming growth factor-beta 1 and FN overproduction.	Berberine	20-23	ras homolog family member A	Rattus norvegicus	46-50
23896433-6	2013	Results showed that BBR effectively inhibited RhoA/ROCK signaling activation in diabetic rat kidneys and high glucose-induced glomerular mesangial cells (GMCs) and simultaneously down-regulated NF-kappaB activity, which was accompanied by reduced intercellular adhesionmolecule-1, transforming growth factor-beta 1 and FN overproduction.	Berberine	20-23	intercellular adhesion molecule 1	Rattus norvegicus	247-314
24025684-6	2013	The expression of nuclear factor-kappaB (NF-kappaB), tumor necrosis factor-alpha (TNF-alpha), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) was markedly suppressed by berberine, indicating the inhibition of inflammatory response.	Berberine	189-198	nitric oxide synthase 2, inducible	Mus musculus	123-154
24025684-7	2013	Treatment of CP-intoxicated animals with berberine also significantly reduced the expression of p53, active caspase-3 as well as autophagy marker light chain 3B (LC3B) in the kidneys.	Berberine	41-50	transformation related protein 53, pseudogene	Mus musculus	96-99
24025684-7	2013	Treatment of CP-intoxicated animals with berberine also significantly reduced the expression of p53, active caspase-3 as well as autophagy marker light chain 3B (LC3B) in the kidneys.	Berberine	41-50	caspase 3	Mus musculus	108-117
24025684-7	2013	Treatment of CP-intoxicated animals with berberine also significantly reduced the expression of p53, active caspase-3 as well as autophagy marker light chain 3B (LC3B) in the kidneys.	Berberine	41-50	microtubule-associated protein 1 light chain 3 beta	Mus musculus	146-160
24025684-7	2013	Treatment of CP-intoxicated animals with berberine also significantly reduced the expression of p53, active caspase-3 as well as autophagy marker light chain 3B (LC3B) in the kidneys.	Berberine	41-50	microtubule-associated protein 1 light chain 3 beta	Mus musculus	162-166
24279644-12	2013	Furthermore, berberine decreased the activation levels of Wnt and EGFR signaling pathways, and down-regulated COX-2 expression in intestinal tumor cells and prostaglandin E2 production in the small intestine.	Berberine	13-22	cytochrome c oxidase II, mitochondrial	Mus musculus	110-115
24279644-14	2013	Down-regulation of Wnt and EGFR signaling pathways and COX-2 expression by berberine may be involved in its anti-tumorigenic effects.	Berberine	75-84	epidermal growth factor receptor	Mus musculus	27-31
24279644-14	2013	Down-regulation of Wnt and EGFR signaling pathways and COX-2 expression by berberine may be involved in its anti-tumorigenic effects.	Berberine	75-84	cytochrome c oxidase II, mitochondrial	Mus musculus	55-60
24063987-0	2013	Berberine counteracts enhanced IL-8 expression of AGS cells induced by evodiamine.	Berberine	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	31-35
24184483-8	2013	However, at 10 mug/mL, berberine reduces cell growth in ADPKD cystic cells only enhancing G0/G1 phase of cell cycle and inhibiting ERK and p70-S6 kinases.	Berberine	23-32	mitogen-activated protein kinase 1	Homo sapiens	131-134
24063987-10	2013	IL-8 expression and the adhesive ability of AGS cells to HUVECs were significantly increased by evodiamine, but were inhibited after being co-treated with berberine in AGS cells.	Berberine	155-164	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
24063987-13	2013	Evodiamine provoked IL-8 secretion via ERK1/2, SAPK/JNK, JAK2 and AP-1 pathways which could be counteracted by berberine.	Berberine	111-120	C-X-C motif chemokine ligand 8	Homo sapiens	20-24
24063987-12	2013	Berberine significantly suppressed the up-regulation of VCAM-1 and the down-regulation of ICAM-1 induced by evodiamine.	Berberine	0-9	vascular cell adhesion molecule 1	Homo sapiens	56-62
24063987-12	2013	Berberine significantly suppressed the up-regulation of VCAM-1 and the down-regulation of ICAM-1 induced by evodiamine.	Berberine	0-9	intercellular adhesion molecule 1	Homo sapiens	90-96
24041461-0	2013	Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation.	Berberine	0-9	sirtuin 3	Rattus norvegicus	94-99
24177287-9	2013	The adjunction of berberine with verapamil improved the neurological outcome in a battery of behavioral paradigms, improved spatial memory in Morris water maze task, ameliorated the oxidative-nitrosative stress, increased acetylcholinesterase (AChE) activity, as well as improved mitochondrial complex (I, II, and IV) activity, reducing tumor necrosis factor-alpha, interleukin-1 beta and caspase-3 levels in brain tissues as compared to berberine alone group in ischemic rats.	Berberine	18-27	acetylcholinesterase	Rattus norvegicus	222-242
24177287-9	2013	The adjunction of berberine with verapamil improved the neurological outcome in a battery of behavioral paradigms, improved spatial memory in Morris water maze task, ameliorated the oxidative-nitrosative stress, increased acetylcholinesterase (AChE) activity, as well as improved mitochondrial complex (I, II, and IV) activity, reducing tumor necrosis factor-alpha, interleukin-1 beta and caspase-3 levels in brain tissues as compared to berberine alone group in ischemic rats.	Berberine	18-27	acetylcholinesterase	Rattus norvegicus	244-248
24177287-9	2013	The adjunction of berberine with verapamil improved the neurological outcome in a battery of behavioral paradigms, improved spatial memory in Morris water maze task, ameliorated the oxidative-nitrosative stress, increased acetylcholinesterase (AChE) activity, as well as improved mitochondrial complex (I, II, and IV) activity, reducing tumor necrosis factor-alpha, interleukin-1 beta and caspase-3 levels in brain tissues as compared to berberine alone group in ischemic rats.	Berberine	18-27	interleukin 1 beta	Rattus norvegicus	366-384
24177287-9	2013	The adjunction of berberine with verapamil improved the neurological outcome in a battery of behavioral paradigms, improved spatial memory in Morris water maze task, ameliorated the oxidative-nitrosative stress, increased acetylcholinesterase (AChE) activity, as well as improved mitochondrial complex (I, II, and IV) activity, reducing tumor necrosis factor-alpha, interleukin-1 beta and caspase-3 levels in brain tissues as compared to berberine alone group in ischemic rats.	Berberine	18-27	caspase 3	Rattus norvegicus	389-398
24188560-0	2013	Improvement of superoxide dismutase and catalase in streptozotocin-nicotinamide-induced type 2-diabetes in mice by berberine and glibenclamide.	Berberine	115-124	catalase	Mus musculus	40-48
24188560-4	2013	Objective: Impacts of berberine on transcriptional regulation of SOD and CAT and their enzyme activities, including the level of malondialdehyde (MDA) formation, were examined in the DM type 2-induced mice to clarify its antioxidation potential, compared with a common hypoglycemic drug, glibenclamide.	Berberine	22-31	catalase	Mus musculus	73-76
24000115-3	2013	In this study, we investigated the efficacy of some new synthetic derivatives of berberine, a phytochemical isolated from Barberry and other plants, to induce growth arrest of HER-2/neu overexpressing SK-BR-3 breast cancer cells.	Berberine	81-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	176-181
24000115-3	2013	In this study, we investigated the efficacy of some new synthetic derivatives of berberine, a phytochemical isolated from Barberry and other plants, to induce growth arrest of HER-2/neu overexpressing SK-BR-3 breast cancer cells.	Berberine	81-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	182-185
24000115-6	2013	Real-time PCR analyses showed that berberine, NAX012 and NAX014 compounds increased the expression of some cell-cycle checkpoint molecules involved in cell senescence such as p53, p21(WAF1) , p16(INK4a) , and PAI-1, already after 24 h of 50 microM treatments.	Berberine	35-44	tumor protein p53	Homo sapiens	175-178
24000115-6	2013	Real-time PCR analyses showed that berberine, NAX012 and NAX014 compounds increased the expression of some cell-cycle checkpoint molecules involved in cell senescence such as p53, p21(WAF1) , p16(INK4a) , and PAI-1, already after 24 h of 50 microM treatments.	Berberine	35-44	cyclin dependent kinase inhibitor 1A	Homo sapiens	180-183
24000115-6	2013	Real-time PCR analyses showed that berberine, NAX012 and NAX014 compounds increased the expression of some cell-cycle checkpoint molecules involved in cell senescence such as p53, p21(WAF1) , p16(INK4a) , and PAI-1, already after 24 h of 50 microM treatments.	Berberine	35-44	cyclin dependent kinase inhibitor 1A	Homo sapiens	184-188
24000115-6	2013	Real-time PCR analyses showed that berberine, NAX012 and NAX014 compounds increased the expression of some cell-cycle checkpoint molecules involved in cell senescence such as p53, p21(WAF1) , p16(INK4a) , and PAI-1, already after 24 h of 50 microM treatments.	Berberine	35-44	cyclin dependent kinase inhibitor 2A	Homo sapiens	192-195
24000115-6	2013	Real-time PCR analyses showed that berberine, NAX012 and NAX014 compounds increased the expression of some cell-cycle checkpoint molecules involved in cell senescence such as p53, p21(WAF1) , p16(INK4a) , and PAI-1, already after 24 h of 50 microM treatments.	Berberine	35-44	cyclin dependent kinase inhibitor 2A	Homo sapiens	196-201
24000115-6	2013	Real-time PCR analyses showed that berberine, NAX012 and NAX014 compounds increased the expression of some cell-cycle checkpoint molecules involved in cell senescence such as p53, p21(WAF1) , p16(INK4a) , and PAI-1, already after 24 h of 50 microM treatments.	Berberine	35-44	serpin family E member 1	Homo sapiens	209-214
24000115-7	2013	Furthermore, berberine, NAX012 and NAX014, all reduced both HER-2/neu expression and phosphorylation on tumor cells, the NAX014 compound showing the higher effectiveness.	Berberine	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-65
24000115-7	2013	Furthermore, berberine, NAX012 and NAX014, all reduced both HER-2/neu expression and phosphorylation on tumor cells, the NAX014 compound showing the higher effectiveness.	Berberine	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-69
24000115-8	2013	These results provide novel information on the mechanisms involved in the anticancer effects of berberine and demonstrate the greater effectiveness of NAX012 and NAX014 analogs in inducing apoptosis and cellular senescence in HER-2/neu overexpressing tumor cell lines.	Berberine	96-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	226-235
24025355-8	2013	Our results showed that berberine increased radiosensitivity of ESCC cells and xenografts, and this was associated with the inhibition of HIF-1alpha and VEGF expression.	Berberine	24-33	hypoxia inducible factor 1 subunit alpha	Homo sapiens	138-148
24025355-8	2013	Our results showed that berberine increased radiosensitivity of ESCC cells and xenografts, and this was associated with the inhibition of HIF-1alpha and VEGF expression.	Berberine	24-33	vascular endothelial growth factor A	Homo sapiens	153-157
24002362-10	2013	At the molecular level, berberine treatment led to a significant increase of WTX expression and G401 cells were protected against berberine-induced growth inhibition by small interfering RNA against WTX.	Berberine	130-139	APC membrane recruitment protein 1	Homo sapiens	199-202
24277991-2	2013	The limitation of berberine seems to be its poor oral bioavailability, which is affected by the presence, in enterocytes, of P-glycoprotein - an active adenosine triphosphate (ATP)-consuming efflux protein that extrudes berberine into the intestinal lumen, thus limiting its absorption.	Berberine	18-27	ATP binding cassette subfamily B member 1	Homo sapiens	125-139
24277991-2	2013	The limitation of berberine seems to be its poor oral bioavailability, which is affected by the presence, in enterocytes, of P-glycoprotein - an active adenosine triphosphate (ATP)-consuming efflux protein that extrudes berberine into the intestinal lumen, thus limiting its absorption.	Berberine	220-229	ATP binding cassette subfamily B member 1	Homo sapiens	125-139
24188560-10	2013	In DM type 2 mice, berberine increased the hepatic CuZn-SOD mRNA expression and the kidney SOD and CAT activities to normal levels.	Berberine	19-28	superoxide dismutase 1, soluble	Mus musculus	51-59
24188560-10	2013	In DM type 2 mice, berberine increased the hepatic CuZn-SOD mRNA expression and the kidney SOD and CAT activities to normal levels.	Berberine	19-28	catalase	Mus musculus	99-102
24188583-0	2013	Attenuation of berberine on lipopolysaccharide-induced inflammatory and apoptosis responses in beta-cells via TLR4-independent JNK/NF-kappaB pathway.	Berberine	15-24	toll-like receptor 4	Rattus norvegicus	110-114
24188583-0	2013	Attenuation of berberine on lipopolysaccharide-induced inflammatory and apoptosis responses in beta-cells via TLR4-independent JNK/NF-kappaB pathway.	Berberine	15-24	mitogen-activated protein kinase 8	Rattus norvegicus	127-130
24188583-0	2013	Attenuation of berberine on lipopolysaccharide-induced inflammatory and apoptosis responses in beta-cells via TLR4-independent JNK/NF-kappaB pathway.	Berberine	15-24	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	131-140
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	Berberine	0-3	chemokine (C-C motif) ligand 2	Mus musculus	75-80
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	Berberine	0-3	interleukin 6	Mus musculus	82-86
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	Berberine	0-3	tumor necrosis factor	Mus musculus	91-100
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	Berberine	0-3	mitogen-activated protein kinase 8	Mus musculus	114-117
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	Berberine	0-3	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	122-131
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	Berberine	0-3	nitrilase 1	Mus musculus	151-156
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	Berberine	0-3	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	179-192
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	Berberine	0-3	insulin 1	Rattus norvegicus	196-201
23982892-0	2013	Berberine acts as a natural inhibitor of Wnt/beta-catenin signaling--identification of more active 13-arylalkyl derivatives.	Berberine	0-9	catenin beta 1	Homo sapiens	45-57
23982892-6	2013	Berberine inhibited beta-catenin transcriptional activity and attenuated anchorage-independent growth.	Berberine	0-9	catenin beta 1	Homo sapiens	20-32
23982892-7	2013	As a result of berberine treatment, cellular levels of active beta-catenin were reduced concomitant with an increase in the expression of E-cadherin.	Berberine	15-24	catenin beta 1	Homo sapiens	62-74
23982892-7	2013	As a result of berberine treatment, cellular levels of active beta-catenin were reduced concomitant with an increase in the expression of E-cadherin.	Berberine	15-24	cadherin 1	Homo sapiens	138-148
23982892-10	2013	Thus, berberine and its synthetic derivatives represent potential therapeutic agents to inhibit Wnt/beta-catenin signaling in tumorigenesis.	Berberine	6-15	catenin beta 1	Homo sapiens	100-112
24025355-0	2013	Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1alpha in vitro and in vivo.	Berberine	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	79-89
24015932-3	2013	Gene chip array reveals that with berberine treatment, c-Myc, the target gene of Wnt pathway, was down-regulated 5.3-folds, indicating that berberine might inhibit Wnt signalling.	Berberine	34-43	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	55-60
24015932-3	2013	Gene chip array reveals that with berberine treatment, c-Myc, the target gene of Wnt pathway, was down-regulated 5.3-folds, indicating that berberine might inhibit Wnt signalling.	Berberine	140-149	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	55-60
24015932-4	2013	TOPflash analysis revealed that Wnt activity was significantly reduced after berberine treatment, and the mechanism of which might be that berberine disrupted beta-catenin transfer to nucleus through up-regulating the expression of adenomatous polyposis coli (APC) gene and stabilized APC-beta-catenin complex.	Berberine	77-86	catenin beta 1	Homo sapiens	159-171
24015932-4	2013	TOPflash analysis revealed that Wnt activity was significantly reduced after berberine treatment, and the mechanism of which might be that berberine disrupted beta-catenin transfer to nucleus through up-regulating the expression of adenomatous polyposis coli (APC) gene and stabilized APC-beta-catenin complex.	Berberine	77-86	catenin beta 1	Homo sapiens	289-301
24015932-4	2013	TOPflash analysis revealed that Wnt activity was significantly reduced after berberine treatment, and the mechanism of which might be that berberine disrupted beta-catenin transfer to nucleus through up-regulating the expression of adenomatous polyposis coli (APC) gene and stabilized APC-beta-catenin complex.	Berberine	139-148	catenin beta 1	Homo sapiens	159-171
24015932-4	2013	TOPflash analysis revealed that Wnt activity was significantly reduced after berberine treatment, and the mechanism of which might be that berberine disrupted beta-catenin transfer to nucleus through up-regulating the expression of adenomatous polyposis coli (APC) gene and stabilized APC-beta-catenin complex.	Berberine	139-148	catenin beta 1	Homo sapiens	289-301
24015932-5	2013	Berberine administration in ApcMin/+ mice exhibited fewer and smaller polyps in intestine, along with reduction in cyclin D1 and c-Myc expression.	Berberine	0-9	cyclin D1	Mus musculus	115-124
24015932-5	2013	Berberine administration in ApcMin/+ mice exhibited fewer and smaller polyps in intestine, along with reduction in cyclin D1 and c-Myc expression.	Berberine	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	129-134
24015932-6	2013	In clinical practice, oral administration of berberine also significantly reduced the familial adenomatous polyposis patients" polyp size along with the inhibition of cyclin D1 expression in polyp samples.	Berberine	45-54	cyclin D1	Homo sapiens	167-176
24015932-7	2013	These observations indicate that berberine inhibits colon tumour formation through inhibition of Wnt/beta-catenin signalling and berberine might be a promising drug for the prevention of colon cancer.	Berberine	33-42	catenin beta 1	Homo sapiens	101-113
24002362-6	2013	AMP-activated protein kinase (AMPK) is suggested to be one of the various cellular targets of berberine, which regulates tumor progression and metastasis.	Berberine	94-103	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	0-28
24002362-6	2013	AMP-activated protein kinase (AMPK) is suggested to be one of the various cellular targets of berberine, which regulates tumor progression and metastasis.	Berberine	94-103	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	30-34
24002362-7	2013	However, the specific involvement of berberine-induced AMPK activation and its effects on the proliferation potential of Wilms" tumor cells remains unknown.	Berberine	37-46	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	55-59
24002362-8	2013	The present study investigated the berberine-induced activation of AMPK and its effects on G401 Wilms" tumor cell proliferation.	Berberine	35-44	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	67-71
24002362-10	2013	At the molecular level, berberine treatment led to a significant increase of WTX expression and G401 cells were protected against berberine-induced growth inhibition by small interfering RNA against WTX.	Berberine	24-33	APC membrane recruitment protein 1	Homo sapiens	77-80
24002362-10	2013	At the molecular level, berberine treatment led to a significant increase of WTX expression and G401 cells were protected against berberine-induced growth inhibition by small interfering RNA against WTX.	Berberine	24-33	APC membrane recruitment protein 1	Homo sapiens	199-202
24041461-5	2013	Interestingly, the recovery of mitochondrial function by berberine was associated with an increased activity of the mitochondrial sirtuin 3 (SirT3).	Berberine	57-66	sirtuin 3	Rattus norvegicus	130-139
24041461-5	2013	Interestingly, the recovery of mitochondrial function by berberine was associated with an increased activity of the mitochondrial sirtuin 3 (SirT3).	Berberine	57-66	sirtuin 3	Rattus norvegicus	141-146
24041461-6	2013	In conclusion, berberine potent protective effects against metabolic syndrome may rely on increasing mitochondrial SirT3 activity, normalizing mitochondrial function and preventing a state of energetic deficit caused by impaired OXPHOS.	Berberine	15-24	sirtuin 3	Rattus norvegicus	115-120
23886934-0	2013	Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling.	Berberine	22-31	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	14-18
23886934-8	2013	Berberine inhibited the polymorphic variants, CYP1B1.3 (V432L) and CYP1B1.4 (N453S), with IC50 values comparable to that for CYP1B1.1 inhibition.	Berberine	0-9	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	46-52
23886934-8	2013	Berberine inhibited the polymorphic variants, CYP1B1.3 (V432L) and CYP1B1.4 (N453S), with IC50 values comparable to that for CYP1B1.1 inhibition.	Berberine	0-9	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	67-73
23886934-8	2013	Berberine inhibited the polymorphic variants, CYP1B1.3 (V432L) and CYP1B1.4 (N453S), with IC50 values comparable to that for CYP1B1.1 inhibition.	Berberine	0-9	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	67-73
23886934-9	2013	Berberine-mediated inhibition was abolished by a mutation of Asn228 to Thr in CYP1B1.1, whereas the inhibition was enhanced by a reversal mutation of Thr223 to Asn in CYP1A2.1.	Berberine	0-9	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	78-84
23886934-9	2013	Berberine-mediated inhibition was abolished by a mutation of Asn228 to Thr in CYP1B1.1, whereas the inhibition was enhanced by a reversal mutation of Thr223 to Asn in CYP1A2.1.	Berberine	0-9	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	167-173
23886934-10	2013	This result in conjugation with the molecular modeling revealed the crucial role of hydrogen-bonding interaction of Asn228 on CYP1B1.1 with the methoxy moiety of berberine.	Berberine	162-171	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	126-132
23886934-11	2013	These findings demonstrate that berberine causes a selective CYP1B1-inhibition, in which Asn228 appears to be crucial.	Berberine	32-41	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	61-67
23886934-5	2013	Kinetic analysis revealed that berberine noncompetitively inhibited EROD activities of CYP1A1.1 and CYP1B1.1, whereas palmatine and jatrorrhizine caused either competitive or mixed type of inhibition.	Berberine	31-40	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	87-93
23886934-12	2013	The inhibitory effects of berberine on CYP1B1 activities toward structurally diverse substrates can be different.	Berberine	26-35	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	39-45
23886934-5	2013	Kinetic analysis revealed that berberine noncompetitively inhibited EROD activities of CYP1A1.1 and CYP1B1.1, whereas palmatine and jatrorrhizine caused either competitive or mixed type of inhibition.	Berberine	31-40	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	100-106
23954465-0	2013	Berberine, a natural antidiabetes drug, attenuates glucose neurotoxicity and promotes Nrf2-related neurite outgrowth.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	86-90
23886934-6	2013	Among protoberberines, berberine caused the most potent and selective inhibitory effect on CYP1B1.1 with the least Ki value of 44+-16 nM.	Berberine	11-20	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	91-97
23954465-8	2013	High glucose down-regulated IGF-1 receptor and phosphorylation of Akt and GSK-3beta, the effects of which were attenuated by BBR treatment.	Berberine	125-128	AKT serine/threonine kinase 1	Homo sapiens	66-69
23886934-7	2013	Berberine also potently inhibited CYP1B1.1 activities toward 7-ethoxycoumarin and 7-methoxyresorufin, whereas the inhibition of benzo(a)pyrene hydroxylation activity was less pronounced.	Berberine	0-9	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	34-40
23954465-8	2013	High glucose down-regulated IGF-1 receptor and phosphorylation of Akt and GSK-3beta, the effects of which were attenuated by BBR treatment.	Berberine	125-128	glycogen synthase kinase 3 beta	Homo sapiens	74-83
23954465-13	2013	In conclusion, BBR attenuated high glucose-induced neurotoxicity, and we are the first to reveal this novel mechanism of BBR as an Nrf2 activator against glucose neurotoxicity, providing another potential therapeutic use of BBR on the treatment of diabetic complications.	Berberine	15-18	NFE2 like bZIP transcription factor 2	Homo sapiens	131-135
24098708-0	2013	MicroRNA-21-3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growth.	Berberine	18-27	microRNA 181a-1	Homo sapiens	0-14
23867651-2	2013	Berberine, an isoquinoline alkaloid isolated from medicinal herbs, can inhibit the degradative action of extracellular MMPs.	Berberine	0-9	matrix metallopeptidase 2	Homo sapiens	119-123
23867651-3	2013	The effect of berberine on the periodontal expression of MMPs was examined in vitro and in vivo.	Berberine	14-23	matrix metallopeptidase 2	Homo sapiens	57-61
23867651-9	2013	When berberine was added to the LPS-treated cultures, the activities of MMPs were significantly reduced in dose-dependent manner.	Berberine	5-14	matrix metallopeptidase 2	Homo sapiens	72-76
23867651-24	2013	We thus propose that berberine may slow periodontal degradation through the regulation of MMPs in periodontitis induced by bacterial plaque.	Berberine	21-30	matrix metallopeptidase 2	Homo sapiens	90-94
23903781-3	2013	The results show that berberine suppresses the growth of cDDP-resistant cells more than the sensitive counterparts, by interfering with the expression of folate cycle enzymes, dihydrofolate reductase (DHFR) and thymidylate synthase (TS).	Berberine	22-31	dihydrofolate reductase	Homo sapiens	176-199
23903781-3	2013	The results show that berberine suppresses the growth of cDDP-resistant cells more than the sensitive counterparts, by interfering with the expression of folate cycle enzymes, dihydrofolate reductase (DHFR) and thymidylate synthase (TS).	Berberine	22-31	dihydrofolate reductase	Homo sapiens	201-205
23903781-3	2013	The results show that berberine suppresses the growth of cDDP-resistant cells more than the sensitive counterparts, by interfering with the expression of folate cycle enzymes, dihydrofolate reductase (DHFR) and thymidylate synthase (TS).	Berberine	22-31	thymidylate synthetase	Homo sapiens	211-231
23903781-3	2013	The results show that berberine suppresses the growth of cDDP-resistant cells more than the sensitive counterparts, by interfering with the expression of folate cycle enzymes, dihydrofolate reductase (DHFR) and thymidylate synthase (TS).	Berberine	22-31	thymidylate synthetase	Homo sapiens	233-235
23903781-6	2013	The data also indicate that berberine inhibits cellular growth by affecting polyamine metabolism, in particular through the upregulation of the key catabolic enzyme, spermidine/spermine N1-acetyltransferase (SSAT).	Berberine	28-37	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	166-206
23903781-6	2013	The data also indicate that berberine inhibits cellular growth by affecting polyamine metabolism, in particular through the upregulation of the key catabolic enzyme, spermidine/spermine N1-acetyltransferase (SSAT).	Berberine	28-37	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	208-212
23903781-7	2013	In this regard, berberine is shown to stimulate the SSAT induction by the spermine analogue N1, N12 bisethylspermine (BESpm), which alone was also able to downregulate DHFR mRNA more than TS mRNA.	Berberine	16-25	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	52-56
23903781-7	2013	In this regard, berberine is shown to stimulate the SSAT induction by the spermine analogue N1, N12 bisethylspermine (BESpm), which alone was also able to downregulate DHFR mRNA more than TS mRNA.	Berberine	16-25	dihydrofolate reductase	Homo sapiens	168-172
23903781-7	2013	In this regard, berberine is shown to stimulate the SSAT induction by the spermine analogue N1, N12 bisethylspermine (BESpm), which alone was also able to downregulate DHFR mRNA more than TS mRNA.	Berberine	16-25	thymidylate synthetase	Homo sapiens	188-190
23808999-0	2013	Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion.	Berberine	10-19	insulin	Homo sapiens	58-65
23808999-1	2013	BACKGROUND: The aim of this study was to evaluate the effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion.	Berberine	64-73	insulin	Homo sapiens	112-119
23808999-9	2013	CONCLUSIONS: Administration of berberine leads to remission of metabolic syndrome and decreases in waist circumference, SBP, triglycerides, and total insulin secretion, with an increase in insulin sensitivity.	Berberine	31-40	insulin	Homo sapiens	150-157
24146542-9	2013	Berberine inhibited the leukocyte-mediated killing of HRECs in vitro, the decrease in antioxidant enzyme activities, the nuclear translocation of nuclear factor kappa B, and the increase in intercellular adhesion molecule-1 and inducible nitric oxide synthase expression and malondialdehyde content in HRECs cultured in high glucose.	Berberine	0-9	intercellular adhesion molecule 1	Homo sapiens	190-223
24146542-10	2013	Berberine also decreased integrin beta-2 expression of leukocytes in vitro and in vivo.	Berberine	0-9	integrin subunit beta 2	Homo sapiens	25-40
24098708-0	2013	MicroRNA-21-3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growth.	Berberine	18-27	methionine adenosyltransferase 2A	Homo sapiens	73-114
24098708-8	2013	In this study, we used microRNA microarrays to find that the expression level of miR-21-3p (previously named miR-21*) increased after berberine treatment in the HepG2 human hepatoma cell line.	Berberine	134-143	microRNA 181a-1	Homo sapiens	81-90
24098708-8	2013	In this study, we used microRNA microarrays to find that the expression level of miR-21-3p (previously named miR-21*) increased after berberine treatment in the HepG2 human hepatoma cell line.	Berberine	134-143	microRNA 21	Homo sapiens	81-87
24098708-9	2013	To predict the putative targets of miR-21-3p, we integrated the gene expression profiles of HepG2 cells after berberine treatment by comparing with a gene list generated from sequence-based microRNA target prediction software.	Berberine	110-119	microRNA 181a-1	Homo sapiens	35-44
23972976-9	2013	Seven alkaloid drugs were also screened against Topo I using DESI-MS. Berberine and palmatine had good binding affinities.	Berberine	70-79	desumoylating isopeptidase 2	Homo sapiens	61-65
23932451-2	2013	Among these hybrids, compounds 4f and 4i, berberine linked with o-methylthiophenyl and o-chlorothiophenyl by a 2-carbon spacer, were observed to be potent inhibitors of AChE, with IC50 values of 0.077 and 0.042 muM, respectively.	Berberine	42-51	acetylcholinesterase (Cartwright blood group)	Homo sapiens	169-173
23932451-4	2013	Kinetic studies and molecular modelling simulations of the AChE-inhibitor complex indicated that a mixed-competitive binding mode existed for these berberine derivatives.	Berberine	148-157	acetylcholinesterase (Cartwright blood group)	Homo sapiens	59-63
24137422-4	2013	In the present study, the effect of BBR on TRAIL-induced antitumor effects was investigated in vitro using recombinant TRAIL and in vivo using a 4T1 murine breast cancer model in combination with anti-DR5 (death-inducing TRAIL receptor) monoclonal antibody therapy.	Berberine	36-39	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	43-48
23824073-0	2013	Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.	Berberine	0-9	microRNA 21	Homo sapiens	63-69
23824073-0	2013	Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.	Berberine	0-9	programmed cell death 4	Homo sapiens	70-75
23824073-2	2013	Interestingly, we have found that berberine could inhibit miR-21 expression in several cancer cell lines.	Berberine	34-43	microRNA 21	Homo sapiens	58-64
23824073-5	2013	Berberine could inhibit miR-21 expression and function in ovarian cancer, as shown by an enhancement of its target PDCD4, an important tumor suppressor in ovarian cancer.	Berberine	0-9	microRNA 21	Homo sapiens	24-30
23824073-5	2013	Berberine could inhibit miR-21 expression and function in ovarian cancer, as shown by an enhancement of its target PDCD4, an important tumor suppressor in ovarian cancer.	Berberine	0-9	programmed cell death 4	Homo sapiens	115-120
23824073-6	2013	The results suggested that berberine could modulate the sensitivity of cisplatin via regulating miR-21/PDCD4 axis in the ovarian cancer cells.	Berberine	27-36	microRNA 21	Homo sapiens	96-102
23824073-6	2013	The results suggested that berberine could modulate the sensitivity of cisplatin via regulating miR-21/PDCD4 axis in the ovarian cancer cells.	Berberine	27-36	programmed cell death 4	Homo sapiens	103-108
23784371-3	2013	We evaluated the antitumor potential of berberine, a naturally bioactive phytochemical from Coptis chinensis Franch against Huh7 cancer cells and WRL68 liver cells.	Berberine	40-49	MIR7-3 host gene	Homo sapiens	124-128
23784371-6	2013	Results showed that berberine induced the apoptosis of liver cancer cells through procaspase-9, and its effector caspases, procaspase-3 and procaspase-7.	Berberine	20-29	caspase 3	Homo sapiens	123-135
23866924-0	2013	Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial.	Berberine	10-19	insulin	Homo sapiens	23-30
23784371-8	2013	The results of reverse transcription-polymerase chain reaction showed that berberine increased the expression of Bax, which resulted in the activation of the caspase cascade.	Berberine	75-84	BCL2 associated X, apoptosis regulator	Homo sapiens	113-116
23784371-9	2013	The present findings demonstrated that berberine induces the apoptosis of Huh7 cells via the mitochondrial pathway.	Berberine	39-48	MIR7-3 host gene	Homo sapiens	74-78
22465347-9	2013	RESULTS: The levels of serum MDA and circulating CD31+/CD42- MPs were significantly reduced in the berberine group compared with the control group, which were associated with improvement of FMD.	Berberine	99-108	platelet and endothelial cell adhesion molecule 1	Homo sapiens	49-53
22465347-13	2013	Berberine treatment contributes to the amelioration of endothelial function through a partially reducing oxidative stress of vascular endothelium induced by circulating CD31+/CD42- microparticles in humans.	Berberine	0-9	platelet and endothelial cell adhesion molecule 1	Homo sapiens	169-173
23732865-6	2013	Pretreatment with berberine in HepG2 cells resulted in a significant increase in phosphorylated AMP-activated protein kinase (AMPK), as well as a marked elevation in phosphorylated Akt levels.	Berberine	18-27	AKT serine/threonine kinase 1	Homo sapiens	181-184
23732865-9	2013	Our study supports the theory that berberine selectively inhibits the growth of human hepatocellular cancer cells by inducing AMPK-mediated caspase-dependent mitochondrial pathway cell apoptosis, and rarely causes cytotoxicity in normal cells.	Berberine	35-44	caspase 9	Homo sapiens	140-147
23757509-0	2013	Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats.	Berberine	59-68	mast cell protease 10	Rattus norvegicus	41-45
23757509-8	2013	Tight junction protein zonula occludens 1 (ZO1) was also decreased in diabetic rats but was restored by Berberine treatment.	Berberine	104-113	tight junction protein 1	Rattus norvegicus	43-46
23757509-9	2013	Glutamine-induced glucagon-like peptide 2 (GLP2) secretion from ileal tissue decreased dramatically in the diabetic group but was restored by Berberine treatment.	Berberine	142-151	mast cell protease 10	Rattus norvegicus	18-41
23757509-9	2013	Glutamine-induced glucagon-like peptide 2 (GLP2) secretion from ileal tissue decreased dramatically in the diabetic group but was restored by Berberine treatment.	Berberine	142-151	mast cell protease 10	Rattus norvegicus	43-47
23757509-11	2013	In type 2 diabetic rats, Berberine treatment not only augments GLP2 secretion and improves diabetes but is also effective in repairing the damaged intestinal mucosa, restoring intestinal permeability, and improving endotoxemia.	Berberine	25-34	mast cell protease 10	Rattus norvegicus	63-67
23866924-3	2013	Berberine has effects on insulin resistance but its use in women with PCOS has not been fully investigated.	Berberine	0-9	insulin	Homo sapiens	25-32
23866924-4	2013	In this paper, we present a research design evaluating the effects of berberine on insulin resistance in women with PCOS.	Berberine	70-79	insulin	Homo sapiens	83-90
23866924-9	2013	DISCUSSION: We postulate that women with PCOS will have improved insulin resistance following berberine administration.	Berberine	94-103	insulin	Homo sapiens	65-72
23840629-7	2013	Involvement of the Cav2.1 (P/Q-type) channels in the berberine action was confirmed by blockade of the berberine-mediated inhibition of glutamate release by the Cav2.1 (P/Q-type) channel blocker omega-agatoxin IVA.	Berberine	53-62	calcium voltage-gated channel subunit alpha1 A	Rattus norvegicus	19-25
24164032-7	2013	Seven isoquinoline alkaloids, namely jatrorrhizine, epiberberine, columbamine, coptisine, corysamine, palmatine and berberine were identified to be active as the inhibitors of ACHE.	Berberine	55-64	acetylcholinesterase (Cartwright blood group)	Homo sapiens	176-180
23869238-0	2013	Berberine Targets AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth.	Berberine	0-9	transcription factor AP-2 alpha	Homo sapiens	18-22
23869238-0	2013	Berberine Targets AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth.	Berberine	0-9	telomerase reverse transcriptase	Homo sapiens	23-28
23869238-0	2013	Berberine Targets AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	30-39
23869238-0	2013	Berberine Targets AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth.	Berberine	0-9	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	40-45
23869238-0	2013	Berberine Targets AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth.	Berberine	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	47-57
23869238-0	2013	Berberine Targets AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth.	Berberine	0-9	vascular endothelial growth factor A	Homo sapiens	58-62
23869238-0	2013	Berberine Targets AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth.	Berberine	0-9	cytochrome c, somatic	Homo sapiens	67-79
24639792-5	2013	OBJECTIVE: To observe effect of a vaginal spermicide nonoxynol-9 (N-9) berberine plural gel on the expression of SLPI SP-D and LF in mice"s vaginas.	Berberine	69-80	secretory leukocyte peptidase inhibitor	Mus musculus	113-117
24639792-5	2013	OBJECTIVE: To observe effect of a vaginal spermicide nonoxynol-9 (N-9) berberine plural gel on the expression of SLPI SP-D and LF in mice"s vaginas.	Berberine	69-80	surfactant associated protein D	Mus musculus	118-122
24639792-5	2013	OBJECTIVE: To observe effect of a vaginal spermicide nonoxynol-9 (N-9) berberine plural gel on the expression of SLPI SP-D and LF in mice"s vaginas.	Berberine	69-80	lactotransferrin	Mus musculus	127-129
23840629-7	2013	Involvement of the Cav2.1 (P/Q-type) channels in the berberine action was confirmed by blockade of the berberine-mediated inhibition of glutamate release by the Cav2.1 (P/Q-type) channel blocker omega-agatoxin IVA.	Berberine	53-62	calcium voltage-gated channel subunit alpha1 A	Rattus norvegicus	161-167
23840629-7	2013	Involvement of the Cav2.1 (P/Q-type) channels in the berberine action was confirmed by blockade of the berberine-mediated inhibition of glutamate release by the Cav2.1 (P/Q-type) channel blocker omega-agatoxin IVA.	Berberine	103-112	calcium voltage-gated channel subunit alpha1 A	Rattus norvegicus	19-25
23840629-7	2013	Involvement of the Cav2.1 (P/Q-type) channels in the berberine action was confirmed by blockade of the berberine-mediated inhibition of glutamate release by the Cav2.1 (P/Q-type) channel blocker omega-agatoxin IVA.	Berberine	103-112	calcium voltage-gated channel subunit alpha1 A	Rattus norvegicus	161-167
23840629-9	2013	Berberine decreased the 4-AP-induced phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and synapsin I, the main presynaptic target of ERK; this decrease was also blocked by the MEK inhibition.	Berberine	0-9	mitogen activated protein kinase 3	Rattus norvegicus	56-101
23840629-9	2013	Berberine decreased the 4-AP-induced phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and synapsin I, the main presynaptic target of ERK; this decrease was also blocked by the MEK inhibition.	Berberine	0-9	mitogen activated protein kinase 3	Rattus norvegicus	103-109
23840629-9	2013	Berberine decreased the 4-AP-induced phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and synapsin I, the main presynaptic target of ERK; this decrease was also blocked by the MEK inhibition.	Berberine	0-9	synapsin I	Rattus norvegicus	115-125
23840629-9	2013	Berberine decreased the 4-AP-induced phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and synapsin I, the main presynaptic target of ERK; this decrease was also blocked by the MEK inhibition.	Berberine	0-9	Eph receptor B1	Rattus norvegicus	103-106
23840629-10	2013	Moreover, the inhibitory effect of berberine on evoked glutamate release was prevented in nerve terminals from mice lacking synapsin I.	Berberine	35-44	synapsin I	Mus musculus	124-134
23840629-11	2013	Together, these results indicated that berberine inhibits glutamate release from rats cortical synaptosomes, through the suppression of presynaptic Cav2.1 channels and ERK/synapsin I signaling cascade.	Berberine	39-48	calcium voltage-gated channel subunit alpha1 A	Rattus norvegicus	148-154
23840629-11	2013	Together, these results indicated that berberine inhibits glutamate release from rats cortical synaptosomes, through the suppression of presynaptic Cav2.1 channels and ERK/synapsin I signaling cascade.	Berberine	39-48	Eph receptor B1	Rattus norvegicus	168-171
23840629-11	2013	Together, these results indicated that berberine inhibits glutamate release from rats cortical synaptosomes, through the suppression of presynaptic Cav2.1 channels and ERK/synapsin I signaling cascade.	Berberine	39-48	synapsin I	Rattus norvegicus	172-182
23539311-3	2013	Treatments with either concentration of berberine (5 and 15 mg/kg) in 6-OHDA-lesioned groups decreased the numbers of tyrosine hydroxylase (TH)-immunopositive neurons in the substantia nigra and the levels of dopamine, norepinephrine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the striatum as compared to 6-OHDA-lesioned groups.	Berberine	40-49	tyrosine hydroxylase	Rattus norvegicus	118-138
23497885-3	2013	Of the non-flavonoid phytochemicals tested, berberine, celastrol, ellagic acid, limonin, oleanolic acid, propyl gallate, sinapic acid and ursolic acid demonstrated significant inhibition of ABCG2-mediated transport.	Berberine	44-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	190-195
23539311-5	2013	However, both concentrations of berberine in 6-OHDA-lesioned groups treated with L-DOPA aggravated the numbers of TH-immunopositive neurons in the substantia nigra and the levels of dopamine, norepinephrine, DOPAC and HVA in the striatum as compared to rats not treated with berberine.	Berberine	32-41	tyrosine hydroxylase	Rattus norvegicus	114-116
23539311-3	2013	Treatments with either concentration of berberine (5 and 15 mg/kg) in 6-OHDA-lesioned groups decreased the numbers of tyrosine hydroxylase (TH)-immunopositive neurons in the substantia nigra and the levels of dopamine, norepinephrine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the striatum as compared to 6-OHDA-lesioned groups.	Berberine	40-49	tyrosine hydroxylase	Rattus norvegicus	140-142
23421648-0	2013	Calmodulin as a potential target by which berberine induces cell cycle arrest in human hepatoma Bel7402 cells.	Berberine	42-51	calmodulin 1	Homo sapiens	0-10
22382522-0	2013	Berberine inhibits norepinephrine-induced apoptosis in neonatal rat cardiomyocytes via inhibiting ROS-TNF-alpha-caspase signaling pathway.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	102-111
23518403-4	2013	The targeting berberine liposomes were shown to cross the CSC membrane, inhibit ABC transporters (ABCC1, ABCC2, ABCC3, ABCG2) and selectively accumulate in the mitochondria.	Berberine	14-23	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	98-103
23518403-4	2013	The targeting berberine liposomes were shown to cross the CSC membrane, inhibit ABC transporters (ABCC1, ABCC2, ABCC3, ABCG2) and selectively accumulate in the mitochondria.	Berberine	14-23	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	105-110
23518403-4	2013	The targeting berberine liposomes were shown to cross the CSC membrane, inhibit ABC transporters (ABCC1, ABCC2, ABCC3, ABCG2) and selectively accumulate in the mitochondria.	Berberine	14-23	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	Mus musculus	112-117
23518403-4	2013	The targeting berberine liposomes were shown to cross the CSC membrane, inhibit ABC transporters (ABCC1, ABCC2, ABCC3, ABCG2) and selectively accumulate in the mitochondria.	Berberine	14-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-124
23421648-5	2013	The results showed that four proteins, that is calmodulin, cytochrome P450 3A4, sex hormone-binding globulin, and carbonic anhydrase II, were suggested to be the potential targets of berberine.	Berberine	183-192	calmodulin 1	Homo sapiens	47-57
22382522-0	2013	Berberine inhibits norepinephrine-induced apoptosis in neonatal rat cardiomyocytes via inhibiting ROS-TNF-alpha-caspase signaling pathway.	Berberine	0-9	caspase 2	Rattus norvegicus	112-119
23421648-5	2013	The results showed that four proteins, that is calmodulin, cytochrome P450 3A4, sex hormone-binding globulin, and carbonic anhydrase II, were suggested to be the potential targets of berberine.	Berberine	183-192	carbonic anhydrase 2	Homo sapiens	114-135
23421648-7	2013	Flow cytometric analysis found that G1 cell cycle arrest induced by berberine in Bel7402 cells was enhanced by cotreatment with calmodulin inhibitors.	Berberine	68-77	calmodulin 1	Homo sapiens	128-138
23421648-8	2013	Western blotting results indicated that berberine treatment decreased phosphorylation of calmodulin kinase II and blocked subsequent MEK1 activation as well as p27 protein degradation.	Berberine	40-49	calmodulin 1	Homo sapiens	89-99
23421648-8	2013	Western blotting results indicated that berberine treatment decreased phosphorylation of calmodulin kinase II and blocked subsequent MEK1 activation as well as p27 protein degradation.	Berberine	40-49	mitogen-activated protein kinase kinase 1	Homo sapiens	133-137
23421648-8	2013	Western blotting results indicated that berberine treatment decreased phosphorylation of calmodulin kinase II and blocked subsequent MEK1 activation as well as p27 protein degradation.	Berberine	40-49	interferon alpha inducible protein 27	Homo sapiens	160-163
23421648-9	2013	These results suggested that calmodulin might play crucial roles in berberine-induced cell cycle arrest in cancer cells.	Berberine	68-77	calmodulin 1	Homo sapiens	29-39
23499694-0	2013	Effect of berberine on cell cycle arrest and cell survival during cerebral ischemia and reperfusion and correlations with p53/cyclin D1 and PI3K/Akt.	Berberine	10-19	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	122-125
23734997-0	2013	Resolution of liver fibrosis by isoquinoline alkaloid berberine in CCl4-intoxicated mice is mediated by suppression of oxidative stress and upregulation of MMP-2 expression.	Berberine	54-63	chemokine (C-C motif) ligand 4	Mus musculus	67-71
23734997-0	2013	Resolution of liver fibrosis by isoquinoline alkaloid berberine in CCl4-intoxicated mice is mediated by suppression of oxidative stress and upregulation of MMP-2 expression.	Berberine	54-63	matrix metallopeptidase 2	Mus musculus	156-161
23734997-2	2013	The aim of this study is to investigate the antifibrotic activity of isoquinoline alkaloid berberine in carbon tetrachloride (CCl4)-induced damage in mice.	Berberine	91-100	chemokine (C-C motif) ligand 4	Mus musculus	126-130
23734997-9	2013	The high-dose berberine (9 mg/kg) ameliorated oxidative stress, decreased TNF-alpha and TGF-beta1 expression, increased the levels of matrix metalloproteinase (MMP)-2, and stimulated the elimination of fibrous deposits.	Berberine	14-23	tumor necrosis factor	Mus musculus	74-83
23734997-9	2013	The high-dose berberine (9 mg/kg) ameliorated oxidative stress, decreased TNF-alpha and TGF-beta1 expression, increased the levels of matrix metalloproteinase (MMP)-2, and stimulated the elimination of fibrous deposits.	Berberine	14-23	transforming growth factor, beta 1	Mus musculus	88-97
23734997-9	2013	The high-dose berberine (9 mg/kg) ameliorated oxidative stress, decreased TNF-alpha and TGF-beta1 expression, increased the levels of matrix metalloproteinase (MMP)-2, and stimulated the elimination of fibrous deposits.	Berberine	14-23	matrix metallopeptidase 2	Mus musculus	134-166
23734997-12	2013	The results of this study suggest that berberine could ameliorate liver fibrosis through the suppression of hepatic oxidative stress and fibrogenic potential, concomitantly stimulating the degradation of collagen deposits by MMP-2.	Berberine	39-48	matrix metallopeptidase 2	Mus musculus	225-230
24066602-6	2013	CONCLUSION: Berberine has no influence on the activities of CYP3A4, CYP1A2 and CYP2C19 below 2 000 microg x L(-1), but can inhibit the activity of CYP2E1 and CYP2D6 in concentration-dependent.	Berberine	12-21	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	147-153
24066602-6	2013	CONCLUSION: Berberine has no influence on the activities of CYP3A4, CYP1A2 and CYP2C19 below 2 000 microg x L(-1), but can inhibit the activity of CYP2E1 and CYP2D6 in concentration-dependent.	Berberine	12-21	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	158-164
23523906-0	2013	Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-kappaB dependant TGF-beta activation: a biphasic experimental study.	Berberine	0-9	transforming growth factor, beta 1	Rattus norvegicus	107-115
23523906-11	2013	Berberine enhanced the antioxidant status, through upregulating the redox sensing transcription factor nuclear factor E2-related factor 2 (Nrf2).	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	139-143
23523906-12	2013	Berberine inhibited the bleomycin mediated activation of inflammatory mediator nuclear factor kappa B (NF-kappaB) and suppressed its downstream target inducible nitric oxide synthase (iNOS).	Berberine	0-9	nitric oxide synthase 2	Rattus norvegicus	151-182
23523906-12	2013	Berberine inhibited the bleomycin mediated activation of inflammatory mediator nuclear factor kappa B (NF-kappaB) and suppressed its downstream target inducible nitric oxide synthase (iNOS).	Berberine	0-9	nitric oxide synthase 2	Rattus norvegicus	184-188
23523906-13	2013	Strikingly, berberine exhibited target attenuation of tumor necrosis factor alpha (TNF-alpha) and key pro-fibrotic mediator, transforming growth factor beta 1 (TGF-beta1).	Berberine	12-21	tumor necrosis factor	Rattus norvegicus	54-81
23523906-13	2013	Strikingly, berberine exhibited target attenuation of tumor necrosis factor alpha (TNF-alpha) and key pro-fibrotic mediator, transforming growth factor beta 1 (TGF-beta1).	Berberine	12-21	tumor necrosis factor	Rattus norvegicus	83-92
23523906-13	2013	Strikingly, berberine exhibited target attenuation of tumor necrosis factor alpha (TNF-alpha) and key pro-fibrotic mediator, transforming growth factor beta 1 (TGF-beta1).	Berberine	12-21	transforming growth factor, beta 1	Rattus norvegicus	125-158
23523906-13	2013	Strikingly, berberine exhibited target attenuation of tumor necrosis factor alpha (TNF-alpha) and key pro-fibrotic mediator, transforming growth factor beta 1 (TGF-beta1).	Berberine	12-21	transforming growth factor, beta 1	Rattus norvegicus	160-169
23523906-14	2013	Taken together, this study reveals the beneficial effects of berberine against bleomycin mediated fibrotic challenge through activating Nrf2 and suppressing NF-kappaB dependent inflammatory and TGF-beta1 mediated fibrotic events.	Berberine	61-70	NFE2 like bZIP transcription factor 2	Rattus norvegicus	136-140
23523906-14	2013	Taken together, this study reveals the beneficial effects of berberine against bleomycin mediated fibrotic challenge through activating Nrf2 and suppressing NF-kappaB dependent inflammatory and TGF-beta1 mediated fibrotic events.	Berberine	61-70	transforming growth factor, beta 1	Rattus norvegicus	194-203
23499694-0	2013	Effect of berberine on cell cycle arrest and cell survival during cerebral ischemia and reperfusion and correlations with p53/cyclin D1 and PI3K/Akt.	Berberine	10-19	cyclin D1	Rattus norvegicus	126-135
23499694-0	2013	Effect of berberine on cell cycle arrest and cell survival during cerebral ischemia and reperfusion and correlations with p53/cyclin D1 and PI3K/Akt.	Berberine	10-19	AKT serine/threonine kinase 1	Rattus norvegicus	145-148
23499694-4	2013	We found that the effect of berberine on cell cycle arrest during ischemia was mediated by decreased p53 and cyclin D1, increased phosphorylation of Bad (higher expression of p-Bad and higher ratio of p-Bad to Bad) and decreased cleavage of caspase 3.	Berberine	28-37	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	101-104
23499694-4	2013	We found that the effect of berberine on cell cycle arrest during ischemia was mediated by decreased p53 and cyclin D1, increased phosphorylation of Bad (higher expression of p-Bad and higher ratio of p-Bad to Bad) and decreased cleavage of caspase 3.	Berberine	28-37	cyclin D1	Rattus norvegicus	109-118
23499694-4	2013	We found that the effect of berberine on cell cycle arrest during ischemia was mediated by decreased p53 and cyclin D1, increased phosphorylation of Bad (higher expression of p-Bad and higher ratio of p-Bad to Bad) and decreased cleavage of caspase 3.	Berberine	28-37	caspase 3	Rattus norvegicus	241-250
23499694-5	2013	Meanwhile, berberine activated the PI3K/Akt pathway during the reperfusion, especially the phosphor-activation of Akt, to promote the cell survival.	Berberine	11-20	AKT serine/threonine kinase 1	Rattus norvegicus	40-43
23499694-5	2013	Meanwhile, berberine activated the PI3K/Akt pathway during the reperfusion, especially the phosphor-activation of Akt, to promote the cell survival.	Berberine	11-20	AKT serine/threonine kinase 1	Rattus norvegicus	114-117
23499694-6	2013	The neural protective effect of berberine was remained in the presence of inhibitor of mitogen-activated protein/extracellular signal-regulated kinase (MEK), but was suppressed by the inhibitors of PI3K and Akt.	Berberine	32-41	AKT serine/threonine kinase 1	Rattus norvegicus	207-210
23540404-0	2013	The protective effect of berberine against neuronal damage by inhibiting matrix metalloproteinase-9 and laminin degradation in experimental autoimmune encephalomyelitis.	Berberine	25-34	matrix metallopeptidase 9	Mus musculus	73-99
23600391-4	2013	The effects of berberine on myosin light chain kinase (MLCK) mRNA expression, MLCK protein content, and myosin phosphorylation in jejunum were also bidirectional.	Berberine	15-24	myosin light chain kinase	Rattus norvegicus	28-53
23600391-4	2013	The effects of berberine on myosin light chain kinase (MLCK) mRNA expression, MLCK protein content, and myosin phosphorylation in jejunum were also bidirectional.	Berberine	15-24	myosin light chain kinase	Rattus norvegicus	55-59
23671580-0	2013	Amelioration of IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway.	Berberine	93-102	interferon gamma	Homo sapiens	16-25
23671580-0	2013	Amelioration of IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway.	Berberine	93-102	tumor necrosis factor	Homo sapiens	30-39
23671580-0	2013	Amelioration of IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway.	Berberine	93-102	myosin light chain kinase 3	Homo sapiens	122-126
23671580-0	2013	Amelioration of IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway.	Berberine	93-102	modulator of VRAC current 1	Homo sapiens	122-125
23671580-4	2013	In this study, we investigate the protective actions of berberine on barrier function and the underlying mechanisms in Caco-2 monolayers challenged with IFN-gamma and TNF-alpha.	Berberine	56-65	interferon gamma	Homo sapiens	153-162
23671580-4	2013	In this study, we investigate the protective actions of berberine on barrier function and the underlying mechanisms in Caco-2 monolayers challenged with IFN-gamma and TNF-alpha.	Berberine	56-65	tumor necrosis factor	Homo sapiens	167-176
23671580-10	2013	The results showed that berberine significantly attenuated TER decrease and paracellular permeability increase in Caco-2 monolayers treated with IFN-gamma and TNF-alpha.	Berberine	24-33	interferon gamma	Homo sapiens	145-154
23671580-10	2013	The results showed that berberine significantly attenuated TER decrease and paracellular permeability increase in Caco-2 monolayers treated with IFN-gamma and TNF-alpha.	Berberine	24-33	tumor necrosis factor	Homo sapiens	159-168
23671580-11	2013	Berberine also dramatically alleviated IFN-gamma and TNF-alpha-induced morphological alteration of tight junction proteins ZO-1, occluding, and claudin-1.	Berberine	0-9	interferon gamma	Homo sapiens	39-48
23671580-11	2013	Berberine also dramatically alleviated IFN-gamma and TNF-alpha-induced morphological alteration of tight junction proteins ZO-1, occluding, and claudin-1.	Berberine	0-9	tumor necrosis factor	Homo sapiens	53-62
23671580-11	2013	Berberine also dramatically alleviated IFN-gamma and TNF-alpha-induced morphological alteration of tight junction proteins ZO-1, occluding, and claudin-1.	Berberine	0-9	claudin 1	Homo sapiens	144-153
23671580-12	2013	The increase of both MLC phosphorylation and MLCK protein expression induced by IFN-gamma and TNF-alpha was significantly inhibited by berberine treatment.	Berberine	135-144	modulator of VRAC current 1	Homo sapiens	21-24
23671580-12	2013	The increase of both MLC phosphorylation and MLCK protein expression induced by IFN-gamma and TNF-alpha was significantly inhibited by berberine treatment.	Berberine	135-144	myosin light chain kinase 3	Homo sapiens	45-49
23671580-12	2013	The increase of both MLC phosphorylation and MLCK protein expression induced by IFN-gamma and TNF-alpha was significantly inhibited by berberine treatment.	Berberine	135-144	interferon gamma	Homo sapiens	80-89
23671580-12	2013	The increase of both MLC phosphorylation and MLCK protein expression induced by IFN-gamma and TNF-alpha was significantly inhibited by berberine treatment.	Berberine	135-144	tumor necrosis factor	Homo sapiens	94-103
23671580-13	2013	Additionally, berberine suppressed the activation of HIF-1alpha, but not NF-kappaB.	Berberine	14-23	hypoxia inducible factor 1 subunit alpha	Homo sapiens	53-63
23671580-14	2013	Taken together, it is suggested that berberine attenuates IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by inhibiting the signaling pathway of MLCK-dependent MLC phosphorylation mediated by HIF-1alpha.	Berberine	37-46	interferon gamma	Homo sapiens	58-67
23671580-14	2013	Taken together, it is suggested that berberine attenuates IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by inhibiting the signaling pathway of MLCK-dependent MLC phosphorylation mediated by HIF-1alpha.	Berberine	37-46	tumor necrosis factor	Homo sapiens	72-81
23671580-14	2013	Taken together, it is suggested that berberine attenuates IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by inhibiting the signaling pathway of MLCK-dependent MLC phosphorylation mediated by HIF-1alpha.	Berberine	37-46	myosin light chain kinase 3	Homo sapiens	171-175
23671580-14	2013	Taken together, it is suggested that berberine attenuates IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by inhibiting the signaling pathway of MLCK-dependent MLC phosphorylation mediated by HIF-1alpha.	Berberine	37-46	modulator of VRAC current 1	Homo sapiens	171-174
23671580-14	2013	Taken together, it is suggested that berberine attenuates IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by inhibiting the signaling pathway of MLCK-dependent MLC phosphorylation mediated by HIF-1alpha.	Berberine	37-46	hypoxia inducible factor 1 subunit alpha	Homo sapiens	218-228
23079743-0	2013	Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux.	Berberine	0-9	phosphoglycolate phosphatase	Mus musculus	101-115
23944062-0	2013	[Intervention effect of berberine on expressions of TNF-alpha and receptor type I in Abeta25-35-induced inflammatory reaction in SH-SY5Y cell lines].	Berberine	24-33	tumor necrosis factor	Homo sapiens	52-61
23944062-1	2013	OBJECTIVE: To investigate the effect of berberine on expressions of tumor necrosis factor alpha (TNF-alpha) and receptor type I (TNFR1) in Abeta25-35-induced inflammatory reaction in SH-SYSY cell lines.	Berberine	40-49	tumor necrosis factor	Homo sapiens	68-95
23944062-1	2013	OBJECTIVE: To investigate the effect of berberine on expressions of tumor necrosis factor alpha (TNF-alpha) and receptor type I (TNFR1) in Abeta25-35-induced inflammatory reaction in SH-SYSY cell lines.	Berberine	40-49	tumor necrosis factor	Homo sapiens	97-106
23944062-1	2013	OBJECTIVE: To investigate the effect of berberine on expressions of tumor necrosis factor alpha (TNF-alpha) and receptor type I (TNFR1) in Abeta25-35-induced inflammatory reaction in SH-SYSY cell lines.	Berberine	40-49	TNF receptor superfamily member 1A	Homo sapiens	129-134
23944062-9	2013	After intervention with berberine, the activity of LDH and TNF-alpha reduced in cell supernatant.	Berberine	24-33	tumor necrosis factor	Homo sapiens	59-68
23944062-10	2013	The intervention with berberine could down-regulate TNFR1 gene and protein expressions, particularly 1, 10 x 10(-6) mol .	Berberine	22-31	TNF receptor superfamily member 1A	Homo sapiens	52-57
23079743-9	2013	P-gp inhibitor tetrandrine (Tet) abolished the efflux of BBR at different extent depending on the expression level of P-gp; however, Tet had no impact on IMB-Y53 efflux.	Berberine	57-60	phosphoglycolate phosphatase	Mus musculus	0-4
23079743-1	2013	OBJECTIVE: Cellular efflux transporters, especially P-glycoprotein (P-gp), impel berberine (BBR) out of cells, and therefore reduce bioavailability of the compound.	Berberine	92-95	phosphoglycolate phosphatase	Mus musculus	52-66
23079743-9	2013	P-gp inhibitor tetrandrine (Tet) abolished the efflux of BBR at different extent depending on the expression level of P-gp; however, Tet had no impact on IMB-Y53 efflux.	Berberine	57-60	phosphoglycolate phosphatase	Mus musculus	118-122
23079743-1	2013	OBJECTIVE: Cellular efflux transporters, especially P-glycoprotein (P-gp), impel berberine (BBR) out of cells, and therefore reduce bioavailability of the compound.	Berberine	92-95	phosphoglycolate phosphatase	Mus musculus	68-72
23079743-2	2013	This study was designed to overcome efflux of BBR using P-gp as a target.	Berberine	46-49	phosphoglycolate phosphatase	Mus musculus	56-60
23079743-3	2013	MATERIALS/METHODS: Molecular docking study was done to identify BBR analogues that were with low affinity to P-gp.	Berberine	64-67	phosphoglycolate phosphatase	Mus musculus	109-113
23241897-6	2013	In addition, the inhibitory mechanism of berberine was associated with suppression of adhesion molecule expression, including VCAM-1 and ICAM-1.	Berberine	41-50	vascular cell adhesion molecule 1	Homo sapiens	126-132
22628222-0	2013	Hepatoprotection of berberine against hydrogen peroxide-induced apoptosis by upregulation of Sirtuin 1.	Berberine	20-29	sirtuin 1	Homo sapiens	93-102
22628222-7	2013	This study demonstrated that the protective effect of BBR against H2 O2 -induced apoptosis was associated with regulation of SIRT1 in hepatic cell line L02, which provided a possible explanation for its antioxidant activity, and implied an application of BBR for the therapeutic relevance in oxidative-stress-related liver diseases.	Berberine	54-57	sirtuin 1	Homo sapiens	125-130
23333393-0	2013	Inhibitory effects of berberine on lipopolysaccharide-induced inducible nitric oxide synthase and the high-mobility group box 1 release in macrophages.	Berberine	22-31	high mobility group box 1	Homo sapiens	102-127
23333393-1	2013	We investigated the molecular mechanism by which berberine reduces nitric oxide (NO) expression and high-mobility group box 1 (HMGB1) release in lipopolysaccharide (LPS)-induced macrophages.	Berberine	49-58	high mobility group box 1	Homo sapiens	100-125
23333393-1	2013	We investigated the molecular mechanism by which berberine reduces nitric oxide (NO) expression and high-mobility group box 1 (HMGB1) release in lipopolysaccharide (LPS)-induced macrophages.	Berberine	49-58	high mobility group box 1	Homo sapiens	127-132
23333393-2	2013	Berberine significantly inhibited the LPS-stimulated NO production and HMGB1 release in macrophages.	Berberine	0-9	high mobility group box 1	Homo sapiens	71-76
23333393-3	2013	In addition, berberine also induced heme oxygenase (HO)-1 in a dose-dependent manner, which was mediated through activation of p38 MAPK and NF-E2-related factor 2 (Nrf2) signaling cascade in macrophages.	Berberine	13-22	heme oxygenase 1	Homo sapiens	36-57
23333393-3	2013	In addition, berberine also induced heme oxygenase (HO)-1 in a dose-dependent manner, which was mediated through activation of p38 MAPK and NF-E2-related factor 2 (Nrf2) signaling cascade in macrophages.	Berberine	13-22	NFE2 like bZIP transcription factor 2	Homo sapiens	140-162
23333393-3	2013	In addition, berberine also induced heme oxygenase (HO)-1 in a dose-dependent manner, which was mediated through activation of p38 MAPK and NF-E2-related factor 2 (Nrf2) signaling cascade in macrophages.	Berberine	13-22	NFE2 like bZIP transcription factor 2	Homo sapiens	164-168
23333393-4	2013	The inhibitory effect of berberine on LPS-stimulated NO and HMGB1 release was reversed by siRNA-Nrf2, SB203580 (p38 MAPK inhibitor) and zinc protoporphyrin (ZnPP; HO-1 inhibitor) within macrophages.	Berberine	25-34	high mobility group box 1	Homo sapiens	60-65
23333393-4	2013	The inhibitory effect of berberine on LPS-stimulated NO and HMGB1 release was reversed by siRNA-Nrf2, SB203580 (p38 MAPK inhibitor) and zinc protoporphyrin (ZnPP; HO-1 inhibitor) within macrophages.	Berberine	25-34	NFE2 like bZIP transcription factor 2	Homo sapiens	96-100
23333393-5	2013	Therefore, we conclude that berberine inhibits the proinflammatory response to LPS in macrophages by up-regulation of the HO-1 level, in which p38 MAPK and Nrf2 have an important role.	Berberine	28-37	NFE2 like bZIP transcription factor 2	Homo sapiens	156-160
23329300-0	2013	Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1.	Berberine	0-9	heme oxygenase 1	Homo sapiens	109-125
23329300-5	2013	Furthermore, BBR induced PI3K/Akt and p38 activation, which are involved in the induction of Nrf2 expression and neuroprotection.	Berberine	13-16	AKT serine/threonine kinase 1	Homo sapiens	30-33
23329300-5	2013	Furthermore, BBR induced PI3K/Akt and p38 activation, which are involved in the induction of Nrf2 expression and neuroprotection.	Berberine	13-16	mitogen-activated protein kinase 14	Homo sapiens	38-41
23329300-5	2013	Furthermore, BBR induced PI3K/Akt and p38 activation, which are involved in the induction of Nrf2 expression and neuroprotection.	Berberine	13-16	NFE2 like bZIP transcription factor 2	Homo sapiens	93-97
23241897-6	2013	In addition, the inhibitory mechanism of berberine was associated with suppression of adhesion molecule expression, including VCAM-1 and ICAM-1.	Berberine	41-50	intercellular adhesion molecule 1	Homo sapiens	137-143
23247593-0	2013	Set9, NF-kappaB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells.	Berberine	41-50	microRNA 21	Homo sapiens	21-32
23065570-0	2013	Berberine inhibits the migration and invasion of T24 bladder cancer cells via reducing the expression of heparanase.	Berberine	0-9	heparanase	Homo sapiens	105-115
23065570-3	2013	Our results showed that both mRNA and protein of heparanase were highly expressed in human bladder cancer T24 cells and markedly downregulated by both heparanase-specific siRNA (hpa-siRNA) and berberine.	Berberine	193-202	heparanase	Homo sapiens	49-59
23065570-5	2013	Therefore, berberine inhibits the metastasis and invasion of bladder cancer cell, possibly via blocking the heparanase expression and thus may be used clinically to reduce the recurrence of bladder cancer.	Berberine	11-20	heparanase	Homo sapiens	108-118
23247593-0	2013	Set9, NF-kappaB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells.	Berberine	41-50	SET domain containing 7, histone lysine methyltransferase	Homo sapiens	0-4
23099256-3	2013	This study was conducted to evaluate the effect of berberine on hippocampal CA1 neuronal apoptosis, synaptic plasticity and learning and memory of streptozotocin (STZ)-diabetic rats.	Berberine	51-60	carbonic anhydrase 1	Rattus norvegicus	76-79
23573121-0	2013	Effect of Berberine on PPAR alpha /NO Activation in High Glucose- and Insulin-Induced Cardiomyocyte Hypertrophy.	Berberine	10-19	peroxisome proliferator activated receptor alpha	Rattus norvegicus	23-33
23247593-6	2013	RESULTS: Treatment of U266 cells with berberine (40-160 mumol/L) suppressed cell proliferation and IL-6 secretion in dose- and time-dependent manners.	Berberine	38-47	interleukin 6	Homo sapiens	99-103
23247593-7	2013	Meanwhile, berberine dose-dependently induced ROS generation, G(2)/M phase arrest and apoptosis in U266 cells, and decreased the levels of miR-21 and Bcl-2.	Berberine	11-20	microRNA 21	Homo sapiens	139-145
23247593-7	2013	Meanwhile, berberine dose-dependently induced ROS generation, G(2)/M phase arrest and apoptosis in U266 cells, and decreased the levels of miR-21 and Bcl-2.	Berberine	11-20	BCL2 apoptosis regulator	Homo sapiens	150-155
23247593-8	2013	Overexpression of miR-21 counteracted berberine-induced suppression of cell proliferation and IL-6 secretion.	Berberine	38-47	microRNA 21	Homo sapiens	18-24
23247593-8	2013	Overexpression of miR-21 counteracted berberine-induced suppression of cell proliferation and IL-6 secretion.	Berberine	38-47	interleukin 6	Homo sapiens	94-98
23247593-9	2013	In U266 cells treated with berberine (80 mumol/L), the activity of NF-kappaB was decreased by approximately 50%, followed by significant reduction of miR-21 level.	Berberine	27-36	nuclear factor kappa B subunit 1	Homo sapiens	67-76
23247593-9	2013	In U266 cells treated with berberine (80 mumol/L), the activity of NF-kappaB was decreased by approximately 50%, followed by significant reduction of miR-21 level.	Berberine	27-36	microRNA 21	Homo sapiens	150-156
23247593-10	2013	berberine (80-160 mumol/L) increased the level of Set9 (lysine methyltransferase) by more than 2-fold, caused methylation of the RelA subunit, which inhibited NF-kappaB nuclear translocation and miR-21 transcription.	Berberine	0-9	SET domain containing 7, histone lysine methyltransferase	Homo sapiens	50-54
23247593-10	2013	berberine (80-160 mumol/L) increased the level of Set9 (lysine methyltransferase) by more than 2-fold, caused methylation of the RelA subunit, which inhibited NF-kappaB nuclear translocation and miR-21 transcription.	Berberine	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	129-133
23247593-10	2013	berberine (80-160 mumol/L) increased the level of Set9 (lysine methyltransferase) by more than 2-fold, caused methylation of the RelA subunit, which inhibited NF-kappaB nuclear translocation and miR-21 transcription.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	159-168
23247593-10	2013	berberine (80-160 mumol/L) increased the level of Set9 (lysine methyltransferase) by more than 2-fold, caused methylation of the RelA subunit, which inhibited NF-kappaB nuclear translocation and miR-21 transcription.	Berberine	0-9	microRNA 21	Homo sapiens	195-201
23247593-11	2013	In U266 cells treated with berberine (80 mumol/L), knockdown of Set9 with siRNAs significantly increased NF-kappaB protein level accompanying with a partial recovery of proliferation.	Berberine	27-36	SET domain containing 7, histone lysine methyltransferase	Homo sapiens	64-68
23247593-11	2013	In U266 cells treated with berberine (80 mumol/L), knockdown of Set9 with siRNAs significantly increased NF-kappaB protein level accompanying with a partial recovery of proliferation.	Berberine	27-36	nuclear factor kappa B subunit 1	Homo sapiens	105-114
23247593-12	2013	CONCLUSION: In U266 cells, berberine suppresses NF-kappaB nuclear translocation via Set9-mediated lysine methylation, leads to decrease in the levels miR21 and Bcl-2, which induces ROS generation and apoptosis.	Berberine	27-36	nuclear factor kappa B subunit 1	Homo sapiens	48-57
23247593-12	2013	CONCLUSION: In U266 cells, berberine suppresses NF-kappaB nuclear translocation via Set9-mediated lysine methylation, leads to decrease in the levels miR21 and Bcl-2, which induces ROS generation and apoptosis.	Berberine	27-36	SET domain containing 7, histone lysine methyltransferase	Homo sapiens	84-88
23247593-12	2013	CONCLUSION: In U266 cells, berberine suppresses NF-kappaB nuclear translocation via Set9-mediated lysine methylation, leads to decrease in the levels miR21 and Bcl-2, which induces ROS generation and apoptosis.	Berberine	27-36	microRNA 21	Homo sapiens	150-155
23247593-12	2013	CONCLUSION: In U266 cells, berberine suppresses NF-kappaB nuclear translocation via Set9-mediated lysine methylation, leads to decrease in the levels miR21 and Bcl-2, which induces ROS generation and apoptosis.	Berberine	27-36	BCL2 apoptosis regulator	Homo sapiens	160-165
23139291-6	2013	As apoE is a potent ligand for the LDL receptor, we next evaluated the effects of TOR in combination with the LDL-lowering drug berberine, which upregulates LDL receptor expression in dyslipidemic hamsters.	Berberine	128-137	low density lipoprotein receptor	Homo sapiens	157-169
23139291-7	2013	Compared with TOR alone, treatment with TOR+berberine 150 mg/kg resulted in lower apolipoprotein E-rich HDL levels.	Berberine	44-53	apolipoprotein E	Homo sapiens	82-98
24335179-0	2013	Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells.	Berberine	0-9	fibronectin 1	Homo sapiens	33-44
24335179-0	2013	Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells.	Berberine	0-9	vascular endothelial growth factor A	Homo sapiens	82-86
24335179-12	2013	CONCLUSION: Taken together, we suggest that BBR may suppress TPA-induced VEGF and FN as well as VEGF-induced FN through the inhibition of the PI-3K/AKT pathway in breast cancer cells.	Berberine	44-47	vascular endothelial growth factor A	Homo sapiens	73-77
24335179-12	2013	CONCLUSION: Taken together, we suggest that BBR may suppress TPA-induced VEGF and FN as well as VEGF-induced FN through the inhibition of the PI-3K/AKT pathway in breast cancer cells.	Berberine	44-47	fibronectin 1	Homo sapiens	82-84
24335179-12	2013	CONCLUSION: Taken together, we suggest that BBR may suppress TPA-induced VEGF and FN as well as VEGF-induced FN through the inhibition of the PI-3K/AKT pathway in breast cancer cells.	Berberine	44-47	fibronectin 1	Homo sapiens	109-111
24335179-12	2013	CONCLUSION: Taken together, we suggest that BBR may suppress TPA-induced VEGF and FN as well as VEGF-induced FN through the inhibition of the PI-3K/AKT pathway in breast cancer cells.	Berberine	44-47	AKT serine/threonine kinase 1	Homo sapiens	148-151
24027594-0	2013	Berberine Reduces the Metastasis of Chondrosarcoma by Modulating the alpha v beta 3 Integrin and the PKC delta , c-Src, and AP-1 Signaling Pathways.	Berberine	0-9	protein kinase C delta	Homo sapiens	101-110
24027594-0	2013	Berberine Reduces the Metastasis of Chondrosarcoma by Modulating the alpha v beta 3 Integrin and the PKC delta , c-Src, and AP-1 Signaling Pathways.	Berberine	0-9	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	113-118
24027594-8	2013	We also found that incubation of chondrosarcoma cells with berberine reduced mRNA transcription for, and cell surface expression of, the alpha v beta 3 integrin, with additional inhibitory effects on PKC delta , c-Src, and NF- kappa B activation.	Berberine	59-68	protein kinase C delta	Homo sapiens	200-209
24027594-8	2013	We also found that incubation of chondrosarcoma cells with berberine reduced mRNA transcription for, and cell surface expression of, the alpha v beta 3 integrin, with additional inhibitory effects on PKC delta , c-Src, and NF- kappa B activation.	Berberine	59-68	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	212-217
24027594-8	2013	We also found that incubation of chondrosarcoma cells with berberine reduced mRNA transcription for, and cell surface expression of, the alpha v beta 3 integrin, with additional inhibitory effects on PKC delta , c-Src, and NF- kappa B activation.	Berberine	59-68	nuclear factor kappa B subunit 1	Homo sapiens	223-234
23247593-0	2013	Set9, NF-kappaB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells.	Berberine	41-50	nuclear factor kappa B subunit 1	Homo sapiens	6-15
23924821-0	2013	Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function.	Berberine	53-62	phosphoglycolate phosphatase	Mus musculus	77-91
23924821-1	2013	This study was designed to improve the absorption and hypoglycemic efficacy of berberine (BBR), which is a substrate of P-glycoprotein (P-gp), by combination with a P-gp inhibitor tetrandrine (Tet).	Berberine	79-88	phosphoglycolate phosphatase	Mus musculus	120-134
23924821-1	2013	This study was designed to improve the absorption and hypoglycemic efficacy of berberine (BBR), which is a substrate of P-glycoprotein (P-gp), by combination with a P-gp inhibitor tetrandrine (Tet).	Berberine	79-88	phosphoglycolate phosphatase	Mus musculus	136-140
23924821-1	2013	This study was designed to improve the absorption and hypoglycemic efficacy of berberine (BBR), which is a substrate of P-glycoprotein (P-gp), by combination with a P-gp inhibitor tetrandrine (Tet).	Berberine	79-88	phosphoglycolate phosphatase	Mus musculus	165-169
23924821-1	2013	This study was designed to improve the absorption and hypoglycemic efficacy of berberine (BBR), which is a substrate of P-glycoprotein (P-gp), by combination with a P-gp inhibitor tetrandrine (Tet).	Berberine	90-93	phosphoglycolate phosphatase	Mus musculus	120-134
23924821-1	2013	This study was designed to improve the absorption and hypoglycemic efficacy of berberine (BBR), which is a substrate of P-glycoprotein (P-gp), by combination with a P-gp inhibitor tetrandrine (Tet).	Berberine	90-93	phosphoglycolate phosphatase	Mus musculus	136-140
24335171-0	2013	Berberine induces apoptosis in p53-null leukemia cells by down-regulating XIAP at the post-transcriptional level.	Berberine	0-9	tumor protein p53	Homo sapiens	31-34
24335171-0	2013	Berberine induces apoptosis in p53-null leukemia cells by down-regulating XIAP at the post-transcriptional level.	Berberine	0-9	X-linked inhibitor of apoptosis	Homo sapiens	74-78
24335171-2	2013	However, the underlying molecular mechanisms of berberine induced p53-independent apoptosis remain unclear.	Berberine	48-57	tumor protein p53	Homo sapiens	66-69
24335171-3	2013	METHODS: The p53-null leukemia cell line EU-4 cells were exposed to berberine.	Berberine	68-77	tumor protein p53	Homo sapiens	13-16
24335171-7	2013	RESULTS: Berberine induced p53-independent, XIAP-mediated apoptotic cell death in p53-null leukemia cells.	Berberine	9-18	tumor protein p53	Homo sapiens	27-30
24335171-7	2013	RESULTS: Berberine induced p53-independent, XIAP-mediated apoptotic cell death in p53-null leukemia cells.	Berberine	9-18	X-linked inhibitor of apoptosis	Homo sapiens	44-48
24335171-7	2013	RESULTS: Berberine induced p53-independent, XIAP-mediated apoptotic cell death in p53-null leukemia cells.	Berberine	9-18	tumor protein p53	Homo sapiens	82-85
24335171-8	2013	Treatment with berberine resulted in suppression of XIAP protein in a dose- and time- dependent manner.	Berberine	15-24	X-linked inhibitor of apoptosis	Homo sapiens	52-56
24335171-9	2013	Berberine induced down-regulation of XIAP protein involving inhibition of MDM2 expression and a proteasome-dependent pathway.	Berberine	0-9	X-linked inhibitor of apoptosis	Homo sapiens	37-41
24335171-9	2013	Berberine induced down-regulation of XIAP protein involving inhibition of MDM2 expression and a proteasome-dependent pathway.	Berberine	0-9	MDM2 proto-oncogene	Homo sapiens	74-78
24335171-10	2013	Moreover, inhibition of XIAP by berberine or siRNA increased the sensitivity of leukemia cells to doxorubicin-induced apoptosis.	Berberine	32-41	X-linked inhibitor of apoptosis	Homo sapiens	24-28
24335171-11	2013	CONCLUSION: Our findings characterize the molecular mechanisms of berberine-induced caspase activation and subsequent apoptosis, and berberine may be a novel candidate inducer of apoptosis in leukemia cells, which normally lack p53 expression.	Berberine	133-142	tumor protein p53	Homo sapiens	228-231
23573121-3	2013	The objective of this study was to evaluate the potential effect of berberine on cardiomyocyte hypertrophy in diabetes and its possible influence on peroxisome proliferator-activated receptor- alpha (PPAR alpha )/nitric oxide (NO) signaling pathway.	Berberine	68-77	peroxisome proliferator activated receptor alpha	Rattus norvegicus	149-198
23573121-3	2013	The objective of this study was to evaluate the potential effect of berberine on cardiomyocyte hypertrophy in diabetes and its possible influence on peroxisome proliferator-activated receptor- alpha (PPAR alpha )/nitric oxide (NO) signaling pathway.	Berberine	68-77	peroxisome proliferator activated receptor alpha	Rattus norvegicus	200-210
23573121-9	2013	MK886 (0.3  mu mol/L), a selective PPAR alpha antagonist, could abolish the effects of berberine and fenofibrate.	Berberine	87-96	peroxisome proliferator activated receptor alpha	Rattus norvegicus	35-45
23573121-11	2013	These results suggest that berberine can blunt HGI-induced cardiomyocyte hypertrophy in vitro, through the activation of the PPAR alpha /NO signaling pathway.	Berberine	27-36	peroxisome proliferator activated receptor alpha	Rattus norvegicus	125-135
23418674-7	2013	The results suggested that both the EtOAc extract and berberine were able to activate PPARalpha/beta/gamma, and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.	Berberine	54-63	peroxisome proliferator activated receptor alpha	Homo sapiens	86-126
23418674-7	2013	The results suggested that both the EtOAc extract and berberine were able to activate PPARalpha/beta/gamma, and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.	Berberine	180-189	peroxisome proliferator activated receptor alpha	Homo sapiens	86-126
23085271-0	2012	Berberine suppresses high glucose-induced TGF-beta1 and fibronectin synthesis in mesangial cells through inhibition of sphingosine kinase 1/AP-1 pathway.	Berberine	0-9	transforming growth factor beta 1	Homo sapiens	42-51
24385682-0	2013	Berberine protects against palmitate-induced endothelial dysfunction: involvements of upregulation of AMPK and eNOS and downregulation of NOX4.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	102-106
24385682-0	2013	Berberine protects against palmitate-induced endothelial dysfunction: involvements of upregulation of AMPK and eNOS and downregulation of NOX4.	Berberine	0-9	nitric oxide synthase 3	Homo sapiens	111-115
24385682-0	2013	Berberine protects against palmitate-induced endothelial dysfunction: involvements of upregulation of AMPK and eNOS and downregulation of NOX4.	Berberine	0-9	NADPH oxidase 4	Homo sapiens	138-142
23065224-1	2013	The thermodynamics of the interaction of two pharmaceutically important isoquinoline alkaloids berberine and palmatine with bovine and human serum albumin was investigated using calorimetric techniques, and the data was supplemented with fluorescence and circular dichroism studies.	Berberine	95-104	albumin	Bos taurus	141-154
23555784-11	2013	In addition, there were significantly lower expression levels of iNOS and TGF-beta in the ARD+BBR group than in the ARD group, with attenuated NFkappaB-DNA binding activity and down-regulated protein levels of subunits p65 and p50 as well as IKKbeta.	Berberine	94-97	nitric oxide synthase 2	Rattus norvegicus	65-69
23555784-11	2013	In addition, there were significantly lower expression levels of iNOS and TGF-beta in the ARD+BBR group than in the ARD group, with attenuated NFkappaB-DNA binding activity and down-regulated protein levels of subunits p65 and p50 as well as IKKbeta.	Berberine	94-97	transforming growth factor, beta 1	Rattus norvegicus	74-82
23555784-11	2013	In addition, there were significantly lower expression levels of iNOS and TGF-beta in the ARD+BBR group than in the ARD group, with attenuated NFkappaB-DNA binding activity and down-regulated protein levels of subunits p65 and p50 as well as IKKbeta.	Berberine	94-97	synaptotagmin 1	Rattus norvegicus	219-222
23555784-11	2013	In addition, there were significantly lower expression levels of iNOS and TGF-beta in the ARD+BBR group than in the ARD group, with attenuated NFkappaB-DNA binding activity and down-regulated protein levels of subunits p65 and p50 as well as IKKbeta.	Berberine	94-97	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	242-249
23372711-0	2013	Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages.	Berberine	96-105	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
23372711-10	2013	The results indicate that P-gp contributed to the efflux of BBR in macrophages.	Berberine	60-63	ATP binding cassette subfamily B member 1	Homo sapiens	26-30
24385682-9	2013	The expressions of eNOS were significantly increased, while NOX4 protein expression was decreased in berberine-treated HUVECs.	Berberine	101-110	nitric oxide synthase 3	Homo sapiens	19-23
24385682-9	2013	The expressions of eNOS were significantly increased, while NOX4 protein expression was decreased in berberine-treated HUVECs.	Berberine	101-110	NADPH oxidase 4	Homo sapiens	60-64
24385682-10	2013	Moreover, berberine upregulated the protein expression of AMPK and p-AMPK in palmitate-treated HUVECs, but had no effect on the levels of Akt.	Berberine	10-19	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	58-62
24385682-10	2013	Moreover, berberine upregulated the protein expression of AMPK and p-AMPK in palmitate-treated HUVECs, but had no effect on the levels of Akt.	Berberine	10-19	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	69-73
24385682-11	2013	Therefore, berberine ameliorates palmitate-induced endothelial dysfunction by upregulating eNOS expression and downregulating expression of NOX4.	Berberine	11-20	nitric oxide synthase 3	Homo sapiens	91-95
24385682-11	2013	Therefore, berberine ameliorates palmitate-induced endothelial dysfunction by upregulating eNOS expression and downregulating expression of NOX4.	Berberine	11-20	NADPH oxidase 4	Homo sapiens	140-144
24385682-12	2013	This regulatory effect of berberine may be related to the activation of AMPK.	Berberine	26-35	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	72-76
22422627-0	2013	Berberine inhibits myofibroblast differentiation in nasal polyp-derived fibroblasts via the p38 pathway.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	92-95
22422627-2	2013	NPDFs were pre-treated with berberine prior to induction by transforming growth factor (TGF)-beta1.	Berberine	28-37	transforming growth factor beta 1	Homo sapiens	60-98
22422627-6	2013	In TGF-beta1-induced NPDFs, berberine significantly inhibited the expression of alpha-SMA and collagen type I mRNA and reduced alpha-SMA and collagen protein levels.	Berberine	28-37	transforming growth factor beta 1	Homo sapiens	3-12
22422627-9	2013	Berberine exerts suppressive effects on phenotype changes and ECM production in NPDFs via p38 signaling pathway interference.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	90-93
23457600-0	2013	Berberine inhibits proliferation and down-regulates epidermal growth factor receptor through activation of Cbl in colon tumor cells.	Berberine	0-9	epidermal growth factor receptor	Homo sapiens	52-84
23457600-0	2013	Berberine inhibits proliferation and down-regulates epidermal growth factor receptor through activation of Cbl in colon tumor cells.	Berberine	0-9	Cbl proto-oncogene	Homo sapiens	107-110
23457600-4	2013	The aim of this study was to investigate the effects and mechanisms of berberine on regulation of EGFR activity and proliferation in colonic tumor cell lines and in vivo.	Berberine	71-80	epidermal growth factor receptor	Homo sapiens	98-102
23457600-5	2013	We reported that berberine significantly inhibited basal level and EGF-stimulated EGFR activation and proliferation in the immorto Min mouse colonic epithelial (IMCE) cells carrying the APC(min) mutation and human colonic carcinoma cell line, HT-29 cells.	Berberine	17-26	epidermal growth factor receptor	Mus musculus	82-86
23457600-7	2013	In this study, we also showed that berberine stimulated ubiquitin ligase Cbl activation and Cbl"s interaction with EGFR, and EGFR ubiquitinylation and down-regulation in these two cell lines in the presence or absence of EGF treatment.	Berberine	35-44	Cbl proto-oncogene	Homo sapiens	73-76
23457600-7	2013	In this study, we also showed that berberine stimulated ubiquitin ligase Cbl activation and Cbl"s interaction with EGFR, and EGFR ubiquitinylation and down-regulation in these two cell lines in the presence or absence of EGF treatment.	Berberine	35-44	Cbl proto-oncogene	Homo sapiens	92-95
23457600-7	2013	In this study, we also showed that berberine stimulated ubiquitin ligase Cbl activation and Cbl"s interaction with EGFR, and EGFR ubiquitinylation and down-regulation in these two cell lines in the presence or absence of EGF treatment.	Berberine	35-44	epidermal growth factor receptor	Homo sapiens	115-119
23457600-8	2013	Knock-down Cbl expression blocked the effects of berberine on down-regulation of EGFR and inhibition of proliferation.	Berberine	49-58	Cbl proto-oncogene	Homo sapiens	11-14
23457600-8	2013	Knock-down Cbl expression blocked the effects of berberine on down-regulation of EGFR and inhibition of proliferation.	Berberine	49-58	epidermal growth factor receptor	Homo sapiens	81-85
23457600-10	2013	Cell proliferation and EGFR expression level was decreased by berberine treatment in this xenograft model and in colon epithelial cells of APC(min/+) mice.	Berberine	62-71	epidermal growth factor receptor	Mus musculus	23-27
23457600-11	2013	Taken together, these data indicate that berberine enhances Cbl activity, resulting in down-regulation of EGFR expression and inhibition of proliferation in colon tumor cells.	Berberine	41-50	Cbl proto-oncogene	Homo sapiens	60-63
23457600-11	2013	Taken together, these data indicate that berberine enhances Cbl activity, resulting in down-regulation of EGFR expression and inhibition of proliferation in colon tumor cells.	Berberine	41-50	epidermal growth factor receptor	Homo sapiens	106-110
23672049-0	2013	[Effect of berberine, liensinine and neferine on HERG channel expression].	Berberine	11-20	potassium voltage-gated channel subfamily H member 2	Homo sapiens	49-53
23672049-1	2013	OBJECTIVE: Immunofluorescence and Western blot methods were adopted for qualitative and quantitative detections of the effect of different concentrations of berberine, liensinine and neferine on the expression of stable transfection in HERG potassium channel in HEK-293 cells, as well as the effect of different concentrations of berberine on protein expression of Ikr channel in cardiac muscular tissues, in order to investigate the anti-arrhythmic mechanism of berberine, liensinine and neferine.	Berberine	157-166	potassium voltage-gated channel subfamily H member 2	Homo sapiens	236-240
23672049-1	2013	OBJECTIVE: Immunofluorescence and Western blot methods were adopted for qualitative and quantitative detections of the effect of different concentrations of berberine, liensinine and neferine on the expression of stable transfection in HERG potassium channel in HEK-293 cells, as well as the effect of different concentrations of berberine on protein expression of Ikr channel in cardiac muscular tissues, in order to investigate the anti-arrhythmic mechanism of berberine, liensinine and neferine.	Berberine	330-339	potassium voltage-gated channel subfamily H member 2	Homo sapiens	236-240
23672049-1	2013	OBJECTIVE: Immunofluorescence and Western blot methods were adopted for qualitative and quantitative detections of the effect of different concentrations of berberine, liensinine and neferine on the expression of stable transfection in HERG potassium channel in HEK-293 cells, as well as the effect of different concentrations of berberine on protein expression of Ikr channel in cardiac muscular tissues, in order to investigate the anti-arrhythmic mechanism of berberine, liensinine and neferine.	Berberine	330-339	potassium voltage-gated channel subfamily H member 2	Homo sapiens	236-240
23672049-3	2013	Immunofluorescence method as well as confocal laser microscope were used to detect the effect of different concentrations of berberine, liensinine and neferine on protein expression of HERG channel.	Berberine	125-134	potassium voltage-gated channel subfamily H member 2	Homo sapiens	185-189
23672049-6	2013	Berberine (10, 30 micromol x L(-1)) remarkably inhibited protein expression of HERG channel in HERG-HEK cells (P &lt; 0.01).	Berberine	0-9	potassium voltage-gated channel subfamily H member 2	Homo sapiens	79-83
23672049-6	2013	Berberine (10, 30 micromol x L(-1)) remarkably inhibited protein expression of HERG channel in HERG-HEK cells (P &lt; 0.01).	Berberine	0-9	potassium voltage-gated channel subfamily H member 2	Homo sapiens	95-99
23672049-11	2013	Berberine shows inhibitory effect on protein expressions of in vitro HERG-HEK cells and Ikr channel in rat ventricular tissues.	Berberine	0-9	potassium voltage-gated channel subfamily H member 2	Homo sapiens	69-73
23085271-2	2012	Recently, we found that berberine suppressed the activation of SphK1 pathway in diabetic kidney, protecting against diabetic nephropathy.	Berberine	24-33	sphingosine kinase 1	Homo sapiens	63-68
23085271-4	2012	Here, we showed that berberine prevented the expression of alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1) and fibronectin (FN) in mesangial cells cultured by high glucose.	Berberine	21-30	transforming growth factor beta 1	Homo sapiens	98-130
23085271-4	2012	Here, we showed that berberine prevented the expression of alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1) and fibronectin (FN) in mesangial cells cultured by high glucose.	Berberine	21-30	transforming growth factor beta 1	Homo sapiens	132-141
23085271-4	2012	Here, we showed that berberine prevented the expression of alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1) and fibronectin (FN) in mesangial cells cultured by high glucose.	Berberine	21-30	fibronectin 1	Homo sapiens	147-158
23085271-4	2012	Here, we showed that berberine prevented the expression of alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1) and fibronectin (FN) in mesangial cells cultured by high glucose.	Berberine	21-30	fibronectin 1	Homo sapiens	160-162
23085271-5	2012	Furthermore, berberine suppressed the activation of SphK1 pathway via inhibition of the activity and expression of SphK1 in mesangial cells cultured by high glucose.	Berberine	13-22	sphingosine kinase 1	Homo sapiens	52-57
23085271-5	2012	Furthermore, berberine suppressed the activation of SphK1 pathway via inhibition of the activity and expression of SphK1 in mesangial cells cultured by high glucose.	Berberine	13-22	sphingosine kinase 1	Homo sapiens	115-120
23085271-6	2012	Surprisingly, berberine blocked the increased activity and expression of SphK1 in mesangial cells transfected by wild type SphK1 under normal glucose condition.	Berberine	14-23	sphingosine kinase 1	Homo sapiens	73-78
23085271-6	2012	Surprisingly, berberine blocked the increased activity and expression of SphK1 in mesangial cells transfected by wild type SphK1 under normal glucose condition.	Berberine	14-23	sphingosine kinase 1	Homo sapiens	123-128
23085271-9	2012	Altogether, these data not only demonstrate that berberine is an important agent against diabetic nephropathy through inhibition of SphK1/AP-1 pathway, but also indicate that the inhibition of SphK1/AP-1 by berberine is independent of ambient glucose concentration.	Berberine	49-58	sphingosine kinase 1	Homo sapiens	132-137
23085271-9	2012	Altogether, these data not only demonstrate that berberine is an important agent against diabetic nephropathy through inhibition of SphK1/AP-1 pathway, but also indicate that the inhibition of SphK1/AP-1 by berberine is independent of ambient glucose concentration.	Berberine	49-58	sphingosine kinase 1	Homo sapiens	193-198
23085271-9	2012	Altogether, these data not only demonstrate that berberine is an important agent against diabetic nephropathy through inhibition of SphK1/AP-1 pathway, but also indicate that the inhibition of SphK1/AP-1 by berberine is independent of ambient glucose concentration.	Berberine	207-216	sphingosine kinase 1	Homo sapiens	193-198
23085271-0	2012	Berberine suppresses high glucose-induced TGF-beta1 and fibronectin synthesis in mesangial cells through inhibition of sphingosine kinase 1/AP-1 pathway.	Berberine	0-9	fibronectin 1	Homo sapiens	56-67
23085271-0	2012	Berberine suppresses high glucose-induced TGF-beta1 and fibronectin synthesis in mesangial cells through inhibition of sphingosine kinase 1/AP-1 pathway.	Berberine	0-9	sphingosine kinase 1	Homo sapiens	119-139
22459600-6	2012	Glycogen synthase kinase (GSK)3, a major kinase involved in APP and tau phosphorylation, was significantly inhibited by BBR treatment.	Berberine	120-123	glycogen synthase kinase 3 beta	Mus musculus	0-31
23682426-9	2012	The up-regulated mRNA and/or protein expressions of Fas, FasL, TNF-alpha, caspase-3 and down-regulation of pro-caspase-3 suggest that the death receptor pathway may be involved in the apoptotic pathway induced by berberine.	Berberine	213-222	tumor necrosis factor	Homo sapiens	63-72
23682426-9	2012	The up-regulated mRNA and/or protein expressions of Fas, FasL, TNF-alpha, caspase-3 and down-regulation of pro-caspase-3 suggest that the death receptor pathway may be involved in the apoptotic pathway induced by berberine.	Berberine	213-222	caspase 3	Homo sapiens	74-83
23682426-9	2012	The up-regulated mRNA and/or protein expressions of Fas, FasL, TNF-alpha, caspase-3 and down-regulation of pro-caspase-3 suggest that the death receptor pathway may be involved in the apoptotic pathway induced by berberine.	Berberine	213-222	caspase 3	Homo sapiens	107-120
23682426-10	2012	Decrease of Bcl-2 and increase of Bax in mRNA and/or protein expressions showed that the Bcl-2 family proteins were involved in berberine-induced apoptosis.	Berberine	128-137	BCL2 apoptosis regulator	Homo sapiens	12-17
23682426-10	2012	Decrease of Bcl-2 and increase of Bax in mRNA and/or protein expressions showed that the Bcl-2 family proteins were involved in berberine-induced apoptosis.	Berberine	128-137	BCL2 associated X, apoptosis regulator	Homo sapiens	34-37
23682426-10	2012	Decrease of Bcl-2 and increase of Bax in mRNA and/or protein expressions showed that the Bcl-2 family proteins were involved in berberine-induced apoptosis.	Berberine	128-137	BCL2 apoptosis regulator	Homo sapiens	89-94
23682426-11	2012	We also found that berberine-induced apoptosis was associated with an upregulated expressions of p53 and prohibitin (PHB), and decreased vimentin expression.	Berberine	19-28	tumor protein p53	Homo sapiens	97-100
23682426-11	2012	We also found that berberine-induced apoptosis was associated with an upregulated expressions of p53 and prohibitin (PHB), and decreased vimentin expression.	Berberine	19-28	prohibitin 1	Homo sapiens	105-115
23682426-11	2012	We also found that berberine-induced apoptosis was associated with an upregulated expressions of p53 and prohibitin (PHB), and decreased vimentin expression.	Berberine	19-28	prohibitin 1	Homo sapiens	117-120
23682426-11	2012	We also found that berberine-induced apoptosis was associated with an upregulated expressions of p53 and prohibitin (PHB), and decreased vimentin expression.	Berberine	19-28	vimentin	Homo sapiens	137-145
23354815-4	2012	As phospholipase A(2) is a target of anti inflammatory drugs, it might be concluded that certain biotransformed derivatives of berberine could be better anti inflammatory agents compared to berberine.	Berberine	127-136	phospholipase A2 group IB	Homo sapiens	3-20
23354815-4	2012	As phospholipase A(2) is a target of anti inflammatory drugs, it might be concluded that certain biotransformed derivatives of berberine could be better anti inflammatory agents compared to berberine.	Berberine	190-199	phospholipase A2 group IB	Homo sapiens	3-20
23269899-1	2012	The purpose of this study was to evaluate whether berberine (BER) administration could attenuate depression- and anxiety-like behaviors and increase corticotrophin-releasing factor (CRF) and tyrosine hydroxylase (TH) expression following chronic morphine withdrawal in rats.	Berberine	50-59	corticotropin releasing hormone	Rattus norvegicus	149-180
23269899-1	2012	The purpose of this study was to evaluate whether berberine (BER) administration could attenuate depression- and anxiety-like behaviors and increase corticotrophin-releasing factor (CRF) and tyrosine hydroxylase (TH) expression following chronic morphine withdrawal in rats.	Berberine	61-64	corticotropin releasing hormone	Rattus norvegicus	149-180
23159854-0	2012	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.	Berberine	132-141	lipocalin 2	Homo sapiens	8-12
23159854-8	2012	Ectopic NGAL expression increased the sensitivity of MCF-7 breast cancer cells to EGFR, Bcl-2 and calmodulin kinase inhibitors as well as the natural plant product berberine.	Berberine	164-173	lipocalin 2	Homo sapiens	8-12
22459600-7	2012	We also found that BBR significantly decreased the levels of C-terminal fragments of APP and the hyperphosphorylation of APP and tau via the Akt/glycogen synthase kinase 3 signaling pathway in N2a mouse neuroblastoma cells stably expressing human Swedish mutant APP695 (N2a-SwedAPP).	Berberine	19-22	thymoma viral proto-oncogene 1	Mus musculus	141-144
22840327-11	2012	Thiazolidinediones show bone loss due to activation of PPAR-gamma in osteoblasts, whereas berberine stimulates PPAR-gamma only in adipocytes and not in osteoblasts, and therefore the decreased bone loss due to use of thiazolidinediones may not be observed in berberine treatment conditions.	Berberine	90-99	peroxisome proliferator activated receptor gamma	Homo sapiens	111-121
23477149-0	2012	[Regulatory effect of berberine on unbalanced expressions of renal tissue TGF-beta1/SnoN and smad signaling pathway in rats with early diabetic nephropathy].	Berberine	22-31	transforming growth factor, beta 1	Rattus norvegicus	74-83
23477149-0	2012	[Regulatory effect of berberine on unbalanced expressions of renal tissue TGF-beta1/SnoN and smad signaling pathway in rats with early diabetic nephropathy].	Berberine	22-31	SMAD family member 7	Rattus norvegicus	93-97
23477149-1	2012	OBJECTIVE: To investigate the effect of berberine (BBR) on unbalanced expression of renal tissue TGF-beta1/SnoN and Smad signal pathway in rats with early diabetic nephropathy (DN), and discuss BBR"s effect on DN rats with early diabetic nephropathy and its possible mechanism.	Berberine	40-49	transforming growth factor, beta 1	Rattus norvegicus	97-106
23477149-1	2012	OBJECTIVE: To investigate the effect of berberine (BBR) on unbalanced expression of renal tissue TGF-beta1/SnoN and Smad signal pathway in rats with early diabetic nephropathy (DN), and discuss BBR"s effect on DN rats with early diabetic nephropathy and its possible mechanism.	Berberine	40-49	SMAD family member 7	Rattus norvegicus	116-120
23477149-8	2012	RESULT: Compared with the model group, BBR-treated groups showed significant decrease in FBG, BUN, Scr, 24 h Upro, 24 h UmAlb, TGF-beta1 protein, mRNA and Smad2/3 protein, abnormal morphological improvement in renal tissues, and notable increase in the expressions of SnoN and Smad7 protein.	Berberine	39-42	transforming growth factor, beta 1	Rattus norvegicus	127-136
23477149-8	2012	RESULT: Compared with the model group, BBR-treated groups showed significant decrease in FBG, BUN, Scr, 24 h Upro, 24 h UmAlb, TGF-beta1 protein, mRNA and Smad2/3 protein, abnormal morphological improvement in renal tissues, and notable increase in the expressions of SnoN and Smad7 protein.	Berberine	39-42	SMAD family member 2	Rattus norvegicus	155-162
23477149-8	2012	RESULT: Compared with the model group, BBR-treated groups showed significant decrease in FBG, BUN, Scr, 24 h Upro, 24 h UmAlb, TGF-beta1 protein, mRNA and Smad2/3 protein, abnormal morphological improvement in renal tissues, and notable increase in the expressions of SnoN and Smad7 protein.	Berberine	39-42	SMAD family member 7	Rattus norvegicus	277-282
23058107-0	2012	Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation.	Berberine	49-58	low density lipoprotein receptor	Homo sapiens	72-76
23058107-2	2012	A series of new derivatives of berberine (BBR) or pseudoberberine (1) was synthesized and evaluated for their activity on AMP-activated protein kinase (AMPK) activation and up-regulatory low-density-lipoprotein receptor (LDLR) gene expression, respectively.	Berberine	31-40	low density lipoprotein receptor	Homo sapiens	187-219
23058107-2	2012	A series of new derivatives of berberine (BBR) or pseudoberberine (1) was synthesized and evaluated for their activity on AMP-activated protein kinase (AMPK) activation and up-regulatory low-density-lipoprotein receptor (LDLR) gene expression, respectively.	Berberine	31-40	low density lipoprotein receptor	Homo sapiens	221-225
23058107-2	2012	A series of new derivatives of berberine (BBR) or pseudoberberine (1) was synthesized and evaluated for their activity on AMP-activated protein kinase (AMPK) activation and up-regulatory low-density-lipoprotein receptor (LDLR) gene expression, respectively.	Berberine	42-45	low density lipoprotein receptor	Homo sapiens	187-219
23062825-4	2012	Berberin, palmatine and chelerythrine, chemically clustered in the so-called isoquinoline group, showed promising cholinesterase inhibitory activity and were therefore further investigated.	Berberine	0-8	butyrylcholinesterase	Homo sapiens	114-128
22955013-4	2012	Reporter gene assays were used in the mouse beta-cell line NIT-1 to test the effect of berberine on the promoter of mouse insulin gene Ins2.	Berberine	87-96	insulin II	Mus musculus	135-139
22955013-8	2012	The results revealed that berberine caused a reversible concentration-dependent inhibition of insulin gene transcription in NIT-1 cells which showed a significant difference from the long term used AMPK activator metformin.	Berberine	26-35	nitrilase 1	Mus musculus	124-129
22765939-0	2012	Interaction mechanism between berberine and the enzyme lysozyme.	Berberine	30-39	lysozyme	Homo sapiens	55-63
22765939-1	2012	In the present paper, the interaction between model protein lysozyme (Lys) and antitumorigenic berberine (BBR) was investigated by spectroscopic methods, for finding an efficient and safe photosensitizer with highly active transient products using in photodynamic therapy study.	Berberine	95-104	lysozyme	Homo sapiens	60-68
22765939-1	2012	In the present paper, the interaction between model protein lysozyme (Lys) and antitumorigenic berberine (BBR) was investigated by spectroscopic methods, for finding an efficient and safe photosensitizer with highly active transient products using in photodynamic therapy study.	Berberine	106-109	lysozyme	Homo sapiens	60-68
21963270-7	2012	The main water soluble monomeric product of berberine oxidation under physiological-near experimental conditions, OP1, was identified as demethyleneberberine cation (2,3-dihydroxy-9,10-dimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium).	Berberine	44-53	bone morphogenetic protein 7	Homo sapiens	114-117
22943182-0	2012	Berberine suppresses amyloid-beta-induced inflammatory response in microglia by inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signalling pathways.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	91-112
22943182-3	2012	In this study, we examined the effects and possible underlying mechanisms of berberine in Abeta-induced neuroinflammation using murine primary microglia cells and cultured BV2 microglia cells.	Berberine	77-86	amyloid beta (A4) precursor protein	Mus musculus	90-95
22943182-4	2012	METHODS: The effects of berberine on Abeta-stimulated inflammatory factor expression and secretion were examined using RT-PCR and ELISA analysis.	Berberine	24-33	amyloid beta (A4) precursor protein	Mus musculus	37-42
22943182-6	2012	RESULTS: In primary microglial and BV2 cells, berberine treatment significantly inhibited Abeta-stimulated production of interleukin-6 and monocyte chemotactic protein-1.	Berberine	46-55	amyloid beta (A4) precursor protein	Mus musculus	90-95
22943182-6	2012	RESULTS: In primary microglial and BV2 cells, berberine treatment significantly inhibited Abeta-stimulated production of interleukin-6 and monocyte chemotactic protein-1.	Berberine	46-55	interleukin 6	Mus musculus	121-134
22943182-6	2012	RESULTS: In primary microglial and BV2 cells, berberine treatment significantly inhibited Abeta-stimulated production of interleukin-6 and monocyte chemotactic protein-1.	Berberine	46-55	chemokine (C-C motif) ligand 2	Mus musculus	139-169
22943182-7	2012	Berberine treatment down-regulated the expression of cyclo-oxygenase-2 and induced nitric oxide synthase in these cells.	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Mus musculus	53-70
22943182-8	2012	Moreover, berberine strongly inhibited the nuclear factor-kappaB (NF-kappaB) activation, presumably through blocking the phosphoinositide 3-kinase/protein kinase B and mitogen-activated protein kinase signalling pathways.	Berberine	10-19	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	43-64
22943182-8	2012	Moreover, berberine strongly inhibited the nuclear factor-kappaB (NF-kappaB) activation, presumably through blocking the phosphoinositide 3-kinase/protein kinase B and mitogen-activated protein kinase signalling pathways.	Berberine	10-19	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	66-75
22943182-9	2012	CONCLUSIONS: Our data indicated berberine is a potent suppressor of neuroflammation, presumably through inhibition of NF-kappaB activation, and suggested berberine has therapeutic potential for the treatment of neuroinflammation that is involved in neurological diseases such as AD.	Berberine	32-41	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	118-127
22922125-0	2012	Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis.	Berberine	51-60	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	65-69
22895634-11	2012	In comparison with the control cells, the protein levels of RAD51 were decreased in the MCF-7 and MDA-MB-468 cells treated with berberine, and in the cells pre-treated with 15 microM berberine for 24 h, the level of RAD51 protein decreased significantly at the indicated time-points (0, 2, 6 and 24 h) following X-ray exposure.	Berberine	128-137	RAD51 recombinase	Homo sapiens	60-65
22895634-11	2012	In comparison with the control cells, the protein levels of RAD51 were decreased in the MCF-7 and MDA-MB-468 cells treated with berberine, and in the cells pre-treated with 15 microM berberine for 24 h, the level of RAD51 protein decreased significantly at the indicated time-points (0, 2, 6 and 24 h) following X-ray exposure.	Berberine	183-192	RAD51 recombinase	Homo sapiens	60-65
22895634-11	2012	In comparison with the control cells, the protein levels of RAD51 were decreased in the MCF-7 and MDA-MB-468 cells treated with berberine, and in the cells pre-treated with 15 microM berberine for 24 h, the level of RAD51 protein decreased significantly at the indicated time-points (0, 2, 6 and 24 h) following X-ray exposure.	Berberine	183-192	RAD51 recombinase	Homo sapiens	216-221
22895634-12	2012	In conclusion, berberine sensitizes human breast cancer cells to ionizing radiation by inducing cell cycle arrest and the downregulation of the homologous recombination repair protein, RAD51.	Berberine	15-24	RAD51 recombinase	Homo sapiens	185-190
22943849-0	2012	Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin beta1 signaling.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	57-85
22943849-0	2012	Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin beta1 signaling.	Berberine	0-9	integrin subunit beta 1	Homo sapiens	113-127
22943849-5	2012	Among the various cellular targets of berberine is AMP-activated protein kinase (AMPK), which regulates tumor progression and metastasis.	Berberine	38-47	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	51-79
22943849-5	2012	Among the various cellular targets of berberine is AMP-activated protein kinase (AMPK), which regulates tumor progression and metastasis.	Berberine	38-47	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	81-85
22943849-6	2012	However, the specific role of berberine-induced AMPK activation and its effects on the metastatic potential of colon cancer remain largely unknown.	Berberine	30-39	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	48-52
22943849-7	2012	The present study investigated berberine-induced activation of AMPK and its effects on colon cancer cell migration.	Berberine	31-40	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	63-67
22943849-9	2012	We found that berberine activated AMPK in human colon cancer cell lines.	Berberine	14-23	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	34-38
22943849-10	2012	Notably, berberine-induced activation of AMPK reduced the integrin beta1 protein levels and decreased the phosphorylation of integrin beta1 signaling targets.	Berberine	9-18	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	41-45
22943849-10	2012	Notably, berberine-induced activation of AMPK reduced the integrin beta1 protein levels and decreased the phosphorylation of integrin beta1 signaling targets.	Berberine	9-18	integrin subunit beta 1	Homo sapiens	58-72
22943849-10	2012	Notably, berberine-induced activation of AMPK reduced the integrin beta1 protein levels and decreased the phosphorylation of integrin beta1 signaling targets.	Berberine	9-18	integrin subunit beta 1	Homo sapiens	125-139
22943849-11	2012	Knockdown of AMPKalpha1 subunits using small interfering RNA significantly attenuated berberine-induced downregulation of integrin beta1 and inhibition of tumor cell migration.	Berberine	86-95	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	13-23
22943849-11	2012	Knockdown of AMPKalpha1 subunits using small interfering RNA significantly attenuated berberine-induced downregulation of integrin beta1 and inhibition of tumor cell migration.	Berberine	86-95	integrin subunit beta 1	Homo sapiens	122-136
22943849-12	2012	Collectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of colon cancer cells by decreasing integrin beta1 protein levels and downstream signaling.	Berberine	39-48	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	57-61
22943849-12	2012	Collectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of colon cancer cells by decreasing integrin beta1 protein levels and downstream signaling.	Berberine	39-48	integrin subunit beta 1	Homo sapiens	143-157
23211304-11	2012	Our preliminary findings suggest that berberine may ameliorate the development of insulin resistance by differentially preventing alterations in expression of IR, IRS-1, and glucagon in beta-cells, alpha-cells, and hepatocytes.	Berberine	38-47	insulin receptor substrate 1	Rattus norvegicus	163-168
21647174-0	2012	Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region.	Berberine	0-9	solute carrier family 6 member 4	Homo sapiens	35-56
21647174-0	2012	Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region.	Berberine	0-9	solute carrier family 6 member 4	Homo sapiens	58-63
21647174-0	2012	Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region.	Berberine	0-9	solute carrier family 6 member 4	Homo sapiens	84-89
21647174-1	2012	The aim of this study was to investigate the effect of berberine and evodiamine on serotonin transporter (5-HTT) expression and then test how allelic variations previously identified in the promoter region could modulate that effect in the serotonergic neuronal cell line RN46A.	Berberine	55-64	solute carrier family 6 member 4	Homo sapiens	83-104
21647174-2	2012	Both berberine and evodiamine, alone and in combination, increased 5-HTT mRNA and protein expression significantly across the various alleles.	Berberine	5-14	solute carrier family 6 member 4	Homo sapiens	67-72
21647174-3	2012	When tested against the S, XS(11), L(G), L(A), XL(17), and XL(18) alleles, respectively, 100 muM berberine increased 5-HTT promoter activities by 67%, 128.7%, 106.9%, 100.4%, 26.2% and 82%, 2 muM evodiamine increased 5-HTT promoter activities by 216.7%, 81.6%, 305.6%, 181.5%, 175.3% and 102.2%.	Berberine	97-106	solute carrier family 6 member 4	Homo sapiens	117-122
21647174-3	2012	When tested against the S, XS(11), L(G), L(A), XL(17), and XL(18) alleles, respectively, 100 muM berberine increased 5-HTT promoter activities by 67%, 128.7%, 106.9%, 100.4%, 26.2% and 82%, 2 muM evodiamine increased 5-HTT promoter activities by 216.7%, 81.6%, 305.6%, 181.5%, 175.3% and 102.2%.	Berberine	97-106	solute carrier family 6 member 4	Homo sapiens	217-222
21647174-4	2012	Berberine and evodiamine increased 5-HTT promoter activity differently depending on the genetic variation of the 5-HTTLPR polymorphism.	Berberine	0-9	solute carrier family 6 member 4	Homo sapiens	35-40
22840327-13	2012	Lastly, it is also reported that berberine has inhibitory effect on parathyroid hormone and enhances marker genes like osteocalcin, which are responsible for the osteoblastic activity.	Berberine	33-42	bone gamma-carboxyglutamate protein	Homo sapiens	119-130
22950834-6	2012	In conclusion, this study suggests that BBR can reduce the metastatic potential of highly metastatic breast cancer cells and may be a useful adjuvant therapeutic agent in the treatment of breast cancer by targeting the Akt pathway.	Berberine	40-43	AKT serine/threonine kinase 1	Homo sapiens	219-222
23627133-4	2012	RESULTS: Among the sixteen orthogonal design groups, the ulcer area of these groups using both beta-sitosterol and berberine was the smallest (P &lt; 0.05), the content of Leptin of these groups using both glycyrrhetic acid and ginsenoside was the highest in blood serum (P &lt; 0.05), the group using glycyrrhetic acid had the minimum concentration of ET-1 in blood plasma.	Berberine	115-124	leptin	Rattus norvegicus	172-178
23627133-5	2012	Compared with model group, berberine could raise the mRNA expression level of Leptin (P &lt; 0.01), and beta-sitosterol could lower the mRNA expression level of ET-1 (P &lt; 0.01).	Berberine	27-36	leptin	Rattus norvegicus	78-84
22950834-0	2012	Berberine, an isoquinoline alkaloid, inhibits the metastatic potential of breast cancer cells via Akt pathway modulation.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	98-101
22668974-4	2012	The present study aims to explore the effect of berberine on the expression of Na(+)/H(+) exchanger3 (NHE3) and aquaporin4 (AQP4) in both diarrhoea mouse model induced by sennosideA and human intestinal epithelium cell line (HIEC).	Berberine	48-57	aquaporin 4	Mus musculus	112-122
22982719-9	2012	Decreased HIF-1alpha, caspase 9, caspase 3 and increased Bcl-2/Bax ratio were responsible for the anti-apoptosis of berberine pretreatment.	Berberine	116-125	caspase 9	Rattus norvegicus	22-31
22982719-9	2012	Decreased HIF-1alpha, caspase 9, caspase 3 and increased Bcl-2/Bax ratio were responsible for the anti-apoptosis of berberine pretreatment.	Berberine	116-125	caspase 3	Rattus norvegicus	33-42
22982719-9	2012	Decreased HIF-1alpha, caspase 9, caspase 3 and increased Bcl-2/Bax ratio were responsible for the anti-apoptosis of berberine pretreatment.	Berberine	116-125	BCL2, apoptosis regulator	Rattus norvegicus	57-62
22982719-9	2012	Decreased HIF-1alpha, caspase 9, caspase 3 and increased Bcl-2/Bax ratio were responsible for the anti-apoptosis of berberine pretreatment.	Berberine	116-125	BCL2 associated X, apoptosis regulator	Rattus norvegicus	63-66
22982719-11	2012	Significant reduction of apoptosis, HIF-1alpha and p53 were found in cerebral tissue of MCAO rats treated with berberine.	Berberine	111-120	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	36-46
22982719-11	2012	Significant reduction of apoptosis, HIF-1alpha and p53 were found in cerebral tissue of MCAO rats treated with berberine.	Berberine	111-120	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	51-54
22668974-0	2012	Berberine increases the expression of NHE3 and AQP4 in sennosideA-induced diarrhoea model.	Berberine	0-9	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	38-42
22998978-3	2012	In addition, since PCSK9 was found up-regulated by STs dampening their effect through an LDL receptors (LDLRs) degradation, and BBR suppressed PCSK9 expression in cellular studies, we supplemented the stable lipid-lowering therapy of 30 genotype-confirmed Familial Hypercholesterolemia heterozygotes (HeFH) with BBR, searching for a further plasma cholesterol reduction.	Berberine	128-131	proprotein convertase subtilisin/kexin type 9	Homo sapiens	143-148
22668974-4	2012	The present study aims to explore the effect of berberine on the expression of Na(+)/H(+) exchanger3 (NHE3) and aquaporin4 (AQP4) in both diarrhoea mouse model induced by sennosideA and human intestinal epithelium cell line (HIEC).	Berberine	48-57	aquaporin 4	Mus musculus	124-128
22668974-0	2012	Berberine increases the expression of NHE3 and AQP4 in sennosideA-induced diarrhoea model.	Berberine	0-9	aquaporin 4	Mus musculus	47-51
22668974-4	2012	The present study aims to explore the effect of berberine on the expression of Na(+)/H(+) exchanger3 (NHE3) and aquaporin4 (AQP4) in both diarrhoea mouse model induced by sennosideA and human intestinal epithelium cell line (HIEC).	Berberine	48-57	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	79-100
22668974-7	2012	It was shown that the expression levels of NHE3 and AQP4 were significantly increased in the diarrhoea mice treated with berberine compared with the untreated diarrhoea mice.	Berberine	121-130	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	43-47
22668974-4	2012	The present study aims to explore the effect of berberine on the expression of Na(+)/H(+) exchanger3 (NHE3) and aquaporin4 (AQP4) in both diarrhoea mouse model induced by sennosideA and human intestinal epithelium cell line (HIEC).	Berberine	48-57	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	102-106
22668974-7	2012	It was shown that the expression levels of NHE3 and AQP4 were significantly increased in the diarrhoea mice treated with berberine compared with the untreated diarrhoea mice.	Berberine	121-130	aquaporin 4	Mus musculus	52-56
22668974-8	2012	Similarly, the expression levels of NHE3 and AQP4 were strikingly enhanced in HIEC co-treated with sennosideA and berberine compared with samples treated with sennosideA only.	Berberine	114-123	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	36-40
22668974-8	2012	Similarly, the expression levels of NHE3 and AQP4 were strikingly enhanced in HIEC co-treated with sennosideA and berberine compared with samples treated with sennosideA only.	Berberine	114-123	aquaporin 4	Mus musculus	45-49
22668974-11	2012	These results showed that berberine was able to increase the expression of NHE3 and AQP4, suggesting that berberine might exhibit its anti-diarrhoeal effect partially by enhancing the absorption of Na(+) and water.	Berberine	26-35	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	75-79
22668974-11	2012	These results showed that berberine was able to increase the expression of NHE3 and AQP4, suggesting that berberine might exhibit its anti-diarrhoeal effect partially by enhancing the absorption of Na(+) and water.	Berberine	26-35	aquaporin 4	Mus musculus	84-88
22668974-11	2012	These results showed that berberine was able to increase the expression of NHE3 and AQP4, suggesting that berberine might exhibit its anti-diarrhoeal effect partially by enhancing the absorption of Na(+) and water.	Berberine	106-115	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	75-79
22668974-11	2012	These results showed that berberine was able to increase the expression of NHE3 and AQP4, suggesting that berberine might exhibit its anti-diarrhoeal effect partially by enhancing the absorption of Na(+) and water.	Berberine	106-115	aquaporin 4	Mus musculus	84-88
22469516-0	2012	Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells.	Berberine	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	20-24
22884476-4	2012	The MTT colorimetric assay, alkaline phosphatase (ALP) activity, and staining tests revealed that berberine could promote hPDLC growth, increase the secretion of ALP in the culture medium, and enhance the formation of mineralized nodule, thus it is a potential osteoplastic ingredient.	Berberine	98-107	alkaline phosphatase, placental	Homo sapiens	28-48
22884476-4	2012	The MTT colorimetric assay, alkaline phosphatase (ALP) activity, and staining tests revealed that berberine could promote hPDLC growth, increase the secretion of ALP in the culture medium, and enhance the formation of mineralized nodule, thus it is a potential osteoplastic ingredient.	Berberine	98-107	alkaline phosphatase, placental	Homo sapiens	50-53
22884476-4	2012	The MTT colorimetric assay, alkaline phosphatase (ALP) activity, and staining tests revealed that berberine could promote hPDLC growth, increase the secretion of ALP in the culture medium, and enhance the formation of mineralized nodule, thus it is a potential osteoplastic ingredient.	Berberine	98-107	alkaline phosphatase, placental	Homo sapiens	162-165
22469516-0	2012	Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells.	Berberine	0-9	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	91-120
22469516-0	2012	Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	121-124
22469516-6	2012	BBR-induced anti-apoptotic function was demonstrated by increasing anti-apoptotic protein Bcl-2 and survival of motor neuron protein (SMN) and by decreasing apoptotic proteins (cytochrome c, Bax and caspase).	Berberine	0-3	B cell leukemia/lymphoma 2	Mus musculus	90-95
22469516-6	2012	BBR-induced anti-apoptotic function was demonstrated by increasing anti-apoptotic protein Bcl-2 and survival of motor neuron protein (SMN) and by decreasing apoptotic proteins (cytochrome c, Bax and caspase).	Berberine	0-3	survival motor neuron 1	Mus musculus	100-132
22469516-6	2012	BBR-induced anti-apoptotic function was demonstrated by increasing anti-apoptotic protein Bcl-2 and survival of motor neuron protein (SMN) and by decreasing apoptotic proteins (cytochrome c, Bax and caspase).	Berberine	0-3	survival motor neuron 1	Mus musculus	134-137
22469516-6	2012	BBR-induced anti-apoptotic function was demonstrated by increasing anti-apoptotic protein Bcl-2 and survival of motor neuron protein (SMN) and by decreasing apoptotic proteins (cytochrome c, Bax and caspase).	Berberine	0-3	BCL2-associated X protein	Mus musculus	191-194
22684430-5	2012	In this study, we found that wild-type plants treated with berberine produced pointed leaves, which are often observed in the single mutants that enhance phenotypes of as1 and as2 mutants.	Berberine	59-68	myb-like HTH transcriptional regulator family protein	Arabidopsis thaliana	168-171
22617025-4	2012	Berberine arrested SW480 cell cycle at G2/M phase, which was supported by induction of p21 expression.	Berberine	0-9	H3 histone pseudogene 16	Homo sapiens	87-90
22617025-6	2012	In addition, berberine also inhibited inflammation, as evidenced by induction of expression of NFkappaB and Cox(2).	Berberine	13-22	nuclear factor kappa B subunit 1	Homo sapiens	95-103
22617025-6	2012	In addition, berberine also inhibited inflammation, as evidenced by induction of expression of NFkappaB and Cox(2).	Berberine	13-22	cytochrome c oxidase subunit 8A	Homo sapiens	108-111
22617025-7	2012	Furthermore, berberine inhibited caspase-8 mediated angiogenesis, as confirmed through expression of tumor necrotic factor related apoptosis-inducing ligand (TRAIL), vascular endothelial growth factor (VEGF) and survivin.	Berberine	13-22	caspase 8	Homo sapiens	33-42
22617025-7	2012	Furthermore, berberine inhibited caspase-8 mediated angiogenesis, as confirmed through expression of tumor necrotic factor related apoptosis-inducing ligand (TRAIL), vascular endothelial growth factor (VEGF) and survivin.	Berberine	13-22	TNF superfamily member 10	Homo sapiens	101-156
22617025-7	2012	Furthermore, berberine inhibited caspase-8 mediated angiogenesis, as confirmed through expression of tumor necrotic factor related apoptosis-inducing ligand (TRAIL), vascular endothelial growth factor (VEGF) and survivin.	Berberine	13-22	TNF superfamily member 10	Homo sapiens	158-163
22617025-7	2012	Furthermore, berberine inhibited caspase-8 mediated angiogenesis, as confirmed through expression of tumor necrotic factor related apoptosis-inducing ligand (TRAIL), vascular endothelial growth factor (VEGF) and survivin.	Berberine	13-22	vascular endothelial growth factor A	Homo sapiens	166-200
22617025-7	2012	Furthermore, berberine inhibited caspase-8 mediated angiogenesis, as confirmed through expression of tumor necrotic factor related apoptosis-inducing ligand (TRAIL), vascular endothelial growth factor (VEGF) and survivin.	Berberine	13-22	vascular endothelial growth factor A	Homo sapiens	202-206
22775417-4	2012	OBJECTIVE: Impacts of berberine on regulation of GPx and SOD messenger RNAs (mRNAs), and glutathione (GSH) content were examined in diabetic mice to clarify its antioxidative stress potential.	Berberine	22-31	superoxide dismutase 1, soluble	Mus musculus	57-60
22775417-10	2012	Interestingly, berberine did not change levels of GPx, copper-zinc SOD (CuZn-SOD), and manganese SOD (Mn-SOD) mRNA in the normal mice but significantly recovered these levels in the diabetic mice to nearly the same levels as the normal.	Berberine	15-24	superoxide dismutase 2, mitochondrial	Mus musculus	102-108
22775417-12	2012	DISCUSSION AND CONCLUSION: Berberine conveyed antioxidative effect via down- and up-regulation of GPx and CuZn-SOD expression, respectively.	Berberine	27-36	superoxide dismutase 1, soluble	Mus musculus	106-114
22673230-4	2012	In the rat relaxin-1 (RLN1, Chr1) gene promoter region we found presence of repeated guanine (G)-rich sequences, which allowed formation and stabilization of G-quadruplexes with the addition of a G-quadruplex interactive ligand berberine.	Berberine	228-237	relaxin 1	Rattus norvegicus	11-20
22673230-4	2012	In the rat relaxin-1 (RLN1, Chr1) gene promoter region we found presence of repeated guanine (G)-rich sequences, which allowed formation and stabilization of G-quadruplexes with the addition of a G-quadruplex interactive ligand berberine.	Berberine	228-237	relaxin 1	Rattus norvegicus	22-26
22673230-10	2012	In cardiac fibroblasts and rats treated with angiotensin II, berberine was found to suppress fibroblast activation, collagen synthesis, and extent of cardiac fibrosis through up-regulating relaxin.	Berberine	61-70	angiotensinogen	Rattus norvegicus	45-59
22684430-9	2012	Berberine treated plants carrying double mutations of AS2 and the large subunit ribosomal protein gene RPL5B showed more severe defects in polarity than did the as2 single mutant plants.	Berberine	0-9	ribosomal protein L5 B	Arabidopsis thaliana	103-108
22684430-10	2012	We suggest that berberine inhibits (a) factor(s) that might be required for leaf adaxial cell differentiation through a pathway independent of AS1 and AS2.	Berberine	16-25	myb-like HTH transcriptional regulator family protein	Arabidopsis thaliana	143-146
22684430-5	2012	In this study, we found that wild-type plants treated with berberine produced pointed leaves, which are often observed in the single mutants that enhance phenotypes of as1 and as2 mutants.	Berberine	59-68	Lateral organ boundaries (LOB) domain family protein	Arabidopsis thaliana	176-179
22684430-10	2012	We suggest that berberine inhibits (a) factor(s) that might be required for leaf adaxial cell differentiation through a pathway independent of AS1 and AS2.	Berberine	16-25	Lateral organ boundaries (LOB) domain family protein	Arabidopsis thaliana	151-154
22684430-6	2012	The berberine-treated as1 and as2 mutants formed abaxialized filamentous leaves.	Berberine	4-13	myb-like HTH transcriptional regulator family protein	Arabidopsis thaliana	22-25
22684430-6	2012	The berberine-treated as1 and as2 mutants formed abaxialized filamentous leaves.	Berberine	4-13	Lateral organ boundaries (LOB) domain family protein	Arabidopsis thaliana	30-33
22684430-8	2012	We further showed that transcript levels of meristem-specific class 1 KNOX homeobox genes and abaxial determinant genes were increased in berberine-treated as1 and as2.	Berberine	138-147	myb-like HTH transcriptional regulator family protein	Arabidopsis thaliana	156-159
22684430-8	2012	We further showed that transcript levels of meristem-specific class 1 KNOX homeobox genes and abaxial determinant genes were increased in berberine-treated as1 and as2.	Berberine	138-147	Lateral organ boundaries (LOB) domain family protein	Arabidopsis thaliana	164-167
22684430-9	2012	Berberine treated plants carrying double mutations of AS2 and the large subunit ribosomal protein gene RPL5B showed more severe defects in polarity than did the as2 single mutant plants.	Berberine	0-9	Lateral organ boundaries (LOB) domain family protein	Arabidopsis thaliana	54-57
23058024-0	2012	Berberine reduces leukocyte adhesion to LPS-stimulated endothelial cells and VCAM-1 expression both in vivo and in vitro.	Berberine	0-9	vascular cell adhesion molecule 1	Homo sapiens	77-83
22762542-10	2012	Consistently, berberine also upregulated LDL receptor (LDLR) mRNA level and suppressed HMGR gene expression.	Berberine	14-23	low density lipoprotein receptor	Rattus norvegicus	41-53
22762542-10	2012	Consistently, berberine also upregulated LDL receptor (LDLR) mRNA level and suppressed HMGR gene expression.	Berberine	14-23	low density lipoprotein receptor	Rattus norvegicus	55-59
22762542-11	2012	Meanwhile, upon berberine-treated rats, there was a significant increase in apolipoprotein E (apoE) mRNA, but no change in apoAI and scavenger receptor (SR) mRNA in the liver.	Berberine	16-25	apolipoprotein E	Rattus norvegicus	76-92
22762542-11	2012	Meanwhile, upon berberine-treated rats, there was a significant increase in apolipoprotein E (apoE) mRNA, but no change in apoAI and scavenger receptor (SR) mRNA in the liver.	Berberine	16-25	apolipoprotein E	Rattus norvegicus	94-98
22762542-13	2012	CONCLUSION: Berberine can counteract HFD-elicited hyperhomocysteinemia and hyperlipidemia partially via upregulating LDLR and apoE mRNA levels and suppressing HMGR gene expression.	Berberine	12-21	low density lipoprotein receptor	Rattus norvegicus	117-121
22762542-13	2012	CONCLUSION: Berberine can counteract HFD-elicited hyperhomocysteinemia and hyperlipidemia partially via upregulating LDLR and apoE mRNA levels and suppressing HMGR gene expression.	Berberine	12-21	apolipoprotein E	Rattus norvegicus	126-130
22469784-0	2012	Berberine inhibits the proliferation of colon cancer cells by inactivating             Wnt/beta-catenin signaling.	Berberine	0-9	catenin beta 1	Homo sapiens	91-103
22469784-6	2012	We found that the protein levels of beta-catenin in the nucleus and cytoplasm were all reduced after treating the colon cancer cells with berberine, and this may not result from accelerating the degradation of beta-catenin in the cytoplasm, but from inhibiting the mRNA expression of beta-catenin.	Berberine	138-147	catenin beta 1	Homo sapiens	36-48
22469784-7	2012	Our results indicate that berberine can be a potential chemoprevention and chemotherapy agent for human colon cancer by targeting Wnt/beta-catenin signaling.	Berberine	26-35	catenin beta 1	Homo sapiens	134-146
23058024-5	2012	Pretreatment of LPS-stimulated rats with berberine for 1 h reduced the leukocyte-endothelium adhesion and vascular cell adhesion molecule-1 (VCAM-1) expression in lung.	Berberine	41-50	vascular cell adhesion molecule 1	Rattus norvegicus	106-139
23058024-5	2012	Pretreatment of LPS-stimulated rats with berberine for 1 h reduced the leukocyte-endothelium adhesion and vascular cell adhesion molecule-1 (VCAM-1) expression in lung.	Berberine	41-50	vascular cell adhesion molecule 1	Rattus norvegicus	141-147
23058024-6	2012	Pretreatment of LPS-stimulated vascular endothelial cells with berberine also dose-dependently decreased the number of adhered THP-1 cells and VCAM-1 expression at both RNA and protein levels.	Berberine	63-72	vascular cell adhesion molecule 1	Homo sapiens	143-149
23058024-7	2012	Berberine was further confirmed to inhibit the nuclear translocation and DNA binding activity of LPS-activated nuclear factor-kappa B (NF-kappa B).	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	135-145
22381172-0	2012	Berberine suppresses the TPA-induced MMP-1 and MMP-9 expressions through the inhibition of PKC-alpha in breast cancer cells.	Berberine	0-9	matrix metallopeptidase 1	Homo sapiens	37-42
22381172-0	2012	Berberine suppresses the TPA-induced MMP-1 and MMP-9 expressions through the inhibition of PKC-alpha in breast cancer cells.	Berberine	0-9	matrix metallopeptidase 9	Homo sapiens	47-52
22381172-0	2012	Berberine suppresses the TPA-induced MMP-1 and MMP-9 expressions through the inhibition of PKC-alpha in breast cancer cells.	Berberine	0-9	protein kinase C alpha	Homo sapiens	91-100
22381172-8	2012	RESULTS: The basal levels of both the MMP-1 and MMP-9 mRNA expressions were decreased by BBR treatment in a dose-dependent manner.	Berberine	89-92	matrix metallopeptidase 1	Homo sapiens	38-43
22381172-8	2012	RESULTS: The basal levels of both the MMP-1 and MMP-9 mRNA expressions were decreased by BBR treatment in a dose-dependent manner.	Berberine	89-92	matrix metallopeptidase 9	Homo sapiens	48-53
22381172-13	2012	CONCLUSION: The TPA-induced PKC-alpha phosphorylation is suppressed and then the MMP-1 and MMP-9 expressions are also inhibited by berberine.	Berberine	131-140	protein kinase C alpha	Homo sapiens	28-37
22381172-13	2012	CONCLUSION: The TPA-induced PKC-alpha phosphorylation is suppressed and then the MMP-1 and MMP-9 expressions are also inhibited by berberine.	Berberine	131-140	matrix metallopeptidase 1	Homo sapiens	81-86
22381172-13	2012	CONCLUSION: The TPA-induced PKC-alpha phosphorylation is suppressed and then the MMP-1 and MMP-9 expressions are also inhibited by berberine.	Berberine	131-140	matrix metallopeptidase 9	Homo sapiens	91-96
22564173-2	2012	Berberine, given orally at 40, 20, 10 mg/kg for 10 days, ameliorated all the supposed inflammatory symptoms of the induced colitis, such as body weightloss, blood hemoglobin reduction, high myeloperoxidase levels, and malondialdehyde content-inflamed mucosa.	Berberine	0-9	myeloperoxidase	Mus musculus	190-205
22483555-11	2012	The possible mechanisms for the renoprotective effects of berberine may be related to inhibition of glycosylation and improvement of antioxidation that in turn upregulate the expressions of renal nephrin and podocin.	Berberine	58-67	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	196-203
22483555-11	2012	The possible mechanisms for the renoprotective effects of berberine may be related to inhibition of glycosylation and improvement of antioxidation that in turn upregulate the expressions of renal nephrin and podocin.	Berberine	58-67	NPHS2 stomatin family member, podocin	Rattus norvegicus	208-215
22564173-5	2012	But the administration of berberine to DSS-induced colitis mice showed lower production of IFN-gamma and IL-12 and higher production of IL-4 and IL-10 than the DSS-induced colitis mice.	Berberine	26-35	interferon gamma	Mus musculus	91-100
22564173-5	2012	But the administration of berberine to DSS-induced colitis mice showed lower production of IFN-gamma and IL-12 and higher production of IL-4 and IL-10 than the DSS-induced colitis mice.	Berberine	26-35	interleukin 4	Mus musculus	136-140
22564173-5	2012	But the administration of berberine to DSS-induced colitis mice showed lower production of IFN-gamma and IL-12 and higher production of IL-4 and IL-10 than the DSS-induced colitis mice.	Berberine	26-35	interleukin 10	Mus musculus	145-150
22517511-4	2012	Compared with the cells in the control group, the expressions of 14-3-3sigma and lamin-A/C of the cells treated by berberine for 48 h increased by 94.12 and 5.24 times, respectively, and the expressions of annexin A5, cytokeratin 17, prohibitin, heat shock cognate 71 kDa protein (HSPA8), programmed cell death 6 and vimentin decreased by 4.1, 1.34, 23.8, 11.85, 4.63 and 5.24 times, respectively.	Berberine	115-124	stratifin	Homo sapiens	65-76
22561209-0	2012	Berberine, a genotoxic alkaloid, induces ATM-Chk1 mediated G2 arrest in prostate cancer cells.	Berberine	0-9	ataxia telangiectasia mutated	Mus musculus	41-44
22561209-0	2012	Berberine, a genotoxic alkaloid, induces ATM-Chk1 mediated G2 arrest in prostate cancer cells.	Berberine	0-9	checkpoint kinase 1	Mus musculus	45-49
22561209-3	2012	While it has been documented that berberine induces G1 arrest by activating the p53-p21 cascade, it remains unclear what mechanism underlies the berberine-induced G2/M arrest, which is p53-independent.	Berberine	34-43	transformation related protein 53, pseudogene	Mus musculus	80-83
22561209-3	2012	While it has been documented that berberine induces G1 arrest by activating the p53-p21 cascade, it remains unclear what mechanism underlies the berberine-induced G2/M arrest, which is p53-independent.	Berberine	34-43	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	84-87
22561209-6	2012	At low concentrations, berberine was observed to induce G1 arrest, concomitant with the activation of p53-p21 cascade.	Berberine	23-32	transformation related protein 53, pseudogene	Mus musculus	102-105
22561209-6	2012	At low concentrations, berberine was observed to induce G1 arrest, concomitant with the activation of p53-p21 cascade.	Berberine	23-32	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	106-109
22561209-8	2012	Pharmacological inhibition of ATM by KU55933, or Chk1 by UCN-01, could efficiently abrogate the G2/M arrest in berberine-treated cells.	Berberine	111-120	ataxia telangiectasia mutated	Mus musculus	30-33
22561209-8	2012	Pharmacological inhibition of ATM by KU55933, or Chk1 by UCN-01, could efficiently abrogate the G2/M arrest in berberine-treated cells.	Berberine	111-120	checkpoint kinase 1	Mus musculus	49-53
22561209-9	2012	Downregulation of Chk1 by RNA interference also abolished the G2/M arrest caused by berberine, confirming the role of Chk1 in the pathway leading to G2/M arrest.	Berberine	84-93	checkpoint kinase 1	Mus musculus	18-22
22561209-9	2012	Downregulation of Chk1 by RNA interference also abolished the G2/M arrest caused by berberine, confirming the role of Chk1 in the pathway leading to G2/M arrest.	Berberine	84-93	checkpoint kinase 1	Mus musculus	118-122
22561209-10	2012	Abrogation of G2/M arrest by ATM inhibition forced more cells to undergo apoptosis in response to berberine treatment.	Berberine	98-107	ataxia telangiectasia mutated	Mus musculus	29-32
22561209-11	2012	Chk1 inhibition by UCN-01, on the other hand, rendered cells more sensitive to berberine only when p53 was inhibited.	Berberine	79-88	checkpoint kinase 1	Mus musculus	0-4
22561209-11	2012	Chk1 inhibition by UCN-01, on the other hand, rendered cells more sensitive to berberine only when p53 was inhibited.	Berberine	79-88	transformation related protein 53, pseudogene	Mus musculus	99-102
22472046-0	2012	Inhibition of cholinesterase activity and amyloid aggregation by berberine-phenyl-benzoheterocyclic and tacrine-phenyl-benzoheterocyclic hybrids.	Berberine	65-74	butyrylcholinesterase	Homo sapiens	14-28
26434288-0	2012	Berberine, an isoquinoline alkaloid, inhibits streptozotocin-induced apoptosis in mouse pancreatic islets through down-regulating Bax/Bcl-2 gene expression ratio.	Berberine	0-9	BCL2-associated X protein	Mus musculus	130-133
26434288-0	2012	Berberine, an isoquinoline alkaloid, inhibits streptozotocin-induced apoptosis in mouse pancreatic islets through down-regulating Bax/Bcl-2 gene expression ratio.	Berberine	0-9	B cell leukemia/lymphoma 2	Mus musculus	134-139
26434288-7	2012	The results showed that berberine administration at one time or before STZ-stimulation significantly (P&lt;0.05) down-regulated the Bax/Bcl-2 genes expression ratio, compared to those in STZ-treatment alone group.	Berberine	24-33	BCL2-associated X protein	Mus musculus	132-135
26434288-7	2012	The results showed that berberine administration at one time or before STZ-stimulation significantly (P&lt;0.05) down-regulated the Bax/Bcl-2 genes expression ratio, compared to those in STZ-treatment alone group.	Berberine	24-33	B cell leukemia/lymphoma 2	Mus musculus	136-141
26434288-8	2012	Our results suggest that berberine"s anti-apoptotic effect on pancreatic primary islets is through down-regulating the Bax/Bcl-2 genes expression ratio in both concurrent and preventive manners.	Berberine	25-34	BCL2-associated X protein	Mus musculus	119-122
26434288-8	2012	Our results suggest that berberine"s anti-apoptotic effect on pancreatic primary islets is through down-regulating the Bax/Bcl-2 genes expression ratio in both concurrent and preventive manners.	Berberine	25-34	B cell leukemia/lymphoma 2	Mus musculus	123-128
22517511-4	2012	Compared with the cells in the control group, the expressions of 14-3-3sigma and lamin-A/C of the cells treated by berberine for 48 h increased by 94.12 and 5.24 times, respectively, and the expressions of annexin A5, cytokeratin 17, prohibitin, heat shock cognate 71 kDa protein (HSPA8), programmed cell death 6 and vimentin decreased by 4.1, 1.34, 23.8, 11.85, 4.63 and 5.24 times, respectively.	Berberine	115-124	lamin A/C	Homo sapiens	81-90
22517511-4	2012	Compared with the cells in the control group, the expressions of 14-3-3sigma and lamin-A/C of the cells treated by berberine for 48 h increased by 94.12 and 5.24 times, respectively, and the expressions of annexin A5, cytokeratin 17, prohibitin, heat shock cognate 71 kDa protein (HSPA8), programmed cell death 6 and vimentin decreased by 4.1, 1.34, 23.8, 11.85, 4.63 and 5.24 times, respectively.	Berberine	115-124	annexin A5	Homo sapiens	206-216
22517511-4	2012	Compared with the cells in the control group, the expressions of 14-3-3sigma and lamin-A/C of the cells treated by berberine for 48 h increased by 94.12 and 5.24 times, respectively, and the expressions of annexin A5, cytokeratin 17, prohibitin, heat shock cognate 71 kDa protein (HSPA8), programmed cell death 6 and vimentin decreased by 4.1, 1.34, 23.8, 11.85, 4.63 and 5.24 times, respectively.	Berberine	115-124	keratin 17	Homo sapiens	218-232
22517511-4	2012	Compared with the cells in the control group, the expressions of 14-3-3sigma and lamin-A/C of the cells treated by berberine for 48 h increased by 94.12 and 5.24 times, respectively, and the expressions of annexin A5, cytokeratin 17, prohibitin, heat shock cognate 71 kDa protein (HSPA8), programmed cell death 6 and vimentin decreased by 4.1, 1.34, 23.8, 11.85, 4.63 and 5.24 times, respectively.	Berberine	115-124	prohibitin 1	Homo sapiens	234-244
22517511-4	2012	Compared with the cells in the control group, the expressions of 14-3-3sigma and lamin-A/C of the cells treated by berberine for 48 h increased by 94.12 and 5.24 times, respectively, and the expressions of annexin A5, cytokeratin 17, prohibitin, heat shock cognate 71 kDa protein (HSPA8), programmed cell death 6 and vimentin decreased by 4.1, 1.34, 23.8, 11.85, 4.63 and 5.24 times, respectively.	Berberine	115-124	heat shock protein family A (Hsp70) member 8	Homo sapiens	246-279
22517511-4	2012	Compared with the cells in the control group, the expressions of 14-3-3sigma and lamin-A/C of the cells treated by berberine for 48 h increased by 94.12 and 5.24 times, respectively, and the expressions of annexin A5, cytokeratin 17, prohibitin, heat shock cognate 71 kDa protein (HSPA8), programmed cell death 6 and vimentin decreased by 4.1, 1.34, 23.8, 11.85, 4.63 and 5.24 times, respectively.	Berberine	115-124	heat shock protein family A (Hsp70) member 8	Homo sapiens	281-286
22517511-4	2012	Compared with the cells in the control group, the expressions of 14-3-3sigma and lamin-A/C of the cells treated by berberine for 48 h increased by 94.12 and 5.24 times, respectively, and the expressions of annexin A5, cytokeratin 17, prohibitin, heat shock cognate 71 kDa protein (HSPA8), programmed cell death 6 and vimentin decreased by 4.1, 1.34, 23.8, 11.85, 4.63 and 5.24 times, respectively.	Berberine	115-124	vimentin	Homo sapiens	317-325
22517511-6	2012	Furthermore, the inverse dock program (INVDOCK) was used to predict the possible drug-target of berberine"s anticancer activity, and the results showed that HSPA8 and annexin A5 might be the drug targets.	Berberine	96-105	heat shock protein family A (Hsp70) member 8	Homo sapiens	157-162
22517511-6	2012	Furthermore, the inverse dock program (INVDOCK) was used to predict the possible drug-target of berberine"s anticancer activity, and the results showed that HSPA8 and annexin A5 might be the drug targets.	Berberine	96-105	annexin A5	Homo sapiens	167-177
22615079-3	2012	Berberine also increases glucose transporter-4 (GLUT-4) and glucagon-like peptide-1 (GLP-1) levels.	Berberine	0-9	solute carrier family 2 member 4	Homo sapiens	25-46
22427564-0	2012	Effect of berberine on proinflammatory cytokine production by ARPE-19 cells following stimulation with tumor necrosis factor-alpha.	Berberine	10-19	tumor necrosis factor	Homo sapiens	103-130
22320346-0	2012	Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-kappaB pathway.	Berberine	20-29	nuclear factor kappa B subunit 1	Homo sapiens	82-91
22320346-7	2012	Berberine also induced caspase-dependent apoptosis and suppressed NF-kappaB activity by inhibiting IkappaB kinase (IKK) phosphorylation, IkappaB phosphorylation and IkappaB degradation, upstream targets of the NF-kappaB pathway, in PEL cells.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	66-75
22320346-7	2012	Berberine also induced caspase-dependent apoptosis and suppressed NF-kappaB activity by inhibiting IkappaB kinase (IKK) phosphorylation, IkappaB phosphorylation and IkappaB degradation, upstream targets of the NF-kappaB pathway, in PEL cells.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	210-219
22615079-3	2012	Berberine also increases glucose transporter-4 (GLUT-4) and glucagon-like peptide-1 (GLP-1) levels.	Berberine	0-9	solute carrier family 2 member 4	Homo sapiens	48-54
22615079-3	2012	Berberine also increases glucose transporter-4 (GLUT-4) and glucagon-like peptide-1 (GLP-1) levels.	Berberine	0-9	glucagon	Homo sapiens	60-83
22615079-3	2012	Berberine also increases glucose transporter-4 (GLUT-4) and glucagon-like peptide-1 (GLP-1) levels.	Berberine	0-9	glucagon	Homo sapiens	85-90
22615079-7	2012	In glucose-consuming tissues, such as adipose, or liver or muscle cells, berberine affects both GLUT-4 and retinol-binding protein-4 in favor of glucose uptake into cells; stimulates glycolysis by AMPK activation; and has effects on the peroxisome proliferator-activated receptor gamma molecular targets and on the phosphorylation of insulin receptor substrate-1, finally resulting in decreased insulin resistance.	Berberine	73-82	solute carrier family 2 member 4	Homo sapiens	96-102
22615079-7	2012	In glucose-consuming tissues, such as adipose, or liver or muscle cells, berberine affects both GLUT-4 and retinol-binding protein-4 in favor of glucose uptake into cells; stimulates glycolysis by AMPK activation; and has effects on the peroxisome proliferator-activated receptor gamma molecular targets and on the phosphorylation of insulin receptor substrate-1, finally resulting in decreased insulin resistance.	Berberine	73-82	retinol binding protein 4	Homo sapiens	107-132
22615079-7	2012	In glucose-consuming tissues, such as adipose, or liver or muscle cells, berberine affects both GLUT-4 and retinol-binding protein-4 in favor of glucose uptake into cells; stimulates glycolysis by AMPK activation; and has effects on the peroxisome proliferator-activated receptor gamma molecular targets and on the phosphorylation of insulin receptor substrate-1, finally resulting in decreased insulin resistance.	Berberine	73-82	peroxisome proliferator activated receptor gamma	Homo sapiens	237-285
22615079-7	2012	In glucose-consuming tissues, such as adipose, or liver or muscle cells, berberine affects both GLUT-4 and retinol-binding protein-4 in favor of glucose uptake into cells; stimulates glycolysis by AMPK activation; and has effects on the peroxisome proliferator-activated receptor gamma molecular targets and on the phosphorylation of insulin receptor substrate-1, finally resulting in decreased insulin resistance.	Berberine	73-82	insulin receptor substrate 1	Homo sapiens	334-362
22615079-7	2012	In glucose-consuming tissues, such as adipose, or liver or muscle cells, berberine affects both GLUT-4 and retinol-binding protein-4 in favor of glucose uptake into cells; stimulates glycolysis by AMPK activation; and has effects on the peroxisome proliferator-activated receptor gamma molecular targets and on the phosphorylation of insulin receptor substrate-1, finally resulting in decreased insulin resistance.	Berberine	73-82	insulin	Homo sapiens	334-341
22615079-9	2012	The antidiabetic and insulin-sensitizing effect of berberine has also been confirmed in a few relatively small, short-term clinical trials.	Berberine	51-60	insulin	Homo sapiens	21-28
22541078-6	2012	The expression of mRNA and protein of VEGFR2 decreased with the increased concentration of berberine.	Berberine	91-100	kinase insert domain receptor	Homo sapiens	38-44
22541078-8	2012	The expression of mRNA and proteins of VEGFR2 decreased after treatment with berberine.	Berberine	77-86	kinase insert domain receptor	Homo sapiens	39-45
22369941-0	2012	Interaction of Berberine derivative with protein POT1 affect telomere function in cancer cells.	Berberine	15-24	protection of telomeres 1	Homo sapiens	49-53
22342832-4	2012	In primary mouse hepatocytes, berberine suppressed the induction of Cyp1a1, Cyp1a2, Cyp2e1, Cyp3a11, Cyp4a10, and Cyp4a14 mRNA expression by their prototypical inducers in a concentration-dependent fashion.	Berberine	30-39	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	68-74
22173918-8	2012	Berberine ameliorated DSS-induced body weight loss, myeloperoxidase activity, shortening of the colon, injury, and inflammation scores.	Berberine	0-9	myeloperoxidase	Mus musculus	52-67
22173918-9	2012	DSS-upregulated proinflammatory cytokine levels in the colon, including TNF, IFN-gamma, KC, and IL-17 were reduced by berberine.	Berberine	118-127	tumor necrosis factor	Mus musculus	72-75
22173918-9	2012	DSS-upregulated proinflammatory cytokine levels in the colon, including TNF, IFN-gamma, KC, and IL-17 were reduced by berberine.	Berberine	118-127	interferon gamma	Mus musculus	77-86
22173918-9	2012	DSS-upregulated proinflammatory cytokine levels in the colon, including TNF, IFN-gamma, KC, and IL-17 were reduced by berberine.	Berberine	118-127	interleukin 17A	Mus musculus	96-101
22173918-12	2012	Activation of signaling pathways involved in stimulation of proinflammatory cytokine production, including MAPK and NF-kappaB, in colonic macrophages and epithelial cells from DSS-treated mice was decreased by berberine.	Berberine	210-219	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-125
22342832-4	2012	In primary mouse hepatocytes, berberine suppressed the induction of Cyp1a1, Cyp1a2, Cyp2e1, Cyp3a11, Cyp4a10, and Cyp4a14 mRNA expression by their prototypical inducers in a concentration-dependent fashion.	Berberine	30-39	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	76-82
22342832-4	2012	In primary mouse hepatocytes, berberine suppressed the induction of Cyp1a1, Cyp1a2, Cyp2e1, Cyp3a11, Cyp4a10, and Cyp4a14 mRNA expression by their prototypical inducers in a concentration-dependent fashion.	Berberine	30-39	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	84-90
22342832-4	2012	In primary mouse hepatocytes, berberine suppressed the induction of Cyp1a1, Cyp1a2, Cyp2e1, Cyp3a11, Cyp4a10, and Cyp4a14 mRNA expression by their prototypical inducers in a concentration-dependent fashion.	Berberine	30-39	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	92-99
22342832-4	2012	In primary mouse hepatocytes, berberine suppressed the induction of Cyp1a1, Cyp1a2, Cyp2e1, Cyp3a11, Cyp4a10, and Cyp4a14 mRNA expression by their prototypical inducers in a concentration-dependent fashion.	Berberine	30-39	cytochrome P450, family 4, subfamily a, polypeptide 10	Mus musculus	101-108
22342832-4	2012	In primary mouse hepatocytes, berberine suppressed the induction of Cyp1a1, Cyp1a2, Cyp2e1, Cyp3a11, Cyp4a10, and Cyp4a14 mRNA expression by their prototypical inducers in a concentration-dependent fashion.	Berberine	30-39	cytochrome P450, family 4, subfamily a, polypeptide 14	Mus musculus	114-121
22342832-5	2012	However, berberine treatment alone increased the expression of Cyp2b9 and Cyp2b10 mRNA.	Berberine	9-18	cytochrome P450, family 2, subfamily b, polypeptide 9	Mus musculus	63-69
22342832-5	2012	However, berberine treatment alone increased the expression of Cyp2b9 and Cyp2b10 mRNA.	Berberine	9-18	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	74-81
22342832-8	2012	Interestingly, berberine itself suppressed the expression of Cyp2e1, an adverse hepatic event-associated enzyme, while the expression of Cyp3a11, Cyp4a10, and Cyp4a14 were restored to normal levels by berberine.	Berberine	15-24	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	61-67
22342832-8	2012	Interestingly, berberine itself suppressed the expression of Cyp2e1, an adverse hepatic event-associated enzyme, while the expression of Cyp3a11, Cyp4a10, and Cyp4a14 were restored to normal levels by berberine.	Berberine	201-210	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	137-144
22342832-8	2012	Interestingly, berberine itself suppressed the expression of Cyp2e1, an adverse hepatic event-associated enzyme, while the expression of Cyp3a11, Cyp4a10, and Cyp4a14 were restored to normal levels by berberine.	Berberine	201-210	cytochrome P450, family 4, subfamily a, polypeptide 10	Mus musculus	146-153
22342832-8	2012	Interestingly, berberine itself suppressed the expression of Cyp2e1, an adverse hepatic event-associated enzyme, while the expression of Cyp3a11, Cyp4a10, and Cyp4a14 were restored to normal levels by berberine.	Berberine	201-210	cytochrome P450, family 4, subfamily a, polypeptide 14	Mus musculus	159-166
22342832-10	2012	Consumption of berberine as an anti-hyperglycemic compound by diabetic patients might provide an extra benefit due to its potential to restore the expression of Cyp2e1, Cyp3a, and Cyp4a to normal levels.	Berberine	15-24	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	161-167
22342832-10	2012	Consumption of berberine as an anti-hyperglycemic compound by diabetic patients might provide an extra benefit due to its potential to restore the expression of Cyp2e1, Cyp3a, and Cyp4a to normal levels.	Berberine	15-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	169-174
22027215-5	2012	Taken together, these data reveal an important role for SIRT1 and mitochondrial biogenesis in the preventive effects of BBR on diet-induced insulin resistance.	Berberine	120-123	insulin	Homo sapiens	140-147
22027215-0	2012	Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis.	Berberine	0-9	sirtuin 1	Homo sapiens	96-101
22318822-0	2012	Berberine inhibited the growth of thyroid cancer cell lines 8505C and TPC1.	Berberine	0-9	two pore segment channel 1	Homo sapiens	70-74
22318822-7	2012	Immunobloting of p-27 expression following berberine treatment showed that berberine induced a little up-regulation of p-27 in 8505c cells but relatively high up-regulation of p-27 in TPC1 cells.	Berberine	75-84	zinc ribbon domain containing 2	Homo sapiens	17-21
22318822-7	2012	Immunobloting of p-27 expression following berberine treatment showed that berberine induced a little up-regulation of p-27 in 8505c cells but relatively high up-regulation of p-27 in TPC1 cells.	Berberine	75-84	zinc ribbon domain containing 2	Homo sapiens	119-123
22318822-7	2012	Immunobloting of p-27 expression following berberine treatment showed that berberine induced a little up-regulation of p-27 in 8505c cells but relatively high up-regulation of p-27 in TPC1 cells.	Berberine	75-84	zinc ribbon domain containing 2	Homo sapiens	119-123
22318822-7	2012	Immunobloting of p-27 expression following berberine treatment showed that berberine induced a little up-regulation of p-27 in 8505c cells but relatively high up-regulation of p-27 in TPC1 cells.	Berberine	75-84	two pore segment channel 1	Homo sapiens	184-188
22027215-1	2012	Berberine (BBR) has recently been shown to improve insulin sensitivity in rodent models of insulin resistance.	Berberine	0-9	insulin	Homo sapiens	51-58
22027215-1	2012	Berberine (BBR) has recently been shown to improve insulin sensitivity in rodent models of insulin resistance.	Berberine	0-9	insulin	Homo sapiens	91-98
22052603-6	2012	Mice treated with berberine showed reduced matrix metalloproteinase-9 (MMP-9) activity.	Berberine	18-27	matrix metallopeptidase 9	Mus musculus	43-69
22027215-1	2012	Berberine (BBR) has recently been shown to improve insulin sensitivity in rodent models of insulin resistance.	Berberine	11-14	insulin	Homo sapiens	51-58
22027215-1	2012	Berberine (BBR) has recently been shown to improve insulin sensitivity in rodent models of insulin resistance.	Berberine	11-14	insulin	Homo sapiens	91-98
22027215-4	2012	Furthermore, we observe that the prevention of mitochondrial dysfunction by BBR, the increase in mitochondrial biogenesis, as well as BBR-induced AMPK activation, are blocked in cells in which SIRT1 has been knocked-down.	Berberine	76-79	sirtuin 1	Homo sapiens	193-198
22027215-4	2012	Furthermore, we observe that the prevention of mitochondrial dysfunction by BBR, the increase in mitochondrial biogenesis, as well as BBR-induced AMPK activation, are blocked in cells in which SIRT1 has been knocked-down.	Berberine	134-137	sirtuin 1	Homo sapiens	193-198
22027215-5	2012	Taken together, these data reveal an important role for SIRT1 and mitochondrial biogenesis in the preventive effects of BBR on diet-induced insulin resistance.	Berberine	120-123	sirtuin 1	Homo sapiens	56-61
22120676-0	2012	Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	18-22
22120676-0	2012	Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	103-106
22120676-0	2012	Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression.	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	120-125
22120676-5	2012	Berberine strongly increased AMPK phosphorylation via reactive oxygen species (ROS) production.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	29-33
22120676-8	2012	Furthermore, berberine inhibited the metastatic potential of melanoma cells through a decrease in ERK activity and protein levels of cyclooxygenase-2 (COX-2) by a berberine-induced AMPK activation.	Berberine	13-22	mitogen-activated protein kinase 1	Homo sapiens	98-101
22120676-8	2012	Furthermore, berberine inhibited the metastatic potential of melanoma cells through a decrease in ERK activity and protein levels of cyclooxygenase-2 (COX-2) by a berberine-induced AMPK activation.	Berberine	13-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	133-149
22120676-8	2012	Furthermore, berberine inhibited the metastatic potential of melanoma cells through a decrease in ERK activity and protein levels of cyclooxygenase-2 (COX-2) by a berberine-induced AMPK activation.	Berberine	13-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	151-156
22120676-8	2012	Furthermore, berberine inhibited the metastatic potential of melanoma cells through a decrease in ERK activity and protein levels of cyclooxygenase-2 (COX-2) by a berberine-induced AMPK activation.	Berberine	13-22	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	181-185
22120676-8	2012	Furthermore, berberine inhibited the metastatic potential of melanoma cells through a decrease in ERK activity and protein levels of cyclooxygenase-2 (COX-2) by a berberine-induced AMPK activation.	Berberine	163-172	mitogen-activated protein kinase 1	Homo sapiens	98-101
22120676-8	2012	Furthermore, berberine inhibited the metastatic potential of melanoma cells through a decrease in ERK activity and protein levels of cyclooxygenase-2 (COX-2) by a berberine-induced AMPK activation.	Berberine	163-172	prostaglandin-endoperoxide synthase 2	Homo sapiens	133-149
22120676-8	2012	Furthermore, berberine inhibited the metastatic potential of melanoma cells through a decrease in ERK activity and protein levels of cyclooxygenase-2 (COX-2) by a berberine-induced AMPK activation.	Berberine	163-172	prostaglandin-endoperoxide synthase 2	Homo sapiens	151-156
22120676-8	2012	Furthermore, berberine inhibited the metastatic potential of melanoma cells through a decrease in ERK activity and protein levels of cyclooxygenase-2 (COX-2) by a berberine-induced AMPK activation.	Berberine	163-172	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	181-185
22120676-12	2012	Collectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of tumor cells through a reduction in the activity of the ERK signaling pathway and COX-2 protein levels.	Berberine	39-48	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	57-61
22120676-12	2012	Collectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of tumor cells through a reduction in the activity of the ERK signaling pathway and COX-2 protein levels.	Berberine	39-48	mitogen-activated protein kinase 1	Homo sapiens	165-168
22120676-12	2012	Collectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of tumor cells through a reduction in the activity of the ERK signaling pathway and COX-2 protein levels.	Berberine	39-48	prostaglandin-endoperoxide synthase 2	Homo sapiens	191-196
22052603-6	2012	Mice treated with berberine showed reduced matrix metalloproteinase-9 (MMP-9) activity.	Berberine	18-27	matrix metallopeptidase 9	Mus musculus	71-76
22052603-10	2012	These data demonstrate that berberine, a plant alkaloid, may protect from hippocampal neuronal damage following transient global ischemia by reducing MMP-9 activity.	Berberine	28-37	matrix metallopeptidase 9	Mus musculus	150-155
21678521-0	2012	The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine.	Berberine	96-105	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	33-39
21678521-0	2012	The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine.	Berberine	96-105	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	41-47
21678521-0	2012	The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine.	Berberine	96-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-58
21678521-1	2012	The purpose of this study was to investigate the in vitro inhibition potential of the three purified herbal constituents tetrahydropalmatine (Tet), neferine (Nef) and berberine (Ber) towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	167-176	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	209-215
21678521-1	2012	The purpose of this study was to investigate the in vitro inhibition potential of the three purified herbal constituents tetrahydropalmatine (Tet), neferine (Nef) and berberine (Ber) towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	167-176	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	217-223
21678521-1	2012	The purpose of this study was to investigate the in vitro inhibition potential of the three purified herbal constituents tetrahydropalmatine (Tet), neferine (Nef) and berberine (Ber) towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	167-176	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	228-234
21678521-1	2012	The purpose of this study was to investigate the in vitro inhibition potential of the three purified herbal constituents tetrahydropalmatine (Tet), neferine (Nef) and berberine (Ber) towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	178-181	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	209-215
21678521-1	2012	The purpose of this study was to investigate the in vitro inhibition potential of the three purified herbal constituents tetrahydropalmatine (Tet), neferine (Nef) and berberine (Ber) towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	178-181	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	217-223
21678521-1	2012	The purpose of this study was to investigate the in vitro inhibition potential of the three purified herbal constituents tetrahydropalmatine (Tet), neferine (Nef) and berberine (Ber) towards recombinant human CYP1A2, CYP2D6 and CYP3A4 metabolic activities.	Berberine	178-181	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	228-234
22512037-1	2012	The aim of the study is to investigate the effects of concentration, intestinal segments, pH, inhibitors of proteins (P-gp), Na(+)-dependent glucose transporter (SGLT1) on the intestinal absorption of berberine, and to compare intestinal absorption of berberine in combinations.	Berberine	201-210	phosphoglycolate phosphatase	Rattus norvegicus	118-122
22081376-0	2012	COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line.	Berberine	48-57	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5
22081376-2	2012	It has been illustrated that the antiinflammatory effect is mediated by suppressing the nuclear factor-kappa B (NF-kappaB) that activates expression of some antiinflammatory and antiapoptotic proteins including cyclooxygenase-2(COX-2), inducible nitric oxide synthase (iNOS) and survivin; therefore, berberine may induce apoptosis by reducing antiinflammatory and antiapoptotic agents, which suggest the relationship between antiinflammatory and apoptosis pathways.	Berberine	300-309	nuclear factor kappa B subunit 1	Homo sapiens	88-110
22081376-2	2012	It has been illustrated that the antiinflammatory effect is mediated by suppressing the nuclear factor-kappa B (NF-kappaB) that activates expression of some antiinflammatory and antiapoptotic proteins including cyclooxygenase-2(COX-2), inducible nitric oxide synthase (iNOS) and survivin; therefore, berberine may induce apoptosis by reducing antiinflammatory and antiapoptotic agents, which suggest the relationship between antiinflammatory and apoptosis pathways.	Berberine	300-309	nuclear factor kappa B subunit 1	Homo sapiens	112-121
22512037-1	2012	The aim of the study is to investigate the effects of concentration, intestinal segments, pH, inhibitors of proteins (P-gp), Na(+)-dependent glucose transporter (SGLT1) on the intestinal absorption of berberine, and to compare intestinal absorption of berberine in combinations.	Berberine	201-210	solute carrier family 5 member 1	Rattus norvegicus	162-167
22081376-2	2012	It has been illustrated that the antiinflammatory effect is mediated by suppressing the nuclear factor-kappa B (NF-kappaB) that activates expression of some antiinflammatory and antiapoptotic proteins including cyclooxygenase-2(COX-2), inducible nitric oxide synthase (iNOS) and survivin; therefore, berberine may induce apoptosis by reducing antiinflammatory and antiapoptotic agents, which suggest the relationship between antiinflammatory and apoptosis pathways.	Berberine	300-309	prostaglandin-endoperoxide synthase 2	Homo sapiens	211-227
22081376-2	2012	It has been illustrated that the antiinflammatory effect is mediated by suppressing the nuclear factor-kappa B (NF-kappaB) that activates expression of some antiinflammatory and antiapoptotic proteins including cyclooxygenase-2(COX-2), inducible nitric oxide synthase (iNOS) and survivin; therefore, berberine may induce apoptosis by reducing antiinflammatory and antiapoptotic agents, which suggest the relationship between antiinflammatory and apoptosis pathways.	Berberine	300-309	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	228-233
22512037-4	2012	It was also suggested that SGLT1 and P-gp might exert some effects on the absorption of berberine.	Berberine	88-97	solute carrier family 5 member 1	Rattus norvegicus	27-32
22081376-2	2012	It has been illustrated that the antiinflammatory effect is mediated by suppressing the nuclear factor-kappa B (NF-kappaB) that activates expression of some antiinflammatory and antiapoptotic proteins including cyclooxygenase-2(COX-2), inducible nitric oxide synthase (iNOS) and survivin; therefore, berberine may induce apoptosis by reducing antiinflammatory and antiapoptotic agents, which suggest the relationship between antiinflammatory and apoptosis pathways.	Berberine	300-309	nitric oxide synthase 2	Homo sapiens	236-267
22081376-2	2012	It has been illustrated that the antiinflammatory effect is mediated by suppressing the nuclear factor-kappa B (NF-kappaB) that activates expression of some antiinflammatory and antiapoptotic proteins including cyclooxygenase-2(COX-2), inducible nitric oxide synthase (iNOS) and survivin; therefore, berberine may induce apoptosis by reducing antiinflammatory and antiapoptotic agents, which suggest the relationship between antiinflammatory and apoptosis pathways.	Berberine	300-309	nitric oxide synthase 2	Homo sapiens	269-273
22081376-5	2012	The level of COX-2, iNOS and survivin proteins decreased in berberine-treated cells; however, treatment of the cells with aspirin and aminoguanidine (AG), COX-2 and iNOS inhibitors, respectively, showed that despite the cell growth-reducing effect of aspirin, AG did not have a significant effect on cell viability.	Berberine	60-69	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	13-18
22081376-5	2012	The level of COX-2, iNOS and survivin proteins decreased in berberine-treated cells; however, treatment of the cells with aspirin and aminoguanidine (AG), COX-2 and iNOS inhibitors, respectively, showed that despite the cell growth-reducing effect of aspirin, AG did not have a significant effect on cell viability.	Berberine	60-69	nitric oxide synthase 2	Homo sapiens	20-24
22081376-5	2012	The level of COX-2, iNOS and survivin proteins decreased in berberine-treated cells; however, treatment of the cells with aspirin and aminoguanidine (AG), COX-2 and iNOS inhibitors, respectively, showed that despite the cell growth-reducing effect of aspirin, AG did not have a significant effect on cell viability.	Berberine	60-69	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	155-160
22512037-4	2012	It was also suggested that SGLT1 and P-gp might exert some effects on the absorption of berberine.	Berberine	88-97	phosphoglycolate phosphatase	Rattus norvegicus	37-41
22081376-5	2012	The level of COX-2, iNOS and survivin proteins decreased in berberine-treated cells; however, treatment of the cells with aspirin and aminoguanidine (AG), COX-2 and iNOS inhibitors, respectively, showed that despite the cell growth-reducing effect of aspirin, AG did not have a significant effect on cell viability.	Berberine	60-69	nitric oxide synthase 2	Homo sapiens	165-169
22081376-6	2012	On the other hand, with the attention to reduction in survivin protein level in berberine-treated cells, the results suggest that the apoptotic effect of berberine may be mediated by reduction in both of the COX-2 and survivin in T47D cell line, while the iNOS does not play any effective role in berberine-induced apoptosis.	Berberine	80-89	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	208-213
22226148-3	2012	Therefore, we verify that if an application of CPU86017-RS (simplified as RS, a derivative to berberine) could alleviate the ER stress and depressed gene expressions of StAR and 3-beta-HSD, and low plasma testosterone in hypoxic rats, these were compared with those of nifedipine.	Berberine	94-103	steroidogenic acute regulatory protein	Rattus norvegicus	169-173
22081376-6	2012	On the other hand, with the attention to reduction in survivin protein level in berberine-treated cells, the results suggest that the apoptotic effect of berberine may be mediated by reduction in both of the COX-2 and survivin in T47D cell line, while the iNOS does not play any effective role in berberine-induced apoptosis.	Berberine	80-89	nitric oxide synthase 2	Homo sapiens	256-260
22081376-6	2012	On the other hand, with the attention to reduction in survivin protein level in berberine-treated cells, the results suggest that the apoptotic effect of berberine may be mediated by reduction in both of the COX-2 and survivin in T47D cell line, while the iNOS does not play any effective role in berberine-induced apoptosis.	Berberine	154-163	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	208-213
22081376-6	2012	On the other hand, with the attention to reduction in survivin protein level in berberine-treated cells, the results suggest that the apoptotic effect of berberine may be mediated by reduction in both of the COX-2 and survivin in T47D cell line, while the iNOS does not play any effective role in berberine-induced apoptosis.	Berberine	154-163	nitric oxide synthase 2	Homo sapiens	256-260
22081376-6	2012	On the other hand, with the attention to reduction in survivin protein level in berberine-treated cells, the results suggest that the apoptotic effect of berberine may be mediated by reduction in both of the COX-2 and survivin in T47D cell line, while the iNOS does not play any effective role in berberine-induced apoptosis.	Berberine	154-163	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	208-213
22081376-6	2012	On the other hand, with the attention to reduction in survivin protein level in berberine-treated cells, the results suggest that the apoptotic effect of berberine may be mediated by reduction in both of the COX-2 and survivin in T47D cell line, while the iNOS does not play any effective role in berberine-induced apoptosis.	Berberine	154-163	nitric oxide synthase 2	Homo sapiens	256-260
22119079-2	2012	In the present study, we examined the influence of the PI3K/Akt pathway in mediating the anti-apoptotic effects of berberine.	Berberine	115-124	AKT serine/threonine kinase 1	Rattus norvegicus	60-63
22119079-4	2012	We found that the anti-apoptotic effects of berberine against ischemia were indeed mediated by the increased phosphor-activation of Akt (higher p-Akt to total Akt), leading to the intensified phosphorylation of Bad and the decreased cleavage of the pro-apoptotic protease caspase-3.	Berberine	44-53	AKT serine/threonine kinase 1	Rattus norvegicus	132-135
22119079-4	2012	We found that the anti-apoptotic effects of berberine against ischemia were indeed mediated by the increased phosphor-activation of Akt (higher p-Akt to total Akt), leading to the intensified phosphorylation of Bad and the decreased cleavage of the pro-apoptotic protease caspase-3.	Berberine	44-53	AKT serine/threonine kinase 1	Rattus norvegicus	146-149
22119079-4	2012	We found that the anti-apoptotic effects of berberine against ischemia were indeed mediated by the increased phosphor-activation of Akt (higher p-Akt to total Akt), leading to the intensified phosphorylation of Bad and the decreased cleavage of the pro-apoptotic protease caspase-3.	Berberine	44-53	AKT serine/threonine kinase 1	Rattus norvegicus	146-149
22119079-4	2012	We found that the anti-apoptotic effects of berberine against ischemia were indeed mediated by the increased phosphor-activation of Akt (higher p-Akt to total Akt), leading to the intensified phosphorylation of Bad and the decreased cleavage of the pro-apoptotic protease caspase-3.	Berberine	44-53	caspase 3	Rattus norvegicus	272-281
22119079-6	2012	The anti-apoptotic effect is maintained in the presence of tyrosine kinase inhibitor genistein and the epidermal growth factor receptor inhibitor PD153035, but is suppressed by the PI3K inhibitor Ly294002 and the Akt inhibitor Akti-1/2.The unique PI3K regulatory subunit p55gamma was upregulated by berberine during ischemia-reperfusion and was not blocked by these inhibitors.	Berberine	299-308	AKT serine/threonine kinase 1	Rattus norvegicus	213-216
22145808-10	2012	Drastically elevated expressions of HIF and VEGF mRNA by tumor cells under hypoxic conditions were also decreased after treatment with berberine.	Berberine	135-144	vascular endothelial growth factor A	Mus musculus	44-48
22140092-0	2012	Suppression of oxLDL-induced MMP-9 and EMMPRIN expression by berberine via inhibition of NF-kappaB activation in human THP-1 macrophages.	Berberine	61-70	basigin (Ok blood group)	Homo sapiens	39-46
22140092-0	2012	Suppression of oxLDL-induced MMP-9 and EMMPRIN expression by berberine via inhibition of NF-kappaB activation in human THP-1 macrophages.	Berberine	61-70	nuclear factor kappa B subunit 1	Homo sapiens	89-98
22140092-0	2012	Suppression of oxLDL-induced MMP-9 and EMMPRIN expression by berberine via inhibition of NF-kappaB activation in human THP-1 macrophages.	Berberine	61-70	GLI family zinc finger 2	Homo sapiens	119-124
22140092-3	2012	In the present study, the function of berberine, a natural extract from Rhizoma coptidis, on MMP-9 and EMMPRIN expression, the role of NF-kappaB activation in oxLDL-stimulated macrophages, and the possible mechanism in which NF-kappaB activation is involved were investigated.	Berberine	38-47	matrix metallopeptidase 9	Homo sapiens	93-98
22140092-3	2012	In the present study, the function of berberine, a natural extract from Rhizoma coptidis, on MMP-9 and EMMPRIN expression, the role of NF-kappaB activation in oxLDL-stimulated macrophages, and the possible mechanism in which NF-kappaB activation is involved were investigated.	Berberine	38-47	basigin (Ok blood group)	Homo sapiens	103-110
22140092-3	2012	In the present study, the function of berberine, a natural extract from Rhizoma coptidis, on MMP-9 and EMMPRIN expression, the role of NF-kappaB activation in oxLDL-stimulated macrophages, and the possible mechanism in which NF-kappaB activation is involved were investigated.	Berberine	38-47	nuclear factor kappa B subunit 1	Homo sapiens	225-234
22140092-4	2012	Berberine inhibited the expression of MMP-9 and EMMPRIN at both mRNA and protein levels.	Berberine	0-9	matrix metallopeptidase 9	Homo sapiens	38-43
22140092-4	2012	Berberine inhibited the expression of MMP-9 and EMMPRIN at both mRNA and protein levels.	Berberine	0-9	basigin (Ok blood group)	Homo sapiens	48-55
22140092-5	2012	The phosphorylation of IkappaB-alpha and nuclear translocation of p65 protein were reduced by berberine, suggesting that NF-kappaB activation was inhibited by berberine in oxLDL-stimulated macrophages.	Berberine	94-103	NFKB inhibitor alpha	Homo sapiens	23-36
22140092-5	2012	The phosphorylation of IkappaB-alpha and nuclear translocation of p65 protein were reduced by berberine, suggesting that NF-kappaB activation was inhibited by berberine in oxLDL-stimulated macrophages.	Berberine	94-103	RELA proto-oncogene, NF-kB subunit	Homo sapiens	66-69
22140092-5	2012	The phosphorylation of IkappaB-alpha and nuclear translocation of p65 protein were reduced by berberine, suggesting that NF-kappaB activation was inhibited by berberine in oxLDL-stimulated macrophages.	Berberine	94-103	nuclear factor kappa B subunit 1	Homo sapiens	121-130
22140092-5	2012	The phosphorylation of IkappaB-alpha and nuclear translocation of p65 protein were reduced by berberine, suggesting that NF-kappaB activation was inhibited by berberine in oxLDL-stimulated macrophages.	Berberine	159-168	NFKB inhibitor alpha	Homo sapiens	23-36
22140092-5	2012	The phosphorylation of IkappaB-alpha and nuclear translocation of p65 protein were reduced by berberine, suggesting that NF-kappaB activation was inhibited by berberine in oxLDL-stimulated macrophages.	Berberine	159-168	RELA proto-oncogene, NF-kB subunit	Homo sapiens	66-69
22140092-5	2012	The phosphorylation of IkappaB-alpha and nuclear translocation of p65 protein were reduced by berberine, suggesting that NF-kappaB activation was inhibited by berberine in oxLDL-stimulated macrophages.	Berberine	159-168	nuclear factor kappa B subunit 1	Homo sapiens	121-130
22140092-6	2012	Overall, berberine suppressed the expression of MMP-9 and EMMPRIN by at least reducing partly the activity of NF-kappaB in oxLDL-induced macrophages.	Berberine	9-18	matrix metallopeptidase 9	Homo sapiens	48-53
22140092-6	2012	Overall, berberine suppressed the expression of MMP-9 and EMMPRIN by at least reducing partly the activity of NF-kappaB in oxLDL-induced macrophages.	Berberine	9-18	basigin (Ok blood group)	Homo sapiens	58-65
22140092-6	2012	Overall, berberine suppressed the expression of MMP-9 and EMMPRIN by at least reducing partly the activity of NF-kappaB in oxLDL-induced macrophages.	Berberine	9-18	nuclear factor kappa B subunit 1	Homo sapiens	110-119
22145808-0	2012	Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators.	Berberine	27-36	vascular endothelial growth factor A	Mus musculus	107-111
22145808-5	2012	Berberine, at 10 mg/kg body weight, showed significant inhibition in tumor-directed capillary formation and in various proangiogenic factors, such as vascular endothelial growth factor (VEGF), and proinflammatory mediators, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor (GM-CSF), which are involved in tumor angiogenesis.	Berberine	0-9	vascular endothelial growth factor A	Mus musculus	150-184
22145808-5	2012	Berberine, at 10 mg/kg body weight, showed significant inhibition in tumor-directed capillary formation and in various proangiogenic factors, such as vascular endothelial growth factor (VEGF), and proinflammatory mediators, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor (GM-CSF), which are involved in tumor angiogenesis.	Berberine	0-9	vascular endothelial growth factor A	Mus musculus	186-190
22145808-5	2012	Berberine, at 10 mg/kg body weight, showed significant inhibition in tumor-directed capillary formation and in various proangiogenic factors, such as vascular endothelial growth factor (VEGF), and proinflammatory mediators, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor (GM-CSF), which are involved in tumor angiogenesis.	Berberine	0-9	interleukin 6	Mus musculus	256-260
22145808-5	2012	Berberine, at 10 mg/kg body weight, showed significant inhibition in tumor-directed capillary formation and in various proangiogenic factors, such as vascular endothelial growth factor (VEGF), and proinflammatory mediators, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor (GM-CSF), which are involved in tumor angiogenesis.	Berberine	0-9	tumor necrosis factor	Mus musculus	262-289
22145808-5	2012	Berberine, at 10 mg/kg body weight, showed significant inhibition in tumor-directed capillary formation and in various proangiogenic factors, such as vascular endothelial growth factor (VEGF), and proinflammatory mediators, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor (GM-CSF), which are involved in tumor angiogenesis.	Berberine	0-9	tumor necrosis factor	Mus musculus	291-300
22145808-5	2012	Berberine, at 10 mg/kg body weight, showed significant inhibition in tumor-directed capillary formation and in various proangiogenic factors, such as vascular endothelial growth factor (VEGF), and proinflammatory mediators, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor (GM-CSF), which are involved in tumor angiogenesis.	Berberine	0-9	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	307-355
22145808-5	2012	Berberine, at 10 mg/kg body weight, showed significant inhibition in tumor-directed capillary formation and in various proangiogenic factors, such as vascular endothelial growth factor (VEGF), and proinflammatory mediators, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor (GM-CSF), which are involved in tumor angiogenesis.	Berberine	0-9	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	357-363
22145808-8	2012	Further, berberine inhibited various transcription factors involved in tumor development and angiogenesis, such as NF-kB, c-Fos, CREB, and ATF-2.	Berberine	9-18	FBJ osteosarcoma oncogene	Mus musculus	122-127
22145808-8	2012	Further, berberine inhibited various transcription factors involved in tumor development and angiogenesis, such as NF-kB, c-Fos, CREB, and ATF-2.	Berberine	9-18	cAMP responsive element binding protein 1	Mus musculus	129-133
22145808-8	2012	Further, berberine inhibited various transcription factors involved in tumor development and angiogenesis, such as NF-kB, c-Fos, CREB, and ATF-2.	Berberine	9-18	activating transcription factor 2	Mus musculus	139-144
22145808-11	2012	This result clearly demonstrates that the antiangiogenic activity of berberine is mainly mediated through the inhibition of various proinflammatory and pro-angiogenic factors and the major ones are HIF, VEGF, COX-2, NO, NF-kB, and proinflammatory cytokines.	Berberine	69-78	vascular endothelial growth factor A	Mus musculus	203-207
22145808-9	2012	mRNA expression levels of proangiogenic factors, such as cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and hypoxia-inducible factor (HIF), were also downregulated in tumor cells after treatment with berberine.	Berberine	219-228	prostaglandin-endoperoxide synthase 2	Mus musculus	57-73
22145808-11	2012	This result clearly demonstrates that the antiangiogenic activity of berberine is mainly mediated through the inhibition of various proinflammatory and pro-angiogenic factors and the major ones are HIF, VEGF, COX-2, NO, NF-kB, and proinflammatory cytokines.	Berberine	69-78	prostaglandin-endoperoxide synthase 2	Mus musculus	209-214
23133498-12	2012	Our results suggest that the expression of P-glycoprotein and organic anion and/or organic cation transporters (OAT/OCT) could take a role in reduced oral bioavailability of ciprofloxacin by berberine and HR.	Berberine	191-200	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	43-57
22019891-2	2012	Berberine (BBR) is an isoquinoline derivative alkaloid extracted from Chinese medicinal herbs that has been used as an insulin sensitizer.	Berberine	0-9	insulin	Homo sapiens	119-126
22019891-2	2012	Berberine (BBR) is an isoquinoline derivative alkaloid extracted from Chinese medicinal herbs that has been used as an insulin sensitizer.	Berberine	11-14	insulin	Homo sapiens	119-126
22019891-8	2012	Similarly, treatment with BBR in comparison to placebo showed decrease in WHR, fasting plasma glucose, fasting insulin, homeostasis model assessment for IR, area under the curve of insulin, TC, LDLC, and TG (P&lt;0.05) as well as increase in HDLC and SHBG (P&lt;0.01).	Berberine	26-29	insulin	Homo sapiens	111-118
22019891-8	2012	Similarly, treatment with BBR in comparison to placebo showed decrease in WHR, fasting plasma glucose, fasting insulin, homeostasis model assessment for IR, area under the curve of insulin, TC, LDLC, and TG (P&lt;0.05) as well as increase in HDLC and SHBG (P&lt;0.01).	Berberine	26-29	insulin	Homo sapiens	181-188
22019891-8	2012	Similarly, treatment with BBR in comparison to placebo showed decrease in WHR, fasting plasma glucose, fasting insulin, homeostasis model assessment for IR, area under the curve of insulin, TC, LDLC, and TG (P&lt;0.05) as well as increase in HDLC and SHBG (P&lt;0.01).	Berberine	26-29	sex hormone binding globulin	Homo sapiens	251-255
22155099-0	2012	Berberine ameliorates COX-2 expression in rat small intestinal mucosa partially through PPARgamma pathway during acute endotoxemia.	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	22-27
22100227-0	2012	Berberine induces heme oxygenase-1 up-regulation through phosphatidylinositol 3-kinase/AKT and NF-E2-related factor-2 signaling pathway in astrocytes.	Berberine	0-9	heme oxygenase 1	Rattus norvegicus	18-34
22474499-0	2012	Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients.	Berberine	0-9	insulin	Homo sapiens	19-26
22474499-3	2012	We have shown that treatment with 10 muM berberine resulted in a major inhibition of human preadipocyte differentiation and leptin and adiponectin secretion accompanied by downregulation of PPARgamma2, C/EBPalpha, adiponectin, and leptin mRNA expression.	Berberine	41-50	adiponectin, C1Q and collagen domain containing	Homo sapiens	135-146
22474499-3	2012	We have shown that treatment with 10 muM berberine resulted in a major inhibition of human preadipocyte differentiation and leptin and adiponectin secretion accompanied by downregulation of PPARgamma2, C/EBPalpha, adiponectin, and leptin mRNA expression.	Berberine	41-50	CCAAT enhancer binding protein alpha	Homo sapiens	202-212
22474499-3	2012	We have shown that treatment with 10 muM berberine resulted in a major inhibition of human preadipocyte differentiation and leptin and adiponectin secretion accompanied by downregulation of PPARgamma2, C/EBPalpha, adiponectin, and leptin mRNA expression.	Berberine	41-50	adiponectin, C1Q and collagen domain containing	Homo sapiens	214-225
22474499-5	2012	These results suggest that berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokine profile in human preadipocytes and metabolic syndrome patients.	Berberine	27-36	insulin	Homo sapiens	46-53
22100227-0	2012	Berberine induces heme oxygenase-1 up-regulation through phosphatidylinositol 3-kinase/AKT and NF-E2-related factor-2 signaling pathway in astrocytes.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	87-90
22100227-0	2012	Berberine induces heme oxygenase-1 up-regulation through phosphatidylinositol 3-kinase/AKT and NF-E2-related factor-2 signaling pathway in astrocytes.	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	95-117
22155099-0	2012	Berberine ameliorates COX-2 expression in rat small intestinal mucosa partially through PPARgamma pathway during acute endotoxemia.	Berberine	0-9	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	88-97
22100227-1	2012	Our previous report has shown that berberine effectively inhibits LPS- and IFN-gamma-induced neuroinflammation in microglia cells.	Berberine	35-44	interferon gamma	Rattus norvegicus	75-84
22850597-3	2012	Our western blot analysis showed that berberine-induced G1 cell cycle arrest was mediated through the increased expression of cyclin-dependent kinase inhibitors (Cdki) proteins (Cip1/p21 and Kip1/p27); a simultaneous decrease in Cdk2 and Cdk4 and cyclins D1, and reduced activity of the Cyclins-Cdk complex.	Berberine	38-47	cyclin dependent kinase inhibitor 1A	Homo sapiens	178-182
22100227-3	2012	The present study examined the ability of berberine, the major constituents of Chinese herb Rhizoma coptidis, to induce expression of HO-1, and analyzed its signaling mechanism in rat brain astrocytes.	Berberine	42-51	heme oxygenase 1	Rattus norvegicus	134-138
22100227-5	2012	Here, we found that berberine increased HO-1 mRNA and protein expression concentration- and time-dependently.	Berberine	20-29	heme oxygenase 1	Rattus norvegicus	40-44
22100227-6	2012	In addition, berberine-induced HO-1 expression was attenuated by PI 3-kinase (phosphatidylinositol 3-kinase) inhibitors LY294002 and wortmannin, and an AKT inhibitor.	Berberine	13-22	heme oxygenase 1	Rattus norvegicus	31-35
22100227-6	2012	In addition, berberine-induced HO-1 expression was attenuated by PI 3-kinase (phosphatidylinositol 3-kinase) inhibitors LY294002 and wortmannin, and an AKT inhibitor.	Berberine	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	152-155
22100227-7	2012	Treatment of astrocytes with berberine also induced p85 (PI 3-kinase) and AKT phospholation, and increased AKT kinase activity.	Berberine	29-38	AKT serine/threonine kinase 1	Rattus norvegicus	74-77
22100227-7	2012	Treatment of astrocytes with berberine also induced p85 (PI 3-kinase) and AKT phospholation, and increased AKT kinase activity.	Berberine	29-38	AKT serine/threonine kinase 1	Rattus norvegicus	107-110
22100227-8	2012	Berberine also increased NF-E2-related factor-2 (Nrf2) accumulation in the nucleus and increased Nrf2-DNA binding activity as determined by the EMSA (electrophoretic mobility shift assay).	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	25-47
22100227-8	2012	Berberine also increased NF-E2-related factor-2 (Nrf2) accumulation in the nucleus and increased Nrf2-DNA binding activity as determined by the EMSA (electrophoretic mobility shift assay).	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	49-53
22100227-8	2012	Berberine also increased NF-E2-related factor-2 (Nrf2) accumulation in the nucleus and increased Nrf2-DNA binding activity as determined by the EMSA (electrophoretic mobility shift assay).	Berberine	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	97-101
22100227-9	2012	Moreover, berberine-induced increase of Nrf2-DNA binding activity was reduced by PI 3-kinase and AKT inhibitors.	Berberine	10-19	NFE2 like bZIP transcription factor 2	Rattus norvegicus	40-44
22100227-9	2012	Moreover, berberine-induced increase of Nrf2-DNA binding activity was reduced by PI 3-kinase and AKT inhibitors.	Berberine	10-19	AKT serine/threonine kinase 1	Rattus norvegicus	97-100
22100227-10	2012	Berberine-increased HO-1-luciferase activity was also inhibited by co-transfection with dominant-negative (DN) mutants of p85 and AKT.	Berberine	0-9	heme oxygenase 1	Rattus norvegicus	20-24
22100227-10	2012	Berberine-increased HO-1-luciferase activity was also inhibited by co-transfection with dominant-negative (DN) mutants of p85 and AKT.	Berberine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	130-133
22100227-11	2012	Moreover, berberine-mediated increase of HO-1 transcriptional activity and protein expression were reduced by transfection with siRNA againt Nrf2.	Berberine	10-19	heme oxygenase 1	Rattus norvegicus	41-45
22100227-11	2012	Moreover, berberine-mediated increase of HO-1 transcriptional activity and protein expression were reduced by transfection with siRNA againt Nrf2.	Berberine	10-19	NFE2 like bZIP transcription factor 2	Rattus norvegicus	141-145
22100227-12	2012	These findings suggest that berberine-increased HO-1 expression is mediated by Nrf2 activation through the PI 3-kinase/AKT pathway in astrocytes.	Berberine	28-37	heme oxygenase 1	Rattus norvegicus	48-52
22100227-12	2012	These findings suggest that berberine-increased HO-1 expression is mediated by Nrf2 activation through the PI 3-kinase/AKT pathway in astrocytes.	Berberine	28-37	NFE2 like bZIP transcription factor 2	Rattus norvegicus	79-83
22100227-12	2012	These findings suggest that berberine-increased HO-1 expression is mediated by Nrf2 activation through the PI 3-kinase/AKT pathway in astrocytes.	Berberine	28-37	AKT serine/threonine kinase 1	Rattus norvegicus	119-122
22850597-3	2012	Our western blot analysis showed that berberine-induced G1 cell cycle arrest was mediated through the increased expression of cyclin-dependent kinase inhibitors (Cdki) proteins (Cip1/p21 and Kip1/p27); a simultaneous decrease in Cdk2 and Cdk4 and cyclins D1, and reduced activity of the Cyclins-Cdk complex.	Berberine	38-47	cyclin dependent kinase inhibitor 1A	Homo sapiens	183-186
22850597-3	2012	Our western blot analysis showed that berberine-induced G1 cell cycle arrest was mediated through the increased expression of cyclin-dependent kinase inhibitors (Cdki) proteins (Cip1/p21 and Kip1/p27); a simultaneous decrease in Cdk2 and Cdk4 and cyclins D1, and reduced activity of the Cyclins-Cdk complex.	Berberine	38-47	cyclin dependent kinase inhibitor 1B	Homo sapiens	191-195
22850597-3	2012	Our western blot analysis showed that berberine-induced G1 cell cycle arrest was mediated through the increased expression of cyclin-dependent kinase inhibitors (Cdki) proteins (Cip1/p21 and Kip1/p27); a simultaneous decrease in Cdk2 and Cdk4 and cyclins D1, and reduced activity of the Cyclins-Cdk complex.	Berberine	38-47	interferon alpha inducible protein 27	Homo sapiens	196-199
22850597-3	2012	Our western blot analysis showed that berberine-induced G1 cell cycle arrest was mediated through the increased expression of cyclin-dependent kinase inhibitors (Cdki) proteins (Cip1/p21 and Kip1/p27); a simultaneous decrease in Cdk2 and Cdk4 and cyclins D1, and reduced activity of the Cyclins-Cdk complex.	Berberine	38-47	cyclin dependent kinase 2	Homo sapiens	229-233
22850597-3	2012	Our western blot analysis showed that berberine-induced G1 cell cycle arrest was mediated through the increased expression of cyclin-dependent kinase inhibitors (Cdki) proteins (Cip1/p21 and Kip1/p27); a simultaneous decrease in Cdk2 and Cdk4 and cyclins D1, and reduced activity of the Cyclins-Cdk complex.	Berberine	38-47	cyclin dependent kinase 4	Homo sapiens	238-242
22850597-4	2012	In additional studies, treatment of QBC939 cells with different concentrations (10, 40, 80 muM) of berberine for 48 h resulted in a significant dose-dependent increase in apoptosis compared to the non-berberine-treated control, which was associated with an increased expression of pro-apoptotic protein Bax and decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-xL.	Berberine	99-108	BCL2 associated X, apoptosis regulator	Homo sapiens	303-306
22850597-4	2012	In additional studies, treatment of QBC939 cells with different concentrations (10, 40, 80 muM) of berberine for 48 h resulted in a significant dose-dependent increase in apoptosis compared to the non-berberine-treated control, which was associated with an increased expression of pro-apoptotic protein Bax and decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-xL.	Berberine	99-108	BCL2 apoptosis regulator	Homo sapiens	359-364
22850597-4	2012	In additional studies, treatment of QBC939 cells with different concentrations (10, 40, 80 muM) of berberine for 48 h resulted in a significant dose-dependent increase in apoptosis compared to the non-berberine-treated control, which was associated with an increased expression of pro-apoptotic protein Bax and decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-xL.	Berberine	99-108	BCL2 like 1	Homo sapiens	369-375
21964832-0	2012	Effect of berberine on p53 expression by TPA in breast cancer cells.	Berberine	10-19	tumor protein p53	Homo sapiens	23-26
22014406-5	2012	Previous studies have indicated that berberine or aminoimidazole carboxamide ribonucleotide (AICAR)-induced activation of AMP-activated protein kinase (AMPK) suppresses the expression of adiponectin but promotes adiponectin multimerization in adipocytes.	Berberine	37-46	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	122-150
22014406-5	2012	Previous studies have indicated that berberine or aminoimidazole carboxamide ribonucleotide (AICAR)-induced activation of AMP-activated protein kinase (AMPK) suppresses the expression of adiponectin but promotes adiponectin multimerization in adipocytes.	Berberine	37-46	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	152-156
22014406-5	2012	Previous studies have indicated that berberine or aminoimidazole carboxamide ribonucleotide (AICAR)-induced activation of AMP-activated protein kinase (AMPK) suppresses the expression of adiponectin but promotes adiponectin multimerization in adipocytes.	Berberine	37-46	adiponectin, C1Q and collagen domain containing	Homo sapiens	187-198
22014406-5	2012	Previous studies have indicated that berberine or aminoimidazole carboxamide ribonucleotide (AICAR)-induced activation of AMP-activated protein kinase (AMPK) suppresses the expression of adiponectin but promotes adiponectin multimerization in adipocytes.	Berberine	37-46	adiponectin, C1Q and collagen domain containing	Homo sapiens	212-223
21964832-12	2012	Taken together, we suggest that BBR may be used as an effective             ingredient for anticancer products, which trigger the transcriptional activity             and the inhibition of the degradation of p53, a tumor suppressor gene, in human             breast cancer.	Berberine	32-35	tumor protein p53	Homo sapiens	208-211
21964832-0	2012	Effect of berberine on p53 expression by TPA in breast cancer cells.	Berberine	10-19	plasminogen activator, tissue type	Homo sapiens	41-44
21557367-8	2012	The effect of berberine involves an inhibition of the mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein alpha (C/EBPalpha).	Berberine	14-23	peroxisome proliferator activated receptor gamma	Homo sapiens	135-144
23087140-2	2012	Here we investigated the effect of berberine, natural plant extracts, on PCSK9-LDLR pathway in C57BL/6 mice with lipopolysaccharide (LPS) induced inflammation.	Berberine	35-44	proprotein convertase subtilisin/kexin type 9	Mus musculus	73-78
23087140-2	2012	Here we investigated the effect of berberine, natural plant extracts, on PCSK9-LDLR pathway in C57BL/6 mice with lipopolysaccharide (LPS) induced inflammation.	Berberine	35-44	low density lipoprotein receptor	Mus musculus	79-83
23087140-5	2012	RESULTS: Berberine pretreatment reduced the expression of hepatic PCSK9, decreased the plasma TC, TG, LDL-C, IFNgamma, TNFalpha, IL-1alpha, and 8-isoprostane concentrations; increased HDL-C level and LDLR expression in mice.	Berberine	9-18	proprotein convertase subtilisin/kexin type 9	Mus musculus	66-71
23087140-5	2012	RESULTS: Berberine pretreatment reduced the expression of hepatic PCSK9, decreased the plasma TC, TG, LDL-C, IFNgamma, TNFalpha, IL-1alpha, and 8-isoprostane concentrations; increased HDL-C level and LDLR expression in mice.	Berberine	9-18	interferon gamma	Mus musculus	109-117
23087140-5	2012	RESULTS: Berberine pretreatment reduced the expression of hepatic PCSK9, decreased the plasma TC, TG, LDL-C, IFNgamma, TNFalpha, IL-1alpha, and 8-isoprostane concentrations; increased HDL-C level and LDLR expression in mice.	Berberine	9-18	tumor necrosis factor	Mus musculus	119-127
23087140-5	2012	RESULTS: Berberine pretreatment reduced the expression of hepatic PCSK9, decreased the plasma TC, TG, LDL-C, IFNgamma, TNFalpha, IL-1alpha, and 8-isoprostane concentrations; increased HDL-C level and LDLR expression in mice.	Berberine	9-18	interleukin 1 alpha	Mus musculus	129-138
21557367-8	2012	The effect of berberine involves an inhibition of the mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein alpha (C/EBPalpha).	Berberine	14-23	CCAAT enhancer binding protein alpha	Homo sapiens	150-186
21557367-8	2012	The effect of berberine involves an inhibition of the mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein alpha (C/EBPalpha).	Berberine	14-23	CCAAT enhancer binding protein alpha	Homo sapiens	188-198
21557367-10	2012	These findings suggest that an antiobesity effect could be a new indication for Orengedokuto and that its active ingredient is berberine, with a mechanism involving the inhibition of PPARgamma and C/EBPalpha expression.	Berberine	127-136	peroxisome proliferator activated receptor gamma	Homo sapiens	183-192
23087140-5	2012	RESULTS: Berberine pretreatment reduced the expression of hepatic PCSK9, decreased the plasma TC, TG, LDL-C, IFNgamma, TNFalpha, IL-1alpha, and 8-isoprostane concentrations; increased HDL-C level and LDLR expression in mice.	Berberine	9-18	low density lipoprotein receptor	Mus musculus	200-204
23087140-6	2012	CONCLUSION: The present results suggest that berberine inhibits dyslipidemia in C57BL/6 mice with LPS induced inflammation through regulating PCSK9-LDLR pathway.	Berberine	45-54	proprotein convertase subtilisin/kexin type 9	Mus musculus	142-147
23087140-6	2012	CONCLUSION: The present results suggest that berberine inhibits dyslipidemia in C57BL/6 mice with LPS induced inflammation through regulating PCSK9-LDLR pathway.	Berberine	45-54	low density lipoprotein receptor	Mus musculus	148-152
21557367-8	2012	The effect of berberine involves an inhibition of the mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein alpha (C/EBPalpha).	Berberine	14-23	peroxisome proliferator activated receptor gamma	Homo sapiens	85-133
21557367-10	2012	These findings suggest that an antiobesity effect could be a new indication for Orengedokuto and that its active ingredient is berberine, with a mechanism involving the inhibition of PPARgamma and C/EBPalpha expression.	Berberine	127-136	CCAAT enhancer binding protein alpha	Homo sapiens	197-207
22880019-3	2012	Increases in the levels of serum lipopolysaccharide-binding protein, monocyte chemoattractant protein-1, and leptin and decrease in the serum level of adiponectin corrected for body fat in HFD-fed rats were also significantly retarded by the co-administration of berberine at 100 mg/kg body weight.	Berberine	263-272	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	151-162
22937115-0	2012	Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models.	Berberine	0-9	fibronectin 1	Rattus norvegicus	18-29
22937115-0	2012	Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models.	Berberine	0-9	sphingosine-1-phosphate receptor 2	Rattus norvegicus	64-68
22937115-5	2012	Berberine (BBR) treatment also effectively inhibits SphK1 activity and S1P production in the kidneys of diabetic models, thus improving renal injury.	Berberine	0-9	sphingosine kinase 1	Rattus norvegicus	52-57
22937115-5	2012	Berberine (BBR) treatment also effectively inhibits SphK1 activity and S1P production in the kidneys of diabetic models, thus improving renal injury.	Berberine	11-14	sphingosine kinase 1	Rattus norvegicus	52-57
23077597-0	2012	Berberine inhibits doxorubicin-triggered cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2 expression.	Berberine	0-9	BCL2, apoptosis regulator	Rattus norvegicus	122-127
22019228-3	2011	Among them, compound 8d, (o-methylphenethyl)amino linked at the 9-position of berberine, was found to be a good antioxidant (with 4.05 muM of Trolox equivalents), potent inhibitor of AChE (an IC(50) value of 0.027 muM), and high active inhibitor of amyloid-beta aggregation (an IC(50) value of 2.73 muM).	Berberine	78-87	acetylcholinesterase (Cartwright blood group)	Homo sapiens	183-187
22666416-3	2012	The affinity of binding was remarkably high by about 5 and 15 times, respectively, for BC1 and BC2 compared to berberine.	Berberine	111-120	charged multivesicular body protein 2A	Homo sapiens	95-98
22193446-8	2011	On the other hand, berberine-induced Cl(-) current was significantly inhibited by the chloride channel blockers NPPB (100 micromol/L) and tamoxifen (20 mumol/L), with the inhibition ratios of (83.1 +- 3.6)% and (95.6 +- 1.2)% respectively.	Berberine	19-28	natriuretic peptide B	Homo sapiens	112-116
22193446-9	2011	These results suggest that berberine can activate the chloride channels that are sensitive to NPPB and tamoxifen, as well as the changes of cell volume in human colorectal carcinoma cells.	Berberine	27-36	natriuretic peptide B	Homo sapiens	94-98
22152059-1	2011	BACKGROUND: Berberine (BER), the major alkaloidal component of Rhizoma coptidis, has multiple pharmacological effects including inhibition of acetylcholinesterase, reduction of cholesterol and glucose levels, anti-inflammatory, neuroprotective and neurotrophic effects.	Berberine	12-21	acetylcholinesterase (Cartwright blood group)	Homo sapiens	142-162
22152059-1	2011	BACKGROUND: Berberine (BER), the major alkaloidal component of Rhizoma coptidis, has multiple pharmacological effects including inhibition of acetylcholinesterase, reduction of cholesterol and glucose levels, anti-inflammatory, neuroprotective and neurotrophic effects.	Berberine	23-26	acetylcholinesterase (Cartwright blood group)	Homo sapiens	142-162
22574158-0	2012	Berberine induces caspase-independent cell death in colon tumor cells through activation of apoptosis-inducing factor.	Berberine	0-9	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	92-117
22574158-7	2012	Rather, berberine stimulated a caspase-independent cell death mediator, apoptosis-inducing factor (AIF) release from mitochondria and nuclear translocation in a ROS production-dependent manner.	Berberine	8-17	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	72-97
22574158-7	2012	Rather, berberine stimulated a caspase-independent cell death mediator, apoptosis-inducing factor (AIF) release from mitochondria and nuclear translocation in a ROS production-dependent manner.	Berberine	8-17	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	99-102
22574158-8	2012	Amelioration of berberine-stimulated ROS production or suppression of AIF expression blocked berberine-induced cell death and LDH release in IMCE cells.	Berberine	93-102	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	70-73
22574158-9	2012	Furthermore, two targets of ROS production in cells, cathepsin B release from lysosomes and PARP activation were induced by berberine.	Berberine	124-133	cathepsin B	Mus musculus	53-64
22574158-9	2012	Furthermore, two targets of ROS production in cells, cathepsin B release from lysosomes and PARP activation were induced by berberine.	Berberine	124-133	poly (ADP-ribose) polymerase family, member 1	Mus musculus	92-96
22574158-10	2012	Blockage of either of these pathways decreased berberine-induced AIF activation and cell death in IMCE cells.	Berberine	47-56	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	65-68
22574158-11	2012	Thus, berberine-stimulated ROS production leads to cathepsin B release and PARP activation-dependent AIF activation, resulting in caspase-independent cell death in colon tumor cells.	Berberine	6-15	cathepsin B	Mus musculus	51-62
22574158-11	2012	Thus, berberine-stimulated ROS production leads to cathepsin B release and PARP activation-dependent AIF activation, resulting in caspase-independent cell death in colon tumor cells.	Berberine	6-15	poly (ADP-ribose) polymerase family, member 1	Mus musculus	75-79
22574158-11	2012	Thus, berberine-stimulated ROS production leads to cathepsin B release and PARP activation-dependent AIF activation, resulting in caspase-independent cell death in colon tumor cells.	Berberine	6-15	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	101-104
21755496-8	2011	Several previously unidentified CYP1A2 inhibitors such as evoxine and berberine were also identified in this study.	Berberine	70-79	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	32-38
21867779-0	2011	Berberine down-regulates the Th1/Th2 cytokine gene expression ratio in mouse primary splenocytes in the absence or presence of lipopolysaccharide in a preventive manner.	Berberine	0-9	heart and neural crest derivatives expressed 2	Mus musculus	33-36
21110076-0	2011	Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes.	Berberine	0-9	insulin	Homo sapiens	57-64
21110076-2	2011	This study aims to investigate effects of berberine on ameliorating insulin resistance and molecular mechanisms involved in HepG2 cells.	Berberine	42-51	insulin	Homo sapiens	68-75
21110076-3	2011	Inflammatory responses and insulin resistance were induced by palmitate (PA) stimulation for 24 h. Treatment of berberine enhanced insulin-mediated glycogen synthesis and restored insulin inhibition of triglyceride secretion.	Berberine	112-121	insulin	Homo sapiens	27-34
21110076-3	2011	Inflammatory responses and insulin resistance were induced by palmitate (PA) stimulation for 24 h. Treatment of berberine enhanced insulin-mediated glycogen synthesis and restored insulin inhibition of triglyceride secretion.	Berberine	112-121	insulin	Homo sapiens	131-138
21110076-3	2011	Inflammatory responses and insulin resistance were induced by palmitate (PA) stimulation for 24 h. Treatment of berberine enhanced insulin-mediated glycogen synthesis and restored insulin inhibition of triglyceride secretion.	Berberine	112-121	insulin	Homo sapiens	131-138
21110076-5	2011	Berberine effectively inhibited IL-6 and TNF-alpha production in a concentration-dependent manner, demonstrating its anti-inflammatory activity in hepatocytes.	Berberine	0-9	interleukin 6	Homo sapiens	32-36
21110076-5	2011	Berberine effectively inhibited IL-6 and TNF-alpha production in a concentration-dependent manner, demonstrating its anti-inflammatory activity in hepatocytes.	Berberine	0-9	tumor necrosis factor	Homo sapiens	41-50
21867779-4	2011	The results showed that berberine down-regulated ratios of the relative Th1 (IL-2)/Th2 (IL-4) cytokines expression fold in mouse primary splenocytes in the absence or presence of LPS in a preventive manner.	Berberine	24-33	interleukin 2	Mus musculus	77-81
21110076-6	2011	Meanwhile, PA-evoked inflammation impaired insulin signaling cascade and berberine improved insulin signaling cascade by modification of Ser/Thr phosphorylation of insulin receptor substrate-1(IRS-1) and downstream Akt (T308).	Berberine	73-82	insulin receptor substrate 1	Homo sapiens	164-192
21110076-6	2011	Meanwhile, PA-evoked inflammation impaired insulin signaling cascade and berberine improved insulin signaling cascade by modification of Ser/Thr phosphorylation of insulin receptor substrate-1(IRS-1) and downstream Akt (T308).	Berberine	73-82	insulin receptor substrate 1	Homo sapiens	193-198
21867779-4	2011	The results showed that berberine down-regulated ratios of the relative Th1 (IL-2)/Th2 (IL-4) cytokines expression fold in mouse primary splenocytes in the absence or presence of LPS in a preventive manner.	Berberine	24-33	heart and neural crest derivatives expressed 2	Mus musculus	83-86
21110076-6	2011	Meanwhile, PA-evoked inflammation impaired insulin signaling cascade and berberine improved insulin signaling cascade by modification of Ser/Thr phosphorylation of insulin receptor substrate-1(IRS-1) and downstream Akt (T308).	Berberine	73-82	AKT serine/threonine kinase 1	Homo sapiens	215-218
21867779-4	2011	The results showed that berberine down-regulated ratios of the relative Th1 (IL-2)/Th2 (IL-4) cytokines expression fold in mouse primary splenocytes in the absence or presence of LPS in a preventive manner.	Berberine	24-33	interleukin 4	Mus musculus	88-92
21110076-7	2011	Above results suggest that berberine improved insulin sensitivity in PA-stimulated hepatocytes and this regulation might relative with its anti-inflammatory activity.	Berberine	27-36	insulin	Homo sapiens	46-53
21867779-5	2011	This study suggests that berberine may possess anti-inflammatory potential by shifting the Th1/Th2 balance toward Th2 polarization.	Berberine	25-34	heart and neural crest derivatives expressed 2	Mus musculus	95-98
21867779-5	2011	This study suggests that berberine may possess anti-inflammatory potential by shifting the Th1/Th2 balance toward Th2 polarization.	Berberine	25-34	heart and neural crest derivatives expressed 2	Mus musculus	114-117
20517657-2	2011	It has been reported that berberine exerts its anti-inflammatory effect via suppressing nuclear factor-kappa B (NF-kappaB) expression.	Berberine	26-35	nuclear factor kappa B subunit 1	Homo sapiens	88-110
20517657-2	2011	It has been reported that berberine exerts its anti-inflammatory effect via suppressing nuclear factor-kappa B (NF-kappaB) expression.	Berberine	26-35	nuclear factor kappa B subunit 1	Homo sapiens	112-121
20517657-5	2011	The most significant cellular growth arrest and apoptotic effects were observed in the cells treated with 75 muM of berberine for 72 h. The results indicate that survivin and iNOS protein levels were decreased in berberine-treated cells.	Berberine	116-125	latexin	Homo sapiens	109-112
20517657-5	2011	The most significant cellular growth arrest and apoptotic effects were observed in the cells treated with 75 muM of berberine for 72 h. The results indicate that survivin and iNOS protein levels were decreased in berberine-treated cells.	Berberine	116-125	nitric oxide synthase 2	Homo sapiens	175-179
20517657-5	2011	The most significant cellular growth arrest and apoptotic effects were observed in the cells treated with 75 muM of berberine for 72 h. The results indicate that survivin and iNOS protein levels were decreased in berberine-treated cells.	Berberine	213-222	latexin	Homo sapiens	109-112
20517657-5	2011	The most significant cellular growth arrest and apoptotic effects were observed in the cells treated with 75 muM of berberine for 72 h. The results indicate that survivin and iNOS protein levels were decreased in berberine-treated cells.	Berberine	213-222	nitric oxide synthase 2	Homo sapiens	175-179
22368864-0	2011	[Effect of berberine on expression of transforming growth factor-beta1 and type IV collagen proteins in mesangial cells of diabetic rats with nephropathy].	Berberine	11-20	transforming growth factor, beta 1	Rattus norvegicus	38-70
22368864-6	2011	RESULT: Berberine could reduce the levels of FBG, KW/BW, BUN, Cr, Upro and the expression of TGF-beta1 and IV-C proteins in renal tissue of diabetic rats with nephropathy.	Berberine	8-17	transforming growth factor, beta 1	Rattus norvegicus	93-102
22368864-7	2011	CONCLUSION: Berberine may protect renal function and slow down the progression of diabetic nephropathy in rats by suppressing the expression of TGF-beta1 and IV-C proteins in renal tissue.	Berberine	12-21	transforming growth factor, beta 1	Rattus norvegicus	144-153
21856447-0	2011	Berberine inhibits the production of thymic stromal lymphopoietin by the blockade of caspase-1/NF-kappaB pathway in mast cells.	Berberine	0-9	thymic stromal lymphopoietin	Homo sapiens	37-65
22393744-5	2011	The excretion of Paeoniae Radix Alba was positive correlated with that of berberine and palmatine in bile.	Berberine	74-83	afamin	Homo sapiens	32-36
21683808-4	2011	Berberine was also evaluated for its ability to inhibit production of TNF-alpha and PGE(2) from A/PR/8/34 infected-RAW 264.7 cells.	Berberine	0-9	eiger	Drosophila melanogaster	70-79
21856447-0	2011	Berberine inhibits the production of thymic stromal lymphopoietin by the blockade of caspase-1/NF-kappaB pathway in mast cells.	Berberine	0-9	caspase 1	Homo sapiens	85-94
21856447-0	2011	Berberine inhibits the production of thymic stromal lymphopoietin by the blockade of caspase-1/NF-kappaB pathway in mast cells.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	95-104
21856447-2	2011	However, it has not been clarified the effect of berberine (BER) on the production of TSLP yet.	Berberine	49-58	thymic stromal lymphopoietin	Homo sapiens	86-90
21787170-0	2011	CYP2D plays a major role in berberine metabolism in liver of mice and humans.	Berberine	28-37	cytochrome P450, 2d region	Mus musculus	0-5
21787170-6	2011	Three unconjugated metabolites of berberine were produced by MLM, HLM, and recombinant human CYPs.	Berberine	34-43	oxysterol binding protein 2	Homo sapiens	66-69
21787170-8	2011	The metabolism of berberine in MLM and HLM was decreased the most by a CYP2D inhibitor, and moderately by inhibitors of CYP1A and 3A.	Berberine	18-27	oxysterol binding protein 2	Homo sapiens	39-42
21787170-8	2011	The metabolism of berberine in MLM and HLM was decreased the most by a CYP2D inhibitor, and moderately by inhibitors of CYP1A and 3A.	Berberine	18-27	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	71-76
21787170-9	2011	CYP2D plays a major role in berberine biotransformation, therefore, CYP2D6 pharmacogenetics and potential drug-drug interactions should be considered when berberine is used.	Berberine	28-37	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-5
21920422-8	2011	However, after the highest dose of berberine (300mg/kg), Cyp3a11 and Cyp3a25 mRNA decreased 67.6 and 87.4%, respectively, whereas Cyp1a2 mRNA increased 43.2%, and enzyme activities of Cyp3a11 and Cyp2d22 decreased 67.9 and 32.4%, respectively.	Berberine	35-44	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	57-64
21787170-9	2011	CYP2D plays a major role in berberine biotransformation, therefore, CYP2D6 pharmacogenetics and potential drug-drug interactions should be considered when berberine is used.	Berberine	155-164	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-5
21787170-9	2011	CYP2D plays a major role in berberine biotransformation, therefore, CYP2D6 pharmacogenetics and potential drug-drug interactions should be considered when berberine is used.	Berberine	155-164	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	68-74
21839075-0	2011	Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver.	Berberine	0-9	insulin receptor substrate 2	Rattus norvegicus	55-60
21920422-8	2011	However, after the highest dose of berberine (300mg/kg), Cyp3a11 and Cyp3a25 mRNA decreased 67.6 and 87.4%, respectively, whereas Cyp1a2 mRNA increased 43.2%, and enzyme activities of Cyp3a11 and Cyp2d22 decreased 67.9 and 32.4%, respectively.	Berberine	35-44	cytochrome P450, family 3, subfamily a, polypeptide 25	Mus musculus	69-76
21920422-8	2011	However, after the highest dose of berberine (300mg/kg), Cyp3a11 and Cyp3a25 mRNA decreased 67.6 and 87.4%, respectively, whereas Cyp1a2 mRNA increased 43.2%, and enzyme activities of Cyp3a11 and Cyp2d22 decreased 67.9 and 32.4%, respectively.	Berberine	35-44	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	130-136
21920422-8	2011	However, after the highest dose of berberine (300mg/kg), Cyp3a11 and Cyp3a25 mRNA decreased 67.6 and 87.4%, respectively, whereas Cyp1a2 mRNA increased 43.2%, and enzyme activities of Cyp3a11 and Cyp2d22 decreased 67.9 and 32.4%, respectively.	Berberine	35-44	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	184-191
21920422-8	2011	However, after the highest dose of berberine (300mg/kg), Cyp3a11 and Cyp3a25 mRNA decreased 67.6 and 87.4%, respectively, whereas Cyp1a2 mRNA increased 43.2%, and enzyme activities of Cyp3a11 and Cyp2d22 decreased 67.9 and 32.4%, respectively.	Berberine	35-44	cytochrome P450, family 2, subfamily d, polypeptide 22	Mus musculus	196-203
21920422-10	2011	CONCLUSIONS: If studies in mice extrapolate to humans, lower doses of berberine appear to present a low risk of producing drug-drug interactions as a result of changed Cyp enzyme activity.	Berberine	70-79	peptidylprolyl isomerase G	Homo sapiens	168-171
21920422-11	2011	However, high doses of berberine may suppress Cyp activities and result in drug-drug interactions.	Berberine	23-32	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	46-49
21839075-5	2011	In comparison with those treated with saline, model rats treated with berberine or pioglitazone underwent significant recovery, including up-regulated IRS-2 mRNA and protein (all P&lt;0.05).	Berberine	70-79	insulin receptor substrate 2	Rattus norvegicus	151-156
21839075-6	2011	Our results indicate that berberine may improve insulin resistance of NAFLD by up-regulating mRNA and protein levels of IRS-2, a key molecule in the insulin signaling pathway, suggesting that berberine may be used to treat NAFLD.	Berberine	26-35	insulin receptor substrate 2	Rattus norvegicus	120-125
21839075-6	2011	Our results indicate that berberine may improve insulin resistance of NAFLD by up-regulating mRNA and protein levels of IRS-2, a key molecule in the insulin signaling pathway, suggesting that berberine may be used to treat NAFLD.	Berberine	192-201	insulin receptor substrate 2	Rattus norvegicus	120-125
21533767-0	2011	Berberine cooperates with adrenal androgen dehydroepiandrosterone sulfate to attenuate PDGF-induced proliferation of vascular smooth muscle cell A7r5 through Skp2 signaling pathway.	Berberine	0-9	S-phase kinase associated protein 2	Rattus norvegicus	158-162
22242436-0	2011	[Study on effect of berberine on modulating lipid and CPT I A gene expression].	Berberine	20-29	carnitine palmitoyltransferase 1A	Rattus norvegicus	54-61
22242436-1	2011	OBJECTIVE: To investigate the modulating effect on lipid and gene expressions of CPT I A caused by berberine (Ber) in experimental hyperlipidemia rats.	Berberine	99-108	carnitine palmitoyltransferase 1A	Rattus norvegicus	81-88
22242436-1	2011	OBJECTIVE: To investigate the modulating effect on lipid and gene expressions of CPT I A caused by berberine (Ber) in experimental hyperlipidemia rats.	Berberine	110-113	carnitine palmitoyltransferase 1A	Rattus norvegicus	81-88
21893041-0	2011	Berberine exerts anti-adipogenic activity through up-regulation of C/EBP inhibitors, CHOP and DEC2.	Berberine	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	67-72
21893041-0	2011	Berberine exerts anti-adipogenic activity through up-regulation of C/EBP inhibitors, CHOP and DEC2.	Berberine	0-9	basic helix-loop-helix family member e41	Homo sapiens	94-98
21893041-1	2011	Berberine exerts an anti-adipogenic activity that is associated with the down-regulation of C/EBPalpha and PPARgamma.	Berberine	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	92-102
21893041-1	2011	Berberine exerts an anti-adipogenic activity that is associated with the down-regulation of C/EBPalpha and PPARgamma.	Berberine	0-9	peroxisome proliferator activated receptor gamma	Homo sapiens	107-116
21893041-3	2011	In the present study, we show that berberine up-regulated the expression of two different sets of C/EBP inhibitors, CHOP and DEC2, while down-modulating C/EBPalpha, PPARgamma and other adipogenic markers and effectors in differentiating 3T3-L1 preadipocytes and mature adipocytes.	Berberine	35-44	CCAAT enhancer binding protein alpha	Homo sapiens	98-103
21893041-3	2011	In the present study, we show that berberine up-regulated the expression of two different sets of C/EBP inhibitors, CHOP and DEC2, while down-modulating C/EBPalpha, PPARgamma and other adipogenic markers and effectors in differentiating 3T3-L1 preadipocytes and mature adipocytes.	Berberine	35-44	basic helix-loop-helix family member e41	Homo sapiens	125-129
21893041-3	2011	In the present study, we show that berberine up-regulated the expression of two different sets of C/EBP inhibitors, CHOP and DEC2, while down-modulating C/EBPalpha, PPARgamma and other adipogenic markers and effectors in differentiating 3T3-L1 preadipocytes and mature adipocytes.	Berberine	35-44	CCAAT enhancer binding protein alpha	Homo sapiens	153-163
21893041-3	2011	In the present study, we show that berberine up-regulated the expression of two different sets of C/EBP inhibitors, CHOP and DEC2, while down-modulating C/EBPalpha, PPARgamma and other adipogenic markers and effectors in differentiating 3T3-L1 preadipocytes and mature adipocytes.	Berberine	35-44	peroxisome proliferator activated receptor gamma	Homo sapiens	165-174
21893041-4	2011	Data also suggested that the berberine-induced up-regulation of CHOP and DEC2 was attributable to selective activation of an unfolded protein response (UPR) and modified extracellular environment, respectively.	Berberine	29-38	basic helix-loop-helix family member e41	Homo sapiens	73-77
21893041-6	2011	Together, up-regulation of C/EBP inhibitors appears to underlie the berberine-induced repression of C/EBPalpha and PPARgamma and, so, the inhibition of adipogenesis.	Berberine	68-77	CCAAT enhancer binding protein alpha	Homo sapiens	27-32
21893041-6	2011	Together, up-regulation of C/EBP inhibitors appears to underlie the berberine-induced repression of C/EBPalpha and PPARgamma and, so, the inhibition of adipogenesis.	Berberine	68-77	CCAAT enhancer binding protein alpha	Homo sapiens	100-110
21893041-6	2011	Together, up-regulation of C/EBP inhibitors appears to underlie the berberine-induced repression of C/EBPalpha and PPARgamma and, so, the inhibition of adipogenesis.	Berberine	68-77	peroxisome proliferator activated receptor gamma	Homo sapiens	115-124
21533767-7	2011	Antiproliferative effects of berberine and/or DHEAS targeting the Skp2/p27 pathways were evaluated.	Berberine	29-38	S-phase kinase associated protein 2	Rattus norvegicus	66-70
21533767-9	2011	Berberine induces cell cycle arrest and potentiates the inhibitory effect of DHEAS through disrupting the binding of p27, p21 with Skp2.	Berberine	0-9	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	117-120
21533767-9	2011	Berberine induces cell cycle arrest and potentiates the inhibitory effect of DHEAS through disrupting the binding of p27, p21 with Skp2.	Berberine	0-9	KRAS proto-oncogene, GTPase	Rattus norvegicus	122-125
21533767-9	2011	Berberine induces cell cycle arrest and potentiates the inhibitory effect of DHEAS through disrupting the binding of p27, p21 with Skp2.	Berberine	0-9	S-phase kinase associated protein 2	Rattus norvegicus	131-135
21533767-10	2011	Berberine and DHEAS decreased the expression of CDK2, CDK4, PCNA, cyclin D1, and cyclin E, which was induced by PDGF-BB.	Berberine	0-9	cyclin dependent kinase 2	Rattus norvegicus	48-52
21533767-10	2011	Berberine and DHEAS decreased the expression of CDK2, CDK4, PCNA, cyclin D1, and cyclin E, which was induced by PDGF-BB.	Berberine	0-9	cyclin-dependent kinase 4	Rattus norvegicus	54-58
21533767-10	2011	Berberine and DHEAS decreased the expression of CDK2, CDK4, PCNA, cyclin D1, and cyclin E, which was induced by PDGF-BB.	Berberine	0-9	proliferating cell nuclear antigen	Rattus norvegicus	60-89
21533767-11	2011	Being treated with berberine and DHEAS also promoted p27 and p21 bind to CDK2, so the proliferation of A7r5 cells induced by PDGF-BB was inhibited.	Berberine	19-28	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	53-56
21533767-11	2011	Being treated with berberine and DHEAS also promoted p27 and p21 bind to CDK2, so the proliferation of A7r5 cells induced by PDGF-BB was inhibited.	Berberine	19-28	KRAS proto-oncogene, GTPase	Rattus norvegicus	61-64
21533767-11	2011	Being treated with berberine and DHEAS also promoted p27 and p21 bind to CDK2, so the proliferation of A7r5 cells induced by PDGF-BB was inhibited.	Berberine	19-28	cyclin dependent kinase 2	Rattus norvegicus	73-77
21533767-12	2011	The data provide evidence that berberine acts through the inhibition of p27-Skp2 and p21-Skp2 with subsequent activation of the cell cycle arrest, which leads to the increase in sensitivity to DHEAS.	Berberine	31-40	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	72-75
21533767-12	2011	The data provide evidence that berberine acts through the inhibition of p27-Skp2 and p21-Skp2 with subsequent activation of the cell cycle arrest, which leads to the increase in sensitivity to DHEAS.	Berberine	31-40	S-phase kinase associated protein 2	Rattus norvegicus	76-80
21533767-12	2011	The data provide evidence that berberine acts through the inhibition of p27-Skp2 and p21-Skp2 with subsequent activation of the cell cycle arrest, which leads to the increase in sensitivity to DHEAS.	Berberine	31-40	KRAS proto-oncogene, GTPase	Rattus norvegicus	85-88
21533767-12	2011	The data provide evidence that berberine acts through the inhibition of p27-Skp2 and p21-Skp2 with subsequent activation of the cell cycle arrest, which leads to the increase in sensitivity to DHEAS.	Berberine	31-40	S-phase kinase associated protein 2	Rattus norvegicus	89-93
21613449-0	2011	Berberine suppresses androgen receptor signaling in prostate cancer.	Berberine	0-9	androgen receptor	Homo sapiens	21-38
21699261-0	2011	Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway.	Berberine	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26
21699261-0	2011	Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway.	Berberine	65-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101
21699261-0	2011	Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway.	Berberine	65-74	AKT serine/threonine kinase 1	Homo sapiens	107-110
21829148-4	2011	In the present paper, we review the multiple activities of berberine, including antioxidant, acetylcholinesterase and butyrylcholinesterase inhibitory, monoamine oxidase inhibitory, amyloid-b peptide level-reducing and cholesterol-lowering activities, which suggest that berberine may act as a promising multipotent agent to combat AD.	Berberine	59-68	acetylcholinesterase (Cartwright blood group)	Homo sapiens	93-113
21613449-5	2011	In this study, we investigated the effect of berberine on AR signaling in prostate cancer.	Berberine	45-54	androgen receptor	Homo sapiens	58-60
21613449-6	2011	We report that berberine decreased the transcriptional activity of AR.	Berberine	15-24	androgen receptor	Homo sapiens	67-69
21613449-7	2011	Berberine did not affect AR mRNA expression, but induced AR protein degradation.	Berberine	0-9	androgen receptor	Homo sapiens	57-59
21613449-9	2011	Interestingly, we found that these variants were more susceptible to berberine-induced degradation than the full-length AR.	Berberine	69-78	androgen receptor	Homo sapiens	120-122
21613449-11	2011	This study is the first to show that berberine suppresses AR signaling and suggests that berberine, or its derivatives, presents a promising agent for the prevention and/or treatment of prostate cancer.	Berberine	37-46	androgen receptor	Homo sapiens	58-60
21613449-11	2011	This study is the first to show that berberine suppresses AR signaling and suggests that berberine, or its derivatives, presents a promising agent for the prevention and/or treatment of prostate cancer.	Berberine	89-98	androgen receptor	Homo sapiens	58-60
21443647-7	2011	Our data provide the first experimental evidence that berberine induces cell death in HCC cells via downregulation of CD147 and suggest a new mechanism to explain its anti-tumor effects.	Berberine	54-63	basigin (Ok blood group)	Homo sapiens	118-123
21645774-1	2011	The fluorescence spectra of berberine, palmatine, jatrorrhizine, and coptisine in ionic liquids were studied and found to increase significantly in ionic liquids, with [C(8)MIM][PF(6)] having the greatest increase.	Berberine	28-37	sperm associated antigen 17	Homo sapiens	178-183
21545824-0	2011	Berberine acutely activates the glucose transport activity of GLUT1.	Berberine	0-9	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	62-67
21545824-11	2011	It appears from this study that a portion of the hypoglycemic effects of berberine can be attributed to its acute activation of the transport activity of GLUT1.	Berberine	73-82	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	154-159
21527846-0	2011	Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells.	Berberine	65-74	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	33-38
21527846-0	2011	Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells.	Berberine	65-74	mitogen-activated protein kinase 1	Homo sapiens	39-42
21527846-2	2011	Here, we report that berberine induced apoptosis in human melanoma cells, through a process that involved mitochondria and caspase activation.	Berberine	21-30	caspase 4	Homo sapiens	123-130
21527846-3	2011	Berberine-induced activation of a number of caspases, including caspases 3, 4, 7, 8, and 9.	Berberine	0-9	caspase 4	Homo sapiens	44-52
21527846-3	2011	Berberine-induced activation of a number of caspases, including caspases 3, 4, 7, 8, and 9.	Berberine	0-9	caspase 3	Homo sapiens	64-90
21527846-5	2011	Berberine also led to the generation of the p20 cleavage fragment of BAP31, involved in directing proapoptotic signals between the endoplasmic reticulum and the mitochondria.	Berberine	0-9	tubulin polymerization promoting protein family member 3	Homo sapiens	44-47
21527846-5	2011	Berberine also led to the generation of the p20 cleavage fragment of BAP31, involved in directing proapoptotic signals between the endoplasmic reticulum and the mitochondria.	Berberine	0-9	B cell receptor associated protein 31	Homo sapiens	69-74
21527846-6	2011	Treatment of SK-MEL-2 melanoma cells with berberine induced disruption of the mitochondrial transmembrane potential, release of cytochrome c and apoptosis-inducing factor from the mitochondria to the cytosol, generation of reactive oxygen species (ROS), and a decreased ATP/ADP ratio.	Berberine	42-51	cytochrome c, somatic	Homo sapiens	128-140
21527846-7	2011	Overexpression of bcl-xL by gene transfer prevented berberine-induced cell death, mitochondrial transmembrane potential loss, and cytochrome c and apoptosis-inducing factor release, but not ROS generation.	Berberine	52-61	BCL2 like 1	Homo sapiens	18-24
21527846-10	2011	These data show that berberine-induced apoptosis in melanoma cells involves mitochondria and caspase activation, but ROS generation was not essential.	Berberine	21-30	caspase 4	Homo sapiens	93-100
21527846-11	2011	Our results indicate that inhibition of B-RAF/ERK survival signaling facilitates the cell death response triggered by berberine.	Berberine	118-127	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	40-45
21527846-11	2011	Our results indicate that inhibition of B-RAF/ERK survival signaling facilitates the cell death response triggered by berberine.	Berberine	118-127	mitogen-activated protein kinase 1	Homo sapiens	46-49
21443647-0	2011	Berberine induces cell death in human hepatoma cells in vitro by downregulating CD147.	Berberine	0-9	basigin (Ok blood group)	Homo sapiens	80-85
21443647-5	2011	Moreover, berberine treatment significantly inhibited CD147 expression by HCC cells in a dose-dependent manner.	Berberine	10-19	basigin (Ok blood group)	Homo sapiens	54-59
21443647-6	2011	Overexpression of CD147 protein markedly reduced berberine-induced cell death.	Berberine	49-58	basigin (Ok blood group)	Homo sapiens	18-23
21747769-0	2011	Berberine Reduces cAMP-Induced Chloride Secretion in T84 Human Colonic Carcinoma Cells through Inhibition of Basolateral KCNQ1 Channels.	Berberine	0-9	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	121-126
21545798-10	2011	We observed that H-Ras and c-fos mRNA and protein expressionswere dose-dependently and time-dependently decreased by berberine treatment.	Berberine	117-126	HRas proto-oncogene, GTPase	Homo sapiens	17-22
21545798-10	2011	We observed that H-Ras and c-fos mRNA and protein expressionswere dose-dependently and time-dependently decreased by berberine treatment.	Berberine	117-126	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	27-32
21545798-13	2011	Berberine can inhibit the oncogentic H-Ras and c-fos in T24 cells, and can induce the activation of the caspase-3 and caspase-9 apoptosis.	Berberine	0-9	HRas proto-oncogene, GTPase	Homo sapiens	37-42
21545798-13	2011	Berberine can inhibit the oncogentic H-Ras and c-fos in T24 cells, and can induce the activation of the caspase-3 and caspase-9 apoptosis.	Berberine	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	47-52
21545798-13	2011	Berberine can inhibit the oncogentic H-Ras and c-fos in T24 cells, and can induce the activation of the caspase-3 and caspase-9 apoptosis.	Berberine	0-9	caspase 3	Homo sapiens	104-113
21545798-13	2011	Berberine can inhibit the oncogentic H-Ras and c-fos in T24 cells, and can induce the activation of the caspase-3 and caspase-9 apoptosis.	Berberine	0-9	caspase 9	Homo sapiens	118-127
21747769-8	2011	Berberine stimulated p38 MAPK, PKCalpha and PKA, but had no effect on p42/p44 MAPK and PKCdelta.	Berberine	0-9	protein kinase C alpha	Homo sapiens	31-39
21873785-0	2011	Berberine inhibits the invasion and metastasis of nasopharyngeal carcinoma cells through Ezrin phosphorylation.	Berberine	0-9	ezrin	Homo sapiens	89-94
21873785-5	2011	Western blot was used to investigate the Ezrin and phos-Ezrin expression in 5-8F cells treated by berberine.	Berberine	98-107	ezrin	Homo sapiens	41-46
21873785-5	2011	Western blot was used to investigate the Ezrin and phos-Ezrin expression in 5-8F cells treated by berberine.	Berberine	98-107	ezrin	Homo sapiens	56-61
21873785-7	2011	The inhibitory effect of berberine on the motility and invasion of 6-10B-pcDNA3.1-Ezrin and 6-10B-pcDNA3.1-Ezrin M was detected, respectively.	Berberine	25-34	ezrin	Homo sapiens	82-87
21873785-7	2011	The inhibitory effect of berberine on the motility and invasion of 6-10B-pcDNA3.1-Ezrin and 6-10B-pcDNA3.1-Ezrin M was detected, respectively.	Berberine	25-34	ezrin	Homo sapiens	107-112
21873785-11	2011	Berberine suppressed the phos-Ezrin expression of 5-8F cells in both time- and concentration-dependent manner (P&lt;0.05), but the effect of berberine was weaker on 6-10B-pcDNA3.1-Ezrin M than on 6-10B-pcDNA3.1-Ezrin.	Berberine	0-9	ezrin	Homo sapiens	30-35
21873785-11	2011	Berberine suppressed the phos-Ezrin expression of 5-8F cells in both time- and concentration-dependent manner (P&lt;0.05), but the effect of berberine was weaker on 6-10B-pcDNA3.1-Ezrin M than on 6-10B-pcDNA3.1-Ezrin.	Berberine	0-9	ezrin	Homo sapiens	180-185
21873785-11	2011	Berberine suppressed the phos-Ezrin expression of 5-8F cells in both time- and concentration-dependent manner (P&lt;0.05), but the effect of berberine was weaker on 6-10B-pcDNA3.1-Ezrin M than on 6-10B-pcDNA3.1-Ezrin.	Berberine	0-9	ezrin	Homo sapiens	180-185
21873785-11	2011	Berberine suppressed the phos-Ezrin expression of 5-8F cells in both time- and concentration-dependent manner (P&lt;0.05), but the effect of berberine was weaker on 6-10B-pcDNA3.1-Ezrin M than on 6-10B-pcDNA3.1-Ezrin.	Berberine	141-150	ezrin	Homo sapiens	180-185
21873785-11	2011	Berberine suppressed the phos-Ezrin expression of 5-8F cells in both time- and concentration-dependent manner (P&lt;0.05), but the effect of berberine was weaker on 6-10B-pcDNA3.1-Ezrin M than on 6-10B-pcDNA3.1-Ezrin.	Berberine	141-150	ezrin	Homo sapiens	180-185
21873785-12	2011	CONCLUSION: Berberine inhibits nasopharyngeal carcinoma cell invasion through inhibiting phos-Ezrin expression and filopodia formation.	Berberine	12-21	ezrin	Homo sapiens	94-99
21747769-9	2011	However, berberine pre-treatment prevented stimulation of p42/p44 MAPK by epidermal growth factor.	Berberine	9-18	proteasome 26S subunit, ATPase 6	Homo sapiens	58-61
21747769-9	2011	However, berberine pre-treatment prevented stimulation of p42/p44 MAPK by epidermal growth factor.	Berberine	9-18	mitogen-activated protein kinase 3	Homo sapiens	62-70
21747769-10	2011	The inhibitory effect of berberine on Cl(-) secretion was partially blocked by HBDDE (~65%), an inhibitor of PKCalpha and to a smaller extent by inhibition of p38 MAPK with SB202190 (~15%).	Berberine	25-34	protein kinase C alpha	Homo sapiens	109-117
21747769-10	2011	The inhibitory effect of berberine on Cl(-) secretion was partially blocked by HBDDE (~65%), an inhibitor of PKCalpha and to a smaller extent by inhibition of p38 MAPK with SB202190 (~15%).	Berberine	25-34	mitogen-activated protein kinase 14	Homo sapiens	159-162
21747769-10	2011	The inhibitory effect of berberine on Cl(-) secretion was partially blocked by HBDDE (~65%), an inhibitor of PKCalpha and to a smaller extent by inhibition of p38 MAPK with SB202190 (~15%).	Berberine	25-34	mitogen-activated protein kinase 3	Homo sapiens	163-167
21747769-11	2011	Berberine treatment induced an increase in association between PKCalpha and PKA with KCNQ1 and produced phosphorylation of the channel.	Berberine	0-9	protein kinase C alpha	Homo sapiens	63-71
21747769-6	2011	In apically permeabilized monolayers and whole-cell current recordings, berberine inhibited a cAMP-dependent and chromanol 293B-sensitive basolateral membrane K(+) current by 88%, suggesting inhibition of KCNQ1 K(+) channels.	Berberine	72-81	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	205-210
21747769-11	2011	Berberine treatment induced an increase in association between PKCalpha and PKA with KCNQ1 and produced phosphorylation of the channel.	Berberine	0-9	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	85-90
21747769-12	2011	We conclude that berberine exerts its inhibitory effect on colonic Cl(-) secretion through inhibition of basolateral KCNQ1 channels responsible for K(+) recycling via a PKCalpha-dependent pathway.	Berberine	17-26	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	117-122
21747769-8	2011	Berberine stimulated p38 MAPK, PKCalpha and PKA, but had no effect on p42/p44 MAPK and PKCdelta.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	21-24
21747769-12	2011	We conclude that berberine exerts its inhibitory effect on colonic Cl(-) secretion through inhibition of basolateral KCNQ1 channels responsible for K(+) recycling via a PKCalpha-dependent pathway.	Berberine	17-26	protein kinase C alpha	Homo sapiens	169-177
21458442-8	2011	Berberine caused significant increase in cardiac fatty acid transport protein-1 (159%), fatty acid transport proteins (56%), fatty acid beta-oxidase (52%), as well as glucose transporter-4 and peroxisome proliferator-activated receptor-gamma (PPARgamma), but decrease in PPARalpha mRNA and protein expression in hyperglycemic/hypercholesterolemic rats.	Berberine	0-9	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	193-241
21458442-8	2011	Berberine caused significant increase in cardiac fatty acid transport protein-1 (159%), fatty acid transport proteins (56%), fatty acid beta-oxidase (52%), as well as glucose transporter-4 and peroxisome proliferator-activated receptor-gamma (PPARgamma), but decrease in PPARalpha mRNA and protein expression in hyperglycemic/hypercholesterolemic rats.	Berberine	0-9	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	243-252
21458442-8	2011	Berberine caused significant increase in cardiac fatty acid transport protein-1 (159%), fatty acid transport proteins (56%), fatty acid beta-oxidase (52%), as well as glucose transporter-4 and peroxisome proliferator-activated receptor-gamma (PPARgamma), but decrease in PPARalpha mRNA and protein expression in hyperglycemic/hypercholesterolemic rats.	Berberine	0-9	peroxisome proliferator activated receptor alpha	Rattus norvegicus	271-280
21262264-3	2011	Berberine, an isoquinoline alkaloid is reported to exhibit anti-diabetic and antioxidant effect, acetylcholinesterase (AChE) inhibitor, and increases GLP release.	Berberine	0-9	acetylcholinesterase	Rattus norvegicus	97-117
21536037-0	2011	Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes.	Berberine	22-31	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	14-18
21536037-0	2011	Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes.	Berberine	22-31	adiponectin, C1Q and collagen domain containing	Homo sapiens	41-52
21536037-3	2011	In this study, we reported that berberine, an isoquinoline alkaloid with insulin-sensitizing effect, inhibits the expression of adiponectin, but promotes the assembly of HMW adiponectin and increases the ratio of HMW to total adiponectin.	Berberine	32-41	adiponectin, C1Q and collagen domain containing	Homo sapiens	128-139
21536037-3	2011	In this study, we reported that berberine, an isoquinoline alkaloid with insulin-sensitizing effect, inhibits the expression of adiponectin, but promotes the assembly of HMW adiponectin and increases the ratio of HMW to total adiponectin.	Berberine	32-41	adiponectin, C1Q and collagen domain containing	Homo sapiens	174-185
21536037-3	2011	In this study, we reported that berberine, an isoquinoline alkaloid with insulin-sensitizing effect, inhibits the expression of adiponectin, but promotes the assembly of HMW adiponectin and increases the ratio of HMW to total adiponectin.	Berberine	32-41	adiponectin, C1Q and collagen domain containing	Homo sapiens	174-185
21536037-4	2011	Berberine activates AMPK.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	20-24
21536037-5	2011	Knockdown of AMPKalpha1 abolishes the effect of berberine.	Berberine	48-57	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	13-23
21536037-7	2011	Our study suggested that activation of AMPK by berberine promotes adiponectin multimerization.	Berberine	47-56	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	39-43
21536037-7	2011	Our study suggested that activation of AMPK by berberine promotes adiponectin multimerization.	Berberine	47-56	adiponectin, C1Q and collagen domain containing	Homo sapiens	66-77
21262264-3	2011	Berberine, an isoquinoline alkaloid is reported to exhibit anti-diabetic and antioxidant effect, acetylcholinesterase (AChE) inhibitor, and increases GLP release.	Berberine	0-9	acetylcholinesterase	Rattus norvegicus	119-123
21569619-0	2011	Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes.	Berberine	17-26	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	68-74
21356280-4	2011	The major alkaloidal ingredients, berberine and evodiamine, inhibited AP-1 activities and/or NF-kappaB activation, and further suppressed hepatocellular transformation.	Berberine	34-43	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	70-74
21356280-5	2011	In conclusion, ZJW and its constituents, berberine and evodiamine, suppressed tumor promotion primarily through AP-1 and/or NF-kappaB pathways in HepG2 cells.	Berberine	41-50	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	112-116
21089182-0	2011	Baekjeolyusin-tang and its active component berberine block the release of collagen and proteoglycan from IL-1beta-stimulated rabbit cartilage and down-regulate matrix metalloproteinases in rabbit chondrocytes.	Berberine	44-53	interleukin-1 beta	Oryctolagus cuniculus	106-114
21108488-6	2011	Berberine was found to inhibit the expression of MMP-1, -3 and -13, and increased the level of TIMP-1 at the mRNA level in a dose-dependent manner.	Berberine	0-9	matrix metallopeptidase 1	Rattus norvegicus	49-66
21108488-6	2011	Berberine was found to inhibit the expression of MMP-1, -3 and -13, and increased the level of TIMP-1 at the mRNA level in a dose-dependent manner.	Berberine	0-9	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	95-101
21108488-7	2011	In IL-1beta-induced rat articular chondrocytes, berberine decreased IL-1beta-induced GAG release and NO production.	Berberine	48-57	interleukin 1 beta	Rattus norvegicus	3-11
21108488-7	2011	In IL-1beta-induced rat articular chondrocytes, berberine decreased IL-1beta-induced GAG release and NO production.	Berberine	48-57	interleukin 1 beta	Rattus norvegicus	68-76
21108488-8	2011	Meanwhile, high-dose berberine exhibited an anticatabolic effect in an IL-1beta-induced rat osteoarthritis (OA) model.	Berberine	21-30	interleukin 1 beta	Rattus norvegicus	71-79
23148176-5	2011	RESULTS: TZD and berberine increased 2DG uptake by 3.3-fold (with respect to control) at 15 muM and 25 muM, respectively.	Berberine	17-26	latexin	Homo sapiens	92-95
23148176-5	2011	RESULTS: TZD and berberine increased 2DG uptake by 3.3-fold (with respect to control) at 15 muM and 25 muM, respectively.	Berberine	17-26	latexin	Homo sapiens	103-106
21569619-14	2011	BBR"s metabolites remained to be active on BBR"s targets (InsR, LDLR, and AMPK) but with reduced potency.	Berberine	0-3	low density lipoprotein receptor	Rattus norvegicus	64-68
21569619-2	2011	The present study explored answers to the question of which CYP450 (Cytochrome P450) isoenzymes execute the phase-I transformation for BBR, and what are the bioactivities of its metabolites on energy pathways.	Berberine	135-138	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	60-66
21569619-2	2011	The present study explored answers to the question of which CYP450 (Cytochrome P450) isoenzymes execute the phase-I transformation for BBR, and what are the bioactivities of its metabolites on energy pathways.	Berberine	135-138	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	68-83
21569619-9	2011	The hepatocyte culture showed that BBR was active in enhancing the expression of insulin receptor (InsR) and low-density-lipoprotein receptor (LDLR) mRNA, as well as in activating AMP-activated protein kinase (AMPK).	Berberine	35-38	insulin receptor	Rattus norvegicus	81-97
21569619-9	2011	The hepatocyte culture showed that BBR was active in enhancing the expression of insulin receptor (InsR) and low-density-lipoprotein receptor (LDLR) mRNA, as well as in activating AMP-activated protein kinase (AMPK).	Berberine	35-38	insulin receptor	Rattus norvegicus	99-103
21569619-9	2011	The hepatocyte culture showed that BBR was active in enhancing the expression of insulin receptor (InsR) and low-density-lipoprotein receptor (LDLR) mRNA, as well as in activating AMP-activated protein kinase (AMPK).	Berberine	35-38	low density lipoprotein receptor	Rattus norvegicus	109-141
21569619-9	2011	The hepatocyte culture showed that BBR was active in enhancing the expression of insulin receptor (InsR) and low-density-lipoprotein receptor (LDLR) mRNA, as well as in activating AMP-activated protein kinase (AMPK).	Berberine	35-38	low density lipoprotein receptor	Rattus norvegicus	143-147
21569619-14	2011	BBR"s metabolites remained to be active on BBR"s targets (InsR, LDLR, and AMPK) but with reduced potency.	Berberine	0-3	insulin receptor	Rattus norvegicus	58-62
21412693-6	2011	However, hERG inhibition by 100 microM of a reference sample of berberine (16.3 +- 1.6%) was less pronounced than previously reported.	Berberine	64-73	ETS transcription factor ERG	Homo sapiens	9-13
21392861-0	2011	Quinolino-benzo-[5, 6]-dihydroisoquindolium compounds derived from berberine: a new class of highly selective ligands for G-quadruplex DNA in c-myc oncogene.	Berberine	67-76	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	142-147
21624228-8	2011	(3) The phosphorylation of EGFR was significantly increased after adding EGF and p-EGFR was decreased in EGF plus Berberine group at a concentration-dependent manner.	Berberine	114-123	epidermal growth factor receptor	Homo sapiens	27-31
21624228-8	2011	(3) The phosphorylation of EGFR was significantly increased after adding EGF and p-EGFR was decreased in EGF plus Berberine group at a concentration-dependent manner.	Berberine	114-123	epidermal growth factor receptor	Homo sapiens	83-87
20969954-5	2011	Prior exposure of adipocytes to berberine decreased the intracellular cAMP production induced by isoproterenol, forskolin, and 3-isobutyl-1-methylxanthine (IBMX), along with hormone-sensitive lipase (HSL) Ser-563 and Ser-660 dephosphorylation, but had no effect on perilipin phosphorylation.	Berberine	32-41	lipase E, hormone sensitive type	Rattus norvegicus	174-198
21496227-0	2011	Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells.	Berberine	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	20-24
21496227-2	2011	Because transcription factor, Activator Protein-1 (AP-1) plays a central role in HPV-mediated cervical carcinogenesis, we explored the possibility of its therapeutic targeting by berberine, a natural alkaloid derived from a medicinal plant species, Berberis which has been shown to possess anti-inflammatory and anti-cancer properties with no known toxicity; however, the effect of berberine against HPV has not been elucidated.	Berberine	179-188	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-49
21496227-2	2011	Because transcription factor, Activator Protein-1 (AP-1) plays a central role in HPV-mediated cervical carcinogenesis, we explored the possibility of its therapeutic targeting by berberine, a natural alkaloid derived from a medicinal plant species, Berberis which has been shown to possess anti-inflammatory and anti-cancer properties with no known toxicity; however, the effect of berberine against HPV has not been elucidated.	Berberine	179-188	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	51-55
21496227-2	2011	Because transcription factor, Activator Protein-1 (AP-1) plays a central role in HPV-mediated cervical carcinogenesis, we explored the possibility of its therapeutic targeting by berberine, a natural alkaloid derived from a medicinal plant species, Berberis which has been shown to possess anti-inflammatory and anti-cancer properties with no known toxicity; however, the effect of berberine against HPV has not been elucidated.	Berberine	382-391	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	51-55
21496227-5	2011	Berberine specifically downregulated expression of oncogenic c-Fos which was also absent in the AP-1 binding complex.	Berberine	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	61-66
21496227-5	2011	Berberine specifically downregulated expression of oncogenic c-Fos which was also absent in the AP-1 binding complex.	Berberine	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	96-100
21496227-6	2011	Treatment with berberine resulted in repression of E6 and E7 levels and concomitant increase in p53 and Rb expression in both cell types.	Berberine	15-24	tumor protein p53	Homo sapiens	96-99
21496227-7	2011	Berberine also suppressed expression of telomerase protein, hTERT, which translated into growth inhibition of cervical cancer cells.	Berberine	0-9	telomerase reverse transcriptase	Homo sapiens	60-65
21496227-8	2011	Interestingly, a higher concentration of berberine was found to reduce the cell viability through mitochondria-mediated pathway and induce apoptosis by activating caspase-3.	Berberine	41-50	caspase 3	Homo sapiens	163-172
21496227-9	2011	CONCLUSION: These results indicate that berberine can effectively target both the host and viral factors responsible for development of cervical cancer through inhibition of AP-1 and blocking viral oncoproteins E6 and E7 expression.	Berberine	40-49	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	174-178
21496227-10	2011	Inhibition of AP-1 activity by berberine may be one of the mechanisms responsible for the anti-HPV effect of berberine.	Berberine	31-40	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-18
21496227-10	2011	Inhibition of AP-1 activity by berberine may be one of the mechanisms responsible for the anti-HPV effect of berberine.	Berberine	109-118	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-18
20969954-5	2011	Prior exposure of adipocytes to berberine decreased the intracellular cAMP production induced by isoproterenol, forskolin, and 3-isobutyl-1-methylxanthine (IBMX), along with hormone-sensitive lipase (HSL) Ser-563 and Ser-660 dephosphorylation, but had no effect on perilipin phosphorylation.	Berberine	32-41	lipase E, hormone sensitive type	Rattus norvegicus	200-203
20969954-6	2011	Berberine stimulated HSL Ser-565 as well as adenosine monophosphate-activated protein kinase (AMPK) phosphorylation.	Berberine	0-9	lipase E, hormone sensitive type	Rattus norvegicus	21-24
20969954-6	2011	Berberine stimulated HSL Ser-565 as well as adenosine monophosphate-activated protein kinase (AMPK) phosphorylation.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	44-92
20969954-11	2011	These results suggest that berberine exerts an antilipolytic effect mainly by reducing the inhibition of PDE, leading to a decrease in cAMP and HSL phosphorylation independent of AMPK pathway.	Berberine	27-36	lipase E, hormone sensitive type	Rattus norvegicus	144-147
21397508-0	2011	Synthesis, biological evaluation and molecular modeling of novel triazole-containing berberine derivatives as acetylcholinesterase and beta-amyloid aggregation inhibitors.	Berberine	85-94	acetylcholinesterase (Cartwright blood group)	Homo sapiens	110-130
20969954-11	2011	These results suggest that berberine exerts an antilipolytic effect mainly by reducing the inhibition of PDE, leading to a decrease in cAMP and HSL phosphorylation independent of AMPK pathway.	Berberine	27-36	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	179-183
21397508-5	2011	Molecular modeling studies indicated that the triazole moiety of berberine derivatives displayed a face-to-face pi-pi stacking interaction in a "sandwich" form with the Trp84 (4.09 A) and Phe330 (4.33 A) in catalytic sites of AChE.	Berberine	65-74	acetylcholinesterase (Cartwright blood group)	Homo sapiens	226-230
21182530-2	2011	The quantum yields Phi(Delta) of singlet molecular oxygen formation of berberine, palmatine and sanguinarine are moderate in dichloromethane (0.2-0.6) and much smaller in acetonitrile or trifluoroethanol.	Berberine	71-80	glucose-6-phosphate isomerase	Homo sapiens	19-22
21073932-2	2011	We found that berberine pretreatment ameliorated lipopolysaccharide-induced direct intestinal injury and mucosal hypoplasia and attenuated impairments of intestinal glutamine transport and glutaminase activity, B(0)AT1 mRNA and protein expressions, and glutaminase protein expression.	Berberine	14-23	solute carrier family 6 member 19	Rattus norvegicus	211-218
21319959-8	2011	Berberine, palmatine, jateorhizine, and coptisine were all P-gp substrates; and at the range of 1-100 muM, berberine, palmatine, jateorhizine, and coptisine had no inhibitory effects on P-gp.	Berberine	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
21178122-10	2011	Treatment of hyperhomocysteinemic rats with berberine for 5 days inhibited HMG-CoA reductase activity and reduced hepatic cholesterol content.	Berberine	44-53	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	75-92
21178122-13	2011	These results suggest that berberine regulates hepatic cholesterol biosynthesis via increased phosphorylation of HMG-CoA reductase.	Berberine	27-36	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	113-130
20926983-0	2011	Pretreatment with berberine and yohimbine protects against LPS-induced myocardial dysfunction via inhibition of cardiac I-[kappa]B[alpha] phosphorylation and apoptosis in mice.	Berberine	18-27	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	120-136
21359922-0	2011	Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats.	Berberine	10-19	uncoupling protein 2	Rattus norvegicus	38-58
21359922-1	2011	OBJECTIVE: To observe the effect of berberine on uncoupling protein-2 (UCP2) mRNA and protein expressions in the hepatic tissue of non-alcoholic fatty liver disease (NAFLD) in rats, and to explore the molecular mechanism.	Berberine	36-45	uncoupling protein 2	Rattus norvegicus	49-69
21359922-1	2011	OBJECTIVE: To observe the effect of berberine on uncoupling protein-2 (UCP2) mRNA and protein expressions in the hepatic tissue of non-alcoholic fatty liver disease (NAFLD) in rats, and to explore the molecular mechanism.	Berberine	36-45	uncoupling protein 2	Rattus norvegicus	71-75
21359922-12	2011	CONCLUSIONS: Berberine can down-regulate the expression levels of UCP2 mRNA and UCP2 proteins of hepatic tissue in NAFLD rats.	Berberine	13-22	uncoupling protein 2	Rattus norvegicus	66-70
21359922-12	2011	CONCLUSIONS: Berberine can down-regulate the expression levels of UCP2 mRNA and UCP2 proteins of hepatic tissue in NAFLD rats.	Berberine	13-22	uncoupling protein 2	Rattus norvegicus	80-84
20828602-6	2011	Berberine significantly up-regulated the declined cyclin-dependent kinase 9, cyclin T1 mRNA and protein expression in diabetic rat liver.	Berberine	0-9	cyclin-dependent kinase 9	Rattus norvegicus	50-75
20828602-6	2011	Berberine significantly up-regulated the declined cyclin-dependent kinase 9, cyclin T1 mRNA and protein expression in diabetic rat liver.	Berberine	0-9	cyclin T1	Rattus norvegicus	77-86
20828602-7	2011	Berberine obviously decreased malondialdehyde level and increased catalase, superoxide dismutase, glutathione peroxidase, and glutathione activities in liver tissue and serum of diabetic rats.	Berberine	0-9	catalase	Rattus norvegicus	66-74
21310849-8	2011	Furthermore, berberine and cryptotanshinone suppressed TF activity induced by lipopolysaccharides in human monocytes by this assay and might be promising new TF inhibitors.	Berberine	13-22	coagulation factor III, tissue factor	Homo sapiens	55-57
21310849-8	2011	Furthermore, berberine and cryptotanshinone suppressed TF activity induced by lipopolysaccharides in human monocytes by this assay and might be promising new TF inhibitors.	Berberine	13-22	coagulation factor III, tissue factor	Homo sapiens	158-160
21130434-0	2011	Berberine reduces insulin resistance: the roles for glucocorticoid receptor and aryl hydrocarbon receptor.	Berberine	0-9	insulin	Homo sapiens	18-25
21095217-0	2011	Hepatoprotective activity of berberine is mediated by inhibition of TNF-alpha, COX-2, and iNOS expression in CCl(4)-intoxicated mice.	Berberine	29-38	tumor necrosis factor	Mus musculus	68-77
21095217-0	2011	Hepatoprotective activity of berberine is mediated by inhibition of TNF-alpha, COX-2, and iNOS expression in CCl(4)-intoxicated mice.	Berberine	29-38	prostaglandin-endoperoxide synthase 2	Mus musculus	79-84
21095217-0	2011	Hepatoprotective activity of berberine is mediated by inhibition of TNF-alpha, COX-2, and iNOS expression in CCl(4)-intoxicated mice.	Berberine	29-38	nitric oxide synthase 2, inducible	Mus musculus	90-94
21095217-4	2011	The rise in serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) in CCl(4)-intoxicated mice was markedly suppressed by berberine in a concentration-dependent manner.	Berberine	179-188	glutamic pyruvic transaminase, soluble	Mus musculus	28-52
21095217-4	2011	The rise in serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) in CCl(4)-intoxicated mice was markedly suppressed by berberine in a concentration-dependent manner.	Berberine	179-188	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	60-86
21095217-6	2011	Histopathological changes were reduced and the expression of tumor necrosis factor-alpha (TNF-alpha), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) was markedly attenuated by berberine 10mg/mg.	Berberine	198-207	tumor necrosis factor	Mus musculus	61-88
21095217-6	2011	Histopathological changes were reduced and the expression of tumor necrosis factor-alpha (TNF-alpha), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) was markedly attenuated by berberine 10mg/mg.	Berberine	198-207	tumor necrosis factor	Mus musculus	90-99
21095217-6	2011	Histopathological changes were reduced and the expression of tumor necrosis factor-alpha (TNF-alpha), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) was markedly attenuated by berberine 10mg/mg.	Berberine	198-207	prostaglandin-endoperoxide synthase 2	Mus musculus	102-118
21095217-6	2011	Histopathological changes were reduced and the expression of tumor necrosis factor-alpha (TNF-alpha), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) was markedly attenuated by berberine 10mg/mg.	Berberine	198-207	nitric oxide synthase 2, inducible	Mus musculus	132-163
21095217-6	2011	Histopathological changes were reduced and the expression of tumor necrosis factor-alpha (TNF-alpha), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) was markedly attenuated by berberine 10mg/mg.	Berberine	198-207	nitric oxide synthase 2, inducible	Mus musculus	165-169
21823461-9	2011	At the same time, berberine increased the activities of GSH-Px and CAT (P &lt; 0.01) and slightly lowed the content of H2O2 in the kidney tissues.	Berberine	18-27	glutathione peroxidase 1	Rattus norvegicus	56-70
19576641-0	2011	Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages.	Berberine	0-9	matrix metallopeptidase 9	Homo sapiens	23-28
20414047-10	2011	Berberine reduced palmitate-induced lipoapoptosis and tended to increase GSIS in HIT-T15 cells, possibly through increased PPAR-gamma expression.	Berberine	0-9	peroxisome proliferator-activated receptor gamma	Mesocricetus auratus	123-133
21044622-0	2011	Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells.	Berberine	105-114	mitogen-activated protein kinase 8	Homo sapiens	8-11
21044622-0	2011	Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells.	Berberine	105-114	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	16-21
21044622-0	2011	Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells.	Berberine	105-114	paraoxonase 1	Homo sapiens	69-82
21044622-3	2011	However, the effect of berberine on PON1 gene expression remains unclear.	Berberine	23-32	paraoxonase 1	Homo sapiens	36-40
21044622-4	2011	Thus, we evaluated how berberine regulates PON1 gene expression.	Berberine	23-32	paraoxonase 1	Homo sapiens	43-47
21044622-5	2011	In human hepatoma HepG2 and Huh7 cells, the PON1 protein levels were increased by berberine in a dose- and time-dependent manner.	Berberine	82-91	paraoxonase 1	Homo sapiens	44-48
21044622-6	2011	Data from real time PCR analysis indicated that berberine could up-regulate PON1 expression at the transcriptional level.	Berberine	48-57	paraoxonase 1	Homo sapiens	76-80
21044622-7	2011	Additionally, treating HepG2 cells with berberine increased the levels of phosphorylated JNK and its downstream target c-Jun.	Berberine	40-49	mitogen-activated protein kinase 8	Homo sapiens	89-92
21044622-7	2011	Additionally, treating HepG2 cells with berberine increased the levels of phosphorylated JNK and its downstream target c-Jun.	Berberine	40-49	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	119-124
21044622-8	2011	The PON1 upstream region contained a consensus binding site for AP1, and the electrophoretic mobility shift assay and chromatin immunoprecipitation analysis indicated that the AP1 factors, especially c-Jun, bind to the upstream sequence of the PON1 promoter upon berberine treatment.	Berberine	263-272	paraoxonase 1	Homo sapiens	4-8
21044622-8	2011	The PON1 upstream region contained a consensus binding site for AP1, and the electrophoretic mobility shift assay and chromatin immunoprecipitation analysis indicated that the AP1 factors, especially c-Jun, bind to the upstream sequence of the PON1 promoter upon berberine treatment.	Berberine	263-272	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	176-179
21044622-8	2011	The PON1 upstream region contained a consensus binding site for AP1, and the electrophoretic mobility shift assay and chromatin immunoprecipitation analysis indicated that the AP1 factors, especially c-Jun, bind to the upstream sequence of the PON1 promoter upon berberine treatment.	Berberine	263-272	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	200-205
21044622-8	2011	The PON1 upstream region contained a consensus binding site for AP1, and the electrophoretic mobility shift assay and chromatin immunoprecipitation analysis indicated that the AP1 factors, especially c-Jun, bind to the upstream sequence of the PON1 promoter upon berberine treatment.	Berberine	263-272	paraoxonase 1	Homo sapiens	244-248
21044622-9	2011	Moreover, pretreatment with SP600125 (JNK inhibitor) or curcumin (AP-1 inhibitor) markedly attenuated the berberine-induced PON1 promoter activity and protein expression.	Berberine	106-115	mitogen-activated protein kinase 8	Homo sapiens	38-41
21044622-9	2011	Moreover, pretreatment with SP600125 (JNK inhibitor) or curcumin (AP-1 inhibitor) markedly attenuated the berberine-induced PON1 promoter activity and protein expression.	Berberine	106-115	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	66-70
21044622-9	2011	Moreover, pretreatment with SP600125 (JNK inhibitor) or curcumin (AP-1 inhibitor) markedly attenuated the berberine-induced PON1 promoter activity and protein expression.	Berberine	106-115	paraoxonase 1	Homo sapiens	124-128
21044622-10	2011	This is the first study to suggest that JNK/c-Jun signalling pathway plays a crucial role in berberine-regulated PON1 transcription in human hepatoma cells.	Berberine	93-102	mitogen-activated protein kinase 8	Homo sapiens	40-43
21044622-10	2011	This is the first study to suggest that JNK/c-Jun signalling pathway plays a crucial role in berberine-regulated PON1 transcription in human hepatoma cells.	Berberine	93-102	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	44-49
21044622-10	2011	This is the first study to suggest that JNK/c-Jun signalling pathway plays a crucial role in berberine-regulated PON1 transcription in human hepatoma cells.	Berberine	93-102	paraoxonase 1	Homo sapiens	113-117
21044622-11	2011	The induction of PON1 by berberine elucidates a potential mechanism through which berberine may protect against atherosclerosis.	Berberine	25-34	paraoxonase 1	Homo sapiens	17-21
21044622-11	2011	The induction of PON1 by berberine elucidates a potential mechanism through which berberine may protect against atherosclerosis.	Berberine	82-91	paraoxonase 1	Homo sapiens	17-21
21170508-0	2011	Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins.	Berberine	0-9	TNF superfamily member 10	Homo sapiens	21-26
21170508-0	2011	Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins.	Berberine	0-9	CASP8 and FADD like apoptosis regulator	Homo sapiens	91-97
21170508-0	2011	Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins.	Berberine	0-9	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	102-107
21170508-4	2011	The BBR-induced downregulation of c-FLIP and Mcl-1 proteins were involved in proteasome dependent pathways, which was confirmed by the result that pre-treatment with the proteasome inhibitor MG132 inhibited berberine-induced downregulation of the c-FLIP and Mcl-1 proteins.	Berberine	207-216	CASP8 and FADD like apoptosis regulator	Homo sapiens	34-40
21170508-4	2011	The BBR-induced downregulation of c-FLIP and Mcl-1 proteins were involved in proteasome dependent pathways, which was confirmed by the result that pre-treatment with the proteasome inhibitor MG132 inhibited berberine-induced downregulation of the c-FLIP and Mcl-1 proteins.	Berberine	207-216	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	45-50
21170508-4	2011	The BBR-induced downregulation of c-FLIP and Mcl-1 proteins were involved in proteasome dependent pathways, which was confirmed by the result that pre-treatment with the proteasome inhibitor MG132 inhibited berberine-induced downregulation of the c-FLIP and Mcl-1 proteins.	Berberine	207-216	CASP8 and FADD like apoptosis regulator	Homo sapiens	247-253
21170508-4	2011	The BBR-induced downregulation of c-FLIP and Mcl-1 proteins were involved in proteasome dependent pathways, which was confirmed by the result that pre-treatment with the proteasome inhibitor MG132 inhibited berberine-induced downregulation of the c-FLIP and Mcl-1 proteins.	Berberine	207-216	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	258-263
21170508-5	2011	Pretreatment with N-acetyl-L-cysteine (NAC) significantly inhibited the cell death induced by the combined treatment with BBR and TRAIL as well as recovered the expression levels of c-FLIP and Mcl-1 downregulated by treatment with BBR.	Berberine	122-125	X-linked Kx blood group	Homo sapiens	39-42
21170508-5	2011	Pretreatment with N-acetyl-L-cysteine (NAC) significantly inhibited the cell death induced by the combined treatment with BBR and TRAIL as well as recovered the expression levels of c-FLIP and Mcl-1 downregulated by treatment with BBR.	Berberine	231-234	X-linked Kx blood group	Homo sapiens	39-42
21170508-5	2011	Pretreatment with N-acetyl-L-cysteine (NAC) significantly inhibited the cell death induced by the combined treatment with BBR and TRAIL as well as recovered the expression levels of c-FLIP and Mcl-1 downregulated by treatment with BBR.	Berberine	231-234	CASP8 and FADD like apoptosis regulator	Homo sapiens	182-188
21170508-5	2011	Pretreatment with N-acetyl-L-cysteine (NAC) significantly inhibited the cell death induced by the combined treatment with BBR and TRAIL as well as recovered the expression levels of c-FLIP and Mcl-1 downregulated by treatment with BBR.	Berberine	231-234	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	193-198
19576641-0	2011	Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages.	Berberine	0-9	basigin (Ok blood group)	Homo sapiens	33-40
19576641-0	2011	Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	74-77
19576641-3	2011	The purpose of our study was to determine if berberine, a natural extract from Rhizoma coptidis, had any effect on the expression of MMP-9 and EMMPRIN in PMA-induced macrophages.	Berberine	45-54	matrix metallopeptidase 9	Homo sapiens	133-138
19576641-3	2011	The purpose of our study was to determine if berberine, a natural extract from Rhizoma coptidis, had any effect on the expression of MMP-9 and EMMPRIN in PMA-induced macrophages.	Berberine	45-54	basigin (Ok blood group)	Homo sapiens	143-150
19576641-6	2011	RESULTS: In the present study, we demonstrated that berberine inhibited the expression of MMP-9 and EMMPRIN at both the mRNA and protein levels in a dose-dependent manner in PMA-induced macrophages, and that it also reduced MMP-9 activity.	Berberine	52-61	matrix metallopeptidase 9	Homo sapiens	90-95
19576641-6	2011	RESULTS: In the present study, we demonstrated that berberine inhibited the expression of MMP-9 and EMMPRIN at both the mRNA and protein levels in a dose-dependent manner in PMA-induced macrophages, and that it also reduced MMP-9 activity.	Berberine	52-61	basigin (Ok blood group)	Homo sapiens	100-107
19576641-6	2011	RESULTS: In the present study, we demonstrated that berberine inhibited the expression of MMP-9 and EMMPRIN at both the mRNA and protein levels in a dose-dependent manner in PMA-induced macrophages, and that it also reduced MMP-9 activity.	Berberine	52-61	matrix metallopeptidase 9	Homo sapiens	224-229
19576641-7	2011	Furthermore, berberine also suppressed p38 signaling pathway activation in PMA-induced macrophages.	Berberine	13-22	mitogen-activated protein kinase 14	Homo sapiens	39-42
19576641-8	2011	CONCLUSIONS: The data indicate that berberine reduces MMP-9 and EMMPRIN expression by suppressing the activation of p38 pathway in PMA-induced macrophages.	Berberine	36-45	matrix metallopeptidase 9	Homo sapiens	54-59
19576641-8	2011	CONCLUSIONS: The data indicate that berberine reduces MMP-9 and EMMPRIN expression by suppressing the activation of p38 pathway in PMA-induced macrophages.	Berberine	36-45	basigin (Ok blood group)	Homo sapiens	64-71
19576641-8	2011	CONCLUSIONS: The data indicate that berberine reduces MMP-9 and EMMPRIN expression by suppressing the activation of p38 pathway in PMA-induced macrophages.	Berberine	36-45	mitogen-activated protein kinase 14	Homo sapiens	116-119
21532151-0	2011	Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver x receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters.	Berberine	0-9	insulin	Homo sapiens	49-56
21532151-5	2011	Then, we investigated the gene expression alterations and explored the molecular mechanisms underlying the therapeutic effect of berberine on fat-induced visceral white adipose tissue insulin resistance in diabetic hamsters by microarray analysis followed by real-time reverse transcription-polymerase chain reaction (RT-PCR) confirmation.	Berberine	129-138	insulin	Homo sapiens	184-191
21532151-8	2011	After 9-week berberine treatment, fat-induced insulin resistance and diabetic phenotype in type 2 diabetic hamsters were significantly improved.	Berberine	13-22	insulin	Homo sapiens	46-53
21532151-10	2011	These results suggest that altered visceral white adipose tissue LXRs, PPARs, and SREBPs transcriptional programs are involved in the therapeutic mechanisms of berberine on fat-induced visceral white adipose tissue insulin resistance in type 2 diabetic hamsters.	Berberine	160-169	insulin	Homo sapiens	215-222
20974686-0	2011	Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E2 and prostaglandin E2 receptors.	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	108-124
20974686-4	2011	We found that treatment of A375 and Hs294 cells with berberine resulted in concentration-dependent inhibition of migration of these cells, which was associated with a reduction in the levels of COX-2, PGE2 and PGE2 receptors (EP2 and EP4).	Berberine	53-62	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	194-199
20974686-4	2011	We found that treatment of A375 and Hs294 cells with berberine resulted in concentration-dependent inhibition of migration of these cells, which was associated with a reduction in the levels of COX-2, PGE2 and PGE2 receptors (EP2 and EP4).	Berberine	53-62	prostaglandin E receptor 2	Homo sapiens	226-229
20974686-4	2011	We found that treatment of A375 and Hs294 cells with berberine resulted in concentration-dependent inhibition of migration of these cells, which was associated with a reduction in the levels of COX-2, PGE2 and PGE2 receptors (EP2 and EP4).	Berberine	53-62	prostaglandin E receptor 4	Homo sapiens	234-237
20974686-7	2011	Berberine reduced the basal levels as well as PGE2-stimulated expression levels of EP2 and EP4.	Berberine	0-9	prostaglandin E receptor 2	Homo sapiens	83-86
20974686-7	2011	Berberine reduced the basal levels as well as PGE2-stimulated expression levels of EP2 and EP4.	Berberine	0-9	prostaglandin E receptor 4	Homo sapiens	91-94
20974686-8	2011	Treatment of the cells with the EP4 agonist stimulated cell migration and berberine blocked EP4 agonist-induced cell migration activity.	Berberine	74-83	prostaglandin E receptor 4	Homo sapiens	32-35
20974686-8	2011	Treatment of the cells with the EP4 agonist stimulated cell migration and berberine blocked EP4 agonist-induced cell migration activity.	Berberine	74-83	prostaglandin E receptor 4	Homo sapiens	92-95
20974686-9	2011	Moreover, berberine inhibited the activation of nuclear factor-kappa B (NF-kappaB), an upstream regulator of COX-2, in A375 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappaB, inhibited cell migration.	Berberine	10-19	nuclear factor kappa B subunit 1	Homo sapiens	48-70
20974686-9	2011	Moreover, berberine inhibited the activation of nuclear factor-kappa B (NF-kappaB), an upstream regulator of COX-2, in A375 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappaB, inhibited cell migration.	Berberine	10-19	nuclear factor kappa B subunit 1	Homo sapiens	72-81
20974686-9	2011	Moreover, berberine inhibited the activation of nuclear factor-kappa B (NF-kappaB), an upstream regulator of COX-2, in A375 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappaB, inhibited cell migration.	Berberine	10-19	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	109-114
20974686-9	2011	Moreover, berberine inhibited the activation of nuclear factor-kappa B (NF-kappaB), an upstream regulator of COX-2, in A375 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappaB, inhibited cell migration.	Berberine	10-19	nuclear factor kappa B subunit 1	Homo sapiens	205-214
20974686-10	2011	Together, these results indicate for the first time that berberine inhibits melanoma cell migration, an essential step in invasion and metastasis, by inhibition of COX-2, PGE2 and PGE2 receptors.	Berberine	57-66	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	164-169
20953398-9	2011	These results suggest that berberine moderates glucose and lipid metabolism through a multipathway mechanism that includes AMP-activated protein kinase-(AMPK-) p38 MAPK-GLUT4, JNK pathway, and PPARalpha pathway.	Berberine	27-36	mitogen-activated protein kinase 14	Mus musculus	160-168
21705841-0	2011	Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	99-102
21705841-7	2011	Berberine also depressed the increasing of phosphorylated GSK-3beta in diabetic mice.	Berberine	0-9	glycogen synthase kinase 3 beta	Mus musculus	58-67
21705841-8	2011	Collectively, Berberine upregulates the activity of Akt possibly via insulin signaling pathway, eventually lowering high blood glucose in alloxan-induced diabetic mice.	Berberine	14-23	thymoma viral proto-oncogene 1	Mus musculus	52-55
20953398-9	2011	These results suggest that berberine moderates glucose and lipid metabolism through a multipathway mechanism that includes AMP-activated protein kinase-(AMPK-) p38 MAPK-GLUT4, JNK pathway, and PPARalpha pathway.	Berberine	27-36	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	169-174
20953398-9	2011	These results suggest that berberine moderates glucose and lipid metabolism through a multipathway mechanism that includes AMP-activated protein kinase-(AMPK-) p38 MAPK-GLUT4, JNK pathway, and PPARalpha pathway.	Berberine	27-36	mitogen-activated protein kinase 8	Mus musculus	176-179
20953398-9	2011	These results suggest that berberine moderates glucose and lipid metabolism through a multipathway mechanism that includes AMP-activated protein kinase-(AMPK-) p38 MAPK-GLUT4, JNK pathway, and PPARalpha pathway.	Berberine	27-36	peroxisome proliferator activated receptor alpha	Mus musculus	193-202
20674665-7	2011	RESULTS: Our results revealed that berberine significantly suppressed LPS-induced cell proliferation and inhibited LPS-induced NF-kappaB nuclear translocation in MCs, as well as protein expression of ICAM-1, TGF-beta1, iNOS and FN.	Berberine	35-44	intercellular adhesion molecule 1	Rattus norvegicus	200-206
21647250-0	2011	Berberine regulated Gck, G6pc, Pck1 and Srebp-1c expression and activated AMP-activated protein kinase in primary rat hepatocytes.	Berberine	0-9	glucokinase	Rattus norvegicus	20-23
21647250-0	2011	Berberine regulated Gck, G6pc, Pck1 and Srebp-1c expression and activated AMP-activated protein kinase in primary rat hepatocytes.	Berberine	0-9	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	25-29
21647250-0	2011	Berberine regulated Gck, G6pc, Pck1 and Srebp-1c expression and activated AMP-activated protein kinase in primary rat hepatocytes.	Berberine	0-9	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	31-35
21647250-0	2011	Berberine regulated Gck, G6pc, Pck1 and Srebp-1c expression and activated AMP-activated protein kinase in primary rat hepatocytes.	Berberine	0-9	sterol regulatory element binding transcription factor 1	Rattus norvegicus	40-48
22363882-6	2011	Berberine lowered plasma free fatty acids and C-reactive protein levels without affecting plasma insulin levels.	Berberine	0-9	C-reactive protein	Rattus norvegicus	46-64
22363882-8	2011	Furthermore, berberine inhibited dipeptidyl peptidase-4 and protein tyrosine phosphatase-1B activities.	Berberine	13-22	dipeptidylpeptidase 4	Rattus norvegicus	33-91
21175812-0	2011	Berberine inhibits angiogenic potential of Hep G2 cell line through VEGF down-regulation in vitro.	Berberine	0-9	vascular endothelial growth factor A	Homo sapiens	68-72
21175812-7	2011	Subsequently analyses reveal that berberine prevents secretion of VEGF from HCC and down-regulates VEGF mRNA expression.	Berberine	34-43	vascular endothelial growth factor A	Homo sapiens	66-70
21175812-7	2011	Subsequently analyses reveal that berberine prevents secretion of VEGF from HCC and down-regulates VEGF mRNA expression.	Berberine	34-43	vascular endothelial growth factor A	Homo sapiens	99-103
20674665-1	2011	BACKGROUND: Our previous studies demonstrated that berberine could improve the renal function in rats and mice with diabetic nephropathy (DN) and inhibit extracellular matrix (ECM) component, fibronectin (FN) expression in rat mesangial cells (MCs) cultured under high glucose.	Berberine	51-60	fibronectin 1	Mus musculus	192-203
20674665-1	2011	BACKGROUND: Our previous studies demonstrated that berberine could improve the renal function in rats and mice with diabetic nephropathy (DN) and inhibit extracellular matrix (ECM) component, fibronectin (FN) expression in rat mesangial cells (MCs) cultured under high glucose.	Berberine	51-60	fibronectin 1	Mus musculus	205-207
20840879-0	2011	Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro.	Berberine	0-9	insulin	Homo sapiens	18-25
20840879-1	2011	Theca cells with dexamethasone-induced insulin resistance showed defective glucose uptake and excessive testosterone production, both of which were effectively antagonized by berberine.	Berberine	175-184	insulin	Homo sapiens	39-46
21297267-5	2011	Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3beta (GSK-3beta) activation, as determined by phosphatase activity assay and GSK-3beta phosphorylation at Tyr216 and Ser9, respectively.	Berberine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	68-98
21297267-5	2011	Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3beta (GSK-3beta) activation, as determined by phosphatase activity assay and GSK-3beta phosphorylation at Tyr216 and Ser9, respectively.	Berberine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	100-109
21297267-5	2011	Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3beta (GSK-3beta) activation, as determined by phosphatase activity assay and GSK-3beta phosphorylation at Tyr216 and Ser9, respectively.	Berberine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	171-180
20674665-7	2011	RESULTS: Our results revealed that berberine significantly suppressed LPS-induced cell proliferation and inhibited LPS-induced NF-kappaB nuclear translocation in MCs, as well as protein expression of ICAM-1, TGF-beta1, iNOS and FN.	Berberine	35-44	transforming growth factor, beta 1	Rattus norvegicus	208-217
20674665-7	2011	RESULTS: Our results revealed that berberine significantly suppressed LPS-induced cell proliferation and inhibited LPS-induced NF-kappaB nuclear translocation in MCs, as well as protein expression of ICAM-1, TGF-beta1, iNOS and FN.	Berberine	35-44	nitric oxide synthase 2	Rattus norvegicus	219-223
20674665-8	2011	CONCLUSION: Berberine significantly repressed LPS-induced cell proliferation and FN expression in rat MCs through inhibiting the activation of NF-kappaB signaling pathway and protein expression of its downstream inflammatory mediators.	Berberine	12-21	fibronectin 1	Rattus norvegicus	81-83
20623609-0	2011	Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model.	Berberine	0-9	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	46-49
20623609-0	2011	Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model.	Berberine	0-9	potassium inwardly-rectifying channel, subfamily J, member 2	Rattus norvegicus	50-56
20623609-11	2011	The relative expression of Kir2.1 in rats in the MI and T2DM+MI group were both significantly decreased (P &lt; 0.05); berberine recovered depressed Kir2.1 to nearly normal levels.	Berberine	119-128	potassium inwardly-rectifying channel, subfamily J, member 2	Rattus norvegicus	149-155
20623609-12	2011	The results suggest that the effects of berberine on I(K1)/Kir2.1 may be an important mechanism for producing anti-arrhythmic effects.	Berberine	40-49	potassium inwardly-rectifying channel, subfamily J, member 2	Rattus norvegicus	59-65
21980456-1	2011	AIMS: Berberine, a botanical alkaloid purified from Coptidis rhizoma, is reported to activate the AMP-activated protein kinase (AMPK).	Berberine	6-15	protein kinase, AMP-activated, alpha 2 catalytic subunit	Mus musculus	128-132
21980456-3	2011	This study was designed to determine whether AMPK is required for berberine-induced reduction of oxidative stress and atherosclerosis in vivo.	Berberine	66-75	protein kinase, AMP-activated, alpha 2 catalytic subunit	Mus musculus	45-49
21980456-6	2011	RESULTS: In ApoE-/- mice, chronic administration of berberine significantly reduced aortic lesions, markedly reduced oxidative stress and expression of adhesion molecules in aorta, and significantly increased UCP2 levels.	Berberine	52-61	apolipoprotein E	Mus musculus	12-16
21980456-6	2011	RESULTS: In ApoE-/- mice, chronic administration of berberine significantly reduced aortic lesions, markedly reduced oxidative stress and expression of adhesion molecules in aorta, and significantly increased UCP2 levels.	Berberine	52-61	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	209-213
21980456-8	2011	In cultured human umbilical vein endothelial cells (HUVECs), berberine significantly increased UCP2 mRNA and protein expression in an AMPK-dependent manner.	Berberine	61-70	uncoupling protein 2	Homo sapiens	95-99
21980456-8	2011	In cultured human umbilical vein endothelial cells (HUVECs), berberine significantly increased UCP2 mRNA and protein expression in an AMPK-dependent manner.	Berberine	61-70	protein kinase, AMP-activated, alpha 2 catalytic subunit	Mus musculus	134-138
21980456-9	2011	Transfection of HUVECs with nuclear respiratory factor 1 (NRF1)-specific siRNA attenuated berberine-induced expression of UCP2, whereas transfection with control siRNA did not.	Berberine	90-99	nuclear respiratory factor 1	Mus musculus	28-56
21980456-9	2011	Transfection of HUVECs with nuclear respiratory factor 1 (NRF1)-specific siRNA attenuated berberine-induced expression of UCP2, whereas transfection with control siRNA did not.	Berberine	90-99	nuclear respiratory factor 1	Mus musculus	58-62
21980456-9	2011	Transfection of HUVECs with nuclear respiratory factor 1 (NRF1)-specific siRNA attenuated berberine-induced expression of UCP2, whereas transfection with control siRNA did not.	Berberine	90-99	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	122-126
21980456-10	2011	Finally, berberine promoted mitochondrial biogenesis that contributed to up-regulation of UCP2 expression.	Berberine	9-18	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	90-94
21980456-11	2011	CONCLUSION: We conclude that berberine reduces oxidative stress and vascular inflammation, and suppresses atherogenesis via a mechanism that includes stimulation of AMPK-dependent UCP2 expression.	Berberine	29-38	protein kinase, AMP-activated, alpha 2 catalytic subunit	Mus musculus	165-169
21915347-9	2011	Furthermore, both RC and berberine significantly increase fasting-induced adipose factor (Fiaf, a key protein negatively regulated by intestinal microbes) expressions in either intestinal or visceral adipose tissues.	Berberine	25-34	angiopoietin-like 4	Mus musculus	58-88
21915347-9	2011	Furthermore, both RC and berberine significantly increase fasting-induced adipose factor (Fiaf, a key protein negatively regulated by intestinal microbes) expressions in either intestinal or visceral adipose tissues.	Berberine	25-34	angiopoietin-like 4	Mus musculus	90-94
21915347-11	2011	These results firstly suggest that antimicrobial activities of RC and berberine may result in decreasing degradation of dietary polysaccharides, lowering potential calorie intake, and then systemically activating Fiaf protein and related gene expressions of mitochondrial energy metabolism in visceral adipose tissues.	Berberine	70-79	angiopoietin-like 4	Mus musculus	213-217
21980456-11	2011	CONCLUSION: We conclude that berberine reduces oxidative stress and vascular inflammation, and suppresses atherogenesis via a mechanism that includes stimulation of AMPK-dependent UCP2 expression.	Berberine	29-38	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	180-184
21738655-5	2011	Berberine exerted anti-invasive effect on HepG2 cells through suppression of matrix metalloproteinase-9 (MMP-9) expression.	Berberine	0-9	matrix metallopeptidase 9	Homo sapiens	77-103
21858113-0	2011	Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51.	Berberine	0-9	RAD51 recombinase	Homo sapiens	114-119
21858113-7	2011	Berberine pretreatment led to a significant downregulation of RAD51, a key player in homologous recombination repair, in ESCC cells, but not in non-malignant human cells.	Berberine	0-9	RAD51 recombinase	Homo sapiens	62-67
21858113-8	2011	Downregulation of RAD51 by RNA interference similarly radiosensitized the cancer cells, and, conversely, introduction of exogenous RAD51 was able to significantly counteract the radiosensitizing effect of berberine, thus establishing RAD51 as a key determinant in radiation sensitivity.	Berberine	205-214	RAD51 recombinase	Homo sapiens	131-136
21858113-8	2011	Downregulation of RAD51 by RNA interference similarly radiosensitized the cancer cells, and, conversely, introduction of exogenous RAD51 was able to significantly counteract the radiosensitizing effect of berberine, thus establishing RAD51 as a key determinant in radiation sensitivity.	Berberine	205-214	RAD51 recombinase	Homo sapiens	131-136
21858113-10	2011	CONCLUSIONS/SIGNIFICANCE: Berberine can effectively downregulate RAD51 in conferring radiosensitivity on esophageal cancer cells.	Berberine	26-35	RAD51 recombinase	Homo sapiens	65-70
21887260-7	2011	Based on results from this study, we hypothesize that berberine can suppress the transcription of DNA in living cell systems, especially suppressing the association between TBP and the TATA box by binding with DNA and, thus, inhibiting TATA box-dependent gene expression in a non-specific way.	Berberine	54-63	TATA-box binding protein	Homo sapiens	173-176
21738655-5	2011	Berberine exerted anti-invasive effect on HepG2 cells through suppression of matrix metalloproteinase-9 (MMP-9) expression.	Berberine	0-9	matrix metallopeptidase 9	Homo sapiens	105-110
21738655-6	2011	Moreover, berberine could significantly inhibit the activity of PI3K-AKT and ERK pathways.	Berberine	10-19	AKT serine/threonine kinase 1	Homo sapiens	69-72
21738655-6	2011	Moreover, berberine could significantly inhibit the activity of PI3K-AKT and ERK pathways.	Berberine	10-19	mitogen-activated protein kinase 1	Homo sapiens	77-80
21738655-7	2011	Combination treatment of ERK pathway inhibitor PD98059 or AKT pathway inhibitor LY294002 and berberine could result in a synergistic reduction on MMP-9 expression along with an inhibition of cell invasion.	Berberine	93-102	mitogen-activated protein kinase 1	Homo sapiens	25-28
21738655-7	2011	Combination treatment of ERK pathway inhibitor PD98059 or AKT pathway inhibitor LY294002 and berberine could result in a synergistic reduction on MMP-9 expression along with an inhibition of cell invasion.	Berberine	93-102	AKT serine/threonine kinase 1	Homo sapiens	58-61
21738655-7	2011	Combination treatment of ERK pathway inhibitor PD98059 or AKT pathway inhibitor LY294002 and berberine could result in a synergistic reduction on MMP-9 expression along with an inhibition of cell invasion.	Berberine	93-102	matrix metallopeptidase 9	Homo sapiens	146-151
21738655-9	2011	In conclusion, our results suggest that berberine may be a potential alternative against invasive hepatoma cells through PI3K-AKT and ERK pathways-dependent downregulation of MMP-9 expression.	Berberine	40-49	AKT serine/threonine kinase 1	Homo sapiens	126-129
21738655-9	2011	In conclusion, our results suggest that berberine may be a potential alternative against invasive hepatoma cells through PI3K-AKT and ERK pathways-dependent downregulation of MMP-9 expression.	Berberine	40-49	mitogen-activated protein kinase 1	Homo sapiens	134-137
21738655-9	2011	In conclusion, our results suggest that berberine may be a potential alternative against invasive hepatoma cells through PI3K-AKT and ERK pathways-dependent downregulation of MMP-9 expression.	Berberine	40-49	matrix metallopeptidase 9	Homo sapiens	175-180
20674666-1	2010	Our previous studies proved that berberine (BBR) up-regulates the insulin receptor (InsR) gene by stimulating its promoter and calphostin C blocks this effect.	Berberine	33-42	insulin receptor	Homo sapiens	66-82
20674666-7	2010	BBR enhanced the PKD1 catalytic activity, but not its expression.	Berberine	0-3	polycystin 1, transient receptor potential channel interacting	Homo sapiens	17-21
20868663-3	2010	Berberine promoted differentiation and inhibited lipid accumulation of 3T3-L1 cells, further decreased PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression and decreased tumor necrosis factor alpha content in supernatants of both control and RNA interference-treated 3T3-L1 cells.	Berberine	0-9	peroxisome proliferator activated receptor alpha	Mus musculus	103-124
20868663-3	2010	Berberine promoted differentiation and inhibited lipid accumulation of 3T3-L1 cells, further decreased PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression and decreased tumor necrosis factor alpha content in supernatants of both control and RNA interference-treated 3T3-L1 cells.	Berberine	0-9	cyclin-dependent kinase 9 (CDC2-related kinase)	Mus musculus	126-130
20868663-3	2010	Berberine promoted differentiation and inhibited lipid accumulation of 3T3-L1 cells, further decreased PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression and decreased tumor necrosis factor alpha content in supernatants of both control and RNA interference-treated 3T3-L1 cells.	Berberine	0-9	cyclin T1	Mus musculus	135-144
20868663-3	2010	Berberine promoted differentiation and inhibited lipid accumulation of 3T3-L1 cells, further decreased PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression and decreased tumor necrosis factor alpha content in supernatants of both control and RNA interference-treated 3T3-L1 cells.	Berberine	0-9	tumor necrosis factor	Mus musculus	187-214
20868663-7	2010	Berberine upregulated PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression in adipose tissue, decreased tumor necrosis factor alpha and free fatty acid content and increased lipoprotein lipase activity in serum and adipose tissue.	Berberine	0-9	peroxisome proliferator activated receptor alpha	Rattus norvegicus	22-43
20868663-7	2010	Berberine upregulated PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression in adipose tissue, decreased tumor necrosis factor alpha and free fatty acid content and increased lipoprotein lipase activity in serum and adipose tissue.	Berberine	0-9	cyclin-dependent kinase 9	Rattus norvegicus	45-49
20868663-7	2010	Berberine upregulated PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression in adipose tissue, decreased tumor necrosis factor alpha and free fatty acid content and increased lipoprotein lipase activity in serum and adipose tissue.	Berberine	0-9	cyclin T1	Rattus norvegicus	54-63
20868663-7	2010	Berberine upregulated PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression in adipose tissue, decreased tumor necrosis factor alpha and free fatty acid content and increased lipoprotein lipase activity in serum and adipose tissue.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	121-148
20868663-7	2010	Berberine upregulated PPARalpha/delta/gamma, CDK9 and cyclin T1 mRNA and protein expression in adipose tissue, decreased tumor necrosis factor alpha and free fatty acid content and increased lipoprotein lipase activity in serum and adipose tissue.	Berberine	0-9	lipoprotein lipase	Rattus norvegicus	191-209
20830746-4	2010	Berberine-induced cell death in human hepatic carcinoma cells was diminished in the presence of the cell death inhibitor 3-methyladenine, or following interference with the essential autophagy gene Atg5.	Berberine	0-9	autophagy related 5	Homo sapiens	198-202
20674666-9	2010	BBR also induces PKD1 translocation from cytosol-to-plasma membrane, further verifying the activation of PKD1.	Berberine	0-3	polycystin 1, transient receptor potential channel interacting	Homo sapiens	17-21
20674666-9	2010	BBR also induces PKD1 translocation from cytosol-to-plasma membrane, further verifying the activation of PKD1.	Berberine	0-3	polycystin 1, transient receptor potential channel interacting	Homo sapiens	105-109
20674666-1	2010	Our previous studies proved that berberine (BBR) up-regulates the insulin receptor (InsR) gene by stimulating its promoter and calphostin C blocks this effect.	Berberine	33-42	insulin receptor	Homo sapiens	84-88
20830746-5	2010	Mechanistic studies showed that berberine may activate mitochondrial apoptosis in HepG2 and MHCC97-L cells by increasing Bax expression, the formation of permeable transition pores, cytochrome C release to cytosol, and subsequent activation of the caspases 3 and 9 execution pathway.	Berberine	32-41	BCL2 associated X, apoptosis regulator	Homo sapiens	121-124
20674666-1	2010	Our previous studies proved that berberine (BBR) up-regulates the insulin receptor (InsR) gene by stimulating its promoter and calphostin C blocks this effect.	Berberine	44-47	insulin receptor	Homo sapiens	66-82
20830746-5	2010	Mechanistic studies showed that berberine may activate mitochondrial apoptosis in HepG2 and MHCC97-L cells by increasing Bax expression, the formation of permeable transition pores, cytochrome C release to cytosol, and subsequent activation of the caspases 3 and 9 execution pathway.	Berberine	32-41	cytochrome c, somatic	Homo sapiens	182-194
20674666-1	2010	Our previous studies proved that berberine (BBR) up-regulates the insulin receptor (InsR) gene by stimulating its promoter and calphostin C blocks this effect.	Berberine	44-47	insulin receptor	Homo sapiens	84-88
20830746-6	2010	Berberine may also induce autophagic cell death in HepG2 and MHCC97-L cells through activation of Beclin-1 and inhibition of the mTOR-signaling pathway by suppressing the activity of Akt and up-regulating P38 MAPK signaling.	Berberine	0-9	beclin 1	Homo sapiens	98-106
20828550-1	2010	Berberine, which is a major constituent of the rhizome of Coptidis japonica (CJ), inhibits IL-8 production in colonic epithelial cells and improves 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice.	Berberine	0-9	chemokine (C-X-C motif) ligand 15	Mus musculus	91-95
20830746-6	2010	Berberine may also induce autophagic cell death in HepG2 and MHCC97-L cells through activation of Beclin-1 and inhibition of the mTOR-signaling pathway by suppressing the activity of Akt and up-regulating P38 MAPK signaling.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	129-133
20830746-6	2010	Berberine may also induce autophagic cell death in HepG2 and MHCC97-L cells through activation of Beclin-1 and inhibition of the mTOR-signaling pathway by suppressing the activity of Akt and up-regulating P38 MAPK signaling.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	183-186
20830746-7	2010	This is the first study to describe the role of Beclin-1 activation and mTOR inhibition in berberine-induced autophagic cell death.	Berberine	91-100	beclin 1	Homo sapiens	48-56
20830746-7	2010	This is the first study to describe the role of Beclin-1 activation and mTOR inhibition in berberine-induced autophagic cell death.	Berberine	91-100	mechanistic target of rapamycin kinase	Homo sapiens	72-76
20828550-2	2010	In our preliminary studies, berberine inhibited lipid peroxidation in liposomes prepared from l-alpha-phosphatidylcholine as well as TLR-4-linked NF-kappaB activation in HEK cells.	Berberine	28-37	toll-like receptor 4	Mus musculus	133-138
20828550-5	2010	Berberine inhibited colonic expression of iNOS, COX-2, IL-1beta, IL-6, and TNF-alpha, but increased IL-10 expression in the colons of TNBS-treated C3H/HeN and C3H/HeJ mice.	Berberine	0-9	nitric oxide synthase 2, inducible	Mus musculus	42-46
20828550-5	2010	Berberine inhibited colonic expression of iNOS, COX-2, IL-1beta, IL-6, and TNF-alpha, but increased IL-10 expression in the colons of TNBS-treated C3H/HeN and C3H/HeJ mice.	Berberine	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	48-53
20828550-5	2010	Berberine inhibited colonic expression of iNOS, COX-2, IL-1beta, IL-6, and TNF-alpha, but increased IL-10 expression in the colons of TNBS-treated C3H/HeN and C3H/HeJ mice.	Berberine	0-9	interleukin 1 beta	Mus musculus	55-63
20828550-5	2010	Berberine inhibited colonic expression of iNOS, COX-2, IL-1beta, IL-6, and TNF-alpha, but increased IL-10 expression in the colons of TNBS-treated C3H/HeN and C3H/HeJ mice.	Berberine	0-9	interleukin 6	Mus musculus	65-69
20828550-5	2010	Berberine inhibited colonic expression of iNOS, COX-2, IL-1beta, IL-6, and TNF-alpha, but increased IL-10 expression in the colons of TNBS-treated C3H/HeN and C3H/HeJ mice.	Berberine	0-9	tumor necrosis factor	Mus musculus	75-84
20935220-0	2010	Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells.	Berberine	47-56	MDM2 proto-oncogene	Homo sapiens	15-19
20828550-5	2010	Berberine inhibited colonic expression of iNOS, COX-2, IL-1beta, IL-6, and TNF-alpha, but increased IL-10 expression in the colons of TNBS-treated C3H/HeN and C3H/HeJ mice.	Berberine	0-9	interleukin 10	Mus musculus	100-105
20828550-6	2010	Berberine also inhibited NF-kappaB activation in TNBS-treated C3H/HeN and C3H/HeJ mice, and inhibited TLR-4 expression in C3H/HeN, but not C3H/HeJ, mice.	Berberine	0-9	toll-like receptor 4	Mus musculus	102-107
20935220-0	2010	Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells.	Berberine	47-56	MDM2 proto-oncogene	Homo sapiens	95-99
20935220-2	2010	Herein, we demonstrate that berberine induces apoptosis in acute lymphoblastic leukemia (ALL) cells by downregulating the MDM2 oncoprotein.	Berberine	28-37	MDM2 proto-oncogene	Homo sapiens	122-126
20213508-0	2010	Binding of berberine to bovine serum albumin: spectroscopic approach.	Berberine	11-20	albumin	Homo sapiens	31-44
20935220-3	2010	The proapoptotic effects of berberine were closely associated with both the MDM2 expression levels and p53 status of a set of ALL cell lines.	Berberine	28-37	MDM2 proto-oncogene	Homo sapiens	76-80
20935220-3	2010	The proapoptotic effects of berberine were closely associated with both the MDM2 expression levels and p53 status of a set of ALL cell lines.	Berberine	28-37	tumor protein p53	Homo sapiens	103-106
20935220-4	2010	The most potent apoptosis was induced by berberine in ALL cells with both MDM2 overexpression and a wild-type (wt)-p53, whereas no proapoptotic effect was detected in ALL cells that were negative for MDM2 and wt-p53.	Berberine	41-50	MDM2 proto-oncogene	Homo sapiens	74-78
20935220-4	2010	The most potent apoptosis was induced by berberine in ALL cells with both MDM2 overexpression and a wild-type (wt)-p53, whereas no proapoptotic effect was detected in ALL cells that were negative for MDM2 and wt-p53.	Berberine	41-50	tumor protein p53	Homo sapiens	115-118
20935220-4	2010	The most potent apoptosis was induced by berberine in ALL cells with both MDM2 overexpression and a wild-type (wt)-p53, whereas no proapoptotic effect was detected in ALL cells that were negative for MDM2 and wt-p53.	Berberine	41-50	tumor protein p53	Homo sapiens	212-215
20935220-5	2010	In contrast to the conventional chemotherapeutic drug doxorubicin, which induces p53 activation and a subsequent upregulation of MDM2, berberine strongly induced persistent downregulation of MDM2 followed by a steady-state activation of p53.	Berberine	135-144	tumor protein p53	Homo sapiens	81-84
20935220-5	2010	In contrast to the conventional chemotherapeutic drug doxorubicin, which induces p53 activation and a subsequent upregulation of MDM2, berberine strongly induced persistent downregulation of MDM2 followed by a steady-state activation of p53.	Berberine	135-144	MDM2 proto-oncogene	Homo sapiens	129-133
20935220-5	2010	In contrast to the conventional chemotherapeutic drug doxorubicin, which induces p53 activation and a subsequent upregulation of MDM2, berberine strongly induced persistent downregulation of MDM2 followed by a steady-state activation of p53.	Berberine	135-144	MDM2 proto-oncogene	Homo sapiens	191-195
20935220-5	2010	In contrast to the conventional chemotherapeutic drug doxorubicin, which induces p53 activation and a subsequent upregulation of MDM2, berberine strongly induced persistent downregulation of MDM2 followed by a steady-state activation of p53.	Berberine	135-144	tumor protein p53	Homo sapiens	237-240
20935220-6	2010	We discovered that downregulation of MDM2 in ALL cells by berberine occurred at a posttranslational level through modulation of death domain-associated protein (DAXX), which disrupted the MDM2-DAXX-HAUSP interactions and thereby promoted MDM2 self-ubiquitination and degradation.	Berberine	58-67	MDM2 proto-oncogene	Homo sapiens	37-41
20935220-6	2010	We discovered that downregulation of MDM2 in ALL cells by berberine occurred at a posttranslational level through modulation of death domain-associated protein (DAXX), which disrupted the MDM2-DAXX-HAUSP interactions and thereby promoted MDM2 self-ubiquitination and degradation.	Berberine	58-67	death domain associated protein	Homo sapiens	161-165
20935220-6	2010	We discovered that downregulation of MDM2 in ALL cells by berberine occurred at a posttranslational level through modulation of death domain-associated protein (DAXX), which disrupted the MDM2-DAXX-HAUSP interactions and thereby promoted MDM2 self-ubiquitination and degradation.	Berberine	58-67	MDM2 proto-oncogene	Homo sapiens	188-192
20935220-6	2010	We discovered that downregulation of MDM2 in ALL cells by berberine occurred at a posttranslational level through modulation of death domain-associated protein (DAXX), which disrupted the MDM2-DAXX-HAUSP interactions and thereby promoted MDM2 self-ubiquitination and degradation.	Berberine	58-67	death domain associated protein	Homo sapiens	193-197
20935220-6	2010	We discovered that downregulation of MDM2 in ALL cells by berberine occurred at a posttranslational level through modulation of death domain-associated protein (DAXX), which disrupted the MDM2-DAXX-HAUSP interactions and thereby promoted MDM2 self-ubiquitination and degradation.	Berberine	58-67	ubiquitin specific peptidase 7	Homo sapiens	198-203
20935220-6	2010	We discovered that downregulation of MDM2 in ALL cells by berberine occurred at a posttranslational level through modulation of death domain-associated protein (DAXX), which disrupted the MDM2-DAXX-HAUSP interactions and thereby promoted MDM2 self-ubiquitination and degradation.	Berberine	58-67	MDM2 proto-oncogene	Homo sapiens	188-192
20564506-8	2010	More importantly, the addition of 8 muM berberine diminished the induction of adipogenesis almost completely accompanied by down-regulated mRNA and protein expression levels of SREBP-1-related proteins.	Berberine	40-49	sterol regulatory element binding transcription factor 1	Mus musculus	177-184
21062898-0	2010	TNFalpha-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFkappaB signaling.	Berberine	21-30	AKT serine/threonine kinase 1	Rattus norvegicus	98-101
21062898-3	2010	Berberine, a herbal therapeutic agent that has been recently established as a therapy for diabetes and hypercholesterinemia, was able to completely antagonize the TNFalpha-mediated barrier defects in the cell model and in rat colon.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	163-171
21062898-6	2010	Berberine alone had no effect while it fully prevented the TNFalpha-induced barrier defects.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	59-67
21062898-9	2010	Berberine prevented TNFalpha-induced claudin-1 disassembly and upregulation of claudin-2.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	20-28
21062898-9	2010	Berberine prevented TNFalpha-induced claudin-1 disassembly and upregulation of claudin-2.	Berberine	0-9	claudin 1	Rattus norvegicus	37-46
21062898-9	2010	Berberine prevented TNFalpha-induced claudin-1 disassembly and upregulation of claudin-2.	Berberine	0-9	claudin 2	Rattus norvegicus	79-88
20564506-0	2010	Berberine inhibits SREBP-1-related clozapine and risperidone induced adipogenesis in 3T3-L1 cells.	Berberine	0-9	sterol regulatory element binding transcription factor 1	Mus musculus	19-26
20213508-1	2010	Fluorescence spectroscopy in combination with UV-vis absorption spectroscopy was employed to investigate the binding of an important traditional medicinal herb berberine to bovine serum albumin (BSA) under the physiological conditions.	Berberine	160-169	albumin	Homo sapiens	180-193
20646989-0	2010	Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway.	Berberine	0-9	sphingosine-1-phosphate receptor 1	Mus musculus	96-99
20880702-2	2010	Compound 10b, with a cyclohexylamino group linked to berberine by a three carbon spacer, gave the most potent inhibitor activity with an IC(50) of 0.020 muM for AChE.	Berberine	53-62	acetylcholinesterase (Cartwright blood group)	Homo sapiens	161-165
20423742-0	2010	Berberine-induced activation of 5"-adenosine monophosphate-activated protein kinase and glucose transport in rat skeletal muscles.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	32-83
20423742-4	2010	In response to BBR treatment, the Thr(172) phosphorylation of the catalytic alpha-subunit of AMPK, an essential step for full kinase activation, increased in a dose- and time-dependent manner.	Berberine	15-18	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	93-97
20691179-8	2010	Western blotting with treated cells revealed that berberine induces apoptosis in MCF-7 cells through a mitochondria-dependent pathway by increasing levels of cytoplasmic cytochrome c, caspase-9 activity and cleavage of PARP while decreasing levels of Bcl-2.	Berberine	50-59	cytochrome c, somatic	Homo sapiens	170-182
20691179-8	2010	Western blotting with treated cells revealed that berberine induces apoptosis in MCF-7 cells through a mitochondria-dependent pathway by increasing levels of cytoplasmic cytochrome c, caspase-9 activity and cleavage of PARP while decreasing levels of Bcl-2.	Berberine	50-59	caspase 9	Homo sapiens	184-193
20691179-8	2010	Western blotting with treated cells revealed that berberine induces apoptosis in MCF-7 cells through a mitochondria-dependent pathway by increasing levels of cytoplasmic cytochrome c, caspase-9 activity and cleavage of PARP while decreasing levels of Bcl-2.	Berberine	50-59	collagen type XI alpha 2 chain	Homo sapiens	219-223
20691179-8	2010	Western blotting with treated cells revealed that berberine induces apoptosis in MCF-7 cells through a mitochondria-dependent pathway by increasing levels of cytoplasmic cytochrome c, caspase-9 activity and cleavage of PARP while decreasing levels of Bcl-2.	Berberine	50-59	BCL2 apoptosis regulator	Homo sapiens	251-256
20976070-5	2010	The results showed that berberine attenuated clinical and pathological parameters of EAE, reduced the permeability of BBB, inhibited the activity and expression of MMP-9 but not MMP-2 in the CSF and brain of EAE mice.	Berberine	24-33	matrix metallopeptidase 9	Mus musculus	164-169
20976070-5	2010	The results showed that berberine attenuated clinical and pathological parameters of EAE, reduced the permeability of BBB, inhibited the activity and expression of MMP-9 but not MMP-2 in the CSF and brain of EAE mice.	Berberine	24-33	matrix metallopeptidase 2	Mus musculus	178-183
20976070-6	2010	CONCLUSIONS/SIGNIFICANCE: These findings suggest that berberine is effective to attenuate the clinical severity of EAE in C57 BL/6 mice by reducing the permeability of BBB, decreasing the expression and activity of MMP-9, and decreasing the inflammatory infiltration.	Berberine	54-63	matrix metallopeptidase 9	Mus musculus	215-220
20646989-9	2010	These findings suggest that the inhibitory effect of BBR on the activation of SphK-S1P signaling pathway in diabetic mouse kidney is a novel mechanism by which BBR partly exerts renoprotective effects on DN.	Berberine	53-56	sphingosine-1-phosphate receptor 1	Mus musculus	83-86
20646989-9	2010	These findings suggest that the inhibitory effect of BBR on the activation of SphK-S1P signaling pathway in diabetic mouse kidney is a novel mechanism by which BBR partly exerts renoprotective effects on DN.	Berberine	160-163	sphingosine-1-phosphate receptor 1	Mus musculus	83-86
20849653-7	2010	RESULTS: Serum ALT and AST activities significantly decreased in a dose-dependent manner in both pre-treatment and post-treatment groups with berberine.	Berberine	142-151	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	23-26
20570724-3	2010	In this work, stimulation of insulin and berberine conferred a glucose uptake or surface glucose transporter 4 (GLUT4) translocation that was less than simple summation of their effects in insulin-sensitive muscle cells.	Berberine	41-50	solute carrier family 2 member 4	Homo sapiens	89-110
20570724-3	2010	In this work, stimulation of insulin and berberine conferred a glucose uptake or surface glucose transporter 4 (GLUT4) translocation that was less than simple summation of their effects in insulin-sensitive muscle cells.	Berberine	41-50	solute carrier family 2 member 4	Homo sapiens	112-117
20570724-3	2010	In this work, stimulation of insulin and berberine conferred a glucose uptake or surface glucose transporter 4 (GLUT4) translocation that was less than simple summation of their effects in insulin-sensitive muscle cells.	Berberine	41-50	insulin	Homo sapiens	189-196
20570724-5	2010	In the presence of berberine, PKCzeta controlled AMPK activation and AMPK blocked PKB activity in perinuclear region.	Berberine	19-28	protein kinase C zeta	Homo sapiens	30-37
20634337-4	2010	After intragastric dosing, approximately half of berberine ran intact through the gastrointestinal tract and another half was disposed of by the small intestine, leading to an extremely low extent of absolute oral bioavailability in rats (0.36%).	Berberine	49-58	RAN, member RAS oncogene family	Rattus norvegicus	59-62
21246838-0	2010	[Preventive effects of berberine on experimental colon cancer and relationship with cyclooxygenase-2 expression].	Berberine	23-32	prostaglandin-endoperoxide synthase 2	Homo sapiens	84-100
21246838-1	2010	OBJECTIVE: To investigate the anti-colon cancer effects of berberine and possible relationship with cyclooxygenase-2.	Berberine	59-68	prostaglandin-endoperoxide synthase 2	Homo sapiens	100-116
20849653-10	2010	CONCLUSION: The present study demonstrates that berberine possesses hepatoprotective effects against CCl4-induced hepatotoxicity and that the effects are both preventive and curative.	Berberine	48-57	C-C motif chemokine ligand 4	Rattus norvegicus	101-105
20622114-0	2010	Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine.	Berberine	138-147	negative elongation factor complex member C/D	Homo sapiens	14-17
20623344-4	2010	PCSK9"s expression, secretion, and plasma levels maybe modulated by the proprotein convertase furin, by natural inhibitors (annexin-A2), or influenced by lipid-altering agents such as statins, fibrates, ezetimibe, and berberine.	Berberine	218-227	proprotein convertase subtilisin/kexin type 9	Homo sapiens	0-5
20506155-0	2010	Anti-atherogenic effect of berberine on LXRalpha-ABCA1-dependent cholesterol efflux in macrophages.	Berberine	27-36	nuclear receptor subfamily 1 group H member 3	Homo sapiens	40-48
20506155-0	2010	Anti-atherogenic effect of berberine on LXRalpha-ABCA1-dependent cholesterol efflux in macrophages.	Berberine	27-36	ATP binding cassette subfamily A member 1	Homo sapiens	49-54
20506155-5	2010	Berberine enhanced the mRNA and protein expression of ATP-binding membrane cassette transport protein A1 (ABCA1) but did not alter the protein level of ABCG1 or other scavenger receptors.	Berberine	0-9	ATP binding cassette subfamily A member 1	Homo sapiens	54-104
20567026-0	2010	Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats.	Berberine	0-9	microsomal triglyceride transfer protein	Rattus norvegicus	37-41
20567026-7	2010	Interestingly, berberine reversed the downregulated expression of these genes and selectively inhibited HFD-induced increase in the methylation of MTTP.	Berberine	15-24	microsomal triglyceride transfer protein	Rattus norvegicus	147-151
20567026-10	2010	These data indicate that DNA methylation of the MTTP promoter likely contributes to its downregulation during HFD-induced NAFLD and, further, that berberine can partially counteract the HFD-elicited dysregulation of MTTP by reversing the methylation state of its promoter, leading to reduced hepatic fat content.	Berberine	147-156	microsomal triglyceride transfer protein	Rattus norvegicus	48-52
20567026-10	2010	These data indicate that DNA methylation of the MTTP promoter likely contributes to its downregulation during HFD-induced NAFLD and, further, that berberine can partially counteract the HFD-elicited dysregulation of MTTP by reversing the methylation state of its promoter, leading to reduced hepatic fat content.	Berberine	147-156	microsomal triglyceride transfer protein	Rattus norvegicus	216-220
20656010-4	2010	We found that Bcl-2/Bax ratio was significantly decreased and cytochrome c was released from mitochondrion to cytosol, which indicated that the mitochondrial pathway was activated by berberine.	Berberine	183-192	BCL2 apoptosis regulator	Homo sapiens	14-19
20656010-4	2010	We found that Bcl-2/Bax ratio was significantly decreased and cytochrome c was released from mitochondrion to cytosol, which indicated that the mitochondrial pathway was activated by berberine.	Berberine	183-192	BCL2 associated X, apoptosis regulator	Homo sapiens	20-23
20656010-4	2010	We found that Bcl-2/Bax ratio was significantly decreased and cytochrome c was released from mitochondrion to cytosol, which indicated that the mitochondrial pathway was activated by berberine.	Berberine	183-192	cytochrome c, somatic	Homo sapiens	62-74
20656010-5	2010	The up-regulation of Fas, FasL, TNF-alpha and TRAF-1 indicated the involvement of the death receptor pathway in the process of berberine-induced apoptosis.	Berberine	127-136	Fas ligand	Homo sapiens	26-30
20656010-5	2010	The up-regulation of Fas, FasL, TNF-alpha and TRAF-1 indicated the involvement of the death receptor pathway in the process of berberine-induced apoptosis.	Berberine	127-136	tumor necrosis factor	Homo sapiens	32-41
20656010-5	2010	The up-regulation of Fas, FasL, TNF-alpha and TRAF-1 indicated the involvement of the death receptor pathway in the process of berberine-induced apoptosis.	Berberine	127-136	TNF receptor associated factor 1	Homo sapiens	46-52
20656010-7	2010	In addition, the increased expression of p53 was also observed in berberine-treated HeLa cells, and as a node point of these different pathways in a protein-protein interaction network constructed by GeneGo software, p53 might be the possible drug-target of berberine"s anti-cancer on HeLa cells, which was predicted by a flexible ligand-protein inverse docking program, INVDOCK.	Berberine	66-75	tumor protein p53	Homo sapiens	41-44
20656010-7	2010	In addition, the increased expression of p53 was also observed in berberine-treated HeLa cells, and as a node point of these different pathways in a protein-protein interaction network constructed by GeneGo software, p53 might be the possible drug-target of berberine"s anti-cancer on HeLa cells, which was predicted by a flexible ligand-protein inverse docking program, INVDOCK.	Berberine	66-75	tumor protein p53	Homo sapiens	217-220
20656010-7	2010	In addition, the increased expression of p53 was also observed in berberine-treated HeLa cells, and as a node point of these different pathways in a protein-protein interaction network constructed by GeneGo software, p53 might be the possible drug-target of berberine"s anti-cancer on HeLa cells, which was predicted by a flexible ligand-protein inverse docking program, INVDOCK.	Berberine	258-267	tumor protein p53	Homo sapiens	41-44
20656010-7	2010	In addition, the increased expression of p53 was also observed in berberine-treated HeLa cells, and as a node point of these different pathways in a protein-protein interaction network constructed by GeneGo software, p53 might be the possible drug-target of berberine"s anti-cancer on HeLa cells, which was predicted by a flexible ligand-protein inverse docking program, INVDOCK.	Berberine	258-267	tumor protein p53	Homo sapiens	217-220
20522589-0	2010	Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine.	Berberine	119-128	F-box protein 32	Mus musculus	0-9
20522589-2	2010	Since an herbal compound, berberine, lowers blood levels of glucose and lipids, we proposed that it would improve insulin/IGF-1 signaling, blocking muscle protein losses.	Berberine	26-35	insulin-like growth factor 1	Mus musculus	122-127
20522589-6	2010	The protein catabolic mechanism depended on berberine-stimulated expression of the E3 ubiquitin ligase, atrogin-1.	Berberine	44-53	F-box protein 32	Mus musculus	104-113
20522589-9	2010	Berberine impaired energy metabolism, activating AMP-activated protein kinase and providing an alternative mechanism for the stimulation of atrogin-1 expression.	Berberine	0-9	F-box protein 32	Mus musculus	140-149
20522589-10	2010	When we increased mitochondrial biogenesis by expressing peroxisome proliferator-activated receptor gamma coactivator-1alpha, berberine-induced changes in muscle protein metabolism were prevented.	Berberine	126-135	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	57-124
20506155-5	2010	Berberine enhanced the mRNA and protein expression of ATP-binding membrane cassette transport protein A1 (ABCA1) but did not alter the protein level of ABCG1 or other scavenger receptors.	Berberine	0-9	ATP binding cassette subfamily A member 1	Homo sapiens	106-111
20506155-6	2010	Additionally, functional inhibition of ABCA1 with a pharmacological inhibitor or neutralizing antibody abrogated the effects of berberine on cholesterol efflux and lipid accumulation.	Berberine	128-137	ATP binding cassette subfamily A member 1	Homo sapiens	39-44
20506155-7	2010	Moreover, berberine induced the nuclear translocation and activation of liver X receptor alpha (LXRalpha) but not its protein expression.	Berberine	10-19	nuclear receptor subfamily 1 group H member 3	Homo sapiens	96-104
20506155-8	2010	Knockdown of LXRalpha mRNA expression by small interfering RNA abolished the berberine-mediated protective effects on ABCA1 protein expression and oxLDL-induced lipid accumulation in macrophages.	Berberine	77-86	nuclear receptor subfamily 1 group H member 3	Homo sapiens	13-21
20506155-8	2010	Knockdown of LXRalpha mRNA expression by small interfering RNA abolished the berberine-mediated protective effects on ABCA1 protein expression and oxLDL-induced lipid accumulation in macrophages.	Berberine	77-86	ATP binding cassette subfamily A member 1	Homo sapiens	118-123
20506155-9	2010	These data suggest that berberine abrogates the formation of foam cells by macrophages by enhancing LXRalpha-ABCA1-dependent cholesterol efflux.	Berberine	24-33	ATP binding cassette subfamily A member 1	Homo sapiens	100-114
20455200-6	2010	Moreover, expression profiling and Ingenuity pathway analysis results showed that the cytotoxicity of berberine was accompanied with an activation of BRCA1-mediated DNA damage response, G1/S and G2/M cell cycle checkpoint regulation, and P53 signalling pathways.	Berberine	102-111	BRCA1 DNA repair associated	Homo sapiens	150-155
20637981-10	2010	In contrast, interleukin-10 in the mice with berberine treatment was significantly greater than in the control group (p &lt; .01).	Berberine	45-54	interleukin 10	Mus musculus	13-27
20658575-0	2010	Identification of berberine as a novel agonist of fatty acid receptor GPR40.	Berberine	18-27	free fatty acid receptor 1	Homo sapiens	70-75
20658575-2	2010	Berberine is its major active constituent and functions as an insulin sensitizer and insulin secretagogue.	Berberine	0-9	insulin	Homo sapiens	62-69
20658575-2	2010	Berberine is its major active constituent and functions as an insulin sensitizer and insulin secretagogue.	Berberine	0-9	insulin	Homo sapiens	85-92
20658575-4	2010	The objective of the current study is to investigate if berberine can function as a ligand of fatty acid receptor GPR40, which stimulates glucose dependent insulin secretion.	Berberine	56-65	free fatty acid receptor 1	Homo sapiens	114-119
20658575-6	2010	Berberine stimulated calcium mobilization with an EC(50) of 0.76 microM in this GPR40 overexpressing cell line.	Berberine	0-9	free fatty acid receptor 1	Homo sapiens	80-85
20658575-8	2010	This suggests that berberine functions as an agonist of fatty acid receptor GPR40 and might be a novel antidiabetic mechanism of action for berberine.	Berberine	19-28	free fatty acid receptor 1	Homo sapiens	76-81
20455200-6	2010	Moreover, expression profiling and Ingenuity pathway analysis results showed that the cytotoxicity of berberine was accompanied with an activation of BRCA1-mediated DNA damage response, G1/S and G2/M cell cycle checkpoint regulation, and P53 signalling pathways.	Berberine	102-111	tumor protein p53	Homo sapiens	238-241
19861153-3	2010	The results demonstrated that in FD mice, berberine reduced mouse weight gain and food intake and serum glucose, triglyceride, and total cholesterol levels accompanied with a down-regulation of PPARgamma expression and an up-regulation of GATA-3 expression.	Berberine	42-51	peroxisome proliferator activated receptor gamma	Mus musculus	194-203
20447389-2	2010	In vivo and in vitro studies demonstrated that berberine could ameliorate renal dysfunction in diabetic rats with nephropathy and inhibit fibronectin expression in mesangial cells cultured under high glucose.	Berberine	47-56	fibronectin 1	Rattus norvegicus	138-149
20447389-4	2010	The purpose of the present study was to investigate the effects of berberine on the nuclear factor-kappa B (NF-kappaB) activation, intercellular adhesion molecule-1, transforming growth factor-beta1 and fibronectin protein expression in renal tissue from alloxan-induced diabetic mice with renal damage.	Berberine	67-76	transforming growth factor, beta 1	Mus musculus	108-198
20447389-9	2010	After berberine treatment, the immunostaining of NF-kappaB was decreased, and the reduced degradation of I kappaB-alpha level was partially restored.	Berberine	6-15	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	49-58
20447389-9	2010	After berberine treatment, the immunostaining of NF-kappaB was decreased, and the reduced degradation of I kappaB-alpha level was partially restored.	Berberine	6-15	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	105-119
20447389-10	2010	The protein levels of intercellular adhesion molecule-1, transforming growth factor-beta 1 and fibronectin were all downregulated by berberine compared with diabetic model group.	Berberine	133-142	intercellular adhesion molecule 1	Mus musculus	22-90
20447389-10	2010	The protein levels of intercellular adhesion molecule-1, transforming growth factor-beta 1 and fibronectin were all downregulated by berberine compared with diabetic model group.	Berberine	133-142	fibronectin 1	Mus musculus	95-106
20447389-11	2010	In conclusion, the ameliorative effects of berberine on extracellular matrix accumulation might associate with its inhibitory function on NF-kappaB signal pathway.	Berberine	43-52	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	138-147
20515652-0	2010	Berberine inhibits PTP1B activity and mimics insulin action.	Berberine	0-9	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	19-24
20515652-0	2010	Berberine inhibits PTP1B activity and mimics insulin action.	Berberine	0-9	insulin	Homo sapiens	45-52
20515652-3	2010	Berberine (BBR) has recently been shown to lower blood glucose levels and to improve insulin resistance in db/db mice partly through the activation of AMP-activated protein kinase (AMPK) signaling and induction of phosphorylation of insulin receptor (IR).	Berberine	0-9	insulin	Homo sapiens	85-92
20515652-3	2010	Berberine (BBR) has recently been shown to lower blood glucose levels and to improve insulin resistance in db/db mice partly through the activation of AMP-activated protein kinase (AMPK) signaling and induction of phosphorylation of insulin receptor (IR).	Berberine	0-9	insulin receptor	Mus musculus	233-249
20515652-3	2010	Berberine (BBR) has recently been shown to lower blood glucose levels and to improve insulin resistance in db/db mice partly through the activation of AMP-activated protein kinase (AMPK) signaling and induction of phosphorylation of insulin receptor (IR).	Berberine	0-9	insulin receptor	Mus musculus	251-253
20515652-3	2010	Berberine (BBR) has recently been shown to lower blood glucose levels and to improve insulin resistance in db/db mice partly through the activation of AMP-activated protein kinase (AMPK) signaling and induction of phosphorylation of insulin receptor (IR).	Berberine	11-14	insulin	Homo sapiens	85-92
20515652-3	2010	Berberine (BBR) has recently been shown to lower blood glucose levels and to improve insulin resistance in db/db mice partly through the activation of AMP-activated protein kinase (AMPK) signaling and induction of phosphorylation of insulin receptor (IR).	Berberine	11-14	insulin receptor	Mus musculus	233-249
20515652-3	2010	Berberine (BBR) has recently been shown to lower blood glucose levels and to improve insulin resistance in db/db mice partly through the activation of AMP-activated protein kinase (AMPK) signaling and induction of phosphorylation of insulin receptor (IR).	Berberine	11-14	insulin receptor	Mus musculus	251-253
19861153-3	2010	The results demonstrated that in FD mice, berberine reduced mouse weight gain and food intake and serum glucose, triglyceride, and total cholesterol levels accompanied with a down-regulation of PPARgamma expression and an up-regulation of GATA-3 expression.	Berberine	42-51	GATA binding protein 3	Mus musculus	239-245
20036710-4	2010	In insulin-resistant state, berberine exhibited synergistic effect on insulin-induced glucose uptake and GLUT4 translocation.	Berberine	28-37	solute carrier family 2 member 4	Rattus norvegicus	105-110
20471843-0	2010	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.	Berberine	55-64	acetylcholinesterase (Cartwright blood group)	Homo sapiens	99-119
20471843-0	2010	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.	Berberine	55-64	butyrylcholinesterase	Homo sapiens	124-145
20471843-1	2010	A series of novel berberine derivatives were designed, synthesized, and biologically evaluated as inhibitors of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).	Berberine	18-27	acetylcholinesterase (Cartwright blood group)	Homo sapiens	117-137
20471843-1	2010	A series of novel berberine derivatives were designed, synthesized, and biologically evaluated as inhibitors of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).	Berberine	18-27	acetylcholinesterase (Cartwright blood group)	Homo sapiens	139-143
20471843-1	2010	A series of novel berberine derivatives were designed, synthesized, and biologically evaluated as inhibitors of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).	Berberine	18-27	butyrylcholinesterase	Homo sapiens	149-170
20471843-1	2010	A series of novel berberine derivatives were designed, synthesized, and biologically evaluated as inhibitors of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).	Berberine	18-27	butyrylcholinesterase	Homo sapiens	172-177
20471843-2	2010	Among these derivatives, compound 48a, berberine linked with 3-methylpyridinium by a 2-carbon spacer, was found to be a potent inhibitor of AChE, with an IC(50) value of 0.048 microM and compound 40c, berberine linked with 2-thionaphthol by a 4-carbon spacer, acted as the most potent inhibitor for BuChE with an IC(50) value of 0.078 microM.	Berberine	39-48	acetylcholinesterase (Cartwright blood group)	Homo sapiens	140-144
20471843-3	2010	Kinetic studies and molecular modeling simulations of the AChE-inhibitor complex indicated that a mixed-competitive binding mode existed for these berberine derivatives.	Berberine	147-156	acetylcholinesterase (Cartwright blood group)	Homo sapiens	58-62
20512929-5	2010	Our findings also demonstrate that berberine significantly down-regulates LPS- or interferon (IFN)-gamma-induced nitric oxide synthase (iNOS) and cyclo-oxygenase-2 (COX-2) expression in BV-2 microglia cells.	Berberine	35-44	nitric oxide synthase 2, inducible	Mus musculus	136-140
20512929-6	2010	Berberine also inhibited LPS- or IFN-gamma-induced nitric oxide production.	Berberine	0-9	interferon gamma	Mus musculus	33-42
20512929-7	2010	In addition, berberine effectively inhibited proinflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 expression.	Berberine	13-22	tumor necrosis factor	Mus musculus	79-88
20512929-7	2010	In addition, berberine effectively inhibited proinflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 expression.	Berberine	13-22	interleukin 1 beta	Mus musculus	90-98
20512929-7	2010	In addition, berberine effectively inhibited proinflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 expression.	Berberine	13-22	interleukin 6	Mus musculus	104-108
20512929-8	2010	On the other hand, upon various inflammatory stimulus including LPS and IFN-gamma, berberine suppressed the phosphorylated of ERK but not p38 and JNK in BV-2 microglia.	Berberine	83-92	interferon gamma	Mus musculus	72-81
20512929-8	2010	On the other hand, upon various inflammatory stimulus including LPS and IFN-gamma, berberine suppressed the phosphorylated of ERK but not p38 and JNK in BV-2 microglia.	Berberine	83-92	mitogen-activated protein kinase 1	Mus musculus	126-129
20512929-8	2010	On the other hand, upon various inflammatory stimulus including LPS and IFN-gamma, berberine suppressed the phosphorylated of ERK but not p38 and JNK in BV-2 microglia.	Berberine	83-92	mitogen-activated protein kinase 8	Mus musculus	146-149
20512929-10	2010	Moreover, berberine induced LKB1 (Ser428), CaMKII (Thr286), and AMPK (Thr172) phosphorylation, but not AMPK (Ser485).	Berberine	10-19	serine/threonine kinase 11	Mus musculus	28-32
20512929-10	2010	Moreover, berberine induced LKB1 (Ser428), CaMKII (Thr286), and AMPK (Thr172) phosphorylation, but not AMPK (Ser485).	Berberine	10-19	calcium/calmodulin-dependent protein kinase II, beta	Mus musculus	43-49
20512929-11	2010	Furthermore, the inhibitory effect of berberine on iNOS and COX-2 expression was abolished by AMPK inhibition via Compound C, an AMPK inhibitor.	Berberine	38-47	nitric oxide synthase 2, inducible	Mus musculus	51-55
20512929-12	2010	Berberine-suppressed ERK phosphorylation was also reversed by Compound C treatment.	Berberine	0-9	mitogen-activated protein kinase 1	Mus musculus	21-24
20383171-0	2010	Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells.	Berberine	0-9	insulin	Homo sapiens	60-67
20383171-2	2010	The aim of this study is to investigate whether the insulin-sensitizing action of berberine is related to reducing ER stress.	Berberine	82-91	insulin	Homo sapiens	52-59
20383171-10	2010	The expressions of ORP150 was decreased both in gene and protein levels when cells were pretreated with berberine, while the activation of JNK was blocked.	Berberine	104-113	hypoxia up-regulated 1	Homo sapiens	19-25
20383171-11	2010	The levels of phosphorylation both on PERK and eIF2 alpha were inhibited in cells pretreated with berberine.	Berberine	98-107	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	38-42
20383171-11	2010	The levels of phosphorylation both on PERK and eIF2 alpha were inhibited in cells pretreated with berberine.	Berberine	98-107	eukaryotic translation initiation factor 2A	Homo sapiens	47-57
20383171-13	2010	AKT ser(473) phosphorylation was also enhanced significantly in the presence of berberine.	Berberine	80-89	AKT serine/threonine kinase 1	Homo sapiens	0-3
20383171-14	2010	CONCLUSION: The antidiabetic effect of berberine in Hep G2 cells maybe related to attenuation of ER stress and improvement of insulin signal transduction.	Berberine	39-48	insulin	Homo sapiens	126-133
20149867-8	2010	The distortion of tight junction morphology and redistribution of tight junction protein occludin was also prevented by berberine treatment.	Berberine	120-129	occludin	Homo sapiens	89-97
20149867-9	2010	Western blot analysis demonstrated that berberine inhibit the dislocation of occludin from raft fractions to non-raft fractions in membrane microdomains of tight junctions.	Berberine	40-49	occludin	Homo sapiens	77-85
19799972-3	2010	We have shown that treatment with 8 microM berberine or 4 microM evodiamine resulted in a major inhibition of HWP differentiation accompanied by up-regulation of both GATA binding protein 2 and 3 (GATA-2 and GATA-3) mRNA and protein expression, suggesting that both compounds may have excellent potential as agents to prevent obesity.	Berberine	43-52	GATA binding protein 2	Homo sapiens	167-195
19799972-3	2010	We have shown that treatment with 8 microM berberine or 4 microM evodiamine resulted in a major inhibition of HWP differentiation accompanied by up-regulation of both GATA binding protein 2 and 3 (GATA-2 and GATA-3) mRNA and protein expression, suggesting that both compounds may have excellent potential as agents to prevent obesity.	Berberine	43-52	GATA binding protein 2	Homo sapiens	197-203
19799972-3	2010	We have shown that treatment with 8 microM berberine or 4 microM evodiamine resulted in a major inhibition of HWP differentiation accompanied by up-regulation of both GATA binding protein 2 and 3 (GATA-2 and GATA-3) mRNA and protein expression, suggesting that both compounds may have excellent potential as agents to prevent obesity.	Berberine	43-52	GATA binding protein 3	Homo sapiens	208-214
24278513-5	2010	The antioxidant NAC inhibited berberine and radiation-induced cell death.	Berberine	30-39	X-linked Kx blood group	Homo sapiens	16-19
24278513-6	2010	Bax, caspase-3, p53, p38, and JNK activation increased, but activation of Bcl-2, ERK, and HO-1 decreased with berberine treatment with or without irradiation.	Berberine	110-119	BCL2 apoptosis regulator	Homo sapiens	74-79
24278513-6	2010	Bax, caspase-3, p53, p38, and JNK activation increased, but activation of Bcl-2, ERK, and HO-1 decreased with berberine treatment with or without irradiation.	Berberine	110-119	mitogen-activated protein kinase 1	Homo sapiens	81-84
24278513-8	2010	Our data demonstrate that berberine inhibited the radioresistant effects and enhanced the radiosensitivity effects in human prostate cancer cells via the MAPK/caspase-3 and ROS pathways.	Berberine	26-35	caspase 3	Homo sapiens	159-168
20822024-1	2010	OBJECTIVE: To investigate the effect of berberine on serum levels of TNF-alpha, IL-6 and adiponectin in obese mice induced by high fat diet and its potential molecular mechanisms.	Berberine	40-49	tumor necrosis factor	Mus musculus	69-78
20822024-1	2010	OBJECTIVE: To investigate the effect of berberine on serum levels of TNF-alpha, IL-6 and adiponectin in obese mice induced by high fat diet and its potential molecular mechanisms.	Berberine	40-49	interleukin 6	Mus musculus	80-84
20822024-1	2010	OBJECTIVE: To investigate the effect of berberine on serum levels of TNF-alpha, IL-6 and adiponectin in obese mice induced by high fat diet and its potential molecular mechanisms.	Berberine	40-49	adiponectin, C1Q and collagen domain containing	Mus musculus	89-100
20822024-11	2010	After two-week treatment of berberine, serum levels of TNF-alpha, IL-6 in BL and BH were lower than those in BM (P &lt; 0.05, respectively).	Berberine	28-37	tumor necrosis factor	Mus musculus	55-64
20822024-11	2010	After two-week treatment of berberine, serum levels of TNF-alpha, IL-6 in BL and BH were lower than those in BM (P &lt; 0.05, respectively).	Berberine	28-37	interleukin 6	Mus musculus	66-70
20822024-15	2010	9: Berberine is able to reduce inflammatory cytokines expression and inhibit activation of IKK-beta (ser181) in obese mice, which may partly explain the therapeutic effect of berberine on insulin resistance and abnormal glucose metabolism.	Berberine	3-12	inhibitor of kappaB kinase beta	Mus musculus	91-99
20822024-15	2010	9: Berberine is able to reduce inflammatory cytokines expression and inhibit activation of IKK-beta (ser181) in obese mice, which may partly explain the therapeutic effect of berberine on insulin resistance and abnormal glucose metabolism.	Berberine	175-184	inhibitor of kappaB kinase beta	Mus musculus	91-99
20211233-6	2010	Both of WEC and berberine stimulated free radical generation, enhanced mitochondrial Delta psi and induced gene expression of Ndufab1, Cox6a2 and Atp5a1.	Berberine	16-25	NADH:ubiquinone oxidoreductase subunit AB1	Mus musculus	126-133
20211233-6	2010	Both of WEC and berberine stimulated free radical generation, enhanced mitochondrial Delta psi and induced gene expression of Ndufab1, Cox6a2 and Atp5a1.	Berberine	16-25	cytochrome c oxidase subunit 6A2	Mus musculus	135-141
20211233-6	2010	Both of WEC and berberine stimulated free radical generation, enhanced mitochondrial Delta psi and induced gene expression of Ndufab1, Cox6a2 and Atp5a1.	Berberine	16-25	ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1	Mus musculus	146-152
20211233-9	2010	The gene expression of Atp5c1 was selectively up-regulated by WEC, while three genes of Uqcrq, Cox8b, and Atp5g2 were induced by berberine.	Berberine	129-138	ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1	Mus musculus	23-29
20211233-9	2010	The gene expression of Atp5c1 was selectively up-regulated by WEC, while three genes of Uqcrq, Cox8b, and Atp5g2 were induced by berberine.	Berberine	129-138	ubiquinol-cytochrome c reductase, complex III subunit VII	Mus musculus	88-93
20211233-9	2010	The gene expression of Atp5c1 was selectively up-regulated by WEC, while three genes of Uqcrq, Cox8b, and Atp5g2 were induced by berberine.	Berberine	129-138	cytochrome c oxidase subunit 8B	Mus musculus	95-100
20211233-9	2010	The gene expression of Atp5c1 was selectively up-regulated by WEC, while three genes of Uqcrq, Cox8b, and Atp5g2 were induced by berberine.	Berberine	129-138	ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C2 (subunit 9)	Mus musculus	106-112
20036710-5	2010	Berberine improved insulin-induced tyrosine-phosphorylation of IRS-1 and the recruitment of p85 to IRS-1.	Berberine	0-9	insulin receptor substrate 1	Rattus norvegicus	63-68
20036710-5	2010	Berberine improved insulin-induced tyrosine-phosphorylation of IRS-1 and the recruitment of p85 to IRS-1.	Berberine	0-9	insulin receptor substrate 1	Rattus norvegicus	99-104
20036710-7	2010	The ameliorated insulin signal transduction was related to the inhibition of mTOR by berberine, which attenuated serine-phosphorylation of IRS-1.	Berberine	85-94	mechanistic target of rapamycin kinase	Rattus norvegicus	77-81
20036710-7	2010	The ameliorated insulin signal transduction was related to the inhibition of mTOR by berberine, which attenuated serine-phosphorylation of IRS-1.	Berberine	85-94	insulin receptor substrate 1	Rattus norvegicus	139-144
19950206-0	2010	BBR induces apoptosis in HepG2 cell through an Akt-ASK1-ROS-p38MAPKs-linked cascade.	Berberine	0-3	mitogen-activated protein kinase 14	Homo sapiens	60-68
19945441-0	2010	Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies.	Berberine	49-58	glucagon	Homo sapiens	14-37
19945441-2	2010	Our previous studies showed that berberine increased GLP-1 secretion in streptozotocin-induced diabetic rats.	Berberine	33-42	glucagon	Rattus norvegicus	53-58
19945441-3	2010	The aim of this study was to investigate whether berberine affected GLP-1 release in normal rats and in NCI-H716 cells.	Berberine	49-58	glucagon	Rattus norvegicus	68-73
19945441-5	2010	Effects of pharmacological inhibitors on berberine-mediated GLP-1 release were studied.	Berberine	41-50	glucagon like peptide 1 receptor	Homo sapiens	60-65
19945441-6	2010	In vivo, 5-week treatment of berberine enhanced GLP-1 secretion induced by glucose load and promoted proglucagon mRNA expression as well as L cell proliferation in intestine.	Berberine	29-38	glucagon like peptide 1 receptor	Homo sapiens	48-53
19945441-7	2010	In vitro, berberine concentration-dependently stimulated GLP-1 release in NCI-H716 cells.	Berberine	10-19	glucagon like peptide 1 receptor	Homo sapiens	57-62
19945441-8	2010	Berberine also promoted both prohormone convertase 3 and proglucagon mRNA expression.	Berberine	0-9	proprotein convertase subtilisin/kexin type 1	Homo sapiens	29-52
19945441-9	2010	Chelerythrine (inhibitor of PKC) concentration-dependently suppressed berberine-mediated GLP-1 secretion.	Berberine	70-79	glucagon like peptide 1 receptor	Homo sapiens	89-94
19945441-10	2010	Compound C (inhibitor of AMPK) also inhibited berberine-mediated GLP-1 secretion.	Berberine	46-55	glucagon like peptide 1 receptor	Homo sapiens	65-70
19945441-11	2010	But only low concentrations of H89 (inhibitor of PKA) showed inhibitory effects on berberine-mediated GLP-1 release.	Berberine	83-92	glucagon like peptide 1 receptor	Homo sapiens	102-107
19945441-12	2010	The present results demonstrated that berberine showed its modulation on GLP-1 via promoting GLP-1 secretion and GLP-1 biosynthesis.	Berberine	38-47	glucagon like peptide 1 receptor	Homo sapiens	73-78
19945441-12	2010	The present results demonstrated that berberine showed its modulation on GLP-1 via promoting GLP-1 secretion and GLP-1 biosynthesis.	Berberine	38-47	glucagon like peptide 1 receptor	Homo sapiens	93-98
19945441-12	2010	The present results demonstrated that berberine showed its modulation on GLP-1 via promoting GLP-1 secretion and GLP-1 biosynthesis.	Berberine	38-47	glucagon like peptide 1 receptor	Homo sapiens	93-98
19945441-14	2010	Elucidation of mechanisms controlling berberine-mediated GLP-1 secretion may facilitate the understanding of berberine"s antidiabetic effects.	Berberine	38-47	glucagon like peptide 1 receptor	Homo sapiens	57-62
19945441-14	2010	Elucidation of mechanisms controlling berberine-mediated GLP-1 secretion may facilitate the understanding of berberine"s antidiabetic effects.	Berberine	109-118	glucagon like peptide 1 receptor	Homo sapiens	57-62
20056426-0	2010	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.	Berberine	60-69	acetylcholinesterase (Cartwright blood group)	Homo sapiens	92-112
20056426-1	2010	By targeting the dual active sites of acetylcholinesterase (AChE), a new series of berberine derivatives was designed, synthesized, and evaluated as AChE inhibitors.	Berberine	83-92	acetylcholinesterase (Cartwright blood group)	Homo sapiens	38-58
20056426-1	2010	By targeting the dual active sites of acetylcholinesterase (AChE), a new series of berberine derivatives was designed, synthesized, and evaluated as AChE inhibitors.	Berberine	83-92	acetylcholinesterase (Cartwright blood group)	Homo sapiens	60-64
20056426-1	2010	By targeting the dual active sites of acetylcholinesterase (AChE), a new series of berberine derivatives was designed, synthesized, and evaluated as AChE inhibitors.	Berberine	83-92	acetylcholinesterase (Cartwright blood group)	Homo sapiens	149-153
20056426-3	2010	Compound 8c, berberine linked with phenol by a 4-carbon spacer, showed the most potent inhibition of AChE.	Berberine	13-22	acetylcholinesterase (Cartwright blood group)	Homo sapiens	101-105
20056426-4	2010	A kinetic study of AChE and BuChE indicated that a mix-competitive binding mode existed for these berberine derivatives.	Berberine	98-107	acetylcholinesterase (Cartwright blood group)	Homo sapiens	19-23
20056426-6	2010	This is the first report where AChE inhibitory activity has been associated with berberine as a lead molecule.	Berberine	81-90	acetylcholinesterase (Cartwright blood group)	Homo sapiens	31-35
19950206-0	2010	BBR induces apoptosis in HepG2 cell through an Akt-ASK1-ROS-p38MAPKs-linked cascade.	Berberine	0-3	AKT serine/threonine kinase 1	Homo sapiens	47-50
19950206-0	2010	BBR induces apoptosis in HepG2 cell through an Akt-ASK1-ROS-p38MAPKs-linked cascade.	Berberine	0-3	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	51-55
20229011-12	2010	Only H-89, an inhibitor of protein kinase A (PKA), may reverse the decrease in disaccharidase activities and SI complex mRNA expression induced by berberine.	Berberine	147-156	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	27-43
20229011-12	2010	Only H-89, an inhibitor of protein kinase A (PKA), may reverse the decrease in disaccharidase activities and SI complex mRNA expression induced by berberine.	Berberine	147-156	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	45-48
20393601-7	2010	Real-time PCR analysis revealed that addition of berberine to the culture medium was able to reduce gp91phox mRNA expression in LPS-treated cells.	Berberine	49-58	cytochrome b-245 beta chain	Homo sapiens	100-108
20393601-10	2010	Such a restoration of cellular redox by berberine is mediated by its selective inhibition of gp91phox expression and enhancement of SOD activity.	Berberine	40-49	cytochrome b-245 beta chain	Homo sapiens	93-101
19950206-10	2010	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of MAP Kinases (JNK and p38 MAPK), ASK1, Akt, and p53.	Berberine	0-3	mitogen-activated protein kinase 14	Homo sapiens	120-123
19950206-10	2010	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of MAP Kinases (JNK and p38 MAPK), ASK1, Akt, and p53.	Berberine	0-3	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	131-135
19950206-10	2010	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of MAP Kinases (JNK and p38 MAPK), ASK1, Akt, and p53.	Berberine	0-3	AKT serine/threonine kinase 1	Homo sapiens	137-140
19950206-10	2010	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of MAP Kinases (JNK and p38 MAPK), ASK1, Akt, and p53.	Berberine	0-3	tumor protein p53	Homo sapiens	146-149
19950206-12	2010	We found that the treatment of HepG2 cells with BBR triggers generation of ROS through Akt phosphorylation, resulting in dissociation of the ASK1-mediated activation of JNK and p38 pathways.	Berberine	48-51	AKT serine/threonine kinase 1	Homo sapiens	87-90
19950206-12	2010	We found that the treatment of HepG2 cells with BBR triggers generation of ROS through Akt phosphorylation, resulting in dissociation of the ASK1-mediated activation of JNK and p38 pathways.	Berberine	48-51	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	141-145
19950206-12	2010	We found that the treatment of HepG2 cells with BBR triggers generation of ROS through Akt phosphorylation, resulting in dissociation of the ASK1-mediated activation of JNK and p38 pathways.	Berberine	48-51	mitogen-activated protein kinase 14	Homo sapiens	177-180
19660925-8	2009	Expression of GLUT4 and PPAR-gamma gene were elevated in chlorogenic acid and berberine treated cells, whereas expression of GLUT4 and PI3K transcripts were significantly enhanced in ferulic acid treated cells.	Berberine	78-87	solute carrier family 2 member 4	Homo sapiens	14-19
20462044-8	2010	Berberine reversed the alternations of T, A2 and 17-OHP levels, but did not influence the level of P. (3) RT-PCR showed that the mRNA expressions of cytochrome 17-hydroxylase (CYP17) and mini-chromosome maintenance protein-2 (MCM-2) elevated, but extracellular regulated protein-1 (ERK-1), protein kinase B (AKT-2) and glycogen synthase kinase-3 (GSK-3beta) lowered in the medium after Dex inducing.	Berberine	0-9	cytochrome P450, family 17, subfamily a, polypeptide 1	Mus musculus	176-181
20462044-8	2010	Berberine reversed the alternations of T, A2 and 17-OHP levels, but did not influence the level of P. (3) RT-PCR showed that the mRNA expressions of cytochrome 17-hydroxylase (CYP17) and mini-chromosome maintenance protein-2 (MCM-2) elevated, but extracellular regulated protein-1 (ERK-1), protein kinase B (AKT-2) and glycogen synthase kinase-3 (GSK-3beta) lowered in the medium after Dex inducing.	Berberine	0-9	minichromosome maintenance complex component 2	Mus musculus	187-224
20462044-8	2010	Berberine reversed the alternations of T, A2 and 17-OHP levels, but did not influence the level of P. (3) RT-PCR showed that the mRNA expressions of cytochrome 17-hydroxylase (CYP17) and mini-chromosome maintenance protein-2 (MCM-2) elevated, but extracellular regulated protein-1 (ERK-1), protein kinase B (AKT-2) and glycogen synthase kinase-3 (GSK-3beta) lowered in the medium after Dex inducing.	Berberine	0-9	minichromosome maintenance complex component 2	Mus musculus	226-231
20462044-8	2010	Berberine reversed the alternations of T, A2 and 17-OHP levels, but did not influence the level of P. (3) RT-PCR showed that the mRNA expressions of cytochrome 17-hydroxylase (CYP17) and mini-chromosome maintenance protein-2 (MCM-2) elevated, but extracellular regulated protein-1 (ERK-1), protein kinase B (AKT-2) and glycogen synthase kinase-3 (GSK-3beta) lowered in the medium after Dex inducing.	Berberine	0-9	mitogen-activated protein kinase 3	Mus musculus	282-287
20462044-8	2010	Berberine reversed the alternations of T, A2 and 17-OHP levels, but did not influence the level of P. (3) RT-PCR showed that the mRNA expressions of cytochrome 17-hydroxylase (CYP17) and mini-chromosome maintenance protein-2 (MCM-2) elevated, but extracellular regulated protein-1 (ERK-1), protein kinase B (AKT-2) and glycogen synthase kinase-3 (GSK-3beta) lowered in the medium after Dex inducing.	Berberine	0-9	thymoma viral proto-oncogene 2	Mus musculus	308-313
20462044-8	2010	Berberine reversed the alternations of T, A2 and 17-OHP levels, but did not influence the level of P. (3) RT-PCR showed that the mRNA expressions of cytochrome 17-hydroxylase (CYP17) and mini-chromosome maintenance protein-2 (MCM-2) elevated, but extracellular regulated protein-1 (ERK-1), protein kinase B (AKT-2) and glycogen synthase kinase-3 (GSK-3beta) lowered in the medium after Dex inducing.	Berberine	0-9	glycogen synthase kinase 3 beta	Mus musculus	347-356
19909759-0	2010	Berberine and a Berberis lycium extract inactivate Cdc25A and induce alpha-tubulin acetylation that correlate with HL-60 cell cycle inhibition and apoptosis.	Berberine	0-9	cell division cycle 25A	Homo sapiens	51-57
19909759-9	2010	Furthermore, berberine and the extract inhibited the expression of the proto-oncogene cyclin D1.	Berberine	13-22	cyclin D1	Homo sapiens	86-95
20410605-6	2010	In contrast, berberine and palmatine slightly upregulated the mRNAs of Mdr1a and Mdr1b, but failed to induce Mdr1a/1b protein expression or stimulate rhodamine 123 efflux.	Berberine	13-22	ATP binding cassette subfamily B member 1A	Rattus norvegicus	71-76
20410605-6	2010	In contrast, berberine and palmatine slightly upregulated the mRNAs of Mdr1a and Mdr1b, but failed to induce Mdr1a/1b protein expression or stimulate rhodamine 123 efflux.	Berberine	13-22	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	81-86
20410605-8	2010	Coptisine and berberine enhanced rhodamine 123 efflux in all three cell types, while palmatine inhibited it, based on the finding that palmatine efficiently activated the Mdr1a ATPase activity as a good substrate for Mdr1a.	Berberine	14-23	ATP binding cassette subfamily B member 1A	Rattus norvegicus	171-176
20410605-8	2010	Coptisine and berberine enhanced rhodamine 123 efflux in all three cell types, while palmatine inhibited it, based on the finding that palmatine efficiently activated the Mdr1a ATPase activity as a good substrate for Mdr1a.	Berberine	14-23	ATP binding cassette subfamily B member 1A	Rattus norvegicus	217-222
20930370-5	2010	Berberine induced ER stress as evidenced by the detection of ER stress-associated molecules such as phosphorylated protein kinase-like ER kinase, eukaryotic translation initiation factor-2alpha, glucose-regulated protein 78/immunoglobulin heavy chain-binding protein, and CCAAT/enhancer-binding protein (C/EBP)-homologous protein/growth arrest and DNA damage-inducible gene 153, which was associated with the activation of caspase-3.	Berberine	0-9	eukaryotic translation initiation factor 2A	Homo sapiens	146-193
20930370-5	2010	Berberine induced ER stress as evidenced by the detection of ER stress-associated molecules such as phosphorylated protein kinase-like ER kinase, eukaryotic translation initiation factor-2alpha, glucose-regulated protein 78/immunoglobulin heavy chain-binding protein, and CCAAT/enhancer-binding protein (C/EBP)-homologous protein/growth arrest and DNA damage-inducible gene 153, which was associated with the activation of caspase-3.	Berberine	0-9	caspase 3	Homo sapiens	423-432
20930370-7	2010	Berberine also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of Bax/Bcl-2 proteins, disruption of the mitochondrial membrane potential, activation of caspase-9 and -3, and cleavage of the poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	100-103
20930370-7	2010	Berberine also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of Bax/Bcl-2 proteins, disruption of the mitochondrial membrane potential, activation of caspase-9 and -3, and cleavage of the poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	104-109
20930370-7	2010	Berberine also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of Bax/Bcl-2 proteins, disruption of the mitochondrial membrane potential, activation of caspase-9 and -3, and cleavage of the poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	caspase 9	Homo sapiens	186-202
20930370-7	2010	Berberine also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of Bax/Bcl-2 proteins, disruption of the mitochondrial membrane potential, activation of caspase-9 and -3, and cleavage of the poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	224-251
20930370-7	2010	Berberine also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of Bax/Bcl-2 proteins, disruption of the mitochondrial membrane potential, activation of caspase-9 and -3, and cleavage of the poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	253-257
20652055-6	2010	RESULTS: Incubation with Rhizoma coptidis and berberine strongly inhibited LPS-induced monocyte chemoattractant protein (MCP)-1 production in RAW cells.	Berberine	46-55	chemokine (C-C motif) ligand 2	Mus musculus	87-127
19570618-3	2009	Clinical AMPK activators such as metformin and berberine may thus have potential in the clinical management of ADPKD.	Berberine	47-56	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	9-13
19570618-4	2009	The traditional use of berberine in diarrhea associated with bacterial infections may reflect, in part, the inhibitory impact of AMPK on chloride extrusion by small intestinal enterocytes.	Berberine	23-32	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	129-133
19800084-0	2010	Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.	Berberine	0-9	insulin receptor	Homo sapiens	87-103
19800084-1	2010	Our previous work demonstrated that berberine (BBR) increases insulin receptor (InsR) expression and improves glucose utility both in vitro and in animal models.	Berberine	36-45	insulin receptor	Homo sapiens	62-78
19800084-1	2010	Our previous work demonstrated that berberine (BBR) increases insulin receptor (InsR) expression and improves glucose utility both in vitro and in animal models.	Berberine	36-45	insulin receptor	Homo sapiens	80-84
19800084-1	2010	Our previous work demonstrated that berberine (BBR) increases insulin receptor (InsR) expression and improves glucose utility both in vitro and in animal models.	Berberine	47-50	insulin receptor	Homo sapiens	62-78
19800084-1	2010	Our previous work demonstrated that berberine (BBR) increases insulin receptor (InsR) expression and improves glucose utility both in vitro and in animal models.	Berberine	47-50	insulin receptor	Homo sapiens	80-84
19800084-4	2010	Accordingly, insulin-stimulated phosphorylations of InsR beta-subunit and Akt were increased after BBR treatment in cultured cells.	Berberine	99-102	insulin	Homo sapiens	13-20
19800084-4	2010	Accordingly, insulin-stimulated phosphorylations of InsR beta-subunit and Akt were increased after BBR treatment in cultured cells.	Berberine	99-102	insulin receptor	Homo sapiens	52-56
19800084-4	2010	Accordingly, insulin-stimulated phosphorylations of InsR beta-subunit and Akt were increased after BBR treatment in cultured cells.	Berberine	99-102	AKT serine/threonine kinase 1	Homo sapiens	74-77
21061468-0	2010	Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL.	Berberine	11-20	oxidized low density lipoprotein receptor 1	Homo sapiens	38-43
21061468-0	2010	Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL.	Berberine	11-20	scavenger receptor class B member 1	Homo sapiens	48-53
21061468-2	2010	Different concentrations of Berberine were co-cultured with THP-1 derived foam cells.	Berberine	28-37	GLI family zinc finger 2	Homo sapiens	60-65
21061468-8	2010	Berberine can inhibit the expression of LOX-1 and promote the expression of SR-BI in macrophage-derived foam cells.	Berberine	0-9	oxidized low density lipoprotein receptor 1	Homo sapiens	40-45
21061468-8	2010	Berberine can inhibit the expression of LOX-1 and promote the expression of SR-BI in macrophage-derived foam cells.	Berberine	0-9	scavenger receptor class B member 1	Homo sapiens	76-81
19660925-8	2009	Expression of GLUT4 and PPAR-gamma gene were elevated in chlorogenic acid and berberine treated cells, whereas expression of GLUT4 and PI3K transcripts were significantly enhanced in ferulic acid treated cells.	Berberine	78-87	peroxisome proliferator activated receptor gamma	Homo sapiens	24-34
19800225-0	2009	Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor.	Berberine	39-48	low density lipoprotein receptor	Homo sapiens	91-123
19800225-0	2009	Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor.	Berberine	39-48	insulin receptor	Homo sapiens	128-144
19800225-1	2009	Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR).	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	74-106
19800225-1	2009	Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR).	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	108-112
19800225-1	2009	Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR).	Berberine	0-9	insulin receptor	Homo sapiens	118-134
19800225-1	2009	Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR).	Berberine	0-9	insulin receptor	Homo sapiens	136-140
19800225-1	2009	Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR).	Berberine	11-14	low density lipoprotein receptor	Homo sapiens	74-106
19800225-1	2009	Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR).	Berberine	11-14	low density lipoprotein receptor	Homo sapiens	108-112
19800225-1	2009	Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR).	Berberine	11-14	insulin receptor	Homo sapiens	118-134
19800225-1	2009	Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR).	Berberine	11-14	insulin receptor	Homo sapiens	136-140
19370549-0	2009	Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp.	Berberine	10-19	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	61-66
19370549-0	2009	Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp.	Berberine	10-19	phosphoglycolate phosphatase	Rattus norvegicus	71-75
19370549-10	2009	In conclusion, berberine produced a dose-dependent increased bioavailability of digoxin and cyclosporine A by inhibition of intestinal P-gp.	Berberine	15-24	phosphoglycolate phosphatase	Rattus norvegicus	135-139
19370549-1	2009	The in vivo effects of berberine (BBR), the widely used bioactive herbal ingredient from many traditional Chinese medicinal herbs, on the pharmacokinetics of carbamazepine (CBZ, a substrate of CYP3A) and its metabolite carbamazepine 10,11-epoxide (ECBZ), digoxin (DIG, a substrate of P-gp) and cyclosporine A (CsA, a dual substrate of CYP3A and P-gp) were evaluated in rats.	Berberine	23-32	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	193-198
19370549-1	2009	The in vivo effects of berberine (BBR), the widely used bioactive herbal ingredient from many traditional Chinese medicinal herbs, on the pharmacokinetics of carbamazepine (CBZ, a substrate of CYP3A) and its metabolite carbamazepine 10,11-epoxide (ECBZ), digoxin (DIG, a substrate of P-gp) and cyclosporine A (CsA, a dual substrate of CYP3A and P-gp) were evaluated in rats.	Berberine	34-37	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	193-198
19687008-0	2009	Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.	Berberine	142-151	HNF1 homeobox A	Homo sapiens	0-32
19687008-0	2009	Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.	Berberine	142-151	proprotein convertase subtilisin/kexin type 9	Homo sapiens	58-63
19687008-4	2009	Interestingly, the plant-derived hypocholesterolemic compound berberine (BBR) up-regulates LDLR expression while down-regulating PCSK9.	Berberine	62-71	low density lipoprotein receptor	Homo sapiens	91-95
19687008-4	2009	Interestingly, the plant-derived hypocholesterolemic compound berberine (BBR) up-regulates LDLR expression while down-regulating PCSK9.	Berberine	62-71	proprotein convertase subtilisin/kexin type 9	Homo sapiens	129-134
19687008-4	2009	Interestingly, the plant-derived hypocholesterolemic compound berberine (BBR) up-regulates LDLR expression while down-regulating PCSK9.	Berberine	73-76	low density lipoprotein receptor	Homo sapiens	91-95
19687008-4	2009	Interestingly, the plant-derived hypocholesterolemic compound berberine (BBR) up-regulates LDLR expression while down-regulating PCSK9.	Berberine	73-76	proprotein convertase subtilisin/kexin type 9	Homo sapiens	129-134
19846952-4	2009	Berberine-induced apoptosis was associated with a reduction of the mitochondrial membrane potential associated with changes in the Bax/Bcl-2 ratio, release of cytochrome c from mitochondria and activation of down stream caspase-3.	Berberine	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	131-134
19661066-0	2009	Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice.	Berberine	0-9	mitogen-activated protein kinase 1	Mus musculus	53-56
19661066-0	2009	Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice.	Berberine	0-9	mitogen-activated protein kinase 14	Mus musculus	58-61
19661066-0	2009	Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice.	Berberine	0-9	mitogen-activated protein kinase 1	Mus musculus	62-66
19661066-0	2009	Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice.	Berberine	0-9	mitogen-activated protein kinase 8	Mus musculus	72-75
19661066-0	2009	Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice.	Berberine	0-9	negative elongation factor complex member C/D, Th1l	Mus musculus	88-91
19661066-4	2009	Here we reported that 2 weeks of oral administration of berberine prevented the progression of type 1 diabetes in half of the NOD mice and decreased Th17 and Th1 cytokine secretion.	Berberine	56-65	negative elongation factor complex member C/D, Th1l	Mus musculus	149-152
19661066-5	2009	Berberine suppressed Th17 and Th1 differentiation by reducing the expression of lineage markers.	Berberine	0-9	negative elongation factor complex member C/D, Th1l	Mus musculus	21-24
19661066-6	2009	We found that berberine inhibited Th17 differentiation by activating ERK1/2 and inhibited Th1 differentiation by inhibiting p38 MAPK and JNK activation.	Berberine	14-23	mitogen-activated protein kinase 3	Mus musculus	69-75
19661066-6	2009	We found that berberine inhibited Th17 differentiation by activating ERK1/2 and inhibited Th1 differentiation by inhibiting p38 MAPK and JNK activation.	Berberine	14-23	negative elongation factor complex member C/D, Th1l	Mus musculus	34-37
19661066-6	2009	We found that berberine inhibited Th17 differentiation by activating ERK1/2 and inhibited Th1 differentiation by inhibiting p38 MAPK and JNK activation.	Berberine	14-23	mitogen-activated protein kinase 14	Mus musculus	124-127
19661066-6	2009	We found that berberine inhibited Th17 differentiation by activating ERK1/2 and inhibited Th1 differentiation by inhibiting p38 MAPK and JNK activation.	Berberine	14-23	mitogen-activated protein kinase 1	Mus musculus	128-132
19661066-6	2009	We found that berberine inhibited Th17 differentiation by activating ERK1/2 and inhibited Th1 differentiation by inhibiting p38 MAPK and JNK activation.	Berberine	14-23	mitogen-activated protein kinase 8	Mus musculus	137-140
19661066-7	2009	Berberine down-regulated the activity of STAT1 and STAT4 through the suppression of p38 MAPK and JNK activation, and it controlled the stability of STAT4 through the ubiquitin-proteasome pathway.	Berberine	0-9	signal transducer and activator of transcription 1	Mus musculus	41-46
19661066-7	2009	Berberine down-regulated the activity of STAT1 and STAT4 through the suppression of p38 MAPK and JNK activation, and it controlled the stability of STAT4 through the ubiquitin-proteasome pathway.	Berberine	0-9	signal transducer and activator of transcription 4	Mus musculus	51-56
19661066-7	2009	Berberine down-regulated the activity of STAT1 and STAT4 through the suppression of p38 MAPK and JNK activation, and it controlled the stability of STAT4 through the ubiquitin-proteasome pathway.	Berberine	0-9	mitogen-activated protein kinase 14	Mus musculus	84-87
19661066-7	2009	Berberine down-regulated the activity of STAT1 and STAT4 through the suppression of p38 MAPK and JNK activation, and it controlled the stability of STAT4 through the ubiquitin-proteasome pathway.	Berberine	0-9	mitogen-activated protein kinase 1	Mus musculus	88-92
19661066-7	2009	Berberine down-regulated the activity of STAT1 and STAT4 through the suppression of p38 MAPK and JNK activation, and it controlled the stability of STAT4 through the ubiquitin-proteasome pathway.	Berberine	0-9	mitogen-activated protein kinase 8	Mus musculus	97-100
19661066-7	2009	Berberine down-regulated the activity of STAT1 and STAT4 through the suppression of p38 MAPK and JNK activation, and it controlled the stability of STAT4 through the ubiquitin-proteasome pathway.	Berberine	0-9	signal transducer and activator of transcription 4	Mus musculus	148-153
19661066-8	2009	Our findings indicate that berberine targets MAPK to suppress Th17 and Th1 differentiation in type 1 diabetic NOD mice.	Berberine	27-36	mitogen-activated protein kinase 1	Mus musculus	45-49
19661066-8	2009	Our findings indicate that berberine targets MAPK to suppress Th17 and Th1 differentiation in type 1 diabetic NOD mice.	Berberine	27-36	negative elongation factor complex member C/D, Th1l	Mus musculus	62-65
19651779-0	2009	Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567.	Berberine	0-9	ezrin	Homo sapiens	102-107
19651779-6	2009	Berberine treatment in vivo resulted in a 51.1% inhibition of tumor metastasis to the lymph nodes and decreased Ezrin phosphorylation at threonine 567 in metastatic samples.	Berberine	0-9	ezrin	Homo sapiens	112-117
19651779-7	2009	Berberine suppressed the presence of phosphorylated Ezrin (phospho-Ezrin) in a dose- and time-dependent manner but had no effect on total Ezrin protein expression at non-cytotoxic concentrations.	Berberine	0-9	ezrin	Homo sapiens	52-57
19651779-7	2009	Berberine suppressed the presence of phosphorylated Ezrin (phospho-Ezrin) in a dose- and time-dependent manner but had no effect on total Ezrin protein expression at non-cytotoxic concentrations.	Berberine	0-9	ezrin	Homo sapiens	67-72
19651779-7	2009	Berberine suppressed the presence of phosphorylated Ezrin (phospho-Ezrin) in a dose- and time-dependent manner but had no effect on total Ezrin protein expression at non-cytotoxic concentrations.	Berberine	0-9	ezrin	Homo sapiens	67-72
19651779-8	2009	Furthermore, the inhibitory effects of berberine on phospho-Ezrin were dependent on the suppression of Rho kinase activity.	Berberine	39-48	ezrin	Homo sapiens	60-65
19651779-9	2009	Reduction of Ezrin phosphorylation at Thr(567) by berberine was associated with its inhibitory effect on filopodia formation in 5-8F cells.	Berberine	50-59	ezrin	Homo sapiens	13-18
19651779-11	2009	These results confirm that berberine inhibits Ezrin phosphorylation at Thr(567).	Berberine	27-36	ezrin	Homo sapiens	46-51
19651779-13	2009	The reduction of Rho kinase-mediated Ezrin phosphorylation mediated by berberine may be a novel anti-metastatic pathway in NPC 5-8F cells.	Berberine	71-80	ezrin	Homo sapiens	37-42
19704371-6	2009	Besides, berberine is a broad spectrum enzyme inhibitor, which affects N-acetyltransferase, cyclooxygenase-2, and topoisomerase activities and gene/protein expression.	Berberine	9-18	prostaglandin-endoperoxide synthase 2	Homo sapiens	92-108
19686728-9	2009	The expressions of eNOS mRNA and protein were significantly increased, while NOX4 protein expression was decreased in aortas from diabetic rats with berberine treatment.	Berberine	149-158	nitric oxide synthase 3	Rattus norvegicus	19-23
19686728-9	2009	The expressions of eNOS mRNA and protein were significantly increased, while NOX4 protein expression was decreased in aortas from diabetic rats with berberine treatment.	Berberine	149-158	NADPH oxidase 4	Rattus norvegicus	77-81
19686728-11	2009	In conclusion, berberine restores diabetic endothelial dysfunction through enhanced NO bioavailability by up-regulating eNOS expression and down-regulating expression of NADPH oxidase.	Berberine	15-24	nitric oxide synthase 3	Rattus norvegicus	120-124
19846952-0	2009	Berberine induced apoptosis via promoting the expression of caspase-8, -9 and -3, apoptosis-inducing factor and endonuclease G in SCC-4 human tongue squamous carcinoma cancer cells.	Berberine	0-9	caspase 8	Homo sapiens	60-80
19846952-0	2009	Berberine induced apoptosis via promoting the expression of caspase-8, -9 and -3, apoptosis-inducing factor and endonuclease G in SCC-4 human tongue squamous carcinoma cancer cells.	Berberine	0-9	endonuclease G	Homo sapiens	112-126
19846952-0	2009	Berberine induced apoptosis via promoting the expression of caspase-8, -9 and -3, apoptosis-inducing factor and endonuclease G in SCC-4 human tongue squamous carcinoma cancer cells.	Berberine	0-9	MAU2 sister chromatid cohesion factor	Homo sapiens	130-135
19846952-2	2009	In this study, we hypothesized that berberine would have anticancer activities in SCC-4 human tongue cancer cells.	Berberine	36-45	MAU2 sister chromatid cohesion factor	Homo sapiens	82-87
19846952-3	2009	Results indicated that berberine reduced the viability of SCC-4 cells, which was initiated by the generation of reactive oxygen species, via an increase in cytosolic Ca(2+).	Berberine	23-32	MAU2 sister chromatid cohesion factor	Homo sapiens	58-63
19846952-4	2009	Berberine-induced apoptosis was associated with a reduction of the mitochondrial membrane potential associated with changes in the Bax/Bcl-2 ratio, release of cytochrome c from mitochondria and activation of down stream caspase-3.	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	135-140
19846952-4	2009	Berberine-induced apoptosis was associated with a reduction of the mitochondrial membrane potential associated with changes in the Bax/Bcl-2 ratio, release of cytochrome c from mitochondria and activation of down stream caspase-3.	Berberine	0-9	cytochrome c, somatic	Homo sapiens	159-171
19846952-4	2009	Berberine-induced apoptosis was associated with a reduction of the mitochondrial membrane potential associated with changes in the Bax/Bcl-2 ratio, release of cytochrome c from mitochondria and activation of down stream caspase-3.	Berberine	0-9	caspase 3	Homo sapiens	220-229
19846952-5	2009	Real-time PCR showed that berberine stimulated gene expression of caspase-8, -9 and -3, apoptosis-inducing factor and endonuclease G.	Berberine	26-35	caspase 8	Homo sapiens	66-86
19846952-5	2009	Real-time PCR showed that berberine stimulated gene expression of caspase-8, -9 and -3, apoptosis-inducing factor and endonuclease G.	Berberine	26-35	endonuclease G	Homo sapiens	118-132
19846952-6	2009	The present study demonstrated that berberine-mediated apoptosis of SCC-4 cells is regulated by ROS, mitochondria, caspase-3-dependent and mitochondria-dependent pathways, suggesting that berberine may be considered for future studies as a promising therapeutic candidate for human tongue cancer.	Berberine	36-45	MAU2 sister chromatid cohesion factor	Homo sapiens	68-73
19846952-6	2009	The present study demonstrated that berberine-mediated apoptosis of SCC-4 cells is regulated by ROS, mitochondria, caspase-3-dependent and mitochondria-dependent pathways, suggesting that berberine may be considered for future studies as a promising therapeutic candidate for human tongue cancer.	Berberine	36-45	caspase 3	Homo sapiens	115-124
19846952-6	2009	The present study demonstrated that berberine-mediated apoptosis of SCC-4 cells is regulated by ROS, mitochondria, caspase-3-dependent and mitochondria-dependent pathways, suggesting that berberine may be considered for future studies as a promising therapeutic candidate for human tongue cancer.	Berberine	188-197	MAU2 sister chromatid cohesion factor	Homo sapiens	68-73
19640223-0	2009	Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.	Berberine	110-119	dipeptidyl peptidase 4	Homo sapiens	14-37
19640223-6	2009	The fact that berberine was recently reported to potently inhibit the pro-diabetic target human protein tyrosine phosphatase 1B (h-PTP 1B) discloses a novel dual natural h-PTP 1B/DPP IV inhibitor.	Berberine	14-23	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	96-127
19640223-6	2009	The fact that berberine was recently reported to potently inhibit the pro-diabetic target human protein tyrosine phosphatase 1B (h-PTP 1B) discloses a novel dual natural h-PTP 1B/DPP IV inhibitor.	Berberine	14-23	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	131-137
19640223-6	2009	The fact that berberine was recently reported to potently inhibit the pro-diabetic target human protein tyrosine phosphatase 1B (h-PTP 1B) discloses a novel dual natural h-PTP 1B/DPP IV inhibitor.	Berberine	14-23	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	172-178
19640223-6	2009	The fact that berberine was recently reported to potently inhibit the pro-diabetic target human protein tyrosine phosphatase 1B (h-PTP 1B) discloses a novel dual natural h-PTP 1B/DPP IV inhibitor.	Berberine	14-23	dipeptidyl peptidase 4	Homo sapiens	179-185
19818314-5	2009	AMPK is a serine/threonine protein kinase and is activated by several natural compounds, including resveratrol, epigallocatechin gallate, berberine, and quercetin.	Berberine	138-147	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	0-4
19640223-0	2009	Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.	Berberine	110-119	dipeptidyl peptidase 4	Homo sapiens	39-45
19640223-1	2009	Berberine was investigated as an inhibitor of human dipeptidyl peptidase IV (DPP IV) in an attempt to explain its anti-hyperglycemic activities.	Berberine	0-9	dipeptidyl peptidase 4	Homo sapiens	52-75
19640223-1	2009	Berberine was investigated as an inhibitor of human dipeptidyl peptidase IV (DPP IV) in an attempt to explain its anti-hyperglycemic activities.	Berberine	0-9	dipeptidyl peptidase 4	Homo sapiens	77-83
19640223-2	2009	The investigation included simulated docking experiments to fit berberine within the binding pocket of DPP IV.	Berberine	64-73	dipeptidyl peptidase 4	Homo sapiens	103-109
19640223-3	2009	Berberine was found to readily fit within the binding pocket of DPP IV in a low energy orientation characterized with optimal electrostatic attractive interactions bridging the isoquinolinium positively charged nitrogen atom (berberine) and the negatively charged acidic residue of glutamic acid-205 (GLU205) of DPP IV.	Berberine	0-9	dipeptidyl peptidase 4	Homo sapiens	64-70
19640223-3	2009	Berberine was found to readily fit within the binding pocket of DPP IV in a low energy orientation characterized with optimal electrostatic attractive interactions bridging the isoquinolinium positively charged nitrogen atom (berberine) and the negatively charged acidic residue of glutamic acid-205 (GLU205) of DPP IV.	Berberine	0-9	dipeptidyl peptidase 4	Homo sapiens	312-318
19640223-3	2009	Berberine was found to readily fit within the binding pocket of DPP IV in a low energy orientation characterized with optimal electrostatic attractive interactions bridging the isoquinolinium positively charged nitrogen atom (berberine) and the negatively charged acidic residue of glutamic acid-205 (GLU205) of DPP IV.	Berberine	226-235	dipeptidyl peptidase 4	Homo sapiens	64-70
19640223-4	2009	Experimentally, berberine was found to inhibit human recombinant DPP IV in vitro with IC(50) = 13.3 microM.	Berberine	16-25	dipeptidyl peptidase 4	Homo sapiens	65-71
19640223-5	2009	Our findings suggest that DPP IV inhibition is, at least, one of the mechanisms that explain the anti-hyperglycemic activity of berberine.	Berberine	128-137	dipeptidyl peptidase 4	Homo sapiens	26-32
19492307-0	2009	The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells.	Berberine	19-28	mitogen-activated protein kinase 14	Homo sapiens	92-95
19721228-5	2009	Real-time and Western blotting revealed that both p21 and p27 expression was markedly reduced by berberine.	Berberine	97-106	KRAS proto-oncogene, GTPase	Rattus norvegicus	50-53
19721228-5	2009	Real-time and Western blotting revealed that both p21 and p27 expression was markedly reduced by berberine.	Berberine	97-106	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	58-61
19721228-6	2009	Berberine also decreased Akt phosphorylation and FoxO1 phosphorylation, which led to FoxO1 nuclear translocation.	Berberine	0-9	forkhead box O1	Rattus norvegicus	49-54
19721228-6	2009	Berberine also decreased Akt phosphorylation and FoxO1 phosphorylation, which led to FoxO1 nuclear translocation.	Berberine	0-9	forkhead box O1	Rattus norvegicus	85-90
19303753-2	2009	But there is no report to show berberine inhibited SCC-4 cancer cells in vivo on a murine xenograft animal model.	Berberine	31-40	MAU2 sister chromatid cohesion factor	Homo sapiens	51-56
19403287-0	2009	Berberine increases expression of GATA-2 and GATA-3 during inhibition of adipocyte differentiation.	Berberine	0-9	GATA binding protein 2	Mus musculus	34-40
19403287-0	2009	Berberine increases expression of GATA-2 and GATA-3 during inhibition of adipocyte differentiation.	Berberine	0-9	GATA binding protein 3	Mus musculus	45-51
19403287-4	2009	Recent reports suggest that berberine, an isoquinoline derivative alkaloid isolated from many medicinal herbs prevents differentiation of 3T3-L1 cells via a down regulation of PPARgamma and C/EBPalpha expression.	Berberine	28-37	peroxisome proliferator activated receptor gamma	Mus musculus	176-185
19403287-4	2009	Recent reports suggest that berberine, an isoquinoline derivative alkaloid isolated from many medicinal herbs prevents differentiation of 3T3-L1 cells via a down regulation of PPARgamma and C/EBPalpha expression.	Berberine	28-37	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	190-200
19403287-5	2009	The aim of this study was to determine the effect of berberine on GATA-2 and 3 gene and protein expression levels during differentiation of 3T3-L1 cells.	Berberine	53-62	GATA binding protein 2	Mus musculus	66-78
19403287-9	2009	These results may lead to the use of berberine to target the induction of specific genes such as GATA-2 and GATA-3 which affect adipocyte differentiation.	Berberine	37-46	GATA binding protein 2	Mus musculus	97-103
19403287-9	2009	These results may lead to the use of berberine to target the induction of specific genes such as GATA-2 and GATA-3 which affect adipocyte differentiation.	Berberine	37-46	GATA binding protein 3	Mus musculus	108-114
19652370-7	2009	Further study revealed that berberine could scavenger the reactive oxygen species (ROS), inhibit the c-jun NH(2)-terminal kinase (JNK), the loss of mitochondrial membrane potential and the release of cytochrome c (Cyt C) and caspase-3.	Berberine	28-37	mitogen-activated protein kinase 8	Homo sapiens	101-128
19652370-7	2009	Further study revealed that berberine could scavenger the reactive oxygen species (ROS), inhibit the c-jun NH(2)-terminal kinase (JNK), the loss of mitochondrial membrane potential and the release of cytochrome c (Cyt C) and caspase-3.	Berberine	28-37	mitogen-activated protein kinase 8	Homo sapiens	130-133
19652370-7	2009	Further study revealed that berberine could scavenger the reactive oxygen species (ROS), inhibit the c-jun NH(2)-terminal kinase (JNK), the loss of mitochondrial membrane potential and the release of cytochrome c (Cyt C) and caspase-3.	Berberine	28-37	cytochrome c, somatic	Homo sapiens	200-212
19652370-7	2009	Further study revealed that berberine could scavenger the reactive oxygen species (ROS), inhibit the c-jun NH(2)-terminal kinase (JNK), the loss of mitochondrial membrane potential and the release of cytochrome c (Cyt C) and caspase-3.	Berberine	28-37	cytochrome c, somatic	Homo sapiens	214-219
19652370-7	2009	Further study revealed that berberine could scavenger the reactive oxygen species (ROS), inhibit the c-jun NH(2)-terminal kinase (JNK), the loss of mitochondrial membrane potential and the release of cytochrome c (Cyt C) and caspase-3.	Berberine	28-37	caspase 3	Homo sapiens	225-234
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	33-42	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	58-83
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	33-42	AKT serine/threonine kinase 1	Homo sapiens	91-94
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	152-161	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	58-83
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	152-161	AKT serine/threonine kinase 1	Homo sapiens	91-94
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	152-161	AKT serine/threonine kinase 1	Homo sapiens	127-130
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	152-161	mitogen-activated protein kinase 8	Homo sapiens	189-192
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	152-161	AKT serine/threonine kinase 1	Homo sapiens	127-130
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	152-161	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	58-83
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	152-161	AKT serine/threonine kinase 1	Homo sapiens	91-94
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	152-161	AKT serine/threonine kinase 1	Homo sapiens	127-130
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	152-161	mitogen-activated protein kinase 8	Homo sapiens	189-192
19652370-8	2009	In addition, we also showed that berberine could activate phosphoinositide-3 kinase (PI3K)/Akt and that pretreatment with PI3K/Akt inhibitors prevented berberine-induced inhibition of ROS, JNK and subsequent apoptosis, suggesting that the protective effects of berberine were PI3K/Akt-dependent.	Berberine	152-161	AKT serine/threonine kinase 1	Homo sapiens	127-130
19652370-9	2009	Taken together, these findings reveal that berberine protects against MSC apoptosis by preventing ROS-dependent and JNK-driven cell apoptosis in a PI3K/Akt-dependent manner.	Berberine	43-52	mitogen-activated protein kinase 8	Homo sapiens	116-119
19652370-9	2009	Taken together, these findings reveal that berberine protects against MSC apoptosis by preventing ROS-dependent and JNK-driven cell apoptosis in a PI3K/Akt-dependent manner.	Berberine	43-52	AKT serine/threonine kinase 1	Homo sapiens	152-155
19546885-0	2009	Berberine promotes the development of atherosclerosis and foam cell formation by inducing scavenger receptor A expression in macrophage.	Berberine	0-9	macrophage scavenger receptor 1	Mus musculus	90-110
19546885-5	2009	By inducing scavenger receptor A (SR-A) expression in macrophages, berberine increased the uptake of modified LDL (DiO-Ac-LDL).	Berberine	67-76	macrophage scavenger receptor 1	Mus musculus	12-32
19546885-5	2009	By inducing scavenger receptor A (SR-A) expression in macrophages, berberine increased the uptake of modified LDL (DiO-Ac-LDL).	Berberine	67-76	macrophage scavenger receptor 1	Mus musculus	34-38
19546885-6	2009	Berberine-induced SR-A expression was also observed in macrophage foam cells in vivo and in the cells at atherosclerotic lesion.	Berberine	0-9	macrophage scavenger receptor 1	Mus musculus	18-22
19546885-7	2009	Analysis in RAW264.7 cells indicated that berberine induced SR-A expression by suppressing PTEN expression, which led to sustained Akt activation.	Berberine	42-51	macrophage scavenger receptor 1	Mus musculus	60-64
19546885-7	2009	Analysis in RAW264.7 cells indicated that berberine induced SR-A expression by suppressing PTEN expression, which led to sustained Akt activation.	Berberine	42-51	phosphatase and tensin homolog	Mus musculus	91-95
19546885-7	2009	Analysis in RAW264.7 cells indicated that berberine induced SR-A expression by suppressing PTEN expression, which led to sustained Akt activation.	Berberine	42-51	thymoma viral proto-oncogene 1	Mus musculus	131-134
19303753-1	2009	Our primary studies showed that berberine induced apoptosis in human tongue cancer SCC-4 cells in vitro.	Berberine	32-41	MAU2 sister chromatid cohesion factor	Homo sapiens	83-88
19492307-4	2009	The evidences of apoptosis, such as apoptotic DNA fragmentation and annexin V staining, were observed in the cells treated with the combination of berberine and irradiation.	Berberine	147-156	annexin A5	Homo sapiens	68-77
19492307-6	2009	The activations of p38, Bax, and caspase-3 were also detected in the irradiated cells pretreated with berberine.	Berberine	102-111	mitogen-activated protein kinase 14	Homo sapiens	19-22
19492307-6	2009	The activations of p38, Bax, and caspase-3 were also detected in the irradiated cells pretreated with berberine.	Berberine	102-111	BCL2 associated X, apoptosis regulator	Homo sapiens	24-27
19492307-6	2009	The activations of p38, Bax, and caspase-3 were also detected in the irradiated cells pretreated with berberine.	Berberine	102-111	caspase 3	Homo sapiens	33-42
19492307-7	2009	The productions of ROS and annexin V staining in the cells treated with the combination of berberine and irradiation were significantly inhibited by the specific inhibitor of p38 MAPK, SB203580.	Berberine	91-100	annexin A5	Homo sapiens	27-36
19492307-7	2009	The productions of ROS and annexin V staining in the cells treated with the combination of berberine and irradiation were significantly inhibited by the specific inhibitor of p38 MAPK, SB203580.	Berberine	91-100	mitogen-activated protein kinase 14	Homo sapiens	175-178
19492307-9	2009	Taken together, the present results clearly indicate that the combination of berberine and gamma-radiation enhance the anti-cancer effects through the p38 MAPK pathway and ROS generation.	Berberine	77-86	mitogen-activated protein kinase 14	Homo sapiens	151-154
19251722-0	2009	Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase.	Berberine	0-9	nitric oxide synthase 3	Rattus norvegicus	145-178
19251361-0	2009	Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9.	Berberine	0-9	MAU2 sister chromatid cohesion factor	Homo sapiens	62-67
19251361-0	2009	Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9.	Berberine	0-9	protein tyrosine kinase 2	Homo sapiens	124-127
19251361-0	2009	Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	134-143
19251361-0	2009	Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9.	Berberine	0-9	plasminogen activator, urokinase	Homo sapiens	145-149
19251361-0	2009	Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9.	Berberine	0-9	matrix metallopeptidase 2	Homo sapiens	154-166
19251361-5	2009	Here, we report that berberine inhibited migration and invasion of human SCC-4 tongue squamous carcinoma cells.	Berberine	21-30	MAU2 sister chromatid cohesion factor	Homo sapiens	73-78
19251361-7	2009	Our Western blowing analysis also showed that berberine inhibited the levels of urokinase-plasminogen activator (u-PA).	Berberine	46-55	plasminogen activator, urokinase	Homo sapiens	80-111
19251361-7	2009	Our Western blowing analysis also showed that berberine inhibited the levels of urokinase-plasminogen activator (u-PA).	Berberine	46-55	plasminogen activator, urokinase	Homo sapiens	113-117
19251361-8	2009	These results suggest that berberine down-regulates u-PA, MMP-2 and -9 expressions in SCC-4 cells through the FAK, IKK and NF-kappaB mediated pathways and a novel function of berberine is to inhibit the invasive capacity of malignant cells.	Berberine	27-36	plasminogen activator, urokinase	Homo sapiens	52-56
19251361-8	2009	These results suggest that berberine down-regulates u-PA, MMP-2 and -9 expressions in SCC-4 cells through the FAK, IKK and NF-kappaB mediated pathways and a novel function of berberine is to inhibit the invasive capacity of malignant cells.	Berberine	27-36	matrix metallopeptidase 2	Homo sapiens	58-70
19251361-8	2009	These results suggest that berberine down-regulates u-PA, MMP-2 and -9 expressions in SCC-4 cells through the FAK, IKK and NF-kappaB mediated pathways and a novel function of berberine is to inhibit the invasive capacity of malignant cells.	Berberine	27-36	MAU2 sister chromatid cohesion factor	Homo sapiens	86-91
19251361-8	2009	These results suggest that berberine down-regulates u-PA, MMP-2 and -9 expressions in SCC-4 cells through the FAK, IKK and NF-kappaB mediated pathways and a novel function of berberine is to inhibit the invasive capacity of malignant cells.	Berberine	27-36	protein tyrosine kinase 2	Homo sapiens	110-113
19251361-8	2009	These results suggest that berberine down-regulates u-PA, MMP-2 and -9 expressions in SCC-4 cells through the FAK, IKK and NF-kappaB mediated pathways and a novel function of berberine is to inhibit the invasive capacity of malignant cells.	Berberine	27-36	nuclear factor kappa B subunit 1	Homo sapiens	123-132
19513545-10	2009	Using a specific GST pull-down assay of activated Rho GTPases, we demonstrated that berberine suppressed the activation of Rho GTPases including RhoA, Cdc42 and Rac1.	Berberine	84-93	ras homolog family member A	Homo sapiens	145-149
19513545-10	2009	Using a specific GST pull-down assay of activated Rho GTPases, we demonstrated that berberine suppressed the activation of Rho GTPases including RhoA, Cdc42 and Rac1.	Berberine	84-93	cell division cycle 42	Homo sapiens	151-156
19513545-10	2009	Using a specific GST pull-down assay of activated Rho GTPases, we demonstrated that berberine suppressed the activation of Rho GTPases including RhoA, Cdc42 and Rac1.	Berberine	84-93	Rac family small GTPase 1	Homo sapiens	161-165
19852296-0	2009	[Of berberine and puerarin on dexamethasone-induced insulin resistance in porcine ovarian thecal cells].	Berberine	4-13	insulin	Homo sapiens	52-59
19323986-4	2009	Both plasma motilin and gastrin were also elevated and reduced remarkably in Berberine-treated subgroup along with the body weight increased and wet stool reduced at the meantime.	Berberine	77-86	motilin	Rattus norvegicus	12-19
19323986-4	2009	Both plasma motilin and gastrin were also elevated and reduced remarkably in Berberine-treated subgroup along with the body weight increased and wet stool reduced at the meantime.	Berberine	77-86	gastrin	Rattus norvegicus	24-31
19960952-2	2009	METHODS: The inhibition of AR by baicalin, berberine and Astragalus polysaccharides and positive drug (Epalrestat) in different concentrations were evaluated, and their combinative effects were studied according to orthogonal t design.	Berberine	43-52	aldo-keto reductase family 1 member B	Homo sapiens	27-29
19960952-3	2009	RESULTS: Baicalin and berberine had remarkable inhibitory effects on AR, the inhibitory rates were (88.4 +/- 7.4)% and (69.0 +/- 9.4)% at the concentration of 300 microg/mL.	Berberine	22-31	aldo-keto reductase family 1 member B	Homo sapiens	69-71
19960952-6	2009	CONCLUSION: Baicalin and berberine are the potential AR inhibitors as they can inhibit the activity of AR in vitro.	Berberine	25-34	aldo-keto reductase family 1 member B	Homo sapiens	53-55
19960952-6	2009	CONCLUSION: Baicalin and berberine are the potential AR inhibitors as they can inhibit the activity of AR in vitro.	Berberine	25-34	aldo-keto reductase family 1 member B	Homo sapiens	103-105
19536921-7	2009	RESULTS: The results showed that CRAE and berberine inhibited significantly the activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and increased the activity of superoxide dismutase (SOD).	Berberine	42-51	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	129-155
19536921-7	2009	RESULTS: The results showed that CRAE and berberine inhibited significantly the activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and increased the activity of superoxide dismutase (SOD).	Berberine	42-51	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	157-160
19401197-0	2009	Berberine-induced decline in circulating CD31+/CD42- microparticles is associated with improvement of endothelial function in humans.	Berberine	0-9	platelet and endothelial cell adhesion molecule 1	Homo sapiens	41-45
19401197-8	2009	After berberine therapy, circulating CD31(+)/CD42(-) microparticles were reduced, which was in parallel with the improvement of flow-mediated vasodilation while nitroglyceride-mediated vasodilation kept unchanged.	Berberine	6-15	platelet and endothelial cell adhesion molecule 1	Homo sapiens	37-41
19401197-10	2009	The EMPs in vitro led to diminished eNOS protein expression in HUVECs and this EMP-mediated detrimental effect was markedly inhibited by berberine.	Berberine	137-146	nitric oxide synthase 3	Homo sapiens	36-40
19401197-11	2009	Berberine-induced decline in circulating CD31(+)/CD42(-) microparticles contributes to upregulation of endothelial function in healthy subjects.	Berberine	0-9	platelet and endothelial cell adhesion molecule 1	Homo sapiens	41-45
19251722-3	2009	METHODS AND RESULTS: In both cultured endothelial cells and blood vessels isolated from rat aorta, berberine concentration dependently enhanced phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser1177 and promoted the association of eNOS with heat shock protein 90 (HSP90), leading to an increased production of nitric oxide.	Berberine	99-108	nitric oxide synthase 3	Rattus norvegicus	163-196
19251722-3	2009	METHODS AND RESULTS: In both cultured endothelial cells and blood vessels isolated from rat aorta, berberine concentration dependently enhanced phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser1177 and promoted the association of eNOS with heat shock protein 90 (HSP90), leading to an increased production of nitric oxide.	Berberine	99-108	nitric oxide synthase 3	Rattus norvegicus	198-202
19251722-3	2009	METHODS AND RESULTS: In both cultured endothelial cells and blood vessels isolated from rat aorta, berberine concentration dependently enhanced phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser1177 and promoted the association of eNOS with heat shock protein 90 (HSP90), leading to an increased production of nitric oxide.	Berberine	99-108	nitric oxide synthase 3	Rattus norvegicus	247-251
19251722-3	2009	METHODS AND RESULTS: In both cultured endothelial cells and blood vessels isolated from rat aorta, berberine concentration dependently enhanced phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser1177 and promoted the association of eNOS with heat shock protein 90 (HSP90), leading to an increased production of nitric oxide.	Berberine	99-108	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	257-278
19251722-3	2009	METHODS AND RESULTS: In both cultured endothelial cells and blood vessels isolated from rat aorta, berberine concentration dependently enhanced phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser1177 and promoted the association of eNOS with heat shock protein 90 (HSP90), leading to an increased production of nitric oxide.	Berberine	99-108	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	280-285
19424587-0	2009	Involvement of reactive oxygen species and caspase-dependent pathway in berberine-induced cell cycle arrest and apoptosis in C6 rat glioma cells.	Berberine	72-81	caspase 8	Rattus norvegicus	43-50
19424587-4	2009	Berberine increased the levels of GADD153 and GRP 78 in C6 cells based on the examination of Western blotting and this is a major hallmark of endoplasmic reticulum (ER) stress.	Berberine	0-9	DNA-damage inducible transcript 3	Rattus norvegicus	34-41
19424587-6	2009	Western blotting assay also showed that berberine inhibited the levels of anti-apoptotic protein Bcl-2 but increased the levels of pro-apoptotic protein Bax before leading to a decrease in the levels of mitochondrial membrane potential (DeltaPsim) followed by cytochrome c release that caused the activations of capase-9 and -3 for apoptotic occurrence.	Berberine	40-49	BCL2 associated X, apoptosis regulator	Rattus norvegicus	153-156
19424587-7	2009	The caspase-8, -9 and -3 were activated by berberine in C6 cells based on the substrate solution (PhiPhiLux-G1D1, CaspaLux 8-L1D2, CaspaLux 9-M1D2 for caspase-3, -8 and -9, respectively) and analyzed by flow cytometer and each inhibitor of caspase-8, -9 and -3 led to increase the percentage of viable C6 cells after exposure to berberine.	Berberine	43-52	caspase 8	Rattus norvegicus	4-24
19424587-4	2009	Berberine increased the levels of GADD153 and GRP 78 in C6 cells based on the examination of Western blotting and this is a major hallmark of endoplasmic reticulum (ER) stress.	Berberine	0-9	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	46-52
19424587-7	2009	The caspase-8, -9 and -3 were activated by berberine in C6 cells based on the substrate solution (PhiPhiLux-G1D1, CaspaLux 8-L1D2, CaspaLux 9-M1D2 for caspase-3, -8 and -9, respectively) and analyzed by flow cytometer and each inhibitor of caspase-8, -9 and -3 led to increase the percentage of viable C6 cells after exposure to berberine.	Berberine	43-52	caspase 3	Rattus norvegicus	151-171
19424587-6	2009	Western blotting assay also showed that berberine inhibited the levels of anti-apoptotic protein Bcl-2 but increased the levels of pro-apoptotic protein Bax before leading to a decrease in the levels of mitochondrial membrane potential (DeltaPsim) followed by cytochrome c release that caused the activations of capase-9 and -3 for apoptotic occurrence.	Berberine	40-49	BCL2, apoptosis regulator	Rattus norvegicus	97-102
19424587-7	2009	The caspase-8, -9 and -3 were activated by berberine in C6 cells based on the substrate solution (PhiPhiLux-G1D1, CaspaLux 8-L1D2, CaspaLux 9-M1D2 for caspase-3, -8 and -9, respectively) and analyzed by flow cytometer and each inhibitor of caspase-8, -9 and -3 led to increase the percentage of viable C6 cells after exposure to berberine.	Berberine	43-52	caspase 8	Rattus norvegicus	240-260
19424587-7	2009	The caspase-8, -9 and -3 were activated by berberine in C6 cells based on the substrate solution (PhiPhiLux-G1D1, CaspaLux 8-L1D2, CaspaLux 9-M1D2 for caspase-3, -8 and -9, respectively) and analyzed by flow cytometer and each inhibitor of caspase-8, -9 and -3 led to increase the percentage of viable C6 cells after exposure to berberine.	Berberine	329-338	caspase 8	Rattus norvegicus	4-24
19336898-1	2009	The structural similarity between papaverine and berberine, a known inhibitor of human protein tyrosine phosphatase 1B (h-PTP 1B), prompted us to investigate the potential of papaverine as h-PTP 1B inhibitor.	Berberine	49-58	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	87-118
19424587-8	2009	This finding was also confirmed by Western blot assay which showed that berberine promoted the active form of caspase-8, -9 and -3.	Berberine	72-81	caspase 8	Rattus norvegicus	110-130
19424587-9	2009	These results demonstrate that the cytotoxicity of berberine in C6 rat glioma cells is attributable to apoptosis mainly through induced G2/M-arrested cells, in an ER-dependent manner, via a mitochondria-dependent caspase pathway regulated by Bax and Bcl-2.	Berberine	51-60	caspase 8	Rattus norvegicus	213-220
19424587-9	2009	These results demonstrate that the cytotoxicity of berberine in C6 rat glioma cells is attributable to apoptosis mainly through induced G2/M-arrested cells, in an ER-dependent manner, via a mitochondria-dependent caspase pathway regulated by Bax and Bcl-2.	Berberine	51-60	BCL2 associated X, apoptosis regulator	Rattus norvegicus	242-245
19424587-9	2009	These results demonstrate that the cytotoxicity of berberine in C6 rat glioma cells is attributable to apoptosis mainly through induced G2/M-arrested cells, in an ER-dependent manner, via a mitochondria-dependent caspase pathway regulated by Bax and Bcl-2.	Berberine	51-60	BCL2, apoptosis regulator	Rattus norvegicus	250-255
19526156-9	2009	The CTB, Ber, and nimodipine also significantly blunted the decrease of SOD and ChAT activities, and the increase of MDA content, AchE activities, and MAO-B expressions and activity in the aluminum-overload rats.	Berberine	9-12	choline O-acetyltransferase	Rattus norvegicus	80-84
19526156-9	2009	The CTB, Ber, and nimodipine also significantly blunted the decrease of SOD and ChAT activities, and the increase of MDA content, AchE activities, and MAO-B expressions and activity in the aluminum-overload rats.	Berberine	9-12	monoamine oxidase B	Rattus norvegicus	151-156
19142714-0	2009	Berberine reduces fibronectin and collagen accumulation in rat glomerular mesangial cells cultured under high glucose condition.	Berberine	0-9	fibronectin 1	Rattus norvegicus	18-29
19142714-9	2009	Berberine significantly decreased protein expression of fibronectin compared with SB203580 treatment group (P &lt; 0.05).	Berberine	0-9	fibronectin 1	Rattus norvegicus	56-67
19142714-11	2009	Both SB203580 and berberine significantly decreased phospho-p38MAPK and phospho-CREB level compared with HG-treated group (P &lt; 0.05).	Berberine	18-27	cAMP responsive element binding protein 1	Rattus norvegicus	80-84
19142714-12	2009	These results indicated that berberine might inhibit fibronectin and collagen synthesis partly via p38MAPK signal pathway in rat glomerular mesangial cells exposed to high glucose.	Berberine	29-38	fibronectin 1	Rattus norvegicus	53-64
19208854-6	2009	Upon various proinflammatory signals including LPS, free fatty acids, and hydrogen peroxide, BBR suppressed the phosphorylation of MAPKs, such as p38, ERK, and JNK, and the level of reactive oxygen species in macrophages.	Berberine	93-96	mitogen-activated protein kinase 14	Mus musculus	146-149
19208854-6	2009	Upon various proinflammatory signals including LPS, free fatty acids, and hydrogen peroxide, BBR suppressed the phosphorylation of MAPKs, such as p38, ERK, and JNK, and the level of reactive oxygen species in macrophages.	Berberine	93-96	mitogen-activated protein kinase 1	Mus musculus	151-154
19208854-6	2009	Upon various proinflammatory signals including LPS, free fatty acids, and hydrogen peroxide, BBR suppressed the phosphorylation of MAPKs, such as p38, ERK, and JNK, and the level of reactive oxygen species in macrophages.	Berberine	93-96	mitogen-activated protein kinase 8	Mus musculus	160-163
19360335-0	2009	Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells.	Berberine	0-9	tumor protein p53	Homo sapiens	19-22
19360335-4	2009	However, the p53 expressing LNCaP cells were more susceptible against berberine than the p53 lacking PC-3 cells.	Berberine	70-79	tumor protein p53	Homo sapiens	13-16
19360335-5	2009	The cell arrest in G0/G1 phase, apoptotic cell death and the expression of apoptotic cell death proteins Bax and caspase-3 was much higher in berberine-treated LNCaP cells than those in PC-3 cells.	Berberine	142-151	BCL2 associated X, apoptosis regulator	Homo sapiens	105-108
19360335-5	2009	The cell arrest in G0/G1 phase, apoptotic cell death and the expression of apoptotic cell death proteins Bax and caspase-3 was much higher in berberine-treated LNCaP cells than those in PC-3 cells.	Berberine	142-151	caspase 3	Homo sapiens	113-122
19360335-6	2009	Exploration of p53 siRNA or pifithrin-alpha, a p53 inhibitor to the LNCaP cells, suppressed berberine-induced cell death and expression of apoptosis-related proteins.	Berberine	92-101	tumor protein p53	Homo sapiens	15-18
19360335-6	2009	Exploration of p53 siRNA or pifithrin-alpha, a p53 inhibitor to the LNCaP cells, suppressed berberine-induced cell death and expression of apoptosis-related proteins.	Berberine	92-101	tumor protein p53	Homo sapiens	47-50
19360335-8	2009	Therefore, these results indicated that berberine inhibited p53-dependent prostate cancer cell death.	Berberine	40-49	tumor protein p53	Homo sapiens	60-63
19336898-1	2009	The structural similarity between papaverine and berberine, a known inhibitor of human protein tyrosine phosphatase 1B (h-PTP 1B), prompted us to investigate the potential of papaverine as h-PTP 1B inhibitor.	Berberine	49-58	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	122-128
19107816-0	2009	Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells.	Berberine	28-37	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	82-90
19156769-1	2009	New methods based on MEEKC coupling with field-amplified sample injection (FASI) induced by ACN were proposed for five isoquinoline alkaloids (berberine, palmatine, jatrorrhizine, sinomenine and homoharringtonine) in no salt and high salt sample solution (HS).	Berberine	143-152	apoptotic chromatin condensation inducer 1	Homo sapiens	92-95
19159633-0	2009	Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage.	Berberine	0-9	tumor protein p53	Homo sapiens	18-21
19159633-8	2009	Interestingly, DNA double-strand breaks, as measured by the phosphorylation of H2AX, were remarkably accumulated in berberine-treated cells in a dose-dependent manner.	Berberine	116-125	H2A.X variant histone	Homo sapiens	79-83
19159633-9	2009	Thus, one major mechanism by which berberine exerts its growth-inhibitory effect is to inflict genomic lesions on cells, which in turn trigger the activation of p53 and the p53-dependent cellular responses including cell cycle arrest and apoptosis.	Berberine	35-44	tumor protein p53	Homo sapiens	161-164
19159633-9	2009	Thus, one major mechanism by which berberine exerts its growth-inhibitory effect is to inflict genomic lesions on cells, which in turn trigger the activation of p53 and the p53-dependent cellular responses including cell cycle arrest and apoptosis.	Berberine	35-44	tumor protein p53	Homo sapiens	173-176
19361364-6	2009	RESULTS: At the concentrations of 0.1, 1 and 10 micromol/L, berberine dose-dependently suppressed the formation of TRAP-positive multinucleated cells, the TRAP activity and the osteoclastic bone resorption.	Berberine	60-69	acid phosphatase 5, tartrate resistant	Rattus norvegicus	115-119
19361364-6	2009	RESULTS: At the concentrations of 0.1, 1 and 10 micromol/L, berberine dose-dependently suppressed the formation of TRAP-positive multinucleated cells, the TRAP activity and the osteoclastic bone resorption.	Berberine	60-69	acid phosphatase 5, tartrate resistant	Rattus norvegicus	155-159
19173654-0	2009	Investigation of the interaction between Berberine and human serum albumin.	Berberine	41-50	albumin	Homo sapiens	61-74
19173654-2	2009	In this study, the interaction between Berberine and human serum albumin (HSA) was investigated by fluorescence spectroscopy and UV-vis absorbance spectroscopy.	Berberine	39-48	albumin	Homo sapiens	59-72
18996945-0	2009	Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats.	Berberine	0-9	glucagon	Rattus norvegicus	19-42
18996945-11	2009	The data support the hypothesis that the anti-diabetic effects of BBR may partly result from enhancing GCG secretion.	Berberine	66-69	glucagon	Rattus norvegicus	103-106
19014947-10	2009	Administration of BBR (100 mg/kg/d) increased TF activity and impaired TFPI expression in carotid artery of ApoE(-/-) mice.	Berberine	18-21	tissue factor pathway inhibitor	Mus musculus	71-75
19014947-10	2009	Administration of BBR (100 mg/kg/d) increased TF activity and impaired TFPI expression in carotid artery of ApoE(-/-) mice.	Berberine	18-21	apolipoprotein E	Mus musculus	108-112
19090767-0	2009	Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.	Berberine	0-9	low density lipoprotein receptor	Mus musculus	44-76
19445159-0	2009	[Effects of ginseng total saponins with berberine on plasma brain natriuretic peptide and Ca2+ concentration in experimental rats with chronic congestive heart failure].	Berberine	40-49	carbonic anhydrase 2	Rattus norvegicus	90-93
19445159-7	2009	Compared with model group, in total saponins of P. ginseng combined with berberine group can increase the contents of LVSP, +dp/dtmax, -dp/dtmax were increased, but were increased contents of LVEDP, plasma brain natriuretic peptide and Ca2+ concentration were decreased.	Berberine	73-82	carbonic anhydrase 2	Rattus norvegicus	236-239
19090767-1	2009	Twenty-nine derivatives of berberine (1) or pseudoberberine (2) were designed, semisynthesized, and evaluated for their up-regulatory activity on the low-density-lipoprotein receptor (LDLR) expression.	Berberine	27-36	low density lipoprotein receptor	Mus musculus	150-182
19090767-1	2009	Twenty-nine derivatives of berberine (1) or pseudoberberine (2) were designed, semisynthesized, and evaluated for their up-regulatory activity on the low-density-lipoprotein receptor (LDLR) expression.	Berberine	27-36	low density lipoprotein receptor	Mus musculus	184-188
19122285-0	2009	Berberine exerts neuroprotective actions against in vitro ischemia-induced neuronal cell damage in organotypic hippocampal slice cultures: involvement of B-cell lymphoma 2 phosphorylation suppression.	Berberine	0-9	B cell leukemia/lymphoma 2	Mus musculus	154-171
19000652-3	2009	The results showed that the combined treatment of ER antagonists and the crude extract of coptis or its purified compound berberine conferred synergistic growth inhibitory effect on MCF-7 cells (ER+), but not on MDA-MB-231 cells (ER-).	Berberine	122-131	estrogen receptor 1	Homo sapiens	195-197
19000652-3	2009	The results showed that the combined treatment of ER antagonists and the crude extract of coptis or its purified compound berberine conferred synergistic growth inhibitory effect on MCF-7 cells (ER+), but not on MDA-MB-231 cells (ER-).	Berberine	122-131	estrogen receptor 1	Homo sapiens	195-197
19000652-5	2009	Analysis of the expression of breast cancer related genes indicated that EGFR, HER2, bcl-2, and COX-2 were significantly downregulated, while IFN-beta and p21 were remarkably upregulated by berberine.	Berberine	190-199	epidermal growth factor receptor	Homo sapiens	73-77
19000652-5	2009	Analysis of the expression of breast cancer related genes indicated that EGFR, HER2, bcl-2, and COX-2 were significantly downregulated, while IFN-beta and p21 were remarkably upregulated by berberine.	Berberine	190-199	interferon beta 1	Homo sapiens	142-150
19000652-5	2009	Analysis of the expression of breast cancer related genes indicated that EGFR, HER2, bcl-2, and COX-2 were significantly downregulated, while IFN-beta and p21 were remarkably upregulated by berberine.	Berberine	190-199	H3 histone pseudogene 16	Homo sapiens	155-158
19122285-7	2009	Both berberine (5, 25 microM) and MK-801 (25 microM) significantly inhibited PI uptake at 24 h after 45-min OGD treatment and PI uptake in OHSCs exposed to NMDA for 24 h. OGD treatment also significantly increased the level of p-Bcl-2 but not that of Bcl-2 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in OHSCs.	Berberine	5-14	B cell leukemia/lymphoma 2	Mus musculus	229-234
19122285-7	2009	Both berberine (5, 25 microM) and MK-801 (25 microM) significantly inhibited PI uptake at 24 h after 45-min OGD treatment and PI uptake in OHSCs exposed to NMDA for 24 h. OGD treatment also significantly increased the level of p-Bcl-2 but not that of Bcl-2 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in OHSCs.	Berberine	5-14	B cell leukemia/lymphoma 2	Mus musculus	251-256
19122285-7	2009	Both berberine (5, 25 microM) and MK-801 (25 microM) significantly inhibited PI uptake at 24 h after 45-min OGD treatment and PI uptake in OHSCs exposed to NMDA for 24 h. OGD treatment also significantly increased the level of p-Bcl-2 but not that of Bcl-2 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in OHSCs.	Berberine	5-14	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	260-300
19122285-7	2009	Both berberine (5, 25 microM) and MK-801 (25 microM) significantly inhibited PI uptake at 24 h after 45-min OGD treatment and PI uptake in OHSCs exposed to NMDA for 24 h. OGD treatment also significantly increased the level of p-Bcl-2 but not that of Bcl-2 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in OHSCs.	Berberine	5-14	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	302-307
19122285-8	2009	Berberine (5-25 microM) significantly suppressed the OGD-induced increase of p-Bcl-2 level in OHSCs when tissue was exposed to the alkaloid prior to OGD or simultaneously with OGD.	Berberine	0-9	B cell leukemia/lymphoma 2	Mus musculus	79-84
19122285-9	2009	These findings suggest that berberine has protective effects against ischemic damage in mouse OHSCs and that the effects are at least partly mediated by suppression of Bcl-2 phosphorylation.	Berberine	28-37	B cell leukemia/lymphoma 2	Mus musculus	168-173
19319464-12	2009	Berberine, a major ingredient of OGT, suppressed ADA expression and reduced the incidence of lethality.	Berberine	0-9	adenosine deaminase	Mus musculus	49-52
18355829-7	2008	CONCLUSION: Berberine may be a useful supplement to statin treatment due to its effects on PCSK9 mRNA and protein levels.	Berberine	12-21	proprotein convertase subtilisin/kexin type 9	Homo sapiens	91-96
19059538-0	2009	Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression.	Berberine	0-9	insulin receptor	Rattus norvegicus	89-105
19059538-5	2009	Berberine increased InsR expression in the L6 rat skeletal muscle cells as well.	Berberine	0-9	insulin receptor	Rattus norvegicus	20-24
19059538-6	2009	Berberine-enhanced InsR expression improved cellular glucose consumption only in the presence of insulin.	Berberine	0-9	insulin receptor	Rattus norvegicus	19-23
19059538-8	2009	Berberine induced InsR gene expression through a protein kinase C (PKC)-dependent activation of its promoter.	Berberine	0-9	insulin receptor	Rattus norvegicus	18-22
19052522-0	2008	Berberine suppresses TNF-alpha-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells.	Berberine	0-9	tumor necrosis factor	Homo sapiens	21-30
19052522-0	2008	Berberine suppresses TNF-alpha-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells.	Berberine	0-9	matrix metallopeptidase 9	Homo sapiens	39-44
18459128-0	2009	p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.	Berberine	15-24	tumor protein p53	Homo sapiens	0-3
18459128-3	2009	Treatment of A549, which express wild-type p53, and H1299, which are p53-deficient, human lung cancer cells with berberine resulted in inhibition of cell proliferation and an increase in apoptotic cell death; however, A549 cells were more sensitive to the berberine-induced cytotoxic effects than H1299 cells.	Berberine	113-122	tumor protein p53	Homo sapiens	43-46
18459128-3	2009	Treatment of A549, which express wild-type p53, and H1299, which are p53-deficient, human lung cancer cells with berberine resulted in inhibition of cell proliferation and an increase in apoptotic cell death; however, A549 cells were more sensitive to the berberine-induced cytotoxic effects than H1299 cells.	Berberine	113-122	tumor protein p53	Homo sapiens	69-72
18459128-4	2009	Further, the treatment of A549 cells with pifithrin-alpha, a specific inhibitor of p53, or transfection of A549 cells with a p53 antisense oligodeoxynucleotide resulted in a reduction in the berberine-induced inhibition of cell proliferation and apoptosis.	Berberine	191-200	tumor protein p53	Homo sapiens	83-86
18459128-4	2009	Further, the treatment of A549 cells with pifithrin-alpha, a specific inhibitor of p53, or transfection of A549 cells with a p53 antisense oligodeoxynucleotide resulted in a reduction in the berberine-induced inhibition of cell proliferation and apoptosis.	Berberine	191-200	tumor protein p53	Homo sapiens	125-128
18459128-5	2009	The berberine-induced apoptosis of both the A549 and H1299 human lung cancer cells was associated with the disruption of mitochondrial membrane potential, reduction in the levels of Bcl-2, Bcl-xl while increase in Bax, Bak, and activation of caspase-3.	Berberine	4-13	BCL2 apoptosis regulator	Homo sapiens	182-187
18459128-5	2009	The berberine-induced apoptosis of both the A549 and H1299 human lung cancer cells was associated with the disruption of mitochondrial membrane potential, reduction in the levels of Bcl-2, Bcl-xl while increase in Bax, Bak, and activation of caspase-3.	Berberine	4-13	BCL2 like 1	Homo sapiens	189-195
18459128-5	2009	The berberine-induced apoptosis of both the A549 and H1299 human lung cancer cells was associated with the disruption of mitochondrial membrane potential, reduction in the levels of Bcl-2, Bcl-xl while increase in Bax, Bak, and activation of caspase-3.	Berberine	4-13	BCL2 associated X, apoptosis regulator	Homo sapiens	214-217
18459128-5	2009	The berberine-induced apoptosis of both the A549 and H1299 human lung cancer cells was associated with the disruption of mitochondrial membrane potential, reduction in the levels of Bcl-2, Bcl-xl while increase in Bax, Bak, and activation of caspase-3.	Berberine	4-13	BCL2 antagonist/killer 1	Homo sapiens	219-222
18459128-5	2009	The berberine-induced apoptosis of both the A549 and H1299 human lung cancer cells was associated with the disruption of mitochondrial membrane potential, reduction in the levels of Bcl-2, Bcl-xl while increase in Bax, Bak, and activation of caspase-3.	Berberine	4-13	caspase 3	Homo sapiens	242-251
18459128-6	2009	Treatment of the cells with pan-caspase inhibitor (z-VAD-fmk) or caspase-3 inhibitor (z-DEVD-fmk) inhibited berberine-induced apoptosis, thus suggesting the role of caspase-3.	Berberine	108-117	caspase 3	Homo sapiens	65-74
18459128-6	2009	Treatment of the cells with pan-caspase inhibitor (z-VAD-fmk) or caspase-3 inhibitor (z-DEVD-fmk) inhibited berberine-induced apoptosis, thus suggesting the role of caspase-3.	Berberine	108-117	caspase 3	Homo sapiens	165-174
18459128-7	2009	Further, the administration of berberine by oral gavage inhibited the growth of s.c. A549 and H1299 lung tumor xenografts in athymic nude mice, however, the growth of tumor xenograft of H1299 cells was faster than A549 cells in mice and the chemotherapeutic effect of berberine was more pronounced in the p53-positive-A549 tumor xenograft than p53-deficient-H1299 tumor xenograft.	Berberine	31-40	transformation related protein 53, pseudogene	Mus musculus	305-308
18459128-7	2009	Further, the administration of berberine by oral gavage inhibited the growth of s.c. A549 and H1299 lung tumor xenografts in athymic nude mice, however, the growth of tumor xenograft of H1299 cells was faster than A549 cells in mice and the chemotherapeutic effect of berberine was more pronounced in the p53-positive-A549 tumor xenograft than p53-deficient-H1299 tumor xenograft.	Berberine	31-40	transformation related protein 53, pseudogene	Mus musculus	344-347
18355829-0	2008	Berberine decreases PCSK9 expression in HepG2 cells.	Berberine	0-9	proprotein convertase subtilisin/kexin type 9	Homo sapiens	20-25
18355829-3	2008	Here we investigated the effect of berberine, a natural plant extract, on PCSK9 expression in HepG2 cells.	Berberine	35-44	proprotein convertase subtilisin/kexin type 9	Homo sapiens	74-79
18355829-4	2008	RESULTS: Berberine decreases PCSK9 mRNA and protein levels in a time- and dose-dependent manner.	Berberine	9-18	proprotein convertase subtilisin/kexin type 9	Homo sapiens	29-34
18355829-6	2008	We also show that a combination of berberine and mevastatin increases LDLR mRNA and protein levels, while suppressing the increase in PCSK9 mRNA levels caused by mevastatin alone.	Berberine	35-44	low density lipoprotein receptor	Homo sapiens	70-74
18355829-6	2008	We also show that a combination of berberine and mevastatin increases LDLR mRNA and protein levels, while suppressing the increase in PCSK9 mRNA levels caused by mevastatin alone.	Berberine	35-44	proprotein convertase subtilisin/kexin type 9	Homo sapiens	134-139
19080170-0	2008	Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus.	Berberine	44-53	retinol binding protein 4	Rattus norvegicus	75-100
17418998-5	2008	Oral administration of berberine (50mg/kg) inhibited the hepatocyte proliferation and iNOS expression, decreased cytochrome P450 content, inhibited activities of CYP2E1 and CYP1A2 in DEN-plus-PB-treated rats in vivo.	Berberine	23-32	nitric oxide synthase 2	Rattus norvegicus	86-90
17418998-5	2008	Oral administration of berberine (50mg/kg) inhibited the hepatocyte proliferation and iNOS expression, decreased cytochrome P450 content, inhibited activities of CYP2E1 and CYP1A2 in DEN-plus-PB-treated rats in vivo.	Berberine	23-32	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	162-168
19189664-0	2008	Berberine inhibits human neuroblastoma cell growth through induction of p53-dependent apoptosis.	Berberine	0-9	tumor protein p53	Homo sapiens	72-75
19189664-3	2008	The p53-expressing cells, SK-N-SH (IC50=37 microM) were more susceptible to berberine than the p53-deficient cells, SK-N-MC (IC50 &gt; or =100 microM) without cytotoxic effect on the cortical neuronal cells.	Berberine	76-85	tumor protein p53	Homo sapiens	4-7
19189664-5	2008	Berberine much greatly decreased G0/G1 phase-associated cyclin and cyclin-dependent kinase (cyclin D1, cyclin E, Cdk2, and Cdk4) expression, and increased apoptotic gene expression and activation of caspase-3 in SK-N-SH cells.	Berberine	0-9	cyclin D1	Homo sapiens	92-101
19189664-5	2008	Berberine much greatly decreased G0/G1 phase-associated cyclin and cyclin-dependent kinase (cyclin D1, cyclin E, Cdk2, and Cdk4) expression, and increased apoptotic gene expression and activation of caspase-3 in SK-N-SH cells.	Berberine	0-9	cyclin dependent kinase 2	Homo sapiens	113-117
19189664-5	2008	Berberine much greatly decreased G0/G1 phase-associated cyclin and cyclin-dependent kinase (cyclin D1, cyclin E, Cdk2, and Cdk4) expression, and increased apoptotic gene expression and activation of caspase-3 in SK-N-SH cells.	Berberine	0-9	cyclin dependent kinase 4	Homo sapiens	123-127
19189664-5	2008	Berberine much greatly decreased G0/G1 phase-associated cyclin and cyclin-dependent kinase (cyclin D1, cyclin E, Cdk2, and Cdk4) expression, and increased apoptotic gene expression and activation of caspase-3 in SK-N-SH cells.	Berberine	0-9	caspase 3	Homo sapiens	199-208
19189664-7	2008	Therefore, these results showed that berberine causes p53-dependent apoptotic death of neuroblastoma cells, and suggested that berberine may be useful as an anticancer agent for neuroblastoma.	Berberine	37-46	tumor protein p53	Homo sapiens	54-57
19189664-7	2008	Therefore, these results showed that berberine causes p53-dependent apoptotic death of neuroblastoma cells, and suggested that berberine may be useful as an anticancer agent for neuroblastoma.	Berberine	127-136	tumor protein p53	Homo sapiens	54-57
17418998-5	2008	Oral administration of berberine (50mg/kg) inhibited the hepatocyte proliferation and iNOS expression, decreased cytochrome P450 content, inhibited activities of CYP2E1 and CYP1A2 in DEN-plus-PB-treated rats in vivo.	Berberine	23-32	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	173-179
18789680-0	2008	Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer.	Berberine	22-31	transforming growth factor beta 1	Homo sapiens	108-141
17418998-6	2008	Moreover, berberine (10, 50 and 100 microM) inhibited the activities of CYP2E1 and CYP1A2 in microsomes isolated from DEN-plus-PB-treated rats in vitro, suggesting that anti-hepatocarcinogenetic potential of berberine might be due to inhibiting oxidative metabolic activities of CYP 2E1 and CYP1A2, and decreasing NO production in rats.	Berberine	10-19	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	72-78
17418998-6	2008	Moreover, berberine (10, 50 and 100 microM) inhibited the activities of CYP2E1 and CYP1A2 in microsomes isolated from DEN-plus-PB-treated rats in vitro, suggesting that anti-hepatocarcinogenetic potential of berberine might be due to inhibiting oxidative metabolic activities of CYP 2E1 and CYP1A2, and decreasing NO production in rats.	Berberine	10-19	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	83-89
17418998-6	2008	Moreover, berberine (10, 50 and 100 microM) inhibited the activities of CYP2E1 and CYP1A2 in microsomes isolated from DEN-plus-PB-treated rats in vitro, suggesting that anti-hepatocarcinogenetic potential of berberine might be due to inhibiting oxidative metabolic activities of CYP 2E1 and CYP1A2, and decreasing NO production in rats.	Berberine	10-19	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	279-286
17418998-6	2008	Moreover, berberine (10, 50 and 100 microM) inhibited the activities of CYP2E1 and CYP1A2 in microsomes isolated from DEN-plus-PB-treated rats in vitro, suggesting that anti-hepatocarcinogenetic potential of berberine might be due to inhibiting oxidative metabolic activities of CYP 2E1 and CYP1A2, and decreasing NO production in rats.	Berberine	10-19	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	291-297
17418998-6	2008	Moreover, berberine (10, 50 and 100 microM) inhibited the activities of CYP2E1 and CYP1A2 in microsomes isolated from DEN-plus-PB-treated rats in vitro, suggesting that anti-hepatocarcinogenetic potential of berberine might be due to inhibiting oxidative metabolic activities of CYP 2E1 and CYP1A2, and decreasing NO production in rats.	Berberine	208-217	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	72-78
18805669-0	2008	Berberine inhibits SDF-1-induced AML cells and leukemic stem cells migration via regulation of SDF-1 level in bone marrow stromal cells.	Berberine	0-9	C-X-C motif chemokine ligand 12	Homo sapiens	19-24
18805669-0	2008	Berberine inhibits SDF-1-induced AML cells and leukemic stem cells migration via regulation of SDF-1 level in bone marrow stromal cells.	Berberine	0-9	C-X-C motif chemokine ligand 12	Homo sapiens	95-100
18805669-4	2008	In this study, we investigated the effects of berberine on the SDF-1-induced HL-60 cells, primary acute myeloid leukemia (AML) cells and leukemic stem cells (LSCs) migration.	Berberine	46-55	C-X-C motif chemokine ligand 12	Homo sapiens	63-68
18805669-6	2008	Results demonstrated that berberine could partly inhibit SDF-1-induced AML cells as well as LSCs migration.	Berberine	26-35	C-X-C motif chemokine ligand 12	Homo sapiens	57-62
18805669-7	2008	Berberine could reduce SDF-1 protein level secreted by BMSCs in the microenvironment but not affect CXCR4 expression on HL-60 cell membrane, and we hypothesized that berberine could inhibit AML cells migration partly by reducing the secreting of SDF-1 by BMSCs and inhibiting HERG1 K(+) channels of leukemic cells.	Berberine	0-9	C-X-C motif chemokine ligand 12	Homo sapiens	23-28
18805669-7	2008	Berberine could reduce SDF-1 protein level secreted by BMSCs in the microenvironment but not affect CXCR4 expression on HL-60 cell membrane, and we hypothesized that berberine could inhibit AML cells migration partly by reducing the secreting of SDF-1 by BMSCs and inhibiting HERG1 K(+) channels of leukemic cells.	Berberine	0-9	C-X-C motif chemokine ligand 12	Homo sapiens	246-251
18805669-7	2008	Berberine could reduce SDF-1 protein level secreted by BMSCs in the microenvironment but not affect CXCR4 expression on HL-60 cell membrane, and we hypothesized that berberine could inhibit AML cells migration partly by reducing the secreting of SDF-1 by BMSCs and inhibiting HERG1 K(+) channels of leukemic cells.	Berberine	0-9	potassium voltage-gated channel subfamily H member 2	Homo sapiens	276-281
18805669-7	2008	Berberine could reduce SDF-1 protein level secreted by BMSCs in the microenvironment but not affect CXCR4 expression on HL-60 cell membrane, and we hypothesized that berberine could inhibit AML cells migration partly by reducing the secreting of SDF-1 by BMSCs and inhibiting HERG1 K(+) channels of leukemic cells.	Berberine	166-175	C-X-C motif chemokine ligand 12	Homo sapiens	23-28
18805669-7	2008	Berberine could reduce SDF-1 protein level secreted by BMSCs in the microenvironment but not affect CXCR4 expression on HL-60 cell membrane, and we hypothesized that berberine could inhibit AML cells migration partly by reducing the secreting of SDF-1 by BMSCs and inhibiting HERG1 K(+) channels of leukemic cells.	Berberine	166-175	C-X-C motif chemokine ligand 12	Homo sapiens	246-251
18805669-7	2008	Berberine could reduce SDF-1 protein level secreted by BMSCs in the microenvironment but not affect CXCR4 expression on HL-60 cell membrane, and we hypothesized that berberine could inhibit AML cells migration partly by reducing the secreting of SDF-1 by BMSCs and inhibiting HERG1 K(+) channels of leukemic cells.	Berberine	166-175	potassium voltage-gated channel subfamily H member 2	Homo sapiens	276-281
18789680-11	2008	CONCLUSION: Berberine significantly reduced the incidence of RILI, improved PF and decreased the levels of sICAM-1 and TGF-beta1.	Berberine	12-21	transforming growth factor beta 1	Homo sapiens	119-128
18644725-0	2008	Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators.	Berberine	50-59	low density lipoprotein receptor	Homo sapiens	90-122
18951337-0	2008	Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells.	Berberine	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	45-50
18951337-6	2008	In addition, berberine treatment was associated with a decrease in expression of ABCG2 relative to untreated controls.	Berberine	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	81-86
18951337-7	2008	These results indicate that the growth inhibitory effects of berberine treatment on MCF-7 cells may be partly via effects on SP and ABCG2 expression.	Berberine	61-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	132-137
18932278-0	2008	Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity.	Berberine	24-33	hepatocyte nuclear factor 4, alpha	Rattus norvegicus	78-108
18932278-0	2008	Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity.	Berberine	24-33	glucokinase	Rattus norvegicus	124-135
18932278-8	2008	Both mRNA and protein expressions of HNF4alpha were up-regulated by berberine in a dose-dependent manner, and GK activity was also increased accordingly.	Berberine	68-77	hepatocyte nuclear factor 4, alpha	Rattus norvegicus	37-46
18932278-10	2008	CONCLUSION: Berberine can enhance GSIS in rat islets, and probably exerts the insulinotropic effect via a pathway involving HNF4alpha and GK, which is distinct from sulphonylureas (SUs).	Berberine	12-21	hepatocyte nuclear factor 4, alpha	Rattus norvegicus	124-133
18932278-10	2008	CONCLUSION: Berberine can enhance GSIS in rat islets, and probably exerts the insulinotropic effect via a pathway involving HNF4alpha and GK, which is distinct from sulphonylureas (SUs).	Berberine	12-21	glucokinase	Rattus norvegicus	138-140
18164189-0	2008	Berberine prevents UV-induced MMP-1 and reduction of type I procollagen expression in human dermal fibroblasts.	Berberine	0-9	matrix metallopeptidase 1	Homo sapiens	30-35
18164189-0	2008	Berberine prevents UV-induced MMP-1 and reduction of type I procollagen expression in human dermal fibroblasts.	Berberine	0-9	collagen type I alpha 2 chain	Homo sapiens	53-71
18164189-3	2008	In this study, antioxidative plant ingredients used in traditional Chinese medicine, berberine (BBR) was investigated for their capacity to regulate MMP-1 and type I procollagen expression in human dermal fibroblasts.	Berberine	85-94	matrix metallopeptidase 1	Homo sapiens	149-154
18164189-3	2008	In this study, antioxidative plant ingredients used in traditional Chinese medicine, berberine (BBR) was investigated for their capacity to regulate MMP-1 and type I procollagen expression in human dermal fibroblasts.	Berberine	85-94	collagen type I alpha 2 chain	Homo sapiens	159-177
18164189-3	2008	In this study, antioxidative plant ingredients used in traditional Chinese medicine, berberine (BBR) was investigated for their capacity to regulate MMP-1 and type I procollagen expression in human dermal fibroblasts.	Berberine	96-99	matrix metallopeptidase 1	Homo sapiens	149-154
18164189-3	2008	In this study, antioxidative plant ingredients used in traditional Chinese medicine, berberine (BBR) was investigated for their capacity to regulate MMP-1 and type I procollagen expression in human dermal fibroblasts.	Berberine	96-99	collagen type I alpha 2 chain	Homo sapiens	159-177
19160796-9	2008	CONCLUSION: It is suggested that the effects of berberine on improving glucose metabolism can be mechanically associated with its up-regulating the HNF4a expression and inducing the activity of hepatic glucokinase.	Berberine	48-57	glucokinase	Mus musculus	202-213
19160796-0	2008	[Effects of berberine on expression of hepatocyte nuclear factor 4alpha and glucokinase activity in mouse primary hepatocytes].	Berberine	12-21	hepatic nuclear factor 4, alpha	Mus musculus	39-71
19160796-0	2008	[Effects of berberine on expression of hepatocyte nuclear factor 4alpha and glucokinase activity in mouse primary hepatocytes].	Berberine	12-21	glucokinase	Mus musculus	76-87
19160796-1	2008	OBJECTIVE: To observe the expression of hepatocyte nuclear factor 4alpha (HNF4alpha) and the activity of key enzyme glucokinase (GK) in glucose metabolism, and further to investigate the possible mechanism of berberine in treating type 2 diabetes.	Berberine	209-218	hepatic nuclear factor 4, alpha	Mus musculus	40-72
19160796-1	2008	OBJECTIVE: To observe the expression of hepatocyte nuclear factor 4alpha (HNF4alpha) and the activity of key enzyme glucokinase (GK) in glucose metabolism, and further to investigate the possible mechanism of berberine in treating type 2 diabetes.	Berberine	209-218	glucokinase	Mus musculus	116-127
19160796-1	2008	OBJECTIVE: To observe the expression of hepatocyte nuclear factor 4alpha (HNF4alpha) and the activity of key enzyme glucokinase (GK) in glucose metabolism, and further to investigate the possible mechanism of berberine in treating type 2 diabetes.	Berberine	209-218	glucokinase	Mus musculus	129-131
19160796-6	2008	RESULT: As compared with the negative control group, at a certain concentration range, the expression of HNF4alpha mRNA and protein and the activity of GK were promoted by berberine.	Berberine	172-181	hepatic nuclear factor 4, alpha	Mus musculus	105-114
19160796-6	2008	RESULT: As compared with the negative control group, at a certain concentration range, the expression of HNF4alpha mRNA and protein and the activity of GK were promoted by berberine.	Berberine	172-181	glucokinase	Mus musculus	152-154
19160796-9	2008	CONCLUSION: It is suggested that the effects of berberine on improving glucose metabolism can be mechanically associated with its up-regulating the HNF4a expression and inducing the activity of hepatic glucokinase.	Berberine	48-57	hepatic nuclear factor 4, alpha	Mus musculus	148-153
18644725-1	2008	Berberine (BBR, 1) is a novel cholesterol-lowering agent that up-regulates low-density-lipoprotein receptor (LDLR) expression through a mechanism different from that of statins.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	75-107
18644725-1	2008	Berberine (BBR, 1) is a novel cholesterol-lowering agent that up-regulates low-density-lipoprotein receptor (LDLR) expression through a mechanism different from that of statins.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	109-113
18644725-1	2008	Berberine (BBR, 1) is a novel cholesterol-lowering agent that up-regulates low-density-lipoprotein receptor (LDLR) expression through a mechanism different from that of statins.	Berberine	11-14	low density lipoprotein receptor	Homo sapiens	75-107
18644725-1	2008	Berberine (BBR, 1) is a novel cholesterol-lowering agent that up-regulates low-density-lipoprotein receptor (LDLR) expression through a mechanism different from that of statins.	Berberine	11-14	low density lipoprotein receptor	Homo sapiens	109-113
18410224-0	2008	Berberine promotes osteoblast differentiation by Runx2 activation with p38 MAPK.	Berberine	0-9	RUNX family transcription factor 2	Homo sapiens	49-54
18616285-7	2008	The most significant finding was that berberine was reoriented in the QacR multidrug binding pocket so that its positive charge was neutralized by side chain oxygen atoms and aromatic residues.	Berberine	38-47	QacR	Staphylococcus aureus	70-74
18710638-1	2008	BACKGROUND: This study investigated the inhibitory effect of berberine (BBR) on lipopolysaccharide (LPS) induced cyclooxygenase-2 (COX-2) expression via the mitogen activated protein kinase (MAPK) signalling cascade pathways in human peripheral blood monocytes (PBMC).	Berberine	72-75	prostaglandin-endoperoxide synthase 2	Homo sapiens	113-129
18710638-1	2008	BACKGROUND: This study investigated the inhibitory effect of berberine (BBR) on lipopolysaccharide (LPS) induced cyclooxygenase-2 (COX-2) expression via the mitogen activated protein kinase (MAPK) signalling cascade pathways in human peripheral blood monocytes (PBMC).	Berberine	61-70	prostaglandin-endoperoxide synthase 2	Homo sapiens	113-129
18644201-2	2008	We hypothesized that CPU86017, derived from berberine, which possesses multi-channel blocking activity, could suppress inflammatory factors, resulting in inhibition of over-expression of ether-a-go-go (ERG) and an augmented incidence of ventricular fibrillation (VF) in ischaemia/reperfusion (I/R).	Berberine	44-53	ETS transcription factor ERG	Homo sapiens	187-200
18644201-2	2008	We hypothesized that CPU86017, derived from berberine, which possesses multi-channel blocking activity, could suppress inflammatory factors, resulting in inhibition of over-expression of ether-a-go-go (ERG) and an augmented incidence of ventricular fibrillation (VF) in ischaemia/reperfusion (I/R).	Berberine	44-53	ETS transcription factor ERG	Homo sapiens	202-205
18640378-1	2008	We have identified berberine (BBR) as a novel cholesterol-lowering drug acting through stabilization of the low-density lipoprotein receptor (LDLR) messenger RNA.	Berberine	19-28	low density lipoprotein receptor	Homo sapiens	108-140
18640378-1	2008	We have identified berberine (BBR) as a novel cholesterol-lowering drug acting through stabilization of the low-density lipoprotein receptor (LDLR) messenger RNA.	Berberine	19-28	low density lipoprotein receptor	Homo sapiens	142-146
18640378-1	2008	We have identified berberine (BBR) as a novel cholesterol-lowering drug acting through stabilization of the low-density lipoprotein receptor (LDLR) messenger RNA.	Berberine	30-33	low density lipoprotein receptor	Homo sapiens	108-140
18640378-1	2008	We have identified berberine (BBR) as a novel cholesterol-lowering drug acting through stabilization of the low-density lipoprotein receptor (LDLR) messenger RNA.	Berberine	30-33	low density lipoprotein receptor	Homo sapiens	142-146
18640378-3	2008	Our results showed that combination of BBR with simvastatin (SIMVA) increased the LDLR gene expression to a level significantly higher than that in monotherapies.	Berberine	39-42	low density lipoprotein receptor	Homo sapiens	82-86
18585703-3	2008	Evidences have demonstrated that berberine possesses central nervous system activities, particularly the ability to inhibit monoamine oxidase-A, an enzyme involved in the degradation of norepinephrine and serotonin (5-HT).	Berberine	33-42	monoamine oxidase A	Mus musculus	124-143
18471986-0	2008	Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose.	Berberine	0-9	aldo-keto reductase family 1 member B1	Rattus norvegicus	19-35
18710638-1	2008	BACKGROUND: This study investigated the inhibitory effect of berberine (BBR) on lipopolysaccharide (LPS) induced cyclooxygenase-2 (COX-2) expression via the mitogen activated protein kinase (MAPK) signalling cascade pathways in human peripheral blood monocytes (PBMC).	Berberine	61-70	prostaglandin-endoperoxide synthase 2	Homo sapiens	131-136
18710638-1	2008	BACKGROUND: This study investigated the inhibitory effect of berberine (BBR) on lipopolysaccharide (LPS) induced cyclooxygenase-2 (COX-2) expression via the mitogen activated protein kinase (MAPK) signalling cascade pathways in human peripheral blood monocytes (PBMC).	Berberine	61-70	mitogen-activated protein kinase 3	Homo sapiens	191-195
18710638-1	2008	BACKGROUND: This study investigated the inhibitory effect of berberine (BBR) on lipopolysaccharide (LPS) induced cyclooxygenase-2 (COX-2) expression via the mitogen activated protein kinase (MAPK) signalling cascade pathways in human peripheral blood monocytes (PBMC).	Berberine	72-75	prostaglandin-endoperoxide synthase 2	Homo sapiens	131-136
18710638-4	2008	RESULTS: COX-2 mRNA and protein expression decreased to a minimum at 12 hours after BBR treatment (P &lt; 0.05).	Berberine	84-87	prostaglandin-endoperoxide synthase 2	Homo sapiens	9-14
18710638-5	2008	With the increasing concentration of BBR treatment, the COX-2 expression decreased progressively (P &lt; 0.01).	Berberine	37-40	prostaglandin-endoperoxide synthase 2	Homo sapiens	56-61
18710638-6	2008	With BBR treatment for 6, 12 or 24 hours at three doses, ERK1/2 protein expression was significantly inhibited.	Berberine	5-8	mitogen-activated protein kinase 3	Homo sapiens	57-63
18710638-7	2008	For the JNK pathway, only with the treatment of BBR at the concentration of 100 micromol/L was JNK protein expression inhibited compared with the LPS stimulation group (P &lt; 0.01).	Berberine	48-51	mitogen-activated protein kinase 8	Homo sapiens	8-11
18710638-7	2008	For the JNK pathway, only with the treatment of BBR at the concentration of 100 micromol/L was JNK protein expression inhibited compared with the LPS stimulation group (P &lt; 0.01).	Berberine	48-51	mitogen-activated protein kinase 8	Homo sapiens	95-98
18710638-10	2008	CONCLUSIONS: Berberine inhibits COX-2 expression via the ERK1/2 signalling pathway and, possibly, at a high dosage via the JNK pathway.	Berberine	13-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	32-37
18710638-10	2008	CONCLUSIONS: Berberine inhibits COX-2 expression via the ERK1/2 signalling pathway and, possibly, at a high dosage via the JNK pathway.	Berberine	13-22	mitogen-activated protein kinase 3	Homo sapiens	57-63
18710638-10	2008	CONCLUSIONS: Berberine inhibits COX-2 expression via the ERK1/2 signalling pathway and, possibly, at a high dosage via the JNK pathway.	Berberine	13-22	mitogen-activated protein kinase 8	Homo sapiens	123-126
18710638-12	2008	Berberine inhibited COX-2 mRNA and protein expression in a dose dependent manner and suppressed COX-2 expression to a minimal level after 12 hours of berberine treatment.	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	20-25
18710638-12	2008	Berberine inhibited COX-2 mRNA and protein expression in a dose dependent manner and suppressed COX-2 expression to a minimal level after 12 hours of berberine treatment.	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	96-101
18710638-12	2008	Berberine inhibited COX-2 mRNA and protein expression in a dose dependent manner and suppressed COX-2 expression to a minimal level after 12 hours of berberine treatment.	Berberine	150-159	prostaglandin-endoperoxide synthase 2	Homo sapiens	96-101
18593939-0	2008	Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis.	Berberine	0-9	NFKB inhibitor alpha	Homo sapiens	35-47
18593939-0	2008	Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	67-88
18593939-2	2008	Because of the critical role of the transcription factor nuclear factor-kappaB (NF-kappaB) in these processes, we investigated the effect of berberine on this pathway.	Berberine	141-150	nuclear factor kappa B subunit 1	Homo sapiens	80-89
18593939-3	2008	We found that berberine suppressed NF-kappaB activation induced by various inflammatory agents and carcinogens.	Berberine	14-23	nuclear factor kappa B subunit 1	Homo sapiens	35-44
18593939-8	2008	Berberine also suppressed the expression of NF-kappaB-regulated gene products involved in antiapoptosis (Bcl-xL, Survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	44-53
18593939-8	2008	Berberine also suppressed the expression of NF-kappaB-regulated gene products involved in antiapoptosis (Bcl-xL, Survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).	Berberine	0-9	BCL2 like 1	Homo sapiens	105-111
18593939-8	2008	Berberine also suppressed the expression of NF-kappaB-regulated gene products involved in antiapoptosis (Bcl-xL, Survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).	Berberine	0-9	baculoviral IAP repeat containing 3	Homo sapiens	123-127
18593939-8	2008	Berberine also suppressed the expression of NF-kappaB-regulated gene products involved in antiapoptosis (Bcl-xL, Survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).	Berberine	0-9	baculoviral IAP repeat containing 2	Homo sapiens	129-133
18593939-8	2008	Berberine also suppressed the expression of NF-kappaB-regulated gene products involved in antiapoptosis (Bcl-xL, Survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).	Berberine	0-9	CASP8 and FADD like apoptosis regulator	Homo sapiens	139-144
18593939-8	2008	Berberine also suppressed the expression of NF-kappaB-regulated gene products involved in antiapoptosis (Bcl-xL, Survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).	Berberine	0-9	cyclin D1	Homo sapiens	162-171
18593939-8	2008	Berberine also suppressed the expression of NF-kappaB-regulated gene products involved in antiapoptosis (Bcl-xL, Survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	188-204
18593939-8	2008	Berberine also suppressed the expression of NF-kappaB-regulated gene products involved in antiapoptosis (Bcl-xL, Survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).	Berberine	0-9	matrix metallopeptidase 9	Homo sapiens	221-247
18593939-10	2008	Overall, our results indicate that chemopreventive, apoptotic, and anti-inflammatory activities displayed by berberine may be mediated in part through the suppression of the NF-kappaB activation pathway.	Berberine	109-118	nuclear factor kappa B subunit 1	Homo sapiens	174-183
18397984-8	2008	RESULTS: In the berberine group, fasting and postload plasma glucose decreased from 7.0 +/- 0.8 to 5.6 +/- 0.9 and from 12.0 +/- 2.7 to 8.9 +/- 2.8 mm/liter, HbA1c from 7.5 +/- 1.0% to 6.6 +/- 0.7%, triglyceride from 2.51 +/- 2.04 to 1.61 +/- 1.10 mm/liter, total cholesterol from 5.31 +/- 0.98 to 4.35 +/- 0.96 mm/liter, and low-density lipoprotein-cholesterol from 3.23 +/- 0.81 to 2.55 +/- 0.77 mm/liter, with all parameters differing from placebo significantly (P &lt; 0.0001, P &lt; 0.0001, P &lt; 0.0001, P = 0.001, P &lt; 0.0001, and P &lt;0.0001, respectively).	Berberine	16-25	hemoglobin subunit alpha 1	Homo sapiens	158-162
18563319-13	2008	The mRNA and protein expression of HNF-4alpha was decreased in the fructose-fed rats, but berberine could promote its expression.	Berberine	90-99	hepatocyte nuclear factor 4, alpha	Rattus norvegicus	35-45
19034703-8	2008	This study demonstrates that berberine may inhibit the expression and production of TNF-alpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages.	Berberine	29-38	tumor necrosis factor	Homo sapiens	84-93
19034703-8	2008	This study demonstrates that berberine may inhibit the expression and production of TNF-alpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages.	Berberine	29-38	C-C motif chemokine ligand 2	Homo sapiens	95-100
19034703-8	2008	This study demonstrates that berberine may inhibit the expression and production of TNF-alpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages.	Berberine	29-38	interleukin 6	Homo sapiens	106-110
18563319-0	2008	Effect of berberine on expression of hepatocyte nuclear factor-4alpha in rats with fructose-induced insulin resistance.	Berberine	10-19	hepatocyte nuclear factor 4, alpha	Rattus norvegicus	37-69
18563319-1	2008	The effects of berberine on the expression of hepatocyte nuclear factor-4alpha (HNF-4alpha) in liver of rats with fructose-induced insulin resistance and the molecular mechanism of berberine preventing insulin resistance were investigated.	Berberine	15-24	hepatocyte nuclear factor 4, alpha	Rattus norvegicus	46-78
18520050-7	2008	Berberine restored the increased blood glucose, hemoglobin A1c, total cholesterol, triglyceride, low density lipoprotein-cholesterol, apolipoprotein B and the decreased high density lipoprotein-cholesterol, apolipoprotein AI levels in diabetic rats to near the control ones.	Berberine	0-9	apolipoprotein B	Rattus norvegicus	134-150
18520050-7	2008	Berberine restored the increased blood glucose, hemoglobin A1c, total cholesterol, triglyceride, low density lipoprotein-cholesterol, apolipoprotein B and the decreased high density lipoprotein-cholesterol, apolipoprotein AI levels in diabetic rats to near the control ones.	Berberine	0-9	apolipoprotein A1	Rattus norvegicus	207-224
18520050-9	2008	Berberine increased PPARalpha/delta expression and reduced PPARgamma expression in liver of diabetic rat to near the control ones.	Berberine	0-9	peroxisome proliferator activated receptor alpha	Rattus norvegicus	20-29
18520050-9	2008	Berberine increased PPARalpha/delta expression and reduced PPARgamma expression in liver of diabetic rat to near the control ones.	Berberine	0-9	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	59-68
18520050-10	2008	Berberine improved glucolipid metabolism both in blood and liver in diabetic rats possibly through modulating the metabolic related PPARalpha/delta/gamma protein expression in liver.	Berberine	0-9	peroxisome proliferator activated receptor alpha	Rattus norvegicus	132-153
19034703-0	2008	Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway.	Berberine	0-9	tumor necrosis factor	Homo sapiens	37-45
19034703-0	2008	Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway.	Berberine	0-9	C-C motif chemokine ligand 2	Homo sapiens	47-52
19034703-0	2008	Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway.	Berberine	0-9	interleukin 6	Homo sapiens	58-62
19034703-0	2008	Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway.	Berberine	0-9	peroxisome proliferator activated receptor gamma	Homo sapiens	103-112
19034703-4	2008	Our previous study found that berberine could increase adipophilin expression in macrophages, which is a target gene of PPARgamma.	Berberine	30-39	perilipin 2	Homo sapiens	55-66
19034703-4	2008	Our previous study found that berberine could increase adipophilin expression in macrophages, which is a target gene of PPARgamma.	Berberine	30-39	peroxisome proliferator activated receptor gamma	Homo sapiens	120-129
19034703-6	2008	In this study, we investigated the effects and the mechanism of action of berberine on the expression and secretion of TNFalpha, MCP-1, and IL-6 in vitro to identify new pharmacological actions of berberine.	Berberine	74-83	tumor necrosis factor	Homo sapiens	119-127
19034703-6	2008	In this study, we investigated the effects and the mechanism of action of berberine on the expression and secretion of TNFalpha, MCP-1, and IL-6 in vitro to identify new pharmacological actions of berberine.	Berberine	74-83	interleukin 6	Homo sapiens	140-144
19034703-7	2008	The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine.	Berberine	43-52	tumor necrosis factor	Homo sapiens	101-128
19034703-7	2008	The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine.	Berberine	43-52	tumor necrosis factor	Homo sapiens	130-138
19034703-7	2008	The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine.	Berberine	43-52	C-C motif chemokine ligand 2	Homo sapiens	141-175
19034703-7	2008	The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine.	Berberine	43-52	C-C motif chemokine ligand 2	Homo sapiens	177-182
19034703-7	2008	The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine.	Berberine	43-52	interleukin 6	Homo sapiens	189-202
19034703-7	2008	The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine.	Berberine	43-52	interleukin 6	Homo sapiens	204-208
19034703-7	2008	The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine.	Berberine	43-52	peroxisome proliferator activated receptor gamma	Homo sapiens	295-343
19034703-7	2008	The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine.	Berberine	43-52	peroxisome proliferator activated receptor gamma	Homo sapiens	345-354
19034703-7	2008	The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine.	Berberine	404-413	tumor necrosis factor	Homo sapiens	101-128
18563319-1	2008	The effects of berberine on the expression of hepatocyte nuclear factor-4alpha (HNF-4alpha) in liver of rats with fructose-induced insulin resistance and the molecular mechanism of berberine preventing insulin resistance were investigated.	Berberine	15-24	hepatocyte nuclear factor 4, alpha	Rattus norvegicus	80-90
18563319-14	2008	It was concluded that berberine could prevent fructose-induced insulin resistance in rats possibly by promoting the expression HNF-4alpha in liver.	Berberine	22-31	hepatocyte nuclear factor 4, alpha	Rattus norvegicus	127-137
18430372-0	2008	Berberine inhibits cyclin D1 expression via suppressed binding of AP-1 transcription factors to CCND1 AP-1 motif.	Berberine	0-9	cyclin D1	Homo sapiens	19-28
18275980-4	2008	Berberine-induced apoptosis was associated with the disruption of the mitochondrial membrane potential, release of apoptogenic molecules (cytochrome c and Smac/DIABLO) from mitochondria and cleavage of caspase-9,-3 and PARP proteins.	Berberine	0-9	cytochrome c, somatic	Homo sapiens	138-150
18275980-4	2008	Berberine-induced apoptosis was associated with the disruption of the mitochondrial membrane potential, release of apoptogenic molecules (cytochrome c and Smac/DIABLO) from mitochondria and cleavage of caspase-9,-3 and PARP proteins.	Berberine	0-9	diablo IAP-binding mitochondrial protein	Homo sapiens	155-159
18275980-4	2008	Berberine-induced apoptosis was associated with the disruption of the mitochondrial membrane potential, release of apoptogenic molecules (cytochrome c and Smac/DIABLO) from mitochondria and cleavage of caspase-9,-3 and PARP proteins.	Berberine	0-9	diablo IAP-binding mitochondrial protein	Homo sapiens	160-166
18275980-4	2008	Berberine-induced apoptosis was associated with the disruption of the mitochondrial membrane potential, release of apoptogenic molecules (cytochrome c and Smac/DIABLO) from mitochondria and cleavage of caspase-9,-3 and PARP proteins.	Berberine	0-9	caspase 9	Homo sapiens	202-214
18275980-4	2008	Berberine-induced apoptosis was associated with the disruption of the mitochondrial membrane potential, release of apoptogenic molecules (cytochrome c and Smac/DIABLO) from mitochondria and cleavage of caspase-9,-3 and PARP proteins.	Berberine	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	219-223
18275980-7	2008	Berberine-induced apoptosis was blocked in the presence of antioxidant, N-acetylcysteine, through the prevention of disruption of mitochondrial membrane potential and subsequently release of cytochrome c and Smac/DIABLO.	Berberine	0-9	cytochrome c, somatic	Homo sapiens	191-203
18275980-7	2008	Berberine-induced apoptosis was blocked in the presence of antioxidant, N-acetylcysteine, through the prevention of disruption of mitochondrial membrane potential and subsequently release of cytochrome c and Smac/DIABLO.	Berberine	0-9	diablo IAP-binding mitochondrial protein	Homo sapiens	208-212
18275980-7	2008	Berberine-induced apoptosis was blocked in the presence of antioxidant, N-acetylcysteine, through the prevention of disruption of mitochondrial membrane potential and subsequently release of cytochrome c and Smac/DIABLO.	Berberine	0-9	diablo IAP-binding mitochondrial protein	Homo sapiens	213-219
18430372-0	2008	Berberine inhibits cyclin D1 expression via suppressed binding of AP-1 transcription factors to CCND1 AP-1 motif.	Berberine	0-9	cyclin D1	Homo sapiens	96-101
18430372-10	2008	Berberine could inhibit the expression of cyclin D1 in PG cells.	Berberine	0-9	cyclin D1	Homo sapiens	42-51
18430372-12	2008	Berberine suppressed the expression of c-Jun and decreased the binding of transcription factors to the CCND1 AP-1 motif.	Berberine	0-9	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	39-44
18430372-12	2008	Berberine suppressed the expression of c-Jun and decreased the binding of transcription factors to the CCND1 AP-1 motif.	Berberine	0-9	cyclin D1	Homo sapiens	103-108
18430372-13	2008	CONCLUSION: Berberine suppresses the activity of the AP-1 signaling pathway and decreases the binding of transcription factors to the CCND1 AP-1 motif.	Berberine	12-21	cyclin D1	Homo sapiens	134-139
18430372-14	2008	This is one of the important mechanisms behind the antitumoral effects of berberine as a regulator of cyclin D1.	Berberine	74-83	cyclin D1	Homo sapiens	102-111
18285556-0	2008	Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action.	Berberine	0-9	insulin	Homo sapiens	214-221
18451495-4	2008	Combined treatment with berberine and cisplatin acted in concert to induce loss of mitochondrial membrane potential (Delta Psi m), release of cytochrome-c from mitochondria, and decreased expression of antiapoptotic Bcl-2, Bcl-x/L, resulting in activation of caspases and apoptosis.	Berberine	24-33	cytochrome c, somatic	Homo sapiens	142-154
18451495-4	2008	Combined treatment with berberine and cisplatin acted in concert to induce loss of mitochondrial membrane potential (Delta Psi m), release of cytochrome-c from mitochondria, and decreased expression of antiapoptotic Bcl-2, Bcl-x/L, resulting in activation of caspases and apoptosis.	Berberine	24-33	BCL2 apoptosis regulator	Homo sapiens	216-221
18451495-4	2008	Combined treatment with berberine and cisplatin acted in concert to induce loss of mitochondrial membrane potential (Delta Psi m), release of cytochrome-c from mitochondria, and decreased expression of antiapoptotic Bcl-2, Bcl-x/L, resulting in activation of caspases and apoptosis.	Berberine	24-33	BCL2 like 1	Homo sapiens	223-230
18285556-1	2008	OBJECTIVE: Berberine (BBR) activates AMP-activated protein kinase (AMPK) and improves insulin sensitivity in rodent models of insulin resistance.	Berberine	22-25	insulin	Homo sapiens	86-93
17661039-7	2008	RESULTS: In these melanoma cell lines, berberine at low doses (12.5-50 muM) is concentrated in mitochondria and promotes G1 arrest.	Berberine	39-48	latexin	Homo sapiens	71-74
17661039-8	2008	In contrast, higher doses (over 50 muM) result in cytoplasmic and nuclear berberine accumulation, and G2 arrest.	Berberine	74-83	latexin	Homo sapiens	35-38
17661039-10	2008	Even at 100 muM, berberine inhibits cell growth with relatively little induction of apoptosis.	Berberine	17-26	latexin	Homo sapiens	12-15
18285556-0	2008	Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action.	Berberine	65-74	insulin	Homo sapiens	214-221
18285556-1	2008	OBJECTIVE: Berberine (BBR) activates AMP-activated protein kinase (AMPK) and improves insulin sensitivity in rodent models of insulin resistance.	Berberine	11-20	insulin	Homo sapiens	86-93
18285556-1	2008	OBJECTIVE: Berberine (BBR) activates AMP-activated protein kinase (AMPK) and improves insulin sensitivity in rodent models of insulin resistance.	Berberine	11-20	insulin	Homo sapiens	126-133
18285556-1	2008	OBJECTIVE: Berberine (BBR) activates AMP-activated protein kinase (AMPK) and improves insulin sensitivity in rodent models of insulin resistance.	Berberine	22-25	insulin	Homo sapiens	126-133
18701023-0	2008	Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase.	Berberine	0-9	aldo-keto reductase family 1 member B1	Rattus norvegicus	119-135
18557425-3	2008	The purpose of this study was to investigate whether berberine attenuates disaccharidase activities and beta-glucuronidase activity in the small intestine of streptozotocin (STZ)-induced diabetic rats.	Berberine	53-62	glucuronidase, beta	Rattus norvegicus	104-122
18557425-7	2008	Our findings suggested that berberine treatment significantly decreases the activities of intestinal disaccharidases and beta-glucuronidase in STZ-induced diabetic rats.	Berberine	28-37	glucuronidase, beta	Rattus norvegicus	121-139
18557425-8	2008	The results demonstrated that the inhibitory effect on intestinal disaccharidases and beta-glucuronidase of berberine might be one of the mechanisms for berberine as an antihyperglycaemic agent.	Berberine	108-117	glucuronidase, beta	Rattus norvegicus	86-104
18557425-8	2008	The results demonstrated that the inhibitory effect on intestinal disaccharidases and beta-glucuronidase of berberine might be one of the mechanisms for berberine as an antihyperglycaemic agent.	Berberine	153-162	glucuronidase, beta	Rattus norvegicus	86-104
18414236-0	2008	Berberine inhibits cytosolic phospholipase A2 and protects against LPS-induced lung injury and lethality independent of the alpha2-adrenergic receptor in mice.	Berberine	0-9	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	19-45
17951041-0	2008	Berberine inhibits TPA-induced MMP-9 and IL-6 expression in normal human keratinocytes.	Berberine	0-9	plasminogen activator, tissue type	Homo sapiens	19-22
17951041-0	2008	Berberine inhibits TPA-induced MMP-9 and IL-6 expression in normal human keratinocytes.	Berberine	0-9	matrix metallopeptidase 9	Homo sapiens	31-36
17951041-0	2008	Berberine inhibits TPA-induced MMP-9 and IL-6 expression in normal human keratinocytes.	Berberine	0-9	interleukin 6	Homo sapiens	41-45
17951041-3	2008	In this study, we investigated the effects of berberine on MMP-9 and IL-6 expression in normal human keratinocytes (NHK).	Berberine	46-55	matrix metallopeptidase 9	Homo sapiens	59-64
17951041-4	2008	Our results demonstrated that berberine dose-dependently inhibited basal and TPA-induced expression and activity of MMP-9, and also suppressed TPA-induced IL-6 expression.	Berberine	30-39	plasminogen activator, tissue type	Homo sapiens	77-80
17951041-4	2008	Our results demonstrated that berberine dose-dependently inhibited basal and TPA-induced expression and activity of MMP-9, and also suppressed TPA-induced IL-6 expression.	Berberine	30-39	matrix metallopeptidase 9	Homo sapiens	116-121
17951041-4	2008	Our results demonstrated that berberine dose-dependently inhibited basal and TPA-induced expression and activity of MMP-9, and also suppressed TPA-induced IL-6 expression.	Berberine	30-39	plasminogen activator, tissue type	Homo sapiens	143-146
17951041-4	2008	Our results demonstrated that berberine dose-dependently inhibited basal and TPA-induced expression and activity of MMP-9, and also suppressed TPA-induced IL-6 expression.	Berberine	30-39	interleukin 6	Homo sapiens	155-159
17951041-5	2008	Berberine prevented TPA-induced ERK activation and AP-1 DNA binding activity.	Berberine	0-9	plasminogen activator, tissue type	Homo sapiens	20-23
17951041-5	2008	Berberine prevented TPA-induced ERK activation and AP-1 DNA binding activity.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	32-35
17951041-6	2008	Therefore, berberine may be used as an effective ingredient for anti-skin aging products, which can prevent skin inflammation and the degradation of extracellular matrix proteins, including collagen, by MMPs.	Berberine	11-20	matrix metallopeptidase 9	Homo sapiens	203-207
18701023-10	2008	AR activity as well as the expression of AR mRNA and protein in the kidney was markedly decreased in the berberine treatment group compared with diabetic model group (P &lt; 0.05).	Berberine	105-114	aldo-keto reductase family 1 member B1	Rattus norvegicus	0-2
18701023-10	2008	AR activity as well as the expression of AR mRNA and protein in the kidney was markedly decreased in the berberine treatment group compared with diabetic model group (P &lt; 0.05).	Berberine	105-114	aldo-keto reductase family 1 member B1	Rattus norvegicus	41-43
18468407-0	2008	Berberine induced down-regulation of matrix metalloproteinase-1, -2 and -9 in human gastric cancer cells (SNU-5) in vitro.	Berberine	0-9	matrix metallopeptidase 1	Homo sapiens	37-74
17973934-11	2008	In addition, histopathological changes, such as steatosis, necrosis and myofibroblast proliferation, were reduced and the expression of a-SMA and TGF-b1 was significantly downregulated in the berberine-treated groups (P &lt; 0.01).	Berberine	192-201	actin gamma 2, smooth muscle	Rattus norvegicus	138-141
17973934-11	2008	In addition, histopathological changes, such as steatosis, necrosis and myofibroblast proliferation, were reduced and the expression of a-SMA and TGF-b1 was significantly downregulated in the berberine-treated groups (P &lt; 0.01).	Berberine	192-201	transforming growth factor, beta 1	Rattus norvegicus	146-152
18379040-0	2008	Berberine induces G1 arrest and apoptosis in human glioblastoma T98G cells through mitochondrial/caspases pathway.	Berberine	0-9	caspase 9	Homo sapiens	97-105
18379040-5	2008	Western blot analysis showed that the berberine-induced G1 arrest was mediated through the increased expression of P27 and the decreased expression of cyclin-dependent kinase (CDK) 2, CDK4, cyclin D, and cyclin E proteins.	Berberine	38-47	interferon alpha inducible protein 27	Homo sapiens	115-118
18379040-5	2008	Western blot analysis showed that the berberine-induced G1 arrest was mediated through the increased expression of P27 and the decreased expression of cyclin-dependent kinase (CDK) 2, CDK4, cyclin D, and cyclin E proteins.	Berberine	38-47	cyclin dependent kinase 2	Homo sapiens	151-182
18379040-5	2008	Western blot analysis showed that the berberine-induced G1 arrest was mediated through the increased expression of P27 and the decreased expression of cyclin-dependent kinase (CDK) 2, CDK4, cyclin D, and cyclin E proteins.	Berberine	38-47	cyclin dependent kinase 4	Homo sapiens	184-188
18379040-6	2008	Berberine treatment also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of the Bax/Bcl-2 proteins, the disruption of mitochondrial membrane potential, and the activation of procaspase-9, caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	114-117
18379040-6	2008	Berberine treatment also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of the Bax/Bcl-2 proteins, the disruption of mitochondrial membrane potential, and the activation of procaspase-9, caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	118-123
18379040-6	2008	Berberine treatment also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of the Bax/Bcl-2 proteins, the disruption of mitochondrial membrane potential, and the activation of procaspase-9, caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	caspase 9	Homo sapiens	211-220
18379040-6	2008	Berberine treatment also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of the Bax/Bcl-2 proteins, the disruption of mitochondrial membrane potential, and the activation of procaspase-9, caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	caspase 3	Homo sapiens	233-242
18379040-6	2008	Berberine treatment also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of the Bax/Bcl-2 proteins, the disruption of mitochondrial membrane potential, and the activation of procaspase-9, caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	248-275
18379040-6	2008	Berberine treatment also markedly enhanced apoptosis in T98G cells through the induction of a higher ratio of the Bax/Bcl-2 proteins, the disruption of mitochondrial membrane potential, and the activation of procaspase-9, caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP).	Berberine	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	277-281
18468407-5	2008	The effect of berberine on the levels of reactive oxygen species (ROS) and matrix metalloproteinase-1, -2, -7 and -9 was then examined using Western blotting and the results showed that berberine induced ROS production for up to 6 hours of incubation.	Berberine	14-23	matrix metallopeptidase 1	Homo sapiens	75-116
18468407-5	2008	The effect of berberine on the levels of reactive oxygen species (ROS) and matrix metalloproteinase-1, -2, -7 and -9 was then examined using Western blotting and the results showed that berberine induced ROS production for up to 6 hours of incubation.	Berberine	186-195	matrix metallopeptidase 1	Homo sapiens	75-116
18468407-6	2008	It was also found that berberine induced downregulation of MMP-1 -2, and -9 but did not affect the level of MMP-7.	Berberine	23-32	matrix metallopeptidase 12	Homo sapiens	59-75
18468407-7	2008	The mRNA levels of MMPs in SNU-5 cells after treatment with berberine for 24 hours were investigated using a polymerase chain reaction and the results showed that berberine inhibited the gene expression of MMP-1, -2 and -9 in human SNU-5 cells but it did not affect MMP-7.	Berberine	60-69	matrix metallopeptidase 1	Homo sapiens	19-23
18468407-7	2008	The mRNA levels of MMPs in SNU-5 cells after treatment with berberine for 24 hours were investigated using a polymerase chain reaction and the results showed that berberine inhibited the gene expression of MMP-1, -2 and -9 in human SNU-5 cells but it did not affect MMP-7.	Berberine	60-69	matrix metallopeptidase 1	Homo sapiens	206-222
18468407-7	2008	The mRNA levels of MMPs in SNU-5 cells after treatment with berberine for 24 hours were investigated using a polymerase chain reaction and the results showed that berberine inhibited the gene expression of MMP-1, -2 and -9 in human SNU-5 cells but it did not affect MMP-7.	Berberine	163-172	matrix metallopeptidase 1	Homo sapiens	19-23
18468407-7	2008	The mRNA levels of MMPs in SNU-5 cells after treatment with berberine for 24 hours were investigated using a polymerase chain reaction and the results showed that berberine inhibited the gene expression of MMP-1, -2 and -9 in human SNU-5 cells but it did not affect MMP-7.	Berberine	163-172	matrix metallopeptidase 1	Homo sapiens	206-222
18468407-7	2008	The mRNA levels of MMPs in SNU-5 cells after treatment with berberine for 24 hours were investigated using a polymerase chain reaction and the results showed that berberine inhibited the gene expression of MMP-1, -2 and -9 in human SNU-5 cells but it did not affect MMP-7.	Berberine	163-172	matrix metallopeptidase 7	Homo sapiens	266-271
18468407-8	2008	In conclusion, berberine appears to exert its anticancer properties by inducing ROS production and prevention of cell migration via inhibition of the gene expression of MMP-1, -2 and -9 in human gastric cancer SNU-5 cancer cells.	Berberine	15-24	matrix metallopeptidase 1	Homo sapiens	169-185
18294404-5	2008	Zymography and Western blot analyses provided information on the effect of As2O3 and berberine on the intracellular translocation and activation of protein kinase C (PKC), and some PKC-related downstream factors.	Berberine	85-94	protein kinase C alpha	Homo sapiens	166-169
18334149-1	2008	OBJECTIVE: To observe the effects of ginsenoside (Gs) and berberine (Ber), two kinds of active components of traditional Chinese herbal medicine, on transforming growth factor-beta1 (TGF-beta1) and prostaglandin E2 (PGE2) in PG cells.	Berberine	58-67	transforming growth factor beta 1	Homo sapiens	183-192
18334149-1	2008	OBJECTIVE: To observe the effects of ginsenoside (Gs) and berberine (Ber), two kinds of active components of traditional Chinese herbal medicine, on transforming growth factor-beta1 (TGF-beta1) and prostaglandin E2 (PGE2) in PG cells.	Berberine	69-72	transforming growth factor beta 1	Homo sapiens	183-192
18294404-12	2008	Treatment of glioma cells with As2O3 and berberine significantly decreased the activation of PKC alpha and epsilon and led to actin cytoskeleton rearrangements.	Berberine	41-50	protein kinase C alpha	Homo sapiens	93-102
18294404-14	2008	CONCLUSION: Upon co-treatment of glioma cells with As2O3 and berberine, cancer cell metastasis can be significantly inhibited, most likely by blocking the PKC-mediated signaling pathway involved in cancer cell migration.	Berberine	61-70	protein kinase C alpha	Homo sapiens	155-158
18240344-0	2008	Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta.	Berberine	0-9	insulin	Homo sapiens	43-50
18240344-0	2008	Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta.	Berberine	0-9	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	101-108
18240344-1	2008	AIM: To investigate the effects and molecular mechanisms of berberine on improving insulin resistance induced by free fatty acids (FFAs) in 3T3-L1 adipocytes.	Berberine	60-69	insulin	Homo sapiens	83-90
18240344-9	2008	However, the above indexes, which indicated the existence of insulin resistance, were reversed by berberine although the expression of GLUT4, IKKbeta and total NF-kappaB p65 protein were not changed during this study.	Berberine	98-107	insulin	Homo sapiens	61-68
18240344-10	2008	CONCLUSION: Insulin resistance induced by FFAs in 3T3-L1 adipocytes can be improved by berberine.	Berberine	87-96	insulin	Homo sapiens	12-19
18240344-11	2008	Berberine reversed free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta.	Berberine	0-9	insulin	Homo sapiens	43-50
18240344-11	2008	Berberine reversed free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta.	Berberine	0-9	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	101-108
18157518-5	2008	We identified the lipophilic organic cation berberine, a fluorescent plant alkaloid exhibiting a broad range of biological activities, as substrate of OCT1 and OCT2 with Michaelis-Menten constants of 14.8 microM and 4.4 microM, respectively.	Berberine	44-53	solute carrier family 22 member 1	Homo sapiens	151-155
18157518-0	2008	Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).	Berberine	42-51	solute carrier family 22 member 1	Homo sapiens	101-129
18157518-0	2008	Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).	Berberine	42-51	solute carrier family 22 member 1	Homo sapiens	131-135
18083161-0	2008	Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.	Berberine	0-9	TNF superfamily member 11	Homo sapiens	19-24
18083161-0	2008	Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	91-100
18083161-0	2008	Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	105-108
18083161-3	2008	This study focused on the suppressive effects of berberine on receptor activator of nuclear factor kappaB (NF-kappaB) ligand (RANKL)-induced osteoclastogenesis and survival.	Berberine	49-58	nuclear factor kappa B subunit 1	Homo sapiens	107-116
18083161-3	2008	This study focused on the suppressive effects of berberine on receptor activator of nuclear factor kappaB (NF-kappaB) ligand (RANKL)-induced osteoclastogenesis and survival.	Berberine	49-58	TNF superfamily member 11	Homo sapiens	126-131
18083161-4	2008	Berberine inhibited RANKL-mediated osteoclast formation and survival while having no cytotoxic effects on bone marrow macrophages or osteoblastic cells.	Berberine	0-9	TNF superfamily member 11	Homo sapiens	20-25
18083161-5	2008	Berberine attenuated RANKL-induced activation of NF-kappaB through inhibiting phosphorylation at the activation loop of IkappaBalpha kinase beta, phosphorylation and degradation of IkappaBalpha, and NF-kappaB p65 nuclear translocation.	Berberine	0-9	TNF superfamily member 11	Homo sapiens	21-26
18083161-5	2008	Berberine attenuated RANKL-induced activation of NF-kappaB through inhibiting phosphorylation at the activation loop of IkappaBalpha kinase beta, phosphorylation and degradation of IkappaBalpha, and NF-kappaB p65 nuclear translocation.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	49-58
18083161-5	2008	Berberine attenuated RANKL-induced activation of NF-kappaB through inhibiting phosphorylation at the activation loop of IkappaBalpha kinase beta, phosphorylation and degradation of IkappaBalpha, and NF-kappaB p65 nuclear translocation.	Berberine	0-9	NFKB inhibitor alpha	Homo sapiens	120-132
18083161-5	2008	Berberine attenuated RANKL-induced activation of NF-kappaB through inhibiting phosphorylation at the activation loop of IkappaBalpha kinase beta, phosphorylation and degradation of IkappaBalpha, and NF-kappaB p65 nuclear translocation.	Berberine	0-9	NFKB inhibitor alpha	Homo sapiens	181-193
18083161-5	2008	Berberine attenuated RANKL-induced activation of NF-kappaB through inhibiting phosphorylation at the activation loop of IkappaBalpha kinase beta, phosphorylation and degradation of IkappaBalpha, and NF-kappaB p65 nuclear translocation.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	199-208
18083161-6	2008	RANKL-induced Akt phosphorylation was strongly inhibited by berberine; however, neither monocyte/macrophage-colony stimulating factor (M-CSF)-induced nor insulin-induced Akt activation was inhibited by the drug.	Berberine	60-69	TNF superfamily member 11	Homo sapiens	0-5
18083161-6	2008	RANKL-induced Akt phosphorylation was strongly inhibited by berberine; however, neither monocyte/macrophage-colony stimulating factor (M-CSF)-induced nor insulin-induced Akt activation was inhibited by the drug.	Berberine	60-69	AKT serine/threonine kinase 1	Homo sapiens	14-17
18083161-7	2008	Under M-CSF- and RANKL-deprived condition, berberine increased the active form of caspase-3 in osteoclasts.	Berberine	43-52	colony stimulating factor 1	Homo sapiens	6-12
18083161-7	2008	Under M-CSF- and RANKL-deprived condition, berberine increased the active form of caspase-3 in osteoclasts.	Berberine	43-52	TNF superfamily member 11	Homo sapiens	17-22
18083161-7	2008	Under M-CSF- and RANKL-deprived condition, berberine increased the active form of caspase-3 in osteoclasts.	Berberine	43-52	caspase 3	Homo sapiens	82-91
18083161-9	2008	These findings indicate that berberine inhibits osteoclast formation and survival through suppression of NF-kappaB and Akt activation and that both pathways in the osteoclast lineage are highly sensitive to berberine treatment.	Berberine	29-38	nuclear factor kappa B subunit 1	Homo sapiens	105-114
18083161-9	2008	These findings indicate that berberine inhibits osteoclast formation and survival through suppression of NF-kappaB and Akt activation and that both pathways in the osteoclast lineage are highly sensitive to berberine treatment.	Berberine	29-38	AKT serine/threonine kinase 1	Homo sapiens	119-122
18157518-0	2008	Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).	Berberine	42-51	solute carrier family 22 member 1	Homo sapiens	137-144
18157518-0	2008	Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).	Berberine	42-51	ATP binding cassette subfamily B member 1	Homo sapiens	166-170
18157518-0	2008	Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).	Berberine	42-51	ATP binding cassette subfamily B member 1	Homo sapiens	187-192
18157518-5	2008	We identified the lipophilic organic cation berberine, a fluorescent plant alkaloid exhibiting a broad range of biological activities, as substrate of OCT1 and OCT2 with Michaelis-Menten constants of 14.8 microM and 4.4 microM, respectively.	Berberine	44-53	solute carrier family 22 member 2	Homo sapiens	160-164
18157518-6	2008	Berberine also inhibited the uptake of the prototypic cations tetraethylammonium and 1-methyl-4-phenylpyridinium by MDCK-OCT1 and MDCK-OCT2 transfectants.	Berberine	0-9	solute carrier family 22 member 1	Homo sapiens	116-125
18157518-6	2008	Berberine also inhibited the uptake of the prototypic cations tetraethylammonium and 1-methyl-4-phenylpyridinium by MDCK-OCT1 and MDCK-OCT2 transfectants.	Berberine	0-9	solute carrier family 22 member 2	Homo sapiens	130-139
18157518-7	2008	When transfected cells were grown polarized on permeable filter supports, berberine was transferred from the basolateral to the apical compartments many times faster by MDCK-OCT1/MDR1 P-gp double transfectants than by MDCK-OCT1 or MDCK-MDR1 P-gp single transfectants.	Berberine	74-83	solute carrier family 22 member 1	Homo sapiens	174-178
18157518-7	2008	When transfected cells were grown polarized on permeable filter supports, berberine was transferred from the basolateral to the apical compartments many times faster by MDCK-OCT1/MDR1 P-gp double transfectants than by MDCK-OCT1 or MDCK-MDR1 P-gp single transfectants.	Berberine	74-83	ATP binding cassette subfamily B member 1	Homo sapiens	179-183
18157518-7	2008	When transfected cells were grown polarized on permeable filter supports, berberine was transferred from the basolateral to the apical compartments many times faster by MDCK-OCT1/MDR1 P-gp double transfectants than by MDCK-OCT1 or MDCK-MDR1 P-gp single transfectants.	Berberine	74-83	phosphoglycolate phosphatase	Homo sapiens	184-188
18157518-7	2008	When transfected cells were grown polarized on permeable filter supports, berberine was transferred from the basolateral to the apical compartments many times faster by MDCK-OCT1/MDR1 P-gp double transfectants than by MDCK-OCT1 or MDCK-MDR1 P-gp single transfectants.	Berberine	74-83	solute carrier family 22 member 1	Homo sapiens	223-227
18157518-7	2008	When transfected cells were grown polarized on permeable filter supports, berberine was transferred from the basolateral to the apical compartments many times faster by MDCK-OCT1/MDR1 P-gp double transfectants than by MDCK-OCT1 or MDCK-MDR1 P-gp single transfectants.	Berberine	74-83	ATP binding cassette subfamily B member 1	Homo sapiens	236-240
18157518-7	2008	When transfected cells were grown polarized on permeable filter supports, berberine was transferred from the basolateral to the apical compartments many times faster by MDCK-OCT1/MDR1 P-gp double transfectants than by MDCK-OCT1 or MDCK-MDR1 P-gp single transfectants.	Berberine	74-83	phosphoglycolate phosphatase	Homo sapiens	241-245
18157518-8	2008	The specific MDR1 P-gp inhibitor, zosuquidar trihydrochloride (LY335979), strongly inhibited berberine efflux into the apical compartment.	Berberine	93-102	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
18157518-8	2008	The specific MDR1 P-gp inhibitor, zosuquidar trihydrochloride (LY335979), strongly inhibited berberine efflux into the apical compartment.	Berberine	93-102	phosphoglycolate phosphatase	Homo sapiens	18-22
17964072-0	2007	Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells.	Berberine	0-9	growth differentiation factor 15	Homo sapiens	52-57
17631668-6	2008	The results showed that metabolic inhibitor KCN and P-glycoprotein inhibitor verapamil could increase berberine concentration within the neurons, indicating that efflux of berberine was energy-dependent and P-glycoprotein was likely to be involved.	Berberine	102-111	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	52-66
17631668-6	2008	The results showed that metabolic inhibitor KCN and P-glycoprotein inhibitor verapamil could increase berberine concentration within the neurons, indicating that efflux of berberine was energy-dependent and P-glycoprotein was likely to be involved.	Berberine	102-111	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	207-221
17631668-6	2008	The results showed that metabolic inhibitor KCN and P-glycoprotein inhibitor verapamil could increase berberine concentration within the neurons, indicating that efflux of berberine was energy-dependent and P-glycoprotein was likely to be involved.	Berberine	172-181	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	52-66
18219290-9	2008	Berberine, an inhibitor of Ca(2+) current, could substantially increase the expression of NM23-H1 and decrease 5-8F cell motility.	Berberine	0-9	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	90-97
18219290-10	2008	The specificity of berberine on NM23-H1 and cell motility was confirmed by RNAi assay.	Berberine	19-28	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	32-39
17964072-0	2007	Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells.	Berberine	0-9	activating transcription factor 3	Homo sapiens	62-66
17964072-4	2007	Berberine induces cell growth arrest, apoptosis, NAG-1, and ATF3 in human colorectal cancer cells.	Berberine	0-9	growth differentiation factor 15	Homo sapiens	49-54
17964072-4	2007	Berberine induces cell growth arrest, apoptosis, NAG-1, and ATF3 in human colorectal cancer cells.	Berberine	0-9	activating transcription factor 3	Homo sapiens	60-64
17964072-5	2007	ATF3 induction by berberine is mediated in a p53-dependent manner, whereas NAG-1 induction by berberine is mediated by multiple signaling pathways.	Berberine	18-27	activating transcription factor 3	Homo sapiens	0-4
17964072-5	2007	ATF3 induction by berberine is mediated in a p53-dependent manner, whereas NAG-1 induction by berberine is mediated by multiple signaling pathways.	Berberine	94-103	growth differentiation factor 15	Homo sapiens	75-80
17964072-6	2007	Our results suggest that berberine facilitates apoptosis and that NAG-1 and ATF3 expression plays an important role in berberine-induced apoptosis.	Berberine	119-128	growth differentiation factor 15	Homo sapiens	66-71
17964072-6	2007	Our results suggest that berberine facilitates apoptosis and that NAG-1 and ATF3 expression plays an important role in berberine-induced apoptosis.	Berberine	119-128	activating transcription factor 3	Homo sapiens	76-80
18338635-0	2007	Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae.	Berberine	10-19	peroxisome proliferator activated receptor alpha	Rattus norvegicus	23-32
18001034-5	2007	The antioxidative activity of berberine was defined by the relative electrophoretic mobility of oxLDL, fragmentation of ApoB, and malondialdehyde production via the Cu(2+)-mediated oxidation of LDL.	Berberine	30-39	apolipoprotein B	Homo sapiens	120-124
18001034-6	2007	Berberine also inhibited the generation of ROS and the subsequent mitochondrial membrane potential collapse, chromosome condensation, cytochrome C release, and caspase-3 activation induced by oxLDL in HUVECs.	Berberine	0-9	cytochrome c, somatic	Homo sapiens	134-146
18001034-6	2007	Berberine also inhibited the generation of ROS and the subsequent mitochondrial membrane potential collapse, chromosome condensation, cytochrome C release, and caspase-3 activation induced by oxLDL in HUVECs.	Berberine	0-9	caspase 3	Homo sapiens	160-169
18198644-0	2007	[Molecular mechanism of berberine in improving insulin resistance induced by free fatty acid through inhibiting nuclear trascription factor-kappaB p65 in 3T3-L1 adipocytes].	Berberine	24-33	insulin	Homo sapiens	47-54
18198644-0	2007	[Molecular mechanism of berberine in improving insulin resistance induced by free fatty acid through inhibiting nuclear trascription factor-kappaB p65 in 3T3-L1 adipocytes].	Berberine	24-33	RELA proto-oncogene, NF-kB subunit	Homo sapiens	140-146
18198644-0	2007	[Molecular mechanism of berberine in improving insulin resistance induced by free fatty acid through inhibiting nuclear trascription factor-kappaB p65 in 3T3-L1 adipocytes].	Berberine	24-33	RELA proto-oncogene, NF-kB subunit	Homo sapiens	147-150
18198644-1	2007	OBJECTIVE: To investigate the effect of berberine on nuclear transcription factor kappaB (NF-kappaB p65) expression and translocation in insulin resistant 3T3-L1 adipocytes induced by free fatty acid (FFA) and its possible molecular mechanism.	Berberine	40-49	RELA proto-oncogene, NF-kB subunit	Homo sapiens	82-88
18198644-1	2007	OBJECTIVE: To investigate the effect of berberine on nuclear transcription factor kappaB (NF-kappaB p65) expression and translocation in insulin resistant 3T3-L1 adipocytes induced by free fatty acid (FFA) and its possible molecular mechanism.	Berberine	40-49	RELA proto-oncogene, NF-kB subunit	Homo sapiens	90-103
18198644-1	2007	OBJECTIVE: To investigate the effect of berberine on nuclear transcription factor kappaB (NF-kappaB p65) expression and translocation in insulin resistant 3T3-L1 adipocytes induced by free fatty acid (FFA) and its possible molecular mechanism.	Berberine	40-49	insulin	Homo sapiens	137-144
18198644-7	2007	CONCLUSION: Berberine significantly improve the insulin resistance induced by FFA in 3T3-L1 adipocytes, its molecular mechanism might through inhibiting the activation and translocation related gene expression of NF-kappaB.	Berberine	12-21	insulin	Homo sapiens	48-55
18198644-7	2007	CONCLUSION: Berberine significantly improve the insulin resistance induced by FFA in 3T3-L1 adipocytes, its molecular mechanism might through inhibiting the activation and translocation related gene expression of NF-kappaB.	Berberine	12-21	nuclear factor kappa B subunit 1	Homo sapiens	213-222
18338635-7	2007	Both berberine (150 and 300 mg x kg(-1)) and rosiglitazone 4 mg x kg(-1) significantly decreased PPARy expression in diabetic retina; while berberine (150 and 300 mg x kg(-1)) and fenofibrate 100 mg x kg(-1) obviously increased both PPARalpha and PPARdelta expressions in diabetic retina.	Berberine	5-14	peroxisome proliferator activated receptor alpha	Rattus norvegicus	233-242
18338635-8	2007	Berberine modulates PPARalpha/delta/gamma protein levels in diabetic retina which may contribute to ameliorate retinopathy complication induced by STZ and a high-carbohydrate/high-fat diet.	Berberine	0-9	peroxisome proliferator activated receptor alpha	Rattus norvegicus	20-29
17978486-7	2007	However, interestingly, extracellular signal-regulated kinases (ERKs), which have been known to be responsible for the expression of glucose transporter (GLUT)1, were significantly activated in berberine-treated 3T3-L1 cells.	Berberine	194-203	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	133-160
17767919-0	2007	Berberine-induced LDLR up-regulation involves JNK pathway.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	18-22
17767919-0	2007	Berberine-induced LDLR up-regulation involves JNK pathway.	Berberine	0-9	mitogen-activated protein kinase 8	Homo sapiens	46-49
17767919-1	2007	Berberine, an herbal alkaloid, has been reported to have a lipid lowering effect by stabilizing hepatic LDLR mRNA in an ERK-dependent manner rather than promoting transcriptional activity.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	104-108
17767919-1	2007	Berberine, an herbal alkaloid, has been reported to have a lipid lowering effect by stabilizing hepatic LDLR mRNA in an ERK-dependent manner rather than promoting transcriptional activity.	Berberine	0-9	mitogen-activated protein kinase 1	Homo sapiens	120-123
17767919-2	2007	However, considering the complexity of interconnected signal pathways in biological processes, it is highly possible that there exist signal pathway(s) other than ERK pathway which contribute to the berberine-induced up-regulation of LDLR.	Berberine	199-208	low density lipoprotein receptor	Homo sapiens	234-238
17767919-3	2007	In the present study, we examined possible involvement of other signal pathways in berberine-induced hepatic LDLR up-regulation.	Berberine	83-92	low density lipoprotein receptor	Homo sapiens	109-113
17767919-4	2007	As evidenced by RT-PCR, berberine-induced LDLR mRNA expression was inhibited by JNK inhibitor SP600125 pretreatment.	Berberine	24-33	low density lipoprotein receptor	Homo sapiens	42-46
17767919-4	2007	As evidenced by RT-PCR, berberine-induced LDLR mRNA expression was inhibited by JNK inhibitor SP600125 pretreatment.	Berberine	24-33	mitogen-activated protein kinase 8	Homo sapiens	80-83
17767919-5	2007	Furthermore, we demonstrate that putative c-jun binding site of LDLR promoter is important in berberine-induced LDLR transcription using luciferase assay.	Berberine	94-103	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	42-47
17767919-5	2007	Furthermore, we demonstrate that putative c-jun binding site of LDLR promoter is important in berberine-induced LDLR transcription using luciferase assay.	Berberine	94-103	low density lipoprotein receptor	Homo sapiens	64-68
17767919-5	2007	Furthermore, we demonstrate that putative c-jun binding site of LDLR promoter is important in berberine-induced LDLR transcription using luciferase assay.	Berberine	94-103	low density lipoprotein receptor	Homo sapiens	112-116
17767919-6	2007	The result of EMSA also shows that berberine induces c-jun binding to LDLR promoter and this is decreased by SP600125 pretreatment.	Berberine	35-44	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	53-58
17767919-6	2007	The result of EMSA also shows that berberine induces c-jun binding to LDLR promoter and this is decreased by SP600125 pretreatment.	Berberine	35-44	low density lipoprotein receptor	Homo sapiens	70-74
17767919-7	2007	The present study demonstrates that berberine increases transcriptional activity of LDLR promoter and this involves JNK pathway.	Berberine	36-45	low density lipoprotein receptor	Homo sapiens	84-88
17767919-7	2007	The present study demonstrates that berberine increases transcriptional activity of LDLR promoter and this involves JNK pathway.	Berberine	36-45	mitogen-activated protein kinase 8	Homo sapiens	116-119
17978486-0	2007	Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes.	Berberine	0-9	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	20-25
17978486-8	2007	As expected, the level of GLUT1 protein was increased both in normal and insulin-resistant cells in response to berberine.	Berberine	112-121	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	26-31
17978486-9	2007	But berberine affected the expression of GLUT4 neither in normal nor in insulin-resistant cells.	Berberine	4-13	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	41-46
17978486-10	2007	In addition, berberine treatment increased AMP-activated protein kinase (AMPK) activity in 3T3-L1 cells, which has been reported to be associated with GLUT1-mediated glucose uptake.	Berberine	13-22	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	151-156
17978486-11	2007	Together, we concluded that berberine increases glucose transport activity of 3T3-L1 adipocytes by enhancing GLUT1 expression and also stimulates the GLUT1-mediated glucose uptake by activating GLUT1, a result of AMPK stimulation.	Berberine	28-37	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	109-114
17978486-11	2007	Together, we concluded that berberine increases glucose transport activity of 3T3-L1 adipocytes by enhancing GLUT1 expression and also stimulates the GLUT1-mediated glucose uptake by activating GLUT1, a result of AMPK stimulation.	Berberine	28-37	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	150-155
17978486-11	2007	Together, we concluded that berberine increases glucose transport activity of 3T3-L1 adipocytes by enhancing GLUT1 expression and also stimulates the GLUT1-mediated glucose uptake by activating GLUT1, a result of AMPK stimulation.	Berberine	28-37	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	150-155
17673978-0	2007	Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL.	Berberine	0-9	mitogen-activated protein kinase 8	Homo sapiens	131-134
17673978-0	2007	Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	135-138
17673978-8	2007	NAC administration, a scavenger of ROS, reversed berberine-induced apoptosis effects via inhibition of JNK, p38 and c-jun activation, and FasL and t-BID expression.	Berberine	49-58	X-linked Kx blood group	Homo sapiens	0-3
17673978-0	2007	Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL.	Berberine	0-9	Fas ligand	Homo sapiens	148-152
17673978-8	2007	NAC administration, a scavenger of ROS, reversed berberine-induced apoptosis effects via inhibition of JNK, p38 and c-jun activation, and FasL and t-BID expression.	Berberine	49-58	mitogen-activated protein kinase 8	Homo sapiens	103-106
17673978-8	2007	NAC administration, a scavenger of ROS, reversed berberine-induced apoptosis effects via inhibition of JNK, p38 and c-jun activation, and FasL and t-BID expression.	Berberine	49-58	mitogen-activated protein kinase 14	Homo sapiens	108-111
17673978-4	2007	Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly.	Berberine	40-49	caspase 3	Homo sapiens	80-89
17673978-8	2007	NAC administration, a scavenger of ROS, reversed berberine-induced apoptosis effects via inhibition of JNK, p38 and c-jun activation, and FasL and t-BID expression.	Berberine	49-58	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	116-121
17673978-4	2007	Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly.	Berberine	40-49	caspase 8	Homo sapiens	94-103
17673978-8	2007	NAC administration, a scavenger of ROS, reversed berberine-induced apoptosis effects via inhibition of JNK, p38 and c-jun activation, and FasL and t-BID expression.	Berberine	49-58	Fas ligand	Homo sapiens	138-142
17673978-4	2007	Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly.	Berberine	40-49	poly(ADP-ribose) polymerase 1	Homo sapiens	117-143
17673978-8	2007	NAC administration, a scavenger of ROS, reversed berberine-induced apoptosis effects via inhibition of JNK, p38 and c-jun activation, and FasL and t-BID expression.	Berberine	49-58	BH3 interacting domain death agonist	Homo sapiens	149-152
17673978-9	2007	These results leads us to speculate that berberine may play an apoptotic cascade in SW620 cells by activation of the JNK/p38 pathway and induction of ROS production, providing a new mechanism for berberine-induced cell death in human colon cancer cells.	Berberine	41-50	mitogen-activated protein kinase 8	Homo sapiens	117-120
17673978-4	2007	Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly.	Berberine	40-49	poly(ADP-ribose) polymerase 1	Homo sapiens	145-149
17673978-9	2007	These results leads us to speculate that berberine may play an apoptotic cascade in SW620 cells by activation of the JNK/p38 pathway and induction of ROS production, providing a new mechanism for berberine-induced cell death in human colon cancer cells.	Berberine	41-50	mitogen-activated protein kinase 14	Homo sapiens	121-124
17673978-4	2007	Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly.	Berberine	40-49	cytochrome c, somatic	Homo sapiens	170-182
17673978-4	2007	Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly.	Berberine	40-49	BH3 interacting domain death agonist	Homo sapiens	211-214
17673978-4	2007	Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly.	Berberine	40-49	baculoviral IAP repeat containing 2	Homo sapiens	241-247
17673978-4	2007	Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly.	Berberine	40-49	BCL2 apoptosis regulator	Homo sapiens	249-254
17673978-4	2007	Treatment of SW620 cells with 50 microM berberine resulted in activation of the caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c; whereas, the expression of BID and anti-apoptosis factor c-IAP1, Bcl-2, and Bcl-(XL) were decreased markedly.	Berberine	40-49	BCL2 like 1	Homo sapiens	260-267
17673978-5	2007	Berberine-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of JNK and p38 MAPK, as well as generation of the ROS.	Berberine	0-9	mitogen-activated protein kinase 8	Homo sapiens	105-108
17673978-5	2007	Berberine-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of JNK and p38 MAPK, as well as generation of the ROS.	Berberine	0-9	mitogen-activated protein kinase 14	Homo sapiens	113-116
17673978-7	2007	In addition, there was an increase in the cellular levels of phospho-c-Jun, FasL and t-BID in the berberine-induced apoptosis via the activation of JNK and p38 signaling modules.	Berberine	98-107	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	69-74
17673978-7	2007	In addition, there was an increase in the cellular levels of phospho-c-Jun, FasL and t-BID in the berberine-induced apoptosis via the activation of JNK and p38 signaling modules.	Berberine	98-107	Fas ligand	Homo sapiens	76-80
17673978-7	2007	In addition, there was an increase in the cellular levels of phospho-c-Jun, FasL and t-BID in the berberine-induced apoptosis via the activation of JNK and p38 signaling modules.	Berberine	98-107	BH3 interacting domain death agonist	Homo sapiens	87-90
17673978-7	2007	In addition, there was an increase in the cellular levels of phospho-c-Jun, FasL and t-BID in the berberine-induced apoptosis via the activation of JNK and p38 signaling modules.	Berberine	98-107	mitogen-activated protein kinase 8	Homo sapiens	148-151
17673978-7	2007	In addition, there was an increase in the cellular levels of phospho-c-Jun, FasL and t-BID in the berberine-induced apoptosis via the activation of JNK and p38 signaling modules.	Berberine	98-107	mitogen-activated protein kinase 14	Homo sapiens	156-159
17970083-10	2007	Prolonged exposure of the HSC-3 cells to berberine causes increased apoptosis through reduced levels of MMP, release of cytochrome c and activation of caspase-3.	Berberine	41-50	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	26-31
17970083-0	2007	Berberine induces apoptosis in human HSC-3 oral cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway.	Berberine	0-9	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	37-42
17970083-3	2007	In this study, the effects of berberine on cell growth, apoptosis and cell cycle regulation in human oral squamous carcinoma HSC-3 cells were examined.	Berberine	30-39	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	125-130
17970083-5	2007	This was also confirmed by phase-contrast microscopy which showed that berberine induced morphological changes in HSC-3 cells.	Berberine	71-80	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	114-119
18229609-2	2007	Compared with untreated group, insulin secretion level, glucose utilization, the activity and protein level of GK in NIT-1 cells stimulated by high concentration of glucose were increased significantly in berberine group (P &lt; 0.05), while the protein level of GKRP in berberine group decreased markedly.	Berberine	205-214	glucokinase	Mus musculus	111-113
18229609-2	2007	Compared with untreated group, insulin secretion level, glucose utilization, the activity and protein level of GK in NIT-1 cells stimulated by high concentration of glucose were increased significantly in berberine group (P &lt; 0.05), while the protein level of GKRP in berberine group decreased markedly.	Berberine	205-214	glucokinase regulatory protein	Mus musculus	263-267
18229609-4	2007	The possible molecular mechanism may be associated with berberine acting as a GK activator, improving glucose utilization, enhancing the activity and protein expression level of GK, as well as decreased the protein level of GKRP.	Berberine	56-65	glucokinase	Mus musculus	78-80
18229609-4	2007	The possible molecular mechanism may be associated with berberine acting as a GK activator, improving glucose utilization, enhancing the activity and protein expression level of GK, as well as decreased the protein level of GKRP.	Berberine	56-65	glucokinase	Mus musculus	178-180
18229609-4	2007	The possible molecular mechanism may be associated with berberine acting as a GK activator, improving glucose utilization, enhancing the activity and protein expression level of GK, as well as decreased the protein level of GKRP.	Berberine	56-65	glucokinase regulatory protein	Mus musculus	224-228
17970083-6	2007	Propidium iodide/annexin V staining for flow cytometric analysis showed that berberine-induced apoptosis correlated with caspase-3 activation.	Berberine	77-86	caspase 3	Homo sapiens	121-130
17970083-9	2007	In conclusion, our data support that berberine initially induces an endoplasmic reticulum stress response based on ROS and Ca2+ production which is followed by dysfunctions of the mitochondria, resulting in apoptosis of these oral cancer HSC-3 cells.	Berberine	37-46	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	238-243
17970083-10	2007	Prolonged exposure of the HSC-3 cells to berberine causes increased apoptosis through reduced levels of MMP, release of cytochrome c and activation of caspase-3.	Berberine	41-50	cytochrome c, somatic	Homo sapiens	120-132
17970083-10	2007	Prolonged exposure of the HSC-3 cells to berberine causes increased apoptosis through reduced levels of MMP, release of cytochrome c and activation of caspase-3.	Berberine	41-50	caspase 3	Homo sapiens	151-160
17970084-0	2007	GADD153 mediates berberine-induced apoptosis in human cervical cancer Ca ski cells.	Berberine	17-26	DNA damage inducible transcript 3	Homo sapiens	0-7
17970084-3	2007	Berberine enhanced the apoptosis of Ca Ski cells with the induction of a higher ratio of p53 and Bax/Bcl-2 proteins, increased levels of reactive oxygen species (ROS) and Ca2+, disruption of the mitochondrial membrane potential, and promotion of caspase-3 activity.	Berberine	0-9	tumor protein p53	Homo sapiens	89-92
17970084-3	2007	Berberine enhanced the apoptosis of Ca Ski cells with the induction of a higher ratio of p53 and Bax/Bcl-2 proteins, increased levels of reactive oxygen species (ROS) and Ca2+, disruption of the mitochondrial membrane potential, and promotion of caspase-3 activity.	Berberine	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	97-100
17970084-3	2007	Berberine enhanced the apoptosis of Ca Ski cells with the induction of a higher ratio of p53 and Bax/Bcl-2 proteins, increased levels of reactive oxygen species (ROS) and Ca2+, disruption of the mitochondrial membrane potential, and promotion of caspase-3 activity.	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	101-106
17970084-3	2007	Berberine enhanced the apoptosis of Ca Ski cells with the induction of a higher ratio of p53 and Bax/Bcl-2 proteins, increased levels of reactive oxygen species (ROS) and Ca2+, disruption of the mitochondrial membrane potential, and promotion of caspase-3 activity.	Berberine	0-9	caspase 3	Homo sapiens	246-255
17970084-4	2007	In CaSki cells pretreated with the pan-caspase inhibitor zVAD-fmk, the berberine-induced caspase-3 activity and apoptosis were significantly blocked as confirmed by flow cytometric analysis.	Berberine	71-80	caspase 3	Homo sapiens	89-98
17970084-5	2007	Western blot also showed that berberine induced the expression of GADD153, a transcription factor involved in apoptosis.	Berberine	30-39	DNA damage inducible transcript 3	Homo sapiens	66-73
17970084-6	2007	Thus berberine increased ROS levels leading to endoplasmic reticulum (ER) stress based on the increase of GADD153 and shown by Ca2+ release from the ER.	Berberine	5-14	DNA damage inducible transcript 3	Homo sapiens	106-113
17681786-0	2007	Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells.	Berberine	0-9	interleukin 1 beta	Homo sapiens	49-66
17681786-0	2007	Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells.	Berberine	0-9	tumor necrosis factor	Homo sapiens	71-98
17585901-26	2007	[a specific neuronal nitric oxide synthase (nNOS) inhibitor] produced potentiation of the action of subeffective dose of berberine (2 mg/kg, i.p.).	Berberine	121-130	nitric oxide synthase 1, neuronal	Mus musculus	12-42
17573342-0	2007	6-S-cysteinylation of bi-covalently attached FAD in berberine bridge enzyme tunes the redox potential for optimal activity.	Berberine	52-61	FA complementation group D2	Homo sapiens	45-48
17573342-1	2007	A mutagenic analysis of the amino acid residues His-104 and Cys-166, which are involved in the bi-covalent attachment of FAD to berberine bridge enzyme, was performed.	Berberine	128-137	FA complementation group D2	Homo sapiens	121-124
17585901-26	2007	[a specific neuronal nitric oxide synthase (nNOS) inhibitor] produced potentiation of the action of subeffective dose of berberine (2 mg/kg, i.p.).	Berberine	121-130	nitric oxide synthase 1, neuronal	Mus musculus	44-48
17585901-28	2007	[direct inhibitor of both nitric oxide synthase (NOS) and soluble guanylate cyclase (sGC)] potentiated the effect of berberine (2 mg/kg, i.p.)	Berberine	117-126	nitric oxide synthase 1, neuronal	Mus musculus	26-47
17645667-13	2007	Although berberine did damage hRPE cells when irradiated with visible light (lambda &gt; 400 nm) approximately 10 times higher concentrations were required to produce the same amount of damage as seen in lens cells.	Berberine	9-18	ribulose-5-phosphate-3-epimerase	Homo sapiens	30-34
17691993-6	2007	Recently, the involvement of ABC transporters in the translocation of berberine alkaloid from root to rhizome was reported, while H(+) antiporters were also suggested as the responsible transporters for vacuolar accumulation of the alkaloid.	Berberine	70-79	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	29-32
17631057-0	2007	Inhibitory effects of Zoagumhwan water extract and berberine on angiotensin II-induced monocyte chemoattractant protein (MCP)-1 expression and monocyte adhesion to endothelial cells.	Berberine	51-60	angiotensinogen	Homo sapiens	64-78
17631057-0	2007	Inhibitory effects of Zoagumhwan water extract and berberine on angiotensin II-induced monocyte chemoattractant protein (MCP)-1 expression and monocyte adhesion to endothelial cells.	Berberine	51-60	C-C motif chemokine ligand 2	Homo sapiens	87-127
17631057-5	2007	Berberine, a major component of Coptis chinensis Franch, also showed similar effects on ROS production and MCP-1 expression induced by Ang II.	Berberine	0-9	C-C motif chemokine ligand 2	Homo sapiens	107-112
17292731-7	2007	Berberine activated extracellular signal-regulated kinase (ERK) 1/2, but PD98059, an ERK kinase inhibitor, only decreased berberine-stimulated glucose uptake by 32%.	Berberine	0-9	mitogen-activated protein kinase 3	Homo sapiens	20-67
17292731-11	2007	However, genistein, a tyrosine kinase inhibitor, completely blocked berberine-stimulated glucose uptake in 3T3-L1 adipocytes and preadipocytes, suggesting that berberine may induce glucose transport via increasing GLUT1 activity.	Berberine	68-77	solute carrier family 2 member 1	Homo sapiens	214-219
17536261-1	2007	OBJECTIVE: To determine the effects of Chinese herbal monomers such as baicalin, berberine, and matrine on the androgen receptor (AR) mRNA expression in SZ95 sebocytes in vitro and to explore the possible mechanism of using traditional Chinese medicines to treat acne.	Berberine	81-90	androgen receptor	Homo sapiens	111-128
17536261-1	2007	OBJECTIVE: To determine the effects of Chinese herbal monomers such as baicalin, berberine, and matrine on the androgen receptor (AR) mRNA expression in SZ95 sebocytes in vitro and to explore the possible mechanism of using traditional Chinese medicines to treat acne.	Berberine	81-90	androgen receptor	Homo sapiens	130-132
17295371-0	2007	The natural product berberine is a human prolyl oligopeptidase inhibitor.	Berberine	20-29	prolyl endopeptidase	Homo sapiens	41-62
17295371-6	2007	The alkaloid berberine was the prolyl oligopeptidase inhibitory molecule isolated from Rhizoma coptidis extract.	Berberine	13-22	prolyl endopeptidase	Homo sapiens	31-52
17295371-7	2007	Berberine inhibited prolyl oligopeptidase in a dose-dependent manner.	Berberine	0-9	prolyl endopeptidase	Homo sapiens	20-41
17292731-11	2007	However, genistein, a tyrosine kinase inhibitor, completely blocked berberine-stimulated glucose uptake in 3T3-L1 adipocytes and preadipocytes, suggesting that berberine may induce glucose transport via increasing GLUT1 activity.	Berberine	160-169	solute carrier family 2 member 1	Homo sapiens	214-219
16923341-6	2006	The administration of berberine significantly reduced plasma TNF-alpha, IFN- gamma, and NO levels, but did not suppress plasma IL-12 levels in mice exposed to LPS.	Berberine	22-31	tumor necrosis factor	Mus musculus	61-70
17125739-0	2007	Berberine alters the processing of Alzheimer"s amyloid precursor protein to decrease Abeta secretion.	Berberine	0-9	amyloid beta precursor protein	Homo sapiens	47-72
17125739-5	2007	Here, we report that berberine reduces Abeta levels by modulating APP processing in human neuroglioma H4 cells stably expressing Swedish-type of APP at the range of berberine concentration without cellular toxicity.	Berberine	21-30	amyloid beta precursor protein	Homo sapiens	39-44
16939707-0	2007	Differential effect of Rhizoma coptidis and its main alkaloid compound berberine on TNF-alpha induced NFkappaB translocation in human keratinocytes.	Berberine	71-80	tumor necrosis factor	Homo sapiens	84-93
16939707-0	2007	Differential effect of Rhizoma coptidis and its main alkaloid compound berberine on TNF-alpha induced NFkappaB translocation in human keratinocytes.	Berberine	71-80	nuclear factor kappa B subunit 1	Homo sapiens	102-110
16939707-5	2007	We conclude that in dermatological disorders berberine exerts its anti-inflammatory effects by inhibiting signal transduction pathways other than the NFkappaB dependent pathway, while the RCE complex acts partially by blocking the NFkappaB dependent pathway.	Berberine	45-54	nuclear factor kappa B subunit 1	Homo sapiens	150-158
17213652-0	2007	Human MDR1 and MRP1 recognize berberine as their transport substrate.	Berberine	30-39	ATP binding cassette subfamily B member 1	Homo sapiens	6-10
17213652-0	2007	Human MDR1 and MRP1 recognize berberine as their transport substrate.	Berberine	30-39	ATP binding cassette subfamily C member 1	Homo sapiens	15-19
17213652-1	2007	To examine whether human ATP-binding cassette (ABC) transporters play a role in the detoxification of plant alkaloid berberine, we investigated berberine transport using multidrug resistance protein1 (MDR1) and multidrug resistance-associated protein1 (MRP1).	Berberine	117-126	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	25-45
17213652-1	2007	To examine whether human ATP-binding cassette (ABC) transporters play a role in the detoxification of plant alkaloid berberine, we investigated berberine transport using multidrug resistance protein1 (MDR1) and multidrug resistance-associated protein1 (MRP1).	Berberine	117-126	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	47-50
17213652-1	2007	To examine whether human ATP-binding cassette (ABC) transporters play a role in the detoxification of plant alkaloid berberine, we investigated berberine transport using multidrug resistance protein1 (MDR1) and multidrug resistance-associated protein1 (MRP1).	Berberine	144-153	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	25-45
17213652-1	2007	To examine whether human ATP-binding cassette (ABC) transporters play a role in the detoxification of plant alkaloid berberine, we investigated berberine transport using multidrug resistance protein1 (MDR1) and multidrug resistance-associated protein1 (MRP1).	Berberine	144-153	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	47-50
17213652-2	2007	Cells expressing MDR1 or MRP1 accumulated less berberine.	Berberine	47-56	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
17213652-2	2007	Cells expressing MDR1 or MRP1 accumulated less berberine.	Berberine	47-56	ATP binding cassette subfamily C member 1	Homo sapiens	25-29
17213652-3	2007	Berberine accumulation depended on the cellular ATP level, and was reversed by typical inhibitors of MDR1, suggesting that human MDR1 and MRP1 directly efflux berberine as their substrate.	Berberine	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
17213652-3	2007	Berberine accumulation depended on the cellular ATP level, and was reversed by typical inhibitors of MDR1, suggesting that human MDR1 and MRP1 directly efflux berberine as their substrate.	Berberine	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
17213652-3	2007	Berberine accumulation depended on the cellular ATP level, and was reversed by typical inhibitors of MDR1, suggesting that human MDR1 and MRP1 directly efflux berberine as their substrate.	Berberine	0-9	ATP binding cassette subfamily C member 1	Homo sapiens	138-142
17213652-3	2007	Berberine accumulation depended on the cellular ATP level, and was reversed by typical inhibitors of MDR1, suggesting that human MDR1 and MRP1 directly efflux berberine as their substrate.	Berberine	159-168	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
17213652-3	2007	Berberine accumulation depended on the cellular ATP level, and was reversed by typical inhibitors of MDR1, suggesting that human MDR1 and MRP1 directly efflux berberine as their substrate.	Berberine	159-168	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
17213652-3	2007	Berberine accumulation depended on the cellular ATP level, and was reversed by typical inhibitors of MDR1, suggesting that human MDR1 and MRP1 directly efflux berberine as their substrate.	Berberine	159-168	ATP binding cassette subfamily C member 1	Homo sapiens	138-142
17295145-1	2007	PURPOSE: To examine the effects of berberine, an alkaloid isolated from some medicinal herbs, on the disruption of the barrier function in a human retinal pigment epithelial cell line (ARPE-19) stimulated with interleukin-1beta (IL-1beta).	Berberine	35-44	interleukin 1 beta	Homo sapiens	210-227
17295145-5	2007	RESULTS: Berberine dose-dependently inhibited decreased TER and increased the permeability to HRP and SF in the cells stimulated with IL-1beta.	Berberine	9-18	interleukin 1 beta	Homo sapiens	134-142
17295145-6	2007	CONCLUSIONS: Berberine dose-dependently inhibited the disruption of the barrier function in the ARPE-19 cell line induced by IL-1beta.	Berberine	13-22	interleukin 1 beta	Homo sapiens	125-133
17164575-0	2007	Effect of berberine on monocyte chemotactic protein-1 and cytokine-induced neutrophil chemoattractant-1 expression in rat lipopolysaccharide-induced uveitis.	Berberine	10-19	C-C motif chemokine ligand 2	Rattus norvegicus	23-53
17164575-0	2007	Effect of berberine on monocyte chemotactic protein-1 and cytokine-induced neutrophil chemoattractant-1 expression in rat lipopolysaccharide-induced uveitis.	Berberine	10-19	C-X-C motif chemokine ligand 1	Rattus norvegicus	58-103
17164575-1	2007	PURPOSE: The aims of this study were to examine the in vivo effects of berberine, an alkaloid isolated from some medicinal herbs, on monocyte chemotactic protein-1 (MCP-1) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) expression in rat lipopolysaccharide (LPS)-induced uveitis.	Berberine	71-80	C-C motif chemokine ligand 2	Rattus norvegicus	133-163
17164575-1	2007	PURPOSE: The aims of this study were to examine the in vivo effects of berberine, an alkaloid isolated from some medicinal herbs, on monocyte chemotactic protein-1 (MCP-1) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) expression in rat lipopolysaccharide (LPS)-induced uveitis.	Berberine	71-80	C-C motif chemokine ligand 2	Rattus norvegicus	165-170
17164575-1	2007	PURPOSE: The aims of this study were to examine the in vivo effects of berberine, an alkaloid isolated from some medicinal herbs, on monocyte chemotactic protein-1 (MCP-1) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) expression in rat lipopolysaccharide (LPS)-induced uveitis.	Berberine	71-80	C-X-C motif chemokine ligand 1	Rattus norvegicus	176-221
17164575-1	2007	PURPOSE: The aims of this study were to examine the in vivo effects of berberine, an alkaloid isolated from some medicinal herbs, on monocyte chemotactic protein-1 (MCP-1) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) expression in rat lipopolysaccharide (LPS)-induced uveitis.	Berberine	71-80	C-X-C motif chemokine ligand 1	Rattus norvegicus	223-229
17164575-7	2007	RESULTS: Berberine dose-dependently inhibited LPS-induced MCP-1 mRNA and CINC-1 mRNA expression of the iris-ciliary body.	Berberine	9-18	C-C motif chemokine ligand 2	Rattus norvegicus	58-63
17164575-7	2007	RESULTS: Berberine dose-dependently inhibited LPS-induced MCP-1 mRNA and CINC-1 mRNA expression of the iris-ciliary body.	Berberine	9-18	C-X-C motif chemokine ligand 1	Rattus norvegicus	73-79
17164575-10	2007	CONCLUSIONS: These findings indicate that berberine dose-dependently inhibited the expression of MCP-1 and CINC-1 induced by LPS and diminished the anterior uveitis.	Berberine	42-51	C-C motif chemokine ligand 2	Rattus norvegicus	97-102
17164575-10	2007	CONCLUSIONS: These findings indicate that berberine dose-dependently inhibited the expression of MCP-1 and CINC-1 induced by LPS and diminished the anterior uveitis.	Berberine	42-51	C-X-C motif chemokine ligand 1	Rattus norvegicus	107-113
17137520-6	2006	Intragastric administration of berberine significantly ameliorated the spatial memory impairment and increased the expression of IL-1beta, iNOS in the rat model of AD.	Berberine	31-40	interleukin 1 alpha	Rattus norvegicus	129-137
17137520-6	2006	Intragastric administration of berberine significantly ameliorated the spatial memory impairment and increased the expression of IL-1beta, iNOS in the rat model of AD.	Berberine	31-40	nitric oxide synthase 2	Rattus norvegicus	139-143
16934942-5	2006	Furthermore, we examined the effects of berberine treatment on N-methyl-D-aspartate (NMDA) receptor channel activity expressed in Xenopus laevis oocytes.	Berberine	40-49	glutamate ionotropic receptor NMDA type subunit 1 L homeolog	Xenopus laevis	63-99
16934942-6	2006	Berberine was found to completely block both morphine-induced locomotor sensitization and analgesic tolerance, and reduce D(1) and NMDA receptor bindings in the cortex.	Berberine	0-9	glutamate ionotropic receptor NMDA type subunit 1 L homeolog	Xenopus laevis	131-144
16934942-7	2006	Moreover, berberine markedly inhibited NMDA current in Xenopus laevis oocytes expressing NMDA receptor subunits.	Berberine	10-19	glutamate ionotropic receptor NMDA type subunit 1 L homeolog	Xenopus laevis	89-102
16890192-0	2006	Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway.	Berberine	0-9	peroxisome proliferator activated receptor gamma	Homo sapiens	64-73
16890192-1	2006	Berberine (BBR), a compound purified from Cortidis rhizoma, reduces serum cholesterol, triglycerides, and LDL-cholesterol of hypercholesterolemic patients and high fat diet fed animals, and increases hepatic LDLR mRNA and protein levels through a post-transcriptional mechanism.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	208-212
16890192-1	2006	Berberine (BBR), a compound purified from Cortidis rhizoma, reduces serum cholesterol, triglycerides, and LDL-cholesterol of hypercholesterolemic patients and high fat diet fed animals, and increases hepatic LDLR mRNA and protein levels through a post-transcriptional mechanism.	Berberine	11-14	low density lipoprotein receptor	Homo sapiens	208-212
17049164-6	2006	Berberine only weakly stimulates the phosphorylation of Akt/PKB, a key molecule in the insulin signaling pathway, but strongly promotes the phosphorylation of AMPK and p38 MAPK.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	56-63
16621886-0	2006	Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP.	Berberine	0-9	proliferating cell nuclear antigen	Homo sapiens	123-129
16621886-0	2006	Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP.	Berberine	0-9	caspase 3	Homo sapiens	202-211
16621886-0	2006	Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP.	Berberine	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	216-220
16621886-4	2006	Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk.	Berberine	38-47	cyclin dependent kinase inhibitor 1A	Homo sapiens	143-147
16621886-4	2006	Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk.	Berberine	38-47	H3 histone pseudogene 16	Homo sapiens	148-151
16621886-4	2006	Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk.	Berberine	38-47	cyclin dependent kinase inhibitor 1B	Homo sapiens	156-160
16621886-4	2006	Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk.	Berberine	38-47	dynactin subunit 6	Homo sapiens	161-164
16621886-4	2006	Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk.	Berberine	38-47	cyclin dependent kinase 2	Homo sapiens	194-198
16621886-4	2006	Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk.	Berberine	38-47	cyclin dependent kinase 4	Homo sapiens	200-204
16621886-4	2006	Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk.	Berberine	38-47	cyclin dependent kinase 6	Homo sapiens	206-210
16621886-4	2006	Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk.	Berberine	38-47	cyclin D1	Homo sapiens	215-235
16621886-6	2006	Pretreatment of A431 cells with the pan-caspase inhibitor (z-VAD-fmk) significantly blocked the berberine-induced apoptosis in A431 cells confirmed that berberine-induced apoptosis is mediated through activation of caspase 3-dependent pathway.	Berberine	96-105	caspase 3	Homo sapiens	215-224
16621886-6	2006	Pretreatment of A431 cells with the pan-caspase inhibitor (z-VAD-fmk) significantly blocked the berberine-induced apoptosis in A431 cells confirmed that berberine-induced apoptosis is mediated through activation of caspase 3-dependent pathway.	Berberine	153-162	caspase 3	Homo sapiens	215-224
16923341-6	2006	The administration of berberine significantly reduced plasma TNF-alpha, IFN- gamma, and NO levels, but did not suppress plasma IL-12 levels in mice exposed to LPS.	Berberine	22-31	interferon gamma	Mus musculus	72-82
16873688-6	2006	Berberine treatment resulted in increased AMP-activated protein kinase (AMPK) activity in 3T3-L1 adipocytes and L6 myotubes, increased GLUT4 translocation in L6 cells in a phosphatidylinositol 3" kinase-independent manner, and reduced lipid accumulation in 3T3-L1 adipocytes.	Berberine	0-9	solute carrier family 2 member 4	Rattus norvegicus	135-140
16448624-0	2006	Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury.	Berberine	0-9	Eph receptor B1	Rattus norvegicus	25-28
16786265-1	2006	A single-chain variable fragment (scFv) specific for berberine was produced in Escherichia coli.	Berberine	53-62	immunglobulin heavy chain variable region	Homo sapiens	34-38
16786265-2	2006	The anti-berberine scFv gene was cloned from hybridoma 1D5-3B-7 producing the monoclonal antibody.	Berberine	9-18	immunglobulin heavy chain variable region	Homo sapiens	19-23
16786265-6	2006	The results of direct ELISA showed that the anti-berberine scFv retained specific binding activity to berberine.	Berberine	49-58	immunglobulin heavy chain variable region	Homo sapiens	59-63
16786265-6	2006	The results of direct ELISA showed that the anti-berberine scFv retained specific binding activity to berberine.	Berberine	102-111	immunglobulin heavy chain variable region	Homo sapiens	59-63
16387334-0	2006	Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.	Berberine	21-30	plasminogen activator, urokinase	Homo sapiens	103-134
16387334-0	2006	Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.	Berberine	21-30	matrix metallopeptidase 2	Homo sapiens	139-165
16387334-4	2006	A549 cell treated with berberine at various concentrations showed reduced ECM proteinases including matrix metalloproteinase-2 (MMP2) and urokinase-plasminogen activator (u-PA) by gelatin and casein zymography analysis.	Berberine	23-32	matrix metallopeptidase 2	Homo sapiens	100-126
16387334-4	2006	A549 cell treated with berberine at various concentrations showed reduced ECM proteinases including matrix metalloproteinase-2 (MMP2) and urokinase-plasminogen activator (u-PA) by gelatin and casein zymography analysis.	Berberine	23-32	matrix metallopeptidase 2	Homo sapiens	128-132
16387334-4	2006	A549 cell treated with berberine at various concentrations showed reduced ECM proteinases including matrix metalloproteinase-2 (MMP2) and urokinase-plasminogen activator (u-PA) by gelatin and casein zymography analysis.	Berberine	23-32	plasminogen activator, urokinase	Homo sapiens	138-169
16387334-4	2006	A549 cell treated with berberine at various concentrations showed reduced ECM proteinases including matrix metalloproteinase-2 (MMP2) and urokinase-plasminogen activator (u-PA) by gelatin and casein zymography analysis.	Berberine	23-32	plasminogen activator, urokinase	Homo sapiens	171-175
16387334-6	2006	Moreover, berberine also exerted its action via regulating tissue inhibitor of metalloproteinase-2 (TIMP-2) and urokinase-plasminogen activator inhibitor (PAI).	Berberine	10-19	TIMP metallopeptidase inhibitor 2	Homo sapiens	59-98
16387334-6	2006	Moreover, berberine also exerted its action via regulating tissue inhibitor of metalloproteinase-2 (TIMP-2) and urokinase-plasminogen activator inhibitor (PAI).	Berberine	10-19	TIMP metallopeptidase inhibitor 2	Homo sapiens	100-106
16387334-6	2006	Moreover, berberine also exerted its action via regulating tissue inhibitor of metalloproteinase-2 (TIMP-2) and urokinase-plasminogen activator inhibitor (PAI).	Berberine	10-19	serpin family B member 2	Homo sapiens	112-153
16387334-6	2006	Moreover, berberine also exerted its action via regulating tissue inhibitor of metalloproteinase-2 (TIMP-2) and urokinase-plasminogen activator inhibitor (PAI).	Berberine	10-19	serpin family B member 2	Homo sapiens	155-158
16789430-0	2006	Berberine potently inhibits protein tyrosine phosphatase 1B: investigation by docking simulation and experimental validation.	Berberine	0-9	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	28-59
16789430-1	2006	Berberine was investigated as an inhibitor of human protein tyrosine phosphatase 1B (h-PTP 1B) in an attempt to explain its anti-hyperglycemic activitiy.	Berberine	0-9	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	52-83
16789430-1	2006	Berberine was investigated as an inhibitor of human protein tyrosine phosphatase 1B (h-PTP 1B) in an attempt to explain its anti-hyperglycemic activitiy.	Berberine	0-9	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	87-93
16789430-2	2006	The investigation included simulated docking experiments to fit berberine within the binding pocket of h-PTP 1B.	Berberine	64-73	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	105-111
16789430-3	2006	Berberine was found to readily fit within the binding pocket of h-PTP 1B in a low energy orientation characterized with optimal electrostatic attractive interactions bridging the isoquinolinium positively charged nitrogen atom of berberine and the negatively charged acidic residue of ASP 48 of h-PTP 1B.	Berberine	0-9	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	66-72
16789430-3	2006	Berberine was found to readily fit within the binding pocket of h-PTP 1B in a low energy orientation characterized with optimal electrostatic attractive interactions bridging the isoquinolinium positively charged nitrogen atom of berberine and the negatively charged acidic residue of ASP 48 of h-PTP 1B.	Berberine	0-9	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	297-303
16789430-3	2006	Berberine was found to readily fit within the binding pocket of h-PTP 1B in a low energy orientation characterized with optimal electrostatic attractive interactions bridging the isoquinolinium positively charged nitrogen atom of berberine and the negatively charged acidic residue of ASP 48 of h-PTP 1B.	Berberine	230-239	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	66-72
16789430-4	2006	Experimentally, berberine was found to potently competitively inhibit recombinant h-PTP 1B in vitro (Ki value = 91.3 nM).	Berberine	16-25	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	84-90
16789430-5	2006	Our findings strongly suggest that h-PTP 1B inhibition is at least one of the reasons for the reported anti-hyperglycemic activities of berberine.	Berberine	136-145	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	37-43
16508037-1	2006	The alkaloid drug berberine (BBR) was recently described to decrease plasma cholesterol and triglycerides (TGs) in hypercholesterolemic patients by increasing expression of the hepatic low density lipoprotein receptor (LDLR).	Berberine	18-27	low density lipoprotein receptor	Homo sapiens	185-217
16508037-1	2006	The alkaloid drug berberine (BBR) was recently described to decrease plasma cholesterol and triglycerides (TGs) in hypercholesterolemic patients by increasing expression of the hepatic low density lipoprotein receptor (LDLR).	Berberine	18-27	low density lipoprotein receptor	Homo sapiens	219-223
16508037-1	2006	The alkaloid drug berberine (BBR) was recently described to decrease plasma cholesterol and triglycerides (TGs) in hypercholesterolemic patients by increasing expression of the hepatic low density lipoprotein receptor (LDLR).	Berberine	29-32	low density lipoprotein receptor	Homo sapiens	185-217
16508037-1	2006	The alkaloid drug berberine (BBR) was recently described to decrease plasma cholesterol and triglycerides (TGs) in hypercholesterolemic patients by increasing expression of the hepatic low density lipoprotein receptor (LDLR).	Berberine	29-32	low density lipoprotein receptor	Homo sapiens	219-223
16098530-4	2006	Our results show that berberine significantly inhibits growth factor, mainly angiotensin II (AngII) and heparin binding epidermal growth factor (HB-EGF), induced VSMC proliferation and migration in vitro, and this effect is achieved by delaying or partially suppressing activation of Akt pathway rather than ERK pathway.	Berberine	22-31	angiotensinogen	Rattus norvegicus	77-91
16098530-4	2006	Our results show that berberine significantly inhibits growth factor, mainly angiotensin II (AngII) and heparin binding epidermal growth factor (HB-EGF), induced VSMC proliferation and migration in vitro, and this effect is achieved by delaying or partially suppressing activation of Akt pathway rather than ERK pathway.	Berberine	22-31	angiotensinogen	Rattus norvegicus	93-98
16098530-4	2006	Our results show that berberine significantly inhibits growth factor, mainly angiotensin II (AngII) and heparin binding epidermal growth factor (HB-EGF), induced VSMC proliferation and migration in vitro, and this effect is achieved by delaying or partially suppressing activation of Akt pathway rather than ERK pathway.	Berberine	22-31	heparin-binding EGF-like growth factor	Rattus norvegicus	104-143
16098530-4	2006	Our results show that berberine significantly inhibits growth factor, mainly angiotensin II (AngII) and heparin binding epidermal growth factor (HB-EGF), induced VSMC proliferation and migration in vitro, and this effect is achieved by delaying or partially suppressing activation of Akt pathway rather than ERK pathway.	Berberine	22-31	heparin-binding EGF-like growth factor	Rattus norvegicus	145-151
16098530-4	2006	Our results show that berberine significantly inhibits growth factor, mainly angiotensin II (AngII) and heparin binding epidermal growth factor (HB-EGF), induced VSMC proliferation and migration in vitro, and this effect is achieved by delaying or partially suppressing activation of Akt pathway rather than ERK pathway.	Berberine	22-31	AKT serine/threonine kinase 1	Rattus norvegicus	284-287
16098530-4	2006	Our results show that berberine significantly inhibits growth factor, mainly angiotensin II (AngII) and heparin binding epidermal growth factor (HB-EGF), induced VSMC proliferation and migration in vitro, and this effect is achieved by delaying or partially suppressing activation of Akt pathway rather than ERK pathway.	Berberine	22-31	Eph receptor B1	Rattus norvegicus	308-311
16448624-0	2006	Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury.	Berberine	0-9	early growth response 1	Rattus norvegicus	39-44
16448624-9	2006	However, berberine significantly attenuated MEK/ERK activation and downstream target (Egr-1, c-Fos, Cyclin D1 and PDGF-A) expression after mechanic injury in vitro.	Berberine	9-18	Eph receptor B1	Rattus norvegicus	48-51
16448624-9	2006	However, berberine significantly attenuated MEK/ERK activation and downstream target (Egr-1, c-Fos, Cyclin D1 and PDGF-A) expression after mechanic injury in vitro.	Berberine	9-18	early growth response 1	Rattus norvegicus	86-91
16448624-9	2006	However, berberine significantly attenuated MEK/ERK activation and downstream target (Egr-1, c-Fos, Cyclin D1 and PDGF-A) expression after mechanic injury in vitro.	Berberine	9-18	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	93-98
16448624-9	2006	However, berberine significantly attenuated MEK/ERK activation and downstream target (Egr-1, c-Fos, Cyclin D1 and PDGF-A) expression after mechanic injury in vitro.	Berberine	9-18	cyclin D1	Rattus norvegicus	100-109
16448624-9	2006	However, berberine significantly attenuated MEK/ERK activation and downstream target (Egr-1, c-Fos, Cyclin D1 and PDGF-A) expression after mechanic injury in vitro.	Berberine	9-18	platelet derived growth factor subunit A	Rattus norvegicus	114-120
16448624-10	2006	Our study showed that berberine blocked injury-induced SMC regrowth by inactivation of ERK/Egr-1 signaling pathway thereby preventing early signaling induced by injury in vitro.	Berberine	22-31	Eph receptor B1	Rattus norvegicus	87-90
16448624-10	2006	Our study showed that berberine blocked injury-induced SMC regrowth by inactivation of ERK/Egr-1 signaling pathway thereby preventing early signaling induced by injury in vitro.	Berberine	22-31	early growth response 1	Rattus norvegicus	91-96
16619512-0	2006	Down-regulation of cyclin B1 and up-regulation of Wee1 by berberine promotes entry of leukemia cells into the G2/M-phase of the cell cycle.	Berberine	58-67	WEE1 G2 checkpoint kinase	Homo sapiens	50-54
16619512-6	2006	The berberine-induced G2/M-phase arrest in both examined cell lines was accompanied by increased levels of Wee1 and 14-3-3sigma, but decreased levels of Cdc25c, CDK1 and cyclin B1.	Berberine	4-13	WEE1 G2 checkpoint kinase	Homo sapiens	107-127
16619512-6	2006	The berberine-induced G2/M-phase arrest in both examined cell lines was accompanied by increased levels of Wee1 and 14-3-3sigma, but decreased levels of Cdc25c, CDK1 and cyclin B1.	Berberine	4-13	cell division cycle 25C	Homo sapiens	153-159
16619512-6	2006	The berberine-induced G2/M-phase arrest in both examined cell lines was accompanied by increased levels of Wee1 and 14-3-3sigma, but decreased levels of Cdc25c, CDK1 and cyclin B1.	Berberine	4-13	cyclin dependent kinase 1	Homo sapiens	161-165
16619512-6	2006	The berberine-induced G2/M-phase arrest in both examined cell lines was accompanied by increased levels of Wee1 and 14-3-3sigma, but decreased levels of Cdc25c, CDK1 and cyclin B1.	Berberine	4-13	cyclin B1	Homo sapiens	170-179
16619512-8	2006	Berberine induced G2/M arrest in both the examined cells via the inhibition of cyclin B1 and the promotion of Wee1.	Berberine	0-9	cyclin B1	Homo sapiens	79-88
16619512-8	2006	Berberine induced G2/M arrest in both the examined cells via the inhibition of cyclin B1 and the promotion of Wee1.	Berberine	0-9	WEE1 G2 checkpoint kinase	Homo sapiens	110-114
16475703-0	2006	Apoptosis of human leukemia HL-60 cells and murine leukemia WEHI-3 cells induced by berberine through the activation of caspase-3.	Berberine	84-93	caspase 3	Mus musculus	120-129
16189662-7	2006	Moreover, berberine induced the activation of caspase-8 and -3, and caused the cleavage of poly ADP-ribose polymerase (PARP) and the cytochrome c release, whereas the expression of Bid and anti-apoptosis factor Bcl-XL were decreased markedly.	Berberine	10-19	caspase 8	Homo sapiens	46-62
16189662-7	2006	Moreover, berberine induced the activation of caspase-8 and -3, and caused the cleavage of poly ADP-ribose polymerase (PARP) and the cytochrome c release, whereas the expression of Bid and anti-apoptosis factor Bcl-XL were decreased markedly.	Berberine	10-19	poly(ADP-ribose) polymerase 1	Homo sapiens	91-117
16189662-7	2006	Moreover, berberine induced the activation of caspase-8 and -3, and caused the cleavage of poly ADP-ribose polymerase (PARP) and the cytochrome c release, whereas the expression of Bid and anti-apoptosis factor Bcl-XL were decreased markedly.	Berberine	10-19	poly(ADP-ribose) polymerase 1	Homo sapiens	119-123
16189662-7	2006	Moreover, berberine induced the activation of caspase-8 and -3, and caused the cleavage of poly ADP-ribose polymerase (PARP) and the cytochrome c release, whereas the expression of Bid and anti-apoptosis factor Bcl-XL were decreased markedly.	Berberine	10-19	cytochrome c, somatic	Homo sapiens	133-145
16189662-7	2006	Moreover, berberine induced the activation of caspase-8 and -3, and caused the cleavage of poly ADP-ribose polymerase (PARP) and the cytochrome c release, whereas the expression of Bid and anti-apoptosis factor Bcl-XL were decreased markedly.	Berberine	10-19	BH3 interacting domain death agonist	Homo sapiens	181-184
16189662-7	2006	Moreover, berberine induced the activation of caspase-8 and -3, and caused the cleavage of poly ADP-ribose polymerase (PARP) and the cytochrome c release, whereas the expression of Bid and anti-apoptosis factor Bcl-XL were decreased markedly.	Berberine	10-19	BCL2 like 1	Homo sapiens	211-217
16189662-10	2006	These results indicated that the potential of anti-hepatoma activity of berberine may be mediated through a caspases-mitochondria-dependent pathway.	Berberine	72-81	caspase 8	Homo sapiens	108-116
16505103-0	2006	Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells.	Berberine	0-9	caspase 3	Homo sapiens	69-78
16505103-4	2006	The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G1-phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk.	Berberine	4-13	cyclin dependent kinase 2	Homo sapiens	214-245
16505103-4	2006	The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G1-phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk.	Berberine	4-13	cyclin dependent kinase 4	Homo sapiens	247-251
16505103-4	2006	The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G1-phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk.	Berberine	4-13	cyclin dependent kinase 6	Homo sapiens	257-261
16505103-4	2006	The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G1-phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk.	Berberine	4-13	cyclin dependent kinase inhibitor 1A	Homo sapiens	325-329
16505103-4	2006	The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G1-phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk.	Berberine	4-13	H3 histone pseudogene 16	Homo sapiens	330-333
16505103-4	2006	The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G1-phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk.	Berberine	4-13	cyclin dependent kinase inhibitor 1B	Homo sapiens	338-342
16505103-4	2006	The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G1-phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk.	Berberine	4-13	dynactin subunit 6	Homo sapiens	343-346
16505103-4	2006	The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G1-phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk.	Berberine	4-13	cyclin dependent kinase 2	Homo sapiens	239-242
16505103-4	2006	The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G1-phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk.	Berberine	4-13	cyclin dependent kinase 2	Homo sapiens	247-250
16505103-5	2006	Berberine also significantly (P &lt; 0.05-0.001) enhanced apoptosis of DU145 and LNCaP cells with induction of a higher ratio of Bax/Bcl-2 proteins, disruption of mitochondrial membrane potential, and activation of caspase-9, caspase-3, and poly(ADP-ribose) polymerase.	Berberine	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	129-132
16505103-5	2006	Berberine also significantly (P &lt; 0.05-0.001) enhanced apoptosis of DU145 and LNCaP cells with induction of a higher ratio of Bax/Bcl-2 proteins, disruption of mitochondrial membrane potential, and activation of caspase-9, caspase-3, and poly(ADP-ribose) polymerase.	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	133-138
16505103-5	2006	Berberine also significantly (P &lt; 0.05-0.001) enhanced apoptosis of DU145 and LNCaP cells with induction of a higher ratio of Bax/Bcl-2 proteins, disruption of mitochondrial membrane potential, and activation of caspase-9, caspase-3, and poly(ADP-ribose) polymerase.	Berberine	0-9	caspase 9	Homo sapiens	215-224
16505103-5	2006	Berberine also significantly (P &lt; 0.05-0.001) enhanced apoptosis of DU145 and LNCaP cells with induction of a higher ratio of Bax/Bcl-2 proteins, disruption of mitochondrial membrane potential, and activation of caspase-9, caspase-3, and poly(ADP-ribose) polymerase.	Berberine	0-9	caspase 3	Homo sapiens	226-235
16505103-5	2006	Berberine also significantly (P &lt; 0.05-0.001) enhanced apoptosis of DU145 and LNCaP cells with induction of a higher ratio of Bax/Bcl-2 proteins, disruption of mitochondrial membrane potential, and activation of caspase-9, caspase-3, and poly(ADP-ribose) polymerase.	Berberine	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	241-268
16440412-6	2006	In SNU-5 cells treated with 25-200 micromol/L berberine, G2/M cell cycle arrest was observed which was associated with a marked increment of the expression of p53, Wee1 and CDk1 proteins and decreased cyclin B.	Berberine	46-55	tumor protein p53	Homo sapiens	159-162
16440412-6	2006	In SNU-5 cells treated with 25-200 micromol/L berberine, G2/M cell cycle arrest was observed which was associated with a marked increment of the expression of p53, Wee1 and CDk1 proteins and decreased cyclin B.	Berberine	46-55	WEE1 G2 checkpoint kinase	Homo sapiens	164-168
16440412-6	2006	In SNU-5 cells treated with 25-200 micromol/L berberine, G2/M cell cycle arrest was observed which was associated with a marked increment of the expression of p53, Wee1 and CDk1 proteins and decreased cyclin B.	Berberine	46-55	cyclin dependent kinase 1	Homo sapiens	173-177
16440412-10	2006	CONCLUSION: Berberine induces p53 expression and leads to the decrease of the mitochondrial membrane potential, Cytochrome C release and activation of caspase-3 for the induction of apoptosis.	Berberine	12-21	tumor protein p53	Homo sapiens	30-33
16440412-10	2006	CONCLUSION: Berberine induces p53 expression and leads to the decrease of the mitochondrial membrane potential, Cytochrome C release and activation of caspase-3 for the induction of apoptosis.	Berberine	12-21	cytochrome c, somatic	Homo sapiens	112-124
16440412-10	2006	CONCLUSION: Berberine induces p53 expression and leads to the decrease of the mitochondrial membrane potential, Cytochrome C release and activation of caspase-3 for the induction of apoptosis.	Berberine	12-21	caspase 3	Homo sapiens	151-160
16610091-10	2006	The protein expression of Caspase 3 increased significantly from 2.06% to 70.89% after treated with berberine at a concentration of 12 mug/ml for 48 hours.	Berberine	100-109	caspase 3	Homo sapiens	26-35
16475703-4	2006	Flow cytometry assay also showed that berberine induced ROS and Ca+2 production, decreased the levels of MMP and increased the activity of caspase-3 in both cell lines examined.	Berberine	38-47	caspase 3	Mus musculus	139-148
16475703-5	2006	Berberine-induced apoptosis was accompanied by increased levels of Ca+2 and a decrease in the mitochondrial membrane potential, leading to the release of cytochrome c and the cleavage of pro-caspase-3.	Berberine	0-9	caspase 3	Mus musculus	191-200
16475703-6	2006	Western blotting also showed that berberine increased the levels of Bax and cytochrome c and decreased the levels of Bcl-2 in both cell lines.	Berberine	34-43	BCL2-associated X protein	Mus musculus	68-71
16475703-6	2006	Western blotting also showed that berberine increased the levels of Bax and cytochrome c and decreased the levels of Bcl-2 in both cell lines.	Berberine	34-43	B cell leukemia/lymphoma 2	Mus musculus	117-122
16475703-7	2006	Inhibition of caspase-3 activation (z-VAD-fmk: cell-permeable broad-spectrum caspase inhibitor) completely blocked berberine-induced apoptosis in both HL-60 and WEHI-3 cells.	Berberine	115-124	caspase 3	Homo sapiens	14-23
16475703-8	2006	Therefore, berberine induced apoptosis in both examined cell lines through the activation of caspase-3.	Berberine	11-20	caspase 3	Mus musculus	93-102
16225755-9	2005	However, the expression of eNOS could be enhanced and iNOS expression could be inhibited by berberine (P&lt;0.01).	Berberine	92-101	nitric oxide synthase 3, endothelial cell	Mus musculus	27-31
16424781-0	2006	Block of HERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels.	Berberine	26-35	potassium voltage-gated channel subfamily H member 2	Homo sapiens	9-13
16424781-4	2006	In HEK-293 cells, the IC50 for berberine was 3.1 +/- 0.5 microM on hERG compared with 11 +/- 4% decreases on KCNQ1/KCNE1 channels by 100 microM berberine.	Berberine	31-40	ETS transcription factor ERG	Homo sapiens	67-71
16424781-4	2006	In HEK-293 cells, the IC50 for berberine was 3.1 +/- 0.5 microM on hERG compared with 11 +/- 4% decreases on KCNQ1/KCNE1 channels by 100 microM berberine.	Berberine	31-40	potassium voltage-gated channel subfamily E regulatory subunit 1	Homo sapiens	115-120
16424781-5	2006	Likewise in oocytes, hERG channels were more sensitive to block by berberine (IC50 = 80 +/- 5 microM) compared with KCNQ1/KCNE1 channels (approximately 20% block at 300 microM).	Berberine	67-76	ETS transcription factor ERG	Homo sapiens	21-25
16424781-7	2006	Mutation to Ala of Y652 or F656 located on the S6 domain, or V625 located at the base of the pore helix of hERG decreased sensitivity to block by berberine.	Berberine	146-155	ETS transcription factor ERG	Homo sapiens	107-111
16424781-8	2006	An inactivation-deficient mutant hERG channel (G628C/S631C) was also blocked by berberine.	Berberine	80-89	ETS transcription factor ERG	Homo sapiens	33-37
16424781-9	2006	Together these findings indicate that berberine preferentially blocks the open state of hERG channels by interacting with specific residues that were previously reported to be important for binding of more potent antagonists.	Berberine	38-47	ETS transcription factor ERG	Homo sapiens	88-92
16541194-10	2006	The BBR-induced increase in emptying time of stomach and small intestine might be another reason for the increase in CsA bioavailability.	Berberine	4-7	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	117-120
16391493-0	2006	Effect of berberine on interleukin 8 and monocyte chemotactic protein 1 expression in a human retinal pigment epithelial cell line.	Berberine	10-19	C-X-C motif chemokine ligand 8	Homo sapiens	23-36
16391493-0	2006	Effect of berberine on interleukin 8 and monocyte chemotactic protein 1 expression in a human retinal pigment epithelial cell line.	Berberine	10-19	C-C motif chemokine ligand 2	Homo sapiens	41-71
16391493-1	2006	PURPOSE: The aims of this study were to examine the effects of berberine, an alkaloid isolated from some medicinal herbs, on interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) expression in a human retinal pigment epithelial cell line (ARPE-19) stimulated with interleukin 1beta (IL-1beta) or tumor necrosis factor alpha (TNF-alpha).	Berberine	63-72	C-X-C motif chemokine ligand 8	Homo sapiens	125-138
16391493-1	2006	PURPOSE: The aims of this study were to examine the effects of berberine, an alkaloid isolated from some medicinal herbs, on interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) expression in a human retinal pigment epithelial cell line (ARPE-19) stimulated with interleukin 1beta (IL-1beta) or tumor necrosis factor alpha (TNF-alpha).	Berberine	63-72	C-X-C motif chemokine ligand 8	Homo sapiens	140-144
16391493-1	2006	PURPOSE: The aims of this study were to examine the effects of berberine, an alkaloid isolated from some medicinal herbs, on interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) expression in a human retinal pigment epithelial cell line (ARPE-19) stimulated with interleukin 1beta (IL-1beta) or tumor necrosis factor alpha (TNF-alpha).	Berberine	63-72	C-C motif chemokine ligand 2	Homo sapiens	150-180
16391493-1	2006	PURPOSE: The aims of this study were to examine the effects of berberine, an alkaloid isolated from some medicinal herbs, on interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) expression in a human retinal pigment epithelial cell line (ARPE-19) stimulated with interleukin 1beta (IL-1beta) or tumor necrosis factor alpha (TNF-alpha).	Berberine	63-72	C-C motif chemokine ligand 2	Homo sapiens	182-187
16391493-1	2006	PURPOSE: The aims of this study were to examine the effects of berberine, an alkaloid isolated from some medicinal herbs, on interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) expression in a human retinal pigment epithelial cell line (ARPE-19) stimulated with interleukin 1beta (IL-1beta) or tumor necrosis factor alpha (TNF-alpha).	Berberine	63-72	interleukin 1 beta	Homo sapiens	274-291
16391493-1	2006	PURPOSE: The aims of this study were to examine the effects of berberine, an alkaloid isolated from some medicinal herbs, on interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) expression in a human retinal pigment epithelial cell line (ARPE-19) stimulated with interleukin 1beta (IL-1beta) or tumor necrosis factor alpha (TNF-alpha).	Berberine	63-72	interleukin 1 beta	Homo sapiens	293-301
16391493-1	2006	PURPOSE: The aims of this study were to examine the effects of berberine, an alkaloid isolated from some medicinal herbs, on interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) expression in a human retinal pigment epithelial cell line (ARPE-19) stimulated with interleukin 1beta (IL-1beta) or tumor necrosis factor alpha (TNF-alpha).	Berberine	63-72	tumor necrosis factor	Homo sapiens	306-333
16391493-1	2006	PURPOSE: The aims of this study were to examine the effects of berberine, an alkaloid isolated from some medicinal herbs, on interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) expression in a human retinal pigment epithelial cell line (ARPE-19) stimulated with interleukin 1beta (IL-1beta) or tumor necrosis factor alpha (TNF-alpha).	Berberine	63-72	tumor necrosis factor	Homo sapiens	335-344
16391493-6	2006	RESULTS: Berberine dose-dependently inhibited IL-8 mRNA and MCP-1 mRNA expression of the cells and protein levels in the media stimulated with IL-1beta or TNF-alpha.	Berberine	9-18	chemokine (C-X-C motif) ligand 15	Mus musculus	46-50
16391493-6	2006	RESULTS: Berberine dose-dependently inhibited IL-8 mRNA and MCP-1 mRNA expression of the cells and protein levels in the media stimulated with IL-1beta or TNF-alpha.	Berberine	9-18	chemokine (C-C motif) ligand 2	Mus musculus	60-65
16391493-6	2006	RESULTS: Berberine dose-dependently inhibited IL-8 mRNA and MCP-1 mRNA expression of the cells and protein levels in the media stimulated with IL-1beta or TNF-alpha.	Berberine	9-18	interleukin 1 beta	Mus musculus	143-151
16391493-6	2006	RESULTS: Berberine dose-dependently inhibited IL-8 mRNA and MCP-1 mRNA expression of the cells and protein levels in the media stimulated with IL-1beta or TNF-alpha.	Berberine	9-18	tumor necrosis factor	Mus musculus	155-164
16391493-7	2006	CONCLUSION: These findings indicate that berberine dose-dependently inhibited the expression of IL-8 and MCP-1 induced by IL-1beta or TNF-alpha.	Berberine	41-50	C-X-C motif chemokine ligand 8	Homo sapiens	96-100
16391493-7	2006	CONCLUSION: These findings indicate that berberine dose-dependently inhibited the expression of IL-8 and MCP-1 induced by IL-1beta or TNF-alpha.	Berberine	41-50	C-C motif chemokine ligand 2	Homo sapiens	105-110
16391493-7	2006	CONCLUSION: These findings indicate that berberine dose-dependently inhibited the expression of IL-8 and MCP-1 induced by IL-1beta or TNF-alpha.	Berberine	41-50	interleukin 1 beta	Homo sapiens	122-130
16391493-7	2006	CONCLUSION: These findings indicate that berberine dose-dependently inhibited the expression of IL-8 and MCP-1 induced by IL-1beta or TNF-alpha.	Berberine	41-50	tumor necrosis factor	Homo sapiens	134-143
16225755-9	2005	However, the expression of eNOS could be enhanced and iNOS expression could be inhibited by berberine (P&lt;0.01).	Berberine	92-101	nitric oxide synthase 2, inducible	Mus musculus	54-58
16309210-1	2005	Previous studies have demonstrated that berberine decreases N-acetyltransferase (NAT) activity in human leukemia HL-60 cells, however, NAT gene expression has not been investigated.	Berberine	40-49	bromodomain containing 2	Homo sapiens	81-84
16309210-2	2005	In this study, berberine was selected for testing the inhibition of N-acetylation of 2-aminofluorene (AF) and NAT gene expression in human HL-60 cells.	Berberine	15-24	bromodomain containing 2	Homo sapiens	110-113
16309210-6	2005	The results indicated that berberine decreased the levels of NAT protein in HL-60 cells.	Berberine	27-36	bromodomain containing 2	Homo sapiens	61-64
16309210-7	2005	The expression of NAT gene (mRNAT NAT1) was determined by polymerase chain reaction (PCR), and it was found that berberine had inhibited the expression of mRNA NAT1 in human HL-60 cells.	Berberine	113-122	bromodomain containing 2	Homo sapiens	18-21
16309210-0	2005	Berberine decreased N-acetylation of 2-aminofluorene through inhibition of N-acetyltransferase gene expression in human leukemia HL-60 cells.	Berberine	0-9	bromodomain containing 2	Homo sapiens	75-94
16309210-1	2005	Previous studies have demonstrated that berberine decreases N-acetyltransferase (NAT) activity in human leukemia HL-60 cells, however, NAT gene expression has not been investigated.	Berberine	40-49	bromodomain containing 2	Homo sapiens	60-79
16046213-0	2005	Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IIE cells: Biphasic effect on CYP1A1.	Berberine	47-56	aryl hydrocarbon receptor	Homo sapiens	18-43
16309210-7	2005	The expression of NAT gene (mRNAT NAT1) was determined by polymerase chain reaction (PCR), and it was found that berberine had inhibited the expression of mRNA NAT1 in human HL-60 cells.	Berberine	113-122	N-acetyltransferase 1	Homo sapiens	34-38
16309210-7	2005	The expression of NAT gene (mRNAT NAT1) was determined by polymerase chain reaction (PCR), and it was found that berberine had inhibited the expression of mRNA NAT1 in human HL-60 cells.	Berberine	113-122	N-acetyltransferase 1	Homo sapiens	160-164
16100034-0	2005	Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine.	Berberine	130-139	mitogen-activated protein kinase 1	Homo sapiens	0-37
16132116-0	2005	Acetaldehyde-induced interleukin-1beta and tumor necrosis factor-alpha production is inhibited by berberine through nuclear factor-kappaB signaling pathway in HepG2 cells.	Berberine	98-107	interleukin 1 beta	Homo sapiens	21-38
16132116-0	2005	Acetaldehyde-induced interleukin-1beta and tumor necrosis factor-alpha production is inhibited by berberine through nuclear factor-kappaB signaling pathway in HepG2 cells.	Berberine	98-107	tumor necrosis factor	Homo sapiens	43-70
16132116-0	2005	Acetaldehyde-induced interleukin-1beta and tumor necrosis factor-alpha production is inhibited by berberine through nuclear factor-kappaB signaling pathway in HepG2 cells.	Berberine	98-107	nuclear factor kappa B subunit 1	Homo sapiens	116-137
16132116-9	2005	Berberine, the major ingredient of these herbs, abolished acetaldehyde-induced NF-kappaB activity and cytokine production in a dose-dependent manner.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	79-88
16335816-4	2005	Flavonoid compounds and their derivates from traditional medicinal herbs are active inhibitors to aldose reductase, such as quercetin, silymarin, puerarin, baicalim, berberine and so on.	Berberine	166-175	aldo-keto reductase family 1 member B	Homo sapiens	98-114
16046213-3	2005	Here we provide evidence that berberine activates the aryl hydrocarbon receptor (AhR) in human hepatoma (HepG2) and rat hepatoma cells stably transfected with a dioxin responsive element fused to the luciferase gene (H4IIE.luc).	Berberine	30-39	aryl hydrocarbon receptor	Homo sapiens	54-79
16046213-3	2005	Here we provide evidence that berberine activates the aryl hydrocarbon receptor (AhR) in human hepatoma (HepG2) and rat hepatoma cells stably transfected with a dioxin responsive element fused to the luciferase gene (H4IIE.luc).	Berberine	30-39	aryl hydrocarbon receptor	Homo sapiens	81-84
16046213-4	2005	AhR was activated by high doses of berberine (10-50 microM) after 6 and 24 h of incubation as revealed by CYP1A1 mRNA expression (HepG2) and AhR-dependent luciferase activity (H4IIE.luc).	Berberine	35-44	aryl hydrocarbon receptor	Homo sapiens	0-3
16046213-4	2005	AhR was activated by high doses of berberine (10-50 microM) after 6 and 24 h of incubation as revealed by CYP1A1 mRNA expression (HepG2) and AhR-dependent luciferase activity (H4IIE.luc).	Berberine	35-44	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	106-112
16046213-4	2005	AhR was activated by high doses of berberine (10-50 microM) after 6 and 24 h of incubation as revealed by CYP1A1 mRNA expression (HepG2) and AhR-dependent luciferase activity (H4IIE.luc).	Berberine	35-44	aryl hydrocarbon receptor	Homo sapiens	141-144
16046213-5	2005	Berberine induced nuclear translocation of AhR-GFP chimera transiently transfected to Hepa1c1c7 cells.	Berberine	0-9	aryl-hydrocarbon receptor	Mus musculus	43-46
16046213-7	2005	HPLC analysis ruled out the hypothesis that the loss of berberine capacity to activate AhR in H4IIE.luc cells is due to metabolic inactivation of the alkaloid.	Berberine	56-65	aryl hydrocarbon receptor	Rattus norvegicus	87-90
16046213-8	2005	We demonstrate that berberine is a potent inhibitor (IC50=2.5 microM) of CYP1A1 catalytic activity (EROD) in HepG2 cell culture and in recombinant CYP1A1 protein.	Berberine	20-29	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	73-79
16046213-8	2005	We demonstrate that berberine is a potent inhibitor (IC50=2.5 microM) of CYP1A1 catalytic activity (EROD) in HepG2 cell culture and in recombinant CYP1A1 protein.	Berberine	20-29	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	147-153
16046213-9	2005	Collectively, our results imply that while berberine activates the Ah receptor, it is accompanied by inactivation of the catalytic activity of CYP1A1 and occurs at concentrations that exceed those predicted to occur in vivo.	Berberine	43-52	aryl hydrocarbon receptor	Homo sapiens	67-78
16046213-9	2005	Collectively, our results imply that while berberine activates the Ah receptor, it is accompanied by inactivation of the catalytic activity of CYP1A1 and occurs at concentrations that exceed those predicted to occur in vivo.	Berberine	43-52	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	143-149
16046213-10	2005	Given these data, it appears that activation of the AhR pathway by berberine has a low toxicological potential.	Berberine	67-76	aryl hydrocarbon receptor	Homo sapiens	52-55
16133554-1	2005	OBJECTIVE: To study the effects of berberine (BBR) on the blood concentration and pharmacokinetics of cyclosporin A (CsA) in renal-transplant recipients.	Berberine	35-44	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	117-120
16133554-1	2005	OBJECTIVE: To study the effects of berberine (BBR) on the blood concentration and pharmacokinetics of cyclosporin A (CsA) in renal-transplant recipients.	Berberine	46-49	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	117-120
16133554-9	2005	After co-administration of BBR in six patients for 12 days, the mean AUC of CsA was increased by 34.5% (P &lt; 0.05).	Berberine	27-30	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	76-79
16079488-0	2005	Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma.	Berberine	49-58	insulin	Homo sapiens	0-7
16079488-6	2005	Significant insulin sensitizing activity was observed in 3T3-L1 adipocytes which were given 50 microM berberine plus 0.2 nM insulin to reach a glucose uptake level increased by 10 nM of insulin alone.	Berberine	102-111	insulin	Homo sapiens	12-19
16079488-8	2005	Berberine also increased glucose-stimulated insulin secretion and proliferation in Min6 cells via an enhanced insulin/insulin-like growth factor-1 signaling cascade.	Berberine	0-9	insulin	Homo sapiens	44-51
16079488-8	2005	Berberine also increased glucose-stimulated insulin secretion and proliferation in Min6 cells via an enhanced insulin/insulin-like growth factor-1 signaling cascade.	Berberine	0-9	insulin	Homo sapiens	110-117
16079488-8	2005	Berberine also increased glucose-stimulated insulin secretion and proliferation in Min6 cells via an enhanced insulin/insulin-like growth factor-1 signaling cascade.	Berberine	0-9	insulin	Homo sapiens	110-117
16079488-9	2005	Data suggested that berberine can act as an effective insulin sensitizing and insulinotropic agent.	Berberine	20-29	insulin	Homo sapiens	54-61
15807993-5	2005	Moreover, treatment with berberine, coptisine, palmatine and epiberberine exerted a protective effect against G(0)/G(1)phase arrest of cell cycle induced by SIN-1.	Berberine	25-34	MAPK associated protein 1	Homo sapiens	157-162
15926873-2	2005	Berberine upregulates the LDL receptor (LDLR) by a mechanism distinct from that of the statins, which involves stabilising the LDLR mRNA.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	26-38
15926873-2	2005	Berberine upregulates the LDL receptor (LDLR) by a mechanism distinct from that of the statins, which involves stabilising the LDLR mRNA.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	40-44
15926873-2	2005	Berberine upregulates the LDL receptor (LDLR) by a mechanism distinct from that of the statins, which involves stabilising the LDLR mRNA.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	127-131
15926873-7	2005	As berberine and statins both upregulate LDLR, their lipid-lowering profiles are similar.	Berberine	3-12	low density lipoprotein receptor	Homo sapiens	41-45
15957369-3	2005	Berberine has been shown to induce apoptosis and affect NAT activity in human leukemia cells.	Berberine	0-9	bromodomain containing 2	Homo sapiens	56-59
15957369-8	2005	Berberine displayed a dose-dependent inhibition to cytosolic NAT activity and intact mice leukemia cells.	Berberine	0-9	solute carrier family 38, member 3	Mus musculus	61-64
15957369-9	2005	Time-course experiments indicated that N-acetylation of AF measured from intact mice leukemia cells were inhibited by berberine for up to 24 h. The NAT1 mRNA and NAT proteins in mouse leukemia cells were also inhibited by berberine.	Berberine	118-127	N-acetyl transferase 1	Mus musculus	148-152
15957369-9	2005	Time-course experiments indicated that N-acetylation of AF measured from intact mice leukemia cells were inhibited by berberine for up to 24 h. The NAT1 mRNA and NAT proteins in mouse leukemia cells were also inhibited by berberine.	Berberine	118-127	solute carrier family 38, member 3	Mus musculus	148-151
15957369-9	2005	Time-course experiments indicated that N-acetylation of AF measured from intact mice leukemia cells were inhibited by berberine for up to 24 h. The NAT1 mRNA and NAT proteins in mouse leukemia cells were also inhibited by berberine.	Berberine	222-231	N-acetyl transferase 1	Mus musculus	148-152
15957369-9	2005	Time-course experiments indicated that N-acetylation of AF measured from intact mice leukemia cells were inhibited by berberine for up to 24 h. The NAT1 mRNA and NAT proteins in mouse leukemia cells were also inhibited by berberine.	Berberine	222-231	solute carrier family 38, member 3	Mus musculus	148-151
15957369-10	2005	This report is the first demonstration, which showed berberine affect mice leukemia cells NAT activity, gene expression (NAT1 mRNA) and levels of NAT protein.	Berberine	53-62	solute carrier family 38, member 3	Mus musculus	90-93
15957369-10	2005	This report is the first demonstration, which showed berberine affect mice leukemia cells NAT activity, gene expression (NAT1 mRNA) and levels of NAT protein.	Berberine	53-62	N-acetyl transferase 1	Mus musculus	121-125
15957369-10	2005	This report is the first demonstration, which showed berberine affect mice leukemia cells NAT activity, gene expression (NAT1 mRNA) and levels of NAT protein.	Berberine	53-62	solute carrier family 38, member 3	Mus musculus	121-124
16274628-5	2005	The results showed that 100 micromol/L and 50 micromol/L of berberine significantly inhibited CD69 expression on T cells stimulated with PDB plus ionomycin or PHA, whereas the effect of 25 micromol/L berberine was not significant.	Berberine	60-69	CD69 molecule	Homo sapiens	94-98
16274628-7	2005	Similarly, the expression of CD25 was also reduced by berberine in a dose-dependent manner over the concentration range of 25-100 micromol/L.	Berberine	54-63	interleukin 2 receptor subunit alpha	Homo sapiens	29-33
15724409-4	2005	CONCLUSION: In vitro, berberine increases the expression of adiponectin in 3T3-L1 adipocyte, insulin inhibits the effect of berberine.	Berberine	124-133	insulin	Homo sapiens	93-100
16335248-1	2005	It has been shown, that some benzo[c]-phenanthridine and diisoquinoline alkaloids isolated from Chelidonium majus L. and Macleaya (Bocconia) cordata and M. microcarpa (berberine, sanguinarine, chelidonine) and of drugs ("Ukrain" and "Sanguirythrine") inhibited the enzyme activity of acetylcholinesterase from human erythrocyte and monoamine oxidase from the rat liver.	Berberine	168-177	acetylcholinesterase (Cartwright blood group)	Homo sapiens	284-304
15828348-8	2004	Under the conditions chosen, the BB concentration in the range of 0.8 x 10(-6) mol x L(-1)-20 x 10(-6) mol x L(-1) is linear to the A(450 nm) value.	Berberine	33-35	immunoglobulin kappa variable 1-16	Homo sapiens	85-93
15724409-0	2005	[Effects of berberine on adiponectin mRNA expression in 3T3-L1 adipocyte].	Berberine	12-21	adiponectin, C1Q and collagen domain containing	Homo sapiens	25-36
15724409-1	2005	OBJECTIVE: To explore the effects of berberine and insulin on adiponectin mRNA expression in 3T3-L1 adipocyte.	Berberine	37-46	adiponectin, C1Q and collagen domain containing	Homo sapiens	62-73
15724409-3	2005	RESULT: The level of adiponetin mRNA in 3T3-L1 adipocyte was increased after treated with berberine only (P &lt; 0.05), the effect of berberine was inhibited by high concentration insulin (P &lt; 0.05).	Berberine	90-99	insulin	Homo sapiens	180-187
15724409-3	2005	RESULT: The level of adiponetin mRNA in 3T3-L1 adipocyte was increased after treated with berberine only (P &lt; 0.05), the effect of berberine was inhibited by high concentration insulin (P &lt; 0.05).	Berberine	134-143	insulin	Homo sapiens	180-187
15724409-4	2005	CONCLUSION: In vitro, berberine increases the expression of adiponectin in 3T3-L1 adipocyte, insulin inhibits the effect of berberine.	Berberine	22-31	adiponectin, C1Q and collagen domain containing	Homo sapiens	60-71
15796182-0	2005	Modulation of apoptosis by berberine through inhibition of cyclooxygenase-2 and Mcl-1 expression in oral cancer cells.	Berberine	27-36	prostaglandin-endoperoxide synthase 2	Homo sapiens	59-75
15796182-0	2005	Modulation of apoptosis by berberine through inhibition of cyclooxygenase-2 and Mcl-1 expression in oral cancer cells.	Berberine	27-36	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	80-85
15796182-1	2005	BACKGROUND: We have previously shown that berberine exerts its anti-inflammatory effects through inhibition of cyclooxygenase-2 (COX-2) expression.	Berberine	42-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	111-127
15796182-1	2005	BACKGROUND: We have previously shown that berberine exerts its anti-inflammatory effects through inhibition of cyclooxygenase-2 (COX-2) expression.	Berberine	42-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	129-134
15796182-2	2005	In this study, we explored the biochemical influence of berberine-induced COX-2 reduction and apoptosis.	Berberine	56-65	prostaglandin-endoperoxide synthase 2	Homo sapiens	74-79
15796182-5	2005	The expression of COX-2, Bcl-2, Mcl-1, Akt and phosphorylated Akt in berberine-treated KB cells, with or without PGE2, were assessed by Western blots.	Berberine	69-78	AKT serine/threonine kinase 1	Homo sapiens	62-65
15796182-7	2005	Berberine treatment inhibited COX-2 and Mcl-1 expression dose-dependently, but not Bcl-2.	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	30-35
15796182-7	2005	Berberine treatment inhibited COX-2 and Mcl-1 expression dose-dependently, but not Bcl-2.	Berberine	0-9	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	40-45
15796182-8	2005	PGE2 induced COX-2 and Mcl-1 expression and reversed the repressive effect of berberine on Mcl-1.	Berberine	78-87	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	91-96
15796182-9	2005	In addition, PGE2 had no effect on total Akt, but slightly reversed the phosphorylated Akt, which was decreased by berberine.	Berberine	115-124	AKT serine/threonine kinase 1	Homo sapiens	87-90
15796182-10	2005	CONCLUSION: These results suggest that berberine-induced apoptosis might be COX-2-dependent and is related to decreased Akt phosphorylation and Mcl-1 expression.	Berberine	39-48	prostaglandin-endoperoxide synthase 2	Homo sapiens	76-81
15796182-10	2005	CONCLUSION: These results suggest that berberine-induced apoptosis might be COX-2-dependent and is related to decreased Akt phosphorylation and Mcl-1 expression.	Berberine	39-48	AKT serine/threonine kinase 1	Homo sapiens	120-123
15796182-10	2005	CONCLUSION: These results suggest that berberine-induced apoptosis might be COX-2-dependent and is related to decreased Akt phosphorylation and Mcl-1 expression.	Berberine	39-48	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	144-149
15322253-0	2004	Berberine inhibits HIF-1alpha expression via enhanced proteolysis.	Berberine	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	19-29
15531889-4	2004	Using human hepatoma cells, we show that BBR upregulates LDLR expression independent of sterol regulatory element binding proteins, but dependent on ERK activation.	Berberine	41-44	low density lipoprotein receptor	Homo sapiens	57-61
15638014-0	2004	[Effect of berberine on the mRNA expression of phosphodiesterase type 5 (PDE5) in rat corpus cavernosum].	Berberine	11-20	phosphodiesterase 5A	Rattus norvegicus	47-71
15638014-0	2004	[Effect of berberine on the mRNA expression of phosphodiesterase type 5 (PDE5) in rat corpus cavernosum].	Berberine	11-20	phosphodiesterase 5A	Rattus norvegicus	73-77
15322253-5	2004	Parallel Western blot analyses revealed that berberine prevented hypoxic SC-M1 cultures from expressing vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1alpha, two key factors in mediating tumor angiogenesis.	Berberine	45-54	X-C motif chemokine ligand 1	Homo sapiens	73-78
15322253-5	2004	Parallel Western blot analyses revealed that berberine prevented hypoxic SC-M1 cultures from expressing vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1alpha, two key factors in mediating tumor angiogenesis.	Berberine	45-54	vascular endothelial growth factor A	Homo sapiens	104-138
15322253-5	2004	Parallel Western blot analyses revealed that berberine prevented hypoxic SC-M1 cultures from expressing vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1alpha, two key factors in mediating tumor angiogenesis.	Berberine	45-54	vascular endothelial growth factor A	Homo sapiens	140-144
15322253-5	2004	Parallel Western blot analyses revealed that berberine prevented hypoxic SC-M1 cultures from expressing vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1alpha, two key factors in mediating tumor angiogenesis.	Berberine	45-54	hypoxia inducible factor 1 subunit alpha	Homo sapiens	150-187
15322253-6	2004	However, overexpression of HIF-1alpha in SC-M1 cells dramatically reversed the inhibitory effect of berberine on SC-M1-induced in vitro HUVEC migration.	Berberine	100-109	hypoxia inducible factor 1 subunit alpha	Homo sapiens	27-37
15322253-6	2004	However, overexpression of HIF-1alpha in SC-M1 cells dramatically reversed the inhibitory effect of berberine on SC-M1-induced in vitro HUVEC migration.	Berberine	100-109	X-C motif chemokine ligand 1	Homo sapiens	41-46
15322253-6	2004	However, overexpression of HIF-1alpha in SC-M1 cells dramatically reversed the inhibitory effect of berberine on SC-M1-induced in vitro HUVEC migration.	Berberine	100-109	X-C motif chemokine ligand 1	Homo sapiens	113-118
15322253-7	2004	These data indicated that HIF-1alpha repression is a critical step in the inhibitory effect of berberine on tumor-induced angiogenesis.	Berberine	95-104	hypoxia inducible factor 1 subunit alpha	Homo sapiens	26-36
15322253-8	2004	Northern blot analyses plus pulse-chase assays revealed that berberine did not down-regulate HIF-1alpha mRNA but destabilized HIF-1alpha protein.	Berberine	61-70	hypoxia inducible factor 1 subunit alpha	Homo sapiens	126-136
14746925-0	2004	Effects of berberine on potassium currents in acutely isolated CA1 pyramidal neurons of rat hippocampus.	Berberine	11-20	carbonic anhydrase 1	Rattus norvegicus	63-66
15039293-5	2004	Moreover, berberine was processed through hepatobiliary excretion against a concentration gradient based on the bile-to-blood distribution ratio (AUC(bile)/AUC(blood)); the active berberine efflux might be affected by P-gp and OCT since coadministration of berberine and CsA or quinidine at the same dosage of 10 mg kg(-1) significantly decreased the berberine amount in bile.	Berberine	10-19	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	218-222
15039293-5	2004	Moreover, berberine was processed through hepatobiliary excretion against a concentration gradient based on the bile-to-blood distribution ratio (AUC(bile)/AUC(blood)); the active berberine efflux might be affected by P-gp and OCT since coadministration of berberine and CsA or quinidine at the same dosage of 10 mg kg(-1) significantly decreased the berberine amount in bile.	Berberine	180-189	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	218-222
15039293-5	2004	Moreover, berberine was processed through hepatobiliary excretion against a concentration gradient based on the bile-to-blood distribution ratio (AUC(bile)/AUC(blood)); the active berberine efflux might be affected by P-gp and OCT since coadministration of berberine and CsA or quinidine at the same dosage of 10 mg kg(-1) significantly decreased the berberine amount in bile.	Berberine	180-189	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	218-222
15039293-5	2004	Moreover, berberine was processed through hepatobiliary excretion against a concentration gradient based on the bile-to-blood distribution ratio (AUC(bile)/AUC(blood)); the active berberine efflux might be affected by P-gp and OCT since coadministration of berberine and CsA or quinidine at the same dosage of 10 mg kg(-1) significantly decreased the berberine amount in bile.	Berberine	180-189	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	218-222
15066220-0	2004	Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion.	Berberine	23-32	insulin	Mesocricetus auratus	89-96
15066220-1	2004	AIM: To explore the anti-diabetic effects of berberine and its influence on insulin secretion.	Berberine	45-54	insulin	Mesocricetus auratus	76-83
15066220-8	2004	In vitro experiment showed that berberine 1-10 micromol/L facilitated insulin secretion of HIT-T15 cells and murine pancreatic islets in a dose-dependent manner.	Berberine	32-41	insulin	Mesocricetus auratus	70-77
15066220-10	2004	CONCLUSION: Berberine possesses anti-diabetic effects, which is related to the property of stimulating insulin secretion and modulating lipids.	Berberine	12-21	insulin	Mesocricetus auratus	103-110
14746925-1	2004	The effects of berberine, an isoquinoline alkaloid with antiarrhythmic action, on voltage-dependent potassium currents were studied in acutely isolated CA1 pyramidal neurons of rat hippocampus by using the whole-cell patch-clamp techniques.	Berberine	15-24	carbonic anhydrase 1	Rattus norvegicus	152-155
15768991-1	2004	The interaction of berberine and Human Serum Albumin (HSA) has been studied by fluorescence and UV-Vis absorption spectroscopy.	Berberine	19-28	albumin	Homo sapiens	39-52
14732220-4	2004	This berberine induced effect occurred rapidly (3 h) as a result of reduced COX-2 protein, but not enzyme activity.	Berberine	5-14	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	76-81
14732220-5	2004	The electrophoretic mobility shift assay revealed that activator protein 1 (AP-1) binding was decreased in oral cancer cells treated with berberine for 2 h. Further analysis showed that berberine inhibited AP-1 binding directly.	Berberine	138-147	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	55-74
14732220-5	2004	The electrophoretic mobility shift assay revealed that activator protein 1 (AP-1) binding was decreased in oral cancer cells treated with berberine for 2 h. Further analysis showed that berberine inhibited AP-1 binding directly.	Berberine	138-147	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	76-80
14732220-5	2004	The electrophoretic mobility shift assay revealed that activator protein 1 (AP-1) binding was decreased in oral cancer cells treated with berberine for 2 h. Further analysis showed that berberine inhibited AP-1 binding directly.	Berberine	138-147	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	206-210
14737589-2	2004	As immunogen, the derivative of berberine, 9-O-carboxymethyl berberrubine was synthesized and conjugated to carrier protein, bovine serum albumin (BSA).	Berberine	32-41	albumin	Mus musculus	132-145
15768991-0	2004	[The interaction of berberine and human serum albumin].	Berberine	20-29	albumin	Homo sapiens	40-54
14732220-5	2004	The electrophoretic mobility shift assay revealed that activator protein 1 (AP-1) binding was decreased in oral cancer cells treated with berberine for 2 h. Further analysis showed that berberine inhibited AP-1 binding directly.	Berberine	186-195	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	55-74
14732220-5	2004	The electrophoretic mobility shift assay revealed that activator protein 1 (AP-1) binding was decreased in oral cancer cells treated with berberine for 2 h. Further analysis showed that berberine inhibited AP-1 binding directly.	Berberine	186-195	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	76-80
14732220-5	2004	The electrophoretic mobility shift assay revealed that activator protein 1 (AP-1) binding was decreased in oral cancer cells treated with berberine for 2 h. Further analysis showed that berberine inhibited AP-1 binding directly.	Berberine	186-195	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	206-210
12610223-1	2003	The vanadate-induced nucleotide trapping technique, which has been conventionally used to characterize mammalian ATP-binding cassette (ABC) proteins, was applied to berberine-producing plant cell cultures, Thalictrum minus and Coptis japonica.	Berberine	165-174	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	113-133
14505547-0	2003	[The inhibit effect of berberine on human colon cell line cyclooxygenase-2].	Berberine	23-32	prostaglandin-endoperoxide synthase 2	Homo sapiens	58-74
14505547-7	2003	When the berberine concentration was higher than 0.3 micro mol/L, berberine could inhibit the COX-2 in mRNA and protein level.	Berberine	9-18	prostaglandin-endoperoxide synthase 2	Homo sapiens	94-99
14505547-7	2003	When the berberine concentration was higher than 0.3 micro mol/L, berberine could inhibit the COX-2 in mRNA and protein level.	Berberine	66-75	prostaglandin-endoperoxide synthase 2	Homo sapiens	94-99
14505547-9	2003	CONCLUSIONS: Berberine can inhibit COX-2 in mRNA and protein level.	Berberine	13-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	35-40
12807487-0	2003	Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, deviates CD4+ T cells from a Th2 to a Th1 response.	Berberine	63-72	heart and neural crest derivatives expressed 2	Mus musculus	139-142
12807487-0	2003	Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, deviates CD4+ T cells from a Th2 to a Th1 response.	Berberine	63-72	negative elongation factor complex member C/D, Th1l	Mus musculus	148-151
12807487-2	2003	Pretreatment with berberine induced IL-12 production in both macrophages and dendritic cells, and significantly increased the levels of IL-12 production in lipopolysaccharide-stimulated macrophages and in CD40 ligand-stimulated dendritic cells.	Berberine	18-27	CD40 antigen	Mus musculus	205-209
12807487-3	2003	Importantly, berberine pretreatment of macrophages increased their ability to induce interferon-gamma (IFN-gamma) and reduced their ability to induce IL-4 in antigen-primed CD4+ T cells.	Berberine	13-22	interferon gamma	Mus musculus	85-101
12807487-3	2003	Importantly, berberine pretreatment of macrophages increased their ability to induce interferon-gamma (IFN-gamma) and reduced their ability to induce IL-4 in antigen-primed CD4+ T cells.	Berberine	13-22	interferon gamma	Mus musculus	103-112
12807487-3	2003	Importantly, berberine pretreatment of macrophages increased their ability to induce interferon-gamma (IFN-gamma) and reduced their ability to induce IL-4 in antigen-primed CD4+ T cells.	Berberine	13-22	interleukin 4	Mus musculus	150-154
12807487-5	2003	Addition of neutralizing anti-IL-12p40 monoclonal antibody to cultures of berberine-pretreated macrophages and CD4+ T cells restored IL-4 production in antigen-primed CD4+ T cells.	Berberine	74-83	interleukin 12b	Mus musculus	30-38
12807487-5	2003	Addition of neutralizing anti-IL-12p40 monoclonal antibody to cultures of berberine-pretreated macrophages and CD4+ T cells restored IL-4 production in antigen-primed CD4+ T cells.	Berberine	74-83	interleukin 4	Mus musculus	133-137
12807487-6	2003	The in vivo administration of berberine resulted in the enhanced induction of IL-12 production by macrophages when stimulated in vitro with lipopolysaccharide or heat-killed Listeria monocytogenes, leading to the inhibition of the Th type 2 cytokine profile (decreased IL-4 and increased IFN-gamma production) in antigen-primed CD4+ T cells.	Berberine	30-39	interleukin 4	Mus musculus	269-273
12807487-6	2003	The in vivo administration of berberine resulted in the enhanced induction of IL-12 production by macrophages when stimulated in vitro with lipopolysaccharide or heat-killed Listeria monocytogenes, leading to the inhibition of the Th type 2 cytokine profile (decreased IL-4 and increased IFN-gamma production) in antigen-primed CD4+ T cells.	Berberine	30-39	interferon gamma	Mus musculus	288-297
12610223-1	2003	The vanadate-induced nucleotide trapping technique, which has been conventionally used to characterize mammalian ATP-binding cassette (ABC) proteins, was applied to berberine-producing plant cell cultures, Thalictrum minus and Coptis japonica.	Berberine	165-174	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	135-138
12610223-3	2003	180 kDa was photoaffinity-labeled with 8-azido-[alpha-(32)P]ATP in the T. minus cells in the presence of vanadate, which was specifically induced by the addition of benzyladenine in a similar manner as the induction of berberine biosynthesis in these cell cultures, whereas three bands were observed in the C. japonica cells in the size region between 120 and 150 kDa corresponding to full-sized ABC protein.	Berberine	219-228	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	396-399
12610223-4	2003	The benzyladenine-induced band in T. minus showed properties similar to those of human MDR1, including the recognition of berberine, which suggests that the ABC protein detected in T. minus takes this endogenous alkaloid as a putative substrate for transport.	Berberine	122-131	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
12610223-4	2003	The benzyladenine-induced band in T. minus showed properties similar to those of human MDR1, including the recognition of berberine, which suggests that the ABC protein detected in T. minus takes this endogenous alkaloid as a putative substrate for transport.	Berberine	122-131	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	157-160
12428952-7	2002	Nonetheless, berberines and palmatines may be useful as lead compounds and new agents for aldose reductase inhibition.	Berberine	13-23	aldo-keto reductase family 1 member B1	Rattus norvegicus	90-106
12434406-0	2002	P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers.	Berberine	37-46	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
12434406-8	2002	These results suggest that the repeated administration of berberine may up-regulate P-gp functions in Caco-2 cells.	Berberine	58-67	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
12434406-9	2002	If this occurs in the gastrointestinal epithelial cells, the repeated administration of berberine may reduce the gastrointestinal absorption of P-gp substrates including chemotherapeutic agents such as daunomycin.	Berberine	88-97	ATP binding cassette subfamily B member 1	Homo sapiens	144-148
14567065-3	2002	The angiotensin-converting enzyme (ACE) activities were inhibited significantly by the addition of berberine in a dose-dependent manner of which the IC50 value of berberine for ACE was 42 micrograms/ml (125 microM).	Berberine	99-108	angiotensin I converting enzyme	Rattus norvegicus	35-38
14567065-3	2002	The angiotensin-converting enzyme (ACE) activities were inhibited significantly by the addition of berberine in a dose-dependent manner of which the IC50 value of berberine for ACE was 42 micrograms/ml (125 microM).	Berberine	99-108	angiotensin I converting enzyme	Rattus norvegicus	177-180
14567065-3	2002	The angiotensin-converting enzyme (ACE) activities were inhibited significantly by the addition of berberine in a dose-dependent manner of which the IC50 value of berberine for ACE was 42 micrograms/ml (125 microM).	Berberine	163-172	angiotensin I converting enzyme	Rattus norvegicus	35-38
14567065-3	2002	The angiotensin-converting enzyme (ACE) activities were inhibited significantly by the addition of berberine in a dose-dependent manner of which the IC50 value of berberine for ACE was 42 micrograms/ml (125 microM).	Berberine	163-172	angiotensin I converting enzyme	Rattus norvegicus	177-180
14567065-7	2002	These results suggest that berberine has a hypotensive effect, at least in part, via the inhibition of ACE and direct release of NO/cGMP in the vascular tissues.	Berberine	27-36	angiotensin I converting enzyme	Rattus norvegicus	103-106
12404195-11	2002	These observations suggest that berberine is able to exert a glucose-lowering effect in hepatocytes, which is insulin independent and similar to that of metformin, but has no effect on insulin secretion.	Berberine	32-41	insulin	Homo sapiens	110-117
12415430-6	2002	The in vivo study showed that the intraperitoneal pretreatment with berberine (0.5 and 5 mg/kg) for 5 days before a single dose of t-BHP (0.1 mmol/kg) significantly lowered the serum levels of hepatic enzyme markers (ALT and aspartate aminotransferase) and reduced oxidative stress in the liver.	Berberine	68-77	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	225-251
12396098-3	2002	In this study, we reported the effects of berberine on arylamine N-acetyltransferase (NAT) activity, gene expression, and DNA adduct formation in human brain tumor cell lines (G95/VGH and GBM 8401).	Berberine	42-51	bromodomain containing 2	Homo sapiens	86-89
12530470-2	2002	The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption.	Berberine	237-246	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	53-67
12530470-2	2002	The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption.	Berberine	237-246	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	53-67
12530470-3	2002	In the rat recirculating perfusion model, berberine absorption was improved 6-times by P-glycoprotein inhibitors.	Berberine	42-51	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	87-101
12530470-6	2002	In Caco-2 cells, berberine uptake was significantly increased by P-glycoprotein inhibitors and by monoclonal antibody C219.	Berberine	17-26	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
12530470-7	2002	P-glycoprotein appears to contribute to the poor intestinal absorption of berberine which suggests P-glycoprotein inhibitors could be of therapeutic value by improving its bioavailability.	Berberine	74-83	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-14
12530470-7	2002	P-glycoprotein appears to contribute to the poor intestinal absorption of berberine which suggests P-glycoprotein inhibitors could be of therapeutic value by improving its bioavailability.	Berberine	74-83	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	99-113
12396098-8	2002	The results demonstrated that NAT activity, levels of mRNA NAT1 and AF-DNA adduct formation in both examined cell were inhibited and decreased by berberine in a dose-dependent manner.	Berberine	146-155	bromodomain containing 2	Homo sapiens	30-33
12396098-8	2002	The results demonstrated that NAT activity, levels of mRNA NAT1 and AF-DNA adduct formation in both examined cell were inhibited and decreased by berberine in a dose-dependent manner.	Berberine	146-155	N-acetyltransferase 1	Homo sapiens	59-63
12530470-0	2002	The involvement of P-glycoprotein in berberine absorption.	Berberine	37-46	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	19-33
12530470-2	2002	The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption.	Berberine	237-246	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-51
11979446-9	2002	An in vitro study showed that C. rhizoma and its major component, berberine, inhibited IL-1-induced IL-6 mRNA expression in a dose-dependent manner in colon 26/clone 20 cells.	Berberine	66-75	interleukin 6	Mus musculus	100-104
11741516-0	2001	Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes.	Berberine	22-31	IKAROS family zinc finger 1 S homeolog	Xenopus laevis	35-38
12034375-0	2002	Involvement of p38 mitogen-activated protein kinase in the induction of interleukin-12 p40 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid.	Berberine	126-135	mitogen-activated protein kinase 14	Mus musculus	15-18
12034375-0	2002	Involvement of p38 mitogen-activated protein kinase in the induction of interleukin-12 p40 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid.	Berberine	126-135	interleukin 12b	Mus musculus	87-90
12034375-2	2002	In this study, we investigated the effects of berberine, a benzodioxoloquinolizine alkaloid with anti-microbial and anti-tumor activities, on the production of IL-12 p40, an inducible subunit of IL-12, in mouse macrophages.	Berberine	46-55	interleukin 12b	Mus musculus	160-169
12034375-3	2002	Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine.	Berberine	0-9	interleukin 12b	Mus musculus	24-27
12034375-3	2002	Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine.	Berberine	0-9	mitogen-activated protein kinase 14	Mus musculus	57-60
12034375-3	2002	Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine.	Berberine	0-9	mitogen-activated protein kinase 14	Mus musculus	166-169
12034375-3	2002	Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine.	Berberine	0-9	mitogen-activated protein kinase 14	Mus musculus	166-174
12034375-3	2002	Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine.	Berberine	0-9	interleukin 12b	Mus musculus	299-302
12034375-3	2002	Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine.	Berberine	338-347	mitogen-activated protein kinase 14	Mus musculus	57-60
12034375-3	2002	Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine.	Berberine	338-347	mitogen-activated protein kinase 14	Mus musculus	166-169
12034375-3	2002	Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine.	Berberine	338-347	mitogen-activated protein kinase 14	Mus musculus	166-174
12034375-4	2002	Furthermore, berberine significantly enhanced IL-12 p40 production in mouse macrophages when combined with lipopolysaccharide, a well-known inducer of IL-12 production.	Berberine	13-22	interleukin 12b	Mus musculus	52-55
11370717-3	2001	When berberine (10, 25 or 50 mg kg(-1)) was administered simultaneously with NDEA, the markers of liver injury (liver weight, gamma-glutamyl transpeptidase activity and glutathione S-transferase level) were reduced significantly compared with animals treated with NDEA only, which resulted in all the values being elevated.	Berberine	5-14	hematopoietic prostaglandin D synthase	Mus musculus	169-194
11248416-4	2001	Anti-activator protein-1 (anti-AP-1) transcriptional activity of non-cytotoxic concentrations of berberine caused the inhibition of the invasiveness of LLC cells through the repression of expression of urokinase-type plasminogen activator (u-PA).	Berberine	97-106	plasminogen activator, urokinase	Mus musculus	202-238
11248416-4	2001	Anti-activator protein-1 (anti-AP-1) transcriptional activity of non-cytotoxic concentrations of berberine caused the inhibition of the invasiveness of LLC cells through the repression of expression of urokinase-type plasminogen activator (u-PA).	Berberine	97-106	plasminogen activator, urokinase	Mus musculus	240-244
11741516-4	2001	Berberine 100 micromol/L increased APD90 from (450 +\- 48) ms to (888 +\- 90) ms (n = 6, P &lt; 0.01), and inhibited IK1 by 65 % +\- 7 % (n = 6, P &lt; 0.01).	Berberine	0-9	IKAROS family zinc finger 1 S homeolog	Xenopus laevis	117-120
11741516-7	2001	Berberine blocked the HERG channels potently with an IC50 value of approximately 75 micromol/L.	Berberine	0-9	potassium voltage-gated channel subfamily H member 2	Homo sapiens	22-26
11741516-9	2001	CONCLUSION: Berberine prolonged APD and possessed blocking effect on IK1, IK, and HERG channel expressed in Xenopus oocytes.	Berberine	12-21	IKAROS family zinc finger 1 S homeolog	Xenopus laevis	69-72
11741516-9	2001	CONCLUSION: Berberine prolonged APD and possessed blocking effect on IK1, IK, and HERG channel expressed in Xenopus oocytes.	Berberine	12-21	potassium voltage-gated channel subfamily H member 2	Homo sapiens	82-86
11741516-10	2001	The antiarrhythmic mechanism of berberine is related to its inhibitory effects on IK1, IK, and HERG channel.	Berberine	32-41	IKAROS family zinc finger 1 S homeolog	Xenopus laevis	82-85
11741516-10	2001	The antiarrhythmic mechanism of berberine is related to its inhibitory effects on IK1, IK, and HERG channel.	Berberine	32-41	potassium voltage-gated channel subfamily H member 2	Homo sapiens	95-99
11741516-0	2001	Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes.	Berberine	22-31	potassium voltage-gated channel subfamily H member 2	Homo sapiens	48-52
11741516-3	2001	RESULTS: Berberine prolonged action potential duration (APD) and inhibited IK1 and IK in a concentration-dependent manner.	Berberine	9-18	IKAROS family zinc finger 1 S homeolog	Xenopus laevis	75-78
10362140-0	1999	Berberine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of nucleophosmin/B23 and telomerase activity.	Berberine	0-9	nucleophosmin 1	Homo sapiens	96-109
10820192-6	2000	Similar alterations in cell morphology and in the expression of PLC-beta1, PLC-beta3, and Galpha(q/11) expression were observed when NT2 cells were differentiated with berberine, a compound structurally unrelated to retinoic acid.	Berberine	168-177	phospholipase C beta 1	Homo sapiens	64-73
10820192-6	2000	Similar alterations in cell morphology and in the expression of PLC-beta1, PLC-beta3, and Galpha(q/11) expression were observed when NT2 cells were differentiated with berberine, a compound structurally unrelated to retinoic acid.	Berberine	168-177	phospholipase C beta 3	Homo sapiens	75-84
10820192-6	2000	Similar alterations in cell morphology and in the expression of PLC-beta1, PLC-beta3, and Galpha(q/11) expression were observed when NT2 cells were differentiated with berberine, a compound structurally unrelated to retinoic acid.	Berberine	168-177	succinate-CoA ligase GDP/ADP-forming subunit alpha	Homo sapiens	90-101
10433483-0	1999	Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells.	Berberine	14-23	prostaglandin-endoperoxide synthase 2	Homo sapiens	27-43
10433483-4	1999	We found that berberine, an isoquinoline alkaloid present in plants of the genera Berberis and Coptis, effectively inhibits COX-2 transcriptional activity in colon cancer cells in a dose- and time-dependent manner at concentrations higher than 0.3 microM.	Berberine	14-23	prostaglandin-endoperoxide synthase 2	Homo sapiens	124-129
11302188-0	2001	Inhibitory activity of berberine on DNA strand cleavage induced by hydrogen peroxide and cytochrome c.	Berberine	23-32	cytochrome c, somatic	Homo sapiens	89-101
11302188-1	2001	The inhibitory activity of berberine on the DNA single-strand cleavage induced by hydrogen peroxide and cytochrome c was measured.	Berberine	27-36	cytochrome c, somatic	Homo sapiens	104-116
10940506-7	2000	We also confirmed that berberine (8-32 microM), a major component of C. rhizoma, dose-dependently inhibited secretion of IL-6 by YES-2 cells in vitro.	Berberine	23-32	interleukin 6	Mus musculus	121-125
10940506-7	2000	We also confirmed that berberine (8-32 microM), a major component of C. rhizoma, dose-dependently inhibited secretion of IL-6 by YES-2 cells in vitro.	Berberine	23-32	YES1 pseudogene 1	Homo sapiens	129-134
10940506-8	2000	Moreover, reverse transcription-PCR assay showed that treatment of YES-2 cells with berberine (8-32 microM) for 24 h reduced IL-6 mRNA expression.	Berberine	84-93	YES1 pseudogene 1	Homo sapiens	67-72
10940506-8	2000	Moreover, reverse transcription-PCR assay showed that treatment of YES-2 cells with berberine (8-32 microM) for 24 h reduced IL-6 mRNA expression.	Berberine	84-93	interleukin 6	Mus musculus	125-129
10940506-9	2000	Our results suggest that C. rhizoma may have an anticachectic effect on esophageal cancer and an effect is associated with the ability of berberine to down-regulate tumor IL-6 production.	Berberine	138-147	interleukin 6	Mus musculus	171-175
10945829-5	2000	Histological lesions, morphological damage, and myeloperoxidase activity were reduced after 1 week of treatment with berberine at a dosage of 15 mg/kg/day.	Berberine	117-126	myeloperoxidase	Rattus norvegicus	48-63
10822084-6	2000	Flow cytometric analysis of peripheral blood cells showed that BB caused a decrease in the number of CD3(+), CD4(+), CD8(+), and sIg(+) lymphocytes in comparison with TIN mice.	Berberine	63-65	CD3 antigen, epsilon polypeptide	Mus musculus	101-104
10822084-6	2000	Flow cytometric analysis of peripheral blood cells showed that BB caused a decrease in the number of CD3(+), CD4(+), CD8(+), and sIg(+) lymphocytes in comparison with TIN mice.	Berberine	63-65	CD4 antigen	Mus musculus	109-112
10822084-8	2000	The control animals treated only with BB showed a decrease in the number of CD3(+), CD4(+), CD8(+) T-lymphocytes in comparison with control nontreated mice.	Berberine	38-40	CD3 antigen, epsilon polypeptide	Mus musculus	76-79
10822084-8	2000	The control animals treated only with BB showed a decrease in the number of CD3(+), CD4(+), CD8(+) T-lymphocytes in comparison with control nontreated mice.	Berberine	38-40	CD4 antigen	Mus musculus	84-87
11449466-3	2000	Pretreatment of animals with berberine (4 mg/kg; orally twice daily for 2 days) prevented the acetaminophen- or CCl4-induced rise in serum levels of alkaline phosphatase (ALP) and aminotransaminases (AST and ALT), suggestive of hepatoprotection.	Berberine	29-38	C-C motif chemokine ligand 4	Rattus norvegicus	112-116
10575322-7	1999	The berberine derivative PTB-6 is an effective antihypertensive agent.	Berberine	4-13	polypyrimidine tract binding protein 1	Rattus norvegicus	25-28
10362140-0	1999	Berberine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of nucleophosmin/B23 and telomerase activity.	Berberine	0-9	nucleophosmin 1	Homo sapiens	110-113
10362140-1	1999	The steady-state level of nucleophosmin/B23 mRNA decreased during berberine-induced (25 microg/ml, 24 to 96 hr) apoptosis of human leukemia HL-60 cells.	Berberine	66-75	nucleophosmin 1	Homo sapiens	26-39
10362140-1	1999	The steady-state level of nucleophosmin/B23 mRNA decreased during berberine-induced (25 microg/ml, 24 to 96 hr) apoptosis of human leukemia HL-60 cells.	Berberine	66-75	nucleophosmin 1	Homo sapiens	40-43
10362140-3	1999	A stable clone of nucleophosmin/B23 overexpressed in HL-60 cells was selected and found to be less responsive to berberine-induced apoptosis.	Berberine	113-122	nucleophosmin 1	Homo sapiens	18-31
10362140-3	1999	A stable clone of nucleophosmin/B23 overexpressed in HL-60 cells was selected and found to be less responsive to berberine-induced apoptosis.	Berberine	113-122	nucleophosmin 1	Homo sapiens	32-35
10362140-5	1999	DNA extracted from pCR3 cells contained more fragmented DNA than pCR3-B23 cells during treatment with 15 microg/ml berberine for 24 to 48 hr.	Berberine	115-124	nucleophosmin 1	Homo sapiens	70-73
10362140-6	1999	Our results indicate that berberine-induced apoptosis is associated with down-regulation of nucleophosmin/B23 and telomerase activity.	Berberine	26-35	nucleophosmin 1	Homo sapiens	92-105
10362140-6	1999	Our results indicate that berberine-induced apoptosis is associated with down-regulation of nucleophosmin/B23 and telomerase activity.	Berberine	26-35	nucleophosmin 1	Homo sapiens	106-109
10223233-5	1999	Whether berberine regulates the expression of pgp-170 in HepG2 and other hepatoma cell lines is unknown and worthy of investigation.	Berberine	8-17	phosphoglycolate phosphatase	Homo sapiens	46-49
10223233-7	1999	Flow cytometry was used to measure retention of a fluorescence dye, rhodamine 123, and the level of immunoreactive pgp-170 in berberine-treated hepatoma cells.	Berberine	126-135	phosphoglycolate phosphatase	Homo sapiens	115-118
10223233-8	1999	RESULTS: Berberine up-regulated the expression of pgp-170 in three human hepatoma cell lines.	Berberine	9-18	phosphoglycolate phosphatase	Homo sapiens	50-53
10223233-11	1999	CONCLUSIONS: Berberine modulates the expression and function of pgp-170 in hepatoma cells.	Berberine	13-22	phosphoglycolate phosphatase	Homo sapiens	64-67
9743248-9	1998	Therefore, to investigate the mechanisms of action of berberine and baicalein which is the active substances of orally administered baicalin, their effects on cyclooxygenase 1 and 2 activities were studied.	Berberine	54-63	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	159-181
10364850-0	1999	Inhibition of activator protein 1 activity by berberine in human hepatoma cells.	Berberine	46-55	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-33
10364850-2	1999	The present study was conducted to investigate the effect of berberine, an isoquinoline alkaloid present in plants of the genera Berberis and Coptis, on the activity of AP-1 using a reporter gene assay in human hepatoma cells.	Berberine	61-70	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	169-173
10364850-3	1999	Berberine was shown to inhibit AP-1 activity in a dose- and time-dependent manner at concentrations higher than 0.3 microM.	Berberine	0-9	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	31-35
10364850-4	1999	Berberine inhibited AP-1 activity almost completely as low as 10 microM after 48 h treatment.	Berberine	0-9	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	20-24
10364850-5	1999	The inhibitory effect on AP-1 activity in cancer cells may further explain the anti-tumor promoting activity of berberine.	Berberine	112-121	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	25-29
10328560-4	1999	Berberine caused an inhibitory effect on parathyroid hormone (PTH)-stimulated bone resorption in neonatal mouse bone.	Berberine	0-9	parathyroid hormone	Mus musculus	41-60
10328560-5	1999	In this report we describe the inhibitory effect of berberine on the formation of osteoclast-like multinucleated cells (OCLs) in the co-culture of mouse osteoblastic cells and bone marrow cells in the presence of 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3], PTH and interleukin-1alpha (IL-1alpha).	Berberine	52-61	interleukin 1 alpha	Mus musculus	271-289
10328560-5	1999	In this report we describe the inhibitory effect of berberine on the formation of osteoclast-like multinucleated cells (OCLs) in the co-culture of mouse osteoblastic cells and bone marrow cells in the presence of 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3], PTH and interleukin-1alpha (IL-1alpha).	Berberine	52-61	interleukin 1 alpha	Mus musculus	291-300
10328560-6	1999	Berberine dose-dependently inhibited the formation of tartrate-resistant acid phosphatase (TRAP)-positive OCLs induced by 1alpha25(OH)2D3, PTH and IL-1alpha.	Berberine	0-9	acid phosphatase 5, tartrate resistant	Mus musculus	54-89
10328560-6	1999	Berberine dose-dependently inhibited the formation of tartrate-resistant acid phosphatase (TRAP)-positive OCLs induced by 1alpha25(OH)2D3, PTH and IL-1alpha.	Berberine	0-9	acid phosphatase 5, tartrate resistant	Mus musculus	91-95
10328560-6	1999	Berberine dose-dependently inhibited the formation of tartrate-resistant acid phosphatase (TRAP)-positive OCLs induced by 1alpha25(OH)2D3, PTH and IL-1alpha.	Berberine	0-9	interleukin 1 alpha	Mus musculus	147-156
10328560-11	1999	Berberine dose-dependently inhibited pit formation and caused a decrease in the number of TRAP-positive OCLs.	Berberine	0-9	acid phosphatase 5, tartrate resistant	Mus musculus	90-94
9743248-10	1998	Berberine was found to inhibit cyclooxygenase 2 activity without inhibition of cyclooxygenase 1 activity, and baicalein inhibited cyclooxygenase 1 activity.	Berberine	0-9	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	31-47
9743248-11	1998	Thus, Coptidis Rhizoma and Scutellariae Radix suppressed experimental colon carcinogenesis, and their chemopreventive effects were explained from the inhibition of berberine on cyclooxygenase 2 activity and baicalein on cyclooxygenase 1 activity.	Berberine	164-173	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	177-193
9743248-11	1998	Thus, Coptidis Rhizoma and Scutellariae Radix suppressed experimental colon carcinogenesis, and their chemopreventive effects were explained from the inhibition of berberine on cyclooxygenase 2 activity and baicalein on cyclooxygenase 1 activity.	Berberine	164-173	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	220-236
10418949-1	1999	Berberine was used to determine inhibition of arylamine N-acetyltransferase (NAT) activity in human bladder tumour cells.	Berberine	0-9	bromodomain containing 2	Homo sapiens	77-80
10418949-4	1999	The NAT activity in human bladder tumour cells was inhibited by berberine in a dose-dependent manner, that is, the higher the concentration of berberine, the higher the inhibition of NAT activity.	Berberine	64-73	bromodomain containing 2	Homo sapiens	4-7
10418949-4	1999	The NAT activity in human bladder tumour cells was inhibited by berberine in a dose-dependent manner, that is, the higher the concentration of berberine, the higher the inhibition of NAT activity.	Berberine	64-73	bromodomain containing 2	Homo sapiens	183-186
10418949-4	1999	The NAT activity in human bladder tumour cells was inhibited by berberine in a dose-dependent manner, that is, the higher the concentration of berberine, the higher the inhibition of NAT activity.	Berberine	143-152	bromodomain containing 2	Homo sapiens	4-7
10418949-4	1999	The NAT activity in human bladder tumour cells was inhibited by berberine in a dose-dependent manner, that is, the higher the concentration of berberine, the higher the inhibition of NAT activity.	Berberine	143-152	bromodomain containing 2	Homo sapiens	183-186
10418949-5	1999	The values of apparent Km and Vmax calculated from cytosol NAT and intact cells were also decreased by berberine.	Berberine	103-112	bromodomain containing 2	Homo sapiens	59-62
10418949-6	1999	This report is the first demonstration to show berberine did affect human bladder tumour cell NAT activity.	Berberine	47-56	bromodomain containing 2	Homo sapiens	94-97
9581981-6	1998	We also found the presence of Alcian blue staining-positive but berberine staining-negative mast cells in the skin of mice heterozygous to GATA-1 knock-down allele.	Berberine	64-73	GATA binding protein 1	Mus musculus	139-145
2037868-1	1991	Kinetic analysis has shown that isoquinoline, papaverine and berberine act as reversible competitive inhibitors to muscle lactate dehydrogenase and mitochondrial malate dehydrogenase with respect to the coenzyme NADH.	Berberine	61-70	malic enzyme 2	Homo sapiens	162-182
11243211-0	1997	[Effect of berberine on intracellular free CA2+ concentration in cultured brain cells].	Berberine	11-20	carbonic anhydrase 2	Homo sapiens	43-46
7592663-1	1995	The berberine bridge enzyme ((S)-reticuline:oxygen oxidoreductase (methylene-bridge-forming), EC 1.5.3.9) catalyzes the oxidative cyclization of the N-methyl moiety of (S)-reticuline into the berberine bridge carbon, C-8, of (S)-scoulerine.	Berberine	4-13	thioredoxin reductase 1	Homo sapiens	51-65
7592663-1	1995	The berberine bridge enzyme ((S)-reticuline:oxygen oxidoreductase (methylene-bridge-forming), EC 1.5.3.9) catalyzes the oxidative cyclization of the N-methyl moiety of (S)-reticuline into the berberine bridge carbon, C-8, of (S)-scoulerine.	Berberine	4-13	homeobox C8	Homo sapiens	217-220
7592663-1	1995	The berberine bridge enzyme ((S)-reticuline:oxygen oxidoreductase (methylene-bridge-forming), EC 1.5.3.9) catalyzes the oxidative cyclization of the N-methyl moiety of (S)-reticuline into the berberine bridge carbon, C-8, of (S)-scoulerine.	Berberine	192-201	thioredoxin reductase 1	Homo sapiens	51-65
7592663-1	1995	The berberine bridge enzyme ((S)-reticuline:oxygen oxidoreductase (methylene-bridge-forming), EC 1.5.3.9) catalyzes the oxidative cyclization of the N-methyl moiety of (S)-reticuline into the berberine bridge carbon, C-8, of (S)-scoulerine.	Berberine	192-201	homeobox C8	Homo sapiens	217-220
1375244-9	1992	However, most mast cells which were induced by rrSCF+IL-3 from peritoneal CTMC contained berberine(-)-safranin(-)-Alcian blue(+) granules.	Berberine	89-98	interleukin 3	Mus musculus	53-57
1679102-0	1991	Down-regulation of c-Ki-ras2 gene expression associated with morphologic differentiation in human embryonal carcinoma cells treated with berberine.	Berberine	137-146	KRAS proto-oncogene, GTPase	Homo sapiens	19-28
2037868-2	1991	The inhibitor constants Ki vary from 7.5 microM and 12.6 microM berberine interaction with malate dehydrogenase and lactate dehydrogenase respectively to 91.4 microM and 196.4 microM with papaverine action on these two enzymes.	Berberine	64-73	malic enzyme 2	Homo sapiens	91-111
33233028-0	2021	Berberine promotes peri-implant osteogenesis in diabetic rats by ROS-mediated IRS-1 pathway.	Berberine	0-9	insulin receptor substrate 1	Rattus norvegicus	78-83
2265407-0	1990	Berberine-induced morphologic differentiation and down-regulation of c-Ki-ras2 protooncogene expression in human teratocarcinoma cells.	Berberine	0-9	KRAS proto-oncogene, GTPase	Homo sapiens	69-78
1696505-0	1990	Interactions of berberine with poly(A) and tRNA.	Berberine	16-25	mitochondrially encoded tRNA glycine	Homo sapiens	43-47
1696505-3	1990	The circular dichroism studies show that binding of berberine to poly(A) causes a significant change in the circular dichroic spectrum of poly(A) itself, as manifested by (i) a decrease of both positive and negative bands and (ii) appearance of a conservative type of extrinsic circular dichroic spectrum in the wavelength range of 300-400 nm, while it does not cause any significant alteration to the A form structure of tRNA.	Berberine	52-61	mitochondrially encoded tRNA glycine	Homo sapiens	422-426
33812218-6	2021	Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.	Berberine	0-9	insulin	Homo sapiens	111-118
33812218-6	2021	Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.	Berberine	0-9	insulin	Homo sapiens	124-131
33812218-7	2021	Baseline body mass index and serum prolactin concentration could predict the effect of berberine on insulin resistance.	Berberine	87-96	prolactin	Homo sapiens	35-44
33812218-7	2021	Baseline body mass index and serum prolactin concentration could predict the effect of berberine on insulin resistance.	Berberine	87-96	insulin	Homo sapiens	100-107
33818910-0	2021	Berberine regulates lipid metabolism via miR-192 in porcine oocytes matured in vitro.	Berberine	0-9	microRNA 192	Homo sapiens	41-48
33818910-4	2021	OBJECTIVES: In this study, we investigated the molecular mechanism by which berberine promotes the IVM and lipid metabolism of porcine oocytes via miR-192.	Berberine	76-85	microRNA 192	Homo sapiens	147-154
33126251-6	2021	AMPK activators-notably berberine and the butyric acid produced by health-promoting microflora-are also beneficial in this regard, as are soy isoflavones, which function as selective agonists for ERbeta.	Berberine	24-33	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	0-4
33126251-6	2021	AMPK activators-notably berberine and the butyric acid produced by health-promoting microflora-are also beneficial in this regard, as are soy isoflavones, which function as selective agonists for ERbeta.	Berberine	24-33	estrogen receptor 1	Homo sapiens	196-202
33808389-0	2021	Discovery of Novel Sultone Fused Berberine Derivatives as Promising Tdp1 Inhibitors.	Berberine	33-42	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	68-72
33805383-9	2021	BBR-treated mice had significantly reduced populations of CD4+Th and CD4+CXCR5+ Tfh cells, and an increased proportion of Foxp3+ Treg at days 14 and 28, as well as reduced expression of co-stimulatory molecules CD28 and CD154 at both endpoints.	Berberine	0-3	CD4 antigen	Mus musculus	58-61
33805383-9	2021	BBR-treated mice had significantly reduced populations of CD4+Th and CD4+CXCR5+ Tfh cells, and an increased proportion of Foxp3+ Treg at days 14 and 28, as well as reduced expression of co-stimulatory molecules CD28 and CD154 at both endpoints.	Berberine	0-3	CD4 antigen	Mus musculus	69-72
33805383-9	2021	BBR-treated mice had significantly reduced populations of CD4+Th and CD4+CXCR5+ Tfh cells, and an increased proportion of Foxp3+ Treg at days 14 and 28, as well as reduced expression of co-stimulatory molecules CD28 and CD154 at both endpoints.	Berberine	0-3	chemokine (C-X-C motif) receptor 5	Mus musculus	73-78
33805383-9	2021	BBR-treated mice had significantly reduced populations of CD4+Th and CD4+CXCR5+ Tfh cells, and an increased proportion of Foxp3+ Treg at days 14 and 28, as well as reduced expression of co-stimulatory molecules CD28 and CD154 at both endpoints.	Berberine	0-3	forkhead box P3	Mus musculus	122-127
33805383-9	2021	BBR-treated mice had significantly reduced populations of CD4+Th and CD4+CXCR5+ Tfh cells, and an increased proportion of Foxp3+ Treg at days 14 and 28, as well as reduced expression of co-stimulatory molecules CD28 and CD154 at both endpoints.	Berberine	0-3	CD28 antigen	Mus musculus	211-215
33805383-9	2021	BBR-treated mice had significantly reduced populations of CD4+Th and CD4+CXCR5+ Tfh cells, and an increased proportion of Foxp3+ Treg at days 14 and 28, as well as reduced expression of co-stimulatory molecules CD28 and CD154 at both endpoints.	Berberine	0-3	CD40 ligand	Mus musculus	220-225
33806918-6	2021	Finally, GTPase ERAL1 and mitochondrial ribosomal proteins including MRPL11, 15, 30, 37, 40, and 52 were identified as hub proteins of berberine-treated colon cancer cells.	Berberine	135-144	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	16-21
33806918-6	2021	Finally, GTPase ERAL1 and mitochondrial ribosomal proteins including MRPL11, 15, 30, 37, 40, and 52 were identified as hub proteins of berberine-treated colon cancer cells.	Berberine	135-144	mitochondrial ribosomal protein L11	Homo sapiens	69-75
33806918-9	2021	This study sheds a light for elucidating the berberine-related regulatory signaling pathways in colon cancer, and suggests that ERAL1 and several mitochondrial ribosomal proteins might be promising therapeutic targets for colon cancer.	Berberine	45-54	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	128-133
33800754-3	2021	We previously showed that intraperitoneal (IP) administration of the BBR-derived NAX014 compound was able to counteract HER-2 overexpressing mammary tumors onset and progression in transgenic mice.	Berberine	69-72	erb-b2 receptor tyrosine kinase 2	Mus musculus	120-125
33428132-8	2020	Moreover, the results revealed the involvement of the mammalian target of rapamycin (mTOR) pathway in the induction of autophagy, and berberine could activate the phosphorylation of mTOR and thus mitigate autophagy.	Berberine	134-143	mechanistic target of rapamycin kinase	Homo sapiens	54-83
33428132-8	2020	Moreover, the results revealed the involvement of the mammalian target of rapamycin (mTOR) pathway in the induction of autophagy, and berberine could activate the phosphorylation of mTOR and thus mitigate autophagy.	Berberine	134-143	mechanistic target of rapamycin kinase	Homo sapiens	85-89
33428132-8	2020	Moreover, the results revealed the involvement of the mammalian target of rapamycin (mTOR) pathway in the induction of autophagy, and berberine could activate the phosphorylation of mTOR and thus mitigate autophagy.	Berberine	134-143	mechanistic target of rapamycin kinase	Homo sapiens	182-186
33235706-8	2020	Significantly decrease in activation of TLR4, Sirt1, and alpha-actin in METH-withdrawal group was found and the percentage of TLR4, Sirt1, and alpha-actin improved in berberine-treated group (P<0.001).	Berberine	167-176	toll-like receptor 4	Rattus norvegicus	40-44
33235706-8	2020	Significantly decrease in activation of TLR4, Sirt1, and alpha-actin in METH-withdrawal group was found and the percentage of TLR4, Sirt1, and alpha-actin improved in berberine-treated group (P<0.001).	Berberine	167-176	sirtuin 1	Rattus norvegicus	46-51
33235706-8	2020	Significantly decrease in activation of TLR4, Sirt1, and alpha-actin in METH-withdrawal group was found and the percentage of TLR4, Sirt1, and alpha-actin improved in berberine-treated group (P<0.001).	Berberine	167-176	toll-like receptor 4	Rattus norvegicus	126-130
33235706-8	2020	Significantly decrease in activation of TLR4, Sirt1, and alpha-actin in METH-withdrawal group was found and the percentage of TLR4, Sirt1, and alpha-actin improved in berberine-treated group (P<0.001).	Berberine	167-176	sirtuin 1	Rattus norvegicus	132-137
33233028-7	2021	Moreover, the DM rats treated with BBR and insulin receptor substrate-1 anti-sense oligonucleotide (IRS-1-ASO) underwent a 4-w implant-healing period and then micro computed tomography (Micro-CT) and histology were performed to verify the mechanism.	Berberine	35-38	insulin receptor substrate 1	Rattus norvegicus	100-105
33233028-9	2021	in vitro experiments revealed that BBR alleviated high-glucose-inhibited osteogenesis of the BMSCs by upregulating reactive oxygen species (ROS)-mediated IRS-1 signaling.	Berberine	35-38	insulin receptor substrate 1	Rattus norvegicus	154-159
33233028-11	2021	In conclusion, targeting ROS-mediated IRS-1 signaling, BBR acted as an efficient agent to advance osseointegration in DM, which indicated that BBR use is a good strategy for future implants restoration in diabetic patients.	Berberine	143-146	insulin receptor substrate 1	Homo sapiens	38-43
32857851-0	2020	Berberine functions as a negative regulator in lipopolysaccharide -induced sepsis by suppressing NF-kappaB and IL-6 mediated STAT3 activation.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	97-106
32857851-0	2020	Berberine functions as a negative regulator in lipopolysaccharide -induced sepsis by suppressing NF-kappaB and IL-6 mediated STAT3 activation.	Berberine	0-9	interleukin 6	Homo sapiens	111-115
31412862-0	2019	Berberine inhibits NLRP3 Inflammasome pathway in human triple-negative breast cancer MDA-MB-231 cell.	Berberine	0-9	NLR family pyrin domain containing 3	Homo sapiens	19-24
32857851-0	2020	Berberine functions as a negative regulator in lipopolysaccharide -induced sepsis by suppressing NF-kappaB and IL-6 mediated STAT3 activation.	Berberine	0-9	signal transducer and activator of transcription 3	Homo sapiens	125-130
32857851-9	2020	We further found that berberine inhibited the expression of tumor necrosis factor (TNF)-alpha, interleukin-(IL)-1beta, and IL-6 via suppressing nuclear factor kappa B subunit 1 (NF-kappaB) signaling activation.	Berberine	22-31	tumor necrosis factor	Homo sapiens	60-93
32857851-9	2020	We further found that berberine inhibited the expression of tumor necrosis factor (TNF)-alpha, interleukin-(IL)-1beta, and IL-6 via suppressing nuclear factor kappa B subunit 1 (NF-kappaB) signaling activation.	Berberine	22-31	interleukin 6	Homo sapiens	123-127
32857851-9	2020	We further found that berberine inhibited the expression of tumor necrosis factor (TNF)-alpha, interleukin-(IL)-1beta, and IL-6 via suppressing nuclear factor kappa B subunit 1 (NF-kappaB) signaling activation.	Berberine	22-31	nuclear factor kappa B subunit 1	Homo sapiens	144-176
32857851-9	2020	We further found that berberine inhibited the expression of tumor necrosis factor (TNF)-alpha, interleukin-(IL)-1beta, and IL-6 via suppressing nuclear factor kappa B subunit 1 (NF-kappaB) signaling activation.	Berberine	22-31	nuclear factor kappa B subunit 1	Homo sapiens	178-187
31412862-6	2019	BBR also caused a marked reduction in the secretion of proinflammatory cytokines, Interleukin-1alpha (IL-1alpha), Interleukin-1beta (IL-1beta), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	Berberine	0-3	interleukin 1 alpha	Homo sapiens	82-100
31412862-6	2019	BBR also caused a marked reduction in the secretion of proinflammatory cytokines, Interleukin-1alpha (IL-1alpha), Interleukin-1beta (IL-1beta), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	Berberine	0-3	interleukin 1 alpha	Homo sapiens	102-111
31412862-6	2019	BBR also caused a marked reduction in the secretion of proinflammatory cytokines, Interleukin-1alpha (IL-1alpha), Interleukin-1beta (IL-1beta), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	Berberine	0-3	interleukin 1 beta	Homo sapiens	114-131
31412862-6	2019	BBR also caused a marked reduction in the secretion of proinflammatory cytokines, Interleukin-1alpha (IL-1alpha), Interleukin-1beta (IL-1beta), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	Berberine	0-3	interleukin 1 alpha	Homo sapiens	133-141
31412862-6	2019	BBR also caused a marked reduction in the secretion of proinflammatory cytokines, Interleukin-1alpha (IL-1alpha), Interleukin-1beta (IL-1beta), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	Berberine	0-3	interleukin 6	Homo sapiens	144-157
31412862-6	2019	BBR also caused a marked reduction in the secretion of proinflammatory cytokines, Interleukin-1alpha (IL-1alpha), Interleukin-1beta (IL-1beta), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	Berberine	0-3	interleukin 6	Homo sapiens	159-163
31412862-6	2019	BBR also caused a marked reduction in the secretion of proinflammatory cytokines, Interleukin-1alpha (IL-1alpha), Interleukin-1beta (IL-1beta), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	Berberine	0-3	tumor necrosis factor	Homo sapiens	170-197
31412862-6	2019	BBR also caused a marked reduction in the secretion of proinflammatory cytokines, Interleukin-1alpha (IL-1alpha), Interleukin-1beta (IL-1beta), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	Berberine	0-3	tumor necrosis factor	Homo sapiens	199-208
26628971-12	2015	Similarly, levels of IL-6 and TNF-alpha were increased in spontaneous hypertension group and decreased in berberine group.	Berberine	106-115	interleukin 6	Rattus norvegicus	21-25
26628971-12	2015	Similarly, levels of IL-6 and TNF-alpha were increased in spontaneous hypertension group and decreased in berberine group.	Berberine	106-115	tumor necrosis factor	Rattus norvegicus	30-39
26629148-0	2015	Berberine alleviates preeclampsia possibly by regulating the expression of interleukin-2/interleukin-10 and Bcl-2/Bax.	Berberine	0-9	interleukin 2	Rattus norvegicus	75-88
26629148-0	2015	Berberine alleviates preeclampsia possibly by regulating the expression of interleukin-2/interleukin-10 and Bcl-2/Bax.	Berberine	0-9	interleukin 10	Rattus norvegicus	89-103
26628971-15	2015	CONCLUSION: Berberine plays a protective role in vascular endothelial cell injury through inhibiting apoptosis and expression of TLR4, Myd88, NF-kappaB, IL-6 and TNF-alpha.	Berberine	12-21	toll-like receptor 4	Rattus norvegicus	129-133
26629148-0	2015	Berberine alleviates preeclampsia possibly by regulating the expression of interleukin-2/interleukin-10 and Bcl-2/Bax.	Berberine	0-9	BCL2, apoptosis regulator	Rattus norvegicus	108-113
26629148-0	2015	Berberine alleviates preeclampsia possibly by regulating the expression of interleukin-2/interleukin-10 and Bcl-2/Bax.	Berberine	0-9	BCL2 associated X, apoptosis regulator	Rattus norvegicus	114-117
26628971-15	2015	CONCLUSION: Berberine plays a protective role in vascular endothelial cell injury through inhibiting apoptosis and expression of TLR4, Myd88, NF-kappaB, IL-6 and TNF-alpha.	Berberine	12-21	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	135-140
26629148-1	2015	The present study is to investigate the effect of berberine on the expression of inflammatory factors interleukin (IL)-2 and IL-10, and the expression of apoptosis proteins Bcl-2 and Bax.	Berberine	50-59	interleukin 2	Rattus norvegicus	102-120
26629148-1	2015	The present study is to investigate the effect of berberine on the expression of inflammatory factors interleukin (IL)-2 and IL-10, and the expression of apoptosis proteins Bcl-2 and Bax.	Berberine	50-59	interleukin 10	Rattus norvegicus	125-130
26629148-11	2015	Berberine up-regulated IL-10 and down-regulated IL-2 in the peripheral blood of SD rats with preeclampsia.	Berberine	0-9	interleukin 10	Rattus norvegicus	23-28
26628971-15	2015	CONCLUSION: Berberine plays a protective role in vascular endothelial cell injury through inhibiting apoptosis and expression of TLR4, Myd88, NF-kappaB, IL-6 and TNF-alpha.	Berberine	12-21	interleukin 6	Rattus norvegicus	153-157
26629148-11	2015	Berberine up-regulated IL-10 and down-regulated IL-2 in the peripheral blood of SD rats with preeclampsia.	Berberine	0-9	interleukin 2	Rattus norvegicus	48-52
26629148-12	2015	Berberine up-regulated Bcl-2 and down-regulated Bax in the placenta of SD rats with preeclampsia.	Berberine	0-9	BCL2, apoptosis regulator	Rattus norvegicus	23-28
26629148-12	2015	Berberine up-regulated Bcl-2 and down-regulated Bax in the placenta of SD rats with preeclampsia.	Berberine	0-9	BCL2 associated X, apoptosis regulator	Rattus norvegicus	48-51
26628971-15	2015	CONCLUSION: Berberine plays a protective role in vascular endothelial cell injury through inhibiting apoptosis and expression of TLR4, Myd88, NF-kappaB, IL-6 and TNF-alpha.	Berberine	12-21	tumor necrosis factor	Rattus norvegicus	162-171
26629148-13	2015	Berberine increases the number and weight of normal fetuses in rats with preeclampsia, possibly by regulating the balance of IL-2 and IL-10, and inhibiting apoptosis.	Berberine	0-9	interleukin 2	Rattus norvegicus	125-129
26629148-13	2015	Berberine increases the number and weight of normal fetuses in rats with preeclampsia, possibly by regulating the balance of IL-2 and IL-10, and inhibiting apoptosis.	Berberine	0-9	interleukin 10	Rattus norvegicus	134-139
34674380-0	2022	Berberine ameliorates erectile dysfunction in rats with streptozotocin-induced diabetes mellitus through the attenuation of apoptosis by inhibiting the SPHK1/S1P/S1PR2 and MAPK pathways.	Berberine	0-9	sphingosine kinase 1	Rattus norvegicus	152-157
20008797-9	2010	In addition, the plasma interleukin-6 level of the LPS-treated group was significantly elevated (P &lt; 0.01) at 24 h compared with that of the control and the berberine-administered group.	Berberine	160-169	interleukin 6	Gallus gallus	24-37
34718103-14	2022	CONCLUSION: Our research shows that the common mechanism of CCF in improving T2DM is as follows: berberine, baicalin, coptisine and other chemical components can directionally regulate DPP-4, CASP3, NOS2, NOS3 and other targets, which are mediated by AGE-RAGE signaling pathway in diabetic complications, MAPK signaling pathway and HIF-1 signaling pathway.	Berberine	97-106	dipeptidyl-peptidase 4	Danio rerio	185-190
34718103-14	2022	CONCLUSION: Our research shows that the common mechanism of CCF in improving T2DM is as follows: berberine, baicalin, coptisine and other chemical components can directionally regulate DPP-4, CASP3, NOS2, NOS3 and other targets, which are mediated by AGE-RAGE signaling pathway in diabetic complications, MAPK signaling pathway and HIF-1 signaling pathway.	Berberine	97-106	caspase 3, apoptosis-related cysteine peptidase a	Danio rerio	192-197
34718103-14	2022	CONCLUSION: Our research shows that the common mechanism of CCF in improving T2DM is as follows: berberine, baicalin, coptisine and other chemical components can directionally regulate DPP-4, CASP3, NOS2, NOS3 and other targets, which are mediated by AGE-RAGE signaling pathway in diabetic complications, MAPK signaling pathway and HIF-1 signaling pathway.	Berberine	97-106	nitric oxide synthase 2a, inducible	Danio rerio	199-203
34674380-0	2022	Berberine ameliorates erectile dysfunction in rats with streptozotocin-induced diabetes mellitus through the attenuation of apoptosis by inhibiting the SPHK1/S1P/S1PR2 and MAPK pathways.	Berberine	0-9	sphingosine-1-phosphate receptor 2	Rattus norvegicus	162-167
34674380-10	2022	BBR partially inhibited the expression of SPHK1 and S1PR2, but the decrease in S1P was not significant.	Berberine	0-3	sphingosine kinase 1	Rattus norvegicus	42-47
34674380-10	2022	BBR partially inhibited the expression of SPHK1 and S1PR2, but the decrease in S1P was not significant.	Berberine	0-3	sphingosine-1-phosphate receptor 2	Rattus norvegicus	52-57
34674380-15	2022	CONCLUSIONS: BBR ameliorated ED in rats with DM, possibly by improving endothelial function and inhibiting apoptosis and fibrosis by suppressing the SPHK1/S1P/S1PR2 and MAPK pathways.	Berberine	13-16	sphingosine kinase 1	Rattus norvegicus	149-154
34674380-15	2022	CONCLUSIONS: BBR ameliorated ED in rats with DM, possibly by improving endothelial function and inhibiting apoptosis and fibrosis by suppressing the SPHK1/S1P/S1PR2 and MAPK pathways.	Berberine	13-16	sphingosine-1-phosphate receptor 2	Rattus norvegicus	159-164
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	Berberine	212-221	cyclin dependent kinase inhibitor 1A	Homo sapiens	233-239
34935059-0	2022	Berberine enhances gemcitabine-induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.	Berberine	0-9	RAD51 recombinase	Homo sapiens	88-93
34935059-0	2022	Berberine enhances gemcitabine-induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	135-138
34935059-8	2022	BER enhanced GEM-induced cytotoxicity, apoptosis and inhibition of migration, whilst attenuating the GEM-induced upregulation of phosphorylated Akt and Rad51 expression.	Berberine	0-3	AKT serine/threonine kinase 1	Homo sapiens	144-147
34935059-8	2022	BER enhanced GEM-induced cytotoxicity, apoptosis and inhibition of migration, whilst attenuating the GEM-induced upregulation of phosphorylated Akt and Rad51 expression.	Berberine	0-3	RAD51 recombinase	Homo sapiens	152-157
34935059-10	2022	Knockdown of Rad51 enhanced GEM-induced cytotoxicity, whilst overexpression of Rad51 reversed the suppressed cell viability induced by BER and GEM.	Berberine	135-138	RAD51 recombinase	Homo sapiens	13-18
34935059-10	2022	Knockdown of Rad51 enhanced GEM-induced cytotoxicity, whilst overexpression of Rad51 reversed the suppressed cell viability induced by BER and GEM.	Berberine	135-138	RAD51 recombinase	Homo sapiens	79-84
34935059-11	2022	Inactivation of the PI3K/Akt pathway by LY294002 or BER enhanced GEM-induced cytotoxicity and downregulated Rad51 expression, whilst overexpression of constitutively active Akt restored Rad51 expression and cell viability that was previously decreased by BER and GEM.	Berberine	52-55	AKT serine/threonine kinase 1	Homo sapiens	25-28
34935059-11	2022	Inactivation of the PI3K/Akt pathway by LY294002 or BER enhanced GEM-induced cytotoxicity and downregulated Rad51 expression, whilst overexpression of constitutively active Akt restored Rad51 expression and cell viability that was previously decreased by BER and GEM.	Berberine	52-55	RAD51 recombinase	Homo sapiens	108-113
34935059-11	2022	Inactivation of the PI3K/Akt pathway by LY294002 or BER enhanced GEM-induced cytotoxicity and downregulated Rad51 expression, whilst overexpression of constitutively active Akt restored Rad51 expression and cell viability that was previously decreased by BER and GEM.	Berberine	255-258	AKT serine/threonine kinase 1	Homo sapiens	173-176
34935059-11	2022	Inactivation of the PI3K/Akt pathway by LY294002 or BER enhanced GEM-induced cytotoxicity and downregulated Rad51 expression, whilst overexpression of constitutively active Akt restored Rad51 expression and cell viability that was previously decreased by BER and GEM.	Berberine	255-258	RAD51 recombinase	Homo sapiens	186-191
34935059-12	2022	BER additively inhibited tumor growth and Ki67 expression when combined with GEM in vivo.	Berberine	0-3	antigen identified by monoclonal antibody Ki 67	Mus musculus	42-46
34890544-5	2022	Quantitative reverse transcription polymerase chain reaction and western blotting assays revealed that berberine activated the adenosine monophosphate-activated protein kinase (AMPK) pathway.	Berberine	103-112	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	127-175
34890544-5	2022	Quantitative reverse transcription polymerase chain reaction and western blotting assays revealed that berberine activated the adenosine monophosphate-activated protein kinase (AMPK) pathway.	Berberine	103-112	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	177-181
34890544-6	2022	This demonstrated that berberine suppressed glycolysis by targeting AMPK, a key metabolic sensor.	Berberine	23-32	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	68-72
34968467-0	2022	Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6.	Berberine	0-9	Janus kinase 2	Homo sapiens	80-84
34968467-0	2022	Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6.	Berberine	0-9	signal transducer and activator of transcription 3	Homo sapiens	85-90
34968467-0	2022	Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6.	Berberine	0-9	interleukin 6	Homo sapiens	118-122
34968467-10	2022	Mechanistically, these findings imply that BBR inhibits GC cell proliferation by modulating the signaling pathways related to IL-6/JAK2/STAT3.	Berberine	43-46	interleukin 6	Homo sapiens	126-130
34968467-10	2022	Mechanistically, these findings imply that BBR inhibits GC cell proliferation by modulating the signaling pathways related to IL-6/JAK2/STAT3.	Berberine	43-46	Janus kinase 2	Homo sapiens	131-135
34968467-10	2022	Mechanistically, these findings imply that BBR inhibits GC cell proliferation by modulating the signaling pathways related to IL-6/JAK2/STAT3.	Berberine	43-46	signal transducer and activator of transcription 3	Homo sapiens	136-141
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	Berberine	212-221	BCL2 apoptosis regulator	Homo sapiens	241-245
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	Berberine	212-221	E2F transcription factor 1	Homo sapiens	247-251
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	Berberine	212-221	protein kinase C beta	Homo sapiens	253-258
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	Berberine	212-221	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	260-263
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	Berberine	212-221	cyclin dependent kinase 2	Homo sapiens	265-269
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	Berberine	212-221	matrix metallopeptidase 9	Homo sapiens	274-278
34489150-0	2022	Berberine-loaded nanostructured lipid carriers mitigate warm hepatic ischemia/reperfusion-induced lesion through modulation of HMGB1/TLR4/NF-kappaB signaling and autophagy.	Berberine	0-9	high mobility group box 1	Rattus norvegicus	127-132
34923373-5	2022	Reduced phosphorylated JAK1/2/3 and STAT1/3 in MNCs from BBR-fed EAMG rats were demonstrated.	Berberine	57-60	Janus kinase 1	Rattus norvegicus	23-31
34923373-5	2022	Reduced phosphorylated JAK1/2/3 and STAT1/3 in MNCs from BBR-fed EAMG rats were demonstrated.	Berberine	57-60	signal transducer and activator of transcription 1	Rattus norvegicus	36-43
34773803-0	2022	Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin.	Berberine	0-9	leptin	Homo sapiens	81-87
34773803-0	2022	Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin.	Berberine	0-9	adiponectin, C1Q and collagen domain containing	Homo sapiens	100-111
34773803-12	2022	The effect of berberine on weight gain may be related to the regulation of leptin, but not adiponectin.	Berberine	14-23	leptin	Homo sapiens	75-81
34489150-0	2022	Berberine-loaded nanostructured lipid carriers mitigate warm hepatic ischemia/reperfusion-induced lesion through modulation of HMGB1/TLR4/NF-kappaB signaling and autophagy.	Berberine	0-9	toll-like receptor 4	Rattus norvegicus	133-137
34687898-0	2022	Oral administration of berberine limits post-traumatic osteoarthritis development and associated pain via AMP-activated protein kinase (AMPK) in mice.	Berberine	23-32	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	136-140
34448246-8	2022	In cDNA microarray, berberine downregulated the expression of RRM1, RRM2, LIG1, POLE2 that involving DNA repair and replication.	Berberine	20-29	ribonucleotide reductase catalytic subunit M1	Homo sapiens	62-66
34448246-8	2022	In cDNA microarray, berberine downregulated the expression of RRM1, RRM2, LIG1, POLE2 that involving DNA repair and replication.	Berberine	20-29	ribonucleotide reductase regulatory subunit M2	Homo sapiens	68-72
34448246-8	2022	In cDNA microarray, berberine downregulated the expression of RRM1, RRM2, LIG1, POLE2 that involving DNA repair and replication.	Berberine	20-29	DNA ligase 1	Homo sapiens	74-78
34448246-8	2022	In cDNA microarray, berberine downregulated the expression of RRM1, RRM2, LIG1, POLE2 that involving DNA repair and replication.	Berberine	20-29	DNA polymerase epsilon 2, accessory subunit	Homo sapiens	80-85
34747550-4	2022	Several natural compounds (NCs), such as resveratrol, sesamin, and berberine, with antioxidative, anti-inflammation, and antiapoptotic effects were evaluated for their potential to suppress the cardiotoxicity induced by DOX via targeting SIRT1 and SIRT3.	Berberine	67-76	sirtuin 1	Homo sapiens	238-243
34687898-1	2022	OBJECTIVE: We investigated the effect of berberine, a natural plant product that can activate AMP-activated protein kinase (AMPK), on OA development and associated pain in mice.	Berberine	41-50	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	124-128
34687898-2	2022	DESIGN: Human primary knee chondrocytes were utilized to investigate how AMPK is activated by berberine.	Berberine	94-103	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	73-77
34687898-8	2022	RESULTS: Berberine induced phosphorylation of AMPKalpha (Thr172) via liver kinase B1 (LKB1), the major upstream kinase of AMPK, in chondrocytes in vitro.	Berberine	9-18	serine/threonine kinase 11	Mus musculus	69-84
34826601-5	2022	Here, we report that berberine, when combined with osimertinib, synergistically and selectively decreased the survival of several MET-amplified osimertinib-resistant EGFR mutant NSCLC cell lines with enhanced induction of apoptosis likely through Bim elevation and Mcl-1 reduction.	Berberine	21-30	met proto-oncogene	Mus musculus	130-133
34826601-5	2022	Here, we report that berberine, when combined with osimertinib, synergistically and selectively decreased the survival of several MET-amplified osimertinib-resistant EGFR mutant NSCLC cell lines with enhanced induction of apoptosis likely through Bim elevation and Mcl-1 reduction.	Berberine	21-30	epidermal growth factor receptor	Mus musculus	166-170
34826601-0	2022	The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.	Berberine	20-29	met proto-oncogene	Mus musculus	81-84
34826601-0	2022	The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.	Berberine	20-29	met proto-oncogene	Mus musculus	140-143
34687898-8	2022	RESULTS: Berberine induced phosphorylation of AMPKalpha (Thr172) via liver kinase B1 (LKB1), the major upstream kinase of AMPK, in chondrocytes in vitro.	Berberine	9-18	serine/threonine kinase 11	Mus musculus	86-90
34826601-5	2022	Here, we report that berberine, when combined with osimertinib, synergistically and selectively decreased the survival of several MET-amplified osimertinib-resistant EGFR mutant NSCLC cell lines with enhanced induction of apoptosis likely through Bim elevation and Mcl-1 reduction.	Berberine	21-30	BCL2-like 11 (apoptosis facilitator)	Mus musculus	247-250
34687898-8	2022	RESULTS: Berberine induced phosphorylation of AMPKalpha (Thr172) via liver kinase B1 (LKB1), the major upstream kinase of AMPK, in chondrocytes in vitro.	Berberine	9-18	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	122-126
34826601-5	2022	Here, we report that berberine, when combined with osimertinib, synergistically and selectively decreased the survival of several MET-amplified osimertinib-resistant EGFR mutant NSCLC cell lines with enhanced induction of apoptosis likely through Bim elevation and Mcl-1 reduction.	Berberine	21-30	myeloid cell leukemia sequence 1	Mus musculus	265-270
34826601-7	2022	Molecular modeling showed that berberine was able to bind to the kinase domain of non-phosphorylated MET, occupy the front of the binding pocket, and interact with the activation loop, in a similar way as other known MET inhibitors do.	Berberine	31-40	met proto-oncogene	Mus musculus	101-104
34826601-7	2022	Molecular modeling showed that berberine was able to bind to the kinase domain of non-phosphorylated MET, occupy the front of the binding pocket, and interact with the activation loop, in a similar way as other known MET inhibitors do.	Berberine	31-40	met proto-oncogene	Mus musculus	217-220
34826601-8	2022	MET kinase assay showed clear concentration-dependent inhibitory effects of berberine against MET activity, confirming its kinase inhibitory activity.	Berberine	76-85	met proto-oncogene	Mus musculus	0-3
34826601-8	2022	MET kinase assay showed clear concentration-dependent inhibitory effects of berberine against MET activity, confirming its kinase inhibitory activity.	Berberine	76-85	met proto-oncogene	Mus musculus	94-97
34826601-9	2022	These findings collectively suggest that berberine can act as a naturally-existing MET inhibitor to synergize with osimertinib in overcoming osimertinib acquired resistance caused by MET amplification.	Berberine	41-50	met proto-oncogene	Mus musculus	83-86
34826601-9	2022	These findings collectively suggest that berberine can act as a naturally-existing MET inhibitor to synergize with osimertinib in overcoming osimertinib acquired resistance caused by MET amplification.	Berberine	41-50	met proto-oncogene	Mus musculus	183-186
34687898-11	2022	IHC analysis of WT DMM knee cartilage further revealed that berberine inhibited concomitant loss of expression and phosphorylation of AMPKalpha and expression of SIRT1 and SIRT3, suggesting an important role of activation of AMPK signaling in mediating beneficial effect of berberine.	Berberine	60-69	sirtuin 1	Mus musculus	162-167
34687898-11	2022	IHC analysis of WT DMM knee cartilage further revealed that berberine inhibited concomitant loss of expression and phosphorylation of AMPKalpha and expression of SIRT1 and SIRT3, suggesting an important role of activation of AMPK signaling in mediating beneficial effect of berberine.	Berberine	60-69	sirtuin 3	Mus musculus	172-177
34687898-11	2022	IHC analysis of WT DMM knee cartilage further revealed that berberine inhibited concomitant loss of expression and phosphorylation of AMPKalpha and expression of SIRT1 and SIRT3, suggesting an important role of activation of AMPK signaling in mediating beneficial effect of berberine.	Berberine	60-69	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	225-229
34687898-11	2022	IHC analysis of WT DMM knee cartilage further revealed that berberine inhibited concomitant loss of expression and phosphorylation of AMPKalpha and expression of SIRT1 and SIRT3, suggesting an important role of activation of AMPK signaling in mediating beneficial effect of berberine.	Berberine	274-283	sirtuin 1	Mus musculus	162-167
34687898-11	2022	IHC analysis of WT DMM knee cartilage further revealed that berberine inhibited concomitant loss of expression and phosphorylation of AMPKalpha and expression of SIRT1 and SIRT3, suggesting an important role of activation of AMPK signaling in mediating beneficial effect of berberine.	Berberine	274-283	sirtuin 3	Mus musculus	172-177
34687898-11	2022	IHC analysis of WT DMM knee cartilage further revealed that berberine inhibited concomitant loss of expression and phosphorylation of AMPKalpha and expression of SIRT1 and SIRT3, suggesting an important role of activation of AMPK signaling in mediating beneficial effect of berberine.	Berberine	274-283	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	225-229
34687898-12	2022	CONCLUSIONS: Berberine acts through AMPK to reduce joint structural damage and pain associated with post-traumatic OA in mice in vivo.	Berberine	13-22	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	36-40
34979291-9	2021	Tunicamycin administration caused significant increase of the expression level of genes related to ER stress and UPR, such as CHOP, Grp78 and ATF6, but the berberine pre-treatment could significantly downregulate the expression level of these genes.	Berberine	156-165	DNA-damage inducible transcript 3	Mus musculus	126-130
34979291-9	2021	Tunicamycin administration caused significant increase of the expression level of genes related to ER stress and UPR, such as CHOP, Grp78 and ATF6, but the berberine pre-treatment could significantly downregulate the expression level of these genes.	Berberine	156-165	heat shock protein 5	Mus musculus	132-137
34979291-9	2021	Tunicamycin administration caused significant increase of the expression level of genes related to ER stress and UPR, such as CHOP, Grp78 and ATF6, but the berberine pre-treatment could significantly downregulate the expression level of these genes.	Berberine	156-165	activating transcription factor 6	Mus musculus	142-146
34944525-5	2021	Evodiamine, berberine, genipin, palmitic acid, genistein, and quercetin were shown to regulate adipocytokine signaling pathway proteins which mainly involved tumor necrosis factor receptor 1, leptin receptor.	Berberine	12-21	leptin receptor	Homo sapiens	192-207
34942622-2	2021	As an isoquinoline alkaloid, Berberine exerts neuroprotective effects in neurological disease models with activated AMPK/PGC1alpha signaling.	Berberine	29-38	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	121-130
34942622-11	2021	Finally, Berberine drastically elevated AMPK/PGC1alpha signaling in the hemisphere of ICH mice.	Berberine	9-18	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	45-54
34942622-12	2021	CONCLUSION: Our findings suggest that Berberine plays an important neuroprotective role against ICH-induced neurological impairments and BBB injury, probably by inhibition of inflammation and activation of AMPK/PGC1alpha signaling.	Berberine	38-47	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	211-220
34930229-11	2021	BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1beta and tumor necrosis factor alpha) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase.	Berberine	0-3	interleukin 1 beta	Rattus norvegicus	217-234
34930229-11	2021	BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1beta and tumor necrosis factor alpha) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase.	Berberine	0-3	tumor necrosis factor	Rattus norvegicus	239-266
34930229-11	2021	BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1beta and tumor necrosis factor alpha) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase.	Berberine	0-3	catalase	Rattus norvegicus	328-336
34860319-8	2022	In addition, BBR significantly enhanced ERK as well as both pro- and anti-inflammatory cytokine expression compared to untreated controls.	Berberine	13-16	mitogen-activated protein kinase 1	Homo sapiens	40-43
34874590-6	2021	Histopathology showed that berberine decreased the activity and number of osteoclasts but increased the expression of proteins related to osteoblast differentiation, including alkaline phosphatase and osterix.	Berberine	27-36	Sp7 transcription factor	Rattus norvegicus	201-208
34288277-1	2021	This study was conducted to explore the molecular mechanisms of berberine (Ber) via peroxisome proliferator-activated receptor gamma (PPARG) in promoting in vitro maturation (IVM) and lipid metabolism of porcine oocytes.	Berberine	75-78	peroxisome proliferator activated receptor gamma	Homo sapiens	134-139
34309956-7	2021	The iSN04-berberine complex exhibited a higher myogenetic activity than iSN04 alone, which was shown to enhance the differentiation of myoblasts into myotubes and the upregulation of myogenic gene expression (MyoD, myogenin, MHC, and myomaker).	Berberine	10-19	myogenin	Gallus gallus	215-223
34309956-7	2021	The iSN04-berberine complex exhibited a higher myogenetic activity than iSN04 alone, which was shown to enhance the differentiation of myoblasts into myotubes and the upregulation of myogenic gene expression (MyoD, myogenin, MHC, and myomaker).	Berberine	10-19	myosin, heavy chain 15	Gallus gallus	225-228
34517069-0	2021	Berberine exerts neuroprotective activities against cerebral ischemia/reperfusion injury through up-regulating PPAR-gamma to suppress NF-kappaB-mediated pyroptosis.	Berberine	0-9	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	111-121
34517069-9	2021	CONCLUSION: BBR protects rats from cerebral I/R injury by up-regulating PPAR-gamma to restrain NF-kappaB-mediated pyroptosis.	Berberine	12-15	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	72-82
34288277-0	2021	Mechanisms of lipid metabolism promoted by berberine via peroxisome proliferator-activated receptor gamma during in vitro maturation of porcine oocytes.	Berberine	43-52	peroxisome proliferator activated receptor gamma	Homo sapiens	57-105
34288277-1	2021	This study was conducted to explore the molecular mechanisms of berberine (Ber) via peroxisome proliferator-activated receptor gamma (PPARG) in promoting in vitro maturation (IVM) and lipid metabolism of porcine oocytes.	Berberine	64-73	peroxisome proliferator activated receptor gamma	Homo sapiens	84-132
34288277-1	2021	This study was conducted to explore the molecular mechanisms of berberine (Ber) via peroxisome proliferator-activated receptor gamma (PPARG) in promoting in vitro maturation (IVM) and lipid metabolism of porcine oocytes.	Berberine	64-73	peroxisome proliferator activated receptor gamma	Homo sapiens	134-139
34288277-1	2021	This study was conducted to explore the molecular mechanisms of berberine (Ber) via peroxisome proliferator-activated receptor gamma (PPARG) in promoting in vitro maturation (IVM) and lipid metabolism of porcine oocytes.	Berberine	75-78	peroxisome proliferator activated receptor gamma	Homo sapiens	84-132
33896366-0	2021	Protective effect of berberine against LPS-induced endothelial cell injury via the JNK signaling pathway and autophagic mechanisms.	Berberine	21-30	mitogen-activated protein kinase 8	Homo sapiens	83-86
33896366-4	2021	Furthermore, BBR could inhibit LPS-induced autophagy, as demonstrated by its inhibitory effects on the LC3-II/LC3-I ratio and Beclin-1 levels and its promotive effect on p62 expression.	Berberine	13-16	beclin 1	Homo sapiens	126-134
33896366-4	2021	Furthermore, BBR could inhibit LPS-induced autophagy, as demonstrated by its inhibitory effects on the LC3-II/LC3-I ratio and Beclin-1 levels and its promotive effect on p62 expression.	Berberine	13-16	nucleoporin 62	Homo sapiens	170-173
33896366-8	2021	The present data indicate that BBR attenuated LPS-induced cell apoptosis by blocking JNK-mediated autophagy in HUVECs and HPMECs.	Berberine	31-34	mitogen-activated protein kinase 8	Homo sapiens	85-88
34592881-8	2021	Here, we proved that in ApoE -/- mice receiving high-fat diet for 12 weeks, BBR can reduce serum lipid levels, improve intimal hyperplasia, and antagonize carotid lipid accumulation, which may be achieved through regulating the PI3K/AKT/mTOR signaling pathway, regulating autophagy, promoting cell proliferation and inhibiting cell apoptosis.	Berberine	76-79	apolipoprotein E	Mus musculus	24-28
34592881-8	2021	Here, we proved that in ApoE -/- mice receiving high-fat diet for 12 weeks, BBR can reduce serum lipid levels, improve intimal hyperplasia, and antagonize carotid lipid accumulation, which may be achieved through regulating the PI3K/AKT/mTOR signaling pathway, regulating autophagy, promoting cell proliferation and inhibiting cell apoptosis.	Berberine	76-79	thymoma viral proto-oncogene 1	Mus musculus	233-236
34592881-8	2021	Here, we proved that in ApoE -/- mice receiving high-fat diet for 12 weeks, BBR can reduce serum lipid levels, improve intimal hyperplasia, and antagonize carotid lipid accumulation, which may be achieved through regulating the PI3K/AKT/mTOR signaling pathway, regulating autophagy, promoting cell proliferation and inhibiting cell apoptosis.	Berberine	76-79	mechanistic target of rapamycin kinase	Mus musculus	237-241
34699329-0	2021	Synergetic protective effect of berberine and ginsenoside Rb1 against tumor necrosis factor alpha-induced inflammation in adipocytes.	Berberine	32-41	tumor necrosis factor	Homo sapiens	70-97
34258700-4	2021	With regard to MTX, the results of this investigation reveal potent amelioration of MTX hepatotoxicity by BBR and UMB through reduction of the elevated serum levels of ALT, ALP, AST, and LDH confirmed by the attenuation of histopathological abrasion in liver tissues.	Berberine	106-109	ATHS	Homo sapiens	173-176
34258700-4	2021	With regard to MTX, the results of this investigation reveal potent amelioration of MTX hepatotoxicity by BBR and UMB through reduction of the elevated serum levels of ALT, ALP, AST, and LDH confirmed by the attenuation of histopathological abrasion in liver tissues.	Berberine	106-109	solute carrier family 17 member 5	Homo sapiens	178-181
34258700-6	2021	More importantly, BBR resulted in reducing P38 mitogen-activated protein kinase (P38MAPK), nuclear factor kappa-B (NF-kappaB), and Kelch-like ECH-associated protein 1 (Keap-1) genes and enhanced mRNA expression of Nrf-2 (P < 0.05).	Berberine	18-21	mitogen-activated protein kinase 14	Homo sapiens	43-79
34258700-6	2021	More importantly, BBR resulted in reducing P38 mitogen-activated protein kinase (P38MAPK), nuclear factor kappa-B (NF-kappaB), and Kelch-like ECH-associated protein 1 (Keap-1) genes and enhanced mRNA expression of Nrf-2 (P < 0.05).	Berberine	18-21	mitogen-activated protein kinase 14	Homo sapiens	81-88
34258700-6	2021	More importantly, BBR resulted in reducing P38 mitogen-activated protein kinase (P38MAPK), nuclear factor kappa-B (NF-kappaB), and Kelch-like ECH-associated protein 1 (Keap-1) genes and enhanced mRNA expression of Nrf-2 (P < 0.05).	Berberine	18-21	nuclear factor kappa B subunit 1	Homo sapiens	91-113
34258700-6	2021	More importantly, BBR resulted in reducing P38 mitogen-activated protein kinase (P38MAPK), nuclear factor kappa-B (NF-kappaB), and Kelch-like ECH-associated protein 1 (Keap-1) genes and enhanced mRNA expression of Nrf-2 (P < 0.05).	Berberine	18-21	nuclear factor kappa B subunit 1	Homo sapiens	115-124
34258700-6	2021	More importantly, BBR resulted in reducing P38 mitogen-activated protein kinase (P38MAPK), nuclear factor kappa-B (NF-kappaB), and Kelch-like ECH-associated protein 1 (Keap-1) genes and enhanced mRNA expression of Nrf-2 (P < 0.05).	Berberine	18-21	kelch like ECH associated protein 1	Homo sapiens	131-166
34258700-6	2021	More importantly, BBR resulted in reducing P38 mitogen-activated protein kinase (P38MAPK), nuclear factor kappa-B (NF-kappaB), and Kelch-like ECH-associated protein 1 (Keap-1) genes and enhanced mRNA expression of Nrf-2 (P < 0.05).	Berberine	18-21	kelch like ECH associated protein 1	Homo sapiens	168-174
34258700-6	2021	More importantly, BBR resulted in reducing P38 mitogen-activated protein kinase (P38MAPK), nuclear factor kappa-B (NF-kappaB), and Kelch-like ECH-associated protein 1 (Keap-1) genes and enhanced mRNA expression of Nrf-2 (P < 0.05).	Berberine	18-21	NFE2 like bZIP transcription factor 2	Homo sapiens	214-219
34258700-7	2021	Interestingly, in silico studies via molecular docking pinpointed the binding modes of BBR and UMB to the binding pocket residues of P38MAPK, NF-kappaB, and Keap-1 and demonstrated a promising inhibition of Keap-1, P38MAPK, and NF-kappaB.	Berberine	87-90	mitogen-activated protein kinase 14	Homo sapiens	133-140
34258700-7	2021	Interestingly, in silico studies via molecular docking pinpointed the binding modes of BBR and UMB to the binding pocket residues of P38MAPK, NF-kappaB, and Keap-1 and demonstrated a promising inhibition of Keap-1, P38MAPK, and NF-kappaB.	Berberine	87-90	nuclear factor kappa B subunit 1	Homo sapiens	142-151
34258700-7	2021	Interestingly, in silico studies via molecular docking pinpointed the binding modes of BBR and UMB to the binding pocket residues of P38MAPK, NF-kappaB, and Keap-1 and demonstrated a promising inhibition of Keap-1, P38MAPK, and NF-kappaB.	Berberine	87-90	kelch like ECH associated protein 1	Homo sapiens	157-163
34258700-7	2021	Interestingly, in silico studies via molecular docking pinpointed the binding modes of BBR and UMB to the binding pocket residues of P38MAPK, NF-kappaB, and Keap-1 and demonstrated a promising inhibition of Keap-1, P38MAPK, and NF-kappaB.	Berberine	87-90	kelch like ECH associated protein 1	Homo sapiens	207-213
34258700-7	2021	Interestingly, in silico studies via molecular docking pinpointed the binding modes of BBR and UMB to the binding pocket residues of P38MAPK, NF-kappaB, and Keap-1 and demonstrated a promising inhibition of Keap-1, P38MAPK, and NF-kappaB.	Berberine	87-90	mitogen-activated protein kinase 14	Homo sapiens	215-222
34258700-7	2021	Interestingly, in silico studies via molecular docking pinpointed the binding modes of BBR and UMB to the binding pocket residues of P38MAPK, NF-kappaB, and Keap-1 and demonstrated a promising inhibition of Keap-1, P38MAPK, and NF-kappaB.	Berberine	87-90	nuclear factor kappa B subunit 1	Homo sapiens	228-237
34258700-8	2021	BBR and UMB reduced the expression of pro-apoptotic protein Bax and apoptotic protein caspase-3 as well as increased the expression of anti-apoptotic protein Bcl-2.	Berberine	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	60-63
34523052-0	2021	Berberine Attenuates Neonatal Sepsis in Mice By Inhibiting FOXA1 and NF-kappaB Signal Transduction Via the Induction of MiR-132-3p.	Berberine	0-9	forkhead box A1	Mus musculus	59-64
34523052-0	2021	Berberine Attenuates Neonatal Sepsis in Mice By Inhibiting FOXA1 and NF-kappaB Signal Transduction Via the Induction of MiR-132-3p.	Berberine	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	69-78
34523052-7	2021	The intestinal injuries induced by CS were also attenuated by berberine, which was associated with inhibition of the production of systemic IL-6, IL-1beta, and TNF-alpha.	Berberine	62-71	interleukin 6	Mus musculus	140-144
34523052-7	2021	The intestinal injuries induced by CS were also attenuated by berberine, which was associated with inhibition of the production of systemic IL-6, IL-1beta, and TNF-alpha.	Berberine	62-71	interleukin 1 alpha	Mus musculus	146-154
34523052-7	2021	The intestinal injuries induced by CS were also attenuated by berberine, which was associated with inhibition of the production of systemic IL-6, IL-1beta, and TNF-alpha.	Berberine	62-71	tumor necrosis factor	Mus musculus	160-169
34523052-9	2021	The effects of berberine on NS-induced impairments were blocked by the injection of the miR-132-3p antagomir, which exacerbated intestinal injuries, induced systemic inflammation, and reactivated the FOXA1 and NF-kappaB pathways.	Berberine	15-24	forkhead box A1	Mus musculus	200-205
34523052-9	2021	The effects of berberine on NS-induced impairments were blocked by the injection of the miR-132-3p antagomir, which exacerbated intestinal injuries, induced systemic inflammation, and reactivated the FOXA1 and NF-kappaB pathways.	Berberine	15-24	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	210-219
34719112-4	2021	For the first time, this paper reviews the evidence from in vitro and in vivo experimental models to explore the anti-inflammatory effects of BBR in periodontitis and exhibits that BBR has the high potency to exert anti-inflammatory effects by reducing expression and secretion of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-17, RANKL, MMP-2, MMP-9 and MCP-1.	Berberine	181-184	tumor necrosis factor	Homo sapiens	318-327
34719112-4	2021	For the first time, this paper reviews the evidence from in vitro and in vivo experimental models to explore the anti-inflammatory effects of BBR in periodontitis and exhibits that BBR has the high potency to exert anti-inflammatory effects by reducing expression and secretion of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-17, RANKL, MMP-2, MMP-9 and MCP-1.	Berberine	181-184	interleukin 1 alpha	Homo sapiens	329-337
34719112-4	2021	For the first time, this paper reviews the evidence from in vitro and in vivo experimental models to explore the anti-inflammatory effects of BBR in periodontitis and exhibits that BBR has the high potency to exert anti-inflammatory effects by reducing expression and secretion of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-17, RANKL, MMP-2, MMP-9 and MCP-1.	Berberine	181-184	interleukin 17A	Homo sapiens	339-344
34719112-4	2021	For the first time, this paper reviews the evidence from in vitro and in vivo experimental models to explore the anti-inflammatory effects of BBR in periodontitis and exhibits that BBR has the high potency to exert anti-inflammatory effects by reducing expression and secretion of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-17, RANKL, MMP-2, MMP-9 and MCP-1.	Berberine	181-184	TNF superfamily member 11	Homo sapiens	346-351
34719112-4	2021	For the first time, this paper reviews the evidence from in vitro and in vivo experimental models to explore the anti-inflammatory effects of BBR in periodontitis and exhibits that BBR has the high potency to exert anti-inflammatory effects by reducing expression and secretion of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-17, RANKL, MMP-2, MMP-9 and MCP-1.	Berberine	181-184	matrix metallopeptidase 2	Homo sapiens	353-358
34719112-4	2021	For the first time, this paper reviews the evidence from in vitro and in vivo experimental models to explore the anti-inflammatory effects of BBR in periodontitis and exhibits that BBR has the high potency to exert anti-inflammatory effects by reducing expression and secretion of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-17, RANKL, MMP-2, MMP-9 and MCP-1.	Berberine	181-184	matrix metallopeptidase 9	Homo sapiens	360-365
34719112-4	2021	For the first time, this paper reviews the evidence from in vitro and in vivo experimental models to explore the anti-inflammatory effects of BBR in periodontitis and exhibits that BBR has the high potency to exert anti-inflammatory effects by reducing expression and secretion of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-17, RANKL, MMP-2, MMP-9 and MCP-1.	Berberine	181-184	C-C motif chemokine ligand 2	Homo sapiens	370-375
34643248-0	2021	Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	102-105
34427876-0	2021	Berberine Attenuates MPP+-Induced Neuronal Injury by Regulating LINC00943/miR-142-5p/KPNA4/NF-kappaB Pathway in SK-N-SH Cells.	Berberine	0-9	long intergenic non-protein coding RNA 943	Homo sapiens	64-73
34427876-0	2021	Berberine Attenuates MPP+-Induced Neuronal Injury by Regulating LINC00943/miR-142-5p/KPNA4/NF-kappaB Pathway in SK-N-SH Cells.	Berberine	0-9	karyopherin subunit alpha 4	Homo sapiens	85-90
34427876-0	2021	Berberine Attenuates MPP+-Induced Neuronal Injury by Regulating LINC00943/miR-142-5p/KPNA4/NF-kappaB Pathway in SK-N-SH Cells.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	91-100
34427876-3	2021	The purpose of this study was to investigate whether LINC00943 was involved in the role of berberine in PD.	Berberine	91-100	long intergenic non-protein coding RNA 943	Homo sapiens	53-62
34427876-13	2021	LINC00943 (or KPNA4) overexpression or miR-142-5p inhibition abated the neuro-protective role of berberine in PD cell model.	Berberine	97-106	long intergenic non-protein coding RNA 943	Homo sapiens	0-9
34427876-13	2021	LINC00943 (or KPNA4) overexpression or miR-142-5p inhibition abated the neuro-protective role of berberine in PD cell model.	Berberine	97-106	karyopherin (importin) alpha 4	Mus musculus	14-19
34427876-15	2021	Additionally, berberine inhibited NF-kappaB pathway by regulating LINC00943/miR-142-5p/KPNA4 axis.	Berberine	14-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	34-43
34427876-15	2021	Additionally, berberine inhibited NF-kappaB pathway by regulating LINC00943/miR-142-5p/KPNA4 axis.	Berberine	14-23	long intergenic non-protein coding RNA 943	Homo sapiens	66-75
34427876-15	2021	Additionally, berberine inhibited NF-kappaB pathway by regulating LINC00943/miR-142-5p/KPNA4 axis.	Berberine	14-23	karyopherin (importin) alpha 4	Mus musculus	87-92
34427876-16	2021	Berberine protected SK-N-SH cell from MPP+-induced neuronal damage via regulating LINC00943/miR-142-5p/KPNA4/NF-kappaB pathway, highlighting novel evidence for the neuro-protective role of berberine in PD.	Berberine	0-9	long intergenic non-protein coding RNA 943	Homo sapiens	82-91
34427876-16	2021	Berberine protected SK-N-SH cell from MPP+-induced neuronal damage via regulating LINC00943/miR-142-5p/KPNA4/NF-kappaB pathway, highlighting novel evidence for the neuro-protective role of berberine in PD.	Berberine	0-9	karyopherin subunit alpha 4	Homo sapiens	103-108
34427876-16	2021	Berberine protected SK-N-SH cell from MPP+-induced neuronal damage via regulating LINC00943/miR-142-5p/KPNA4/NF-kappaB pathway, highlighting novel evidence for the neuro-protective role of berberine in PD.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	109-118
34427876-16	2021	Berberine protected SK-N-SH cell from MPP+-induced neuronal damage via regulating LINC00943/miR-142-5p/KPNA4/NF-kappaB pathway, highlighting novel evidence for the neuro-protective role of berberine in PD.	Berberine	189-198	long intergenic non-protein coding RNA 943	Homo sapiens	82-91
33417512-0	2021	Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells.	Berberine	0-9	notch receptor 1	Homo sapiens	24-30
33417512-0	2021	Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells.	Berberine	0-9	phosphatase and tensin homolog	Homo sapiens	31-35
33417512-0	2021	Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	41-44
33417512-0	2021	Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	45-49
33417512-0	2021	Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells.	Berberine	0-9	N-methylpurine DNA glycosylase	Homo sapiens	91-94
33417512-12	2021	BBR dose-dependently up-regulated PTEN, while inhibited Notch1, PI3K, Akt and mTOR proteins at 1.0-9.0 muM (p < 0.05).	Berberine	0-3	phosphatase and tensin homolog	Homo sapiens	34-38
33417512-12	2021	BBR dose-dependently up-regulated PTEN, while inhibited Notch1, PI3K, Akt and mTOR proteins at 1.0-9.0 muM (p < 0.05).	Berberine	0-3	notch receptor 1	Homo sapiens	56-62
33417512-12	2021	BBR dose-dependently up-regulated PTEN, while inhibited Notch1, PI3K, Akt and mTOR proteins at 1.0-9.0 muM (p < 0.05).	Berberine	0-3	AKT serine/threonine kinase 1	Homo sapiens	70-73
33417512-12	2021	BBR dose-dependently up-regulated PTEN, while inhibited Notch1, PI3K, Akt and mTOR proteins at 1.0-9.0 muM (p < 0.05).	Berberine	0-3	mechanistic target of rapamycin kinase	Homo sapiens	78-82
33539718-0	2021	Berberine attenuates septic cardiomyopathy by inhibiting TLR4/NF-kappaB signalling in rats.	Berberine	0-9	toll-like receptor 4	Rattus norvegicus	57-61
33539718-5	2021	RESULT: Berberine could recover myocardial injury by partially increased +- dp/dt max (1151, 445 mmHg/s) and LVEDP levels (1.49 mmHg) with LPS-induced rats, as well as an ameliorated increase of cTnT (217.53 pg/mL) in the Ber group compared with that in the LPS group (at 24 h).	Berberine	8-17	troponin T2, cardiac type	Rattus norvegicus	195-199
33539718-8	2021	DISCUSSION AND CONCLUSIONS: Berberine showed a protective effect on septic cardiomyopathy rats possibly through inhibiting the activation of TLR4/NF-kappaB signalling pathway.	Berberine	28-37	toll-like receptor 4	Rattus norvegicus	141-145
34643248-0	2021	Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway.	Berberine	0-9	mechanistic target of rapamycin kinase	Homo sapiens	106-110
34643248-0	2021	Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway.	Berberine	0-9	solute carrier family 2 member 1	Homo sapiens	111-116
34643248-7	2021	Augmentation of Akt phosphorylation levels by the Akt activator, SC79, abolished the BBR-induced decrease in ATP synthesis, glucose uptake, GLUT1 expression and cell proliferation, and reversed the proapoptotic effect of BBR.	Berberine	85-88	AKT serine/threonine kinase 1	Homo sapiens	16-19
34643248-7	2021	Augmentation of Akt phosphorylation levels by the Akt activator, SC79, abolished the BBR-induced decrease in ATP synthesis, glucose uptake, GLUT1 expression and cell proliferation, and reversed the proapoptotic effect of BBR.	Berberine	85-88	AKT serine/threonine kinase 1	Homo sapiens	50-53
34643248-7	2021	Augmentation of Akt phosphorylation levels by the Akt activator, SC79, abolished the BBR-induced decrease in ATP synthesis, glucose uptake, GLUT1 expression and cell proliferation, and reversed the proapoptotic effect of BBR.	Berberine	85-88	solute carrier family 2 member 1	Homo sapiens	140-145
34643248-7	2021	Augmentation of Akt phosphorylation levels by the Akt activator, SC79, abolished the BBR-induced decrease in ATP synthesis, glucose uptake, GLUT1 expression and cell proliferation, and reversed the proapoptotic effect of BBR.	Berberine	221-224	AKT serine/threonine kinase 1	Homo sapiens	16-19
34643248-8	2021	These findings indicated that the antineoplastic effect of BBR may involve the reversal of the Warburg effect by downregulating the Akt/mTOR/GLUT1 signaling pathway.	Berberine	59-62	AKT serine/threonine kinase 1	Homo sapiens	132-135
34643248-8	2021	These findings indicated that the antineoplastic effect of BBR may involve the reversal of the Warburg effect by downregulating the Akt/mTOR/GLUT1 signaling pathway.	Berberine	59-62	mechanistic target of rapamycin kinase	Homo sapiens	136-140
34643248-8	2021	These findings indicated that the antineoplastic effect of BBR may involve the reversal of the Warburg effect by downregulating the Akt/mTOR/GLUT1 signaling pathway.	Berberine	59-62	solute carrier family 2 member 1	Homo sapiens	141-146
34747965-0	2021	Glucocorticoid receptor-mediated alleviation of inflammation by berberine: in vitro, in silico and in vivo investigations.	Berberine	64-73	nuclear receptor subfamily 3 group C member 1	Homo sapiens	0-23
34747965-2	2021	In this work, glucocorticoid receptor (GR)-mediated alleviation of inflammation by berberine was investigated by a combination of in vitro, in silico, and in vivo approaches.	Berberine	83-92	nuclear receptor subfamily 3 group C member 1	Homo sapiens	14-37
34787617-6	2021	Moreover, a total of 160 significantly altered proteins were screened, among which AKAP12 presented significantly increased levels under berberine treatment.	Berberine	137-146	A-kinase anchoring protein 12	Homo sapiens	83-89
34787617-11	2021	Regulating AKAP12 signalling by berberine might provide a promising strategy for HCC treatment.	Berberine	32-41	A-kinase anchoring protein 12	Homo sapiens	11-17
34883645-11	2021	Treatment with CA/HA/BER or CA/HA/ME downregulated RANKL and upregulated Osterix associated with a reduction in RANKL/OPG ratio, at p < 0.05.	Berberine	21-24	TNF superfamily member 11	Homo sapiens	51-56
34883645-11	2021	Treatment with CA/HA/BER or CA/HA/ME downregulated RANKL and upregulated Osterix associated with a reduction in RANKL/OPG ratio, at p < 0.05.	Berberine	21-24	Sp7 transcription factor	Homo sapiens	73-80
34883645-11	2021	Treatment with CA/HA/BER or CA/HA/ME downregulated RANKL and upregulated Osterix associated with a reduction in RANKL/OPG ratio, at p < 0.05.	Berberine	21-24	TNF superfamily member 11	Homo sapiens	112-117
34883645-11	2021	Treatment with CA/HA/BER or CA/HA/ME downregulated RANKL and upregulated Osterix associated with a reduction in RANKL/OPG ratio, at p < 0.05.	Berberine	21-24	basic transcription factor 3 pseudogene 11	Homo sapiens	118-121
34747965-2	2021	In this work, glucocorticoid receptor (GR)-mediated alleviation of inflammation by berberine was investigated by a combination of in vitro, in silico, and in vivo approaches.	Berberine	83-92	nuclear receptor subfamily 3 group C member 1	Homo sapiens	39-41
34747965-3	2021	The fluorescence polarization assay showed that berberine bound to GR with an IC50 value of 9.14 +- 0.16 pM.	Berberine	48-57	nuclear receptor subfamily 3 group C member 1	Homo sapiens	67-69
34747965-4	2021	Molecular docking and molecular dynamics simulation suggested that berberine bound stably to the active site of GR via hydrogen bonding and hydrophobic interactions.	Berberine	67-76	nuclear receptor subfamily 3 group C member 1	Homo sapiens	112-114
34747965-5	2021	Berberine induced GR nuclear translocation but did not activate the glucocorticoid response element in HeLa cells.	Berberine	0-9	nuclear receptor subfamily 3 group C member 1	Homo sapiens	18-20
34747965-6	2021	Furthermore, both gene and protein expressions of PEPCK were significantly attenuated by berberine in HepG2 cells.	Berberine	89-98	phosphoenolpyruvate carboxykinase 2, mitochondrial	Homo sapiens	50-55
34747965-7	2021	Interestingly, berberine downregulated CBG mRNA and protein levels without up-regulating TAT mRNA and protein levels in HepG2 cells, demonstrating its dissociated characteristics that could separate transrepression from transactivation.	Berberine	15-24	glucosylceramidase beta 3 (gene/pseudogene)	Homo sapiens	39-42
34747965-9	2021	In conclusion, berberine might serve as a potential selective GR modulator.	Berberine	15-24	nuclear receptor subfamily 3, group C, member 1	Mus musculus	62-64
34943140-1	2021	Berberine, the most known quaternary protoberberine alkaloid (QPA), has been reported to inhibit the SIK3 protein connected with breast cancer.	Berberine	0-9	SIK family kinase 3	Homo sapiens	101-105
34943140-2	2021	Berberine also appears to reduce the bcl-2 and XIAP expression-proteins responsible for the inhibition of apoptosis.	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	37-42
34943140-2	2021	Berberine also appears to reduce the bcl-2 and XIAP expression-proteins responsible for the inhibition of apoptosis.	Berberine	0-9	X-linked inhibitor of apoptosis	Homo sapiens	47-51
34866036-0	2022	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53.	Berberine	108-118	MDM2 proto-oncogene	Homo sapiens	15-19
34481875-0	2021	Berberine activates the beta-catenin/TCF4 signaling pathway by down-regulating miR-106b to promote GLP-1 production by intestinal L cells.	Berberine	0-9	catenin (cadherin associated protein), beta 1	Mus musculus	24-36
34358871-0	2021	Berberine improves intestinal barrier function and reduces inflammation, immunosuppression, and oxidative stress by regulating the NF-kappaB/MAPK signaling pathway in deoxynivalenol-challenged piglets.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	131-140
34358871-6	2021	BBR significantly increased the protein expression levels of zonula occludens 1 (ZO-1), Occludin and Claudin-1 in the ileal and jejunal mucosa and increased the morphological parameters of the jejunum.	Berberine	0-3	tight junction protein 1	Homo sapiens	61-79
34358871-6	2021	BBR significantly increased the protein expression levels of zonula occludens 1 (ZO-1), Occludin and Claudin-1 in the ileal and jejunal mucosa and increased the morphological parameters of the jejunum.	Berberine	0-3	tight junction protein 1	Homo sapiens	81-85
34358871-6	2021	BBR significantly increased the protein expression levels of zonula occludens 1 (ZO-1), Occludin and Claudin-1 in the ileal and jejunal mucosa and increased the morphological parameters of the jejunum.	Berberine	0-3	occludin	Homo sapiens	88-96
34358871-6	2021	BBR significantly increased the protein expression levels of zonula occludens 1 (ZO-1), Occludin and Claudin-1 in the ileal and jejunal mucosa and increased the morphological parameters of the jejunum.	Berberine	0-3	claudin 1	Homo sapiens	101-110
34358871-7	2021	Moreover, we found that BBR significantly reduced the DON-induced gene and protein expression levels of ERK, JNK, and NF-kappaB in the jejunum and ileum.	Berberine	24-27	mitogen-activated protein kinase 1	Homo sapiens	104-107
34358871-7	2021	Moreover, we found that BBR significantly reduced the DON-induced gene and protein expression levels of ERK, JNK, and NF-kappaB in the jejunum and ileum.	Berberine	24-27	mitogen-activated protein kinase 8	Homo sapiens	109-112
34358871-7	2021	Moreover, we found that BBR significantly reduced the DON-induced gene and protein expression levels of ERK, JNK, and NF-kappaB in the jejunum and ileum.	Berberine	24-27	nuclear factor kappa B subunit 1	Homo sapiens	118-127
34677968-0	2021	Berberine Molecular Recognition of the Parallel MYC G-Quadruplex in Solution.	Berberine	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	48-51
34778460-0	2021	SOCS1 Mediates Berberine-Induced Amelioration of Microglial Activated States in N9 Microglia Exposed to beta Amyloid.	Berberine	15-24	suppressor of cytokine signaling 1	Homo sapiens	0-5
34778460-2	2021	Berberine (BBR) can reduce microglial activation in Abeta-treated microglial cells; the mechanism, however, is still illusive.	Berberine	0-9	amyloid beta precursor protein	Homo sapiens	52-57
34778460-2	2021	Berberine (BBR) can reduce microglial activation in Abeta-treated microglial cells; the mechanism, however, is still illusive.	Berberine	11-14	amyloid beta precursor protein	Homo sapiens	52-57
34803675-0	2021	Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4-BLT1 Axis.	Berberine	0-9	leukotriene B4 receptor	Homo sapiens	81-85
34803675-4	2021	Berberine (BBR) has been shown to relieve insulin resistance due to its anti-inflammatory properties.	Berberine	0-9	insulin	Homo sapiens	42-49
34803675-4	2021	Berberine (BBR) has been shown to relieve insulin resistance due to its anti-inflammatory properties.	Berberine	11-14	insulin	Homo sapiens	42-49
34803675-10	2021	Conclusions: Our study demonstrated that BBR treatment could reduce intracellular insulin resistance and inflammation of hepatic cells, as well as chemotaxis of macrophages induced by LTB4.	Berberine	41-44	insulin	Homo sapiens	82-89
34795594-0	2021	Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial beta-glucuronidase.	Berberine	0-9	glucuronidase beta	Homo sapiens	151-169
34686466-0	2021	Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis.	Berberine	0-9	sirtuin 1	Homo sapiens	69-74
34686466-0	2021	Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis.	Berberine	0-9	forkhead box O1	Homo sapiens	75-80
34686466-0	2021	Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis.	Berberine	0-9	sterol regulatory element binding transcription factor 2	Homo sapiens	81-87
34686466-8	2021	Both SIRT1 inhibitor SIRT1-IN-1 and FoxO1 inhibitor AS1842856 blocked the BBR-mediated therapeutic effects.	Berberine	74-77	sirtuin 1	Homo sapiens	5-10
34686466-8	2021	Both SIRT1 inhibitor SIRT1-IN-1 and FoxO1 inhibitor AS1842856 blocked the BBR-mediated therapeutic effects.	Berberine	74-77	sirtuin 1	Homo sapiens	21-26
34686466-8	2021	Both SIRT1 inhibitor SIRT1-IN-1 and FoxO1 inhibitor AS1842856 blocked the BBR-mediated therapeutic effects.	Berberine	74-77	forkhead box O1	Homo sapiens	36-41
34686466-10	2021	CONCLUSION: BBR can mitigate FFA-induced steatosis in HepG2 cells by activating SIRT1-FoxO1-SREBP2 signal pathway.	Berberine	12-15	sirtuin 1	Homo sapiens	80-85
34686466-10	2021	CONCLUSION: BBR can mitigate FFA-induced steatosis in HepG2 cells by activating SIRT1-FoxO1-SREBP2 signal pathway.	Berberine	12-15	forkhead box O1	Homo sapiens	86-91
34686466-10	2021	CONCLUSION: BBR can mitigate FFA-induced steatosis in HepG2 cells by activating SIRT1-FoxO1-SREBP2 signal pathway.	Berberine	12-15	sterol regulatory element binding transcription factor 2	Homo sapiens	92-98
34389401-0	2021	The inhibitory effect of PLGA-encapsulated berberine on hepatotoxicity and alpha-smooth muscle actin (alpha-SMA) gene expression.	Berberine	43-52	actin gamma 2, smooth muscle	Rattus norvegicus	75-100
34389401-10	2021	Although the expression level of alpha-SMA was downregulated in the CCl4-injected rats that were treated with BBR, alpha-SMA expression in this group was still remarkably higher than the control group.	Berberine	110-113	C-C motif chemokine ligand 4	Rattus norvegicus	68-72
34258700-8	2021	BBR and UMB reduced the expression of pro-apoptotic protein Bax and apoptotic protein caspase-3 as well as increased the expression of anti-apoptotic protein Bcl-2.	Berberine	0-3	caspase 3	Homo sapiens	86-95
34258700-8	2021	BBR and UMB reduced the expression of pro-apoptotic protein Bax and apoptotic protein caspase-3 as well as increased the expression of anti-apoptotic protein Bcl-2.	Berberine	0-3	BCL2 apoptosis regulator	Homo sapiens	158-163
34867376-0	2021	Blocking HMGB1/RAGE Signaling by Berberine Alleviates A1 Astrocyte and Attenuates Sepsis-Associated Encephalopathy.	Berberine	33-42	high mobility group box 1	Mus musculus	9-14
34867376-0	2021	Blocking HMGB1/RAGE Signaling by Berberine Alleviates A1 Astrocyte and Attenuates Sepsis-Associated Encephalopathy.	Berberine	33-42	advanced glycosylation end product-specific receptor	Mus musculus	15-19
34867376-5	2021	Reduced expression levels of TNF-alpha, IL-1alpha, and C1qA were exhibited in the hippocampus of the berberine treatment group, and attenuated effect of declining neo-neuron, activation of microglia and astrocytes in the hippocampus of mice with sepsis were also found.	Berberine	101-110	tumor necrosis factor	Mus musculus	29-38
34867376-5	2021	Reduced expression levels of TNF-alpha, IL-1alpha, and C1qA were exhibited in the hippocampus of the berberine treatment group, and attenuated effect of declining neo-neuron, activation of microglia and astrocytes in the hippocampus of mice with sepsis were also found.	Berberine	101-110	interleukin 1 alpha	Mus musculus	40-49
34867376-5	2021	Reduced expression levels of TNF-alpha, IL-1alpha, and C1qA were exhibited in the hippocampus of the berberine treatment group, and attenuated effect of declining neo-neuron, activation of microglia and astrocytes in the hippocampus of mice with sepsis were also found.	Berberine	101-110	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	55-59
34867376-6	2021	Moreover, berberine inhibits microglia-stressed A1 astrocytes by inhibiting HMGB1 signaling was revealed, then the molecular mechanism of HMGB1/RAGE signaling inhibition leads to the better outcome of SAE was elucidated.	Berberine	10-19	high mobility group box 1	Mus musculus	76-81
34867376-6	2021	Moreover, berberine inhibits microglia-stressed A1 astrocytes by inhibiting HMGB1 signaling was revealed, then the molecular mechanism of HMGB1/RAGE signaling inhibition leads to the better outcome of SAE was elucidated.	Berberine	10-19	high mobility group box 1	Mus musculus	138-143
34867376-6	2021	Moreover, berberine inhibits microglia-stressed A1 astrocytes by inhibiting HMGB1 signaling was revealed, then the molecular mechanism of HMGB1/RAGE signaling inhibition leads to the better outcome of SAE was elucidated.	Berberine	10-19	advanced glycosylation end product-specific receptor	Mus musculus	144-148
34867376-7	2021	To summarize, this research indicated that berberine targets HMGB1/RAGE signaling to inhibit microglia-stressed A1 astrocyte and neo-neuron decline, which consequently alleviates sepsis-induced cognitive impairment.	Berberine	43-52	high mobility group box 1	Mus musculus	61-66
34867376-7	2021	To summarize, this research indicated that berberine targets HMGB1/RAGE signaling to inhibit microglia-stressed A1 astrocyte and neo-neuron decline, which consequently alleviates sepsis-induced cognitive impairment.	Berberine	43-52	advanced glycosylation end product-specific receptor	Mus musculus	67-71
34562655-1	2021	Berberine is a natural isoquinoline alkaloid present in various herbs and is effective against metabolic syndrome in the pre-diabetic stage and high insulin resistance.	Berberine	0-9	insulin	Homo sapiens	149-156
34562655-2	2021	The present study aimed to determine the effectiveness of WJCPR11, a berberine derivative that is commonly used for diabetes treatment, in ameliorating insulin resistance and diabetes treatment.	Berberine	69-78	insulin	Homo sapiens	152-159
34766459-0	2022	Effects of berberine on the pharmacokinetics of florfenicol and levels of cytochrome P450 3A37, multidrug resistance 1, and chicken xenobiotic-sensing orphan nuclear receptor mRNA expression in broilers.	Berberine	11-20	nuclear receptor subfamily 1 group I member 3	Gallus gallus	124-174
34609010-7	2021	Our results showed that berberine-LCNs significantly reduced the expression of CCl-20, CXCL-8 and HO-1 at dose of 5microM.	Berberine	24-33	C-C motif chemokine ligand 20	Homo sapiens	79-85
34609010-7	2021	Our results showed that berberine-LCNs significantly reduced the expression of CCl-20, CXCL-8 and HO-1 at dose of 5microM.	Berberine	24-33	C-X-C motif chemokine ligand 8	Homo sapiens	87-93
34609010-7	2021	Our results showed that berberine-LCNs significantly reduced the expression of CCl-20, CXCL-8 and HO-1 at dose of 5microM.	Berberine	24-33	heme oxygenase 1	Homo sapiens	98-102
34609010-8	2021	Collectively, our findings suggest that berberine-LCNs have inhibitory effect on inflammation/oxidative stress related cytokines i.e. CCL20, CXCL-8, and HO-1 which could be a novel therapeutic target for the management of lung cancer.	Berberine	40-49	C-C motif chemokine ligand 20	Homo sapiens	134-139
34609010-8	2021	Collectively, our findings suggest that berberine-LCNs have inhibitory effect on inflammation/oxidative stress related cytokines i.e. CCL20, CXCL-8, and HO-1 which could be a novel therapeutic target for the management of lung cancer.	Berberine	40-49	C-X-C motif chemokine ligand 8	Homo sapiens	141-147
34609010-8	2021	Collectively, our findings suggest that berberine-LCNs have inhibitory effect on inflammation/oxidative stress related cytokines i.e. CCL20, CXCL-8, and HO-1 which could be a novel therapeutic target for the management of lung cancer.	Berberine	40-49	heme oxygenase 1	Homo sapiens	153-157
34609010-11	2021	Our study showed that Berberine LCNs significantly downregulate the expression of CXCL-8, CCL-20 and HO-1 which suggests that Berberine loaded nanoparticles could be a promising therapeutic alternative for the management of lung cancer.	Berberine	126-135	C-X-C motif chemokine ligand 8	Homo sapiens	82-88
34609010-11	2021	Our study showed that Berberine LCNs significantly downregulate the expression of CXCL-8, CCL-20 and HO-1 which suggests that Berberine loaded nanoparticles could be a promising therapeutic alternative for the management of lung cancer.	Berberine	126-135	C-C motif chemokine ligand 20	Homo sapiens	90-96
34609010-11	2021	Our study showed that Berberine LCNs significantly downregulate the expression of CXCL-8, CCL-20 and HO-1 which suggests that Berberine loaded nanoparticles could be a promising therapeutic alternative for the management of lung cancer.	Berberine	126-135	heme oxygenase 1	Homo sapiens	101-105
34773184-0	2021	Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation.	Berberine	0-9	tribbles pseudokinase 1	Mus musculus	101-106
34802527-12	2021	Berberine treatment ameliorated the CPF-induced downregulation of Bcl-2, Bax translocation, and up-regulation of caspase-3 in F1 pups.	Berberine	0-9	BCL2, apoptosis regulator	Rattus norvegicus	66-71
34802527-12	2021	Berberine treatment ameliorated the CPF-induced downregulation of Bcl-2, Bax translocation, and up-regulation of caspase-3 in F1 pups.	Berberine	0-9	BCL2 associated X, apoptosis regulator	Rattus norvegicus	73-76
34802527-12	2021	Berberine treatment ameliorated the CPF-induced downregulation of Bcl-2, Bax translocation, and up-regulation of caspase-3 in F1 pups.	Berberine	0-9	caspase 3	Rattus norvegicus	113-122
34716337-0	2021	Author Correction: Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.	Berberine	19-28	insulin	Homo sapiens	35-42
34716337-0	2021	Author Correction: Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.	Berberine	19-28	potassium voltage-gated channel subfamily H member 6	Homo sapiens	70-75
34481875-0	2021	Berberine activates the beta-catenin/TCF4 signaling pathway by down-regulating miR-106b to promote GLP-1 production by intestinal L cells.	Berberine	0-9	transcription factor 4	Mus musculus	37-41
34481875-0	2021	Berberine activates the beta-catenin/TCF4 signaling pathway by down-regulating miR-106b to promote GLP-1 production by intestinal L cells.	Berberine	0-9	microRNA 106b	Mus musculus	79-87
34481875-0	2021	Berberine activates the beta-catenin/TCF4 signaling pathway by down-regulating miR-106b to promote GLP-1 production by intestinal L cells.	Berberine	0-9	glucagon	Mus musculus	99-104
34481875-1	2021	Berberine facilitates the production of glucagon-like peptide-1 (GLP-1) by intestinal L cells.	Berberine	0-9	glucagon	Mus musculus	40-63
34481875-1	2021	Berberine facilitates the production of glucagon-like peptide-1 (GLP-1) by intestinal L cells.	Berberine	0-9	glucagon	Mus musculus	65-70
34481875-2	2021	Here, we aimed to reveal the mechanism of berberine facilitating the production of GLP-1 by intestinal L cells.	Berberine	42-51	glucagon	Mus musculus	83-88
34481875-4	2021	Meanwhile, the mechanism analysis demonstrated that a dose of 100 muM berberine down-regulated the miR-106b expression by elevating the methylation levels of miR-106b in STC-1 cells and miR-106b bound to TCF4 in 293T cells.	Berberine	70-79	microRNA 106b	Homo sapiens	99-107
34481875-4	2021	Meanwhile, the mechanism analysis demonstrated that a dose of 100 muM berberine down-regulated the miR-106b expression by elevating the methylation levels of miR-106b in STC-1 cells and miR-106b bound to TCF4 in 293T cells.	Berberine	70-79	microRNA 106b	Homo sapiens	158-166
34481875-4	2021	Meanwhile, the mechanism analysis demonstrated that a dose of 100 muM berberine down-regulated the miR-106b expression by elevating the methylation levels of miR-106b in STC-1 cells and miR-106b bound to TCF4 in 293T cells.	Berberine	70-79	microRNA 106b	Homo sapiens	186-194
34481875-4	2021	Meanwhile, the mechanism analysis demonstrated that a dose of 100 muM berberine down-regulated the miR-106b expression by elevating the methylation levels of miR-106b in STC-1 cells and miR-106b bound to TCF4 in 293T cells.	Berberine	70-79	transcription factor 4	Homo sapiens	204-208
34481875-5	2021	Moreover, the 100 mg/kg berberine daily through diet activated the beta-catenin/TCF4 signaling pathway by decreasing miR-106b, thereby facilitating GLP-1 production in intestinal L cells through the in vivo assays.	Berberine	24-33	catenin beta 1	Homo sapiens	67-79
34481875-5	2021	Moreover, the 100 mg/kg berberine daily through diet activated the beta-catenin/TCF4 signaling pathway by decreasing miR-106b, thereby facilitating GLP-1 production in intestinal L cells through the in vivo assays.	Berberine	24-33	transcription factor 4	Homo sapiens	80-84
34481875-5	2021	Moreover, the 100 mg/kg berberine daily through diet activated the beta-catenin/TCF4 signaling pathway by decreasing miR-106b, thereby facilitating GLP-1 production in intestinal L cells through the in vivo assays.	Berberine	24-33	microRNA 106b	Homo sapiens	117-125
34481875-5	2021	Moreover, the 100 mg/kg berberine daily through diet activated the beta-catenin/TCF4 signaling pathway by decreasing miR-106b, thereby facilitating GLP-1 production in intestinal L cells through the in vivo assays.	Berberine	24-33	glucagon like peptide 1 receptor	Homo sapiens	148-153
34481875-6	2021	Conclusively, our experimental data illustrated that berberine decreased miR-106b expression by increasing its methylation levels and then activated the beta-catenin/TCF4 signaling pathway, thereby facilitating GLP-1 production by intestinal L cells.	Berberine	53-62	microRNA 106b	Homo sapiens	73-81
34481875-6	2021	Conclusively, our experimental data illustrated that berberine decreased miR-106b expression by increasing its methylation levels and then activated the beta-catenin/TCF4 signaling pathway, thereby facilitating GLP-1 production by intestinal L cells.	Berberine	53-62	catenin beta 1	Homo sapiens	153-165
34481875-6	2021	Conclusively, our experimental data illustrated that berberine decreased miR-106b expression by increasing its methylation levels and then activated the beta-catenin/TCF4 signaling pathway, thereby facilitating GLP-1 production by intestinal L cells.	Berberine	53-62	transcription factor 4	Homo sapiens	166-170
34481875-6	2021	Conclusively, our experimental data illustrated that berberine decreased miR-106b expression by increasing its methylation levels and then activated the beta-catenin/TCF4 signaling pathway, thereby facilitating GLP-1 production by intestinal L cells.	Berberine	53-62	glucagon like peptide 1 receptor	Homo sapiens	211-216
34803500-0	2021	Berberine improves insulin-induced diabetic retinopathy through exclusively suppressing Akt/mTOR-mediated HIF-1alpha/VEGF activation in retina endothelial cells.	Berberine	0-9	insulin	Homo sapiens	19-26
34768896-10	2021	In addition, BBR induced not only a high degree of co-localization of GPER1 and microtubule-associated protein 1 light chain 3 (MAP1LC3), but also the accumulation of sequestosome 1 (SQSTM1/p62) by the inhibition of the nuclear translocation of the nuclear factor-kappa B (NF-kappaB) subunit (RELA/p65), which indicates NF-kappaB inhibition and anti-cancer effects.	Berberine	13-16	G protein-coupled estrogen receptor 1	Homo sapiens	70-75
34768896-10	2021	In addition, BBR induced not only a high degree of co-localization of GPER1 and microtubule-associated protein 1 light chain 3 (MAP1LC3), but also the accumulation of sequestosome 1 (SQSTM1/p62) by the inhibition of the nuclear translocation of the nuclear factor-kappa B (NF-kappaB) subunit (RELA/p65), which indicates NF-kappaB inhibition and anti-cancer effects.	Berberine	13-16	sequestosome 1	Homo sapiens	167-181
34768896-10	2021	In addition, BBR induced not only a high degree of co-localization of GPER1 and microtubule-associated protein 1 light chain 3 (MAP1LC3), but also the accumulation of sequestosome 1 (SQSTM1/p62) by the inhibition of the nuclear translocation of the nuclear factor-kappa B (NF-kappaB) subunit (RELA/p65), which indicates NF-kappaB inhibition and anti-cancer effects.	Berberine	13-16	sequestosome 1	Homo sapiens	183-189
34768896-10	2021	In addition, BBR induced not only a high degree of co-localization of GPER1 and microtubule-associated protein 1 light chain 3 (MAP1LC3), but also the accumulation of sequestosome 1 (SQSTM1/p62) by the inhibition of the nuclear translocation of the nuclear factor-kappa B (NF-kappaB) subunit (RELA/p65), which indicates NF-kappaB inhibition and anti-cancer effects.	Berberine	13-16	sequestosome 1	Homo sapiens	190-193
34768896-10	2021	In addition, BBR induced not only a high degree of co-localization of GPER1 and microtubule-associated protein 1 light chain 3 (MAP1LC3), but also the accumulation of sequestosome 1 (SQSTM1/p62) by the inhibition of the nuclear translocation of the nuclear factor-kappa B (NF-kappaB) subunit (RELA/p65), which indicates NF-kappaB inhibition and anti-cancer effects.	Berberine	13-16	nuclear factor kappa B subunit 1	Homo sapiens	249-271
34768896-10	2021	In addition, BBR induced not only a high degree of co-localization of GPER1 and microtubule-associated protein 1 light chain 3 (MAP1LC3), but also the accumulation of sequestosome 1 (SQSTM1/p62) by the inhibition of the nuclear translocation of the nuclear factor-kappa B (NF-kappaB) subunit (RELA/p65), which indicates NF-kappaB inhibition and anti-cancer effects.	Berberine	13-16	nuclear factor kappa B subunit 1	Homo sapiens	273-282
34768896-10	2021	In addition, BBR induced not only a high degree of co-localization of GPER1 and microtubule-associated protein 1 light chain 3 (MAP1LC3), but also the accumulation of sequestosome 1 (SQSTM1/p62) by the inhibition of the nuclear translocation of the nuclear factor-kappa B (NF-kappaB) subunit (RELA/p65), which indicates NF-kappaB inhibition and anti-cancer effects.	Berberine	13-16	RELA proto-oncogene, NF-kB subunit	Homo sapiens	293-297
34768896-10	2021	In addition, BBR induced not only a high degree of co-localization of GPER1 and microtubule-associated protein 1 light chain 3 (MAP1LC3), but also the accumulation of sequestosome 1 (SQSTM1/p62) by the inhibition of the nuclear translocation of the nuclear factor-kappa B (NF-kappaB) subunit (RELA/p65), which indicates NF-kappaB inhibition and anti-cancer effects.	Berberine	13-16	RELA proto-oncogene, NF-kB subunit	Homo sapiens	298-301
34768896-10	2021	In addition, BBR induced not only a high degree of co-localization of GPER1 and microtubule-associated protein 1 light chain 3 (MAP1LC3), but also the accumulation of sequestosome 1 (SQSTM1/p62) by the inhibition of the nuclear translocation of the nuclear factor-kappa B (NF-kappaB) subunit (RELA/p65), which indicates NF-kappaB inhibition and anti-cancer effects.	Berberine	13-16	nuclear factor kappa B subunit 1	Homo sapiens	320-329
34768896-11	2021	This result proved that the promotional effect of BBR on the GPER1/NF-kappaB pathway was closely related to its inhibitory effect on autophagy, which may serve as a new mechanism by which to explain the inhibitory effect of BBR on MDA-MB-231 cells and expand our understanding of the function of both BBR and GPER1.	Berberine	50-53	G protein-coupled estrogen receptor 1	Homo sapiens	61-66
34768896-11	2021	This result proved that the promotional effect of BBR on the GPER1/NF-kappaB pathway was closely related to its inhibitory effect on autophagy, which may serve as a new mechanism by which to explain the inhibitory effect of BBR on MDA-MB-231 cells and expand our understanding of the function of both BBR and GPER1.	Berberine	50-53	nuclear factor kappa B subunit 1	Homo sapiens	67-76
34768896-11	2021	This result proved that the promotional effect of BBR on the GPER1/NF-kappaB pathway was closely related to its inhibitory effect on autophagy, which may serve as a new mechanism by which to explain the inhibitory effect of BBR on MDA-MB-231 cells and expand our understanding of the function of both BBR and GPER1.	Berberine	50-53	G protein-coupled estrogen receptor 1	Homo sapiens	309-314
34768896-11	2021	This result proved that the promotional effect of BBR on the GPER1/NF-kappaB pathway was closely related to its inhibitory effect on autophagy, which may serve as a new mechanism by which to explain the inhibitory effect of BBR on MDA-MB-231 cells and expand our understanding of the function of both BBR and GPER1.	Berberine	224-227	G protein-coupled estrogen receptor 1	Homo sapiens	61-66
34768896-11	2021	This result proved that the promotional effect of BBR on the GPER1/NF-kappaB pathway was closely related to its inhibitory effect on autophagy, which may serve as a new mechanism by which to explain the inhibitory effect of BBR on MDA-MB-231 cells and expand our understanding of the function of both BBR and GPER1.	Berberine	224-227	nuclear factor kappa B subunit 1	Homo sapiens	67-76
34745081-8	2021	Lung immune cell flow cytometry analysis showed that adjunctive berberine treatment decreased neutrophil, CD11b+ dendritic cell and recruited interstitial macrophage numbers.	Berberine	64-73	integrin subunit alpha M	Homo sapiens	106-111
34803500-11	2021	Conclusion: Berberine improves insulin-induced diabetic retinopathy in type I and II diabetes through inhibiting insulin-induced activation of retinal endotheliocytes via Akt/mTOR/ HIF-1alpha/VEGF pathway.	Berberine	12-21	mechanistic target of rapamycin kinase	Mus musculus	175-179
34803500-11	2021	Conclusion: Berberine improves insulin-induced diabetic retinopathy in type I and II diabetes through inhibiting insulin-induced activation of retinal endotheliocytes via Akt/mTOR/ HIF-1alpha/VEGF pathway.	Berberine	12-21	hypoxia inducible factor 1, alpha subunit	Mus musculus	181-191
34803500-11	2021	Conclusion: Berberine improves insulin-induced diabetic retinopathy in type I and II diabetes through inhibiting insulin-induced activation of retinal endotheliocytes via Akt/mTOR/ HIF-1alpha/VEGF pathway.	Berberine	12-21	vascular endothelial growth factor A	Mus musculus	192-196
34803500-0	2021	Berberine improves insulin-induced diabetic retinopathy through exclusively suppressing Akt/mTOR-mediated HIF-1alpha/VEGF activation in retina endothelial cells.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	88-91
34803500-0	2021	Berberine improves insulin-induced diabetic retinopathy through exclusively suppressing Akt/mTOR-mediated HIF-1alpha/VEGF activation in retina endothelial cells.	Berberine	0-9	mechanistic target of rapamycin kinase	Mus musculus	92-96
34803500-0	2021	Berberine improves insulin-induced diabetic retinopathy through exclusively suppressing Akt/mTOR-mediated HIF-1alpha/VEGF activation in retina endothelial cells.	Berberine	0-9	hypoxia inducible factor 1, alpha subunit	Mus musculus	106-116
34803500-0	2021	Berberine improves insulin-induced diabetic retinopathy through exclusively suppressing Akt/mTOR-mediated HIF-1alpha/VEGF activation in retina endothelial cells.	Berberine	0-9	vascular endothelial growth factor A	Mus musculus	117-121
34803500-4	2021	This study aims to investigate the effect of berberine in decelerating DR progression in insulin-treated DM.	Berberine	45-54	insulin	Homo sapiens	89-96
34803500-5	2021	Methods: To better understand the therapeutic potential of berberine in the presence of insulin, we elaborated the action of mechanism whether berberine inhibited retinal expression of HIF-1alpha and VEGF through regulating AKT/mTOR pathway.	Berberine	59-68	insulin	Homo sapiens	88-95
34664067-9	2021	The relative AChE inhibitory activities of jatrorrhizine, berberine and palmatine in the Coptidis Rhizoma sample were equal to that of 257.0, 2355 and 283.9 mug/mL of galanthamine, respectively.	Berberine	58-67	acetylcholinesterase (Cartwright blood group)	Homo sapiens	13-17
34803500-5	2021	Methods: To better understand the therapeutic potential of berberine in the presence of insulin, we elaborated the action of mechanism whether berberine inhibited retinal expression of HIF-1alpha and VEGF through regulating AKT/mTOR pathway.	Berberine	59-68	hypoxia inducible factor 1, alpha subunit	Mus musculus	185-195
34803500-5	2021	Methods: To better understand the therapeutic potential of berberine in the presence of insulin, we elaborated the action of mechanism whether berberine inhibited retinal expression of HIF-1alpha and VEGF through regulating AKT/mTOR pathway.	Berberine	59-68	vascular endothelial growth factor A	Mus musculus	200-204
34803500-5	2021	Methods: To better understand the therapeutic potential of berberine in the presence of insulin, we elaborated the action of mechanism whether berberine inhibited retinal expression of HIF-1alpha and VEGF through regulating AKT/mTOR pathway.	Berberine	59-68	thymoma viral proto-oncogene 1	Mus musculus	224-227
34803500-5	2021	Methods: To better understand the therapeutic potential of berberine in the presence of insulin, we elaborated the action of mechanism whether berberine inhibited retinal expression of HIF-1alpha and VEGF through regulating AKT/mTOR pathway.	Berberine	59-68	mechanistic target of rapamycin kinase	Mus musculus	228-232
34803500-5	2021	Methods: To better understand the therapeutic potential of berberine in the presence of insulin, we elaborated the action of mechanism whether berberine inhibited retinal expression of HIF-1alpha and VEGF through regulating AKT/mTOR pathway.	Berberine	143-152	insulin	Homo sapiens	88-95
34803500-5	2021	Methods: To better understand the therapeutic potential of berberine in the presence of insulin, we elaborated the action of mechanism whether berberine inhibited retinal expression of HIF-1alpha and VEGF through regulating AKT/mTOR pathway.	Berberine	143-152	hypoxia inducible factor 1, alpha subunit	Mus musculus	185-195
34803500-5	2021	Methods: To better understand the therapeutic potential of berberine in the presence of insulin, we elaborated the action of mechanism whether berberine inhibited retinal expression of HIF-1alpha and VEGF through regulating AKT/mTOR pathway.	Berberine	143-152	vascular endothelial growth factor A	Mus musculus	200-204
34803500-5	2021	Methods: To better understand the therapeutic potential of berberine in the presence of insulin, we elaborated the action of mechanism whether berberine inhibited retinal expression of HIF-1alpha and VEGF through regulating AKT/mTOR pathway.	Berberine	143-152	thymoma viral proto-oncogene 1	Mus musculus	224-227
34803500-5	2021	Methods: To better understand the therapeutic potential of berberine in the presence of insulin, we elaborated the action of mechanism whether berberine inhibited retinal expression of HIF-1alpha and VEGF through regulating AKT/mTOR pathway.	Berberine	143-152	mechanistic target of rapamycin kinase	Mus musculus	228-232
34803500-6	2021	Suppression of insulin-induced neovasculature of retina endothelial cells by berberine was also studied.	Berberine	77-86	insulin	Homo sapiens	15-22
34803500-8	2021	Results: Among various types of retinal cells, the activity of HIF-1alpha and VEGF in retinal endothelial cells could be particularly and exclusively stimulated by insulin intervention, which could be inhibited by berberine treatment in a dose- and time-dependent manner.	Berberine	214-223	hypoxia inducible factor 1, alpha subunit	Mus musculus	63-73
34803500-8	2021	Results: Among various types of retinal cells, the activity of HIF-1alpha and VEGF in retinal endothelial cells could be particularly and exclusively stimulated by insulin intervention, which could be inhibited by berberine treatment in a dose- and time-dependent manner.	Berberine	214-223	vascular endothelial growth factor A	Mus musculus	78-82
34803500-8	2021	Results: Among various types of retinal cells, the activity of HIF-1alpha and VEGF in retinal endothelial cells could be particularly and exclusively stimulated by insulin intervention, which could be inhibited by berberine treatment in a dose- and time-dependent manner.	Berberine	214-223	insulin	Homo sapiens	164-171
34803500-9	2021	Berberine suppressed Akt/mTOR activity in these cells, and restoration of Akt/mTOR signalling attenuated berberine"s inhibition on HIF-1alpha and VEGF expression.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	21-24
34803500-9	2021	Berberine suppressed Akt/mTOR activity in these cells, and restoration of Akt/mTOR signalling attenuated berberine"s inhibition on HIF-1alpha and VEGF expression.	Berberine	0-9	mechanistic target of rapamycin kinase	Mus musculus	25-29
34803500-9	2021	Berberine suppressed Akt/mTOR activity in these cells, and restoration of Akt/mTOR signalling attenuated berberine"s inhibition on HIF-1alpha and VEGF expression.	Berberine	105-114	thymoma viral proto-oncogene 1	Mus musculus	74-77
34803500-9	2021	Berberine suppressed Akt/mTOR activity in these cells, and restoration of Akt/mTOR signalling attenuated berberine"s inhibition on HIF-1alpha and VEGF expression.	Berberine	105-114	hypoxia inducible factor 1, alpha subunit	Mus musculus	131-141
34803500-9	2021	Berberine suppressed Akt/mTOR activity in these cells, and restoration of Akt/mTOR signalling attenuated berberine"s inhibition on HIF-1alpha and VEGF expression.	Berberine	105-114	vascular endothelial growth factor A	Mus musculus	146-150
34803500-11	2021	Conclusion: Berberine improves insulin-induced diabetic retinopathy in type I and II diabetes through inhibiting insulin-induced activation of retinal endotheliocytes via Akt/mTOR/ HIF-1alpha/VEGF pathway.	Berberine	12-21	insulin	Homo sapiens	31-38
34803500-11	2021	Conclusion: Berberine improves insulin-induced diabetic retinopathy in type I and II diabetes through inhibiting insulin-induced activation of retinal endotheliocytes via Akt/mTOR/ HIF-1alpha/VEGF pathway.	Berberine	12-21	insulin	Homo sapiens	113-120
34803500-11	2021	Conclusion: Berberine improves insulin-induced diabetic retinopathy in type I and II diabetes through inhibiting insulin-induced activation of retinal endotheliocytes via Akt/mTOR/ HIF-1alpha/VEGF pathway.	Berberine	12-21	thymoma viral proto-oncogene 1	Mus musculus	171-174
34712379-0	2021	Berberine Suppresses EMT in Liver and Gastric Carcinoma Cells through Combination with TGFbetaR Regulating TGF-beta/Smad Pathway.	Berberine	0-9	transforming growth factor alpha	Homo sapiens	107-115
34712379-0	2021	Berberine Suppresses EMT in Liver and Gastric Carcinoma Cells through Combination with TGFbetaR Regulating TGF-beta/Smad Pathway.	Berberine	0-9	SMAD family member 6	Homo sapiens	116-120
34712379-6	2021	GO Enrichment analysis of KEGG pathway showed that BBR significantly inhibited TGF-beta/Smad at 12 h, then, PI3K/Akt and Wnt/beta-catenin signaling pathways at 24 h, which were closely related to the proliferation, migration, and EMT.	Berberine	51-54	transforming growth factor alpha	Homo sapiens	79-87
34712379-6	2021	GO Enrichment analysis of KEGG pathway showed that BBR significantly inhibited TGF-beta/Smad at 12 h, then, PI3K/Akt and Wnt/beta-catenin signaling pathways at 24 h, which were closely related to the proliferation, migration, and EMT.	Berberine	51-54	SMAD family member 6	Homo sapiens	88-92
34712379-6	2021	GO Enrichment analysis of KEGG pathway showed that BBR significantly inhibited TGF-beta/Smad at 12 h, then, PI3K/Akt and Wnt/beta-catenin signaling pathways at 24 h, which were closely related to the proliferation, migration, and EMT.	Berberine	51-54	AKT serine/threonine kinase 1	Homo sapiens	113-116
34712379-6	2021	GO Enrichment analysis of KEGG pathway showed that BBR significantly inhibited TGF-beta/Smad at 12 h, then, PI3K/Akt and Wnt/beta-catenin signaling pathways at 24 h, which were closely related to the proliferation, migration, and EMT.	Berberine	51-54	catenin beta 1	Homo sapiens	125-137
34712379-8	2021	It showed that the expression of epithelial marker E-cadherin and ZO-1 remarkably augmented with BBR treatment, as well as declined mesenchymal markers, including N-cadherin and Vimentin, decreased transcription factor Snail and Slug.	Berberine	97-100	cadherin 1	Homo sapiens	51-61
34712379-8	2021	It showed that the expression of epithelial marker E-cadherin and ZO-1 remarkably augmented with BBR treatment, as well as declined mesenchymal markers, including N-cadherin and Vimentin, decreased transcription factor Snail and Slug.	Berberine	97-100	tight junction protein 1	Homo sapiens	66-70
34712379-8	2021	It showed that the expression of epithelial marker E-cadherin and ZO-1 remarkably augmented with BBR treatment, as well as declined mesenchymal markers, including N-cadherin and Vimentin, decreased transcription factor Snail and Slug.	Berberine	97-100	cadherin 2	Homo sapiens	163-173
34712379-8	2021	It showed that the expression of epithelial marker E-cadherin and ZO-1 remarkably augmented with BBR treatment, as well as declined mesenchymal markers, including N-cadherin and Vimentin, decreased transcription factor Snail and Slug.	Berberine	97-100	vimentin	Homo sapiens	178-186
34712379-8	2021	It showed that the expression of epithelial marker E-cadherin and ZO-1 remarkably augmented with BBR treatment, as well as declined mesenchymal markers, including N-cadherin and Vimentin, decreased transcription factor Snail and Slug.	Berberine	97-100	snail family transcriptional repressor 1	Homo sapiens	219-224
34712379-8	2021	It showed that the expression of epithelial marker E-cadherin and ZO-1 remarkably augmented with BBR treatment, as well as declined mesenchymal markers, including N-cadherin and Vimentin, decreased transcription factor Snail and Slug.	Berberine	97-100	snail family transcriptional repressor 2	Homo sapiens	229-233
34712379-10	2021	Furthermore, beta-catenin and phosphorylation of AKT, Smad2, and Smad3 were changed dose-dependently by BBR treatment, which upregulated p-Smad2 and downregulated the others.	Berberine	104-107	catenin beta 1	Homo sapiens	13-25
34712379-10	2021	Furthermore, beta-catenin and phosphorylation of AKT, Smad2, and Smad3 were changed dose-dependently by BBR treatment, which upregulated p-Smad2 and downregulated the others.	Berberine	104-107	AKT serine/threonine kinase 1	Homo sapiens	49-52
34712379-10	2021	Furthermore, beta-catenin and phosphorylation of AKT, Smad2, and Smad3 were changed dose-dependently by BBR treatment, which upregulated p-Smad2 and downregulated the others.	Berberine	104-107	SMAD family member 2	Homo sapiens	54-59
34712379-10	2021	Furthermore, beta-catenin and phosphorylation of AKT, Smad2, and Smad3 were changed dose-dependently by BBR treatment, which upregulated p-Smad2 and downregulated the others.	Berberine	104-107	SMAD family member 3	Homo sapiens	65-70
34712379-10	2021	Furthermore, beta-catenin and phosphorylation of AKT, Smad2, and Smad3 were changed dose-dependently by BBR treatment, which upregulated p-Smad2 and downregulated the others.	Berberine	104-107	SMAD family member 2	Homo sapiens	139-144
34284014-0	2021	Berberine administrated with different routes attenuates inhaled LPS-induced acute respiratory distress syndrome through TLR4/NF-kappaB and JAK2/STAT3 inhibition.	Berberine	0-9	toll like receptor 4	Homo sapiens	121-125
34586799-0	2021	Solution Structure of Ternary Complex of Berberine Bound to a dGMP-Fill-In Vacancy G-Quadruplex Formed in the PDGFR-beta Promoter.	Berberine	41-50	platelet derived growth factor receptor alpha	Homo sapiens	110-120
34586799-4	2021	Herein, we report the high-resolution NMR structure of a ternary complex of berberine bound to the dGMP-fill-in PDGFR-beta vG4 in potassium solution.	Berberine	76-85	platelet derived growth factor receptor alpha	Homo sapiens	112-122
34586799-6	2021	This ternary complex has a 2:1:1 binding stoichiometry with a berberine molecule bound at each the 5"- and 3"-end of the 5"-dGMP-fill-in PDGFR-beta vG4.	Berberine	62-71	platelet derived growth factor receptor alpha	Homo sapiens	137-147
34265298-4	2021	The results showed that BBR could significantly improve the pathological characteristics of gastric tissue, alleviate the serum biochemical indexes and reduce the mRNA expression of nuclear factor-kappaB, tumor necrosis factor-alpha, Cyclooxygenase-2, monocyte chemoattractant protein-1, Interleukin-17A and I interferon-gamma.	Berberine	24-27	tumor necrosis factor	Rattus norvegicus	205-232
34265298-4	2021	The results showed that BBR could significantly improve the pathological characteristics of gastric tissue, alleviate the serum biochemical indexes and reduce the mRNA expression of nuclear factor-kappaB, tumor necrosis factor-alpha, Cyclooxygenase-2, monocyte chemoattractant protein-1, Interleukin-17A and I interferon-gamma.	Berberine	24-27	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	234-250
34265298-4	2021	The results showed that BBR could significantly improve the pathological characteristics of gastric tissue, alleviate the serum biochemical indexes and reduce the mRNA expression of nuclear factor-kappaB, tumor necrosis factor-alpha, Cyclooxygenase-2, monocyte chemoattractant protein-1, Interleukin-17A and I interferon-gamma.	Berberine	24-27	C-C motif chemokine ligand 2	Rattus norvegicus	252-286
34265298-4	2021	The results showed that BBR could significantly improve the pathological characteristics of gastric tissue, alleviate the serum biochemical indexes and reduce the mRNA expression of nuclear factor-kappaB, tumor necrosis factor-alpha, Cyclooxygenase-2, monocyte chemoattractant protein-1, Interleukin-17A and I interferon-gamma.	Berberine	24-27	interleukin 17A	Rattus norvegicus	288-303
34265298-4	2021	The results showed that BBR could significantly improve the pathological characteristics of gastric tissue, alleviate the serum biochemical indexes and reduce the mRNA expression of nuclear factor-kappaB, tumor necrosis factor-alpha, Cyclooxygenase-2, monocyte chemoattractant protein-1, Interleukin-17A and I interferon-gamma.	Berberine	24-27	interferon gamma	Rattus norvegicus	310-326
34684819-0	2021	Inhibitory Role of Berberine, an Isoquinoline Alkaloid, on NLRP3 Inflammasome Activation for the Treatment of Inflammatory Diseases.	Berberine	19-28	NLR family pyrin domain containing 3	Homo sapiens	59-64
34684819-3	2021	Various in vitro and in vivo studies have reported the anti-inflammatory role of berberine (BRB), an organic heteropentacyclic phytochemical and natural isoquinoline, in inhibiting NLRP3 inflammasome-dependent inflammation against many disorders.	Berberine	81-90	NLR family pyrin domain containing 3	Homo sapiens	181-186
34690771-0	2021	Berberine and Its Main Metabolite Berberrubine Inhibit Platelet Activation Through Suppressing the Class I PI3Kbeta/Rasa3/Rap1 Pathway.	Berberine	0-9	RAS p21 protein activator 3	Mus musculus	116-121
34690771-0	2021	Berberine and Its Main Metabolite Berberrubine Inhibit Platelet Activation Through Suppressing the Class I PI3Kbeta/Rasa3/Rap1 Pathway.	Berberine	0-9	RAS-related protein 1a	Mus musculus	122-126
34690771-8	2021	Furthermore, BBR and M2 selectively inhibited class I PI3Kbeta, perhaps through binding to its active site.	Berberine	13-16	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Mus musculus	54-62
34690771-10	2021	After oral administration, BBR significantly inhibited the PI3K/Akt pathway and Rap1 activation and suppressed ADP-induced platelet activation and carrageenan-induced thrombosis in mice without prolonging bleeding time.	Berberine	27-30	thymoma viral proto-oncogene 1	Mus musculus	64-67
34690771-10	2021	After oral administration, BBR significantly inhibited the PI3K/Akt pathway and Rap1 activation and suppressed ADP-induced platelet activation and carrageenan-induced thrombosis in mice without prolonging bleeding time.	Berberine	27-30	RAS-related protein 1a	Mus musculus	80-84
34607550-0	2022	Antitumor activity of zinc nanoparticles synthesized with berberine on human epithelial colorectal adenocarcinoma (Caco-2) cells through acting on Cox-2/NF-kB and p53 pathways.	Berberine	58-67	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	147-152
34607550-0	2022	Antitumor activity of zinc nanoparticles synthesized with berberine on human epithelial colorectal adenocarcinoma (Caco-2) cells through acting on Cox-2/NF-kB and p53 pathways.	Berberine	58-67	tumor protein p53	Homo sapiens	163-166
34600570-9	2021	Our outcomes of TNF-a, IL-1B, and MDA evaluation show a significant ameliorating effect of the Berberine (BBR) and BBR-loaded micelles in pretreated groups.	Berberine	106-109	tumor necrosis factor	Rattus norvegicus	16-21
34600570-9	2021	Our outcomes of TNF-a, IL-1B, and MDA evaluation show a significant ameliorating effect of the Berberine (BBR) and BBR-loaded micelles in pretreated groups.	Berberine	115-118	tumor necrosis factor	Rattus norvegicus	16-21
34600570-9	2021	Our outcomes of TNF-a, IL-1B, and MDA evaluation show a significant ameliorating effect of the Berberine (BBR) and BBR-loaded micelles in pretreated groups.	Berberine	115-118	interleukin 1 beta	Rattus norvegicus	23-28
34790723-0	2021	Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway.	Berberine	0-9	apolipoprotein E	Mus musculus	70-74
34284014-0	2021	Berberine administrated with different routes attenuates inhaled LPS-induced acute respiratory distress syndrome through TLR4/NF-kappaB and JAK2/STAT3 inhibition.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	126-135
34790723-0	2021	Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway.	Berberine	0-9	proprotein convertase subtilisin/kexin type 9	Mus musculus	102-107
34790723-0	2021	Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway.	Berberine	0-9	mitogen-activated protein kinase 3	Mus musculus	112-118
34790723-2	2021	However, although the previous studies showed that the beneficial impact of BBR on atherosclerosis might be associated with proprotein convertase subtilisin/kexin type 9 (PCSK9), the exact underlying mechanism are not fully determined.	Berberine	76-79	proprotein convertase subtilisin/kexin type 9	Mus musculus	124-169
34284014-0	2021	Berberine administrated with different routes attenuates inhaled LPS-induced acute respiratory distress syndrome through TLR4/NF-kappaB and JAK2/STAT3 inhibition.	Berberine	0-9	Janus kinase 2	Homo sapiens	140-144
34790723-2	2021	However, although the previous studies showed that the beneficial impact of BBR on atherosclerosis might be associated with proprotein convertase subtilisin/kexin type 9 (PCSK9), the exact underlying mechanism are not fully determined.	Berberine	76-79	proprotein convertase subtilisin/kexin type 9	Homo sapiens	171-176
34790723-11	2021	Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells.	Berberine	36-39	low density lipoprotein receptor	Homo sapiens	96-100
34284014-0	2021	Berberine administrated with different routes attenuates inhaled LPS-induced acute respiratory distress syndrome through TLR4/NF-kappaB and JAK2/STAT3 inhibition.	Berberine	0-9	signal transducer and activator of transcription 3	Homo sapiens	145-150
34790723-11	2021	Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells.	Berberine	36-39	proprotein convertase subtilisin/kexin type 9	Homo sapiens	120-125
34284014-8	2021	In addition, the primary TLR4/NF-kappaB and secondary JAK2/STAT3 signaling pathways which were activated by LPS in lung were totally inhibited by berberine administration.	Berberine	146-155	toll like receptor 4	Homo sapiens	25-29
34790723-11	2021	Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells.	Berberine	36-39	mitogen-activated protein kinase 3	Homo sapiens	145-151
34284014-8	2021	In addition, the primary TLR4/NF-kappaB and secondary JAK2/STAT3 signaling pathways which were activated by LPS in lung were totally inhibited by berberine administration.	Berberine	146-155	nuclear factor kappa B subunit 1	Homo sapiens	30-39
34790723-12	2021	Conclusions: Data indicated that BBR significantly attenuated lipid disorder, reduced aortic plaque formation, and alleviated hepatic lipid accumulation in ApoE-/- mice fed with HFD, which was associated with down-regulation of PCSK9 through ERK1/2 pathway.	Berberine	33-36	apolipoprotein E	Mus musculus	156-160
34284014-8	2021	In addition, the primary TLR4/NF-kappaB and secondary JAK2/STAT3 signaling pathways which were activated by LPS in lung were totally inhibited by berberine administration.	Berberine	146-155	Janus kinase 2	Homo sapiens	54-58
34790723-12	2021	Conclusions: Data indicated that BBR significantly attenuated lipid disorder, reduced aortic plaque formation, and alleviated hepatic lipid accumulation in ApoE-/- mice fed with HFD, which was associated with down-regulation of PCSK9 through ERK1/2 pathway.	Berberine	33-36	proprotein convertase subtilisin/kexin type 9	Mus musculus	228-233
34790723-12	2021	Conclusions: Data indicated that BBR significantly attenuated lipid disorder, reduced aortic plaque formation, and alleviated hepatic lipid accumulation in ApoE-/- mice fed with HFD, which was associated with down-regulation of PCSK9 through ERK1/2 pathway.	Berberine	33-36	mitogen-activated protein kinase 3	Mus musculus	242-248
34284014-8	2021	In addition, the primary TLR4/NF-kappaB and secondary JAK2/STAT3 signaling pathways which were activated by LPS in lung were totally inhibited by berberine administration.	Berberine	146-155	signal transducer and activator of transcription 3	Homo sapiens	59-64
34284014-10	2021	Considering that molecular docking simulation indicated that berberine could bind with TLR4, the present suggested that the inhibition of the inflammation related TLR4/NF-kappaB and JAK2/STAT3 signaling pathways might be involved in the pulmonary protective effect of berberine in LPS-induced ARDS.	Berberine	61-70	toll like receptor 4	Homo sapiens	87-91
34284014-10	2021	Considering that molecular docking simulation indicated that berberine could bind with TLR4, the present suggested that the inhibition of the inflammation related TLR4/NF-kappaB and JAK2/STAT3 signaling pathways might be involved in the pulmonary protective effect of berberine in LPS-induced ARDS.	Berberine	61-70	toll like receptor 4	Homo sapiens	163-167
34284014-10	2021	Considering that molecular docking simulation indicated that berberine could bind with TLR4, the present suggested that the inhibition of the inflammation related TLR4/NF-kappaB and JAK2/STAT3 signaling pathways might be involved in the pulmonary protective effect of berberine in LPS-induced ARDS.	Berberine	61-70	nuclear factor kappa B subunit 1	Homo sapiens	168-177
34284014-10	2021	Considering that molecular docking simulation indicated that berberine could bind with TLR4, the present suggested that the inhibition of the inflammation related TLR4/NF-kappaB and JAK2/STAT3 signaling pathways might be involved in the pulmonary protective effect of berberine in LPS-induced ARDS.	Berberine	61-70	Janus kinase 2	Homo sapiens	182-186
34284014-10	2021	Considering that molecular docking simulation indicated that berberine could bind with TLR4, the present suggested that the inhibition of the inflammation related TLR4/NF-kappaB and JAK2/STAT3 signaling pathways might be involved in the pulmonary protective effect of berberine in LPS-induced ARDS.	Berberine	61-70	signal transducer and activator of transcription 3	Homo sapiens	187-192
34284014-10	2021	Considering that molecular docking simulation indicated that berberine could bind with TLR4, the present suggested that the inhibition of the inflammation related TLR4/NF-kappaB and JAK2/STAT3 signaling pathways might be involved in the pulmonary protective effect of berberine in LPS-induced ARDS.	Berberine	268-277	toll like receptor 4	Homo sapiens	87-91
34284014-10	2021	Considering that molecular docking simulation indicated that berberine could bind with TLR4, the present suggested that the inhibition of the inflammation related TLR4/NF-kappaB and JAK2/STAT3 signaling pathways might be involved in the pulmonary protective effect of berberine in LPS-induced ARDS.	Berberine	268-277	toll like receptor 4	Homo sapiens	163-167
34284014-10	2021	Considering that molecular docking simulation indicated that berberine could bind with TLR4, the present suggested that the inhibition of the inflammation related TLR4/NF-kappaB and JAK2/STAT3 signaling pathways might be involved in the pulmonary protective effect of berberine in LPS-induced ARDS.	Berberine	268-277	nuclear factor kappa B subunit 1	Homo sapiens	168-177
34284014-10	2021	Considering that molecular docking simulation indicated that berberine could bind with TLR4, the present suggested that the inhibition of the inflammation related TLR4/NF-kappaB and JAK2/STAT3 signaling pathways might be involved in the pulmonary protective effect of berberine in LPS-induced ARDS.	Berberine	268-277	Janus kinase 2	Homo sapiens	182-186
34284014-10	2021	Considering that molecular docking simulation indicated that berberine could bind with TLR4, the present suggested that the inhibition of the inflammation related TLR4/NF-kappaB and JAK2/STAT3 signaling pathways might be involved in the pulmonary protective effect of berberine in LPS-induced ARDS.	Berberine	268-277	signal transducer and activator of transcription 3	Homo sapiens	187-192
34504563-0	2021	Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR.	Berberine	0-9	microsomal triglyceride transfer protein	Rattus norvegicus	134-138
34504563-0	2021	Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR.	Berberine	0-9	low density lipoprotein receptor	Rattus norvegicus	143-147
34504563-9	2021	Compared with the saline-treated NAFLD rats, the BBR-treated rats had reduced liver wet weight, improved liver steatosis and a significant decrease in liver TG levels, while ALT, AST, TC, TG, and LDL serum levels significantly decreased and MTTP levels were significantly upregulated.	Berberine	49-52	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	179-182
34504563-9	2021	Compared with the saline-treated NAFLD rats, the BBR-treated rats had reduced liver wet weight, improved liver steatosis and a significant decrease in liver TG levels, while ALT, AST, TC, TG, and LDL serum levels significantly decreased and MTTP levels were significantly upregulated.	Berberine	49-52	microsomal triglyceride transfer protein	Rattus norvegicus	241-245
34504563-11	2021	Furthermore, BBR reversed the abnormal expression of MTTP and LDLR in rats with high-fat diet induced-NAFLD.	Berberine	13-16	microsomal triglyceride transfer protein	Rattus norvegicus	53-57
34504563-11	2021	Furthermore, BBR reversed the abnormal expression of MTTP and LDLR in rats with high-fat diet induced-NAFLD.	Berberine	13-16	low density lipoprotein receptor	Rattus norvegicus	62-66
34504563-12	2021	The present findings suggest that fatty liver could be improved by BBR administration, via reversing the abnormal expression of MTTP and LDLR and inhibiting lipid synthesis.	Berberine	67-70	microsomal triglyceride transfer protein	Rattus norvegicus	128-132
34504563-12	2021	The present findings suggest that fatty liver could be improved by BBR administration, via reversing the abnormal expression of MTTP and LDLR and inhibiting lipid synthesis.	Berberine	67-70	low density lipoprotein receptor	Rattus norvegicus	137-141
34353734-0	2021	Corrigendum to "Anti-arthritis effect of berberine associated with regulating energy metabolism of macrophages through AMPK/HIF-1alpha pathway".	Berberine	41-50	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	119-123
34353734-0	2021	Corrigendum to "Anti-arthritis effect of berberine associated with regulating energy metabolism of macrophages through AMPK/HIF-1alpha pathway".	Berberine	41-50	hypoxia inducible factor 1 subunit alpha	Homo sapiens	124-134
34765276-0	2021	Transformation of berberine to its demethylated metabolites by the CYP51 enzyme in the gut microbiota.	Berberine	18-27	cytochrome P450, family 51	Mus musculus	67-72
34765276-3	2021	This study focused on the CYP51 enzyme of intestinal bacteria to elucidate a new mechanism of BBR transformation by demethylation in the gut microbiota through multiple analytical techniques.	Berberine	94-97	cytochrome P450, family 51	Mus musculus	26-31
34765276-4	2021	First, the docking of BBR and CYP51 was performed; then, the pharmacokinetics of BBR was determined in ICR mice in vivo, and the metabolism of BBR in the liver, kidney, gut microbiota and single bacterial strains was examined in vitro.	Berberine	22-25	cytochrome P450, family 51	Mus musculus	30-35
34765276-8	2021	The results showed that CYP51 in the gut microbiota could bind stably with BBR, and the addition of voriconazole (a specific inhibitor of CYP51) slowed down the metabolism of BBR, which prevented the production of the demethylated metabolites thalifendine and berberrubine.	Berberine	75-78	cytochrome P450, family 51	Mus musculus	24-29
34765276-8	2021	The results showed that CYP51 in the gut microbiota could bind stably with BBR, and the addition of voriconazole (a specific inhibitor of CYP51) slowed down the metabolism of BBR, which prevented the production of the demethylated metabolites thalifendine and berberrubine.	Berberine	75-78	cytochrome P450, family 51	Mus musculus	138-143
34765276-8	2021	The results showed that CYP51 in the gut microbiota could bind stably with BBR, and the addition of voriconazole (a specific inhibitor of CYP51) slowed down the metabolism of BBR, which prevented the production of the demethylated metabolites thalifendine and berberrubine.	Berberine	175-178	cytochrome P450, family 51	Mus musculus	24-29
34765276-8	2021	The results showed that CYP51 in the gut microbiota could bind stably with BBR, and the addition of voriconazole (a specific inhibitor of CYP51) slowed down the metabolism of BBR, which prevented the production of the demethylated metabolites thalifendine and berberrubine.	Berberine	175-178	cytochrome P450, family 51	Mus musculus	138-143
34765276-9	2021	This study demonstrated that CYP51 promoted the demethylation of BBR and enhanced its intestinal absorption, providing a new method for studying the metabolic transformation mechanism of isoquinoline alkaloids in vivo.	Berberine	65-68	cytochrome P450, family 51	Mus musculus	29-34
34333328-14	2021	Protein expression in ovary and mRNA expression in granulosa cell of LHCGR and CYP19A1 were decreased in Mod group and rescued by the intervention of berberine.	Berberine	150-159	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	69-74
34333328-14	2021	Protein expression in ovary and mRNA expression in granulosa cell of LHCGR and CYP19A1 were decreased in Mod group and rescued by the intervention of berberine.	Berberine	150-159	cytochrome P450, family 19, subfamily a, polypeptide 1	Rattus norvegicus	79-86
34333328-16	2021	CONCLUSIONS: Berberine could improve ovulation in PCOS and the mechanism might be associated with up-regulating LHCGR and CYP19A1.	Berberine	13-22	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	112-117
34333328-16	2021	CONCLUSIONS: Berberine could improve ovulation in PCOS and the mechanism might be associated with up-regulating LHCGR and CYP19A1.	Berberine	13-22	cytochrome P450, family 19, subfamily a, polypeptide 1	Rattus norvegicus	122-129
34333328-17	2021	Berberine could also improve endometrial receptivity through down-regualting alphavbeta3 and LPAR3.	Berberine	0-9	lysophosphatidic acid receptor 3	Rattus norvegicus	93-98
34342315-7	2021	Berberine"s actions were abolished by pre-treatment with 3-methyladenine (an autophagy inhibitor) or compound c (an AMPK inhibitor) in the MPP+-treated SH-SY5Y cells.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	116-120
34981012-7	2021	Results: Study showed significant increase in levels of HIF-1alpha, TGF-1beta, HDAC activity & NRSF gene expression in epilepsy group & decrease in these levels in berberine treated epilepsy group.	Berberine	164-173	hypoxia inducible factor 1, alpha subunit	Mus musculus	56-66
34981012-8	2021	Significant decrease in BDNF levels in epilepsy & elevation in them in berberine treated epilepsy group.	Berberine	71-80	brain derived neurotrophic factor	Mus musculus	24-28
34738437-10	2021	Active components such as baicalin and berberine had high binding affinity with EGFR.	Berberine	39-48	epidermal growth factor receptor	Homo sapiens	80-84
34556670-0	2021	Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.	Berberine	0-9	insulin	Homo sapiens	16-23
34556670-0	2021	Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.	Berberine	0-9	potassium voltage-gated channel subfamily H member 6	Homo sapiens	51-56
34556670-3	2021	Here, we report the effects of its main active component, berberine (BBR), on stimulating insulin secretion.	Berberine	58-67	insulin	Homo sapiens	90-97
34556670-3	2021	Here, we report the effects of its main active component, berberine (BBR), on stimulating insulin secretion.	Berberine	69-72	insulin	Homo sapiens	90-97
34556670-9	2021	The pre-specified primary outcomes are assessment of the differences of serum insulin and C-peptide levels between BBR and placebo treatment groups during the hyperglycemic clamp study.	Berberine	115-118	insulin	Homo sapiens	78-85
34556670-10	2021	BBR significantly promotes insulin secretion under hyperglycemic state comparing with placebo treatment, while does not affect basal insulin secretion in humans.	Berberine	0-3	insulin	Homo sapiens	27-34
34630099-0	2021	Berberine Potentiates Insulin Secretion and Prevents beta-cell Dysfunction Through the miR-204/SIRT1 Signaling Pathway.	Berberine	0-9	microRNA 204	Mus musculus	87-94
34630099-0	2021	Berberine Potentiates Insulin Secretion and Prevents beta-cell Dysfunction Through the miR-204/SIRT1 Signaling Pathway.	Berberine	0-9	sirtuin 1	Mus musculus	95-100
34630099-11	2021	The BBR treatment effectively improved insulin synthesis, reduced miR-204 levels, and increased SIRT1 expression in islet tissue in diabetic mice.	Berberine	4-7	microRNA 204	Mus musculus	66-73
34630099-11	2021	The BBR treatment effectively improved insulin synthesis, reduced miR-204 levels, and increased SIRT1 expression in islet tissue in diabetic mice.	Berberine	4-7	sirtuin 1	Mus musculus	96-101
34630099-12	2021	Overexpression of miR-204 reversed the protective effect of BBR on apoptosis and insulin secretion in MIN6 cells.	Berberine	60-63	microRNA 204	Mus musculus	18-25
34630099-13	2021	Our study identifies a novel correlation between miR-204 and beta-cell dysfunction in T2DM and shows that administration of BBR leads to remission of beta-cell dysfunction by regulating the miR-204/SIRT1 pathway.	Berberine	124-127	microRNA 204	Mus musculus	49-56
34630099-13	2021	Our study identifies a novel correlation between miR-204 and beta-cell dysfunction in T2DM and shows that administration of BBR leads to remission of beta-cell dysfunction by regulating the miR-204/SIRT1 pathway.	Berberine	124-127	microRNA 204	Mus musculus	190-197
34630099-13	2021	Our study identifies a novel correlation between miR-204 and beta-cell dysfunction in T2DM and shows that administration of BBR leads to remission of beta-cell dysfunction by regulating the miR-204/SIRT1 pathway.	Berberine	124-127	sirtuin 1	Mus musculus	198-203
34342315-5	2021	Berberine also significantly decreased the level of alpha-synuclein and enhanced the microtubule-associated protein light chain 3 (LC3-II)-associated autophagy in the SN of MPTP-treated mice.	Berberine	0-9	synuclein, alpha	Mus musculus	52-67
34342315-6	2021	Furthermore, adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK) was activated by berberine.	Berberine	95-104	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	72-76
34342315-8	2021	These results suggested that the protective effects of berberine on the toxicity of MPTP could be attributed to berberine-enhanced autophagy via the AMPK dependent pathway.	Berberine	55-64	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	149-153
34342315-8	2021	These results suggested that the protective effects of berberine on the toxicity of MPTP could be attributed to berberine-enhanced autophagy via the AMPK dependent pathway.	Berberine	112-121	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	149-153
34174323-6	2021	On the contrary, BBR and/or Zn produced marked protection against MTX-induced intestinal toxicity via amelioration of oxidative stress, improving NRF2, SIRT1, FOXO-3, GSK-3beta, Akt, mTOR, JAK1, and STAT-3 alterations.	Berberine	17-20	NFE2 like bZIP transcription factor 2	Rattus norvegicus	146-150
34603061-8	2021	BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-kappaB activation in the liver.	Berberine	27-36	nuclear receptor subfamily 1, group H, member 4	Mus musculus	148-151
34603061-8	2021	BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-kappaB activation in the liver.	Berberine	27-36	nuclear receptor subfamily 1, group H, member 4	Mus musculus	209-212
34603061-8	2021	BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-kappaB activation in the liver.	Berberine	27-36	fibroblast growth factor 15	Mus musculus	217-244
34603061-8	2021	BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-kappaB activation in the liver.	Berberine	27-36	fibroblast growth factor 15	Mus musculus	246-251
34603061-8	2021	BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-kappaB activation in the liver.	Berberine	27-36	fibroblast growth factor 15	Mus musculus	286-291
34603061-8	2021	BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-kappaB activation in the liver.	Berberine	175-184	nuclear receptor subfamily 1, group H, member 4	Mus musculus	57-60
34603061-8	2021	BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-kappaB activation in the liver.	Berberine	175-184	nuclear receptor subfamily 1, group H, member 4	Mus musculus	209-212
34603061-8	2021	BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-kappaB activation in the liver.	Berberine	175-184	fibroblast growth factor 15	Mus musculus	217-244
34603061-8	2021	BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-kappaB activation in the liver.	Berberine	175-184	fibroblast growth factor 15	Mus musculus	246-251
34603061-9	2021	Whereas the beneficial effects of berberine are blunted in FXR knockout mice.	Berberine	34-43	nuclear receptor subfamily 1, group H, member 4	Mus musculus	59-62
34603061-10	2021	Our results reveal that berberine alleviates NASH by modulating the interplay of gut microbiota and bile acid metabolism, as well as the subsequent intestinal FXR activation.	Berberine	24-33	nuclear receptor subfamily 1, group H, member 4	Mus musculus	159-162
34566663-8	2021	The results showed that TC, TG, ALT, AST, HDL-C, LDL-C, FBG, FINS, and FFA in the group treated with BBR were significantly restored compared with those in the model group.	Berberine	101-104	solute carrier family 17 member 5	Homo sapiens	37-40
34566663-11	2021	Finally, we summarized the molecular mechanisms by which berberine regulated NAFLD/NASH, mainly focusing on activating the AMPK pathway, improving insulin sensitivity and glucose metabolism, regulating mitochondrial function, reducing inflammation and oxidative stress, regulating cell death and ER stress, reducing DNA methylation, and regulating intestinal microenvironment and neurotoxicity.	Berberine	57-66	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	123-127
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Berberine	122-131	C-X-C motif chemokine receptor 4	Homo sapiens	222-227
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Berberine	122-131	intercellular adhesion molecule 1	Homo sapiens	229-234
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Berberine	122-131	C-X-C motif chemokine ligand 8	Homo sapiens	236-241
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Berberine	122-131	C-X-C motif chemokine ligand 10	Homo sapiens	243-249
34603061-0	2021	Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation.	Berberine	0-9	nuclear receptor subfamily 1, group H, member 4	Mus musculus	105-108
34603061-2	2021	Farnesoid X receptor (FXR) is a bile acid receptor and a drug target for NASH, however, the underlying mechanisms of berberine on regulating FXR are still unknown.	Berberine	117-126	nuclear receptor subfamily 1, group H, member 4	Mus musculus	0-20
34603061-2	2021	Farnesoid X receptor (FXR) is a bile acid receptor and a drug target for NASH, however, the underlying mechanisms of berberine on regulating FXR are still unknown.	Berberine	117-126	nuclear receptor subfamily 1, group H, member 4	Mus musculus	22-25
34603061-2	2021	Farnesoid X receptor (FXR) is a bile acid receptor and a drug target for NASH, however, the underlying mechanisms of berberine on regulating FXR are still unknown.	Berberine	117-126	nuclear receptor subfamily 1, group H, member 4	Mus musculus	32-50
34603061-2	2021	Farnesoid X receptor (FXR) is a bile acid receptor and a drug target for NASH, however, the underlying mechanisms of berberine on regulating FXR are still unknown.	Berberine	117-126	nuclear receptor subfamily 1, group H, member 4	Mus musculus	141-144
34603061-8	2021	BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-kappaB activation in the liver.	Berberine	27-36	nuclear receptor subfamily 1, group H, member 4	Mus musculus	57-60
34174323-9	2021	SIGNIFICANCE: BBR plus Zn could be used as a novel therapy for the treatment of MTX-induced intestinal damage through modulation of GSK-3beta/NRF2, Akt/mTOR, JAK1/STAT-3, and SIRT1/FOXO-3 signaling pathways.	Berberine	14-17	glycogen synthase kinase 3 alpha	Rattus norvegicus	132-141
34174323-9	2021	SIGNIFICANCE: BBR plus Zn could be used as a novel therapy for the treatment of MTX-induced intestinal damage through modulation of GSK-3beta/NRF2, Akt/mTOR, JAK1/STAT-3, and SIRT1/FOXO-3 signaling pathways.	Berberine	14-17	NFE2 like bZIP transcription factor 2	Rattus norvegicus	142-146
34174323-9	2021	SIGNIFICANCE: BBR plus Zn could be used as a novel therapy for the treatment of MTX-induced intestinal damage through modulation of GSK-3beta/NRF2, Akt/mTOR, JAK1/STAT-3, and SIRT1/FOXO-3 signaling pathways.	Berberine	14-17	AKT serine/threonine kinase 1	Rattus norvegicus	148-151
34174323-9	2021	SIGNIFICANCE: BBR plus Zn could be used as a novel therapy for the treatment of MTX-induced intestinal damage through modulation of GSK-3beta/NRF2, Akt/mTOR, JAK1/STAT-3, and SIRT1/FOXO-3 signaling pathways.	Berberine	14-17	mechanistic target of rapamycin kinase	Rattus norvegicus	152-156
34174323-9	2021	SIGNIFICANCE: BBR plus Zn could be used as a novel therapy for the treatment of MTX-induced intestinal damage through modulation of GSK-3beta/NRF2, Akt/mTOR, JAK1/STAT-3, and SIRT1/FOXO-3 signaling pathways.	Berberine	14-17	Janus kinase 1	Rattus norvegicus	158-162
34174323-9	2021	SIGNIFICANCE: BBR plus Zn could be used as a novel therapy for the treatment of MTX-induced intestinal damage through modulation of GSK-3beta/NRF2, Akt/mTOR, JAK1/STAT-3, and SIRT1/FOXO-3 signaling pathways.	Berberine	14-17	signal transducer and activator of transcription 3	Rattus norvegicus	163-169
34174323-9	2021	SIGNIFICANCE: BBR plus Zn could be used as a novel therapy for the treatment of MTX-induced intestinal damage through modulation of GSK-3beta/NRF2, Akt/mTOR, JAK1/STAT-3, and SIRT1/FOXO-3 signaling pathways.	Berberine	14-17	sirtuin 1	Rattus norvegicus	175-180
34174323-9	2021	SIGNIFICANCE: BBR plus Zn could be used as a novel therapy for the treatment of MTX-induced intestinal damage through modulation of GSK-3beta/NRF2, Akt/mTOR, JAK1/STAT-3, and SIRT1/FOXO-3 signaling pathways.	Berberine	14-17	forkhead box O3	Rattus norvegicus	181-187
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Berberine	122-131	interleukin 6	Homo sapiens	251-254
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Berberine	122-131	interleukin 2	Homo sapiens	256-259
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Berberine	122-131	C-C motif chemokine ligand 2	Homo sapiens	261-265
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Berberine	122-131	interleukin 1 beta	Homo sapiens	267-271
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Berberine	122-131	interleukin 4	Homo sapiens	273-276
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Berberine	122-131	interferon gamma	Homo sapiens	278-282
34174323-6	2021	On the contrary, BBR and/or Zn produced marked protection against MTX-induced intestinal toxicity via amelioration of oxidative stress, improving NRF2, SIRT1, FOXO-3, GSK-3beta, Akt, mTOR, JAK1, and STAT-3 alterations.	Berberine	17-20	sirtuin 1	Rattus norvegicus	152-157
34174323-6	2021	On the contrary, BBR and/or Zn produced marked protection against MTX-induced intestinal toxicity via amelioration of oxidative stress, improving NRF2, SIRT1, FOXO-3, GSK-3beta, Akt, mTOR, JAK1, and STAT-3 alterations.	Berberine	17-20	forkhead box O3	Rattus norvegicus	159-165
34174323-6	2021	On the contrary, BBR and/or Zn produced marked protection against MTX-induced intestinal toxicity via amelioration of oxidative stress, improving NRF2, SIRT1, FOXO-3, GSK-3beta, Akt, mTOR, JAK1, and STAT-3 alterations.	Berberine	17-20	glycogen synthase kinase 3 alpha	Rattus norvegicus	167-176
34174323-6	2021	On the contrary, BBR and/or Zn produced marked protection against MTX-induced intestinal toxicity via amelioration of oxidative stress, improving NRF2, SIRT1, FOXO-3, GSK-3beta, Akt, mTOR, JAK1, and STAT-3 alterations.	Berberine	17-20	AKT serine/threonine kinase 1	Rattus norvegicus	178-181
34174323-6	2021	On the contrary, BBR and/or Zn produced marked protection against MTX-induced intestinal toxicity via amelioration of oxidative stress, improving NRF2, SIRT1, FOXO-3, GSK-3beta, Akt, mTOR, JAK1, and STAT-3 alterations.	Berberine	17-20	mechanistic target of rapamycin kinase	Rattus norvegicus	183-187
34174323-6	2021	On the contrary, BBR and/or Zn produced marked protection against MTX-induced intestinal toxicity via amelioration of oxidative stress, improving NRF2, SIRT1, FOXO-3, GSK-3beta, Akt, mTOR, JAK1, and STAT-3 alterations.	Berberine	17-20	Janus kinase 1	Rattus norvegicus	189-193
34174323-6	2021	On the contrary, BBR and/or Zn produced marked protection against MTX-induced intestinal toxicity via amelioration of oxidative stress, improving NRF2, SIRT1, FOXO-3, GSK-3beta, Akt, mTOR, JAK1, and STAT-3 alterations.	Berberine	17-20	signal transducer and activator of transcription 3	Rattus norvegicus	199-205
34407851-0	2021	Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.	Berberine	94-103	insulin	Homo sapiens	29-36
34526965-0	2021	Berberine Acts on C/EBPbeta/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells.	Berberine	0-9	CCAAT/enhancer binding protein alpha	Rattus norvegicus	18-27
34526965-0	2021	Berberine Acts on C/EBPbeta/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells.	Berberine	0-9	growth arrest specific 5	Rattus norvegicus	35-39
34526965-0	2021	Berberine Acts on C/EBPbeta/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells.	Berberine	0-9	microRNA 18a	Rattus norvegicus	40-47
34411001-7	2021	Furthermore, BB regulated the activation of macrophages via NF-kappaB signaling pathway inhibition in the BPH rat model.	Berberine	13-15	nuclear factor kappa B subunit 1	Homo sapiens	60-69
34411001-10	2021	These findings propose that BB suppresses androgen-dependent BPH development by targeting NF-kappaB-mediated pro-inflammatory signaling.	Berberine	28-30	nuclear factor kappa B subunit 1	Homo sapiens	90-99
34417576-0	2022	Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3.	Berberine	0-9	sirtuin 3	Mus musculus	81-90
34417576-5	2022	BBR alleviated adipose tissue inflammation and fibrosis by inhibiting macrophage infiltration, pro-inflammatory macrophage polarization and the abnormal deposition of extracellular matrix, and the effect was mediated by BBR directly binding and activating the deacetylase Sirtuin 3 (SIRT3) and suppressing the activation of the mitogen-activated protein kinases and nuclear factor-kappaB signalling pathways.	Berberine	0-3	sirtuin 3	Mus musculus	272-281
34417576-5	2022	BBR alleviated adipose tissue inflammation and fibrosis by inhibiting macrophage infiltration, pro-inflammatory macrophage polarization and the abnormal deposition of extracellular matrix, and the effect was mediated by BBR directly binding and activating the deacetylase Sirtuin 3 (SIRT3) and suppressing the activation of the mitogen-activated protein kinases and nuclear factor-kappaB signalling pathways.	Berberine	0-3	sirtuin 3	Mus musculus	283-288
34417576-5	2022	BBR alleviated adipose tissue inflammation and fibrosis by inhibiting macrophage infiltration, pro-inflammatory macrophage polarization and the abnormal deposition of extracellular matrix, and the effect was mediated by BBR directly binding and activating the deacetylase Sirtuin 3 (SIRT3) and suppressing the activation of the mitogen-activated protein kinases and nuclear factor-kappaB signalling pathways.	Berberine	220-223	sirtuin 3	Mus musculus	272-281
34417576-5	2022	BBR alleviated adipose tissue inflammation and fibrosis by inhibiting macrophage infiltration, pro-inflammatory macrophage polarization and the abnormal deposition of extracellular matrix, and the effect was mediated by BBR directly binding and activating the deacetylase Sirtuin 3 (SIRT3) and suppressing the activation of the mitogen-activated protein kinases and nuclear factor-kappaB signalling pathways.	Berberine	220-223	sirtuin 3	Mus musculus	283-288
34417576-9	2022	The modulation of adipose tissue remodelling by activating SIRT3 could contribute to the anti-hyperlipidemic and anti-hyperglycemic effects of BBR.	Berberine	143-146	sirtuin 3	Mus musculus	59-64
34407851-1	2021	BACKGROUND: Multiple oral insulin-sensitizing agents, such as metformin, thiazolidinediones, inositols, and berberine, have been proven safe and efficacious in improving the endocrine, metabolic, and reproductive abnormalities seen in polycystic ovary syndrome (PCOS), providing more options for healthcare providers and patients.	Berberine	108-117	insulin	Homo sapiens	26-33
34422435-5	2021	In addition, water content of the eutectic solvent system was 30%, ratio of material to liquid was 30 g/mL, ultrasonic time was 30 min, ultrasonic power was 200 W, and ultrasonic temperature was 60 C. At this time, the contents of palmatine and berberine in Coptis chinensis were 16.7145 mg/g and 57.4013 mg/g, respectively, which were predicted to be the same as the value, and the extraction effect was better than that of traditional extraction solvent method.	Berberine	245-254	thrombopoietin	Mus musculus	104-106
34422209-3	2021	We have previously shown that berberine (BBR), an isoquinoline alkaloid isolated from Chinese herbs, was able to protect human RPE cells from H2O2-induced oxidative damage through AMPK activation.	Berberine	30-39	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	180-184
34422209-3	2021	We have previously shown that berberine (BBR), an isoquinoline alkaloid isolated from Chinese herbs, was able to protect human RPE cells from H2O2-induced oxidative damage through AMPK activation.	Berberine	41-44	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	180-184
34422209-5	2021	Given the essential role of AMPK in autophagy activation, we postulated that BBR may confer protection against H2O2-induced oxidative damage by stimulating AMPK-dependent autophagy.	Berberine	77-80	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	28-32
34422209-5	2021	Given the essential role of AMPK in autophagy activation, we postulated that BBR may confer protection against H2O2-induced oxidative damage by stimulating AMPK-dependent autophagy.	Berberine	77-80	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	156-160
34554677-5	2021	Our results showed that berberine and quercetin effectively inhibited the proliferation and migration of hypoxia-induced PASMCs in a manner likely to be mediated by the suppression of MAPK1, NADPH oxidase 4 (NOX4), and cytochrome P450 1B1 (CYP1B1) expression.	Berberine	24-33	mitogen activated protein kinase 1	Rattus norvegicus	184-189
34443321-0	2021	Berberine, A Phytoalkaloid, Inhibits Inflammatory Response Induced by LPS through NF-Kappabeta Pathway: Possible Involvement of the IKKalpha.	Berberine	0-9	nuclear factor kappa B subunit 1	Homo sapiens	82-94
34443321-0	2021	Berberine, A Phytoalkaloid, Inhibits Inflammatory Response Induced by LPS through NF-Kappabeta Pathway: Possible Involvement of the IKKalpha.	Berberine	0-9	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	132-140
34443321-3	2021	The effect of BBR on AA/LPS activated proinflammatory markers including TNF-alpha, MCP-1, IL-8 and COX-2 was measured by ELISA or quantitative real-time PCR.	Berberine	14-17	tumor necrosis factor	Homo sapiens	72-81
34443321-3	2021	The effect of BBR on AA/LPS activated proinflammatory markers including TNF-alpha, MCP-1, IL-8 and COX-2 was measured by ELISA or quantitative real-time PCR.	Berberine	14-17	C-C motif chemokine ligand 2	Homo sapiens	83-88
34443321-3	2021	The effect of BBR on AA/LPS activated proinflammatory markers including TNF-alpha, MCP-1, IL-8 and COX-2 was measured by ELISA or quantitative real-time PCR.	Berberine	14-17	C-X-C motif chemokine ligand 8	Homo sapiens	90-94
34443321-3	2021	The effect of BBR on AA/LPS activated proinflammatory markers including TNF-alpha, MCP-1, IL-8 and COX-2 was measured by ELISA or quantitative real-time PCR.	Berberine	14-17	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	99-104
34443321-4	2021	Furthermore, the effect of BBR on LPS-induced NF-kappaB translocation was determined by immunoblotting and confocal microscopy.	Berberine	27-30	nuclear factor kappa B subunit 1	Homo sapiens	46-55
34443321-5	2021	AA/ LPS-induced TNF-alpha, MCP-1, IL-6, IL-8, and COX-2 markers were markedly attenuated by BBR treatment in THP-1 cells by inhibiting NF-kappaB translocation into the nucleus.	Berberine	92-95	tumor necrosis factor	Homo sapiens	16-25
34443321-5	2021	AA/ LPS-induced TNF-alpha, MCP-1, IL-6, IL-8, and COX-2 markers were markedly attenuated by BBR treatment in THP-1 cells by inhibiting NF-kappaB translocation into the nucleus.	Berberine	92-95	C-C motif chemokine ligand 2	Homo sapiens	27-32
34443321-5	2021	AA/ LPS-induced TNF-alpha, MCP-1, IL-6, IL-8, and COX-2 markers were markedly attenuated by BBR treatment in THP-1 cells by inhibiting NF-kappaB translocation into the nucleus.	Berberine	92-95	interleukin 6	Homo sapiens	34-38
34443321-5	2021	AA/ LPS-induced TNF-alpha, MCP-1, IL-6, IL-8, and COX-2 markers were markedly attenuated by BBR treatment in THP-1 cells by inhibiting NF-kappaB translocation into the nucleus.	Berberine	92-95	C-X-C motif chemokine ligand 8	Homo sapiens	40-44
34443321-5	2021	AA/ LPS-induced TNF-alpha, MCP-1, IL-6, IL-8, and COX-2 markers were markedly attenuated by BBR treatment in THP-1 cells by inhibiting NF-kappaB translocation into the nucleus.	Berberine	92-95	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	50-55
34443321-5	2021	AA/ LPS-induced TNF-alpha, MCP-1, IL-6, IL-8, and COX-2 markers were markedly attenuated by BBR treatment in THP-1 cells by inhibiting NF-kappaB translocation into the nucleus.	Berberine	92-95	nuclear factor kappa B subunit 1	Homo sapiens	135-144
34394712-1	2021	Results: Prolonged exposure to palmitate increased the expression of ACE and AngII type 1 receptor (ATR1) and decreased the ACE2 expression, which was partly offset by berberine.	Berberine	168-177	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	69-72
34394712-1	2021	Results: Prolonged exposure to palmitate increased the expression of ACE and AngII type 1 receptor (ATR1) and decreased the ACE2 expression, which was partly offset by berberine.	Berberine	168-177	atrophin 1	Mus musculus	100-104
34394712-1	2021	Results: Prolonged exposure to palmitate increased the expression of ACE and AngII type 1 receptor (ATR1) and decreased the ACE2 expression, which was partly offset by berberine.	Berberine	168-177	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	124-128
34394712-2	2021	In ob/ob mice, berberine increased in tolerance to glucose, improved abnormal beta-cell and alpha-cell distributions, upregulated ACE2 expression, and decreased autophagosomes and the expression of LC3 and SQSTM1/p62.	Berberine	15-24	leptin	Mus musculus	3-5
34394712-2	2021	In ob/ob mice, berberine increased in tolerance to glucose, improved abnormal beta-cell and alpha-cell distributions, upregulated ACE2 expression, and decreased autophagosomes and the expression of LC3 and SQSTM1/p62.	Berberine	15-24	leptin	Mus musculus	6-8
34394712-2	2021	In ob/ob mice, berberine increased in tolerance to glucose, improved abnormal beta-cell and alpha-cell distributions, upregulated ACE2 expression, and decreased autophagosomes and the expression of LC3 and SQSTM1/p62.	Berberine	15-24	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	130-134
34394712-2	2021	In ob/ob mice, berberine increased in tolerance to glucose, improved abnormal beta-cell and alpha-cell distributions, upregulated ACE2 expression, and decreased autophagosomes and the expression of LC3 and SQSTM1/p62.	Berberine	15-24	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	198-201
34394712-2	2021	In ob/ob mice, berberine increased in tolerance to glucose, improved abnormal beta-cell and alpha-cell distributions, upregulated ACE2 expression, and decreased autophagosomes and the expression of LC3 and SQSTM1/p62.	Berberine	15-24	sequestosome 1	Mus musculus	206-212
34394712-2	2021	In ob/ob mice, berberine increased in tolerance to glucose, improved abnormal beta-cell and alpha-cell distributions, upregulated ACE2 expression, and decreased autophagosomes and the expression of LC3 and SQSTM1/p62.	Berberine	15-24	sequestosome 1	Mus musculus	213-216
34438693-0	2021	Regulation of Nutritional Metabolism in Transition Dairy Goats: Energy Balance, Liver Activity, and Insulin Resistance in Response to Berberine Supplementation.	Berberine	134-143	insulin	Capra hircus	100-107
34319490-0	2021	Berberine Reverses Nitroglycerin Tolerance through Suppressing Protein Kinase C Alpha Activity in Vascular Smooth Muscle Cells.	Berberine	0-9	protein kinase C, alpha	Rattus norvegicus	63-85
34319490-7	2021	The mechanistic study revealed that PKCalpha participated in the development of NTG tolerance as NTG increased the activity of PKCalpha with enriched PKCalpha membrane localization and elevated phosphorylation of PKCalpha in VSMCs, which was reversed by berberine or PKCalpha inhibitors.	Berberine	254-263	protein kinase C, alpha	Rattus norvegicus	36-44
34319490-7	2021	The mechanistic study revealed that PKCalpha participated in the development of NTG tolerance as NTG increased the activity of PKCalpha with enriched PKCalpha membrane localization and elevated phosphorylation of PKCalpha in VSMCs, which was reversed by berberine or PKCalpha inhibitors.	Berberine	254-263	protein kinase C, alpha	Rattus norvegicus	127-135
34319490-7	2021	The mechanistic study revealed that PKCalpha participated in the development of NTG tolerance as NTG increased the activity of PKCalpha with enriched PKCalpha membrane localization and elevated phosphorylation of PKCalpha in VSMCs, which was reversed by berberine or PKCalpha inhibitors.	Berberine	254-263	protein kinase C, alpha	Rattus norvegicus	150-158
34319490-7	2021	The mechanistic study revealed that PKCalpha participated in the development of NTG tolerance as NTG increased the activity of PKCalpha with enriched PKCalpha membrane localization and elevated phosphorylation of PKCalpha in VSMCs, which was reversed by berberine or PKCalpha inhibitors.	Berberine	254-263	protein kinase C, alpha	Rattus norvegicus	213-221
34319490-8	2021	CONCLUSION: This study is probably the first demonstration that berberine reverses NTG tolerance through inhibiting PKCalpha activity in VSMCs and PKCalpha is an important contributor to the development of NTG tolerance.	Berberine	64-73	protein kinase C, alpha	Rattus norvegicus	116-124
34319490-8	2021	CONCLUSION: This study is probably the first demonstration that berberine reverses NTG tolerance through inhibiting PKCalpha activity in VSMCs and PKCalpha is an important contributor to the development of NTG tolerance.	Berberine	64-73	protein kinase C, alpha	Rattus norvegicus	147-155
34319490-9	2021	These new findings suggest that berberine could become a promising drug for prevention of NTG tolerance and that targeting PKCalpha in VSMCs is likely to be a potential therapeutic strategy for reversal of NTG tolerance in blood vessels.	Berberine	32-41	protein kinase C, alpha	Rattus norvegicus	123-131
34393786-9	2021	The diurnal patterns of PR and CR effects were respectively consistent with those of puerarin (a main active constituent of PR, a REV-ERBalpha antagonist) and berberine (a main active constituent of CR, a REV-ERBalpha agonist).	Berberine	159-168	nuclear receptor subfamily 1, group D, member 1	Mus musculus	205-217
34554677-5	2021	Our results showed that berberine and quercetin effectively inhibited the proliferation and migration of hypoxia-induced PASMCs in a manner likely to be mediated by the suppression of MAPK1, NADPH oxidase 4 (NOX4), and cytochrome P450 1B1 (CYP1B1) expression.	Berberine	24-33	NADPH oxidase 4	Rattus norvegicus	191-206
34554677-5	2021	Our results showed that berberine and quercetin effectively inhibited the proliferation and migration of hypoxia-induced PASMCs in a manner likely to be mediated by the suppression of MAPK1, NADPH oxidase 4 (NOX4), and cytochrome P450 1B1 (CYP1B1) expression.	Berberine	24-33	NADPH oxidase 4	Rattus norvegicus	208-212
34554677-5	2021	Our results showed that berberine and quercetin effectively inhibited the proliferation and migration of hypoxia-induced PASMCs in a manner likely to be mediated by the suppression of MAPK1, NADPH oxidase 4 (NOX4), and cytochrome P450 1B1 (CYP1B1) expression.	Berberine	24-33	cytochrome P450, family 1, subfamily b, polypeptide 1	Rattus norvegicus	219-238
34554677-5	2021	Our results showed that berberine and quercetin effectively inhibited the proliferation and migration of hypoxia-induced PASMCs in a manner likely to be mediated by the suppression of MAPK1, NADPH oxidase 4 (NOX4), and cytochrome P450 1B1 (CYP1B1) expression.	Berberine	24-33	cytochrome P450, family 1, subfamily b, polypeptide 1	Rattus norvegicus	240-246
34312718-0	2021	Prospecting the therapeutic edge of a novel compound (B12) over berberine in the selective targeting of Retinoid X Receptor in colon cancer.	Berberine	64-73	retinoid X receptor alpha	Homo sapiens	104-123
34312718-5	2021	Upon binding of B12 to RXR, the high instability elicited by RXR was markedly reduced; similar observation was seen in the berberine-bound RXR.	Berberine	123-132	retinoid X receptor alpha	Homo sapiens	139-142
34312718-9	2021	We observed that B12 and berberine could induce a disparate conformational change in regions Gly250-Asp258 located on the His-RXRalpha/LBD domain.	Berberine	25-34	retinoid X receptor alpha	Homo sapiens	126-134
34312718-12	2021	Also, Arg371, which plays a crucial role in the activity of RXR, formed a strong hydrogen bond with B12; however, a weak interaction was elicited between Arg371 and berberine.	Berberine	165-174	retinoid X receptor alpha	Homo sapiens	60-63
34421358-0	2021	Berberine modulates deacetylation of PPARgamma to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.	Berberine	0-9	peroxisome proliferator activated receptor gamma	Mus musculus	37-46
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	12-21	interleukin 1 beta	Rattus norvegicus	198-202
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	12-21	vasoactive intestinal peptide	Rattus norvegicus	204-207
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	12-21	aquaporin 8	Rattus norvegicus	209-213
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	12-21	nitric oxide synthase 1	Rattus norvegicus	247-251
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	117-126	5-hydroxytryptamine receptor 4	Rattus norvegicus	173-177
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	117-126	F2R like thrombin or trypsin receptor 3	Rattus norvegicus	179-184
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	117-126	neuropeptide Y	Rattus norvegicus	186-189
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	117-126	corticotropin releasing hormone receptor 2	Rattus norvegicus	191-196
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	117-126	interleukin 1 beta	Rattus norvegicus	198-202
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	117-126	vasoactive intestinal peptide	Rattus norvegicus	204-207
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	117-126	aquaporin 8	Rattus norvegicus	209-213
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	117-126	nitric oxide synthase 1	Rattus norvegicus	247-251
34349501-15	2021	BBR also inhibited expression of URAT1 and exhibited strong affinity with this target in silico docking.	Berberine	0-3	solute carrier family 22 (organic anion/cation transporter), member 12	Mus musculus	33-38
34349501-16	2021	Conclusion: BBR exerts anti-HUA and nephroprotective effects via inhibiting activation of NLRP3 inflammasome and correcting the aberrant expression of URAT1 in kidney.	Berberine	12-15	NLR family, pyrin domain containing 3	Mus musculus	90-95
34349501-16	2021	Conclusion: BBR exerts anti-HUA and nephroprotective effects via inhibiting activation of NLRP3 inflammasome and correcting the aberrant expression of URAT1 in kidney.	Berberine	12-15	solute carrier family 22 (organic anion/cation transporter), member 12	Mus musculus	151-156
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	12-21	5-hydroxytryptamine receptor 4	Rattus norvegicus	173-177
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	12-21	F2R like thrombin or trypsin receptor 3	Rattus norvegicus	179-184
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	12-21	neuropeptide Y	Rattus norvegicus	186-189
34284820-7	2021	CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier.	Berberine	12-21	corticotropin releasing hormone receptor 2	Rattus norvegicus	191-196
34349640-3	2021	In the present study, berberine was shown to ameliorate ER stress and cognitive impairment in APP/PS1 mice.	Berberine	22-31	presenilin 1	Mus musculus	98-101
34421358-0	2021	Berberine modulates deacetylation of PPARgamma to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.	Berberine	0-9	sirtuin 1	Mus musculus	111-116
34349640-6	2021	Mechanically, berberine can reduce GSK3beta activity, contributing to the downregulation of tau phosphorylation.	Berberine	14-23	glycogen synthase kinase 3 alpha	Mus musculus	35-43
34349640-7	2021	Berberine also suppressed Abeta42 production via inhibiting the PERK/eIF2alpha/BACE1 signaling pathway.	Berberine	0-9	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	64-68
34421358-4	2021	We have further demonstrated that berberine activated energy metabolic sensing pathway AMPK/SIRT1 axis to increase the level of PPARgamma deacetylation, which leads to promoting adipose tissue remodeling and increasing the expression of the thermogenic protein UCP-1.	Berberine	34-43	sirtuin 1	Mus musculus	92-97
34349640-7	2021	Berberine also suppressed Abeta42 production via inhibiting the PERK/eIF2alpha/BACE1 signaling pathway.	Berberine	0-9	eukaryotic translation initiation factor 2A	Mus musculus	69-78
34349640-7	2021	Berberine also suppressed Abeta42 production via inhibiting the PERK/eIF2alpha/BACE1 signaling pathway.	Berberine	0-9	beta-site APP cleaving enzyme 1	Mus musculus	79-84
34421358-4	2021	We have further demonstrated that berberine activated energy metabolic sensing pathway AMPK/SIRT1 axis to increase the level of PPARgamma deacetylation, which leads to promoting adipose tissue remodeling and increasing the expression of the thermogenic protein UCP-1.	Berberine	34-43	peroxisome proliferator activated receptor gamma	Mus musculus	128-137
34421358-4	2021	We have further demonstrated that berberine activated energy metabolic sensing pathway AMPK/SIRT1 axis to increase the level of PPARgamma deacetylation, which leads to promoting adipose tissue remodeling and increasing the expression of the thermogenic protein UCP-1.	Berberine	34-43	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	261-266
34421358-5	2021	These findings suggest that berberine that enhances the AMPK/SIRT1 pathway can act as a selective PPARgamma activator to promote adipose tissue remodeling and thermogenesis.	Berberine	28-37	sirtuin 1	Mus musculus	61-66
34421358-5	2021	These findings suggest that berberine that enhances the AMPK/SIRT1 pathway can act as a selective PPARgamma activator to promote adipose tissue remodeling and thermogenesis.	Berberine	28-37	peroxisome proliferator activated receptor gamma	Mus musculus	98-107
34113144-0	2021	Berberine Ameliorates Hepatic Insulin Resistance by Regulating microRNA-146b/SIRT1 Pathway.	Berberine	0-9	microRNA 146b	Mus musculus	63-76
34211579-13	2021	Compared with the model group, the body mass of rats in the berberine group was significantly increased (P < 0.05); the general morphology and pathological changes of colon tissue were significantly improved; CMDI score, serum and colon tissue IL-1beta, TNF-alpha content, and protein expression were decreased significantly (P < 0.05); and IL-4 content and protein expression increased significantly (P < 0.05).	Berberine	60-69	interleukin 1 alpha	Rattus norvegicus	244-252
34211579-13	2021	Compared with the model group, the body mass of rats in the berberine group was significantly increased (P < 0.05); the general morphology and pathological changes of colon tissue were significantly improved; CMDI score, serum and colon tissue IL-1beta, TNF-alpha content, and protein expression were decreased significantly (P < 0.05); and IL-4 content and protein expression increased significantly (P < 0.05).	Berberine	60-69	tumor necrosis factor	Rattus norvegicus	254-263
34211579-13	2021	Compared with the model group, the body mass of rats in the berberine group was significantly increased (P < 0.05); the general morphology and pathological changes of colon tissue were significantly improved; CMDI score, serum and colon tissue IL-1beta, TNF-alpha content, and protein expression were decreased significantly (P < 0.05); and IL-4 content and protein expression increased significantly (P < 0.05).	Berberine	60-69	interleukin 4	Rattus norvegicus	341-345
34211397-4	2021	Methods: Degradation of berberine/jatrorrhizine/coptisine/palmatine from CREA/CREB/CREC in rat/mouse intestinal contents and their impact on nine common gastrointestinal bacteria were investigated.	Berberine	24-33	cAMP responsive element binding protein 1	Rattus norvegicus	78-82
34113144-0	2021	Berberine Ameliorates Hepatic Insulin Resistance by Regulating microRNA-146b/SIRT1 Pathway.	Berberine	0-9	sirtuin 1	Mus musculus	77-82
34113144-2	2021	In previous study, Gegen Qinlian Decoction containing berberine could enhance hepatic insulin sensitivity by SIRT1-dependent deacetylation of FOXO1.	Berberine	54-63	sirtuin 1	Mus musculus	109-114
34113144-2	2021	In previous study, Gegen Qinlian Decoction containing berberine could enhance hepatic insulin sensitivity by SIRT1-dependent deacetylation of FOXO1.	Berberine	54-63	forkhead box O1	Mus musculus	142-147
34113144-3	2021	However, it is not clear whether berberine also can improve hepatic insulin sensitivity by SIRT1/FOXO1 pathway.	Berberine	33-42	sirtuin 1	Mus musculus	91-96
34113144-3	2021	However, it is not clear whether berberine also can improve hepatic insulin sensitivity by SIRT1/FOXO1 pathway.	Berberine	33-42	forkhead box O1	Mus musculus	97-102
34113144-11	2021	Overexpression of miR-146b abolished the protective effect of berberine on palmitic acid-induced impaired glycogen synthesis in HepG2 cells.	Berberine	62-71	microRNA 146b	Homo sapiens	18-26
34113144-13	2021	Conclusion: The present findings suggest that berberine could attenuate hepatic insulin resistance through the miR-146b/SIRT1 pathway, which may represent a potential therapeutic target for the prevention and treatment of metabolic diseases, particularly diabetes.	Berberine	46-55	microRNA 146b	Homo sapiens	111-119
34113144-13	2021	Conclusion: The present findings suggest that berberine could attenuate hepatic insulin resistance through the miR-146b/SIRT1 pathway, which may represent a potential therapeutic target for the prevention and treatment of metabolic diseases, particularly diabetes.	Berberine	46-55	sirtuin 1	Homo sapiens	120-125
34185423-11	2021	A natural product berberine was selected as functional inhibitor of LDHA, which reduced activity and expression of the protein in PAAD cells.	Berberine	18-27	lactate dehydrogenase A	Mus musculus	68-72
33883444-5	2021	Lastly, a recent study showed berberine, an existing lipid-lowering drug, to be acting via a TRIB1-dependent mechanism, highlighting both a novel regulator of TRIB1 expression and the potential of studying TRIB1 through existing therapeutics.	Berberine	30-39	tribbles pseudokinase 1	Mus musculus	93-98
34185423-13	2021	The restoration of LDHA attenuated the suppressive effect of berberine on PAAD.	Berberine	61-70	lactate dehydrogenase A	Mus musculus	19-23
33883444-5	2021	Lastly, a recent study showed berberine, an existing lipid-lowering drug, to be acting via a TRIB1-dependent mechanism, highlighting both a novel regulator of TRIB1 expression and the potential of studying TRIB1 through existing therapeutics.	Berberine	30-39	tribbles pseudokinase 1	Mus musculus	159-164
34476441-0	2021	(Berberine promotes osteogenic differentiation of rat adipose-derived stem cells through JNK signaling pathway).	Berberine	1-10	mitogen-activated protein kinase 8	Rattus norvegicus	89-92
34016844-0	2021	Quercetin, Perillyl alcohol and Berberine ameliorate right ventricular disorders in experimental pulmonary arterial hypertension: Effects on miR-204, miR-27a, fibrotic, apoptotic and inflammatory factors.	Berberine	32-41	microRNA 204	Rattus norvegicus	141-148
34016844-0	2021	Quercetin, Perillyl alcohol and Berberine ameliorate right ventricular disorders in experimental pulmonary arterial hypertension: Effects on miR-204, miR-27a, fibrotic, apoptotic and inflammatory factors.	Berberine	32-41	microRNA 27a	Rattus norvegicus	150-157
34483445-6	2021	Berberine significantly counteracted (P<0.05) the increase of TNF-alpha, IL-6, caspase-3 and BAX and counteracted the increase in plasma cTn-T and serum MDA.	Berberine	0-9	tumor necrosis factor	Rattus norvegicus	62-71
34483445-6	2021	Berberine significantly counteracted (P<0.05) the increase of TNF-alpha, IL-6, caspase-3 and BAX and counteracted the increase in plasma cTn-T and serum MDA.	Berberine	0-9	interleukin 6	Rattus norvegicus	73-77
34483445-6	2021	Berberine significantly counteracted (P<0.05) the increase of TNF-alpha, IL-6, caspase-3 and BAX and counteracted the increase in plasma cTn-T and serum MDA.	Berberine	0-9	caspase 3	Rattus norvegicus	79-88
34483445-6	2021	Berberine significantly counteracted (P<0.05) the increase of TNF-alpha, IL-6, caspase-3 and BAX and counteracted the increase in plasma cTn-T and serum MDA.	Berberine	0-9	BCL2 associated X, apoptosis regulator	Rattus norvegicus	93-96
34483445-7	2021	Berberine produces a significant elevation (P<0.05) in cardiac IL-10 and serum GSH with a significant reduction in (P<0.05) cardiac injury.	Berberine	0-9	interleukin 10	Rattus norvegicus	63-68
34167623-9	2021	Finally, cellular assays disclosed that the pretreatment of neuronal cultures with berberine-HSA nanoparticles decreased the H2O2-stimulated cytotoxicity and relevant morphological changes and enhanced the CAT activity.	Berberine	83-92	catalase	Homo sapiens	206-209
34476441-11	2021	The phosphorylation level of JNK was increased after treated with 10 mumol/L berberine culture medium.	Berberine	77-86	mitogen-activated protein kinase 8	Rattus norvegicus	29-32
34476441-14	2021	CONCLUSIONS: Berberine has no effect on cell proliferation of ADSCs, and can up-regulate osteogenic differentiation of ADSCs through activation of JNK signaling pathway.	Berberine	13-22	mitogen-activated protein kinase 8	Rattus norvegicus	147-150
34064687-0	2021	Berberine Improves Cognitive Impairment by Simultaneously Impacting Cerebral Blood Flow and beta-Amyloid Accumulation in an APP/tau/PS1 Mouse Model of Alzheimer"s Disease.	Berberine	0-9	presenilin 1	Mus musculus	132-135
34094026-5	2021	Results: The results showed that ALT, AST, lipid profile, insulin, glucose, MDA, and TNF-alpha were significantly improved in high-fat rats treated with Berberine/ Sitagliptin compared with HF and Sitagliptin, and Berberine alone groups.	Berberine	153-162	tumor necrosis factor	Rattus norvegicus	85-94
34094026-5	2021	Results: The results showed that ALT, AST, lipid profile, insulin, glucose, MDA, and TNF-alpha were significantly improved in high-fat rats treated with Berberine/ Sitagliptin compared with HF and Sitagliptin, and Berberine alone groups.	Berberine	214-223	tumor necrosis factor	Rattus norvegicus	85-94
34094026-6	2021	SOD and adiponectin levels in Berberine/ Sitagliptin group were also significantly increased compared with the other groups.	Berberine	30-39	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	8-19
34094026-7	2021	Immunoblot analysis showed that the expression of pho-ERK/ERK was significantly decreased and expression of AdipoR2 significantly increased in the Berberine/ Sitagliptin group compared with other groups.	Berberine	147-156	Eph receptor B1	Rattus norvegicus	54-57
34094026-7	2021	Immunoblot analysis showed that the expression of pho-ERK/ERK was significantly decreased and expression of AdipoR2 significantly increased in the Berberine/ Sitagliptin group compared with other groups.	Berberine	147-156	Eph receptor B1	Rattus norvegicus	58-61
34094026-7	2021	Immunoblot analysis showed that the expression of pho-ERK/ERK was significantly decreased and expression of AdipoR2 significantly increased in the Berberine/ Sitagliptin group compared with other groups.	Berberine	147-156	adiponectin receptor 2	Rattus norvegicus	108-115
34981469-9	2021	The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment.	Berberine	222-231	Wnt family member 1	Homo sapiens	117-121
34137676-11	2021	Berberine also effectively decreased the expression of hippocampal tau protein, phosphorylated Tau, and increased insulin receptor antibodies.	Berberine	0-9	insulin receptor	Rattus norvegicus	114-130
34269665-0	2021	The intracellular mechanism of Berberine-induced inhibition of CYP3A4 activity.	Berberine	31-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
34269665-2	2021	BBR is partially metabolized by cytochrome 3A4 (CYP3A4) in vivo.	Berberine	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
34269665-3	2021	Some reports indicated that BBR could inhibit the activity of CYP3A4.	Berberine	28-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
34269665-10	2021	In addition, BBR accelerated the degradation of CYP3A4 protein via the polyubiquitination pathway.	Berberine	13-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
35609366-0	2022	Berberine exerts protective effects on cardiac senescence by regulating the Klotho/SIRT1 signaling pathway.	Berberine	0-9	Klotho	Rattus norvegicus	76-82
35609366-0	2022	Berberine exerts protective effects on cardiac senescence by regulating the Klotho/SIRT1 signaling pathway.	Berberine	0-9	sirtuin 1	Rattus norvegicus	83-88
35609366-10	2022	Additionally, BBR markedly reversed downregulation of sirtuin1 (SIRTI) in the aged heart.	Berberine	14-17	sirtuin 1	Rattus norvegicus	54-62
35526324-0	2022	Bcl-xL is required for the protective effects of low-dose berberine against doxorubicin-induced cardiotoxicity through blocking apoptosis and activating mitophagy-mediated ROS elimination.	Berberine	58-67	BCL2 like 1	Homo sapiens	0-6
35429745-0	2022	Berberine reduces hepatic ceramide levels to improve insulin resistance in HFD-fed mice by inhibiting HIF-2alpha.	Berberine	0-9	endothelial PAS domain protein 1	Mus musculus	102-112
35430394-5	2022	Moreover, berberine (a major component in HB) repressed the IL-17 signalling pathway, and promoted wound healing in diabetes mellitus.	Berberine	10-19	interleukin 17A	Rattus norvegicus	60-65
34467691-5	2021	The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects.	Berberine	73-82	C-reactive protein, pentraxin-related	Mus musculus	200-218
34467691-5	2021	The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects.	Berberine	73-82	C-reactive protein	Homo sapiens	219-222
34467691-5	2021	The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects.	Berberine	73-82	estrogen receptor 1	Homo sapiens	245-249
34467691-5	2021	The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects.	Berberine	73-82	interleukin 6	Mus musculus	292-305
34467691-5	2021	The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects.	Berberine	73-82	interleukin 6	Homo sapiens	306-310
34467691-8	2021	The results demonstrated that berberine was potent in reducing the activities and standing times of mice, down-regulating the levels of CRP and IL-6 mRNA in the hypothalamus, and up-regulating the expression of 5-HT(P<0.01); however, no significant effect on ESR1 was observed.	Berberine	30-39	C-reactive protein, pentraxin-related	Mus musculus	136-139
34467691-8	2021	The results demonstrated that berberine was potent in reducing the activities and standing times of mice, down-regulating the levels of CRP and IL-6 mRNA in the hypothalamus, and up-regulating the expression of 5-HT(P<0.01); however, no significant effect on ESR1 was observed.	Berberine	30-39	interleukin 6	Mus musculus	144-148
34981469-9	2021	The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment.	Berberine	222-231	catenin beta 1	Homo sapiens	123-129
34981469-9	2021	The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment.	Berberine	222-231	hepatocyte nuclear factor 4 alpha	Homo sapiens	131-134
34981469-9	2021	The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment.	Berberine	222-231	mechanistic target of rapamycin kinase	Homo sapiens	136-140
34981469-9	2021	The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment.	Berberine	222-231	AKT serine/threonine kinase 1	Homo sapiens	142-146
34981469-9	2021	The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment.	Berberine	222-231	baculoviral IAP repeat containing 5	Homo sapiens	148-153
34981469-9	2021	The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment.	Berberine	222-231	cyclin D1	Homo sapiens	159-164
34961418-7	2021	FPG, FPI, HOMA-IR, HbA1, TG, BMI, and WC were significantly lower in patients who received berberine compared to placebo after 12 weeks of treatment ((Formula: see text)< 0.05).	Berberine	91-100	hemoglobin subunit alpha 1	Homo sapiens	19-23
35504329-8	2022	By decreasing beta-catenin expression, increasing GSK-3beta expression and decreasing N-cadherin expression, increasing E-cadherin expression, which proved that epiberberine, berberrubine and dihydroberberine inhibited of metastasis of breast cancer cells through Wnt signaling pathway and reversed EMT except berberine.	Berberine	310-319	cadherin 1	Homo sapiens	120-130
35460707-12	2022	The therapeutic agents, most of them are phytochemicals such as resveratrol, berberine and curcumin, induce Nrf2 signaling in I/R injury alleviation.	Berberine	77-86	NFE2 like bZIP transcription factor 2	Homo sapiens	108-112
35526324-7	2022	Bcl-xL knockdown in AC16 cells and zebrafish demonstrated that Bcl-xL is required for BBR"s anti-apoptotic activity.	Berberine	86-89	BCL2 like 1	Homo sapiens	0-6
35526324-7	2022	Bcl-xL knockdown in AC16 cells and zebrafish demonstrated that Bcl-xL is required for BBR"s anti-apoptotic activity.	Berberine	86-89	BCL2 like 1	Danio rerio	63-69
35526324-11	2022	Intriguingly, BBR increased Bcl-xL binding to Bnip3, sequestration, and mitophagy, indicating that Bcl-xL may play a beneficial role in BBR-induced mitophagy.	Berberine	14-17	BCL2 like 1	Danio rerio	28-34
35526324-11	2022	Intriguingly, BBR increased Bcl-xL binding to Bnip3, sequestration, and mitophagy, indicating that Bcl-xL may play a beneficial role in BBR-induced mitophagy.	Berberine	14-17	BCL2 interacting protein 3	Homo sapiens	46-51
35526324-11	2022	Intriguingly, BBR increased Bcl-xL binding to Bnip3, sequestration, and mitophagy, indicating that Bcl-xL may play a beneficial role in BBR-induced mitophagy.	Berberine	14-17	BCL2 like 1	Danio rerio	99-105
35526324-11	2022	Intriguingly, BBR increased Bcl-xL binding to Bnip3, sequestration, and mitophagy, indicating that Bcl-xL may play a beneficial role in BBR-induced mitophagy.	Berberine	136-139	BCL2 like 1	Danio rerio	28-34
35526324-11	2022	Intriguingly, BBR increased Bcl-xL binding to Bnip3, sequestration, and mitophagy, indicating that Bcl-xL may play a beneficial role in BBR-induced mitophagy.	Berberine	136-139	BCL2 interacting protein 3	Homo sapiens	46-51
35526324-11	2022	Intriguingly, BBR increased Bcl-xL binding to Bnip3, sequestration, and mitophagy, indicating that Bcl-xL may play a beneficial role in BBR-induced mitophagy.	Berberine	136-139	BCL2 like 1	Danio rerio	99-105
35526324-14	2022	CONCLUSION: These findings indicate that the protective effects of low-dose BBR against DOX-induced cardiotoxicity are mediated by Bcl-xL.	Berberine	76-79	BCL2 like 1	Danio rerio	131-137
35495613-0	2022	Berberine attenuates sepsis-induced cardiac dysfunction by upregulating the Akt/eNOS pathway in mice.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	76-79
35495613-0	2022	Berberine attenuates sepsis-induced cardiac dysfunction by upregulating the Akt/eNOS pathway in mice.	Berberine	0-9	nitric oxide synthase 3, endothelial cell	Mus musculus	80-84
35495613-9	2022	In addition, it increased the heart total nitric oxide synthase (NOS) activity and upregulated the protein expressions of p-Akt and phosphorylated endothelial (e)NOS, which indicated that the Akt/eNOS pathway was activated by berberine.	Berberine	226-235	thymoma viral proto-oncogene 1	Mus musculus	124-127
35495613-9	2022	In addition, it increased the heart total nitric oxide synthase (NOS) activity and upregulated the protein expressions of p-Akt and phosphorylated endothelial (e)NOS, which indicated that the Akt/eNOS pathway was activated by berberine.	Berberine	226-235	thymoma viral proto-oncogene 1	Mus musculus	192-195
35495613-9	2022	In addition, it increased the heart total nitric oxide synthase (NOS) activity and upregulated the protein expressions of p-Akt and phosphorylated endothelial (e)NOS, which indicated that the Akt/eNOS pathway was activated by berberine.	Berberine	226-235	nitric oxide synthase 3, endothelial cell	Mus musculus	196-200
35495613-10	2022	However, the cardioprotective effects of berberine were counteracted by L-NAME, an NOS inhibitor, which inhibited the eNOS activity.	Berberine	41-50	nitric oxide synthase 3, endothelial cell	Mus musculus	118-122
35495613-11	2022	In conclusion, berberine attenuated sepsis-induced cardiac dysfunction by upregulating the Akt/eNOS pathway in mice.	Berberine	15-24	thymoma viral proto-oncogene 1	Mus musculus	91-94
35495613-11	2022	In conclusion, berberine attenuated sepsis-induced cardiac dysfunction by upregulating the Akt/eNOS pathway in mice.	Berberine	15-24	nitric oxide synthase 3, endothelial cell	Mus musculus	95-99
35318164-0	2022	Berberine inhibits osteogenic differentiation of aortic valve interstitial cells by interfering Smad1/5/8 and NF-kappaB pathways.	Berberine	0-9	SMAD family member 1	Homo sapiens	96-105
35318164-9	2022	Western blot was used to examine upstream receptors of Smad1/5/8, the results showed that BBR inhibited the activation of Smad1/5/8 by downregulating ALK2 and ALK3.	Berberine	90-93	SMAD family member 1	Homo sapiens	55-64
35318164-9	2022	Western blot was used to examine upstream receptors of Smad1/5/8, the results showed that BBR inhibited the activation of Smad1/5/8 by downregulating ALK2 and ALK3.	Berberine	90-93	SMAD family member 1	Homo sapiens	122-131
35318164-9	2022	Western blot was used to examine upstream receptors of Smad1/5/8, the results showed that BBR inhibited the activation of Smad1/5/8 by downregulating ALK2 and ALK3.	Berberine	90-93	activin A receptor type 1	Homo sapiens	150-154
35318164-9	2022	Western blot was used to examine upstream receptors of Smad1/5/8, the results showed that BBR inhibited the activation of Smad1/5/8 by downregulating ALK2 and ALK3.	Berberine	90-93	bone morphogenetic protein receptor type 1A	Homo sapiens	159-163
35318164-10	2022	CONCLUSION: BBR decreased the inflammatory factors and suppressed the osteogenic differentiation of VICs, which might be associated with the inhibition of Smad1/5/8 and NF-kappaB signaling pathways.	Berberine	12-15	SMAD family member 1	Homo sapiens	155-164
34064687-7	2021	The results showed that BBR ameliorated cognitive deficits in 3xTg AD mice, reduced the Abeta accumulation, inhibited the apoptosis of neurons, promoted the formation of microvessels in the mouse brain by enhancing brain CD31, VEGF, N-cadherin, Ang-1.	Berberine	24-27	platelet/endothelial cell adhesion molecule 1	Mus musculus	221-225
35633490-9	2022	Finally, a rescue experiment was performed and the results demonstrated that the effect of BBR on cell viability, apoptosis and mitochondrial function in PA-induced INS-1 cells were cancelled by PINK1 knockdown.	Berberine	91-94	PTEN induced kinase 1	Rattus norvegicus	195-200
34064687-7	2021	The results showed that BBR ameliorated cognitive deficits in 3xTg AD mice, reduced the Abeta accumulation, inhibited the apoptosis of neurons, promoted the formation of microvessels in the mouse brain by enhancing brain CD31, VEGF, N-cadherin, Ang-1.	Berberine	24-27	vascular endothelial growth factor A	Mus musculus	227-231
34064687-7	2021	The results showed that BBR ameliorated cognitive deficits in 3xTg AD mice, reduced the Abeta accumulation, inhibited the apoptosis of neurons, promoted the formation of microvessels in the mouse brain by enhancing brain CD31, VEGF, N-cadherin, Ang-1.	Berberine	24-27	cadherin 2	Mus musculus	233-243
34064687-7	2021	The results showed that BBR ameliorated cognitive deficits in 3xTg AD mice, reduced the Abeta accumulation, inhibited the apoptosis of neurons, promoted the formation of microvessels in the mouse brain by enhancing brain CD31, VEGF, N-cadherin, Ang-1.	Berberine	24-27	angiopoietin 1	Mus musculus	245-250
35535536-1	2022	OBJECTIVE: To investigate the effect of intra-articular berberine injection on the structural remodeling of subchondral bone plate and osteoprotegerin/receptor activator of nuclear factor kappa-B ligand(OPG/RANKL) system expression in rabbits with osteoarthritis(OA).	Berberine	56-65	tumor necrosis factor receptor superfamily member 11B	Oryctolagus cuniculus	135-150
35612892-6	2022	The focus of this study was to determine the role of Berberine on mitochondrial uncoupling protein (UCP1), ATP production, and cytotoxic effect of HEK293T cell at a time and dose-dependent manner analysis by CCK8 assay.	Berberine	53-62	uncoupling protein 1	Homo sapiens	100-104
35612892-12	2022	The first time, we used molecular docking and dynamic of Berberine with UCP1 gene in this study and revealed therapeutic potential of Berberine via modulation of mitochondrial UCP1 gene.	Berberine	57-66	uncoupling protein 1	Homo sapiens	72-76
35612892-12	2022	The first time, we used molecular docking and dynamic of Berberine with UCP1 gene in this study and revealed therapeutic potential of Berberine via modulation of mitochondrial UCP1 gene.	Berberine	57-66	uncoupling protein 1	Homo sapiens	176-180
35612892-12	2022	The first time, we used molecular docking and dynamic of Berberine with UCP1 gene in this study and revealed therapeutic potential of Berberine via modulation of mitochondrial UCP1 gene.	Berberine	134-143	uncoupling protein 1	Homo sapiens	72-76
35612892-12	2022	The first time, we used molecular docking and dynamic of Berberine with UCP1 gene in this study and revealed therapeutic potential of Berberine via modulation of mitochondrial UCP1 gene.	Berberine	134-143	uncoupling protein 1	Homo sapiens	176-180
35597409-19	2022	RESULTS: Berberine, jateorhizine, coptisine, epiberberine, columbamine, demethyleneberberine, and berberrubine could significantly inhibit hOCT1 and hOCT2 activity.	Berberine	9-18	solute carrier family 22 member 1	Homo sapiens	139-144
35628500-5	2022	Using biophysical techniques, the berberine binding thermodynamics and the associated conformational and hydration changes of RG-1 could be characterized and compared with human telomeric DNA-G4Q 22AG.	Berberine	34-43	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	126-130
35628500-7	2022	Substantial changes were observed in the interaction of berberine with 22AG and RG-1, which adopt different topologies that can also change upon ligand binding.	Berberine	56-65	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	80-84
35583808-8	2022	Sulfation of the TRPV1 receptor resulted in vagus nerve activation and promoted the c-fos and ChAT in the nucleus tractus solitaries with berberine.	Berberine	138-147	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	17-22
35583808-8	2022	Sulfation of the TRPV1 receptor resulted in vagus nerve activation and promoted the c-fos and ChAT in the nucleus tractus solitaries with berberine.	Berberine	138-147	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	84-89
35583808-8	2022	Sulfation of the TRPV1 receptor resulted in vagus nerve activation and promoted the c-fos and ChAT in the nucleus tractus solitaries with berberine.	Berberine	138-147	choline O-acetyltransferase	Rattus norvegicus	94-98
35583808-11	2022	H2 S stimulates the vagus nerve through TRPV1 is responsible for the berberine-induced gut-brain axis signal transmission.	Berberine	69-78	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	40-45
35428692-9	2022	injected with LPS, the increase of serum TNF-alpha and the drop of blood glucose were attenuated by berberine treatment.	Berberine	100-109	tumor necrosis factor	Mus musculus	41-50
35586690-0	2022	Berberine Alleviates Gastroesophageal Reflux-Induced Airway Hyperresponsiveness in a Transient Receptor Potential A1-Dependent Manner.	Berberine	0-9	transient receptor potential cation channel subfamily A member 1	Cavia porcellus	85-116
35341784-0	2022	Combination of berberine and low glucose inhibits gastric cancer through the PP2A/GSK3beta/MCL-1 signaling pathway.	Berberine	15-24	protein phosphatase 2 phosphatase activator	Homo sapiens	77-81
35341784-0	2022	Combination of berberine and low glucose inhibits gastric cancer through the PP2A/GSK3beta/MCL-1 signaling pathway.	Berberine	15-24	glycogen synthase kinase 3 alpha	Homo sapiens	82-90
35341784-0	2022	Combination of berberine and low glucose inhibits gastric cancer through the PP2A/GSK3beta/MCL-1 signaling pathway.	Berberine	15-24	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	91-96
35341784-8	2022	Based on these results, we conclude that the berberine/low-glucose combination can inhibit the growth of gastric cancer through the PP2A/GSK3beta/MCL-1 signaling pathway.	Berberine	45-54	protein phosphatase 2 phosphatase activator	Homo sapiens	132-136
35341784-8	2022	Based on these results, we conclude that the berberine/low-glucose combination can inhibit the growth of gastric cancer through the PP2A/GSK3beta/MCL-1 signaling pathway.	Berberine	45-54	glycogen synthase kinase 3 alpha	Mus musculus	137-145
35341784-8	2022	Based on these results, we conclude that the berberine/low-glucose combination can inhibit the growth of gastric cancer through the PP2A/GSK3beta/MCL-1 signaling pathway.	Berberine	45-54	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	146-151
35158228-7	2022	Meanwhile, BBR treatment increased the proportion of Treg cells and CTLA-4 in Treg cells.	Berberine	11-14	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	68-74
35158228-8	2022	Treg cells from BBR treatment mice could decrease the pro-inflammatory response by inhibiting the activation of macrophages, thus exerting a protective effect on CLP-induced intestinal injury, and CTLA-4 mediated cell-cell contact pathway is required for this protective effect.	Berberine	16-19	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	197-203
35572672-22	2022	The level of HDAC1 mRNA was reduced in HT29 cells treated with BBR or PS (p < 0.05), the mice treated with BBR revealed a significantly increased concentration of SB in serum (p < 0.05), and the inhibitory effect of SB on the proliferation of HT29 cells was stronger than panobinostat and TSA.	Berberine	63-66	histone deacetylase 1	Homo sapiens	13-18
35572672-22	2022	The level of HDAC1 mRNA was reduced in HT29 cells treated with BBR or PS (p < 0.05), the mice treated with BBR revealed a significantly increased concentration of SB in serum (p < 0.05), and the inhibitory effect of SB on the proliferation of HT29 cells was stronger than panobinostat and TSA.	Berberine	107-110	histone deacetylase 1	Homo sapiens	13-18
35563167-7	2022	Berberine, such as the drug metformin, is a clinically useful activator of AMPK.	Berberine	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	75-79
35509629-15	2022	Among these components, puerarin, berberine, and liquiritin appear to have a better effect on activating Nrf2 in vitro.	Berberine	34-43	NFE2 like bZIP transcription factor 2	Homo sapiens	105-109
35624895-9	2022	In contrast, treatment with berberine (BBR), an NOX2 inhibitor, significantly mitigated these effects.	Berberine	28-37	cytochrome b-245, beta polypeptide	Mus musculus	48-52
35624895-9	2022	In contrast, treatment with berberine (BBR), an NOX2 inhibitor, significantly mitigated these effects.	Berberine	39-42	cytochrome b-245, beta polypeptide	Mus musculus	48-52
35596224-11	2022	FMT experiment determined that the mice fed with stool from BBR treated AOM/DSS mice demonstrated a relatively lower abundance of macroscopic polyps and a significantly lower expression of beta-catenin, and PCNA in intestinal tissue than mice fed with stool from AOM/DSS mice.	Berberine	60-63	catenin (cadherin associated protein), beta 1	Mus musculus	189-201
35596224-11	2022	FMT experiment determined that the mice fed with stool from BBR treated AOM/DSS mice demonstrated a relatively lower abundance of macroscopic polyps and a significantly lower expression of beta-catenin, and PCNA in intestinal tissue than mice fed with stool from AOM/DSS mice.	Berberine	60-63	proliferating cell nuclear antigen	Mus musculus	207-211
35596224-13	2022	In addition, the NF-kappaB expression was greatly suppressed in mice fed with stool from BBR treated AOM/DSS mice.	Berberine	89-92	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	17-26
35596224-15	2022	CONCLUSIONS: Stool obtained from BBR treated AOM/DSS mice was able to increase colon length while simultaneously decreasing the density of macroscopic polyps, cell proliferation, inflammatory modulators and the expression of NF-kappaB.	Berberine	33-36	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	225-234
35597409-20	2022	Isoquinoline alkaloids, including berberine, jateorhizine, coptisine, epiberberine, columbamine, and palmatine, were substrates of hOCT1 and hOCT2, but not the indole alkaloids evodiamine and rutaecarpine.	Berberine	34-43	solute carrier family 22 member 1	Homo sapiens	131-136
35580317-2	2022	We aimed to investigate the ameliorative effect of berberine on VC via the activation of Akt signaling and inhibition of endoplasmic reticulum stress (ERS).	Berberine	51-60	AKT serine/threonine kinase 1	Rattus norvegicus	89-92
35580317-7	2022	The ameliorative effects of berberine on VC, ERS, and the Akt signaling pathway were all prevented by inhibitor IV.	Berberine	28-37	AKT serine/threonine kinase 1	Rattus norvegicus	58-61
35428692-5	2022	Glucose transporter (GLUT)1 expression and total cellular hexokinase activity increased gradually in BMDMs in the presence of berberine.	Berberine	126-135	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	0-27
35608614-0	2022	Corrigendum to "Berberine Reduces Renal Cell Pyroptosis in Golden Hamsters with Diabetic Nephropathy through the Nrf2-NLRP3-Caspase-1-GSDMD Pathway".	Berberine	16-25	NACHT, LRR and PYD domains-containing protein 3	Mesocricetus auratus	118-123
35608614-0	2022	Corrigendum to "Berberine Reduces Renal Cell Pyroptosis in Golden Hamsters with Diabetic Nephropathy through the Nrf2-NLRP3-Caspase-1-GSDMD Pathway".	Berberine	16-25	gasdermin-D	Mesocricetus auratus	134-139
35586690-9	2022	Conclusions: Mechanistically, berberine was found to suppress GERAHR-induced upregulation of TRPA1, SP, and TNF-alpha in many tissues.	Berberine	30-39	transient receptor potential cation channel subfamily A member 1	Cavia porcellus	93-98
35586690-9	2022	Conclusions: Mechanistically, berberine was found to suppress GERAHR-induced upregulation of TRPA1, SP, and TNF-alpha in many tissues.	Berberine	30-39	tumor necrosis factor	Cavia porcellus	108-117
35600365-0	2022	Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer.	Berberine	0-9	AKT serine/threonine kinase 1	Homo sapiens	99-102
35561873-10	2022	Additionally, the mRNA expression of several metal transport related genes of the chick small intestine, including zinc transporter 1, copper transporter 1 and divalent metal ion transporter 1, was elevated by the treatment with berberine.	Berberine	229-238	solute carrier family 30 member 1	Gallus gallus	115-133
35624737-10	2022	Similarly, in 16HBE cells, berberine-LCNs inhibited the cigarette smoke-induced senescence as revealed by X-gal staining, gene expression of CDKN1A (p21), and immunofluorescent staining of p21.	Berberine	27-36	cyclin dependent kinase inhibitor 1A	Homo sapiens	141-147
35624737-10	2022	Similarly, in 16HBE cells, berberine-LCNs inhibited the cigarette smoke-induced senescence as revealed by X-gal staining, gene expression of CDKN1A (p21), and immunofluorescent staining of p21.	Berberine	27-36	cyclin dependent kinase inhibitor 1A	Homo sapiens	149-152
35624737-10	2022	Similarly, in 16HBE cells, berberine-LCNs inhibited the cigarette smoke-induced senescence as revealed by X-gal staining, gene expression of CDKN1A (p21), and immunofluorescent staining of p21.	Berberine	27-36	cyclin dependent kinase inhibitor 1A	Homo sapiens	189-192
35571083-0	2022	Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway In Vivo and In Vitro.	Berberine	33-42	thymoma viral proto-oncogene 1	Mus musculus	109-112
35571083-0	2022	Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway In Vivo and In Vitro.	Berberine	33-42	thioredoxin interacting protein	Mus musculus	113-118
35563195-0	2022	Berberine Suppresses Leukocyte Adherence by Downregulating CX3CL1 Expression and Shedding and ADAM10 in Lipopolysaccharide-Stimulated Vascular Endothelial Cells.	Berberine	0-9	C-X3-C motif chemokine ligand 1	Rattus norvegicus	59-65
35563195-0	2022	Berberine Suppresses Leukocyte Adherence by Downregulating CX3CL1 Expression and Shedding and ADAM10 in Lipopolysaccharide-Stimulated Vascular Endothelial Cells.	Berberine	0-9	ADAM metallopeptidase domain 10	Rattus norvegicus	94-100
35563195-2	2022	In a lipopolysaccharide (LPS)-induced endotoxemic acute lung injury (ALI) rat model, berberine alleviated lung injury through different anti-inflammatory mechanisms; however, treatment effects on CX3CL1 expression and shedding remain to be examined.	Berberine	85-94	C-X3-C motif chemokine ligand 1	Rattus norvegicus	196-202
35563195-10	2022	Berberine mitigated the LPS-induced activation of the NF-kappaB and STAT3 signaling pathways.	Berberine	0-9	signal transducer and activator of transcription 3	Rattus norvegicus	68-73
35563195-11	2022	In THP-1 cells, berberine mitigated the LPS-induced upregulation of CX3CR1.	Berberine	16-25	C-X3-C motif chemokine receptor 1	Homo sapiens	68-74
35563195-12	2022	Furthermore, the membrane expression of ADAM10 in LPS-stimulated HUVECs was suppressed by the berberine treatment.	Berberine	94-103	ADAM metallopeptidase domain 10	Rattus norvegicus	40-46
35563195-13	2022	Berberine dose-dependently inhibited the LPS-induced activation of the CX3CL1/CX3CR1 axis and fractalkine shedding through ADAM10.	Berberine	0-9	C-X3-C motif chemokine ligand 1	Homo sapiens	71-77
35563195-13	2022	Berberine dose-dependently inhibited the LPS-induced activation of the CX3CL1/CX3CR1 axis and fractalkine shedding through ADAM10.	Berberine	0-9	C-X3-C motif chemokine receptor 1	Homo sapiens	78-84
35563195-13	2022	Berberine dose-dependently inhibited the LPS-induced activation of the CX3CL1/CX3CR1 axis and fractalkine shedding through ADAM10.	Berberine	0-9	ADAM metallopeptidase domain 10	Rattus norvegicus	123-129
35597409-19	2022	RESULTS: Berberine, jateorhizine, coptisine, epiberberine, columbamine, demethyleneberberine, and berberrubine could significantly inhibit hOCT1 and hOCT2 activity.	Berberine	9-18	POU class 2 homeobox 2	Homo sapiens	149-154
35063579-0	2022	beta-catenin correlates with the progression of colon cancers and berberine inhibits the proliferation of colon cancer cells by regulating the beta-catenin signaling pathway.	Berberine	66-75	catenin beta 1	Homo sapiens	143-155
35460012-0	2022	Berberine Improves TNF-alpha-Induced Hepatic Insulin Resistance by Targeting MEKK1/MEK Pathway.	Berberine	0-9	tumor necrosis factor	Homo sapiens	19-28
35460012-0	2022	Berberine Improves TNF-alpha-Induced Hepatic Insulin Resistance by Targeting MEKK1/MEK Pathway.	Berberine	0-9	insulin	Homo sapiens	45-52
35460012-0	2022	Berberine Improves TNF-alpha-Induced Hepatic Insulin Resistance by Targeting MEKK1/MEK Pathway.	Berberine	0-9	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	77-82
35460012-0	2022	Berberine Improves TNF-alpha-Induced Hepatic Insulin Resistance by Targeting MEKK1/MEK Pathway.	Berberine	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	83-86
35460012-1	2022	Berberine (BBR), a natural isoquinoline alkaloid exhibiting insulin sensitizing activity, has been applicated in the treatment of diabetes.	Berberine	0-9	insulin	Homo sapiens	60-67
35460012-1	2022	Berberine (BBR), a natural isoquinoline alkaloid exhibiting insulin sensitizing activity, has been applicated in the treatment of diabetes.	Berberine	11-14	insulin	Homo sapiens	60-67
35460012-4	2022	Western blot and immunoprecipitation were used to investigate the effect of BBR on the crosstalk between TNF-alpha pathway and insulin signaling pathway.	Berberine	76-79	tumor necrosis factor	Homo sapiens	105-114
35460012-4	2022	Western blot and immunoprecipitation were used to investigate the effect of BBR on the crosstalk between TNF-alpha pathway and insulin signaling pathway.	Berberine	76-79	insulin	Homo sapiens	127-134
35460012-6	2022	BBR inhibits the MEKK1 and MEK1/2, and thus suppresses the activation of their downstream ERK1/2.	Berberine	0-3	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	17-22
35460012-6	2022	BBR inhibits the MEKK1 and MEK1/2, and thus suppresses the activation of their downstream ERK1/2.	Berberine	0-3	mitogen-activated protein kinase kinase 1	Homo sapiens	27-33
35460012-6	2022	BBR inhibits the MEKK1 and MEK1/2, and thus suppresses the activation of their downstream ERK1/2.	Berberine	0-3	mitogen-activated protein kinase 3	Homo sapiens	90-96
35460012-10	2022	In conclusion, BBR ameliorates TNF-alpha-induced hepatic insulin resistance by targeting MEKK1 and MEK1/2.	Berberine	15-18	tumor necrosis factor	Homo sapiens	31-40
35460012-10	2022	In conclusion, BBR ameliorates TNF-alpha-induced hepatic insulin resistance by targeting MEKK1 and MEK1/2.	Berberine	15-18	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	89-94
35460012-10	2022	In conclusion, BBR ameliorates TNF-alpha-induced hepatic insulin resistance by targeting MEKK1 and MEK1/2.	Berberine	15-18	mitogen-activated protein kinase kinase 1	Homo sapiens	99-105
35063579-3	2022	We also explored the role of berberine on progression of human colon cancers in vitro and in vivo and clarified weather the antitumor effects of berberine was mediated by Wnt/beta-catenin pathway.	Berberine	145-154	catenin beta 1	Homo sapiens	175-187
35063579-10	2022	Furthermore, the in vitro assay results showed beta-catenin signaling was highly activated in human colon cancer cells and berberine inhibited the cell viability of colon cancer cells in vitro and in vivo in a dose-and time-dependent manner.	Berberine	123-132	catenin beta 1	Homo sapiens	47-59
35063579-11	2022	Moreover, berberine induced the translocation of beta-catenin to cytoplasm from nucleus.	Berberine	10-19	catenin beta 1	Homo sapiens	49-61
35063579-13	2022	Berberine inhibited the proliferation of colon cancer cells by regulating the beta-catenin signaling pathway.	Berberine	0-9	catenin beta 1	Homo sapiens	78-90
35415871-7	2022	RT-PCR showed that Arabidopsis responds to berberine by inhibiting root growth through repressing the expression of thalianol and marneral gene clusters, which was independent on the upstream effectors ARP6 and HTA9-1.	Berberine	43-52	actin-related protein 6	Arabidopsis thaliana	202-206
35582103-0	2022	Berberine retarded the growth of gastric cancer xenograft tumors by targeting hepatocyte nuclear factor 4alpha.	Berberine	0-9	hepatocyte nuclear factor 4 alpha	Homo sapiens	78-110
35582103-9	2022	AIM: To investigate the effect and mechanism of berberine against tumor growth in gastric cancer xenograft models and to explore the role of hepatocyte nuclear factor 4alpha (HNF4alpha)-WNT5a/beta-catenin pathways played in the antitumor effects of berberine.	Berberine	249-258	hepatocyte nuclear factor 4 alpha	Homo sapiens	141-173
35582103-9	2022	AIM: To investigate the effect and mechanism of berberine against tumor growth in gastric cancer xenograft models and to explore the role of hepatocyte nuclear factor 4alpha (HNF4alpha)-WNT5a/beta-catenin pathways played in the antitumor effects of berberine.	Berberine	249-258	hepatocyte nuclear factor 4 alpha	Homo sapiens	175-184
35582103-9	2022	AIM: To investigate the effect and mechanism of berberine against tumor growth in gastric cancer xenograft models and to explore the role of hepatocyte nuclear factor 4alpha (HNF4alpha)-WNT5a/beta-catenin pathways played in the antitumor effects of berberine.	Berberine	249-258	Wnt family member 5A	Homo sapiens	186-191
35582103-17	2022	In the SGC7901 and MGC803 subcutaneously transplanted tumor models, berberine down-regulated the expression of HNF4alpha, WNT5a and beta-catenin in tumor tissues from both transcription and protein levels.	Berberine	68-77	hepatocyte nuclear factor 4 alpha	Homo sapiens	111-120
35582103-17	2022	In the SGC7901 and MGC803 subcutaneously transplanted tumor models, berberine down-regulated the expression of HNF4alpha, WNT5a and beta-catenin in tumor tissues from both transcription and protein levels.	Berberine	68-77	Wnt family member 5A	Homo sapiens	122-127
35582103-17	2022	In the SGC7901 and MGC803 subcutaneously transplanted tumor models, berberine down-regulated the expression of HNF4alpha, WNT5a and beta-catenin in tumor tissues from both transcription and protein levels.	Berberine	68-77	catenin beta 1	Homo sapiens	132-144
35582103-18	2022	Besides, berberine also suppressed the protein expression of HNF4alpha, WNT5a and beta-catenin in liver tissues.	Berberine	9-18	hepatocyte nuclear factor 4 alpha	Homo sapiens	61-70
35582103-18	2022	Besides, berberine also suppressed the protein expression of HNF4alpha, WNT5a and beta-catenin in liver tissues.	Berberine	9-18	Wnt family member 5A	Homo sapiens	72-77
35582103-18	2022	Besides, berberine also suppressed the protein expression of HNF4alpha, WNT5a and beta-catenin in liver tissues.	Berberine	9-18	catenin beta 1	Homo sapiens	82-94
35582103-19	2022	CONCLUSION: Berberine retarded the growth of MGC803 and SGC7901 xenograft model tumors, and the mechanism behind these anti-growth effects might be the downregulation of the expression of HNF4alpha-WNT5a/beta-catenin signaling pathways both in tumor tissues and liver tissues of the xenograft models.	Berberine	12-21	hepatocyte nuclear factor 4 alpha	Homo sapiens	188-197
35582103-19	2022	CONCLUSION: Berberine retarded the growth of MGC803 and SGC7901 xenograft model tumors, and the mechanism behind these anti-growth effects might be the downregulation of the expression of HNF4alpha-WNT5a/beta-catenin signaling pathways both in tumor tissues and liver tissues of the xenograft models.	Berberine	12-21	Wnt family member 5A	Homo sapiens	198-203
35582103-19	2022	CONCLUSION: Berberine retarded the growth of MGC803 and SGC7901 xenograft model tumors, and the mechanism behind these anti-growth effects might be the downregulation of the expression of HNF4alpha-WNT5a/beta-catenin signaling pathways both in tumor tissues and liver tissues of the xenograft models.	Berberine	12-21	catenin beta 1	Homo sapiens	204-216
34984656-9	2022	Pretreatment of rats with berberine nanocomplexes significantly reduced the paw edema in inflamed rat paws, decreased the production of nitrite and TNF-alpha in plasma and repressed the mRNA expression levels of TNF-alpha and IL-1beta in paw tissue in comparison to berberine per se treated rats.	Berberine	26-35	tumor necrosis factor	Rattus norvegicus	148-157
35254584-0	2022	Berberis lycium fruit extract and its phytoconstituents berberine and rutin mitigate collagen-CFA-induced arthritis (CIA) via improving GSK3beta/STAT/Akt/MAPKs/NF-kappaB signaling axis mediated oxi-inflammation and joint articular damage in murine model.	Berberine	56-65	glycogen synthase kinase 3 alpha	Mus musculus	136-144
35254584-0	2022	Berberis lycium fruit extract and its phytoconstituents berberine and rutin mitigate collagen-CFA-induced arthritis (CIA) via improving GSK3beta/STAT/Akt/MAPKs/NF-kappaB signaling axis mediated oxi-inflammation and joint articular damage in murine model.	Berberine	56-65	thymoma viral proto-oncogene 1	Mus musculus	150-153
35254584-0	2022	Berberis lycium fruit extract and its phytoconstituents berberine and rutin mitigate collagen-CFA-induced arthritis (CIA) via improving GSK3beta/STAT/Akt/MAPKs/NF-kappaB signaling axis mediated oxi-inflammation and joint articular damage in murine model.	Berberine	56-65	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	160-169
35254584-7	2022	Furthermore, reduced activation of p-ERK and p-GSK3beta and enhanced splenic Tregs was only noticed in BLFE and berberine.	Berberine	112-121	mitogen-activated protein kinase 1	Mus musculus	37-40
35254584-7	2022	Furthermore, reduced activation of p-ERK and p-GSK3beta and enhanced splenic Tregs was only noticed in BLFE and berberine.	Berberine	112-121	glycogen synthase kinase 3 alpha	Mus musculus	47-55
35571453-0	2022	Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway.	Berberine	0-9	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	85-89
35571453-0	2022	Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway.	Berberine	0-9	mitogen-activated protein kinase 8	Homo sapiens	90-93
35571453-10	2022	BBR induced apoptosis in NSCLC cells as evidenced by caspase-3 cleavage, cytochrome c release, and mitochondrial membrane depolarization.	Berberine	0-3	caspase 3	Homo sapiens	53-62
35571453-10	2022	BBR induced apoptosis in NSCLC cells as evidenced by caspase-3 cleavage, cytochrome c release, and mitochondrial membrane depolarization.	Berberine	0-3	cytochrome c, somatic	Homo sapiens	73-85
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	0-3	mitogen-activated protein kinase 8	Homo sapiens	99-115
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	0-3	mitogen-activated protein kinase 8	Homo sapiens	117-120
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	0-3	mitogen-activated protein kinase 8	Homo sapiens	130-133
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	0-3	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	277-313
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	0-3	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	315-319
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	0-3	mitogen-activated protein kinase 8	Homo sapiens	325-328
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	180-183	mitogen-activated protein kinase 8	Homo sapiens	99-115
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	180-183	mitogen-activated protein kinase 8	Homo sapiens	130-133
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	180-183	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	277-313
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	180-183	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	315-319
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	Berberine	180-183	mitogen-activated protein kinase 8	Homo sapiens	325-328
35571453-12	2022	Conclusions: The results suggest that BBR induces apoptosis of NSCLC cells via ROS-mediated ASK1/JNK activation and the mitochondrial pathway.	Berberine	38-41	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	92-96
35571453-12	2022	Conclusions: The results suggest that BBR induces apoptosis of NSCLC cells via ROS-mediated ASK1/JNK activation and the mitochondrial pathway.	Berberine	38-41	mitogen-activated protein kinase 8	Homo sapiens	97-100
35217376-2	2022	Berberine, californidine and govaniadine induced LDLR with an effect similar to 2.5 microM simvastatin.	Berberine	0-9	low density lipoprotein receptor	Homo sapiens	49-53
35217376-3	2022	Californidine and berberine at tested doses reduced the expression of PCSK9, with an opposite behaviour to simvastatin on this target.	Berberine	18-27	proprotein convertase subtilisin/kexin type 9	Homo sapiens	70-75
35384371-7	2022	A viability assay confirmed the specific effect of berberine on the apoptotic pathway, paralleled by the internalization of the sealing tight-junction (TJ) proteins claudin-1, claudin-3, and occludin within 6 h. Hence, the barrier function of the cells was reduced, as shown by the reduced transepithelial electrical resistance and the increased (3 H)-D-Mannitol flux.	Berberine	51-60	claudin 1	Homo sapiens	165-174
35384371-7	2022	A viability assay confirmed the specific effect of berberine on the apoptotic pathway, paralleled by the internalization of the sealing tight-junction (TJ) proteins claudin-1, claudin-3, and occludin within 6 h. Hence, the barrier function of the cells was reduced, as shown by the reduced transepithelial electrical resistance and the increased (3 H)-D-Mannitol flux.	Berberine	51-60	claudin 3	Homo sapiens	176-185
35384371-7	2022	A viability assay confirmed the specific effect of berberine on the apoptotic pathway, paralleled by the internalization of the sealing tight-junction (TJ) proteins claudin-1, claudin-3, and occludin within 6 h. Hence, the barrier function of the cells was reduced, as shown by the reduced transepithelial electrical resistance and the increased (3 H)-D-Mannitol flux.	Berberine	51-60	occludin	Homo sapiens	191-199
34984656-9	2022	Pretreatment of rats with berberine nanocomplexes significantly reduced the paw edema in inflamed rat paws, decreased the production of nitrite and TNF-alpha in plasma and repressed the mRNA expression levels of TNF-alpha and IL-1beta in paw tissue in comparison to berberine per se treated rats.	Berberine	26-35	tumor necrosis factor	Rattus norvegicus	212-221
34984656-9	2022	Pretreatment of rats with berberine nanocomplexes significantly reduced the paw edema in inflamed rat paws, decreased the production of nitrite and TNF-alpha in plasma and repressed the mRNA expression levels of TNF-alpha and IL-1beta in paw tissue in comparison to berberine per se treated rats.	Berberine	26-35	interleukin 1 alpha	Rattus norvegicus	226-234
35199120-5	2022	Concurrently, an in vitro model of OA using primary mouse chondrocytes demonstrated that the release of berberine at a concentration as low as 1 mug mL-1 is sufficient to restore the production of sulphated glycosaminoglycans (sGAG) to levels comparable to healthy chondrocytes while avoiding the cytotoxic concentrations (IC50 = 33 mug mL-1) on skin keratinocytes.	Berberine	104-113	L1 cell adhesion molecule	Mus musculus	149-153
35199120-5	2022	Concurrently, an in vitro model of OA using primary mouse chondrocytes demonstrated that the release of berberine at a concentration as low as 1 mug mL-1 is sufficient to restore the production of sulphated glycosaminoglycans (sGAG) to levels comparable to healthy chondrocytes while avoiding the cytotoxic concentrations (IC50 = 33 mug mL-1) on skin keratinocytes.	Berberine	104-113	L1 cell adhesion molecule	Mus musculus	337-341
35303184-4	2022	Scanning electron microscopy images and cellular material leakage assays showed that carvacrol at this concentration neither altered the morphology nor the permeability of the membrane alone but when combined with 75 mug mL-1 berberine.	Berberine	226-235	L1 cell adhesion molecule	Mus musculus	221-225
35051489-3	2022	This study was to investigate the hypothesis that BBR treats depressive-like behavior by shifting the balance of the kynurenine (KYN)/serotonin (5-HT) pathway toward the 5-HT pathway through downregulated indoleamine 2,3-dioxygenase 1 (IDO1), monoamine oxidase A (MAOA) and upregulated dopamine decarboxylase (DDC) in hippocampus.	Berberine	50-53	indoleamine 2,3-dioxygenase 1	Mus musculus	205-234
35051489-3	2022	This study was to investigate the hypothesis that BBR treats depressive-like behavior by shifting the balance of the kynurenine (KYN)/serotonin (5-HT) pathway toward the 5-HT pathway through downregulated indoleamine 2,3-dioxygenase 1 (IDO1), monoamine oxidase A (MAOA) and upregulated dopamine decarboxylase (DDC) in hippocampus.	Berberine	50-53	indoleamine 2,3-dioxygenase 1	Mus musculus	236-240
35051489-3	2022	This study was to investigate the hypothesis that BBR treats depressive-like behavior by shifting the balance of the kynurenine (KYN)/serotonin (5-HT) pathway toward the 5-HT pathway through downregulated indoleamine 2,3-dioxygenase 1 (IDO1), monoamine oxidase A (MAOA) and upregulated dopamine decarboxylase (DDC) in hippocampus.	Berberine	50-53	monoamine oxidase A	Mus musculus	243-262
35051489-3	2022	This study was to investigate the hypothesis that BBR treats depressive-like behavior by shifting the balance of the kynurenine (KYN)/serotonin (5-HT) pathway toward the 5-HT pathway through downregulated indoleamine 2,3-dioxygenase 1 (IDO1), monoamine oxidase A (MAOA) and upregulated dopamine decarboxylase (DDC) in hippocampus.	Berberine	50-53	monoamine oxidase A	Mus musculus	264-268
35051489-3	2022	This study was to investigate the hypothesis that BBR treats depressive-like behavior by shifting the balance of the kynurenine (KYN)/serotonin (5-HT) pathway toward the 5-HT pathway through downregulated indoleamine 2,3-dioxygenase 1 (IDO1), monoamine oxidase A (MAOA) and upregulated dopamine decarboxylase (DDC) in hippocampus.	Berberine	50-53	dopa decarboxylase	Mus musculus	286-308
35051489-3	2022	This study was to investigate the hypothesis that BBR treats depressive-like behavior by shifting the balance of the kynurenine (KYN)/serotonin (5-HT) pathway toward the 5-HT pathway through downregulated indoleamine 2,3-dioxygenase 1 (IDO1), monoamine oxidase A (MAOA) and upregulated dopamine decarboxylase (DDC) in hippocampus.	Berberine	50-53	dopa decarboxylase	Mus musculus	310-313
35051489-11	2022	Compared with the normal group, the mRNA of IDO1 and MAOA were significantly upregulated (p#<0.05) in the control group, MAOA and IDO1 gene were downregulated by FLU and BBR treatment.	Berberine	170-173	indoleamine 2,3-dioxygenase 1	Mus musculus	44-48
35051489-11	2022	Compared with the normal group, the mRNA of IDO1 and MAOA were significantly upregulated (p#<0.05) in the control group, MAOA and IDO1 gene were downregulated by FLU and BBR treatment.	Berberine	170-173	monoamine oxidase A	Mus musculus	53-57
35051489-11	2022	Compared with the normal group, the mRNA of IDO1 and MAOA were significantly upregulated (p#<0.05) in the control group, MAOA and IDO1 gene were downregulated by FLU and BBR treatment.	Berberine	170-173	monoamine oxidase A	Mus musculus	121-125
35051489-11	2022	Compared with the normal group, the mRNA of IDO1 and MAOA were significantly upregulated (p#<0.05) in the control group, MAOA and IDO1 gene were downregulated by FLU and BBR treatment.	Berberine	170-173	indoleamine 2,3-dioxygenase 1	Mus musculus	130-134
35051489-13	2022	BBR treatment downregulated IDO1 and MAOA, upregulated DDC.	Berberine	0-3	indoleamine 2,3-dioxygenase 1	Mus musculus	28-32
35051489-13	2022	BBR treatment downregulated IDO1 and MAOA, upregulated DDC.	Berberine	0-3	monoamine oxidase A	Mus musculus	37-41
35051489-13	2022	BBR treatment downregulated IDO1 and MAOA, upregulated DDC.	Berberine	0-3	dopa decarboxylase	Mus musculus	55-58
35350612-12	2022	Moreover, BBR inhibited FMO3 expression and plasma TMA/TMAO production in hypertensive mice.	Berberine	10-13	flavin containing monooxygenase 3	Mus musculus	24-28
35085532-5	2022	Berberine had an antagonistic effect for the majority of genes mutual for AD and toxic metal mixture: ACHE, APP, BAX, BCL2, CASP3, HMOX1, IL1B, MAPT, SOD2, TNF.	Berberine	0-9	acetylcholinesterase (Cartwright blood group)	Homo sapiens	102-106
35230500-9	2022	Mechanistically, berberine downregulated the expression of genes related to pain and inflammation, such as TRPV1, COX-2, VEGF and OTR, impaired the inflammatory response at the DRG site, and inhibited the expression of TLR4 in DRG and uterine tissues.	Berberine	17-26	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	107-112
35230500-9	2022	Mechanistically, berberine downregulated the expression of genes related to pain and inflammation, such as TRPV1, COX-2, VEGF and OTR, impaired the inflammatory response at the DRG site, and inhibited the expression of TLR4 in DRG and uterine tissues.	Berberine	17-26	cytochrome c oxidase II, mitochondrial	Mus musculus	114-119
35230500-9	2022	Mechanistically, berberine downregulated the expression of genes related to pain and inflammation, such as TRPV1, COX-2, VEGF and OTR, impaired the inflammatory response at the DRG site, and inhibited the expression of TLR4 in DRG and uterine tissues.	Berberine	17-26	vascular endothelial growth factor A	Mus musculus	121-125
35230500-9	2022	Mechanistically, berberine downregulated the expression of genes related to pain and inflammation, such as TRPV1, COX-2, VEGF and OTR, impaired the inflammatory response at the DRG site, and inhibited the expression of TLR4 in DRG and uterine tissues.	Berberine	17-26	oxytocin receptor	Mus musculus	130-133
35230500-9	2022	Mechanistically, berberine downregulated the expression of genes related to pain and inflammation, such as TRPV1, COX-2, VEGF and OTR, impaired the inflammatory response at the DRG site, and inhibited the expression of TLR4 in DRG and uterine tissues.	Berberine	17-26	toll-like receptor 4	Mus musculus	219-223
35093536-6	2022	PPARdelta, rather than PPARalpha or PPARgamma, is involved in the anti-ROS effect of BBR, as evidenced by the siRNA transfection and specific antagonist treatment data.	Berberine	85-88	peroxisome proliferator activator receptor delta	Mus musculus	0-9
35093536-9	2022	Collectively, our results indicate that BBR confers neuroprotective effects by activating PPARdelta to scavenge ROS, providing a novel mechanistic insight for the antioxidant action of BBR.	Berberine	40-43	peroxisome proliferator activator receptor delta	Mus musculus	90-99
35093536-9	2022	Collectively, our results indicate that BBR confers neuroprotective effects by activating PPARdelta to scavenge ROS, providing a novel mechanistic insight for the antioxidant action of BBR.	Berberine	185-188	peroxisome proliferator activator receptor delta	Mus musculus	90-99
35085532-5	2022	Berberine had an antagonistic effect for the majority of genes mutual for AD and toxic metal mixture: ACHE, APP, BAX, BCL2, CASP3, HMOX1, IL1B, MAPT, SOD2, TNF.	Berberine	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	113-116
35085532-5	2022	Berberine had an antagonistic effect for the majority of genes mutual for AD and toxic metal mixture: ACHE, APP, BAX, BCL2, CASP3, HMOX1, IL1B, MAPT, SOD2, TNF.	Berberine	0-9	BCL2 apoptosis regulator	Homo sapiens	118-122
35085532-5	2022	Berberine had an antagonistic effect for the majority of genes mutual for AD and toxic metal mixture: ACHE, APP, BAX, BCL2, CASP3, HMOX1, IL1B, MAPT, SOD2, TNF.	Berberine	0-9	caspase 3	Homo sapiens	124-129
35085532-5	2022	Berberine had an antagonistic effect for the majority of genes mutual for AD and toxic metal mixture: ACHE, APP, BAX, BCL2, CASP3, HMOX1, IL1B, MAPT, SOD2, TNF.	Berberine	0-9	heme oxygenase 1	Homo sapiens	131-136
35085532-5	2022	Berberine had an antagonistic effect for the majority of genes mutual for AD and toxic metal mixture: ACHE, APP, BAX, BCL2, CASP3, HMOX1, IL1B, MAPT, SOD2, TNF.	Berberine	0-9	interleukin 1 beta	Homo sapiens	138-142
35085532-5	2022	Berberine had an antagonistic effect for the majority of genes mutual for AD and toxic metal mixture: ACHE, APP, BAX, BCL2, CASP3, HMOX1, IL1B, MAPT, SOD2, TNF.	Berberine	0-9	microtubule associated protein tau	Homo sapiens	144-148
35085532-5	2022	Berberine had an antagonistic effect for the majority of genes mutual for AD and toxic metal mixture: ACHE, APP, BAX, BCL2, CASP3, HMOX1, IL1B, MAPT, SOD2, TNF.	Berberine	0-9	superoxide dismutase 2	Homo sapiens	150-154
35085532-5	2022	Berberine had an antagonistic effect for the majority of genes mutual for AD and toxic metal mixture: ACHE, APP, BAX, BCL2, CASP3, HMOX1, IL1B, MAPT, SOD2, TNF.	Berberine	0-9	tumor necrosis factor	Homo sapiens	156-159
35121005-7	2022	Also, it was determined that SOD, CAT, GPx and GSH levels increased after BBR treatment.	Berberine	74-77	catalase	Rattus norvegicus	34-37
35301252-0	2022	Ferulic acid and berberine, via Sirt1 and AMPK, may act as cell cleansing promoters of healthy longevity.	Berberine	17-26	sirtuin 1	Homo sapiens	32-37
35301252-0	2022	Ferulic acid and berberine, via Sirt1 and AMPK, may act as cell cleansing promoters of healthy longevity.	Berberine	17-26	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	42-46
35301252-9	2022	Hence, it is proposed that ferulic acid may exert complementary or synergistic health-promoting effects when used in conjunction with clinically useful AMPK activators, such as the nutraceutical berberine.	Berberine	195-204	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	152-156
35284463-0	2022	Berberine Ameliorates Inflammation in Acute Lung Injury via NF-kappaB/Nlrp3 Signaling Pathway.	Berberine	0-9	NLR family, pyrin domain containing 3	Mus musculus	70-75
35284463-5	2022	We demonstrated that BBR could suppress the expression of phosphorylated nuclear factor-kappa B (NF-kappaB) and further restrain the downstream gene nucleotide-binding domain and leucine-rich repeat protein-3 (Nlrp3).	Berberine	21-24	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	73-95
35284463-5	2022	We demonstrated that BBR could suppress the expression of phosphorylated nuclear factor-kappa B (NF-kappaB) and further restrain the downstream gene nucleotide-binding domain and leucine-rich repeat protein-3 (Nlrp3).	Berberine	21-24	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	97-106
35284463-5	2022	We demonstrated that BBR could suppress the expression of phosphorylated nuclear factor-kappa B (NF-kappaB) and further restrain the downstream gene nucleotide-binding domain and leucine-rich repeat protein-3 (Nlrp3).	Berberine	21-24	NLR family, pyrin domain containing 3	Mus musculus	210-215
35284463-7	2022	After knocked down of Nlrp3 by using siRNA, the protective role of BBR was abrogated in vitro.	Berberine	67-70	NLR family, pyrin domain containing 3	Mus musculus	22-27
35284463-9	2022	Notably, in Nlrp3 deficient mice, the protective effect of BBR was abolished.	Berberine	59-62	NLR family, pyrin domain containing 3	Mus musculus	12-17
35189055-11	2022	CONCLUSION: Our findings demonstrated that a possible strategy for combating disease severity with berberine treatment in Staphylococcus aureus induced septic arthritis in mice, which targets the Th17 and Treg cells have driven the NF-kappaB/JNK-RANKL axis.	Berberine	99-108	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	232-241
35189055-11	2022	CONCLUSION: Our findings demonstrated that a possible strategy for combating disease severity with berberine treatment in Staphylococcus aureus induced septic arthritis in mice, which targets the Th17 and Treg cells have driven the NF-kappaB/JNK-RANKL axis.	Berberine	99-108	mitogen-activated protein kinase 8	Mus musculus	242-245
35189055-11	2022	CONCLUSION: Our findings demonstrated that a possible strategy for combating disease severity with berberine treatment in Staphylococcus aureus induced septic arthritis in mice, which targets the Th17 and Treg cells have driven the NF-kappaB/JNK-RANKL axis.	Berberine	99-108	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	246-251
35093536-0	2022	Novel mechanistic insight on the neuroprotective effect of berberine: The role of PPARdelta for antioxidant action.	Berberine	59-68	peroxisome proliferator activator receptor delta	Mus musculus	82-91
35359076-0	2022	(Berberine alleviates programmed necrosis of metabolic-associated fatty liver disease via activating Nrf2 pathway in mice).	Berberine	1-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	101-105
35359076-14	2022	Compared with H group, berberine intervention group liver biochemical indexes, lipid levels, pro-inflammatory mediator expression, fatty liver index, and SAF score were significantly reduced, and the expression of RIPK3 and p-MLKL were down-regulated, while Nrf2 levels were further increased, and the differences were statistically significant (P<0.05).	Berberine	23-32	receptor-interacting serine-threonine kinase 3	Mus musculus	214-219
35121005-8	2022	It was observed that BTZ caused inflammation by triggering NF-kappaB, TNF-alpha, IL-1beta and IL-6 cytokines, on the other hand, with BBR treatment, these cytokines were suppressed and inflammation was alleviated.	Berberine	134-137	tumor necrosis factor	Rattus norvegicus	70-79
35121005-8	2022	It was observed that BTZ caused inflammation by triggering NF-kappaB, TNF-alpha, IL-1beta and IL-6 cytokines, on the other hand, with BBR treatment, these cytokines were suppressed and inflammation was alleviated.	Berberine	134-137	interleukin 1 alpha	Rattus norvegicus	81-89
35121005-8	2022	It was observed that BTZ caused inflammation by triggering NF-kappaB, TNF-alpha, IL-1beta and IL-6 cytokines, on the other hand, with BBR treatment, these cytokines were suppressed and inflammation was alleviated.	Berberine	134-137	interleukin 6	Rattus norvegicus	94-98
35121005-11	2022	It was observed that GFAP levels increased with BTZ administration and decreased with BBR administration.	Berberine	86-89	glial fibrillary acidic protein	Rattus norvegicus	21-25
35250593-6	2022	As per mechanism, bicyclol enhanced lipolysis and beta-oxidation through restoring the p62-Nrf2-CES2 signaling axis and p62-Nrf2-PPARalpha signaling axis, respectively, while berberine suppressed de novo lipogenesis through downregulating the expression of acetyl-CoA carboxylase and fatty acid synthetase, along with enrichment of lipid metabolism-related Bacteroidaceae (family) and Bacteroides (genus).	Berberine	175-184	nucleoporin 62	Mus musculus	87-90
35209140-4	2022	It stimulates glycolysis, improving insulin secretion, and inhibits gluconeogenesis and adipogenesis in the liver; by reducing insulin resistance, berberine also improves ovulation.	Berberine	147-156	insulin	Homo sapiens	36-43
35209140-4	2022	It stimulates glycolysis, improving insulin secretion, and inhibits gluconeogenesis and adipogenesis in the liver; by reducing insulin resistance, berberine also improves ovulation.	Berberine	147-156	insulin	Homo sapiens	127-134
35250593-6	2022	As per mechanism, bicyclol enhanced lipolysis and beta-oxidation through restoring the p62-Nrf2-CES2 signaling axis and p62-Nrf2-PPARalpha signaling axis, respectively, while berberine suppressed de novo lipogenesis through downregulating the expression of acetyl-CoA carboxylase and fatty acid synthetase, along with enrichment of lipid metabolism-related Bacteroidaceae (family) and Bacteroides (genus).	Berberine	175-184	carboxylesterase 2H	Mus musculus	96-100
35250593-6	2022	As per mechanism, bicyclol enhanced lipolysis and beta-oxidation through restoring the p62-Nrf2-CES2 signaling axis and p62-Nrf2-PPARalpha signaling axis, respectively, while berberine suppressed de novo lipogenesis through downregulating the expression of acetyl-CoA carboxylase and fatty acid synthetase, along with enrichment of lipid metabolism-related Bacteroidaceae (family) and Bacteroides (genus).	Berberine	175-184	nucleoporin 62	Mus musculus	120-123
35250593-6	2022	As per mechanism, bicyclol enhanced lipolysis and beta-oxidation through restoring the p62-Nrf2-CES2 signaling axis and p62-Nrf2-PPARalpha signaling axis, respectively, while berberine suppressed de novo lipogenesis through downregulating the expression of acetyl-CoA carboxylase and fatty acid synthetase, along with enrichment of lipid metabolism-related Bacteroidaceae (family) and Bacteroides (genus).	Berberine	175-184	nuclear factor, erythroid derived 2, like 2	Mus musculus	124-128
35250593-6	2022	As per mechanism, bicyclol enhanced lipolysis and beta-oxidation through restoring the p62-Nrf2-CES2 signaling axis and p62-Nrf2-PPARalpha signaling axis, respectively, while berberine suppressed de novo lipogenesis through downregulating the expression of acetyl-CoA carboxylase and fatty acid synthetase, along with enrichment of lipid metabolism-related Bacteroidaceae (family) and Bacteroides (genus).	Berberine	175-184	peroxisome proliferator activated receptor alpha	Mus musculus	129-138
35216170-5	2022	The activity of AMPK can be stimulated with the phytochemical berberine.	Berberine	62-71	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	16-20
35202329-7	2022	BBR reduced (p <= 0.05) malondialdehyde (MDA) and increased (p <= 0.05) total antioxidant capacity (TAC), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) in blood, colostrum, and milk.	Berberine	0-3	catalase	Capra hircus	171-179
35202329-7	2022	BBR reduced (p <= 0.05) malondialdehyde (MDA) and increased (p <= 0.05) total antioxidant capacity (TAC), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) in blood, colostrum, and milk.	Berberine	0-3	catalase	Capra hircus	181-184
35215376-6	2022	Additionally, pre-administration with BBR suppressed the expression of pro-inflammatory factors (interleukin (IL)-6, IL-1beta, cyclooxygenase (COX)-2 and tumor necrosis factor (TNF)-alpha) and the cell-proliferation marker Ki67, while expression of the tight junction proteins (ZO-1 and occludin) were increased in colon tissue.	Berberine	38-41	interleukin 6	Mus musculus	97-115
35215376-6	2022	Additionally, pre-administration with BBR suppressed the expression of pro-inflammatory factors (interleukin (IL)-6, IL-1beta, cyclooxygenase (COX)-2 and tumor necrosis factor (TNF)-alpha) and the cell-proliferation marker Ki67, while expression of the tight junction proteins (ZO-1 and occludin) were increased in colon tissue.	Berberine	38-41	interleukin 1 alpha	Mus musculus	117-125
35215376-6	2022	Additionally, pre-administration with BBR suppressed the expression of pro-inflammatory factors (interleukin (IL)-6, IL-1beta, cyclooxygenase (COX)-2 and tumor necrosis factor (TNF)-alpha) and the cell-proliferation marker Ki67, while expression of the tight junction proteins (ZO-1 and occludin) were increased in colon tissue.	Berberine	38-41	cytochrome c oxidase II, mitochondrial	Mus musculus	127-149
35215376-6	2022	Additionally, pre-administration with BBR suppressed the expression of pro-inflammatory factors (interleukin (IL)-6, IL-1beta, cyclooxygenase (COX)-2 and tumor necrosis factor (TNF)-alpha) and the cell-proliferation marker Ki67, while expression of the tight junction proteins (ZO-1 and occludin) were increased in colon tissue.	Berberine	38-41	tumor necrosis factor	Mus musculus	154-187
35215376-6	2022	Additionally, pre-administration with BBR suppressed the expression of pro-inflammatory factors (interleukin (IL)-6, IL-1beta, cyclooxygenase (COX)-2 and tumor necrosis factor (TNF)-alpha) and the cell-proliferation marker Ki67, while expression of the tight junction proteins (ZO-1 and occludin) were increased in colon tissue.	Berberine	38-41	antigen identified by monoclonal antibody Ki 67	Mus musculus	223-227
35215376-6	2022	Additionally, pre-administration with BBR suppressed the expression of pro-inflammatory factors (interleukin (IL)-6, IL-1beta, cyclooxygenase (COX)-2 and tumor necrosis factor (TNF)-alpha) and the cell-proliferation marker Ki67, while expression of the tight junction proteins (ZO-1 and occludin) were increased in colon tissue.	Berberine	38-41	tight junction protein 1	Mus musculus	278-282
35215376-6	2022	Additionally, pre-administration with BBR suppressed the expression of pro-inflammatory factors (interleukin (IL)-6, IL-1beta, cyclooxygenase (COX)-2 and tumor necrosis factor (TNF)-alpha) and the cell-proliferation marker Ki67, while expression of the tight junction proteins (ZO-1 and occludin) were increased in colon tissue.	Berberine	38-41	occludin	Mus musculus	287-295
35204775-0	2022	APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.	Berberine	67-76	tumor protein p53	Homo sapiens	19-23
35204775-0	2022	APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.	Berberine	90-100	tumor protein p53	Homo sapiens	19-23
35204775-5	2022	We examined the ability of the TP53 reactivator APR-246 to interact with eleven modified berberine compounds (NAX compounds) in the presence and absence of WT-TP53 in two PDAC cell lines: the MIA-PaCa-2, which has gain of function (GOF) TP53 mutations on both alleles, and PANC-28, which lacks expression of the WT TP53 protein.	Berberine	89-98	tumor protein p53	Homo sapiens	31-35
35204775-6	2022	Our results indicate the TP53 reactivator-induced increase in therapeutic potential of many modified berberines.	Berberine	101-111	tumor protein p53	Homo sapiens	25-29
35062058-10	2022	Berberine counteracted the effect of diabetes on the bone formation marker (osteocalcin) concentration, the growth plate, and some parameters of cancellous bone microarchitecture, but did not improve bone mineralization and bone mechanical properties in the diabetic rats.	Berberine	0-9	bone gamma-carboxyglutamate protein	Rattus norvegicus	76-87
35250593-6	2022	As per mechanism, bicyclol enhanced lipolysis and beta-oxidation through restoring the p62-Nrf2-CES2 signaling axis and p62-Nrf2-PPARalpha signaling axis, respectively, while berberine suppressed de novo lipogenesis through downregulating the expression of acetyl-CoA carboxylase and fatty acid synthetase, along with enrichment of lipid metabolism-related Bacteroidaceae (family) and Bacteroides (genus).	Berberine	175-184	nuclear factor, erythroid derived 2, like 2	Mus musculus	91-95
34994821-8	2022	RESULTS: The results of this study demonstrated that berberine was able to protect remarkably the kidney from CP-induced injury through decreasing the level of BUN, Cr, NGAL, KIM-1, NO, MDA TNF-alpha, IL-1beta and increasing the level of GSH, CAT, SOD, and GPx activities.	Berberine	53-62	lipocalin 2	Mus musculus	169-173
34994821-8	2022	RESULTS: The results of this study demonstrated that berberine was able to protect remarkably the kidney from CP-induced injury through decreasing the level of BUN, Cr, NGAL, KIM-1, NO, MDA TNF-alpha, IL-1beta and increasing the level of GSH, CAT, SOD, and GPx activities.	Berberine	53-62	hepatitis A virus cellular receptor 1	Mus musculus	175-180
34994821-8	2022	RESULTS: The results of this study demonstrated that berberine was able to protect remarkably the kidney from CP-induced injury through decreasing the level of BUN, Cr, NGAL, KIM-1, NO, MDA TNF-alpha, IL-1beta and increasing the level of GSH, CAT, SOD, and GPx activities.	Berberine	53-62	tumor necrosis factor	Mus musculus	190-199
34994821-8	2022	RESULTS: The results of this study demonstrated that berberine was able to protect remarkably the kidney from CP-induced injury through decreasing the level of BUN, Cr, NGAL, KIM-1, NO, MDA TNF-alpha, IL-1beta and increasing the level of GSH, CAT, SOD, and GPx activities.	Berberine	53-62	interleukin 1 alpha	Mus musculus	201-209
34994821-8	2022	RESULTS: The results of this study demonstrated that berberine was able to protect remarkably the kidney from CP-induced injury through decreasing the level of BUN, Cr, NGAL, KIM-1, NO, MDA TNF-alpha, IL-1beta and increasing the level of GSH, CAT, SOD, and GPx activities.	Berberine	53-62	catalase	Mus musculus	243-246
35173608-10	2021	Mechanistically, berberine treatment down regulated the expression of FOXM1which closely related to survival, survival related genes in Cell cycle and DNA replication pathway, and significantly down regulated the expression of survival related POLE2.	Berberine	17-26	DNA polymerase epsilon 2, accessory subunit	Homo sapiens	244-249
34984827-0	2022	Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition.	Berberine	0-9	toll-like receptor 4	Mus musculus	59-63
34984827-0	2022	Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition.	Berberine	0-9	NLR family, pyrin domain containing 3	Mus musculus	122-127
35001506-0	2022	Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway.	Berberine	0-9	thymoma viral proto-oncogene 1	Mus musculus	115-118
35001506-0	2022	Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway.	Berberine	0-9	TBC1 domain family, member 4	Mus musculus	119-124
35001506-0	2022	Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway.	Berberine	0-9	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	125-130
35173608-11	2021	Interestingly, we found that the transcription factor FOXM1 could act as a bridge between berberine and POLE2.	Berberine	90-99	forkhead box M1	Homo sapiens	54-59
35173608-11	2021	Interestingly, we found that the transcription factor FOXM1 could act as a bridge between berberine and POLE2.	Berberine	90-99	DNA polymerase epsilon 2, accessory subunit	Homo sapiens	104-109
35173608-12	2021	Conclusion: Berberine significantly inhibited LUAD progression via the FOXM1/POLE2, and FOXM1/POLE2 may act as a clinical prognostic factor and a therapeutic target for LUAD.	Berberine	12-21	forkhead box M1	Homo sapiens	71-76
35173608-12	2021	Conclusion: Berberine significantly inhibited LUAD progression via the FOXM1/POLE2, and FOXM1/POLE2 may act as a clinical prognostic factor and a therapeutic target for LUAD.	Berberine	12-21	DNA polymerase epsilon 2, accessory subunit	Homo sapiens	77-82
35173608-12	2021	Conclusion: Berberine significantly inhibited LUAD progression via the FOXM1/POLE2, and FOXM1/POLE2 may act as a clinical prognostic factor and a therapeutic target for LUAD.	Berberine	12-21	DNA polymerase epsilon 2, accessory subunit	Homo sapiens	94-99
35153744-0	2021	Berberine Alleviate Cisplatin-Induced Peripheral Neuropathy by Modulating Inflammation Signal via TRPV1.	Berberine	0-9	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	98-103
35173608-0	2021	Berberine Inhibits FOXM1 Dependent Transcriptional Regulation of POLE2 and Interferes With the Survival of Lung Adenocarcinoma.	Berberine	0-9	forkhead box M1	Homo sapiens	19-24
35173608-0	2021	Berberine Inhibits FOXM1 Dependent Transcriptional Regulation of POLE2 and Interferes With the Survival of Lung Adenocarcinoma.	Berberine	0-9	DNA polymerase epsilon 2, accessory subunit	Homo sapiens	65-70
35173608-3	2021	However, the specific molecular mechanism of berberine interfering with POLE2 expression in lung adenocarcinoma (LUAD) is still unknown to a great extent.	Berberine	45-54	DNA polymerase epsilon 2, accessory subunit	Homo sapiens	72-77
35173608-10	2021	Mechanistically, berberine treatment down regulated the expression of FOXM1which closely related to survival, survival related genes in Cell cycle and DNA replication pathway, and significantly down regulated the expression of survival related POLE2.	Berberine	17-26	forkhead box M1	Homo sapiens	70-75
35359076-14	2022	Compared with H group, berberine intervention group liver biochemical indexes, lipid levels, pro-inflammatory mediator expression, fatty liver index, and SAF score were significantly reduced, and the expression of RIPK3 and p-MLKL were down-regulated, while Nrf2 levels were further increased, and the differences were statistically significant (P<0.05).	Berberine	23-32	mixed lineage kinase domain-like	Mus musculus	226-230
35359076-14	2022	Compared with H group, berberine intervention group liver biochemical indexes, lipid levels, pro-inflammatory mediator expression, fatty liver index, and SAF score were significantly reduced, and the expression of RIPK3 and p-MLKL were down-regulated, while Nrf2 levels were further increased, and the differences were statistically significant (P<0.05).	Berberine	23-32	nuclear factor, erythroid derived 2, like 2	Mus musculus	258-262
35359076-15	2022	Compared with B group, treatment with Nrf2 inhibitor had antagonized the protective effect of berberine on fatty liver.	Berberine	94-103	nuclear factor, erythroid derived 2, like 2	Mus musculus	38-42
35359076-17	2022	Conclusion: Berberine can significantly improve the metabolic-associated fatty liver disease injury in mice, and its mechanism is related to activation of Nrf2 and inhibition of programmed necrosis of hepatocytes.	Berberine	12-21	nuclear factor, erythroid derived 2, like 2	Mus musculus	155-159
35153744-5	2021	We confirmed that berberine mediated the neuroinflammatory reaction induced by cisplatin by inhibiting the overexpression of TRPV1 and NF-kappaB and activating the JNK/p38 MAPK pathways in early injury, which inhibited the expression of p-JNK and mediated the expression of p38 MAPK/ERK in late injury in vivo.	Berberine	18-27	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	125-130
35153744-5	2021	We confirmed that berberine mediated the neuroinflammatory reaction induced by cisplatin by inhibiting the overexpression of TRPV1 and NF-kappaB and activating the JNK/p38 MAPK pathways in early injury, which inhibited the expression of p-JNK and mediated the expression of p38 MAPK/ERK in late injury in vivo.	Berberine	18-27	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	135-144
35153744-5	2021	We confirmed that berberine mediated the neuroinflammatory reaction induced by cisplatin by inhibiting the overexpression of TRPV1 and NF-kappaB and activating the JNK/p38 MAPK pathways in early injury, which inhibited the expression of p-JNK and mediated the expression of p38 MAPK/ERK in late injury in vivo.	Berberine	18-27	mitogen-activated protein kinase 8	Mus musculus	164-167
35153744-5	2021	We confirmed that berberine mediated the neuroinflammatory reaction induced by cisplatin by inhibiting the overexpression of TRPV1 and NF-kappaB and activating the JNK/p38 MAPK pathways in early injury, which inhibited the expression of p-JNK and mediated the expression of p38 MAPK/ERK in late injury in vivo.	Berberine	18-27	mitogen-activated protein kinase 14	Mus musculus	168-176
35153744-5	2021	We confirmed that berberine mediated the neuroinflammatory reaction induced by cisplatin by inhibiting the overexpression of TRPV1 and NF-kappaB and activating the JNK/p38 MAPK pathways in early injury, which inhibited the expression of p-JNK and mediated the expression of p38 MAPK/ERK in late injury in vivo.	Berberine	18-27	mitogen-activated protein kinase 14	Mus musculus	274-282
35153744-5	2021	We confirmed that berberine mediated the neuroinflammatory reaction induced by cisplatin by inhibiting the overexpression of TRPV1 and NF-kappaB and activating the JNK/p38 MAPK pathways in early injury, which inhibited the expression of p-JNK and mediated the expression of p38 MAPK/ERK in late injury in vivo.	Berberine	18-27	mitogen-activated protein kinase 1	Mus musculus	283-286
35153744-6	2021	Moreover, genetic deletion of TRPV1 significantly reduced the protective effects of berberine on mechanical and heat hyperalgesia in mice.	Berberine	84-93	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	30-35
35153744-7	2021	In TRPV1 knockout mice, the expression of NF-kappaB increased in late stage, and berberine inhibited the overexpression of NF-kappaB and p-ERK in late injury.	Berberine	81-90	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	3-8
35153744-7	2021	In TRPV1 knockout mice, the expression of NF-kappaB increased in late stage, and berberine inhibited the overexpression of NF-kappaB and p-ERK in late injury.	Berberine	81-90	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	42-51
35153744-7	2021	In TRPV1 knockout mice, the expression of NF-kappaB increased in late stage, and berberine inhibited the overexpression of NF-kappaB and p-ERK in late injury.	Berberine	81-90	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	123-132
35153744-7	2021	In TRPV1 knockout mice, the expression of NF-kappaB increased in late stage, and berberine inhibited the overexpression of NF-kappaB and p-ERK in late injury.	Berberine	81-90	mitogen-activated protein kinase 1	Mus musculus	139-142
35153744-8	2021	Our results support berberine can reverse neuropathic inflammatory pain response induced by cisplatin, TRPV1 may be involved in this process.	Berberine	20-29	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	103-108
35180901-6	2022	In vitro experiments showed that BBR loaded CA/HA electrospun fiber scaffolds have highly enhanced cell viability (>99) and proliferation of L929 fibroblastic cells after 7 days of incubation.	Berberine	33-36	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	44-49
35280677-0	2022	Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction through microbiota-dependence and Wnt/beta-catenin pathway.	Berberine	0-9	catenin (cadherin associated protein), beta 1	Mus musculus	111-123
35280677-8	2022	Moreover, a proteomic study revealed that Wnt/beta-catenin pathway was remarkably enhanced in colonic tissue of BBR-treated mice, and the therapeutic effect of BBR was disappeared after the intervention of Wnt pathway inhibitor FH535.	Berberine	112-115	catenin (cadherin associated protein), beta 1	Mus musculus	46-58
35280677-8	2022	Moreover, a proteomic study revealed that Wnt/beta-catenin pathway was remarkably enhanced in colonic tissue of BBR-treated mice, and the therapeutic effect of BBR was disappeared after the intervention of Wnt pathway inhibitor FH535.	Berberine	160-163	catenin (cadherin associated protein), beta 1	Mus musculus	46-58
34348611-8	2022	BBR diminished hydrogen peroxide-induced neuronal damage by enhancing the PI3k / Akt / Nrf-2 based pathway and showed a preventive impact on neurites of SH-SY5Y cells by averting the formation of ROS and inhibiting apoptosis.	Berberine	0-3	AKT serine/threonine kinase 1	Homo sapiens	81-84
34348611-8	2022	BBR diminished hydrogen peroxide-induced neuronal damage by enhancing the PI3k / Akt / Nrf-2 based pathway and showed a preventive impact on neurites of SH-SY5Y cells by averting the formation of ROS and inhibiting apoptosis.	Berberine	0-3	NFE2 like bZIP transcription factor 2	Homo sapiens	87-92
34635990-12	2022	CONCLUSION: The results indicated that berberine and magnolol are the main active ingredients of HH related to its anti-influenza virus effect, which is related to the improvement of IFN-beta secretion.	Berberine	39-48	IFN1@	Homo sapiens	183-191
35142272-11	2022	Moreover, levels of IL-4 and IL-10 expression increased significantly after berberine treatment.	Berberine	76-85	interleukin 4	Rattus norvegicus	20-24
35142272-11	2022	Moreover, levels of IL-4 and IL-10 expression increased significantly after berberine treatment.	Berberine	76-85	interleukin 10	Rattus norvegicus	29-34
35142272-12	2022	CONCLUSION: Berberine may mitigate vascular cognitive dysfunction by promoting neuronal plasticity, inhibiting microglial activation, promoting transformation from an M1 to an M2 phenotype, and increasing levels of IL-4 and IL-10 expression.	Berberine	12-21	interleukin 4	Rattus norvegicus	215-219
35142272-12	2022	CONCLUSION: Berberine may mitigate vascular cognitive dysfunction by promoting neuronal plasticity, inhibiting microglial activation, promoting transformation from an M1 to an M2 phenotype, and increasing levels of IL-4 and IL-10 expression.	Berberine	12-21	interleukin 10	Rattus norvegicus	224-229
34994284-0	2022	Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes.	Berberine	53-62	histone deacetylase 9	Homo sapiens	84-103
34994284-4	2022	Recently, we demonstrated berberine as pan inhibitor for HDAC.	Berberine	26-35	histone deacetylase 9	Homo sapiens	57-61
34994284-7	2022	We derived four berberine derivatives based on common HDAC inhibition pharmacophore, compound 4 possesses highest bit score by molecular docking and compound stability by HOMOs-LUMOs analysis.	Berberine	16-25	histone deacetylase 9	Homo sapiens	54-58
34994284-8	2022	It is concluded that, structurally modified berberine derivatives shown better inhibition of HDAC enzymes offering improved clinical efficacy.	Berberine	44-53	histone deacetylase 9	Homo sapiens	93-97
35180901-7	2022	In addition, in vivo evaluations in rats showed that the as-fabricated CA/HA/BBR bandage decreased wound size; moreover, it had accelerated healing ability (>95%) and collagen development with increasing treatment duration.	Berberine	77-80	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	71-76
35221284-9	2022	Berberine treatments involve 3 distinct proteins in the RIG-I-like receptor signaling.	Berberine	0-9	DEAD/H box helicase 58	Mus musculus	56-61
35221284-11	2022	RIG-I mediated neuroinflammation could participate in the process of depression and RIG-I may become a target for berberine against depression.	Berberine	114-123	DEAD/H box helicase 58	Mus musculus	0-5
35221284-11	2022	RIG-I mediated neuroinflammation could participate in the process of depression and RIG-I may become a target for berberine against depression.	Berberine	114-123	DEAD/H box helicase 58	Mus musculus	84-89